4106,Analysis of efficacy
4107,Comparisons of postoperative CA19 9 levels on survival of ESPAC 4 with the CONOKO 01 and JASPAC 1 trials
4108,Pattern of disease relapse
4109,Grade 15 adverse events with gemcitabine alone and gemcitabine plus capecitabine
4112,Treatment with zoledronic acid
4113,Treatment with docetaxel
4114,Treatments ever used at relapse, at the discretion of the treating clinician
4115,Worst adverse event   grade   reported over entire time on trial
4117,Chemotherapy delivery and trial drug discontinuation
4118,Adverse events
4121,Screening effectiveness for selective and universal ultrasonographic screening for infants who are small and severely small for gestational age
4122,Diagnostic effectiveness of selective versus universal ultrasonographic screening for infants who are small and severely small for gestational age
4123,Association between perinatal outcomes of estimated fetal weight less than the 10th percentile and abdominal circumference growth velocity
4124,Age started smoking regularly versus cause specific mortality rate ratio   RR   among urban and rural men in about 2010   second study   and about 1995   first study
4125,Amount last smoked versus cause specific mortality rate ratio   RR   among urban and rural men in about 2010   second study   and about 1995   first study
4126,Deaths attributed to tobacco in China, 2010
4127,Percentage contribution of disease categories to total deaths by age groups in states grouped by ETL, 2016
4128,Percentage contribution of disease categories to total deaths by age groups for all of India, 2016
4129,Change in summary exposure value of individual leading risk factors in states grouped by ETL from 1990 to 2016
4130,Male deaths attributed to smoking and total male deaths in the study, by population group and disease category
4131,Female deaths attributed to smoking and total female deaths in the study, by population group and disease category
4133,Primary and secondary outcomes
4134,Serious adverse events related to hypotension
4135,Side effects potentially related to blood pressure management
4136,Randomised trials of long term blood pressure lowering in patients with stroke or TIA
4138,Association of birthweight, conditional relative weight gain, and conditional height with adverse outcomes
4140,Total dose received by patients and dose intensity achieved
4141,Response to treatment
4142,Grade 3 or 4 adverse events
4144,Antibiotic therapy by class and treatment group
4145,Antibiotic associated diarrhoea and morbidity in the first 3 weeks after recruitment
4147,Additional colonic investigation by reason for investigation, overall and by sex
4148,Results of additional colonic investigation, by reason for investigation
4149,Detection rates of colorectal cancer and large polyps
4151,Serious adverse events by treatment and body system affected
4152,Circumstances of death and indications for coronial referral
4153,Autopsy causes of death by type of pathology and organs involved
4154,Major discrepancy rate between autopsy and radiology cause of death
4155,Comparison of the two independent reports for MRI and CT
4156,Most common sources of major discrepancy between autopsy and consensus radiology cause of death
4167,Cancer incidence and cancer mortality by site
4168,Effects of allocation to simvastatin plus ezetimibe on muscle and hepatobiliary system
4170,Treatment received
4171,Main outcome measures
4172,Toxic effects, weeks 112
4175,Effects of maternal anthelmintic treatment in pregnancy on infant response to BCG, tetanus, and measles immunisation
4176,Effect of maternal anthelmintic treatment on response to BCG, tetanus, and measles immunisation, by maternal helminth infection status
4177,Effects of maternal anthelmintic treatment in pregnancy on incidence of malaria, diarrhoea, and pneumonia in infancy
4178,Effect of maternal anthelmintic treatment in pregnancy on disease incidence, by maternal helminth status
4179,Effects of Phytoestrogens in Basic, Animal and Human Studies
4183,Final Cox Proportional Hazards Model for Hard Events
4184,Predicted Rates of Hard Events by Six Month Intervals in Patients With No History of Previous CAD
4185,Predicted Rates of Hard Events by Six Month Intervals in Patients With History of Known CAD
4186,Time   Days   From Index Test to 0.5 , 1.0 , 1.5 , and 2.0  Predicted Risk of Hard Events in Patients With No History of Previous Coronary Artery Disease
4187,Time   Days   From Index Test to 0.5 , 1.0 , 1.5 , and 2.0  Predicted Risk of Hard Events in Patients With Known Coronary Artery Disease
4188,Clinical Features of MCH
4189,Echocardiographic and Pathologic Features
4191,Independent Predictors of Cardiovascular Events   Cox Model
4193,Inclusion and Exclusion Criteria for Permanent Jarvik 2000 Implantation
4195,Intraoperative and Postoperative Patient Data
4199,Causes of Death Before and After Transplantation
4203,Adverse Events During the Initial Hospitalization and at One Year
4204,Estimated Risk Ratios for Death in Patients With Successful Percutaneous Revascularization Procedures
4205,Changes in Heart Rate Before and After Ablation
4208,Clinical Correlates of Coronary Artery Calcification Score
4209,Clinical Correlates of Aortic Calcification Score
4210,Multivariable Linear Regression With Extent of Coronary Calcification as Dependent Variable
4211,Multivariable Linear Regression With Extent of Aortic Calcification as Dependent Variable
4212,Treatment Groups
4214,Extent of Coronary Artery Disease and Subsequent Treatment According to the CRF and the Angiographic ACL
4215,Worst Major Adverse Events, in Ranking Order, and Event Free Survival for the Four Subgroups at One Year
4216,Extent and Quality of Incompleteness in Both Groups Treated With Bypass Operation or Stented Angioplasty Assessed by the ACL
4218,Univariate Predictors of Pump Failure and LV Aneurysm legend
4219,Multiple Logistic Regression Analysis for Pump Failure legend
4220,Multiple Logistic Regression Analysis for LV Aneurysm legend
4221,Univariate and Multivariate Cox Proportional Hazards Analysis for Cardiac Events legend legend
4223,Univariate Analysis
4224,Multivariate Analysis
4226,Relative Risks   95  CI   for Total, Fatal and Nonfatal MI Associated With Alcohol Consumption Among Men With Type 2 Diabetes   n   2,419   Enrolled in the Health Professionals Follow up Study   19861996
4227,Multivariate   RR   95  CI   of Total CHD Associated with Alcohol Consumption Among Men With Type 2 Diabetes   n   2,419   Enrolled in the Health Professionals Follow up Study   19861996
4228,Relative Risk   95  CI   of CHD by Types of Alcoholic Beverage Among Men With Type 2 Diabetes   n   2,419
4229,Amplitude of Paced P Waves
4230,Duration of Paced P Waves
4231,Evaluation of Surface Electrocardiographic Criteria
4232,Effects of Placebo or Oral Conjugated Equine Estrogen on Glycosylated Hemoglobin and Lipid Levels in Type II Diabetic Postmenopausal Women
4233,Effects of Placebo or Oral Conjugated Equine Estrogen on Endothelial Function in Type II Diabetic Postmenopausal Women
4235,Sensitivity, Specificity and Predictive Accuracy for Complete Isthmus Block legend
4237,Comparison of Patients With Pure AFl and Patients With Paroxysmal AF legend
4238,Individual Clinical and Echocardiographic Parameters of Patients With a Thrombogenic Milieu legend
4240,Activation Mapping of the Right and Left Side of the Anterior IAS in Patients With Focal Atrial Tachycardia Originating Next to the Atrioventricular Node legend legend
4241,Polarity of the P Wave During Atrial Tachycardia legend
4244,Mutations in MYBPC3That Cause Hypertrophic Cardiomyopathy legend
4245,Clinical Features of Index Patients and Family Members Carrying MYBPC3 Mutations legend
4248,Noninvasive Risk Assessment
4250,Results of Electrophysiological Study legend
4254,Symptoms During First ICD Therapy in Patients According to the Presenting Arrhythmia legend
4255,Clinical Variables in Groups Defined by the Presence or Absence of Hypertension or Diabetes legend
4256,Diastolic Filling Parameters in Groups Defined by the Presence or Absence of Hypertension or Diabetes legend
4257,Diastolic Filling Parameters in Groups Defined by the Presence or Absence of Hypertension or Diabetes    legend
4258,Indices of Diabetes Control and LV Diastolic Filling in the Diabetic Population legend
4261,Electrophysiologic Parameters of Two Initiation Patterns of AF legend
4262,Electrophysiologic Parameters: Relationship With Left Atrium Enlargement legend
4263,Ventricular Tachycardia Morphology, Mapping and Ablation Sites
4267,Predictive Value of Various Echocardiographic Parameters legend legend
4268,Effects of Treatment on Number of Defibrillation, Postresuscitation Ventricular Arrhythmias and Duration of Survival legend
4269,Adrenergic Receptors Actions on the Heart and Peripheral Arteries legend
4270,Global Distribution of Atrial Ectopic Foci Appearing Successful Electrical Cardioversion of Persistent AF With and Without Antiarrhythmic Drugs legend
4272,A Comparison of Women With and Without a History of Anxiety Disorders on Three Indices of CAD Severity legend
4273,Risk of Inducing Electrophysiologic Abnormalities With a Baseball Propelled at 30 mph and Impacting the Chest Wall at Different Anatomic Sites During the Vulnerable Time Period for Induction of Ventricular Fibrillation   10 to 30 ms Before the T wave Peak   legend
4276,Mean Values of Age Standardized Factors for Men 35 to 65 Years Old With   MCE    and Without   MCE   Development of MCEs Within 10 Years legend
4277,Relative Risk of MCEs According to Elevated Lp  a   and Other Risk Factors legend
4278,Mean Values and Prevalences of Age Standardized Risk Factors of Men With Estimated Global Risk in the 4th and 5th MLF Quintiles and With Lp  a     or  0.20 g liter legend legend
4281,Parameters of the Ablation Procedure legend
4287,Relationship Between Echocardiographic Indices and Pulmonary Capillary Wedge Pressures legend
4290,Apolipoprotein E Genotypes and Response of Coronary Atherosclerosis and Clinical Events to Treatment With Fluvastatin   n   287   legend legend
4291,Lipoproteins and Glucose Before and After Five High Fat Meals in 10 Healthy Subjects legend
4293,Preoperative Clinical and Operative Data legend legend
4294,Clinical and Hemodynamic Outcomes and Valve Function legend legend
4295,Doppler Echocardiographic Variables in Patients Grouped According to Pulmonary Venous and Mitral Flow Indices legend legend
4296,Interobserver Variability in Patients With Optimal or Near Optimal Pulmonary Venous Flow Velocity Recordings legend legend
4297,Predictors of Cardiac Events   Cardiac Death or Hospitalization for Worsening Heart Failure   as Assessed by Univariate Cox Model legend
4298,Predictors of Clinical Events at Multivariate Cox Models legend
4300,Angiographic Data in All 39 Patients and in 16 Patients Undergoing Hypothermia Who Underwent Angiography for Suspected Acute Coronary Syndrome legend
4301,Data of Mild Hypothermia Treatment
4302,Cerebral Performance Categories at Hospital Discharge in 23 Patients Undergoing Mild Hypothermia
4306,Pacing at 120 Beats Min legend legend
4307,Summary of Postnatally and Antenatally Diagnosed DAA legend
4308,Histology of the Ductal Tissue legend
4309,Results of Exercise Testing legend legend
4311,Lipid Profiles and Vitamin E Concentrations Before Treatment in the Placebo and Active Therapy Subgroups legend legend
4314,Individual Improvement of Exercise Capacity and Quality of Life During Both Programs legend legend
4315,Clinical and Exercise Test Data on the Early Exercise Test Group   n   216; Mean  Standard Error of the Mean or the Number of Patients, With Percentages Within that Group in Brackets   legend
4317,Clinical and Investigational Data on the Six Groups of Patients   n   540; Mean  Standard Error of the Mean or the Number of Patients, With Percentages Within that Group in Brackets   legend
4318,Follow up Information on the Patients Discharged Alive   n   510; the Number of Patients, With Percentages Within that Group in Brackets   legend
4320,Transmural MBF  in Lased and Nonlased Regions 1 and 6 h post TMR legend
4321,Mean MWC in Lased and Nonlased Regions 6 h Post TMR legend
4324,Radiofrequency Ablation of Supraventricular Tachycardias and Other Procedural Issues legend
4325,Current Patient Status at Last Follow up legend
4326,End Tidal Carbon Dioxide Before Arrest and During Cardiopulmonary Resuscitation
4329,Hemodynamic, Left Ventricle Function, ANP and BNP Data of the Two Groups According to ECG Pattern legend
4330,Two Dimensional Echocardiographic Data According to ECG Pattern legend
4331,Transmitral Doppler Variables in Patients Grouped According to ECG Pattern legend legend
4332,Exercise Treadmill Data During Symptom Limited Treadmill Exercise Testing According to ECG Pattern
4338,Procedural Variables: Clopidogrel versus Ticlopidine
4339,30 Day Clinical Outcomes: Clopidogrel Versus Ticlopidine legend
4340,In Hospital Hemorrhagic Complications legend
4343,Comparison Between the Group That Underwent Direct   Group 1   and the Group That Underwent Traditional   Group 2   Single Vessel Stent Implantation
4345,Angiographic Patterns and Distribution of Stigmata of an Impaired Coronary Blood Flow in the Subgroups I to III
4353,Procedural Factors Associated With Higher Cardiac Troponin I Levels After RF Ablation legend
4355,Discharge Treatments by Location of Ventricular Arrhythmia Presentation legend
4356,Mortality Rate by Location of Presentation
4358,Procedural Complications in CK MB Elevation and Normal CK MB Group legend
4359,Multivariate Predictors of CK MB Elevation legend
4360,In Hospital Course and Adverse Cardiac Events in all Patients legend
4363,Ventricular Arrhythmias Detected During Follow up legend
4364,Type of Recurrence in Relation to Induced Arrhythmia at the Electrophysiologic Study legend
4365,Hemodynamic Data legend
4366,Hematologic Data legend
4367,Renal Involvement legend
4373,Comparative Clinical and Echocardiographic Data in the Present Study Compared With That in a Previously Published Series legend
4375,Surgical Procedures in Addition to Arterial Switch Operation   ASO   legend
4376,Operative and Postoperative Variables    legend
4377,Univariate Analysis of Risk Factors for Early Mortality legend
4378,Multivariate Analysis of Risk Factors for Early Mortality legend
4380,Effects of Treatments in Patients With High Remnants Levels legend
4381,Effects of Treatments in Patients With Low Remnants Levels
4383,The Relationship Between the Number of ST Segment Episodes and the Level of Cardiac Troponin T at Inclusion Among Patients in Whom Both ST Segment Monitoring and Biochemical Analyses Were Performed   n   213   legend
4384,Univariate Analysis of Selected Risk Variables for Cardiac Death AMI at 30 Days legend legend
4385,Multivariate Stepwise Cox Regression Analysis of Potential Risk Variables in Order to Detect Independent Predictors of Cardiac Death or Acute Myocardial Infarction at 30 Days legend
4386,The Relationship Between the Number of ST Segment Episodes and the Level of Cardiac Troponin T at Inclusion Among Patients With Unstable Angina Pectoris in Whom Both ST Segment Monitoring and Biochemical Analyses Were Performed   n   140   legend
4387,Occurrence of Cardiac Death AMI at 30 Days According to the Level of Cardiac Troponin T at Inclusion and Continuous ST Segment Monitoring in the Subset of Patients With Unstable Angina Pectoris   n   152   legend
4388,Precipitator of Cardiac Events in Symptomatic LQTS1and LQTS2Carriers legend
4392,Prevalence of Spontaneous Ventricular Arrhythmias During Holter Monitoring and Reduced Left Ventricular Ejection Fraction in 657 Patients Following Myocardial Infarction legend
4393,Reasons for Not Performing Programmed Ventricular Stimulation in 304 Patients With Abnormal Holter ECG or Reduced EF legend
4394,Response to Programmed Ventricular Stimulation in 146 Patients Following Acute Myocardial Infarction legend
4396,Predictors of Arrhythmic Events and Non Sudden Cardiac Death in 657 post MI Patients legend
4397,Independent Risk Factors for Arrhythmic Events and Non Sudden Cardiac Death in 657 Patients Following Myocardial Infarction legend
4399,Distribution and Cause of Implantable Cardioverter Defibrillator Therapies During Follow up legend
4400,Clinical Outcome of Patients Relative to Response at Programmed Electrical Stimulation  legend
4401,Clinical Outcome of Patients With Coronary Artery Disease Relative to Response at Programmed Electrical Stimulation
4403,Hemodynamic Variables of Study Subjects legend
4408,Left Ventricular Inflow and Outflow Tract Doppler Velocities and Timing  legend
4409,Right Ventricular and Septal Long Axis Function legend
4410,Right Ventricular Inflow and Outflow Values  legend
4416,Study Groups legend
4417,QCA Assessment of Arterial and Balloon Diameter at the Site of Intervention legend
4418,Morphometry
4419,Assessment of Cell Proliferation     BrdU Positive Cells    legend
4420,Aortic Homograft Valves: Hemodynamic Results in 57  Patients 1 Week and 7 Months Postoperatively  legend legend legend
4421,Aortic Homograft Valves: Results by Annulus Diameter in 57  patients 7 Months Postoperatively legend legend
4422,Aortic Homograft Valves: Results at Rest and at Peak Symptom limited Supine Exercise in 31 Patients legend legend
4423,Effect of Radiofrequency Current Application According to the Type of Site  legend
4424,Associated Cardiac Lesions in 101 RAI Patients  legend
4425,Palliative Procedures and Outcome in 65 RAI Patients legend
4426,Postoperative Supraventricular Tachycardia   SVT   and Early Surgical Death legend
4427,Electrophysiological Data in Seven RAI Patients
4428,Patient Profiles  legend
4429,Echocardiographic Values legend
4430,Lipid and Alpha Tocopherol Serum Levels  legend
4434,Selection criteria in SICCO Study  legend
4436,Clinical Events legend
4437,Clinical Status at Follow Up   mean 34  5 months      legend
4438,Predictors for Occurrence of Major Adverse Cardiac Events    legend
4439,Hemodynamic Variables Before and After Balloon Mitral Valvotomy and at Follow Up in Group I Patients  legend
4440,Pathologic Findings After Emergent Balloon Mitral Valvotomy legend
4441,Specific Congenital Heart Defects and Incidence of Sudden and Nonsudden Cardiac Death  legend
4442,Probability of Sudden Death Free Survival by Surgical Era and Duration of Follow Up  legend
4443,Probability of Sudden Death Free Survival by Age at Operation and Duration of Postoperative Follow Up  legend
4444,Clinical Details of the Subjects  legend
4445,Neuropathic Details of the Subjects
4446,Change in Heart Rate and Systolic Blood Pressure Before and After Adenosine Administration
4447,Study Groups and Estradiol Levels
4449,Incidence and Crude Relative Risk of Thromboembolic Events According to Gender and Left Ventricular Ejection Fraction Quartiles in Studies of Left Ventricular Dysfunction   SOLVD   Trial  a
4450,Risks of Anticoagulation: Rates of Major Hemorrhage
4452,Comparisons of Quality of Life Scores Between Patients After Atrioventricular Junction Ablation and Atrioventricular Junction Modification
4453,Comparisons of Cardiac Performance Between Patients After Atrioventricular Junction Ablation and Atrioventricular Junction Modification
4454,Comparisons of Quality of Life and Cardiac Performance Between Patients With Paroxysmal Atrial Fibrillation and Chronic Atrial Fibrillation After Atrioventricular Junction Ablation
4455,Comparisons of Quality of Life and Cardiac Performance Between Patients With Paroxysmal Atrial Fibrillation and Chronic Atrial Fibrillation After Atrioventricular Junction Modification
4458,In Hospital Outcome and Follow Up Events at 1 Year by Study Period
4459,Most Aggressive Therapy  a  by Study Period for Patients Who Were Alive and Angina Free at 1 Year
4462,Bundle Branch Blocks After Percutaneous Transluminal Septal Myocardial Ablation
4467,Costs, Length of Stay and Complications
4470,Univariate Predictors of Time to Cardiac Event
4471,Multivariate Predictors of Time to Cardiac Event
4473,Lesion Morphology by Coronary Angiography
4474,Quantitative Coronary Angiography
4476,Contribution of Sudden Death to Total Mortality in Relation to Gender in Different Age Groups
4477,Site of Sudden Cardiac Arrest in 501 Victims
4478,Complaints in 227 Witnessed Patients Before Sudden Cardiac Arrest
4480,Angiographic Findings After Primary Angioplasty and Abrupt Coronary Closure
4481,Intravascular Ultrasound Findings and Abrupt Closure
4482,Postangioplasty Angiographic and Intravascular Ultrasound Variables as Predictors of Abrupt Coronary Occlusion
4483,Hemodynamic Measurements
4484,Exercise Electrocardiographic and Scintigraphic Test Results Versus Mortality
4485,Mortality in ACME Follow Up Study
4486,Late Coronary and Revascularization Events in ACME Study  a
4492,Hemodynamic Data
4495,Measurements of Diffuse Capacity of Carbon Monoxide
4496,Adverse Events
4498,Results of Programmed Ventricular Stimulation in Relation to Type of Underlying Heart Disease
4501,Intervals Measured During Ventricular Tachycardia, Responses to Pacing During Ventricular Tachycardia and Sinus Rhythm and Presence of Isolated Diastolic Potential During Sinus Rhythm
4503,Comparison of Exercise Time, Peak Heart Rate, Functional Class and Subjective Symptom Score Among the Three Pacing Modes
4504,Effects of Lovastatin, Vitamin E and Amlodipine on Serum Malondialdehyde, Cholesterol, Vitamin E and Plasma Superoxide Dismutase Activity in High CholesterolFed Rabbits
4505,Effects of Lovastatin and Amlodipine on Low Density Lipoprotein Oxidation Induced by Leukocytes and on Superoxide Dismutase Activity in Leukocytes
4510,Univariate Predictive Value of High Resolution Dimension in Cox Regression Model By Therapy Group Status
4511,Multivariate Cox Regression Model of Arrhythmic Death Cardiac Arrest
4512,Multivariate Cox Regression Model of Nonarrhythmic Death
4515,Preoperative and Postoperative Hemodynamic Data by Group
4516,Surgical Procedures by Group
4517,Comparison Between Survivors and Early Deaths
4519,Study Drug Treatment
4520,Compliance With Study Drug Treatment
4522,Clinical Outcome Through 14 Days  a
4524,Endothelium Dependent Relaxation of Segments of Canine Coronary Arteries With Endothelium
4525,Endothelium Independent Relaxation of Segments of Canine Coronary Arteries
4526,Endothelium Independent Vascular Smooth Muscle Contractions of Segments of Canine Coronary Arteries
4530,Angiographic Data
4531,Clinical, Echocardiographic and Myocardial Scintigraphic Findings in 12 Patients With Familial Amyloid Polyneuropathy
4533,Effect of Dalteparin on the Rate of Death or Myocardial Infarction in Relation to Troponin T Level  0.1 or 0.1 g liter at Inclusion   n   971
4534,Univariate and Multivariate Logistic Regression Analysis Evaluating the Effect of Randomized Treatment, Troponin T Level and Interaction Between Treatment and Troponin T Level on the Rate of Death or Myocardial Infarction During 40 Days of Follow Up   n   971
4536,Burden Analysis of Rare, Protein Altering Variants in DCM Related Genes Between Cohorts
4539,Cardiac Involvement in the Cohort
4541,PREVAIL Primary Efficacy Endpoints
4542,Efficacy Rates at 5 Years   2:1 Randomization
4546,Linear Regression Analysis Evaluating Predictors of Left Ventricular Mass
4549,Univariate Analyses
4550,Multivariable Analyses
4551,Event Rates According to Device Type and Midwall Fibrosis Status
4556,Outcomes
4558,Definitions of Major Stroke, Minor Stroke, and Myocardial Infarction in the Included Trials
4559,Absolute Risk Metrics of Outcomes of Major Interest
4562,30 Day and 1 Year Clinical Outcomes
4565,Prevalence of Medication Use or Lifestyle Counseling in Patients With PAD Seeing Physicians in U.S. Ambulatory Care Visits, 2006 to 2013
4568,Overview of Pathogenic and Likely Pathogenic Variants in SADS Cohort
4569,Association of Predictors and Positive Post Mortem Genetic Testing
4571,Results of Multivariable Cox Regression Analysis
4573,Correlation of 2D and Doppler Measurements With LVFilling Pressure
4574,Distribution of 2D and Doppler Variables
4575,Accuracy of Diagnosis of Elevated LV Filling Pressure: Total Population
4576,Accuracy of Diagnosis of Elevated LV Filling Pressure: Subgroup Analysis
4577,Flow Cytometric Analysis
4581,Comparison of Standardized Differences in the Means of Continuous and Binary Variable Covariates Between Treatment Groups Before and After Propensity ScoreMatching
4584,Novel Loci Significantly Associated With CAD
4585,Significant Associations of CAD Variants With Selected CV Risk Factors
4586,Association of CAD Loci With Other Diseases or Traits
4587,E1A and E2A Values
4590,Comparison of Acetylsalicylic Acid Pharmacokinetics
4591,Comparison of Aspirin Cmax in EC Treated Responders and Nonresponders
4593,Group A: Presence of Pathogenic Likely Pathogenic Mutations
4594,Electrocardiogram Parameters
4595,Imaging and Biopsies
4597,Safety and Clinical Efficacy
4598,Recipient cPRA Change 6 Months Post TESI
4602,30 Day Clinical Outcomes
4603,Echocardiographic and Functional Outcomes at Day 30 in Survivors With Valve In Situ
4606,Clinical Course During Admission
4607,Clinical and Functional Outcomes
4609,Surgical Variables and Discharge Medications By Treatment Group
4610,Outcomes in Patients on DAPT and Aspirin Monotherapy
4611,Outcomes in Clinically Important Subgroups
4614,Breakdown of the Currently Used Cardiac Magnetic Resonance Imaging Diagnostic Criteria for Left Ventricular Noncompaction in the WholePopulation and by Sex
4616,Comparison of Left Ventricular Measures Between Those Meeting 1, 2, 3, or 4 Left Ventricular Noncompaction Criteria
4619,RV Deformation
4620,RV Geometry and Basal Deformation
4622,Clinical Endpoints
4624,Intraoperative Details and In Hospital, Follow Up Outcomes
4625,Changes of Diameters of the TL, FL, and TA at Different Measuring Levels
4627,Full Models: Association of Frailty and Geriatric Domains With Poor Outcomes
4628,Clinical Models: Association of Frailty and Geriatric Domains With PoorOutcomes
4631,CHD, Stroke, or Mortality Events
4634,Maternal and Fetal Outcomes
4636,Coronary Flow and Cardiac Cycle Timing
4637,Separated Cumulative Wave Intensity
4638,Proportion of Net Cumulative Wave Intensity       at Rest and Hyperemia
4640,Cumulative Incidence
4642,Multivariable Predictors of Cardiac Recovery and Prognostic Score System
4645,Pharmacotherapy for PCI in Patients With and Without a History of AF
4650,Relationship Between Subclinical Atherosclerosis and Clinical Events
4651,Binary Disease Guided Reclassification Approaches     to Statin Allocation
4656,Clinical, Laboratory, Echocardiographic, Hemodynamic, and Pulmonary Parameters Associated With New York Heart Association Class in Patients With Heart Failure With Preserved Ejection Fraction
4657,Predictors of Outcome
4658,Cox Regression of Multivariate Significant Predictors of Outcome From the Parameter Clusters
4660,Early and Late Outcomes
4663,Association Between Telomere Measurements and CVD Risk Factors Stratified by Sex and Adjusted by Age
4668,Unmatched and Propensity Matched In Hospital Outcomes of Patients With and Without a History of AF Undergoing PCI
4671,Risk Dependent NNS for Subclinical Atherosclerosis
4676,Safety Endpoints
4683,Plaque Presence and Total Plaque Burden
4686,Association of LTL and  LTL 3 kb With Plaque Burden
4687,Pathological Macroscopic and Microscopic Criteria Defining Main UnderlyingDiseases
4689,Multivariate Analysis of Death During Exercise
4691,Clinical Study: CMR Derived Parameters
4692,Sensitivity Analysis of CMR Derived Parameters in Patients Receiving IV Metoprolol
4693,Animal Study: CMR Derived Parameters
4695,Results of Endomyocardial Biopsy
4696,CMR Imaging Techniques
4697,Diagnostic Performance of 1.5 T CMR Imaging
4699,CMR and TTE Results
4704,Changes in Efficacy Endpoints and Laboratory Values
4705,Subgroup Specific Effects of Statins According to Minimal Lumen Area, Plaque Burden, and VH TCFA
4706,Changes in Efficacy Endpoints Between Patients With Stable Versus Unstable Angina
4710,Odds Ratios of Subclinical Atherosclerosis Presence   vs. Absence   for CV Risk Factors   Age Adjusted
4711,Diagnostic ORs of Carotid and Femoral Plaques for Detection of Positive   1   or High   300   CACS, Adjusted for CV Risk Factors and Age, and Changes in Areas Under the Curve for Prediction
4712,Relationship of Risk Factors in 1998 1999 and CAC Agatston Scores in the CHS CS   n  311 Free of CVD in 1998 1999
4713,Causes of Death by Dementia Status to 2015 in the CHS CS   n  422  79   of532Deaths
4714,Death and Dementia Rates     to 2011 and CAC Agatston Score Among CHS CS Participants, White Participants Only, Alive, Not Demented, and No CVD at 1998 1999 by Sex
4715,Age Adjusted Incidence of CHD   Excluding Participants With CVD  CHD, CHF, Stroke, MI  at 1998 1999   and Dementia by Carotid Artery Measures and ABI by Sex Among CHS CS Participants, White Participants Only
4716,Comparison of Incidence of Dementia and CHD by Age, Race, and Sex in 1998 1999 Among CHS CS Participants With CACMeasurement Only
4720,Early and Late Outcomes of Hospital Survivors of AMI and Cardiogenic Shock According To Myocardial Infarction Type
4721,Clinical Features of Affected Patients With ALPK3 Mutations
4723,6 Month Secondary Endpoints by Intention to Treat
4724,Adverse Drug Reactions Reported in CYCLE
4726,Echocardiographic, Histological, and Flow Cytometric Results
4731,CMR Imaging
4732,Secondary Endpoints
4733,30 day Adverse Cardiac Events
4734,Safety Endpoints
4736,Summary of Outcomes by Study Groups
4737,Univariate and Multivariate Cox Regression Analyses of Potential Risk Factors for VT Recurrence
4739,Hemodynamic Assessment   pre TAVR
4740,Procedural Evaluation and Performance of Patients Undergoing TAVR
4741,Post Procedure TAVR Valve Performance
4742,Cardiovascular and Device Complications   Prior to Discharge   of Patients Undergoing TAVR
4743,In Hospital Mortality and Cause of Death of Patients Undergoing TAVR
4745,Periprocedural Details in the CR and IRA Only Groups
4746,Pre Discharge and Follow Up CMR
4747,Clinical Outcomes
4749,Modifiable Risk Factors by Sex and Country
4754,Severity Scores for Potential Outcomes in Anti SSA Ro Exposed Fetuses
4756,Cord Blood Biomarkers Associated With Cardiac NL
4757,MRI Examination Sequences for Study Scan
4762,In Hospital Course
4763,Predictors of the Presence of Severe    70    Carotid Stenosis
4764,CREST Results in Patient Subgroups
4765,Factors in Choice of Carotid Revascularization Methods
4766,Elements of Intensive Medical Therapy in SAMMPRIS Study
4767,Annual Risk of Stroke in Patients With AsymptomaticStenosis
4768,Current and Future Carotid Stenosis Trials
4770,Hazard Ratios   95  CI   for Primary and Secondary MACE Endpoints Associated With CAC and cPB
4771,Impact of Adding cPB or CAC to Conventional Risk Factors on Model Performance for Prediction of Primary and SecondaryMACE Endpoints
4773,Medical Treatment Before Procedure and During Follow Up
4774,HRs of Outcome Events During Follow Up Depending on Post Treatment DWI Lesions
4776,Patients With HCM Related Deaths or Major Events and Interventions
4777,Univariate and Multivariate Predictors of HCM Related Mortality or Life Threatening Event
4779,ECG Data for Athletes and ARVC Patients
4780,Echocardiographic and CMRI Data for Athletes and ARVC Patients
4781,SAECG, Holter Monitor, and Exercise Data for Athletes and ARVC Patients
4785,Modified Poisson Regression Analysis of the Associations Between HDL C P Ratio, HDL P Number, HDL C, and the Progression of Carotid Atherosclerosis
4787,Procedural and Post operative Data
4788,Overall Incidence of Complications
4789,Odds Ratios for Death Derived From Multivariate Analysis
4790,Odds Ratios for Various Complications Derived From Multivariate Analysis
4792,Risk Factors for SCD in Patients With DCM
4793,Risk Factors for SCD in Patients With HCM
4794,Risk Factors for SCD in Patients With LVNC
4797,Clinical Outcomes in the As Treated Population
4798,Clinical Parameters of Donors and iDCM Patients
4799,Clinical Data of Patients Included in the Validation Cohort
4800,Cardiomyocyte Contractility and Ca2  Transient Parameters: SlowerContraction and Relaxation Velocities
4802,Angiographic Results
4803,Major Adverse Clinical Events
4805,Comparison of Intraoperative Results and Clinical Outcome in HCM Patients With and Without Chordal Cutting
4806,Geometry of the MV Apparatus Before and After Surgical Myectomy in 39 HCM Patients With and 25 Without Chordal Cutting
4807,American College of Cardiology In TrainingExamination Blueprint
4808,In Training Examination Fellow Participants
4809,In Training Examination Statistics
4810,Cohort Score Changes Across Fellowship Years
4811,Distinguishing Features of LQT1 AMCs
4813,Association Between Cardiac Structure and Age Using a Linear Regression Model
4814,PROTECT AF and CAP: Largest Data Sets to Evaluate Totality of Data
4816,Histopathologic Exclusions   N   33
4818,Indications for Echocardiography
4819,PFE Size in Patients Presenting With and Without NE
4820,Symptoms in Group 1a and 1b Patients
4821,Observed     Versus Expected   CVA Rates
4823,Clinical Outcomes According to MAGGIC Risk Score Category
4824,Occurrence of Pre Specified Adverse Events by MAGGIC Risk Score Category
4826,Clinical Outcomes in PARADIGM HF Patients     According to EMPHASIS HF Risk Score
4828,Mortality, MIR, and MIRR
4833,Procedural Data and 30 Day Results
4836,Clinical Outcomes at 1 Year
4837,Landmark Analysis of Key Clinical Outcomes Between 30 Days and 1Year
4838,Echocardiographic Follow Up at 1 Year
4839,Changes in PVL for Balloon  and Self Expandable Valves: Echocardiography at Discharge Compared With 1 Year   Patients With Data atBoth Time Points
4841,Procedural Results and Use of Medications During the Trial
4842,Outcome Rates at 12 Months According to Treatment Group
4846,Age  and Sex Adjusted Rates of Peripheral Vascular Interventions, Surgical Revascularization Procedures, and HybridProceduresper 100,000 Medicare Beneficiaries by Year
4847,Age  and Sex Adjusted Rates of Peripheral Vascular Interventions per 100,000 Medicare Beneficiaries by Clinical Setting and Year
4848,Total Costs of Peripheral Vascular Intervention by Procedure, Setting, and Year
4850,Differences in Flow and Pressure in the Main Vessel Between the 2 Different Computational Models
4852,Types of Late Cardiac Reinterventions
4853,Standard 12 Lead and 24 h Holter Electrocardiogram, Bicycle Ergometry, and Echocardiography
4854,Results of Additional Diagnostic Tests Performed Only in 2012
4856,Univariable and Multivariable Adjusted HRs for the Primary 5 Dose Analysis and the Secondary Analysis Comparing Low  25 of Target Dose   Versus High   50  of Target Dose   Dose on the Basis of the Pre Specified Analyses and Using the ExtendedSetofCovariates
4857,Sensitivity Analyses Showing Adjusted HRs for 3 Year Mortality Compared With the  50  of Target Dose Group UsingthePre Specified MV Analysis, and the MV Analysis With the Extended Set of Covariates and Propensity Score Analysis for the 4Beta Blocker Dose Groups
4858,HRs and 95  CIs From MV Analysis of 2 Year Mortality in the 2 Pre Specified Analyzed Cohorts According to Predictor
4859,HRs and 95  CIs From the Multivariable Analysis With the Extended Set of Covariates of 3 Year Mortality in the 4Treated Beta Blocker Dose Groups
4862,Landmark Analysis of the Risk of Clinical Endpoints for Patients With and Without DM Treated With 12 Months Versus12Months of Clopidogrel After Index Percutaneous Coronary Revascularization With DES
4863,Landmark Analysis of the Risk of Clinical Endpoints for Patients With and Without DM Treated With 12 Months Versus12Months of Clopidogrel After an Index Percutaneous Coronary Revascularization With BMS
4864,Landmark Analysis of the Risk of Clinical Endpoints for Patients With and Without DM Treated With 12 Months Versus12Months of Clopidogrel After Percutaneous Coronary Revascularization With DES
4865,Landmark Analysis of the Risk of Clinical Endpoints for Patients With and Without DM Treated With 12 Months Versus12Months of Clopidogrel After IndexPercutaneous Coronary Revascularization With BMS
4866,Clinical Data of the Families Analyzed in This Study
4868,Features Associated With High Risk of Carotid Endarterectomy
4869,Multidisciplinary Carotid Stent Guidelines
4870,Features Suggested to Increase the Risk of a Carotid Stent Procedure
4872,Multivariate and Propensity Matched Cox Regression Results
4873,Subgroup Analysis: Association of Digoxin With Mortality
4875,Summary of Published hiPSC Models of Cardiovascular Disease
4878,Recapitulation of the Classification Systems for Cardiomyopathies in the Last50Years
4879,Genetic Testing: Position of the Scientific Societies
4883,Multivariate Predictors of an Inadequate DSM
4884,Adverse Events Stratified by Defibrillation Safety Margin Status
4885,Success and Failure of CTO Intervention
4886,Associations With CTO Failure After MultivariateAnalysis
4887,Associations With Mortality After Multivariate Analysis
4892,Patterns of LGE
4894,Predictors of Overall Survival After Surgical AVR on Univariate and Multivariate Cox Analysis
4897,Major Adverse Events at 30 Days and at 12 Months
4898,MitraClip Device Complications
4900,Hospitalizations for Heart Failure
4901,Safety and Effectiveness Outcomes by MR Cause   Degenerative or Functional
4903,Coprimary Efficacy Endpoint Results   Stroke, Systemic Embolism, or Cardiovascular Unexplained Death
4904,Coprimary Efficacy Endpoint Observed Events by Type: PREVAIL Subjects Only   Intention to Treat
4905,Late Ischemic Coprimary Endpoint: PREVAIL Subjects Only   Intention to Treat
4906,Safety Coprimary Endpoint Results and Events by Type   Intention to Treat  : Device Group Only
4908,Comparison of Outcomes in Device Patients in PROTECT AF, CAP, and PREVAIL
4911,Multivariate Predictors of LV Recovery
4914,Cross Tabulation of the Clinical and Device Derived AF Classifications
4915,Cardiac Function Assessed by LV Pressure Volume Loops in WT and TG Mice
4917,6MW Distance by Treatment Group, HF Etiology, and NYHA Functional Class
4919,Mortality Rates and HRs for Randomized Treatments, by 6MW Distance Tertile
4922,The 12 Most Common Discharge Diagnoses for Patients Admitted to Hospital, According to the First High Sensitivity Cardiac Troponin T Level
4923,Details of 15 Patients With Chest Pain and a First High Sensitivity Cardiac Troponin T Level of 5 ng l Combined With No Signs of Ischemia on an Electrocardiogram, Who Had a Final Diagnosis of Myocardial Infarction
4926,Selected Predictors of Meeting Indications for an ICD at Time of Generator Replacement
4928,HRs for Clinical Outcomes of Early Surgery Compared With Conventional Treatment
4930,HRs for Clinical Outcomes of Early Surgery Compared With Conventional Treatment in the Propensity Score Matched Cohort
4931,HRs for Clinical Outcomes of Early Surgery Compared With Conventional Treatment According to Age
4933,Coronary Grafting Profiles
4934,Adjusted HRs for Death Following Off Pump CABG Compared With On Pump CABG
4935,HRs for Death Following Off Pump CABG Compared With On Pump CABG: Stratified Analysis Based on Operative Years in Quintiles
4936,Adjusted HRs for Death Following Off Pump CABG Compared With On Pump CABG: Stratified by Operators and Grafting Profiles
4937,Inotropic Drugs: Mechanisms and Outcomes
4938,EVEREST II Randomized Trial
4939,COAPT High Risk Randomized Trial
4940,RESHAPE HF Randomized Trial
4942,European Society of Cardiology Classification of Changes of the Athlete s Electrocardiogram
4944,Prevalence of Group 1 and Group 2 ECG Patterns inNonathletes Compared With Athletes
4946,Hazard Ratios, 95  CI, and p Values for Different Variables and Thresholds of BNP
4949,1 Year All Cause Mortality According to In Hospital BARC Bleeding Type
4950,1 Year All Cause Mortality According to In hospital Bleeding Status for the Different Bleeding Definitions
4952,One Year All Cause Mortality According to BARC Bleeding Data Elements
4953,Clinical and Angiographic Data
4954,Infarct Size in Relation to Myocardium at Risk in the Total Population and Subgroups
4955,Clinical Events at Day 45  15
4956,Cardiac MRI, Biomarker, ECG, and Angiographic End Points
4958,Clinical Studies With Pharmacological Strategies Against the Complement Cascade
4959,Clinical Studies With Pharmacological Strategies Against Cytokines
4960,Clinical Studies With Pharmacological Strategies Against Metalloproteinases
4961,Sources Used to Identify Sudden Deaths in NCAAAthletes
4963,Mortality Rates in NCAA Athletes Compared With the General Population
4964,Mortality Rates in NCAA Athletes Compared With the General Population Stratified According to Race Ethnicity
4970,Yield of Downstream Testing After ETT
4973,Risk Prediction Model for 90 Day Waiting List Mortality
4974,Distribution of Risk Factors for Waiting List Mortality Among Risk Groups
4975,Risk Prediction Models for 90 Day and 1 Year Post Transplantation Mortality
4980,Clinical Outcomes After Any Cardioversion, Within 30Days, in Patients Assigned to Either Warfarin orApixaban
4986,Clinical Outcomes in Diabetic Patients in the High Risk Cohort of the PARTNER Trial
4990,Resource Use and Cost
4992,Echocardiographic Measurements at 1 Week Post Myocardial Infarction
4995,Clinical Outcomes
4997,TTE and CMR Parameters in HCM Patients
4998,Pearson Correlation Coefficients of Significantly Increased miRNAs and Prognostic Clinical Parameters of HCM
5002,Recommended Frailty Assessment Tools
5007,Baseline Characteristics Stratified by Presence or Absence of Subsequent Adverse Events
5008,Predictors of Death or Ventricular Tachycardia
5009,Comparison of Findings on Cardiac PET Examination Versus Clinical Criteria and Extra Cardiac Findings
5010,Plasma Concentrations of Total Dabigatran After Oral Administration of Dabigatran 110 or DE 150, and Dose Normalized Concentrations
5012,Trough Concentrations of Dabigatran   ng ml mg   Grouped by Outcome Event Occurrence
5014,Surrogate Markers of Right Ventricular Function Among CCMP, NICMP, and ICMP
5015,Clinical Outcomes of All Groups
5017,Multivariate Cox Regression Analyses for All Cause and Cardiovascular Mortality at 5 Years
5018,Performance of the Models for All Cause Mortality at 5 Years
5019,Performance of the Models for Cardiovascular Mortality at 5 Years
5020,Direct Comparison of Performance for All Cause and Cardiovascular Mortality at 5 Years of Models Containing Gal 3 and ST2
5023,Trends in Short Term Mechanical Circulatory Support Outcomes
5024,Management by Indication for Hospital Stay From 2008 to 2011
5027,Genes Associated With LVNC
5030,ABR and ABR in Patients and Controls
5031,Correlation Between ABR and Read Out Parameters of PET CT and MRI
5033,Prediction of Severe AKI by Biomarker Composites
5034,Prediction of AKI  2 Days by Biomarker Composites
5035,Prediction of Transient AKI by Biomarker Composites
5038,Velocity Vector Display Data in Obstructive HCM, NonobHCM, andControlPatients
5039,Maximum Vortex in Obstructive HCM, NonobHCM, andControls
5041,Multivariable Logistic Regression of Risk of In Hospital Major Bleed and 30 Day Mortality
5043,Impact of Radial Access Site on the ORs for 30 Day Mortality Outcomes Stratified According to Mehran Bleeding Score   TFA as Comparator   in a Propensity ScoreMatched Cohort
5045,Main Vortex Features Averaged During Diastole for the 3 Study Populations
5046,Determinants of Relative Vortex Filling Fraction
5048,Medication at Study Entry
5050,Results of Body Composition Analysis, Treadmill Exercise Test, Echocardiography, Holter Electrocardiography and Biomarker Analyses in Chemotherapy Treated Patients and in Therapy Nave Patients
5051,Simple Regression Analyses   With the Respective p Value   With Peak VO2   ml min   Serving as the Dependent Variable in Control Subjects and inPatients WithCRCor CHF
5054,Cardiovascular Adverse Outcomes in Relation to the Extent of LV Trabeculations
5056,AF Outcomes
5060,Overall Mortality or Cardiovascular Events at Follow Up
5061,Univariate and Multivariate Predictors of the Composite Endpoint of Overall Mortality or Cardiovascular Event
5065,Adverse Events Reported and Laboratory Abnormalities of Interest
5068,Unadjusted Comparison of Primary and Secondary Endpoints for the 3 Groups
5069,Propensity Adjusted 2 Staged Group and 3 Group Comparisons for the Primary Composite Endpoint
5073,ACTION RegistryGWTG Processes of Care Metrics: Composite Metric Performance   2011
5074,ACTION RegistryGWTG Processes of Care Metrics: AMI Institutional Performance Measures   2011
5075,ACTION RegistryGWTG Processes of Care Metrics: AMI Institutional Quality Metrics   2011
5079,CathPCI Registry Processes of Care Metrics: PCIAppropriate Use Criteria Metrics   2011
5096,Clinical Presentation and Management of CoronaryObstruction Following TAVI   n  44
5097,Computed Tomography Data, According to the Occurrence of Coronary Obstruction Following TAVI
5098,CT Data From the Case Matched Analysis, According to the Occurrence of CoronaryObstruction Following TAVI
5105,Estimates   95  Confidence Intervals   of Association Between Circulating Leukocyte Derived Microparticles and PlaqueInstability
5107,InVitro Mitochondrial Chain Complex Activities According to Post Operative Atrial Fibrillation Onset
5108,Pre Operative Variables Associated With Post OperativeAtrial Fibrillation Onset
5109,Studies Investigating Effects of Obesity on Ventricular Mass, Dimensions, and Function in Children and Adolescents
5110,Studies Investigating Effects of Obesity on Vascular Structure and Function in Children and Adolescents
5111,Studies Investigating the Effects of Obesity on Autonomic Function in Children and Adolescents
5113,Correlations Between Hs cTnT and Echocardiographic Data in 183 HCM Patients
5115,Cardiovascular Events in 183 Patients With Normal hs cTnT Values and With Abnormal Hs cTnT Values   Univariate Analysis
5116,Multivariate Analysis of All Cardiovascular Events or Cardiac Events
5119,Univariate and Multivariate Predictors of Definite Thromboembolism After Cardioversion for Atrial Fibrillation
5120,Thromboembolic Complications in Patients With No Anticoagulation After Cardioversion of Acute    48 h   Atrial Fibrillation in Previous Studies
5122,Blood Work, Nutrition, and Exercise
5123,Coronary Artery Status   n  203
5124,Vascular Testing in KD and Control Populations
5125,Control Group and KD Patients by Worst Ever Coronary Artery Status
5129,Hemodynamic and Biochemical Profile Before and After LVAD Unloading
5130,Serial Echocardiographic Assessment of the Effects of LVAD Unloading on Myocardial Structure and Systolic Function
5131,Serial Echocardiographic Assessment of the Effects of LVAD Unloading on Left Ventricular Diastolic Function
5132,Key Concepts
5133,Classification of High Sensitivity Cardiac Troponin Assays
5135,Interobserver and Intraobserver Variability and Minimal Detectable Change for EF Measurements by All 6 Techniques
5136,Interobserver and Intraobserver Variability for EDV and ESV Measurements and Minimal Detectable Change by All 6 Techniques
5140,SCD Population Attributable Fractions
5142,Vascular and Biochemical Measures by BMI Categories
5143,Associations of Vascular Measures With Adiposity Measures
5144,Associations of Birth Weight, Catch Up Growth, and Persistent Obesity With Vascular Measures   n   6,919
5145,Agenda for Establishing the Role of Advanced Lipoprotein Analysis in Individualizing Treatment for Preventing Cardiovascular Disease
5147,Cumulative Incidence of Heart Failure or Cardiomyopathy During First 3 Years After Diagnosis by Cancer Therapy
5148,Cumulative Incidence of Heart Failure or Cardiomyopathy During the First 3 Years in Breast Cancer Patients Without Adjuvant Therapy Versus Cancer Free Controls
5151,Cardiac Morphology, Function, and Regional Fibrosis
5153,Relationships With Post Contrast Ventricular T1 Time
5155,Secretion, Biological Effect, and Prognostic Role of Main Inflammatory Markers Related to Atrial Fibrillation
5156,Inflammatory Markers Associated With Subtypes of Atrial Fibrillation
5157,Hemostatic Factors Conferring the Prothrombotic State in Atrial Fibrillation
5158,Comparisons Between the Pathological Processes Underlying Aortic Stenosis and Atherosclerosis
5161,Changes in Laboratory Data After Slow Continuous Ultrafiltration
5163,Sample Size by LBBB Type and Treatment Group Across Years in the Study From Randomization   Year 0   Through Year 3
5165,Summary of Ablation Procedures
5168,Procedural Details and Medications
5169,Angiographic Measures Post PCI
5171,Clinical Events at 30 Day Follow Up
5172,Cardiac Magnetic Resonance Imaging Substudy Results at Days 3 to 5
5173,Sensitivity and Specificity of QGE LMNA  in 311 Consecutive individuals Blinded to Genotype
5175,Impact of Copayment Reductions on Resource Utilization
5176,Impact of Copayment Reductions on Changes in Patient, Insurer, and Combined Pharmacy, Medical, and Total Spending
5179,Long Term Post AMI Outcomes of Patients With Various Levels of Chronic Perceived Stress
5181,Main Findings on LV EAM
5184,Cohort Stratified and Pooled RR and 95  CI of High Carotid IMT According to MetS Groups and Decreasing cMetS Score
5185,Cohort Stratified and Pooled RR and 95  CI of T2DM According to MetS Groups and Decreasing cMetS Score
5188,Multivariate Predictors of In Hospital Stroke or Death
5189,NCDR CAS Risk Score System
5190,Completed and Planned RCTs of PCI Compared With CABG for the Treatment of Unprotected Left Main CAD
5191,Recommendations Pertaining to Unprotected Left Main Intervention in the American College of Cardiology Foundation American Heart Association Society of Cardiovascular Angiography and Intervention 2011 Guidelines for PCI
5193,Cox Proportional Hazards Analyses of Baseline Variables in Relation to Clinical Outcome in Patients With DCM
5195,Definitions of Carotid IMT Ultrasonographic Variables
5197,HRs   95  CI   of Combined Vascular Endpoints per 1 SD Increase for Ultrasonographic Continuous   Log Transformed   Variables
5198,HRs   95  CI   of Coronary and Cerebrovascular Endpoints per 1 SD Increase for Ultrasonographic Continuous   Log Standardized   Variables
5199,Reclassification Statistics for Ultrasonographic Variables as Compared With Classification Based on CC IMTmean Only in Risk Models With Combined, Coronary, or Cerebrovascular Endpoints
5200,Reclassification Statistics Comparing Ultrasonographic Variables and Plaque Information   Presence of at Least 1 Plaque   in Risk Models With Combined Vascular Endpoints
5201,Reclassification Statistics for the Added Value of Ultrasonographic Variables in Risk Models With Combined Endpoints, Carotid Segments, and Carotid Outcomes as Compared With a Reference Model Based on FRFs Only
5202,Risk Reclassification Comparing the Extrapolated 10 Year Risk According to FRFs Before and After Adding ICCAD and IMTmean max in the Prediction of Combined Vascular Events
5204,Correlation Coefficients   Pearson   of Univariate Correlations Between Blood Pressure and Arterial Parameters
5205,Risk Ratio   Cox Regression Analysis   for Total Mortality and Major CV Events According to Blood Pressure and Pulse Wave Velocity
5206,Clinical Features of Genotype Positive Family Members
5210,Key Input Parameters
5211,Base Case Results
5213,Probands With AF Enrolled in the Vanderbilt AF Registry   Cases   and Controls Who Were Resequenced for Variants in Ion Channel and NonIon Channel Genes
5214,An Interaction Between Rare   Ion Channel and NonIon Channel   and Common Genetic Variants to Determine Susceptibility to the Development of Familial AF
5215,Genetic Association Between Common and Rare Variants Unstratified and Stratified by Age of Onset and Age of Unaffected Members of the Families
5216,Genetic Association of Rare Variants Alone   Ignoring Common Variants   Unstratified and Stratified by Age of Onset and Age of Unaffected Members of the Families
5217,Allele Frequencies of Chromosome 4q25 Single Nucleotide Polymorphisms
5218,Genetic Association of Common Variants in the Subset of Data With All Subjects Harboring Rare Variants: Unstratified and Stratified by Age of Onset and Age of Unaffected Members of the Families
5220,Classification of Patients Into AUC Categories During Study Period
5221,Primary Study Outcome: Change in AUC Across Study Period
5222,Secondary Study Endpoint: CCTA Use Across Physician Specialties
5225,Prevalence of Coronary Artery Calcium by CRP Cutpoints Among Waist Circumference Categories
5226,Odds Ratio for Coronary Artery Calcium With High CRP or Framingham Risk Score by BMI Category
5227,Correlation Coefficients for CRP and Framingham Risk Score With Aortic Wall Thickness and Aortic Plaque Burden by BMI Category
5228,C Statistic of CRP for Coronary Artery Calcium, Aortic Wall Thickness, and Aortic Plaque Burden by BMI Category
5231,CMR Protocol
5233,Numbers of Patients in Each Group and Reason for Entry Into Group
5234,Cardiac Catheterization Data
5235,CMR Data
5236,Clinical Outcome Across Cohorts
5237,Linear Measurements in C M
5239,Surgical Data
5240,Pre Operative MRI Parameters   n   118
5241,Changes in MRI Parameters   n   67
5242,Comparison Between Patients With Optimal Versus Suboptimal Outcome
5243,Independent Predictors for Suboptimal Outcome
5244,Clinical Variables of the Population in CMR 1 and CMR 2
5245,Multiple Regression Model for the Prediction of Increment of LGE Extent at CMR 2
5248,Lone AF     Using Data From the National Patient Register and Causes of Death Register, Denmark, 19772008
5250,IRRs of Lone AF in 9,507 Individuals Age  60 Years According to Family History of Lone AF Stratified by Type and Sex of Relative With Lone AF, Denmark, 19772008
5257,Predicted Difference in cIMT for a 1 SD Greater HDL C or HDL P Concentration Among MESA Participants   n   5,541  , 2000 to 2002
5262,Between Group Comparisons From Longitudinal Growth Curve Models
5265,Echocardiographic Risk Factor for RV Failure
5266,Predictive Model for RV Failure, Including Michigan Risk Score and Selected Echocardiographic Variables
5269,Procedural Results
5270,In Hospital Outcome
5271,Clinical Outcomes at 30 Days
5273,Clinical and Cardiac MRI Predictors of Time to Event
5274,Relationship of Scar Morphology Variables With Time to Event
5276,Multifactorial Analysis of Covariance for the Decadic Logarithm of the Plasma Concentration of PENK A
5277,Parameters for the Assessment of Aortic Stenosis
5278,Clinical Data of the Family Members
5279,Follow Up and Treatment of the Family Members
5281,FDG PET Imaging Results
5282,Multiple Linear Regression Analyses in the Whole Study Population Using Glucose Corrected FDG Uptake Parameters
5283,Multiple Linear Regression Analyses in Subjects With and Without Diabetic Disease
5286,MBF and BOLD SI in Stenosed, Remote, and Normal Segments
5287,Performance of BOLD and Perfusion Imaging for Detecting Anatomically Significant CAD Using QCA as the Reference Standard
5288,Performance of BOLD Imaging for Detecting Functionally Significant CAD Using Stress Perfusion CMR as the Reference Standard
5292,Adjusted Risk   HR   of All Cause Mortality and CV Mortality According to Sex in the Overall Population
5295,Comparative Evaluation of Plaque Histological Features With Increased Plaque Thermal Difference
5296,Comparative Evaluation of Plaque Immunohistological Features With Increased Plaque Thermal Difference
5299,Univariate Analysis: All Cause Mortality
5300,Univariate Analysis: Cardiac Mortality
5301,Univariate Analysis: SCD
5306,On Treatment Medications and Risk Factor Control
5309,Biometric and Echocardiographic Parameters of Mice Fed an Alcohol Diet for 2 Months
5311,Subgroup Analysis: Close Agreement Between the iFR and FFR Across Subgroups Analyzed
5314,Angiographic Outcomes at 6 Months
5315,Angiographic Outcomes at 6 Months According to Type of Restenotic Stent
5316,Clinical Outcomes at 6 Months
5318,Quantitative Coronary Angiography
5319,Clinical Outcomes at 12 Months
5320,Hyperemic Stimuli for State of the Art FFR Measurement
5321,Reasons for Nonischemic FFR Despite Apparently Tight Stenosis
5323,Cardiovascular Parameters 10   1   Years Post Transplantation
5324,Counting of Y ChromosomePositive Negative Spindle  to Ovoid Shaped Nuclei in Areas of Increased Fibrosis
5325,Allele Constitution at 2 Loci of the COL3A1 Gene in Donor and Recipient Tissues
5328,Prevalence of Peri Device Flow and Flow Severity On Follow Up TEE
5329,Primary Efficacy Event Rates According to Peri Device Flow and Warfarin Use
5330,Primary Efficacy Event Rates in Patients With and Without Peri Device Flow
5331,Characteristics of 16 Clinical Trials Included in the Meta Analysis
5336,Cox Univariate Analysis of Parameters Significantly Associated With Risk of Overall 3 Year Mortality
5339,Multivariate Logistic Regression Analysis
5342,Correlation Between Symptoms, Stress Test, and CCTA Findings
5343,Predictors of Obstructive Coronary Artery Disease
5344,Correlation Between Abnormal Stress Tests, CCTA, and Invasive Angiography
5348,Malignant Ventricular Arrhythmias and End Stage Heart Failure   N   269
5350,Surrogate Measures of Hibernating Myocardium
5352,Positron Emission Tomography
5353,Single Photon Emission Computed Tomography
5354,Echocardiography
5355,Cardiovascular Magnetic Resonance
5357,Hazard Ratio of Death Associated With the Presence of PCA, Compared With the Normal ABI and PAD Groups
5358,Variables Associated With Relative Hazard Ratio of Dying
5360,PDE5Is for HAPE and HAPH
5362,Enrollment Numbers and Age and Sex Distribution for the Overall Population and for Individual Ethnic Groups
5364,Distribution of RF Among Control Subjects and Patients Divided on the Basis of hsCRP  2 or 2 mg l
5366,Carotid 3. T Magnetic Resonance Imaging and B mode Ultrasound Parameters for Carriers of LCAT Gene Mutations and Controls
5367,Preoperative Predictors of Mortality Associated With Type A Dissection
5368,Intra Operative Predictors of Mortality Associated With Type A Dissection
5369,Independent Pre Operative Risk Factors for Mortality in Patients With Acute Type A Aortic Dissection
5371,Univariable and Adjusted Multivariable Predictors of the Presence of 50  Coronary Stenosis on CCTA Among Patients With a CAC Score of 0   n   4,738
5372,Early     Revascularization Rates Among Patients With and Without CAC Stratified by Stenosis Severity on CCTA
5373,Adverse Events Among Patients From 8 Sites With Composite Endpoint Assessment for MAE During a Median Follow up of 2.1 Years
5374,Hazard Ratios for the Composite Outcome of All Cause Mortality, Nonfatal MI, and Late Revascularization According to Morise Risk Score, CAC Score, and CCTA
5376,Overview of the Intracranial Recanalization Devices
5377,Overview and Comparison of the Largest Studies on CAS in Acute Stroke
5379,Association of Fetuin A With Continuous Measures of Subclinical CVD: The Rancho Bernardo Study
5380,Association of Fetuin A With Categorical Definitions of Subclinical CVD: The Rancho Bernardo Study
5381,Different Truncating Mutations in the MYBPC3 Gene
5382,HR   95  CI   for the Relation of Blood Pressure in Early and Mid Adulthood With All Cause and CVD Mortality   N   18,881  HAHS
5384,HR   95  CI   for the Relation of Blood Pressure in Early and Mid Adulthood With CHD and Stroke Mortality   N   18,881  HAHS
5385,Comparisons of HR   95  CI   for the Relation of Blood Pressure Patterns in Early Adulthood With CHD Mortality: Our Results in Relation to Previously Published Studies
5388,Evaluation of the Performance of Predictive Models After Adding a Urinary Biomarker to the Clinical Model
5389,Summary of Biomarker Combinations in the Model: Significance, AUC Improvement, NRI, and IDI
5390,National Kidney Foundation Classification of CKD Based on GFR
5391,Antiplatelet and Antithrombotic Agents, Recommended Doses, Routes of Elimination, Effect of Renal Failure on Dose, and Potential Strategies to Reverse Their Effect
5392,Safety and Efficacy of Antiplatelet and Antithrombotic Agents Stratified by Category of CKD
5394,miRs Differentially Expressed   p   0.05   on Screening Microarray and Confirmation of Expression by Individual Taqman Real Time PCR With Pre Amplification
5396,VAD Support Alters miR Expression But Does Not Induce a Recovery MiR Profile
5400,Patient Characteristics Associated With a Relevant Improvement or Worsening in SF 36 Scores from Baseline to End of Study
5404,Patients With Detectable MES During the Different Phases of CAS
5405,Predictors of Total MES
5407,Impact of Periprocedural Events on Health Status Scores at 1 Year Follow Up
5409,Quantitative Cardiac Parameters Before and After Hiatal Hernia Repair Stratified by Left Atrial Compression Severity
5410,Respiratory Function Before and After Hiatal Hernia Repair
5411,Relationship Between Exercise Capacity Improvement Following Hiatal Hernia Repair and Changes in Cardiorespiratory Parameters
5414,Ischemic and Safety Outcomes in the 2 Arms
5416,Medication Use in the Study Population at the Time of ICD Implantation, Follow Up, and First Appropriate ICD Intervention
5417,Predictors of Appropriate ICD Intervention
5419,Sensitivity and Specificity of hs cTnT for AMI at Selected Cutoffs, Stratified by Time From Symptom Onset
5420,Evaluation of hs cTnT Use in Clinical Practi Diagnostic Performance of Initial hs cTnT Level for Predicting Any Subsequent hs cTnT Elevation
5422,Specific Activities at Time of Exertional Sudden Death in 361 Young Adults
5423,Cause Specific Findings in 902 Cases of Adjudicated Unanticipated Sudden Cardiac Death Stratified by Age  35 Years and 35 Years in a Cohort Undergoing Active Surveillance
5424,Leading Cause Specific Findings in Adjudicated Unanticipated Sudden Cardiac Death Stratified by Age  35 Years and 35 Years and Exertional Status in a Cohort Undergoing Active Surveillance
5428,Predictors of Death Transplantation and HF Hospitalization
5432,Patient Characteristics, Clinical Outcomes, and Adverse Events   N   92
5434,Pre Operative Vital Clinical Signs and Hemodynamic Data
5435,Pre Operative Laboratory Measurement
5436,Multivariate Analysis of Predictors of 90 Day In Hospital Mortality
5437,Anthropometric and Clinical Parameters of HF Patients and Control Group
5438,Biochemical and Insulin Sensitivity Parameters of HF Patients and Control Group
5439,Tumor Diagnosis Prediction Table
5441,Technical Characteristics
5443,Tumor Myocardium Signal IR
5445,Procedural Variables and In Hospital Outcomes   n   35
5447,Outcomes in Patients With and Without sCVD
5448,Multivariable Adjusted Risk of Stroke or Death, Stroke, and Death in the Study Population
5449,Multivariable Adjusted Risk of Perioperative Stroke During Heart Transplant Hospitalization
5456,Predictors of the Combined Endpoint of Death or Transplantation   n   34
5459,Univariate and Multivariate Analysis
5460,VT PVC Anatomic Localization by Electrocardiography
5461,General Features of the 61 Study Patients With HCM
5462,Individual Patient Features, Dip MBF, and Mutational Screening Results
5463,Logistic Regression Analysis Assessing Predictors of Genotype Positive Status
5465,Quality of Prospective Studies
5466,Quality of Retrospective Studies
5473,Patient Characteristics of Merged Datasets
5475,Test Characteristics at 3 BNP Cutoff Points in Predicting 30 Day MACEs
5476,Incidence of Adverse Cardiac Events Stratified According to the Screening, General Optimal, and Diagnostic BNP Values   n   632
5477,Change in Risk Stratification and its Relationship to Frequency of MACEs Following the Application of an NP Threshold
5480,Univariate and Adjusted MDCT Plaque Predictors of Coronary Events
5486,Univariate Predictors of Mortality
5487,Multivariate Predictors of Mortality
5490,Morphometric Analyses of Carotid Arteries From WT or Platelet Derived Growth Factor Beta Receptor F3 F3 Mice 21 Days After Balloon Injury
5492,Change in MRI Indexes After Surgery   x  s
5493,Change in WMIS by Echocardiography Indexes After Surgery   x  s
5494,Change in SPECT Indices After Surgery   x  s
5495,Results of 6 Min Walking Test   x  s
5496,BNP Value Before and After Surgery   x  s
5498,Relative Coding DNA Length Versus Mutation Frequency
5499,Sequence Conservation and Missense Mutations in ARVC Genes
5500,Sequence Conservation and Missense Mutations in PKP2
5501,Sequence Conservation and Missense Mutations in DSG2
5504,Predictors of HCM Related Adverse Events in Univariate and Multivariate Analysis of MVO and Established Major Primary Prevention Risk Factors for Sudden Death
5511,Echocardiography Measurements
5512,Food and Water Intake by Control and Cav 3 OE Mice
5514,Multiple Logistic Regression Analysis to Determine Predictors of Post CABG Stroke   n   33
5515,Association of Post CABG Stroke With Types of Atherosclerotic Disease
5517,Atherosclerotic Diseases in Atherosclerotic Stroke Patients
5518,Genes Reported in Association With Nonsyndromic DCM
5519,Dilated Cardiomyopathy Gene Ontology
5520,Considerations for Molecular Genetic Testing
5522,Cox Regression Univariate Analysis for All Cause Death
5523,Cox Regression Multivariate Analysis for All Cause Death
5525,Multiple Regression Model: Relation of cfPWV to Risk Factors and Measures of Atherosclerosis Calcification
5528,Within Pair Comparison of Myocardial Perfusion Imaging Data According to CFR Status
5529,Percentage Decrease in Inflammatory Biomarkers per 1 U Increase in CFR
5532,Protocol Required Alert Programming   Clinical Events
5534,Summary of Time to Decision by Alert Event Type
5536,Definition of Compassionate Use Criteria
5538,In Hospital Complications and Death, Overall and Stratified by Compassionate Use
5539,Adjusted Odds Ratios of Risk of In Hospital All Cause Mortality After PCI in the Commonwealth of Massachusetts
5540,Different Prevalence Reports of Myocardial Scarring Fibrosis of the LV in Various Nonischemic Cardiac Pathologies as Defined With Qualitative Analysis of LGE Cardiovascular Magnetic Resonance
5543,Adjusted Associations of 2 Year Change in Functional Performance Measures With Mortality and Mobility Loss Among Participants With PAD
5546,Frequencies of CAS Severity by the Degree of CAD Severity
5547,Multivariate Correlates of Doppler Defined CAS
5553,Hospitalizations During the 12 Month Follow Up Period
5556,Periprocedural   Within 30 Days   Outcomes in CEA and CAS Populations
5557,Periprocedural Stroke or Death Risk: Subgroup Analysis
5559,Hemodynamic and Biochemical Values in All Patients in Cardiogenic Shock
5560,Hemodynamic and Biochemical Values in ICM and NICM Patients in Cardiogenic Shock
5561,Safety and Efficacy of Use of Tandem Heart Percutaneous Ventricular Assist Devi Complication Rate in Our Center
5563,Comparison of Survivors and Nonsurvivors
5564,Univariate Analysis of Pre LVAD Values Between Survivors and Nonsurvivors
5565,Multivariate Analysis of Survivors and Nonsurvivors
5569,Outcome After Coronary Artery Bypass Graft Surgery in the Study Population
5570,Bleeding Complications During and After CABG
5573,Stratified Analyses of Pooled Relative Risk of Atrial Fibrillation for Highest Alcohol Intake Versus Lowest Alcohol Intake
5576,Absence of Tumor Formation Related to Intramyocardial CDC or Cardiosphere Injection
5578,Summary of AEs Occurring Within 24 h Post Dose
5581,Profiles of Medication at Discharge
5582,Clinical Outcomes During Follow Up
5583,Cox Regression Analysis: Predictors of Composite Clinical Outcomes
5585,Effect of Resistin Transgene on Lesion Formation in Collared Rabbit Carotid Arteries
5586,Homology of Mammalian Resistins
5588,Sex Specific Cardiac Outcomes Among 352 HIV Negative Infants Born to HIV Positive Mothers, by Exposure to Antiretroviral Therapy
5589,Cardiac and Anthropomorphic Outcomes Among 352 HIV Negative Infants Born to HIV Positive Mothers, by Exposure to Antiretroviral Therapy
5601,Pharmacokinetic Parameters of Met CCL2 and PA508
5602,Cell Counts of Leukocyte Populations
5603,In Vivo Assessment of Cardiac Function 7 Days After Myocardial Ischemia Reperfusion
5604,Heparin and Protamine Management During CPB for Both HMS I and II Protocols
5607,Clinical Outcomes   p Values From Models Adjusted for Age at Surgery, Surgery Aristotle Score, and Surgeon
5608,Blood Transfusions   p Values From Models Adjusted for Age at Surgery, Surgery Aristotle Score, and Surgeon
5609,Association of Age, Sex, and Race Ethnicity With ABI Category, and Age , Sex , and Race Ethnicity Adjusted Distributions of Risk Factors by ABI Category
5610,Risk of Incident Cardiovascular Events by ABI Level
5612,Catheterization Laboratory Protocol for Assessing LVAD Function
5613,An Example of a Normal Study
5614,Comparison of CO and LVAD Flows in Normal and IVR Patients   LVAD Patients Are in Auto Mode
5615,Subgroup Analysis: Transplant Vasculopathy
5616,Angiotensin II Receptor Expression in Subgroups According to Average Biopsy Score
5618,Duplex Criteria for Classification of Carotid Stenosis
5620,Bilateral Stenosis: Change in Doppler Classification of Contralateral Stenosis After Ipsilateral Stenting
5621,Anthropomorphic, Metabolic, and Vascular Profiles by Metabolic Syndrome Status
5622,Prevalence of Individual Components and Clusters of Components of the Metabolic Syndrome by Age Quartiles
5623,Multiple Regression Models Evaluating the Independent Determinants of Carotid Intima Medial Thickness
5624,Multiple Regression Models Evaluating the Independent Determinants of Carotid Stiffness
5625,Mean Adjusted Values of Carotid IntimaMedia Thickness and Stiffness, Calculated by the Least Mean Squares Method, in the Absence or Presence of the Metabolic Syndrome
5627,Relationship Between Echolucency of Carotid Plaques and Angiographic Complex Coronary Plaques
5628,Summary of Coronary Events During the Follow Up Period in Patients With Stable Coronary Artery Disease
5629,Univariate Cox Proportional Hazards Analysis of Risk Factors for a Coronary Event in Patients With Stable Coronary Artery Disease
5630,Multivariate Cox Proportional Hazards Analysis of Risk Factors for a Coronary Event in Patients With Stable Coronary Artery Disease
5634,Lipid Profile of Patients With Carotid Atherosclerosis
5635,Basic Procedural Data of Percutaneous Device Closure of Ventricular Septal Defects Via the Transcatheter Approach   n   77 Procedures
5636,Adverse Events After Device Closure of Muscular Ventricular Septal Defects   n   75 Patients
5637,Follow Up After Device Closure of Muscular Ventricular Septal Defects: Echocardiographic and Clinical Data
5639,Total Mean Hospital  and Physician Derived Costs of TEE Guided and Conventional Management Strategies for 833 U.S. Patients Over an Eight Week Pericardioversion Period
5640,Mean Costs and Added Costs   for Treatment of Patients  Adverse Events During the Eight Week Study Period in the ACUTE Clinical Trial
5641,ACUTE Trial Analytic Model of Treatment Costs Using ACUTE Trial Data on 833 Patients
5642,ACUTE Trial Analytic Model of Outcomes Costs Using ACUTE Trial Results on 833 Patients
5643,ACUTE Trial Analytic Model Summary
5644,Patient Population
5645,The Extracellular Solutions Used in the Experiments
5647,Risk Factors for Postoperative Stroke   Multivariate Analysis
5650,Dystrophin Average Staining Scores in End Stage Cardiomyopathy and After Mechanical Support Therapy
5654,Retrospective Cohort: In Hospital Outcomes Variables
5655,Retrospective Cohort: Multivariate Predictors of Long Term Mortality
5657,Case Matched: In Hospital Outcomes
5658,Multivariate Predictors of Mortality for AF and No AF Populations
5659,Risk Factor Prevalence for Patients Undergoing Off Pump and On Pump CABG Surgery in New York State, 19972000
5660,Unadjusted and Adjusted Inpatient Mortality for Off Pump and On Pump CABG Surgery in New York State, 19972000
5661,Intraoperative and Postoperative Complications for Patients Undergoing Off Pump and On Pump CABG Surgery in New York State, 19972000
5664,Coronary Flow and the Slope of the Pressure Flow Loops Measured in the LAD and LCX of the HCM Group   n   11   and the LAD of the Control Group   n   9
5666,Prevalence of CGP by Gender
5676,Frequencies of ACD, CD, and HE Per Year as a Function of the Stress Myocardial Perfusion Single Photon Emission Computed Tomographic Result
5677,Rates of Referral to Early Catheterization and Revascularization as a Function of the Extent and Severity of Inducible Ischemia
5678,Observed and Predicted Hard Event Rates in Patients With and Without Revascularization After Stress Myocardial Perfusion Single Photon Emission Computed Tomography
5679,Semi Quantitative Scores
5681,SPECT Results of Those Undergoing Early Revascularization    60 Days   Versus Non Early Revascularization Patients
5682,Unadjusted, Univariable Two Year Cox Cardiac Death or Myocardial Infarction Free Survival by Clinical History and SPECT
5683,Risk Adjusted   Multivariable Cox Model Estimating Cardiac Death or Myocardial Infarction
5684,Annualized Cardiac Death or Nonfatal Myocardial Infarction Rates for SPECT Results in Key Patient Subsets
5685,Post Test Use of Coronary Angiography, PCI, and CABG by SPECT Results
5688,Early Outcome of Thrombolytic Therapy
5689,Outcome of Thrombolytic Therapy According to NYHA Class at Presentation
5690,Complications of Thrombolytic Therapy of Prosthetic Valve Thrombosis in 107 Patients
5691,Univariate Predictors of Any Complication After Thrombolysis
5695,Crude Mortality by Gender
5696,Univariate Predictors of Mortality in Women
5697,Univariate Predictors of Mortality in Men
5698,Multivariate Predictors of Mortality in Women
5699,Multivariate Predictors of Mortality in Men
5700,Multivariate Predictors of Mortality in Women and Men
5701,Study Patients
5702,Phospholipid Composition in BTHS Patients With TAZMutation
5703,Cardiolipin in Heart
5704,Cardiolipin in Skeletal Muscle
5705,Cardiolipin in Platelets
5707,Causes of SD by Gender and Age in Athletes and Non Athletes
5713,Logistic Regression Multivariate Independent Predictors of Spontaneous Conversion to Sinus Rhythm
5714,Myocardial Creatine by Proton Magnetic Resonance Spectroscopy
5716,Angiographic Findings of Patients Assigned to Early Revascularization and Undergoing PCI in the SHOCK Trial by One Year Survival Status   n   82
5717,Angiographic Outcome and One Year Survival After PCI in Patients Assigned to Early Revascularization in the SHOCK Trial   n   82
5718,Multivariate Cox Regression Results for One Year Survival
5722,Multivariate Model for One Year Survival   n   214  : All Angiography Patients
5723,Multivariate Model for One Year Survival   n   73  : Left Ventriculogram Cohort
5725,Coronary Angiography Findings in ACS Patients With Single and Multiple Coronary Plaques
5726,Ultrasonographic Measurements of the Common Carotid Arteries
5727,Significant Independent Predictors of Carotid Positive Remodeling   IMTmean 1.1 mm and IAD  8.0 mm   Identified by Logistic Regression Analysis
5729,Carotid Atherosclerosis and Brachial Artery Endothelial Function Studies
5730,Pearson Correlation Coefficients Between Carotid Artery Ultrasound and Brachial Artery Endothelial Function Variables
5732,Procedure Parameters
5736,Primary and Secondary End Points by Diabetic Status and Treatment Group
5739,Survival Probabilities in HCM Study Population
5740,HCM Related Clinical Markers in Study Patients With Systemic Hypertension
5743,Multivariate Cox Regression Model for Sudden Death in Patients Age 30 or Younger at Holter
5744,The Fetal Maternal Ratios of Sotalol
5748,Clinical Outcome: Correlation by Age
5749,PCR Results: Viral Genome Amplified
5750,Various Data in the Three Groups of Patients With Apical Hypertrophic Cardiomyopathy
5751,Severity and Location of Defects on Thallium SPECT Immediately After Exercise in the Total 598 Segments of 46 Patients
5752,Correlation Coefficients Between cCOT, QTc, RWA, and Defect Score in Total Patients   n   46
5754,Clinical and Echocardiographic Data in Children With Duchenne Muscular Dystrophy
5755,cIBS, cvIBS, and Time Delay Mean Values in Children With Duchenne Muscular Dystrophy and Controls
5756,Results of Haplotype Mapping for 11 Genes and 10 Informative Microsatellite Markers for the Patient and First Degree Family Members
5758,Serial Changes in Number of Patients With Certain Transesophageal Echocardiographic Indexes
5760,Statistical Measures of Performance of Different Risk Stratifiers
5761,Phenotypic and Family Data for Patients With Familial Atrial Fibrillation
5762,Phenotypic Data for Affected Family Members in FAF 1 to 4
5767,Numbers of Events According to FMD
5768,Independent Predictors of a Postoperative Event
5769,Echocardiographic Features of Affected Family Members From Families 1 and 2
5771,Respiratory Chain Complex Activities in Skeletal Muscle Mitochondria and Cardiac   Left Ventricle   Mitochondria From the Index Case   Patient IV 03   of Family 1
5776,Predictors of the Composite Primary End Point
5778,Predicted Upper Limits of LVWT Derived From 250 Healthy Non Athletic Controls
5780,Gender Differences in Cardiac Dimensions for 720 Elite Adolescent Athletes
5781,LVWT and LVMI Within Each Sporting Discipline for 720 Elite Adolescent Athletes
5783,Medications Within 24h
5784,Procedures
5785,Hospital events
5786,Multivariate Logistic Regression Analysis of Predictors of Hospital Death
5788,Task Force Criteria Present in Live Index Patients, Affected and Probable Affected Relatives
5789,Cardiovascular Abnormalities Detected on Evaluation of Relatives
5790,Proposed Modification of Task Force Criteria for the Diagnosis of Familial ARVC
5792,Echocardiographic Determinants of Left Atrial Maximal Volume in the Study Population   Univariate Analysis
5793,Echocardiographic Determinants of Left Atrial Maximal Volume in the Study Population   Multivariate Analysis
5794,Predictors of Death in the Study Population   Cox Univariate Analysis
5795,Predictors of Death in the Study Population   Cox Bivariate Models
5798,Carotid Artery Pressures, Structure, and Stiffness in Normotensive and Hypertensive Subjects
5799,Independent Correlates of Carotid Anatomy and Stiffness
5800,Effects of NTG Treatment on Potency   ED50   and Efficacy   Maximal Relaxations   to Endogenous and Exogenous Nitrovasodilators in Aortas from Untreated and NTG Treated Animals
5801,Lipid Profile of Controls and Hypercholesterolemic   WHHL   Rabbits With and Without NTG Treatment
5802,LV EDV, ESV, SV, CO, EF, Mass and Heart Rate in Volunteers, Patients with HHD, AVD, and DCM
5803,General Data According to Hepatic Lipase Genotype
5804,Cell Composition    of Carotid Endarterectomy Specimens and Hepatic Lipase Genotype
5805,Multiple Regression Models for Factors Potentially Linked to the Number of Macrophages per Area Unit in the Plaque
5806,Logistic Regression Analysis   p Values   for Prediction of Cerebrovascular Events
5807,Putative Mutations in X Linked DCM Patients
5810,Hemodynamics
5811,DNA Repair Enzymes
5813,Predictors of the Development of Ventricular Tachycardia
5814,Multivariate Cox Proportional Hazards Analyses for Cardiac Sudden Death
5822,Prevalence of Any High Grade and Multivessel Coronary Atherosclerosis by Age and Gender
5824,Univariate Correlations With Time to ST Segment Depression of 0.15 mV
5826,Stepwise Multivariate Analysis
5827,Immunologic Data
5834,Prevalence of Structural Cardiovascular Abnormalities in 355 Competitive Athletes With Ventricular Tachyarrhythmias
5835,The Relationship of Clinical Variables to PCI in Patients With and Without an Acute MI
5836,The Relationship of Angiographic and Outcome Variables to PCI in Patients With and Without an Acute MI
5837,The Relationship of PCI Related Complications to In Hospital Mortality
5838,Multivariate Correlates of In Hospital Mortality
5839,Unimputed Multivariate Model
5840,Nomogram to Predict Death
5841,Correlation of Score Based on Nomogram With Predicted Probability of In Hospital Mortality
5843,Clinical Follow Up or Further Evaluation
5845,Plasma Substrates and Insulin, MBF, MVO2, and Myocardial Substrate Uptake
5850,Comparison of Ventricular and Myocardial Function Indices
5852,Device Data   n   97
5853,Relative Risk of Early Recurrence of Atrial Fibrillation for Clinical and Device Variables   Univariate Analysis
5854,Relative Risk of Early Recurrence of Atrial Fibrillation for Clinical and Device Variables   Multivariate Analysis
5857,The Evolution of the 6 min Walked Distance, Peak VO2, QoL and NYHA Class at M6, M9 and M12
5858,Echocardiographic Data and Ejection Fraction for the Sinus Rhythm Group and the Atrial Fibrillation Group at M6, M9 and M12
5859,Hospitalizations for Heart Failure
5861,The Effect of the Presence Versus Absence of Anemia on De Novo Cardiovascular Disease
5863,Patient Profiles
5865,Etiology of Pericardial Effusion   n
5867,PR segment Deviation and ST TWave Changes
5869,Regression Coefficients for Men and Women Separately, Describing the Increase in Log Calcium Score per Unit Increase of the Extracoronary Variables
5870,Age Adjusted Standardized Regression Coefficients for Men and Women Separately, Describing the Increase in Log Calcium Score per Standardized Unit Increase of the Extracoronary Variables
5873,One Year Mortality Rates of the Cohort by Hemoglobin Quartile
5874,IART Clinical Severity Score
5875,Anatomical Diagnoses and Surgical Status of Study Group
5876,Analyses of Acute Procedural Outcomes
5877,Analyses of Chronic Procedural Outcomes
5878,Clinical and Electrocardiographic Data
5879,Electrophysiologic Data
5880,Therapy and Follow Up
5881,Change in Heart Body Weight Ratio   mg g   in Wistar Rats Treated With AB or ADR After 2, 8 and 14 Weeks   n   8
5882,Left Ventricular Function, Expressed as dP dtmax  kPa s  , in Each Group at Different Times   n   6
5883,Anatomic Measurements of Hearts   mm2   From Each Group at the End of the Experiment
5884,Collagen Volume Fraction       of the Left Ventricle in Both the Aortic Banding and Adriamycin Groups   n   8
5885,Changes in the Ratio of CD4  CD8 Before and After Treatment in Both the AB and ADR Groups   n   8
5887,Clinical Features and Plasma ANP and BNP Levels in HCM Patients and Control Subjects
5888,Correlation Between ANP and BNP Levels at Rest and Echocardiographic and Hemodynamic Variables
5889,Clinical Features of HCM Patients With or Without Inducible Myocardial Ischemia
5895,Surgical Procedures
5896,Cardiac Marker Levels   ng ml, mean  SD, range   of All Patients   n   224  , Uncomplicated   n   203   and Complicated   n   21
5897,Cardiac Marker Levels   ng ml, mean  SD, range   of Uncomplicated Patients   n   203   Versus Patients With Individual Complications Such as New MI   n   6  , Cardiogenic Shock   n   16   and Death   n   9
5898,Autosomal Dominant FDC Disease Genes and or Loci
5901,Clinical and Echocardiographic Variables in Patients With Successful Cardioversion of Nonvalvular AF and One Year Follow Up   n   186
5902,Univariate and Multivariate Predictors of One Year Maintenance of SR
5903,Diagnostic Value of Clinical and Echocardiographic Parameters for Assessment of Long Term Maintenance of SR
5904,Near Infrared Spectroscopic Determination of Lipid to Protein Ratio and Histologic Features of Atherosclerotic Plaques
5905,Statistical Analysis of the Temporal Changes for the T1W and T2W Data
5906,Sensitivity and Specificity of the Observers in Age Classifications
5908,Sensitivity, Specificity and Negative Predictive Value of CIMT  0.55 mm and AoIMT  3 mm in the Pilot and Prospective Studies
5909,Logistic Regression Analyses for Predicting Significant Coronary Artery Disease
5911,Univariate Association of Cardiac History and Anginal Status With In Hospital Mortality
5912,Univariate Association of Other Noncoronary Disease Processes With In Hospital Mortality
5913,Univariate Association of Angiographic Factors With In Hospital Mortality
5914,Univariate Association of Procedural Factors With In Hospital Mortality
5915,Multivariate Analysis of Factors Significantly Associated With Mortality: Results in the Training Dataset   n   50,123
5917,Multivariate Analysis of Factors Significantly Associated With Mortality for Patients With Acute Myocardial Infarction Within 24 h: Results in the Training Dataset   n   8,921
5918,Multivariate Analysis of Factors Significantly Associated With Mortality for Patients With No Acute Myocardial Infarction Within 24 h: Results in the Training Dataset  n   41,202
6012,Univariate and Multivariate Predictors of Mortality of 84 Patients With Congestive Heart Failure According to Cardiovascular Death
6266,Results of PCR: Viral Genome Amplified
6269,Medication at the Time of Hospital Discharge After Defibrillator Implant and at Most Recent Follow Up
6273,Complications Associated With the Implantation of the Device   Peri Implant   or During Follow Up
6276,Efficacy of Antitachycardia Pacing
6281,Age specific and age standardised prevalence of spirometry defined COPD in the general Chinese adult population aged 20 years or older in 2015
6282,Multiple adjusted ORs for COPD associated with risk factors in the general Chinese adult population aged 20 years or older in 2015
6284,Categorical outcomes at week 12
6286,Adverse events
6288,Efficacy measures
6289,Adverse events
6291,Most common adverse events
6294,Adverse events and serious adverse events   safety population
6296,Adverse events by week 48 in SWORD 1 and SWORD 2
6298,Clinical management and outcome during the intervention period   day 0 through day 7
6299,Outcomes
6301,Adverse events related or possibly related to the procedure or device
6303,The most commonly used medications among treated adults with hypertension
6306,Summary of response and survival data
6307,Treatment related adverse events
6309,Treatment emergent adverse events   safety population
6313,Virological outcomes at week 48
6314,Adverse events
6317,Virological outcomes at week 48
6318,Adverse events
6320,Association of number of fruit, vegetable, and legume servings per day with cardiovascular outcomes and mortality
6321,Association of raw vegetable intake with cardiovascular disease and mortality
6322,Association of cooked vegetable intake with cardiovascular disease and mortality
6324,Treatment emergent adverse events of any grade reported in at least 10  of patients in either group in the safety population
6327,Treatment related adverse events
6331,Adverse events
6334,Serious Adverse Events Reported During the Two Year Follow Up Period
6335,Reported TEAEs   as treated population
6337,Summary of total adverse events and treatment related adverse events through week 96 in the safety maintenance population
6338,Data quality rating from 0 to 5 stars, maximum percent well certified per 5 year interval and percent well certified across time series by country, 19802016
6339,Global deaths, age standardised death rates per 100000, YLL numbers, and age standardised YLL rates per 100000, and percent change between 2006 and 2016 for both sexes combined for all GBD causes and levels 1 through 4 of the cause hierarchy
6340,Selected causes of global neonatal, childhood, and under 5 deaths in 2016 with mean percent change between 2006 and 2016 for both sexes combined
6341,Global all age DALYs and age standardised DALY rates in 1990, 2006, and 2016 with mean percentage changes between 1990 and 2016, 2006 and 2016, and 1990 and 2016 for all causes
6344,Global prevalence, incidence, and YLDs for 2016, percentage change of YLD counts, and percentage change of age standardised YLD rates between 2006 and 2016 for all causes and nine impairments
6347,Effect of treatment on asthma related quality of life   AQLQ   domains
6348,Adverse events
6350,Patient responses by clinical stage at baseline
6351,Treatment emergent adverse events
6353,Primary composite outcome at 2 years   modified intention to treat analysis
6354,Oncological outcomes at 3 years   Kaplan Meier
6355,Morbidity and side effects at 2 years according to type of surgery   post hoc exploratory analysis
6357,Primary outcomes of venous thromboembolism events during 3 month follow up
6361,Causes for which mortality is amenable to health care mapped to GBD 2015 causes
6362,Correlations between different constructions of the HAQ Index and existing indicators of health care access or quality
6365,Number of cases in which the gold standard outcome was different from the autopsy finding, and reasons for the change
6366,Discrepancies in cause of death against the gold standard
6367,Discrepancies with the gold standard in cause of death or clinically significant findings of the cause of death
6369,Summary of important treatment emergent adverse events reported in all patients
6371,Patient disposition at data cutoff   Aug 8, 2016
6372,Safety and tolerability of nivolumab in the dose escalation phase
6373,Nivolumab efficacy in the dose expansion phase
6374,PD L1 expression on tumour cells and response
6377,Safety overview
6380,Ocular adverse events in study eye by treatment group at week 52
6381,APTC defined events by treatment group
6384,Treatment emergent adverse events reported by 5  of all patients by preferred term   safety set
6386,Global deaths, disability adjusted life years, and age standardised rates attributable to ambient particulate matter pollution in 2015
6387,2015 estimates of mortality and disability adjusted life years attributable to ambient particulate matter pollution and population weighted mean particulate matter pollution in the world s ten most populous countries
6390,Adverse events and serious adverse events   safety population
6395,Adverse events
6397,Zero inflated negative binomial model predicting Tsimane CAC scores
6400,Adverse events and serious adverse events
6405,Effect of screening on help seeking and pharmaceutical use
6407,Cost analysis
6408,Incidence of major adverse events in the standard prophylactic treatment   H    and no prophylactic treatment   H   groups
6411,Adverse events
6414,Summary of adverse events in the safety population
6417,Summary of adverse events
6420,Adverse events regardless of study drug relationship in the safety set    15  of patients in either group
6421,Diagnostic accuracy of TRUS biopsy and MP MRI in the detection of clinically significant prostate cancer using alternative secondary definitions of clinically significant cancer
6423,Adverse events
6424,Serum concentrations by dose group
6426,Adjusted absolute and differences in restricted mean patient survival of HLAi compared with matched cohort listed only, and listed or transplant in months
6427,Inter  and Intraobserver Variability of Myocardial Blush Grades
6430,Solicited and unsolicited adverse reactions
6431,Univariate and Multivariate Predictors of Cumulative Mortality
6432,Glycoprotein specific antibody responses
6436,Safety summary over 24 week treatment period
6437,Long term safety according to incidence in patient months
6439,Treatment variables by group
6440,mRS score frequencies for the 30 day and 180 day timepoints
6441,Serious adverse events by treatment group
6443,Multivariate age adjusted progression free survival and overall survival
6444,Confirmed response in assessable patients
6445,Notable toxic effects defined by Common Toxicity Criteria 3.0 category
6447,Summary results of all 11 day experiments
6449,Objective response by PD L1 status on tumour infiltrating immune cells
6451,Treatment related adverse events
6453,Tumour response   efficacy population
6454,Treatment emergent adverse events and treatment emergent drug related adverse events        safety population
6455,New and total input data by estimation methods
6456,Estimated numbers of deaths by cause and cause specific mortality rate in 2015
6459,Adverse events with a frequency of more than 5  in any treatment group irrespective of causality in the safety analysis population
6461,Adverse event summary
6464,Eradication frequencies with first line and second line therapies
6465,Adverse events with first line therapy
6466,Factors affecting eradication frequencies in first line therapy in the intention to treat population
6469,Adverse events
6476,Adverse events of any cause reported in more than 5  of patients in either of the everolimus treatment groups
6478,Adverse events and serious adverse events
6479,Global deaths   thousands   and mortality rates   per 1000 livebirths   for stillbirths, early neonatal, late neonatal, post neonatal, child, and under 5 age groups, both sexes combined, 19802015
6480,Stillbirth rates, neonatal, post neonatal, child, and under 5 mortality rates   per 1000 livebirths  , total under 5 deaths, and total stillbirths in 2015, annualised rates of change for under 5 mortality for 19902000, 200015, and 19902015, by countries and territories and subnational units in the United Kingdom, both sexes combined
6482,Number of geographies and causes at each hierarchical level for GBD 2015
6483,Distribution of empirical life tables by GBD super region and decade, 19502015
6484,Global life expectancy at birth and at age 50, age standardised death rates, age standardised YLL rate, and total deaths, by sex, 19802015
6485,Global deaths in 2005 and 2015 for all ages and both sexes combined and age standardised death rates, with percentage change between 2005 and 2015 for 249 causes
6486,Selected causes of global child deaths for both sexes combined in 2005 and 2015, with percentage change between 2005 and 2015
6487,Global counterfactual deaths and population attributable fractions for diarrhoea and lower respiratory infection pathogens for 2005 and 2015, with percentage change between 2005 and 2015
6488,Global all age DALYs and age standardised DALY rates in 2005 and 2015 with median percentage change between 2005 and 2015 for all causes
6490,Global incidence of short duration   less than 3 months   sequelae in 2005 and 2015 for all ages and both sexes combined, with percentage change between 2005 and 2015 for level 4 causes with incidence greater than 1 million cases per year
6491,Global prevalence of longer duration   more than 3 months   sequelae in 2005 and 2015 for all ages and both sexes combined, with percentage change between 2005 and 2015 for Level 4 causes with prevalence greater than 1
6492,Global prevalence and YLDs for 2015, percentage change of counts, and percentage change of age standardised rates between 2005 and 2015 for all causes, Level 5 sequelae, and nine impairments
6493,Paired case and control samples tested by quantitative real time PCR, by age stratum and study site
6494,Adjusted attributable fractions for pathogens causing moderate to severe diarrhoea assessed with quantitative molecular diagnostic methods
6498,Progression of the patient s haematological parameters and hepatic and renal biochemistry after suspected poisoning on day 1
6499,Measurements of polonium 210 in post mortem samples and model predictions of organ content and excretion
6500,Cumulative doses to organs or tissues of a reference adult man after ingestion of 44 GBq of polonium 210, assuming 10  absorption to blood
6503,Patency rates of arteriovenous fistulae
6504,Change in vessel diameters before and immediately after administration of anaesthesia
6506,Risk factors for transmission of MERS CoV in all patient contacts and in patients in group A
6509,Serious adverse events associated with procedure, device, or therapy at 12 months  follow up
6513,Treatment emergent adverse events and serious adverse events
6519,Primary and secondary endpoints
6521,Time to event outcomes
6522,Maximal grade toxicity during induction and during high dose treatment, ASCT, and follow up, by treatment group
6524,Total number of post study anticancer treatments received   phase 2
6525,Adverse events   phase 2
6527,Recurrence sites
6528,Adverse events in the per protocol population
6530,Platelet responses
6531,Incidence of adverse events
6533,Primary outcomes and their components for women entered into the treatment phase of the OPPTIMUM study and their babies
6535,Secondary outcomes
6536,Safety outcomes
6538,Grade 3 or worse adverse events
6540,Clinical results
6542,Epidemiology and outcomes by region
6545,Logistic regression for mortality
6546,Comparison of type 1 autoimmune pancreatitis and type 2 autoimmune pancreatitis   IDCP
6548,Objective response rate by PD L1 immune cell score
6549,Treatment related adverse events in the 310 patients who received atezolizumab
6551,Reported adverse events among 16568 patients in the safety population
6552,Primary and secondary outcomes and exacerbations of chronic obstructive pulmonary disease
6554,Overall safety profile
6556,Adverse events in the safety population
6557,Hemodynamic Effects of Immunoadsorption in Patients With Dilated Cardiomyopathy and Effects of Column Eluent   Dilution 1:5   on Ca2 Transient and Systolic Cell Shortening of Isolated, Field Stimulated Rat Cardiomyocytes
6559,Adverse events
6560,Duration of secondary prophylaxis in patients with rheumatic heart disease and global and regional recommendations  40,49
6562,Risk factors associated with tuberculosis
6563,New or repurposed drugs against active tuberculosis in phase 2 and 3 clinical trials
6565,Progression free survival   full analysis set
6566,Treatment related adverse events reported in at least 10  of patients   safety population
6568,Efficacy outcomes
6569,Treatment emergent adverse events by system organ class
6573,Adverse events
6575,Proportion of individuals who had one grade 3 or 4 adverse event
6577,Adverse events
6578,Influential phase 3 trials for localised prostate cancer
6579,Cost of treatments for advanced castration resistant prostate cancer
6581,Paired angiographic analysis
6582,Intravascular ultrasound and optical coherence tomography measurements per lesion
6584,Malaria related perinatal outcomes by treatment group in the intention to treat population   all gravidities
6585,Serious adverse events
6586,Barriers to implementation of tuberculosis preventive therapy and proposed responses
6587,Treatment of M tuberculosis infection as part of a comprehensive approach to improve worldwide tuberculosis control
6591,Global all age DALYs and age standardised DALYs for 306 causes in 2005 and 2013 with percentage change
6593,Life expectancy at birth and HALE at birth for 1990, 2005, and 2013 for both sexes and 188 countries
6595,Primary, secondary, and safety endpoints
6597,Cumulative vaccine efficacy against Helicobacter pylori infection in the per protocol efficacy cohort
6598,Serious adverse events and adverse reactions in the safety cohort
6600,Mean change in bone mineral density between 048 months and 2448 months
6602,Chemotherapy related toxic effects
6603,Radiotherapy related toxic effects
6604,Tumour response rates after treatment
6605,Types of surgery and outcomes
6606,Performance of the ReEBOV rapid diagnostic test versus real time RT PCR   altona
6607,Positive predictive value of the ReEBOV rapid diagnostic test, by positivity score
6608,Interoperator agreement for ReEBOV rapid diagnostic test results
6609,GBD 2013 data representativeness index by cause
6610,GBD 2013 data representativeness index by impairment, calculated as fraction of countries with data for each impairment and period
6611,Global incidence of acute sequelae   for less than 3 months   by cause for incidence greater than 1 million cases per year
6612,Global prevalence of chronic sequelae   for longer than 3 months   by cause for prevalence greater than 1
6613,Prevalence and YLDs, with percentage of total, for anaemia by cause in 1990 and 2013, and prevalence by severity in 2013
6614,Prevalence and YLDs, with percentage of total, for hearing impairment by cause in 1990 and 2013, and prevalence by severity in 2013
6615,Prevalence and YLDs, with percentage of total, for heart failure by cause in 1990 and 2013, and prevalence by severity in 2013
6616,Prevalence and YLDs, with percentage of total, for intellectual disability by cause in 1990 and 2013, and prevalence by severity in 2013
6617,Prevalence and YLDs, with percentage of total, for vision impairment by cause in 1990 and 2013, and prevalence by severity in 2013
6618,Prevalent cases and YLDs for 2013, percentage change, and percentage change of age standardised rates between 1990 and 2013 for all causes
6620,Primary outcome results, unadjusted and adjusted for stone location   lower vs middle vs upper ureter  , stone size   5 mm vs  5 mm  , and centre   random effect
6621,Pain variables and time to stone passage
6624,Reported TEAEs and exposure adjusted incidence rates organised by selected system organ classifications and preferred terms experienced by at least 10  of patients in either treatment group   safety population
6625,Reported TEAEs and exposure adjusted incidence rates organised by severity   safety population
6627,Onset of delivery for randomly assigned women
6628,Maternal outcomes
6629,Neonatal outcomes
6630,Estimates of median time to alleviation of all symptoms by treatment group in the intention to treat infected and intention to treat populations, both overall and for each trial
6631,Meta analyses findings for key on treatment adverse events in the safety population, by treatment received
6633,Overview of primary and secondary endpoints
6634,Complications and adverse events
6636,Effect of vitamin A on endpoints
6637,Serum retinol and retinol binding protein concentrations in infants and mothers after supplementation
6638,In Vivo Data in Control Rats and Rats With Pressure Overload Hypertrophy With or Without Pulmonary Congestion
6639,Adverse events within 3 days
6640,Ex Vivo Data in Control Rats and Rats With Pressure Overload Hypertrophy With or Without Pulmonary Congestion
6641,Left Ventricular Chamber and Myocardial Systolic and Diastolic Function in the Control and Pressure Overload Hypertrophy Groups
6642,Left Ventricular and Myocardial Function in Pressure Overload Hypertrophy With or Without Heart Failure
6643,Changes to DDG2P over time
6644,Total number of single nucleotide variants and insertion deletions flagged by the clinical reporting workflow in all 1133 probands   in the November, 2013 version of DDG2P   compared with the number of variants that would have been flagged in the same probands in the absence of parental data
6645,Likely diagnoses in the first 1133 families
6647,Clinical, Histologic and Immunohistochemical Changes in Patients With DCM, Relatives With LVE and Control Subjects
6648,Echocardiographic Data in Patients With Isolated Ventricular Noncompaction
6652,Proposed Definition of Ischemic Cardiomyopathy legend
6655,Serious adverse events in any treatment group and treatment emergent adverse events occurring in 5  or more of patients
6658,Primary and secondary efficacy endpoints for the overall intention to treat population, and populations with overt cardiovascular disease or at increased risk of cardiovascular disease
6659,Adverse side effects
6661,Efficacy of pentavalent rotavirus vaccine for prevention of rotavirus gastroenteritis and gastroenteritis for complete follow up in Asia
6662,Efficacy of the pentavalent rotavirus vaccine for prevention of severe rotavirus gastroenteritis   Vesikari score 11   in Asia by country and follow up period
6664,Serious adverse events 114 days after any dose of pentavalent rotavirus vaccine or placebo
6668,Overview of adverse events
6671,Adverse events
6674,Targets and target sequences in Zaire Ebola virus   ZEBOV   of small interfering RNAs
6675,Macaques given four   study 1   or seven treatments   study 2   with stable nucleic acid lipid particles containing Zaire Ebola virus   ZEBOV   small interfering RNAs   siRNAs   after ZEBOV challenge
6676,Plasma viral load in rhesus monkeys infected with Zaire Ebola virus   ZEBOV   and given four   study 1   and seven   study 2   postexposure treatments with anti ZEBOV small interfering RNAs   siRNAs
6678,Primary and secondary outcomes
6679,Side effects
6681,Pooled estimates of adjusted hazard ratios   95  CI   for all cause and cardiovascular mortality according to categories of eGFR   listed in the left column   and ACR
6682,Pooled estimates of adjusted hazard ratios   95  CI   for all cause and cardiovascular mortality according to categories of eGFR   listed in the left column   and dipstick urinalysis for proteinuria
6683,Estimated numbers of deaths by cause in 2008
6684,Estimated numbers of deaths by cause in children younger than 5 years by WHO region and country
6685,Base case assumptions for the costs of tests and visits relating to type 2 diabetes, hypertension, and cholesterol
6686,Disutilities assigned to various states relating to type 2 diabetes and its complications
6687,Mean lead time in diagnosis gained by each screening strategy compared with control
6688,Sensitivity of cost per quality adjusted life year to different assumptions about costs of screening, treatment costs, quality weights, disutility associated with amputation, and discount rate, by screening strategy
6689,Sensitivity of cost per quality adjusted life year   QALY   to assumptions about the disutility of type 2 diabetes diagnosed because of symptoms but before the onset of complications
6691,Reduction of systolic blood pressure by category for the 8 week treatment period
6693,Adverse events during the 8 week treatment period
6695,Outcomes in the intention to treat population and in patients aged 65 years or older
6696,Adverse events
6698,Summary of events
6699,Overall survival in RE04 30012 compared with data from Motzer and colleagues,  12   by Memorial Sloan Kettering Cancer Centre risk group
6700,Worst toxic effects reported during treatment, by Common Toxicity Criteria grade
6701,Common Toxicity Criteria grade 3 and 4 toxic effects reported in both treatment groups, by symptom
6703,Pathological responses to treatment
6704,Selected adverse events and LVEF in the safety population
6705,Overview of previous analyses of mortality rates in Darfur
6706,Number of surveys by year and indicators
6707,Regression variables in surveys of mortality rates
6708,Quasi Poisson regression analyses of mortality rates
6711,Proportion of patients with viral RNA concentration less than 50 copies per mL at week 24 in the SWITCHMRK studies
6712,Types and frequencies of clinical and laboratory adverse events during the SWITCHMRK studies
6714,Resistance mutations in HIV from 16 patients with confirmed virological failure and vRNA concentration more than 400 copies per mL by week 24, by treatment group
6718,Nutritional status in focus districts and national comparison areas before and after ACSD in Benin, Ghana, and Mali
6719,Mortality in children younger than 5 years and age specific mortality per 1000 livebirths in focus districts and national comparison areas before and after ACSD in Benin, Ghana, and Mali
6721,Primary and secondary outcomes
6722,Side effects after treatment and participants  reports of their intolerability
6724,Primary and secondary outcomes
6725,Side effects after treatment and participant s reports of their intolerability
6728,Treatment emergent adverse events
6730,Primary outcome and major clinical events of interest
6732,Number of participants with adverse events that were possibly or probably related to the study or study drug
6734,Participants with adverse events after vaccine or placebo
6735,Participants with adverse reactions by dose
6736,Pre existing antibody against 2009 pandemic influenza A H1N1 in participants, by age group
6737,Haemagglutination inhibition antibody response 21 days after first dose of vaccine or placebo
6738,Haemagglutination inhibition antibody response 21 days after second dose of vaccine or placebo
6739,Prevalence of health disorders and mean WHODAS 2.0 scores by site
6740,Between site variation in zero inflation and WHODAS 2.0 score counts as modelled by zero inflated negative binomial regression, before and after adjustment for compositional factors
6741,Relative risks for associations between disability and self reported impairments and chronic disease diagnoses
6742,Population attributable prevalence fractions for 90th centile of WHODAS 2.0 scores and health disorders
6743,Contributions of chronic diseases and disorders to disability according to Global Burden of Disease estimates of years lived with disability     and median population attributable prevalence fractions from 10 66 population based studies
6754,Changes in bodyweight, waist circumference, blood pressure, and prediabetes status from randomisation   after a diet and placebo run in period   to week 20
6755,Changes in bodyweight and blood pressure from screening   including a 2 week diet and placebo run in period   to week 20
6756,Safety data at week 20
6757,Adverse events with an incidence of 10  or more in any treatment group, by system organ class and preferred term
6758,Antipneumococcal IgG antibody responses 1 month after primary vaccination with PHiD CV, DTPa HBV IPV Hib, and human rotavirus vaccine with or without prophylactic administration of paracetamol   ATP immunogenicity cohort
6759,OPA responses 1 month after primary vaccination with PHiD CV, DTPa HBV IPV Hib, and human rotavirus vaccine with or without prophylactic administration of paracetamol   ATP immunogenicity cohort
6760,Antibody responses after primary vaccination with PHiD CV, DTPa HBV IPV Hib, and human rotavirus vaccine with or without prophylactic administration of paracetamol   ATP immunogenicity cohort
6761,Antipneumococcal IgG antibody responses 1 month after booster vaccination with PHiD CV and DTPa HBV IPV Hib with or without prophylactic administration of paracetamol   ATP immunogenicity cohort
6762,OPA responses 1 month after booster vaccination with PHiD CV and DTPa HBV IPV Hib with or without prophylactic administration of paracetamol   ATP immunogenicity cohort
6763,Antibody responses after booster vaccination with PHiD CV and DTPa HBV IPV Hib with or without prophylactic antipyretic administration   ATP immunogenicity cohort
6764,Effect of antipyretic administration on antipneumococcal ELISA antibody responses in 376 children primed at 2, 3, and 4 months of age with 7vCRM and DTPa HBV IPV Hib   ATP cohort for immunogenicity
6766,Episodes of cholera in study participants during 2 years of follow up in per protocol and modified intention to treat populations
6767,Comparison of episodes of cholera according to year of follow up in all age groups in per protocol and modified intention to treat populations
6768,Most common adverse events reported up to 14 days after receipt of either vaccine or placebo dose, by age group
6772,Treatment emergent adverse events in 5  of patients or more
6775,Annual rates of decline in prebronchodilator and postbronchodilator FEV1, FVC, and SVC
6776,Exacerbations in patients with GOLD stage II, III, or IV COPD in the tiotropium and control groups
6777,Exacerbations resulting in hospital admissions in patients with GOLD stage II, III, and IV COPD in tiotropium and control groups
6778,Deaths in patients with GOLD stage II COPD, by analysis population
6781,Drug related toxic effects
6782,Post discontinuation anticancer systemic therapy
6784,Clinical response in patients with measurable lesions
6785,Frequency of grade 3 or 4 adverse events
6787,Serious adverse events and loss to follow up for infants in each study group   data from both sites combined
6788,Reported number of adverse events       at days 1, 2, 3, and 7 after intermittent preventive treatment for infants   all treatments combined from both sites
6789,Primary and secondary outcomes of intermittent preventive treatment for infants at the moderate transmission site
6793,Adverse events for all randomly assigned patients
6796,Adverse events occurring in at least 2  of patients in one of the treatment groups in the salmeterol plus roflumilast   M2 127   and tiotropium plus roflumilast   M2 128   trials
6799,Adverse events occurring in at least 25  of patients in one of the treatment groups
6802,Occurrence of pneumonia as an adverse event or serious adverse event
6803,Adjusted risk factors for pneumonia as an adverse event or serious adverse event
6805,Regression coefficients and development of updated BODE index by variable   i
6806,Assignment of points for the updated BODE index
6807,Prediction of 3 year mortality in patients with chronic obstructive pulmonary disease   COPD   by updated BODE score
6808,Regression coefficients and development of simplified ADO index by variable   i
6809,Assignment of points for the ADO index
6810,Prediction of 3 year mortality in patients with chronic obstructive pulmonary disease   COPD   by ADO score
6812,Incidence of the secondary outcome, its components, and death from any cause by randomisation group
6813,Adverse reactions by randomised group
6815,Presenting manifestations in cases with pandemic H1N1 influenza virus infections in the USA, from April 15 to May 18, 2009
6816,Deaths in pregnant women due to pandemic H1N1 influenza virus infection in the USA, from April 15 to June 16, 2009
6817,Typical MRI variables for three dimensional   isotropic   T2 weighted fast spin echo sequence
6818,Comparison of high field   94 T   MRI, conventional   15 T   MRI, and invasive autopsy
6819,Comparison of diagnoses obtained with MRI at 94 T and 15 T, and invasive autopsy for cases 117
6820,Comparison of image quality scores obtained with MRI at 94 T and 15 T
6821,Tissue contrast with MRI at 15 T and 94 T with three dimensional turbo spin echo sequences
6824,Clinical and laboratory associated adverse events
6825,Drug related clinical adverse events of moderate to severe intensity      recorded in 2  or more patients in either treatment group
6826,Grade 3 or 4 laboratory associated abnormalities
6832,Exposure to community interventions in IMCI and comparison areas   ten catchments each
6835,Adverse events occurring in at least 15  of patients on either interferon gamma 1b or placebo
6836,Immediate cause of death
6838,Tumour necrosis factor  inhibitors previously used to treat rheumatoid arthritis
6841,Adverse events before rescue therapy phase   weeks 116
6842,Adverse events before and after rescue therapy phase   weeks 124
6844,Main outcomes
6845,Clinical outcomes   carer reported patient symptoms
6846,Indicators of Synbiotic safety
6848,Most frequently reported adverse events
6852,Treatment emergent adverse events
6854,Efficacy outcome by treatment group   primary and secondary analyses
6855,Number of patients with drug related adverse events, by treatment group
6856,Number of patients with laboratory drug related adverse events, by treatment group
6857,Summary of safety data, by treatment group
6859,Therapy details and protocol adherence according to study group
6860,Main outcomes according to study group
6861,Function and muscle strength outcomes according to study group
6862,Subsequent location of patients after hospital discharge
6864,Compliance with randomised treatment
6865,Events contributing to disease free survival and numbers of distant relapses, second cancers, and deaths
6866,Frequency of grade 3 or 4 adverse events during chemotherapy
6869,Simultaneous adjustment analysis by multivariables   Cox regression analysis
6870,Frequency of adverse events
6872,Adverse events in the safety population
6875,Reasons for permanent discontinuation of study drugs
6876,Selected adverse effects
6877,Projected and estimated effects of a polypill, comparing estimates from Wald and Law  68   versus that obtained in the Polycap study
6879,Adverse events   intention to treat group
6880,EQ 5D health related quality of life scores
6881,Change in bone mineral density of lumbar spine and femoral neck after 1 year of treatment
6882,Clinicopathological features
6883,Common adverse events
6884,Maximum grade of adverse events per patient
6885,Summary of randomised controlled trials testing the benefit of imatinib in metastatic and unresectable gastrointestinal stromal tumour
6895,Adverse events reported in 3  or more of patients
6898,Safety data to week 36
6900,6 month follow up data according to treatment assignment
6901,Mean costs according to treatment assignment
6904,Multivariate analysis of time to CSME development
6906,Decreases in HbA1c at 52 weeks for each trial intervention by previous treatment
6908,Treatment emergent adverse events reported by more than 5  of participants, by system organ class and preferred term
6910,Adverse events   of more than 10  frequency
6911,Age adjusted risk factors and coronary heart disease mortality by employment grade
6912,Best practice interventions and primordial prevention effects on coronary heart disease mortality
6913,Best practice interventions and primordial prevention effects on excess risk and relative risk of coronary heart disease mortality for low versus high employment grades
6915,MRI and clinical endpoints
6916,Adverse events in the placebo controlled treatment period
6918,Proportion of patients achieving a weight loss of 5 kg or more, or 10 kg or more
6920,Adverse events per treatment group
6921,Treatment emerging adverse events with probable or definite relation to study drug, leading to discontinuation of treatment
6923,Treatment outcomes of patients with MDR tuberculosis
6924,Individualised characteristics of treatment for patients with MDR tuberculosis
6926,Occurrence and management of adverse events
6927,Smoking scenarios
6928,Scenarios of household solid fuel use
6929,Relative risks of smoking and solid fuel use on COPD, lung cancer, and tuberculosis
6930,Severity and lesions defining level on the Early Treatment Diabetic Retinopathy Study scale used for the DIabetic REtinopathy Candesartan Trials   DIRECT   Programme
6934,Adverse events for the safety population
6935,Severity and lesions defining level on the Early Treatment Diabetic Retinopathy Study scale used for the DIabetic REtinopathy Candesartan Trials   DIRECT   Programme
6938,Adverse events in DIabetic REtinopathy Candesartan Trials   DIRECT   Prevent 1 and DIRECT Protect 1
6939,Age standardised death rates for broad cause categories and broad health care categories in Agincourt subdistrict, 19922005
6940,Five most common causes of death by age and time period in Agincourt subdistrict, 19922005
6941,Key elements of primary health care in practiceintegration of HAART and chronic non communicable disease care
6943,Proportions of patients with HIV RNA below 50 copies per mL at week 48
6945,Grade 24 adverse events through week 48
6946,Selected grade 34 laboratory abnormalities in 2  patients through week 48
6948,Participants who had a treatment response or change to within normal range, by genotype
6950,Adverse events
6954,Codes for the clinical activity indicators on the quality and outcomes framework included in the study
6955,Best and worst performing 5  of practices for reported overall achievement and exclusion rates from each deprivation quintile from year 1   200405   to year 3   200607
6959,Hazards Ratios for Primary End Point   Major Cardiovascular Events   in Predefined Strata and Subgroups legend
6960,End Point Results legend
6961,Forward Multivariate Cox Regression Analysis for Secondary End Point   Death   legend
6965,Summary of efficacy measures
6966,Treatment related adverse events of interest and those that occurred in at least 10  of patients in the everolimus group and laboratory abnormalities
6968,Adverse events by treatment group
6972,Adverse events that occurred in 5  or more of patients in either group
6974,Adverse events that occurred with a frequency of at least 5  in patients who received at least one dose of vitespen or had at least one post baseline assessment
6976,Patients included and excluded from analyses, and reasons for exclusion
6978,Incidence of events   efficacy
6979,Safety outcomes
6980,Adverse events during treatment
6981,Selected local and systemic adverse events reported after vaccination
6983,Diarrhoea incidence and severity
6984,Pathogens detected in study participants
6985,Diarrhoea episode duration and mean number of loose stools per episode
6987,Risk ratio of exacerbation affected by GOLD defined COPD severity and treatment with carbocisteine
6989,Comparison of medication related adverse events between carbocisteine and placebo groups   safety population
6992,Adverse effects
6994,Adverse events   all causality   that occurred with a frequency of at least 5 , including at least one grade 3 or worse event, and thromboembolic events
6996,Comparison between remission group and non remission group before and after treatment
6999,Incidence of new onset diabetes
7000,Adverse events in patients who took at least one tablet of study medication
7001,Abnormal laboratory results in patients who took at least one tablet of study medication
7005,Hazard ratios   95  CIs   for events of cardiovascular disease and incident diabetes associated with metabolic syndrome, and individual criteria for metabolic syndrome
7007,Reasons for patient discontinuation from studies
7008,Number of patients in the modified intention to treat population with 75  reduction in psoriasis area and severity index   PASI 75   scores at different timepoints
7009,Summary of all adverse events occurring in 5  or more of the patients in each group
7010,Revised Geneva clinical prediction rule
7012,Diagnostic contribution of tests in each group in the per protocol analysis
7013,Mean cost   US    per patient for both diagnostic strategies in per protocol and intention to diagnose analyses
7014,Proportion of participants reporting at least one severe rotavirus gastroenteritis   RVGE   episodes   per protocol clinical definition   and vaccine efficacy against severe RVGE during three efficacy periods   according to protocol cohorts for the 2 years  efficacy subset
7015,Efficacy of RIX4414 against severe rotavirus gastroenteritis and severe gastroenteritis during the 2 years  efficacy period   ATP cohort for the 2 years  efficacy subset
7016,Proportion of participants reporting severe rotavirus gastroenteritis   RVGE   episodes with a score of 11, 19 and 20 on the Vesikari scale and efficacy of vaccine during the 2 years  efficacy period   according to protocol cohort for efficacy
7019,Adverse events during chemotherapy and postoperative complications
7020,Patients who received surgery and resection
7021,Previous studies of adjuvant chemotherapy in patients with resected liver metastases from colorectal cancer
7023,Clinical response to treatment
7026,Summary of adverse events   safety population
7030,Summary of adverse events
7031,Adverse events with an incidence of 5  or higher
7035,Fasting plasma glucose thresholds above which the prevalence of retinopathy increases
7036,Sensitivity, specificity, and positive and negative predictive value for retinopathy at different fasting plasma glucose cutoffs
7038,Distribution of selected covariates by propensity score deciles, according to type of lung transplantation
7041,Incidence of durable platelet response
7042,Adverse events occurring in at least 10  of patients in either treatment group
7045,Overview of adverse events
7047,Rate of cardiovascular and fatal events
7048,Rate of left ventricular ejection fraction   LVEF   less than lower limits of normal, increased troponin concentration, and hypertension
7051,Electrolyte, acid base changes, and markers of haemolysis and cardiovascular stability
7052,Mean ambulatory systolic and diastolic blood pressure at 24 h post dose on day 10 after administration of anacetrapib or placebo in healthy middle aged and elderly people   N 22
7053,Incidence of adverse events in patients with dyslipidaemia
7054,Incidence of adverse events in ambulatory blood pressure study
7055,Number of laser treatment courses per patient during follow up and cumulative totals by allocated treatment group
7058,Main outcomes for the ophthalmology substudy
7059,Distribution of mediating variables that were assessed before   1997   and after   2003   the intervention in the 24 sentinel areas in Salvador, Brazil
7062,Mean haemoglobin levels by treatment period in per protocol population
7063,Adverse events
7065,Allergen induced FEV1 response during the late phase
7066,Allergen induced FEV1 response during the early phase
7067,Treatment emergent adverse events by system organ class    15  of participants
7069,Zinc and copper status by treatment group, 12 months after supplementation began
7070,Mortality by treatment group
7071,Cause specific mortality by treatment group
7072,Morbidity incidence rates by treatment group
7073,Proportion of children with multiple episodes per year by treatment group
7074,Characteristics of trials and participants
7075,Congestive heart failure events reported in the thiazolidinedione trials
7076,Congestive heart failure and cardiovascular deaths by type of thiazolidinedione
7077,The Comorbid Conditions in Two Groups
7080,Efficacy outcomes during the treatment period
7081,Bleeding events during the treatment period
7082,Adverse events
7087,Relation between self reported passive smoking exposure   using different measures   and COPD in never smokers
7088,Relation between self reported passive smoking exposure and respiratory symptoms in never smokers
7089,Summary of sampling designs by site
7091,Estimated population prevalence of COPD according to GOLD stage
7092,Estimated population prevalence of GOLD stage II or higher COPD, separated by age and smoking exposure
7094,Correlation between VmaxFRC of infants and lung function at ages 11, 16, and 22
7095,Association between infant VmaxFRC and lung function at ages 11, 16, and 22 years
7098,Risk factors for incident diabetes patients with recent myocardial infarction
7100,Risk of diabetes or diabetes and IFG according to consumption of a Mediterranean type diet in patients with recent myocardial infarction
7102,Safety and tolerability of study treatments
7104,Response by treatment, age, and stage
7105,Toxic effects by treatment
7106,Chemotherapy regimens
7108,Grade 3 or 4 adverse events reported
7109,Overall survival log rank comparisons
7110,Is deferred combination   strategy B   non inferior to first line combination   strategy C  ?
7111,RECIST      response and progression free survival
7113,Efficacy results
7114,Adverse effects associated with sequential versus combination treatment over all lines
7115,Adverse effects associated with sequential versus combination treatment first line treatment
7117,Adverse events
7119,Summary of adverse events through to week 48
7121,Adverse events
7126,Investigator reported adverse events
7127,Relative risk of tobacco attributable mortality in snus users compared with current smokers by cause
7128,Uncertainty assumptions and distributions
7131,Predictors of poor outcome on univariate analysis
7132,Admission blood culture results by HIV status and age
7133,Urinary antimicrobial activity on admission and subsequent yield of organisms and response to therapy
7134,Organisms isolated from children who were investigated for failing to respond by HIV status and age
7136,Estimated per dose protective efficacy of mOPV1 and trivalent vaccine against paralysis by type 1 poliovirus in India
7140,Drug related adverse events occurring with an incidence of at least 5  in at least one of the treatment groups
7141,Reasons for discontinuation
7145,AIDS Clinical Trials Group grade 3 or 4 adverse events recorded in 1  of patients in either treatment group up to week 48, regardless of causality
7147,Subgroup analysis
7148,Adverse experiences
7150,Effect of zinc supplementation on overall mortality and by sex and age groups
7151,Effect of zinc supplementation on cause specific mortality
7153,Cumulative risk of failure at day 42
7155,Events by treatment group   ITT
7156,HR   95  CI   for other efficacy endpoints   exemestane vs tamoxifen group
7157,Numbers of toxic effects reported on treatment, by Common Toxicity Criteria grade
7158,Numbers of toxic effects reported on treatment and post treatment, by Common Toxicity Criteria grade
7160,Primary treatment outcomes
7161,Blinded imaging diagnosis compared to final clinical diagnosis
7162,Paired proportion analysis of CT vs MRI for the diagnosis of stroke
7163,Agreement between diagnoses by the four readers
7164,Sensitivity and specificity of blinded imaging diagnosis by time from onset to scan
7166,Site of first disease free survival event   ITT analysis
7167,Adverse events
7168,Cardiac safety
7170,Adherence to treatment strategies during follow up
7173,Summary of primary and secondary outcomes with comparative statistics
7176,Distribution of dose changes in antidiabetic medications
7177,Safety data at 1 year and adverse events in randomised and exposed patients
7178,Characteristics of the six trials included in our meta analysis
7180,Subgroup analyses with both the rate differences and rate ratios
7182,Adverse events that occurred with a frequency of at least 5  greater on sunitinib than on placebo in per protocol population
7184,Primary and secondary outcomes by treatment group
7186,Primary and other outcomes
7187,Adverse events after two doses
7188,Haemagglutinin inhibition antibody response
7189,Virus neutralisation antibody response
7194,Adverse events
7196,Cox model for time to re start HAART in scheduled treatment interruption group   n 243   by predictor
7197,Number       of patients with adverse events during randomised treatment phase
7199,Study outcomes at week 48 based on TLOVR analysis    400 copies mL  , ITT E population
7201,Number       of drug related adverse events   grades 24   and laboratory abnormalities   grades 34   in 2  of patients through 48 weeks
7204,Treatment modalities
7205,Outcomes according to treatment group
7206,Adverse events according to treatment group
7208,Treatment received
7209,New AIDS defining events   number of fatal events
7210,Grade 3 and 4 adverse events and all treatment modifying adverse events
7211,Summary of screened statemented population by consensus ASD diagnoses with ADI R, ADOS G, and ICD 10 symptom count scores
7212,Prevalence estimates
7214,Association between age and CVD risk
7216,Parasitological responses to antimalarial treatment
7217,Relation between gametocytaemia and age
7218,Gametocyte responses to antimalarial treatment
7219,Haemoglobin values after treatment
7220,Adverse effects within the first week after treatment
7221,Ten leading causes of death by income group, 2001
7222,Age distribution of deaths   thousands   among children younger than age 5 years including stillbirths, 2001  28
7223,Ten leading causes of burden of disease   DALYs   by income group, 2001
7224,Burden of disease in low income and middle income countries, high income countries, and worldwide, 2001  7
7225,Neglected low cost opportunities and high cost interventions in south Asia and sub Saharan Africa
7228,Adverse events   all causalities   reported in at least 5  of patients in either treatment group
7230,Results of observational assessment
7231,Clinical examples of overdiagnosis and overtreatment
7233,12 month post supplementation iron status indicators by treatment group   substudy
7234,Mortality by treatment group
7235,Cause specific mortality by treatment group
7236,Morbidity incidence rates by treatment group
7238,M Mode Echocardiographic Variables
7241,Main grade 3 and grade 4 toxic effects
7242,Event free survival probability in retrospective subgroup analyses
7246,Number of children with specific diagnoses at scheduled follow up and illness visits
7247,Deaths during the study
7248,Response rates at the household, questionnaire, and spirometry levels
7249,Percentage of non response by sex, age, and smoking status
7250,Description of the samples in the five sites of the PLATINO study
7251,Prevalence of COPD   post bronchodilator FEV1 FVC, 070   according to some relevant exposures
7252,Prevalence of COPD according to GOLD severity strata
7253,Mean altitude and adjusted COPD prevalence by site
7257,Sites affected in 402 patients for whom information was available   FUA assessment
7262,Age and sex structure of two survey samples and population of Cambodia aged 25 years and older
7263,Number of participants, prevalence of diabetes, number of newly diagnosed cases, and prevalence of impaired glucose tolerance   IGT  , by age   years
7266,Relation between age and blood glucose, BMI, waist hip ratio, and blood pressure
7271,Adverse events occurring in more than 5  of either treatment group or with a difference of at least 3  between treatment groups
7274,Number of medical officer diagnoses in the clinic
7275,Cause of death
7276,Treatment algorithm
7278,Percentage of time on antihypertensive medication by treatment group and study period
7279,Adverse events with an incidence of more than 5  in one treatment group and a difference between treatment groups of more than 1
7282,Chronic obstructive pulmonary disease exacerbations
7283,Adverse events occurring in at least 5  of patients in any treatment group
7285,Recurrences and deaths by treatment group
7286,Serious adverse events by treatment group
7287,Predefined adverse events by treatment group in ABCSG trial 8
7289,Echocardiographic Data
7291,Treadmill Test Responses With Univariate Comparison Between Those Who DIed and Those Who Survived
7292,Previously Published Prognostic Studies Relating to the Decrease of HR After Exercise
7294,Regional Distribution of Electrograms Amplitude, Duration and Amplitude Duration Ratio Values in the Control Group
7299,Left Ventricular Ejection Fraction and Contractile Reserve After 3 Year Follow Up in Survivors and Nonsurvivors
7301,Analysis of Significance and Prognostic Value of End Diastolic Volume, Stroke Volume, Left Ventricular Ejection Fraction and Heart Rate Obtained During Dobutamine Infusion  a
7302,Analysis of Significance and Prognostic Value of Cardiac Output, Stroke Work and End Systolic Volume Obtained During Dobutamine Infusion  a
7303,Analysis of Significance and Prognostic Value of Systolic Blood Pressure, Diastolic Blood Pressure and Mean Arterial Blood Pressure Obtained During Dobutamine Infusion  a
7305,Clinical and Ambulatory Blood Pressure Values for the Three Genotypes
7309,Clinical Features, Alcohol Consumption and Antimyosin Uptake in Alcoholic Patients, With and Without Associated Cardiac Disease, Actively Consuming Alcohol
7310,Doppler Echocardiographic and Antimyosin Studies Before and After Short Term Alcohol Intake for Three Consecutive Days in Six Healthy Volunteers
7312,Peak Emptying Velocities of Left Atrial Appendage and Degree of Spontaneous Echo Contrast Before and After Internal Atrial Defibrillation
7313,U.S. Office Visits With Cholesterol Testing, Cholesterol Counseling and Lipid Lowering Medications: National Ambulatory Medical Care Survey, 1991 and 1992
7314,Likelihood of Cholesterol Services in Adults Without Known Hyperlipidemia: National Ambulatory Medical Care Survey, 1991 and 1992
7315,Likelihood of Cholesterol Services in Adults With Hyperlipidemia: National Ambulatory Medical Care Survey, 1991 and 1992
7317,Atrioventricular Node Properties and HisVentricular Interval Before and After Radiofrequency Modification in Eight Patients
7321,Lipid Profile
7322,Multivariable Cox Regression Analysis of CVEPredictors
7323,Multivariable Linear Regression Analysis of Factors Associated With UrinaryLog 11 dh TxB2
7329,Univariate and Multivariate Cox Regression Analysis of Outcome Predictors
7335,Mortality in Transplant Recipients: Propensity Matched Cohorts
7336,Donor Inotrope or Vasopressor Use During Donor Management
7339,Complications
7340,Acute Conversion Testing
7341,Extracardiac Abnormalities of French and Japanese AV Block
7342,Filtering of Variants Identified in French and Japanese Congenital AV Block Cases
7343,Profiles of the Rare Variations Identified in French and Japanese AV Block Families
7344,Comparison of Clinical Phenotypes of Families With Cx45 p.R75H and ODDD
7345,Complications and Interventions After FontanProcedures
7347,Association Between PedsQL Physical Summary Score and Exercise
7348,Subjects With Paired Functional Health Status Data at Fontan 1, 2, and 3
7349,Cox Model for Predictors of Death or Cardiac Transplantation   TotalN 545;54Events
7350,Rate of Death and Cardiac Transplantation Since Fontan 1 by Center
7351,Types and Frequency of VHD Patients in ENGAGE AF TIMI 48
7353,Efficacy Outcomes by Presence or Absence of Valvular Heart Disease in ENGAGE AF TIMI 48
7354,Safety and Net Clinical Outcomes by Presence or Absence of VHD in ENGAGE AF TIMI 48
7357,Model 4: OxPL apoB and Events
7360,Cardiovascular Event Risk
7364,Univariate and Multivariate Predictor Analysis of Adverse Aorta Related Events in IMH
7371,Risk of CAD in Those With Elevated LDL Cholesterol   190 mg dl   According to FH Mutation Status in CAD Case Control Studies
7372,Prevalence of FH According to Different LDL Cholesterol Thresholds and Mutation Classification Schemes
7374,Cox Regression Analysis for MACE in AMI Patients
7375,Stratified Cox Regression Analysis for MACE According to AMI Type
7376,Cox Regression Analysis for All Cause Mortality, HF Hospitalization, and Recurrent AMI
7380,Clinical Outcomes of Patients With High FFR According to CFR and IMR
7381,Independent Predictors of Patient Oriented Composite Outcomes Among PatientsWith High FFR
7383,Proportions of Patients With High P2Y12 Mediated Platelet Reactivity According to Pre Defined Threshold Values
7391,Reproducibility of Echocardiographic Parameters
7393,IDI and NRI for Outcomes by Adding the Serum CITP:MMP 1 Ratio to a Model Including Covariables
7394,Habitat and Potential Portals of Entry of the Causative Microorganisms of Infective Endocarditis
7395,Identified Portals of Entry in 238 Patients With Infective Endocarditis
7396,Cutaneous Portals of Entry of Infective Endocarditis
7397,Microorganisms in Infective Endocarditis With a Cutaneous Portals of Entry
7398,Oral and Dental Portals of Entry of InfectiveEndocarditis
7399,Microorganisms in Infective Endocarditis With an Oral or Dental Portal of Entry
7400,Gastrointestinal Portals of Entry of InfectiveEndocarditis
7401,Microorganisms in Infective Endocarditis With Gastrointestinal Portals of Entry
7402,Microorganisms in 82 Episodes of Infective Endocarditis With Nonidentified Portals of Entry
7408,Efficacy and Safety of Ticagrelor in Patients With PAD
7409,Limb Vascular Efficacy With Ticagrelor
7410,Overview of Used Risk Scores: Risk Factors Used in ATRIA Risk Score
7411,Overview of Used Risk Scores: Risk Factors Used in CHA2DS2 VASc Risk Score and CHADS2 Risk Score
7414,Ischemic Stroke Event Rates Stratified by the Sum of Points for ATRIA, CHADS2, and CHA2DS2 VASc Risk Scores
7416,Characterization of Plasma and HDL in Mice Lacking apo M
7417,ECM and Adhesion Molecule Genes Overexpressed Following p1158 59 Peptide Treatment
7418,Trial Acronyms
7422,Statistical Analysis of Targeted Metabolites   Between Control Subjects and Stage C Heart Failure Patients in the Discovery Phase Study
7423,Univariable and Multivariable Analyses of the Associations of BNP and Metabolites With Heart Failure Diagnosis
7424,Univariable Analysis on Prognostic Value in HF Patients
7427,Results for Primary and Secondary Endpoints at 9 Months and in Landmark Analysis From 6 Weeks to 9 Months
7429,Post Discharge Antithrombotic Medication Persistence
7430,Patient Characteristics, Procedural Details, and Outcome   N  31
7432,Measures of Study Quality
7433,Summary Estimates for the Outcomes of Interest
7435,Triglycerides, LDL C, and HDL C   mg dl   at InitialRandom Assignment and on Assigned Treatment
7437,Summary of Antiplatelet Therapy Switching
7441,Management and Outcomes of Acute Aortic Dissection
7445,Novel Heterozygous Disease Causing Variants in LDLR and APOB
7456,Clinical Outcome at 30 Days
7457,Clinical Outcome at 1 Year
7460,Angiographic Findings of TCFA
7461,OCT Findings of TCFA
7462,IVUS Findings of TCFA
7464,Incidence Rates of SSS Among Women in ARIC and CHS
7465,Incidence Rates of SSS Among Men in ARIC and CHS
7466,Risk for Major Cardiovascular Events, by Achieved LDL C Concentration
7467,Risk for Major Cardiovascular Events, by Achieved Non HDL C Concentration
7468,Risk for Major Cardiovascular Events, by Achieved ApoB Concentration
7469,Categorization of Deaths in PARTNER A Patients
7470,Categorization of Deaths in PARTNER B Patients
7471,Other Noncardiovascular Deaths
7473,Summary of the Most Important Cytokines, Proteins, and Enzymes Involved in the Atherosclerotic Process
7474,Overview of Diverse Statin Action Through SeveralDifferent Targets
7475,Summary of Key Clinical Trials Examining the Role of Statins in Primary and Secondary Prevention of Cardiovascular Events
7477,Hemodynamic Measurements of Sham, TAC V, andTAC G Mice at End of Study
7480,Adverse Events
7484,Associations Between Plasma Lipid and PCSK9 Levels in Controls, Patients With FH, and Patients With FHBL
7487,Long Term Follow Up of Children With Brugada Syndrome
7488,Genetic Causes of Familial Hypercholesterolemia Phenotypes
7492,Composite Genotypes Used in the Study
7494,ORs for CAD    50  Diameter Stenosis   According to Quartiles of OxPL ApoB in IL 1      and IL 1     Patients, by Age Subgroup
7495,ORs for CAD    50  Diameter Stenosis   According to Quartiles of Lp  a   in IL 1      and IL 1     Patients, by Age Subgroup
7496,Human Subject Groups Evaluated in this Study of SLC35F3 Genetic Variation and BP, byGroup Genotyped for SLC35F3   N  32,063
7497,Effects of SLC35F3 Intronic Variant rs17514104 on the Quantitative BP Traits   SBP and DBP, in mm Hg   in 2 Independent Population Samples: Meta Analysis
7498,SBP DBP Determination by SLC35F3 Tagging Variant rs16842784: Replication by Meta Analysis Across 2 Independent StudyGroups
7499,SLC35F3 Variant rs17514104: Effect on Heritable Autonomic Traits in Twins and Siblings
7507,Periprocedural Variables According to Inoperable Category and STS Score
7508,30 Day Outcomes   Kaplan Meier Analysis   According to Inoperability Category and STS Score
7511,The Interaction of Inoperability Category and STS Score on Mortality
7513,Summary of Patients With Ischemic Events and Unadjusted and Adjusted HRs for the Primary Efficacy Endpoint According to Smoking Status
7520,Change in HR During Cold Stress in Twins and Siblings
7521,HR Traits in Twin Pairs: Heritability and Shared Genetic Determination   Pleiotropy
7522,Effects of CYB561 3 UTR Variant on HR Traits
7523,Effects of CYB561 3 UTR Variant G 1485A on Basal Resting HR in Multiple Independent Groups: Meta Analysis
7525,Clinical Outcomes of CLD Patients Included in the Randomization: TAVR Versus Control
7527,Clinical Outcomes of TAVR Patients
7529,Metrics to Compare Cardiovascular Disease Mortality
7530,Heart Disease Mortality by Asian American Subgroup   2003 to 2010
7531,Cerebrovascular Disease Mortality by Asian American Subgroup   2003 to 2010
7533,Association of NT proBNP With Incident CVD
7534,Association of NT proBNP With Cardiovascular Mortality, Incident Fatal and Nonfatal MI, and Incident Fatal and Nonfatal Stroke
7535,Changes to 10 Year CVD Risk Prediction Statistics After Adding NT proBNP to Existing Risk Prediction Models
7537,Major Bleeding Events During the 2 Year Follow Up Period
7538,Multivariate Predictors of Major Bleeding
7540,Efficacy and Bleeding Endpoints
7541,Vorapaxar Compared With Placebo for Stroke by Qualifying Disease State
7542,Types of Major Late Bleeding   30 Days   After TAVR   n  142
7550,Univariate Covariates of DHEA and DHEA S Levels
7551,Multivariate Correlations of DHEA and DHEA S Levels
7552,Adjusted Hazard Ratios of DHEA and DHEA S as Continuous Variables forCHDand CBD Events
7557,Main Meta Analyses Comparing Clinical Outcomes With Different Types of Drug Eluting Stents and Bare Metal Stents
7558,Current FDA Approved Drug Eluting Stents
7559,Clinical, Echocardiography, and Anthropometric Parameters
7560,Right Heart Catheterization and Laboratory Parameters
7562,Predictors of Adverse Outcome by Cox Proportional Hazards Analysis in All HF Subjects   N  408
7566,Association Between a 1 SD Increase in Apo and Lp  a   Levels After 1 Year of Treatment   and CV Events
7568,Summary of Clinical Trials Using Bone Marrow Mononuclear Cells in Acute Coronary Syndrome Patients With Summary of Trial Findings
7570,Baseline Angiographic and Interventional Data
7571,Outcomes in Study Patients at 12 Months Follow Up
7575,Safety Overview: Treatment Emergent AEs
7578,CCEs of Patients Receiving Qili Qiangxin Capsule Therapy or Placebo
7579,Summary of Adverse Events
7581,Benefit and Safety Outcomes in Multiple Antithrombotic Regimens Within 1 Year in AF Patients After MI PCI
7582,Adjusted Hazard Ratios for Death and Weights for Ischemic and Bleeding Events in the RE LY and ACTIVE Trials
7583,Weighted Net Clinical Benefit of Dabigatran 110 mg bid Compared With Warfarin, Dabigatran 150 mg Compared With Warfarin,and Dabigatran 150 mg bid Compared With Dabigatran 110 mg bid
7584,Effect of Dabigatran 150 mg bid Compared With Dabigatran 110 mg bid on Mortality, Different Composites of Serious Thrombotic and Bleeding Events, and Unweighted Net Clinical Benefit
7585,Reclassification by Directly Measured LDL C in Strata of Friedewald Estimated LDL C and Triglyceride Levels
7593,Results of Univariate and Multivariate Linear Regression Analyses for Log  cTnT   CS Ao
7595,Results of Univariate and Multivariate Logistic Regression Analyses for Parameters That Correlated with Highest Tertile Value of cTnT   CS Ao
7599,Kaplan Meier Outcomes for TV in TV and TVE at 1 Year
7605,Thromboembolic and Bleeding Risk Scores   N   89
7606,LAA Ligation Results   N   89
7608,Procedural Details   N  150
7609,Procedure and Device Related Serious Adverse Events   N  150
7610,Clinical Outcomes
7611,Plasma Concentrations of NO2  in Healthy Controls and Patients With Coronary Artery Disease
7614,Changes in FMD During Forearm Vascular Ischemia and Reperfusion
7616,Category Free Net Reclassification Improvement
7619,Univariate Analysis of Factors Associated With 3 Year Death HTx VAD Requirement
7620,Summary of the Multivariate Analysis Including MELD Models With the Factors Associated With 3 Year Death HTx VAD Requirement
7622,Efficacy and Safety for New Atrial Fibrillation Patients Treated With Dabigatran
7623,Subgroup Analysis on Dabigatran Users With More Than 1 Year Follow Up
7629,Adverse Events at 6 Months
7631,Cardiovascular Events According to Thirds of Gait Speed
7632,Cox Proportional Hazards Analysis for Cardiovascular Events in Patients With ST Segment Elevation Myocardial Infarction
7633,Hazard Ratio by Gait Speed in Multiple Adjusted Models
7634,C Statistics for Cox Proportional Hazards Models to Predict Cardiovascular Events in STEMI Patients
7635,Reclassification by Addition of Gait Speed to Framingham Risk Score, BNP, and Comorbidity Index
7636,Clinical and Operative Data
7637,Doppler Echocardiographic and CT data
7638,Laboratory Data
7639,Determinants of ApoB ApoA I Ratio in Univariable and Multivariable Analysis
7641,Unadjusted and Multivariable Adjusted Associations of LVH
7649,Risk of Any Ischemic Event During 34 Years of Follow Up According to CETP Genotype in the General Population
7651,Analysis of Covariance After Adjustment for Confounding Risk factors
7655,Risk Reclassification Based on Oxidation Markers   OxPL ApoB, Cu OxLDL IgG, and MDA IgM   in Patients Who Experienced a Cardiovascular Disease Endpoint   n   138   and in Those Who Remained Free of Cardiovascular Disease during Follow Up   n   627; 1995 to 2010
7658,In Hospital Outcomes, According to the Occurrence of New Onset LBBB
7660,Late Clinic Outcomes, According to the Presence of New Onset, Persistent LBBB   With No Pacemaker Implantation   at Hospital Discharge
7665,Cause of Death for Patients Undergoing CABG Within 7 Days From Last Intake of Study Drug
7666,Death After CABG With Infection or Bleeding as Direct Cause or Contribution Factor   N   1,261
7669,Performance of Predictive Models for 90 Day Mortality
7670,Mortality Rates by MARKED Risk Score Categories
7674,Clinical Correlates of Gal 3 in 3,353 Participants
7675,Gal 3 Associations With Echocardiographic Traits in 2,425 Participants
7676,Association of Plasma Gal 3 Levels, Incident HF, and Mortality
7677,Performance Metrics of Gal 3 in Risk Prediction Models
7679,Outcomes at 3 Months With Anticoagulant Strategies in the Overall Population of Patients Receiving Aortic Valve Bioprostheses
7682,AUC Values for Various Tests to Identify Any Form of cTOD With or Without Ischemia
7683,Incremental Contribution of Addition of BNP and cTnT to AUC for CV Risk Scores to Identify cTOD
7684,Number of Missed Cases of cTOD When Cutoff Is Applied of BNP  15 pg ml or hs cTnT  5.93 ng l
7686,Outcomes and BB Dose at Randomization
7687,Cardiovascular Adverse Events by BB Use at Randomization
7690,Summary of Treatment Emergent Adverse Events   Safety Population
7692,Risk of First CVD Event or Death for On Treatment Lipids, Apolipoproteins, and Ratios According to Tertiles
7693,Risk of First CVD Event or Death for Standardized On Treatment Lipids, Apolipoproteins, and Ratios
7694,Risk of First CVD Event or Death for Standardized On Treatment Lipids, Apolipoproteins, and Ratios According to Subgroups
7701,Multivariable Cox Proportional Hazards Models for Risk of Death or CVD per 1 SD Increase in log10NGAL and Other Biomarkers
7704,Univariable Analysis for Predictors of 30 Day Mortality Rate
7705,Univariable Analysis for Predictors of 6 Month Mortality Rate
7706,Unadjusted and Adjusted Hazard Ratio for 30 Day Mortality Rate Across Quartiles
7707,Unadjusted and Adjusted Hazard Ratio for 6 Month Mortality Rate Across Quartiles
7708,Clinical Outcomes
7711,Echocardiographic Data According to the Occurrence of Events
7713,Baseline Characteristics of the Patients With and Without Adverse Events
7714,Univariate Cox Regression Analysis for Predictors of Adverse Events After Catheter Ablation
7715,Multivariate Cox Regression Analysis for Predictors of Adverse Events After Catheter Ablation Using the CHADS2 Score
7716,Multivariate Cox Regression Analysis for Predictors of Adverse Events After Catheter Ablation Using the CHA2DS2 VASc Score
7718,Procedural Data and Intraprocedural Complications
7720,Procedural Outcomes
7721,Current Publications
7724,Multivariate Analysis to Predict the Combined Endpoint: Derivation Set
7732,Dual Chamber ICD Recipients With an Indication for Pacemaker Therapy
7733,Single  Versus Dual Chamber ICD Implantation Complication Rates
7734,Odds of Adverse Events Associated With Dual Chamber ICD Implantation
7736,Summary of Coprimary Endpoints
7737,Summary of Adverse Events
7743,Adverse Events at 6 Month Follow Up
7747,Vascular Data
7748,Clinical Correlations
7750,Distribution of the Number of Components of MetS and Events
7751,Stepwise Cox Regression of MetS Components by Outcome
7752,Rates of Death or MI by MetS DM Subset and Treatment Group
7754,Incidence Rates per 1,000 Person Years   Number of Cases   and Adjusted HRs   95  Confidence Intervals   for Major CVD Events by Quartiles of NT proBNP in Men Without Diagnosed CVD and Without Diagnosis of Heart Failure
7755,Incidence Rates per 1,000 Person Years   Number of Cases   and Adjusted HRs   95  Confidence Intervals   for Major CVD Events by Quartiles of NT proBNP in Men With Diagnosed CVD and Without Diagnosis of Heart Failure
7756,Adjusted Standardized HRs for 1 SD Increases in log NT proBNP and log CRP and C Statistics
7757,Reclassification Among Men Who Develop Major CVD Events and Those Who Do Not Experience CVD Events on Follow Up in Men With and Without Pre Existing CVD
7759,Lipid Profiles and ECG Parameters Before and 24 h After rHDL Infusion
7762,Incidence of Adverse Events   Ischemic and Bleeding   According Genotype and Clopidogrel Responsiveness Status
7765,Numbers and Rates   per 100 Person Years   of Treatment Emergent Adverse Events by Treatment Group and Attained LDL C
7771,Pre Operative Risk Factors
7774,Adverse Events
7776,Relationship Between Platelet Reactivity and ASA Responsiveness, Measured 3 Days After CABG Surgery, and 6 Month SVG Patency
7777,Relationship Between Platelet Reactivity and ASA Responsiveness, Measured 6 Months After CABG Surgery, and 6 Month SVG Patency
7778,Multivariate Models of Factors Associated With Odds of SVG Occlusion Versus Patency
7781,Relationship Between Percentage Change in Biochemical Parameters and Change in Percent Atheroma Volume by Treatment Group
7782,Change in Percent Atheroma Burden by Tertile of Change in Biochemical Parameter
7783,Change in Total Atheroma Burden by Tertile of Change in Biochemical Parameter
7786,Cox Proportional Hazards Regression Analysis
7787,Adverse Events in Overall Study Population
7789,Associations Among CHGB Genetic Variants, Isoprostane Excretion, and Plasma CHGB
7792,Predictors of Adverse Maternal Cardiac Events in Women With Heart Disease
7795,Multivariate Analysis for Mortality
7798,Association of Predominant Rhythm on Resting ECG and Exercise Testing With History of IART
7799,Association of Anatomy and Function With History of IART
7800,Multivariable Cox Regression Model for IART   n   464
7806,Determinants of High D Dimer Levels   0.5 g ml   by Logistic Regression Analysis
7820,Dose Equivalence of Beta Blockers Used in Study
7821,Respiratory Function Outcomes
7822,Secondary Outcomes
7823,NT proBNP Changes
7824,Adverse Events After Switching Beta Blockers
7830,Treatment Emergent Adverse Events by Dose Group   Mipomersen Treated 10
7833,Predictors of Major Cardiac Events in HF Patients   Bivariate Cox Proportional Hazard Analysis
7835,Causes and Proportions of Death in 32,569 Patients From 162 Centers
7836,Fatality Rates According to Type of Complication
7838,Mean   SD   LDL C, HDL C, Triglyceride, and Apo Levels in Subjects From Asia and Other Regions
7839,Proportion of Subjects, n      , With Different LDL C and HDL C Categories in Asia and Other Regions
7840,Atherosclerosis and Control Animal Groups and Nature of Interventions
7841,Clinical Criteria for HeFH in Adolescent Patients
7847,Treatment Emergent Adverse Events Occurring in 5  or More of Subjects Through the End of Step 2   33 Weeks Total   in the Pooled Ezetimibe Plus Simvastatin 40 mg Group and Pooled Simvastatin 40 mg Group
7850,In Hospital Complications of Patients With Acute Type B Aortic Dissection
7855,Percentages of Patients After 16 Weeks of Statin Therapy at an LDL C or NonHDL C Target Who Also Reached ApoB  90 mg dl
7856,Percentages of Patients After 16 Weeks of Statin Therapy at ApoB  90 mg dl Who Also Reached LDL C or NonHDL C Targets
7858,Multivariate Predictors of Detectable TnT or Elevated NT proBNP
7860,Cardiac Anatomic Diagnosis of 546 Fontan Cross Sectional Study Subjects
7867,Change in QCA Parameters, Atheroma Volume, and Remodeling Index 18 Months After Statin Therapy in the 2 Groups
7871,Association Between TpP and Clinical Events Through 10 Months
7878,Cox Regression Analysis for Death After AMI
7883,Correlation   r2   Between Changes in Levels of Lipoproteins and Associated Parameters and Markers of Oxidative Stress After Statin Therapy
7884,Sterol Composition of Plant Sterol Ester Supplements Compared With Sterol Composition of Commercially Available Spread
7885,Physiologic Parameters During Cerebral Ischemia
7887,Effect of Sterol Enriched Margarine Consumption on Plasma and Aortic Valve Campesterol Concentrations
7888,Changes in BP, Cardiac Function, and ECG Properties in the rHDL or Control Groups
7890,Primary End Points: MACE During 1 Month Follow Up
7891,Secondary End Points: Bleeding During 1 Month Follow Up
7893,Hazard Ratio for Mortality of Patients in Relation to NT proBNP Dichotomized at Various Cutoff Values
7895,LVEF Over Time Between Study Groups
7896,LV Diameters After rAAV1.SERCA2a Gene Transfer
7901,Associations Between Osteoprotegerin Concentrations and Events During Follow Up in Acute Coronary Syndromes
7902,Isolated Cardiomyocyte Contractility in the Different Groups
7903,Intracellular Calcium Measurements in the Different Groups
7905,Food Profile of Dietary Interventions
7912,Cumulative 1 Year Event Rates
7913,Association Between Stent Type   DES vs. BMS   and 1 Year Adverse Outcomes
7914,One Year Event Rates    for Complex Lesion Types in Patients by Stent Type
7916,Distribution of Blood Lipid Parameters According to the CET Rate
7919,Pearson Correlation Analysis for the Association for Age at MI Onset and Biologic Parameters   n   347
7920,Age and Blood Lipid Parameters Stratified by Gender   n   347
7922,Outcomes
7923,Adverse Events
7925,Association of F11R With Cardiovascular Risk Factors and Medication Use
7926,Correlation Analysis Between Plasma F11R and Other Biomarkers
7927,Univariate Analyses for CAD Score
7928,Multivariate Analysis for CAD Score
7930,Impact of Main Parameters on Plasma proBNP Concentration in a Population With Dyspnea
7932,Electrophysiological Parameters at Idioventricular Rhythm
7933,Electrophysiological Parameters at Paced Cycle Length of 1,000 ms
7935,Pulmonary Artery Diameters
7936,Biventricular Function and Pulmonary Flow Dynamics
7937,Coagulation Screening and Platelet Function Assays
7939,VT VF Onset Pattern by Initiating Sequence and Pacing Mode
7940,Occurrence of Pacing Facilitated S L S VT VF Within the Study Population
7941,Relative Occurrence of Pacing Facilitated S L S Among Patients With Any Spontaneous VT VF
7942,Comparative Features of Pacing Facilitated S L S VT VF
7944,Key Time Measure Interval Data
7945,Key Time Measure Interval Data by Time of Day
7948,Outcomes at 30 Days by CrCl   Full Trial Population
7949,Outcomes at 30 Days by Treatment Assignment
7953,Clinical Outcomes Through 30 Days
7954,Safety Outcomes Through 30 Days
7955,Net Clinical Benefit Through 30 Days
7957,Propensity to Undergo PCI by 30 Days
7959,Efficacy, Safety, and Net Clinical Benefit Outcomes by Treatment Group Among Patients Undergoing PCI by 30 Days
7960,Outcomes by Treatment Group Among Patients Who Underwent PCI While on Treatment With Blinded Study Drug
7961,Changes in Payment and RVUs, 1999 to 2004
7962,Numbers of Echocardiography Services by Site and Type of Service, 1999 and 2004
7963,Impact of Site of Service Shift, 1999 to 2004
7964,Summary of Growth in Volume and Spending, 1999 to 2004
7965,Estimated Count of Beneficiaries Using Echocardiography and Number of Scans Beneficiary Using Echocardiography, 2001 to 2004
7966,Specialty of Physicians Performing Echocardiography
7967,Specialty of Requesting Physicians on Echocardiography Claims, 2004
7969,Average   SD   TC, LDL C, HDL C, and TG Levels by tSNP Allele Carriage
7970,Comparison of tSNP Alleles Between CAD Case and Non CAD Control Patients in the Primary Study Population
7971,Proportion of Common   Frequency   0.01   Haplotypes and Association to CAD for the LD Groups Containing More Than 1 tSNP
7973,Inpatient Medications and Procedures Stratified by BNP Quartile
7975,Patient Outcomes Stratified by BNP Levels
7979,Comparison of MR proADM and NTproBNP Levels in Different Patient Subgroups
7980,Multivariate Cox Proportional Hazards Regression Model of Significant Predictors of Death or Heart Failure
7983,Concentration of Natriuretic Peptides   Medians in pg ml   at Presentation for End Point Groups
7985,Summary of Logistic Regression Tests for Baseline Concentrations and the Incremental Contribution of 90 Min Values, Standard Deviation of All Values, or the Average of All Values
7987,Assay Details
7989,Potency for Stimulation of cGMP Production in Primary Human Vascular Cells Treated With BNP and proBNP
7990,Cross Reactivity of BNP Forms in 3 Assays
7993,Normal Values for Mitral and Pulmonary Vein Doppler Flows by Age
7995,Diastolic Function in All Patients and Left Atrial Volume Index by Diastolic Function Class
7996,Univariate and Multivariate Analyses of Factors Related to CV Death or HF Hospitalization
7997,LV Size, Mass, Systolic, and Diastolic Function by Treatment Allocation
8001,Risk of Incident Atrial Fibrillation, Univariate Model
8002,Risk of Incident Atrial Fibrillation, Multivariate Models
8009,Clinical and Laboratory Parameters in Nonobese and Obese Women
8010,Spearmans Correlation Coefficients Among the Various Parameters Analyzed in 40 Obese Women
8012,Hematological and Biochemical Measurements After Clinical Stabilization in 37 Patients With End Stage Heart Failure and Anemia
8015,Beta Blocker Use at Discharge and BDI Scores During the First Year After MI
8020,Multivariable Cox Proportional Hazard Analyses for the Prediction of Death in Female and Male Patients
8022,Degrees of IGF 1 and IGF 1 Receptor Staining in the Myocardial Biopsy Tissues Obtained From Patients With Impaired and Normal Left Ventricular Function
8027,One Year Mortality in Relation to Performed Revascularization in the Initial 30 Days and Levels of Biomarkers
8032,Relative Risk of Coronary Heart Disease Across Quintiles of Oxidized LDL Among 798 Men From the Health Professional Follow Up Study and 705 Women From the Nurses Health Study
8033,OxLDL in Comparison With Mutually Adjusted ApoB or Total HDL Cholesterol Ratio in Multivariate Models
8034,Diagnostic Accuracy of Multidetector Computed Tomographic Angiography to Detect  50  Coronary Obstruction
8035,Lung Injury Parameters in Sham and CLP Septic Mice
8036,Respiration Parameters and Membrane Potential of Isolated Heart Mitochondria
8040,Univariate and Multivariate Analyses of the Value of Each Variable in Predicting Cardiac Events
8046,Electrocardiographic Parameters
8047,Effect of Sodium Channel Blocker Challenge on QT and QTc
8048,Association Between Previous and New Arrhythmic Events
8049,Association Between QTc  460 ms and New Arrhythmic Events
8051,Disposition of Patients Entered Into the 48 Week Extension Study
8053,Safety and Tolerability Summary for 48 Week Extension Study
8061,Echocardiographic and Hemodynamic Parameters
8063,Patients With Syncopal Episodes During Follow Up
8066,Final Model of a Backward Multiple Stepwise Regression Analysis for Cardiovascular Risk Predictors
8068,Results of Atrial Pacing on Select Indices of Apnea Severity
8070,Age  and Gender Specific Ranges   5th to 95th Percentiles   for Plasma NT proBNP   pg ml   in Normal Patients
8071,Parameters That Significantly Contributed to NT proBNP Values in Multivariate Analysis
8074,NT proBNP Cutpoints, Sensitivity, and Specificity for Age and Gender Strata for the Detection of an Ejection Fraction  40
8078,One Year Outcomes for the Lean, Overweight, and Obese Categories Stratified by Median BNP   452 pg ml
8079,B Type Natriuretic Peptide   BNP   as a Determinant of One Year Mortality in Lean, Overweight, and Obese Patients With Advanced Heart Failure
8086,Unadjusted Mortality and Morbidity Rates According to Physician Volume Quartile
8087,Comparative Analysis of Patients Stratified by Serum Thromboxane Value
8088,Frequency of ISA in BMS and SES
8090,Persistent and Late Acquired ISA
8094,Univariate and Multivariate Predictors of Adverse Outcome
8095,Economic Inputs
8097,Laboratory Data of the Three Groups of Patients
8098,Percentage of Cells Exhibiting NF kB Activation in Patients With Unstable Angina   UA  , Stable Angina   SA  , and Control Subjects
8101,Diagnostic Performance of Different BNP Cutoff Values in the Diagnosis of Acute Heart Failure
8103,Occurrence of the Primary End Point
8105,Unscheduled Cardiac Procedures
8106,Electrocardiographic Parameters
8107,Holter Recording Parameters
8108,Signal Averaged Electrocardiographic Parameters
8110,Plasma Concentration of Insulin, Glucose, and Free Fatty Acids During PET Study
8111,Paired Data Before and After Pulmonary Vasodilator Therapy of the Responder and Nonresponder Groups
8113,Echocardiographic Data
8114,Comparison of Echocardiographic Data
8115,Comparison of Echocardiographic Data
8116,Patients With Primary End PointsApparent Versus Silent
8118,Pairwise Linkage Disequilibrium and r2Between PCSK9Polymorphisms
8119,PCSK9Common Haplotypes and Their Number and Estimated Population Frequencies
8120,Plasma Levels of Lipids and Severity of Coronary Atherosclerosis According to 23,968A G   E670G   Genotypes   N   372
8122,Echocardiographic Variables and BNP according to Patient Outcome
8123,Cox Proportional Hazards Univariate Predictors of Outcome
8129,Predictors of Retroperitoneal Hematoma Formation After Percutaneous Coronary Intervention
8130,Effect of IKrBlock With or Without Pretreated IKsBlock on the QT Interval, APD90, and Transmural Dispersion of Repolarization
8131,Transmural Heterogeneity of IKsand IKrin Feline Left Ventricle
8133,BNP and CRP by Presence of CAD on Catheterization and Troponin I Status on Admission
8134,Six Month Outcomes by Presence or Absence of CAD and Troponin I Status
8135,Six Month Outcomes by Presence or Absence of CAD and Marker Status   Troponin I, BNP, and CRP
8139,Exercise Testing and Gated Imaging Results
8143,Specificity of NTproBNP in Nonischemic Patients
8146,Anticoagulation Values in Different Therapeutic Groups
8147,Number of Events in Each Treatment Group at Follow Up
8148,Ischemic and Hemorrhagic Stroke and Systemic Embolism
8149,Clinical Data
8150,Primary Antibodies
8152,Mortality in the Study Population
8153,Effect of Using Different Cutoff Values for BNP on Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value, and Accuracy in Predicting Death   All Cause Including the Cardiac Death   in Referred and Not Referred Groups
8157,Quantitative Volumetric Analysis of the Stented Segment by Intravascular Ultrasound
8158,Quantitative Coronary Angiography of the Four Prespecified Coronary Segments
8159,Clinical Follow Up of Study Population
8160,Primary End Points According to Diabetes Type
8164,Association Between Biomarkers and Clinical Outcomes
8165,Association Between Biomarkers, Coronary Flow, and Electrocardiographic Abnormalities
8171,Effects of L NAME, MEG Sodium Succinate, and FeTPPS on Endotoxin Induced Myocardial Dysfunction at 16 h After Treatment
8173,New York Heart Association Functional Classes and Hemodynamic Variables
8175,Clinical End Points
8176,Correlations With Preoperative BNP Levels
8178,Results of the Multivariate Analyses: Independent Predictors of Cardiac Survival and of Cardiac EventFree Survival
8179,Independent Predictors of Cardiac Survival in Subgroups of Patients Divided According to Peak Vo 2
8180,Independent Predictors of Cardiac Survival in Subgroups of Patients Divided According to Plasma BNP
8182,Body and Heart Weights of Deoxycorticosterone Acetate Salt Rats Treated With the Peroxisome Proliferator Activated Receptor Alpha Activator, Fenofibrate
8183,Hemodynamics in Deoxycorticosterone Acetate Salt Rats Treated With the Peroxisome Proliferator Activated Receptor Alpha Activator, Fenofibrate
8184,Hemodynamics, Infarct Size, and Heart Weight in BN and BNK Rats
8185,Sensitivity of MDCT in the Detection of Different Coronary Plaques in Evaluable Vessels   58 of 68   and Specificity to Exclude Coronary Lesions
8188,Early   1 Month   and Long Term Evolution of Thrombosis as a Function of the Size
8190,Lifetime Costs and Outcomes for Each Screening Strategy for a Cohort of 1,000 Men
8191,Lifetime Costs and Outcomes for Different Screening Strategies for a Cohort of 1,000 Women
8193,Nonimmunological and Infectious Variables
8194,Immunological Variables
8198,LV Function and LV Mass Among AF and RSR Groups
8199,Main Characteristics of the Patients in the Two Groups and Adverse Events After Discharge
8200,Univariate Cox Analysis Showing the Association Between Various Variables and the Risk of Death or Re Admission During the Six Months of Follow up in the Derivation Study
8202,P Values for Univariate Predictors   p   0.1 on Univariate Analysis   of the Rest and Exercise Plasma Concentrations and of the Increase in Concentrations Between Rest and Exercise for Natriuretic Peptides
8203,Multivariate Analysis: Best Independent Predictors of the Resting Plasma Concentration of Natriuretic Peptides
8204,Multivariate Analysis: Best Independent Predictors of the Exercise Increase in the Plasma Concentration of Natriuretic Peptides
8206,Diastolic Indexes for the Study Population
8207,Univariate and Multivariate Relationships of Clinical and Echocardiographic Indexes to LognB Type Natriuretic Peptide
8210,Cholesterol and Apolipoprotein Levels of Subjects in the Three Groups
8211,In Vivo Hemodynamic Parameters
8212,In Vivo Echocardiographic and Post Mortem Parameters
8213,Collagen Content and Synthesis
8214,Atrial Myocyte Morphometry
8215,Electrocardiographic Changes Before and After Administration of Pilsicainide
8216,Pilsicainide Induced VA in Patients With Brugada Type ECG
8218,Follow Up of Treated Patients With Regard to the Respective Ablation Type: Patients Are Categorized With Respect to Results of Line Validation After the Final Ablation Session
8220,Adverse Events Reported After Treatment With Tecadenoson
8222,Intra  and Inter Observer Variability of Reference Segment
8224,IVUS Findings
8225,Baseline Clinical Characteristics of Patients in the Entire Study Group, and Those With and Without an Adverse Event Analyzed Separately
8226,Post Discharge Medication Use in the Study Group
8229,Type of Surgical Procedure
8230,Procedural Information About the Eight Patients Who Suffered Adverse Ischemic Events
8231,Bleeding Complications and Transfusion Requirements
8232,Body Composition Data, Peripheral and Central Hemodynamic Indexes, and Fasting Biochemical Parameters in Healthy Female Twins
8233,Univariate Correlation Coefficients Between Age Adjusted Augmentation Index and Anthropometric and Direct Measures of Total Body and Central Abdominal Adiposity in Healthy Female Twins   n   684
8234,Independent Determinants of Augmentation Index in Healthy Female Twins: Multiple Regression Analysis   n   681
8235,Epidemiologic Data and Preoperative Hemodynamics
8237,Cardiovascular Mortality and Morbidity
8238,Contribution of Fibrinogen, Creatinine Clearance, and Homocysteine to the Survival Model
8240,Univariate Predictors of Systolic Versus Non Systolic Dysfunction
8241,Logistic Regression in Attempt to Differentiate Systolic From Diastolic Heart Failure
8242,Required Programming at Randomization
8244,Medications Used in the Efficacy Cohort
8245,AT AF Burden and Frequency in the Efficacy Cohort
8246,Protocol Similarities and Differences Among the Analyzed Clinical Trials
8247,Qualitative and Quantitative Coronary Angiographic Analysis
8248,Follow Up Quantitative Coronary Angiographic Analysis
8251,Proportion of Patients Experiencing Cardiac Events Before and After AIDS Diagnosis
8252,Potential Predictors of Adverse Cardiac Outcomes and Mortality byUnivariate Analysis
8253,Multiple Regression Analysis of Predictors of Mortality and Cardiac Outcomes
8258,Procedural Outcomes and In Hospital Events
8260,Neurohumoral and Hemodynamic Measurements Immediately After Myocardial Infarction
8261,Patient Ethnicity and ACE Genotype
8262,Results of a Cox Proportional Hazards Model Analysis of Factors Predictive of Death as an End Point for the MI Cohort
8264,Fibrinolytic Regimen
8265,Efficacy According to the prosthetic Value Type
8266,LV Weight, Plasma Aldosterone Levels, Media Cross Sectional Area of Arterioles, Results of Gene Expression Experiments, and Immunostaining to Laminin in the LV Tissue of the Five Experimental Groups
8268,Event Rate in the Study Population
8269,Event Rate for Combined Factors
8270,Univariate and Multivariate Logistic Analysis of Outcome Determinants
8273,Correlations   R value   Among OxLDL Autoantibodies and LDL IC
8277,Univariate and Multivariable AssociationsDeath MI 6 Months
8280,Examining the Impact of Time to ECG and Time to cTnT on Their Prognostic Significance
8283,Quantitative Coronary Analysis by Core Laboratory
8284,Volumetric Intravascular Ultrasound Measurements by Core Laboratory
8285,Individual 9 Month Outcome in 16 Patients Treated With Sirolimus Eluting Stent for ISR
8287,End Points at 30, 60 min, 24 h, and 30 days
8288,Most Frequent Concomitant Medications
8293,Distribution of Conventional Risk Factors by Causes of Death and Genotype
8294,Extent of Coronary Narrowing and Atherosclerotic Lesion Areas   Mean  SD   in the Most Affected Artery Among Men With SCD and Men Who Died From Other Causes
8295,Alpha2B Adrenoceptor Genotype Frequencies Among Men Who Died of Cardiac Diseases or Other Causes and the Corresponding Odds Ratios
8297,Patients With Syncope Documented by Implantable Loop Recorder
8298,Mechanism of Syncope, as Detected by Implantable Loop Recorder, in Patients and Control Subjects With Adenosine Sensitive Syncope   Both Tilt Negative and B4 Positive
8300,Risk of Cardiac Events Through Six Months Stratified by Quartile of Elevated BNP
8301,Effect of Invasive Versus Conservative Management on Outcomes at Six months Stratified by BNP Level
8303,Doppler and Echocardiographic Findings According to Final Diagnosis
8304,Value of Various BNP Cutoff Values, LVEF  0.45, and Doppler Mitral Pattern to Diagnose Acute CHF
8307,Fatal Outcomes in 10 Patients
8310,Changes in Quality of Life   Assessed by the MLHFQ  , Sitting SBP, and HR in Patients Not Treated With Angiotensin Converting Enzyme Inhibitors
8311,Permanent Study Treatment Discontinuations
8313,Multivariate Determinants of Myocardial Flow Variables
8314,Adverse Events in Randomized Atms
8316,Procedural Details
8317,Cardiac Events at 30 and 180 Days
8319,Logistic Regression   Univariate   for Death MI and Composite End Point Stratified According to CK Elevation and Troponin Status
8325,The Relation Between the Level of NT proBNP and Diagnosis
8326,Cox Regression Analysis
8331,Included SCN5AMutations
8333,ECG Before and After Class I Antiarrhythmic Drug Challenge
8336,MMP 2, MMP 3 and MMP 12 Genotypes and Alleles
8337,Matrix Metalloproteinase 9 Alleles
8338,Multivariate Analysis
8342,Target Vessel Revascularization Rates in the Different Trials
8343,Clinical and Angiographic Six Month Follow Up
8345,Procedural and Angiographic Variables
8346,Intravascular Ultrasound Findings
8347,Correlation Between Neointimal Regrowth and Calculated Dose
8350,Mortality Rates for Study Patients at the Different Periods of Follow Up
8351,Estimated Mortality and Absolute Benefit of Streptokinase Treatment According to Extent of Infarct
8352,Expression Levels of IL6, IL6R and gp130 in CTRL Biopsies, All Chambers of Donor Hearts and RV of FH
8358,Concomitant Medications During Initial Study Drug Therapy   Number and Percent of Subjects
8359,Healthcare Utilization and Mortality
8360,Selected Cardiovascular Adverse Events During the First 24 h of Dosing   Number and Percent of Subjects
8363,Endothelin 1 Ligand and Receptor Protein Expression in Normal Hearts and Syngeneic and Allogeneic Grafts 5 Days After Transplantation
8364,Effect of Bosentan   Ro 47 0203   on Endothelin 2 Ligand and Receptor Protein Expression in Cardiac Allografts 60 Days After Transplantation
8365,Analysis of Vessel Segments
8367,Angiographic Results   Includes Patients Who Received Study Drug
8368,Safety and Clinical Events Through 30 Days   All Randomized Patients
8369,Echocardiographic, Exercise and Clinical Variables in All, Group A and Group B
8370,Global Time Intervals in All, Group A and Group B
8371,Regional Time Intervals in All, Group A, and Group B
8373,Serial Changes in Lumen Dimensions
8374,Cardiac Hemodynamics at 48 h After MI or Sham Operation legend
8375,Effects of Tezosentan on Heart Weights After MI or Sham Operation legend
8381,In Hospital Clinical Outcome legend
8382,Clinical Outcome at Six Months legend
8386,Clinical and Angiographic Outcomes legend
8394,Angiographic Follow Up   Six Months   legend legend
8396,Long Term Clinical Follow Up legend legend
8397,Clinical Data legend
8400,Median   Interquartile Range   Serum CRP Levels   mg l   in 57 Subjects Before, During and 14 Days After 31 Days of Treatment With ASA or Placebo legend legend
8401,Median   Interquartile Range   Serum Tx Levels in 57 Subjects Before, During and 14 Days After 31 Days of Treatment With ASA or Placebo legend legend
8404,Body Composition of 120 Consecutive Patients With CHF as Assessed by Dual Energy X ray Absorptiometry legend legend
8405,Clinical Predictors of Peak Vo 2in ml min kg, peak Vo 2in ml min and VE VCo 2Slope in a Population of 120 Patients With CHF   Univariate Analysis   legend
8406,Predictors of Peak Vo 2  ml min kg   and Absolute Vo 2  ml min   in a Population of 120 Patients With CHF   Multivariate Analyses   legend
8408,Comparison of Exercise Performance 8 and 12 Weeks After LVAD Implantation in the Same Patients   n   10   legend
8409,Exercise Performance 12 Weeks After Left Ventricular Assist Device Implantation   n   15   legend legend
8410,Sequential Analysis of Exercise Performance in Nine Patients at 12 Weeks After Implantation and Then at 12 Weeks and One Year After HTx legend legend
8413,All Variables That Were Significantly Different Between the Genotype Groups legend
8414,Relative Risk for an Acute Coronary Event: Results of Multivariate Cox Regression Models legend legend
8415,Prevalence of Treatment for Hypertension and the Level of Blood Pressure in the 2B AR Genotypes legend
8418,Population Description legend legend
8419,Gender and Age Comparisons legend legend
8420,Linear Multiple Regression Analysis of Pulse Pressure as Dependent Variable legend
8421,Arterial and Cardiac Variables legend
8423,Results of the Two Way Repeated Measures Analysis of Variance legend
8425,Changes in Doppler Flow Velocities and Coronary Flow Reserve in 10 Patients With Late Percutaneous Transluminal Coronary Angioplasty legend
8426,Comparison of Clinical, Instrumental and Therapeutic Data in Group A   Increased Videointensity   and in Group B   Unchanged Videointensity   legend
8428,Subdivision of 10 Patients in Whom Doppler Flow Velocities and Reserve Were Computed Into Group A   Increased Videointensity   and Group B   Unchanged Videointensity   legend
8429,Relationship Between Geographical Miss and Edge Restenosis in Irradiated   192Ir   and Placebo Groups legend
8430,Quantitative Angiographic Edge Analysis legend
8432,Univariate Analysis of Variables legend
8433,Multivariate Analysis Using All Significant Variables With BNP Analyzed Last for All 250 Cases and for Cases Where Patients Do Not Present With a History of CHF legend
8434,Exercise ECG Parameters in Substudy B legend
8435,Comparison of Medical History Data Between Group A and Group B legend
8436,Comparison of Surgical History Data Between Group A and Group B legend
8437,Comparison of Echocardiographic Variables Between Group A and Group B legend legend
8438,Comparison in the Treatment of AVR Obstruction Between Group A and Group B legend
8439,Accuracy of TTE and TEE in Diagnosing the Pathologic Mechanism of Mechanical AVR Obstruction legend
8440,Accuracy of TTE and TEE in Diagnosing the Pathologic Mechanism of Bioprosthetic AVR Obstruction legend
8441,Clinical, Hemodynamic, Therapeutic and Follow Up Data According to Inducibility of Ventricular Arrhythmias After Coronary Artery Revascularization legend
8442,Clinical, Hemodynamic, Therapeutic and Follow Up Data According to the Presence of Recurrent Arrhythmic Events During Follow up legend
8443,Changes in Plasma Lipids and Lipoproteins legend
8444,Changes in the Concentration of LDL derived TBARS, Diameter of LDL Particles and the Prevalence of LDL Subclass Patterns legend legend
8445,Changes in Plasma Lipids and Lipoproteins According to Triglyceride Increase legend
8446,Changes in the Concentration of LDL derived TBARS, Diameter of LDL Particles and the Prevalence of LDL Subclass Patterns According to Triglyceride Increase legend legend
8449,Prevalence and Type of Perfusion Abnormalities Before and After EECP Treatment legend
8450,Hemodynamics and Collateral Vessels legend legend
8451,Plasma Levels of ANP and BNP Before and After EECP Treatment legend legend
8453,Effects of Hormone Therapy on Hormone and Lipid Values legend
8454,Effects of Hormone Therapy on Markers of Inflammation and MMP 9 Expression in Serum legend legend
8456,Location of the Relocated MLD legend
8457,QCA Data From the Four Predefined Segments legend
8463,Clinical Findings in Eight Patients with Repetitive Atrial Tachycardia legend
8464,Relationship Between Paced Atrial Cycle Length and the Presence of Atrial Tachycardia
8465,Results of Computer Assisted Histomorphometric Analysis of Thick Sections from Arteries of Pigs in Control and Radiation Treated Groups in Arteries With Injury legend legend
8466,Parameters of Dissection and Thrombus After PTCA With and Without Irradiation legend legend
8468,In Hospital Clinical Course legend
8469,Cardiac Complications During Long Term Follow up legend
8470,Independent Predictors of Long Term Event Free Survival legend
8471,Cardiac Function of the Survivors at Follow up legend legend
8477,Assessment of Change in Heart Failure Status
8481,Dose Related Changes in Neurohormone Levels Over 12 Weeks legend
8484,Vitamin B12 and Folate Determination of the Study Groups legend
8485,Vitamin B12 and Folate Determination of the Posttransplant Subgroups legend
8486,Treatment Subgroups in the BERT and MVP Studies
8488,Evolution of Dissections in Both the BERT and MVP Trials
8489,Patients With Dissections Following Intracoronary Beta Radiation legend
8490,Rate of Late Total Occlusion by Studies, Emitters, and Doses
8493,Autonomic Cardiovascular Tests legend
8494,Hormonal Metabolic Parameters During Insulin Glucose Infusion   Test B   legend
8495,Adrenaline and Noradrenaline Levels   nmol l   During Saline   Test A   and Insulin Glucose   Test B   Infusions
8496,Angioscintigraphic Parameters During Saline   Test A   and Insulin Glucose   Test B   Infusions legend
8497,Two Way Repeated Measures ANOVA legend
8498,Statistical Evaluation of Prolactin and Cortisol Response to the Head Up Tilt Test With Clomipramine in the Three Groups of Subjects legend legend
8502,Effect of Aortic Constriction on Steady State Hemodynamic Parameters legend
8503,Effect of Calcium Infusion on Steady State Hemodynamic Parameters legend
8505,Number of Patients Randomized to Each Drug Group Compared With Final Dose Achieved legend
8506,Acute Effects of Moxonidine on Plasma Norepinephrine Concentration
8507,Clinical Outcomes Worsening Heart Failure and Death legend
8509,Laboratory Variables Stratified by Fasting Blood Glucose legend legend
8510,Relationship Between Blood Glucose and PDT Arranged in Quartiles legend
8511,Effect of Spermine NO on Histomorphometric Parameters legend legend
8512,Platelet Aggregation Responses legend
8514,Comparison of Hemodynamics, Neurohumoral Factors and Immune Factors Before Treatment in 23 CHF Patients Divided Into Two Groups: Candesartan Cilexetil Treatment or Placebo legend
8515,Hemodynamic Data and Serum Lipids legend
8517,Predictors of Drug Infusion Rate legend
8519,Primary End Point legend legend
8520,Comparative Clinical and Coronary Arteriographic Findings in the Study Patients With   Group A   and Without   Group B   Exercise Induced U Wave Changes legend
8521,Comparison of the Ischemic Status During Balloon Inflation in the Study Patients With   Group A   and Without   Group B   Exercise Induced U Wave Changes legend
8526,Influence of ACE Genotypes on Progression or Regression of Coronary Lesions and Clinical events legend
8532,Hemodynamic, Angiographic and Plasma Norepinephrine Measurements Obtained Before Randomization and After Three Months of Follow Up legend legend
8533,Hemodynamic, Angiographic and Plasma Norepinephrine Measurements Obtained Before Initiating Therapy and After Three Months of Therapy legend legend
8534,The Change Between Pretreatment and Post treatment Hemodynamic, Angiographic and Plasma Norepinephrine Levels in Control Dogs and Bosentan Treated Dogs legend legend
8535,Histomorphometric Findings legend
8536,Average Values of Mean Blood Pressure and Heart Rate  SE During 80 HUT legend
8540,Wall Motion Score With Incremental Dose Dobutamine   040 microgram kg min   Echocardiography   n   14   legend
8542,Summary of High Energy Phosphate Content legend legend
8543,Summary of Data From the Beta Adrenergic Receptor Study legend
8545,Results of the ECG Substudy: Incidence of Complete, Partial and No ST Resolution at 90 min and 180 min in Patients Allocated to Lepirudin or Heparin Treatment
8546,Clinical Events During the 30 Day Study Period and One Year Mortality legend
8547,Safety Variables Within 30 Days After Treatment
8548,Clinical Features of the Two Groups of Patients legend
8549,Anatomic and Hemodynamic Features of the Two Groups of Patients legend
8551,Incidence of Postoperative Atrial Fibrillation
8552,Impact of Beta blocker Therapy in Placebo and Sotalol Groups legend
8554,Pulmonary Vascular Histopathology
8558,Summary of Results Using Snare Assisted Technique on Moderate to Large PDAs legend
8559,Complete Occlusion by PDA Types legend
8560,Comparison of Study Group to Small PDA Group
8562,Summary of the Published Series of Surgical Treatment of Brachiocephalic and Subclavian Obstruction legend
8563,Summary of the Published Series of Percutaneous Stenting of Brachiocephalic and Subclavian Obstruction
8566,Causes of Death Among 432 Octogenarians and Nonagenarians Who Had a Pacemaker Implanted Between 1980 and 1992
8568,Independent Predictors of Poor Survival From Total and Cardiovascular Related Deaths After Pacemaker Implantation in Octogenarians and Nonagenarians, 1980 to 1992, Multivariate Model for Survival    legend
8569,Predictors of Dual Chamber Pacemaker Selection in the Very Elderly, 1980 to 1992 legend
8575,Influence of Abciximab on PTRA Induced Hypoperfusion legend
8578,Mean Group Data legend
8580,Patients With In Hospital Death According to Treatment Group legend
8583,Hemodynamic Findings  legend
8584,Quantitative Results of Positron Emission Tomography With N 13 Ammonia legend
8585,Visual Analysis of Regional Myocardial Perfusion in Children After ASO for TGA legend
8586,Clinical and Angiographic Data  legend
8588,Comparative Sensitivity, Specificity and Predictive Values of Early Myocardial Contrast Echocardiography   MCE  , Late MCE, Dobutamine Echocardiography   DE   and Serial MCE in Predicting Functional Recovery in Individual Segments  legend
8589,Visualization of Wall Segments in Group C
8592,Spectral and Time Domain Analyses According to Treatment Regime  legend
8593,VES and VT During Infusion of Exogenous Big ET and ET  legend
8594,Left Ventricular Function, Hemodynamics and Neurohormonal Profiles With Rapid Pacing Heart Failure: Effects of Endothelin Receptor Blockade During the Progression of Heart Failure  legend
8596,Systemic Hemodynamics legend legend
8597,Regional Myocardial Function, Blood Flow and Oxygen Consumption  legend legend
8599,Left Ventricular Function  legend
8600,In Hospital Clinical Outcome legend legend
8601,Long Term   2 Year   Clinical Outcome legend
8603,Effects of Placebo, Simvastatin, HRT and the Combination of Simvastatin and HRT on Serum Lipids and Lipoprotein Levels of 16 Postmenopausal, Hypercholesterolemic Women With Coronary Artery Disease  legend
8606,Echocardiographic Results in Groups A, B and C Patients  legend
8607,Cardiac Events in Groups A, B and C Patients
8609,Follow up Echocardiographic Results of Patients Without Cardiac Events and Those With Late Cardiac Events legend
8612,Clinical Outcomes
8613,Monoclonal Antibodies Used in This Study
8614,Plaque Histology in Atherectomy Specimens  legend
8616,Frequency of Methylenetetrahydrofolate Reductase Genotype and Odds Ratios of Nonfatal Coronary Heart Disease Among 500 Case and 500 Control Subjects  legend
8617,Odds Ratios of Nonfatal Coronary Heart Disease for     Methylenetetrahydrofolate Reductase Genotype versus    or   Genotype, Stratified by Age, Alcohol Consumption, Intake of Folate, Vitamins B12, B2, B6and Methionine legend
8620,Distribution of Significant Arrhythmia Complications legend
8621,Patients With New or Increased Ventricular Arrhythmias  legend
8623,Clinical and Laboratory Variables for Safety Evaluation  legend
8624,Adverse Events Attributed to Test Agent  legend
8625,Mortality by Gestational Age and Era of Birth
8626,Outcome of 49 Pregnancies Immediately Subsequent to Birth of a Child With Congenital Heart Block
8627,Effect of HOE 140 on Steady State Hemodynamic Data Before and After Pacing Induced Congestive Heart Failure in Eight Dogs
8628,Effect of HOE 140 on the PesVes, dP dtmaxVedand SWVedRelations Before and After Pacing Induced Congestive Heart Failure in Eight Dogs
8629,Average Values of Evaluated Variables in Groups A and B
8630,Correlation of Transplant Rejection Detected by Endomyocardial Biopsy and Antimyosin Scan
8631,Interobserver Variability in Interpretation of Endomyocardial Biopsy by Three Pathologists   X, Y and Z
8632,Infarct Size Data for Single Dose Studies
8633,Hemodynamic Variables During Ischemia Reperfusion in Single Dose Studies
8634,Hemodynamic Variables During Ischemia Reperfusion in Long Term Intermittent Dosing Study
8635,Infarct Size Data for Long Term Intermittent Dosing Study
8640,Angiographic Findings
8641,In Hospital Clinical Course
8643,Correlation of Lipoprotein  a   With Other Risk Factors
8644,Adjusted Risk Ratios for Ischemic Heart Disease According to Tertile of Risk Factors
8645,Significant Risk Factors in Stepwise Discriminant Analysis of Risk Factors for Ischemic Heart Disease
8646,Interaction Between Lipoprotein  a   and Other Lipid Risk Factors for Ischemic Heart Disease
8650,Clinical Data and Results for 22 Patients Who Underwent Patent Ductus Arteriosus Coil Occlusion
8651,Comparison Between Reopened Patent Ductus Arteriosus Group and All Other Patients
8652,Hemodynamic Variables and Cardiac Function in Patients With Right Ventricular Overload
8653,Correlation Coefficients Between Natriuretic Peptide Levels and Hemodynamic or Cardiac Functional Variables
8656,Angiographic and Intravascular Ultrasound Data From 31 Patients Submitted to Overdilation   n   31
8657,Angiographic and Intravascular Ultrasound Results at End of Procedure and at 6 Months
8659,Multivariate Predictors of Angiographic Restenosis at 6 Months   Logistic Regression
8664,Perioperative Outcome and Complications
8666,Hemostatic Variables of the Comparative Study
8668,Resetting Responses in the 14 Study Patients
8674,Comparison of Electrocardiographic Data Based on ST Segment Elevation   ST   in Lead V1
8675,Comparison of Angiographic Data Based on ST Segment Elevation   ST   in Lead V1
8676,Clinical and Coronary Angiographic Features of the Study Patients
8677,Rate Pressure Product During Balloon Inflation
8679,Summary of Infarct Size Data in Experiment 1
8681,Summary of Infarct Size Data in Experiment 2
8684,Complications
8685,Procedural Success  a  by Lesion
8686,Angiographic Complications
8689,Effect of Atropine on Variables of Systolic Time Interval in Young and Older Volunteers  a
8690,Effect of Pirenzepine on Variables of Systolic Time Interval in Young and Older Volunteers  a
8691,Therapy Strata After Suspicion of HIT
8692,Treatment Regimens and the Duration of Therapy With Alternative Anticoagulants
8694,4Ts Scores Stratified According to Treatment Regimen
8695,Laboratory Diagnostics for HIT
8696,Complications During Alternative Anticoagulation Stratified per First Line Anticoagulant
8697,Complications of First Line Alternative Anticoagulation per Treatment Day
8700,Kaplan Meier Rates of Outcomes in Randomized Subjects With Versus Without Anatomic Lesion Complexity Between 12 to 30 Months AfterPercutaneous Coronary Intervention
8701,Treatment Comparison of Continued Thienopyridine Versus Placebo in Randomized Subjects With Versus Without Anatomical Complexity
8702,Number of Patients With Discrete Events Within Each Time Period and During the Total 1 Year Study Period
8703,Relationships Between Ischemic and Bleeding Events
8704,Average Daily Rates for Adverse Events in the Acute, Subacute, Early, and Late Periods
8705,Differences in Average Daily Rates for Adverse Events in the Acute, Subacute, Early, and Late Periods
8706,Case Sequence Categories of Patients
8709,Outcomes
8710,Procedural Characteristics
8711,Operator Radiation Exposure for Radial and Femoral Access
8712,Operator Radiation Exposure for Left and Right Radial Access
8715,Cardiovascular and Renal Variables
8717,Clinical Outcomes at 1 and 2 Years With a DCS or BMS
8719,1 Year Mortality Following a Major Bleed or Coronary Thrombotic Event
8721,Efficacy and Safety Endpoints at 48 h After Randomization in Patients Receiving and Not Receiving GPIs
8723,Medications
8724,Unadjusted and Adjusted Associations Between Number of Antithrombotic Drugs and the Risk of Bleeding Before Coronary Angiography
8725,Unadjusted and Adjusted Associations Between Treatment Assignment and the Risk of Bleeding Before CoronaryAngiography
8726,In Hospital, 1 Month, and 1 Year Clinical Outcomes
8727,Unadjusted and Adjusted Association Between Bleeding Before Coronary Angiography and Death Within 1 Year
8728,Overview of the Volume of the RECHARGE Registry and Annually Performed Cases Per Center
8731,In Hospital MACCE and Complications of All Procedures   N  1,253
8733,Use of CrossBoss, Stingray, Wire Based ADR, or Retrograde Techniques
8736,Disposition After Coronary Angiography in the Study Population
8738,Event and Compliance Rates in Enrolled Patients   012 Months
8739,Ischemic and Bleeding Events in Randomized Patients   1230 Months
8740,Clinical Utility of MI Status Versus DAPT Score Stratification
8743,Predictors of Composite Adverse Events in MAVD Patients
8745,Adverse Events in MAVD and Control Groups
8748,Independent Predictors of 2 Year Coronary Thrombosis and Major Bleeding
8749,Integer Risk Score for Major Bleeding
8750,Integer Risk Score for Coronary Thrombotic Events
8755,Cumulative Mortality After Bleeding
8758,Distribution of All Bleeding Events
8761,Unadjusted 1 Year Event Rates for Specified Outcomes in the Full Cohort andbyDES Era
8764,Individual Efficacy and Safety Endpoints Versus Placebo for the Pooled Ticagrelor Doses, 90 mg Dose, and 60 mg Dose in Patients With Diabetes
8766,Procedural Information
8767,Clinical Outcomes of the Intention to Treat Population
8769,Adjusted RR of CHD With 95  CI for HbA1c6.5  Stratified by Hp Genotypes in Men 46 to 80 Years of Age at Blood Draw From theNested Case Control Study of CHD Events in the HPFS   1994 to 2010   and in Women 44 to 69 Years of Age at Blood Draw From the NestedCase Control Study of CHD Events in the NHS   1990 to 2004
8772,2 Year Outcomes According to PDB Occurrence
8776,1 Year Clinical Outcomes in the Intention to Treat Study Population
8777,1 Year Clinical Outcomes in the High Risk ACS Intention to Treat StudyPopulation
8779,Procedural and 30 Day Outcomes
8780,Predictors of Long Term All Cause Mortality
8783,Patient and Physician Reasons Provided for LVAD or OMM
8784,Primary Endpoint and Components that Prevented Success
8786,Adverse Events
8787,Reasons for Rehospitalizations
8791,Invasive Hemodynamic Data   N  16
8792,Univariable Associations of PH Development
8793,Summary of PM2.5 and Meteorological Variables   Arithmetic Mean  SD   in Outdoor Air, Sham Purified Indoor Air,and Purified Indoor Air During the Intervention Periods
8794,Summary of Health Endpoints   Geometric Mean  SD   in Sham Purified Indoor Air and Purified Indoor Air During the Intervention Periods
8795,Percent Change   Geometric Mean and 95  CI   in Health Endpoints Comparing the True Purified Air Scenario to the Sham Purified Air Scenario
8796,Percent Change   Geometric Mean and 95  CIs   in Health Endpoints Associated With an Interquartile Range Change   64 g m3   of Continuous Indoor PM2.5 Concentration
8797,Study Population
8798,Multivariate Model of Risk Factors for Combined Outcome   RandomIntercept,With Interaction Between Age Category and Prematurity
8800,Procedural In Hospital Clinical Outcomes
8801,Echocardiographic Variables Before and After TMVR
8803,Laboratory and Hemodynamic Assessments at TimeofPLE Diagnosis
8804,Medical and Surgical Treatment Strategies for PLE After Fontan Operation
8805,Suggested Evaluation of Patients With PLE
8807,Major Bleeding by Location   First Major Hemorrhage at Each Location
8811,Adverse Events
8813,Bivariable Logistic Regression for CRT Response
8814,Multivariable Logistic Regression Model for Echocardiographic CRT Response
8815,Multivariable Linear Regression Model for Percent Change in LVESV
8817,Procedural Details Comparing the 2 Groups
8818,The Primary Endpoint Was More Likely to Occur intheBMS Group
8821,30 Day and 1 Year Adverse Event Rates According to Occurrence of Major Bleeding Inside 30 Days
8825,Prevalence and Incidence of Bleeding, Stroke, and Pump Thrombosis After Discharge
8826,Pre Operative Statistically Significant Univariable Correlates   p  0.1   and Multivariable Risk Factors for Post Discharge Bleeding
8827,Pre Operative Statistically Significant Univariable Correlates   p  0.1   and Multivariable Risk Factors for Post Discharge Hemorrhagic Stroke
8829,Pre Operative Univariable Correlates With p  0.1 and Multivariable Risk Factors for Post Discharge Pump Thrombosis
8830,Inclusion and Exclusion Criteria
8835,Independent Predictors of 3 Year Cardiac Mortality
8840,Serious Adverse Events
8843,Clinical Outcomes at 12 Months Stratified According to the P2Y12 Inhibitor Used in HPR
8844,Clinical, Procedural, and Pharmacological Predictors of All Cause Death, MI, Stent Thrombosis, or Stroke at 1 Year
8850,Bicuspid Aortic Valve Type
8856,Cox Regression Analysis for the Composite of Major Hemorrhagic Events
8857,Evaluating the Predictive Ability of the HAS BLED Score Versus CHADS2 or CHA2DS2 VASc Score for the Detection of MajorBleeding Using C Statistics, Relative NRI, and IDI Indexes
8858,Cox Regression Analysis: Predictive Value of CHADS2 and CHA2DS2 VASc Scores for Bleeding Events by Themselves and Adjusted by HAS BLED Score
8860,Bleeding Subtypes and Recurrent Major Bleeding Events After HeartMate II Implantation
8861,Factors Related to Major Bleeding After HMII Implantation
8862,Factors Related to Death Incorporating Timing and Incidence of Major Bleeding After HeartMate II Implantation
8864,Hospitalizations and Outcomes of Infective Endocarditis in Medicare Fee for Service Beneficiaries, 1999 to 2010
8865,Hospitalizations for Endocarditis and Outcomes by Age, Sex, and Race
8868,Comparison of PCI In Hospital Outcomes in Extremely Obese Patients   BMI40 kg m2   and Normal Weight Patients   BMI 20 to 25 kg m2
8869,Unadjusted and Multivariate Adjusted ORs of the Association of Extreme Obesity Versus Normal Weight With Bleeding and In Hospital Mortality Stratified by Presentation With STEMI and Non STEMI
8870,Baseline Clinical and Demographic Characteristics by Nuisance Bleeding at Any Time Point
8875,Independent Predictors of Bivalirudin Use
8876,Hospital Patterns of Inotrope Use   N   225
8879,Association Between Hospital Use of Inotropes and In Hospital Risk Standardized Mortality Rate
8882,30 Day Post Procedural Complications and Outcomes
8883,Influence of Incremental Adjustment on Cox Models of Female HR for Mortality
8885,AMADEUS Cohort Stratified by the HEMORR2HAGES, HAS BLED, and ATRIA Schemes
8886,AUCs   or C Indexes   for HEMORR2HAGES, ATRIA, and HAS BLED Scores
8887,Cox Regression Analysis of the HEMORR2HAGES, HAS BLED, and ATRIA Score for the Outcomes of All Cause Mortality, Major Bleeding, and Any Clinical Relevant Bleeding
8888,Comparison of AUCs or C Indexes for HEMORR2HAGES, ATRIA, and HAS BLED Scores
8889,Reclassification Table for Any Clinical Relevant Bleeding Risk Estimated by HAS BLED, HEMORR2HAGES, and ATRIA Schemas
8890,NRI Analysis for the Outcomes of Any Clinically Relevant Bleeding, Major Bleeding, and All Cause Mortality
8893,Post Operative Outcomes for the Isolated CABG Cohort
8896,Temporal Reduction in Annual Bleeding Risk
8898,Comparison of Procedural Variables Between Patients on Dabigatran and Warfarin
8899,Comparison of Complications Between Patients on Dabigatran and Warfarin
8900,Univariate and Multivariate Predictors of Complications   Composite of Bleeding and Thromboembolic Complications
8902,Histology Findings
8903,Quantitative PCR Results for Nuclear Receptors, Scavenger Receptors, and ABC Transporters in M  Hb   Versus Control Macrophages   n   4 Experiments per Group
8904,Hospital Discharge Mortality for Patients Undergoing Stage I Palliation, 20022009
8905,Strategies for Reducing the Likelihood of Effusion Development Following Stage II Palliation
8906,Original Criteria for Fontan s Operation: The 10 Anatomic and Physiologic Commandments
8907,Risk Factors for the Development of SVT
8908,Indications for Heart Transplantation With HLHS
8911,Intraprocedure Hemodynamic Data Pre  and Post Pulmonary Valve Implantation
8912,Intraprocedure Adverse Events
8913,Patient Information
8916,Regional Myocardial Perfusion and Percentage of Diameter Stenosis
8921,Cost, Clinical Effectiveness, and Cost Effectiveness of Strategies for Asymptomatic Men
8922,Cost, Clinical Effectiveness, and Cost Effectiveness of Strategies for Asymptomatic Women
8923,Optimal Strategy in 1 Way Sensitivity Analysis, With a Willingness to Pay of  50,000 QALY in Men
8924,Optimal Strategy in 1 Way Sensitivity Analysis, With a Willingness to Pay of  50,000 QALY in Women
8926,Predictors of All Cause Mortality
8928,Frequency of Patient Withdrawal and Early Drug Discontinuation
8929,Adverse Events and Monitoring
8931,Per Segment Analysis of Individuals Who Were Alive Versus Dead During the Follow Up Period
8933,Clinical Predictors of Nonobstructive Plaque Extent and Burden
8938,Associated Operative Procedures
8939,Causes of Death
8941,Adverse Events
8943,Primary Study Outcomes and Individual Outcome Definitions
8944,Study Medications
8945,Study Quality
8947,Risk Factors for PE and Comorbid Conditions
8948,Signs and Symptoms at Presentation
8949,Functional Status and Comorbid Conditions
8950,In Hospital and 30 Day Outcomes
8951,Contemporary Bleeding Risk Stratification Schemas
8953,Risk Factors for Major Bleeding by Univariate and Multivariate Analyses
8954,Major Bleeding Rates by HAS BLED Score in the Overall SPORTIF Cohort   n   7,329   and Those Taking Warfarin Only   n   3,665
8955,Risk Factors for Major Bleeding According to the HAS BLED Score: Whole Cohort   n   7,329
8956,Risk Factors for Major Bleeding According to the HAS BLED Score: Warfarin Patients Only   n   3,665
8958,Hazard Ratios   95  Confidence Interval   of Risk Categories for the 5 Bleeding Risk Stratification Schemas Among Warfarin Patients   n   3,665
8960,Perioperative Data in Relation to Tertile Distribution of the Percentage of Platelet Inhibitory Response to Clopidogrel
8963,Predictive Power of Selected Variables for Post Operative Transfusion Requirement According to Logistic Regression Analysis
8965,Composition of Matched Flavanol Containing Test Materials Ingested Twice Daily
8968,Genotype Distribution of Intervention Group Patients
8969,Unadjusted Incident Hospitalization Rates
8970,Warfarin Dosage Changes Following Genotyping
8972,Independent Predictors of NonCABG Related Major Bleeding Within 30 Days, With Multiple Logistic Regression
8973,Incidence of NonCABG Related Major Bleeding Within 30 Days According to Risk Score Category
8974,Independent Predictors of 1 Year Mortality From Multivariable Cox Regression
8975,Hierarchical Incidence of NonCABG Related Major Bleeding Within 30 Days
8977,Breakdown of the Primary Composite End Point
8978,Univariate Analysis of Predictors of Primary Composite End Point
8979,Multivariate Analysis of Predictors of Primary Composite End Point
8980,Summary of Secondary End Points
8983,Unadjusted 30 Day and 1 Year Event Rates According to Time to PCI
8984,Multivariable Predictors of Death at 30 Days and 1 Year
8985,Multivariable Predictors of the Combined End Point of Death or Myocardial Infarction at 30 Days and 1 Year
8988,End Points at 30 Day Follow Up
8989,Experience With Periprocedural Impella 2.5 Support in Elective High Risk PCI
8993,Hospital Results
8994,Late Results
8995,Linearized Rate of Valve Related Events
8996,Cox Hazards Regression: Independent Predictors of Late Mortality
8999,30 Day and 1 Year Clinical Outcomes of Patients With and Without GIB Triaged to PCI, CABG, or Medical Management
9000,Medication Use at Different Time Intervals in Patients With and Without GIB
9002,Bleeding Events in Relation to Age  80 or 80 Years
9003,Odds Ratios Associated With Bleeding Risk
9005,Death, MI, Refractory Ischemia, Major Bleeding, and Net Clinical Outcome at 30 Days in Those Treated With a GP IIb IIIa Inhibitor
9006,Death, MI, or Refractory Ischemia or Major Bleeding in Patients Undergoing PCI by Loading Dose of Clopidogrel or Type of GP IIb IIIa Inhibitor
9008,Death, MI, Refractory Ischemia, Major Bleeding, and Net Clinical Outcome at 30 Days in Those Treated With Thienopyridines
9011,Cardiac Procedures and Concomitant Medications During Hospitalization
9012,Event Rates       in Each Treatment per Age Category at 30 Days and 1 Year for All Patients
9013,Events Rates       in Each Treatment per Age Category at 30 Days and 1 Year for PCI Patients
9016,Ischemic and Bleeding Incidents at 30 Days
9017,Post PCI Bleeding Events, Transfusion, and Thrombocytopenia
9019,Average Peak Periprocedural Necrosis Marker Release and Mean Platelet Aggregation and TIP FCS
9020,Clinical Outcomes
9022,Mixed Treatment Comparison Probabilities of Each Treatment at Reducing All Cause Mortality and CVD Mortality
9023,Mixed Treatment Comparisons of Effectiveness, All Cause Mortality
9024,Mixed Treatment Comparisons of Effectiveness, Cardiovascular Disease Mortality
9028,Angiographic Complications and Subsequent NonQ Wave MI
9029,In Hospital and 30 Day MACE
9030,Incidence of Post Procedural Bleeding
9034,Clinical Outcome According to Pre Discharge RPA
9035,Reasons for Prematurely Discontinuing Study Drug in the Safety Population
9037,Incidence and Risk of Confirmed Venous Thromboembolism   VTE   and Proximal Deep Vein Thrombosis   DVT
9038,Incidence of Bleeding End Points
9041,Predictors of Longitudinal SBP Derived From a Linear Mixed Effects Regression Model
9044,Incidence of Ischemic Stroke Event After MR Surgery Overall and by Surgical Procedure and Post Operative Phase
9045,First Ischemic Stroke Risk After MR Surgery Expressed as Risk Ratio to Expected First Ischemic Stroke Rates in the Population
9046,Independent Predictors of First Ischemic Stroke After MR Surgery
9047,Risk of the Combined End Point First IS TIA After MRSurgery Compared With Expected First IS TIA Rates in the Population
9048,Incidence of Any Thromboembolic Event After MR Surgery Overall and by Surgical Procedure and PO Phase
9051,Cox Proportional Hazards Survival Model
9057,Antithrombotic Regimen Adopted in AF Patients at Discharge
9058,Differences Between the AF Patients Undergoing PCI Stenting, Treated at Discharge With Anticoagulation Compared to Those Not Treated With Anticoagulation
9059,Events During Follow Up
9060,Cox Regression for the Analysis of Major Adverse Cardiovascular Events
9061,Cox Regression Analysis for Major Adverse Events
9063,30 Day Ischemic and Bleeding Complications in 1 Year Survivors and Nonsurvivors
9064,Independent Predictors of 1 Year Mortality
9065,Predictive Accuracy of MI, Urgent Revascularization, or Bleeding Within 30 Days After PCI Regarding 1 Year Mortality
9067,Unadjusted Outcome of the Cohort Categorized by Treatment
9068,In Hospital Outcomes of the Propensity Matched Cohort Categorized by Treatment
9070,Bleeding Events: Number of Events and Kaplan Meier Event Rates
9071,Clinical End Points: Number of Events and Kaplan Meier Event Rates
9072,Crude Incidence Rates of Investigator Reported Adverse Events
9073,Arrhythmia Events Detected on Continuous ECG Monitoring Begun at Randomization
9076,Procedural Results
9077,Clinical Events Through 2 Years
9078,Angiographic Follow Up Results at 8 Months Stratified by Vessel Size
9080,Intracranial Hemorrhage Event Rates
9081,Adjusted Hazard Ratio for Intracranial Hemorrhage
9082,Percent Time Receiving Warfarin That INR Values Were 2, 23, and 3 by Race Ethnicity
9083,Anticoagulation Intensity at the Time of Intracranial Hemorrhage by Race Ethnicity
9086,Angiographic and Procedural Results
9087,Electrocardiographic and Laboratory Results
9088,One Month Left Ventricle Function Recovery
9091,Antithrombotic Medications in Patients With and Without Major Bleeding
9098,Treadmill Performance in the Intention to Treat Population
9101,Selected Adverse Events Observed at Increased Frequency With NM 702
9102,Cardiac Serious Adverse Events
9104,Inclusion and Exclusion Criteria
9107,Statistical Comparisons   p Values   Among Treatment Groups in the Medications Ability to Modify Lipids, High Sensitivity C Reactive Protein   hsCRP     mg l  , and Lipoprotein Associated Phospholipase A2  Lp PLA2     ng ml
9109,CTFC, CFI, and CFR at Various Time Points
9110,Univariate and Multivariate Correlates of Post PCI TMPG 3
9112,Bleeding Events Through 48 Hours
9114,Rates of Bleeding Events and Transfusions According to Prior Antithrombin
9115,Frequency of Specific Complications During ICD Hospitalizations for the Entire Study Population, Stratified by Type of Implant
9117,Adjusted Incremental Hospital Resource Utilization Associated With Treating Patients Experiencing the Complication of Interest
9120,Bleeding and Hematologic Complications After Stenting
9121,Quantitative Coronary Angiographic Results of Stented Segment
9122,Intravascular Ultrasound Results
9123,In Hospital Primary Outcomes After Stenting
9125,Age, Gender, Index INR Value, and Site of Hemorrhage for Each of the 13 Individuals With Major Bleeding
9126,Mean Number of Days Warfarin Was Withheld by Index INR and Target INR Range
9129,Data for 35 Patients Who Underwent the Attempt of Transcatheter Closure of Perimembranous VSD
9130,Data Before and After Implantation of the Amplatzer Membranous VSD Occluder
9132,Procedural Data
9134,Post Treatment Angiography
9135,Clinical EventsIn Hospital
9136,Clinical Events Through 30 Days
9137,Definition of IB Values in Each of Histological Categories in Plaque
9145,Incidence of Primary and Secondary Events According to Assigned Treatment in SPORTIF III    47
9148,Number and Percentage of Primary and Secondary Outcome Events
9150,Odds Ratios of Individual and Composite End Points According to Clopidogrel Pretreatment
9151,Bleeding Complications
9153,Efficacy End Points
9154,Bleeding Events
9156,Cerebrovascular Events
9158,Clinical Features and Follow Up Results of Patients With or Without an Initial Response to Aspirin
9159,Etiology of Acute Pericarditis According to Clinical Risk Groups
9161,Summary of Exposure to Study Drugs   All Treated Population, N   1,216
9162,Summary of Efficacy Results: Adjudicated Clinical End Points at 30 Days for Pooled Enoxaparin and UFH Groups   Intention to Treat Population, N   1,224
9163,Summary of Efficacy Results: Adjudicated Clinical End Points at 30 Days for Pooled Tirofiban and Placebo Groups   Intention to Treat Population, N   1,224
9164,Summary of Efficacy Results: Adjudicated Clinical End Points at 30 Days   Intention to Treat Population, N   1,224
9165,Hemorrhage Rates at 30 Days   All Treated Population, N   1,216
9168,Procedural Data in Octogenarians Undergoing PCI
9169,Bleeding Complications in Octogenarians Undergoing PCI With or Without a Glycoprotein Receptor Inhibitor
9170,In Hospital Outcomes in Octogenarians Undergoing PCI With or Without a Glycoprotein Receptor Inhibitor
9172,Comparison of Final Outcomes in the 3664 and 65 Years Old Groups With Respect to the 35 Years Old Group
9174,Angiographic and Electrocardiographic Efficacy Data
9175,Clinical Efficacy and Procedures   Through 30 Days   and Safety   Through Discharge
9177,Bleeding Complications
9178,Vascular Complications
9179,Bleeding Complications in Those Receiving Closure Devices
9180,Vascular Complications in Those ReceivingClosure Devices
9181,Angiographic Complications
9182,Clinical End Points at 48 h
9184,Pharmacologic Interventions and Invasive Diagnostic or Therapeutic Procedures in Excluded and Non Excluded Patients
9185,Predictors of Major or Minor Bleeding in the Whole Population
9186,Predictors of Death or Myocardial Infarction at 30 Days in the Whole Population
9187,Eligible Trials
9188,Subgroup Analyses for Mortality
9189,Secondary Outcomes
9191,Individual Results of the Nine Included Randomized, Controlled Trials
9192,Sensitivity Analyses of Thrombolytic Regimen, Clinical and Radiologic Severity of Pulmonary Embolism, and Methodologic Quality
9196,Chest Tube Outputs and Transfusions
9197,Clinical Outcomes
9198,Patients With Clopidogrel Exposure
9199,Patients Without Clopidogrel Exposure
9202,Results of Univariable Proportional Hazards Modeling: Hazard Ratios, 95  Confidence Intervals and p Values for Echocardiographic Variables
9203,Results of Univariable Proportional Hazards Modeling: Hazard Ratios, 95  Confidence Intervals and p Values for Clinical and Hemodynamic Variables
9204,Results of Multivariable Modeling: Hazard Ratios, 95  Confidence Intervals and p Values for Significant Multivariable Predictors of Outcome in Models That Incorporate Echocardiographic, Clinical and Hemodynamic Variables
9205,Patient Overview
9206,Complications Reported by Different Authors
9208,In Hospital Ischemic and Hemorrhagic Stroke Among Postmenopausal Women With Acute Myocardial Infarction According to Use of Hormone Therapy on Admission
9210,Mean Variable and Total Cost, by Department
9211,Multiple Regression Analysis of Total Cost and Length of Stay   n   1,949
9213,Hemodynamic and Echocardiographic Parameters of Patients With PPH legend
9214,Coronary Doppler Velocities   Diastolic and Systolic   and Hemodynamic Data at Rest and Hyperemia in 24 Control Subjects and 43 Patients With LAD Disease legend
9217,Morphometric Analysis of Pig Coronary Arteries 72 H After Angioplasty legend
9219,Tear Location legend
9220,General Management legend
9221,Univariate Analysis legend
9222,Accuracy for the Detection of CAD According to Extent of Disease legend
9223,Segmental Findings on DMIBI and DASE According to Vascular Territory and Angiographic Data   Peak Stress Data   legend
9230,History, Risk Factors and Procedural Details of the Study Group legend
9231,A Summary of Time Frames of PTCA, Surgery, Antiplatelet Therapy and Complications in Patients Who Experienced Major Complications After Noncardiac Surgery Preceded by Intracoronary Stent Placement legend
9233,Incidence of Strands and Thrombi at Nine Days legend
9234,Incidence of Strands and Thrombi at Five Months
9235,Principal Outcome Events at One Year
9236,Early Thrombi and Morbidity legend
9237,Risk Factors of Morbidity legend legend
9239,Enzymatic and Echocardiographic Data of Patients With Elevated Troponin legend
9240,Relationship Between Abnormal Troponin I and Clinical, Radiological, ECG, and Echocardiography Data
9241,Relationship Between Abnormal CK and Clinical, Radiological, ECG, and Echocardiography Data
9246,Selected Mitral Leaflet Variables in Relation to Papillary Muscle Settings legend legend
9247,Chordal Force Distribution in Relation to Papillary Muscle Settings legend legend
9248,Impact of Chordal Force Distribution on Occlusional Leaflet Area and Mitral Regurgitant Fraction legend
9251,Histological Findings
9254,Angiographic Data of the Patient Groups legend
9255,Medical Therapy
9256,In Hospital Clinical Outcome
9257,One year Follow up From Admission   110 Patients
9258,Distribution of Major and Minor Complications
9259,Mortality legend
9260,Interventional Cardiac Procedures and Related Complications
9261,Independent Risk Factors for Any Complication
9262,Independent Risk Factors for Major Complications
9265,Comparison of Procedural Results
9266,Comparison of Economic Variables
9269,Relation of Clinical Outcomes at 30 Days With Thrombocytopenia  by Treatment Assignment
9271,Relation of Bleeding Events at 30 Days With Thrombocytopenia  by Treatment Assignment
9275,Clinical Variables of Patients Grouped According to the Occurrence of Restenosis
9277,Significant Correlates of Restenosis by Logistic Regression Analysis
9282,Reasons for Discontinuation Among 776 Patients With Acute Myocardial Infarction Randomized to Treatment With Dalteparin or Placebo
9283,Left Ventricular Thrombus Formation Among Patients With Acute Anterior Myocardial Infarction Randomized to Receive Dalteparin or Placebo
9284,Odds Ratios   95  confidence intervals   of Left Ventricular Thrombosis in Patients With Acute Anterior Myocardial Infarction by Study Treatment, Peak Aspartate Aminotransferase Values and Gender  a
9285,Type of Hemorrhage According to Assigned Treatment in Patients Given Dalteparin or Placebo for Acute Myocardial Infarction
9287,Procedural Information for 50 Patients With 50 Lesions
9288,Angioscopic Findings in 50 Patients With 50 Lesions
9289,Angioscopic Findings in 50 Lesions According to Presence or Absence of Calcifications on Angiography
9292,Procedure Related Variables
9293,Outcome Statistics for Type of Dressing
9295,Thirty Day Outcomes and Diabetic Status
9296,Thirty Day Outcome According to Thrombolytic Strategy
9297,Other Clinical Outcomes at 30 Days
9298,Coronary Angiographic Findings
9299,Early Mortality and Diabetic Status in Randomized Trials
9300,In Hospital Outcomes of 908 Randomized Patients Risk Stratified Into High Risk and Low Risk Groups
9302,Secondary In Hospital Outcomes in 437 Randomized High Risk Patients
9303,Vascular and Hemorrhagic Complications in the Study Cohort
9304,Reasons for Excluding 144 High Risk Patients From Randomization
9305,Selected Outcomes in High Risk Registry Patients Stratified by Requirement for Intraaortic Balloon Counterpulsation
9307,Association Between Elevated Depressive Symptoms and Definite Probable MI or Death
9311,Depression, Anxiety, and Risk of CHD and AMI
9312,Causes of Syncope   n   341
9313,Comparison of Clinical Features of Syncope legend
9314,Diagnostic Examinations That Established the Cause of Syncope   n   341   legend legend
9315,Predictors of the Cause of Syncope in Patients With Suspected or Certain Heart Disease After the Initial Evaluation   n   191   legend
9316,Predictors of the Cause of Syncope in Patients Without Suspected or Diagnosed Heart Disease After the Initial Evaluation   n   146   legend
9317,Sensitivity, Specificity and Post Test Probability of the Variables Predictive of Cardiac and Neurally Mediated Causes of Syncope in Patients With and Without Suspected or Certain Heart Disease After the Initial Evaluation
9318,General Features of Cardiac Patients and Controls legend
9319,Results of the Psychological Tests in Cardiac Patients and Controls According to Sex and Age
9320,Results of Cluster Analysis in Cardiac Patients and Controls  legend
9322,Multivariable Logistic Regression Analysis for Risk Factors of CAD in Diabetic Patients
9326,Risk of Death, MI, HF, Stroke, and Repeat Revascularization in Patient With T1D Who Underwent Multivessel PCI or CABG in Sweden From 19952013
9327,Absolute Risks of Death From Any Cause, MI, HF, Stroke, Repeat Revascularization, and Death From CHD in Patients With T1D Who Underwent PCI or CABG From 19952013 in Sweden
9332,Comparison of Hemodynamic Change With Nitroprusside in Low Flow and Normal Flow Low Gradient Severe Aortic Stenosis
9333,Comparison of Invasive Hemodynamic Variables on Nitroprusside in Low Flow and Normal Flow Low Gradient Severe Aortic Stenosis
9341,Echocardiographic Parameters of the Test and Validation Cohorts
9343,Echocardiographic Parameters of the Test Cohort
9344,AUC for Continuous Single Leads and the Proposed Criteria   SD  SV4   Predictive Performance of LVH in the TestCohort
9345,McNemar Test Among the Electrocardiographic Criteria Against the Left Ventricular Mass Index in the Test Cohort
9347,AUC for Continuous Single Leads and the Proposed Criteria   SD  SV4   Predictive Performance of LVH in the Validation Cohort
9348,McNemar Test Among the Electrocardiographic Criteria Against the Left Ventricular Mass Index in the Validation Cohort
9349,McNemar Test Among the Electrocardiographic Criteria Against the Left Ventricular Mass Index in the Combined Population
9351,Adjusted Associations Between LTPA Levels and Risk of Overall HF and its Subtypes
9352,Adjusted Associations Between BMI Categories and Risk of Overall HF and Its Subtypes
9354,1 Year Adjusted Risk of Stroke Systemic Embolic Events
9358,Comorbidity Pattern Stratified by T2DM
9360,Unadjusted and Adjusted HRs of Mortality by T2DM Status in Groups Stratified by History of IHD and Revascularization
9362,Statistical Analysis of Diagnostic Biomarkers: Discovery Phase
9365,Medications at Deferral
9366,Cumulative Events at Follow Up
9367,Cox Proportional Hazards Model
9369,Unadjusted, Trial Adjusted, and Multivariable Adjusted HRs for the Composite Endpoint and the Individual Components From Cox Regression Models   N  5,034
9371,Primary Composite Outcomes
9372,Primary Outcome Measure Components
9373,Secondary Outcomes
9374,Costs
9376,Pharmacokinetic Profiles of Prasugrels Active Metabolite After Administration of LD of Whole Versus CrushedPrasugrel
9377,Cumulative 6 Month Resource Use and Costs
9379,Plasma Lipid and Lipoprotein Concentrations
9380,LLT and LDL C Goal Achievement   Cohort
9381,Baseline Characteristics
9382,Summary of Long Term Effectiveness and Cumulative Long Term Effectiveness Over 3 Years Post Ablation
9387,Association Between Time Varying HbA1c Values and Incidence of Ischemic Stroke Using Different Rules for Classifying Time Varying HbA1c Values
9389,Adjusted Hazard Ratios for Composite Cardiovascular Events Associated With Each Hypertension Classification Compared With Participants With Normal Blood Pressure
9392,HbA1c and DM Duration in Patients With T1DM andT2DM
9393,Absolute and Relative Risks of Death or MACE Death After Primary Isolated CABG in Patients With T1DM or T2DM Compared With Patients Without DM Stratified bySex
9396,Incident Rates and HRs for Black and White Patients and ACE Inhibitor Use
9403,Perioperative Data, Death, and Nonfatal Events
9404,Univariate and Multivariate Predictors of 30 Day Mortality
9405,Univariate and Multivariate Analysis of Overall Survival
9406,Joggers Categorized as Light Joggers, Moderate Joggers, or Strenuous Joggers on the Basis of Self Reported Pace, Quantity, andFrequency of Jogging
9409,Association Between Quartile of Percent PVC Count, LVEF Reduction, IncidentCHF, and Mortality
9411,HR   95  CI   of Diagnosis With a Clinical CVD Risk Factor   Diabetes, Hypertension, or Hypercholesterolemia       by HealthyLifestyle Factors
9414,Echocardiographic Parameters of the 4 Groups of Patients With Aortic Stenosis
9415,Relative Risk of All Cause Mortality in Patients With Severe Aortic Stenosis   LG LF, LG NF, and HG   Compared With Moderate Aortic Stenosis
9417,Event Rates and Relative Risks for a Combination of All Cause Mortality or Major Adverse Cardiovascular Events     After PrimaryIsolated Coronary Artery Bypass Grafting in 764 Patients With Type 1 Diabetes, According to Baseline HbA1c
9419,Comparison of Global Strain in Patients and HealthyVolunteers
9421,ROC Cutoff Values Predicting 24 Month Mortality
9422,Kaplan Meier Cutoffs to Predict Mortality
9423,Bland Altman Data for Repeated Measures
9425,CAC Score Ratios     by BMI Categories in 14,828 Metabolically Healthy Participants
9426,Prevalence Ratios     for CAC by BMI Categories in 14,828 Metabolically Healthy Participants
9427,Mediation Analysis of the Association Between BMI Categories and CAC in 14,828 Metabolically Healthy Participants
9428,CAC Score Ratios     by BMI Categories in Clinically Relevant Subgroups of Metabolically Healthy Participants
9431,Adverse Events
9434,Echocardiography and CMR Parameters at the Time ofCMR Examination
9435,Correlation of ECV and LGE With Diastolic Function Parameters
9436,Clinical Outcome at 4 Years
9437,Adherence to DAPT
9439,Echocardiography, Electrophysiology, and Scar Size
9440,KCNQ1 G269S Affects the Activation Gate of I Ks Channels
9443,ORs   95  CIs   of ACEI ARB Initiation During the First Year of the Cohort
9444,Pharmacokinetic Parameters of Clopidogrel and its Active Metabolite After a Loading Dose of 600 mg
9445,Exploratory Analysis of Genetic Polymorphisms and Differences in Clopidogrel Active Metabolite
9446,American Heart Association Recommended Criteria for Right Ventricular Hypertrophy by Study
9449,Sensitivity, Specificity, PPV, and NPV for AHA Criteria for Right Ventricular Hypertrophy in Participants With Normal Left Ventricular Morphology
9452,Practice and Patient Factors Associated With Optimal Combined Prescriptions of Secondary Prevention Medications Following Multivariable Adjustment
9455,ITDM Versus Non ITDM Hazard Ratios for FREEDOM Trial Outcomes
9456,Kaplan Meier Event Free Estimated Event Rates for CABG Versus PCI
9457,5 Year Kaplan Meier Estimated Event Rates for the Primary Endpoint   Death Stroke MI
9458,5 Year Kaplan Meier Estimated Event Rates With 95  CI and HR for the Primary Endpoint   Death Stroke MI   for ITDM Status by SYNTAX Score
9459,PCI Versus CABG Hazard Ratios for FREEDOM Primary Outcome of All Cause Death Stroke MI: Time Dependent Cox Regression Modeling Results
9461,Hazard Ratios for All Cause Mortality After Incident HF
9464,Feasibility and Correlation of EchocardiographicParameters With Mean PCWP   N  40
9465,Accuracy of Echocardiographic Parameters to Predict PCWP  15 mmHg
9469,Left Ventricular Compliance and Distensibility
9471,Relative Risk of Myocardial Infarction Associated With Modifiable Lifestyle Factors in 20,721 Men
9472,Effect of Combined Low Risk Behaviors in Relation to Risk of Myocardial Infarction
9474,Effects of LVMI and LVH on BMI and SBP   LinearandLogistic Regression Analyses
9475,Effects of BMI and SBP on LV Remodeling Patterns, Adjusted forRace, Sex, andAdulthood Age   Logistic Regression Analysis
9478,Results on a Per Patient and Per Vessel Level Using Hyperemic MBF as a Perfusion Parameter to Assess Diagnostic Accuracy of  15O H2O PET
9479,Diagnostic Accuracy of Quantitative  15O H2O PET MPI Using Hyperemic MBF as a Perfusion Parameter
9480,Diagnostic Accuracy of Quantitative  15O H2O PET MPI for Detecting Angiographic Obstructive CAD
9481,Univariate and Multivariable Regression Analysis Describing the Relationship Between Hyperemic MBF, CAD Risk Factors, and Functional CAD Severity
9482,The Influence of Sex and Age on the Diagnostic Performance of  15O H2O Hyperemic MBF Imaging
9485,Medication Discontinuation Following Weight Loss Across Treatment Classes Stratified by Insulin Status
9486,Classification of Patients According to Doppler Echocardiographic Assessment of Stenosis Severity
9487,Clinical, Doppler Echocardiographic, and MDCT Data According to Group Classification
9488,Univariable and Multivariable Analysis of Predictors of MG or Vmax
9489,Accuracy of AVC, AVCi, and AVCd to Identify Severe AS
9490,Prevalence of Patients With Evidence of SevereStenosis on the Basis of AVC or AVCd Criteria
9492,Risk of Vascular Events by HDL C According to Lipid Lowering Treatment
9493,Risk of Vascular Events by HDL C According to LDL C Level
9494,Risk of Vascular Events by HDL C in Categories of Increasingly Potent Lipid Lowering Therapy
9497,Cumulative Proportions of CV Events Over 4.3 Years inGroups of Patients With Normal Weight, Overweight, and Obesity
9498,Impact of Overweight and Obesity on Outcome in Univariate Analyses
9499,Impact of Overweight and Obesity on Outcome in Multivariate Analyses
9508,Interaction Between Sex and Association Between Adiposity and Cardiometabolic Risk
9510,Multiple Logistic Regression Analysis for Silent Cerebral Infarcts
9511,Ongoing Trials of Anti Inflammatory Therapies for Atherosclerosis
9512,Professional Society Recommendations for hsCRP Testing
9517,Within Person Variability of HbA1c Values by Mean HbA1c Categories During Follow Up
9518,Number of Subjects, Proportion With Each Outcome, and Incidence of Outcomes per 1,000 Person Years Adjusted for Age, Sex, and Duration of Diabetes, by HbA1c Category
9522,Clinical Events
9527,Univariate and Multivariate Results of Combined Clinical and Echocardiographic Cox Regression Models
9528,Relation Between GLS and Outcome
9529,Reclassification TableWith Added Value of GLS in Relation to Outcome
9533,Safety Summary
9541,30 Year Cumulative Risk for HF at Index Age by SexRace Group in the CHA Study by BMI Strata
9542,30 Year Cumulative Risk for HF at Index Age 45 by SexRace Group in CHA by BP Strata
9543,Cumulative Risk for HF at Selected Index Ages Through Given Follow Up Ages by Sex Race Groups
9545,CMR Changes Seen After Allopurinol Treatment
9546,Effect of Allopurinol on Hemodynamics and Endothelial Function
9549,Primary and Secondary Endpoints
9550,Risk Factors for Adverse Outcome in PCI
9552,Final Cox Proportional Hazards Models for the WC and WHR Ratio Predictors
9554,Overview of Treatment Rates for CAD Quality of Care Indicators, by Healthcare Insurance Status
9555,Association Between Insurance Status and Treatment Rates for CAD Quality of Care Indicators
9557,Medication Use in the First Year After Initial CABG or PCI
9560,Circulating Humoral Factors
9562,Imputation and Sequence Confirmation of rs10757278 Genotypes of the Lymphoblastoid Cells Used in This Study
9565,Concomitant Medications
9566,OR Estimate of Each Outcome for Each Drug Treatment Group Compared With Placebo
9568,Univariable Hazard Ratios for Cardiac Death   n   6,037
9569,Multivariable Cox Proportional Hazard Models Estimating Cardiac Death   n   6,036
9570,Risk Reclassification for Risk in 6,037 Patients With and Without Cardiac Death
9573,Details of Multiple Variable Regression Analyses of Factors Associated With Troponin I TDefined PPMI
9576,Primers for Real Time Quantitative PCR
9578,Individual Mutations Identified in the Non SA Population
9579,Absolute HR and HR Changes      During ExStrT in Washout in the Entire Study Population, According to Genetic and Clinical Status
9581,Correlation Between Cholesterol Efflux and Inflammatory Markers Among Patients With ESRD HD and Controls
9583,Matching Thresholds in Different Datasets
9586,Univariate and Multivariate Associations Between Total Plasma Lp PLA2 Mass and Activity, HDL Lp PLA2 Mass and Activity, Ratios of Lp PLA2 to HDL Lp PLA2 Mass and Activity, Natural Log of hsCRP, and Cardiac Death at Follow Up
9587,Patient Variables
9588,Transesophageal Echocardiogram Parameters Examined
9590,Results of Coronary CTA in Relation to Summary XECG Results
9591,Major Adverse Cardiac Events According to Summary XECG and Severity of CAD by Coronary CTA Subset
9592,Univariate and Multivariate Analysis for Prediction of Major Adverse Cardiac Events
9593,C Statistics for Prediction of 5 Year Risk of Major Adverse Cardiac Event Using XECG, Coronary CTA   Severity of CAD  , and Combined Model
9595,Summary of Hemodynamic Data for All Participants During Imaging Studies
9596,Quantitative Perfusion Values in Patients With and Without Significant CAD
9598,Subgroup Analysis
9599,Recommendations for Normal SE With Submaximal APHR
9605,RR   95  CI   of SCH for All Cause and CVD Mortality in Several Different Models
9606,RR   95  CI   of SCH for All Cause and CVD Mortality Stratified by Age and by TSH Levels at Entry
9608,PR   in PRU   at the End of Treatment Periods
9610,Medical Therapies According to the rSS
9611,rSS Components in Patients With Incomplete Revascularization According to Tertile
9612,30 Day and 1 Year Outcomes According to the rSS
9614,Receiver Operating Characteristic Curve Analysis of rSS and 1 Year Ischemic Outcomes
9620,Univariate and Multivariate Logistic Regression Analyses for Prediction of Cardiac Troponin Elevation
9624,Multivariable Cox Proportional Hazards Models for the Association of Quartile of Fetuin A With CVD Mortality
9625,Multivariable Hazard Ratios for CVD Mortality by Low Fetuin A   Quartile 1   Versus Higher   Quartiles 2 to 4   Stratified by Potential Moderators
9626,Multivariable Hazard Ratios for CVD Mortality by Low Fetuin A   Quartile 1   Versus Higher   Quartiles 2 to 4   Adjusting for, or Excluding, Potential Covariates and Effect Modifiers
9627,Patient Demographic Data
9628,18F NaF and 18F FDG SUV Max and TBR Max Values
9630,Correlation of 10 Year Framingham Risk Scores With the Coronary Calcium Score and PET Uptake
9632,Prolongation of QTc and Risk of Incident Stroke in the REGARDS Study
9634,ClopidogrelAM Pharmacokinetics With and Without PPIs
9635,VASP P2Y12 PRI in Clopidogrel Treated Subjects With and Without 9 Days of PPI Coadministration
9636,Platelet Aggregation Measured by Light Transmission Aggregometry in Response to 5 and 20 mol l ADP in Clopidogrel Treated Subjects With and Without 9 Days PPI Coadministration
9637,Platelet Aggregation Measured by VerifyNow P2Y12 PRU in Clopidogrel Treated Subjects With and Without 9 Days of PPI Coadministration
9638,Change in HPR Status After the Coadministration of PPIs With Clopidogrel Compared With the Administration of Clopidogrel Alone
9641,Univariate Analyses for Prediction of Cardiac Events
9642,Multivariable Cox Proportional Hazards Model for Prediction of Cardiac Events
9649,Maximum and Minimum Values of Aortic Annulus Dimensions in Normal Subjects and Patients With Severe Aortic Stenosis
9651,Associations of Reported CHD SNPs With CHD Risk in NHS, HPFS, and JHS
9652,Joint Effect of the Loci Significantly Associated With CHD
9653,Potential Advantages and Disadvantages of Targeting Chemokines
9655,Study Outcomes With Adjusted HRs
9656,Study Outcomes With Adjusted HRs for the Propensity ScoreMatched Cohort Analysis
9658,Adjusted HRs for the Impact of ACE Inhibitors or ARBs on Outcomes Stratified by the Severity of Regurgitation
9664,Clinical Variables
9665,Early and Late Clinical Events
9666,Study Outcomes: Efficiency, Cost, and Safety
9672,Relationship Among the 5 Metabolic Criteria Used in the Definition of MetS, the Presence of MetS, BMI, and HF Incidence During the 6 Year Follow Up Period
9675,Histological and Immunohistochemical Data 21 Days After MI
9679,Coronary Artery Stenosis Severity by Segment For Individuals Who Lived Versus Died
9680,Univariable and Adjusted Hazard Ratios for All Cause Mortality by Per Patient, Per Vessel, and Per Segment Analysis by Obstructive CAD at the 50  and 70  Stenosis Level
9681,Adjusted Hazard Ratios for All Cause Mortality for Patients  65 Versus 65 Years of Age
9682,Adjusted Hazard Ratios for All Cause Mortality for Female Versus Male Patients
9683,Multivariable Adjusted Hazard Ratios for All Cause Mortality as Stratified by Age and Sex
9685,Comparison of Patients With and Without Hard Cardiac Events
9686,Comparison of Patients With and Without MACE
9687,Incidence of Hard Cardiac Events and MACE Across Group Categories
9688,Multivariable Cox Models of Hard Cardiac Events for Prognostic Value of MFR Compared With SSS
9692,Total Number of Events
9693,Adjusted and Unadjusted HRs for All Cause Mortality and CV Events
9694,Adjusted HRs for All Cause Mortality and CV Events Stratified by Severity of AS
9697,Association of Serum Phosphate Concentration With Aortic Valve Sclerosis, Mitral Annular Calcification, and Aortic Annular Calcification
9698,OR   95  CI   of Aortic Valve Sclerosis, Mitral Annular Calcification, and Aortic Annular Calcification by PTH and 25 OHD Levels
9699,Contraction and Relaxation Time Intervals
9703,Tag SNPs From the IRS 1 Gene Region and Genotype Frequency
9704,Prevalence of Patients With HPR Among Carriers and Noncarriers of the C Allele of the rs956115 Marker
9705,Examples of Adiposity and Adiposopathy Disorders Related to Cardiovascular Disease
9706,Adiposopathy   Sick Fat  : Summary of Causality and Examples of Anatomic, Pathophysiological, and Clinical Manifestations
9707,Adipose Tissue as an Endocrine Organ: Adipocytes and Adipose Tissue Produce Factors Actively Involved in Metabolic Processes Important for Human Health
9708,Adipose Tissue as an Immune Organ: Adipocytes and Adipose Tissue Produce Factors Actively Involved in Immunological Processes Important for Human Health
9709,Examples of Diseases Other Than Adiposopathy That Cause Common Metabolic Diseases
9710,Clinical Presentations of Patients in the Test Set
9712,Pathophysiology of Pressure Overload TAC Heart in Mice Given Captopril Chronotherapy at Sleep Versus Wake Time
9713,Echocardiography Measurements
9723,Relationships Among Diameter Stenosis and TIMI Flow Grade, TIMI Frame Count, and CCO Gradients Vessels With Obstructive CAD
9724,CCO in Patients With Abnormal Resting Coronary Blood Flow
9725,Abnormal and Normal CCO Gradients
9729,Biochemical Safety Parameters
9731,Echocardiographic Parameters in HFNEF Versus Controls
9732,Collagen Cross Linking in Patients With HFNEF Versus Controls
9733,Correlation of Diastolic Indexes From Mitral Flow and Tissue Doppler With CVF, Insoluble Collagen, Collagen Cross Linking, and LOX Expression
9734,Clinical Parameters
9735,Plasma Parameters
9736,Details of Fetuses Diagnosed With AS, Severe MR, and Severe LA Dilation
9737,Echocardiographic Findings in 14 Fetuses With AS, Severe MR, and Severe LA Dilation
9739,Pollutant Levels and Environmental Conditions During Exposures
9740,Effects of CAP and Ozone Exposure on cTp e Interval Changes During Exposures
9741,Effects of CAP and Ozone Exposure on QT Dispersion Interval Changes During Exposures
9743,MRI Data
9744,Segment Location and Orientation of CC and SI Channels
9746,FBF Responses
9747,Analysis of Lipid Parameters
9749,Procedural Results and Angiographic Outcomes in Diabetic and Nondiabetic Cohorts
9750,Clinical Outcomes at 1 Year According to Presence of Diabetes
9751,Clinical Outcomes at 1 Year in Noninsulin  and Insulin Dependent Diabetic Patients
9753,Clinical Outcomes at 12 Months According to Stent Randomization
9755,Clinical Outcomes at 24 Months According to Stent Randomization
9758,Strongest Risk Factors for Sudden Cardiac Death Among Men
9759,Comparison of Sudden Cardiac Death Prediction Models Without   Model 1   and With   Model 2   Cardiorespiratory Fitness
9760,Effect of Adding Cardiorespiratory Fitness to Traditional Risk Factors: Reclassification of Men Between Predicted Cardiovascular Risk Categories and Comparison of Observed and Predicted Risk of Sudden Cardiac Death
9762,Protocols for Cardiosaver and DETECT Phase I Studies
9764,Sensitivity and Specificity for BMIPP SPECT Images for the Efficacy Population   n   448
9766,Evaluation of BMIPP SPECT Imaging Compared With Angiography Results: Correlation With Culprit Lesion Anatomy
9769,Hemodynamic Parameters, Cardiac Dimensions, and Function in the Study Population
9770,Univariable and Multivariable Linear Regression Analysis of Liver Triglyceride Content, Myocardial Metabolic Rate of Glucose, and PCr ATP Ratio
9771,Characteristics of the Studies Included in the Meta Analysis
9772,Sensitivity Analyses of CYP2C19 Genetic Variants
9773,Sensitivity Analyses of the Impact of PPI Coadministration
9776,Antibody Profiles of 111 Children With   Yes   or Without   No   Noncardiac NLE
9777,Exclusion Criteria
9780,Clinical Outcome at 12 Months of Follow Up
9784,Potential Mechanism of Heart Failure With Preserved Ejection Fraction
9790,Univariate and Multivariate Cox Proportional Hazards Ratio Comparison for CAC Progression in Propensity Matched Cohort
9792,Platelet Activation Profiles According to HPPR Status
9794,1 Year Clinical Outcomes in Patients With and Without Medically Treated Diabetes
9795,1 Year Clinical Outcomes in Diabetic Patients Treated With Oral Hypoglycemic Agents or Insulin
9797,Analysis of Lipid Parameters
9800,Magnetic Resonance Imaging Variables
9802,Major End Points at 1 Year
9803,Outcomes in Subgroups of Interest
9806,SPECT Protocol and Tc 99m Radiopharmaceutical Doses
9807,Annualized All Cause Mortality Rates Between Subgroups
9808,Univariate and Multivariable Predictors of Mortality
9809,Comparison Between Echocardiographic and MSCT Measurements
9810,Impact of the Method of Aortic Annulus Measurement on TAVI Strategy
9812,Hypertension and Left Ventricular Hypertrophy by Race Ethnicity and Hispanic Subgroups
9813,Odds Ratios of Left Ventricular Hypertrophy by Race Ethnicity and Hispanic Subgroups After Sequential Adjustment for Covariates
9814,Odds Ratios of Ventricular Remodeling   Elevated M C Ratio 95th Percentile   by Race Ethnicity and Hispanic Subgroup After Sequential Adjustment for Covariates
9816,Angiographic Findings and Clinical Presentation
9817,Observations in the Group With Late Optical Coherence Tomography
9820,Comparison of the 10 Year Estimated Vascular Risks by the Model With Traditional Framingham Variables    and the NOMAS GVRS
9821,Procedural and Angiographic Findings, Comparison Between BMS and PES
9822,Procedural and Angiographic Findings, Comparison Between BMS and SES
9826,Angiographic Complications of the Patients Enrolled in the 2 Groups
9827,Changes in Cardiac Enzymes After PCI in the Patients Enrolled in the 2 Groups
9829,Compendium of RYR2 Mutations and Polymorphisms Reported to Date
9833,Multivariable Predictors of Events
9834,Subjects With a Normal Stress SPECT: Relative Risk of Events Based on CACS Severity
9835,Histological Definition and Grading of the Aortic Tunica Media
9836,Elastic Tissue Configuration of the Pulmonary Trunk
9840,Exposure to Respiratory Disturbance During Hazard Period and 3 Matched Referent Periods   n   62 Matched Sets
9841,Risk of Arrhythmia After Respiratory Disturbance Compared With Risk of Arrhythmia During Normal Nocturnal Breathing
9843,Risk of Death Transplantation in Year 2 Based on cTnT Profiles During Year 1 of Clinical Follow Up
9845,Criteria for the Definition of Heart Failure With Preserved Systolic Function
9850,Baseline Characteristics of STRENGTH Cohort Stratified by the CAE
9851,Reduced Function Alleles of Statin Pharmacokinetic Genes and Frequency in the STRENGTH Study
9852,Simvastatin and Pravastatin Metabolite Concentrations in the STRENGTH Study
9853,Sensitivity Analyses Using Various End Point Definitions
9858,Outcomes in Patients With the Acute Coronary Syndrome   GUSTO IV   at Different Cutoff Levels of the High Sensitivity cTnI Access Assay
9861,A Comparison of the Effects of Dietary and Surgical Weight Loss
9863,MRI, Functional, and Laboratory Results
9864,Relationship Between Noninvasive Measures
9865,Relationship Between Imaging and Functional Parameters
9867,Procedural Features in the Atorvastatin Reload and Placebo Groups
9868,Individual and Combined Outcome Measures of the Primary End Point at 30 Days in the Atorvastatin Reload and Placebo Groups
9870,Load, Contractility, and Ventricular Arterial Coupling
9872,Incidence of MACE and Cardiac Death   10 Year Follow Up
9873,Predictors of Events at Univariate and Multivariate Analyses
9876,Comparison of Clinical Profile of All Subjects Who Did and Did Not Develop ACS
9877,Multivariate Cox Regression Analysis for Development of Acute Coronary Syndrome
9878,Comparison of Clinical Profile of Subjects With 2  or 1 Feature Positive Plaques in Whom ACS Did and Did Not Develop
9882,Cytokine Concentrations in the Collateral and Coronary Samples   in pg ml
9883,Correlations of Collateral Coronary Cytokine Gradients With Oxygen Gradient in Patients With Subtotal Stenosis
9885,Exercise Echocardiographic Data of the 4,004 Patients
9886,Univariate Predictors of Mortality and Major Cardiac Events
9887,Multivariate Predictors of All Cause Mortality
9888,Multivariate Predictors of Major Cardiac Events
9889,Inclusion and Exclusion Criteria
9890,Baseline Characteristics of 368 Patients Who Presented to the Emergency Department With Acute Chest Pain But Negative Initial Biomarkers and Nonischemic Electrocardiogram
9891,Diagnostic Accuracy of Coronary CTA for the Detection of Acute Coronary Syndrome and Myocardial Infarction During Index Hospitalization Among Patients With Acute Chest Pain Based on the Presence of Any Coronary Plaque or the Presence of Coronary Artery Stenosis    50  Luminal Narrowing
9895,Adjusted RR of Restenosis Pairwise Comparison Between Stents
9896,Drug Regimens Used in Each Constituent Trial
9909,Distribution of ST Across Quintiles
9910,Clinical Outcome
9912,Univariate Logistic Regression Analysis of Clinical and Humoral Factors for Prediction of IR in Patients With HF
9913,Multiple Logistic Regression for Each Variable to Predict IR in Patients With HF
9914,Correlations Among Absolute Values and Percentage Inhibition Values With Different Methods
9916,Antiarrhythmic Medications Utilized for the Treatment of JET
9917,Medications Reported to be Successful in the Treatment of JET
9918,Outcomes of Radiofrequency Ablation and Cryoablation for Junctional Tachycardias
9919,Comorbidities or Complications During the Treatment of Patients With JET
9921,Imaging Results
9922,Univariate Predictors of Events
9925,Clinical and Therapeutic Data in 16 Patients With Electrical Storm
9926,Nucleotide Sequences of TLR2, TLR4, and Scrambled siRNA
9927,Chemokine Release After Stimulation With TLR Agonists
9934,Measurements of the SAECG, HRV, and QT Dispersion in Patients With and Without SCD
9935,Univariate and Multivariate Cox Proportional Hazard Analysis for the Identification of CHF Patients at Risk of Sudden, Pump Failure, and Cardiac Death in Total Study Patients
9936,Univariate and Multivariate Cox Proportional Hazard Analysis for the Identification of CHF Patients at Risk of Sudden, Pump Failure, and Cardiac Death in Patients With Sinus Rhythm
9937,Prediction of SCD and Cardiac Death in Patients With Chronic Heart Failure by a Combination of Abnormal WR and LVEF 35  in Total Study Patients
9938,Correlation Between the Measured Parameters and the Results of Cardiac Metaiodobenzylguanidine Imaging in Total Study Patients
9940,Brachial Artery Diameter and Blood Flow
9942,Comparison of Medication Usage
9947,DSE Data
9948,Anglographic Data
9949,Results
9950,Univariate and Multivariate Predictors
9951,Normal Reference Values of Effective Orifice Areas for Prostheses Implanted in This Series
9953,Univariate and Multivariate Predictors of Late Overall Mortality
9954,Univariate and Multivariate Predictors of Late Cardiovascular Mortality
9956,PRI in the VASP Phosphorylation Assay of Clopidogrel Patients Treated With Different Classes of CCBs
9957,Gene Identification and Primer Sequences
9958,Clinical, Biochemical, and Cardiac Catheterization Data of the Study Subjects
9959,Differences in CD34  Subpopulations
9960,Serum RANKL, OPG, and MGP Levels in the Study Subjects
9962,Association of Cardiovascular Risk Factors and Severity of CAD Diagnosed by CTA
9963,Hazard Ratios of Death and 95  Confidence Interval   in Parentheses   According to CAD Status
9964,Hazard Ratios of Death and 95  Confidence Interval   in Parentheses   Across Groups of Patients With Increasing CACS Among Those With CTA Diagnosed Nonobstructive CAD   n   1,060
9966,Use of AVJ Ablation in AF Patients
9971,Results of Multiple Variable Analysis
9976,Hemodynamic Response to Exercise
9977,Neurohormonal Response to Exercise in Subjects With or Without an Exaggerated BP Response to Exercise
9983,Association of Plasma Levels of Adiponectin and Leptin With Coronary Artery Calcification in Tobit Multivariable Models
9984,Incremental Value of Metabolic Syndrome, CRP, Adipocytokines, or HOMA IR in Predicting Coronary Calcium Scores Beyond Established Risk Factors
9991,Components of Primary End Point   ITT Population
9992,Secondary and Tertiary Clinical Events
9994,Components of the Primary End Point Within SUA Subgroups   ITT Population
9999,Biological and Clinical Features of the Whole Study Population With Silent CAD at Baseline, of Patients With and Without ED, and of Patients With and Without MACE
10000,Biological and Clinical Features of ED Patients With and Without MACE
10001,The Role of NOS
10003,Lack of a Role of Distending Pressure in L FMC
10004,FMD and L FMC in Health and Disease
10005,Features Associated With TAV Versus BAV in Girls and Women With TS
10006,Genotype and BAV Prevalence
10014,Clinical Outcomes for African American Compared With NonAfrican American Patients
10015,Independent Association of African American Race and Quality of Care
10018,Associations of Functional Performance Measures With Mortality Among Participants With PAD After Additional Adjustment for Physical Activity Levels: Normal Paced 4 m Walking Velocity
10019,Associations of Functional Performance With Total and Cardiovascular Mortality Among Participants With PAD After Additional Adjustment for Physical Activity Levels: Fast Paced 4 m Walking Velocity
10022,Effects of Weight Loss on LV Geometry and Systolic Function
10023,Effects of Weight Loss on Left Ventricular Diastolic Function
10026,Associations between Calendar Year and Mortality in 21,484 Survivors of MI: Impact of Increasing Utilization of Coronary Interventions     and of Recommended Cardiovascular Medications after Discharge
10029,Quantitative Angiographic Measurements
10030,Angiographic Patterns of Restenosis
10031,Clinical Outcomes at 9 Months
10032,Predictors of Angiographic Restenosis and Clinical Outcomes on Multivariate Analysis
10033,Adverse Drug Effects
10036,Antiplatelet Treatment at the Time of ST
10037,Multivariate Analysis for Predictors of ST in a Subgroup of 14,120 Patients
10038,Clinical Presentation, Treatment, and Outcome
10039,Independent Predictors for Mortality and Recurrent Thrombosis
10041,Percentage of Plaque Showing CS   CV  20 cm s   or CB   CV  10 cm s   During Pacing From the Plaque Corners
10042,Total Plaque Activation Time   Inferior Corner Pacing
10043,Conduction Anisotropy: Anisotropy Index
10044,Conduction Heterogeneity
10049,4 Year Efficacy Outcomes
10050,4 Year Safety Outcomes
10051,Efficacy and Safety Outcomes Among Diabetic Patients According to Insulin Dependent Status
10054,Iloprost Dosing
10058,Multivariate Analysis of Clinical Factors Predicting Cardiac Death in Hemodialysis Patients Using Stepwise Cox Hazard Model
10065,Anatomy From the Initial Echocardiogram at Presentation
10066,Z Scores of Left Heart Structures at Presentation
10067,Significant Predictors for Time Related Outcomes
10069,Effects of In Vivo GTN Treatment or In Vitro ALDH 2 Inhibition on Vascular Reactivity
10070,ALDH Activity in Human Bypass Graft Vessels Without Prior GTN Treatment
10077,Presenting Signs and Symptoms   n   24
10078,Positive Post Operative Ischemia Tests   n   9
10079,Breakdown of Hyperkalemia Outcomes in CHARM Overall
10080,Clinically Important Hyperkalemia in CHARM
10085,Age Adjusted Hazard Ratio
10086,Univariate and Multivariate Predictors of Cardiovascular Events   Myocardial Infarction and Cardiac Death
10087,Stepwise Cox Proportional Model for the Prediction of Cardiovascular Events
10089,Comparison of RV EDV, ESV, SV, and EF Between 3D US and MRI
10091,Relationships Between Calcium in Different Vascular Beds and HTN
10093,Laboratory Data of the Entire Cohort and According to Quartiles of Platelet Aggregation
10094,Platelet Function Profile Analyses
10097,Multivariate Analysis of Predictors of Time to Reoperation
10098,Multivariate Analysis of Predictors of Recurrence
10100,Univariate and Multivariate Prognostic Predictors
10101,The Small Artery and Arteriolar Diameter Measurements at Rest and During Cardiac Pacing
10102,Hemodynamic Status at Rest and During Cardiac Pacing
10104,Univariate and Multivariate Predictors of Cardiac Events   Myocardial Infarction and Cardiac Death
10105,Age Adjusted Relative Risk
10107,Outcomes for Ticlopidine  and Clopidogrel Associated TTP Cases
10109,BP and HR at Rest Before and After Treatment
10110,Blood Biochemistry Before and After Treatment
10112,Risk Factors for Cardiac Mortality
10118,Post Discharge 60  to 90 Day Clinical Outcomes by Ventricular Function
10119,Discharge Medications and Risk  and Propensity Adjusted Outcomes After Hospital Discharge in Patients With Reduced and Preserved Systolic Function
10127,Functional Assessment Before and After LDLLT
10128,Latest WHO Functional Class
10133,Safety of grazoprevir plus elbasvir with or without ribavirin
10140,Heart Failure Hospitalization and Mortality by Diabetic Drug Category
10142,Mean Daily Intake of Individual Foods According to Quartiles of Energy Adjusted Dietary Glycemic Load
10143,Adjusted Hazard Ratios   With 95  CI   of Cardiovascular Disease According to Quartiles of Energy Adjusted Dietary Glycemic Load and Glycemic Index Among 15,714 Women
10144,Adjusted    Hazard Ratios   With 95  Confidence Intervals   of Cardiovascular Disease According to Quartiles of Energy Adjusted Carbohydrates, Mono  and Disaccharides, and Polysaccharides Among 15,714 Women
10145,Adjusted    HRs Among BMI Subgroups According to Quartiles of Dietary Glycemic Load and Glycemic Index
10147,Correlation Coefficients Between Serum Concentrations of LBP and Coronary Risk Factors in Men   n   247
10148,Multivariable Logistic Regression Predicting the Likelihood of CAD According to Quartiles of LBP Levels, Markers of Systemic Inflammation, and Established Cardiovascular Risk Factors
10150,Assessment of Regional Myocardial Function in the Systemic RV Free Wall Compared With the RV and LV Free Wall in Healthy and Operated Control Subjects
10151,Assessment of Regional Myocardial Function in the IVS of the Senning Operated TGA Patients Compared With the IVS in Healthy and Operated Control Subjects
10156,Spearman Correlation Coefficients Between HOMA IR and the Continuously Distributed Individual Components of the Metabolic Syndrome
10157,Relationship Between the Metabolic Syndrome Based on IDF Criteria, HOMA IR Expressed Both as a Categoric Variable and as a Continuous Variable, and Risk of Cardiovascular Disease With Successive Inclusion of Variables in the Models
10158,Relationship Between the Metabolic Syndrome Based on NCEP Criteria, HOMA IR Expressed Both as a Categoric Variable and as a Continuous Variable, and Risk of Cardiovascular Disease With Successive Inclusion of Variables in the Models
10159,Relationship Between Risks of Cardiovascular Events According to the Individual Components in the Metabolic Syndrome Compared With Their Respective Counterparts Based on Both IDF Criteria and NCEP Criteria
10160,Relationship Between the Metabolic Syndrome Based on IDF Criteria, HOMA IR Expressed Both as a Categoric Variable and as a Continuous Variable, and Risk of Cardiovascular Disease With Adjustment for the Framingham Risk Score
10161,Relationship Between the Metabolic Syndrome Based on NCEP Criteria, Insulin Resistance as Assessed by Homeostasis Model Assessment, Expressed Both as a Categorical Variable and as a Continuous Variable, and Risk of Cardiovascular Disease With Adjustment for Framingham Risk Score
10163,Cox Proportional Hazards Analysis of Factors Predictive of Death
10164,3 Chlorotyrosine Levels in Total Plasma Protein From MI Patients With High or Low MPO and Protein Carbonyls
10166,Simple Linear Regression Analysis for Determinants of sCD40L and 8 OHdG in Children
10168,Cox Regression Investigating Predictors of Survival After MI
10180,Frequency of Revascularization Procedures and Cardiac Events During Follow Up Results in the CAC Cohort
10181,Frequency of Revascularization Procedures and Cardiac Events During Follow Up in the MPS Referral Cohort
10190,Multivariate Analysis of Determinants of Left Ventricular Internal Dimension in Diastole
10194,Early and 6 Month Clinical Outcomes
10196,Hemodynamic Measurements in Rats With ACF and Age Matched Sham Rats
10197,Isolated Cardiomyocyte Function in Age Matched Sham and ACF Rats
10199,Hemodynamic and Morphometric Parameters in 2 Day Untreated ACF, 2 Day ACF   Hoe 140, and 2 Day ACF   Ang II
10205,Clinical Outcome in ARTS II According to Clinical Presentation
10210,Summary Estimates of Event Rates After a Negative Test and Negative Predictive Values for MI and Cardiac Death, and Revascularization and Unstable Angina After a Negative Test
10211,Summary Estimates of Rates After a Negative Test and Negative Predictive Value for Myocardial Infarction or Cardiac Death for Women and Men in Exercise Myocardial Perfusion Imaging and Exercise Echo
10215,Comparison of Indexes of Diastolic and Systolic Asynchrony as Well as Myocardial Systolic and Diastolic Velocities Among Patients With DHF, SHF, and Normal Controls
10225,Incidence and Interobserver Agreement for the Qualitative Magnetic Resonance Variables
10227,Predictors of Exercise WMSI  1
10239,In Hospital Outcomes
10240,Multiple Cox Model for Long Term Mortality
10244,Multivariate Proportional Hazards Regression Model Results
10256,Left Ventricular Ejection Fraction   LVEF   and Left Ventricular Diastolic Diameter   LVDD   at 6 Months by 344 Genotype and Treatment
10259,Raw and Weight Change Adjusted Differences in Metformin Versus Placebo Recipients for Change in Vascular Response   AUC for ACh Mediated Perfusion  , HOMA IR, and ST Segment Depression
10270,p Values for Comparisons of Effects of Different Loading Doses on Inhibition of Platelet Aggregation
10272,Incidence of Bleeding Complications by Treatment Group, Day 1 to Hospital Discharge
10286,Platelet Function Profiles of the Study Population
10287,Multivariate Linear Regression Analysis of ADP Induced Platelet Aggregation
10289,Risk Factors, Cardiac Functions, and Medications During the Follow Up Period in Patients With Acute Myocardial Infarction
10292,Effect of Patient Group on Heart Rate Dependence of Cardiac and Hemodynamic Parameters
10296,Severity of PAD Based on Pulse Volume Recordings
10299,Cardiac Geometry in Normal Weight, Overweight, and Obese Adolescents
10300,Cardiac Function in Normal Weight, Overweight, and Obese Adolescents
10302,Daily Caffeine Consumption
10304,Site of Ischemia in Relationship to Major Vessels
10305,Perfusion Defect Extent and Size Without and With Caffeine
10307,Incidence of Clinical Worsening
10308,Treatment Related Side Effects
10311,ANOVA for Repeated Measures Results   df   1,17   on the Improvement of Subjects Performance From Trial 1 to Trial 5
10312,Test Retest Reliability Values and Standardized Coefficient Alpha Values for the 18 Subjects Across Five Different Measures
10315,Results in 20 BAV Patients and 20 Age  and Gender Matched Healthy Subjects
10316,Clinical Manifestations of Metabolic Syndrome and Control Subjects
10318,Partial Correlation Coefficient Adjusted for Smoking Status Between Clinical and Biochemical Parameters With Rho Kinase Activity Among Metabolic Syndrome Subjects
10319,Adjusted Odds Ratios of Greater ROCK Activity With the Number of MetS Components
10321,FBF Responses: Ratio of Infused to Noninfused Arm
10322,FBF Responses: Ratio of Infused to Noninfused Arms
10323,Comparison of the CAC and MPS Patient Groups
10326,Comparison of Patient Populations
10328,Comparison of 64 Slice CT Myocardial Lack of Hyperenhancement With Low Dose Dobutamine Echocardiography
10330,Detection of CAD by Cardiac PET CT in 64 Patients Who Underwent Coronary Angiography
10331,Extent of CAD by Cardiac PET CT in the 44 Patients With Significant Angiographic CAD
10339,Diagnostic Efficiency
10342,Effect of Hoe 140 on Hemodynamic and Echocardiographic Measurements in Control Rats   2 Day SHM   and Rats 2 Days After ACF
10344,Effect of RAM on Hemodynamic and Echocardiographic Measurements in Control Rats   4 Week SHM   and Rats After 4 Weeks of ACF
10362,Comparison of 16  Versus 64 Slice Multi Slice Computed Tomography   MSCT
10365,MBF and MGU, Tissue Fraction, and Glucose Extraction in Patients With Normal Glucose Tolerance and Those With T2DM
10367,Task Force Criteria for the Diagnosis of Arrhythmogenic Right Ventricular Dysplasia Cardiomyopathy
10372,Univariate Predictors of Death and Combined End Point
10374,Short Axis Left Ventricular Function With Circumferential S and SR and Radial S and SR in Control, Dysfunctional, and Subendocardial Infarct and Transmural Infarct Segments
10375,Long Axis Function With Longitudinal S and SR in Control, Dysfunctional, Subendocardial Infarct, and Transmural Infarct Segments
10377,Comparison of Measurements in Normal Subjects Versus MR Patients
10379,Detection of Significant Coronary Artery Stenosis    50    With 64 Slice Computed Tomography
10396,Age  and Sex Adjusted Means and Proportions of Risk Factors by Ethnic Group
10397,Traditional Risk Factors for PAD
10398,Odds of PAD Associated With a 1 SD Increment in Each Novel Risk Factor
10406,Cardiac Events Over the Follow Up Period for Different Summed Stress Scores
10408,Cardiac Events Over the Follow Up Period for Ischemia and Summed Stress Score
10409,Image Quality Comparison and Diagnostic Certainty of Image Comparison Between 99mTc SPECT and 82Rb PET MPI
10410,Cardiac Events in Obese Patients
10412,Summary of Hemodynamic Variables of the Subjects in Each Group
10416,Incidence of Bleeding Complications by Treatment Group, Day 1 to Hospital Discharge
10427,Secondary outcomes at days 7 and 90
10428,Number of site years in database by source type
10429,Global deaths for 235 causes in 1990 and 2013 for all ages and both sexes combined and age standardised death rates
10430,Selected causes of global child deaths in 1990 and 2013
10431,Counterfactual deaths and population attributable fractions for diarrhoea and lower respiratory infection pathogens for 1990 and 2013
10432,Comparison of GBD and CHERG estimated child deaths for select causes in 2010
10435,Pairwise and network estimates of the effects of different drug regimens compared with placebo on primary and some secondary safety outcomes
10438,Effect of vitamin A on primary and secondary outcomes
10439,Adverse events between supplementation and 3 days after dosing
10440,Serum retinol concentrations of infants aged 2 weeks, infants aged 3 months, and mothers of infants aged 3 months
10443,Adverse events occurring in at least 25  of patients in either treatment group
10444,Key safety outcomes
10446,Proportion of patients with plasma hepatitis C virus RNA concentration lower than the quantification limit
10447,Adverse events and abnormalities on laboratory tests during treatment
10449,Antihypertensive medications
10450,Adverse events related to arteriovenous coupler placement or device
10453,Virological response
10454,Safety and adverse events   initial treatment period and first 14 days after completion of treatment
10460,Safety and tolerability profile of secukinumab until week 16   placebo controlled period   and for the entire treatment period
10466,Adverse events, changes from baseline in vital signs, and treatment emergent dulaglutide antidrug antibodies from baseline to 52 weeks
10468,Adverse events in the safety population
10470,Hazard ratios for progression free and overall survival by number of risk factors
10471,Treatment emergent adverse events with an incidence of 10  or more in the brentuximab vedotin group, in the safety analysis set
10474,Adverse events
10475,Reasons for follow up of less than 21 months
10478,Adverse events occurring in 1  or more of patients in either treatment group
10479,Comparison of Biochemical Data for Peripheral Blood Treated With or Without the Column
10483,Adverse events
10485,On treatment and post treatment HCV virological response
10486,Discontinuations, adverse events, and haematological abnormalities in patients who received 12 weeks or 24 weeks of combined sofosbuvir and ribavirin
10488,Primary outcomes at various timepoints
10491,Treatment emergent adverse events
10494,Common adverse events   all grades   in 5  of patients
10496,Summary of solicited adverse reactions and unsolicited adverse reactions occurring within 28 days of vaccination
10497,Antibody responses to the glycoprotein of the 2014 Zaire Ebola virus
10499,Adverse events after treatment with dabigatran etexilate alone and after administration of idarucizumab or placebo
10503,Postsurgery FIGO stage and histological diagnosis
10504,Surgery details
10505,Postoperative grade 3 or 4 adverse events and mortality
10506,Chemotherapy received
10510,Factors associated with change in cycle endurance time at 3 months
10511,Responder rates according to lung function, health status, and exercise criteria
10512,Adverse events
10514,Serious adverse events, defined as major morbidity
10517,Primary and key secondary endpoints
10518,Serious adverse events
10520,Details of suture techniques
10521,Secondary outcomes
10523,Incidence and HR for all cause mortality and subdistribution HR for outcomes per 5 kg reduction in grip strength
10524,HR for all cause mortality and subdistribution HR for cardiovascular mortality and cardiovascular disease
10528,Longitudinal clinical data and drugs used
10529,Mean systolic and diastolic blood pressure levels and prevalence of hypertension by age group and sex in the 2011 Health Survey for England
10530,Blood pressure levels and hypertension from 1994 to 2011
10531,Type of drugs used among participants treated for hypertension
10532,Randomised, controlled, cardiovascular outcome trials    1000 subjects,  1 year of follow up   of glucose lowering drugs or strategies in people with type 2 diabetes
10533,Ongoing cardiovascular outcome trials of glucose lowering drugs or strategies   in order of starting date
10537,Occurrence of contrast induced acute kidney injury
10538,Occurrence of contrast induced acute kidney injury in prespecified patient subgroups
10539,Major adverse events at 30 days and 6 months
10547,Safety assessments and vital signs up to 26 weeks  follow up
10548,Clinical endpoints for first and second phases
10549,Tobit regression model exponentiated estimatesdependent variable natural log 6 month NOAEL
10550,Adverse events during treatment presented
10552,Outcomes for plasma HIV 1 RNA of less than 50 copies per mL at week 48
10553,Common adverse events   5  incidence in either treatment group
10554,Summary of serious adverse events by system organ class
10555,Summary and statistical analysis of HIV Treatment Satisfaction Questionnaire scores by week
10557,Additional estimated costs for high and medium scenario compared to low scenario   US , 2011
10558,Estimated direct cost per intervention package
10559,Additional health workers needed based on coverage increases above 2012 estimated coverage in respective scenario
10560,Summary investment metrics, by region to 2035 and 2050, at 3  discount rate
10561,Summary investment metrics, for economic benefits and all benefits, all countries, selected periods and discount rates
10563,Treatment emergent adverse events occurring in 10  or more of patients in either group during the double blind period   safety population
10566,Adverse events occurring in at least 10  of patients or of special interest irrespective of cause
10569,Summary of adverse events in the pembrolizumab 2mg kg and 10 mg kg groups
10571,Kaplan Meier estimates of relapse free efficacy at 6 months after treatment in the intention to treat population
10572,Results by country for Kaplan Meier estimates of relapse free efficacy at 6 months after treatment
10573,Median parasite and fever and gametocyte clearance times
10574,Most frequent adverse events of any cause reported in the safety   intention to treat   population
10575,All serious adverse events of any cause reported in the safety   intention to treat   population
10578,Most common adverse events during study phase 1, by dose
10579,Most common adverse events during study phases 2 and 3
10580,Frequency of Death and Conversion to an SV Circulation
10581,Nausea, vomiting, and abnormal LFT results during study phases 2 and 3, by dose
10582,Distribution of Threshold Scores Among New Patients   n   89   Who Did   Survivors   and Did Not   Events   Survive With a Biventricular Circulation
10586,Efficacy of the vaccine against gastroenteritis in the per protocol population
10587,Protective efficacy of the vaccine against severe gastroenteritis caused by different RV genotypes
10588,Serious adverse events coded by the Medical Dictionary for Regulatory Activities system of organ classification and preferred terms
10590,Adverse events by body system
10591,Estimated change per month in secondary and metabolic outcome measures
10593,Outcomes
10594,Adverse events
10596,Diagnostic results by modality
10600,Overall adverse events and serious adverse events
10602,Virological responses
10603,SVR12 by subgroup
10604,Summary of on treatment safety
10606,Summary of findings for catheter venography and ultrasound criteria, by group
10607,Catheter venography and ultrasound findings by centre
10608,Number of ultrasound criteria met by the participants, grouped by whether or not CCSVI criteria were fulfilled
10609,Structural abnormalities detected by ultrasound
10610,Agreement between ultrasound   at least two of five criteria positive   and presence of venous narrowing on catheter venography
10612,Effect of isoniazid on rate of tuberculosis or death
10613,Effect of isoniazid on the rate of all tuberculosis stratified by markers of Mycobacterium tuberculosis infection status at enrolment
10614,Effect of isoniazid on the risk of stopping the study drug because of adverse events
10619,Systolic and Post Systolic Measurements in Six Regions in the LV Anterior Wall in Patients With Recent LAD Occlusion   n   10   and Healthy Volunteers   n   15
10624,Virological response over time   RVR and SVR12  , and on treatment failure and relapse, according to treatment group in the intention to treat population
10625,Proportion of patients meeting criteria for response guided treatment in the simeprevir, peginterferon alfa 2a and ribavirin group and corresponding SVR12 in the intention to treat population
10627,Summary of adverse events during the first 12 weeks and during the entire treatment
10629,Virological response with time   RVR and SVR12  , on treatment failure, and relapse in the intention to treat population
10630,Patients meeting criteria for response guided therapy in the simeprevir group and corresponding SVR12 in the intention to treat population
10632,Summary of adverse events during the first 12 weeks of treatment and during the entire treatment
10633,Summary of adverse events during the entire treatment by type of peginterferon alfa
10635,Proportion of patients with plasma HIV 1 RNA less than 50 copies per mL at week 24 or week 48, or both
10636,Clinical adverse events and laboratory abnormalities at week 48
10640,Multivariable Model for Prediction of Cardiac Death in Patients With Known CAD
10641,Multivariable Model for Prediction of Cardiac Death in Patients With Suspected CAD
10642,Three Year Risk Adjusted Rates of Cardiac Death in Patients With Known CAD by MPS Results, Gender, Age, Stress Type, and LVEF
10643,Three Year Risk Adjusted Rates of Cardiac Death in Patients With Suspected CAD by MPS Results, Gender, Age, Stress Type, and LVEF
10644,Wilson Jungner  23   principles of early disease detection and screening for chronic kidney disease
10645,Haematological and blood chemical values for patient 1
10646,Haematological and blood chemical values for patient 2
10647,Genetic analysis of specimens
10648,Mortality rates and variables for selected municipalities   N 2853
10649,Fixed effect negative binomial models for association between under 5 mortality rates and Bolsa Familia Programme   BFP   and Family Health Programme   FHP   coverage
10650,Fixed effect negative binomial models for adjusted associations between Bolsa Familia Programme   BFP   and Family Health Programme   FHP   coverage and under 5 mortality rates for some relevant groups of causes
10651,Fixed effect models for associations between primary care indicators, rates of admission to hospital, and Bolsa Familia Programme   BFP   coverage
10653,Changes in bone mineral density and differences between groups at 12 months
10655,Adjusted attributable fraction   AF, expressed as weighted percent of total episodes with 95  CI   of pathogens significantly associated with moderate to severe diarrhoea   MSD  , by age stratum and site
10656,Weighted annual incidence   per 100 child years   of total MSD, MSD attributable to a pathogen, and MSD attributable to a specific pathogen, with 95  confidence interval, by age stratum and site, in ordinal rank for specific pathogens
10657,Mortality in children with moderate to severe diarrhoea and their matched controls between enrolment and follow up, by site
10658,Weighted unadjusted and adjusted hazard ratios for selected pathogens and risk of death between enrolment and follow up, in cases of moderate to severe diarrhoea   MSD
10659,Comparison of enrolment length or height for age Z score   HAZ  , and change in HAZ   HAZ   between enrolment and follow up 5090 days later,      between cases with moderate to severe diarrhoea and their matched controls, by site
10662,Anthropometric status at 6, 18, and 24 months of age by trial group
10667,Barriers and recommendations to reduce childhood deaths due to diarrhoea and pneumonia
10668,Annual rates of change in cause specific mortality 200010.
10669,Five disorder meta analysis results for regions with p 5108
10670,Modelling analysis results for single nucleotide polymorphisms   SNP   showing genome wide significant association in previous genome wide association studies from the Psychiatric Genome Wide Association Study Consortium
10671,Expression quantitative trait loci enrichment analysis for single nucleotide polymorphisms   SNPs   from primary meta analysis by p value cutoffs
10673,Summary of safety data
10675,Global and regional burden of diarrhoea and pneumonia per year in children aged 04 years, by WHO region
10676,Contribution of specific pathogens to severe episodes of, and deaths from, childhood diarrhoea and pneumonia, by WHO region
10677,Risk factors with direct biological links to diarrhoea and pneumonia
10679,Interventions common to both childhood diarrhoea and pneumonia
10681,Interventions for the prevention and management of diarrhoea
10682,Interventions for the prevention and management of pneumonia
10683,Diarrhoea and pneumonia deaths averted in the 75 high burden Countdown countries between 2011 and 2025 with the historical trends and ambitious scale up approaches
10684,Estimated incremental costs   US  million   by packages in 2025 for the 75 Countdown countries
10685,Summary of studies of diagnostic molecular markers on thyroid FNAB specimens with indeterminate cytology
10686,Comparison of different molecular diagnostic approaches to FNAB with indeterminate cytology
10687,Results of clinical trials of kinase inhibitors in patients with radioiodine refractory differentiated thyroid cancer
10689,Representative clinical features of the autoimmune rheumatic diseases
10690,Comparison of clinicopathological features of systemic vasculitides
10691,Autoantibody prevalence in autoimmune rheumatic diseases
10694,Episodes of invasive pneumococcal disease and the vaccine effectiveness for the ten valent PHiD CV10 in infants enrolled before 7 months of age
10695,Number of episodes of culture confirmed invasive pneumococcal disease by serotype
10697,GMT, seroconversion rate, and GMFI of neutralising antibody against EV71
10699,Incidence of adverse reactions within 28 days after vaccinations, by treatment and age groups
10700,Notable events in the history of Bangladesh
10702,Major learning and innovations in cyclone management
10703,Major learning and examples of innovations in flood management
10705,Drug related adverse events in 10  of patients during double blind treatment period
10707,Treatment related adverse events occurring in 5  of patients in either group from start of treatment to 30 days after end of treatment   safety population
10710,Treatment emergent adverse events
10712,Patients with plasma HIV 1 RNA less than 50 copies per mL at week 48
10713,Plasma HIV 1 RNA less than 50 copies per mL at week 48 in per protocol analysis, and Kaplan Meier estimates
10718,Adverse events
10719,HIV incidence by subgroup
10721,Helicobacter pylori eradication in first line and second line treatments
10722,Adverse events in first line and second line treatment
10723,Factors affecting eradication in first line treatment
10728,Overall safety and selected adverse events
10732,Summary of adverse events at week 16 and week 24
10734,Proportion of patients with HCV genotype 1 and undetectable hepatitis C virus RNA
10735,Treatment emergent adverse events
10736,Grade 3 or 4 haematological and liver chemistry abnormalities
10738,Adverse events of any cause experienced by 10  or more patients in the everolimus treatment group, by grade
10740,Number with known dementia status and dementia prevalence
10741,Number with known dementia status and dementia prevalence by age, sex, and residential status
10742,Sensitivity analyses for effect of sample non response on estimate of dementia prevalence in 2011
10743,Age standardised death rates, YLLs, and YLDs, and life expectancy at birth and HALE at birth for 1990 and 2010 for both sexes combined for 19 members countries of the G20
10744,Deaths   in thousands   and age standardised death rates per 100000 for 231 causes in 1990 and 2010 for all ages, both sexes combined, and percentage change from 1990 to 2010 in China
10745,Deaths   in thousands  , percentage of all cause mortality, and median percentage change by cause from 1990 to 2010 for children younger than 5 years   both sexes   in China
10746,DALYs   in thousands   for 285 causes in 1990 and 2010 for all ages, both sexes, and per 100000 with 95  UI and percentage change, in China
10747,Disability adjusted life years   in thousands   attributable to risk factors or risk factor clusters in China
10748,Development   SYNTAX Trial   and validation   DELTA Registry   data for SYNTAX score II
10751,Summary of enrolment for primary and secondary endpoints
10752,Effects of the intervention
10753,Effects of the programme pathways
10755,Comparison between initial diagnosis of rejection made by international classification and the diagnosis of the new approach
10756,Multivariate analysis of factors associated with graft loss in patients with antibody mediated vascular rejection
10757,Age standardised death rates, YLLs, and YLDs, and life expectancy at birth and HALE at birth for 1990 and 2010 for both sexes combined
10758,DALYs for 259 causes in 1990 and 2010 for all ages and both sexes combined, and per 100000 for the UK
10759,Disability adjusted life years   in thousands   attributablerisk factors or risk factor clusters in the UK
10760,Decomposition analysis of the change of global death numbers   thousands   by level 1 causes from 1990 to 2010 into total population growth, population ageing, and changes in age specific, sex specific, and cause specific death rates
10761,Global deaths for 235 causes in 1990 and 2010 for all ages and both sexes combined   thousands   and age standardised rates   per 100000   with 95  UI and percentage change
10762,Global disability adjusted life years for 291 causes in 1990 and 2010 for all ages, both sexes combined, and per 100000 with 95  UI and percentage change
10763,Decomposition analysis of the change of global disability adjusted life years   thousands   by level 1 causes from 1990 to 2010 into total population growth, population ageing, and changes in age specific, sex specific, and cause specific disability adjusted life year rates
10764,Disability adjusted life years for 291 causes by region for 1990 and 2010, and the percentage change from 1990 to 2010
10771,Estimated numbers of deaths by cause in 2010
10772,Global and regional average annual rate of change in cause specific child mortality rates between 2000 and 2010, by age range and WHO region
10775,Baseline Patient Characteristics
10776,Diagnostic Performance of Individual CMR Components in Detecting Future Adverse Cardiac Outcome
10781,Overview of strategies for prevention, detection, evaluation, and management to improve outcomes of chronic kidney disease in adults
10784,Adverse events
10785,Diagnostic criteria for prediabetes
10789,Rate of symptomatic, severe, and nocturnal hypoglycaemia during 24 week treatment with glargine or sitagliptin in the safety population
10790,Serious treatment emergent adverse events in the safety population
10792,Effect of zinc given orally on treatment failure
10793,The effect of zinc given orally on secondary clinical outcomes
10794,Component symptoms and signs of probable serious bacterial infection at the time of treatment failure
10796,Prognostic factors for progression free survival
10797,Common adverse events
10798,Patients with increased concentrations of liver enzymes
10800,Mothers reporting exclusive, mixed, or no breastfeeding during study intervals by group
10802,Rates of clinical serious adverse events by group and study period
10806,Treatment emergent adverse events in at least 5  of patients at week 16
10807,Global prevalence of the 50 most common sequelae
10808,Global years lived with disability   YLDs   for a comprehensive set of 289 causes and select sequelae in 1990 and 2010, for all ages, both sexes combined, and per 100000
10809,Decomposition analysis of the change of global years lived with disability   thousands   by level 1 causes from 1990 to 2010 into total population growth, population ageing, and changes in age specific, sex specific, and cause specific years lived with disability rates
10811,Hazard ratios for all cause and cardiovascular mortality in the combined general and high risk populations according to eGFR and albuminuria clinical categories in individuals with and without diabetes
10812,Hazard ratios for end stage renal disease in chronic kidney disease populations according to eGFR and albuminuria clinical categories by the presence or absence of diabetes
10814,Side effects from treatment with vaginal misoprostol or placebo
10815,Cervical outcome variables
10816,Immediate and delayed complications of vacuum aspiration for first trimester abortion surgery
10819,Adverse events and laboratory results
10821,Incidence of veno occlusive disease up to 30 days after HSCT
10822,Drug related adverse events in patients included in the safety analysis
10825,Summary of clinical adverse events during 2 years in the treated set of patients
10829,Adverse events
10831,Patients with HIV RNA concentration of 50 copies per mL or less at week 48
10832,Treatment emergent adverse events leading to premature discontinuation of study drug
10833,Treatment emergent adverse events occurring in at least 10  of patients in either group
10837,Treatment emergent adverse events
10838,Patients reporting hypoglycaemia at any time during the study
10840,Drug related adverse events in at least 10  of patients   safety set
10843,Common treatment emergent all causality adverse events
10845,Analysis of endpoints in the intention to treat population
10846,Response to treatment by treatment group
10847,Toxic effects by treatment group
10849,Cluster adjusted cumulative treatment failure by day 6   primary outcome   in children with severe pneumonia in the intervention and control clusters
10850,Reasons for relapse between days 6 and 14 in children with severe pneumonia in the intervention and control clusters
10851,Antibiotics given to children with severe pneumonia in the control clusters and treatment outcomes
10857,Adverse events, safety variables, and adjudicated cardiovascular events throughout the study
10858,Translational processes underlying the effect of risk exposure on brain and behavioural development
10860,Neural consequences of institutionalisation
10861,High priority developmental risk and protective factors
10862,General base case model inputs
10863,Base case model inputs for quality of life weights and costs
10864,Base case analysis results   probabilistic analysis  cost effectiveness
10865,Sensitivity analyses results   deterministic analysis; men aged 60 years
10866,Clinical Data in 141 Patients With Stable or Unstable Angina
10867,Medical Treatment at the Time of Directional Coronary Atherectomy
10868,Histology and Immunocytochemistry in Patients With Stable or Unstable Angina
10869,Histologic Morphology and Immunocytochemistry According to Clinical Presentation; Unstable Angina Is Analyzed in Acute or Subacute Subgroups
10871,Hemodynamic Results and Myocardial Blood Flow   MBF   During Positron Emission Tomography
10872,Entire Study Group
10873,Overweight Group
10874,Obese Group
10875,Clinical and Echocardiographic Features of the Study Group, Categorized by Stress Echocardiography Results
10876,Clinical and Echocardiographic Features of the Study Group, Categorized by LAVI Results
10877,Logistic Regression Showing the Effect of Normal LAVI   28 ml m2   on Normal Stress Echocardiography After Adjusting for Age, Gender, Low Resting EF    0.50  , LVH, and LVDD
10878,Exercise Parameters of Male Versus Female Subjects Before and After Exercise Training   Mean  SD
10879,Exercise Parameters of Young Versus Older Subjects Before and After Exercise Training   Mean  SD
10880,Mean Values for Exercise Parameters of All Subjects Before and After Training   Mean  SD
10881,Clinical Characteristics
10882,Dobutamine Stress Echocardiographic Data
10883,Predictors of All Cause Mortality
10884,Predictors of Cardiovascular Morbidity
10885,Independent Predictors of All Cause Mortality and Cardiovascular Morbidity Using a Three Step Model
10888,Exacerbation rate in patients allocated N acetylcysteine or placebo
10890,Modified intention to treat analysis day 28 cure rates
10891,Mean lumefantrine concentrations on days 3 and 7
10896,Patients reporting adverse events   5  in any treatment group
10897,Serious adverse events by system organ class during the double blind period of the trial
10898,Patients reporting adverse events leading to discontinuation
10900,Incidence of cardiovascular events during the 10 year follow up in healthy men, snorers, and patients untreated and treated for OSAH
10901,Unadjusted, part adjusted, and fully adjusted odds ratio for cardiovascular death associated with clinical variables and diagnosis status, according to the logistic regression analysis
10902,Unadjusted, part adjusted, and fully adjusted odds ratio for non fatal cardiovascular events associated with clinical variables and diagnosis status, according to the logistic regression analysis
10905,Treatment Induced Laboratory Parameter Changes
10906,Treatment Induced Receptor Expression and Collateral Flow Changes
10909,Main outcome data for patients with proteinuric chronic nephropathies included in randomised trials of intensified and conventional blood pressure control
10912,UPDRS secondary analyses and ancillary study efficacy assessments
10913,Incidence of dopaminergic adverse events by affected body system
10914,Interleukin 6 response      of icodextrin containing dialysate and icodextrin in the PBMC assay from three representative donors
10915,Relation between complaints per million units sold and peptidoglycan concentration in icodextrin solution
10916,Cases reported to the WHO database of the SSRI and neonatal convulsions and or neonatal withdrawal syndrome association until the second quarter of 2003
10917,Symptoms   WHO preferred terms   concomitantly reported with neonatal withdrawal syndrome and or neonatal convulsions on the 51 cases of neonatal withdrawal syndrome associated with paroxetine
10918,Potency   Ki inhibition constant in nmol L   of some antidepressants for monoamines transporters
10919,Potency   Ki inhibition constant in nmol L   of some neurotransmitter transporters
10920,Educational inequalities by cause specific mortality in men in western Europe, by age
10921,Contribution       of specific causes of death to the difference between low and high educational groups in total mortality in men
10922,Educational inequalities in cause specific mortality in women in western Europe
10923,Contribution       of specific causes of death to the difference in total mortality between low and high educational groups in women
10924,Educational inequalities in total mortality by population in men and women aged 45 years
10925,Contribution       of specific causes of death to the difference between low and high educational groups in total mortality in men and women aged .45 years
10926,Symptoms of participants
10927,Diagnosis of tuberculosis in patients with HIV
10929,Response at the end of treatment and the end of follow up
10930,Common adverse events
10932,Mortality rates for major complex emergencies 19912002
10933,Numbers of refugees and internally displaced people in countries with 500000 in 1992 or 2001  6166
10934,Refugee population by region      of asylum, 19922001   thousands    61
10937,Enrolment by study site
10938,Cumulative treatment failures by specific causes at 48 h, 5 days, and 14 days
10940,Isolation and resistance frequency of nasopharyngeal organisms
10942,Treatment interruptions and dose reductions in patients who started protocol treatment
10943,Side effects by grade of toxic effect
10944,Comparison of toxic effects between treatment groups
10945,Best overall response to treatment   intention to treat analysis
10947,Efficacy of tacrolimus and ciclosporin microemulsion in children after liver transplantation
10948,Reasons for study withdrawal
10949,Reasons for graft loss after liver transplantation
10950,Most frequent adverse events
10951,Overall incidence of infections
10955,Rate of primary and secondary tonsillar haemorrhage by surgical technique
10957,Treatment group outcomes
10958,Outcomes in high risk subgroups of patients
10960,Patients with events on phase A
10962,Patients with events on phase B
10963,Serum creatinine concentration mol L   in patients throughout phase B
10964,Summary of study methods and data sources
10965,Estimates of children s exposure to four environmental risk factors in the European subregions
10966,Deaths and DALYs attributable to selected environmental factors among children and adolescents in the European region
10967,Distribution of deaths and DALYs from injury by external cause and age group in the European region
10968,Deaths and DALYs attributable to selected environmental factors as a proportion of deaths and DALYs from all causes among children and adolescents in the European region by age group
10969,Sensitivity analyses for outdoor air pollution and deaths
10970,Sensitivity analyses for indoor air pollution and deaths and DALYs from acute lower respiratory tract infections
10971,Sensitivity analyses for inadequate water and sanitation and diarrhoea deaths and DALYs
10972,Sensitivity analyses for lead exposure and DALYs due to mild mental retardation
10974,Antihypertensive and other medications in the study
10977,Adverse events
10981,L hongkongensis isolation from targeted food surveillance
10983,Documentation of important clinical signs for classification and treatment of malaria and pneumonia
10984,Performance indicators with system organisation implications
10985,Parenteral drug doses prescribed
10987,Number of patients with the most frequently reported treatment emergent signs and symptoms
10988,Number of randomised patients with available data whose laboratory indices were judged clinically significant at any time during study follow up
10989,Laboratory values: all randomised patients with data available
10990,G6PD status for patients with  20 g L fall in haemoglobin
10991,Breakdown of PCR confirmed new infections and recrudescence by trial site   all randomised patients with data available
10992,Summary of treatment outcome   all randomised patients with data available
10994,Time course of rejection and infection episodes
10996,Diagnostic accuracy of three classifiers
10998,Outcome of efficacy analyses before and after protocol change in randomisation
10999,Number of patients with treatment failure, components of treatment failure, and number of patients with plasma HIV 1 RNA concentration  50 copies per mL
11000,Numbers of patients with treatment failure or virological failure by region
11001,Reasons for temporary or permanent discontinuation of study drugs
11002,Numbers of patients with at least one grade 3 or 4 clinical adverse event and laboratory toxicities
11008,Radiographic analysis at 52 weeks
11009,Treatment emergent adverse events
11012,Microbiology results in different diagnostic subgroups
11013,Bacteria grown from sputum, bronchoalveolar lavage, and blood cultures in different subgroups
11014,Clinical outcome in all patients with lower respiratory tract infections according to treatment algorithm
11015,Clinical outcome in subgroup with acute exacerbations of COPD
11016,Serum cytokine concentrations of patients with influenza subtype H5N1, patients with influenza A and B infection, and healthy controls
11021,Follow up Outcomes at 36 Months, Unadjusted
11022,Serious adverse events   SAE   and study drug discontinuations
11023,Factors Independently Associated With Risk of Death or MI in a Multivariable Analysis
11025,Adjusted Hazard Ratios   95  Confidence Intervals   for Follow up Events by MEDS
11027,Adverse events to week 48
11030,Magnetic resonance gradient echo sequences
11031,Sensitivity and specificity of L M ratio for every sequence
11032,Correlation between L M ratio and B HIC with determination of B HICmax according to every magnetic resonance sequence
11033,Risk of Ischemic Heart Disease as a Function of ABCA1K776N Genotype in the Case Control Study
11034,Facilities in participating households 199598
11035,Relation between height and household water source
11036,Relation between height and water storage
11037,Relation between height and sanitation facility
11038,Diarrhoeal diseases by water and sanitation
11039,Household water source, water storage practices, sanitation facilities, and prevalence of C parvum and G lamblia
11042,Adverse reactions to both injections of influenza A Hong Kong 1073 99   H9N2   vaccine
11043,Seroconversions on day 21 and day 42
11044,Haemagglutinin inhibition results for A Hong Kong 1073 99   H9N2   in relation to European Committee of Proprietary Medicinal Products   CPMP   criteria
11046,Structures entered with MRI guidance only, or by use of fluoroscopic images
11047,Comparison of flow and pulmonary vascular resistance calculated with Fick s method and with MRI
11048,Advantages, limitations, and potential refinements of cardiac catheterisation guided by fluoroscopy or MR
11049,Sequence comparison of SARS CoV isolates of hospital and community outbreaks restricted to nucleotide positions with sequence differences between community and hospital isolates
11051,Rates of primary and secondary events according to assigned treatment
11052,Adverse events            among patients in each treatment group
11053,Individuals with positive SMR concentrations by disease category
11055,Echo Doppler Indices in Patients With AL Pain and in Normal Control Patients During the Maximal Dosage of Dobutamine
11057,Biochemical Analysis in Patients With AL Pain With and Without Abnormal IFV
11058,Primers used for MCP screening
11059,Biochemical data for proband and her brother
11060,Rotavirus antigen in serum samples obtained from children and animals during the acute stage of intestinal infection
11061,Mean systolic blood pressure   SBP   and diastolic blood pressure   DSP   by birthweight and childhood social class at every age
11062,Regression coefficients   95  CIs   from individual models fitted at each age, adjusted for sex
11063,Effect of birthweight and childhood social class on blood pressure between age 36 and 53 years
11064,Joint effect of birthweight and childhood social class on systolic blood pressure between age 36 and 53 years
11065,Primary clinical problems necessitating hospital admission in 100 patients
11066,Classification of pivotal findings of physical examination
11067,Patients with pivotal physical findings   n 26
11069,HIV 1 transmission and HIV 1 free survival at birth and at ages 68 weeks, 1416 weeks, 12 months, and 18 months
11070,Prognostic factors for HlV 1 infection
11071,Number of mothers and infants with adverse events
11072,Estimated mortality attributable to smoking in developing and industrialised countries in 2000
11073,Estimated global mortality attributable to smoking by age, sex, and cause of death in 2000
11074,Estimated mortality attributable to smoking in people aged 30 years and older by GBD subregion in 2000
11075,Estimated mortality   thousands of deaths   attributable to smoking in industrialised countries by age, sex, and cause of death in 2000
11076,Estimated mortality   thousands of deaths   attributable to smoking in developing countries by age, sex, and cause of death in 2000
11077,Protection induced by primary infections with Escherichia coli positive for different enterotoxins
11078,20 leading global risk factors, exposure variables, theoretical minima, and contributions to global burden of disease   GBD
11079,Individual and joint contributions of 20 selected risks to ten leading diseases and total burden of disease   expressed in disability adjusted life years, DALY   in the world
11080,Individual and joint contributions of 20 selected risks to ten leading diseases and total burden of disease   expressed in disability adjusted life years, DALY   in high mortality developing regions
11081,Individual and joint contributions of 20 selected risks to ten leading diseases and total burden of disease   expressed in disability  adjusted life years, DALY   in lower mortality developing regions
11082,Individual and joint contributions of 20 selected risks to ten leading diseases and total burden of disease   expressed in disability  adjusted life years, DALY   in developed regions
11083,Origin of patients fitting WHO case definition for SARS
11084,Diagnosis of SARS CoV and human metapneumovirus in patients fitting the WHO SARS case definition
11085,Excretion of SARS CoV by experimentally inoculated cynomolgus macaques
11086,Virological detection of SARS CoV in postmortem tissues of experimentally infected cynomolgus macaques
11087,Risk factors associated with development of ARDS requiring ventilatory support and intensive care
11088,Independent risk factors predicting development of ARDS by multivariate analysis
11089,Outcomes in SARS patients at the time of writing
11090,Subsequent analysis of clinical samples of 20 patients with initial RT PCR positive nasopharyngeal aspirates and antibody seroconversion to SARS associated coronavirus
11091,Virological investigations of patients with fatal SARS
11092,Summary of histological findings
11094,Serious adverse events
11095,Other drug related adverse events
11097,Effect of intervention on reported breastfeeding practices at age 3 months
11098,Effect on intervention on reported breastfeeding practices at age 4, 5, and 6 months
11099,Effect of intervention on diarrhoea morbidity during the first 6 months of life
11100,Weights and lengths of all children and low birthweight children at age 6 months
11102,Echocardiography and haemodynamic variables
11103,Echocardiography and potential sources of cardiogenic embolism
11105,Univariate Cox regression analysis of survival in patients on dialysis   n 312
11106,Change of p values in a forward stepwise Cox regression analysis of all cause and cardiovascular mortality
11108,Coronary   Agatston score   and aortic ring calcifications   semi quantitative score  , and individual AHSG serum concentrations in subgroups of patients on long term and short term dialysis
11110,Distance and Velocity Moved in the Two Groups
11112,Worst symptom related to trial regimen reported by clinicians
11113,Comparison of randomised and non randomised patients in MRC CR06 trial
11115,Association Between TF BRS and Major Clinical Variables With Categorical Scale   n   228
11116,Results From Cox Analysis and Figures of Predictive Accuracy for Dichotomized TF BRS   3.1 ms mm Hg vs.  3.1 ms mm Hg   and for the TF Index
11118,Composition of Cocoa Drinks
11120,Anthropometric and Laboratory Parameters of Study Groups
11121,Left Ventricular Morphology and Systolic Function
11122,Left Ventricular Diastolic Function
11123,Results of the Linear Regression Analysis Between the PCr ATP Ratio and Uremia, Diabetes, and LVMI
11125,Echocardiographic Parameters and Electrocardiogram Findings
11126,Comparisons of TDI, SRI, and WMS Among Trans MI, Nontrans MI, Subendo MI, and Control Segments
11127,TDI and SRI Measurements in Normal Subjects
11129,Dobutamine Stress Hemodynamic and Echocardiographic Data
11130,Univariate and Multivariate Association of Clinical, Electrocardiographic, and Echocardiographic Data With Cardiac Death
11131,Univariate and Multivariate Association of Clinical, Electrocardiographic, and Echocardiographic Data With All Cause Mortality
11139,Mean Differences Between Treatments in Change in HR, QT, and QTcI
11140,Mean Difference Between Treatments in the Change in QTc Measured at TmaxH Using Five QT Correction Methods
11144,Responsiveness to Clopidogrel by Blood Preservative and Tests of Platelet Function Used
11146,Predictors of the Primary End Point   Death or Myocardial Infarction
11149,Incidence and Severity of Aminotransferase Abnormalities
11151,Comparison of LV Geometry and Function
11152,Independent Predictors of LV Diastolic Dysfunction
11153,Independent Predictors of LV Systolic Dysfunction Defined as an LV Ejection Fraction  50
11159,Proportion of Patients With Enzymatically Confirmed AMI or Myocardial Necrosis Among Those With LBBB at Randomization
11160,Application of ST Segment Criteria for the Diagnosis of AMI in the 300 Patients With LBBB at Randomization
11161,Enzymatically Confirmed AMI and Mortality in Patients With and Patients Without ST Segment Changes    During LBBB
11162,Multivariable Logistic Regression Models for Predictors of 30 Day Mortality
11166,Inflammatory Markers and Daily Fish Consumption
11167,Inflammatory Markers and Fish Consumption   in g Week
11169,Primer Sequences, Sequence Accession Numbers, Annealing Temperatures, and Cycle Numbers
11170,No Expansion of Th2 or Th0 Cells in Patients With Different Stages of Atherosclerosis
11171,Reasons for Excluding Mice From the Study for Infarct Size
11176,Adverse Effects of Atorvastatin, Combined Therapy, and Fenofibrate in Patients With Combined Hyperlipidemia
11178,Effect of Folate on Hemodynamic Variables   Mean  SD
11179,Effect of Folate on MBF   Mean  SD
11181,Multivariate Linear Regression Analysis
11183,Relationships of Coronary Risk Factors   Continuous Variables   With the Percent       Changes in Diameter of Epicardial Coronary Arteries and Coronary Blood Flow Response to ACh Using Univariate Linear Regression Analysis
11184,Comparisons of Percent       Changes in Diameter of Epicardial Coronary Arteries and Coronary Blood Flow Response to ACh Using Categorical Variables to Classify Patients
11185,Multiple Linear Regression Analysis for the Association of Risk Factors With Relative Changes in Epicardial Coronary Diameters and Coronary Flow Response to ACh
11188,Mean MBF Responses and Coronary Vascular Resistance to CPT for Each Study Group
11189,Cardiovascular Events During Long Term Follow Up   n   72
11190,Univariate and Multivariate Cox Regression Analysis in the Study Group   n   72   Implying Cardiovascular Events   A   or Cardiac Events   B
11192,Multiple Linear Regression Analyses Between Progenitor Cells   Dependent Variables   and Risk Factors or Clinical Conditions   Independent Variables
11195,Procedural Outcomes in Patients Stratified by the Presence of Diabetes Mellitus
11196,Clinical Outcomes Through 12 Months Stratified by Diabetes
11197,Angiographic Measures at Nine Months Stratified by the Presence of Diabetes
11198,Angiographic Outcomes in the Diabetic Subgroup According to Diabetic Treatment
11200,MR Determined Regional E Ea
11201,MR and Doppler Parameters of LV Filling
11204,Binary Logistic Regression Analysis of Various Predictors of Left Ventricular Systolic Dysfunction
11205,ROC AUCs for Plasma and Urinary N BNP for Diagnosis of LVSD in High Risk Subjects   Age  65 Years, History of Hypertension, or Ischemic Heart Disease
11206,ROC AUCs With 95  CI for Plasma, Urinary, and Plasma  Urinary N BNP Product for Diagnosis of LVSD in At Risk Groups   as Defined   and Also in Remainder of Population Without Risk Factors Indicated
11207,A Number of Different Strategies for Screening Are Analyzed for the Total Number of Scans and N BNP Tests Resulting From the Screening
11208,ROC AUCs for Detection of Other Cardiac Abnormalities in Those With Preserved Systolic Function and ina Combined Group Comprising Those With Atrial Fibrillation, Valvular Abnormalities, and LVSD   These Diagnoses Are Not Mutually Exclusive
11209,Regional Myocardial Deformation and Time Intervals: Comparison Between Healthy Control Subjects and Patients After Tetralogy of Fallot Repair
11211,Regional Myocardial Deformation and Time Intervals: Comparison Between Patients After TOF Repair Without and Those With LV Asynchrony
11213,Anatomic Observations
11214,Quantative Data
11216,Combined Outcomes of Death or Arrhythmia
11217,Arrhythmia and Mode of Death
11219,Applications With Transient AV Block
11220,AVNRT Versus AVRT
11222,Logistic Regression in Those Without Prevalent Anemia at Randomization and With Complete Data at One Year   n   4,174  , Demonstrating the Effect of Enalapril on the Development of New Anemia at One Year, With Adjustment for Confounders
11224,Logistic Regression in all SOLVD Participants With Complete Data at Randomization   n   6,436  , Demonstrating the Effect of Enalapril on the Development of Anemia at Any Time During the Trial, With Adjustment for Confounders
11225,Results of Adjusted Cox Regression of All Cause Mortality by Anemia Episode During the Trial
11226,Results of Adjusted Cox Regression of All Cause Mortality by Time Varying Hematocrit During the Trial
11231,Medications
11232,Results of Multivariable Cox Regression Model Using Backward Stepwise Selection, for Combined End Point of Death, Ventricular Assist Device Implantation, or United Network for Organ Sharing 1 Transplantation
11233,Revascularization Therapy of LMCA
11237,Long Term Follow Up
11238,Univariate Predictors of MACE
11239,Multivariate Predictors of MACE
11241,Number of Patients Who Were Hyporesponsive or Hyper Responsive to Clopidogrel Based on the Change in ADP Induced Aggregation Who Were Determined to be Hyporesponsive and Hyper Responsive by Other Methods of Measuring Platelet Inhibition
11242,Diagnostic Performance of Multi Slice Computed Tomography Coronary Angiography to Detect 50  Stenoses
11244,Valvular and Cardiac Chamber Dimensions and Functional Parameters
11245,P Values From Adjusted Multivariate Association Models
11247,Dobutamine Stress Echocardiographic Data
11248,Follow Up Events in Both Genders
11249,Univariate Predictors of Hard Cardiac Events
11250,Multivariate Predictors of Hard Cardiac Events
11252,Univariate Analysis of Potential Clinical Predictors of the RH PAT Index
11255,ACE Inhibitor Utilization
11256,Relative Risk of Events by Treatment
11260,In Hospital Clinical Complications
11262,Univariate Hazard Ratios for the Combined End Point   Cardiac Death, MI, CVA, or Revascularization
11263,Multivariate Hazard Ratios for the Combined End Point Using Uncorrected   Absolute   Leptin Values or Leptin Values Corrected for BMI   i.e., Leptin BMI ratio
11266,Unadjusted Correlation Between MCP 1 Levels and Continuous Variables
11267,Variables Independently Associated With Log MCP 1   n   2,777
11268,Odds of Subclinical Atherosclerosis   CAC  10
11269,125I fibrin  ogen   Deposition   Mean Values  SEM   on Stents After 120 Min Perfusion in the Three Different Sets of Experiments
11273,Multivariate Predictors of One Year Mortality
11274,Adjusted All Cause Mortality Risks With Prescribed Medications
11277,Risk of Death Associated With 10 ml min Increment Decreases of Creatinine Clearance Among Women With Heart Failure and Coronary Disease
11278,Association Between Renal Insufficiency and Mortality, Stratified by Use of Angiotensin Converting Enzyme Inhibitors
11280,Intracardiac and Peripheral Hemodynamic Parameters and Weight Data on Day 28 After Surgery
11282,Echocardiographic and Weight Parameters on Day 27 After Surgery
11285,Diagnostic Accuracy of MSCT for the Detection of Bypass Graft Stenosis and Occluded Grafts in Evaluable Segments
11288,Cox Proportional Hazards Results for One Year Mortality
11290,Comparison of Independent Variables in Patients With Ventricular Arrhythmias Who Received ICD Therapy and Those Without Ventricular Arrhythmias
11292,Infarct Size Data
11293,Basal Hemodynamics and Enzyme Release for All Experimental Groups
11295,Distribution of Follow up Events in the Study Population
11296,CD Rate by Presence of AF in Different Clinical Subsets of Patients
11297,Significant Unavailable Predictors of Cardiac Death in the Study Population
11298,Final Multivariable Cox Proportional Hazards Model   Global Chi Square of the Model   1,146.1, p   0.001
11301,Univariate Correlates of Left Ventricular End Diastolic Dimension and Left Ventricular Mass in Trained Male Endurance Athletes and Untrained Men
11302,Left Ventricular Dimension and Mass Indexed to Various Measures of Body Size
11303,Age Regressions for Ventricular Vascular Coupling, Its Components and Its Determinants
11305,Cox Regression Analysis for Time to Presyncope Computed Slopes
11307,Correlations Between Plasma Oxidized LDL Level and Other Parameters
11308,Correlations Between Plasma oxLDL Levels and Coronary Vasomotor Responses to Bradykinin
11309,Univariate and Multivariate Linear Models of Epicardial Coronary Vasomotor Responses to Bradykinin
11310,Univariate and Multivariate Linear Models of Resistance Coronary Vasomotor Responses to Bradykinin
11313,Follow Up
11320,Occurrence of Atrial Fibrillation According to Antihypertensive Treatment: IR per 1,000 Person Years of New Onset Atrial Fibrillation, Adjusted Hazard Ratio, and 95  CI
11321,Occurrence of Atrial Fibrillation According to Antihypertension Treatment: IR per 1,000 Person Years of Atrial Fibrillation Related Hospitalization, Adjusted Incidence Ratio, and 95  CI
11322,IR per 1,000 Person Years of AF Related Hospitalizations, Adjusted Incidence Ratio, and 95  CI
11325,Multivariate Analysis, Including Risk Factors for Coronary Artery Disease and Clinical Presentation for Acetylcholine Induced Forearm Blood Flow   Dependent Variable
11326,Polymerase Chain Reaction and Pyrosequencing Primers and Conditions
11327,Genotype Frequency       Among 95 African Americans and 95 European Americans
11329,Lesion Location and Procedural Information
11331,Initial Left Heart Structure Size Versus Need for Re Intervention
11333,Clinical Management and Outcomes
11334,Summary of Clinical and Exercise Data of Our Study Cohort   n   22
11340,Multivariate Logistic Regression Analysis: Variables Differing Between Patients With and Without Coronary Artery Disease
11341,Comparison of Drugs Administered During the Follow Up Period in Patients With and Without Coronary Events
11342,Univariate Cox Hazards Analysis of Risk of Future Coronary Events According to Fasting Levels of RLP Cholesterol in Patients With Type II Diabetes Mellitus and Coronary Artery Disease
11343,Multivariate Cox Hazards Analysis of Risk of Future Coronary Events According to Fasting Levels of RLP Cholesterol in Patients With Type II Diabetes Mellitus and Coronary Artery Disease
11348,Platelet Aggregation and P Selectin Expression Induced by ADP   10 mol l   or TRAP   10 mol l   in Patients With an Acute Coronary Syndrome Before and 24 Hours After Administration of Clopidogrel   n   21
11350,ACEIs and ARB Use
11353,Baseline Alcohol Consumption and Adverse Cardiovascular Outcomes
11354,Level of Alcohol Consumption Reported Three Months Post MI and Adverse Cardiovascular Outcomes
11355,Relationship Between Calibrated Contrast Intensity and Remote Stage Asynergy
11361,Comparison Between Patients With and Those Without Atrioventricular Conduction Disturbance
11362,Reported Atrioventricular Conduction Disturbance Associated With Device Closure of Atrial Septal Defects
11364,Mean    SD   Scores on the SF 36 Subscales and the MLWHF Scales for Younger   Age 64 Years   and Older   Age  64 Years   Heart Failure Patients
11365,Correlation Coefficients of Quality of Life Measures With Depression Score, Age, and Left Ventricular EF
11366,Mean    SD   Scores on the SF 36 Subscales for Depressed and Non Depressed Heart Failure Patients
11367,Mean    SD   Scores on the MLWHF Subscales for Depressed and Non Depressed Heart Failure Patients
11369,Left Ventricular Dilation From Days 1 to 90 in Diabetics and Non Diabetics With and Without Angina
11373,Clinical Presentation
11374,Extent of Coronary Artery Disease
11376,Frequency of Mutation and Polymorphism in Adiponectin Gene
11377,Clinical Profile of the Subjects With I164T Mutation
11379,Association of NANSAIDs With MI, Stratified by Aspirin Use
11380,Assessment of Effects of Recall and Non Participation Bias
11382,Cross Sectional Echocardiographic Indexes in All Patients Versus Controls
11383,Doppler Indexes in All Patients Versus Controls
11384,Echocardiographic Indexes in Patients With Vascular Complications Versus Those Without
11388,Distribution of Study Drug Dosage at Time of End Point or End of Follow Up
11389,Clinical and Exercise Data
11390,Two Dimensional and Conventional Doppler Echocardiographic Data
11391,Tissue Doppler Derived Mitral Annular Velocities and Flow Propagation Velocity
11392,Values of Integrated Backscatter   IB   in the Septum and Posterior Wall, Corrected for Pericardial IB
11397,APV at Rest and After Stress and CFR
11399,Ang 1, Ang 2, Ang Receptor Tie 2, and VEGF Levels in CHF
11401,Risk Stratification Based on CS and GSS
11402,Univariate and Bivariate   Two Variable   Associations of CS and GSS With End Points
11403,Seven Year Event Free Survival Based on CS and GSS
11405,Aortic Sclerosis and Cardiovascular Outcomes
11406,Unadjusted Risk of Adverse Cardiovascular Events at 12 Months
11409,Diagnostic Performance of RT MCE on a Segmental Basis
11410,Diagnostic Performance of RT MCE and SPECT to Detect Significant Coronary Artery Disease in Individual Vascular Territories
11411,Diagnostic Performance of RT MCE and SPECT to Detect Significant Coronary Artery Disease in Individual Patients
11413,Distribution of the Conduction Disorders According to the Cardiac Disease
11415,Multivariate Cox Regression Analysis for Identifying Patients With Rehospitalization
11416,Comparison Between Patients With and Without Intra LV Electromechanical Asynchrony
11417,Multivariate Logistic Regression Analysis for Identifying Patients With Intra LV Electromechanical Asynchrony
11419,Laboratory Data for Diabetic and Nondiabetic Patients
11420,Angiographic Data
11421,Follow Up Data
11423,End Points After Three Months of Inactive or Active Pacing
11424,End Points After Three Months of Inactive or Active Pacing for Patients in the Long QRS Group   QRS  150 ms
11425,End Points After Three Months of Inactive or Active Pacing for Patients in the Short QRS Group   QRS 120 to 150 ms
11427,Stress Hemodynamics and Echocardiographic Results
11428,Angiography and Bypass Grafting
11430,Procedural Data and Quantitative Coronary Angiographic Analysis
11431,Intravascular Ultrasound Findings
11432,In Hospital Events
11433,Distribution of the Study Population 1 by Quartiles of TID Ratio
11435,Results of Univariable Analysis for Prediction of TE
11436,Final Cox Proportional Hazards Model for the Prediction of TE
11441,Comparison of Electrocardiographic Parameters Before and After Flecainide Administration in Subjects With Negative and Positive Test
11443,Global Parameters of Sham Operated Rats   Sham   and Rats With LV Dysfunction 10 Weeks After MI: Effects of Aldosterone Receptor Inhibition, ACE Inhibition, or Combined Aldosterone and ACE Inhibition
11444,Temporal Changes in Seniors   Age 65 Years   Hospitalized With Newly Diagnosed Congestive Heart Failure in Alberta, Canada During 19941995 to 19992000
11445,Severity of Illness and Comorbidity in Seniors   Age 65 Years   Hospitalized With CHF in Alberta, Canada During 19941995 to 19992000
11446,Physician and Hospital Factors for Seniors   Age 65 Years   Hospitalized With Newly Diagnosed CHF in Alberta, Canada, During April 1, 1994, to March 31, 2000
11447,Adjusted Mortality in Seniors   Age 65 Years   Hospitalized With Newly Diagnosed CHF in Alberta, Canada During 19951996 to 19992000
11449,Hemodynamic Responses During Dipyridamole Stress Study With Placebo, Low Dose Metoprolol, and High Dose Metoprolol
11450,Clinical Effects of Low Dose and High Dose Metoprolol on Dipyridamole Stress Testing End Points
11451,Dipyridamole Tc 99m Sestamibi Imaging Results
11453,Distribution of CK MB Values and Follow Up
11454,Patient Data
11455,Ejection Fraction, End Diastolic Ventricular Volume, and End Systolic Ventricular Mass: Magnetic Resonance Imaging Values
11461,Univariate and Multivariate Predictors of Cardiac Events
11463,Physiologic Parameters Post Pre Exercise or Sedentary Period
11465,Effect of GIK on 30 Day Mortality in All Patients and in Subgroups
11466,Effect of GIK on 30 Day Mortality in Patients With Killip Class 1, 2, 3, and 4
11467,Causes of Death in GIK Group and Control Group
11468,Clinical End Points at 30 Days in Overall Population and Killip Class 1 Patients
11473,Distribution of Prognostic Variables in Underweight, Normal Weight and Overweight Groups of Increasing BMI at Admission
11474,Distributions of Early Clinical Outcomes in Underweight, Normal Weight and Overweight Groups of Increasing BMI
11475,Adjusted ORs for Early Clinical Outcomes in Underweight, Normal Weight and Overweight Groups of Increasing BMI
11476,Reasons for Exclusion in the AAIR Versus DDDR Trial
11478,M Mode Echocardiographic Measurements
11479,Two dimensional Echocardiographic Measurements
11481,Morphological Echocardiographic Data
11482,Standard and Tissue Doppler Echocardiographic Measurements in Athletes With DD, ID, and II Genotype
11483,Clinical Features of the Two Groups of Patients
11484,Anatomic and Hemodynamic Features of the Two Groups of Patients
11487,Multivariate Predictors of Cardiac Allograft Vasculopathy
11489,Multivariate Analysis of Predictors of Segmental Wall Function
11491,Concentrations of Water, DNA, Collagen, and Total GAGs
11495,Genetic Data of the Individual Families at Various Map Positions
11496,Clinical Data of Individuals With Crucial Recombinations
11497,Results of Substrate Mapping
11502,Incidence of Bleeding
11503,Blood Pressure
11504,Echocardiographic Data
11505,Vascular Function
11506,Predictors of 24 h Systolic BP by Multiple Regression Analysis
11507,Predictors of Left Ventricular Mass Analyzed by Multiple Regression Analysis
11509,Incidence of Major Adverse Events in Patients With the DD Genotype During the Early 30 Day Period After Coronary Stenting
11510,Follow Up Quantitative Coronary Angiography of Patients With the DD Genotype
11511,Mean Responses to Atropine   Mean  SE   in Young and Older Subjects
11512,Diastolic Filling Responses to Atropine by Age and Gender
11513,Mice Allocation
11514,Device and Pharmacologic Considerations for Therapy in Brugada Syndrome
11515,Assayed Vitamin and Nitrate Content of Juice Plus and Vineyard
11518,Summary of Principal Inclusion and Exclusion Criteria
11521,Most Common AEs During Active Treatment With Ximelagatran and Warfarin
11522,Clinical Evaluation
11523,Epworth Sleepiness Scale
11525,Distribution of Coronary Artery Disease in Patients With Negative and Positive Results With Metoprolol
11528,Comparisons Between Patients With and Without Tilt Induced VVS and Control Subjects, With and Without Age Adjustment
11529,Cox Multivariate Analysis for Tilt Induced VVS
11531,Adenosine MPS Variables in Women and Men
11532,Unadjusted Rates of Referral to Early Coronary Catheterization and Revascularization as a Function of Inducible Ischemia in Women and Men
11533,Multivariable Predictors of Cardiac Death in the Overall Population, Women and Men
11534,Clinical and Adenosine MPS Data by Diabetic Status
11537,Follow Up and Clinical Events
11539,Relationship of Risk Factors   SBP, BMI, and Insulin   to LV Mass Index Group by Race and Gender at Year 10
11540,Relationship of Risk Factors   SBP, BMI, and Insulin   to Relative Wall Thickness Subgroup by Race and Gender at Year 10
11541,Pearson Correlation Coefficients of LV Mass Index and Relative Wall Thickness With Slope From Individual Regressions of Longitudinal BMI and SBP
11543,Association of LA Size With Age, Gender, and Body Size by Bivariable Analysis in the Reference Subgroup   n   767
11544,Relationship Between Indexes of LA Size and Age, Gender, and Body Size by Multivariable Analysis in the Reference Subgroup
11545,Relationship Between LAD or LAV Indexed to BSA, BMI, or Ht and Age, Gender, and Body Size by Multivariable Analysis in the Reference Subgroup
11546,Reference Ranges for LAD and LAV From the Reference Subgroup
11547,Association of Cardiovascular Disease and Indexes of Left Atrial Size in the Population Based Cohort
11548,Agreement   Between Left Atrial Enlargement as Defined by LAD BSA or LAV BSA in the Population Based Cohort
11549,Prevalence of LAE as Defined by LAD BSA and LAV BSA According to Presence or Absence of Cardiovascular Disease in the Population Based Cohort
11550,Morphologic Evaluation of Gene Therapy
11554,Clinical and Angiographic Data
11558,Parameters of Radial Segmental Deformation Measured During Occlusion in the Group A   Collateralized Segments Graded as 2 to 3 According to the Rentrop Scale  , and Group B   Collateralized Segments Graded as 1 According to the Rentrop Scale  , and Group C   Noncollateralized Segments
11560,Contents of Various Blood Components
11561,Videodensity Values of Various Blood Products
11563,Effect of 52 weeks  treatment on lung function
11564,Effect of 52 weeks  treatment on exacerbation rate
11565,Effect of 52 weeks  treatment on health status and symptoms
11566,Treatment related adverse events
11572,Characteristics of patients given gefitinib
11573,Contributions by individual poison control centres
11574,Age distribution among symptomatic exposures to dietary supplements by severity categories and unintentional circumstances
11575,Symptoms associated with calls related to dietary supplements or other substances in eight poison control centres in 1998
11576,Selected hazards associated with dietary supplements
11577,Products, ingredients, and adverse events reported in five data sources
11578,Number of cases assessed, number of cells recovered from maternal plasma, and number identified as male   XY   by fluorescence in situ hybridisation   FISH
11582,Adverse events occurring in  5  of patients
11583,Countries with displaced persons  camps that met inclusion criteria
11587,Efficacy and safety of treatment regimens
11591,Outcome of patients by treatment group
11592,Stool concentrations of study drugs and their relation to minimum inhibitory concentration   MIC   of infecting strains of V cholerae
11593,Cost in Bangladesh and USA of regimens for the treatment of cholera in a 10 kg child
11596,Probable cause of death by HIV stratum and treatment group
11597,Clinical and parasitological response and mortality rates by treatment group
11598,Clinical and parasitological response rates of subgroup of children 4 days after receiving additional 3 day course of open label nitazoxanide
11600,Causes of deaths
11601,Overall and disease free survival and time to colon cancer related death   CCRD
11602,Key adverse events
11603,Overall survival and disease free survival in stage III colon cancerresults of previously reported randomised adjuvant trials
11604,Risks of cancer incidence and mortality after treatment with human pituitary growth hormone
11606,Clinical Outcomes at Six Months According DSE Results
11608,Multivariate   Stepwise   Logistic Regression Analysis, Including Clinical Variables and DSE
11614,Summary of data for controls and patients with type 2 diabetes mellitus   means and SDs
11616,Reasons for premature discontinuation
11617,Effect of acarbose and placebo on deterioration or improvement      of glucose tolerance in patients with IGT
11618,Frequency of adverse events
11621,Clinical and Imaging Data of the Patient Population
11622,Myocardial Perfusion by 13N ammonia PET and Wall Motion Analysis by 2D Echocardiography Versus Coronary Angiography
11624,Tissue Characterization by PET versus Histopathology
11625,Initial 12 weeks of protocol treatment
11626,Grade 3 or 4 toxic effects reported by clinicians up to 12 weeks
11627,Clinicians assessment of response at 12 weeks
11628,Acceptability of treatment regimens to patients at 12 weeks
11630,Specification of primary outcome
11631,Accuracy of PET in prediction of need for thoracotomy
11634,Endpoints
11635,Number of participants on study drug at endpoint or end of follow up
11636,Adverse events
11639,Overview of Swedish trials included in overview
11640,Number of women randomised by trial study group and 5 year age group
11641,Trial time for invited group and follow up time by age at randomisation and trial
11642,All trials combined, number of 1000 women years and number of cases with breast cancer as underlying cause of death according to Statistics Sweden by age at randomisation
11643,Number of 1000 women years and number of cases with breast cancer as underlying cause of death according to Statistics Sweden in invited and control groups by age at randomisation and trial
11644,Differences in cumulative breast cancer mortality per 100000 women at 8, 12, and 16 years after randomisation between control and invited groups by trial and age at randomisation
11645,Total mortality in invited and control groups
11646,Number of women randomised to invited and control groups by year of birth and date of randomisation in Malm trial
11647,Number of women randomised to invited group and control group by year of birth date of randomisation and method of randomisation in the Gteborg trial
11648,Number of women randomised to invited and control groups by year and day of birth and date of randomisation in Stockholm trial
11649,Number of women randomised to invited and control groups by date of randomisation and cluster in stergtland part of Two County trial   n 92 872
11651,Presence of polyomavirus and herpesvirus sequences in non Hodgkin lymphoma and control samples from HIV 1  infected and HIV 1 uninfected patients
11652,Presence of SV40 and Epstein Barr virus DNA sequences by histological type of non Hodgkin lymphoma from HIV 1 infected and HIV 1 uninfected patients
11654,Association between education and socioeconomic factors and WISC R test scores
11655,Relations of stunting, diarrhoeal disease and G lamblia infection to WISC R test scores
11657,Changes in mean ambulatory blood pressure during sleep and wake as defined in the patient s diary and changes in overall systolic and diastolic blood pressure
11658,Serial Electrocardiogram Parameters in Five Affected Family Members
11659,Diagnosis and exposure to potentially gonadotoxic treatment by sperm count of all study patients
11666,Results of MPI by Visual Assessment
11667,Results of MPI by Quantitative Assessment
11668,Determinates of Abnormal Delayed Imaging
11669,Plasma Substrates and Insulin During the PET Study
11670,Hemodynamics During the PET Study
11673,Analysis of patient PBMC DNAs for porcine sequences and patient plasma for anti PERV antibodies
11675,Numbers of women enrolled and pregnancies reported
11677,Pregnancy rates by treatment group and time since unprotected coitus
11678,Side effects
11680,Drug therapy received after trial entry
11681,Treatment   other than acetazolamide and furosemide   for hydrocephalus before shunt placement
11682,Adverse effects of acetazolamide and furosemide, respiratory status, and time to hospital discharge
11683,Primary outcomedeath, shunt insertion, or both
11684,Neurological examination and medical diagnoses in survivors at 1 year
11685,Overall status at 1 year
11691,Analysis for cyanobacterial microcystins by three procedures in serum before and after haemoperfusion from one patient from IDR haemodialysis clinic, Brazil
11693,Rank of independent predictors of pulmonary function in individuals with airway obstruction by step up ANCOVA
11694,Age, symptom severity, and diarrhoea duration relative to rotavirus excretion estimated by reverse transcription PCR
11696,Exacerbation scores for each group
11699,Treatment at the end of the study
11701,Events in relation to target blood pressure groups   n 6264, 6264, and 6262 in the target groups 90 mmHg, 85 mmHg, and 80 mmHg, respectively
11703,Events in relation to acetysalicylic acid   n 9399   or placebo   n 9391
11704,Bleeding events reported in acetylsalicylic acid treated and placebo treated patients
11706,Progression of cancer   for all eligible patients
11707,Prognostic factors for survival in univariate analysis
11709,Incidence of first operative procedure in children aged under 5 years per 1000 livebirths by country of birth within the UK
11710,Number of children identified through stated data source in Scotland and the Northern and Wessex regions
11711,Complexity of first operative procedure by source of data in Scotland and the Northern and Wessex regions
11714,Adherence rates by drug regimen
11715,Tuberculosis in study participants by chemoprophylaxis regimen
11717,Dose Dependent Effects of Carvedilol on HW BW and Myocardial Histology on Day 7
11718,Symptom scores recorded in daily record cards
11719,Effects of Carvedilol, Metoprolol, and Propranolol on HW BW and Myocardial Histology on Day 7
11721,Number and severity of exacerbations
11722,Serum cortisol   nmol L   after 6 months of treatment
11723,Rate of CDAD and weeks of observation for all patients initially colonised and non colonised with C difficile
11724,Toxigenic status of isolates in colonized patients and weeks of observation
11725,Toxigenic restriction endonuclease groups of C difficile isolates in symptom free colonised patients and patients with CDAD
11726,Rate of CDAD and weeks of observation for patients initially colonised and non colonised with C difficile who received antibiotics
11727,Clinical, microbiological, and histological outcomes
11728,Execution times of component tasks and complete laparoscopic cholecystectomy
11729,Surgeons  ratings of image quality
11730,Surgeons  subjective scores for adverse effects of imaging systems after surgery
11733,Postoperative median linear analogue pain and expectation scores
11734,Plasma t PA and PAI 1 Antigen and t PA Activity Concentrations
11740,Univariate analysis of determinants of glycaemic control   HbA1c
11741,Univariate analysis of hospital admissions for diabetic ketoacidosis
11742,Univariate analyses of hospital admissions for acute diabetes associated complications
11744,Incidence rates for respiratory symptoms by airways responsiveness status
11745,Remission rates for respiratory symptoms by airways responsiveness status
11747,Outcome of previous pregnancies
11748,Distribution of pre eclampsia according to ISSHP classification and CLASP classification
11749,Distribution of complications associated with hypertension
11753,Number and type of adverse events
11754,Side effects within 5 days of vaccination
11755,Protective efficacy of RRV TV against health care system intervention and clinical features of rotavirus gastroenteritis, and according to rotavirus G type
11756,Protective efficacy of RRV TV during rotavirus epidemic season January to June, 1995, in relation to calendar time of dosing
11760,Microbiology results
11761,Blood pressure and urinary sodium and potassium excretion in 47 participants throughout study
11762,Blood pressure and urinary sodium and potassium excretion in normotensive and hypertensive participants
11763,Preoperative and postoperative urodynamic findings
11764,Profile of included and excluded studies
11766,Effect of NIPPV on study outcomes
11768,Results from multivariable logistic regression model of factors associated with mortality at 3 months and at 12 months post transplantation
11769,Expected and observed number of deaths at 3 months and at 12 months post transplantation stratified by regression score   1 lowest; 10 highest score   in training and validation samples
11770,Causes of death at 3 months and at 12 months post transplantation
11772,Distribution of personal habits by sex and study groups
11773,Screening history of individuals invited to screening
11774,Stage distribution of oral cancer cases
11775,Oral cancer incidence and mortality rates in all eligible individuals and eligible individuals with or without tobacco or alcohol drinking habits, or both
11776,Oral cancer incidence and mortality rates in all eligible individuals and eligible individuals with or without tobacco or alcohol drinking habits, or both, stratified by sex
11779,ORs and RRs   95  Confidence Intervals   for Other Correlates of Preserved Left Ventricular Systolic Function in Order of Entry Into the Full Logistic Model
11785,Final model for HPV status as a time dependent covariate in regression of cervical LSIL   n 187
11786,Frequency of monosomy X in peripheral white blood cells
11787,Vitamin D precursors in skin in burn patients and controls
11795,Heart Rate Variability Measurements in Patients With Chronic Heart Failure in Relation to Cardiac Events
11796,Univariate and Multivariate Cox Proportional Hazard Analyses for the Identification of Patients With Chronic Heart Failure at Risk for Cardiac Events
11797,Prediction of Cardiac Events in Patients With Chronic Heart Failure by a Combination of Abnormal Washout Rate and Normalized Very Low Frequency Power
11800,Group comparison analysis, with different nominal p values
11801,Correlation of Affymetrix expression data with sqRT PCR derived values.
11802,Antibodies and inhibitors
11804,1317 month patients  and kidney graft survival and 1 year serum creatinine in the 47 recipients with functioning grafts
11805,Description of the EPIC cohort
11806,Patients  and graft survival and incidence of weaning in intestine and pancreas recipients at end of study
11808,Final diagnoses of the causes of the pleural effusions in all 50 patients who entered the trial
11809,Comparison of final diagnosis with the two biopsy methods in the 47 patients who actually underwent pleural biopsy
11810,Clinical and Angiographic Features of the 18 Study Patients
11811,Prevalence of Angina and Ischemic Electrocardiographic Changes, Myocardial Lactate Metabolism, Systemic Hemodynamics, and the Degree of Epicardial Constriction at Acetylcholine Testings
11814,  area of immunoreactivity of vanilloid receptor 1 and other markers
11815,Clinical outcomes for all women
11816,Laterality of subsequent invasive mammary carcinoma in relation to biopsy side in 252 women with atypical lobular hyperplasia treated by biopsy only
11817,Relative risk of invasive mammary carcinoma in women with atypical lobular hyperplasia and without proliferative disease or complex fibroadenoma
11818,Immunohistochemical, in situ hybridisation, and PCR results for paraffin specimens of human colonic polyps, adenocarcinomas, and non neoplastic tissues
11820,Relative risk of death from all causes, cardiovascular disease   CVD  , coronary heart disease   CHD  , stroke, and external causes by alcohol intake during the week before the interview
11821,Relative risks   95  CIs   of death from all causes, cardiovascular disease   CVD  , coronary heart disease   CHD  , stroke, and external causes by typical dose per occasion in men who drink at least once a month
11822,Relative risks   95  Cis   of death from all causes, cardiovascular disease   CVD  , coronary heart disease   CHD  , stroke, and external causes, by frequency of drinking
11823,Relative risks   95  Cis   of death from all causes, cardiovascular diseases, and coronary heart disease, by frequency of drinking, stratified by typical dose per drinking occasion drinkers only
11826,Adjusted hazard ratios of coronary artery disease and graft failure based on C reactive protein concentrations during the first 3 months post transplantation
11828,Primary outcomes at 12 months
11829,Primary cause of all deaths and reasons for all retransplants
11830,Rejection patterns
11831,Primary reason for withdrawal unrelated to composite primary outcome or rejection
11832,Reported side effects of immunosuppression treatment within 12 months of trial entry
11833,White cell and differential counts of index case
11835,Biliary events during follow up
11836,Complications of cholecystectomy
11837,Univariate risk factor analysis for patients to develop at least one recurrent biliary event during follow up
11838,Clinical outcome after mean follow up of 241 years, by symptoms at onset
11839,ISKDC grade of first kidney biopsy specimen and primary treatment
11840,Clinical outcome for 19 participants in 1981 and 2000
11841,Numbers of patients with poor outcome, by severity of renal symptoms at onset of Henoch Schnlein purpura
11842,Clinical and laboratory data of children with vasculitis at time of sampling
11843,Proteolysis of high molecular weight kininogen   HK   and bradykinin and HBP concentrations in patients
11845,Concentrations in skeletal muscle of ATP, ADP, AMP, phosphocreatine, and creatine
11846,Activities of mitochondrial complexes and concentrations of reduced glutathione and nitrite nitrate in skeletal muscle
11847,Mutations, inclusions, and severity of disease in the five families studied
11850,Follow up and completeness in the PBC1, Myeloma 4, and ovarian cancer datasets
11855,Survival at 6 months   intention to treat analysis
11856,Adverse events occurring with greater frequency in either of the treatment groups
11858,Comparison of microbiological, serological, and immunological results by presence or absence of histologically diagnosed endometritis
11861,Number of women who developed incident vulvovaginal or perianal lesions
11862,Univariate and multivariate analysis of potential risk factors for development of vulvovaginal or perianal lesions
11863,Multivariate analysis of potential risk factors for developing vulvovaginal or perianal lesions in HIV 1 positive women
11865,: Number of countries, institutions, and patients participating in the ITP Registry
11866,Clinical, molecular, and immunohistological data of patients from the retrospective series
11869,Final diagnoses of patients fulfilling criteria for irritable bowel syndrome
11870,Coeliac antibody results
11873,Estimates of time spent and financial cost of the screening campaign, 199799
11874,Clinical features and laboratory results
11875,Yellow fever viruses characterised by nucleotide sequencing
11876,Identification of yellow fever viral isolates by indirect immunofluorescence
11877,Serum plaque reduction neutralising antibody responses and one way cross neutralisation tests of clinical samples from yellow fever vaccinees against patients  isolates and reference isolates
11878,Complete genomic characterisation of yellow fever viruses isolated from cases 1 and 2
11879,Quasispecies nature of yellow fever virus isolated from case 1
11882,Sensitivity, specificity, and predictive value of the six marker fibrosis indexsecond year group
11887,Results for recipient   A3, A24   and donor   A9, 24, A19
11888,Correlation between rejection score and presence of host type cells in peritubular capillaries
11889,Non transmitted HLA alleles
11891,Responses
11892,Adverse events during treatment
11894,Comparison of serial liver biopsy samples in case and control HCV infected women
11895,Genotypes identified in affected neonates
11896,Immunoreactive trypsin and sweat chloride concentrations according to genotype
11897,Estimation of cost of neonatal screening programme in 1998
11898,Respiratory chain enzyme activity in circulating lymphocytes of patients 1 and 3 and of 163 controls
11899,Functional and cognitive improvement in patients given ubidecarenone
11901,Testing for SLA LP autoantibodies in 2000 serum Samples
11902,Exclusion of cytokeratin 8 and 18 as major target antigen
11903,Exclusion of glutathione S transferase isoenzyme as major target antigen
11904,Treatment regimen and outcome in 14 girls with vaginal yolk sac tumours
11905,Virological and histopathological results in 45 sustained responders to interferon alfa plus ribavirin
11906,Crude rates of polyp occurrence during follow up and adjusted odds ratios according to polyp presence at first surveillance examination
11907,Odds ratios of polyp occurrence during the follow up according to polyp multiplicity at first surveillance examination
11908,Results of endometrial biopsy and blood hormone concentrations
11910,Number of end points in randomised controlled trials of UDCA versus placebo
11911,Results of sensitivity analyses   Mantel Haenszel method
11914,Effect of detection of occult lymph node metastases on 10 year disease free survival and overall survival
11915,Intestinal biopsy findings in group A
11917,Specificity of primers and probes for bacterial DNA tested
11918,PCR detection and quantitative PCR results for  M tuberculosis  DNA
11919,PCR detection and quantitative PCR results for  P acnes  and  P granulosum  DNA
11920,Overall results for the two non invasive diagnostic techniques
11927,Standardised incidence rates of breast cancer by age groups and time after aspiration of first cyst
11928,Standardised incidence rate of breast cancer in relation to women classified by factors at first cyst aspiration
11929,Standardised incidence rates of breast cancer in women with palpable breast cysts
11930,Results derived from time intensity curves
11932,Potential prognostic factors in 51 evaluable patients by recurrence of tumours
11933,Potential prognostic factors in 51 evaluable patients by expression of CK20
11934,Test results by study phase
11936,Results of screening tests
11937,Detection rates and predictive values for VIA and Pap smear
11938,Phase II screening test results by reference standard outcomes
11939,Phase II sensitivity and specificity of each test
11941,Necropsy lymphoreticular tissues
11942,Clinical features and investigations in patients with positive tonsil biopsy samples
11943,Clinical features and investigation of patients with negative tonsil biopsy samples
11945,Frequencies of MRD positivity per treatment group at the various follow up time points
11946,Numbers of relapses and cumulative relapse rates at 3 years for different degrees of MRD during follow up
11947,Multivariate analysis of treatment group and MRD information at I BFM SG time points one and two
11948,Patients   n 129   categorised according to degree of MRD at time points one and two
11950,Rate of treatment effectiveness by group
11951,Prenatal detection of congenital abnormality includingand excluding ultrasound markers
11952,Prenatal detection of congenial abnormilities in the Oxford population 1996 91
11953,Detection of specified anomalies as a result of reporting of some ultrasound soft markers
11954,Reasons for termination of 171 pregnancies and severity of fetal condition
11955,Clinical, immunological, neurophysiological, and radiological features of 28 patients with gluten ataxia
11956,Feasibility and toxic effects of up front FE120C chemotherapy   289 courses   in all patients before randomisation
11957,Clinical and pathological responses to up front FE120C chemotherapy
11958,Haemopoietic recovery after PBPCreinfusion in 35 patients on high dose chemotherapy
11960,Clinical and biological findings in patients with macrophagic myofasciitis
11961,Symptoms of patients with macrophagic myofasciitis
11962,Abnormal laboratory findings in patients with macrophagic myofasciitis
11963,Myopathological findings in patients with macrophagic myofasciitis
11964,Histopathological categories and palpability
11965,Multivariate analysis for all patients except those with premalignant lesions   lobular carcinoma in situ or atypia
11966,Median values and positivity rates at 90  sensitivity for cross validated index by disease severity in palpable lesions
11967,Influence of high cumulative annual frequency of rejection on development of TCAD
11968,Positive lymphocyte growth assay as predictor of progression of a low grade biopsy to high grade cellular rejection in recipients of cardiac transplantation
11969,Presence of IgG antibodies against MHC class II molecules   IgG anti II   as predictor of progression of a low grade biopsy to high grade cellular rejection in cardiac transplantation patients with complete donor recipient mismatches at HLA DR locus
11970,Multivariate equation      describing incremental factors in patients associated with 90 day progression from a low grade biopsy to a high grade rejection during first year after cardiac transplantation
11972,Clinical disorders and tryptophan hydroxylase antibodies in 80 patients with APS1
11973,Clinical and biochemical findings and liver histology
11974,Antibody, alanine, and small intestine biopsy follow up
11976,Hazard ratios of HCC   multivariate analysis
11977,Frequency of HIV 1 p24 and HIAP immunoblot reactivity in patients with primary biliary cirrhosis and comparison groups
11978,Frequency of IgG autoantibodies in all patients with chronic liver diseases
11979,Autoantibody prevalence compared with serum reactivity to HIV 1 p24 and HIAP in chronic liver disease patients
11980,Classification of CT diagnoses by high resolution CT
11981,Location of tumours in CT detected lung cancer
11982,Multivariate analysis of survival of 240 evaluable patients
11983,Multivariate analysis of survival
11984,Leukaemia markers used to study minimal residual disease by double or triple colour flow cytometry
11985,Detection of residual disease with immunological markers in children with ALL in clinical remission
11986,Continuous complete remission and cumulative incidence of leukaemic relapse according to detection of residual disease
11987,Results of strip test
11989,Biochemical and immunological measurements before transplant, at diagnosis of autoimmune hepatitis, and during treatment
11990,Histological score of seven index patients at time of graft dysfunction,      at diagnosis of autoimmune hepatitis, and at follow up
11992,Operative findings
11993,Postoperative outcome
11995,Results of trial
11997,Frequency of HHV 8, mycobacterial, and Epstein Barr virus   EBV   DNA sequences in sarcoid and non sarcoid tissues
11998,Assignment of HHV 8 sequences into groups and mycobacterial DNA sequences into species, and identification of base substitutions in unique HHV 8 sequences
12000,Rejection episodes 6 months after transplantation   intention to treat analysis
12002,Graft and patient survival 12 months after transplantation   intention to treat analysis
12005,Neurohormonal Values
12006,Nerve ingrowth into deeper levels of intervertebral disc as assessed by PGP95 staining in control and biopsy samples
12007,Criteria for pathological diagnosis of a gastric lesion
12008,Distribution of diagnoses by individual pathologists
12009,Diagnoses and findings of biopsies and endoscopic resections from all 19 gastric lesions
12010,Agreement between viewpoints for all 35 slides
12012,Results of endoscopic stone removal after EBD and EST
12013,Early complications    15 days after ERCP   after EBD and EST and complications during follow up    15 days after ERCP
12014,Results of endoscopic stone removal after EBD and EST in relation to stone size and number
12016,Rate of fibrosis progression in patients by risk factors
12017,Validation of estimated rate of liver fibrosis progression per year
12018,Age and sex distribution and results of stool examination according to study group
12019,Colonoscopic findings and ELISA results
12020,Number of participants with histological abnormalities found in colonic biopsy samples
12021,Response to initial course of treatment in all symptomatic patients
12022,Follow up data
12023,Clinical and laboratory data
12024,Production of EMA by in vitro cultured intestinal explants from CD patients and controls
12026,Alcohol drinking
12027,Use of cannabis and other illicit drugs
12028,Association between cannabis, tobacco, and alcohol use
12029,Association between cannabis use, LSD, and Ecstasy
12030,HAD scores
12032,Associated medical conditions
12033,Repeat procedures required to establish biliary drainage
12034,Complications within 72 h
12036,Overall success for both treatment groups
12037,Subgroup analysis for patients with initially abnormal defaecation dynamics: relation with treatment success
12038,Relationship between post treatment defaecation dynamics and success in all patients, independent of the treatment group
12039,Results of anorectal manometry   median and range
12040,Tissue concentration near ischaemic ulcers   mcg g wet weight   and blood concentration   mcg mL   of gentamicin and clindamycin: comparison of intravenous and intra arterial infusion with transvenous pressure injection in Bier s arterial arrest
12041,Median TCA enhancement factors and confidence intervals   CI   of the individual ratios of TVA Bier   C   vs intravenous   A  and TVA Bier   C   vs intra arterial   B   application at both measurement times
12043,Axillary node metastases according to pathological variables
12044,Distribution of 85 cases with positive axillary nodes according to sentinel node biopsy results
12045,Clinical details of patients receiving IA
12046,Volumes of plasma treated by one or two immediately pretransplant IA sessions and effects of IA on patient serum donor cell crossmatches and on serum IgG
12047,Details of transplantation and outcome
12050,Treatment emergent adverse events in the safety population
12052,Primary outcome and outcomes related to delivery
12053,Maternal and neonatal outcomes
12055,Primary and secondary outcomes
12061,Continence at a median follow up of 77 months in 38 patients without a stoma or further surgery after sphincter repair
12062,Continence scores in 38 patients without a stoma or further surgery after sphincter repair
12063,Analysis to seek predictive variables
12065,Results of voiding incontinence diary measures comparing pre treatment   pre   with subchronic test period   test  , 6 months, and last follow up   last
12066,Urodynamic data before implant   pre   and 6 months after implant
12070,Postoperative complications
12072,Results of Magnetic Resonance Imaging Parameters and uptake by Positron Emission Tomography, According to Wall Motion
12073,Magnetic Resonance Imaging Parameters in Severely Dysfunctional Segments   n   165   According to the Viability Status by Positron Emission Tomography
12075,Sensitivity and Specificity of Different Thresholds of Segmental Extent of Hyperenhancement for the Detection of Non Viable Myocardium by 18F FluorodeoxyglucosePositron Emission Tomography
12076,Viability by Contrast Enhanced Magnetic Resonance Imaging According to Viability Status by Positron Emission Tomography
12077,Outcomes of the randomised intention to treat set   patients with positive PET 2 recruited before June, 2011, and all patients with negative PET 2
12078,Therapy adherence, acute toxicities and supportive measures during chemotherapy of patients with negative PET 2, randomised intention to treat set
12080,Logistic regression model including 628 patients predicting incident postoperative delirium
12081,Postoperative pain levels by visual analogue scale for pain, 0100 mm
12082,Postoperative opioids in morphine equivalents
12084,Remission, response, and mucosal healing rates at week 12 with central and local endoscopy readings
12085,Safety characteristics of patients
12087,Kaplan Meier estimates of the likelihood of recurrent upper gastrointestinal bleeding and serious cardiovascular events at 18 months
12089,Baseline characteristics
12091,Adverse events   on treatment at week 12
12092,Definitions of PRAE assessed
12094,Anaesthetic management of participants
12095,Frequency of PRAE during perioperative, intraoperative, and postoperative periods
12096,Frequency of perioperative respiratory adverse events in infants having deep or awake airway device removal during minor elective surgery
12099,Most common treatment emergent adverse events occurring in at least 2  of patients receiving LMTM that were greater than in the control group
12102,Perioperative variables
12103,Effectiveness outcomes
12104,Safety outcomes
12106,Common drug related adverse events
12107,Global, regional, and national or territory number of maternal deaths, maternal mortality ratio   MMR; number of deaths per 100000 livebirths  , and annualised rates of change in percent, 19902015
12108,Average coverage of reproductive health services between including one visit of antenatal care   ANC  , four ANC visits, in facility delivery, and skilled birth attendance by MMR strata, all years from 1990 to 2015 combined
12110,Key secondary efficacy endpoints
12111,Treatment emergent adverse events up to week 24 in the safety population
12115,Adverse events
12116,Various definitions of acute chest syndrome from highly cited studies
12117,Asthma definitions in individuals with sickle cell disease and main findings of the article
12118,Top ten causes of death in males, females, and both for ages 1014 years, 1519 years, and 2024 years, 1990, 2005, and 2013
12119,Top ten causes of years lost due to disability   YLDs   in males, females, and both for ages 1014 years, 1519 years, and 2024 years, 1990, 2005, and 2013
12120,Top 10 causes of disability adjusted life years   DALYs   in males, females, and both for ages 1014 years, 1519 years, and 2024 years, 1990, 2005, and 2013
12122,Incidence of Selected Outcomes in Cardiovascular Health Study Participants by Creatinine Level
12125,Hazard Ratios and 95  CIs for Association Between Serum Creatinine and Incident Cardiovascular Outcomes, Stratified by Gender
12127,Overall best responses
12128,Most common   20    treatment emergent adverse events
12134,Serious adverse events
12137,Descriptive statistics Bayley III and MacAthur Bates scores by group
12138,Between group comparisons in Bayley III and MacArthur Bates scores
12139,2 year non psychometric outcome data
12141,Interruptions to treatment because of clinical or laboratory adverse events, by participant
12142,Bacterial sexually transmitted infections
12144,Subgroup analysis and interaction between transfusion groups and mortality
12145,Underlying primary cause of death overall and by transfusion strategy
12147,Incidence of adverse events for each group and by age
12149,Active range of motion for each patient of the affected limb after brachial plexus reconstruction but before amputation
12150,Functional outcome scores for all patients before and after bionic reconstruction
12152,Differences between eligible patients who were enrolled versus those not enrolled
12153,Protocol adherence, red blood cell transfusion, and haemoglobin results
12154,Clinical outcomes   patients with haemoglobin concentration of less than 120 g L
12156,Effects of methylprednisolone on outcomes
12158,Disease free survival and overall survival events in the intention to treat population
12159,Adverse events occurring in at least 5  of any one group
12161,Grade 3 and 4 toxicities, and grade 2 neurotoxicities possibly related to CD19 CAR T cell therapy
12163,Efficacy outcomes
12164,Adverse events
12166,Number and simple rates of the efficacy and safety outcomes of the study
12168,Adverse events, except bleeding, occurring in more than 5  of the patients or more than grade 2 in severity in any of the treatment groups
12171,Coverage and quality of the interventions by study group
12172,Malaria outcomes in the child cohort by treatment allocation
12173,Stratification by geographical area and cluster size
12174,Efficacy against clinical malaria   primary case definition   of a primary schedule with or without a booster dose and incremental efficacy of the booster dose
12175,Efficacy against severe malaria   primary case definition   of a primary schedule with or without a booster dose
12176,Number of cases averted per 1000 participants in children or young infants immunised with a primary vaccination schedule with or without a booster dose
12178,Primary outcome
12179,Procedure details
12180,Procedure related complications
12182,Anaesthetic and other intraoperative procedures
12183,Outcomes
12184,Adverse events
12187,Primary and secondary outcomes
12189,Transplant outcome after HLA matched related donor transplants   n 21
12190,Transplant outcome in HLA matched unrelated donor transplant recipients   n 35
12192,Pooled safety outcomes for cohorts 1 and 2 during treatment
12193,Treatment of uncomplicated malaria
12195,Response during and after treatment
12196,Treatment emergent adverse events in more than two patients
12198,Outcomes of the study
12199,Adverse drug reactions
12201,Objective tumour response
12202,Adverse events, according to grade
12203,Patient demographics and baseline characteristics in all randomly assigned patients
12204,Adverse events in the safety population   all randomly assigned patients
12206,Drug related adverse events
12211,Treatment resistance, IVIG infusion reactions, duration of hospital stay, and days of fever in the study population by treatment group
12215,Adverse events
12216,Factors that differentiated caseload midwifery and standard care in the trial groups
12218,Primary and secondary maternal and infant outcomes
12219,Perineal status after vaginal birth
12220,Other infant outcomes
12221,Adverse outcomes in individual infants older than 24 weeks  gestational age, by trial group
12222,Hospital cost   AUS   , by mode of birth
12223,Prevalence of vitamin A deficiency   19952005  , iodine deficiency   2013  , inadequate zinc intake   2005  , and iron deficiency anaemia   2011
12224,Global deaths in children younger than 5 years attributed to nutritional disorders
12225,Prevalence and numbers of children younger than 5 years with stunting, wasting, severe wasting, and underweight using estimates from UN and NIMS, by UN regions for 2011
12226,Review of nutrition interventions for women of reproductive age and during pregnancy
12227,Review of nutrition interventions in neonates
12228,Review of evidence for nutrition interventions for infants and children
12230,Effect of packages of nutrition interventions at 90  coverage
12231,Total additional annual cost of achieving 90  coverage with nutrition interventions, excluding management of moderate acute malnutrition, in 34 countries with more than 90  of the burden
12232,Thresholds for cost effectiveness of interventions worldwide in 2010, by income group or region
12236,Primary outcome and its components
12237,Secondary outcomes
12238,Neonatal outcomes
12239,Sensitivity analyses of the primary outcome
12246,Completion times   s   and total scores in the action research arm test
12247,Performance in the three cone stacking task
12249,Characteristics and outcomes during and after surgery
12250,Causes of death
12251,Estimated number of cases and age standardised and sex standardised prevalence of cannabis, amphetamine, cocaine, and opioid dependence in 2010, by region
12252,Estimated YLDs, YLLs, and DALYs for drug use disorders, by sex, in 2010
12253,Estimated DALYs attributable to illicit drug use as a risk factor for other health outcomes, 2010
12254,Donation intervals   weeks   in countries with national guidelines for blood donation
12255,Storage time for transfusion products
12256,90 day mortality by age and sex
12257,Changes in mortality by year of primary operation
12258,Univariable and multivariable Cox proportional hazards models of 90 day mortality
12259,Post approval clinical trials of erythropoiesis stimulating agents
12261,Detection rates of colorectal cancer and large polyps
12262,Additional colonic investigation in patients who had their randomised procedure, by reason for investigation
12263,Results of additional colonic investigation in patients who had their randomised procedure, by reason for investigation
12266,Numbers of clinically important complications and serious adverse events
12267,Summary of patients with serious adverse events
12269,Data from transfusion studies in patients with sickle cell disease
12271,Exploratory subgroup analysis to assess the progression free survival benefit of bendamustine plus rituximab versus CHOP plus rituximab
12272,Haematological toxic events in patients receiving at least one dose of study treatment
12273,All grades of non haematological toxic events in patients receiving at least one dose of study treatment
12275,Primary endpoints
12276,Clinical events during the trial and status at end of the trial
12277,Grade 3 and 4 clinical and laboratory events
12278,Comparison of recommendations or guidelines for the management of cervical cancer during pregnancy in patients wishing initially to preserve pregnancy   management for common histological subtypes: adenocarcinoma, squamous cell, or adenosquamous carcinoma
12279,Drugs used for the treatment of ovarian and cervical cancer during pregnancy
12281,Cumulative incidence of HIV 1 infection or death in infants uninfected at age 6 weeks
12282,Adverse events, rash, and grade 3 or higher laboratory abnormalities in infants who received at least one dose of study drug
12283,Spinal length and curvature before and after implantation of magnetically controlled growing rod in patients 1 and 2
12284,SRS 30 mean clinical outcome assessment scores
12285,Paralympic Games, 19482012
12286,Paralympic sports
12288,Bactericidal activity of agents and regimens determined by growth of log10CFU of Mycobacterium tuberculosis on solid media
12289,Activity of agents and regimens determined by time   h   to positivity in liquid culture
12290,Adverse events
12291,Risk factors included, exposure variables, theoretical minimum risk exposure distributions, and outcomes affected
12292,Proportion of ischaemic heart disease disability adjusted life years attributable to individual risk factors, worldwide, 2010
12293,Deaths attributable to risk factors and risk factor clusters, worldwide
12294,Disability adjusted life years   1000s   attributable to risk factors and risk factor clusters, worldwide
12296,Adverse events by treatment group
12297,Efficacy outcomes by treatment group
12298,Survival rate by treatment group   per protocol analysis set
12300,Effect of preoperative anaemia on mortality and morbidity at 30 days
12301,ORunadjusted and ORadj 2 of mortality at 30 days for patients with anaemia or risk factors and anaemia and risk factors, compared with reference populations of patients with neither anaemia nor risk factors
12302,ORunadjusted and ORadj 2 of morbidity at 30 days for patients with anaemia or risk factors and anaemia and risk factors, compared with reference populations of patients with neither anaemia nor risk factors
12303,Effect of immunosuppressive drugs on cardiovascular risk factors
12304,Risk factors for admission to hospital with bacteraemia, 19992002
12308,Cardiovascular events and all cause mortality in the two treatment groups
12310,Efficacy and safety
12312,Description of all cause mortality up to day 360
12315,DTPA GFR   primary endpoint
12317,Comparisons between entry and exit values   secondary endpoint
12318,Adverse events
12321,Prevalence at enrolment, and incidence and clearance of human papillomavirus   HPV   infections in men
12322,Factors independently associated with infection with human papillomavirus   HPV
12325,Patients with first on study skeletal related events by type
12327,Adverse events and adverse events of interest in patients receiving at least one dose of study treatment
12328,Studies of antiresorptive drugs for the prevention of skeletal related events in castration resistant prostate cancer
12331,Secondary outcome measures at 56 days, by allocation
12332,Adverse events
12334,Angiographic and Procedural Details in the Study Population
12335,Population At Risk and Cumulative Three Year Mortality Rates Associated With Ascending Levels of CK MB Elevation
12339,Effect of Oral CEE or Transdermal Estradiol on Hormones and Lipids After One Month
12340,Effect of Oral Conjugated Equine Estrogen or Transdermal Estradiol on Hemostatic Factors After One Month
12342,Reports Evaluating Hemostatic and Fibrinolytic Markers in Postmenopausal Women After Estrogen
12344,Echocardiographic Parameters in Healthy Volunteers and in Patients
12346,Outcomes After CABG vs. PCI
12347,Multivariate Correlates of In Hospital Mortality   C Index 0.807, Validated 0.801
12348,Multivariate Correlates of Long Term Mortality   C Index 0.687, Validated 0.684
12349,Distribution of Male, Female, and Indeterminate ECG Patterns Among Males and Females of Different Age Groups
12350,Distribution of Heart Rate, QTc Duration, and T Wave Amplitude
12351,ST Segment Angle  20 in Males and Females With Male Pattern
12352,Comparison of ECG Patterns Recorded at Different Times and at Different Heart Rates   Group I
12353,Predictors of All Cause Mortality and Predictors Specific to Progressive Heart Failure Death
12354,Physician Perceptions of the Barriers of Care in Managing Cardiovascular Disease Risk in Patients With Diabetes
12355,Clinical Goals of the American Diabetes Association
12357,Comparison Between Coronary Artery Lesions Demonstrated by the Angiography and CFVR Values Measured by Transthoracic Doppler Echocardiography
12358,Relationship Between Coronary Artery Lesions and Perfusion Defects on Thallium 201 Single Photon Emission Computed Tomography
12360,Admission Medication According to Diagnosis of Diabetes and Glycemic Status
12361,Admission Electrocardiogram and Course in Hospital According to Diagnosis of Diabetes and Glycemic Status
12362,Independent Predictors of Outcome
12364,LA Volumes and Fractions in the Two Groups
12365,Pulmonary Vein Flow Parameters for the Two Groups   Mean  SD
12366,Bland Altman Analysis for Interobserver and Intraobserver Variability
12371,Intensity of preamputation pain during treatment with bupivacaine and morphine   blockade group   or saline   control group
12372,Effect of bupivacaine and morphine or saline on rate of phantom pain, intensity of stump and phantom pain, and consumption of opioids during first year after amputation
12374,Mean   SD   oral and parenteral morphine requirements
12375,Differences in pain scores between treatment groups
12377,Withdrawals and deaths during main follow up   to 52 weeks
12378,Rates of admissions and outpatients visits by group and by follow up period in all children who started supplementation, including those withdrawn during study
12379,Incidence of severe anaemia   PCV  25    and malaria during main follow up period
12380,Transmission intensity estimates among five childhood populations
12381,Age specific period prevalence rates      of severe malaria, cerebral malaria, severe malaria anaemia and acute respiratory tract infections from five communities in The Gambia and Kenya
12382,Age distribution      of patients admitted with malaria or acute respiratory tract infection presenting to hospital from five communities in The Gambia and Kenya
12383,Abdominal injuries in children age 014 years
12384,Pattern of injuries in abused children
12386,Estimated annual running costs of providing preventive interventions for child survival at 2000 coverage levels and universal coverage levels
12387,Estimated annual running costs of delivering treatment interventions for child survival at 2000 coverage levels and universal coverage levels
12388,Effects of varying selected assumptions on the estimated additional annual running costs of providing child survival interventions at universal coverage, from reported levels in 2000   US 5134 million
12391,Predictors of NVAF, Adjusted for Age and Gender
12392,Multivariate Models for Prediction of NVAF
12394,Imaging Tests Used to Diagnose Pulmonary Embolism
12396,Echocardiographic Parameters of Study Patients Grouped According to Left Ventricular Geometric Pattern
12397,Clinical Echocardiographic, and Hemodynamic Features of 13 Patients With False Positive Results for Dobutamine Stress Echocardiography
12398,Clinical Echocardiographic, and Hemodynamic Features of 22 Patients With False Negative Results for Dobutamine Stress Echocardiography
12399,Treatment phases of the hybrid chemotherapy protocol
12401,Grade 3 and 4 toxic events by treatment phase
12402,Univariate and multivariate analysis of prognostic factors
12403,Outcomes of treatment protocols for acute lymphoblastic leukaemia in infants
12404,Prespecified criteria for upper gastrointestinal clinical events
12406,Upper gastrointestinal clinical events in intention to treat population
12408,Upper gastrointestinal clinical events related to concomitant use of low dose aspirin or PPIs for at least 75  of the study period in intention to treat population
12409,Upper gastrointestinal clinical events related to combinations of concomitant PPIs and low dose aspirin use for at least 75  of the study period in intention to treat population
12410,Patient discontinuations due to dyspepsia related to concomitant use of low dose aspirin and PPIs for at least 75  of the study period in intention to treat population
12411,Summary of clinical trials of antihypertensive drugs that reported new cases of diabetes
12412,Results of sensitivity analyses
12413,Treatment during phases of the BFM ALL 95 intermediate risk trial protocol
12415,Pattern of events by time after random assignment
12417,Incidence of thrombotic cardiovascular events
12418,Incidence of thrombotic cardiovascular event types in per protocol population
12420,Virological suppression in head to head trials of initial HAART with an NNRTI versus a PI
12421,Withdrawal due to adverse events in head to head trials of initial HAART with an NNRTI versus a PI
12422,Virological suppression in trials of initial HAART versus two drug treatment
12423,Comparison of outcomes between direct and indirect estimates of initial highly HAART with an NNRTI versus a PI
12425,Numbers of events and percentage rates at 5 years by thiopurine randomisation
12426,Effect of 6 thioguanine on isolated CNS relapse within subgroups
12427,Causes of deaths in remission by randomised treatment
12430,Number needed to treat for various background proportions of spontaneous stone passage
12431,Outcomes of the studies pooled and of the studies excluded for absence of a true control, stratified by treatment regimen
12434,Hemodynamic Changes Between 10 Min and Exercise Termination in Younger Versus Older Subjects
12435,Main features of the HOPE, EUROPA and PEACE trials
12437,Effect of ACE inhibitors on main outcomes
12439,Primary and secondary outcome measures
12440,Incidence of new onset diabetes in various studies  40
12441,Endpoints for amlodipine and perindopril versus atenolol and thiazide   ASCOT trial    42
12442,Specific indications for various classes of antihypertensive drugs  32
12447,Extent of plasma viraemia by week
12448,Frequency of infection in resting CD4  T cells on standard HAART
12449,Frequency of infection in resting CD4 T cells before and after addition of enfuvirtide and valproic acid to HAART
12450,Recruitment from the different centres
12452,Outcome after treatment
12453,Mitral Valve Features and Associated Echocardiographic Features of MVP
12454,Features of LA and LV Chambers
12455,Proportion of Increased LA and LV Measures
12460,History of fertility problems by treatment status
12461,Infertility investigations and diagnoses in women who had seen a doctor because they were having trouble becoming pregnant, by treatment for tall stature
12464,Symptoms and physical signs of allergic disease in Tirana, Albania, and West Sussex, UK
12465,Selected symptoms and physical signs of allergic disease by skin prick test response in each center
12466,Prognostic factors in minimal residual disease defined groups at day 36
12468,Symptoms suggestive of allergic disorders
12469,Different outcomes in risk groups compared with the high risk control group
12470,Sensitisation to dust mites, cat, dog, mixed grasses, milk, and egg assessed by skin prick testing at age 1 year
12471,History of hypersensitivity reactions and contact allergies
12472,Risk factors for development of coronary artery disease and restenosis
12474,Effects of IL 12 on biomarker responses to allergen challenge
12476,Treatment outcome
12477,Allergy related symptoms, diagnoses, and sensitisations by age of entry to day nursery in children aged 514 years
12479,Number of children with information on all covariates by age   months   at entry to day nursery
12480,Effect of age of entry to day nursery on allergy related variables in children aged 514 years with information on all covariates
12482,Grade 3 or 4 toxic effects   WHO   experienced during treatment
12483,Results of 2 tests to assess whether CAP or carboplatin was more or less effective in different subgroups on endpoint of overall survival
12484,Treatment on progression by treatment allocated
12485,Distribution by age, sex, and smoking status in urban and rural groups
12486,Percentages of participants reporting wheeze in the previous year, asthma, and cough for 3 months of the year by age in urban and rural groups
12487,Percentage of participants with positive allergen skin tests by age in urban and rural groups
12488,Exposure rates and odds ratios for wheeze and skin sensitivity to D pteronyssinus adjusted for age, sex, and urban or rural residence
12489,Coefficients of variation within and between hormone assays
12490,Enrolment and follow up
12491,Distribution of measures of previous malaria exposure before vaccine administration
12492,Number of children with side effects observed within 1 week of vaccination
12493,Measures of vaccine efficacy
12494,Number of children with severe malaria
12495,Geometric mean parasite density in first cases of malaria
12496,Number of children with pure P vivaxmalaria
12498,Aneurysm locations
12499,Technical outcome of first procedure
12500,Time to second procedure on same aneurysm
12501,Outcome at 2 months in 1906 patients
12502,Outcome at 1 year in 1594 patients   primary outcome
12503,Non procedural bleeding from target aneurysm
12504,Age and sex distribution of 368 individuals with loss of vision in the non amblyopic eye
12505,Category of vision loss at presentation by category at 1 year follow up
12506,Total population lifetime risk and annual rate of permanent visual impairment or blindness attributable to loss of vision in the non amblyopic eye
12507,Projected lifetime risk and annual rate of permanent visual impairment or blindness attributable to loss of vision in the non amblyopic eye in individuals with amblyopia
12508,Disorders causing vision loss by age group
12509,Frequency and transmission of HIV 1 in child bearing women attending rural immunisation clinics in KwaZulu Natal
12510,Age distribution of HIV 1 infected children born to HIV 1 positive mothers
12511,Comparison of absolute and relative numbers of HIV 1 RNA copies within erythrocyte and leucocyte preparations of 17 HIV 1 infected individuals
12513,Variables involved in formation and binding of immune complexes   total
12515,Distribution of events
12516,Annual recurrence rates
12517,Hazard ratios for different prognostic factors for breast cancer events
12518,Occurrence of prespecified adverse events
12519,New primary cancers with an incidence of more than 02  before recurrence in all patients who received trial treatment
12520,Overall adverse events
12521,Factors associated with low serum retinol concentrations in 301 women infected with HIV 1
12523,Distribution of alcohol intake over subtypes of alcoholic beverage in the Rotterdam Study
12524,Hazard ratios of dementia and subtypes of dementia according to alcohol consumption
12525,Hazard ratios of dementia and subtypes of dementia according to alcohol consumption, stratified for APOE      4 status
12526,Plasma BNP   Biosite  BNP B  and Shionogi  BNP S  Assays   by Age and Gender in Normal Subjects
12527,Age and Gender Specific Ranges   5th95th Percentiles   for Plasma BNP   pg ml     Biosite and Shionogi Assays   Derived From the Regression Analysis in Normal Subjects
12528,Variables Examined for Association With Age, Gender, and Plasma BNP Concentration in Normal Subjects
12529,Parameters Independently Associated With BNP
12530,Sensitivity and Specificity of BNP for Detection of Systolic Dysfunction at the Discriminatory Value for BNP as Determined by the ROC Analysis and at the 95th Percentile Reference Limit by Age, Gender, and Assay System
12532,Genital tract infections and HIV 1 shedding   n 311
12533,Relation between HIV 1 shedding in the genital tract and presence of HIV 1 RNA or infectious virus in blood
12534,Association of virologic, immunologic, and clinical variables with HIV 1 shedding in genital secretions   n 247
12535,Association of clinical variables with HIV 1 shedding in genital secretions   n 247
12537,Odds ratios of coronary heart disease in men who had values of the relevant cell adhesion molecule in the top third of the distribution of controls relative to those who had values in the bottom third of this distribution
12543,Number of patients who received concomitant medications during stay in hospital
12544,Frequency of composite and single endpoints at hospital discharge and at 30 days
12545,Frequency of in hospital cardiac events and procedures
12546,In hospital stroke rates
12547,Rate of in hospital thrombocytopenia and non cerebral bleeding complications
12548,Mean   SD   birthweight of individual twins
12550,Distribution of all patients with necrotising enterocolitis
12551,Details of patients with necrotising enterocolitis
12552,Risk factors for definite necrotising enterocolitis
12553,Definite necrotising enterocolitis and recruitment by hospital
12554,Summary of predictors of counterfeit artesunate
12555,Regional prevalence of xerophthalmia and active trachoma
12556,Variables associated with active trachoma
12560,Adjusted mean values for markers of systemic inflammation according to daily alcohol intake
12561,Adjusted mean values for markers of alcohol consumption in categories of daily alcohol intake
12563,Mean blood concentrations of homocysteine,      folate, vitamins B6 and B12 after 3 weeks consumption of red wine, beer, spirits and water
12564,25 hydroxycholecalciferol concentrations in untreated tuberculosis patients and tuberculosis contacts
12565,VDR genotype in tuberculosis patients and tuberculosis contacts
12566,Association between tuberculosis and combinations of VDR genotypes and 25 hydroxycholecalciferol status
12567,Relative risk of HIV 1 induced death and AIDS associated with changes in TREC, HIV 1 RNA, CD4 T cell count, and age at seroconversion
12568,User satisfaction by provider and type of operation
12569,Cost effectiveness of cataract surgery   costs per operation in Indian rupees
12570,Studies that report cataract surgery outcomes in developing countries
12572,Percentage of patients who received concomitant medications given during stay in hospital
12573,30 day mortality
12574,30 day mortality in subgroups
12575,Frequency of in hospital cardiac events and procedures
12576,Frequency of strokes
12577,Non cerebral bleeding complications
12579,Outcomes during double blind treatment period
12580,Outcome during total treatment period
12581,Death, myocardial infarction, or both in predefined subgroups in double blind treatment period
12582,Safety during double blind treatment period
12592,Risk of developing diabetes mellitus associated with white cell count and various metabolic factors
12593,Risk of developing diabetes mellitus for individuals in subgroup with values higher than the median for sialic acid and three acute phase proteins
12594,CYP2C9 genotype distribution
12595,Comparison of low dose group with random clinic controls
12596,Age Standardized Distribution of Potential Coronary Risk Factors According to History of Diabetes and CHD in the Health Professionals Follow Up Study in 1986
12599,Relative Risks and 95  CIs of Death From All Causes and CHD According to Duration of Diabetes in the Health Professionals Follow Up Study 19861996
12607,Cerebrospinal fluid and plasma HIV 1 RNA before and after treatment
12609,Intention to treat analysis
12610,Per protocol analysis
12612,Crude and adjusted odds ratios for risk of breast cancer associated with intake of phyto oestrogens
12613,Excretion rates of lignans, isoflavonoid phyto oestrogens, and total nitrogen  ?
12615,Follow up events and 1 year estimates      for cars
12616,INR measurements for all treatment groups at weeks 1 and 4, and month 6
12617,Study groups
12618,Visual status at 1 year follow up in the first operated eye of 1827 patients
12619,Causes of poor functional visual outcome and blindness at 1 year follow up in the operated eye of 1827 patients
12621,Source and number of upper gastrointestinal bleedings after randomisation by intention to treat
12622,Comparison of laboratory data   mean  SD    of both treatment groups during a follow up of 12 months
12623,Multivariate analysis of the prognostic value of selected clinical variables on the first occurrence of variceal rebleeding, death, and clinically significant or refractory encephalopathy
12624,General data of the two populations
12625,Mean   SD   percentage composition of main fatty acids of plasma lipids and their ratios in participants matched for age and sex
12629,Relation of changes in plasma creatinine following steroid withdrawal to presence or absence of early rejection episodes and to DR antigen matching
12630,Changes in metabolic, cardiovascular, and haematological indices after steroid withdrawal
12634,Association between percentage energy from macronutrients and clinical outcomes   n 135335
12635,Association between percentage energy from types of different fat and clinical outcomes   n 135335
12637,Tumour response
12638,Adverse events
12640,Reasons for changes in recommended antibiotic therapy in the per protocol population
12642,Proportion of patients in the full analysis set who had an ACR response, low disease activity, or remission
12643,Summary of adverse events, serious adverse events, and discontinuations in the safety analysis set
12644,Liver function tests as multiples of upper limit of normal
12647,Adverse events in initial treatment and treatment withdrawal periods
12648,Adverse events in re treatment period
12651,Adverse events of special interest
12653,Adverse events
12655,Recurrence at 12 months after procedure
12656,Serious adverse events
12657,The mean difference in total costs and QALYs for HAL versus RBL
12659,Deaths avoided   in thousands   due to changes in dietary and weight related risk factors between 2010 and 2050 for different climate and socioeconomic scenarios
12661,Antibiotic items dispensed per 1000 weighted population for the feedback intervention, September, 2014, to April, 2015
12663,Antibiotic items dispensed per 1000 weighted population for the patient focused intervention, December, 2014, to March, 2015
12665,Antibiotic items dispensed per 1000 weighted population for all experimental groups, September, 2014, to April, 2015
12666,Effects of interventions on breastfeeding outcome measures, by setting
12667,Estimated economic losses from cognitive deficits associated with regional infant feeding practices compared with every infant breastfeeding until at least 6 months of age
12668,Electrocardiographic Data of the Study Population
12669,Electrocardiographic Variables in the Different HERG K897T Genotypes
12670,Potentially effective control interventions and challenges in the development of generalisable policies
12671,Policies that require international collaboration
12672,Overall recommendations for policy interventions
12673,Potential national indicators in the WHO global action plan, by policy area
12674,Benefits and costs accrued by a coherent package
12676,Key elements of a data driven, locally tailored approach to tuberculosis elimination
12677,Possible data items to be collected on individual tuberculosis cases, in addition to the WHO minimum set of variables,  13   by purpose and data type
12678,Examples of potential benchmarks for success of locally targeted strategies to end tuberculosis in five emblematic settings
12679,Increase in vitamin A and folate deficiencies by region
12680,Health burden attributed to losses of indigenously grown versus imported foods and nutrients
12682,Results based on questionnaire at 16 weeks
12683,Results based on monthly questionnaires
12684,Results based on notes review
12686,Stratified disease approach to acute appendicitis
12687,Clinical trials comparing primary antibiotic treatment versus surgery for acute appendicitis
12689,Primary outcome analyses of patients with vertebral osteomyelitis according to duration of antibiotic treatment
12690,Secondary outcomes and adverse events
12691,Duration and type of antibiotics used in the study
12693,Reasons for treatment failure, by treatment group
12694,Comparison of the secondary outcomes and post hoc analyses, by treatment group
12696,Treatment adherence and follow up of enrolled infants
12697,Per protocol analysis
12698,Intention to treat analysis
12699,Elements of smart food policy design in three policy areas
12703,Key adverse events and laboratory abnormalities
12704,Accountability relations and mechanisms for enforcing accountability by governments and the private sector for actions and policies on food environments
12706,Reasons for not reintroducing CAPOX B after first progression with 5  incidence
12707,Outcome according to response after six cycles of treatment given before randomisation
12708,Outcome according to stage of disease
12709,Treatment related adverse events during observation or maintenance treatment with an incidence of 5
12710,Cost effectiveness of childhood obesity prevention interventions
12711,Patient characteristics at study entry and initial study medication
12712,Endoscopic and clinical outcomes based on modified intention to treat analysis
12715,Adjudicated and non adjudicated clinical outcomes
12717,Number of participants diagnosed with tuberculosis and cryptococcal meningitis at trial enrolment
12719,Adherence to antiretroviral therapy during the previous 28 days, as measured at 6 and 12 months
12720,Mortality according to cryptococcal serum antigen status in the clinic plus community support group
12723,Modified intention to treat outcomes by treatment group   unless stated
12724,Adverse events associated with receipt of either study drug
12726,Locus tags of chromosomal antimicrobial resistance gene orthologues in reference sequences from the S flexneri 2a lineage
12727,Availability of data from randomised trials beginning before the year 2000 and comparing radiotherapy to the chest wall and regional nodes after mastectomy and axillary surgery versus no radiotherapy but the same surgery
12728,Overview of interventions showing effect on selected outcomes
12731,Effect of provision of facility care on lives saved by 2020, hence reducing the quality gap
12732,Incremental cost of the scale up plan by intervention package for the years 2020 and 2025
12734,Bivariate Pearson Correlations of Year 10 LV Mass   g   With Predictor Variables by Race Gender Group
12735,Multiple Linear Regression Coefficients Relating Year 10 LV Mass to Predictor Variables, by Race Gender Group
12736,Predictor Variables by Percent Change in LV Mass   Mean Level of Predictor, Adjusted for Race and Sex
12738,Number of biobanked isolates with drug specific genotypic and phenotypic resistance
12739,Outcomes of 107 patients with extensively drug resistant tuberculosis after treatment, by duration of follow up
12740,Outcomes of the 45 patients who were discharged into the community
12741,Treatment related outcomes by conversion status
12742,Number of patients achieving first culture conversion, net conversion, or net reversion, by follow up time
12743,Cox cause specific hazards model of time from treatment start to net conversion   under competing risk of death   and multivariate Cox proportional hazards model for risk of death from treatment start
12745,Primary and secondary endpoints
12746,Serious adverse events reported
12748,Primary and secondary analysis
12749,HPA s daily situation reports and updates of events
12750,Mean number of medical presentations per day during Euro 2012
12752,Specific causes of death, 19992011
12753,Incidence rate ratios of underlying cause of death, by year
12755,Safety summary
12756,Solicited injection site adverse events
12757,Release schedule for biofortified crops and status of related nutrition studies
12758,Epidemiological and clinical features of patients with avian influenza A H7N9 virus infection
12759,Laboratory measurements in four patients with avian influenza A H7N9 virus infection
12760,Virological findings in patients with avian influenza A H7N9 virus infection
12761,Substitutions of critical aminoacid residues in human and avian isolates of avian influenza A H7N9 virus, by residue
12762,Antibiotic resistance patterns for M abscessus isolates; by patient number
12763,Design and eligibility criteria of included trials
12764,Number of people with incident cancers at specific sites, by duration of treatment
12768,Description of Study Population
12769,Outcomes Stratified by DM and Treatment
12771,Causes of Death Stratified by Treatment for DM
12773,Primary and secondary trial outcomes
12774,Sensitivity analysis of interaction between recruiting hospital and primary outcome
12775,Timing of report of CAUTI relative to catheterisation status
12777,Manifestations, brief clinical case definitions, and recommended diagnostic approach for the diagnosis of Lyme borreliosis in routine clinical practice
12778,Considerations for differential diagnosis of Lyme borreliosis
12779,Recommended treatment for patients with Lyme borreliosis
12781,Cumulative treatment failure
12782,Cluster specific cumulative treatment failure by day 6
12783,Relapse at days 714
12784,Treatment received by children in the control clusters
12786,Adverse events reported by 10  of patients   safety population
12791,Reasons for exclusion from the study and per protocol analysis at short term follow up
12793,Clinical outcomes in the per protocol population
12795,Secondary outcomes
12796,Class of consensus indications for catheter ablation of atrial fibrillation
12798,Unadjusted Incidence and Relative Risk for Progression Asymptomatic Left Ventricular Dysfunction in Black and White Participants According to Randomization to Enalapril or Placebo
12799,Multivariate Analyses: Risk Associated With Randomization to Enalapril Versus Placebo for Progression of Asymptomatic Left Ventricular Dysfunction
12800,Adjusted Risk for Progression to End Points in Black Relative to White Participants in SOLVD Prevention Trial
12801,Subtypes of non Hodgkin lymphoma according to the 2008 WHO classification  13
12802,Ann Arbor staging system
12804,Angiographic and clinical efficacy endpoints
12805,Safety endpoints and intracranial haemorrhage subtypes
12806,Pre  Versus Post PTE Echocardiographic and Hemodynamic Parameters
12807,Cost effectiveness results for selected interventions evaluated in Australia
12809,Adherence to treatment of patients that returned for 6 week follow up, by treatment group
12810,Helicobacter pylori eradication by treatment group for three definitions of analysis population
12812,RyR2 Mutations Detected in Affected Families
12813,Arrhythmic Symptoms in Patients Carrying RyR2 Mutations
12814,Twelve Lead ECG, SAECG and Two Dimensional Echocardiographic Findings in RyR2 Mutation Carriers
12815,Median urinary iodine concentrations in participating UK centres
12816,Probability of iodine deficiency in Belfast compared with other UK centres following binary logistic regression analysis
12817,Urinary iodine concentrations analysed according to dietary habits
12819,Incidence of primary endpoint events and complicated appendicitis with peritonitis and postoperative peritonitis within 30 days after the start of treatment in both groups   intention to treat population
12820,Duration of post therapeutic pain, hospital stay, and disability   intention to treat population
12821,Aspects of appendices during appendicectomies done in 44 of 120 patients treated initially with antibiotics   intention to treat population
12822,Association between risk factors and complicated appendicitis with peritonitis in the appendicectomy group
12823,Association between risk factors and absence of improvement of appendicitis in the antibiotic treatment group
12825,Rates of tuberculosis and death in participants receiving 6 months  open label isoniazid followed by 30 months  masked placebo   control group   or isoniazid   continued isoniazid group
12826,Multivariable analysis of the effect on tuberculosis incidence of antiretroviral therapy
12827,Effect of interventions estimated by use of a model based on the Lives Saved Tool
12828,Modelled interventions, data sources, and effect estimates used for analysis
12829,Interventions modelled at various stillbirth rates
12833,Ranking of research priorities for development of interventions to reduce stillbirths in low income and middle income countries
12834,Laboratory procedures
12836,HIV statuses in patients with suspected cases of tuberculosis and multidrug resistant tuberculosis
12837,Sensitivity, specificity, and predictive values of a one off direct MTB RIF test
12838,Sensitivity and specificity of smear microscopy   two to three microscopy examinations as per routine practice   and a one off direct MTB RIF test, stratified by HIV status of patients
12839,MTB RIF test sensitivity and specificity for detection of rifampicin resistance after change to software cutoff
12840,Thousands of cases and hundreds of deaths from cholera projected between March 1 and Nov 30, 2011, by province under base case and under each intervention scenario
12841,Variables used to distinguish viral from bacterial pneumonia
12842,Occurrence of pneumonia and other findings in 4277 children with laboratory confirmed viral respiratory infection at Turku University Hospital, Finland
12843,Possibilities for antiviral treatment and prevention of severe viral pneumonia
12844,Treatment and prophylaxis of Ebola haemorrhagic fever
12845,Triggers for non fatal myocardial infarction
12846,Prevalence of exposure within the population, pooled OR, and PAF for the studied triggers of myocardial infarction
12848,Summary of selected emerging infectious diseases in southeast Asia
12851,ADHD rating scale, abbreviated Conners  scale, and structured psychiatric interview scores at start and end of the first phase
12853,Grade 3 and 4 adverse events      experienced by 2  or more of patients and adverse events leading to treatment discontinuation, after randomisation to rituximab maintenance or observation
12855,Summary of coverage, main effects, and costs of selected preventive interventions
12856,Effectiveness and cost effectiveness of interventions after 20 years and 50 years
12857,Estimated yearly cost per head   in US    of a chronic disease prevention package by intervention and country
12858,Immunohistochemistry scoring for HER2 in gastric and gastro oesophageal junction cancer, by type of diagnostic specimen
12860,Secondary efficacy endpoints
12861,Adverse events
12863,Estimated population level effect of pricing policies on alcohol consumption and health outcomes
12864,Estimated population level effect of pricing policies on alcohol consumption and health economic outcomes
12865,Estimated effect on alcohol related disorders of a 050 minimum price policy on disease prevalence by age   10 years after implementation
12866,Estimated population subgroup effect of alcohol pricing policies
12870,Actuarial life table for cumulative proportion of healing for both treatment groups, by time interval
12871,M ulcerans isolated by culture of tissue specimens after 8 week treatment period
12873,Efficacy of ticagrelor versus clopidogrel
12874,Safety of ticagrelor versus clopidogrel in patients intended to undergo an invasive strategy
12877,Silent Cerebrovascular Disease
12878,Neurohumoral Profiles
12881,Findings in the Three Groups of Subjects: NT, WHT and EHT
12883,Cox Regression: Univariate Predictors of CHD Events
12884,Comparison of Individual and Combined Test Performance in the Prediction of Coronary Events
12886,Propranolol Induced Changes in the Mean cQTe, Mean cQTp, Mean cTp e, Maximum cQTe, Minimum cQTeand cQTe D in the LQT1 and LQT2 Groups
12888,Epinephrine Induced Changes With Oral Propranolol in the Mean cQTe, Mean cQTp, Mean cTp e, Maximum cQTe, Minimum cQTeand cQTe D in the LQT1 and LQT2 Groups
12889,HR and QT Interval Responses to Exercise, Atropine and Isoproterenol
12892,Reported adverse effects
12893,Change in body mass index after antipsychotic drug treatment
12894,Association of genotype with weight gain
12895,General features of NM2 genome compared with those of N315 and Mu50
12898,Treatments received during study by patients assessed for primary efficacy outcome
12899,Frequency of venous thromboembolic events by day 11
12900,Safety outcomes
12902,Treatments received during study by patients assessed for primary efficacy
12903,Frequency of venous thromboembolic events by day 11
12904,Safety outcomes
12906,Surgical details
12907,Examination of resected specimen
12908,Sites of first failure, survival status, and cause of death
12909,Dysphagia and performance status scores at 1 year
12910,Chemotherapy regimens and hazard ratios for randomised trials comparing surgical resection with or without preoperative chemotherapy
12912,Radiological and biological findings in 52 patients with community acquired Staphylococcus aureus pneumonia
12913,Median   IQR   concentrations of folate, vitamin B12, and total homocysteine concentrations in the two interventions
12915,Intervention studies testing the effect of specified doses of folic acid, up to 1 mg day, on serum folate concentration
12916,Serum folate concentrations after increases in folic acid intake in younger women according to background serum folate and the predicted reduction in neural tube defect risk
12917,Significant and important non significant associations of acute lymphoblastic leukaemia with variables for which there was direct evidence of an association with childhood leukaemia before analysis
12918,Significant associations of acute lymphoblastic leukaemia with variables for which we had no specific hypothesis of an association with childhood leukaemia before the analysis was done
12919,Details of use of iron and folate supplements
12921,Overview of drugs, diseases, and factors
12923,Logrank analysis for treatment and prognostic factors
12924,Regression analysis of chemoradiotherapy adjusted by prognostic factors and background chemotherapy and chemotherapy adjusted by prognostic factors and background chemoradiotherapy
12926,Age and anthropometric variables 35 years after discontinuation of intervention
12927,Differences between calcium supplemented and placebo groups in standing height and L2L4 height gains
12928,Differences between calcium supplemented and placebo groups in lumbar spine bone mineral content
12930,Relative resistance of P falciparum DHFR genotypes to trimethoprim and pyrimethamine
12933,Postoperative outcomes
12934,The effects of warming therapies compared with standard treatment
12936,Age adjusted genotype resistance index   GRI   and genotype failure index   GFI   at three sites in Mali from 1997 to 1999
12939,Rates of miscarriages and crude and adjusted risks of miscarriage among women pregnant for the first time in Jiaxing city, according to the use of folic acid pills during pregnancy
12941,Regular follow up, treatment, and symptoms during preceding 3 months
12944,Risks of food cooked or prepared outside the home by source and timing of exposure
12948,Quantitative angiographic data at angiographic follow up, and target vessel revascularisation during the year after stent placement
12949,Odds ratios for treatment effect on angiographic restenosis and target vessel revascularisation in strata defined by C pneumoniae titres
12951,Patient treatment
12952,Diary data from last 3 days and last 7 days of each treatment period
12953,Outpatient antibiotic sales in 1997 in the European Union
12959,Rate ratios of prostate cancer according to fish consumption
12960,Resistance to other antimicrobials in sulphonamide resistant and sulphonamide susceptible E coli isolates
12961,Frequencies of sulI and sulII genes among E coli isolates in 1991 and 1999
12963,Main clinical features of neutropenic patients with S prolificans infection
12964,General features of Staphylococcus aureus N315 and Mu50 genomes
12965,Genes likely to have undergone horizontal transfer
12966,Antibiotic resistance genes identified in N315 and Mu50 genomes
12967,Known virulence genes and new candidates identified in N315 and Mu50 genomes
12968,Susceptibility results for linezolid resistant VREF
12970,Total IgE antibodies, antigen specific IgE antibodies, and skin prick test reaction
12971,Distribution of 84 people with vCJD by standard region of residence on Jan 1, 1991
12972,Comparison of cumulative vCJD incidence between the north      and south     of Great Britain
12973,Regional variations in quantities of foods consumed per week from 1986 to 1987
12974,Regional variations in quantities of foods per week brought into the home from 1984 to 1986
12975,Hemodynamic Measurements at 56 Days After Infarction
12980,Summary of the effect of an increase of 2  energy in trans fatty acid intake on coronary heart disease      reported in prospective studies
12981,Cell wall deficient blood culture isolates from BMT recipients and their antibiotic sensitivity patterns
12984,Details of diagnosis and other factors in patients with syncope and presyncope
12985,Results of autonomic tests in major groups of patients with chronic autonomic failure, vasovagal syncope, carotid sinus hypersensitivity, psychiatric comorbidity and no definitive diagnosis
12986,Cardiovascular Medication Taken at the Time of the Study
12987,Hemodynamic Parameters for the Three Groups at the Time of IVUS Study of the LAD
12988,Morphologic and Mechanical Properties of the Proximal LAD in the Three Groups
12989,Average K1 distribution volume   mL gm  , and Bmax Kd of  C 11 raclopride of obese individuals and controls
12990,Regional brain metabolic measures   mmol 100gm min   in obese individuals and controls
12991,Severity of index reactions   before management   and subsequent follow up reactions in patients with peanut and nut allergy
12992,Treatment self administered by patients who had a follow up reaction
12993,Link between amount of nut eaten and severity of follow up reaction
12995,Comparison of severity of index and follow up reactions in 88 patients
12996,Treatment administered in hospital for patients who had follow up reactions
12997,Link between current asthma control and the severity of follow up reactions
12998,t  11;18, q21;q21   in H pylori eradication responsive and non responsive gastric MALT lymphomas
12999,Susceptibility to ciprofloxacin for clinical isolates of N gonorrhoeae from 1991 to 1999
13000,Details of primary and health care worker cases
13001,Absolute and relative risks of secondary meningococcal disease in health care workers   HCW   and sensitivity analysis
13004,Tailored FEC doses
13005,FEC dose modification schedule
13007,Number of patients receiving tailored FEC doses
13008,Number of patients experiencing grade 3 or 4 toxicity at any time during therapy
13009,Study population and response rates
13010,Concentrations of major mite and cat allergens in carpet and mattress dust samples at different times
13011,Odds ratios for exposure to indoor allergens at age 6 months and asthma at age 7 years
13013,Drugs taken by patients
13014,Renal disease in fluorspar mining and non mining areas of Upper Weardale and local renal clinic
13015,Occupational silica exposure, and renal diagnosis of identified cases
13017,Occurrence of early   during oral ganciclovir prophylaxis   and late cytomegalovirus disease
13020,Inhaled and intravenous pharmacokinetic parameters
13022,Survival hazard ratios for experimental over bolus fluoropyrimidines   control  , according to initial performance status and tumour response to treatment
13023,Plasma uracil concentrations before 18F fluorouracil injection in each period
13024,Blood flow in spleen and tumour
13025,AUCs for time activity curves
13026,Concentrations of selected dioxin congeners
13028,Birth and deaths before age 1 year and between 1 and 5 years
13031,Clinicopathological features of patients
13032,Univariate analysis of survival
13033,Univariate analysis of survival benefit from chemotherapy for tumour site and sex
13035,Correlation between house dust endotoxin concentrations and proportions of T lymphocytes in peripheral blood expressing type 1 or type 2 cytokines
13036,Randomised trials of MAB vs AS in advanced prostate cancer
13037,Causes of death other than prostate cancer
13039,Number of patients who had taken oral, parenteral, nasal, or dermal corticosteroids in the past
13043,Cells received by patients
13044,Immune cell populations 4 weeks after transplantation
13048,Number of trials   patients   by type and timing of chemotherapy in meta analysis comparing locoregional treatment with and without chemotherapy
13049,Meta analysis of locoregional treatment with and without chemotherapy: effect on survival
13050,Randomised trials comparing neoadjuvant combination of cisplatin   C   and fluorouracil   F   followed by radiotherapy in responders or by radical surgery plus radiotherapy in non responders   arm 1   with radical surgery plus radiotherapy   arm 2
13051,Larynx preservation: patients  status for disease free Survival
13054,Frequency of Major Adverse Cardiac Events
13055,Number of isolates collected from each hospital during 3 years
13056,Code below as a table
13062,Geometric mean   approximate SD   homocysteine concentrations   mol L   in cases and controls, for Europeans and Asians separately
13063,Percentage difference in homocysteine concentrations between cases and controls, for Europeans and Indian Asians separately
13064,Percentage difference in homocysteine concentrations, for controls alone, in Indian Asians compared with Europeans
13065,Deaths from CHD attributable to elevated homocysteine concentrations in Europeans and Indian Asians
13066,Proportions of eligible cases and controls interviewed by age, sex, and current residence
13067,Association of hip fracture with potentially confounding variables
13068,Lifetime exposure of study participants   cases and controls combined   to fluoride in drinking water according to current residence
13069,Associations of hip fracture with exposure to fluoride in drinking water
13070,Casein,  lactoglobulin, and mTG in samples of salmon mean   SD
13072,Strongest risk factors for acute coronary events in conditional multivariate logistic regression models
13074,Final mortality results in three heart failure trials with negative trends
13075,Results for two cancer prevention trials of  carotene
13076,Dose response for HFA and CFC formulations
13077,Antimicrobial activity in the urine as detected by Bacillus stearothermophilus, Streptococcus pyogenes and Escherichia coli
13078,Number of serum folate tests, rate of testing, number and per centage of test results  27 g L, and 20 g L, and medi an serum folate value, 199498
13080,Endocervical microbial flora cultures from the mock ET and ET catheter tips
13081,Embryology events, implantation and clinical pregnancy rates
13083,Mean Segmental TRin Healthy Volunteers   CONTROL Group
13086,Overall efficacy profile of n 3 PUFA treatment
13087,Overall efficacy profile of vitamin E treatment
13088,Overall efficacy profile of n 3 PUFA plus vitamin E treatment
13090,Abnormal laboratory and clinical findings and toxic effects   WHO grade 3
13091,Status of patients at median follow up of 72 months
13092,Types of recurrence
13093,Birth rates, death rates, and net migration rates
13094,Primary source of food by year
13097,Hemodynamic Responses to Dobutamine
13098,Neurochemical Responses to Dobutamine
13100,Signs of atopy according to clinical examination, skin  prick test, and blood tests in children from Steiner schools and control schools
13101,Odds ratios for atopy   95  CI   associated with exposure to factors typical for children in Steiner schools, plus heredity and sex
13102,Clinical syndromes in 314 patients with pneumococcal infection
13103,Antimicrobial susceptibility test results of S pneumoniae isolates
13104,Distribution of serotypes by age group
13105,Distribution of serotypes from blood and CSF
13107,Relative risk of cancer by quintile of total heterocyclic amine intake
13108,Relative risk of cancer by quintile of estimated intake of the five heterocyclic amines studied
13109,Relative risk of cancer by quintile of total meat and fish intake
13112,STD prevalence symptoms at round 1   before intervention   and rounds 2, 3   follow up   intention to treat cohort
13115,STD prevalence at delivery in mother and infant study
13116,Distribution of population and of observed and expected numbers of cases of variant CJD living within specified distances of 52 plants rendering bovine material in 1988
13117,Cases of variant CJD and distance from plants rendering bovine material in 1988
13118,Serological and molecular typing and presence of prtF1 gene in strains recovered from patients with eradication failure
13119,Systolic Blood Pressure, Left Ventricular Weight and Echocardiographic Variables at the Left Ventricular Hypertrophy and Congestive Heart Failure Stages
13121,Serum Hormone Measurements
13122,Skeletal Muscle Mass and Function
13125,Mortality risk according to alcohol intake and age group
13128,Antibiotic regimens and intestinal colonisation with Oxalobacter formigenes in CF patients
13129,Urine analyses of CF patients
13130,Availability of data from randomised trials that began before 1990 of prolonged polychemotherapy
13131,Clinical findings related to 102 cases of sutama in February, 1997
13132,Serological cross reactivity between sutama patient serum and R prowazekii and R typhii antigens before and after adsorption tests
13133,Nationwide surveillance and serological findings among sutama patients between January and September, 1997
13134,Comparison of attack rates and death rates for sutama among inmates of three jails in Burundi
13136,Failure of therapy
13137,Predictors of therapy failure by multivariate analysis
13138,Therapy failures among bacteraemic children by treatment allocation, drug sensitivity of isolate, and species isolated
13140,Status of IUD 90 days after insertion
13141,Clinic visits for gynaecological care within 90 days of IUDinsertion
13142,Univariate matched analysis of food exposure variables
13143,Univariate matched analysis of animal and other exposure variables
13144,Conditional logistic regression analysis
13146,Quinolone resistance   MIC g mL   in K pneumoniae, E coli, and P aeruginosa
13147,Mutation frequency
13148,Quinolone susceptibility   MIC g mL   of E coliJ53 pMG252 ciprofloxacin resistant mutants
13149,Reasons for exclusion before randomisation
13151,Clinicians  final diagnoses and patterns of antibiotic use
13152,Management at initial consultation, and subsequent use of health facilities
13153,Clinical Data of the Patients
13154,Metabolite Contents
13155,Clinical and Angiographic Data on 45 Patients
13157,Means and 95  Upper Limits for Raw, Height Adjusted, and BSA Adjusted LV Variables
13159,Grading Scale of the Contractile Proteins
13161,Proportion of patients free from relapses at different time points
13162,Annualised relapse rate, expanded disability status scale   EDSS   score at end of study, and number of patients with EDSS score progression during the study
13164,Outcomes of magnetic resonance imaging   MRI   at different time points
13165,Adverse events
13167,Data on kidneys and ureters for all patients
13168,Outcome for glomerular filtration rate   GFR   at 4 and 10 years  follow up
13170,Outcome at 6 months
13172,Intended and actual amount of therapy
13173,Primary outcomes
13174,Secondary outcomes
13176,Site of first recurrence by treatment
13177,Effect of radiotherapy on disease free survival and overall survival
13178,Frequency and localisation of local recurrences by treatment
13179,Cox s proportional hazards models by time periods since surgery
13180,Cox s proportional hazard model by time periods since surgery
13183,Numbers of patients on various DMARDs and glucocorticoid use, and median dose of drugs during study
13184,Number of patients who had adverse events during the trial
13185,Logistic regression analysis for the odds to reach remission after 2 years of treatment
13186,Effects of Atorvastatin Therapy on Lipids and Glucose
13188,Clinical endpoints
13190,Adverse events     of patients   in first 3 months of therapy
13191,Clinical features of nine patients with pulmonary hypertension
13192,Results of echocardiography in all patients
13196,Withdrawals and adverse events
13200,Health related goals, targets, and health related SDG indicators used in the present analysis and further details regarding any indicator modifications, and inclusion in the health related MDG index or health related non MDG index
13201,Health related SDG goals and targets proposed by the Inter Agency and Expert Group on SDG Indicators, and health related SDG indicators used in this analysis
13203,Performance of health related SDG indicators across all countries, 2015
13205,Serious adverse events
13207,Efficacy outcomes from the pooled data
13209,Safety outcomes at 90 days
13214,Treatment emergent adverse events   MedDRA HLT or PT   occurring in 5  or more of patients in the placebo or combined dupilumab doses groups
13216,Causes of death
13217,Frequency of cancers other than breast cancer
13218,Adverse events of any severity reported at any time
13219,Definitions
13221,Change in daily prednisolone dose before and after randomisation, by group
13222,Adverse events
13223,Grade 34 adverse events
13224,Blood concentrations of rituximab
13226,Risk factors for macrosomia
13227,Risk of caesarean section by birthweight percentile
13228,Indication for caesarean section by birthweight in primiparous and multiparous mothers who underwent caesarean section
13229,Risk for maternal and perinatal morbidity and mortality by birthweight percentile
13232,Results of secondary efficacy analysis
13233,Safety results
13235,Adverse effects
13239,Effect of HP802 247 on wound area and wound closure
13240,Adverse events reported by at least 3  of patients
13243,Exposure to violence perpetrated by occupation forces or settlers in 2005
13244,Odds ratios   95  CIs   of intimate partner violence by type of political violence exposure in separate adjusted      multinomial regression models
13245,Odds ratios   95  CIs   of intimate partner violence by political violence exposures modelled simultaneously in adjusted     multinomial regression model
13248,Patients with adverse events in the kyphoplasty and non surgical care groups
13250,Thrombotic events
13251,Thrombotic events in secondary randomised comparisons
13254,Self reported benefit, compliance, and frequency of use of health service resources by randomisation group
13257,Association between two single nucleotide polymorphisms and bone mineral density at lumbar spine
13258,Effect of both single nucleotide polymorphisms on bone mineral density at lumbar spine, osteoporotic fracture, and osteoporosis
13261,Risk of Treatment Failure Based on Randomization SDC Group
13263,Individual and joint contributions of risk factors in  table 1  to mortality from site specific cancers
13264,Total cancer deaths   thousands   by age and cancer site
13266,Survival and progression free survival
13267,Association between TPE response and pathological pattern of multiple sclerosis, expanded disability status scale score, and neurological deficit
13269,Vaccine efficacy against first episode of radiological pneumonia   per protocol analysis
13270,Vaccine efficacy against first episode of clinical or severe clinical pneumonia   per protocol analysis
13271,Vaccine efficacy against first episode of invasive pneumococcal disease   per protocol analysis
13272,Vaccine efficacy against first admission and all cause mortality   per protocol analysis
13273,Number of consultations, with primary diagnoses, in the week after every dose of vaccine or placebo   intention to treat analysis
13275,Degree of symptomatic carotid stenosis stratified according to subgroup variables
13276,Relation between subgroup variables and risk of each main element of the primary outcome measure
13277,Significance of treatment effect modifiers for relative and absolute treatment effect for subgroup variables
13278,Estimated yearly atrophy rates according to time and method of measurement of atrophy
13279,Rate ratios   n   of cerebral palsy by Z score band in gestational age groups with use of conventional and fetal growth standards
13280,Main familial tumour syndromes associated with gliomas
13281,Effects of adjuvant CT in patients with primary CNS lymphoma treated with or without whole brain radiotherapy
13285,Temporal relation between onset of cytomegalovirus reactivation during lactation and symptomatic primary infection of preterm infants
13286,Discordant HCMV transmission to twins during lactation
13287,Antibodies to neuronal antigens in cerebellar syndromes   Sera were screened by routine immunohistochemistry on frozen sections of rat cerebellum and positive staining patterns1 were confirmed, as appropriate, by western blotting on rat cerebellar extracts or recombinant Hu or Yo polypeptides. VGCC antibodies were measured by immunoprecipitation of 125I  conotoxin MVIIC labelled VGCCs extracted from human cerebellum,  2   and antibodies to glutamic acid decarboxylase measured with a commercial kit   RSR Ltd, Cardiff, UK  .
13289,Fetal death in same sex twins and different sex twins   199395
13290,Cerebral palsy in live born twins of same sex stillborn co twins and different sex stillborn co twins
13291,Cerebral impairments in live born twin of same sex stillborn co twin, and different sex stillborn co twin
13292,Gestational age specific cerebral palsy prevalence rates
13293,MRI diagnoses by suspected type of CJD
13294,Estimates of the sensitivity of radiological diagnosis of vCJD by different MRI criteria for positivity
13295,Neuroradiological assessment of MRI from 36 histologically confirmed cases of vCJD
13297,Patients  severity of illness scores, haemodynamics, biological data and treatments at inclusion
13298,Comparison of iNOS activity between tissues and degrees of infection
13299,Comparison of TNF concentrations between tissues and degrees of infection
13300,Comparison of IL 1 concentrations between tissues and degrees of infection
13301,Virological studies on 21 patients with neurological manifestations of dengue infection
13302,Clinical features
13303,Distribution of deprivation index
13304,Distribution of cases and controls by age, sex, deprivation index, and diagnosis of case
13305,Distribution of exposure by age and deprivation status among cases and controls
13306,Odds ratios for acute lymphoblastic leukaemia, all leukaemia, cancers of the central nervous system, and other malignant disease by exposure
13307,Estimated exposure before and after adjustment for historical line load data, among those with relevant external source questionnaires, for cases and controls
13309,Clinical manifestations and outcome of EV71 infection in patients with pulmonary oedema
13310,Factors significantly associated with CNS involvement without pulmonary oedema
13311,Factors significantly associated with pulmonary oedema
13313,Hendra IgM antibodies and results of viral culture
13315,Summary of presenting symptoms, signs, and investigations
13316,Correlation Coefficients   Pearsons R2Values   Comparing Selected Vascular Blood Flow Parameters With Indices of Plasma RAS Activation
13318,Summary of therapy directed at central nervous system for patients who received prophylactic irradiation on Total protocols X, XI, and XII
13319,Relation between parasite count and a in cultured parasites
13322,Cellular distribution of complexin mRNAs in human hippocampus and cerebellum
13323,Complexin mRNAs in schizophrenia
13324,Complexin proteins in schizophrenia
13326,Mean   range   values for MDMA use
13327,Mean   SE   values of injected doses
13328,Clinical and laboratory data
13329,Increases in blood flow during an induced attack of acute cluster headache compared with the pain free state
13330,Unadjusted proportion of participants with chronic disease, symptoms, and poor quality of life by action level
13331,Odds ratios   95  CI   for chronic disease, symptoms, and poor quality of life with reference to action level 1, adjusted for age, smoking, alcohol consumption, education and physical activity, and for quality of life, employment status, household
13332,Notch3 mutations in CADASIL patients
13333,Polymorphisms in Notch3 coding sequence
13334,Haplotype analysis in families with recurrent Notch3 mutations
13335,Logistic regression of association between PCR result of virus detection in CSF nd clinical features in Oxford cohort
13336,Correlation of PCR result with clinical classification of viral infection of the CNS
13337,SDNN, RMSSD, pNN50, QRS, QRSd, QTd and QTcd: Comparison Between Patients With and Without Arrhythmias
13338,MIBG Scintigraphy Results: Comparison Between Patients Operated On and the Control Group
13339,Sensitivity and specificity of the EITB with HAMA
13340,MIBG Scintigraphy Results: Analysis of the Operated Patients With and Without Arrhythmias
13342,Correlations Between Scintigraphic and HRV Data   16 patients
13344,Mean   SE   concentration of serum GH, plasma, GHRH, and plasma noreprephrine before and after clonidine infusion
13345,Blood clearance of mannose terminated glucocerebrosidase   mt GCR
13346,Clearance of 123I mt GCR from liver and spleen over a 48 h period
13347,Estimated number of patients diagnosed with an index cancer worldwide each year around 2012
13348,Definition of malignancies and number of contributing countries and registries by calendar period of diagnosis
13349,Data quality indicators: patients diagnosed during 200014 by continent and country
13350,Population covered by participating registries   number of people and percentage of national population   and number of adults diagnosed with cancer of the oesophagus, stomach, colon, rectum, liver, pancreas, or lung, or melanoma of the skin during 200014 by continent and country
13351,Population covered by participating registries   number of people and percentage of national population   and number of patients diagnosed with cancer of the breast   women  , cervix, ovary, prostate, or brain, or myeloid or lymphoid malignancies   adults  , and brain, acute lymphoblastic leukaemia, or lymphoma   children   during 200014 by continent and country
13352,Age standardised 5 year net survival       with 95  CI: adults   1599 years   diagnosed with one of eight common malignancies   oesophagus, stomach, colon, rectum, liver, pancreas, lung, or melanoma of the skin   by continent, country, and calendar period of diagnosis
13353,Age standardised 5 year net survival       with 95  CI: adults   1599 years   diagnosed with one of seven common malignancies   breast, cervix, ovary, prostate, brain, myeloid, and lymphoid   and children   014 years   diagnosed with one of three common malignancies   brain, acute lymphoblastic leukaemia, and lymphoma   by continent, country, and calendar period of diagnosis
13355,Summary results of primary and secondary endpoints
13356,Summary of SAEs
13358,Risk of adverse events of interest
13359,Rates of all adverse events, stratified by system organ classification, in the blinded randomised phase
13360,Rates of all adverse events, stratified by system organ classification, in the non blinded non randomised phase
13364,Number of deaths and person years in the 2001 Spanish Census Cohort of people aged 1074 years, by indicators of household wealth and calendar year
13365,Comparison of time trends in premature mortality before and during the 2008 economic crisis, by cause of death   ICD 10 code        and socioeconomic group according to household space in the 2001 Spanish Census Cohort of people aged 1074 years
13366,Comparison of time trends in premature mortality before and during the 2008 economic crisis, by cause of death   ICD 10        and socioeconomic groups     and household car ownership, in the 2001 Spanish Census Cohort of people aged 1074 years
13367,Comparison of time trends in all cause premature mortality before and during the 2008 economic crisis, by two indicators of household wealth      and sex and age group    , in the 2001 Spanish Census Cohort of people aged 1074 years
13371,Adverse reactions deemed by investigator to be possibly, probably, or definitely related to treatment
13372,Health care costs and QALYs over 12 months
13374,Intraoperative data and early postoperative complications within 6 months of surgery
13375,Causes of small bowel obstruction
13377,Multivariable logistic regression analysis for the effect of treatment on the primary endpoint   ACR20 at 48 weeks post randomisation
13378,Univariable analysis    2 test of independence   for the proportion of patients in the evaluable patient population achieving a response at 48 weeks post randomisation for the key secondary endpoints
13379,Intrasubject and Intersubject Variabilities and Reproducibilities
13382,Primary outcome at 6 months
13383,Mortality at 6 months
13384,Thrombotic events and adverse events
13388,Adverse events
13390,Estimated average differences between levodopa and levodopa sparing groups, and between dopamine agonist and MAOBI, in the different PDQ 39 subscales and in EQ 5D utility score
13392,Adverse events possibly or probably related to study drug, by dose group
13393,Adverse events overview
13398,Total and specific treatment emergent adverse events reported by at least 3  of patients in either treatment group
13401,Site of first disease free survival event
13402,Adverse events   safety populations
13404,Types of diseases and surgical procedures in patients undergoing upper gastrointestinal surgery
13405,Types of diseases and surgical procedures in patients undergoing lower gastrointestinal surgery
13406,Primary outcome and its components in modified intention to treat population
13407,Secondary outcomes in the modified intention to treat population
13409,Emergent mutations in participants who had virological failure
13410,Safety results: deaths, serious adverse events, and adverse events
13415,Serious adverse events
13419,Treatment related adverse events of grade 2 or higher reported in at least 5  of patients by dose
13423,Comparisons of secondary participant and carer outcomes and depression severity
13424,Adverse reactions definite, probable, and possibly related to study intervention by week 39
13425,Overview of the locus, gene, and function of definite and probable genetic risk factors for ankylosing spondylitis
13426,Pooled analysis of the effect of allocation to aspirin on risk of death due to cancer during the seven trials from which individual patient data were available,  1721,23,24   stratified by type of primary tumour and period of follow up
13427,Pooled analysis of the effect of allocation to aspirin on the 20 year risk of death due to cancer during and after the trial treatment periods in the 10502 patients with scheduled treatment duration of 5 years or longer in the three trials with long term follow up,  1719   stratified by type of primary tumour and period of follow up
13430,Effects on primary and major secondary endpoints
13431,Incidence of relevant serious adverse events during the study by system organ class
13432,Selected adverse events and those leading to definitive withdrawal of study drug
13434,Efficacy of pentavalent rotavirus vaccine for prevention of rotavirus gastroenteritis and gastroenteritis for complete follow up in Africa
13435,Efficacy of the pentavalent rotavirus vaccine for prevention of severe rotavirus gastroenteritis   Vesikari score 11   in Africa by country and follow up period
13437,Serious adverse events 114 days after any dose of pentavalent rotavirus vaccine or placebo
13439,Dose conversion for inhaled insulin to rapid acting insulin analogue
13441,Treatment emergent adverse events   safety population
13442,Hypoglycaemia incidence and event rate   safety population
13443,Severe hypoglycaemia event rates by time of the day   safety population
13446,Recurrence and survival   all patients  , after a median follow up of 45 months
13447,Recurrence and survival for patients at true high intermediate risk after pathology review   n 366
13448,Design and eligibility criteria of primary prevention trials
13449,Comparison of proportional and absolute effects of aspirin in primary and secondary prevention trials
13450,Rate ratios   95  CI   associated with risk factors for selected outcomes in people with no known vascular disease in primary prevention trials
13451,Inclusion and exclusion of the study participants who underwent randomisation
13453,Incidence of events for efficacy analysis
13454,Safety outcomes
13455,Admission risk markers for GBS  5
13457,Endoscopic findings in phase one, by GBS
13458,Comparison of GBS and admission and full Rockall scores for prediction of intervention or death across the four study sites
13459,Comparison of data before and after introduction of GBS low risk criteria into clinical practice
13461,Vaccine efficacy against any and severe rotavirus gastroenteritis, admission, and medical attention   according to protocol cohort
13462,Vaccine efficacy against any and severe rotavirus gastroenteritis according to detected rotavirus G types   according to protocol cohort
13463,Vaccine efficacy against all cause severe gastroenteritis and admission   according to protocol cohort for efficacy
13465,Incidence of venous thromboembolic events up to day 14 in the efficacy group
13466,Occurrence of venous thromboembolism   VTE   and deep vein thrombosis   DVT   according to National Institutes of Health Stroke Scale   NIHSS
13467,Occurrence of haemorrhage according to National Institutes of Health Stroke Scale   NIHSS
13468,Safety outcomes
13471,Effect of treatment on primary and secondary outcomes  15
13473,Clinical and laboratory evidence of safety of fenofibrate
13475,Efficacy of treatment
13476,Secondary outcomes
13477,Morbidity and survival
13480,Vaccine efficacy for incident HPV 16 18 infections
13481,Vaccine efficacy for persistent HPV16 18 infections
13482,Vaccine efficacy in preventing cytological abnormalities associated with HPV 16 18 infection   intention to treat cohort
13483,Timeline of virological, cytological, and histological findings among the seven women with HPV   associated abnormal cytology that was histologically confirmed as CIN   intention to treat cohort
13484,Adverse events after any vaccine dose in according to protocol cohort for safety
13485,Anti HPV antibody response to HPV 16 and HPV 18 virus like particles   according to protocol cohort
13488,Response classified by underlying cause
13489,Adverse events reported during first 14 days of study
13492,Numbers of fractures in the olpadronate and placebo groups
13493,Clinical features of patients with MADH4 mutations
13494,Features of previously reported juvenile polyposis patients with associated hereditary haemorrhagic telangiectasia phenotypes
13496,Cox proportional hazards models
13497,Adverse events in 553 patients   safety population
13499,Secondary endpoints
13501,Endpoints of PROSPER
13502,Incidence of primary end point, according to subgroup
13503,First new cancer diagnoses by site and year
13505,Outcomes in the two study groups
13506,Per protocol analysis
13507,Most relevant side effects   grade 2 and 3   during first 8 weeks, dose reductions, and dose intensity
13509,Duration and severity of illness in intention to treat population and influenza infected patients
13510,Effect of oseltamivir treatment on antibiotic use
13512,Concomitant drug treatments
13513,Figures, hazard ratios and p values for the study cumulative endpoints and individual components
13514,Summary of adverse events
13515,Event rate in patients taking  blockers with or without diltiazem
13516,Macronutrient composition per L and fatty acid composition of standard and supplemented study formula as percentage of total fat
13518,Withdrawals in the randomised trial because of adverse events
13519,Developmental outcomes in the randomised trial at 9 months
13520,Formula tolerance and intake in randomised trial
13521,Growth of infants in the randomised trial during the intervention period and throughout follow up
13522,Exploratory analysis on infection related events arising up to 9 months in the course of the randomised trial
13524,Effect of raw and cooked parent, parent GNA, and GNA GM potatoes on histological indices of rat gut
13525,GNA binding to the jejunum and ileum of rats given diets containing GNA GM potatoes or parent potato diets spiked with GNA
13526,Incidence   per 100000, 95  CI   of inflammatory bowel disease among individuals below 17 years of age in northern Stockholm, Sweden, 199098
13527,Effect of Placebo, Quinapril and Losartan on Plasma t PA Antigen and Activity Concentrations in the Infused and Noninfused Forearms During Substance P, Sodium Nitroprusside and Bradykinin Infusion
13529,Incidence of PCP
13536,Cases of intracranial haemorrhage up to day 7 in patients who actually received treatment
13538,Adverse events during initial curative treatment and chemosuppression
13539,Percentage predictive efficacy of treatment
13540,Clinical profile of 12 cases of influenza A subtype H5N1 infection
13541,Risk factors associated with severe disease requiring intensive care and ventilatory support
13542,Clinical and laboratory data at randomisation
13543,Rate of and reasons for treatment failure
13545,Adverse events during infusion period
13546,Number of live births per neonatal screening period by team
13547,Neonatal screening by location and risk categories and presence of individual risk factors
13548,Percentage of babies not given neonatal screening during screening periods two, three, and four by annual birth rate, hospital, and cause
13549,Numbers of babies by severity of PCHI in periods with and without neonatal screening by risk status, source of referral, and age distribution at stages of management
13550,Comparison of periods with and without neonatal screening by increment in yield and relative risk of yield of PCHI
13551,Contraindications to warfarin therapy among patients with AF
13552,Risk factors for stroke among patients with AF
13553,Proportion of patients with AF eligible for anticoagulation and those anticoagulated by risk classification
13554,Proportions of patients with AF with irreversible contraindications, and with reversible contraindications and clinical and echocardiographic risk factors
13555,Symptoms of people examined
13557,Experimental neuropsychological measures at time 1
13558,Change scores on experimental neuropsychological measures
13559,Experimental neuropsychological measures at time 2
13561,Number of study participants who mowed lawns by sex
13562,Serological results for cases
13563,Details of probands with their affected offspring
13564,Recurrence data by defect category
13565,Risks to siblings and offspring
13567,Risk for ovarian cancer by use of over the counter or prescription analgesics
13568,Risk for ovarian cancer by features of used paracetamol
13569,Odds ratio for paracetamol use and various histological types and grades of ovarian cancer
13571,Univariate logistic regression analysis
13573,Accuracy of BNP   cut off 179 pg mL   in detection of left ventricular systolic dysfunction
13574,Results of multivariate logistic regression analysis
13575,Diagnostic value of natriuretic peptides in detecting heart failure when negative predictive value is 98
13576,Prediction of presence of heart failure in logistic regression analyses of 106 referred patients for whom concentrations of all three natriuretic peptides were available
13577,Prediction of presence of heart failure in logistic regression analyses of 96 referred patients for whom cardiothoracic ratio   CTR   and BNP concentration were available
13579,Presence of ICA and GADA at different ages of diagnosis
13580,Association of ICA with different concentrations of GADA by age group
13581,Sensitivity, specificity, and positive predictive value of ICA and GADA measurements for insulin requirement by 6 years
13582,Stepwise logistic regression analysis of contribution of clinical variables, ICA and GADA in prediction of insulin requirement
13583,Pacemaker complications necessitating reoperation
13584,Causes of death
13585,Multivariate Cox proportional hazard regression analysis of clinical variables evaluated as risk factors for evelopment of death, thromboembolic events, and chronic atrial fibrillation during follow up
13586,Association between thromboembolism, brady tachy syndrome at randomisation, and atrial fibrillation during follow up
13590,Fractures that occurred during treatment period
13591,Selection of children with early BCG vaccination and controls
13592,Signs of atopy according to clinical examination, SPT, and serological tests in children with early BCG vaccination and controls
13594,Clinical and histological features of four women with unclassified coeliac disease
13595,Serological pattern of four women with unclassified coeliac disease
13596,Clinical characterisrics of 171 consecutive CHF patients
13597,Univariate analysispredictors of 18 month mortality in 171 patients with CHF   Cox proportional hazard
13598,Multivariate analysispredictors of 18 month mortality in 171 patients with CHF   Cox proportional hazard
13599,Tissue factor antigen concentrations and activity
13602,Primary and secondary events according to assigned therapy number   event rate per patient year
13603,Association between genotypes of proteases on chromosome 14 and atopic diseases
13604,Clinical details of participants
13606,Core Laboratory Quantitative Coronary Angiography Data
13607,Odds Ratios for In Stent Restenosis at Follow Up Angiography
13610,Availability of individual and classes of medications among all primary health care sites
13611,Distribution of the annual number of safe, less safe, and least safe abortions by UN DESA, Population Division region for the period 201014
13612,Distribution of abortion safety categories for countries grouped by legal status and income level
13616,Outcome of treatment of incomplete abortion by provider
13617,Reported secondary outcomes
13625,Patients who had at least one AE and SAE reported from baseline to month 25   safety analysis set   and reactogenicity events reported within 28 days after any injection   subset analysis
13628,Effect of cardiac function and sex on lung and skin disease in patients with systemic sclerosis
13629,Echocardiogram, right heart cardiac catheter parameters before and after fluid challenge, and cardiac MRI in 12 consecutive patients with systemic sclerosis referred for HSCT
13630,Quality of life by SF 36 before and after HSCT
13634,Serotype specific and overall efficacy of CYD tetravalent dengue vaccine against virologically confirmed dengue disease
13635,Summary of all reported SAEs and of AEs reported in the reactogenicity subset after at least one injection
13637,Summary of dengue episodes classified as severe according to independent data monitoring committee or WHO 1997 classifications  20
13641,Quality of life
13646,Adverse events and laboratory abnormalities
13648,Primary and secondary outcomes
13649,Hazard ratios   top vs bottom quintile   for risk of subsequent stroke   ie, after the measurement period   in the UK TIA trial from a model combining mean SBP and visit to visit variability in SBP   SD or CV or VIM  , repeated with increasingly precise estimates of both variables
13652,Rates of virological failure, mortality, and admission by group
13653,Diagnoses at first admission after start of antiretroviral therapy
13654,Frequency of outpatient attendance overall and in which a physician was seen and a new clinical disorder diagnosed
13655,Distribution of drug substitutions to first line regimens according to initial regimen
13656,Costs of health service delivery and costs incurred by patients to access care   in US
13658,Kaplan Meier estimates of the time from meeting the criteria for switch based on viral load  500 copies per mL to meeting the criteria for the other monitoring strategies
13659,Predicted outcomes of monitoring strategies at 5, 10, and 20 years from start of antiretroviral treatment
13660,Life years, discounted costs over 20 years, and incremental increases for each strategy
13661,Univariate comparison of S pneumoniae infections that were susceptible or not susceptible to levofloxacin isolated from children aged under 15 years in South Africa between 2000 and 2006   nationwide surveillance
13662,Univariate comparison of S pneumoniae infections that were susceptible or not susceptible to levofloxacin isolated from children aged under 15 years in South Africa between 2003 and 2006   enhanced sentinel surveillance
13663,Phenotypic and genotypic characterisation of levofloxacin non susceptible pneumococci causing invasive disease in children under age 15 years in South Africa, 200006
13665,Mortality in HIV infected adults during co trimoxazole prophylaxis and antiretroviral therapy   ART   in Tororo and Busia Districts, Uganda, 200105
13666,Hospital admissions in HIV infected adults during co trimoxazole prophylaxis and antiretroviral therapy   ART   in Tororo and Busia Districts, Uganda, 200105
13667,Study design
13669,Risk of HIV transmission and death among infants at 6 weeks and 6 months by study regimen and country   modified intention to treat population
13670,Risk ratios for HIV transmission, death, and HIV transmission or death in the full intention to treat population
13671,Infants with grade 3 and 4 adverse events   modified intention to treat population
13676,Outcomes of treatment by treatment group
13677,Relative risk of failure to achieve complete abortion and failure to terminate pregnancy
13678,Women with pregnancy related symptoms and side effects related to the abortion process, listed by group at different timings
13681,Complications by country and provider
13682,Number       of women reporting adverse symptoms from follow up interviews at the clinic, by telephone, or a home visit, by country and provider, excluding women with confirmed complications
13683,Estimates of hospitalisation rates from induced abortion complications from 13 countries, 19892003
13684,Estimates of number of women admitted to hospital for induced abortion complications each year in developing world regions and subregions, 2005
13685,Relative risks of clinical events for primary and secondary prevention with selected drugs
13686,Region based costs of cardiovascular disease interventions
13687,Lifetime risk of death from cardiovascular disease according to regimen strategies      for World Bank regions
13688,Incremental cost effectiveness ratios     QALY   for treatment regimens compared with no treatment
13689,Recommendations for initiating ART on the basis of immunological and clinical stage
13690,Age specific CD4 cell threshold for defining severe immunodeficiency
13691,Plasma viraemia of non human primates after challenge with MARV and treatment with rVSV vectors
13692,Serological response profiles of MARV infection after treatment with VSVG MARVGP vectors
13693,Effectiveness of single dose live attenuated Japanese encephalitis vaccine   SA14 14 2
13695,In trial associations between accumulated mean concentrations of selected variables and coronary and stroke events   Cox regression analyses
13696,Pooled HR   95  CI   for coronary and stroke events associated with amlodipine based therapy compared with atenolol based therapy adjusted after serial mean matching of systolic blood pressure
13697,HRs associated with amlodipine based therapy compared with atenolol based therapy after adjustment for accumulated mean values of each of the selected variables
13698,End of life decisions for children aged younger than 1 year
13701,Responses to mucosal immunisation with BHPIV3 SARS S and BHPIV3 Ctrl
13702,Responses to challenge with SARS coronavirus in monkeys immunised with BHPIV3 SARS S or BHPIV3 Ctrl
13703,Primers used for PCR amplification of human P450 oxidoreductase
13704,Primers for site directed mutagenesis of wild type P450 oxidoreductase cDNA
13705,Kinetic constants   SE   for cytochrome c reductase activity of bacterially expressed human wild type and mutant P450 oxidoreductase proteins
13706,Hazard ratios for events in immediate blood pressure responders     compared with non immediate responders to initial treatment, and in controlled     compared with non controlled patients, respectively
13707,Comparison of EPS and traditional purge by study site for the excretion of scolices, gravid proglottids, and the number of eggs evacuated
13708,Infant relinquishment among mothers according to HIV 1 infection and prenatal care status, St Petersburg, Russia, 2002
13711,Unadjusted proportion of babies infected with HIV 1 by group
13712,Adjusted probability of HIV 1 infection between birth and 68 weeks
13713,Activity of compounds against SARS associated coronavirus in Vero cell cultures
13715,Patients  evaluation of the consent process
13722,Distribution of MDR1, CYP2D6, CYP2C19, CYP3A4, and CYP3A5 genotypes in 113 study participants
13723,Suspected adverse drug reactions reported by family doctors during prescription event monitoring studies 19972000
13725,Comparison of the main efficacy and tolerability measures for the oral triptans versus 100 mg sumatriptan
13726,Included trials; numbers of patients based on 2 h headache response rates
13727,Excluded trials for efficacy analysis
13728,Efficacy and tolerability in direct comparator trials
13729,Pregnant Zambian women s preferences on strategies for perinatal nevirapine prophylaxis   n 310
13731,Primary and secondary outcomes according to treatment group
13732,Rate of blood loss of 1000 mL or more by centre
13733,Shivering, body temperature greater than 38C, and other side effects according to treatment group
13734,Shivering and body temperature above 38C according to treatment group and use of epidural analgesia during labour and delivery
13735,Design of trials included in the meta analysis.
13736,Out of hospital symptomatic venous thromboembolism
13737,Out of hospital symptomless venographic deep vein thrombosis
13738,Out of hospital data: minor and major bleeding, and death
13739,Out of hospital symptomatic venous thromboembolism
13740,Out of hospital symptomless venographic thrombosis
13741,Out of hospital data: minor and major bleeding, and death
13743,Reasons for selection of misoprostol administration site and experiences with home administration
13744,Pain management and unscheduled consultations
13745,Satisfaction with method
13748,Base case values for model epidemiological parameters
13749,Base case values for model economic parameters
13750,1 year cost effectiveness of HIV 1 VCT per 10 000 clients
13751,One way sensitivity analysis
13752,Multiway sensitivity analysis
13753,Study Population   n   308
13755,Follow Up Events   n    per year
13756,Lymphoma status, therapy, and outcome of patients
13757,CD4 cell counts and HIV 1 RNA load before and after stem cell transplantation
13758,Estimated base case values and ranges for model input parameters
13759,Cost effectiveness of HIVNET 012
13760,Cost effectiveness of HIVNET 012, PETRA, and Thai regimens at 30  HIV 1 seroprevalence
13761,Results of sensitivity analysis
13762,Threshold analysis
13765,Body composition and metabolic variables in 105 protease inhibitor recipients followed up for a mean 21 months according to lipodystrophy self report scale
13767,Lipodystrophy severity after 21 months of protease inhibitor therapy in relation to metabolic variables after 14 months of therapy
13768,Misoprostol dose and phenotypic effects
13769,Summary of investigated polymorphisms
13770,Frequency of wild type allele and mutant alleles M1, M2, and M3 among patients and controls
13771,Summary of patient details
13772,Crude vaccination rates and age   median and interquartile range   at first vaccination   under 5 years
13773,Odds ratios   95  CI   for IBD in vaccine recipients
13774,Reasons for withdrawal from study after immunisation
13776,Frequencies of acute adverse reactions by treatment group
13777,Frequencies of persistent adverse reactions by treatment group
13779,Model fit for the production of cytokines from a pedigree based maximum likelihood method
13780,Production of cytokines in relatives of patients who survived or did not survive meningococcal disease
13781,Gene frequencies in first degree relatives of patients with meningococcal disease
13783,Postoperative outcomes in the African Surgical Outcomes Study
13784,Postoperative complications in the African Surgical Outcomes Study
13785,Association between the primary indication for surgery and postoperative complications and in hospital mortality.
13787,Clinical symptoms and quality of life outcomes
13788,Objective measures of prolapse at 1 year clinical review
13789,Serious adverse effects related to prolapse surgery, readmissions, and treatment
13790,Trials included in the individual patient data meta analysis   IPDMA
13792,Pregnancy history of study participants
13793,Primary, secondary, and safety outcomes
13794,Primary outcome according to patient subgroup
13795,Outcomes associated with abdominal entry
13796,Outcomes associated with repair of uterus
13797,Outcomes associated with closure of uterus
13798,Outcomes associated with closure of peritoneum
13799,Outcomes associated with uterine repair sutures
13800,Age standardised and sex standardised mortality ratios of all cause, suicide related, and cancer related mortality in patients with chronic fatigue syndrome, compared with the general population in England and Wales in 2011
13802,Univariate and multivariate analysis outcomes for risk factors of suicide mortality by competing risk regressions in patients with chronic fatigue syndrome   n 2174
13804,Change in BMI between first and second pregnancies and adjusted      relative risks of stillbirth and infant, neonatal, and postneonatal mortality
13805,Change in BMI between first and second pregnancies and adjusted      relative risks of stillbirth, infant, neonatal, and postneonatal mortality after the second pregnancy according to BMI in the first pregnancy
13806,Top ten countries for absolute numbers of stillbirths and maternal and neonatal deaths in 2015
13807,Proportion of all stillbirths reported to be associated with congenital abnormalities in 18 national reports and subnational reports in South Africa showing status of screening and legality of termination of pregnancy
13808,Disorders associated with stillbirth reviewed for risk factor analysis
13809,Common mental disorders and health risks in adolescence and young adulthood before conception in women with at least one pregnancy during the study period
13810,Perinatal depressive symptoms overall and by parity
13811,Perinatal depressive symptoms according to preconception mental health problems
13812,Preconception predictors of perinatal depressive symptoms
13814,Incident suicide attempts at 3 and 12 month follow up
13816,Elements of the extensive health and psychosocial assessment for potential living kidney donors
13817,Summary of medium term and long term health outcomes after living kidney donation
13818,Proposed policies and practice guidelines to protect living kidney donors from medical and financial risks
13821,Main, secondary, and other maternal outcomes
13822,Other neonatal outcomes
13823,HIV prevalence among samples of men who sell sex, 200012
13824,Commercial sex behaviours that are significant risk factors for HIV infection among men who have sex with men, 200012
13826,Human rights violations and their effect on HIV and safety
13827,Health and human rights profiles across policy climates
13828,Research agenda for sex workers and HIV
13829,Studies on the molecular epidemiology of HIV 1 in sex workers
13832,Clinical outcomes at 12 months after stent implantation
13833,Interventions and assumed unit costs
13836,Interventional procedure and results
13837,Clinical outcomes at 1 year
13838,Outcomes of discharged patients treated for shellshock at a not yet diagnosed nervous centre near St Omer between Jan 2, and Nov 9, 1917
13839,A comparison of UK war pensions by diagnosis
13841,Equations for the estimation of the mean and SD   in mm   of each fetal biometry measurement according to exact gestational age   in weeks
13842,Results of primary   local recurrence in the conserved breast  , secondary   death  , and exploratory   any other recurrence   outcomes for all patients and the two strata as per timing of randomisation and delivery of TARGIT
13843,Causes of death other than breast cancer in all patients
13844,Calculation of pnon inferiority for the whole cohort, the mature cohort, and the earliest cohort
13845,Women aged 1549 years in developing countries wanting to avoid pregnancy, by need for and use of contraception, and number not in need, in 2003, 2008, and 2012
13846,Number   millions   of women aged 1549 years in developing countries and those wanting to avoid pregnancy, by region and subregion and by country income in 2003, 2008, and 2012
13847,Number   millions   of women using modern methods and proportion of those wanting to avoid pregnancy using modern methods, by region and subregion and by country income in 2003, 2008, and 2012
13848,Percentage distribution of women in developing countries using modern contraceptives, by type of method, region and subregion, and country income, in 2003, 2008, and 2012
13849,Number   millions   of women with an unmet need for modern methods and proportion of those wanting to avoid pregnancy with unmet need for modern methods, by region and subregion and by country income, in 2003, 2008, and 2012
13851,Survival outcomes
13852,Sensitivity analysis excluding non treatment related terminations of pregnancy
13853,Other outcomes
13854,Complications of vesicoamniotic shunting
13855,Prevalence of Chlamydia trachomatis, human papillomavirus, and Neisseria gonorrhoeae in urine in participants aged 1644 years, by age group and sex
13856,Risk factors for Chlamydia trachomatis in urine in participants aged 1644 years, by sex
13857,Uptake of sexual health interventions and services, by sex
13858,Risk factors for high risk human papillomavirus in urine among in participants aged 1644 years, by sex
13859,A research agenda for MSM and HIV with questions to be addressed
13862,Prevalence of sexually transmitted infections in control and intervention cities
13864,Hemodynamics and LV Function at the Acute Phase and After One Month
13865,Neurohumoral Factors
13866,Univariate and Multivariate Linear Model of LVEDVI One Month After Onset in 57 Patients With AMI
13868,Coverage and timing of intervention
13869,Cord infections
13870,Neonatal deaths and mortality risks
13871,Paediatric and adult psychiatric population based and community based studies
13872,Paediatric cognitive population based and community based studies
13873,Epilepsy syndromes and anticipated cognitive and psychiatric complications
13874,Temporal relations between psychiatric disorders and epilepsy
13875,Cognitive and psychotrophic effects of seizure drugs
13876,Categories of HIV prevention interventions for MSM and effects on frequency of unprotected anal intercourse and incidence of HIV infection
13877,Key drivers of HIV epidemics in MSM and related biomedical and behavioural interventions
13878,Candidate HIV prevention packages for MSM, by intervention type
13879,Dose changes based on FENO and ACQ results for the FENO intervention algorithm
13880,FENO algorithm treatment steps
13881,Dose changes based on clinical assessment for the clinical algorithm   control
13882,Clinical algorithm treatment steps
13884,Efficacy results at end of study
13885,Unethical behaviours and willingness to report ethical violations among soldiers deployed to Iraq, according to US army Mental Health Assessment Team reports
13887,Association of battlefield ethics training with ethical attitudes and behaviours of soldiers
13889,Interventions and strategies to address priority areas for stillbirth prevention
13890,Top ten research priorities in discovery science
13891,Top five research priorities in epidemiological information and top five in epidemiological measurement
13892,Top ten research priorities in development and delivery
13893,Estimated stillbirth rates and percentage of intrapartum stillbirth by world region in 2008
13894,Top ten countries for absolute number of stillbirths, maternal deaths, and neonatal deaths in 2008
13895,Countries grouped by stillbirth rate, with variation of maternal and neonatal outcomes and health system indicators
13896,Variation in the distribution of antepartum stillbirth causation and associated maternal conditions
13897,Variation in the distribution of intrapartum stillbirth causation and associated maternal conditions
13899,Characteristics of women in the PIERS study
13900,Occurrence of adverse maternal outcomes by mortality or morbidity event
13902,Risk stratification table assessing the value of the fullPIERS model in risk prediction, by predicted probability of adverse maternal outcome within 48 h
13903,Collaborative stepped care intervention
13908,Process indicators of fidelity and quality for intervention facilities
13910,Primary efficacy outcome: HIV 1 incidence in the primary and secondary efficacy analyses
13911,Secondary efficacy outcomes
13912,Reported serious adverse events, selected genital adverse events, and primary safety events
13914,Trials assessing the effect of vitamin A supplementation on maternal mortality, by target group
13916,Adherence to study treatment
13917,Effect of weekly vitamin A supplementation on serum retinol concentration in pregnant and non pregnant women
13918,Effect of weekly vitamin A supplementation on pregnancy related deaths
13919,Effect of weekly vitamin A supplementation on all cause female mortality   intention to treat analysis
13920,Effect of weekly vitamin A supplementation on pregnancy related hospital admissions   intention to treat analysis
13921,Effect of maternal weekly vitamin A supplementation on rate of stillbirth and perinatal, neonatal, and infant mortality   intention to treat analysis
13923,Salvage, area at risk, and final infarct size, according to vessel patency before primary percutaneous coronary intervention   pPCI  , with or without remote conditioning, and infarct location   per protocol analysis
13924,Left ventricular ejection fraction estimated by echocardiography 24 h and 30 days after primary percutaneous coronary intervention   pPCI  , with or without remote conditioning   intention to treat analysis
13925,International centres and accrual in the three main strata, by site and country
13927,Extent of surgery
13928,All complications
13929,Clinically significant complications
13930,Sample size calculations for different scenarios
13932,Intent to treat analysis of early onset sepsis in neonates and maternal post partum sepsis by intervention group and HIV exposure status
13933,Intent to treat analysis of vertical transmission of selected maternal vaginal colonising bacteria from mother to newborn babies in the chlorhexidine and control groups, by neonatal colonisation status
13935,Female partner retention rates
13936,HIV acquisition at 6 months in female partners in the control group and in the intervention group by timing of resumption of sexual intercourse
13937,Sexual behaviours and sexually transmitted infections in female partners during follow up, by study group
13939,Prevalence of sexual violence   lifetime or past 12 months   in girls younger than 18 years, reported by girls and women aged 1324 years
13940,Circumstances of first incidents of sexual violence in girls younger than 18 years, reported by girls and women aged 1324 years
13941,Self reports of lifetime experience of health related conditions and behaviours reported by girls and women aged 1324 years, who had or had never had experience of sexual violence before age 18 years
13944,Cumulative probability of seroconversion at month 24 in select population subgroups, in the efficacy population
13945,Summary of safety findings, by group, in the intention to treat population
13951,Expected transmission probabilities   with lower and upper uncertainty bounds   per sexual act and cumulatively over 100 acts in a serodiscordant partnership, assuming the HIV infected person has a viral load of 10 copies per mL
13952,Expected number of HIV seroconversions out of 10000 serodiscordant couples in a hypothetical population over 1000 acts per partnership, with lower and upper uncertainty bounds
13953,Percentage of ever partnered women reporting selected symptoms of ill health      according to experience of physical or sexual violence, or both, by an intimate partner, by site
13954,Logistic regression models for the associations      between selected health conditions and experience of intimate partner violence in ever partnered women, on pooled dataset for 15 sites
13955,Mean SRQ 20 scores for emotional distress in ever partnerned women according to experience of physical or sexual violence, or both, by an intimate partner, by site
13956,Prevalence of injures among physically abused women; severity and frequency of injuries in women ever injured by an intimate partner, by site
13958,Findings from clinical examinations at 6 and 12 months after end of pregnancy
13959,Findings from interviews at 3, 6, and 12 months after end of pregnancy
13960,Odds ratios for adjusted comparisons of each group of women with severe obstetric complications with the group with uncomplicated deliveries for selfreported health at 3, 6, and 12 months
13962,Summary of HIV seroconversions, overall and by site   n 4948
13964,Reported adverse events and serious adverse events, by group
13965,Trial retention rates
13967,HIV incidence by study group and follow up interval, and cumulative HIV incidence over 2 years
13969,Prevalence of self reported symptoms of sexually transmitted infections per visit, cumulatively over 24 months follow up
13970,Sexual risk behaviours by study group and follow up visit
13972,Adjusted effect of the timing and type of prenatal treatment on the risk of mother to child transmission in European prenatal screening centres in subsample of treated mothers   n 1438 mothers, 398 infected children
13973,Adjusted effect of timing and type of prenatal treatment on risk of clinical manifestations diagnosed during first year of life in infected children identified by prenatal and neonatal screening in European centres
13977,Adjusted odds ratios for adverse perinatal outcomes during second pregnancy in relation to change in BMI from the first pregnancy for all women and for women with a BMI of less than 25 at the time of both pregnancies
13980,Life expectancy and years spent in different states of dependency at age 65 years in 1991 and 2011, and differences between 1991 and 2011
13981,Projected numbers of people aged 65 years or older and of care home places needed by 2025 and 2035
13984,Participants with reductions in episodes of faecal incontinence at follow up   n 227
13985,Treatment related adverse events
13986,Monogenic forms of Parkinson s disease, by gene
13987,Pharmacological treatments for motor symptoms and complications
13988,Pharmacological treatments for non motor symptoms
13990,Randomised controlled trials of surgical interventions for early management of traumatic brain injury
13992,Odds ratios for primary and secondary endpoints at 90 days
13993,Most relevant or frequent adverse events reported during the study
13995,Gas Exchanges During the Incremental Exercise Test legend legend legend legend
13996,Enzymes and MHC legend legend legend
13998,Efficacy endpoints
13999,Safety endpoints
14001,Clinical prediction rule variables
14002,The predictive value of the AIS grading system to discriminate between the ability to walk independently or not 1 year after injury
14004,Primary and secondary study endpoints
14005,Major adverse events and device functionality
14006,Case fatality rates for pandemic influenza A H1N1 infection and population mortality rates by age in England from June 26, 2009, to March 22, 2010
14007,Frequency of presenting symptoms and signs among children who died from pandemic influenza A H1N1 infection
14009,Frequency of pre existing disorders in paediatric deaths related to pandemic influenza A H1N1 infection
14010,Age standardised mortality rate for deaths related to pandemic influenza A H1N1 for children aged between 6 months and 18 years with specific pre existing disorders
14011,Variability of Regional Pulse Wave Velocity by Age
14012,Surgical compliance, mortality, and morbidity
14013,Clinical outcomes for congenital anomaly groups   with a minimum of ten recorded pregnancies   notified to the Northern Congenital Abnormality Survey, 19852003
14014,Estimates of survival at selected ages up to 20 years for congenital anomalies        with a minimum of ten recorded livebirths   notified to the Northern Congenital Abnormality Survey, 19852003
14015,Number of livebirths and compliance with screening objectives throughout Japan   198098
14016,Cases of neuroblastoma diagnosed at younger than 72 months of age and rates of incidence for the three cohorts
14017,Stages of neuroblastoma diagnosed between 6 and 72 months of age in the three cohorts
14018,Distribution of cases of neuroblastoma diagnosed at younger than 72 months of age according to age at diagnosis and stage in the three cohorts
14019,Mortality rates of neuroblastoma diagnosed at younger than 72 months of age for the three cohorts
14021,Neurosensory deficits at 5 years of age in children born very preterm   2432 completed weeks  gestation
14022,Neurodevelopmental outcome by week of gestational age, sex, and type of pregnancy
14023,MPC scores for very preterm children compared with those for a reference group born at term
14024,Scores for MPC and achievement scale for children born very preterm compared with those for a reference group born at term
14025,Overall disabilities and use of special health care and rehabilitation by gestational age group
14026,Use of special health care and rehabilitation of children by level of disability
14028,Prevalence of severe mental and neurological disorders in Maputo and Cuamba, Mozambique
14030,Causal models and help seeking for cases of severe mental and neurological disorders in Maputo and Cuamba, Mozambique
14032,Radiological data
14033,Motion at the affected discs
14036,Patients with a favourable neurological outcome at 30 days after cardiac arrest
14037,Estimation of kuru incubation periods in 11 patients identified in current study
14038,Genetic analysis in kuru patients identified in current study
14039,Types of neural tube defects in babies born between Oct 1, 2002, and Sept 30, 2003, in two areas of Balrampur District, Uttar Pradesh, India
14041,Major adverse events and postnatal complications
14043,Primary outcome logistic regression results   n 218
14045,Clinical features of ten individuals with Parkinson s disease in families with the mutation
14046,Surgical compliance, mortality, and morbidity during first 5 years after randomisation
14047,Probable type and severity of worst non perioperative stroke within 5 years of randomisation
14049,Combined analysis of results from ACST and ACAS
14051,Average use of statin   study or non study  , and average plasma LDL cholesterol concentrations, during follow up
14052,Amount of PrPres detected as a percentage of that present in the brain
14054,p values for comparisons of ischaemia score, apoptosis score, TNF expression, and iNOS expression in patients with septic shock and two control groups
14055,Cardiac measurements in patients 2 and 3 before and after treatment
14056,Distribution of pregnancies other than the proband according to maternal age, gravidity, outcome, and order in families at risk of NTD
14057,Details of families with aneuploidy
14058,Down s syndrome cases observed   O   and expected   E   from the maternal age distribution in families at risk of NTD
14059,Details of NTD cases in families at risk of Down s syndrome
14060,Differences between users and non users of N2O
14063,Exposures associated with West Nile virus seropositivity
14064,Renal function, protein concentrations, and plasma and urinary TNF  in patients treated with pentoxifylline
14066,Average   95  CI   joint space narrowing after 3 years
14067,Average   95  CI   total WOMAC percent change after 3 years
14068,Proportion of patients reporting adverse events recorded with an at least 5  frequency
14070,Distributions of preliminary neuropathological diagnosis   without knowledge of clinical status   by observed dementia status for first neuropathological diagnosis   rank 1   and all diagnoses   All ranks
14071,Number of individuals      with general neuropathological findings by age at death and dementia status
14073,Cases discussed by expert group up to May, 2000
14074,Ten most commonly occurring confirmed diagnoses
14080,Quantitative Results of Myocardial Interstitial Collagen in the Noninfarcted Regions of Left Ventricle   Septum   and RV After AMI legend
14081,Quantitative Results of Macrophages and Activated Myofibroblast Infiltration in the Infarct Zone as Well as Transforming Growth Factor 1 in the Noninfarcted Regions of Left Ventricle   Septum   and RV in Rats After AMI legend
14083,Multivariable hazard ratios of clinical prediction models
14085,Surveillance recommendations of patients according to risk groups
14086,Mortality from all causes, 195297
14087,Mortality from Parkinson s disease and other degenerative neurological disease, 195297
14089,Number of deliveries after in vitro fertilisation in Swedish Medical Birth Registry by type of birth and delivery
14090,Risk ratios   95  CI   for short duration of gestation and low birthweight among singletons born after in vitro fertilisation
14091,Odds ratios   95  CI   for short duration of gestation    37 weeks   of low birthweight    2500 g   according to in vitro fertilisation method
14092,Observed and expected number of children with specific malformations
14093,Delivery outcome in 1994 and 1995 in Sweden
14094,Livebirths and stillbirths by decade, social class, and birth order   non Sellafield cohort
14095,Livebirths and stillbirths by decade, social class, and birth order and paternal age   Sellafield cohort
14096,External preconceptional doses of ionising radiation   radiation worker cohort
14097,Total internal preconceptional gonadal doses of ionising radiation   radiation worker cohort
14098,Results of logistic regression analysis of external preconceptional doses   radiation worker cohort
14099,Effects of nucleoside exposure before and during pregnancy, and after birth
14100,Respiratory chain enzyme investigations in isolated skeletal muscle mitochrondria, tissue homogenates, and circulating lymphocytes from patients
14101,Respiratory chain enzyme investigations in isolated skeletal muscle mitochrondria, tissue homogenates, and circulating lymphocytes from controls
14102,Change in anal manometry and PNTML after first and second vaginal deliveries   n 59
14104,The clinical signs and symptoms seen in each subgroup
14105,Consumption of fruit and herbal tea in cases and controls
14106,Odds ratio associated with consumption of fruit and herbal tea
14107,Patient details
14110,Neurodevelopmental findings at 1415 years in controls and cases according to MRI
14113,Annual incidence rates   per million   for neuroblastoma in four European countries
14114,Mantel Haenszel      relative rates for neuroblastoma by country, stage, and age group
14115,Manner of diagnosis of neuroblastoma in three European countries
14116,Background information on cases of congenital anomaly and controls
14117,Odds ratios for non chromosomal congenital anomalies for each study area
14118,Odds ratios for congenital anomalies among residents within 3 km of a hazardous waste landfill site
14119,Clinical features of 12 patients
14120,Clinical neurological data and findings of necropsy
14121,Cohort of 649 patients treated for a first cancer in childhood
14122,First and second cancer types among 25 patients in case control study
14124,Sites of cancers with onset at age  45 years among family members of probands in case control study
14125,Odds ratio of SMN according to familial aggregation index and local radiation dose
14126,Odds ratio of SMN according to FI and local radiation dose when accounting for interaction
14127,Clinical classification of all conjugal pairs
14128,Results of cranial magnetic resonance imaging   MRI   in 39 offspring of 45 conjugal pairs with multiple sclerosis
14129,Tuber location In 18 patients with and without autistic psychopathology
14130,Laboratory findings in post malaria neurological syndrome
14136,Incidence of incisional hernia in all patients with 2 year follow up and by subgroups
14138,Quality of life scores for patients with and without incisional hernia
14141,Further surgical interventions and patient reported recurrence
14142,Serious adverse events by treatment received
14144,Serum retinol and retinol binding protein levels in infants at 2 weeks and 3 months of age and in mothers at 3 months post supplementation, by trial group
14145,Adverse events within 3 days of supplementation, by trial group
14146,Effect of vitamin A on primary and secondary outcomes, overall and stratified by sex
14148,Haemostatic efficacy and rapid INR reduction by type of procedure   ITT E population
14149,Summary of adverse events   ITT S population
14150,Development indicators and health outcomes for Bangladesh and neighbouring countries and regions
14151,Health system indicators and health outputs in Bangladesh and neighbouring Asian countries and regions
14152,Coverage and concentration index of family planning, maternal, and child health services in Bangladesh   2011  , Nepal   2011  , India   2006  , and Pakistan   2007
14153,Effects of albendazole allocation on prevalence of worm infection, weight, height, haemoglobin, and recent ill health   generally as reported by the child s guardian   in a subsample from each of the 72 blocks during the second half of the study, by age
14154,Associations within 116 of the 4180 control villages between faecal worm eggs   absent present   and mean weight, height, and haemoglobin during the second half of the study   analyses of individuals
14155,Effects of albendazole allocation on pre school child mortality: absolute numbers of deaths per anganwadi child care centre   AWC   by allocated treatment, albendazole versus control   A vs C  , and, from these, mortality rate ratio   A C   and approximate absolute risk of death from age 10 to 60 years
14158,Correlations between maternal 25  OH  D concentrations in pregnancy, exposure to ultraviolet B in the third trimester, and offspring 25  OH  D concentrations
14159,Deaths and Hospital Admissions: Comparison Between Patients With Normal Cardiac Troponin I Levels and Those With Elevated Levels legend legend
14160,Multivariable associations between predicted maternal third trimester 25  OH  D concentrations and offspring BMC
14161,Multivariable associations between predicted third trimester maternal 25  OH  D categories and offspring BMC
14162,Multivariable associations between maternal estimated exposure to ultraviolet B in the third trimester and offspring BMC
14164,Effects of novel CYP2C variation on warfarin dose prediction with the IWPC dosing algorithm
14165,Pharmacokinetic parameters of warfarin R enantiomer and S enantiomer by rs12777823 genotype
14167,Incidence rate of first or the only episode of pneumonia   intention to treat analysis
14168,Person time at risk and incidence rate of repeat episodes of pneumonia from all sources   intention to treat analysis
14170,Treatment characteristics for patients who were randomly allocated and received at least one dose of study drug
14171,Patients with recurrent venous thromboembolism   primary efficacy endpoint   during treatment and follow up
14172,Safety outcomes during the study period for all patients randomly allocated to treatment groups
14173,Post trial follow up of outcomes   other than cancer and death  , by year of follow up
14174,In trial and post trial statin use   study and non study  , by year of follow up
14177,Cumulative incidence before and after 9 11 of physical disorders, mental health symptoms, and spirometric abnormalities in the World Trade Center Screening, Monitoring, and Treatment Program study population
14178,Annual conditional incidence after 9 11 of physical disorders, mental health symptoms, and spirometric abnormalities in the World Trade Center Screening, Monitoring, and Treatment Program study population
14180,Secondary efficacy endpoints at week 72
14181,All cause and idiopathic pulmonary fibrosis related mortality in the pooled population
14182,Treatment emergent adverse events
14183,Basic health professional statistics for countries in southeast Asia
14184,Production capacity of doctors, nurses, and midwives in southeast Asian countries
14185,Level of engagement in trade in health services in southeast Asian countries
14186,Number of doctors and nurses from southeast Asia working in OECD countries, by country of birth and country of training
14190,Efficacy outcomes
14191,Bleeding events during treatment
14192,Summary of safety endpoints with onset during treatment and follow up
14193,Adverse events reported by investigators during treatment   not including study endpoints
14194,Single nucleotide polymorphisms identified in genome wide association analyses for 25 hydroxyvitamin D concentrations
14195,Mean 25 hydroxyvitamin D concentrations by genotype, season, and supplementation status
14196,Genetic variants and risk of vitamin D insufficiency
14198,Primary and secondary clinical outcomes
14199,Maternal and neonatal outcomes
14200,Growth measures at birth and at postnatal follow up   612 weeks of age
14203,Children aged 24 years who screened positive for disability to the Ten Questions in the 200506 Multiple Indicator Cluster Survey, by breastfeeding status and country
14204,Children aged 24 years who screened positive for disability to the Ten Questions in the 200506 Multiple Indicator Cluster Survey, by vitamin A supplementation and country
14205,Children who screened positive for disability to the Ten Questions in the 200506 Multiple Indicator Cluster Survey, by participation in early learning activities, school attendance, and country
14206,Definitions of asthma at 22 years on the basis of physician diagnosed asthma and current symptoms
14208,Prebronchodilator and postbronchodilator FEV1 FVC ratio and response to bronchodilator for asthma groups at age 22 years
14209,Proportion of participants with early life risk factors and current smoking by asthma group at age 22 years
14210,Multinomial odds ratio for asthma groups at age 22 years by different risk factors in early life
14212,Comparison of non health system changes between 1999 and 2005 that might be expected to affect child survival
14214,Risk factors for child stunting in families in Indonesia
14215,Risk factors for child stunting in families in Bangladesh
14216,Multivariate logistic regression model for maternal education, paternal education, and other risk factors in relation to stunting in children in Indonesia
14217,Multivariate logistic regression model for maternal education and other risk factors in relation to stunting in children in Bangladesh
14218,Effect of length of primary school education on the odds of child stunting
14219,Effect of combined level of parental education on risk of child stunting
14220,Maternal and paternal education and caregiving behaviours in families in Indonesia
14221,Vitamin A supplementation schedule
14222,Tests and sample collection
14224,Plasma and breastmilk retinol concentrations
14225,Indicators of respiratory and gastric mucosal infection
14226,Indicators of damage to mucosal defences
14227,Lymphocyte counts
14228,Morbidity rates of study infants
14229,Plasma acute phase markers
14230,Association between 8 year lung function growth and several indicators of residential traffic exposure
14232,Joint effect of regional pollution and local distance to a freeway on 8 year FEV1 growth
14233,Cumulative effect of residential distance in the 1445 children with full 8 year follow up
14236,Maternal pregnancy outcomes by treatment allocation
14237,Pre eclampsia stratified by risk at enrolment
14238,Neonatal outcomes by treatment allocation
14241,Umbilical vein blood chemistry and whole body BMC at age 9 years
14242,Smoking status at each survey for participants with data about change in lung function
14243,Age, lung function, and BMI at ECRHS I by smoking group
14244,Smoking intensity between surveys   26 centres  , and unadjusted FEV1, FVC, and BMI by smoking group
14245,Difference in change in lung function from those who had never smoked, adjusted for centre, age, age squared, and height
14246,Change in lung function from smoking, change in weight, or change in BMI
14252,Within group changes and differences between groups after 12 months  follow up for quality of life scores   MOS SF 36 domains
14254,Outcomes by decision rule and secondary variables at 3 months
14255,Adverse events and complications at 3 months
14256,Effect of covariables on primary and secondary outcomes
14257,Compliance with study vitamins   80  taken   during follow up
14258,Average plasma concentrations of vitamins and lipids during follow up
14259,Variables and variable values used to estimate effectiveness and cost effectiveness
14261,Adverse effects in 466 patients who underwent re treatment with second line drugs
14262,Follow up and treatment outcome in patients who underwent re treatment with second line drugs
14263,Average cost per patient treated for patients who completed the full course of treatment,      standardised second line drug treatment programme implemented in Peru 19972000
14264,Mean cost, affordability, effectiveness, and cost effectiveness indicators for alternative strategies, highest cost scenarios assessed        5th and 95th centiles
14265,Cost and cost effectiveness indicators for alternative strategies under different cost assumptions
14266,25 hydroxyvitamin D 1  hydroxylase   1OHase   mRNA expression in tumour and paired healthy mucosa samples and in control samples, and ages of individuals biopsied
14267,Description of study population
14268,The effect of vitamin A supplementation, sex, and one versus two doses of vitamin A on measles specific antibody concentrations
14274,Physiological variables in climbers with and without clinical evidence of oedema, at low and high altitude
14276,Incidence rate and rate ratio   RR   of type 1 diabetes by the use of vitamin D supplements and suspected rickets in infancy
14277,Results of automated perimetry
14278,Effectiveness of confrontation field tests
14280,Mean percentage change in FEV1 over each treatment period   final FEV1 minus initial FEV1, expressed as a percentage of initial FEV1
14283,Mean costs   UK   over each 12 week treatment period, and differences between treatment groups
14284,Forearm Blood Flow Responses legend
14285,Distribution of variables by sex specific quintiles of ascorbic acid in men and women
14286,Age adjusted rates for all cause, cardiovascular disease, and ischaemic heart disease mortality by sex specific ascorbic acid quintile in men and women
14287,Cox multivariate regression for all cause, cardiovascular, and ischaemic heart disease mortality with ascorbic acid in 8860men and 10636 women
14292,Predictors of vertebral fractures after cardiac or liver transplantation
14294,Efficacy profile of aspirin and vitamin E treatment
14295,Safety profile of aspirin and vitamin E treatmentssevere and unexpected non fatal events according to treatment group
14298,Intravascular Ultrasound Results for Debulking Plus Stenting and Stenting Only Groups legend legend
14299,Univariate Predictors of Angiographic Restenosis legend legend
14301,Systemic Hemodynamics at Rest, 1 mm ST Depression and at Peak Exercise, Before and After Treatment With Enalapril legend legend
14303,Adjusted Odds of Developing AMI According to Levels of Circulating Monocyte Platelet Aggregates legend
14313,Multivariate Predictors of Troponin I Positivity legend legend
14314,Maximum Troponin I   g l   Concentrations According to Univariate Predictors of Troponin Release legend legend
14315,Troponin Status According to ACE genotype legend legend
14317,Cytokines legend
14319,Incidence of Angiographic Complications legend
14321,Incidence of CK MB Enzyme Elevation Among Patients With Angiographic Complications   Excluding Patients With Abnormal CK MB Enzyme Elevation Immediately Before or During Procedure   legend
14322,Incidence of CK Enzyme Elevation Among Patients With Angiographic Complications Excluding Patients With Abnormal CK MB Enzyme Elevation Before or During Procedure legend
14323,Clinical End Points in Patients With Versus Without Angiographic Complications During Coronary Intervention
14324,Effects of Eptifibatide Observed in This Study, Extrapolated to an Imaginary Cohort of 1,000 Patients legend
14326,Single Photon Emission Computed Tomographic Results
14327,Referral to Coronary Angiography legend
14328,Referral to Revascularization legend
14329,Magnetic Resonance Imaging and Exercise Data Unadjusted for Age and Gender   Mean  Standard Error of the Estimate   legend
14330,Magnetic Resonance Imaging and Exercise Data Adjusted for Age and Gender   Mean  Standard Error of Estimate   legend
14331,Predictors of Peak Oxygen Consumption legend
14333,Final Hemodynamic Data on the Four BMI Categories After the Pulmonary Artery Catheter Guided Unloading Protocol legend
14334,Medicine Use Among the Four Categories of BMI legend
14335,Prediction of One Year Survival by Univariate Analysis legend
14336,Predictors of Survival by Multivariate Cox Regression Analysis legend
14340,Patients Data legend
14341,Cardiac Magnetic Resonance legend
14346,Clinical Predictors of Chronic AF legend
14347,Hazard Ratios and 95  Confidence Intervals for Subgroup Analysis legend
14349,Echocardiographic Findings legend legend
14351,Peak Pulmonary Vein Blood Flow Velocity   cm s   of Patients With Pulmonary Venous Pathway Obstruction from MR Velocity Mapping and Doppler Echocardiography legend legend
14352,Comparison of MR, Doppler Echocardiography and Catheterization Derived Peak Pulmonary Vein Blood Flow Gradients   mm Hg   in Patients With Pulmonary Venous Pathway Obstruction
14354,Comparison of Sensitivities, Specificities, NPVs and PPVs for Prediction of Functional Recovery on a Segmental Basis Using Early and Delayed Myocardial Contrast Echocardiography legend
14355,Chi Square and Significance Values for Univariate Predictors of Segmental Functional Recovery legend
14356,Unipolar Electrogram Amplitude and Linear Local Shortening in Regions Defined by Nuclear Imaging legend
14358,Right Ventricular Apical Pacing Data of Patients Paced for 1 to 19 Years legend
14359,Predictors of Left Ventricular Fractional Area of Change in Patients Who Had Right Ventricular Apical Pacing   n   24
14361,Follow Up of Patients With Negative Nondiagnostic Tests legend
14362,Results of the Follow Up Questionnaire for 229 Patients Who Responded legend legend
14364,Angiographic Results by Agency for Health Care Policy and Research Risk Group legend legend
14365,Angiographic Results by Agency for Health Care Policy and Research Risk Group Excluding Normal Angiograms and Mild CAD Patients legend legend
14366,PCR Conditions for Amplification of NHE 1, NBC 1 and GAPDH legend
14368,Platelet Aggregation   Ohms   in Response to 1 mol liter ADP in Whole Blood From Normal Subjects, Nonischemic Patients   NIP  , Patients With Stable Angina Pectoris   SAP   and Patients With Acute Coronary Syndromes   ACS   legend
14369,Multivariate Analysis: Significant Correlates of Impaired    28    Platelet Response to Sodium Nitroprusside   10 mol liter   in Blood Samples From Patients With Stable Angina Pectoris   n   82   or Acute Coronary Syndromes   n   153   legend
14370,Hemodynamic Data legend
14372,Mean 24 h Values: Effect of Spironolactone or Placebo on Various Biochemical, Hemodynamic and Autonomic Indices legend
14373,Diurnal Effects of Spironolactone and Placebo on Autonomic Indices legend
14374,Resting Hemodynamics, Stenosis Severity and Function legend
14375,Subendocardial Perfusion   ml min g   and Connective Tissue Staining       legend
14377,Clinical Features of Patients With and Without Hard Cardiac Events legend
14378,Exercise Stress Test and Echocardiographic Data of Patients With and Without Cardiac Events legend
14380,Independent Predictors of Cardiac Events Using Four Step Model
14381,Comparison of Brugada Patient and Control Groups legend
14382,Univariate and Multivariate Analyses of Three Noninvasive Indices Associated With Life Threatening Events legend
14383,Predictive Values of Three Noninvasive Indices Associated With Life Threatening Events legend
14385,Patients Hospitalized by Treatment Group and Reason for Admission legend
14386,Total Number of Hospitalizations and Hospitalizations per Patient   Mean  SD
14387,Effect on Inpatient Resource Utilization and Costs legend
14388,Utilization of Selected Cardiovascular Procedures, by Treatment Group legend
14389,Clinical Features and Medical Therapy legend legend
14390,Effects of Lidocaine and Verapamil on Local Conduction Times Measured During Entrainment legend
14393,Clinical Outcome by Treatment Group Among Patients With Paired Echocardiograms legend
14397,Effects of Etiology and Functional Class on Venous Endothelial Function legend
14401,Dose Response Effects of Nitroglycerin on Cerebral Blood Flow legend
14402,Effects of Nitroglycerin or Nicorandil on Epicardial Coronary Artery Diameter During Continuous Administration of Nitroglycerin legend legend
14403,Independent Predictors of Total Cardiac Mortality Based on Clinical Variables and Results of Dobutamine Echocardiography legend
14404,Predictors of Cardiac Death in Patients With Negative Dobutamine Echocardiograms legend
14405,The Sequence for the Primers
14407,Comparison of mRNA and Protein Expression for Patients With Persistent and Paroxysmal AF With their Matched Controls in Sinus Rhythm legend
14411,Instrumentation Settings for Pulse Inversion Doppler Imaging With Intravenous Optison and Definity
14413,Global Ventricular Function of Patients and Age Matched Control Subjects legend legend
14414,Regional Myocardial Function in the Perfusion Territory of the Left Anterior Descending Coronary Artery   LAD Infarct Area   and the Area Adjacent to and Remote From the LAD Perfusion Territory, as Assessed by Wall Thickening and Strain Analysis legend legend
14417,Ischemic Burden Demonstrated by Tc 99m Sestamibi   MIBI   and Tc 99m Tetrofosmin   TETRO   in Mild to Moderate Coronary Artery Disease
14418,Segmental Analysis of Perfusion Defects in Patients With Mild to Moderate Coronary Artery Disease legend legend
14419,Image Quality legend legend
14422,Regional Myocardial Blood Flow at Rest and During Pharmacological Stress
14423,Echocardiographic Variables in the Normal Population legend
14424,LV Mechanics During and After ARF legend
14425,Group II Patients Treated With   n   5   and Without   n   14   Surgery legend legend
14426,Patient Data, Scintigraphic Findings and Coronary Flow Reserve at 100 Beats Min in Patients With Permanent Ventricular Pacing legend
14429,Clinical and Echocardiographic Data Stratified According to the X Chromosomal Located 1675 G A Polymorphism of the Angiotensin II AT2 receptor Gene legend
14430,Clinical Data Stratified According to the  1675 G A Polymorphism of the Angiotensin II AT2 Receptor Gene legend
14431,Echocardiographic Data Stratified According to the  1675 G A Polymorphism of the Angiotensin II AT2 Receptor Gene legend
14439,Hemodynamics   Mean  SD  Positron Emission Tomographic Study legend
14440,Hemodynamics   Mean  SD  Dobutamine Echo Study legend legend
14441,Regional Myocardial Blood Flow   ml min g; Mean  SD   by Viability Criteria legend
14442,Adhesion Molecule Expression on Aortic Valve Endothelium legend
14443,Correlation Between Soluble Adhesion Molecule Levels and the Intensity of Staining on Valvular Endothelium legend
14445,Correlation of Antimyosin Uptake Heart to lung Ratio With Clinical and Echocardiographic Variables legend
14446,Multiple Linear Regression Analysis of Heart to lung Ratio of Antimyosin Uptake legend legend
14448,Effect of the Two Enalapril Dose Regimens on Mortality in Patient Subgroups legend legend
14451,One Year Morbidity   Hospital Admissions   in the Two Study Groups
14453,Prevalence of Coronary Calcification   Score   0   by Diabetes Status and Gender
14454,Age Adjusted Odds Ratio   95  CI   for the Association Between Each Risk Factor and Coronary Calcification by Gender and Diabetes Status legend
14455,Clinical Profiles of the Study Patients legend
14458,Univariate Predictors of Cardiac Death legend legend
14459,Multivariate Cox Proportional Survival Analysis for Independent Predictors of Cardiac Death legend
14460,Cardiac Pathology legend
14461,Neurohumoral Data legend
14463,Clinical Outcomes Stratified by Cardiac Troponin I Results legend legend
14464,Multivariate Adjusted Risk Relation Between Elevated Cardiac Troponin I and Adverse Outcomes at 14 Days legend legend
14465,Clinical Information for the 23 Study Patients
14468,Ventricular Parameters and Distal LAD Diameter Before and After AVR legend legend
14469,Distal Left Anterior Descending Coronary Artery Flow Velocities and Flow Reserve Before and After AVR legend legend
14472,FVR Responses in the Infused Arm After Placebo and Losartan Treatment legend
14474,Clinical Data of the Patient Population legend
14478,Multivariable Logistic Regression Models for Perioperative Complications by Outcome    legend
14479,Multivariable Cox Regression Models for Mortality    legend
14480,Multivariable Cox Regression Models for Hospitalization    legend
14483,Interaction of Factor V Leiden With Other Risk Factors legend
14485,Clinical Presentation
14486,Mechanisms of Aortic Regurgitation in Patients With Minimal Versus Significant Aortic Regurgitation
14487,Case Analysis of Patients Undergoing Aortic Valve Repair or Replacement: The Mechanisms and Severity of Aortic Regurgitation Correlated With the Type of Aortic Valve Surgery legend
14488,Identifying Diagnostic Features of LAI
14489,Summary of Cardiac Defects
14490,Extracardiac Conditions and Anomalies
14492,Independent Factors Associated With Time Related Mortality    legend
14493,Left Ventricular Volumes Determined by RT3DE and 2DE in the Sheep Animal Model legend
14494,The LV EDV, ESV and EF Determined by RT3DE, 2DE and MRI in Patients legend
14497,Effects of Fatty Meals on Serum Lipoproteins, Insulin, Glucose, Free Fatty Acids and Homocysteine Levels legend
14500,Quantitative Data of IVUS legend legend legend legend
14501,Multiple Regression Analysis of  Intima   Media Area legend
14503,Gas Exchange and Hemodynamic Variables After Breathing the Test Gas Mixture at Rest, at the End of the 6 Minute Exercise Period and After 3 Minutes of Resting Recovery legend legend
14506,Cox Proportional Hazards Analysis of Survival in 159 CHF Patients legend
14507,Regional Contraction   V c    and Lengthening Rate   V e    in the Control Group legend legend
14508,Myocardial Velocities at Rest and During Dobutamine Challenge legend
14510,Withdrawals After Randomization legend
14513,The Descriptive Data of the AMI Patients legend
14515,Effects of Long Term Treatment With Carvedilol, Metoprolol and Captopril on Infarct Size and Cardiac Tissue Weights in Rats With MI legend legend
14516,Effects of Long Term Treatment With Carvedilol, Metoprolol and Captopril on Hemodynamic Parameters in Rats with MI legend legend
14518,Bleeding, Hematological and Transfusion Parameters in All Patients legend
14519,Bleeding, Hematological and Transfusion Parameters in CABG Patients legend legend legend
14520,Bleeding, Hematological and Transfusion Parameters in Non CABG Patients legend legend legend
14521,30 Day Clinical Outcomes legend
14522,Six Month Clinical Outcomes legend
14525,Serum Tumor Necrosis Factor Alpha Levels in Patients With Aortic Stenosis and Mitral Regurgitation, According to New York Heart Association Functional Class legend
14526,Serum Levels of Tumor Necrosis Factor Receptors in Patients With Aortic Stenosis and Mitral Regurgitation, According to New York Heart Association Functional Class legend legend
14528,Hemodynamic Data legend legend legend
14529,Positron Emission Tomographic Measurements legend legend
14530,Correlation Between Coronary Vascular Resistance and Lipids legend
14532,Sensitivity, Specificity, Accuracy, Relative Risk, Positive Predictive Value, and Negative Predictive Value for Each Testing Method legend
14533,Electron Beam Computed Tomographic Coronary Calcium Score Threshold Value: Increasing Threshold Value Lowers Sensitivity and Raises Specificity legend
14535,Reasons for Patient Exclusion legend
14536,Morphometric Analysis legend
14537,Stanford Classification Distribution legend
14539,Individual Effects of Pulse Pressure, Mean Arterial Pressure, Systolic Blood Pressure, Diastolic Blood Pressure and Hypertension Classification on the Study End Points    legend
14540,Joint Effects of Pulse Pressure and Other Blood Pressure Parameters on the Study End Points legend
14541,Use of ASA Early After MI in the Four Different Trials legend
14546,Prevalence and Extent of Coronary Artery Disease in Patients With a Positive or Negative Cardiac Troponin T Result legend legend
14548,Ability of Multivariate Models to Predict One Year Adverse Cardiac Events legend
14550,RR Interval Power Spectral Analysis Results   Mean  SEM   legend legend
14551,Blood Pressure Results   mean  SEM   legend
14562,In Hospital Clinical Events by CK MB Levels legend
14563,Late Outcome by CK MB Group Levels legend
14564,Logistic Regression Analyses legend
14576,Univariate Correlation Between Serum Neopterin Levels and Angiographic Data
14577,Multiple Regression Analysis With Significant Univariate Predictive Variables for Number of Complex Lesions legend legend legend
14579,Hemodynamic Measurements Pre  and Post ASD Device Closure legend legend
14580,Comparison of groups
14581,Patients affected by adverse events
14583,Types of severe combined immunodeficiency
14584,Group differences in memory and correlations with age
14585,Cases of clozapine associated myocarditis
14586,Cases of clozapine associated cardiomyopathy
14588,Maximum flow velocity of superior ophthalmic vein on colour doppler flow imaging in patients and controls
14589,Maximum doses
14591,Incidence of adverse events
14593,RR of SUDEP associated with other disorders
14595,RR of SUDEP associated with different antiepileptic drug therapies
14596,RRs of SUDEP associated with combinations of seizure frequency and number of antiepileptic drugs
14598,Prevalence and incidence of treated epilepsy in 1995
14599,Age specific fertility rates
14600,Patients excluded from study
14601,Clinically diagnosed seizure types in 300 first seizure patients
14602,Epileptiform EEG abnormalities in 300 patients with clinically diagnosed epilepsy syndromes
14603,Diagnosis of epilepsy syndromes in 300 patients based on clinical, EEG, and MRI data
14604,Epileptogenic lesions shown by MRI and computed tomography   CT
14605,Classification of specific epileptic syndromes
14609,Side effects reported at clinic and numbers of children who did not complete the trial for any reason
14610,Distribution of behavioural problems at outcome
14611,Multiple logistic regression model for behavioural problems at outcome
14613,Outcome by treatment group
14618,Adverse events
14620,Participants reporting solicited injection site reactions or systemic adverse events after any dose in the different study cohorts
14621,Immunogenicity for the different study groups 14 days after the third vaccination, with GMTs in groups with more than 50  responders, by injection route and application device
14624,Treatment emergent adverse events
14625,Successfully Tested Anti PDGF Agents
14627,Main podcast episodes
14629,Main results
14634,Self reported intervention use in the previous 3 months, recorded at 3, 12, and 24 months
14638,Cumulative incidence of and mortality from colorectal cancer and the number needed to screen to prevent one event in the follow up period
14641,Differences between number of male individuals circumcised in each village pair
14643,Diagnostic accuracy of ultrasound and iuMRI by age of fetus in the 570 cases constituting the primary group
14645,The tabulated results of prognostic grade given to pregnant women before and after iuMRI assessments
14649,Primary and secondary outcomes
14650,Costs per person and QALYs gained   2015 international dollars
14651,Cost effectiveness analyses from health system and societal perspectives   2015 international dollars
14655,Postprocedure OCT measures
14656,Procedural safety outcomes
14657,Clinical outcomes at 30 days
14659,Participant ratings of appropriateness and helpfulness of brief intervention
14660,Weight loss actions taken by 3 and 12 months
14666,Births, abortions, and pregnancies in the intervention and control groups
14667,Relative risk estimates for any pregnancy before the age of 20 years
14668,Competing risks model for a birth or induced abortion before the age of 20 years
14670,Clinical outcomes
14676,Summary of primary neuropsychiatric composite safety endpoint and its components
14677,Columbia Suicide Severity Rating Scale   C SSRS
14678,Mild, moderate, or severe adverse events      coding to the MedDRA category psychiatric disorders reported by at least 1  of participants in any treatment group
14682,Descriptive statistics of objectively assessed environmental attributes
14683,Pooled associations of environmental attributes with daily minutes of moderate to vigorous physical activity by model   n 6679
14686,Long term clinical outcomes from randomised access and open access periods
14689,Primary and secondary outcomes
14694,Calculations of vaccine efficacy and vaccine effectiveness based on different study populations
14695,Distribution of confirmed Ebola virus disease cases in vaccinated and unvaccinated individuals in immediate and delayed clusters
14699,Primary outcome at 2 years corrected age
14700,Developmental and neurosensory outcomes in survivors to 2 years
14702,Local reactions
14703,Systemic reactions
14704,Antibody responses 4 weeks after the third vaccination
14707,Self reported adverse events during the study and health care register follow up
14708,Design features of 27 trials, with numbers of women and of those with a documented history of vascular disease
14711,Analysis of primary outcome
14712,Mean scores on knowledge subscales
14713,Analysis of secondary outcomes
14714,Use and acceptability of decision aids
14716,Findings of CTCA   n 1778
14718,Changes in investigations and treatments at 6 weeks
14719,Percentage of Rats With Ventricular Fibrillation in the Three Groups legend
14720,Clinical outcomes
14721,Myocardial Infarct Size in the Three Groups of Rats legend
14723,Tumour stage and histological risk groups
14724,Event free and overall survival for the intention to treat and per protocol populations
14725,Sites of relapse in the intention to treat population
14728,Rates of adverse events and key safety variables of interest
14731,Treatment related adverse events
14733,Impairments and predictors of quality of life   QoL   for young people with cerebral palsy who self reported QoL
14734,Description of each KIDSCREEN domain
14735,KIDSCREEN scores on each domain for self reporting adolescents with cerebral palsy   cross sectional sample, n 431
14736,Linear regression models relating KIDSCREEN scores on each domain to type and level of impairment in adolescents with cerebral palsy   cross sectional sample, n 431
14737,KIDSCREEN scores on each domain for young people with cerebral palsy who self reported in both childhood and adolescence   longitudinal sample, n 355
14741,Vaccine efficacy against 6 month persistent infection with vaccine and non vaccine oncogenic HPV types   according to protocol cohort for efficacy
14742,Safety and pregnancy outcomes up to month 48   total vaccinated cohort
14744,Treatments received for depression
14747,Change from allocated trial treatment to non trial treatment for each group
14748,Summary of serious and non serious adverse events, by group
14749,Adjusted      annual costs and quality adjusted life years
14751,Vaccine efficacy against varicella in the per protocol efficacy cohort
14752,Participants reporting solicited injection site   local   symptoms up to 4 days after each dose and of fever up to 15 days after each dose in the reactogenicity subset
14753,Serious adverse events deemed by the investigator to be related to vaccination in the total vaccinated cohort
14761,Number of physiotherapy appointments attended by women in the intervention group
14763,Change in prolapse   pelvic organ prolapse quantification   stage at 6 months, and uptake of further prolapse treatment by 12 months
14764,Self reported effect of prolapse symptoms, and prevalence of urinary and bowel symptoms at 6 months and 12 months
14766,Treatment emergent adverse events
14773,5 year clinical outcomes in the SORT OUT III trial
14775,Adjusted mean scores for body mass index and eating disorder pathology, by treatment group
14779,Performance of smear microscopy, clinic based nurse administered Xpert MTB RIF, and laboratory based technician administered Xpert MTB RIF, per treatment site and overall
14781,Patients with a positive smear microscopy, Xpert MTB RIF, or culture result, and days to result, per allocation group
14782,Proportions of patients on anti tuberculosis treatment, and days to treatment initiation according to reason for treatment initiation, per allocation group
14789,Secondary outcomes for all cross sectional participants   N 751
14791,Summary of admission outcomes at follow up
14792,Secondary outcome measures by randomisation group
14793,Summary of admission outcomes at follow up by randomisation group for black subgroup
14794,Projected deaths averted from cardiovascular diseases, cancers, and chronic respiratory diseases by reduction of key risk factors in people aged 3069 years in Pakistan in 2025 and cumulatively from 2015 to 2025
14795,Evidence based priority interventions for prevention and control of non communicable diseases and injuries in Pakistan
14803,Patients with at least one serious adverse event
14806,Summary of adverse events during 24 weeks in the treated set of patients
14807,Summary of adverse events during 24 weeks in the treated set of patients not receiving concomitant sulfonylurea treatment
14809,Adverse events
14810,Outcomes by study group
14811,Outcomes in women with a cervical length of less than 38 mm
14812,Outcomes in women with a cervical length of at least 38 mm
14821,Adverse events and abnormal laboratory values
14825,Clinical symptoms at diagnosis, reported for 5  or more of all patients with confirmed pulmonary hypertension   PH confirmed  , according to pulmonary hypertension groups and subgroups
14828,Incidence of clinical endpoints
14829,Subgroup analysis of the primary endpoint at 6 months
14835,Overall hazard ratios for each endpoint per one SD increase in mean common carotid artery intima media thickness in four models
14836,Pooled analysis of five trials of aspirin versus control showing the effect of allocated treatment on the risk of in trial incident cancers stratified by metastatic status and by histological type
14839,Eligibility of CTT participants without a history of vascular disease for statin therapy under existing major guidelines, by estimated 5 year major vascular event risk
14841,Daily insulin dose in the insulin degludec and insulin glargine groups
14842,Hypoglycaemic episodes in the insulin degludec and insulin glargine groups
14843,Summary of adverse events
14846,Hypoglycaemic episodes
14847,Treatment emergent adverse events reported by 5  or more of participants
14848,Causes of death in the safety analysis set
14849,Study population
14850,Cox proportional hazards analysis and Poisson regression for colorectal cancer, non colorectal Lynch syndrome cancers, and all Lynch syndrome cancers   adjusted for sex   in participants randomly assigned to aspirin or aspirin placebo
14852,Mode of delivery
14853,Maternal and neonatal outcome
14855,Biopsy based rates of detection and relative sensitivity estimates for the HPV and cytology screening strategies according to the per protocol or the intention to screen analyses
14856,Positive predictive value of the HPV test and Pap cytology test by age
14857,Per protocol relative sensitivity and PPV of HPV versus Pap for a CIN2 or worse endpoint in different age groups with different cutoffs of HPV tests
14866,Mortality risk, by exercise volume and intensity
14867,Hazard ratios for cancer mortality and incidence, by volume of leisure time physical activity
14869,Primary and secondary outcomes
14870,Angiographic and clinical composite outcomes at 18 months
14871,Sensitivity analyses on the composite primary outcome
14872,Independently assessed modified Rankin score at 18 months
14873,Composite primary outcome by hydrogel treatment achieved   per protocol analysis
14874,Composite primary good outcomes by use of assist device
14875,Efficacy of Vero cell culture derived vaccine in culture confirmed influenza infection
14876,Immunological response   reciprocal haemagglutination inhibition titre   to immunisation with Vero cell culture derived influenza vaccine or placebo
14877,Sensitivity and specificity of different cutoff haemagglutination inhibition titres for matching A Brisbane 59 2007 strains   n 63
14878,Relative risk of treatment emergent non serious related adverse events with incidence greater than 1  in any treatment group
14881,Secondary events during 6 months  follow up
14882,Secondary clinical outcomes
14884,Treatment effects
14888,HPV incidence in women by study group and follow up interval for participants with amplifiable cellular or viral DNA at sequential study visits
14889,Genotype specific female high risk HPV incidence during 2 years, by study group
14891,Clearance of pre existing genotype specific female high risk HPV infections, by study group
14892,Dosing scheme
14895,Adverse events
14897,CHD and CVD events by CAC status in the MESA population eligible for JUPITER
14898,Estimated 5 year NNT to prevent an event of CHD or CVD, by CAC burden in population eligible for JUPITER
14899,CAC versus hsCRP for risk prediction in patients eligible for JUPITER
14900,Compliance with study simvastatin    80  taken   at scheduled follow up visits
14901,Reasons for stopping study simvastatin tablets before scheduled end of study
14902,Mean differences in plasma concentrations of lipids during follow up, by allocated treatment
14903,Myopathy and raised alanine aminotransferase and creatine kinase concentrations
14906,Interventional Procedures legend
14908,In Hospital Procedural Results and Clinical Outcomes at 12 Months Follow up legend
14909,Independent Predictors of Any Cardiac Event and TLR During One Year Follow up Period
14911,Participation and cumulative yield of smear positive tuberculosis cases in the community during six rounds of intervention
14912,Prevalence of tuberculosis disease before intervention and before round six of intervention
14916,Patient reported rating of side effects
14922,Antiretroviral therapy   ART   use and risk of HIV 1 transmission
14923,HIV 1 transmission rates by CD4 cell count and plasma HIV 1 concentration in couples in whom the HIV 1 infected partner had not initiated antiretroviral therapy
14926,Cumulative incidence of and mortality from colorectal cancer, and the number needed to screen to prevent one event in the present follow up period
14928,Study drug coverage during follow up by study group
14930,Comparison of biomedical clinical trials of non antiretroviral therapy interventions to reduce HIV 1 disease progression
14932,Births, deaths, and crude mortality rates in intervention and control clusters during the trial period   200507
14933,Comparison of mortality rates in intervention and control clusters   200507
14934,Process indicators in intervention and control clusters
14939,Outcomes of APCam01 and APCam03
14940,Secondary comparisons in APCam01 and APCam03
14941,Comparisons in APCam02
14942,Frequency and duration of hypoglycaemia and hyperglycaemia during closed loop delivery and continuous subcutaneous insulin infusion
14943,Comparisons between closed loop delivery and continuous subcutaneous insulin infusion after pooling APCam01 and APCam03 data
14945,Efficacy of emergency contraception in single studies and meta analysis, according to time from unprotected sexual intercourse to intake of emergency contraception   efficacy evaluable population
14947,Haemagglutination inhibition antibody response against 2009 influenza A H1N1 before and 21 days after one injection of vaccine or placebo
14949,Participants with at least one solicited injection site or systemic reaction within 7 days after vaccination with 2009 influenza A H1N1 vaccine or placebo by age group
14951,Clinical and safety outcomes
14952,Risk ratios   RRs   for coronary heart disease and ischaemic stroke per three fold higher usual C reactive protein   CRP   concentration with progressive adjustment for usual levels of potential confounders
14953,Risk ratios   RRs   for coronary heart disease and ischaemic stroke per three fold higher usual C reactive protein   CRP   concentration with adjustment for usual levels of conventional risk factors plus different inflammatory markers
14956,Vaccine efficacy against HPV 16 18 incident and persistent infection in cervical samples and HPV 16 18 associated cytological and histopathological endpoints up to 64 years of follow up
14957,Cumulative number of endpoint events associated with HPV 16 18
14958,Vaccine efficacy against cytological and histopathological endpoints independent of HPV DNA in lesions up to 64 years of follow up
14959,Occurrence of adverse events, serious adverse events, and new onset chronic disease in the follow up study
14961,Outcomes after 18 weeks of treatment with inhaled corticosteroid plus placebo or salmeterol in B16 Arg Arg and B16 Gly Gly participants
14962,Number of enrolled participants, number eligible, and percentage enrolled by sex, ethnic and racial origin, diabetes status, and treatment group
14964,Incidence   cases per 100 person years   of diabetes during DPP, bridge period, and DPPOS
14965,Cardiovascular disease risk factors averaged over all follow up since randomisation to DPP
14967,Pregnancy outcome and onset of labour in randomised patients
14968,Maternal outcome
14969,Method of delivery
14970,Neonatal outcome
14974,Secondary analyses of primary and secondary BDI outcomes at 4 month and 8 month follow ups
14976,Primary outcome   proportion of women delivering or with intrauterine death before 34 weeks   overall and by subgroup of chorionicity
14977,Gestational age at birth and duration of labour   secondary outcomes
14978,Method of delivery   hierarchical; secondary outcome
14979,Neonatal complications   secondary outcomes
14980,Safety issues   secondary outcomes
14984,Summary of sexual history at enrolment
14985,Efficacy against the combined incidence of vaccine type related infection of at least 6 months  duration, cervical intraepithelial neoplasia, and external genital lesions
14986,Summary of clinical adverse events   days 115 after any vaccination visit
14992,Major efficacy and safety endpoints at 30 days
14993,Major efficacy and safety endpoints at 15 months
14994,Main outcomes of comparative studies for open and laparoscopic pyloromyotomies
14995,Minimisation criteria
14997,Primary outcomes
14998,Secondary outcomes
14999,Comparison of primary outcomes stratified by grade of primary surgeon
15004,Summary of HIV seroconversions, overall and by subgroups of sex, region, study drug adherence, and genital ulcer disease at enrolment
15005,Relative risk of incidence of genital ulcers
15006,Incidence of serious adverse events by study group
15008,Comparison of outcomes at 3 months
15009,Service delivery strategies by study arm
15014,Incidence of diabetes, CVD, and mortality in the active intervention   198692   and entire follow up period   19862006  , and CVD and mortality in the post intervention period   19932006
15019,Endpoints
15020,Pathogens isolated from 87 patients with an infectious complication
15022,Number of participants with diabetes by trial
15026,Person years and numbers of deaths attributed to IHD, stroke, and other vascular causes, by age at risk
15027,Combined PSC and MRFIT hazard ratios for IHD, stroke, and other vascular mortality for 1 mmol L lower usual total cholesterol
15029,Incidence rates for intervals of follow up
15030,Adverse events recorded by severity and relatedness to the surgery
15036,Distribution of FGM status and total FGM by country
15038,Estimated rates of perinatal death per 1000 births in infants born to women with and without FGM
15040,Distribution of pairs of placebo controlled trials by clinical topic
15044,Anatomical extent of FGM among respondents
15045,Types of FGM classified according to WHO criteria
15046,Association between extent of FGM and primary infertility
15048,Proportion of primary and secondary endpoints
15049,Risk of treatment failure in individuals with suspected meningitis
15054,Type and frequency of vascular events
15058,Summary of interventions from 392 case notes audited, by treatment group
15060,Participants  assessment of overall change at 12 months  follow up, by treatment group
15061,Secondary outcome measures at 3 months  and 12 months  follow up, by treatment group
15062,Estimated 5 year rate of a first major vascular event   MVE  , major coronary event   MCE  , or vascular death in univariate and multivariate risk subgroups
15063,Total   first and subsequent   vascular and non vascular outcomes during 5 year mean follow up
15064,Mean days in hospital and costs of hospitalisation per person during 5 year mean follow up
15065,Days on statin and costs of statin per person during 5 year mean follow up
15069,Participants concern about future breast cancer after being offered results
15071,Estimated effect of gabapentin vs placebo
15075,Mortality and hospital and institutional admissions
15078,Per protocol population: mortality, hospital and institutional admissions
15080,Comparison of results with meta analysis
15090,Number of pregnancies recruited by gestational age and umbilical artery end diastolic flow velocity   EDF   waveform result
15092,Main fetal outcomes at 2 years of age
15093,Cause of death
15094,Disability details
15095,Outcomes of Griffiths assessments
15099,Lipoprotein profile in relation to early diet
15100,Regression analyses of lipoprotein profile on human milk intake
15104,Mean peak flow and symptom scores immediately before and during treatment with the study inhalers
15105,Mean peak flow and symptom scores immediately before and during treatment with the study inhalers in individuals taking 1000 g day or less of inhaled corticosteroid   n 162
15106,Total patients recruited and followed up by background drug
15107,Included trials
15109,Day 14 failures categorised as early
15110,Serious adverse effects events: clinical details by study
15117,Compliance with study drug
15118,Primary composite endpoint results for intention to treat and on treatment analyses
15119,Secondary endpointsintention to treat analysis
15120,Bleeding eventsintention to treat analysis
15121,Liver enzyme concentrations
15124,Average use of statin   study or non study   and average plasma LDL cholesterol concentrations during follow up
15125,Average differences in plasma lipid concentrations during follow up in participants with or without diabetes at study entry
15126,Effects of simvastatin allocation on first and all major vascular events in participants with or without diabetes
15128,Outpatient semi rush hyposensitisation regimen
15130,Outcomes of randomised study phase
15131,Sting challenge reaction grade and previous worst reaction grade in the placebo group
15132,Adverse reactions to VIT from randomised and crossover phases
15135,Clinical and parasitological outcomes after 14 days of follow up
15136,Odds ratios of treatment failure at 2 week intervals after each episode of malaria
15139,Numbers of deaths attributed to stroke, ischaemic heart disease   IHD  , other vascular causes, and non vascular causes, by age at risk
15140,Relative ability of different blood pressure indices   measured once only   to predict stroke and ischaemic heart disease   IHD   mortality rates
15143,Status 12 months after start of chemotherapy
15144,Death rates by HIV status and allocated treatment group
15147,Significant regression coefficients   B  , standard errors   SE   and 95  CI from regression of MDI, PDI, cooperation and emotional tone   n 168
15149,Sites of disease progression
15150,Multivariate prognostic factors model
15151,Risk categories
15152,Compliance with study simvastatin   80  taken   and or use of non study statin during follow up
15153,Differences in plasma concentrations of lipids during follow up
15154,Average use of statin   study or non study  , and average plasma LDL cholesterol concentrations, during follow up
15155,Numbers of participants with elevated liver or muscle enzymes during follow up
15156,Self reported difficulty hearing
15157,Results of whispered voice test
15158,Hearing aid ownership in people who failed the whispered voice test
15159,Perceived benefit and level of use of hearing aids in hearing aid owners
15162,Incidence of death or myocardial infarction by allocated treatment
15163,Summary of efficacy results by allocated treatment
15165,Rate of death or myocardial infarction by allocated treatment according to early use of coronary revascularisation
15166,30 day safety endpoints by allocated treatment
15167,Criteria for the three fatigue syndromes
15170,Logistic regression models for the empirically defined fatigue syndrome
15171,Logistic regression models for the Oxford and CDC criteria for CFS
15172,Logistic regression models for mood disorders
15174,Participants  reports of the informed consent process
15175,Participants  and providers  responses to selected questions on the quality of informed consent   QuIC
15176,Correlates of improved knowledge score in cancer clinical trial participants
15178,Incidence rate ratios of squamous cell carcinoma by treatment for patients who used ciclosporin
15179,Incidence rate ratios for squamous cell carcinoma for all cohort patients by time, ciclosporin treatment, and amount of PUVA and methotrexate
15180,Adjusted incident rate ratio      for squamous cell carcinoma associated with ciclosporin treatment by amount of use of PUVA at first ciclosporin use
15182,Interferon treatment
15183,Response rates
15184,Patient details
15185,Postoperative outcome
15188,Adverse events
15190,Local and systemic reactions to both injections
15191,Number of seroconversions
15192,SRH results in relation to CPMP criteria      for the assessment of interpandemic influenza vaccine
15194,Respondent age, sex, experience with negative reactions, and h of clinical work per week by specialty
15195,Doctors experiences with various types of negative reactions from patients or relatives
15196,Logistic regression analysis of the likelihood of having experienced an actual negative reaction   n 869
15197,Action taken by doctors in response to scenarios presented with or without threats
15201,Treatment emergent adverse events attributed to study drug
15202,Treatment limiting adverse events attributed to study drug
15203,Estimates of minimum and maximum efficacy for malaria prophylaxis
15205,Treatment compliance according to treatment group
15206,Risk of adenoma recurrence associated with fibre or calcium treatment
15209,Age, procedure, analgesic type, and nocturnal melatonin AUC for postoperative nights one, two, and three
15210,Main findings and subgroup analyses
15213,Retention rates
15218,Presence of dyspepsia at 2 years according to treatment group
15219,Dyspepsia symptom types at 2 years according to treatment group
15220,Quality of life at 2 years according to treatment group
15221,Expected and reported deaths for the study cohort
15222,Proportional mortality ratios
15224,HLA haplotype, HLA class I expression, and lymphocyte subpopulation from peripheral blood
15226,Relative risks of outcomes
15227,Outcomes for intracranial haemorrhage
15228,Cause of death and associated disorders
15230,Incidence of skin cancers in terms of people treated for skin cancer and tumours treated on the head, neck, arms, and hands by sunscreen treatment group
15231,Incidence of skin cancers on all sites by betacarotene treatment group
15233,Outcomes   number of patients   by treatment group
15235,Mean   SD   antibody concentration to the three viral strains
15236,Repeated measures ANOVA between groups over time by each viral strain
15237,Cumulative probabilities of hospital admission for UTI
15238,Findings on risk of UTI and circumcision
15245,Number of events and incidence rates for three categories of the frontal T axis
15246,Hazard ratios of abnormal and borderline T axis and cardiovascular risk factors for cardiac death, sudden death, non fatal cardiac events, fatal or non fatal cardiac events and total mortality
15247,Hazard ratios for cardiac death of abnormal and borderline T axis and other ECG abnormalities
15248,Study Population legend
15250,Follow up and compliance
15251,Other cancers and events
15252,Univariate analysis of prognostic factors for breast cancer free survival in all 2494 participants
15254,Odds ratios for AMI associated with acute respiratory  tract infection, urinary tract infection, body mass index, and smoking status
15256,Effect of breathing rate on respiratory indices in patients with CHF and controls
15257,Respiratory indices in CHF patients and controls
15259,Laboratory results for 2018BP
15260,Structure of CBT and control programmes
15261,Summary of psychological tests used
15262,Group differences in psychological variables measured by 2 analysis at postcourse and follow up
15263,Job seeking activities
15264,Between group differences in job seeking activities
15265,Job seeking outcomes for CBT and control groups
15266,Distribution of types of AMI by region
15268,Odds ratios for AMI in relation to use of combined OCs by region
15269,Odds ratios for AMI in relation to current use of combined OCs by age, oestrogen dose, and whether blood pressure was checked before current episode of OC use
15270,Odds ratios for AMI in relation to current use of combined OCs according to other risk factors
15271,Odds ratios for AMI associated with current use of combined OCs among low risk women      by reported blood pressure check before current episode of OC use and smoking status
15272,Estimated incidence rates and attributable risks per 106 woman years associated with current OC use by age and smoking status among European women
15274,Cases of cholera requiring inpatient care in vaccine and no vaccine groups, and protective impact of vaccination
15275,Cases of cholera requiring inpatient care among fully vaccinated participants and no vaccine participants, and protective efficacy of vaccination
15276,Visits for treatment of diarrhoea to hospital, polyclinics, and commune health centres   CHCs   in vaccine and no vaccine groups
15277,Age and sex distributions at entry to study
15278,Acceptance of first FOB screening by sex and age
15279,Outcome of screening
15280,Stage of CRC in screening and control groups
15281,CRC incidence and mortality rates and mortality ratios in screening and control groups
15282,Patients with adenomas in screening and control groups
15283,Age and sex of participants at initial screening
15284,Compliance during repeated screening
15285,Screening group individuals who underwent further investigations after a positive FOB test and predictive value of a positive test for neoplasia
15286,Stage of CRC and presence of large adenomas in screening and control groups between August, 1985, and August, 1995
15287,Causes of death in screening and control groups between August, 1985, and August, 1995
15288,Incidence and mortality rates for CRC between August, 1985, and August, 1995
15289,5 year risk of death definitely or probably due to CHD or non fatal MI in WOSCOPS placebo group men
15290,Benefits of treatment in WOSCOPS, 4S, and MRC trial
15292,Frequency of symptoms of chronic bronchitis by smoking status and sex
15293,Risk ratios for first coronary event and coronary death associated with symptoms of chronic bronchitis, adjusted for age and study year   model 1  , for age, study year, and amount of smoking        model 2  , and multifactorially adjusted       model 3
15294,Risk ratios for first coronary event and coronary death associated with symptoms of chronic bronchitis stratified by smoking status   13 year follow up, multifactorially adjusted
15295,Risk ratios for first coronary event and coronary death associated with symptoms of chronic bronchitis stratified by occupation   13 year follow up, multifactorially adjusted
15297,HIV related minor clinical events by treatment group
15299,Hazard ratios for major cardiovascular outcomes in current drinkers, without and with adjustment for usual levels of systolic blood pressure, high density lipoprotein cholesterol, or body mass index
15302,Clinical primary and secondary outcomes at 18 months
15304,Physical activity by country income level
15305,Summary of fatal and non fatal events by physical activity
15306,Summary of risk of mortality and major CVD events stratified by country income level and physical activity
15308,Safety events by achieved LDL cholesterol concentration at 4 weeks after randomisation
15309,Stillbirth rate, neonatal, postneonatal, child, and under5 mortality rates, number of stillbirths, and total number of under5 deaths in 2016 and annualised rate of change in under5 mortality for 200016, for global, SDI groups, GBD regions and superregions, countries, and territories, both sexes combined
15312,Univariate and multivariate analysis of neural tissue activity vs cardiovascular disease events
15313,Subgroup analyses of amygdalar activity vs cardiovascular disease
15314,Analysis of neural tissue activity vs eventsadditional event definitions
15316,Correlation of amygdalar activity with haemopoietic activity and arterial inflammation
15318,Platelet reactivity and antiplatelet therapy
15319,Endpoints at 12 month follow up
15321,Electrocardiographic Findings of Affected Patients
15322,Echocardiography and Right Ventricular Cineangiography legend
15323,Histological Findings of Endomyocardial Biopsy Samples legend
15324,Direct, indirect, and total costs attributable to physical inactivity, by country and WHO region   in 1000 Int , 2013
15325,Multipoint LOD Score   LOD   at Theta   0 and Two Point LOD Scores for Different Recombination Fractions for Eight Different Markers of the Chromosome 1q42q43
15326,Direct health care costs attributable to physical inactivity paid by the public sector, private sector, and households, by country and WHO region   in 1000 Int , 2013
15328,Comparison of mean direct and indirect costs of physical inactivity and lifetime disease burden   measured by disability adjusted life years, DALYs   by country income group   2013
15329,Meta regression analysis of the association between total Teenage Pregnancy Strategy funding per head and absolute and percentage change in the conception rate in women younger than 18 years between 199498 and 200913
15331,Current participation of women aged 1824 years in England by experience of early motherhood   199091, 19992001, and 201012
15332,Estimated abortion rates per 1000 women 1544 years old, by geographic area and time period
15333,Estimated annual numbers of abortions   in millions   by geographic area and time period
15334,Percent of pregnancies ending in abortion, by geographical area and time period
15335,Abortion rate per 1000 women aged 1544, by grounds under which abortion is legally allowed, 201014
15336,Abortion rates per 1000 women aged 1544 years in groups of women defined by marital status, 201014
15338,Peri procedural and post procedural risks for CEA and CAS treatment, by age group
15341,Descriptions of individual serious allergic reactions
15342,Efficacy endpoints
15343,Bleeding endpoints
15345,Association between alcohol consumption and outcomes
15347,Risk of composite primary and secondary endpoints and components by history of heart failure at baseline
15348,Risk of composite prespecified exploratory endpoint and first occurrence of components
15351,Intention to treat analysis of cumulative risks and hazard ratios of main outcome events
15352,Per protocol analysis of cumulative risks and hazard ratios of main outcome events
15353,Past severe nuclear accidents   International Nuclear and Radiological Event Scale level 5 or higher
15354,Irradiation dose and number of workers involved with the emergency and recovery operations at Fukushima Daiichi nuclear power plant   March 11, 2011, to Aug 31, 2013
15357,Study outcomes by selected LARC method
15361,Intervention summary
15363,Deaths and serious complications at 3 months
15367,Changes in Heart Rate and Blood Pressure After Albuterol and Glyceryl Trinitrate in Patients With Type II Diabetes Mellitus and Control Subjects legend
15369,Patient safety
15370,Patient experience of care, overall satisfaction, health status, and problem resolution, by group
15372,Propensity score matched survival models by timepoints up to 8 years by outcome
15373,Crude and matched logistic models for complications
15374,Reasons for revision in unicompartmental knee replacement   UKR   and total knee replacement   TKR; matched analysis, revisions recorded in NJR only
15375,Type of revision operation   matched analysis, revisions recorded in NJR
15377,Study treatments in the safety population
15379,Kaplan Meier estimates for effects of losmapimod on major adverse cardiac events in the safety population
15380,Effect of losmapimod on laboratory endpoints in the efficacy population
15383,Use of antiplatelet drugs during trial
15384,Study endpoints during follow up
15385,Mediators analysed by participating cohorts in the main analysis
15386,Number of analysed cohorts, participants, and events by region
15387,HRs and excess risk of overweight and obesity mediated through different combinations of metabolic risk factors
15389,Age adjusted annual incidence and mortality rates   per 100000 person years  , disability adjusted life years   DALYs   lost, prevalence   per 100000 people  , and mortality to incidence ratio   MIR   by age groups in high income and low income and middle income countries, and globally in 1990, 2005, and 2010
15390,Mean age of incident stroke in 1990, 2005, and 2010 by country income level
15392,Outcomes at 12 month follow up
15393,Treatment process
15396,Primary outcomes, adjusted scores, differences, p values, and ICC according to questionnaire
15399,Efficacy of prasugrel versus clopidogrel by angiographic status
15400,Ischaemic events
15401,Safety outcomes
15402,Study outcomes at 5 years follow up, by baseline SYNTAX score tercile
15403,Study outcomes at 5 years follow up in patients in the PCI only and CABG only registries
15405,Effects of allocation   continue tamoxifen to 10 years vs stop at 5 years   on mortality with and without previous recurrence in each category of ER status at entry, and on various outcomes without previous recurrence in all women of any ER status
15406,Event rate ratios   95  CIs   in ER positive disease, by time period from diagnosis
15408,Suboutcomes of treatment failure for ciclosporin and infliximab
15409,Severe adverse events during the study period according to treatment received
15410,SMR by causes of death according to ICD 10 groups
15411,SMRs for external and all underlying causes of death in the study sample by socioeconomic deprivation category on the basis of the IMD 2007 for the postcode of the location of the most recent episode of self harm
15413,Population projections   201050  , by region, UN medium variant
15415,Efficacy endpoints at 3 years
15416,Safety and combined endpoints at 3 years
15417,Sex ratio at birth, conditional on sex of previous birth   99  CIs   by birth order from 19901997
15418,Sex ratio at birth, conditional on sex of previous birth   99  CIs   by birth order from 19982005
15419,Estimates of annual gaps in girls to boys at ages 06 years due to selective abortion of female fetuses, in millions by birth year
15420,Estimates of decennial gaps in girls to boys at ages 06 years due to selective abortion of female fetuses, in millions
15421,Coverage of indicators for reproductive, maternal, and child health from national surveys
15422,Prevalence of selected risk factors for chronic diseases
15423,Intervention strategies categorised by level of health system and cost effectiveness
15424,National policies for chronic diseases and injuries in India
15425,Mental health status of Afghan 1116 year old students and caregivers
15426,Variables associated with child mental health outcomes
15427,Interaction of social labour market protections with the effect of unemployment on suicide rates   in people younger than 64 years  , 19802003
15428,Associations of a 1  rise in alternative economic measures with percentage change in death rates in European Union countries, 19702007
15429,Data sources used for estimating fire related deaths in India in 2001
15430,Estimates of fire related deaths in India in 2001
15431,Ratios of females to males in national estimates of fire related deaths
15432,Ratios of females to males in local studies of fire related deaths
15434,Association of spousal violence with early and late fetal loss
15435,Preventive fractions at different levels of effectiveness of spousal abuse intervention
15436,Relation between violence, violence subtype, and recurrent fetal loss
15441,Intracerebral haemorrhages detected by CT MR study at 2236 h and at any imaging scans after treatment
15443,Global and regional estimated numbers of induced abortion and abortion rates, 2003 and 1995
15444,Estimated number of safe and unsafe induced abortions and abortion rates by region and subregion, 2003
15445,Global, regional, and subregional estimated abortion ratios and percentages of pregnancies that ended in abortion, 2003
15447,Incidence of asthma and occupation
15448,Occupations and exposures      at high risk of asthma
15449,New onset asthma and inhalation events
15451,Status of patients 2 years after admission to hospital
15452,Associations between type of service
15454,Intracerebral haemorrhages detected by CT or MRI study at 2236 h after treatment and any post treatment imaging scans
15457,2 day, 7 day, and 90 day risk of stroke by California score
15458,2 day, 7 day, and 90 day risk of stroke by ABCD score.
15459,2 day, 7 day, and 90 day risk of stroke by ABCD2 score
15460,Predictors from multivariable models of stroke at 2 days, 7 days, and 90 days after TIA in the six groups combined
15461,Leading 15 causes of death and numbers of deaths by age group for both sexes in WHO European Region, 2002  4
15462,Standardised injury mortality rates and rate ratios comparing low and middle income countries   LMIC   with high income countries   HIC   in the WHO European Region, 2002  4,10
15466,Pregnancy intendedness instrument  4
15468,Association between mean age   years   and intendedness
15469,Trends in maternal age, gestational stage, and pregnancy intendedness among women using emergency contraception
15470,Relative risk for 1 mmol L increase in FPG, by age group   after adjustment for confounding and regression dilution bias
15471,Age standardised mean   SD   of FPG   mmol L   by sex and region
15472,Number   thousands   and proportion of deaths attributable to higher than optimum FPG by World Bank region, age group   years  , and sex for ischaemic heart disease and stroke
15473,Sensitivity of estimated attributable mortality to choice of exposure variable, data sources on relative risk, and TMRED
15474,Inclusion and exclusion criteria
15476,Outcome events up to 30 days after treatment
15477,Primary endpoint results in predefined subgroup
15480,Occurrence of first outcome events, according to treatment
15482,Quantitative Coronary Angiography Variables in 20 Patients Before and After Standard Balloon Angioplasty, After IVUS Guided Balloon Angioplasty and After Stent Implantation legend
15483,Intravascular Ultrasound Variables After Standard Balloon Angioplasty, After IVUS Guided Balloon Angioplasty and After Stent Implantation legend
15487,Cerebrovascular and common clinical features in young adult patients with cryptogenic stroke with and without Fabry disease
15489,7 day risk of stroke after presenting TIA in relation to potential risk factors
15490,7 day risk of stroke stratified according to ABCD score at first assessment in the OXVASC validation cohort of patients with probable or definite TIA
15491,Multivariate Cox regression analysis of predictors of 7 day risk of stroke in patients with probable or definite TIA derived from the pooled data   stratified by study   from OCSP and OXVASC
15492,7 day risk of stroke stratified according to ABCD score at first assessment in all referrals with suspected TIA to OXVASC and risk of stroke before scheduled clinic appointment in all referrals with suspected TIA to the non OXVASC hospital referred weekly TIA clinic
15494,Incidence rates per 100000 population of first ever stroke, by age and sex
15495,Age specific and sex specific incidence rates per 100000 of first ever stroke, by pathological subtype
15496,Frequency, incidence, and case fatality rate of first ever infarction, by subtype
15497,Case fatality rates of incident stroke, by pathological subtype
15499,Prognosis at 6 months after first ever stroke, by sex and age group
15500,Outcome at 6 months after first ever stroke, by pathological and infarction subtype
15501,Causes of death after stroke
15502,Age standardised annual incidence   95  CI   per 1000 strokes, by pathological subtypes, in Iquique Chile and other population based studies
15503,Weighted mean difference in plasma homocysteine concentrations according to the MTHFR C677T genotype   TT vs CC   among people without cardiovascular disease
15504,Assessment of consistency between odds ratios derived by extrapolation from phenotypedisease studies and those derived from meta analysis of genetic studies
15505,Chemotherapy and surgical requirements of the 15 patients who did not have histology at the time of pregnancy termination
15506,Comparison of surgical and chemotherapeutic interventions needed in patients who did and did not have histology at the time of pregnancy termination
15508,Primary endpoint analysis
15509,Frequency of secondary endpoint events
15510,Number       of patients with bleeding events
15511,Age and sex structure of the study populations and crude incidence per 1000 population of first ever stroke
15512,Standardised      overall incidence per 1000 per year   95  CI   of first stroke in OCSP and OXVASC stratified by sex, age, pathological type, and degree of disability at follow up 30 days after stroke
15513,Overall incidence of transient ischaemic attack in OXVASC and OCSP by sex and age
15516,Description of studies included in analyses of the risk of breast cancer after abortion
15517,Stimulation type, peak oestradiol concentration, and follicle sizes on day of human chorionic gonadotropin administration, and oocyte retrieval outcome from ovarian transplant
15519,Frequency of parenchymal haematoma between 0 and 360 min after treatment
15521,Cause of death
15522,Number of patients having a serious adverse event within 48 h of trial entry
15523,Data used in base case analysis
15524,Quality adjusted life years, cost, and incremental cost utility ratios by age
15526,Miscarriage cohort, group according to the date of sample collection relative to diagnostic ultrasound
15528,Overall mortality in carriers of haemophilia
15529,Cause specific mortality in carriers of haemophilia
15531,Relative reduction in crash risk associated with a conviction
15533,Frequency     of total per period   of accidents per half hour for each work period and relative risks for all periods combined
15535,Risks death and stroke or death within 30 days surgery in patients who underwent trial surgery by degree symptomatic carotid stenosis
15536,Pregnancies included in the study
15537,Adjusted relative risks of fetal death according to fever in pregnancy week 116
15539,Mortality rates for accidents at work in UK fishing and seafaring, all workers, and workers in five main industrial sectors, in Great Britain
15540,Proportion of boys born to individuals exposed and unexposed to dioxins, 198099
15541,Risk of death and severe injury for drivers and front seat passengers by front and rear seatbelt use
15542,Risk of death and severe injury for belted drivers and front seat passengers by rear seatbelt use and by mode of car crash
15543,Frequency of thyroid cancer in the Gomel region of Belarus   19982000
15544,Age, use of contraception, and sexual competence at first intercourse; parenthood and abortion before age 18 years
15545,Prevalence and adjusted odds ratios for first intercourse before 16 years, non use of contraception, and sexual noncompetence at first intercourse   1624 year olds
15546,Prevalence of contextual factors surrounding first intercourse, 1624 year olds
15547,Prevalence and adjusted ORs for motherhood and abortion before 18 years and for even having had an STI   1824 year olds  , among women who had first intercourse before 18 years
15548,Prevalence and adjusted odds ratios for ever having had an STI   1824 years olds  , among men who had first intercourse before 18 years
15549,Contraceptive use and unmet need by area, 1984 and 1990
15553,Logistic regression model of stroke recovery for Boston patients
15554,Illustration of the logistic regression model for the original Boston patients and its application to Australian patients for the allotted categories
15555,A three item scale for the prediction of stroke recovery shortly after admission
15556,Observed   of patients with stroke recovery across three probability ranges of the logistic regression model and three levels of the three item scale
15558,Risk and duration of HPV infection and risk of high grade CIN according to HPV type
15559,Risk of moderate or severe dyskaryosis in relation to time from first HPV exposure
15560,Risk of high grade CIN in relation to time since first exposure to HPV 16
15562,Rates of perioperative   30 day   stroke and death by age category in 1415 patients who actually underwent carotid endarterectomy
15563,Absolute reduction in risk of ipsilateral ischaemic stroke and number needed to treat at 2 years according to degree of stenosis and age category
15564,Kaplan Meier risk estimates of cause of death at 2years according to age category
15565,Age standardised death rates per 100000 at age 1524 years for selected causes of death
15566,Age standardised death rates per 100000 at age 1574 years for selected causes of death
15570,Secondary endpoints for patients with ischaemic stroke
15571,Secondary endpoints for all treated patients
15572,Adverse events occurring up to 7 days after treatment or before hospital discharge in all treated patients
15574,Assessment of agreement between observers
15575,Source of information about deaths resulting from intentional and unintentional injuries in Bangladesh
15577,Reported causes and numbers of intentional and unintentional injury related deaths
15578,Reported causes of intentional and unintentional injury related deaths by age group
15580,Women s ability to estimate pregnancy duration and differences between women s and providers  estimates
15581,Microsatellite polymorphisms identified after PCR, gel electrophoresis, and GeneScan analysis
15584,Clinically important errors in junior doctors  and nurse practitioners  assessments of patients
15585,Radiographic requests compared with judgment of research registrar and interpretation compared with radiologist s report
15586,Outcome of patients at 28 days
15587,Unplanned follow up visits reported by patients at 28 days
15589,Clinical predictors of M tuberculosis bacteraemia in febrile hospital inpatients
15590,Therapy and diagnostic testing on or before the day of admission
15591,Antimicrobial resistance among M tuberculosis isolates from blood
15592,Validity of checklist
15594,Study outcomes by treatment group
15595,Developmental stages and abnormalities in failed pregnancies
15598,Main outcomes after surgery
15599,Results for secondary outcomes and wound pain
15602,Comparison Between Patients With Normal and Increased PVR legend
15603,Odds ratios for developing antibodies to thyroid by age, sex, and radiation exposure
15604,Mean   SD   serum free T4, free T3, and TSH
15606,Pregnancy outcome for the 4374 randomised women
15607,Estimated gestational age at first amniocentesis attempt based on crown rump length   mm
15608,Procedure analysis
15609,Congenital anomalies   reported at birth
15610,Developmental and background variables and risk of death during follow up
15611,Independence of risk factors for   sub  intentional self destruction
15612,Association of vaginal flora morphology and prevalence of HIV 1
15613,HIV 1 prevalence associated with vaginal flora morphology and numbers of sexual partners in previous year
15614,HIV prevalence associated with bacterial vaginosis in women with concurrent STDs
15615,Classification of causes of death
15616,Life expectancy at birth in Russia by sex and year  1
15617,Age standardised   to European population   mortality rates per 106 for Russia by sex, year, and cause
15618,Mortality in 1987 and relative changes in mortality 198494 by cause and sex at age 4044 years in Russia
15620,Adjusted relative risk of death according to reproductive status after diagnosis of breast cancer, age at
15622,Main clinical events in hospital during scheduled   4 week   treatment period by allocated treatment
15623,Functional status at discharge
15625,Main outcome events within 14 days
15627,Effect of heparin and aspirin on recurrent stroke within 14 days among patients with and without atrial fibrillation
15628,Direct randomised comparison of effects of subcutaneous heparin 12500 and 5000 IU twice daily
15629,Absolute benefits observed in the IST of low dose heparin or aspirin compared with control
15630,Summary of study data
15631,Relations of skull fracture shown on radiography and presence of neurological abnormalities to CT defined intracranial abnormality
15633,Neuroexcitatory aminoacids in plasma and CSF samples
15634,Multiple logistic regression analysis of progressing ischaemic stroke with plasma concentrations of excitatory aminoacids as covariates
15635,Multiple logistic regression analysis of progressing ischaemic stroke with CSF concentrations of excitatory aminoacids as covariates
15636,VEE virus strains characterised genetically and or antigenically
15637,Distribution of location and direction of spinal curve
15638,Potential risk factors for progression in relation to final magnitude of the curve in 30 patients followed up after age 20 years
15639,Nucleotide and aminoacid sequence homologies of the gene segments of HK97 and CkHK97
15641,Plasma Levels of CRP and SAA and Serum Levels of IL 6 During the Study Period legend
15645,Hispanic Enrollment by Region
15647,Socioeconomic Information from GUSTO III legend
15648,Time to Treatment
15649,Use of Cardiac Medications legend
15651,Major Clinical Outcomes
15652,Outcomes by Thrombolytic Treatment
15654,ART received
15655,Incidence of measles in 32 participating European countries   200607
15656,Measles cases with known vaccination status   200607
15660,Statistical association of risk variables with mortality
15661,AUC of ROC of deceleration capacity   DC  , acceleration capacity   AC  , LVEF, and SDNN, as well as of combinations of DC and LVEF, AC and LVEF, and SDNN and LVEF, by cohort
15662,Association of risk variables with total mortality in a multivariate analysis
15663,Sensitivity and positive predictive accuracy of high risk groups
15664,Clinical and serological features of Rickettsia sibirica infection in affected paleontologists
15665,Coverage achieved during measles catch up vaccination campaigns and routine vaccination
15666,Results of measles case based surveillance, southern Africa, 2000
15667,Timing of follow up measles vaccination campaigns, southern Africa, 200002
15668,Rotashield administration, and number and excess infant intussusception admissions during the Rotashield period in ten US states, 199399
15669,Summary data on excess hospital admissions for intussusception and population attributable risk estimates, for infants 45210 days old
15671,Cause of death
15672,Risk factors for death
15673,Logistic regression analysis to predict death
15674,Risk factors for coronary events
15675,Clinical, Hormonal and Metabolic Details of the Subjects in the Study   Mean  SE   legend legend
15676,Similarities and Differences Between Cardiac and Metabolic Syndrome X legend
15678,mRNA expression in various human tissues
15679,Quantification of verapamil metabolites in microsomal ventricular tissue
15680,Details of primers used to amplify rickettsial genes
15681,Details of PCR cycles used to amplify rickettsial genes
15682,Median   in elapsed months of age   for age at diagnosis, age at parental concern, and age at regression, and intervals between these, according to diagnostic category
15683,Relative incidence and numbers of events in risk periods after vaccination with one or more MMR vaccine or one or more MMR, single antigen measles and mumps plus rubella vaccines, by event type in children with core or atypical autism
15685,Estimates of the mean difference in KI score between each S21400 group and the placebo group
15686,Linear and multiple regression analysis of severity of nephrotoxicity on potential risk factors
15690,Clinical outcomes
15691,Adverse events   number of patients   and safety outcomes
15694,Adverse events and laboratory results
15696,Treatment adherence and follow up
15697,Per protocol analysis
15698,Intention to treat analysis
15700,Glycaemic control in each treatment group
15702,Procedures and study drugs
15703,Clinical outcomes at 90 days
15706,Adverse events
15708,Adverse events in cardiac stem cell treated and control patients
15709,Pulmonary embolism severity index
15712,Effectiveness and safety outcomes
15713,Medical resources used by treatment group
15715,Overdose mortality rate in Vancouver between Jan 1, 2001, and Dec 31, 2005   n 290  , stratified by proximity to the SIF
15716,Effectiveness and cost input variables used in the analysis
15717,Incremental health outcomes, costs, and cost effectiveness of prereferral artesunate treatment for a cohort of 1000 children younger than 5 years living in a stable endemic area during 5 years
15722,Study drug, cardiac drugs, and procedures
15723,Efficacy outcomes up to 7 days
15724,Safety outcomes up to 7 days
15726,Effects of trial treatment on early and later mortality and on permanent disability in Africa   three study sites  , Asia   one study site  , and all four study sites
15727,Effects of trial treatment   artesunate or placebo   on death or permanent disability, subdivided by study site and time taken to reach clinic
15728,Non comatose patients only: effects of trial treatment   artesunate or placebo   on death or permanent disability, subdivided by time taken to reach clinic
15729,Standard treatments of children with pneumonia in hospitals in Papua New Guinea
15730,Risk of mortality for children with pneumonia in Papua New Guinea in the five study hospitals
15731,Costs of the improved oxygen system
15733,Birthweight and gestational age of singletons in the general population and of consecutive singleton siblings conceived spontaneously and after assisted fertilisation
15734,Risk of adverse outcomes in singletons in the general population and in consecutive singleton siblings conceived spontaneously and after assisted fertilisation
15735,Risk of adverse outcomes in singletons after in vitro fertilisation and intracytoplasmic sperm injection
15737,Clinical responses at week 12 and week 28 as reported by physicians and patients
15738,Adverse events during the three phases of the trial
15744,Plasma Glucose and Insulin Levels and Serum Levels of Lipids, HDL C, and Apolipoproteins in 54 Pairs of Cases and Controls legend
15746,Associations Among HOMA Insulin Resistance, HDL C and CHD Before and After Adjusting for Concomitant Variation in Serum Lipids and Conventional Risk Factors: Multivariate Conditional Logistic Analysis of 54 Case Control Pairs legend
15747,Comparison of the Association Among Hyperinsulinemia, Hypoalphalipoproteinemia and CHD With the Association Between Hyperinsulinemic Hypoalphalipoproteinemia and CHD by a Conditional Logistic Regression Analysis of 54 Case Control Pairs
15748,Stepwise Conditional Logistic Regression Analysis of Variables Associated with CHD and Conventional Risk Factors
15750,Adverse events
15752,Study design and comparison of protocols 007, 013, and 015
15754,Number of individuals included in the efficacy analyses and reasons for exclusion from the indicated efficacy analysis populations
15755,Vaccine efficacy in preventing high grade vulval and vaginal lesions associated with HPV16 or HPV18, and all high grade vulval and vaginal lesions   irrespective of cause
15760,Susceptibility of Candida spp isolates from patients in the micafungin group who had recurrence of infection during follow up in the per protocol population
15761,Summary of adverse events and changes in laboratory values in the intention to treat population
15763,Severe and mild asthma exacerbations in patients using maintenance budesonideformoterol plus alternative reliever medications
15764,Changes from run in in symptom control and lung function in patients using maintenance budesonide formoterol plus alternative reliever medications
15765,Adverse events reported as asthma and pharmacologically predictable adverse events
15767,Primary clinical outcomes for liveborn infants, assessed before hospital discharge
15768,Measures of infant growth for liveborns at birth and at discharge from hospital
15769,Neonatal morbidity for liveborn babies in the first hospital stay
15770,Side effects at time of trial injection and maternal outcomes
15771,Multivariate logistic regression of factors associated with syringe sharing
15779,Observed and population based expected drug related deaths in health board areas for 2000 and 2001
15780,Observed and expected drug related deaths for each sex in 2001
15781,Observed and expected drug related deaths by age group for 2001
15782,Case reports of non cardiogenic pulmonary oedema after intravenous radiographic contrast
15785,Outcome measures
15786,Bacteria and antibiotic sensitivities from blood culture and lung aspirate isolates
15787,Summary of all previously published European data on CAG repeat numbers among infertile men and controls
15790,Details of treatment cycles
15791,Outcome of treatment
15792,Number of years between last HIV negative and first HIV positive test result
15793,Number of controls matched per case
15794,Risk factors assessed at first follow up interview after positive HIV antibody test result and corresponding control interview
15796,Risk factors for HIV seroconversion in multivariate analysis
15798,Comparison between diseases for degree of pain, treatment by specialist, desire for additional therapy, and reasons why additional therapy was not sought
15799,Extent of pain, degree of treatment, and type of care provider
15800,Assessment of vascular occlusive disease with DSA in six patients   121 vessel segments
15801,Assessment of vascular occlusive disease with MRA by two readers in six patients   180 vessel segments
15802,Number of assessable segments in 31 patients
15803,Reasons for non assessability of vessel segments
15804,Diagnostic accuracy of MSCT coronary angiography to detect stenoses of  50  diameter
15806,Follow up status of vaccine groups in trial resurveys
15807,Frequency of visceral leishmaniasis overall and by village
15808,Frequency of visceral leishmaniasis by vaccine group, age, and sex
15809,Rates of conversion on leishmanin skin test at follow up visits
15810,Frequency of visceral leishmaniasis in relation to leishmanin response   induration size   at first follow up visit   42 days
15812,Details of surgery
15813,Clinical outcomes at 1 week after operation
15814,Patients  return to usual activities at 3 months   for those in whom it is relevant
15815,Outcomes at 1 year after operation
15818,Clinical and subclinical measles after exposure by age at exposure and vaccination status
15819,Clinical and subclinical measles after exposure by titre of measles haemagglutinin inhibiting antibody at exposure and vaccination status
15820,Clinical and subclinical measles after exposure by intensity of exposure and vaccination status
15821,Geometric mean antibody titres at exposure and 1 month and 6 months after exposure for children with clinical measles, subclinical measles, and no measles
15823,Grey values within total echocardiographic sector
15824,Absolute and relative average endocardial grey value
15825,Absolute and relative average myocardial grey value
15829,Side effects and results of leishmanin skin test following vaccination
15830,Cases of leishmaniasis in vaccine groups by time since vaccination
15831,Prophylactic efficacy of a single dose of ALM BCG compared with BCG alone against cutaneous leishmaniasis
15833,Side effects
15834,Findings of US government funded studies of efficacy of needle exchange programmes
15836,Side effects reported as possibly or probably due to study drug administration
15839,Recent HIV seroincidence studies among injecting drug users in New York City area
15840,Proportional hazards regression for HIV incidence in pooled sample   n 1630, 45 seroconverters
15841,HIV incidence hazard ratios for non use versus continuing use of syringe exchange
15844,Study outcomes by treatment group
15845,Health related quality of life by treatment groups without interaction of displacement
15846,Medically related adverse events
15849,Nomenclature for suicidal and related behaviours and suicidal ideation
15850,Thematic sentences derived from meta synthesis of studies assessing psychological effect of stillbirth on parents and on health care professionals.
15854,Antenatal corticosteroid use and delivery care by intervention group
15855,Perinatal and 28 day neonatal outcomes by intervention group
15856,Prevalence, incidence, and sex differences   when reported   for major depressive disorder from large population cohort studies of adolescents by age   years
15858,Examples of global public health goals and the contribution of adolescence
15860,Primary and secondary outcomes for the intention to treat population
15861,Other outcomes of the intention to treat population
15863,Disease activity in cohort with inflammatory bowel disease
15864,Risks of venous thromboembolism by activity of inflammatory bowel disease and hospitalisation
15866,Descriptive data for patients with venous thromboembolism and their population control cohorts
15867,Relative risks of arterial cardiovascular disease during follow up in patients with venous thrombosis or pulmonary embolism, and in population controls
15868,Risks of arterial cardiovascular disease in patients with unprovoked venous thrombosis or pulmonary embolism, and in population controls
15869,Relative risks of arterial cardiovascular disease in patients with provoked venous thrombosis or pulmonary embolism, and in population controls
15875,12 month service use by sectors in the WMH surveys
15876,12 month service use by severity of mental disorders in the WMH surveys
15877,Mental health specialty sector use for respondents using any services in the WMH surveys
15878,Follow up treatment for respondents using services in the WMH surveys
15879,Minimally adequate treatment use for respondents using services in the WMH surveys
15881,Methodological quality of eligible studies
15882,Subgroup analyses
15885,Comparison of GFR, height, and mean growth velocity the CAD and LRD groups over 5 years
15886,Multivariance analysis between HSDS at years 15 after transplantation, GFR at time of transplantation   Tx  , and LRD versus CAD recipients   p 004 for overall analysis
15887,Covariance analyses
15892,Asbestos exposure by case control status
15893,Occupations associated with 10 fibre years of asbestos exposure among the RPF cases and the controls
15894,Adjusted odds ratios for potential risk factors for retroperitoneal fibrosis
15896,ERT use in cases and control diagnostic groups
15897,Odds ratio of VTE in relation to ERT use
15898,Odds ratio of VTE by duration of current episode of use, oestrogen dose, and ERT regimen
15903,SF 36 outcomes according to treatment group and follow up assessments
15905,Talairach coordinates and Brodmann s areas for regions of reduced grey matter volume in people in the cross sectional comparison who developed psychosis
15908,Deaths possibly or certainly related to pulmonary embolism
15909,Venous thromboembolic events during 3 month follow up in untreated patients with low or intermediate clinical probability and negative findings on spiral CT and leg venous compression ultrasonography
15910,3 month thromboembolic risk of untreated patients in whom PE was excluded on the basis of various diagnostic strategies
15913,Description of studies included in the final sample
15914,Aggregate effect sizes and 95  CIs for type of intervention and symptom group
15915,Effects of interventions on post traumatic stress disorder   PTSD   and other symptoms
15917,Interobserver variation between two observers for magnetic resonance angiography
15918,Results of magnetic resonance angiography versus digital subtraction angiography
15919,Sensitivity of magnetic resonance angiography   MRA   in the diagnosis of pulmonary embolism as a function of size of emboli
15921,ICD10 diagnoses for 15 people with Prader Willi syndrome who had a detailed psychiatric assessment
15922,Respiratory and haemodynamic variables during and after treatment with O nitrosoethanol gas   ENO
15923,Risk factors for relapse or reinfection in 326 patients   univariate analysis
15924,Adjusted hazard ratios for risk factors for relapse or reinfection in 326 patients
15925,Unadjusted and adjusted hazard ratios according to HIV 1 status for riskfactors for recurrent tuberculosis in 326 patients
15929,Growth velocity, predicted adult height, testis volume, and pubertal stage during follow up
15930,Serum IGF I and IGFBP3 concentrations during follow up
15932,Estimated effect of CBT compared with support groups and natural course on fatigue severity   CIS   and functional impairment   SIP
15933,Estimated effect of CBT compared with support groups and natural course on secondary endpoints
15934,Clinically significant improvement in the treatment groups for fatigue severity, Karnofsky performance status, and self rated improvement
15937,Frequency and adjusted odds ratio of congenital malformations according to different exposure
15938,Frequency and adjusted odds ratio of congenital malformations according to exposure, types of life events
15939,Frequency and adjusted odds ratio of groups of congenital malformations according to time of exposure to death of a child and whether the death was expected
15940,Current use of combined oral contraceptives
15946,Frequency of serious psychiatric disorder and substance dependence
15947,Comparison of defendants with serious psychiatric disorders referred and not referred to court diversion programme
15949,Protocols for lung and nasal components of trial
15950,Estimates of prevalence of   inherited   thrombophilic defects in patients with confirmed deep vein thrombosis and in general population
15951,Symptomatic venous thrombotic events during 36 months  follow up
15952,Meta analysis of 13 randomised trials comparing LMWH with unfractionated heparin in initial treatment of venous thromboembolism
15954,Diagnostic yield of D dimer measurement and lower limb venous compression ultrasonography in patients with suspected venous thromboembolism, DVT, or PE
15955,Accuracy of empirical clinical probability assessment
15956,3 month thromboembolic risk in patients in whom venous thromboembolism was ruled out by diagnostic stragegy
15957,Tests necessary to reach definitive diagnosis in various stragegies for venous thromboembolism
15960,Clinical and Angiographic Features and In Hospital Clinical Course in Patients Who Developed an Early Adverse Event legend
15961,Clinical Events at One Year Follow Up legend
15962,Logistic Regression Analysis for Early Adverse Events legend
15963,Logistic Regression Analysis for Clinical Restenosis at One Year Follow Up legend
15964,Social class gradient in poor health      at ages 23 years and 33 years
15965,Odds ratios for poor health      at age 23 years  9   and 33 years   in classes IV and V versus I and II
15967,Poor health      at age 33   classes IV and V vs I and II  , adjusted     for child, adolescent, and early adulthood factors
15969,Risk of death after transplantation relative to continued waiting
15970,Background details of patients
15973,Mean scores on satisfaction scale at 3 and 9 months
15974,Randomised trials of amiodarone after MI and in CHF
15976,Mortality summary
15977,Subgroup analyses for total mortality
15978,Subgroup analyses for arrhythmic sudden death
15979,Major adverse experiences associated with early permanent drug discontinuation in placebo controlled trials
15980,Age adjusted odds ratios of new reports of CHD according to employment grade in the Civil Service
15982,Age adjusted odds ratios of new reports of CHD at phase 2 or 3 by sex specific quartiles of height, unadjusted and adjusted for employment grade at phase 1
15984,Age specific incidence rates of primary PE, 197692
15985,Risk of primary PE by postmenopausal hormone use among postmenopausal women and OC use by whole cohort
15987,Rate of venogram proven DVT
15988,Adverse events and laboratory data
15989,Anthropometric and endocrine data of 16 short children at start of treatment with r hGH compared with 7 short untreated children
15990,Changes in blood glucose and serum insulin after oral glucose tolerance test during treatment with r hGH
15992,Primary and secondary outcomes
15993,Intervention effect modification by prespecified subgroup
15994,Methods of self harm   fatal and non fatal   other than self poisoning in individuals aged 14 years or older
15995,Descriptive cataloguing of the epidemiological evidence used to assess whether each risk outcome paper meets the causal criteria for inclusion in the Global Burden of Disease Study 2016 by risk level
15996,GBD 2016 risk factor hierarchy and accompanying exposure definitions, theoretical minimum risk exposure level, and data representativeness index for each risk factor, pre 2006, 200616, and total   across all years
15997,Global age standardised SEVs for all risk factors, 1990, 2006, and 2016, with mean percent change for three time periods, between 1990 and 2006, 2006 and 2016, and 1990 and 2016, by risk level
15998,Global all age attributable deaths and DALYs, in 2006 and 2016, and percentage change of deaths, age standardised death rates, DALYs, and age standardised DALY rates between 2006 and 2016, for all risk outcome pairs, both sexes combined
16000,Incidence rate and incidence rate ratio of severe pneumonia defined according to IMCI criteria, oxygen saturation less than 90 , or death
16001,Meals cooked using intervention cookstoves at 3, 12, and 24 month follow up visits
16002,Incidence rate and incidence rate ratio of serious adverse events excluding pneumonia
16004,Descriptive statistics by country
16005,Attributable mortality by country
16006,Tobacco control policies at national and local level in China published by government bodies, 200814
16007,Complications, treatment, and clinical outcome of the patient
16008,Clinical blood biochemistry tests
16009,Mutations in AH 1 and JX346 viruses, by gene
16011,Primary and secondary nausea and vomiting outcomes
16013,Comparison of Left Ventricular Morphology and Function at Rest Between Patients With a Stented Bioprosthesis and Patients With a Stenless Bioprosthesis legend
16014,Comparison of Maximal Workload and Oxygen Consumption During Maximal Exercise Between Patients With a Stented Bioprosthesis and Patients With a Stentless Bioprosthesis legend
16018,Descriptions of the different pollutants and two traffic intensity indicators at participant addresses in each cohort
16019,Results of random effects meta analyses for the association between natural cause mortality and exposure to air pollution and traffic intensity indicators   using main confounder models 1, 2, and 3
16020,Results from random effects meta analyses for the adjusted association between natural cause mortality and exposure to PM25 below various threshold values
16021,Results from random effects meta analyses from one pollutant and two pollutant models for adjusted association between natural cause mortality and various pollutants
16022,Main European Union bodies for health
16024,Treatment outcomes in the minocycline versus control group
16025,Pain associated with treatment in the minocycline versus control group
16026,Thoracoscopic surgical findings and outcomes for patients with pneumothorax recurrence
16027,Long term pulmonary function tests
16029,Emergence of the NA R292K mutation that confers resistance to NA inhibitors
16030,MERS CoV genome data
16031,MERS CoV genome variation in support of human transmission pairs
16033,Cox proportional hazards models for 5 year overall mortality in the Kaiser Permanente validation cohort
16034,Cox proportional hazards models for 5 year overall mortality in the China Clinical Trials Consortium validation cohort
16035,Algorithm genes
16037,Features of the microarray gene expression profiling for defined molecular subtypes of breast cancer
16038,Commercially available prognostic multigene signatures for breast cancer
16040,Associations between randomised chimney stove intervention and pneumonia by endpoint of ALRI
16041,Health outcomes included in this assessment, effect estimate for exposure to second hand smoke, and rating of the strength of evidence for every outcome
16042,Proportion of children and adult non smokers exposed regularly to second hand smoke based on survey data and modelling for 2004, by WHO subregion
16043,Number of deaths from exposure to second hand smoke in 2004, by WHO subregion
16044,Number of DALYs from exposure to second hand smoke in 2004, by WHO subregion
16045,Number of blood culture specimens tested
16046,Frequency of bacteria identified from blood culture specimens during assessment by reference method and sepsis assay
16047,Frequency of organisms identified from blood culture specimens that are not covered by sepsis assay
16048,Accuracy of sepsis assay analysed with all blood culture specimens   3284
16049,Discrepancies between Prove it sepsis assay and reference method for identification of bacteria from blood culture
16053,Number of studies with Streptococcus pneumoniae disease burden data that populated the meningitis and non pneumonia, non meningitis disease models     , by WHO region
16054,Pneumococcal cases and deaths, with uncertainty estimates, by syndrome and WHO region
16059,Patients with adverse events more than 3  and at least twice the rate of the other group
16060,Adverse events and deaths
16064,Distribution of symptoms
16066,Changes in US admission rates by December, 2004
16069,Occurrence of coronary heart disease events in different tertiles of mean telomere length
16070,Changes in plasma lipid levels and other markers from recruitment to end of year 1 with pravastatin treatment in individuals in different tertiles of mean telomere length
16072,Percentages of ever   former current  , former, and current smokers in controls by region, sex, and age
16073,Risk of AMI associated with various durations of cessation in former smokers
16074,Prevalence       of exposure to SHS   per week   in controls by sex and smoking status
16075,Effect of tobacco use in strata defined by presence of other risk factors
16076,PAR as percentage   95  CI   from current smoking by region, sex, and age
16080,Bone marrow trephine histology, erythropoietin, and iron stores.
16081,Major thrombotic, haemorrhagic, and transformation events after trial entry and in the year before diagnosis
16085,Age distribution, crude and age standardised prevalence of HPV in women without cervical abnormalities in IARC HPV prevalence surveys by study area
16086,Type specific HPV prevalence in 15613 women without cervical abnormalities in IARC HPV prevalence surveys
16088,Multilevel models for aircraft noise and reading comprehension and recognition
16089,Cognitive and health outcomes and aircraft noise exposure
16090,Multilevel models for road traffic noise and cued recall
16091,Cognitive and health outcomes and exposure to road traffic noise
16092,Frequency of JAK2 Val617Phe mutation in patients with myeloproliferative disorders and controls.
16093,Pattern of mutation frequency in different haemopoietic colonies from four patients with myeloproliferative disorders who showed a mixed pattern of mutation on sequencing
16095,Antibodies used in immunocytochemistry
16096,Primers used for RT PCR analysis
16097,Isolation of skeletal muscle stem cells from adult human skeletal muscle samples
16098,Escalation of proliferation of skeletal muscle stem cells by PDGF BB
16099,Prevalence of anti HIV and anti HCV antibodies in the 3049 donors of organs, tissues, or corneas
16100,Prevalence of anti HIV and anti HCV antibodies in TMA reactive and TMA negative donors of organs, tissues, or corneas
16102,Analysis of overall mortality in children
16103,Analysis of mortality in uninfected children
16104,Analysis of mortality in infected children
16105,Unadjusted and adjusted infant mortality rates for infected children from age at acquisition of infection   n 693
16108,Clinical data and MAP test results of participants
16110,Variation in RT PCR positive rates for SARS coronavirus in different specimens with day after onset of illness
16111,Variation in geometric mean titre   GMT, copies per L   for SARS coronavirus with day after onset of illness
16112,Comparison of results from microscopy and nested PCR for detection of Plasmodium species
16116,Nasal responses after exposure to allergen plus clean air or allergen plus diesel exhaust particles
16117,Effects of GSTM1, GSTT1, and GSTP1 genotype on nasal IgE   U mL   and histamine   nmol L   when exposed to allergen plus clean air or allergen plus diesel exhaust particles   DEP
16118,IgE   U mL   and histamine   nmol L   differences by joint GSTM1 and GSTP1 genotype
16119,Effects of GSTM1, GSTT1, and GSTP1 genotype comparing differences and ratio of responses to allergen plus diesel exhaust with allergen plus clean air
16120,MICs   mg L   for parental strain, transformants, and transconjugant
16121,Cost effectiveness analysis of treatment costs for 100 patients admitted to a district hospital when antitoxin was and was not available
16122,Expression analysis of myelination and oligodendrocyte related genes in schizophrenia and bipolar disorder
16124,Nuclear morphology and lamin localisation
16125,Schedule of routine vaccinations for participants
16126,Criteria for inclusion in subgroup analyses
16127,Vaccine allocation by study group and main reasons for exclusion from per protocol analysis
16129,Frequency of invasive disease and PnCRM7 vaccine efficacy by analysis group and vaccine type
16130,Serotype distribution of invasive disease in primary efficacy group as of May 31, 2001
16131,Regional polyposis registers and families with MYH polyposis
16132,Mutations and phenotypes in 25 index cases of MYH polyposis
16134,Survival data in the CLL subsets defined by P2X7R genotype and VH gene mutation status
16135,Frequency of the P2X7R 1513A polymorphism in patients with CLL and healthy controls
16137,Identification, functional assignment, and variation in mean hepatic mRNA expression of infants with biliary atresia at 4 months of age or younger   fold change above or below expression in age matched infants with neonatal intrahepatic cholestasis
16138,Reprogramming of genes during clinical progression of biliary atresia
16140,Age standardised mortality rates for Dublin County Borough before   198490   and after   199096   ban of sale of coal, by season
16141,Change in age standardised total, cause specific, and age specific mortality rates for Dublin County Borough for 72 months before and after ban of sale of coal in Dublin
16143,Number of deaths during follow up, 198694, NLCS subcohort   n 4492
16144,Description of estimated air pollution exposures   g m3   in the NLCS subcohort   n 4466
16145,Risk of cardiopulmonary, non cardiopulmonary non lung cancer, and all cause mortality associated with long term exposure to traffic related air pollution, NLCS subcohort 198694
16147,Univariate Predictors of Nonculprit 90 min Flow   CTFC  : Categorical Variables    legend
16148,Univariate Predictors of Nonculprit 90 min Flow   CTFC  : Continuous Variables
16149,Relationship Between Pulsatile Flow in Culprit Artery and Flow in Nonculprit Artery legend
16150,Lung diseases identified at necropsy, by HIV 1 status
16151,Three most common lung diseases found at necropsy, by HIV status and age
16152,Selected pathological findings by age and HIV status
16153,Sequence analysis of protein kinase A RL transcripts from T cells of patients with SLE and of healthy controls
16154,Types of nucleotide substitutions observed in protein kinase A RI gene transcripts of SLE T lymphocytes
16155,Frequency distribution of mutations identified in protein kinase A RI subunit gene transcripts from T lymphocytes of SLE patients
16156,Neutralisation of American dengue 2, Asian dengue 2, and dengue 1 viruses by dengue 1 and dengue 2 sera
16157,Numbers of people with polyps or cancer detected in distal colon
16158,Numbers of people with polyps or cancer detected in proximal colon
16159,Numbers of patients with cancer according to method of treatment, Dukes  stage, and TNM status
16160,Acceptability of flexible sigmoidoscopy screening
16161,Angiotensin Converting Enzyme Inhibitor Genotype Distributions in Subjects 85 Years Old and Young Subjects Whose Families Originated From the Same Geographic Region legend
16163,Plasminogen Activator Inhibitor 1 Genotype Distributions in Subjects 85 Years Old and Young Subjects Whose Families Originated From the Same Geographic Region legend
16166,Hemodynamic Parameters During Rest legend
16167,Hemodynamic Parameters During Dobutamine Stress legend
16168,Myocardial Blood Flow: Nonischemic Regions legend
16169,Myocardial Blood Flow: Ischemic Regions legend
16170,Dobutamine Coronary Reserve legend
16171,Interventions and action to prevent and respond to stillbirths along the continuum of women s and children s health care  2,24,48
16172,Summary of materials and methods by policy domains
16174,Coverage of indicators of intervention for stillbirth prevention
16175,Tuberculosis case notification rates and World Development Indicators of poverty and deprivation
16176,Life expectancy at birth by quintile of deprivation
16178,Capacity building for universal health coverage and action on social determinants of health
16179,Use of antenatal corticosteroids in preterm births   n 17705 deliveries
16180,Coverage of antenatal corticosteroids and tocolytic drugs in countries studied
16182,Use of tocolytic drugs in women with uncomplicated, spontaneous preterm deliveries at 2634 weeks  gestation
16183,The theoretical domains of homelessness in European Typology on Homelessness and Housing Exclusion  4
16184,Prevalence of infectious diseases in homeless people
16185,Prevalence estimate for non communicable diseases in homeless people
16186,Prevalence of neuropsychiatric disorders in homeless people
16188,Smoothed centiles for birthweight of boys and girls according to gestational age
16189,Smoothed centiles for birth length of boys and girls according to gestational age
16190,Smoothed centiles for head circumference of boys and girls according to gestational age
16191,Progress toward Millennium Development Goals   MDGs   4, 5, and 6 in Rwanda
16192,Descriptive statistics by variable for 2001 and 2010 surveys
16193,Associations of risk of maternal death and independent factors
16194,Clinical outcome of the non oncological fertility preservation
16195,Livebirths after ovarian cortical tissue transplantation
16196,Pregnancy and livebirth rates after ovarian cortical tissue transplantation
16197,Clinical, Electrocardiographic and Imaging Data in Nine Patients Who Presented With Large T Wave Inversion and Marked QT Prolongation After an Episode of Nonischemic Pulmonary Edema legend
16200,Mortality in pooled Analysing Longitudinal Population based HIV AIDS data on Africa   ALPHA   network data by pregnancy and HIV status, 19902012
16201,Deaths in women and girls aged 1549 years by study site, pregnancy, and HIV status
16202,Crude rate ratio of mortality rates in HIV infected and HIV uninfected women and population attributable fraction for HIV, by study site
16203,Planning status of pregnancy by age at interview, outcome, relationship status, and number of children
16205,Age at menarche   women only  , first sexual intercourse, first live in relationship, and first born child by age at interview
16207,Effect of the Newhints intervention on coverage of key behaviours and coverage gaps
16208,Effect of the Newhints intervention on neonatal mortality rates after the end of training of community based surveillance volunteers and after introduction of new implementation strategies
16211,Maternal, newborn, and child deaths averted at 90  coverage with care packages
16212,Key features of specific health related commitments in 2013 manifestos for some of the main political parties
16213,Health relevant subjects enumerated in the 18th Constitutional Amendment s legislative lists
16215,Primary and secondary outcomes
16216,Rebound and recurrent hypoglycaemia in babies assigned to dextrose or placebo gel
16217,Distribution of preterm birth according to gestational age subgroup based on metaanalysis of 345 datapoints from 41 countries   n  131296785 live births
16218,Variables tested for prediction of preterm birth rates in statistical models showing risk ratio estimates
16219,Estimated preterm birth rates and total number of preterm births for 2010, by Millennium Development Goal region
16220,The ten countries with the highest numbers of preterm births in 2010
16221,Preterm birth rates and totals for 1990 and 2010 for Developed and Latin America and Caribbean Millennium Development Goal regions
16223,Multivariable assessment of associations between number of embryos transferred, livebirth, multiple birth, and adverse perinatal outcomes
16224,Adjusted relative association of number of embryos transferred with any livebirth and adverse perinatal outcomes stratified by women s age
16225,Adjusted absolute association of number of embryos transferred with any livebirth and adverse perinatal outcomes stratified by women s age
16226,Correlation of hCG concentrations at 6 months with time from initial uterine evacuation to remission
16227,Regional summary of maternal deaths averted in 2008 by contraceptive use estimated by model I
16228,Maternal deaths averted in 2008 by contraceptive use in 172 countries estimated by model I
16229,Maternal deaths averted in 2008 by contraceptive use in 167 countries estimated by model II
16231,Primary and secondary outcomes in the cervical pessary and expectant management groups
16232,Causespecific proportions of neonatal deaths by days since birth in China from 1996 to 2008
16233,Annual rate of change in neonatal mortality by socioeconomic region and cause of death in China from 1996 to 2008
16234,Neonatal mortality rates, relative risks, and preventable fractions by place of birth and socioeconomic region from 2002 to 2008
16235,Causespecific neonatal mortality rates and relative risks by place of birth and socioeconomic region in China between 2002 and 2008
16236,Characteristics of the study population in the 200408 WHO Global Survey on Maternal and Perinatal Health
16237,Comparison of  references   16    for classification      of infants SGA with respect to the ability to predict adverse perinatal outcomes
16238,Major causes of death in mothers, stillborn babies, and neonates in low income countries
16239,Output indicators and payments
16240,Services and weights used to construct the quality score for P4P formula
16245,Summary of stillbirth rate data inputs meeting inclusion criteria, by  Millennium Development Goal region
16247,Predicted stillbirth rates and totals for 1995 and 2009, by Millennium Development Goal region
16248,Comparison of estimated stillbirth rates for 18 countries with reported rates by use of the same definition between 2007 and 2009
16249,Responses regarding perceptions of the stillborn baby and the mother, and regarding causes, from the web based survey of health care professionals
16250,Comparative responses from the web based surveys of parents affected by stillbirth and of health care professionals
16251,Responses regarding advocacy and understanding from the web based survey of health care professionals
16252,Percentage of deaths averted with 99  coverage of selected interventions for the ASEAN region and for subgroups, as defined by mortality reduction patterns
16253,Intervention package description
16257,Household practices before, during, and after delivery from surveillance rounds 28
16258,Early neonatal, late neonatal, postneonatal, childhood, and under 5 mortality in 2011
16259,Maternal mortality ratio per 100000 livebirths, annualised rate of decline, and maternal deaths by country for 1990, 2000, and 2011
16260,Worldwide official development assistance to maternal, newborn, and child health, 200308
16261,Official development assistance to maternal, newborn, and child health by type and source of aid flow for the 68 Countdown priority countries, 200308
16262,Official development assistance to maternal, newborn, and child health by donor for the 68 Countdown priority countries, 200308
16263,Official development assistance to maternal, newborn, and child health by aid modality and project purpose for the 68 Countdown priority countries, 200308
16264,Official development assistance to child health per child and to maternal and neonatal health per livebirth, total to maternal, newborn, and child health in 2007 and 2008, and trends statistics, 200308
16267,Primary and secondary outcomes
16268,Incidence of adverse events reported   safety population
16269,Most common serious adverse events reported by gestational age   safety population
16271,Analysis of association between receipt of financial assistance from Janani Suraksha Yojana and intervention coverage and health outcomes by use of three analytical approaches at the national level
16272,Analysis of association between receipt of financial assistance from Janani Suraksha Yojana and intervention coverage and health outcomes by use of two analytical approaches by high focus, northeast, and non high focus states
16273,Under 5 mortality   uncertainty interval   per 1000, by decade
16274,Neonatal, postneonatal, and childhood mortality   uncertainty interval   per 1000 in 1990 and 2010
16275,Definitions of maternal death and maternal mortality
16276,Summary of site years of observation by source, 19802008
16277,Maternal mortality ratio   uncertainty interval   per 100000 livebirths by region      and country
16280,In Hospital Events legend
16281,Serum samples obtained in 2008 with antibody titre equal to or more than the minimum detection limit and with antibody titre at least four times higher than the minimum detection limit, by age group and test method
16286,Comparison of mortality rates in intervention and control clusters
16287,Kessler 10 depression scores in mothers in intervention and control clusters
16288,Process indicators in intervention and control clusters
16289,Cause specific mortality for early neonatal deaths during study
16292,Comparison of mean height for age and BMI for age Z scores, and cognitive, language, and behaviour scores
16299,Logistic regression analyses     between ever married women aged 2024 years, who were married as adults or children, and both fertility and fertility control outcomes
16301,Children aged less than 5 years who were protected by an insecticide treated bednet   ITN   in 2007 according to classes of Plasmodium falciparum and poverty risks across 40 malaria endemic countries
16302,Unregistered births   1000s   in 2003 by region and level of development
16303,Overall life expectancy   years   in 15 high income countries
16304,Estimated effects of family policy generosity on infant mortality
16305,Estimated effects of pension rights on old age excess mortality
16306,Changes in coverage of malaria interventions and febrile illness between 2000 and 2006, shown in multiple indicator cluster surveys   MICS   in The Gambia
16309,Direct household visits by community health workers   overall coverage by intervention arm
16310,Group interventions   approximate monthly coverage per intervention cluster
16312,Comparison of mortality rates by study arms
16314,Indicators measured during household surveys in Cyangugu province after introduction of performance based pay initiative
16315,Progress toward the MDG 4 target for reduction of child mortality in 68 priority countries
16316,Progress toward the MDG 5 target for maternal mortality in 68 priority Countdown countries
16317,Ten best and ten worst performing countries on progress towards MDG 4 since 1990
16318,Ranking of selected countries for maternal mortality as a proxy for progress towards MDG 5
16319,Changes for selected interventions since 2000 for Countdown countries with at least two measurements
16320,Attributable deaths and disability adjusted life years   DALYs   for high blood pressure for various cardiovascular endpoints in 2001 by World Bank region
16321,Attributable deaths and disability adjusted life years   DALYs   per 100000 population per year for high blood pressure for various cardiovascular endpoints in 2001 by region
16322,Deaths and disability adjusted life years   DALYs   attributable to high blood pressure in 2001
16324,Amounts paid to Oportunidades beneficiaries by age group in 1997 Mexican pesos
16327,Dependent variables
16328,Effect of doubling cash transfers in Oportunidades on developmental outcomes in children   2468 months   55 years after programme inception
16329,Maternal mortality estimates for 2005 by UN MDG regions
16330,Country estimates of maternal mortality ratios for 2005
16331,Random effects model estimates of trends in the maternal mortality ratio by income region, data source type, and initial level of ratio
16332,Comparison of 1990 and 2005 regional and global estimates of maternal mortality ratios
16333,Other maternal outcomes
16334,Other infant outcomes
16335,Subgroup analyses of pre eclampsia outcome
16336,PARIS number needed to treat with sample baseline event rates
16337,Sample sizes for the 20  sample of the 1990 and 2000 censuses
16338,U5MR per 1000 population, by quintiles of household economic status
16341,Pregnancy outcome after mild and standard IVF treatment
16342,Total costs of IVF treatment per couple over 12 months
16343,Maternal age and gestational age for the 60 patient samples
16344,Comparison of mean fetal DNA ratios for chromosome 13 and 21 in 60 maternal plasma samples
16345,Description of SCPE data on children with cerebral palsy included in the study
16348,PCA and MPR by quarter for 987 patients who started antiretroviral treatment
16351,Description of surveys by country
16352,Variable definitions: living standards and out of pocket health payments by country
16353,Out of pocket payments for health care as percentage of total household resources by country
16354,Poverty head counts: effect of accounting for out of pocket payments for health care
16355,Poverty gaps: effect of accounting for out of pocket payments for health care
16357,Pregnancies after intrauterine insemination in relation to follicular growth patterns
16358,Final model used for prediction of the log of the stillbirth rate per 1000 deliveries, by independent variable
16359,Estimated stillbirth rates per 1000 deliveries and uncertainty values, by world region for the year 2000
16360,The Expression of Tenascin C in the Patent and Occluded Human Vein Grafts legend
16361,Effect of Intravenous Losartan   1.0 mg kg   0.03 mg kg min  , EXP3174   0.1 mg kg   0.01 mg kg min  , Captopril   1.0 mg kg   0.5 mg kg h   or Vehicle on Sinus Heart Rate, Mean Arterial Pressure and Electrocardiographic Intervals in Postinfarction Dogs legend
16362,Effect of Intravenous Losartan   1.0 mg kg   0.03 mg kg min  , EXP3174   0.1 mg kg   0.01 mg kg min  , Captopril   1.0 mg kg   0.5 mg kg h   or Vehicle on Cardiac Electrophysiologic Parameters in Postinfarction Dogs legend
16363,Plasma Renin Activities in Postinfarction Dogs Administered Intravenous Losartan   1.0 mg kg   0.03 mg kg min  , EXP3174   0.1 mg kg   0.01 mg kg min  , Captopril   1.0 mg kg   0.5 mg kg h   or Vehicle legend
16364,Effect of Intravenous Losartan   1.0 mg kg   0.03 mg kg min  , EXP3174   0.1 mg kg   0.01 mg kg min  , Captopril   1.0 mg kg   0.5 mg kg h   or Vehicle on the Incidence of Lethal Ischemic Arrhythmias Developing in Response to Secondary Acute Posterolateral Myocardial Ischemia in Postinfarction Dogs
16366,QT Intervals at Specified Heart Rates During Exercise and Recovery
16367,QT Heart Rate Slopes   ms min1   During Exercise and Recovery legend
16368,Application of Various Diagnostic Alternatives in LQTS in Regard to Molecular Classification of Patients and Controls Subjects
16370,Blood Pressure, Heart Rate and Rate Pressure Product Changes During Handgrip legend legend
16375,ReninAngiotensin System Genotypes in 80 Endurance Athletes
16376,Left Ventricular Mass   g m   in Different Genotypes
16377,Comparison of Athletes with Different AGT Genotypes legend legend
16378,Exercise Parameters Recorded on Study Patients legend
16379,Relative Performance of the Three Tests for the Diagnosis of CAD legend legend
16380,Sensitivity of Dipyridamole, Dobutamine Stress Echocardiography and Myocardial Perfusion Scintigraphy for the Detection of Single , Double  and Triple Vessel Disease
16381,Sensitivity of Dipyridamole, Dobutamine Stress Echo and Myocardial Perfusion Scintigraphy for the Detection of Isolated Left Anterior Descending Coronary Artery Disease With and Without Multivessel Disease legend
16382,Patients Developing Angina, Diagnostic ST segment Depression or Both, During Dipyridamole and Dobutamine Stress Echocardiography legend legend
16384,Immunoreactive Endothelin Concentrations legend
16386,Coronary risk factors in men and women in Mysore
16387,Percentages of men and women with coronary heart disease according to birth measurements
16388,Odds ratios for coronary heart disease in men and women aged 45 years and over according to weight, length, and head circumference at birth
16389,Mean weight, length, and head circumference at birth and prevalence of coronary heart disease according to mother s weight in pregnancy
16390,Frequency of coronary heart disease according to birthweight and mother s weight in pregnancy
16391,SMRs among men in Hertfordshire according to birthweight and weight at 1 year
16392,SMRs among men born in Sheffield according to birthweight and head circumference
16393,SMRs and relative risks among 13249 men born in Hertfordshire and Sheffield according to birthweight
16394,SMRs for stroke among men born in Sheffield according to head circumference, birthweight, and placental weight
16395,SMRs among men born in Sheffield according to placental weight
16396,Mean birthweight, head circumference, and placental weight for infants born in Sheffield whose mothers had flat pelvises
16398,Results of multivariate regression analysis on tPTEF tE
16399,Cases of congenital heart disease by group
16400,Distribution of types of arterial stroke by region
16402,Odds ratios of haemorrhagic stroke in relation to combined OC use by region
16403,Odds ratios of haemorrhagic stroke in relation to current combined OC use by age group and oestrogen dose
16404,Odds ratios of haemorrhagic stroke in relation to current combined OC use by smoking status
16405,Odds ratios of haemorrhagic stroke in relation to current combined OC use by history of hypertension
16406,Odds ratios of intracerebral and subarachnoid haemorrhage in relation to current combined OC use
16407,Objectives for each visit in the new programme
16412,Causes of maternal mortality
16414,Odds ratios for invasive breast cancer in relation to perinatal factors reported by mothers
16415,Odds ratios for invasive breast cancer in relation to birthweight reported by mothers and stratified by age at diagnosis in daughters
16416,Odds ratio for invasive breast cancer in relation to birthweight reported by nurses
16418,Angiographic Outcome After 27 Procedures
16419,Semiquantitative Analysis of Plaque Material in Vein Graft Aspirates legend legend
16420,Interpretation of Regional Endocardial Motion legend legend
16421,Statistics of Agreement of the Conventional Interpretation of Gray scale Images by the Inexperienced Reviewers and the Objective Evaluation of Regional Endocardial Motion Based on Segmental Analysis of Systolic Color Kinesis Images legend legend
16422,Diagnoses of Ischemic Response to Dobutamine on a Patient by Patient Basis Made by Two Inexperienced Reviewers of Conventional Gray scale Images, and the Objective Technique Based on Color Kinesis legend legend
16423,Estimated yearly risk of infection by region of the world
16424,Average contact numbers for smear positive tuberculosis cases calculated from the ratio of the annual risk of infection and smear positive tuberculosis prevalence by country
16425,Meta analysis of BCG efficacy against tuberculous meningitis and miliary tuberculosis from casecontrol studies
16426,Effectiveness and cost of BCG for the prevention of tuberculous meningitis and miliary tuberculosis, by region and for the world
16428,Tuberculosis diagnosis by type and age in each group
16429,Efficacy of revaccination against tuberculosis by tuberculosis type and city, controlled for age.
16430,Results of post travel tuberculin skin tests with purified protein derivative   PPD   of M tuberculosis and of M scrofulaceum among 656 long term travellers to high endemicity areas
16431,Destination specific incidence rates of tuberculin conversion among 656 long term travellers to high endemicity areas
16434,Summary of events by treatment and stage
16435,Summary of clinical effects of widow spider bites from different regions of the world  29,3135
16436,Health care use, expenditure, and resources in Japan compared with selected OECD member countries, 2008
16439,Changes in self rated health around retirement
16440,Estimated number of AIDS related deaths for the years 2015, 2030, 2050, and 200850 with different strategies
16441,Study population size, stratified by exposure to green space and by income deprivation
16442,Probable causes of death in 574 adults aged older than 14 years
16443,Probability of dying between the ages of 15 and 60, 20 and 50, and 30 and 65 years in the surveillance population before opening of the antiretroviral therapy clinic in June, 2005, adjusted for area
16444,Trends in adult mortality before and after opening of the antiretroviral clinic in Karonga district
16446,Visit and medication compliances
16447,Major endpoints at 5 years and end of study
16449,Incidence of cancers
16450,Country totals for numbers of centres and children, response rate, 12 month prevalence of asthma, allergic rhinoconjunctivitis, and eczema symptoms in both phases, average change per year, and SE of the change by age group   full information in  webtables 1 and 2
16451,Number of centres with changes   increase 1SE, decrease 1SE and little change  1SE   by region, disorder, and age group
16453,Absolute numbers of CEP and concentrations of angiogenic factors in circulation of participants
16454,Estimated costs of 3 by 5, 200405   US  billions
16455,Summary of clinical, virological and immunological studies of participants
16456,Excess death rates   EDR   per 1000 patient years in Swiss patients of the SHCS, 19972001
16458,Patients who received additional maintenance anti asthma therapy
16460,Overall result and influence of age, sex, and smoking status on the 1 year and 3 year changes in prebronchodilator FEV1     predicted
16463,Incidence of infusion reactions during infliximab infusions by antibodies to infliximab status up to week 54
16464,Summary of safety findings for all patients   n 573   up to week 54
16466,Mortality hazard ratio for methotrexate use compared with no methotrexate use
16467,Mortality hazard ratios for use of disease modifying antirheumatic drugs   DMARD   compared with no drug use
16468,Interferon gamma gene polymorphism and susceptibility to rheumatoid arthritis
16469,Interferon gamma gene polymorphism and severity of rheumatoid arthritis
16471,3 year cumulative incidence      of stroke, according to the presence of retinal microvascular abnormalities
16472,Relative risk of incident stroke in relation to retinal microvascular abnormalities
16473,Relative risk of incident stroke in people with and without hypertension or diabetes, in relation to retinal microvascular abnormalities
16474,Relative risk of incident stroke in relation to retinal microvascular abnormalities   all retinal variables entered simultaneously
16476,Summary of initial findings in 20 patients who complained of visual symptoms after viewing solar eclipse
16477,Language and video questionnaire used, response rates, and sample sizes by centre
16478,Distribution of centres by tertiles, based on written and video asthma questionnaires
16480,Concentrations of study drug in plasma
16481,Safety variables and adverse events
16483,Primary and secondary outcomes in the modified intention to treat population
16484,Rates of adjudicated clinical events in the safety population
16485,Definition of malignant diseases
16486,Data quality indicators for patients diagnosed during 19952009, by continent and country   all cancers combined
16487,Population coverage and number of patients diagnosed during 19952009, by continent and country
16488,5 year age standardised net survival for adults   aged 1599 years   diagnosed with one of ten common malignant diseases and children   aged 014 years   with ALL, by continent, country, and calendar period of diagnosis
16490,Accuracy of screening methods for detection of major and critical congenital heart disease in asymptomatic newborn babies
16491,Detection rate for individual critical congenital heart disease in asymptomatic newborn babies
16492,Accuracy of screening methods for detection of critical congenital heart disease by age in asymptomatic newborn babies   n 120707
16494,Estimated UK population effects for cancers with evidence of a net positive association with body mass index   BMI
16495,Comparison of prevalence of congenital anomalies in the BiB and BINOCAR datasets
16498,Clinical application of engineered tissues
16500,Outcomes
16501,Haematological toxicity
16502,Non haematological toxicity
16503,Estimated radiation doses to the brain and red bone marrow from one CT scan, by scan type, sex, and age at scan, as used in this study for scans after 2001
16504,Cases of leukaemia and brain tumours and person years for patients in the assessed cohort
16505,Excess relative risk per mGy for cancer subtypes in relation to organ specific radiation doses received from CT scans
16509,Definition and quality grade of structural and sustainable indicators
16510,Structural and sustainable indicators by country
16511,Results of meta regression analyses assessing association between healthy life years at 50 years of age and the structural and sustainable indicators for all 25 EU countries
16512,Results of meta regression analyses assessing association between healthy life years at 50 years of age and the structural and sustainable indicators for EU country groups
16514,Hazard ratios for graft survival in the first year after transplantation, and after 10 years of follow up for kidney transplants which were functioning 1 year after transplantation
16515,Multivariable Cox regression analysis
16516,Enrolled children
16518,Primary diagnoses by site and age group for severe illness requiring hospital admission
16519,Prevalence of individual clinical signs, and odds ratios for association with severe illness requiring hospital admission   random effects meta analysis
16520,Independent clinical predictors of severe illness requiring hospital admission in the 06 days age group   excluding jaundice
16521,Sensitivity and specificity of a range of decision rules   algorithms   for identification of the sick infant requiring hospital admission, for each study site and age group, with combined estimates obtained by random effects meta analysis
16523,Cumulative probabilities of neutrophil and platelet recovery
16524,Multivariable analysis of acute and chronic GVHD
16525,Multivariable analysis of transplant related mortality, relapse, and treatment failure
16526,Causes of death and type of transplant
16527,Yearly case reports of syphilis classified by stage, nationwide STD surveillance system
16528,Age of people with syphilis in 2005 by region
16532,Estimated hazard ratios   95  CI   associated with assigned treatment, by time from first complete remission
16538,ANXA1 protein expression in B cell lymphomas
16540,Details of patients with discordant findings
16541,Hazard ratios for the effects of ZAP 70 protein, CD38, and IgVH gene status on survival
16543,Primary and secondary outcomes
16544,Number of hospital admissions for worsening heart failure
16545,Permanent study drug discontinuation for adverse events, by reason for previous ACE inhibitor intolerance
16547,Reasons for permanent treatment withdrawal
16548,Frequency of primary and selected secondary outcomes
16552,Quantitative Angiography in the 476 Lesions With Angiographic Follow up legend
16555,Multiple Logistic Regression Analysis for the Dependent Variable of Restenosis legend
16556,Primary and secondary outcomes
16558,Number of hospital admissions for worsening heart failure
16559,Multiple Logistic Regression Analysis for the Dependent Variable of Late Vessel Occlusion legend
16560,Permanent study drug discontinuation for adverse events
16561,Results of Prior Studies on Angiographic Outcome in Diabetic Patients legend
16563,New breast disease events and deaths by treatment received
16564,New breast events in patients in the tamoxifen comparison
16565,New breast events in patients in the radiotherapy comparison
16566,Events in patients randomised to tamoxifen stratified by whether or not they had radiotherapy
16567,Effect of tamoxifen in patients by age at randomisation: a comparison with results from the NSABP B 24 trial
16568,Exposure to study medication
16570,Number of segments affected by hibernation, or hibernation or ischaemia
16572,GATA1 exon 2 alterations in patients with Down s syndrome with transient myeloid disorder or acute megakaryoblastic leukaemia
16574,Inclusion criteria
16575,Crude rates and relative risks for prespecified
16576,Causes of death
16577,Adverse events
16580,Clinical and laboratory features of patients according to type of 11q23 abnormality
16581,Prognostic factors of event free survival according to a stratified Cox s proportional hazards model
16582,Estimates of event free survival at 5 years according to type of 11q23 abnormality and age
16583,Types of failures and estimated hazard ratios for disease free survival according to transplant subgroup versus chemotherapy alone in complete responders with the t  4;11   translocation
16584,Estimated hazard ratios for overall survival according to transplant subgroup versus chemotherapy alone in complete responders with the t  4;11   translocation
16585,Frequency of the 1513AC polymorphic allele for the P2X7 receptor in unrelated patients with chronic lymphocytic leukaemia   CLL   and in aged matched unrelated controls
16586,Expression and function of P2X7 receptor in T lymphocytes from members of two families in  figure 2  with chronic lymphocytic leukaemia   CLL
16587,Clinical data and response to treatment
16588,Point mutations and clinical sample analysis
16590,Genes highly differentially expressed in acute lymphoblastic leukaemia cells, which are secondarily resistant to STI571
16591,Odds ratios for chromosomal anomaly in residents within 3 km of a hazardous waste landfill site
16592,Odds ratios for chromosomal anomaly in residents within 3 km of a hazardous waste landfill site
16593,Response of left ventricular mass to a 10 week training period
16594,Incidence of childhood cancer in Yorkshire across 5 year periods and percentage change in incidence between 197497 and 198097
16595,Germline PTEN mutations detected in patients with Proteus syndrome and Proteus like syndrome
16596,Features in Cowden syndrome, Bannayan Riley Ruvalcaba syndrome, and Proteus syndrome and four patients with PTEN mutation
16598,Biomarkers of exposure
16600,Dose effect relations
16602,Flow Mediated Dilation Pre  and Postprandial During Placebo, Quinapril and Losartan Treatment
16603,Lipid Values Before and After Oral Fat Load During Placebo, Quinapril and Losartan Treatment legend
16604,Nitroglycerine Induced Dilation Pre  and Postprandial During Placebo, Quinapril and Losartan Treatment legend
16606,Blood Pressure and Forearm Hemodynamics in the Three Treatment Groups   Means  SEM   Before Randomization legend
16607,Correlation of Baroreflex Sensitivity Measured by the Downward Tilting or Phenylephrine Method With Frequency Domain Analysis of Heart Rate Variability legend
16610,Detection of Neisseria meningitidis by nasopharyngeal swabbing and immunohistochemistry
16611,Results of Mapping and Injection Procedures
16612,Frequency of adolescent onset multiple sclerosis in BC
16616,Heart Rate Variability Analysis legend
16617,Studies included in the meta analysis
16618,Clinical variables
16619,Counts of gadolinium enhancing lesions
16620,Predictive value of gadolinium enhancing lesion counts for relapse rate
16621,Predictive value of gadolinium enhancing lesion count for increase in EDSS
16623,Changes in body morphology over 10 week training period in army recruits by ACE genotype
16627,Relative Content of Myosin Heavy Chain       in Patients With Class IIIII CHF and Normal Subjects
16628,Skeletal Muscle Enzyme Activity in Patients With Class IIIII CHF and Normal Subjects   mol kg protein h
16630,Frequency of infections by protocol and by intention to treat
16632,Angiography and PTCA results
16633,Clinical events, 30 days  follow up
16634,Clinical events during 6 months of follow up
16635,Medication at discharge and at 6 month follow up     of patients
16636,Features of patients at entry to the trial by treatment group
16637,Change in median EDSS, ambulatory index, and arm index between treatment groups
16638,The Mitral Regurgitation Index: Grading of Its Six Constituent Variables legend
16639,Clinical, Doppler and Echocardiographic Variables   Mean  SD   Among the Three Grades of Mitral Regurgitation
16640,The MR Index   Mean  SD   of Normal and Low Ejection Fraction   EF   Subgroups
16642,Cox Regression Analysis for Predicting Cardiac related Mortality
16646,Countries included in analyses with number of communities, households, and patients with cardiovascular disease
16647,Monthly household capacity to pay, and costs of each of the four cardiovascular disease medicines in different countries
16648,Participants with a history of cardiovascular disease who reported medicine use across tertiles of income in a range of country incomes
16649,Associations between availability and affordability and use of cardiovascular disease medicines in patients with a history of this disease in low income and middle income   including India   countries
16651,Event rates during follow up
16652,Outcomes at 5 year follow up
16653,Components of the genetic risk score, listed by locus
16654,Risk of coronary heart disease across genetic risk score categories, by study
16655,Risk of coronary heart disease associated with statin therapy across genetic risk score categories
16660,Primary and secondary outcomes after ruptured abdominal aortic aneurysm in England and the USA
16661,Comparison of outcomes in teaching and non teaching hospitals in England and the USA
16662,Comparison of outcomes in low, middle, and high bed capacity hospitals in England and the USA
16665,Comparison of treatment groups for the primary endpoint, secondary endpoints, and other major adverse events
16666,Comparison of treatment groups for the primary endpoint in pre specified subgroups
16669,Angiographic follow up at 68 months
16670,Clinical results at 1 year by treatment group
16672,Findings of Cardiac Catheterization and Bubble Contrast Echocardiography legend legend
16673,Summary of included trials
16675,Clinical outcomes during 3 years of follow up
16676,Adjusted risk for outcomes associated with early generation and newer generation DES compared with bare metal stents
16679,Clinical outcomes
16680,Randomised controlled trials included in the meta analysis
16681,Odds ratios and 95  CIs for definite stent thrombosis up to 2 years between different stent types
16682,Odds ratios and 95  CIs for definite or probable stent thrombosis between different stent types
16688,Clinical adverse events
16691,Primary, secondary, safety, and exploratory outcomes
16692,Procedural complications and outcomes and patient preference
16694,Overall patient related and stent related composite and detailed clinical outcomes at 2 years
16695,Timing and event details for the six patients who had an ARC definite or probable stent thrombosis event in year 2
16696,Stent related efficacy and safety of early and new generation drug eluting stents from randomised trials in unrestricted populations at 2 years
16698,Association between SNPs and incident coronary heart disease, cardiovascular disease, and myocardial infarction
16699,Association between genetic risk score and incident coronary heart disease, cardiovascular disease, and myocardial infarction
16700,Association between genetic risk score and prevalent coronary heart disease, cardiovascular disease, and myocardial infarction
16701,Reclassification of individuals in the FINRISK 1992 and 1997 cohorts on the basis of 10 year predicted risk of coronary heart disease with and without genetic risk score
16702,Net reclassification improvement of genetic risk score for coronary heart disease in the FINRISK 1992 and 1997 cohorts
16704,Efficacy and safety outcomes for the clopidogrel dose comparison
16705,Efficacy and safety outcomes for the aspirin dose comparison
16707,Outcome events occurring within 120 days of randomisation   intention to treat analysis
16708,Outcome events occurring within 30 days of treatment   per protocol analysis
16710,Mean TRV with 95  Confidence Intervals for Athletes Versus Nonathletes by Workload legend
16715,Angina episodes
16719,Clinical outcomes
16720,Definite stent thrombosis and symptom driven restenosis
16722,Time from randomisation and from most recent ipsilateral event to allocated treatment
16723,Outcome measures within 120 days of randomisation   intention to treat population
16724,Number of outcome events between randomisation and 120 days in the intention to treat   ITT   analysis and between initiation of treatment and 30 days after treatment in the per protocol analysis
16725,Outcome measures between initiation of treatment and 30 days after treatment   per protocol analysis
16729,Clinical events during follow up
16731,Overall clinical outcomes by treatment assignment
16734,Summary effects from direct comparisons and combined direct and indirect comparisons
16735,Hemodynamic Data legend
16737,Coronary Cross Sectional Area: Absolute Values legend
16739,Rate of bleeding events in the primary percutaneous coronary intervention cohort over 60 days of maintenance therapy
16740,Major secondary efficacy outcomes for primary percutaneous coronary intervention cohort over 60 days of maintenance therapy
16741,Safety outcomes in patients receiving study drug who subsequently needed coronary artery bypass grafting
16742,Rate of bleeding events during 60 days of maintenance therapy in the secondary non percutaneous coronary intervention cohort   treated medically
16744,Clinical events for prasugrel versus clopidogrel in patients with at least one stent
16745,Clinical events for prasugrel versus clopidogrel stratified by stent type
16746,Stent thrombosis rates for prasugrel compared with clopidogrel using Academic Research Consortium definitions and stratified by stent type
16749,Multivariable Logistic Regression Analysis for the Prediction of ACS UsingClinical Predictors and Coronary CTA Assessment
16751,Occurrence of Major Adverse Cardiac Events During Initial Hospital Attendance or 30 Day Follow Up According to Individual and Combinations of the ADP Test Parameters in the ADAPT and APACE Cohorts
16752,Accuracy   95  CI   of ECG, hs TnI, TIMI, and ADP for Exclusion of MACE
16754,Frequency of Major Adverse Cardiac Events During Initial Hospital Attendance or 30 Day Follow Up Period in the ADAPT and APACE Cohorts
16755,Participants With Detectable Troponin Values    1.2ng l   on Presentation
16757,Subsegmental quantitative coronary angiographic analysis   matched pairs
16758,Serial intravascular ultrasound analysis
16759,Serial radiofrequency backscattering analysis   virtual histology
16761,Metabolite Levels in Angiographic Controls and in Angioplasty Induced Ischemia Patients
16762,Metabolite Levels in Patients With Spontaneous Chest Pain With and Without Final Diagnosis of Myocardial Ischemia
16764,Diagnostic Accuracy of CTA for Detecting 50  Coronary Arterial Stenosis
16765,Distribution of Calcium Scores and Associated Disease Prevalences
16767,Odds ratios, confidence intervals, and C indices in the prediction of postoperative renal dysfunction with propensity adjustment and the renal risk model
16769,ICERs in different subgroups
16774,Use of Reperfusion Therapy by Pre  Versus In Hospital ECG Utilization
16775,Acute   24 h   Medications by Pre  Versus In Hospital ECG Utilization
16776,Timing of Reperfusion Therapy by Pre  Versus In Hospital ECG Utilization
16777,In Hospital Clinical Outcomes by Pre  Versus In Hospital ECG Utilization
16780,Angiographic results in 224 patients who underwent follow up angiography
16781,Major adverse cardiac events within 6 months
16782,Drug discontinuation in the celecoxib group
16786,Clinical Outcomes at 1 Year in Patients Undergoing PCI
16791,Angina status during hospital stay and at follow up intervals after 4, 6, 12 months
16792,Clinical events during hospital stay and at follow up
16793,Quantitative coronary angiographic data
16795,Medications Taken at the Time of Myocardial Infarction, According to the Presence or Absence of OSA
16796,Medications at the Time of the Sleep Study, According to the Presence or Absence of OSA
16798,Diagnostic Performance and Predictive Value of 64 Slice CT Coronary Angiography for the Detection of 50  Stenosis on QCA: Analysis for High, Intermediate, and Low Pretest Likelihood for Obstructive CAD
16801,Presence and Severity of Plaque by CCTA in Different Coronary Arterial Segments
16802,Univariable and Multivariable Cox Models of CCTA Results for All Cause Mortality
16803,Prognostic Value of CCTA Results in Subsets of Population
16805,False Positives by Troponin I and or ECG Criteria
16806,Comparison of ECG Criteria With ceMRI Scan
16809,Study medications
16810,Procedural details
16811,Core angiographic laboratory analysis
16814,Medication therapy at discharge and during follow up
16815,Event rates and hazard ratios for cardiovascular events
16816,Event rates from hospital discharge until end of follow up
16819,Univariate and multivariate Cox proportional hazards analysis
16820,Periprocedural and postprocedural clinical outcomes of patients with stent thrombosis
16824,Precipitating Factors
16825,Causes of Death
16826,Univariate Analysis for Predictors of Death After ABS Index Presentation
16828,In Hospital Events and Cumulative Events After 5 Years
16832,Predictors of death, by group   time dependent covariate model
16833,Predictors of death, by group   logistic regression model
16836,In Hospital Outcomes
16838,Cox Proportional Hazards Survival Model Results for Long Term Survival
16839,OXVASC population by age and sex
16840,Rates of invasive investigations and interventions for vascular disease in OXVASC population
16841,Rates of acute events in men and women in the OXVASC population
16842,Relative event rates in men versus women by age for different types of acute vascular events
16844,Performance Indexes of CTCA and SPECT CTCA for Detection of Hemodynamically Significant Coronary Lesions in 170 Segments in 44 Patients
16848,Costs per patient
16850,MDCT Measurements of Coronary Vessel Lumen and Atherosclerotic Plaque
16852,Medication Use
16853,Procedures and Clinical Outcomes
16854,Gender Differences in Invasive Procedures and Clinical Outcomes by TIMI Risk
16855,PAMI Database
16858,Comparison of Six Month Clinical Outcomes Between Study Groups
16860,Rates of revascularisation
16861,Cause of death and primary events over all follow up assessments
16862,Multivariate predictors of death or myocardial infarction at 5 years  follow up
16863,Treatment effect by risk of death or myocardial infarction to 5 years  follow up
16864,Baseline Clinical and Short Term Characteristics in the PPCP Versus No PPCP Groups
16866,Incidence of VF Relative to the Timing and Energy of Chest Wall Impact
16867,Consequences of Chest Wall Impact at a Variety of Velocities in the Experimental Commotio Cordis Model
16869,Procedures, Complications and Clinical Outcomes of Patients at Hospital Discharge in Invasive and Conservative Therapy Groups
16871,Procedures, Complications and Clinical Outcomes of Patients at Hospital Discharge in Invasive and Conservative Therapy Groups Following Matching by Propensity Analysis
16872,Clinical and Angiographic Features of Studied Patients
16878,Odds ratios of invasive endometrial cancer and endometrial atypical hyperplasia in relation to use of oral oestriol   12 mg
16879,Odds ratios   OR   of endometrial cancer after menopausal use of oral oestriol, by histological grade and degree of invasion of the myometrium
16880,Odds ratios of invasive endometrial cancer and endometrial atypical hyperplasia in relation to use of vaginal oestrogens
16884,Clinical and pathological features of patients with FPTMC
16885,Number of patients at risk of relapse by concentration of TNF
16886,Most commonly studied genetic changes in sporadic colorectal cancer4
16887,Possible colorectal cancer screening programmes for at risk populations
16888,Survival results of trials comparing 5FU FA with control in adjuvant treatment
16890,Electron Beam Tomography for Hard and All Coronary Events at Various Calcium Score Thresholds legend
16891,Multivariate Analyses of the Association of Coronary Artery Calcium Scores and Traditional Risk Factors With All Events legend
16893,Late toxic effects of radical radiotherapy
16895,Kinetics Parameters During 125I Ang I Infusion and Arterial Venous Concentrations of Endogenous Ang I and II legend
16896,Comparison of Coronary Risk Factors in Three Patient Groups of Single Vessel CAD, Multivessel CAD and Controls legend
16897,Multiple Logistic Regression Analysis for Discriminating CAD Patients From Control Subjects legend
16898,Multiple Logistic Regression Analysis for Discriminating Acute Coronary Syndrome From Chronic CAD legend
16902,Ages of cases and controls
16905,Sensitivity and Specificity of Serum Markers for Acute Myocardial Infarction    legend
16909,Association of Clinical and Electrocardiographic Factors With the Occurrence of Myocardial Infarction legend legend
16911,Main problems at presentation and final diagnosis
16912,Performance of CAM 171 mucin assay in patients with and without jaundice
16913,Sensitivity of investigations for diagnosis of pancreatic cancer
16914,Sensitivity of investigations for diagnosing pancreatic cancer according to presence of jaundice
16917,Moderate or severe   WHO grade 2 or worse   adverse effects of treatment reported by clinicians during the first 3 months of treatment
16919,Contingency table of differences between attained and projected adult height by GH therapy status
16921,Comparison of Admitting Diagnosis and Initial Hospital Bed Assignments of 29,585 Patients With LBBB and Acute MI in the National Registry for Myocardial Infarction 2   June 1, 1994March 31, 1998   legend
16922,Comparison of Treatments Received by 29,585 Patients With Acute MI and LBBB With and Without Chest Pain in the National Registry for Myocardial Infarction 2   June 1, 1994March 31, 1998   legend legend
16923,Mortality Estimates and Causes of Death for Patients With LBBB Stratified by Presence of Chest Pain in the National Registry for Myocardial Infarction 2   June 1, 1994March 31, 1998   legend legend
16924,In hospital Mortality of LBBB Patients With MI Stratified by Age and the Presence of Chest Pain
16927,Sensitivity and Specificity of the Exercise Treadmill Test Using the 1 mm ST Segment Depression Criterion legend legend legend
16928,Sensitivity and Specificity of the Exercise Treadmill Test in Patients With Resting ST Segment Depression When Using 2 mm or More of Additional ST Segment Depression to Define an Abnormal Exercise Treadmill Test legend legend legend legend
16930,Recommendations for national and international agencies
16931,Patient Population legend
16932,Sensitivity, Specificity and Cost of Individual and Combined Screening Tests for Recoarctation, Aneurysm and Recoarctation or Aneurysm
16933,Cost of the Most Sensitive Combinations for Recoarctation or Aneurysm
16934,Presence of an integrated non communicable disease policy, operational status, and inclusion of specific risk factors for 22 countries with high burdens of non communicable diseases
16935,Presence of surveillance data in national health reporting systems in 22 countries with high burdens of non communicable diseases
16936,Countries reporting key elements of non communicable disease prevention capacity, 2000 and 2010
16939,Rate of hypertension in people aged 20 years and older in world regions
16941,Age specific rate of hypertension by world region
16942,Comparison of Patients With and Without Moderate to Severe Mitral Regurgitation legend
16943,In Hospital Complications
16944,Insonated venous segments
16946,Subgroup analysis of ulcer healing rates
16947,Adverse events
16949,Summary of genome wide screen results on 1599 families
16950,Locus counting analysis
16951,Clinical features of PTLD cases
16952,IgH genotype and presumed cell of origin of PTLD
16957,Suture material used and time taken to complete repair
16958,Secondary outcome measures
16962,Clinical activity index
16965,Hospital and 6 Month Outcome legend
16966,Number of patients at each stage of trial
16967,Non serious adverse events of possible, probable, or uncertain association with medication
16969,Exercise Test Variables, DTS Groups and Cardiac Catheterization Results  legend
16970,Multivariable Models Testing for Interaction Between the DTS and Gender for the Diagnosis of Significant, Severe Disease, and Survival
16971,Incremental Information Provided by Duke Treadmill Score Over Clinical Predictors for Significant Disease
16972,Frequency of Coronary Disease Subsets in Women and Men legend
16974,Final Diagnosis and Major Cardiac Events  Within 72 h After Presentation to Emergency Department  legend
16976,Diagnostic Performance of First Sample of Cardiac Troponin I 0.4 ng ml for Acute Myocardial Infarction and Major Cardiac Events Within 72 h in 808 Study Patients
16977,Diagnostic Performance of Peak Cardiac Troponin I 0.4 ng ml and Creatine Kinase MB Fraction Mass 5.0 ng ml for Major Cardiac Events Within 72 h in Entire Cohort and in Patients Ruled Out for Myocardial Infarction
16978,Probability of Major Cardiac Events Within 72 h by Presence of Independent Predictors  or Ischemia on Admission Electrocardiogram and Peak Cardiac Troponin I Level in First 24 h After Presentation to Emergency Department for All Patients
16980,Use of Aspirin and Heparin on Hospital Admission and Aspirin at Discharge Among Patients Without Contraindications
16981,Use of Aspirin and Heparin on Hospital Admission and Aspirin at Discharge Among Patients Without Contraindications by Time Period
16983,Distribution of total lipid corrected DDT and PCB serum concentrations in cases of non Hodgkin lymphoma and matched controls
16984,Total lipid corrected serum concentrations of DDT and PCB and risk of non Hodgkin lymphoma
16985,Interaction between total lipid corrected PCB serum concentration and EBV EA for risk of non Hodgkin lymphoma
16987,Mean   SEM   urinary excretion of total nitrate and 15N nitrate after infusion of 15N labelled arginine
16989,Individual Results of Atrial and Ventricular Stimulations in Patients With Syndrome X
16992,Median and 5 year overall and progression free survival
16996,Summary of False Positive Early Perfusion Imaging Studies Based on Results of Coronary Angiography
16998,Summary of response data
16999,Adverse events reported in 5  or more of patients in either treatment group
17000,Inclusion and exclusion criteria, predictor variables, and outcome measures of PECARN, CATCH, and CHALICE clinical decision rules  8,9,12
17002,Presence of PECARN, CATCH, and CHALICE predictor variables in the validation and comparison cohort analysis
17003,Diagnostic accuracy of PECARN, CATCH, and CHALICE clinical decision rules when analysed using rule specific inclusion criteria, exclusion criteria, predictor variables, and outcome measures
17004,Diagnostic accuracy of PECARN, CATCH, and CHALICE clinical decision rules in the comparative analysis of all patients with mild injury presenting within 24 h
17007,Adverse events after first, single incontinence procedures in Scotland, 199798 to 201516
17008,Direct comparison of adverse events following specific mesh first, single incontinence procedures in Scotland, 200607 to 201516
17009,Adverse events following first, single prolapse procedures in Scotland, 199798 to 201516
17010,Direct comparison of adverse events after specific mesh and non mesh first, single procedures for prolapse, by anatomical compartment of index procedure in Scotland, 200607 to 201516
17012,Life expectancy, cognitive impairment free life expectancy   CIFLE  , and proportion of life free of cognitive impairment at age 65 years in 1991 and 2011
17013,Life expectancy, healthy life expectancy   self perceived health  , and proportion of life spent healthy at age 65 years in 1991 and 2011
17014,Life expectancy, disability free life expectancy   DFLE  , and proportion of life free of disability at age 65 years in 1991 and 2011
17016,In Hospital, 1 Year and 5 Year Survival
17017,Multivariate Analysis Assessing Predictors of Death During 5 Year Follow Up
17019,Primary outcomes
17021,Analysis of stool culture and PCR results on stools collected at 2 weeks postnatal and 36 weeks postmenstrual age
17022,Secondary analysisprimary outcomes by colonisation status at 2 weeks postnatal age
17024,Clinical severity scores of all patients with MoCD type A treated with cPMP
17026,1 year angiographic and intravascular ultrasound outcomes
17027,Cardiac biomarkers less than 48 h after the index procedure
17028,Results of exercise testing
17029,Secondary clinical outcomes at 1 year follow up
17033,Randomisation, participants, and results of screening all centres   core age group, cutoff date Dec 31, 2010, data truncated at 13 years of follow up
17034,Prostate cancer incidence in the intervention and control groups during three time periods truncated   all centres, core age group, France excluded except for years 19
17036,Prostate cancer mortality in the intervention and control groups during three time periods truncated   all centres, core age group, France excluded except for years 19
17038,All cause and prostate cancer mortality by age at randomisation   France excluded
17040,Absence of Necrosis
17044,Women s assessment of participating in the trial
17048,Health service resource use: mean   SD   resource use per patient and unit costs of resource items by type of care   UK, 2009 prices
17050,Continuous smoking abstinence and 7 day point prevalence, nicotine e cigarettes versus patches
17051,Continuous abstinence and 7 day point prevalence, nicotine e cigarettes versus placebo e cigarettes
17053,Adverse events by type   serious or non serious   and relation to study treatment
17054,Characterization of Infarction, Therapy and Outcome Based on Race
17055,Independent Predictors of Therapy and Outcome
17056,Characterization of Infarction, Therapy and Outcome Based on Age
17057,ST Segment Elevation Among Racial Groups: Use of Thrombolytic Agents and Invasive Therapy
17058,Timeliness of Thrombolytic Therapy During Hospital Shifts
17059,Patient Profiles Based on Evolution of Q Waves
17060,Patient Profile and Treatment During Index Hospital Period
17061,Studies of Acute Myocardial Infarction: Management and Outcome
17063,Effect of treatment at 6 months on fatigue severity, functional impairment, and school attendance in FITNET and usual care groups
17064,Recovery at 6 months in FITNET and usual care groups
17065,Results of reassessment at 12 months   n 127
17066,Detection of enzyme deficiencies and corresponding lysosomal storage disorders   n 34736
17067,Mutations and enzyme activities of neonates
17068,Reported incidences of lysosomal storage disorders
17069,Typical Effective Doses of Some Sources of Radiation
17071,Epidemiological Studies of Thyroid Cancer After Childhood Radiotherapy
17073,Comparison of Estimated ERR Gy Between Selected Medical Studies and the LSS of Japanese Atomic Bomb Survivors
17075,Treatment related adverse events grade 2 or higher, experienced by at least 5  of patients on either group
17081,Study outcomes by treatment group   per patient analysis
17082,Microbiological and clinical information for 15 positive blood cultures from 13 patients
17083,Comparison of resource use and costs by treatment group   per patient analysis
17087,Numbers and incident rate ratios for recorded referrals and identifications of women experiencing domestic violence in general practice and domestic violence referrals received by specialist agencies, 12 months after intervention
17089,Primary and secondary endpoints
17090,Serious adverse events reported
17091,Multivariable analyses to identify factors associated with pancreatic fistula occurrence
17092,Structured Questionnaire
17094,Symptom Frequency During Tachycardia Episodes
17095,Multivariate Logistic Regression Results for the Diagnosis of AVNRT   vs. ORT
17096,Distribution of prediction rule variables and outcomes, according to age group and study phase
17097,Multivariate Logistic Regression Results for the Diagnosis of AVNRT   vs. ORT   in Patients With and Without Positive ECG Findings
17098,Bivariable analysis of tree predictor variables of ciTBI for children younger than 2 years
17099,Bivariable analysis of tree predictor variables of ciTBI for children aged 2 years and older
17101,Hazard ratios for AIDS or death for deferral of combination antiretroviral therapy to a lower CD4 cell count range versus initiation at a higher CD4 cell count range
17102,Hazard ratios for death for deferral of combination antiretroviral therapy to a lower CD4 cell count range versus initiation at a higher CD4 cell count range
17105,Lead Removal Indications, Techniques, and Outcomes
17106,Studied Risk Factors for TTR in Univariate and Multivariate Analysis
17108,Outcomes
17109,Medium chain acyl CoA dehydrogenase deficiency cases in screened and unscreened cohorts, age at diagnosis, and numbers of cases with severe adverse events by 4 years of age
17110,Medium chain acyl CoA dehydrogenase   MCAD   deficiency diagnosed by the age of 2 years in babies born in Australia from April, 1994 to March, 2004
17111,Number of hospital admissions and length of stay for cohorts born April, 1994 to March, 2002
17114,Major Clinical Events at Six Months
17116,Report of Side Effects and Their Severity Associated With the Study Medication
17118,Clinical attributes and incident characteristics of adverse events by indigeneity
17119,Rates of adverse events by indigeneity
17120,Adjusted odds ratios of patient related factors for association with a preventable in hospital adverse event
17121,Age standardised distribution of preventable in hospital adverse events by indigeneity and areas of effort for prevention
17123,Multivariable Model of Mortality After Surgery for Constrictive Pericarditis: Results of Sequential Bootstrapping Cox Proportional Hazards Analyses
17129,Nosocomial infections and period of exposure by group
17130,Nosocomial infection IRR comparisons between treatment groups and the control group
17131,Agents of nosocomial infections by treatment group
17133,Valvular Disease Following Irradiation
17134,LV Size and Function Following Irradiation
17135,Electrocardiogram Findings Following Irradiation
17137,Health resource use over weeks 060
17138,Countries included in the early discharge analysis
17140,30 day and 1 year mortality by early discharge eligibility by country and trial
17142,Outcome at discharge and at 3 months
17143,Recovery and adverse events
17144,Incidence of GM Using the Different Radiation Sources
17145,Incidence of Restenosis Within Different Analyzed Segments at Follow Up
17146,Angiographic Results at Follow Up Comparing Various Injured Segments
17148,Neuropsychological test scores of low grade glioma patients, NHL CLL patients, and healthy controls
17151,Quantitative Coronary Angiography
17152,Major Clinical Events at Six Months
17153,Predictors of Angiographic Restenosis and MACE   TVR   at Six Months
17155,Reported psychopathology in exposed and non  exposed children
17157,Effect of streptolysin S gene mutation on group G streptococcus and group A streptococcus virulence in the murine model of necrotising fasciitis
17160,Difference in overall   123I    CIT binding ratios
17161,Differences in regional   123I    CIT binding ratios in men and women
17162,Test scores of DDT exposed individuals and controls
17163,Significant relations of DDT application years with test outcome   n 54
17164,Thallium SPECT Models for Prediction of All cause Mortality With Akaike Information Criterion Scores and Weights legend
17166,Nuclear and Exercise Predictors of Risk of Death After Adjustment for Potential Confounders: Results of Multivariable Cox Regression Analyses
17167,Results of observational studies of statin use and fractures
17169,Number of fractures necessitating hospital admission by body region and study group
17170,Hazard ratios of fracture with pravastatin use
17171,Metabolic activity before grafting   T3   and at the final assessment   T5
17172,Comparison of results of neuropsychological tests between T3 and T5
17174,Odds ratios of developing venous thromboembolism associated with use of antipsychotic and antidepressant medications
17175,Categories of antipsychotic drugs
17178,Adverse events
17179,Postsurgical recurrence
17180,Analyses on recurrence
17183,Week 54: Related  Adverse Events Experienced by at Least 3  of Patients in Any Randomized Treatment Group    Number     of Patients
17184,Patient profile upon referral: the 7 patients who underwent transplant
17185,Toxic effects.
17186,Resting and activated T cells CD69 expression before and after transplantation
17187,Interleukin 4 and interferon gamma expression beforeand after transplantation
17189,Number of positive, percentage, and mean differences for all parasites assessed   except S mansoni  , at beginning and end
17190,Adverse events due to artemether treatment after 24 h and reported illness episodes
17193,Clinical Outcomes
17194,Predictors of CICU Mortality
17196,Objective work problems in cases and controls
17197,Logistic regression analysis to predict cases
17198,Logistic regression analysis to predict cases versus controls
17199,Neutralising antibodies to dengue viruses in the student cohort
17203,Comparison Between PAV Regression and Progression
17207,Cellular yield during the 14 cell selection and expansion procedures
17208,Haematopoietic recovery and transfusion use
17209,Results of a masked screening test for sphingolipid storage diseases
17210,Neutralising antibody titres to H9N2 viruses in serum samples from blood donors in Hong Kong
17212,Efficacy and Safety Outcomes
17213,Clinical, Procedural, and Bioimpedance Data of StudyPopulation
17216,Multivariable Logistic Regression Models of Predictors of CI AKI
17217,Correlation between three measures of myelopathy both preoperatively and postoperatively   two tailed Spearman s test, p 0001 in each case
17219,Results of Conditional Analysis at the Chromosome 4q25 Locus in the AFGen Consortium
17220,Marginal and SNP Adjusted Associations Between Distinct AF Susceptibility SNPs and AF in the AFGen Consortium and BioBankJapan Sample
17221,Association Between Multimarker Risk Scores and AF in the AFGen Consortium andBioBank Japan Samples
17222,Percentages   95  CI   renting homes according to Registrar General s Social Class and educational qualifications
17223,Prevalence and odds ratios for neurotic disorder by sex and social class
17224,Prevalence and odds ratios for neurotic disorder by sex, housing tenure, and car access
17225,Prevalence and odds ratios for neurotic disorder by sex and educational qualifications
17226,Hantavirus serotyping by focus reduction netralisation test   FRNT
17227,Prevalence and Incidence of the Brugada Type ECG from 1958 to 1999
17228,Distribution of conventional prognostic factors between menstrual phases
17229,Seven Cases of Unexpected Death, With a Brugada Type Electrocardiogram legend
17231,Age  and Gender Standardized Mortality of 32 Subjects With a Brugada Type Electrocardiogram and 4,756 Control Subjects
17232,Mean preoperative z scores for each cognitive area by preoperative depression status
17233,Relation of decline in cognitive area to change in depression status at 1 month and at 1 year after surgery
17234,Cognitive testing at intake   mean, SD
17235,CSF findings
17236,Diagnostic serological tests for EMV
17238,Cardiovascular Prognosis legend
17239,Cox Regression Analysis for Stroke   n   958   legend
17240,Relative Risks for Stroke and Silent Cerebral Infarct   n   585   legend
17241,Frequency of Right Bundle Branch Block and ST Segment Elevation in the Right Precordial Leads   V1to V3   in a Japanese Working Population in the Tokyo Metropolitan Area legend
17245,Reclassification of 10 year predicted risk and changes in risk discrimination for cardiovascular disease after addition of adiposity measures to a model including Framingham risk score covariates
17249,Biochemical Values Before and After Catheterization
17250,Two Way Repeated Measures ANOVA for the Biochemical Parameters
17251,The Change      in Biochemical Values Before and After Catheterization
17252,Design features of cohort studies of cancer incidence in people with HIV AIDS included in the meta analysis
17253,Design features of cohort studies of cancer incidence in people after organ transplantation included in the meta analysis
17254,Cancer in people with HIV AIDS: study specific standardised incidence ratios
17255,Cancer in transplant recipients: study specific standardised incidence ratios
17256,Operations for abdominal aortic aneurysm   AAA   and subsequent 30 day mortality
17257,Mortality related to abdominal aortic aneurysm   AAA   and incidence of ruptured AAA
17258,All cause mortality
17259,Timing of incidence of ruptured abdominal aortic aneurysm   AAA   and deaths for individuals invited for screening
17260,Mortality related to abdominal aortic aneurysm   AAA  , ruptured AAA incidence, and all cause mortality, by attendance at screening
17261,Mood and health status outcomes
17262,Patient Data  legend
17263,Episodes of acute abdominal pain in patients with hereditary angioneurotic oedema
17264,Correlation Coefficients Relating Hemodynamic Parameters to Plasma Levels of ANP and BNP  legend
17265,The effect of eradication on frequency of clinical manifestations and drug dose
17267,Details of patients in the EuroSIDA study
17268,Association between latest CD4 lymphocyte count, treatment regimen, and incidence of ADIs
17269,Contribution of individual ADIs over time
17270,Sex, age, admission delay, and hospital stay related to clinical severity and cause for pancreatitis patients
17271,Final diagnoses for controls
17272,Value of clinicobiochemical systems, plasma C reactive protein, and urinary TAP concentrations in prediction of severe acute compared with mild acute pancreatitis
17274,Heart Rate and Mean Blood Pressure Before and After Sublingual Administration of Nitroglycerin legend
17275,Forearm Blood Flow   ml min 100 ml arm   and Platelet cGMP Level   pmol 109Platelets   Before and After Sublingual Administration of Nitroglycerin legend
17276,Number of readmissions
17277,Outcome readmissions
17278,Rate of readmissions
17279,Mean costs and cost differences by resource category
17284,In Hospital Adverse Events
17286,Clinical Trial Participation of Women Across CVD Areas
17287,Screened and Enrolled Participants by Gender
17288,Age standardised asthma mortality for the 534 year age group for 46 countries
17289,Crude asthma mortality for the 534 year age group for nine countries, for the years 19602012, weighted by country population
17290,Numbers of unconfounded randomised trials of an adjuvant bisphosphonate identified, and numbers with data received, by duration and type of bisphosphonate treatment
17291,Estimation of the effect of 5 years of an aromatase inhibitor versus no endocrine treatment
17293,Primary outcomes 90 days after hospital admission
17294,Secondary outcomes, processes of care measures for fever, glucose, and swallowing screening
17295,Number of individuals screened and incidence of low grade cervical cytological abnormalities and high grade cervical histopathological abnormalities before and after introduction of the national human papillomavirus vaccination programme, by age group
17296,Comparison of trends in incident high grade cervical abnormalities in the two youngest age groups, before and after introduction of the HPV vaccination programme
17297,Availability of data from randomised trials of radiotherapy after breast conserving surgery for invasive cancer that began before the year 2000
17304,DAPT Use and Adherence
17305,Clinical Outcomes Through 3 Years
17306,Multivariable Predictors of Outcomes
17307,Clinical Outcomes Through 3 Years Stratified by CoreLaboratory Assessed Reference Vessel Diameter of Treated Lesions
17310,Instrumental Diagnostic Findings According to EM Different Etiologies
17311,In Hospital Events and Treatment and Post Discharge Events According to EM Different Etiologies
17313,Comparison of Resting Indices According to Different Angiographic and Hemodynamic Stenosis Severity
17314,Comparison of Clinical Outcomes According to Resting Pressure Derived Physiological Indices
17317,Mortality and complications according to treatment group
17318,Recovery times in surviving patients according to treatment group
17319,Categorisation of risk of recurrence in endometrial cancer
17322,Overall, disease specific, and recurrence free survival of patients with endometrial carcinoma according to type of lymphadenectomy and risk of recurrence
17323,Multivariate analysis of prognostic factors in overall survival for patients with endometrial carcinoma of intermediate or high risk of recurrence   n 407
17324,Distribution of adjuvant therapy across patients with endometrial carcinoma of intermediate or high risk of recurrence
17325,Multivariate analysis of prognostic factors in overall survival for patients with intermediate risk or high risk endometrial carcinoma who were treated with adjuvant radiotherapy or chemotherapy   n 328
17329,3 year local recurrence rates for the plane of surgery achieved
17330,3 year disease free survival rates for plane of surgery achieved
17331,Factors associated with local recurrence
17333,Cumulative Incidence of Arterial Thromboembolism, Stratified by Cancer Type
17334,Relative Hazards of Arterial Thromboembolism During Discrete Time Periods, Stratified by Cancer Type and ThromboembolismType
17335,Cumulative Incidence of Secondary Outcomes, Stratified by Cancer Type
17336,Relative Hazards of Arterial Thromboembolism During Discrete Time Periods, Stratified by Cancer Stage and Thromboembolism Type
17337,Cumulative Incidence of Arterial Thromboembolism, Stratified by Cancer Stage
17341,Intravascular Ultrasound Measurements
17342,RPA class definitions
17343,RTOG CNS toxicity criteria
17345,Reasons for not receiving stereotactic radiosurgery
17346,Treatment related toxicities
17347,Causes of death
17348,Univariate and multivariate survival analyses
17349,Performance measurements at 6 months  follow up
17350,Radiographic responses at 3 months  follow up
17351,Summary of radiosurgery treatment variables
17352,Literature review of adjuvant treatments with or without WBRT for brain metastases
17354,Unadjusted In Hospital Mortality
17355,Full and Pre Cath Simplified Risk Models
17356,NCDR CathPCI Risk Score System
17357,C Indices for NCDR Models
17359,Pathogens cultured at the first AOM episode after completion of the vaccination scheme
17360,Geometric mean concentrations   mg L   of IgG anti pneumococcal antibodies against conjugate vaccine pneumococcal serotypes
17361,Per Cell Fluorescence 24 h After IV Injection
17362,Heart and Body Weights
17363,Incidence of invasive melanoma   level 2 or higher
17364,Survival by age group and tumour thickness
17365,Survival by year of diagnosis
17367,Frequency of major wound complications with criteria for 182 evaluable patients
17368,Type of wound closure, and wound complications by anatomical site and wound reconstruction in evaluable patients
17370,Mortality and causes of death for all eligible patients
17372,Results for Measures of CMR After 5 Days and 6 Months
17373,Left Ventricular Wall Thickness in the Infarcted Myocardium and in the Remote Nonischemic Myocardium at 5 Days and 6 Months
17374,Proportion of M1 and M6 isolates detected during two different periods
17376,Results from lung cancer trial at about annual intervals
17377,Results from head and neck cancer trial at about annual intervals
17380,CTA Imaging Parameters and Results
17381,Severity of CAD   Models 1 and 2   and Adverse Cardiac Events   N   2,076
17383,Cox Models of CTA Measures   CAD Model 1   and MACE
17384,Cox Models of CTA Measures   CAD Model 1   and All Cause Mortality and Nonfatal MI
17385,Cox Models of CTA Measures   CAD Model 1   and All Cause Mortality
17387,Effect of preoperative radiotherapy, at biologically effective dose 30 Gy, and of postoperative radiotherapy, on risk of isolated local recurrence by Dukes  stage, age, sex and radiotherapy schedule for curatively resected patients
17388,Effect of preoperative radiotherapy, at biologically effective dose 30 Gy, on death from rectal cancer, on death from other cause, and overall mortality by age and stage in patients who have been curatively resected
17392,Procedural Results
17393,Stent Thrombosis
17395,Association between fracture risk and dispensing of statins and non statin lipid lowering drugs
17396,Randomised trials of radiotherapy versus the same management without radiotherapy
17397,Availability of data from unconfounded randomised trials of radiotherapy versus control that began before 1990
17398,Effects of radiotherapy allocation on 10 year probability of recurrence, by type of surgery and nodal status
17399,Effects of radiotherapy   RT   allocation on particular causes of death for women dying without any breast cancer recurrence
17401,Differences in ophthalmic findings at 24 weeks between patients in radiotherapy and sham irradiation groups
17403,Clinical Outcome at 3 Years
17404,Clinical Events During 12  to 36 Month Follow Up
17407,Angiographic Outcomes at 8 Months
17408,IVUS Findings at 8 Months
17409,Clinical Outcomes at 30 Days
17410,Clinical Outcomes at 9 and 12 Months
17411,Multivariate Predictors of TLR and TVF at 12 Months
17416,Results of tests before and after study period
17417,Crude survival and cause of death
17418,Number of patients and relative hazard of ischaemic heart disease and acute myocardial infarction by radiotherapy group, side of tumour, and menopausal status
17419,Number of patients and relative hazard of ischaemic heart disease according to radiotherapy and side of tumour censored at time of recurrent breast cancer
17420,Patient Data, by Culprit Lesion
17424,MI Status, by Culprit Lesion or Thrombus Age
17425,Morphometry Data
17426,Hemodynamic Data
17429,D2B Alliance Hospitals  Participation in Activities Sponsored by the D2B Alliance
17430,Association Between D2B Alliance Enrollment and Door to Balloon Time Within 90 Min
17432,Long Term Mortality Risk After First AMI Associated With Smoking Categories Modeled as Time Varying Covariates
17433,Number of Any CV and Deaths
17434,Relationships Among Culprit Plaque Morphology, Embolization, Occlusive Thrombus, Myocardial Necrosis, and Sex
17435,Clinical profiles of patients
17436,Laboratory data
17437,Results of microbiological tests
17438,Expansion of Vb2 positive T cells in NTED patients
17439,Sequence analysis of junctional regions of T cellreceptor b chains containing Vb2 elements in peripheral T cells of patients 10 and 11
17442,30 Day and Long Term Mortality According to Degree of ST Segment Resolution at 90 Min and 4 Hours After Initiation of Reperfusion Therapy
17443,Predictors of Long Term Outcome in Relation to ST Segment Resolution 4 Hours After Start of Reperfusion Therapy
17444,30 Day and Long Term Reinfarction According to Degree of ST Segment Resolution at 90 Min and 4 Hours After Initiation of Reperfusion Therapy
17447,Sensitivity of main results to exclusion of patients
17449,Health State Specific Life Expectancy by Age and Sex From Framingham Data
17450,Costs, Life Years Lost, and QALY of 30 Days and Lifetime by Treatment Group
17451,Cost Effectiveness
17453,Distribution of factors affecting prognosis by cervical diameter in patients in surgery and radiotherapy groups
17454,Pathological risk factors in surgery group patients by cervical diameter
17455,Relapses and morbidity
17456,Univariate and multivariate analysis of overall survival
17457,Index cases for all newborn infants delivered
17458,Index cases of infants with VUR
17459,Sex distribution of index cases and infants with VUR
17460,Confirmed assumed VUR in index cases
17461,Average age of patients and intended initial treatment according to cancer grade in patients with clinically localised prostate cancer
17462,10 year disease specific survival in patients with clinically localised prostate cancer by intention to treat and by treatment received
17463,10 year overall survival in patients with clinically localised prostate cancer and age matched cohorts
17464,Survival in patients with grade 3 disease 5 years after diagnosis
17465,10 year prostate cancer specific survival   with 95  CI   in patients with clinically localised prostate cancer
17467,Comparison of the Invasive and Noninvasive Measures of Microvascular Perfusion
17468,Left Ventricular Volumes and Ejection Fraction at 2 Days and 6 Months and Infarct Size at 6 Months
17469,Unblinded study of APA in SBI recipients, women with autoimmune disease, and healthy blood donors
17470,Proportions of participants positive for APA and ANA   blinded study
17473,Late complications during first 5 years after surgery
17475,Type of surgery by allocated treatment
17476,Postoperative complications by allocated treatment
17477,Pathological assessments by allocated treatment
17479,Cumulative Clinical Outcomes Up to 5 Years and Between 1 and 5 Years
17480,Incidence of ST According to Academic Research Consortium Definition
17481,Annualized Hazard Ratio per 100 Patient Years
17482,Clinical Outcomes in Diabetic Patients
17485,Crude and Adjusted Hazard Ratios of Clinical Outcomes According to Stent Group
17486,Cohorts of patients followed up for tonsillar SCC, other oral SCC, and anogenital SCC after initial HPV associated and HPV unrelated cancers, SEER 197394
17487,Tonsillar SCC, other oral SCC, and anogenital SCC after initial HPV associated cervical, vulvar vaginal, and anal SCC and HPV unrelated cancers of colon, stomach, and breast, SEER 197394
17489,Clinical Outcomes After Index PCI Among On  and Off Label Patients
17490,Clinical Outcomes Associated With the Use of DES in Patients With Off Label Indications: Multivariate Cox Proportional Hazards Models
17491,Controls used in multiple regression and sensitivity analyses
17492,Population estimates of countries included in multiple regression and time series analyses, 2009
17493,Cancer mortality rates in year of unemployment controlling for universal health coverage   UHC
17494,Rate ratios between projected mortality rates based on 200007 observation base and observed mortality rates in 2008, 2009, and 2010 for all cancers and all age groups   084 years   in different country categories
17495,Cancer mortality in year of rise in public sector expenditure on health care controlling for universal health coverage
17496,Cumulative Clinical Events at 1  and 5 Year Clinical Follow Up
17497,Stent Thrombosis According to the Protocol and ARC Definitions   Up to 5 Years Follow Up
17498,Cumulative Clinical Events at 5 Year Clinical Follow Up, SES Versus BMS, in Patients With and Without DM
17501,Frequency of Different Off Label Criteria
17506,Outcome concordance in individual patients   by patient number   during AF 219 treatment in per protocol dataset, ranked by percentage change in daytime cough frequency
17507,Treatment emergent adverse events reported by more than one AF 219 treated patient
17508,Randomised controlled trials comparing percutaneous coronary intervention with the use of stents against coronary artery bypass grafting
17511,Factors associated with oral human papillomavirus   HPV   incidence
17513,Comparison of transplant outcomes
17514,Cox proportional hazards regression model for graft failure with interactions
17516,Number of Cardiac Deaths, MIs, and the Combination of Cardiac Death or MI While Patients Were Taking Dual Antiplatelet Therapy
17517,Poisson Multivariable Analysis Assessing the Incidence Rate Ratio of Cardiac Mortality and MI During the Course of Dual AP and After Clopidogrel Discontinuation
17518,Incidence of Cardiac Mortality and MI After Stopping Clopidogrel in Relation to Dual Antiplatelet Therapy Duration
17522,Paired greyscale measurements with intravascular ultrasonography   per lesion
17523,Serial radiofrequency backscattering analysis
17526,Multivariable risk factors for 3 year survival after lung transplantation
17529,Quantitative Coronary Angiography Analysis of the Lesions Treated in the Total Cohort and in the Angiographic Subgroup
17530,In Hospital, Cumulative 30 Day, and Cumulative 9 Month Clinical Events
17531,Serial Intravascular Ultrasound Serial Analysis of Lesions Treated
17533,Factors associated with the absence of antibodies to measles virus in oral fluid from 943 Zambian children
17535,Clinical outcomes at 2 years
17536,Results from imaging methods immediately after the procedure, at 6 months, and at 2 years
17537,Details of studies and women included
17538,Relative risk of ovarian cancer in users of oral contraceptives compared with never users, by duration of oral contraceptive use
17539,Relative risk of ovarian cancer in ever users of oral contraceptives compared with that in never users, by time since last use and duration of use of oral contraceptives
17540,Relative risk of ovarian cancer in ever users of oral contraceptives compared with that in never users, by age at first use and duration of use of oral contraceptives
17541,Relative risk of ovarian cancer in ever users of oral contraceptives compared with that in never users, by calendar year of use and time since last use of oral contraceptives
17542,Estimated proportion of ovarian cancers prevented before age 75 years by past patterns of use of oral contraceptives in different countries over five decades
17544,Lesions Treated With DES or BMS in Western Denmark From January 2002 Through June 2005
17545,Incidence Rate and RR of Definite Stent Thrombosis in Lesions Treated With DES   n   5,422, SES   3,426, PES   1,991   or BMS   n   11,730   in Western Denmark From January 2002 Through June 2005
17546,RR Estimates for Death, Myocardial Infarction, and Stent Thrombosis   Definite, Probable, and Possible   Among Patients Treated With BMS   n   8,847   or DES   n   3,548   in Western Denmark
17547,RR Estimates of Definite ST and Mortality in Lesions Treated With DES   n   5,422, SES   3,426, PES   1,991   or BMS   n   11,730  , Cumulative Time Periods
17549,Univariate and multi covariate analysis of NSAID and paracetamol use, smoking status, and oral cancer risk
17550,Risk of cardiovascular disease related death in long term users of NSAIDs and paracetamol
17551,Summary of patients
17552,Cervical cancer death rate per 100000 in England and Wales
17554,Risk Adjusted     Odds Ratio for In Hospital Mortality by Various Annual Hospital and Physician Volume Thresholds for Primary PCI
17555,Average Mortality by Physician and Hospital Volume
17556,Patient characterisitics and transgender CNS engraftment
17557,Neuron chromosome analysis
17558,Donor s relationship to the recipient
17559,Perioperative mortality and morbidity according to graft type
17560,Operative morbidity
17561,Two most frequent complications by graft type
17562,Postoperative hospital stay according to graft
17563,Graft type and frequency of reoperation
17564,Mortality from breast, uterine, and ovarian cancer in relation to total duration of oral contraceptive use and number of cigarettes smoked per day at entry to the study
17565,Mortality from other cancers in relation to total duration of oral contraceptive use and number of cigarettes smoked per day at entry to the study
17566,Mortality from cardiovascular disease in relation to total duration of oral contraceptive and body mass index use   months   and number of cigarettes smoked per day at entry to the study
17567,Mortality from other causes and all causes in relation to total duration of oral contraceptive use   months   and number of cigarettes smoked per day at entry to the study
17568,Mortality from all causes in relation to age and number of cigarettes smoked per day
17570,Prevalence of glucose abnormalities at discharge and 3 months after discharge in patients with myocardial infarction
17572,Multiple logistic regression analysis of independent predictors of diabetes mellitus and abnormal glucose tolerance at oral glucose tolerance test 3 months after discharge
17573,Multiple logistic regression analysis of independent predictors of diabetes mellitus and abnormal glucose tolerance at oral glucose tolerance test 3 months after discharge
17578,Early efficacy of HIV 1 infection and HIV 1 infection or death
17580,Frequency of laboratory and congenital abnormalities, and neurological events observed, according to treatment arms
17582,Cardiac Magnetic Resonance Imaging Results
17584,Outcome measurements among the races
17586,Results of univariate analysis for patient survival at 2 years
17587,Results of multivariate Cox regression model for patient survival at 2 years
17588,Results of multivariate Cox regression model for graft survival at 2 years
17590,Probability of HIV 1 infection diagnosis in 391 children during the first 15 months of life
17591,Mean values for assessment data at time of acceptance for transplantation
17592,Univariate regression values
17594,Frequency of kidney damage
17595,Type of kidney damage
17596,Kidney damage according to organs retrieved and surgical teams
17599,Incidence of myocardial infarction, stroke, or cardiovascular death
17601,Bleeding complications
17602,Primary outcome events at 3 months
17603,Failure rates at 30 days and 3 months after endarterectomy
17607,Mobilization of CD34 CD133 VEGFR2  EPCs, CD34 CXCR4  Cells, and linCD133 CD45 VSELs in Patients With Acute MI in Comparison With Healthy Control Subjects
17609,Outcome of treatment
17610,Adverse events
17612,Medical Therapy and Invasive Coronary Revascularization Within 30 Days of Index Myocardial Infarction
17613,Intercurrent Hospitalizations in the First Year After Index Myocardial Infarction
17615,Multivariable Multistate Modeling for Predictors of Heart Failure or Mortality
17616,Prevalence of current use and ever use of HRT among cases and control subgroups
17617,Odds ratios of VTE in relation to current HRT use
17619,Distribution of types of arterial stroke by region
17621,Odds ratios of ischaemic stroke in relation to combined OC use by region
17622,Odds ratios of ischaemic stroke in relation to current combined OC use by age group and whether blood pressure   BP   was checked before current episode of OC use
17623,Odds ratios of ischaemic stroke in relation to current combined OC use by smoking status and history of hypertension
17624,Odds ratios of ischaemic stroke in relation to current combined OC use by progestagen type and oestrogen dose
17625,Odds ratios of ischaemic stroke in relation to current use of combined OCs containing second generation progestagen by whether blood pressure   BP   was checked before current episode of use
17626,Classification of Animals Used in the Study
17627,Echocardiographic Parameters of LV Remodeling and Function
17634,Cumulative sodium and water balance over days 04
17635,Secondary endpoints
17636,Side effects and complications
17639,Operative interventions and neonatal outcome analysed according to intention to treat
17640,Operative interventions and neonatal outcome analysed after exclusions of inadequate recordings and fetal malformations
17644,CD14 16 and CD14 69 cells in individual participants
17645,Age and sex distribution of cases   n 182
17646,Clinical signs at entry into the study   definite and probable CJD cases n 104
17647,Concentrations of neuron specific enolase   NSE   and detection of p130 p131   n 176 sporadic cases plus n 6 genetic cases
17648,Initial classification of neuropathologically confirmed sporadic cases   n 52
17651,Frequency of distribution of HLA alleles
17652,Distribution of genotypes and frequency of alleles of A G polymorphism in exon 1 of CTLA4 gene
17656,Classification of thyroid sizes by means of WHO s 1960 and 1994 criteria
17657,Angiographic Analysis
17658,Prevalence of goitre as assessed by WHO 1960 and WHO1994 classifications, and by ultrasonography
17659,In Hospital and 6 Month Follow Up Outcomes
17660,values on agreement of goitre diagnosis between examiners A, B, and C, between different classification systems in morning sessions, and between morning and afternoon sessions with the same classification system
17661,Mean width, depth, and length of two thyroid lobes from morning ultrasonography session in children without visible goitre by 1960 system
17662,Sensitivity and specificity of repeated goitre diagnosis by palpation
17665,Prevalence and awareness of chronic kidney disease by socioeconomic status in cohort participants
17666,Randomized Controlled Trials Included in the Meta Analysis
17667,Hazard ratio for five stages of chronic kidney disease from all causes, cardiovascular disease, expanded cardiovascular disease, and non cardiovascular disease mortality
17668,Registries Included in Meta Analysis
17669,Attributable fraction of all cause mortality from different stages of chronic kidney disease
17670,Results of Pooled Analysis With Point Estimates for Clinical Events in RCTs and Registries
17672,Hazard ratios   95  CIs        for stress urinary incontinence surgery when comparing exposed and unexposed cohorts
17673,Risk for stress urinary incontinence surgery after hysterectomy in relation to number of vaginal childbirths
17674,Risk for stress urinary incontinence surgery in relation to mode of hysterectomy
17675,Occurrence of intraventricular haemorrhage
17676,Patent ductus arteriosus
17677,Complications and renal effects
17678,Distributions of age and major cardiovascular risk factors by 24 h urinary sodium excretion in men and women
17679,Hazards ratios of coronary heart disease, cardiovascular, and all cause mortality associated with 24 h urinary sodium excretion
17680,Hazards ratios of coronary heart disease and stroke incidence associated with 24 h urinary sodium excretion
17681,Adjusted hazards ratios of cardiovascular and all cause mortality associated with 24 h urinary sodium excretion in men of normal weight and in overweight men
17682,Urinary total isothiocyanate concentration in relation to risk of lung cancer in men in Shanghai
17683,GSTM1 and GSTT1 genotypes in relation to lung cancer risk among a cohort of men in Shanghai
17684,Urinary total isothiocyanate concentration in relation to risk of lung cancer according to GSTM1 and GSTT1 genotypes
17685,GSTM1 and GSTT1 genotypes in relation to lung cancer risk according to urinary total isothiocyanate concentration
17689,Multiple regression analysis   follow up
17693,Registered infant and newborn mortality rates in three townships
17694,Odds ratios of iodine treatment and other variables on neonatal and infant mortality
17697,Procedural Success and Outcomes After PCI
17698,Multivariate Predictors of 30 Day and Long Term Outcome
17700,Secondary endpoints
17702,Results of scintigraphy
17703,Complications within first 30 days after treatment
17704,Histopathological and clinical data
17705,Hormone concentrations in college aged people before and after liquorice consumption
17706,Ethnic origin of patients with tuberculosis who were tested for HIV 1 infection
17707,Patients with tuberculosis who tested positive for HIV 1
17710,Relative risk of endometrial cancer in relation to tamoxifen use
17711,Immunohistochemical Distribution of Adhesion Complex Proteins in Myocardial Specimens Obtained From Patients With and Without Infarct Rupture
17712,Effects of weight, body mass index, and HRT on the relation between tamoxifen use and endometrial cancer
17714,Prognostic factors influencing endometrial cancer specific survival
17717,Unadjusted Clinical Outcomes
17718,Results of Multivariable Models: Clinical Outcomes
17720,Results From Multiple Logistic Regression Analysis That Evaluated the Association Between Physical Activity Status and Cardiovascular Events
17722,Clinical Outcomes at 30 Days by Diabetic Status
17724,Clinical Outcomes at 30 Days in Diabetic Patients by Randomized Treatment Group
17727,Myocardial Deformation and ceMRI Parameters Before Revascularization for Segments With and Without Functional Recovery at Follow Up
17728,Prediction of Segmental Functional Recovery After Revascularization Using Myocardial Deformation and ceMRI Parameters
17730,Mean Lipid Values at Each Time Point
17731,Changes in LDL C Over Time After Hospitalization for ACS
17732,Cardiac Morphometry, Hemodynamics, and Levels of Glucose and Insulin at End of Study
17739,Correlation Between Lp PLA2 and Other Risk Factors
17740,HRs   95  CIs   for Incident CHD by Lp PLA2 Quartile
17744,RCTs of BMS Versus DES With MACE as an Outcome
17745,Use of the Term MACE as an Outcome in the Journal   2006
17747,Post Index PCI Medications Use by Stent Type and Procedure Indication
17748,Cox PH Multivariate Analysis of Nonfatal MI or Death and Stent Thrombosis to 2 Years
17750,Correlation   R Value   Between Measures of Microvascular Function and Peak CK and 3 Month WMS
17752,Association of KIF6 Trp719Arg With CHD, MI, and Ischemic Stroke
17753,Association Between KIF6 719Arg and Risk of CHD
17755,Association of 35 Polymorphisms With MI in CARE and CHD in WOSCOPS
17759,Absolute Risk and Absolute Risk Reduction of MI in the CARE Trial and of CHD in the WOSCOPS Trial: Effect of Pravastatin in KIF6 Trp719Arg Subgroups
17760,Use of Nonstudy Lipid Lowering Therapies During Follow Up
17762,Cumulative Probability of Outcome Measures During Extended Follow Up
17763,Bezafibrate  Versus Placebo Allocated Patients Risk for the Combined End Point of Cardiac Death or Nonfatal Myocardial Infarction During the Extended Follow Up Period: Overall Effect
17764,Bezafibrate  Versus Placebo Allocated Patients Risk for the Combined End Point of Cardiac Death or Nonfatal Myocardial Infarction During the Extended Follow Up Period: Effect in Risk Groups
17765,Clinical and Angiographic Features in the 2 Groups of Patients
17771,Detection of the Culprit Plaque by IVUS
17772,IVUS Analysis in Patients With LAD Reperfusion
17773,IVUS Analysis in Patients With LAD Total Occlusion
17775,Hazard Ratios for 1 Year All Cause Mortality
17776,TnI and H FABP Concentration Quartiles
17777,All Cause Mortality According to H FABP Diagnostic Cutoff With Hazard Ratio Adjusted Using GRACE Risk Factors Plus hs CRP With TnI as an Additional Continuous Variable
17780,QCA Analysis of the Main and Side Branch
17781,IVUS Analysis of the Main Branch
17784,Reasons for No Revascularization or No Revascularization Work Up in Patients With High or Medium Viability
17785,Reasons for Revascularization or Revascularization Work Up in Patients With Low Amounts of Viability
17786,Reasons for Not Undergoing Revascularization in 30 Patients With High or Moderate Viability Who Underwent Revascularization Work Up
17788,Short Term and Long Term Major Adverse Clinical Events in PCI Patients
17789,Major Bleeding in PCI Patients According to the Day After Randomization
17790,Clinical Outcomes at Day 9 in Patients Undergoing Early PCI   Within 24 h of Randomization
17791,PCI Related Angiographic and Clinical Outcomes According to Use of Open Label UFH Given in the Catheterization Laboratory Before PCI
17792,Graft Area   mm2
17795,Procedural Outcomes and Angiographic Results   Intention to Treat
17796,30 Day Hierarchical MACE: Intention to Treat
17797,Multivariable Predictors of MACE   to 30 Days  : Intention to Treat Analysis
17798,Multivariable Predictors of MACE   to 30 Days  : Device Analysis
17800,End Point Definitions in Each Trial Included in the Meta Analysis
17802,Morbidity and Mortality
17803,Cumulative Incidence of MACE Observed Up to 5 Years in 120 SES Versus 118 BMS Recipients
17804,Stent Thromboses Adjudicated Per Protocol and According to the ARC Definitions in Each Study Group
17805,Deaths During Follow Up in Each Study Group
17808,Preintervention IVUS Findings
17809,Valuation of Infarct Size in Each Risk Factor and Subgroup
17810,Multiple Logistic Regression Analysis for LVEF  50  at Chronic Phases
17814,Unadjusted Adverse Outcomes at 9 Months Comparing SES and PES Groups
17815,Unadjusted and Adjusted Hazard Ratios for Clinical Outcomes Comparing SES and PES Groups at 9 Months
17818,Distribution of Ruptured Plaque and Fibrous Cap Atheroma by Gender, Cause of Death, and Presence of Rupture
17819,Morphometric Dimensions of Ruptured Plaques and Fibrous Cap Atheromata
17821,Clinical and Cardiac Parameters Assessed in Normotensive Subjects and in the Whole Group of Patients With Chronic Heart Failure
17824,Classification of Thrombus Burden
17825,Independent Predictors of Clinical Outcomes
17826,Procedural Outcome
17827,Independent Predictors of Infarct Related Artery Stent Thrombosis
17829,Lesions Treated With DES or BMS in Western Denmark, January 2002 Through June 2005
17830,Risk of Definite Stent Thrombosis in Lesions Treated With BMS   n   11,730   or DES   n   5,422   in Western Denmark
17831,Relative Risk Estimates for Death, Myocardial Infarction and Stent Thrombosis   Definite, Probable, and Possible   Among Patients Treated With BMS   n   8,847   or DES   n   3,548   in Western Denmark
17833,Cox Model for Predictors of Cardiac Death
17834,Cox Model for Predictors of Cardiac Death or Nonfatal Acute Myocardial Infarction
17840,Results of Univariable Logistic Regression Analysis Regarding CAD Status   Stable CAD vs. ACS   in Whole Patient Group   n   212
17841,Results of Multivariable Logistic Regression Analysis Regarding CAD Status   Stable CAD vs. ACS   in Whole Patient Group   n   212
17843,Event Rates Per 1,000 Person Years According to Cumulative Mean Follow Up Anxiety Score Classification
17844,Relationship Between the Cumulative Mean Anxiety Score and the Primary Outcome   Nonfatal Myocardial Infarction or All Cause Mortality
17846,Relationship Between Cumulative Mean Follow Up Anxiety Score and Cardiac Events and Total Mortality
17848,Procedural Results
17849,Angiographic Results at 1 Year Follow Up
17850,Clinical Outcome at Hospital Discharge and at 1 Year
17852,Hemodynamic Assessment of Pig Hearts
17853,Regional Myocardial Blood Flow in Epicardial and Endocardial Tissue Samples
17855,Procedural Features in the Atorvastatin and Placebo Groups
17856,Individual and Combined Outcome Measures of the Primary End Point at 30 Days in the Atorvastatin and Placebo Groups
17861,Patient Data
17862,Trial Design of Rescue PCI Trials
17863,Sensitivity Analysis of the Effect of Rescue PCI or Repeat Fibrinolytic Therapy on Mortality
17864,Trial Design of Repeat Fibrinolytic Therapy Trials
17865,INSPIRE Inclusion and Exclusion Criteria    14
17866,Medication Ranking for Determining the Intensity of Medical Therapy
17867,Therapeutic Considerations for Patients Randomized to Strategy 2    14
17869,Comparison Between Patients Who Did or Did Not Have Repeat SPECT
17870,Medical Therapy Administered to Patients in Both Strategies Who Had Two SPECT Studies
17871,Coronary Revascularization Results Based on Stenosis Severity in Patients Randomized to Strategy 2 Who Had Two SPECT Studies
17872,Primary End Point: Gated SPECT Results: Strategy 1 Versus Strategy 2 Patients
17874,Quantitative Coronary Angiography and Intravascular Ultrasound Volumetric Analysis of Lesions Treated in the Two Groups
17875,In Hospital, 30 Day, and 6 Month Clinical Events in the Two Groups
17880,Overview of the Results of the Conventional Diagnostic Tests, Compared With the Results of LE CMR
17881,Results of the Non CMR Tests of Patients With Small Versus Large Right Ventricular Infarcts, as Defined by LE CMR
17884,Frequency of Discharge Diagnoses for ACS Patients, Other Study Patients, and Non Study Patients
17885,Odds Ratios   With 95  Confidence Intervals   for Univariate Predictors of Mortality and for Those Same Predictors Together With Log10Troponin in Bivariate Models
17895,One Year Clinical Outcome
17896,Randomized Trials That Have Examined the Role of Rescue PCI
17897,Early and Systematic Versus Guided or Delayed PCI   Stent Era and Balloon Era   After Fibrinolysis for STEMI
17898,Facilitated PCI With Thrombolytic Agents
17900,Logistic Regression Analysis for the Presence of Complex Coronary Lesions in Patients With Stable Coronary Artery Disease
17901,Polytomous Logistic Regression Analysis of Factors Associated With Single and Multiple Complex Lesions in Patients With Stable Coronary Artery Disease
17904,Daily Weather Summaries by Season in Olmsted County, Minnesota, 1979 to 2002
17905,Standardized Rates and RRs   95  CI   of MI and SCD for Seasonal and Climatic Variables
17909,Individual Trials As Well As the Numbers of Patients Treated With Single Versus Multiple Overlapped SES or BMS   Control
17912,Post Procedure and Late   8 Month   Quantitative Coronary Angiography by Stent Type and Stent Overlap Status
17913,Periprocedural and Late   1 Year   Clinical Events by Stent Type and Stent Overlap Status
17914,Predictors of In Stent Binary Stenosis by Multiple Logistic Regression
17917,Pathological Mechanisms of Stent Thrombosis  30 Days Other Than Delayed Stent Healing
17919,Initial and Follow Up Angiographic Results
17920,In Hospital and One Year Clinical Events
17921,Data Completion, by Treatment Arm
17922,Average Costs and Utilization, by Treatment Arm
17923,Accumulated Discounted Costs, Discounted Life Expectancy, and the iCER, at 3.5 Years
17926,Odds Ratios as Estimates of Relative Risk for Premature Myocardial Infarction in Carriers of 807T and 1648A Alleles
17931,Physical Examination and Laboratory Parameters   n   654
17932,Angiographic   QCA   and IVUS Measures of Disease Burden   n   654
17933,Univariate Predictors of IVUS Disease Burden   n   654
17934,Univariate Predictors of Angiographic Percent Area Stenosis   n   654
17935,Multivariate Predictors of IVUS Disease Burden   n   654
17936,Multivariate Predictors of QCA Disease Burden   n   654
17937,Disease Burden in Patients With Diabetes Versus Patients Without Diabetes
17938,Disease Burden in the Metabolic Syndrome
17941,Two Year Kaplan Meier Cumulative Probabilities of All Cause Mortality and Sudden Cardiac Death in Each Subgroup of CR Type by Time From CR
17948,Case Selection Protocol at ISJ
17949,Definition of In Hospital Clinical Outcomes
17952,In Hospital Clinical Outcomes
17953,Requirements for a PCI Program Without Onsite Cardiac Surgery
17955,Associations Between Metabolic Syndrome and Clinical Outcomes
17957,Cumulative Effect of Multiple Risk Factors on the Rates of Outcomes
17958,Technical Parameters and Infarct Size Measured by MRI at Day 1, Day 2, and by Observer 2
17961,Number of Events Between One and Two Years
17962,Separate Cox Regression Analyses Performed to Determine Independent Predictors of MACE and TVR at Two Year Follow Up
17963,Cumulative Clinical Events at One and Two Years Clinical Follow Up
17964,Stent Thrombosis   Up to Two Years Follow Up
17967,Accuracy of Multislice Computed Tomography for the Detection of Significant Coronary Plaque    : Comparison With IVUS for the Entire Region of Interest and for its 5 mm Subsegments
17972,Strains   Mean  SD   According to Traditional Risk Factors
17973,Multivariable Regression Coefficients   95  Confidence Intervals   for Myocardial Strain According to Categories of DBP and SBP
17974,Multivariate Regression Coefficients   95  Confidence Intervals   for Myocardial Strain According to Categories of Traditional CHD Risk Factors
17976,Death or MI at 30 Days and 12 Months Among the Two Risk Groups
17977,Echocardiographic Parameters in Sham Operated and Banded WT and Nox2 Mice
17978,Hemodynamic Parameters in Sham Operated and Banded WT and Nox2 Mice
17982,Assessment of IB IVUS and Conventional IVUS Parameters for Classifying Vulnerable Plaques
17983,Probability of Outcomes Used in the Decision Model
17984,Costs, Effectiveness, and Incremental Cost Effectiveness Ratio for Upstream Use Strategy Compared With Selective Use Strategy
17985,Incremental Cost Effectiveness Ratios in Sensitivity Analyses
17990,In Hospital Outcomes by Door to Balloon Time
17991,Multivariable Predictors of Late Cardiac Mortality by Cox Regression
17992,Late Cardiac Mortality by Door to Balloon Time in Patient Subsets
18001,Factors Associated with Blood Transfusion
18002,In Hospital Death and Myocardial Infarction by Transfusion Status
18004,Percentage of MBG 2 3, Transmural Necrosis, and Severe Microvascular Obstruction in Patients According to TIMI Flow Grade at Index Angiography
18005,Ischemic Time and Enzymatic Data According to the CE MR Evidence of TN and or SMO in Patients Without TIMI Flow Grade 3 of Infarct Related Artery at Index Angiography
18009,Univariate Survival Analysis
18010,Multivariable Analysis of the Predictors of Death or MI
18013,Included Observational Studies: Quality of Reported Multivariable Modeling
18014,Treatment Effects of OPCAB on Mortality and Morbidity
18015,Post Hoc Stratified Analyses That Employed Data From Randomized Trials
18016,Effect of Study Quality and Statistical Model on Estimated Treatment Effects
18017,Events at Early and Long Term Clinical Follow Up
18018,Parameters of LV Function and Postmortem Morphometry
18023,Total Number of Patients With Major Clinical Events Within Interval of Time   Randomization to 1, 3, and 5 Years
18024,Listing of Deaths and Causes of Death
18025,Major Adverse Cardiac Events at 5 Years in Patients With Diabetes Stratified According to Treatment
18026,Major Adverse Cardiac Events at 5 Years in Patients Without Diabetes Stratified According to Treatment
18028,Lesion and Procedural Characteristics
18031,Major Adverse Cardiac Events   MACE   Hierarchical Analysis   Intent to Treat Population
18032,Comparison With Other Bifurcation Studies With Bare Metal Stents and One With Sirolimus Eluting Stents
18036,Type and Results of PCI Procedure of Lesions Undergoing PCI According to Bifurcation or Nonbifurcation Lesions
18037,Major Adverse Cardiac Events at Nine Months According to Bifurcation or Nonbifurcation Lesions
18039,Major Adverse Cardiac Events at Nine Months in Patients With Bifurcation Lesions According to Enrollment or Not in the Angiographic Substudy
18040,Predictors of MACE and TVR at Follow Up in Patients With Bifurcation Lesions
18042,Correlation Between Mean Platelet Volume and Other Laboratory Measurements
18046,Secondary End Points
18047,Thirty Day Major Adverse Events
18051,Postprocedural Angiographic Data
18052,Electrocardiographic Analysis
18053,Clinical Outcome at One  and Six Month Follow Up   MACCE Are Given in Hierarchical Order per Patient
18055,Final Predictive Models of Overall Mortality, CVE, Hospitalization for CHF, and Late Onset Diabetes for Control Subjects, Patients With METS, and Diabetic Patients Adjusted for Potential Confounders   see Methods  : Distribution, RR, 95  CI, p Value
18056,Release Formulations
18058,Baseline Lesion Characteristics and Procedural Outcomes
18059,Clinical Events and MACE
18060,Serial QCA Analyses
18061,IVUS Analyses
18062,Patient Profile
18063,Determinants of the MR Fraction
18065,Twenty Year Cumulative Mortality, Absolute Benefits of Reperfusion Therapy, and Life Expectancy Overall and in Specific Subgroups
18066,Life Expectancy   Years   Comparing a 1 Year Model    8    With a 20 Year Model
18068,Apparent Diffusion Coefficients of Lipid Rich and Fibrotic Tissues Obtained From Homogenous Aortic Samples Representing the Extreme Tissue Type for 100  and 0  Lipid Concentration, Respectively
18069,Correlation of MRI Diagnosis and Histopathology in Intermediate Coronary Lesions
18071,Evaluation of Cardiac Segments for the Visualization of Acute Myocardial Infarction
18075,Major Adverse Cardiac Events During Hospitalization and at Follow Up
18076,Proportion of Patients in the PROVE IT TIMI 22 Trial Reaching Dual Goals of Low Density Lipoprotein Cholesterol  70 mg dl and C Reactive Protein  2 mg l in the Total Cohort and According to Statin Allocation
18077,Relative Efficacy of Pravastatin 40 mg and Atorvastatin 80 mg in Achieving LDL C Levels  70 mg l and CRP Levels  2 mg l in the PROVE IT TIMI 22 Trial
18080,Stepwise Multiple Regression Analysis of Variables Associated With the Cumulative CK Release
18081,Stepwise Multiple Regression Analysis of Variables Associated With the Cumulative CK Release in Patients Without Preinfarction Angina
18086,Procedural Results in Patients With Acute Coronary Syndromes
18087,Clinical Outcomes in Patients With Acute Coronary Syndromes
18088,Angiographic Follow Up in Patients With Acute Coronary Syndromes
18090,Odds Ratio From Multiple Logistic Regression for Triglyceride and HDL Categories
18091,Odds Ratios for Different Combinations of Plasma Triglycerides and HDL Cholesterol
18093,Left Ventricular Volumes, Mass, and Volumes of Nonenhanced and Enhanced Tissue
18094,Test Performance of Contrast Enhanced Magnetic Resonance Imaging in the Diagnosis of Preserved Wall Thickening in the Chronic Phase
18096,End Points in Patients With and Without Atrial Fibrillation
18098,End Points in Losartan  and Atenolol Treated Patients With Atrial Fibrillation
18100,CeMRI Myocardial Enhancement Over Time in Comparison With SPECT Perfusion Defect and Other Parameters of Infarct Size
18102,Results   Normalized to the Normal Remote Bed
18103,Selected Results From Groups 2 and 3 Dogs
18105,Hospital Stay and Frequency of Cardiac Revascularizations and Testing
18106,Reference Costs of Resources and Costs Per Patient by Reperfusion Group
18107,Sensitivity Cost Analysis Using U.K and U.S. Costs
18111,Intravascular Ultrasound Measurements at the Lesion Segment
18112,Patients With Angiographic Restenosis
18114,Type of Acute Coronary Syndrome in Patients With Recurrence According to Aspirin Intake
18117,Risk Factors for Non Reperfusion Following Fibrinolytic Therapy for Acute Myocardial Infarction
18118,Risk Factors for Death, Reinfarction, or Urgent PCI at 24 h
18120,Indications for PCI
18121,Valve   CABG Surgery
18122,Bleeding and Other Complications
18123,Statistical Analysis
18124,Clinical Data of Patients
18126,Hierarchical Incidence of MACE During Hospitalization and 12 Month Follow Up in Patients With Successful Recanalization of a CTO
18127,Target Vessel Failure After Recanalization of a CTO in Patients With and Without Diabetes Mellitus
18128,Overview of Studies on Stent Therapy in CTOs Compared With the Present Study
18132,Adverse Clinical Outcomes at 30 Days and 9 Months After PCI
18134,Cox Proportional Hazards Models for Death, MI, and TVR
18135,Adjusted Cox Proportional Hazards Models for Death, MI, and TVR
18137,Procedural Resource Utilization and Cost
18138,Initial Hospital Outcomes, Resource Utilization, and Cost
18139,Follow up Events, Resource Utilization, and Cost
18142,Identification of the Analyzed Proteins
18143, 1 Antitrypsin Isoforms in Plasma From Patients During an Acute Coronary Syndrome
18144,Fibrinogen Gamma Chain Isoforms in Plasma From Patients During an Acute Coronary Syndrome
18145,Expression of Apolipoprotein A I Isoforms and Gamma Immunoglobulin Heavy Chains in Plasma From Patients During an Acute Coronary Syndrome
18147,Serial Quantitative Coronary Angiographic Analyses
18148,Most Severe   Hierarchical   and Total Count of Cardiac Events Up to 12 Months in Each Treatment Group
18149,Incidence of Vessel Segment Restenosis in Patients With and Without Intravascular Ultrasound
18152,Clinical Outcomes at 30 Days and Time from Symptom Onset to Treatment
18154,Predictors of Adverse Events at Nine Months   Univariate Analysis
18157,Attributable Risk of Non Participation, in the Entire Cohort, Stratified by Age and Gender and Quartile of Propensity Score
18158,Frequency of Atherosclerosis Risk Factors, Previous Cardiac or Cerebrovascular Events, and Aortic Atherosclerotic Plaques
18159,Risk of CAD or CVD End Points in Relation to Clinical Risk Factors
18160,Risk of CAD or CVD End Points in Relation to Clinical Risk Factors, Adjusted for Age and Gender
18161,Multivariate Cox Proportional Hazard Models of Cardiac or Cerebrovascular End Points
18162,Risk of CAD or CVD End Points in Relation to Severity of Aortic Atherosclerosis
18167,Relationship Between TIMI Risk Index and In Hospital Mortality
18168,Odds Ratios for Mortality and Discriminative Capacity   cStatistic   for Individual Components of the Risk Index and for the Index as a Continuous Variable
18170,Variables Independently Associated With CABG in Multivariate Analysis
18172,Doppler Data and CTFC Data
18173,Correlates of CTFC
18174,Correlates of CFVR
18177,Microvessel Data
18180,Intravascular Ultrasound Volumetric Measurements in 60 Stented and Reference Segments
18181,Intravascular Ultrasound Morphologies in 60 Culprit Lesions
18182,Coronary Angiographic Results
18184,In Hospital Treatment
18185,Thirty Day End Points
18186,Thirty Day End Points for Anterior Myocardial Infarction
18187,Regional Wall Motion Score at 30 Days
18188,Predictors of the Composite Secondary End Point by Multivariate Logistic Regression Analysis
18191,In Hospital Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention
18192,Major Adverse Cardiovascular Events Based on the Mayo Clinic Risk Score and ACC AHA Lesion Score
18193,Discriminatory Measures of Mayo Clinic and ACC AHA Lesion Risk Scores
18194,Description of Studies Included in the Meta Analysis
18195,Description of Populations and Procedures of Included Studies
18196,Subgroup and Sensitivity Analyses
18198,Odds Ratio for the Development of Collateral Vessels
18199,Odds Ratio for In Hospital Death   Below 70 Years of Age
18200,Odds Ratio for In Hospital Death   Above 70 Years of Age
18204,Time to Treatment in the Air PAMI No SOS Study
18205,Treatments Received in the Air PAMI No SOS Study
18206,Angiographic Data
18207,In Hospital Complications
18208,Multivariate Predictors of Mortality at One Year in the Air PAMI No SOS Study
18209,Noninfarcted   Nonhyperenhanced  , Infarcted   Hyperenhanced  , and Total LV Masses   Noninfarcted Plus Infarcted   at 3 Days, 10 Days, 4 Weeks, and 8 Weeks After Infarction
18211,Crude In Hospital Mortality Rates
18212,Hospital Annual PCI Volume and Odds of In Hospital Mortality
18217,Multivariate Cox Proportional Hazard Model
18219,Comparison Between EDWT and Myocardial Perfusion as Prognostic Indexes of Recovery of Contractile Function at Two Months  Follow Up
18221,Cause of Death by Treatment Group
18222,Chronology of Cardiac Death by Treatment Group
18223,Location of Sudden and Non Sudden Cardiac Death by Treatment Group
18225,Capillary Density One Month After Cell Transplantation
18226,Myocardial Contrast Intensity   AU2   One Month After Cell Transplantation
18227,Ratio of Wall Thickness   Systole Diastole
18231,Procedural Success and Complications
18232,In Hospital and 30 Day Outcome
18233,Six Month Clinical Outcome
18234,Predictors of TLR, TVR, and MACE by Cox Regression Analysis
18239,Ischemic Outcomes at Six Month Follow Up
18241,Important Multivariable Predictors of Six Month Death, MI, or Stroke
18248,Most Common Drugs Given After the Intervention
18249,Scintigraphic Results
18251,Kaplan Meier Estimates of Adverse Events at 30 Days and at 300 Days
18252,Multivariate Predictors of 300 Day Major Adverse Cardiac Events
18254,Resting and Exercise Test Values, With Univariate Comparison Between Ages Above and Below 65 Years for Total, Surviving, and Nonsurviving Patients From Cardiac Causes of Death
18255,Clinical and Exercise Test Variables, Chosen in the Cox Proportional Hazards Model as Significantly and Independently Associated With Time Until Death Due to Cardiac and All Causes
18259,Number       of Patients With Each Condition
18260,The Charlson Comorbidity Index as Compared With the CAD Specific Index
18261,Frequency of Scores by the Charlson and CAD Specific Indexes
18262,Cox Linear Regression Models
18263,Hemodynamic Data
18264,Echocardiography Data
18270,Outcomes in Relation to Treatment Modality
18273,Reasons for Failed Percutaneous Coronary Intervention Leading to Urgent Coronary Artery Bypass Graft
18275,Accuracy of the  VIC to Predict the Recovery of Segmental Contractile Function
18276,Patient Selection for Current Analysis
18278,Incidence of Ischemic Events on the Day Before Treatment Discontinuation   Day 1  , and the First Day and the First Week After UFH or Short Term Enoxaparin Treatment Cessation
18280,Crude Mortality, Relative Risk, Univariate Odds Ratios, and Risk Scores for Clinical Risk Factors
18281,Risk Classification
18282,Multivariate Logistic Regression Model of In Hospital Mortality
18284,Various Combinations of Risk Factors That Would Fit Individual Risk Classes
18286,Determinants of ERO at Rest
18288,Determinants of the ERO Changes During Exercise
18290,Angiographic Data and Cath Lab Complications of Study Patients
18291,In Hospital Complications and Long Term Outcomes
18292,Adjusted Odds Ratios of Clinical Variables Associated With the Risk of Final TIMI 2 Flow
18293,Inclusion Criteria
18298,Multivariate Analysis to Predict All Cause First Year Mortality
18299,Multivariate Analysis to Predict All Cause First Year Mortality
18300,Incremental Value of HRV Measurement and cTnI in Predicting All Cause Mortality
18303,Univariate Association of Angiographic Risk Factors With Major Procedural Complications in the NHLBI Dynamic Registry
18305,Multivariate Predictors of Major Procedural Complications After Percutaneous Coronary Intervention in the NHLBI Dynamic Registry
18307,STS TMR Outcomes by Procedure Type
18308,STS TMR Outcomes by Patient Subgroups
18309,Outcomes Among Patients With Three Vessel Disease Receiving Two or Fewer Bypass Grafts With or Without TMR in STS
18314,Multivariate Predictors of Heart Failure Development and Heart Failure and Death in Long Term Survivors of MI
18315,Description of the Risk Profiles Based on the Final Model
18316,PAMI Database
18319,Distribution of Patients in the Different Subgroups
18323,Bleeding Episodes After Urgent PCI Compared With Elective PCI and No PCI in ASSENT 3 Population
18325,Clinical Events During 30 Day Follow up in Six of 111 Patients Who Underwent MRI Within Eight Weeks of Coronary Stent Placement
18326,Deaths, MIs, and New Interventions During a Median Seven Year Follow Up
18329,Clinical End Points at 30 Days, 6 Months, and 1 Year According to Clopidogrel Pretreatment
18330,Influence of Clopidogrel Pretreatment on Relative Efficacy of Tirofiban Versus Abciximab on Various End Points
18332,Incidence of Bleeding and Transfusion During Index Hospitalization
18334,Procedural Data and Outcomes
18335,Predictors of Adverse Clinical Events at One Year: Results From Multivariate Analysis
18339,Predictors of One Year Mortality at Multivariate Analysis
18341,Results: Electrocardiographic ST Segment Changes and Thrombolytic Therapy in the Overall Study Population and in Males Alone
18344,Histological Analysis of Atrial Myocardium in Human PVs
18345,Anatomical Dimensions of Pulmonary Veins
18348,Relationship Between Clinical Presentation and High Risk Angiographic Findings
18349,Angiographic Predictors of Outcome
18350,Independent Correlates of 30 Day Composite Incidence of Death, MI, or Urgent TVR
18353,Multilevel Logistic Regression Analysis
18354,Logistic Regression Analysis for the Prediction of the Change in Ejection Fraction
18355,Clinical Features of Patients That Did and Did Not Reach 85  of the Age Predicted Maximum HR
18356,Exercise Stress Test and Echocardiographic Data of Patients That Did and Did Not Reach 85  of the Age Predicted Maximum HR
18357,Association of Various Measures of Chronotropic Response to Exercise With the End Points of All Cause Mortality, Cardiac Death, and Myocardial Infarction Before   Relative Risk   and After   Adjusted Risk   Correction for Confounding Variables
18358,Effects of Guanethidine on Plasma NE Concentration and LV NE Contents in Normal Rats
18359,Body Weight, Ventricular Weight, and Hemodynamic Data 28 Days After Myocardial Infarction
18363,Blood Chemistry at Four Weeks After Streptozotocin or Vehicle Injection in Mice
18364,Echocardiographic, Hemodynamic Data, and Organ Weights of Mice
18365,Left Ventricular Angiotensin Converting Enzyme Activity and Amount of Reactive Oxygen Species in Mice
18368,In Hospital Events by Early Use of GP IIb IIIa Inhibitor
18370,Association of Early GP IIb IIIa Inhibitor Use and In Hospital Mortality
18371,NRMI NSTE MI Risk Model   9
18373,Incidence of Recurrent MI by In Hospital Medication Use
18374,Mortality by In Hospital Reinfarction and Use of PCI
18377,Echocardiographic Data at 13 Months
18378,Hemodynamic Data at 13 Months
18380,Unadjusted Rates of Discharge Medical Therapy, 30 Day Cardiac Procedures, and 30 Day and 6 Month Outcomes   Data Shown Are Percentages
18381,Unadjusted Rates of Medical Therapy, Procedures, and Outcomes Stratified by Age   Data Shown Are Percentages Unless Otherwise Indicated
18382,Adjusted Hazard Ratios of Discharge Medical Therapy and 30 Day Cardiac Procedures, and Adjusted Hazard Ratios of 30 Day and 6 Month Death or Recurrent MI for Low Income Patients Relative to High Income Patients
18384,Technical and Procedural Success and In Hospital Complications of 376 Patients
18386,Multivariable Predictors of Technically Unsuccessful Procedures
18387,12 Month Clinical Outcome of 369 Patients Discharged Free of Q Wave MI and CABG
18388,Clinical Status After 12 Months of a PCI on a CTO in Patients Discharged Free of Q Wave MI and CABG and MACE Free During Follow Up
18390,Quantitative Coronary Angiographic Data
18391,Clinical Events During Follow Up
18392,Eligibility Criteria
18394,Clinical Events
18395,Change in Heart Failure Score
18396,Adverse Events During Randomized Treatment and Within 48 Hours After the End of Treatment
18397,Adverse Events Requiring Discontinuationof Treatment
18398,Blood Pressure Changes During Study Treatment
18400,The Effect of Serial Exercise in Early   IEP   and Late   SWOP   Preconditioning Groups
18401,Myocardial Hemodynamic and Ischemic Changes During PCI
18404,Analyses of Time to Event Among Patients According to Aspirin Sensitivity
18410,Correlates of Long Term Mortality for All Patients
18414,Independent Predictors of Cardiovascular Events at 5 Years Follow Up by Stepwise Multivariate Logistic Regression Analysis
18415,Events for the Interval PET1PET2 in All 409 Patients   Without Exclusions
18418,Procedural Data
18419,Angiographic Data at Follow up
18421,All Trials
18422,Trials Without Stents
18423,Trials With Stents
18424,Trials of Single Vessel   Proximal LAD   Disease Only
18425,Trials of Multivessel Disease
18426,Trials of Diabetics and Nondiabetics
18429,Unadjusted Rates of In Hospital Outcomes of Women and Men Undergoing a PCI in Northern New England by Era of Stenting
18430,Adjusted   Rates of In Hospital Outcomes of Women and Men Undergoing a PCI in Northern New England by Era of Stenting
18431,Mortality During Two Years in Six Month Periods in the Invasive and Noninvasive Groups
18432,Patients With Myocardial Infarctions During Two Years in Six Month Periods in the Invasive and Noninvasive Groups
18433,Number of Spontaneous and Procedure Related MIs   During the First Six Months in the Invasive and Noninvasive Groups
18434,Death or Myocardial Infarction in Six Month Periods in the Invasive and Noninvasive Groups
18435,Revascularized Patients During Two Years in Six Month Periods in the Invasive and Noninvasive Groups
18436,Patients Re Admitted to the Hospital During Two Years in Six Month Periods in the Invasive and Noninvasive Groups
18438,MACCE at Midterm Follow Up   by Intention to Treat Analysis
18439,Clinical Outcome at Midterm Follow Up  by Intention to Treat Analysis
18441,Coronary Blood Flow Velocity Variables
18442,Coronary Flow Velocity and Hemodynamic Variables in Patients With Inferior Acute Myocardial Infarction
18443,Temporal Changes in Left Ventricular Function and Volume and Clinical Outcomes
18445,30 Day Adverse Cardiac Events in 48 Patients Undergoing SVG Intervention of 60 Lesions With FilterWire Distal Protection in the Phase I Registry
18446,Procedural Results, Comparing Patients Enrolled in Phase I and Phase II
18447,Variables Correlating With MACE Within 30 Days
18450,Adverse Events at One Year Follow Up
18451,Total Plasma Homocysteine Levels According to Event Type at One Year Follow Up
18452,Univariate Predictors of Endpoints by Cox Regression Analysis
18456,Infarct Size, Body Weight, and Cardiac Magnetic Resonance Imaging Parameters of Rats With Myocardial Infarction
18459,Angiographic and Coronary Collateral Data
18460,Cardiac Ischemic Events
18463,Relationship Between Pulsed Doppler Parameters Adequately Recorded in 52 Patients Distributed According to Recanalization or TIMI Flow Scores
18466,Myocardial Beta AR Density and Blood Flow for Each of the 61 Patients
18467,Relationship Between TIMI Flows and Left Ventricular Volumes   Improved vs. Dilated   at Six Months
18468,Ventricular Fibrillation, Death, and Survival in the Experimental Groups
18471,Heart Rate, Aortic Pressure, and Left Ventricular Function
18473,MABP   mm Hg  , HR   beats min  , RPP   MABP  HR 1,000  , and Body Mass   g   in Mice Given Either Vehicle or 0.5 mg kg Rosuvastatin 18 h Before Hemodynamic Assessment   n   4 group
18475,Treatments Received
18476,Complications
18477,Procedures Performed
18478,Clinical Events
18480,Patients Complications
18482,Angiographic Findings at the Site of IVUS Plaque Rupture in 225 Lesions in 223 Patients
18483,IVUS Comparison Between Rupture Site and MLA Site
18486,Medications at Time of Coronary Angiogram
18488,Percutaneous Intervention
18489,Clinical Events
18492,Prevalence Rates of Major Cardiovascular Risk Factors in Patients With Familial P CAD and Their Respective Age  and Gender Matched Control Subjects, According to Parental History of CAD in Patients with Familial P CAD
18493,Number of Siblings With Major Cardiovascular Risk Factors in 64 Sibling Pairs    Affected With Familial Premature Coronary Artery Disease
18496,Quantitative Angiographic Analysis in the 267 Patients With Angiographic Follow Up
18498,Association Between Myoglobin Elevation and Angiographic Findings in TACTICS TIMI 18
18503,Association Between Female Gender and Outcome
18504,Independent Predictors of Death or Myocardial Infarction During Follow Up in Multivariate Analysis
18506,Age Specific Gains in Life Expectancy Resulting From Statin Therapy in Men and Women in the Low LDL High CRP Group
18507,Gains in Life Expectancy With Various Preventive Interventions
18509,Unadjusted OR    95  Confidence Limits   for Coronary Angiography, Specialty Follow Up Care and Mortality in Women Relative to Men According to Age group Categories for Patients Hospitalized With AMI in Ontario Between April 1, 1992, and December 31, 1993
18513,TIMI 2 and 3 Flow on the Initial Coronary Angiogram
18514,Clinical Outcome Variables of the Two Groups
18515,Clinical Outcome Variables According to Initial TIMI Flow
18517,Air Primary Angioplasty in Myocardial Infarction Trial: Time to Treatment
18518,Air Primary Angioplasty in Myocardial Infarction Study: Treatments Received
18519,Air Primary Angioplasty in Myocardial Infarction Study: Multivariate Predictors of Major Adverse Cardiac Events at 30 Days
18522,Kaplan Meier Estimates   95  Confidence Interval   of 90 Day Events by Postprocedural Troponin I Status
18523,Kaplan Meier Estimates   95  Confidence Interval   of 90 Day Events by Postprocedural Troponin I Quartiles
18525,Adverse Events in Randomized Patients
18529,In Hospital Outcomes by Gender From the 19971998 Dynamic Registry
18530,Status at One Year by Gender for the 19971998 Dynamic Registry
18532,Comparison of 201Tl Uptake and the Morphometric Variables in Segments With and Without Recovery of Function After Revascularization
18534,Relationship Between Infarct Location and Right Ventricular Dysfunction
18535,Relationship Between Right Ventricular Dysfunction and Outcome
18536,Multivariate Regression Assessing Risk of Various Outcomes
18538,Angiographic Culprit Lesions Identified as Cause of MI
18539,Stenosis Morphology, TIMI Flow and Collaterals in Single Nontotal Occlusion
18540,Clinical, Angiographic Data and Functional Outcome of Patients Belonging to the Reperfusion Group   Reduction of Initial MCE Perfusion Defect 50  at 24 h versus Nonreperfusion Group   Reduction of MCE Perfusion Defect  50
18541,Coronary Flow Velocity Data and Hemodynamics Immediately After Intervention and After 24 h of Patients Belonging to the Reperfusion Group   n   13     Reduction of Initial MCE Perfusion Defect 50  at 24 h   versus Nonreperfusion Group   n   12     Reduction of MCE Perfusion Defect  50
18542,Myocardial Infarction Patients With and Without Antecedent Hypertension   n   1,093
18543,Plasma Hormones   Mean  SD   After MI in Patients With and Without Antecedent Hypertension
18545,Relative Odds of Coronary Events in CHD Patients With 100 ng ml Increase in sICAM 1 Concentration
18547,Relative Odds of Future Acute Coronary Events According to sICAM 1, LDL C and HDL C Concentrations
18548,Inclusion Threshold Criteria
18551,Outcomes of Procedures Included and Excluded From Registry
18552,Class I Indications for Procedure by ACC Criteria
18553,Hospital Outcomes by Clinical Presentation and Procedure Setting
18554,Success and Complication Rates by Device Use
18555,Success and Length of Hospital Stay for Selected Clinical Subgroups
18557,Cardiac Catheterization Data
18559,Overview of Patients With Events Related to the Intermediate Lesion During One Year Follow Up
18560,Primary Outcome Events Related to the Intermediate Lesion Presented for the Dichotomized Results of CFVR and SPECT for Patients in Whom a PTCA Was Deferred and Follow Up Was Available   Groups A, B and C; n   180
18561,Results of 2 Multivariate Logistic Regression Models for Prediction of Primary Outcome Events, Using the 180 Patients   Groups A, B and C   in Whom a PTCA of the Intermediate Lesion was Deferred and Follow Up Was Available
18563,Clinical Differences Between Patients Treated With PA or With Thrombolysis
18565,Robustness of the Correlation of Plaque Burden and Specific Aortic Elastance Against Potential Confounding Variables
18566,Comparison of Different Parameters of Arterial Mechanics a Measures of Aortic Plaque Burden
18567,OCT Image Features of Vessel Wall Structure by Histopathologic Finding    1113
18568,IVUS and OCT Findings for Corresponding Image Pairs   n   17
18569,Semi Quantitative Scoring Used to Assess Function From Resting and Dobutamine Magnetic Resonance Imaging, and Uptake of Both Thallium and Tetrofosmin
18572,Stent Implantation Strategy
18575,Quantitative Coronary Angiographic Analysis
18576,Major Adverse Cardiac Events at 31 Days in Intention to Treat Patients   n   437
18577,Major Adverse Cardiac Events at 300 Days in Intention to Treat Patients   n   437
18581,CABG and PCI 36 Month Survival, Survival Free of Unstable Angina and Survival Free of Unstable Angina or Repeat Revascularizations legend
18583,Procedural Data and Results legend legend
18585,Comparison of the Prognostic Value of the Three Measurements in the Overlap Group   n   753   legend
18586,Six Month Mortality by Left Ventricular Ejection Fraction and End Systolic Volume Index legend
18587,Six Month Mortality by Ejection Fraction and Infarct Size
18589,Energy Adjusted Correlations Among Different Types and Sources of Dietary Fiber
18590,Adjusted Relative Risk   95  CI   of CVD  According to Quintiles of Dietary Fiber Intake, the Womens Health Study, 19931999 legend
18591,Adjusted Relative Risk   95  CI   of MI According to Quintiles of Dietary Fiber Intake, the Womens Health Study, 19931999 legend legend
18592,Adjusted Relative Risk   95  CI   of CVD  According to Quintiles of Dietary Fiber Intake Among Subgroups of Women, the Womens Health Study, 19931999 legend
18595,Flow Mediated Dilation in Subjects Undergoing Exercise Myocardial Perfusion Imaging
18596,Exercise Treadmill Time and Flow Mediated Dilation
18598,Results of the Exercise Test
18599,Incidence of Events
18600,Independent Predictors of Events During Follow Up
18603,Clinical Outcomes in the HRQOL Substudy at 6 and 12 Months After Randomization
18604,Six Month HRQOL According to Treatment Assignment and the Need for Ischemia Driven TVR During the One Year Follow Up
18605,Study Logic   Inclusions and Exclusions
18607,Outcomes in WBC Count Groups
18608,Outcomes in WBC Groups
18609,Thirty Day Mortality in Patients With AMI by WBC Count Quintile
18610,Association Between WBC Count Quintile and 30 Day Mortality by Age and Gender
18611,Association Between WBC Group and 30 Day Mortality by Age and Gender
18613,Intravascular Ultrasound Measurements
18615,TIMI Flow Patency and Function of Left Ventricle
18617,AneuRx Patients Comorbid Conditions legend
18618,Primary Procedure Results
18619,Endoleaks legend
18620,Follow Up Results legend
18622,Candidate Predictive Factors
18623,Crude and Adjusted Relative Risk of Death or Myocardial Infarction by 42 Days legend legend
18624,Points Assigned to Each Risk Factor legend
18625,Risk of Death or MI by 42 and 365 days, by Risk Category legend legend
18627,In Hospital Outcomes of Coronary Angioplasty in Patients With and Without Thrombus legend
18629,Unadjusted Case Fatality in Men and Women up to 30 Days Following a First AMI legend
18630,Adjusted Probability of Death in Men and Women up to 30 Days Following a First AMI legend
18632,Angiographic Data legend
18633,Incidence of Pericardial Effusion and Congestive Heart Failure legend
18634,Stepwise Linear Regression Analysis legend legend
18636,Univariate and Multivariate Predictors of the No Reflow Phenomenon legend
18638,Outcomes by ST Segment Depression Categories: PARAGON A and GUSTO IIb Studies legend legend
18640,Outcomes Among Patients With Electrocardiographic Confounders ST segment Depression Categories: PARAGON A Data legend legend
18644,Short Term Outcomes of Patients Randomly Assigned to CABG or PCI legend
18645,Coronary Artery Bypass Graft Surgery and PCI 36 Month Survival, Survival Free of Unstable Angina and Survival Free of Unstable Angina or Repeat Revascularizations legend
18647,Risk of Acute Coronary Events and Coronary and CVD Death According to the Presence of Silent Myocardial Ischemia in an Exercise Electrocardiogram in Men Without Prior Coronary Heart Disease
18648,Multivariate Risk Factor Analysis for CHD Death or Nonfatal MI legend
18649,Predicted Rates of CHD Death or Nonfatal MI Within 5 Years and Corresponding NNT legend
18651,Concomitant Medications During the First 48 h After Admission and Hospital Events legend
18652,Univariate Analysis of Subgroup Mortality Depending on Type of Revascularization legend
18655,Unadjusted One Year Mortality legend
18658,Multivariable Adjusted Risk of Dying During Hospitalization From Initial Q Wave or Non Q Wave Myocardial Infarction legend
18659,Multivariable Adjusted Risk of Dying Within Two Years of Hospital Discharge From Initial Q Wave or Non Q Wave Myocardial Infarction legend
18660,Bipolar Voltage, Unipolar Voltage, Unipolar Signal Slew Rate and Impedance Values in the Noninfarcted LV and Within the Various Extent of Infarct Transmurality legend
18662,Actual Number of Events by Smoking Status and Trial legend
18663,Relative Risk of Current Smokers Versus Current Nonsmokers legend legend
18664,Mortality and Morbidity: Current Smoking, Ex Smoking 2 Years, Ex Smoking  2 Years Versus Never Smoking legend legend
18667,Multiple Logistic Regression Models With Backward Selection for Predicting the Risk Ratio of Death at 30 Days and Four Years With Emphasis on Thrombolytic Therapy legend
18668,Multiple Logistic Regressions With Backward Selection Model for Predicting the Risk of In hospital Stroke With Emphasis on Thrombolytic Therapy legend
18671,Psychosocial Assessment in the Short Stay Strategy and Two Control Groups    legend
18673,Distribution of Risk Factors Among Cases and Controls    legend
18674,Association Between Nicotine Patch Use and Myocardial Infarction: Nicotine Patch Use in Index Week legend
18675,Association Between Nicotine Patch Use and Myocardial Infarction: Effects of Adjustment by Potential Confounders legend
18677,Temperature Differences Between Patients With and Those Without Adverse Events in Each Subgroup legend legend
18678,Independent Predictors of Adverse Cardiac Events legend
18679,Clinical Risk Factors Studied as Possible Predictors of Mortality After an AMI legend
18680,Risk Factors Included in the Ontario Acute Myocardial Infarction Mortality Prediction Rules legend
18681,Logistic Regression Models for Predicting 30 Day and One Year Mortality After an Acute Myocardial Infarction in Ontario, 1994 951996 97
18683,Types of Restenosis
18693,In Hospital Major Clinical Events legend
18694,Long Term Cumulative Clinical Events legend
18695,Multivariable Modeling and Predictors of Mortality at One Year legend legend
18696,Predictors of Vascular and or Bleeding Complications legend legend
18698,Multivariate Cox Proportional Hazard Models legend
18699,Multivariate Cox Model Analysis legend
18701,Tissue Levels of Cyclic Adenosine Monophosphate and Cyclic Guanosine Monophosphate and Activities of Cyclic Adenosine Monophosphate Dependent Protein Kinase and of Protein Kinase C in Serially Perfused Heart No. 2: Effect of Nonischemic and Postischemic Coronary Effluent of Heart No. 1 legend
18704,Overall Results at Five Months legend
18705,Effects of Warfarin by Stratifying Countries Into Those With or Without Good Compliance legend legend
18706,Meta Analysis of All Trials Evaluating Moderate Intensity Oral Anticoagulation in Addition to Aspirin in Patients With Unstable Angina legend
18709,Effect of Stents on Outcomes
18711,Results of Noninvasive and Invasive Studies and Revascularization Procedures in Post Thrombolytic and Spontaneous NQMI Patients legend
18712,Clinical Outcomes in Post lytic and Spontaneous NQMI Patients legend
18714,Outcomes of Post lytic and Spontaneous NQMI Patients According to Assessment Strategy legend
18715,Revascularization Procedures in Post Lytic NQMI Patients Randomized to Invasive   INV   or Conservative   CON   Management Strategies legend
18716,Reported Cause of Death and Procedures Performed in Post Lytic NQMI Patients Randomized to Invasive   INV   and Conservative   CON   Management Strategies legend
18718,Angiographic Lesion Morphology of Study Group   n   125   legend
18719,Correlation of Angiographic Morphology and Ultrasound Variables
18720,Correlation of Ultrasound Variables With Clinical Presentation legend
18722,In Hospital and 30 Day Results of Patients Randomized to PTCA and CABG legend
18723,Thirty Day Mortality in Patients Randomized to PTCR or CABG According to Angina Class legend
18724,Multiple Stepwise Logistic Regression Analysis of MACE   Death, Myocardial Infarction, Stroke, Repeat Procedures   legend
18725,Cost of Revascularization Procedures
18726,Comparative Incidence of Death and Nonfatal Myocardial Infarction During the Entire Follow up in Patients with Multivessel Disease Treated With Surgery
18727,Major Adverse Cardiac and Cerebrovascular Events in Descending Order of Severity and Followed by the Total Number of Events legend
18728,Causes of Death legend
18730,Myocardial Strains in Remote, Risk and Infarcted Regions legend
18735,Clinical Events Stratified by Year of Treatment in Patients Treated With Primary Angioplasty Compared With Patients Treated With Thrombolysis legend
18737,Sensitivity for Detection of Acute Coronary Artery Occlusion Using ST Segment Deviation and High Frequency QRS Components legend
18738,Significant Changes in High Frequency QRS Components    0.60 V or  20    During Inflation in Patients With High Frequency Data From All 12 Leads in the LAD, LCX, and RCA Groups legend
18741,Death Rate and Univariate Significance for the Various Risk Factors legend
18742,Final Multiple Variable Cox Regression Model Showing the Independent Protective Effect of Statins legend legend
18743,Comparison of Clinical and Radionuclide Data of Pediatric Patients After Arterial Switch Operation legend
18748,Angiographic Findings legend
18749,In hospital Outcome legend
18750,Cumulative One year Outcome legend
18752,Correlation Between FVII Genotypes, FVIIc and FVIIa legend
18753,30 Day Composite End Point and FVII Genotypes legend
18754,Relative Risk for the Composite End Point in Logistic Regression Analysis legend
18755,Prevalence and In patient Mortality Rates for Risk Factors Related to Primary Angioplasty: New York State 1993 to 1996 legend
18756,Significant Multivariate Preprocedural Risk Factors for In patient Mortality for Primary Angioplasty: New York State, 1993 to 1996 legend legend
18757,Significant Multivariate Preprocedural Risk Factors for In patient Mortality for Primary Angioplasty   Shock Patients Excluded  : New York State, 1993 to 1996 legend legend
18758,Significant Multivariate Preprocedural Risk Factors for Long Term Mortality for Primary Angioplasty: New York State, 1993 to 1996 legend
18759,Kaplan Meier Adverse Outcome Rates for Primary Angioplasty New York State, 1993 to 1996       legend
18760,In Hospital and Kaplan Meier Mortality Rates for Primary Angioplasty for Selected Risk Factors: New York State, 1993 to 1996 legend
18761,Comparison of Different Summary Measures of ST Segment Depression for Detection of Nitrate Treatment Effects
18762,Influence of Increasing Time Prior to Peak Exercise on Detection of Nitrate Treatment Effect
18763,Bias in Measurement of the Nitrate Effect From Regression to the Mean Due to Lead Matching
18767,Intravascular Ultrasound Analysis legend
18768,Clinical Events legend
18770,Distribution of PlA1 A2 Genotypes in Relation to Causes of Sudden Death legend
18771,Distribution of PlA1 A2 Genotypes in Men with Acute Fatal Thrombosis and Men With SCD Without Acute Thrombosis legend
18772,Distribution of PlA1 A2 Genotypes in Men With MI With Without Thrombosis in Different Age Groups legend
18779,Six month Angiographic Results legend legend
18781,Wallstent Implantation and Quantitative and Qualitative Angiographic Data legend
18782,Major Cardiovascular Events During Hospital Stay and After Discharge legend
18784,Anatomic Data legend legend
18787,Comparisons of the Hepatocyte Growth Factor Levels   ng ml   legend
18790,Major Adverse Events During the First 30 Days After Stent Placement According to PlA Genotype legend legend
18791,Main Results in Different Subsets During the First 30 Days After Stenting legend legend
18792,Angiographic Recurrent Restenosis Rates After Laser Angioplasty in 89 Patients With Different Lesion Length and Residual Stenosis After Ablation, Treatment With Different Types of Catheters and Catheter Vessel Ratios and Different Risk Factors for the Development of Restenosis
18793,Recurrent Restenosis Six Months After Excimer Laser Angioplasty in 89 Patients With Different Coronary Risk Factors
18796,Plasma Levels of Soluble Adhesion Molecule P Selectin, Soluble Thrombomodulin, von Willebrand Factor and Fibrinogen in Patients With Chronic Atrial Fibrillation and in Control Subjects legend legend
18798,Diurnal Changes in Markers of Thrombogenesis in Chronic Atrial Fibrillation    legend
18801,Comparison Between Corrected TIMI Frame Counts, TIMI Flow and Ventricular Function at Three Weeks legend legend
18802,Univariate Predictors of Late Mortality legend
18803,Multivariate Predictors of Late Mortality legend
18806,Initial Angiographic Data for Patients Randomized to Angioplasty legend legend
18807,Angiographic and Procedural Data for Patients Randomized to Angioplasty Who Underwent Intervention legend legend
18808,Angiographic Data for Patients Randomized to Angioplasty Who Did Not Undergo Intervention legend legend
18809,Coagulation Data According to Diabetic Status legend legend
18810,In hospital Events legend
18812,Variable Entered Into Multivariate Analysis
18815,Angiographic Analysis
18817,Follow up Results legend
18818,Univariate Predictors of Target Lesion Revascularization After Repeat Intervention legend
18819,Multivariate Predictors of Target Lesion Revascularization After Repeat Intervention legend
18820,Six  and 12 month TLR for Different Patterns of In Stent Restenosis legend
18823,Interventional Procedures in All Lesions legend
18824,Pre  and Postintervention IVUS Analysis legend
18825,Procedural Results and Clinical Outcome at One Year legend
18827,Angiographic Data During Primary PTCA legend
18828,Hemodynamic and Flow Velocity Data legend
18829,Regional Blood Flow Ratios legend
18831,Serum Lipoprotein  a   Levels and Incidence of Lipoprotein  a   Levels  25 mg dl in Study Patients legend
18832,Comparative Data of Risk Factors and Serum Lipid Profiles in Study Patients With Coronary Spasm With and Without Prior MI legend
18833,Comparison of the Incidence of Patients With Higher    25 mg dl   Serum Level of Lipoprotein  a   in Study Patients With and Without a History of Prior MI legend
18834,Comparison of the Incidence of a History of Previous MI in Patients With Higher    25 mg dl   and Lower Serum Level of Lipoprotein  a   in Study Patients legend
18838,Predictors of Wall Motion Recovery Index at One Month   Univariate Analysis   legend
18840,Treatment Modality and Lesion Location legend
18841,Quantitative Angiographic Results legend legend
18842,In Hospital Outcomes legend
18843,One Year Follow up Results legend
18848,In Hospital Events legend legend
18850,Treatment Variables legend legend
18851,In hospital Events legend legend
18852,Predictors of Mortality legend legend
18856,Uni  and Multivariate Logistic Regression Analysis for Predictors of In Hospital Heart Failure legend
18857,Univariate Cox Regression Analysis and Cox Proportional Hazards Analysis of Predictors of Cardiac Death legend
18859,Interventional Procedures legend legend
18861,In Hospital Procedural Results and Clinical Outcomes at 18 Month Follow Up legend legend
18862,Independent Predictors of Any Cardiac Event, Target Lesion Revascularization and Any Revascularization Rate During 18 Month Follow Up
18865,Early Coronary Angioplasty Outcomes Stratified by Infarct related Vessel Type   Core Laboratory Analysis   legend
18866,In Hospital Major Adverse Cardiac Events legend
18868,Infarct Related Artery Patency Before Angioplasty legend
18869,In hospital Clinical Outcome legend
18872,Outcomes legend legend
18873,Logistic Regression Models legend legend
18879,Cardiac Catheterization Data in Patients With and Without Lateral ST Segment Depression legend legend
18881,Summary of Infarct Size Data in Experiment 1 legend legend
18882,Effects of Diazoxide on Mitochondrial Dysfunction by Ischemia Reperfusion legend legend
18883,Effect of Diazoxide on Mitochondrial Respiration In Vitro legend legend
18885,Angiographic Data of the Total Study Population   n   216   legend
18886,Univariate Analysis of Angiographic Data legend
18887,Location of Culprit Lesion: Univariate Analysis legend legend
18888,Region at Risk in Patients With Acute Occlusion on LCA: Univariate Analysis legend
18889,Multivariate Analysis: Angiographic Predictors of Out of Hospital VF legend
18891,Bivariate Analyses Directly Comparing Subjects with Recognized   n   700   and Unrecognized   n   201   Myocardial Infarction: Significant Predictors of Unrecognized Infarction
18892,Logistic Regression Analysis Directly Comparing Subjects with Unrecognized Myocardial Infarction   n   201   to Those with RMI   n   700  : Independent Predictors of UMI legend
18893,Chi Square Analyses of Six Year Mortality in Participants with UMI, RMI, and No History of MI
18894,Independent Predictors of Mortality Post MI legend
18897,In Hospital Clinical Outcome
18898,Long term Outcome
18899,Cause of Death Among the 89,299 Eligible Participants
18901,RR of Total Mortality According to Level of Alcohol Consumption legend
18902,RR   95  CI   of CVD Mortality According to Level of Alcohol Consumption legend
18903,RR   95  CI   of Cancer Mortality According to Level of Alcohol Consumption legend
18904,RR   95  CI   of Other Mortality According to Level of Alcohol Consumption legend
18906,Coronary Flow Velocity Measurements by TTCDE legend
18909,Predictive Value of Various Risk Stratifiers legend
18912,Left Ventriculographic Parameters legend
18913,Parameters Predicting Development of CAVB in the Thrombolytic Era legend legend
18914,Odds Ratios and Hazard Ratios of Mortality of Patients With CAVB Complicating AMI
18916,Crude Mortality Rates of Patients With CAVB Complicating AMI
18917,Univariate Comparisons of Tobacco Habits Between 25  to 64 Year Old Male Patients With First MI and Age Matched Controls
18919,Conditional Logistic Regression Analysis of Independent Predictors of AMI Excluding Present Smokers: 658 Valid Observations in the Analysis of Fatal and Nonfatal Events Combined and 106 Valid Observations in the Analysis of Fatal Events
18921,Genotypic Distributions and Allelic Frequencies of PAI 14GPolymorphism Among Patients and Controls
18922,Multivariate Logistic Regression Models for CAD and MI legend
18925,Use of Therapies in Patients With Acute Myocardial Infarction According to Occurrence of Heart Failure: Worcester Heart Attack Study legend
18926,Time Trends in the Multivariable Adjusted Odds of Developing Heart Failure in Patients With AMI: Worcester Heart Attack Study legend
18927,Time Trends in the Multivariate Adjusted Odds of Dying in Hospital Following Heart Failure Complicating AMI: Worcester Heart Attack Study legend
18929,Annualized Rates of Procedures by Terciles
18935,Procedural and 6 month Angiographic Findings legend
18936,Procedural, In Hospital and Long Term Follow up Clinical Outcomes legend legend
18938,Number of Clinical Events 6 to 12 Months After Recruitment in the Clinical Follow up and Angiographic Follow up Groups legend
18939,Patient Symptoms and Medication at Both Six month and One year Follow up According to Randomization legend
18940,Six month Symptomatic Status and Medication, of Those Patients Who Experienced Events Between 6 and 12 Months After Recruitment Into the Benestent II Study legend
18941,Difference in Clinical Event Rate Six Months to One Year When Those Who Received a Stent and Balloon Angioplasty Were Compared legend
18942,Linear Regression Model to Predict In Hospital Cost legend
18944,Clinical Outcome Data for All U.S. Patients
18945,Clinical Outcome Data for Cost Substudy Patients
18946,Mean Cost Data    SD
18948,Serum Cardiac Marker Concentrations and Indexes in the Study Group legend legend
18950,Diagnostic Performance of the 60 min Myoglobin Ratio
18954,Clinical Variables
18955,Angiographic Findings
18956,IVUS Findings legend
18957,Multivariate Predictors of Cardiac Events at Follow up Procedures legend
18959,Myocyte Intracellular Calcium Kinetics and Contractile Responses to  Ca2  o legend
18961,Electrocardiographic Predictors of Left Anterior Descending Coronary Artery   LAD   Occlusion Proximal to the First Septal Perforator   S1   and or the First Diagonal Branch   D1   legend
18962,Electrocardiographic Predictors of LAD Occlusion Distal to S1 and or D1 legend
18963,Electrocardiographic Predictors of LAD Occlusion Site legend
18964,Study Group legend
18967,Classes of Antianginal Medications Given at Exercise Tl 201 SPECT and Subsequently Prescribed for Follow up: Description in the Overall Population and Comparison Between the Three Groups legend
18971,Comparison Between TIMI Flow and Corrected TIMI Frame Counts legend
18972,Univariate Predictors of Late Mortality legend
18973,Multivariate Predictors of Late Mortality legend
18977,Patients With Complications and Residual Diameter Stenoses by Largest Diameter Catheter Used legend
18978,Clinical Complications After Laser Treatment and Adjunctive Balloon Angioplasty in 440 Patients legend
18979,Success by Lesion Location and Lesion Length legend
18980,Success by Vessel Diameter, Largest Catheter Size and Catheter Vessel Ratio legend
18981,Comparison of Matched and Unmatched Patients legend
18983,Hospital Level ComparisonProcess of Care and Outcome
18985,Patient Level ComparisonHospital Course and Medications
18986,Patient Level ComparisonIn Hospital Mortality legend
18987,External Validity Comparison legend
18992,Adverse Experiences legend legend
18994,Crude, Age Adjusted and Multivariable Adjusted Risk of Dying During Hospitalization for Initial Acute Myocardial Infarction: Worcester Heart Attack Study legend
18995,Crude, Age Adjusted and Multivariable Adjusted Risk of Surviving Within One Year of Hospital Discharge After Initial Acute Myocardial Infarction: Worcester Heart Attack Study legend
18998,Stenosis Variables Associated With Myocardial Infarction   Multivariate Analysis   legend
18999,Interactions Between the Stenosis Variables and Aspirin Use   Univariate Analysis
19001,Spearman Correlation Coefficients Between Fibrinogen Levels and Coronary Risk Factors Among 199 Men With Myocardial Infarction   Case Subjects   and 199 Matched Control Subjects in the Physicians Health Study legend
19002,Contingency Table of Reinjection g SPECT Visual Wall Motion Scores Against Cine MRI Visual Wall Motion Scores legend
19003,Contingency Table of MIBI g SPECT Visual Wall Motion Scores Against Cine MRI Visual Wall Motion Scores legend
19004,Contingency Table of Reinjection g SPECT Visual Wall Thickening Scores Against Cine MRI Visual Wall Thickening Scores legend
19005,Contingency Table of MIBI g SPECT Visual Wall Thickening Scores Against Cine MRI Visual Wall Thickening Scores legend
19006,The Difference Between Reinjection g SPECT and MRI legend
19007,The Difference Between MIBI g SPECT and MRI
19012,Interventional Procedures in Stented Lesions
19014,In hospital Procedural Results and Clinical Outcome at One Year
19015,Multivariate Analysis to Predict Any Cardiac Events, Target Lesion Revascularization and any Revascularization at One Year of Follow Up
19019,Cumulative Rates of Major Adverse Cardiac Events at Six Months Follow up Among 3,899 Patients Without In Hospital Complications legend
19021,Agreement Between Techniques   RVG EF and Cath EFa   With Clinical End Points legend
19022,Cox Regression Analysis Dependent Variable: CHF or Mortality legend
19024,Within the Cholesterol and Recurrent Events Trial: Lipids in Scandinavian Simvastatin Survival Study
19026,Admission Biochemistry legend
19027,Multivariate Predictors of Discharge Diagnosis  legend
19030,Adverse Cardiovascular Events During the 30 Day Follow up Period  legend
19031,Results of Follow up Angiography  legend
19032,Results of Follow up Angiography in Diabetic Patients According to the Therapeutic Regimen  legend
19033,Profiles of Sudden Cardiac Deaths in Minnesota High School Athletes legend
19035,Multiple Logistic Regression Analysis of In Hospital Complications With Presence of Any Debris   1  to 3     legend
19036,Overall Incidence of Debris According to Catheter Type  legend
19038,Technical Features and Angiographic Results of the Successful Procedures  legend
19039,Long Term Clinical Outcome
19041,TIMI Flow, Mortality and Ejection Fraction Versus Time to Reperfusion  legend
19043,Multivariate Predictors of 30 DayPlus Late Cardiac Mortality by Cox Regression    legend
19045,Clinical Event Rate According to Presence or Absence of ST Segment Elevation of 0.1 mV in Lead V4R
19046,Thirty Day Mortality According to Presence or Absence of ST Segment Elevation of 0.1 mV in Lead V4R legend
19047,Multivariate Analysis for Prediction of 30 Day Cardiac Mortality on the Basis of Presence of RVI 0.1 mV and 9 Other Variables   A   and After Offering Peak CK  12 Fraction of the Upper Normal Limit as Additional Variable   B    legend
19048,Angiographic Right Coronary Artery Data According to Presence or Absence of ST Segment Elevation of 0.1 mV in Lead V4R  legend
19051,Payer Type for Patients of Cardiologists and Primary Care Physicians  legend
19052,Length of Stay for Patients of Cardiologists and Primary Care Physicians  legend
19054,Trends in NY States CABG Population
19058,Angiographic Outcomes  legend
19059,Univariable Outcomes  legend
19060,Multivariable Analysis legend
19061,Predictors of 6 Month Mortality by Stepwise Logistic Regression
19062,Characteristics of the Study Population According to the Clinical Outcome of the Patients  legend
19063,Characteristics of the Study Population According to the Procedural Outcome of the Patients  legend
19065,Plasma NOxin Control and AMI Patients  legend
19066,Calculation of Cardiac NOxProduction Equivalent  legend
19068,In Hospital Clinical Outcome  legend
19069,Six Month Clinical Outcome legend
19073,Kaplan Meier Untoward Event Rates legend
19077,Clinical Events at One Month  legend
19078,Angiographic and Clinical Data at Follow Up  legend
19082,Hemodynamic Variables  legend
19087,Cardiovascular Events in Women
19088,Cardiovascular Events in Men legend
19090,Weights, Risk and Infarct Size Data
19092,Use of Cardiac Procedures in Study Patients According to Payor Type
19093,Use of Discretionary and Nondiscretionary Angiography in Study Patients According to Payor Type
19094,Adverse Events  in Study Patients According to Payor Type
19095,Univariable and Multivariable Analysis: Predictors of Seven Year Outcome in 282 Patients With Unstable Angina
19097,Blood Pressure, Heart Rate and Ischemic Episodes in Nondippers, Dippers and Overdippers
19098,Comparison of Variables of 19 Patients With Extreme Myocardial Salvage    10  vs.  90  salvage index
19099,Assessment of Historical and Hemodynamic Variables Potentially Associated With Residual Blood Flow and Myocardial Salvage
19101,Procedural Data
19102,Clinical Outcome of Randomized Patients
19103,Angiographic Outcome of Randomized Patient Groups
19104,Clinical and Angiographic Outcomes of Nonrandomized Patient Group
19108,Odds Ratios for Intravascular Ultrasound Coronary Plaque Calcification by ACE Genotype and Other Variables: Multiple Logistic Regression Analysis  a
19109,Univariate Predictors of Extent of Atherosclerosis in 149 Patients
19110,Multivariate Analysis for Predictors of Extent of Atherosclerosis
19113,Genotypic and Allelic Frequencies in Patients With Disease and Control Subjects
19114,DD and Non DD Genotype Frequencies in Women by Age and Myocardial Infarction Status
19116,Unadjusted Risk and Adjusted Hazard Ratios for All Cause Mortality and Death or Hospital Admission for Heart Failure in Warfarin Users Versus Nonusers in the Studies of Left Ventricular Dysfunction Combined Trial
19117,Unadjusted Relative Risk and Adjusted Hazard Ratios for Causes of Death in Warfarin Users Versus Nonusers in the Studies of Left Ventricular Dysfunction Combined Trial
19118,Hospital Admission for Unstable Angina or Nonfatal Myocardial Infarction in Warfarin Users Versus Nonusers in the Studies of Left Ventricular Dysfunction Combined Trial
19119,Adjusted Hazard Ratios for All Cause Mortality in Warfarin Users Versus Nonusers in Subgroups of the Studies of Left Ventricular Dysfunction Combined Population
19121,Phenylephrine and Spectral Measurements of Baroreflex Gain in All Patients and Patients With LVEF 40  or  40
19122,Global Results of Comparison Between Spectral Measurements of Baroreflex Gain and Phenylephrine Measurement
19124,Patency at 90 Minutes by Coronary Artery: Heparin in Early Patency Pilot Study
19126,Plaque Dimensions
19127,Aortic Atheroma: Follow Up Events
19129,Radionuclide Variables by Classification   expressed as percent of left ventricle
19130,Regional Left Ventricular Ejection Fraction Values
19131,Effects of Second Hand Smoke and Gender on Infarct Size
19133,Univariate Cox Model Rankings of Doppler Echocardiographic and Clinical Variables Predicting Cardiac Death
19134,Multivariate Cox Model Analysis
19135,Analysis of Procedural Success Rate by Occlusion Length
19136,Analysis of Procedural Success Rate by Occlusion Age
19137,Clinical Variables in the 26 Study Patients
19138,Regional Intramyocardial Percent Circumferential Shortening in Normal Subjects and in Patients at Day 5 and Week 8 After Anterior Myocardial Infarction
19140,Patient Outcome
19144,Coronary Angioplasty Variables for 244 Lesions
19145,Quantitative Angiographic Analysis
19146,Periprocedural Complications in 215 Patients
19147,Major In Hospital End Points   includes cardiac catheterization laboratory events
19148,Comparison of Outcomes in Laser  and Coronary Angioplasty Assigned Patients Substratified by Presence of Previous Myocardial Infarction and Lesional Thrombus
19150,In Hospital Outcomes  a
19153,Quantitative Angiographic and Hemodynamic Data in 19 Patients
19154,Quantitative Measurements of Wall Thickness, Simulated Wall Motion and Simulated Wall Thickening Using the Variable Thickness Heart Phantom
19155,Agreement Table Relating Quantitative Motion and Visual Motion Scores in the 1,580 Segments Studied
19156,Agreement Table Relating Quantitative Thickening and Visual Thickening Scores in the 1,580 Segments Studied
19158,Genotypic and Allelic Frequencies in Patients With Myocardial Infarction or Coronary Artery Disease and Control Subjects
19162,Angiographic Data Before and After Stenting
19163,In Hospital Outcome of 186 Patients
19164,Clinical Follow Up Outcomes of 177 Patients
19165,Follow Up Angina Pectoris and Activity Classes in Surviving Patients
19166,Signal Intensity of Normal and Reperfused Infarcted Myocardium in the Three Experimental Groups
19171,Five Year Cause of Death in the 19851986 NHLBI PTCA Registry   n   2,127
19173,Predictors of Cardiac and All Cause Mortality
19175,Results of Longitudinal    1 year   Coronary Interventional Studies  a
19180,Angiographic Results
19181,Clinical Events During Follow Up
19182,University of Vermont Payer Mix, 1995
19183,Costs, Incremental Costs and Contribution Margins of Complications and Salvage Techniques
19185,Exercise Testing Results
19186,Results of Diary Analysis  a
19187,Results of Ambulatory Electrocardiographic Analysis  a
19190,Procedural Characteristics and Outcome
19191,Quantitative and Qualitative Angiographic Results
19192,Major Adverse Cardiovascular Events and Clinical Follow Up
19194,Timing of Clinical Events or Withdrawal of Study Medication
19196,Change in Culprit Lesion
19197,Results of the Three Walks
19198,Number of Patients Showing Improvement for Each Ischemic Variable
19204,Indications for Transesophageal Echocardiography  a
19207,Results of Stepwise Discriminant Analysis
19209,Univariate and Multivariable Association Between Outcomes and Procedure Type
19210,Association of Procedure Type With Major Complications for Different Risk Groups of Patients  a
19211,Guide Wires Used in the Present Study
19214,Angiographic Predictors of Success
19216,Adverse In Hospital Events in Study Group
19217,Adverse Events at 6 Months for 43 Hospital Survivors
19218,Patients Undergoing Rescue Stent Placement Versus Emergent Coronary Artery Bypass Graft Surgery for Failed Percutaneous Transluminal Coronary Angioplasty
19221,Outcomes of Patients Admitted to the Hospital With Congestive Heart Failure and Treated by a Generalist Alone or by a Generalist in Consultation With a Cardiologist or a Cardiologist Alone
19225,Clinical Variables According to Angiotensin Converting Enzyme Genotype
19227,Results at 6 Months
19228,Total Medical Charges in Dutch Guilders
19230,End Point by Treatment Group  a
19231,Complications by Treatment Group
19232,Timing of Complications by Treatment Group
19236,Rates of Major In Hospital Complications
19237,Logistic Regression Analysis of Core Laboratory Factors Associated With Major Complications   death, Q wave myocardial infarction or emergency coronary artery bypass graft surgery  : Odds Ratio   95  confidence interval
19238,Clinical Data in Medically Treated Patients   group C
19239,Clinical Data for Groups A, B and C
19240,Echocardiographic and Hemodynamic Data
19242,Clinical Presentation
19243,Thrombolytic Therapy
19244,Clinical End Points
19247,Incidence of Angiographic Findings in Patients With an Identifiable Single Culprit Lesion
19248,Correlation of Recent Rest Angina   Braunwald class III   With Angiographic Variables: Multivariate Analysis
19249,Correlation of Postinfarction Angina   Braunwald class C   With Angiographic Variables: Multivariate Analysis
19250,Correlation of Refractory Unstable Angina   Braunwald class c   With Angiographic Variables: Multivariate Analysis
19251,Correlation of Combination of Braunwald Classes With Angiographic Variables: Multivariate Analysis
19252,Validation of Individual Braunwald Classes as Independent Predictors of Angiographic Morphology: Multivariate Analysis
19254,Number of Deaths According to Gender and Underlying Cause of Death During the First 5 Years of Follow Up From Time of Coronary Artery Bypass Graft Surgery
19255,Relative Risk of Early Mortality With 95  Confidence Interval in Women Versus Men
19256,Relative Risk of Mortality With 95  Confidence Interval 1 and 5 Years After Coronary Artery Bypass Graft Surgery in Male and Female Patients Surviving 30 Days After Operation
19259,Immediate Angiographic Results: Nonstented Versus Stented Lesions
19260,Immediate Angiographic Results: Nonstented Versus Stented Left Main Coronary Stenoses Classified by Ostial Location
19262,Outcome of the 2,431 GUSTO I Angiographic Study Patients According to Gender
19263,Gender and 90 Minute Angiographic Patency   n   1,075    a
19264,Indexes of Global and Regional Ventricular Function According to Gender, After Thrombolysis, in Patients With Patent Infarct Related Arteries
19265,Multivariate Analysis: Clinical and Angiographic Independent Determinants of Global and Regional Left Ventricular Function After Acute Myocardial Infarction
19267,Hemodynamic Effects of WRC 0470 During Reflow
19268,PET Flow and Glucose Uptake, Percent MIBI Uptake, Ventricular Function and Percent Fibrosis in Anterior Wall Biopsy Specimen
19269,Comparison of MIBI and PET Findings With Functional Follow Up Data
19271,Systolic Function Variables in the Two Patient Groups
19272,Diastolic Function Variables in the Two Patient Groups
19273,Morphometric Data in the Two Patient Groups
19275,Relation of Angiographic Markers of Disease Severity to Presence or Absence of Definite Complex Plaque
19277,In Hospital Clinical Outcomes of Patients Undergoing Isolated Tricuspid Valve Surgery From 2004 to 2013   Unweighted
19278,Multivariate Logistic Regression for Predictors of In Hospital Death in Patients Undergoing Isolated Tricuspid ValveSurgery From 2004 to 2013
19281,Procedural Data of the 15 Patients Enrolled in the SCOUT Trial
19282,Measures of Technical Success
19288,Overall and Cause Specific 30 Day and Long Term Mortality
19289,Findings in Patients With Echocardiographic Long Term Follow Up
19291,Clinical Outcomes
19292,Median Total New Lesion Volume and Number of New Lesions   Unadjusted Analysis, Day 2 to 7
19295,Cerebral Events on MRI
19296,Cerebral Events on MRI in Patients With or Without a Clinical Stroke TIA
19298,Ischemic and Bleeding Endpoints
19299,Previous Studies Investigating the Risk of Cerebral Events by DW MRI
19301,ECHO Findings Among Incident HD Patients   N   567   With SHD Based on ECHO Criteria Proposed by the Acute Dialysis Quality Initiative
19302,Association of Age  and Sex Adjusted Structural Heart Disease Variables With Overall Mortality
19306,Temporal Change in Medicare Fee for Service Patients With Pulmonary Embolism With and Without Inferior Vena Caval Filter Placement in 1999 and 2010
19309,Observed Rates of Mortality and Nonfatal Outcomes by Year Group
19311,Multivariable Model of Predictors of 30 Day Mortality
19314,Annualized Ischemic Stroke Rates in Relation to Duration of Quarantine Period
19316,Crude Event Rates per SBP and Length of Follow Up
19317,Crude and Adjusted Hazards Ratios for Mortality ESRD by SBP
19318,Adjusted HR on the Basis of DBP
19319,Stratified Analysis: HR for Mortality ESRD
19324,Pannus and or Thrombus in OTPHV Diagnosed atSurgery
19325,Anticoagulation Status at Time of ClinicalPresentation
19326,Summary of Pooled Data of Thrombolysis in 756 Patients for 801 Episodes of Left Heart OTPHV
19328,Summary of Pooled Data With Surgical Treatment for Left Heart OTPHV
19329,Suggested Therapeutic Strategies for OTPHV
19331,Procedure Time, Contrast Volume, and Fluoroscopy Duration
19332,Site Reported Safety Outcomes at 30 Days and 12 Months
19340,Index Admission Resource Use and Costs, Transfemoral Cohort   Treated as Randomized Population
19341,Index Admission Resource Use and Costs, Transapical Cohort   Treated as Randomized Population
19342,Cumulative 1 Year Resource Use and Costs, Transfemoral Cohort   mITT Population
19343,Cumulative 1 Year Resource Use and Costs, Transapical Cohort   mITT Population
19344,Life Years and QALYs Over the 12 Month Follow Up Period   mITT Population
19345,Primary Cost Effectiveness Results   mITT Population
19347,Factors Associated With Lower Extremity Amputation
19348,Rate of Lower Extremity Amputations per U.S. Census Bureau During Study Period
19350,Unadjusted and Adjusted HRs While Listed
19351,Cumulative Hazard of Adverse Events While Listed In Status and in Any Status After Initial Listing
19352,Post Transplant Mortality Adjusted for Age
19355,30 Day and Late Cardioembolic Events and Death According to the Occurrence of NOAF
19358,DW MRI Findings Following TAVI
19362,Multivariate Cox Models of All Cause and Cardiovascular Mortality
19363,5 Risk Stratification Schemes Used to Predict Thromboembolism in Persons With Nonvalvular Atrial Fibrillation
19366,Summary of Adverse Events During and After Implantation
19368,Acute Results, Subgroup Analysis
19370,Long Term Results Subcohort Analysis Per Lesion
19371,Study Sample
19373,Residual Flows at Most Recent Follow Up
19374,Complications
19375,Results of Successful and Unsuccessful Procedures
19376,Published Results of Uncomplicated ASD Closure: Comparison of ASD Devices
19377,Successful Outcomes: Comparison
19378,Correlations of MR Flow Rate With Mitral Valve Deformations in Early  and Late Systolic Peaks
19379,The Relationships of MR Flow Ratio With Clinical and Echocardiographic Findings
19380,The Effect of CRT on Mitral Valve Deformations and MR Flow Rate
19382,Atrial FibrillationAnalysis of Factors in the High Risk Not Receiving Warfarin Cohort Associated With Perceived or Actual Bleeding Risk
19383,Use of Warfarin in Patients 80 Years of Age
19384,Variables Associated With Treatment With Warfarin
19385,NABOR Study Results Comparison Published Atrial Fibrillation Anticoagulation Studies
19387,Association of Migraine Headache With Interatrial Shunts and Impact of Transcatheter Closure
19388,Pattern of Headache Improvement in Patients After Closure of Interatrial Communication
19391,Implanted Devices
19392,Recurrent Events
19394,Procedural Resource Utilization and Cost
19395,Initial Hospital Outcomes, Resource Utilization, and Cost
19396,Follow up Events, Resource Utilization, and Cost
19397,Multivariable Linear Regression Model of Initial Hospital Costs
19398,Subgroup Analyses of Efficacy, Cost, and Cost Effectiveness
19400,Risk Adjusted Mortality by Race
19401,Mortality by Race in Selected Subgroups
19402,Risk Adjusted Rates of Healthcare Utilization
19403,Overview of Studies Used for the Analysis of Mechanical Aortic Valves
19404,Overview of Studies Used for the Analysis of Mechanical Mitral Valves
19405,Incidence Rates of Thromboembolic and Hemorrhagic Complications in Patients With Mechanical Aortic Valve, According to Vitamin K Antagonist Intensity
19406,Incidence Rates of Thromboembolic and Hemorrhagic Complications in Patients With Mechanical Mitral Valve, According to Vitamin K Antagonist Intensity
19407,Risk Ratios of Thromboembolic and Hemorrhagic Events for Patients With a Mechanical Aortic Valve Compared With Mechanical Mitral Valve
19410,Two Year Event Rates in Patients With SA and PFO Compared With Patients Without SA or PFO
19412,Two Year Event Rates in Patients With SA and PFO With EV or RA Filamentous Strands Compared With Patients Without SA, PFO, EV, or RA Filamentous Strands
19413,Two Year Event Rates in Patients With Both SA and PFO Treated With Warfarin or Aspirin
19414,Diagnostic Criteria of CES
19415,Incidence of Definite and Possible CES
19419,Multivariate Analysis of Predictors for Postprocedure CES
19421,Mortality Rate at 14 days, in Patients With       and Without      RHTh According to Reported Treatment
19422,Mortality Rate at 3 Months, in Patients With       and Without      RHTh According to Reported Treatment
19424,Distribution of Clinical Severity Factors According to the Presence or Absence of RHTh in Patients Treated With Heparin Alone
19435,Patient Results legend
19438,Angioplasty Devices legend
19439,In Hospital Outcomes legend
19440,One Year Clinical Outcomes legend legend
19441,Multivariate Predictors of Late Cardiac Events legend
19442,Multivariate Predictors of Target Lesion Revascularization legend
19443,Clinical and Hemodynamic Data   n   14   legend legend
19444,Indexes of Wave Reflection legend legend
19446,Summary Results    legend
19447,Subgroup Analyses legend
19448,Pre  and Post fragmentation Circulatory Parameters of the Noninterference Group   n   15   legend legend
19450,Residual Shunt
19451,Follow up Data legend
19452,Stratified Kaplan Meier Lifetable Analyses legend
19453,New Lesions legend
19454,Univariate Analysis for New Lesions legend
19455,Postoperative Neurologic Complications legend
19456,Univariate Analysis for Strokes legend
19458,P Values of the Repeated Measures Analysis of Variance legend
19460,Immediate Hemodynamic Results in 438 Completed Procedures
19462,Independent Predictors of Long Term Event Free Survival  legend
19464,Expansion Rate and Clinical Outcomes According to Tertiles of 18FSodium Fluoride Uptake
19468,Data Representativeness in GBD 2015 Fatal and Nonfatal Modeling by CVDCause
19469,Global and Regional All Age Deaths and Age Standardized Death Rates in 2015, by Sex, for Selected Causes of CVD Mortality
19470,Global and Regional All Age Prevalence and Age Standardized Prevalence Rates in 2015, by Sex, for Selected Causes of CVD Mortality
19472,IVUS Parameters
19473,Difference in Proportions of Mean VA and LA Changes
19474,Plaque Composition of Mean Plaque Cross Sectional Area
19475,Balloon Diameters and Balloon Artery Ratios
19476,Multivariate Analysis: Predictors of Expansive Remodeling
19478,Reproductive Factors and Incident Total HF
19479,Reproductive Factors and Incident HF With Reduced Ejection Fraction
19480,Reproductive Factors and Incident HF With Preserved Ejection Fraction
19481,Ages at Menarche and Menopause and Incident HF
19482,Reproductive Factors and Incident Total HF Among Women Without Use of Oral Contraceptive Pills or MenopausalHormoneTherapy
19483,Reproductive Factors and Incident Total HF Among Women With Natural Menopause
19484,Reproductive Factors and Incident Total HF Among Women With Surgical Menopause
19487,The 5 Year NNT to Prevent 1 Cardiovascular Event for Very High , High , Moderate , and Lower Risk Individuals on Maximal Statin Therapy
19488,NNT to Prevent 1 ASCV Eventfor LDL C Thresholds in the  Central Illustration  and Corresponding Cost Effectiveness per QALY for PCSK9 Monoclonal Antibodies
19489,Case Study of a 43 Year Old Woman With LDL C  190 mg dl
19491,Age Standardized Cause Specific Mortality
19494,Risk of THV Thrombosis in Relation to Post TAVR Antithrombotic Therapy Until 1  to 3 Month Post TAVR Follow Up   Routine Follow Up Visit 1
19495,Echocardiograph at 1  to 3 Month Post TAVR Follow Up   Routine Follow Up Visit 1   and 30 Day Complication Rate
19496,12 Month Post TAVR Follow Up 2   Routine Follow UpVisit 2
19498,Age  and Sex Adjusted Pearson Correlation Coefficients Between Changes in Abdominal Fat Volume and Attenuation With Changes in Cardiovascular Disease Risk Factors
19504,Biochemically Confirmed Smoking Cessation Endpoints
19505,Continuous Abstinence Between Months 6 and 18   Primary Outcome   inSubgroups
19509,Comparison of Risk Estimator Components
19510,Common Causes of Secondary Hyperlipidemia
19512,Annual Procedure Volumes Among Those Physicians Providing Services
19513,Compensation According to Sex in Meaningful Subgroups
19514,Parsimonious Model for Compensation; Variables Selected Through StepwiseSelection
19516,All Cause Mortality
19517,Cardiovascular and Noncardiovascular Mortality
19525,Sequencing Summary
19526,Accumulation of Rare Coding Variants in Individuals With HTG and Control Subjects
19527,Analysis of Coronary Artery Disease Patients With the Diagnosis Determined by Angiography
19532,Lipid Profile in the Study Group According to the Presence of CVD
19533,Cox Proportional Hazards Model Showing Relationships Between Different Cardiovascular Risk Factors and CVD in Patients With FH
19535,Results From Multiple Linear Regression Models Examining Correlations Between Fasting Values of Growth Hormone and Traditional Cardiovascular Risk Factors
19537,Reclassification of Risk Estimates   Category Free NRI   0    for Addition of Growth Hormone to 1 Model With ConventionalCardiovascular Risk Factors   Basic   and 1 Model With 2 Additional Risk Factors
19539,Index Leg ABI Values
19541,HRs for Association of PAD Status With Mortality Outcomes
19542,Adjusted HRs for Association of ABI Severity Status With All Cause Mortality
19543,C Index for PAD Status Classified With Traditional and Alternative ABI Methods
19547,Effect of Atorvastatin and Pravastatin on Lipid Serum Levels, CAC, and EAT
19549,Angiographic and Intravascular Ultrasound Parameters
19550,Virtual Histology Findings by Fractional Flow Reserve
19551,Correlates of Fractional Flow Reserve  lt;0.8: Multivariable Logistic Regression
19554,Multivariable Logistic Regression Predictors of ICA Utilization
19555,Multivariable Logistic Regression Predictors of Early ICA Use Within 90 Days of CCTA
19556,Multivariable Logistic Regression Predictors of Catheterization in 12,408 Patients With CCTA Stenosis 50
19559,Predictors of ACS at Multivariate Analysis
19560,Association of rs5065 MA With MI and MACE at Follow Up
19561,Cox Proportional Hazard Analysis for the Association of rs5065 MA Carriers With MACE in SA and rSA Populations
19562,Diagnostic Performance of SPECT, CMR, and PET Perfusion Imaging on Patient and Coronary Artery Territory Basis
19568,Risk Factors for Mortality for Entire Cohort
19569,Surgical Procedures and Mortalities
19571,Risk Factors for Mortality After Neonatal Surgery
19572,Risk Factors for Mortality After BCPS
19576,Relation of P1, AP, AIx, and cPP to PWV, Femoral Aortic Diameter, and Other Factors at Follow Up According to Multivariable Regression Analysis
19579,CAD Status According to Quartile of HII
19582,Outcomes
19583,Predictors of Mortality at 1 Year
19586,Results From Observational Studies That Evaluated the Effect of MD on Components of MS
19587,Results From Clinical Trials That Evaluated Effect of MD on Components of MS
19588,Sensitivity Analysis of Selected Studies in Present Meta Analysis
19590,HRs for All Cause Mortality and CVD Events for Screen Based Entertainment Groups     Excluding Previous CVD Hospital Stays
19592,Genes Associated With Angiogenesis Significantly Up  or Down Regulated in CD31 Cells Compared to CD31Cells
19593,Biomechanical Properties of Crimped, Uncrimped, and Explanted Vascular Cell  and Stem Cell Based TEHV
19594,Quantitative Tissue Analysis of Explanted TEHV on Basis of Vascular Derived Cells and Stem Cells
19595,Cardiac Magnetic Resonance Scan Parameters
19604,Results, OR, and 95  CI for Total Stroke in Single Randomized Controlled Clinical Trials Testing Efficacy of Statins, Fibrates, and Other Interventions
19608,Categorization of Individuals     by 10 Year CHD Risk Calculated by Framingham Risk Score and ARIC Risk Score
19609,Event Rates per 1,000 Person Years Adjusted for Age, Race, and Sex
19610,HRs   95  CI   Adjusted for Age, Race, and Sex Comparing hs CRP Groups   2.0 to  2.0 mg l   Within Each LDL C Strata and Comparing LDL C Groups   130 mg dl to  130   Within Each hs CRP Strata
19612,Comparison of ARIC JUPITER Eligible Group, JUPITER Placebo Arm, and JUPITER Treated Arm: Event Rates
19614,Primary Cause of Hospitalization According to Year of Diagnosis and Sex
19615,Primary Cause of Noncardiovascular Hospitalizations Based on ICD 9 Codes
19618,Predictors of Mortality in HFpEF
19619,The JUPITER Study Eligibility Criteria
19620,Population Estimates of Men Age 50 and Women Age 60 Years in Millions   95  CI   Meeting the JUPITER Study Eligibility by hsCRP and LDL C Levels
19621,Population Estimates of Adults Age 20 Years in Millions   95  CI   Meeting JUPITER Study Eligibility by hsCRP and LDL C Levels
19622,Population Estimates of Men Age 50 Years and Women Age 60 Years in Millions   95  CI   at NCEP ATP III Goals With hsCRP 2 mg l
19623,Population Estimates of Adults Age 20 Years in Millions   95  CI   at NCEP ATP III Goals With hsCRP 2 mg l
19625,Assessability of Coronary Segments by Helical Scan and Prospective Gating
19626,Diagnostic Accuracy of Helical Scan and Prospective Gating
19627,Radiation Doses of Helical Scan and Prospective Gating
19630,Relationship of Use of Spironolactone to Fractures   vs. Nonuse
19631,Relationship of Duration of Use of Spironolactone to Total Fractures   vs. Nonuse
19634,Use of Established Medical Therapies and Degree of Risk Factor Control of Subjects Stratified According to Gender
19636,MetS Component Values for Male and Female Participants
19637,Age Specific MetS Cut Points and Corresponding Percentiles for Males
19638,Age Specific MetS Cut Points and Corresponding Percentiles for Females
19639,Age Specific BMI Cut Points   kg m2   and Corresponding Percentiles for Males and Females
19640,Prevalence of MetS in 12  to 19 Year Olds by Gender, Age, and Race in NHANES, 19992002
19643,Intravascular Ultrasound Measurements
19644,Angiographic Results at Follow Up
19646,Effects of Short Term CPAP Application
19655,Summary of SafetyNumber of Subjects
19656,Longitudinal Analysis of Changes in Blood Pressure: Average of All Follow Up Measures Over the Course of the Study   All Subjects, Observed Cases
19661,Summary of SafetyNumber of Patients         All Patients Received Background Atorvastatin 20 mg day
19662,Longitudinal Analysis of Changes in Blood Pressure: Average of All Follow Up Measures Over the Course of the Study   All Patients, Observed Cases; All Patients Received Background Atorvastatin 20 mg day
19663,Distribution of 10 Year Risk for CHD Among U.S. Adults Ages 20 to 79 Years, Overall and by Gender and Race Ethnicity: NHANES III and NHANES 1999 to 2002
19664,Distribution of 10 Year Risk for CHD Among U.S. Adults Ages 20 to 79 Years Without CHD or CHD Equivalent: NHANES III and NHANES 1999 to 2002
19665,Prevalence of Component Risk Factors Used for 10 Year CHD Risk Assessment Among Survey Participants Ages 20 to 79 Years
19670,Correlation Coefficients Between PON1 Activity and Concentration and Selected Variables
19671,Multivariate Analysis of Predictors Affecting Global Percent Diameter Stenosis Index
19674,Results of Virtual Histology and In Vitro Histology Correlation Analysis
19675,Frequency of Each Plaque Phenotype Presence in In Vitro Histopathology Sections and In Vivo Virtual Histology
19682,Results for Age, Gender, and Race Adjusted Linear Regression Models of Myocardial Perfusion Measurements   PR and Hyperemic MBF, Respectively   With Coronary Heart Disease Risk Factors as Predictors
19683,Results for Multivariate Adjusted Linear Regression Models of Myocardial Perfusion Measurements   PR and Hyperemic MBF, Respectively   With Coronary Heart Disease Risk Factors as Predictors
19687,Descriptive Statistics
19688,Clinical Service Statistics
19689,Example: Pro Forma Cumulative, Survival Adjusted Hospital Contribution Analysis
19690,Accuracy of 64 Slice CT to Detect Coronary Stenosis in Comparison to QCA
19691,Consensus Table of Stenosis Severity Determined by 64 Slice CT Versus QCA
19692,Accuracy of 64 Slice CT to Detect Coronary Lesions in Comparison to IVUS
19696,Plasma Concentrations in the Fasted State
19697,Metabolic Responses to the Test Meal
19698,Echocardiographic Parameters
19699,Left Atrial Action Potential Parameters in the Control, APS, and APSR States
19703,Gensini Score and Plasma FCR of the Emulsion Triglycerides in ACAD Group Patients Separated According to the Presence or Absence of Severe Angiographic Progression
19704,Paclitaxel Concentration in 15 mm Segments of Coronary Arteries at Various Times After the Injection of 80 ml Iopromide 370 With 200 mol l Paclitaxel in the LAD and Cx of Nine Pigs
19706,Histomorphometry of Stented Porcine Coronary Arteries After 28 Days
19708,Twenty Most Common Noncardiac Chronic Disease Conditions for Patients Age 65 Years With CHF   n   122,630
19709,Association of Noncardiac Comorbidity With Ambulatory Care Sensitive CHF Hospitalization Among Medicare Beneficiaries With CHF
19710,Association of Noncardiac Comorbidity With Any Ambulatory Care Sensitive Condition Hospitalization Among Medicare Beneficiaries With CHF
19711,Association of Noncardiac Comorbidity With Death Among Medicare Beneficiaries With CHF
19713,Plasma and Tissue Biochemical Markers
19714,Single Nucleotide Polymorphisms in the Hepatic Lipase Promoter
19715,Lipids and Lipoproteins by Hepatic Lipase Promoter Single Nucleotide Polymorphisms in Cross Sectional Study of the General Population
19718,Distribution of Follow Up Events According to CETPGenotypes
19719,Hazard Risk Ratios of Future Cardiovascular Death According to CETPGenotype
19720,Interaction Between Statin Therapy and CETP C 629AGenotype on Future Cardiovascular Death
19723,Hemodynamics
19724,Results of the Multiple Regression Analysis With Augmentation Index as the Dependent Variable
19725,Results of the Multiple Regression Analysis With Estimated Aortic Pulse Wave Velocity   TR   as the Dependent Variable
19726,Risk Factors by Ethnicity
19727,Racial Differences in Prevalence of CAC and Obstruction on Angiography
19728,Coronary Artery Disease Model With Risk Factors, Including 95  CI   as Compared with Whites
19729,Analysis of Maximum Likelihood Estimates to Test Coronary Artery Disease Likelihood
19730,Comparison of Electron Beam Tomography to Coronary Angiography in Detecting Coronary Obstruction
19732,Percent Change in Each Drug Response for Per Unit Change in Risk Factor   With 95  Confidence Interval
19733,Difference in Drug Response Per Quartile Increase in Framingham Risk Score   2000     95  Confidence Interval   in Men and Women
19734,Percent Variance in Drug Response Explained by Framingham Risk Score Beyond That Explained by Age and Gender
19735,Results of Radiofrequency Ablation
19739,Associated Cardiac Lesions legend legend
19740,Preoperative Transthoracic Echocardiographic Detection of Associated Lesions by Era of Repair legend legend
19741,Detection of Missed Lesions on Repeat Review of Transthoracic Echocardiographic Recordings legend
19742,Results of Papillary Muscle Measurements legend
19743,Results of Aortic and Subaortic Measurements legend
19744,Abnormalities of the Left Ventricular Outflow Tract legend
19745,Comparison of Caucasian Patients With CAD and Controls legend
19746,Logistic Regression Analysis Investigating the Predictive Value of ApoA IV, HDL Cholesterol and Triglyceride Concentrations for CAD legend
19748,Frequency of Risk Factors by Group legend
19749,Stepwise Logistic Regression legend
19753,Age  and Gender Adjusted Mean Values of Lipids, Lipoproteins Lipid, Apolipoproteins, and FERHDLin Patients With   CAD    and Without   CAD   Significant Coronary Stenosis legend legend
19754,Age  and Gender Adjusted Linear Trends Across Fractional Ranks of Coronary Atherosclerosis related Variables, as Tested by a Multiple Logistic Regression Analysis legend
19755,Age  and Gender Adjusted Associations between FERHDLand Coronary Atherosclerosis by HDL C   in Tertiles   and HDL C by FERHDLInteraction as Assessed by a Multiple Logistic Regression Analysis legend
19756,Age  and Gender Adjusted Relationships Between FERHDLValues and Other Lipid Variables in Patients With and Without Coronary Artery Disease as Assessed by a Multiple Regression Analysis legend
19757,Multiple Logistic Function Analysis of Coronary Risk Factors and Accompanying Odds Ratios for Each Combination of FERHDLand HDL C After Adjusting for Age and Gender legend
19759,Anatomic Defects of Eisenmengers Syndrome   n   73
19760,Management and Outcome of Pregnant Women With Eisenmengers Syndrome   n   73    legend
19761,Management and Outcome of Pregnant Women With Primary Pulmonary Hypertension   n   27    legend
19762,Management and Outcome of Pregnant Women With Secondary Vascular Pulmonary Hypertension   n   25    legend
19763,Logistic Regression Analysis: p Value and Odds Ratio   95  confidence interval    for Maternal Outcome as Dependent Variable
19765,Potential Preoperative Patient Specific Predictors of 3 Year Graft Occlusion by Univariate Analysis
19766,Potential Intraoperative and Perioperative Patient Specific Predictors of 3 Year Graft Occlusion by Univariate Analysis
19767,Potential Graft Specific Predictors of 3 Year Graft Occlusion by Univariate Analysis
19768,Multivariate Analysis: Coefficient and Standard Errors for Logistic Regression Equation for Model in Which Patient, Graft and Time Correlation Effects Were Taken Into Account
19769,Data Before Supraannular Mitral Valve Replacement
19770,Details at Time of Supraannular Mitral Valve Replacement and Clinical Course After the Procedure
19772,Procedural Data
19773,Procedural and Clinical Outcomes
19776,Echocardiographic Data   N 2,952
19777,Procedural and In Hospital Outcomes   N 2,952
19778,30 Day and 1 Year Clinical Outcomes
19779,Procedure Results and Outcomes According to Post Implant Mitral Regurgitation
19782,Community Women Survey Results   n 1,011
19784,Physicians Do Not Feel Well Prepared
19785,More Physicians Who Use Email, Facebook, or Twitter Have Heard of the ASCVD Risk Assessment Calculator Than Those Who Are Less Digitally Engaged
19790,Outcomes
19791,Outcomes per Year of Inclusion Within Centers Involved in Both Registries
19793,Clinical Outcomes and Health Care Costs Before and After PAP Sensor Implantation for the 6  and 12 Month Cohorts
19796,Device  or Procedure Related Adverse Events   n  35
19800,TAVR Outcomes
19802,Mitral Leaflet Clip Outcomes
19804,TMViV or TMViR In Hospital Outcomes
19806,Stroke and Bleeding Risk Scores   N  15,092
19807,Outcomes in the Post FDA Approval Experience
19808,Device Embolization Details
19809,Comparison of Procedural Parameters Across Watchman Studies
19810,Comparison of Procedural Complications Across Watchman Studies
19812,Factors Correlating With the WCE in 653 Subjects With WCH
19816,CT and Procedural Data
19817,Procedural and Clinical Outcomes
19818,Predictors of All Cause Mortality
19821,Factors Associated with Increased Transvalvular Gradient Progression
19824,All Treated Cohort: Efficacy Endpoint and Components at 5 Years
19831,Risk of Ischemic Stroke in AF patients With a CHA2DS2 VASc Score of 0   Male   or 1   Female   Stratified by Age
19832,Sensitivity and Specificity in Predicting Ischemic Stroke on the Basis of Different Cutoff Values of Age
19835,Safety Outcomes at 24 Months
19836,Causes of Death     Through 24 Months
19840,Variables for ACS Development
19842,Cardiac Events After CTA 2
19843,Predictors of Early and Late Stroke After TAVR
19844,Predictors of Early and Late Stroke or TIA After TAVR
19853,Procedural Outcomes
19854,Echocardiographic Findings at Discharge
19856,Observed Event Rates by Year of Ventricular Assist Device Implantation
19857,Results of Multivariable Models for Each Outcome
19858,Observed Event Rates by Year and Hospital Implant Volume
19859,Echocardiographic Assessment of TEHV Directly After Implantation, at 1, 4, 8, 16, and24 Weeks Follow Up
19860,Pooled Adjusted Hazard Ratios   95  CIs   of a 1 SD Increase in Loge Transformed aPWV for All Cause Mortality, CVD Mortality, CHD Events, Stroke Events, and CVD Events
19861,Improvement in Discrimination and Reclassification of 5 Year Risk Prediction With the Inclusion of log aPWV as a Risk Factor
19862,Net Reclassification Statistics Showing Percent Change in 5 Year Risk Prediction   and 5  and 10 Year Overall Reclassification   Associated With Including loge aPWV as a Risk Factor in the Fully Adjusted Model
19865,Failure Prevalence by Lead Family
19866,Lead Failures: Clinical Presentation, Treatment Strategy, and Manufacturer Analysis by Case
19867,Predictors of Lead Failure: Simple Cox Regression Analysis
19869,Association Between Number of Ectopic Beats   Ectopic Burden   and Likelihood of Low BIV Pacing    97    Versus High Percentage   97
19870,Multivariate Cox Regression Analysis of Endpoint of Hospitalization for HF or Death, VTAs, and Death Alone
19872,Event Rate of Ischemic Stroke Per 100 Person Years in AF Patients With an ATRIA Score of 05
19873,Event Rate of Ischemic Stroke Per 100 Person Years in AF Patients With an ATRIA Score of 05 Substratified by CHA2DS2 VASc Scores
19874,Risk of Ischemic Stroke in Patients with an ATRIA Score of 0 to 5, Stratified on the Basis of Their CHA2DS2 VASc Scores
19877,Impact of PPM on 2 Year Mortality in the SAVR RCT and TAVR RCTArms
19880,PRA and HLA Match Levels by Race Ethnicity
19881,Univariate Predictors of Graft Failure   Cox Regression     n  5,314
19882,Multivariate Predictors of Graft Failure   Cox Regression     n  5,314
19884,Multivariate Cox Regression Analysis for Inappropriate Therapy for Primary Endpoints
19885,Multivariate Cox Regression Analysis for Inappropriate Therapy for Atrial Fibrillation
19886,Multivariate Cox Regression Analysis for Inappropriate Therapy for Atrial Tachyarrhythmias
19888,Transcatheter Valve Therapy Registry Overview
19889,Major Questions and Applications Potentially Addressed by the Transcatheter Valve TherapyRegistry
19892,Effectiveness Endpoint and Components at 4 Years
19896,Association Between Electrical Parameters and CRTResponse: Univariate Analysis
19899,Multivariable Predictors of 90 Day Mortality in Derivation Cohort and Formula for Calculating HMRS
19900,Comparisons of AUCs Between Different Risk Models Used to Predict 90 Day Mortality
19901,Survival on the Basis of HMRS in the Total HMII Sample and in the Derivation and Validation Cohorts After LVAD Implant
19902,Ramp Test Protocol   for HeartMate II
19904,Summary of Speed Optimization Ramp Tests   28 Tests
19906,Multivariate Analysis: Impact of Active Device Treatment on the Occurrence of VTE in All Patients and by QRS Morphology
19907,Multivariate Analysis: Impact of Time Dependent VTEs on the Occurrence of a First Heart Failure Event or Death in the Total Study Population
19908,Multivariate Analysis: Impact of Nonresponder Status at 12 Months of Follow Up on the Occurrence of Recurrent VTEs
19912,Associations Between Short Term PM2.5 Concentrations and the Brachial Artery Outcomes
19914,Race Specific Incidence Rates of HF per 100,000 Person Years, the ARIC Cohort Study, 19872008
19917,Univariate Hazard Ratios of Mortality
19918,Hazard of All Cause Mortality and Cardiovascular Mortality at Different Levels of RAC
19919,C Statistics, IDI, and NRI for the Assessment of CAC and RAC in Addition to FRS in Predicting All Cause and Cardiovascular Mortality
19921,Percentage of Patients With Each Component of DTRS
19922,Univariate Associations   p Value   of DTRS Components With 90 Day In Hospital Mortality
19926,Univariate and Multivariate Regression Analyses on the Effect of Each Variable on LV Reverse Remodeling at 6 Months
19929,Procedural Results, Treatment Received, Per Protocol Cohort
19930,Safety to 30 Days, Intention to Treat Population
19933,Nonhierarchical Major Adverse Events
19935,HRS Patient Deaths Through 12 Months
19937,Rates and Hazard Ratio for All Cause Mortality in Hypertensive Men by Thirds of Muscular Strength
19938,Criteria for Moderate to Severe or Severe Mitral Regurgitation
19941,Hemodynamic and Echo Doppler Effects of MitraClip Therapy
19944,Subgroup Analysis
19945,Meta Regression Analysis
19947,Procedural Outcomes
19950,Pair Wise Comparisons Between GTF  and NPMA CASP or GTF  and SBP2 CASP
19951,Comparison Between CAFE Study Treatment Regimens for Brachial and Central Systolic Pressure Estimated as GTF P, NPMA, and SBP2 CASP
19953,Comparison of Invasive Aortic Root Pressures With Oscillometric, Noninvasive Brachial Pressure Measurements and NPMA Derived Noninvasive CASP
19957,Univariate and Multivariate Logistic Regression Analysis for Strokes
19960,MiRNAs That Normalize After LVAD Support
19963,Causes of Inappropriate Shocks
19967,Factors Associated With Off Label CRT Implantation   Hierarchical Logistic Regression Model
19968,Comparison of Clinical Parameters in Subgroups Stratified by Individual Guideline Criteria
19970,Multivariable Cox Proportional Regression Analysis Showing Significant Predictors of Outcome   Death, Heart Transplant, or Left Ventricular Assist Device Implantation   in Cardiac Resynchronization Therapy Patients
19971,Bibliographic Search Strategy
19973,Pattern of Follow Up and Monitoring Approach in the 32 Studies Included
19974,Study Outcome Summary: Event Incidence   Incidence Rate   and 95  Confidence Interval
19975,Meta Analysis of the Selected Outcomes
19976,Comparison of Our Results With Selected Published Meta Analyses
19980,Key Eligibility Criteria and Key Exclusion Criteria
19981,Mitral Regurgitation Grade Criteria
19983,In Hospital Outcomes
19987,Relationship Between Change in LV End Diastolic Volume and Change in Impedance
19988,Relationship Between LAP and Change in Impedance
19990,Data From 24 h 12 Lead Holter Recordings
19993,Survival of Patients in the 3 Groups
19994,Hazard Ratios for Post Transplant Mortality
19995,Risk of Cause Specific Death Within the First 12 Months After Transplant
19996,Risk of Cause Specific Death More Than 60 Months After Transplant
19998,HF Clinical Composite Response Details in the CRT OFF and CRT ON Groups
20000,LV Structural Data
20001,Conventional and Tissue Doppler Echocardiographic Data
20002,Multivariate Analysis: Adjusted Values for E and for E E According to Ethnicity
20006,Inclusion and Exclusion Criteria
20010,Predictors of Graft Function at 6 Months: Separate Logistic Regression Models for SVG and GEA
20012,EAPC in Unadjusted Mortality Rates From Coronary Heart Disease Among U.S. Adults Age 35 Years, 1980 to 2002
20013,EAPC in Age Specific Mortality Rates From Coronary Heart Disease Among U.S. Adults Age 35 Years, 1980 to 2002
20015,Procedural Data and Devices Used
20016,Preoperative and Operative Data of Patients Undergoing CABG, With and Without Metabolic Syndrome
20017,Prevalence and Distribution of the NCEP ATPIII Criteria for Metabolic Syndrome in Patients With and Without Metabolic Syndrome
20018,Univariate Analysis of Potential Risk Factors for Operative Mortality
20019,Multivariable Adjusted Relative Risk of Operative Mortality
20020,Perioperative Cause of Mortality for Patients Undergoing CABG According to Metabolic Syndrome Status
20021,Perioperative Complications After CABG
20023,Background and Outcome of PP
20024,Characterization of PP Site
20028,Rates of Contrast Induced Nephropathy Defined as a Rise in Cr 0.5 mg dl: Analysis by Patient Subgroup
20031,IVUS Parameters Within the Stented Segment
20032,Neointimal Proliferation per Diabetes Status, Stent Length, and Stent Diameter
20033,Clinical Events at One Year Follow Up
20034,Mode of Death Overall, and Within Each Treatment Group
20035,Mode of Death in Selected Heart Failure Trials
20039,MEDLINE Queries Used to Retrieve Papers on FMD
20041,Relation Between Endothelial Function and Cardiovascular Risk Factors, by Tertiles of Cardiovascular Risk
20044,Operative Findings
20045,Reported Cases of Tricuspid Valve Leaflet Perforation by a PPM Lead    1218
20047,Comparison of Patients With and Without IVR
20049,Hemodynamics Before and After Ventricular Assist Device Support
20051,Volumetric Intravascular Ultrasound Measurements
20054,Clinical Outcomes at 30 Days and 1 Year
20055,Angiographic Results at Nine Months
20057,Electrocardiographic and Pacing Variables
20058,Pacemaker Models Tested
20059,Details of the Positive Tests
20061,Mechanical Parameters of Isolated Trabeculae at Isoproterenol Stimulation
20062,Bmaxand KdValues for  3H DHA Binding to Beta Adrenergic Receptors in LV and RV of Nonfailing, Medical, and LVAD Supported Hearts
20065,Stepwise Multivariate Modeling Results of Overall Patients Enrolled in PRESTO Trial
20066,Stepwise Multivariable Modeling Results of De Novo Lesions Treated With Intracoronary Stents
20067,Effects of Subsequent Perfusion of Blood Containing One of the Anti GP IIb IIIa Agents on the Height and the Volume of the Pre Existing Platelet Thrombi
20070,Postprocedural and Six Month Follow Up Quantitive Angiographic Data for the Sirolimus Eluting Stent   Patient Number n   33
20073,Cox Proportional Hazards 5 Year Survival in Key Diabetic Patient Subsets Undergoing Electron Beam Tomography Coronary Calcium Measurements Including Female, Hyperlipidemic, Hypertensive, and Elderly   70 Years of Age   Diabetic Patients
20074,Multivariable Model Predicting All Cause Mortality in Asymptomatic Diabetic Patients Undergoing Coronary Calcium Screening
20075,Multivariable Model Predicting All Cause Mortality in Asymptomatic Nondiabetic Subjects Undergoing Coronary Calcium Screening
20077,Presenting Symptoms and Signs of Heart Failure Patients and WRF
20079,Risk Score and WRF
20082,Thoracic Aortic Diameter at the Four Aortic Sites, Stratified by Age and Gender
20084,Relation of Blood Pressure and Additional Atherosclerosis Risk Factors With Thoracic Aortic Diameter
20085,Relation of Regional Aortic Atherosclerotic Plaques   With Thoracic Aortic Diameter, Adjusting for Age, Gender, and Body Surface Area
20086,Implantable Pacemakers Studied
20087,Implantable Pacemaker Leads Studied
20088,Implantable Cardioverter Defibrillators Studied
20089,Leads Used in Patients With an Implantable Cardioverter Defibrillator
20091,Median CAC Scores of Men and Women With and Without Diabetes
20092,Association Between CAD Risk Factors and the Highest Age and Gender Quartile of Coronary Artery Calcium Score    75    Among Men and Women   n   30,904
20093,Indications for Robotically Assisted LV Lead Transplantation
20096,Independent Predictors of Change in LV Function
20097,Fitted Absolute and Incremental Changes in EF
20102,Main and Subgroup Analysis of Angiographic Data Obtained by a Mixed Linear Model With Group, Diameter and Group  Diameter Interaction and Fixed Effects
20105,In Hospital Complications for CTO and Non CTO Cohorts legend legend
20106,In Hospital Complications for CTO Success and CTO Failure Cohorts legend legend
20107,Multivariable Predictors of Survival After PCI of CTO legend
20108,Multivariable Predictors of Survival for Patients Undergoing CABG After Failed Attempt of CTO legend
20110,Epiaortic Ultrasound Data in Patients With Atherosclerotic Disease of the Ascending Aorta   n   241
20111,Logistic Multiple Regression Analysis of Postoperative Stroke on Predictive Variables   n   921   legend
20112,Relationship Between Postoperative Stroke and Extent of Atherosclerotic Disease of the Ascending Aorta   n   220
20113,Logistic Multiple Regression Analysis of Postoperative Stroke on Predictive Variables   n   921   legend
20115,Multiple Linear Regression Analysis: Determinants of LVM Ht2.7  n   875   legend
20116,Multiple Linear Regression Analysis: Determinants of LVM Ht2.7excluding CAD   n   818   legend
20118,Quantitative Coronary Angiography Results legend
20119,Intravascular Ultrasound Results legend
20121,Predictive Value of Clinical and Echocardiographic Variables on Event Free Survival by Univariable Analysis legend
20122,Independent Predictors of Event Free Survival by Cox Proportional Hazards Model
20124,Deadly Quartet Hazard Ratio   HR   Estimating the Risk of Mortality with 95  Confidence Intervals   95  CI   Estimated from Cox Proportional Hazards Models Unadjusted, Age Adjusted and Age  and Surgical Variable Adjusted
20126,Comparison of Immediate and Follow up Results
20127,Atrial Septal Defect Closure Devices legend
20128,Preliminary Results of ASD Closure Devices    4,18,19,23,2837     legend
20129,Risk Factors of Patients Undergoing Coronary Angioplasty or Stent Placement on One Lesion for the First Time in New York State, July 1994December 1996 legend
20130,Unadjusted and Adjusted Short term Outcomes for Balloon Angioplasty and Stent Placement legend
20135,Predicted Values of CFVR legend
20140,Differences Between Native Coronary Arteries and Saphenous Vein Grafts legend
20141,Clinical Features of Participants Based on Pattern of Atrial Fibrillation legend
20142,Factors Associated With Ischemic Stroke in Intermittent Versus Sustained AF: Age adjusted Relative Risks    legend
20143,Independent Predictors of Ischemic Stroke in Patients With Intermittent and Sustained AF legend
20144,Risk Stratification for Ischemic Stroke: SPAF III Exploratory Analysis Criteria    legend
20147,Univariate Correlations Between Cardiovascular Risk Factors and Vasodilator Response to Nitroglycerin in All 800 Subjects legend
20148,Multivariate Model for Vasodilator Response to Nitroglycerin in All 800 Subjects    legend
20149,Pertinent Patient Data  a  and Outcome After Transcatheter Atrial Septal Defect Closure With the Amplatzer Prosthesis
20150,Quantification of Atrial Shunts by Echocardiography
20152,Analysis of the Influence of Clinical, Lesional and Procedural Factors on the Degree of Late Lumen Loss After Stenting of 1,399 Lesions in 1,084 Patients
20154,Results of Percutaneous Transluminal Coronary Angioplasty in 29 Patients
20155,Results of Transcutaneous Oximetry
20156,Results of AnkleBrachial Index Measurement
20157,Clinical Phenotype of Living Genotype Positive Individuals in Family D.R.
20158,Model Derived Values for APD90for the Nygren and Courtemanche Human Atrial Action Potential Models
20159,Diagnoses and Associated Findings After Testing or Surgery or Both legend
20161,Atrial Septal Defect Size by MRI Magnetic Resonance Imaging Versus Shunt Fraction legend
20162,Agreement Analysis legend
20163,Clinical and Hemodynamic Data of Patients With DCM and ICM
20168,Number of nDNAf per 1,000 Cardiomyocytes in Untreated Dogs With HF and Dogs with HF Treated With Metoprolol legend legend legend
20172,Cumulative Hazard of Mortality by Urgency Group and Donor Risk Group at One Year
20173,Net Survival Benefit Between Waiting and Transplant Groups
20177,IQIC Sites Contributing Data
20179,Univariate Associations With Mortality
20182,Multivariable Predictors of 3 Year All Cause Mortality
20188,Targeted PH Therapies
20189,Discontinuations of PH Therapies
20191,Acute Vasodilator Response Criteria
20193,Crosstab of Acute Vasodilator Response Criteria
20196,Patient Clinical Features at Presentation
20197,Clinical Features of Patients Enrolled in Clinical Surveillance
20198,10 Year Event Rates for Patients Enrolled in Clinical Surveillance
20199,Predictors of All Cause Mortality in Patients Enrolled in Clinical Surveillance
20203,Risk of VT and Death by Model
20204,Risk of VT by RWT
20206,Definition of Poor, Intermediate, and Ideal Cardiovascular Health in Adults
20208,Proportions   SEs   of Each Individual Cardiovascular Health Metric According to Sex, Age, Urbanization, and Economic Development in Chinese Adults Age20 Years in 2010
20209,Proportions   SEs   of Numbers of Ideal Cardiovascular Health Metrics, Ideal Health Behaviors, and Ideal Health Factors According to Sex, Age, Urbanization, and Economic Development in ChineseAdultsAge20 Years in 2010
20210,Proportions   SEs   of Each Individual Cardiovascular Health Metric According to Major Ethnic Groups and Geographic Regions in ChineseAdultsAge20Years in 2010
20211,Proportions   SEs   of Numbers of Ideal Cardiovascular Health Metrics, Ideal Health Behaviors, and Ideal Health Factors According to Major Ethnic Groups and Geographic Regions in Chinese Adults Age20 Years in 2010
20214,Distribution of Nerves Stratified According to Total Number and Distance From Lumen in Relative Proximal, Middle, and Distal Location
20215,Distribution of Nerves Stratified According to Total Number and Distance From Lumen on the Basis of Anatomic Location
20216,Comparison of Nerve Anatomy Between Hypertensive Samples Compared With Nonhypertensive Samples
20218,Hazard Ratios for Disease Specific Mortality and Nonfatal CVD, by CRF Level, in Men   n  34,211
20219,Hazard Ratios for Disease Specific Mortality and Nonfatal CVD, by CRF Level, in Women   n  9,145
20220,Discrimination Statistics of Measured and Estimated CRF for Disease Specific Mortality and Nonfatal CVD
20221,AUCs   95  CI   for the Modifiable Constituent Components of the Nonexercise CRF Algorithms   Separately and Clustered   andfor Estimated CRF
20222,Reclassification of the Predicted Risk for All Cause Mortality in Men and Women on the Basis of Estimated CRF VersusMeasuredCRF
20224,Treatment Strategy Stratified by Center Cohort
20226,Multivariate Backward Stepwise Cox Regression Analysis of Parameters Associated With Survival   N  196
20227,Predictors of Outcome Stratified by Treatment Strategy
20228,Predictors of Outcome Stratified by Use of IV SC Prostanoids and PAH Targeted Mono , Dual, and Triple Therapy
20229,Indications for CTA Studies Prior to AADA Onset
20231,Mechanisms of Retrograde Aortic Dissection Type A
20233,Thoracic Aorta Diameters Prior to Aortic Dissection Type A Onset
20234,Aortic Geometry Change Due to Dissection in Primarily Nondissected Segments
20236,Associations of Serum 25  OH  D and PTH With Incident Hypertension Among 3,002 Participants
20241,Risk of Heart Failure in Relation to Individual Lifestyle Factors, The WHI Observational Study
20242,Risk of Heart Failure in Relation to the Healthy Lifestyle Score, The WHI Observational Study
20244,Multivariable Logistic Regression Analysis for Prediction of Response to Renal Sympathetic Denervation
20248,Incidence of SCD in MSHSL Athletes Compared With Italian and NCAA Rates
20250,All Reoperations and Re Interventions   n  124
20252,The Association of Ectopic Fat Depots With Incident CVD   n  90  , Cancer   n  141  , and All Cause Mortality   n  71
20253,Association of Multiple Fat Depots With Incident CVD   40 Events in Women, 50 Events in Men   and Incident Cancer   68 Events in Women, 73 Events in Men   Stratified by Sex
20256,Echocardiographic and Catheterization Parameters of Patients With Low Gradient Severe Aortic Stenosis Despite Preserved Ejection Fraction   Paradoxic   and With Conventionally Defined Severe Aortic Stenosis
20257,Classification of Patient Data According to Mean Transaortic Gradient   Low Gradient 40 mm Hg, High Gradient  40 mm Hg   and Stroke Volume Index   Low Flow  35 ml m2, High Flow 35 ml m2   Measured by Echocardiography
20261,Estimated Annual Rates of Progression   Increase if Positive and Decrease if Negative   of Each Outcome for Each Treatment Group
20263,Hemodynamic Determinants of Pre Hypertension, Compared With Normotensive and Hypertensive Subjects
20264,Autonomic Function in Pre Hypertension
20265,Heritabilities and Correlations of Autonomic and Hemodynamic Traits With Systolic Blood Pressure
20266,Echocardiographic and Morphometric Variables of Rats at Sacrifice
20267,Sodium Current Properties
20269,Echocardiographic Measurements in Chronic Thromboembolic Pulmonary Hypertension Patients
20279,Reclassification of Participants by 1 Year All Cause Mortality Status Using Model With PASP
20280,Reclassification of Participants by 1 Year Cardiovascular Mortality Status Using Model With PASP
20281,Selected Studies Reporting on PASP in the Literature 2000 to 2010
20284,Doppler Criteria for Classification of Diastolic Function and Estimation of LV Filling Pressure
20286,Univariable Surgical Predictors of POAF
20287,Univariable Echocardiographic Predictors of POAF
20301,Operative and Post Operative Results
20302,Independent Predictors of Long Term Death After Aortic Root Replacement
20303,Indication, Operative Findings, and Outcomes of Patients Requiring Redo Surgery
20305,Determinants of cPP and pPP Other Than Augmentation Pressure by Regression Analysis
20306,Determinants of P1 and Paugby Regression Analysis
20307,Determinants of P1 and Paugby Regression Analysis in a Subset of 186 Subjects With SV Measurements
20308,Intraclass Correlations for MZ and DZ Twin Pairs
20309,Heritability Estimates and 95  CIs for Best Fitting Univariate
20311,Distribution of Label Prosthesis Size According to Type of Aortic Bioprosthesis
20313,Aortic Regurgitation Data at Discharge and at Follow Up Grouped According to Type of Aortic Bioprosthesis
20315,Indexed Effective Orifice Area and Incidence of Severe Patient Prosthesis Mismatch Grouped According to Aortic Annulus Size and Type of Bioprosthesis
20321,Comparison of Global Mechanics Parameters in Dysfunction   n   7   and Elastic Ring   n   6   Groups
20328,Univariate Association of In Hospital Outcomes With an Early Abnormal Creatinine Increase After Percutaneous Coronary Intervention
20329,Multivariable Association Between an Early Abnormal Increase in Creatinine Level After PCI and V CrCl Ratio
20331,C Reactive Protein Concentrations According to Gender, Region, and Residence   mg l
20332,Spearman Partial Correlation Coefficients Between CRP, BMI, and Elements of Metabolic Syndrome
20333,Prevalence of Metabolic Syndrome According to Quartile of CRP
20334,Odds Ratios and 95  Confidence Interval for MetS and its Individual Components According to Quartile of CRP
20336,Central and Peripheral Hemodynamic Parameters
20337,Left Ventricular Structure and Systolic Function
20338,Left Ventricular Diastolic Function and Left Atrial Morphology and Function
20340,Gender Specific Mean and Standard Deviation of LV Mass, End Diastolic Volume, Stroke Volume, Ejection Fraction, and Cardiac Output by Cardiac MRI in MESA Participants
20342,Results of Correlation Analysis for MSCT and CVG as Compared With MRI for Evaluation of Global Left Ventricular Function in 88 Patients
20343,Results of Correlation Analysis for MSCT and Echo as Compared With MRI for Evaluation of Global Left Ventricular Function in 30 Patients
20350,Relationship Between Echocardiographic Parameters and Systolic Blood Pressure at Four Months of Follow Up
20352,Risk Factors for AR
20353,Threshold Levels for the Definition of MS    7
20354,Visit 1: Age    SD   and Prevalence       of CV Risk Factors According to Gender
20358,Number of Coronary Segments With Diagnostic Image Quality
20359,Diagnostic Accuracy of MDCT Per Segment and Per Vessel
20362,Left Ventricular Pressures, Aortic Pressures, and Cardiac Index Values in 24 HHT and 43 OCT Patients
20363,SBP in Different Subgroups of Heterotopic Transplant Patients
20364,Unadjusted and Backward Stepwise Multiple Regression Models
20366,Correlation and Mean Difference Between the Sequential   Test Retest   StudiesWith 2DE and RT 3DE   n   50
20367,Inter Observer Agreement With 2DE and RT 3DE   n   20   Showing Correlationsand Mean Difference Between the Studies
20368,Intra Observer Agreement With 2DE and RT 3DE   n   20   Showing R Values and Mean Difference Between the Studies
20369,Mean Difference Between Echocardiographic and MRI Measurements   n   50
20370,Mean Acquisition and Calculation Times   n   20
20372,Multiple Regression Analysis of the Relationship Between Left Ventricular Mass Index and Other Variables for the Entire Group
20378,Relationship of Hematocrit to LVM, End Diastolic Dimension, and Wall Thickness
20380,Severe Lesion Detection
20381,Differences Between Diagnostic Patients and Nondiagnostic Patients
20384,Anthropometric Measures, Resting Energy Expenditure for Basal Homeostasis, and Calculated Total Daily Energy Expenditure in Patients and Controls of the Study
20385,Nutritional Intakes, Nitrogen Excretion, Calorie and Nitrogen Balances, and Energy Availability for Physical Activity in Patients and Controls of the Study
20386,Plasma Cortisol and Insulin Levels, and Cortisol Insulin Ratio in Patients and Controls of the Study
20387,BW, LWI, RVI, and AWI of Spontaneously Hypertensive Rats, Either Control or Treated With 1, 5, 10, and 20 mg kg day of R
20388,SAP, DAP, MAP, HR, CI, and TPR in Spontaneously Hypertensive Rats, Either Control or Treated With 1, 5, 10, and 20 mg kg day of R
20389,BF and VR under Basal Conditions and MVR   After Dipyridamole Infusion   in Kidney, Liver, Skin, Muscle, and Brain of SHR Rats, Either Control or Treated With 1, 5, 10, and 20 mg kg day of R
20390,Plasma Levels of Chol, HDL, LDL, or Trigl in Control SHR and SHR Treated With 10 or 20 mg kg day of R
20391,MAP, CI, TPRI, RBF, RVR, SBF and SVR, MBF and MVR, CBF and CVR, MCVR, and CFR in Control WKY, WKY Given Rosuvastatin for Six Weeks, WKY Treated With L NAME for Six Weeks, and WKY Given L NAME and Rosuvastatin for Six Weeks
20392,Hemodynamic InterVA and IntraVA Values Before and After Induction of LBBB
20395,Effect of Training on the Incremental Maximal Exercise Test of HTR
20396,Effect of Training on Enzyme Activities and MyHC Distribution in HTRs
20397,Signs Indicating an Abnormal Clinical Test
20398,Diagnostic Value of Clinical Test, Electrocardiogram, and BNP to Detect LVSD
20400,Diagnostic Value of BNP in Relation to Risk Group
20401,Price and Cost Effectiveness of BNP Compared With Echocardiogram in Relation to Risk Group
20403,LV Function and Geometry Before and After Aortic Valve Replacement Compared With Control Subjects
20405,Type and Duration of Physical Activity
20406,Effect of Left Ventricular Hypertrophy on Risk of Stroke Depending on Presence of Physical Activity
20407,Effect of PA on LVM by Duration of PA in the Entire Cohort
20408,Interaction of LVH and Physical Activity on the Risk of Stroke
20410,Impact of AV Delay Changes on Hemodynamics for the Population, the Responder Subgroup and Nonresponders
20411,Measurements Made During the Final 5 Min of Tilt
20416,Differences Among End Diastolic Volume, End Systolic Volume, Ejection Fraction and Left Ventricular Mass as Revealed on Cine MRI and Real Time MRI legend
20417,Left Ventricular Volume and Mass Determined by Cine MRI and Real Time MRI in Heart Failure Patients legend
20418,Intra  and Interobserver Variability   Mean Difference  SD   legend
20419,Determinants of Pulse Pressure and the PP to SVi Ratio legend
20420,Causes of Death and of Fatal and Nonfatal Cardiovascular Events During Follow up
20422,Relative Hazard Rate of PP and of the PP to SVi Ratio for Cardiovascular Events and All cause Mortality After Cumulative Adjustment for: A   Age and Gender, B   Mean Brachial Artery Pressure, and C   Heart Rate legend
20423,Correlation and Mean Difference Between DCD Method in Two Orthogonal Planes and Flow Meter Method for Measuring Stroke Volumes and Regurgitant Fractions in an In Vitro Model legend
20424,Correlation and Mean Difference Between DCD Method in Two Orthogonal Planes and Electromagnetic Method for Measuring Stroke Volumes and Regurgitant Fractions in a Chronic Animal Model legend
20429,Activity of Adenylyl Cyclase legend
20432,Frequency of Events at One Year legend
20433,Relation of Echocardiographic Parameters to Event Rate, by Cox Proportional Hazards Regression legend
20434,Association of Left Ventricular Mass and Ejection Fraction With Clinical Events legend
20435,Indications for Implantation of Self Expanding Wallstents legend
20436,Angiographic and Hemodynamic Data Immediately After Stent Implantation and at Follow up Catheterization Restudy legend
20441,Likelihood of True Changes in LV Mass for Different Thresholds of Intraindividual Variability
20442,Sample Size   n   per Group Needed for Statistical Power of 90  or 80  to Detect Changes in LV Mass at Alpha Errors of 5  and 1  legend
20443,Relation Between Change of LV Mass and Dimensions and Hemodynamic Parameters legend
20444,Echocardiographic Measurements of LV Systolic Function legend
20450,DCA Procedures legend
20451,Effect of IVUS on DCA legend
20452,Acute and In hospital Complications legend
20453,QCA Analysis legend
20454,QCU Analysis legend
20455,Cumulative Clinical Events legend
20456,Iliac Artery Morphometry 12 Weeks After Stent Implantation and Subsequent External Beam Irradiation legend
20458,Adjusted Mean Values   and Standard Errors   of Echocardiographic Measurements in LVH Siblings and a Comparison Group Matched by Age and Gender legend
20459,Prevalence   in     and Adjusted Odds Ratio of LVH in LVH Siblings and A Comparison Group Matched by Age and Gender, Applying Three Different Indexations of Left Ventricular Mass legend
20460,Prevalence   in     and Adjusted Odds Ratio of Increased Relative Wall Thickness in LVH Siblings and a Comparison Group Matched by Age and Gender, Stratifying by Hypertension and Overweight legend
20461,Echocardiographic Findings in Patients Referred for Systolic Murmurs
20463,Doppler Echocardiographic Measurements of Patients With and Without Increased Intraventricular Velocities  legend
20464,Vasocontraction legend
20465,Vasorelaxation legend
20467,Left Ventricular Mass and Risk of Sudden Death
20468,Left Ventricular Hypertrophy and Risk of Sudden Death
20470,Transthoracic Echocardiographic Doppler Parameters of Malfunctioning Valves With Pannus or Thrombus Formation  legend
20472,Sensitivity, Specificity and Predictive Accuracy of Inadequate Anticoagulation and TEE Parameters for Prediction of Prosthetic Thrombosis in 24 Obstructed Valves legend
20475,Heart Rate Variability in Group I and Group II legend
20476,Average Amount of Drinking Water Consumed per Maternal Rat
20477,Maternal Parameters and Summary legend
20478,Types of Heart Malformations legend
20479,Patients, Procedures and Outcomes  legend
20480,Comparison of Hemodynamic Variables for Survival and Nonsurvival in Patients With Two Ventricle Repair legend
20481,Comparison of Morphometric Variables for Survival and Nonsurvival in Patients With Two Ventricle Repair  legend
20484,Echocardiographic Results of Mass, Volume and Wall Thickness Indexed to Body Surface Area in the Patients Undergoing Late Arterial Switch Operation   n   37
20485,Postoperative Outcome Measurements in the Early and Late Arterial Switch Operation Group Patients
20486,Postoperative Outcome Measurements in Relation to the Pattern of Preoperative Left Ventricular Geometry in the Late Arterial Switch Operation Group   n   37
20487,Diagnoses and Previous Surgical Interventions
20488,Univariate Procedural Predictors of In Stent Restenosis
20489,Univariate Angiographic Predictors of In Stent Restenosis
20490,Univariate Intravascular Ultrasound Predictors of In Stent Restenosis
20491,Multivariate Predictors of Follow Up Angiographic Results   restenosis, diameter stenosis, late lumen loss and minimal lumen diameter
20493,Unadjusted Procedure Rates for Cardiovascular Disease Cohort and Refined Cohorts
20496,Unadjusted Survival Rates for Cardiovascular Disease Cohort
20497,Age and Body Weight of Senescent Rats
20498,Left Ventricular Dimensions
20499,Left Ventricular Systolic and Diastolic Functional Measures
20500,Histopathologic Findings of the Ventricular Septa
20501,Patient Data
20502,Statistical Description of Results in 20 Patients
20503,Statistical Analysis of Results  a
20504,Comparison of Five Human Anatomic Validation Studies
20505,Validation Studies Using Magnetic Resonance Imaging
20507,Results of Multivariate Analysis
20509,Risk of Different Endpoints According to AF Type at Randomization
20512,30 Day Outcomes   n 310
20513,Early and Late Survival and Cardiac Reinterventions
20515,Outcomes in Propensity Score Matched Patients
20520,VARC 2 Safety Endpoints at 30 Days Based on Use of the Repositioning Feature of the THV
20521,Device Annular Sizing and Early Outcomes
20523,Frailty Scales and Geriatric Domains
20524,Incremental Value of Frailty Scales
20525,Multivariable Model to Predict 1 Yr Mortality
20527,Clinical Outcomes to 1 Yr, Stratified by Surgical Risk   STS PROM
20532,Lymphatic Imaging and Lymphatic Interventions
20533,Intervention Outcomes
20540,Procedural and Clinical Outcomes
20542,Therapy at Time of Index Echocardiography   N  305
20544,Procedural Data of the Overall Study Group and According to the Occurrence of EM After Catheter Ablation
20546,Univariate and Multivariable Logistic Regression Analyses Testing the Association Between Clinical and Procedural Variables and EM After Catheter Ablation
20547,Details of Patients Who Died In Hospital After a Major Procedure Related Complication
20549,Echocardiographic Variables
20550,Predictors of Long Term Mortality
20551,Association Between LV Dimensions and Mortality
20552,Criteria for Echocardiographic Grading of TR Used in the Trial Protocols
20557,Comparison of Clinical Prediction Models by Endpoint
20558,AIC Comparison of Clinical Prediction Models
20560,Matrix of Tested Configurations
20561,Single Clip Treatments
20562,Single Clip Treatments: Specific to Treatment Data
20563,2 Clip Treatments
20564,Pregnancy Outcomes and Verification Rates According to HeartDefectCategories
20565,Impact of the Discordances on Planned NeonatalTreatment
20566,Impact of the Discordances on Long Term Care Strategies
20567,Types of Anatomical Discordances
20569,Number of Initial Strokes and Initial Strokes per 1,000 Person Years of Follow Up After Initial AF Diagnosis
20570,Hazard of Stroke by Race Ethnicity, Relative to White Patients, After Controlling for CHA2DS2 VASc Score   Model 1   and CHA2DS2 VASc Score Plus Anticoagulant Use   Model 2
20571,Comparison of CHA2DS2 VASc and CHA2DS2 VASc R Scores in Predicting Stroke: Relative Hazard Associated With 1 Point Increase in Stroke Risk Score, and C Statistic
20572,Relative Contribution of Each Risk Factor of CHA2DS2 VASc R Score in Stroke Prediction
20574,Data Completeness
20576,Survival and Freedom From Reintervention by AVR Type
20578,3 Year Clinical Outcomes
20582,Unadjusted In Hospital Outcomes Stratified by LVEF
20583,Unadjusted In Hospital Outcomes Stratified by Mean AVG
20587,Proximal Aortic Diameters and Phenotypes in Both Study Groups
20588,Rheological Aortic Root Parameters and Sum Scores in Both Patient Groups
20589,Indicators of Indexed Cross Sectional Aortic Diameter22 mm m2 as Determined by Multivariable Logistic Regression
20590,Adverse Events Considered Major
20591,Definitions of Procedural Success
20593,Univariate Comparison of Definitions of Procedural Success
20594,Multivariate Models of Procedural Success
20595,Multivariate Model of Adverse Events: All Patients
20596,Multivariate Model of Major Adverse Events: Biventricular Patients
20597,ACS NSQIP Classification of CHD Based on Residual Lesion Burden and Functional Status
20598,Propensity Matching for Controls and CHD Patients
20599,Mortality and Post Operative Outcomes for Matched Controls and Severe CHD Patients
20600,Mortality and Post Operative Outcomes for Matched Controls and Major CHD
20601,Mortality and Post Operative Outcomes for Matched Controls and Minor Congenital Heart Disease Patients
20602,Nonhierarchical and Hierarchical Count of Clinical Events Over 5 Years   n  101
20604,Clinical Outcomes: Propensity ScoreMatched Cohort
20605,Clinical Outcomes: Entire Cohort
20606,Summary of Clinical Studies in Percutaneous Pulmonary Valve Implantation
20608,Clinical Outcomes After 2 Years in the As Treated Population
20609,Additional Outcomes at 2 Years
20610,Angiographic and Functional Nomenclature of CAV
20611,Association Between Angiographic Vasculopathy Grade and Ejection Fraction
20612,Association of Hemodynamic Abnormalities With Angiographic Vasculopathy Grade
20614,Top 5 Most Common Cardiac Discharge Diagnoses for PediatricPatients With CHD Hospitalized in California, 1983 vs. 2011
20615,Suggested Preoperative Echocardiographic Criteria        With Threshold Z Scores   for Performance of Balloon Valvuloplasty
20617,Pregnancy Outcomes Among FCI Patients by Procedure Type
20620,Odds Ratios of Worsening Angina for Patients Treated With CABG Compared With Patients Treated With Medical Therapy Alone
20622,Determinants of Recurrent TR   Moderate or Greater
20623,Determinants of RV Function Recovery During Follow Up
20625,Top 10 Diagnoses for Hospitalization After the Index PCI
20627,Cost Effectiveness Analysis: PSBB Adjusted
20628,Cost Effectiveness Analysis: Matched Analytic Population
20629,Cost Effectiveness Analysis for Matched Analytic Population Subgroups
20630,Echocardiographic Measures of RV Size and Function
20631,Echocardiographic Measures of Valve andAortic Size and Function
20632,Summary Statistics for Pre Fontan Echocardiographic Measures byInitialShunt Group
20633,Summary Statistics for 14 Month and Pre Fontan Echocardiographic Measures   MBTS Group
20634,Summary Statistics for 14 Month and Pre Fontan Echocardiographic Measures   RVPAS Group
20635,Univariate Analysis of 14 Month Echocardiographic Indices as Predictors of Transplant Free Survival From the Time of Study to Fontan Surgery
20637,Angiographic Findings
20638,OCT Findings
20639,IVUS Findings
20643,Summary Estimates for Weighted Mean Sensitivity, Specificity, PPV, NPV, and Accuracy of CCTA for theEvaluation of the Presence of Any CAV Compared With CCAG
20644,Summary Estimates for Weighted Mean Sensitivity, Specificity, PPV, NPV, and Accuracy of CCTA for the Evaluation of Significant CAV Compared With CCAG
20646,VARC Defined Device Success
20647,VARC Defined Safety at 30 Days   N  75
20649,Aortic Regurgitation by Echocardiography
20651,Comparison of Cardiovascular Magnetic Resonance Findings in Transplant Patients and Healthy Volunteers
20655,Parameters Predicting Risk of First Reoperation on the RVOT or the PAs by Cox Proportional Hazards Regression Analysis
20656,Mean Number of Variants Identified
20657,Variants Included in Disease Cosegregation Studies
20660,Odds Ratios   95  Confidence Intervals   for AcuteKidney Injury for Coronary Artery Bypass Grafting VersusPercutaneous Coronary Intervention Overall and in Selected Subgroups
20662,Specific Causes of Death in the RELAX AHF Study
20664,Clinical Event Distribution During 1 Year Follow Up
20665,LCBI Levels Equal to and Above the Median Value and MACCE
20669,Electrical and Hemodynamic Data Derived From Computer Simulations of a Failing Heart During LBBB, LVP, and BiVP
20675,Analysis of Risk of Bias: Internal Validity
20676,Metric Elaboration for TOF Illustrating the Steps in Achieving Operationalization on the Basis of Review of Published Data
20677,All Candidate Quality Indicators and Rating Scores for Round 1 and Round 2 Ratings by the Expert Panel Separated by Lesion, Including Categorization of Indicators by Process and Structure Within Each Lesion and the Level of Evidence of Each Indicator
20678,Definitions Used to Qualify ACHD and CHD Expertise
20679,Quality Indicators Common to Several of the CHD Lesions
20680,Associated Anomalies
20681,Analyzed Parameters
20682,Follow Up Results and Complications   N   74
20685,Factors Related to Maintenance of SR After Ablation
20687,Reproducibility of Strain and Strain Rate Measurements
20690,Coronary Computed Tomography Angiography Parameters of Studied Lesions as a Function of FFR Value
20691,Univariable Logistic Regression Analysis for Coronary Computed Tomography Angiography Measures to Identify Ischemic Lesions
20695,Total Number of Participants per Site and Proportion at Each Site Reporting Gap in Care
20696,Reported Reasons Why Participants Had a Gap in Cardiology Care
20697,Most Common Reasons for Gaps in Cardiology Care by Disease Complexity
20698,Reasons for Returning to Cardiology Care
20701,Clinical Events, as Estimated According to Kaplan Meier Method
20703,Heart Failure Hospital Stay Rate 100,000 Persons
20704,Mean Length of Stay for Heart Failure Hospital Stay
20705,In Hospital Mortality for Heart Failure Hospital Stay 100
20706,Morbidities in the Fontan Cohort   n   103
20708,Demographic and Clinical Data
20709,Correlates of Adverse Outcome
20710,Cox Proportional Hazards Regression Model
20711,Correlates of Outcome of Death or Cardiac Transplantation
20713,Mean Age, Weight, and Saturations, n   58
20714,Interstage and Associated Procedures, n   58
20715,Volumetric and Flow Data   n   58
20716,Model for Change in Indexed End Diastolic Volume   r2   0.79, adjusted r2   0.75  , n   58
20717,Pulmonary Artery and Aortic Sizes, n   58
20720,Clinical and Angiographic Outcomes
20721,Predictors of Clinical and Angiographic Outcome
20724,Factors Associated With Thrombosis in Multivariable Regression Model
20727,Incremental Risk Factors for Death
20728,Hospital Outcomes After LITA or SV Grafting of the LAD at Reoperative CABG
20735,EOA and EOAi in AS and VP PM
20736,Summary of Studies That Used Measured EOAi to Assess VP PM: Data of Moderate and Severe VP PM Analyzed Separately
20737,Summary of Studies That Use Measured EOAi to Assess VP PM: Data of Moderate and Severe VP PM Are Combined
20738,EOA Determined at 6 Months After AVR for PHV Labeled Size 23
20739,PHV Areas From Randomized In Vivo Trials
20740,Factors to Consider When Choosing a PHV
20742,Odds Ratio, Heterogeneity, and Publication Bias Across Randomized Controlled Trials and Observational Studies Included in the Meta Analysis
20743,Standard of Symptom Scoring for Orthostatic Intolerance
20745,Comparisons of Symptom Scores, Changes of Heart Rate in POTS Children Treated by Midodrine Hydrochloride
20746,Comparisons of Symptom Scores, Changes of Heart Rate, and MR proADM Between POTS Children With Different Response to Midodrine Hydrochloride
20748,Procedural and 30 Day Outcomes
20749,HRs for Moderate or Severe Versus Mild or Less MR
20751,Multivariate Predictors of Reduced MR at 1 Year Follow Up
20753,Surgical Procedures Performed   N   89
20754,Types of TV Prostheses Used for TV Replacement   n   65
20755,Univariate Predictors of Death During Follow up
20757,Reasons for Not Taking a Beta Blocker or Not Taking Target Dose
20761,End of Study Cumulative Incidence of Endpoints According to QRS Duration and LBBB
20762,HRs for QRS Duration 100 to 119 ms and LBBB Versus QRS Duration  85 ms
20767,Unadjusted Association of Quartiles of Left Atrial Functional Index With Heart Failure Hospitalization
20772,Vascular Complications According to Valve Academic Research Consortium Definitions    12,13
20775,MDCT Measurements in Patients Without and With Vascular Complications   n   82
20776,Overview of Activities and WGs Within the ACC s AC PC Section
20777,Inclusion and Exclusion Criteria
20779,Acute Outcomes
20780,Short Term Follow Up Outcomes
20781,Short Term Follow Up Outcomes by Integrated Imaging
20782,Intermediate Follow Up Outcomes
20783,Intermediate Follow up Outcomes by Integrated Imaging
20784,Reintervention
20785,Subgroup Analysis, Age 6 to 12 Years
20786,Hemodynamics
20787,Procedural Variables
20788,CAPS Scoring System
20791,Clinical Variables   N   657
20792,Primary and secondary outcomes at 3, 6, and 12 months
20794,Length of hospital stay and therapy input
20795,Univariable Analysis: CCTA Variables
20796,Cox Models of CCTA Measures
20797,Evaluating the Incremental Value of CAPS to a Model With Clinical Variables Only   Additive EuroSCORE
20799,Use of services in first 6 months
20800,Outcome at 6 months for carers
20801,Outcome at 6 months for patients
20802,Size of differences between family support and control groups stratified by method of response
20803,Size of differences between family support and control groups stratified by admission to specialist rehabilitation wards
20804,Mean   range   sex hormone concentrations
20808,Adverse events
20809,Event registration, survey, and quality score data by population
20810,Age standardised levels and trends of coronary event rates and risk factors in men aged 3564 years
20811,Age standardised levels and trends of coronary event rates and risk factors in women aged 3564 years
20812,Correlations between trends in risk factors, risk score, and coronary event rates
20813,Regression of trends in coronary event rates on trends in risk scores and individual risk factors in people aged 3564 years
20814,Regression of coronary event rates on trends in risk scores and individual risk factors in people aged 5564 years
20815,Valve Dimensions for Selected 18  to 23 mm Stented Surgical Bioprostheses, per Manufacturer Product Information
20816,Valve Dimensions for Selected 24  to 29 mm Stented Surgical Bioprostheses, per Manufacturer Product Information
20817,Valve Dimensions for Selected Stentless Valves, per Manufacturer Product Information
20818,Clinical and Hemodynamic Outcomes of V in V Implantation
20819,Clinical rating scales
20825,Secondary outcomeadverse effects
20826,Inheritance of ankylosing spondylitis among sons and daughters of patients
20827,Inheritance of ankylosing spondylitis among brothers and sisters of patients
20828,Data and extrapolation of inheritance of ankylosing spondylitis to children
20833,Age and educational attainment of cases and controls
20834,Association of the A49T missense substitution in  SRD5A2  gene with risk of prostate cancer
20835,In vitro kinetic properties of mutant and wild type SRD5A2 enzyme
20836,Subscores of modified TWSTRS scale
20838,Intraobserver and Interobserver Variability of Largest Aortic Root and Ascending Aorta Measurements in Patients With Severe Aortic Stenosis
20839,Agreement Among CMR, CCT, and TTE
20840,Association of the CTLA 4A G polymorphism in Graves  disease patients   TAO group and Graves  disease group   and controls
20841,Extra life expectancy gain attributable to doubled rate of decline in specified diseases, 19902020
20842,Rank order of disabling effect of health conditions by severity
20843,Disability ranks associated with different health conditions by country
20844,Disablement ranks of different health conditions by informant group
20845,A comparison of the rank order between Global Burden of Disease study  1   and this study
20846,Adjusted means and proportions of risk factors for coronary heart disease by quintile of soluble thrombomodulin in cohort random sample   n 753   of ARIC study
20847,Adjusted means and proportions of haemostatic factors and inflammatory markers by quintile of soluble thrombomodulin in cohort random sample   n 753   of ARIC study
20848,Odds ratio of carotid atherosclerosis by quintile of soluble thrombomodulin in white and black participants of ARIC study
20850,Statistical association of risk variables with mortality
20852,Association of risk variables with total mortality in a univariate analysis
20854,Relative hazards of significant and independent risk variables in a multivariate analysis
20855,Medication Use as Mean Changes in Dosages During the Course of the Study
20856,Relative hazards of individual variables in a multivariate analysis involving combination of turbulence onset and slope
20857,Outcomes in the PROTECT Study
20858,Serious Adverse Events During the Study as a Function of Treatment Allocation
20861,Psychiatric aftercare
20863,Probability of reaching undetectable viral load with initial treatment regimen
20866,Surgical Outcomes
20867,Determinants of Interventions for Aortic Stenosis in Patients With Discrete Subaortic Stenosis
20868,Vaccination history of cases and controls
20869,Risk factors associated with diphtheria cases among children aged 68 years
20875,Numbers of deaths according to reported underlying cause on the death certificate by treatment group
20876,Observed versus expected numbers of individuals with different haplotypes for the CCR5 gene in blood donors
20877,Cox proportional hazard models of the data in  figure 3
20883, Blocker Trials: Patients and Events
20884,All Cause Mortality Endpoint Comparison in  Blocker Heart Failure Trials: U.S. vs. ROW
20885,Medical history and the risk of CJD
20886,Occupational history and animal exposure and the risk of CJD
20887,Consumption of organ, meat, and milk products and the risk of CJD
20888,Consumption of meat and the risk of CJD
20891,2 and 5 year actuarial outcomes for patients with  BRCA1  mutation related and sporadic breast cancer
20892,Crude and adjusted hazard ratios for patients with  BRCA1  related versus sporadic breast cancer
20893,Estimated annual costs of intervention at December, 1993, prices
20895,Summary of key results on cost and cost effectiveness of intervention
20896,Analysis of sensitivity of cost effectiveness estimates to assumptions
20897,Morbidity and symptom prevalence at age 33 years by social class at birth
20898,Physical measurements by social class at birth
20899,Economic circumstances by social class at birth
20900,Health related behaviour by social class at birth
20901,Social and family functioning and structure by social class at birth
20903,Characteristics of diseases and vaccines that increase the allocation of resources for new vaccine development, introduction, and routine use
20904,Infectious agents and improved vaccines of importance in the USA and developing countries targeted for accelerated vaccine development in 1985 and their status in 1996
20907,10 year mortality risks
20908,5 year mortality risks for three groups of participants
20911,Univariate Cox Proportional HR Model of Patient Factors With Relative Risk for Reintervention and Reoperation After BD for Arch Obstruction After the NP
20912,Working hours and days off work because of ill health among local government employees in Raisio, 199195
20913,Sick leave due to musculoskeletal disorders and trauma by degree of downsizing
20914,Absence rates and rate ratios of factors that predict long periods of sick leave
20915,Interactions between downsizing by occupation and other predictors of sick leave
20916,Proportion of 93 head injured patients with each APOE genotype
20917,Comparison of head injured patients with and without an APOE  4 allele
20918,Distribution of final WHO stages according to initial WHO stage for HIV positive prevalent and incident cases
20919,Stage defining disorders for entry into stages 3 and 4
20920,Cumulative probability of progression to AIDS by initial stage and from entering a new stage
20921,Mortality rate by initial stage for prevalent and incident groups
20922,Cumulative probability of death by initial stage and from entering a new stage
20923,Diagnostic categories by sample status
20924,Prevalence of cognitive impairment by severity, sex, and age group
20925,Percentage   95  CI   of elderly Canadians in each diagnostic category living in institutions
20926,Percentage of participants with each degree of cognitive impairment who experience functional limitations
20928,Details of operations and complications
20929,Details of postoperative symptoms and complications
20930,Follow up details
20931,Pre Operative and Intraoperative Data
20932,Use of general practitioner services before and after surgery
20933,Intraoperative and Early Post Operative Results
20934,Causes of Follow Up Deaths
20935,IDDM patients born in Lazio of either both or one Sardinian parent
20936,Observed and expected cases of newly diagnosed
20937,Age adjusted cumulative incidence of coronary heart disease by birthweight and BMI tertiles
20938,Parameters   standard error   for logistic regression of log birthweight on cumulative incidence of coronary heart disease adjusted for age, risk factors, and socioeconomic status
20939,Father s social class and adult social class
20940,Childhood family amenity score and proportion of manual workers according to father s social class and adult social class
20941,Father s social class and cardiovascular risk factors at Q1
20942,Relative odds of cardiovascular disease according to father s social class with non manual as reference group
20943,Relative age adjusted odds of myocardial infarction and recall of a physician diagnosed ischaemic heart disease according to adult social class and father s social class
20945,WHO estimated and projected HIV prevalence in adults by macro region, July, 1995
20946,Oestrogen exposure in cases and controls by dose and by duration of use
20948,Babies in 199091 geographically defined cohort study and inclusion in volume expansion trial
20949,Deaths in trial groups
20950,Sensorineural impairment at age 2 years
20951,Neuromotor impairment at age 2 years
20953,Procedural Details
20955,Congenital Heart Defects Requiring Specialist Care
20956,Congenital Heart Defects Requiring Specialist or Shared Care
20957,Congenital Heart Defects for Which Nonspecialist Care Is Sufficient
20959,Treatment doses and treatment discontinuation by allocated treatment
20961,Outcomes of safety and tolerability
20962,National study cohort of parents in Sweden who lost their child due to a malignant disease between 1992 and 1997
20963,Bereaved parents  perception of being asked about their child s disease and death due to cancer
20966,Effect of the death of a child on parental mortality
20967,Effect of the death of a child on parental mortality
20970,Flesch reading ease score
20973,Median   IQR   psychological scores at 3 and 9 months in bereaved relatives by group
20974,Deaths from any cause and aneurysm related causes, according to time since randomisation in the intention to treat population
20975,Causes of death in patients, by time since randomisation in the intention to treat population
20976,First re interventions in patients, according to time since randomisation in the intention to treat population
20978,30 Day and 2 Year Clinical Follow Up
20979,Clinical outcomes during 4 year follow up, overall and according to a landmark analysis at 1 year
20980,Stent thrombosis
20986,Numbers of patients and arteries per modality and bands of percentage of stenosis
20987,Meta analysis of sensitivity and specificity for all stenosis groups and imaging techniques
20988,Test for heterogeneity in the meta analyses of 7099  stenosis data
20989,Key design features of trials
20990,Death or myocardial infarction, death, and myocardial infarction by qualifying event at the end of treatment
20991,Details of arthropod species identified
20992,Prevalence of self reported chronic pain
20994,Logistic regression model of factors significantly associated with chronic pain
20995,Self reported cause of pain
20996,Self reported chronic pain severity
20997,Expressed need of patients with chronic pain
20999,Results of regression analysis
21001,Invasively Measured Hemodynamic Outcomes After Percutaneous Pulmonary Valve Implantation
21002,Magnetic Resonance Imaging Data Before, Early After, and Late After PPVI in the Pulmonary Stenosis and Pulmonary Regurgitation Groups
21003,Cardiopulmonary Exercise Testing Data Before, Early After, and Late After PPVI in the PS and PR Groups
21004,Results of paired samples of synovial membrane B19 DNA and IgG antibodies to B19
21006,Reported intake of antiepileptic drugs
21007,Comedication with other antiepileptic drugs and presence of other confounding factors in cases of SJS and TEN
21008,Univariate risk estimates for short and long duration of antiepileptic therapy and individual antiepileptic drugs for SJS and TEN
21009,Univariate and multivariate risk estimates for short and long duration of antiepileptic therapy combined for SJS and TEN
21011,Symptoms and symptom severity associated with single dose treatment
21013,Diet and lifestyles of the four populations
21017,Yearly onsets, classifications, and deaths from vCJD
21018,Effects on risk of zoster of contacts with limited numbers of children living in household and via childcare work in past 10 years
21019,Effects on risk of zoster of contacts with many children and exgenous exposure to varicella zoster virus in the past 10 years
21020,IgG against varicella zoster virus   VZV   in serum of blood donors by CCR5 32 genotype
21021,Incidence of disease and mean incubation period in RIII mice injected intracerebrally with 20 L tissue homogenates or blood fractions from patients with vCJD
21022,Manifest and early pseudoexfoliation syndrome in abdominal aneurysm and carotic artery occlusion patients
21024,Adjusted risk ratio estimates for various exposures compared with non exposed and hyperlipidaemia
21025,Distribution of statin users in participants by duration of use and type of statin
21026,Annual number of onsets, classifications, and deaths from vCJD in UK
21027,Proportions of secondary structures in PrPSc before and 48 h after incubation with or without iPrP13
21028,Mean   SE   time to onset of symptoms for mice inoculated with PrPSc alone or with iPrP13
21030,Postoperative complications
21033,Effect of VPB in Healthy Volunteers on Ventilatory and Hemodynamic Parameters
21035,Age adjusted odds ratios of Alzheimer s disease, vascular dementia, and other dementias by indicators of atherosclerosis
21036,Age adjusted odds ratios of Alzheimer s disease, vascular dementia, and all dementia by atherosclerosis score and apolipoprotein genotype
21037,Modern contraceptive prevalence rate   mCPR  , unmet need for modern methods, and demand satisfied with modern methods in 2017 for 68 Family Planning 2020 countries
21038,Changes between 2012 and 2017 in the modern contraceptive prevalence rate   mCPR  , unmet need for modern methods, demand satisfied with modern methods, and the number of women of reproductive age who are married or in a union using modern methods of contraception
21039,Results of a counterfactual analysis of changes in modern contraceptive prevalence rate   mCPR   since 2012
21041,Pre Intervention and Acute Post Intervention Aortic Valve Function Among 509 Early   30 Day   Survivors of Balloon Aortic Valvuloplasty for Congenital AS, 1984 to 2008
21042,Aortic Valve Reinterventions Among 509 Early   30 Day   Survivors of BAVP for Congenital AS, 1984 to 2008
21043,Results of Univariate and Multivariate Cox Regression Analyses of Freedom From Any Aortic Valve Surgery and Freedom From AVR
21044,HRs for AVR Among Patients With Different Combinations of Post Dilation Residual AS and Acute AR
21045,Crude and adjusted consultation rates   per 10000 person years   with a general practitioner or nurse, by age, sex, and year
21046,Temporal trends in GP and nurse consultations by subtype of face to face, telephone, and home visit contacts
21047,Duration of consultations   min   with all types of general practitioner or nurse
21048,Total number of days   two3 h sessions   per 10000 person years of face to face, telephone, or visit consultations with a general practitioner or nurse
21049,Estimates       and uncertainty intervals of contraceptive prevalence and unmet need for family planning for 1990 and 2010, and the median absolute percentage points change   19902010
21050,Estimates and uncertainty intervals of the number of MWRA   millions   aged 1549 years, for total contraceptive use, unmet need, total demand, and unmet need for modern methods, for 2010 and 2015
21055,Results of laboratory testing for influenza in people possibly exposed to HPAI A H7 in the Netherlands, grouped by presenting symptoms
21056,Reported cases by risk group and laboratory result
21057,Results of laboratory testing by category of symptoms in contacts from cases with confirmed A H7 infection
21058,Symptoms in A H7 positive, and  H7 and A H3 negative cases
21060,Outcome Variables, Stratified by Gait Speed
21061,Incremental Value of Gait Speed Above Core Risk Factors to Predict Mortality or Major Morbidity
21062,Incremental Value of Gait Speed Above the STS Risk Score to Predict Mortality or Major Morbidity
21063,Adjusted matched relative risk estimates
21064,Adjusted     relative risk estimates restricted to unexposed women and women exposed to progestagens alone
21066,Standardised incidence rates for endometrial and breast cancer per 1000 women over a 5 year period in current users and never users of HRT at recruitment
21068,Rate of known non compliance in the two treatment groups by time since study entry
21069,Rate ratios for reinfarction, cardiac death, or any death by 24 months
21070,Rate ratio of any death or a cardiac death at 3, 6, 12, and 18 months follow up
21071,Secondary outcome events by 24 months
21073,Diagnostic findings in patients that underwent endoscopy
21074,Resource use per patient
21076,Web table: Unit costs applied in economic analysis
21078,Symptoms, quality of life, and patients  satisfaction with management at entry, after 1 month, and after 1 year
21079,Mean   per patient   use of resources
21081,Incidence per 1000 person years of cardiovascular diseases, breast cancer, and endometrial cancer during follow up
21082,Mortality rate and sudden cardiac deaths per 1000 person years during follow up
21084,Age distribution of women in trial
21085,Phlebitis and thrombosis
21087,Endometrial cancer in users of oestrogen combined with cyclic progestagen therapy: influence of number of days per month progestagen is added
21088,Duration of therapy and endometrial cancer in users of oestrogen combined with cyclic progestagen
21089,Duration of therapy and endometrial cancer in current users of oestrogen combined with cyclic progestagen
21091,Secondary outcomes
21092,Site years of data, by decade
21093,Country specific malaria mortality estimates for children younger than 5 years
21094,Country specific malaria mortality estimates for individuals aged 5 years or older
21095,Country specific malaria mortality estimates for individuals of all ages
21096,Verbal autopsy sensitivity analysis for all models
21100,Hierarchical Classification of Congenital Heart Disease
21102,Deaths in the 6 Restricted Cohorts of Patients With CHD
21103,Adjusted Mortality Rate Ratios in Subtypes of Congenital Heart Disease in 2002 to 2005 Relative to 1987 to 1990
21104,Cancer attributed deaths in the present study and estimated national totals by age and sex in India
21105,Estimated rates of cancer mortality for main cancer sites by place of residence and sex in individuals aged 3069 years
21106,Age standardised mortality rates for selected cancers by education level and sex of deceased individuals aged 3069 years for all India
21107,Age standardised mortality ratios for main cancer sites by religion for men and women aged 3069 years
21110,Frequency of selected adverse events
21112,HIV 1 RNA viral load assays used in British Columbia, Canada, 19962009
21113,Distribution of the highest HIV 1 RNA plasma concentrations for all individuals in British Columbia, Canada who ever had an HIV 1 RNA level in a plasma test, 19962009
21115,Frequency of episodes per child in each group during single blind phase   ATP8521   in cohort 1
21117,Estimates of Effective Doses for Selected Cardiac Imaging Procedures   in mSv
21119,Number of Enrollees Undergoing Cardiac Imaging Procedures With Radiation Exposure, 20052007
21120,Number of Cardiac Imaging Procedures With Radiation Exposure   per 1,000 Enrollees per Year
21121,Number of Cardiac Imaging Procedures   per 1,000 Enrollees per Year   and Proportion of Overall Radiation Dose According to Location
21122,Annual Rates of Radiation Exposure From Cardiac Imaging Procedures   per 1,000 Enrollees
21125,Admission values
21126,Hospital course variables
21132,Long term outcomes according to randomisation
21133,Frequency of multi organ dysfunction, sepsis, and survival by plasminogen activator inhibitor 1 genotype
21134,Agespecific and species specific parasite rates and spleen rates in children on Aneityum, Malakula, and Futuna
21135,Malaria prevalence on Aneityum
21137,Study drug administration and treatment compliance
21138,Primary and secondary efficacy results
21139,Per protocol analysis   as treated, on treatment   of primary endpoints
21140,Safety endpoints by treatment
21142,Long Term End Points
21143,Number and distribution of DAT immunoreactive neurons
21145,Results obtained by the heparin induced platelet activation test   HIPA  , and heparin platelet factor 4 ELISA   ELISA  , and the new ID HPF4   n 135
21146,Individuals with mutations associated with resistance to RTIs at the time of primary HIV 1 infection
21147,Occurrence of HIV 1 variants with mutations associated with resistance to protease inhibitors
21148,Individuals with mutations associated with resistance to protease inhibitors at the time of primary HIV 1 infection
21151,Incidence of PCP and deaths among patients who stop any PCP prophylaxis after treatment with HAART
21153,Normal and abnormal inhibitory responses
21154,Inhibition of thrombin stimulated or ionomycin stimulated 86Rb  efflux in platelets of patients with Alzheimer s disease and in controls
21155,Outcome measures
21159,Vocational, admission, and drop out outcomes
21160,Socioeconomic sources of heterogeneity
21162,Protective efficacy of intermittent preventive treatment by age group
21163,Protective efficacy of intermittent preventive treatment according to the parasite threshold used to define a clinical attack of malaria with an intention to treat analysis
21164,Adverse reactions after 941 random drug administrations in three doses
21165,The prevalence of molecular markers of sulphadoxine pyrimethamine resistance in children who received intermittent preventive treatment with sulphadoxine pyrimethamine and artesunate or placebo before and after intervention, and at two time points in the year after treatment
21169,Outcome by treatment group
21171,Controlled trials of antimicrobial treatment of cholera in children
21175,Intention to treat analysis
21176,Evaluability analysis
21183,Reclassification of 30 Day Mortality Risk With Incorporation of Geriatric Conditions
21185,Primary and secondary outcomes at 6 month follow up
21187,Subgroup analyses of 6 month outcomes
21188,Reclassification of 5 Year Mortality Risk With Incorporation of Geriatric Conditions
21190,Proportions of people who took up screening
21191,Adjusted odds for screening uptake, overall and by deprivation quintile
21192,Expected yields for different active case finding strategies
21193,Key activities and strategies to be considered for prevention of tuberculosis transmission
21194,Administrative and environmental strategies for airborne infection control
21196,Use of treatments, procedures, and tests among patients with STEMI
21197,Estimated excess incidence of ovarian cancer in England associated with 5 years and with 10 years of hormone therapy use, starting at age 50 years
21198,Mortality after four surgical procedures, the number of procedures that occur annually, and how many would be necessary to detect poor performance with different statistical powers
21199,Proportion of surgeons who do sufficient numbers of different procedures every year to identify cases of poor performance
21200,A brief history of the political and health developments in Pakistan during the past six decades
21202,Health expenditure in Pakistan by sources
21203,A snapshot of the challenges and opportunities in the governance of Pakistan
21206,Clinical events during follow up
21207,Key features of MVP and AMC approaches to development and deployment of new vaccines for low income countries and their potential for replication
21209,Death, myocardial infarction   MI  , or both after 5 years
21210,Interventions during 5 years after randomisation
21211,Effect of treatment strategies on occurrence of death, myocardial infarction, or both at 5 years in predefined strata and subgroups and in different risk groups
21212,Occurrence of death, myocardial infarction   MI  , or both after 2 years and 5 years in relation to risk stratification with FRISC score
21213,Outbreak associated strains of N meningitides serogroup C isolated in Anhui province by year   month
21214,Mean temperatures of water in solar cooker during study period
21217,Frequency of end of life decisions
21218,Angiographic Changes After Arterial Duct Stenting   Group I   or Modified Blalock Taussig Shunt   Group II
21221,Guarani Indians living in Paraguay belonging to the Tupi Guarani linguistic family
21224,Biochemical, molecular, and clinical features in patients with raised concentrations of octanoylcarnitine in neonatal blood spots
21225,Effect of the meningococcal vaccination campaign in Ghana
21229,Results of knowledge questionnaire
21230,Effect of video on patients with severe anxiety
21232,1 AR mRNAs and Proteins in Human Epicardial Coronary Arteries
21233,Cardiac 1 AR Subtypes in Human, Mouse, and Rat
21234,Trial population and woman years of follow up
21235,Proportions of women attending for screening according to SES 2
21236,Breast cancer mortality during 14 years of follow up
21237,Breast cancer mortality by SES 2 in cohort 1   4564 years
21239,Diameter and Cross Sectional Area Measured by MSCT at the Ventricular End of the CRS
21240,Diameter and Cross Sectional Area Measured by MSCT at the Level of the Nadir of the CRS Leaflets
21241,Diameter and Cross Sectional Area Measured by MSCT at the Level of the Central Coaptation of the CRS Leaflets
21242,Diameter and Cross Sectional Area Measured by MSCT at the Level of the Commissures of the CRS Leaflets
21244,Axial Shape of the CRS at the Various Levels as Assessed Visually
21245,Distribution of patients in AT and PT groups
21246,Incomplete Apposition at the Ventricular End of the CRS Was Not Associated With Significant Aortic Regurgitation    Grade 2 of 4   as Assessed by Transthoracic Echocardiography Immediately Post Procedure
21247,Univariate and multiple logistic regression analysis of the three significant variables influencing outcome measures
21248,Subjective global assessment of AT and PT and the relationship between subjective global assessment and outcome measures of the treatments
21251,Distribution of population and of CABG rates across small areas of Ontario, 199293
21252,Correlation of appropriateness with rate by county of residence for CABG in Ontario, 199293
21254,Median transmission coefficients   and 95  credible intervals   estimated for each route of infection
21258,Study population before and after the introduction of point of care CD4 testing at primary health clinics in Mozambique
21259,Results from a multivariable logistic regression analysis of the effect of independent variables on loss to follow up before CD4 staging and initiation of antiretroviral therapy at primary health clinics in Mozambique
21262,Clinical Factors Affecting Heart Failure Survival
21266,Mortality rates
21267,Clinical features of patients with liver related causes of death
21268,Predictive factors of liver related death
21269,Overview of anti H Y responses in the female patient
21271,Mortality rates by cause, HIV 1 status, and HBsAg status
21272,Comparison of liver related mortality by HIV 1 and HBsAg status
21273,Risk factors for liver death in individuals with HIV 1, according to HBsAg status
21274,Thrombosis risk for several concentrations of IgG against C pneumoniae
21279,T cell data and viral load
21280,Summary of cell mediated immune responses before and after DNA immunisation with HIV 1 regulatory genes
21283,Descriptive statistics for the CCG sample in 201415 and 201516
21284,Predictors of CCG performance in 201415
21285,Predictors of change in CCG performance between 201415 and 201516
21286,Predictors of CCG performance in 201516
21288,Overview of types of violence against women and girls
21290,An institutional history of health systems in Latin America
21291,Historical milestones for four phases of health system history in selected Latin American countries
21292,Health system type and segmentation in Latin America
21293,Paths to health system integration in Latin America
21294,Incidents of self harm by year and sex in all prisoners in England and Wales, 200409
21295,Risk factors associated with the first episode of self harm among prisoners in England and Wales during 200609
21296,Suicide in prison among individuals who self harmed and for the whole prison population, by sex and year   200409
21297,Risk factors associated with suicide among male prisoners who self harmed, 200609
21298,Risk factors associated with suicide among female prisoners who self harmed, 200609
21300,Association between methylation at sites in HIF3A on chromosome 19 in whole blood DNA and BMI in the discovery and replication cohorts
21301,Association between BMI and methylation at sites in HIF3A in adipose tissue and skin DNA in the MuTHER cohort
21302,Association between methylation level at cg22891070 and single nucleotide polymorphisms at the HIF3A locus
21307,Distribution, sex, and number of various formal and informal health care providers per 10000 population in Bangladesh in 2007
21309,Prevalence of intimate partner violence within the past 12 months and in lifetime at each site
21311,Patients  experiences, knowledge, and perceptions about intimate partner violen participants  answers to specific questions
21313,Case fatality ratio due to severe acute lower respiratory infections in children younger than 5 years who were admitted, by region
21314,Summary of global annual predicted estimates of neonates with the HbS allele
21315,Summary of regional annual predicted estimates of HbAS and HbSS neonates
21318,Percentage of sexually active participants reporting problems with individual sexual response lasting 3 months or more in the past year, by sex and age group
21319,Potential effect of the internet on physical activity interventions   based on effect estimates from web based physical activity interventions and other physical activity interventions   and the potential effect of mobile phones on physical activity interventions   based on effect estimates from telephone based physical activity interventions and from other physical activity interventions  , by country income
21320,Potential effect of car ownership on active travel min per day, by country income
21322,Events During Long Term Follow Up According to the Extent of LV Reverse Remodeling After CRT
21324,Incidence   per 1000 person years   for 10 66 dementia, by country, site, sex, and age
21325,Directly standardised incidence   per 1000 person years   for 10 66 dementia, by site
21327,Associations with incident 10 66 dementia
21329,Material goods, 19702010
21330,Coverage and use of health care service, 19702010
21331,Estimated health spending in 2006
21332,Supply of services, equipment, and human resources, 19702010
21333,Health financing in India and selected countries during 2005
21334,Health outputs, outcomes, and financing in 14 most populous Indian states
21335,Selected indicators for Tamil Nadu and Madhya Pradesh
21336,Contribution of National Rural Health Mission   NRHM   to health expenditures in states   200708
21337,Medical insurance schemes introduced by central and state governments
21338,Adults   1599 years   diagnosed with colorectal, lung, breast   women  , or ovarian cancer between 1995 and 2007 and followed up to Dec 31, 2007
21339,Age standardised relative survival       at 1 and 5 years, and 5 year survival conditional on survival to the first anniversary of diagnosis
21340,Study Population   n   45
21341,Intraoperative Findings in 29 Patients With Definite Infective Endocarditis
21342,Diagnostic Performance of CT
21343,Prevalence of CAD in All Patients and Valvular Stenosis Insufficiency in Patients Who Underwent Surgery
21344,Age standardised mean years of education   95  uncertainty intervals   for men and women aged 25 years or older, by country, for 1970, 1990, and 2009
21345,Changes in educational attainment between 1970 and 2009 for men and women aged 2534 years in the world s most populous countries
21346,Coefficients from first differences model for the effect of income per person, education of women of reproductive age   1544 years  , and HIV prevalence on child mortality between 1970 and 2009
21347,Results of counterfactual analysis of the effect of education in women of reproductive age, income per person, and HIV on child mortality by use of 1970 as the year of comparison
21348,Results of counterfactual analysis of the effect of education of women of reproductive age, income per person, and HIV on child mortality rate by use of 1990 as the year of comparison
21350,Cumulative probability of survival during first 10 years of life according to age at the start versus end of the cohort and survival of mother
21351,Cumulative probability of survival in the first 10 years of life according to age at start versus end of the cohort and survival of the father
21352,Age specific death rates in children according to survival status of the mother
21353,Age specific death rates in children according to survival status of the father
21354,Causes of death in children according to age group and survival status of the mother during 19872005
21355,Age specific death rates in children according to sex of child and survival status of the mother
21356,Age specific death rates in children according to sex of child and survival status of the father
21360,Effect of privatisation on adult male standardised mortality rates, 19892002
21361,Effect of privatisation on log male unemployment rates, 19912002
21362,Effect of unemployment on age standardised mortality rates in working age men, 19912002
21364,Path analysis of the effect on log adult male mortality rates in the former Soviet Union, 19912002
21366,Change in total adult male standardised mortality rates and the amount of privatisation and unemployment in post communist countries from 1991 to 1994
21368,Placebo Corrected Treatment Effect of Bosentan in Hemodynamic Secondary End Points, All Randomized Analysis Set
21370,Multivariate regression model testing the independent effect of socioeconomic components, involuntary admissions, organisational changes, and prominence of outpatient services, on the regional variation in suicide risk
21372,Effects of Tolvaptan on Hemodynamic Parameters
21373,Empirical studies of programme sustainability for low income and middle income countries, and disadvantaged populations in high income countries
21374,Empirical studies of programme sustainability in high income countries sustained for 2 years or more after the initial funding period
21375,Reviews of multiple programmes and factors relating to sustainability
21377,Association of four SNPs with uric acid concentration and gout
21378,Exposures related to the H5N1 cases and case fatality in Indonesia
21379,Clinical presentation during first 2 days of onset of human H5N1 virus infection cases in Indonesia   n 108
21380,Clinical and laboratory features on hospital admission of human H5N1 virus infection cases in Indonesia
21381,Factors associated with H5N1 case fatality in Indonesia, 200507
21383,CPR and post CPR variables in the extracorporeal CPR group and the conventional CPR group
21384,Outcome of the extracorporeal CPR group and conventional CPR group
21385,Multivariate Cox regression analysis for the factors associated with the survival to hospital discharge
21388,Difference between effect of atole compared with fresco supplementation during different age ranges on income measures
21391,Variables Related to the Occurrence of Cardiac Events During Follow Up in the Entire Population   Cox Regression Model
21393,Pooled analyses of data from the British Doctors Aspirin Trial and the UK TIA Aspirin Trial on the effect of randomisation to a period of treatment with aspirin on the incidence of common cancers during a median of 23 years of follow up
21394,Incidence of colorectal cancer in all patients in the UK TIA Aspirin Trial and the British Doctors Aspirin Trial stratified into 10 year follow up periods
21395,Hazard ratios   95  CI   for incidence of colorectal cancer in a pooled analysis   stratified by trial   of data from the British Doctors Aspirin Trial and the UK TIA Aspirin Trial of long term follow up after the scheduled trial treatment period, stratified into 5 year periods after randomisation
21397,Relationship Between On Treatment LDL C Levels and Incident Cancer
21399,Preventives tried without sustained improvement and doses   total mg per day
21400,Transitional treatments tried for cluster headache and responses
21401,Responses to abortive drugs before implantation
21402,Follow up for main outcomes
21403,Patients  estimates of cluster frequency, severity, and duration of attacks before and after use of stimulator
21404,Settings used for occipital nerve stimulation
21405,Complications
21407,Success of Different Techniques of LAA Closure
21408,Variables That Are Related to Successful LAA Closure
21409,Allocation factors used to apportion integrated and disease specific funds to maternal, newborn, and child health
21410,Worldwide ODA to maternal, newborn, and child health by broad purpose, type, and source of aid flow
21411,Worldwide ODA to maternal, newborn, and child health by donor
21412,Worldwide ODA to maternal, newborn, and child health by aid modality and purpose of project
21413,Aggregate and per child ODA to maternal, newborn, and child health by WHO region
21414,Aggregate and per child ODA to maternal, newborn and child health, under 5 mortality rates   per 1000 livebirths  , and maternal mortality rates   per 100000 livebirths   in the 60 priority countries
21415,Number of court cases per country
21417,Main arguments quoted in unsuccessful cases   n 12
21418,Suicide rates and standardised mortality ratios by age and sex
21419,ACC AHA Heart Failure Performance Measures ICD 9 CM Diagnosis Codes
21420,Hospitalization Rates   per 100,000   for Heart Failure as the First Listed Diagnosis or as Additional   2nd to 7th   Diagnosis by Age and Gender, 1979 and 2004: National Hospital Discharge Survey
21425,Clinical Outcomes of Follow Up Cohort With LVSD by Beta Blocker Treatment Group: Unadjusted
21426,Effect of Beta Blocker Treatment Group on All Cause Mortality and Death Rehospitalization at 60 to 90 Days After Discharge: Risk  and Propensity Adjusted Analyses
21428,Echocardiographic and Catheterization Variables Before Fontan
21429,Operative and Post Operative Courses at Fontan
21430,Independent Risk Factors at S1P for Death Through Fontan Completion
21431,ACC AHA Indications by Clinical Subgroup
21432,Criteria for Normal and Abnormal ECGs
21434,Univariate Predictors of ECG Abnormalities in American Professional Football Players
21435,Multivariable Predictors of ECG Abnormalities in American Professional Football Players
21440,Clinical Outcomes at 30 Days
21441,Clinical Outcomes at 30 Days According to Consistent Therapy on UFH Versus Switch From UFH to Bivalirudin
21442,Clinical Outcomes at 30 Days According to Consistent Therapy on Enoxaparin Versus Switch From Enoxaparin to Bivalirudin
21443,Definition of the RAP Score
21444,Pre Natal Classification of Cases and Prediction of Post Natal Surgical Pathway Versus Actual Route and Current Status
21445,Inter  and Intra Observer Variability of TV and PV and RV Length
21446,Classification Quality of the Predictive Scores, Showing the Proportion of Fetuses Assigned Correctly to a BV or UV Circulation
21449,Underlying Diseases and Causes of Death of Individual Patients Who Died
21450,Multivariate Cox Regression Analysis of Hazard Ratio of Key Risk Variables
21454,Per Segment Analysis of DSCT for the Detection of Coronary Stenoses
21455,Per Vessel Analysis of DSCT for the Detection of Coronary Stenoses
21456,Per Patient Analysis of DSCT for the Detection of Coronary Stenoses
21458,Global Biventricular Function
21459,Segmental Myocardial Function
21461,Mode of Cardiac Death
21462,Causes of Sudden and Cardiovascular Deaths
21463,Observed and Expected Causes of Deaths Unrelated to Congenital Heart Defect
21464,Temporal Trends in Coronary Revascularization, by Type, in Olmsted County, 1990 to 2004
21465,Lifetime Number and Pattern of Revascularizations Among Olmsted County Residents
21467,Diagnostic Performance and Predictive Value of DSCT Coronary Angiography for the Detection of Significant   50    Stenoses
21468,Influence of Agatston Score on Diagnostic Accuracy of DSCT Coronary Angiography   a Segment Based Analysis
21469,Influence of Heart Rate on the Diagnostic Accuracy of DSCT Coronary Angiography   a Segment Based Analysis
21470,Diagnostic Performance and Predictive Value of DSCT Coronary Angiography for the Detection of Significant   50    Stenoses in Patients With Atypical Angina, Typical Angina, or Unstable CAD
21475,Clinical Outcomes
21477,Subject Medical History
21478,Procedure Summary
21479,Number of Subjects by Category of Major Adverse Events, Successful Device Delivery, or Surgical Closure Events Reported Through 12 Month Follow up
21480,Residual Defect Status: Final Echo Core Lab Review
21481,Clinical Success End Point
21482,Propensity Score Analysis: Clinical Success
21484,Procedures Prior to the Ross Operation
21485,Predictors of Neo Aortic Root Outcomes
21486,Neo Aortic Reintervention
21489,Documented Contraindications to Acute Medical Therapies
21490,In Hospital Treatments Among Patients Without Contraindications
21491,In Hospital Outcomes
21492,Odds Ratio of In Hospital Mortality According to Acute Therapy Received Among Patients Age 75 Years
21495,Percentage of Patients With Atrial Fibrillation Taking Anticoagulation by Time Period and Age Group
21498,Procedural Angiographic Results and In Hospital Clinical Events
21500,Clinical Events at Nine Months
21501,Survival time and attack rate in mice inoculated with RML scrapie strain and treated with CpG oligodeoxynucleotides, and in controls
21502,Exposure to UV light derived from questionnaire responses
21505,Efficacy of NE 1530 in prevention of acute otitis media
21506,Nasopharyngeal carriage of pathogen bacteria
21508,Cumulative new AIDS cases and HIV positive births, and life expectancy in 2005
21509,Modelled total costs, proportion per person health  care expenditure, and cost per life year gained required to finance antiretroviral use, by scenario
21512,Outcomes at 30 Days and 1 Year in PCI Patients With or Without Nonsignificant LMCAD
21513,Crude Outcomes of the Total Cohort, by Subsequent Treatment
21518,Estimates of Self and Peer Life Expectancies in Years for Patients With Congenital Heart Disease   CHD   and a Comparison Sample of Undergraduates
21520,Multivariate Logistic Regression Predicting Shorter Perceived Life Expectancy Among Patients With Congenital Heart Disease   CHD
21521,Medications affecting weight gain and alternative approaches
21523,Surgical procedures for treatment of obesity
21524,Follow up of clinical events for up to 5 years
21525,Predicted change in odds of coverage by intervention
21526,Predicted change in coverage of interventions in 74 Countdown countries by 2020, 2025, and 2035
21527,Number of Countdown countries achieving different under 5 and neonatal mortality rates in 2010 and projected for 2035
21530,Procedural results
21531,Clinical outcomes at 12 months
21533,Source and Characterization of Primary Antibodies
21534,Circumferential Nerve Densities at the PV LA Junction
21536,Effect of Age and Left Ventricular Hypertrophy on Structural Features and Autonomic Nerve Density
21537,Baseline lesion and procedure characteristics
21538,Use of antiplatelet and antithrombin medications at discharge
21539,Incidence of clinical outcomes at 3 years according to Kaplan Meier estimates
21540,Measures of the response to HIV in injecting drug users in six selected countries: an assessment matrix, 200810  3,4,20
21543,Procedural results
21544,Clinical outcomes
21545,Stent thrombosis
21546,Angiographic follow up results
21548,Absolute and Relative Reductions in Target Vessel Revascularization at 8.5 Months and 1 Year
21550,Two way frequency table on the agreement between the sumSTR and maxSTE risk groups
21552,Causes of death at 30 days by risk groups
21554,Proportion of patients with various TIMI flow grades 90 min after start of streptokinase infusion related to the three groups of ST segment recovery
21555,Atrial Fibrillation Study Cohorts and Treatment Strategies
21556,Incremental Cost Effectiveness Ratios   ICER   in Base Case Estimates, Stratified by Ischemic Stroke Risk
21557,Multivariable Sensitivity Analyses
21561,Mean Values of Cardiovascular Risk Factors at the Time of Menopause
21563,Relationship Between Premenopausal Cardiovascular Risk and Age at Menopause by Linear Regression Analysis
21565,Effect of Premenopausal Increasing or Decreasing Cholesterol Level, Relative Weight, and Blood Pressure
21567,Initial Clinical Presentation
21569,Overall Survival and Clinical Events of 58 Patients With Initial Angiographic Success
21570,ORs   95  CI   for stroke, VTE, or AMI associated with current use of therapeutic progestagens relative to non users of any type of SHCs
21571,Effectiveness estimates
21572,Resourse use and cost per patient treated   UK, 1998
21573,Cost effectiveness of brief GP counselling plus nicotine patch treatment, incremental to brief GP counselling alone
21574,Sensitivity analysis of incremental cost per life year saved by nicotine patch treatment versus brief counselling alone for the 3544 years group
21576,Bivariate Predictors of All Cause Mortality Against SV PP
21578,Mortality rates in all patients
21579,Mortality in all patients stratified by minimum CD4 lymphocyte count
21580,Mortality rates by treatment regimen in patients with minimum CD4 count of 200 mL or lower
21581,Clinical model for predicting pretest probability for deep vein thrombosis
21583,Prevalence of venous thromboembolism initially and on follow up, according to pretest probability of deep vein thrombosis derived by the clinical model
21584,Scoring system for mild to moderate or severe post thrombotic syndrome
21588,Causes of death in people diagnosed with hepatitis B, hepatitis C, or hepatitis B and C co infection in NSW 19902002 by ICD 10 code
21589,PR Interval for AOO Mode With Shortened PR Interval With CDOO and BDOO Mode, Pacing Order for Each Patient
21590,Causes of death related to viral hepatitis in NSW 19902002 by ICD 10 code
21591,QRS Duration, Systolic Blood Pressure, and Cardiac Index   Calculated by Assumed Oxygen Consumption   for the Three Different Pacing Modes
21592,Tissue Doppler Derived Strain Rate Data for the Three Different Modes of Pacing
21594,Anti HBs concentrations   IU L   in children and recruits vaccinated more than 10 years previously
21595,Anti HBs concentrations at 2 weeks after booster vaccination in children with non protective antibody concentrations at enrolment
21596,Anti HBs concentrations at 2 weeks after booster vaccination in recruits with non protective antibody concentrations at enrolment
21597,Anti HBs response after a second full course of vaccination according to anti HBs concentrations elicited after first booster injection
21598,Clinical findings
21599,Hepatobiliary pathology
21600,Liver function tests
21601,Mean choline creatine ratios   SD   from the basal ganglia and white matter
21603,Titres from seven HBeAg positive neonates and their mothers
21604,COMPANION Follow Up Hospital Admissions by Treatment Group and Modeled Cost of Admission
21605,Additional Base Case Model Parameters
21607,Costs and Survival at Selected Time Points Over the Modeled Treatment Episode
21608,Summary Results of Cost Effectiveness Analysis   Base Case
21609,Results of One Way Sensitivity Analysis
21611,Standardised mortality rates for liver cirrhosis at all ages per 100000 per year
21612,Comparative mortality ratios for liver cirrhosis, 19972001 relative to 19871991, by age group
21613,Liver cirrhosis age standardised mortality rates per 100000 in England and Wales and in Scotland
21614,Mortality and prevalence of malnutrition among civillian population in Bahr El Gazal, southern Sudan, 1998
21616,Global Lipid Genetic Consortium 12 SNP LDL C gene score calculation
21617,Outcome data in Whitehall II controls according to weighted LDL C gene score deciles
21618,Examples of international collaboration and research design
21622,Predictors for Emergency Coronary Artery Bypass Grafting During the Pre Stent Era   1979 to 1994
21623,Predictors for Emergency Coronary Artery Bypass Grafting During the Stent Era   1995 to 2003
21624,Cause of Death and Indication for Bypass Surgery in 41 Patients With In Hospital Death After Emergency Surgery
21625,Determinants of aid, year of data, and source of data
21626,Worldwide official development assistance to maternal, newborn, and child health by source of aid flow, 200306
21627,Worldwide official development assistance to maternal, newborn, and child health by type of aid and purpose of projects between 2003 and 2006
21628,Worldwide official development assistance to maternal, newborn, and child health by donor between 2003 and 2006
21629,Aggregate official development assistance to maternal, newborn, and child health, to child health per child, and to maternal and newborn health per livebirth in 2005 and 2006, and percentage change for the two categories between 2003 and 2006
21630,OLS estimation of log   official development assistance   to child health per child between 2003 and 2006
21631,OLS estimation of log   official development assistance   to maternal and newborn health per livebirth between 2003 and 2006
21632,Effect of new versus standard antibiotic on febrile morbidity in four age strata and overall
21633,Interim stopping levels   p values   for different numbers of planned interim analyses by group sequential design  14,15
21635,Standardised and crude mortality rates   including organ transplantation  by genotype
21637,Standardised mortality rates   including transplantation   as deaths by CFTR functional class
21640,Comparison of low risk and high risk clinical examination with low risk and high risk final diagnosis
21641,Comparison of low risk and high risk examinations with OAR
21645,Overview of serious adverse events
21647,Laboratory data for patients studied
21648,Enzyme activities in patients with WD and control groups
21650,Number of interventions during labour in women with delivery details available
21651,Neonatal outcome
21652,Details of deliveries for 100 neonates with arterial cord pH  715
21653,Profile of pregnant patients
21656,Fatty acid profiles of poppyseed and rapeseed oils
21657,Right Ventricular Function Before and After Pulmonary Valve Replacement
21658,Physicochemical properties of iodised oils
21660,Cost implications of mandatory drugs tests: cost generating events
21661,Establishment of 500 inmates: cost per month of mandatory drugs testing
21662,Prisons  need for resources
21667,5 year all cause mortality in all patients and according to disease type
21669,Key features of includes trials
21672,Adjusted relative rates of clinical outcomes in each risk group
21674,Diagnostic Accuracy of Coronary MSCT Compared to QCA for Detection of Lesions  50  in Patients
21675,The Effect of Coronary Calcification on Diagnostic Accuracy of Coronary MSCT Compared to QCA
21676,The Effect of Obesity on Diagnostic Accuracy of Coronary MSCT Compared to QCA
21677,The Effect of Heart Rate on Diagnostic Accuracy of Coronary MSCT Compared to QCA
21678,Diabetes prevalence by age group and sex in 1995, 2000, and 2005
21680,Diabetes incidence by sex and agegroup, 1997 and 2003
21681,Death rates per 1000 in prevalent diabetes cases by age group in 1995, 2000, and 2005
21682,Children with first operative procedures by year of observation
21683,Children with first operative procedures by time of screening and screening results
21685,Ultrasonography before age 8 weeks
21686,Hip management up to 2 years of age
21687,Hip status by age 2 years
21688,Measurements Before Replacement of the Tricuspid Valve
21689,Primary outcomes stratified by laterality, level of clinical suspicion, and clinical diagnosis at trial entry
21690,Measurements After Replacement of the Tricuspid Valve
21691,Mean resources used per patient, and mean total costs
21692,Measurements After One Month in Animals From Group 2
21694,Reperfusion therapy by geographic region
21695,Reperfusion therapy according to type of hospital
21696,Reperfusion therapy in subsets of patients
21697,Multivariate correlates of failure to receive reperfusion therapy
21698,Odds ratios for atopic diseases
21699,Incidence ratios of atopic dermatitis
21700,Catalase activities of Hungarian acatalasaemic, hypocatalasaemic, and normocatalasaemic first degree relatives.
21701,Frequency of diabetes mellitus in Hungarian acatalasaemic and hypocatalasaemic individuals compared with normocatalasaemic relatives and a sample of the Hungarian population
21702,Prospective studies included in meta analysis
21703,Relative risk of in hospital mortality after myocardial infarction in patients with hyperglycaemia on admission compared with patients without hyperglycaemia
21704,Relative risk of pump failure after myocardial infarction in patients with hyperglycaemia on admission compared with patients without hyperglycaemia
21705,Populations included in the prospective mortality analysis of the DECODE study
21706,Classification of diabetes and glucose intolerance according to ADA fasting and WHO 2 h glucose criteria
21707,Hazard ratios for death   95  CI   adjusted for age, sex, and study centre, according to the fasting glucose and 2 h glucose classifications in individuals not known as diabetic
21708,Sex specific estimated absolute number of excess deaths for individuals not diagnosed as having diabetes
21709,Geometric Dimensions of the Implanted Bioprostheses   mm
21710,Preoperative Data
21711,Operative Data
21712,Hemodynamic Results Grouped by Valve Type and Aortic Annulus Diameter
21713,Incidence of Patient Prosthesis Mismatch Grouped by Aortic Annulus Diameter
21714,Hemodynamic Results Grouped by Aortic Annulus Diameter and PPM
21715,T cell stimulation index   mean  SD    to different antigens in people studied
21716,Pandemic excess mortality calculations, based on vital registration data from 191820
21717,Results from two ordinary least squares regression models on the log of the pandemic excess mortality rate 191820 for countries with complete vital registration data
21718,Estimated number of deaths caused by the emergence of a pandemic influenza strain in 2004
21721,What Thai teenagers remember being taught in sex education classes
21722,Attitudes of Thai parents towards teaching children about sex
21723,Effect of Increasing Voltage Applied to the Autonomic Ganglia on Sinus Rate
21724,Fewest Number of APDs Required to Induce AF Without and With Voltage Applied to the AG
21725,Recommended qualitative descriptions with EU assigned frequency bands, and participants  estimates from the pilot study
21726,Estimates of probability and Likert scores   16  , in response to the terms very common and 15 , by age group
21728,Mean   SD    11C   R   PK11195 binding potential
21732,Patients Clinical and Surgical Data
21733,Lipids, total homocysteine, and associated factors before and after 6 weeks of treatment with gemfibrozil or micronised fenofibrate in 22 men
21735,Doppler Echocardiographic Findings
21736,Health spending, health spending by source, and growth, 201540
21737,Three scenarios of pooled health spending, UHC index, and covered lives in 2030
21738,Average annual increases of development assistance for health by focus area
21739,Site years of population based cancer registry data, vital registration, and verbal autopsy data for breast and cervical cancer, 1980 to 2010
21740,The cumulative probability of breast and cervical cancer incidence for individuals aged 1579 years
21741,Deaths from breast and cervical cancer by region and age group, 2010
21743,The cumulative probability of breast and cervical cancer death for individuals aged 1579 years
21744,Stent Implantation and Procedural Results of Patients With LAD Lesions
21745,Clinical Outcomes After Stent Implantation in LAD Lesions
21746,Angiographic Results at Nine Month Follow Up of Patients With LAD Lesions
21747,Results Among Randomized Patients With Lesions in the Proximal LAD
21748,Comparative Results of Bare Metal Stent Implantation Among the Three Coronary Arteries
21749,Comparative Results of Paclitaxel Eluting Stent Implantation Among the Three Coronary Arteries
21750,Response rate by method of contact attempted
21751,Response rates for individuals who were sent questionnaires
21753,Previous deployments
21754,Potentially traumatic experiences on last deployment
21755,Distribution of main outcomes by original cohort
21756,Relation between health outcomes and deployment stratified by regular reservist status
21757,Distribution of main outcomes after reassigning Era participants to Iraq war group if they had served in subsequent TELIC deployments   regulars only
21758,Effect of date of deployment on mental health outcomes   regulars only
21759,Effect of combat on health   regulars in Iraq war group only
21760,Psychiatric morbidity by time elapsed   months   since end of last TELIC deployment   regulars deployed to Iraq war only
21762,Variation in lifetime prevalence of abuse in studies of gynaecology and obstetric patients
21764,Prevalence of emotional abuse and current effects
21765,Prevalence of physical abuse and current effects
21766,Prevalence of sexual abuse and current effects
21767,Prevalence of lifetime emotional, physical, or sexual abuse
21769,Babies with probable group B streptococcal infection
21772,End Points in Patients With and Without New onset Atrial Fibrillation
21773,Univariate Predictors of New Onset Atrial Fibrillation
21774,Multivariate Predictors of New Onset Atrial Fibrillation
21775,Variances   bold, diagonal  , covariances   below diagonal  , and correlations   italics, above diagonal   between general health questionnaire   GHQ  , depersonalisation   DP  , emotional exhaustion   EE  , and personal accomplishment   PA  , at time1   1997   and time2   2000
21777,Proportion of children with symptoms at enrolment and on days 1 and 2
21778,Age and proportion of adults among contact cases and primary cases by place and vaccination coverage in the pertussis study, France, 199394
21779,Patient Data and Results of Broad Beam Spectral Doppler and Magnetic Resonance Imaging Measurements
21780,Prevalence of stress as measured by GHQ in doctors
21781,Low birthweight births, stillbirths, and sex ratio   198191   and fetal abnormality rates   198693
21782,Targets and realities
21783,Cost of family planning and reproductive health services
21784,Impact of selecting cost effective family planning services assuming current 70  contraceptive prevalence
21787,Mortality after 13 years according to quartile of physical fitness at survey 2   PF2
21790,Safety and Efficacy Outcomes Derived From Acutely Successful Patients at 3 , 6 , and 9 Month Follow up
21794,Acute Measurements of Ventricular Pacing or Defibrillation Leads WithCurrent of Injury
21795,Acute Measurements of Ventricular Pacing or Defibrillation Leads WithoutCurrent of Injury
21796,Acute Measurements of Atrial Pacing Leads With Current of Injury
21797,Acute Measurements of Atrial Leads Without Current of Injury
21799,Changes in Heart Rate Variability and Heart Rate Turbulence Before Spontaneous Onset of AF
21800,Changes in R R Dynamics Before Spontaneous Onset of AF
21801,Laboratory findings in study group and controls
21804,Total costs in the treatment groups by 12 months of follow up
21805,Total costs per patient by 12 months of follow up
21806,Blood chemistry values during CPR and rewarming
21809,Univariate Predictors of Cardiac Death
21811,Changes in haemodynamic and metabolic indices
21813,Ages, BMI, and Concomitant Coronary Artery Bypass, LV to Aortic PSG, and AV Areas in Seven AV Weight Groups in Men and Women
21814,Mean responses over first 3 min for swims at 25C, 18C, and 10C
21815,Ages, BMI, Concomitant Coronary Bypass, and AV Weights in Men Versus Women According to AV Structure
21816,Mean values for physiological and physical measures for three 90 min swims
21817,Gender, BMI, Concomitant Coronary Artery Bypass, AV Weights, LV to Aortic PSG, and AV Areas in Three Age Groups
21818,Gender, Ages, Concomitant Coronary Artery Bypass, AV Weights, LV to Aortic PSG, and AV Areas in Three BMI Groups
21819,Ages, BMI, AV Weights, LV to Aortic PSG, and AV Areas in Patients Without Versus Patients With Concomitant Coronary Artery Bypass Grafting
21820,Gender, Age, BMI, Concomitant Coronary Artery Bypass, AV Weights, LV to Aortic PSG, and AV Areas in Three Ejection Fraction Groups
21821,Clinical Findings on 13 Patients With Moderate or Severe AR
21822,Independent determinants of rates of major obstetric interventions in rural Guckdou, 198896
21823,Classification of samples in training cohort according to proteomic pattern
21824,Class prediction of samples in test cohort according to proteomic pattern
21829,Effects of high and low sympathetic activity   induced by maximum whole body cooling and warming
21831,Relation between tuberculin skin test response and variables related to household contact
21832,Relation between tuberculin skin test response   induration 5 mm   and variables related to the index patient and the household setting
21833,Multivariate analysis of the relation between the tuberculin response   induration  5 mm   and variables related to the household contact, index case, and the household
21834,Multivariate analysis of the relation between the tuberculin response   induration 5 mm   and variables related to the housegold contact, index case, and the household, among household contacts 215 years of age
21835,Respiratory score used by parents to complete the symptom diary
21837,7 day day time and night time symptom score and daily uses of salbutamol
21838,Comparison of binary outcomes
21840,Self treatment regimens in the intervention group
21841,Number of relapses in each group
21842,Economic outcomes
21843,Time Adjusted Radiation Exposure   mGy  cm2 s   to an Alderson Rando Phantom in Dependency on Tube Angulation
21844,Mean Operator Radiation Exposure   Sv h   During Fluoroscopy at a Rando Phantom as a Function of Tube Angulation
21845,Dose Corrected Operator Scatter Exposure   Sv Gy  cm2   During Fluoroscopy as a Function of Tube Angulation
21846,Pneumocystis carinii  dihydropteroate synthase     DHPS     genotypes detected in patients with confirmed  P carinii  pneumonia by initial treatment regimen
21847,Occupational Operator Dose Reduction by Less Irradiating Tube Angulations in Invasive Cardiology
21849,Risk of poor outcomes by initial treatment and by genotype
21851,Distribution of 74 white Australian and 92 Japanese women by age and percentage oestrogen receptor a positive cells in normal breast tissue
21852,Association of percent of oestrogen receptor  positive cells in normal breast tissue with origin of the tissue from white Australian and Japanese women, after age
21855,Reasons for withdrawals
21856,Intention to treat analysis of serum creatinine, increase in serum creatinine, and creatinine clearance at 24 months or at time of dropout
21857,Odds ratios   95  CI   of ischaemic, haemorrhagic, and all strokes in relation to type of current oral contraceptive used compared with non users
21859,Mortality and Morbidity Rates by Age With Various Operations From the STS National Database, 19952000
21861,Absolute Differences in Quality Adjusted Survival   in Months   Across Peak Aortic Valve Gradient   Rows  and Ages   Columns
21863,CAC Scores and CAC Prevalence by Ethnicity and Gender
21864,OR    of Positive CAC by Risk Factors
21865,Summary Statistics by CAC Classification
21866,Echocardiographic Protocol
21867,Distribution of Relative Pairs Entering the Analysis
21868,Relative risk of incident Alzheimer s disease associated with use of oestrogen during postmenopausal period
21869,Duration of oestrogen use
21870,Randomised trials of ovarian ablation or suppression versus control that began before 1990
21871,Patients  data
21875,Additional Surgical or Transcatheter Interventions in Patients Undergoing Bidirectional Superior Cavopulmonary Anastomosis
21876,Distribution of variables at routine and interim visits
21877,Risk of parasitaemia and clinical malaria at routine visits by HIV serostatus, CD4 cell count, and WHO stage
21878,Rates of all interim visits and interim vists with clinical malaria, and risk of clinical malaria at interim visits by HIV serostatus, CD4 cell count, and WHO stage
21879,Attack precipitants in 200 patients
21881,Composition of synthetic UK
21882,Estimates of the effect of the QOF on age adjusted and sex adjusted mortality per 100000 population
21884,Multivariate Predictors of Restenosis for PCI of Allograft Coronary Disease
21885,The Era Effect on PCI of Allograft Coronary Disease
21887,Electrocardiogram, echocardiography, Holter test, and exercise stress test findings in first degree relatives of SADS victims
21888,Fatty acid composition of capsules used
21890,Effects of dietary oil treatment on the fatty acid composition of LDL lipid fractions
21891,Fatty acid composition of carotid plaque lipid fractions in different oil treatment groups
21892,Carotid plaque morphology in different oil treatment groups
21893,N 3 polyunsaturated fatty acid content of carotid plaque lipids according to AHA classification and macrophage   anti CD68   staining intensity
21894,T lymphocyte and macrophage staining in carotid plaques from patients in different oil treatment groups
21895,Association of APOE  2 3 4 genotype with myocardial infarction   MI   risk
21896,Risk of myocardial infarction   MI   in cigarette smokers versus non smokers by APOE genotype
21898,Mortality rates by quartiles of cholesterol
21899,Cox proportional hazard models for association
21900,Relative risk for mortality based on change in cholesterol between examinations three and four
21901,Presence and extent of MRI hyperenhancement for patients with healed infarction
21906,Linear Regression Coefficient and Intraclass Correlation Coefficient Between Noninvasive Methods   Averaged Value of Two Observers  Measurements   and Gorlin Estimated MVA in Both Centers
21907,Mitral Score as Assessed by Two Independent Observers by 2D and RT3D
21908,Muscular signs and symptoms in 127 carriers of Duchenne and Becker muscular dystrophy
21909,Dilated cardiomyopathy and left ventricle dilation in DMD BMD carriers
21910,Affected muscle groups in 22 carriers with muscle weakness
21912,Number of patients with each important outcome by degree of stenosis and treatment allocation
21913,Causes of death
21914,Surgical operations and adverse events from trial surgery
21915,Frequency       of major outcome events among patients with 80100  symptomatic carotid stenosis
21916,Results from Cox proportional hazards model of major stroke or death from any cause
21921,Variables associated with risk of all cause and CVD mortality in Cox proportional hazards regression   full model
21922,Criteria for Interventional Procedural Success
21924,Indications for Early Post Operative Catheterization
21925,Major Diagnostic Groups, Surgical and Catheterizations Procedures Performed
21926,Interventional Procedures Performed
21927,Angioplasty Stent Sites Involving Suture Lines
21929,Hazard ratios for all cause and cardiovascular mortality according to eGFR and albuminuria clinical categories, by hypertensive status in combined general and high risk population cohorts
21930,Hazard ratios for end stage renal disease according to eGFR and albuminuria clinical categories, by hypertension status in chronic kidney disease cohorts
21932,Incidence of adverse events
21933,Hemodynamic Data
21935,Relative Rates   95  CI   of CVD Mortality, Incident CHD, and Total Mortality in Gender Specific Quintiles of the Heart Rate Adjusted QT
21936,Relative Rates   95  CI   of CVD Mortality, Incident CHD, and Total Mortality in the Highest Gender Specific 10  Compared with the Other 90  of the QT Distribution
21937,Relative Rates   95  CI   of CVD Mortality, Incident CHD, and Total Mortality in the Highest Gender Specific 10  Compared with the Other 90  of the QT Distribution , According to Health Status
21938,Comparison of Prognostic Value of Manual and Machine Measured QT in the Case Cohort Sample: Relative Rates   95  CI   of Highest Gender Specific 10  Compared With the Other 90  of the QTc Distribution
21939,Official development assistance to reproductive health, 200910
21940,Worldwide official development assistance to reproductive health by donor, 200910
21941,Official development assistance to reproductive health to the 74 Countdown priority countries by type of aid and purpose of projects, 200910
21942,Official development assistance to reproductive health to the 74 Countdown priority countries 200910
21943,Results of ordinary least squares regression models
21944,Ranking of top HIV investment      countries by criminalisation and PEPFAR focus status and epidemic scenario
21946,Sensitivity analysis showing proportion of individuals with one or more drug resistance mutation, by region and years after rollout of antiretroviral treatment   ART
21949,45q15   uncertainty interval   per 1000 for women and men in 1970, 1990, and 2010
21950,Distributions of yearly rates of change in adult mortality      , by decade
21952,Causative Microorganisms
21954,Main Indications for Surgery
21955,Mitral Lesions     Surgical Findings   According to the Timing of Surgery
21956,Surgical Techniques   According to the Timing of Surgery
21957,Ranked order of self reported symptoms
21958,15 most frequent self reported symptoms by deployment status
21959,Relation between deployment and fatigue and between deployment and perceived fair or poor general health
21961,Multivariable Analyses of the Association Between Race and Prevalent Atrial Fibrillation Among Hospitalized Patients With Heart Failure
21962,Frequency of resistant H3N2 viruses by geographic origin and year of isolation
21963,Biological data for rimantadine susceptibility
21964,Rate changes for selected countries and regions
21965,HIV prevalence and details of Global Fund awards by country, for rounds 13   December, 2003
21966,Interviews by respondent category and country
21967,Composition of country coordinating mechanism, in May, 2003, by country
21969,Predictors of Survival at 36 Months in Chronic Heart Failure Patients Derivation Study
21970,Clinical Details of the Patients in the Validation Study
21971,Comparison of Patients Below and Above the Predetermined Cut Off Value for Cholesterol in the Validation Study
21972,Adult crude HIV 1 prevalence rate       by round
21973,Predictors of Three Year Survival in the Validation Study
21974,Adult crude HIV 1 prevalence rate by survey round and migration status
21975,Results of laboratory studies done before and after seroconversion
21977,Frequencies of HLA B57, HLA B   5701, and combination of HLA B   5701 and HLA DR7
21979,Frequency of condom use
21980,Effect of health education and method of condom provision on the probability of condom use
21981,Comparison of Responders With Non Responders
21982,Preoperative, Postoperative, and Normative Mean QOL Values   in Different Age Groups
21983,Multivariable Analysis of the Effect of Age on Change in MCS and PCS Scores
21985,p Values Representing Heart Rate Variability Differences
21986,HRV Preceding the Onset of AF
21988,Families With Recurrent Congenital Heart Disease
21989,Overall Concordance for Families With One, Two, or Three Recurrences
21990,Recurrence Type Seen Where the Index Case Has a Left Heart Defect
21991,Recurrence Type Seen When the Index Case Has a Septal Defect
21992,Recurrence Type Seen When the Index Case Has an Outflow Tract Defect
21993,Comparison of Sclerotic Process in Aortic Stenosis With That in Atherosclerosis
21994,Risk Factors Associated with Aortic Stenosis
21996,Etiologies of Mitral Regurgitation Among 274 Patients Who Underwent Mitral Valve Plasty
21997,Changes of Echocardiographic Data Before and After Mitral Valve Repair Among 171 Patients
21998,Univariate Correlation of Postoperative Ejection Fraction With Preoperative Clinical or Echocardiographic Variables
21999,Incidence of Postoperative LV Dysfunction According to Classes of Preoperative LVEF
22000,Incidence of Postoperative LV Dysfunction Stratified by Preoperative LVDs
22001,Incidence of Postoperative LV Dysfunction According to Preoperative LVEF and Preoperative LVDs
22002,Results
22003,Independent Variables Found to Correlate With Follow Up Neo Aortic Valve Annulus, Root, and Sinotubular Junction Z Scores Above the Median for This Population
22004,Comparison of Mean Z Score for All Patients Who Underwent Interim Staging With BSCA Compared With Those Who Had Stage 1 Reconstruction Followed by Fontan Operation
22005,Independent Variables Found to Correlate With Follow Up Neo Aortic
22007,Causes of Death and Adverse Events During Follow Up
22009,Impact of Treatment on Hospitalization in Patients Grouped According to the Occurrence of Recurrent Atrial Fibrillation
22011,Age and Gender Distribution for Ischemic Stroke Cases and Control Subjects
22012,Observed Prevalence       of Atrial Fibrillation Among Rochester Residents, Stratified by Gender, Age, Presence or Absence of Ischemic Stroke, and Decade
22013,Modeled Prevalence       of Atrial Fibrillation Among Rochester Residents, Stratified by Gender, Age, Presence or Absence of Ischemic Stroke, and Decade
22014,Change in Prevalence   Odds Ratio   for Five Year Changes in Calendar Time for Various Comorbid Conditions
22015,Use of Electrocardiography Within 30 Days of Stroke in Case Patients or Reference Date in Control Subjects for Three Decades
22016,Number of Arteries   LAD, LCX, and RCA   That Underwent 0 to 6 IVUS Exams
22018,Comparison of Unadjusted Physical and Mental Health Status Outcomes From the SF 36
22020,Filling Dynamics During Development of Pacing Induced Heart Failure
22022,Quantitative Intravascular Ultrasound Data
22023,Quantitative Intravascular Ultrasound Data
22024,Quantitative Intravascular Ultrasound Data
22025,Multiple Regression Analysis of Intima Media Thickness
22026,Long Term Mortality After AVR
22027,Severity of VP PM
22029,Predictors of All Cause Three Year Mortality
22031,Effects of CRT on Echocardiographic Parameters
22032,PCR Primers and Optimized PCR Conditions for Amplification of Rabbit Potassium and Calcium Channel Genes
22033,Biophysical Properties of ICa,Land Ito
22034,State of the Art on Human Skeletal Myoblasts, Embryonic, and Bone Marrow Stem Cells
22035,Markers of Cardiomyocyte Differentiation from Human Skeletal Myoblasts, Embryonic, and Bone Marrow Stem Cells
22038,Radiation Failure Patients According to IRT Study
22040,Clinical Events Six Months after Radiation Failure   n   282
22042,Hospital Readmission, Health Status and Social Support in Men and Women at Six Weeks After CABG Surgery   Unadjusted
22044,Clinical and Angiographic Data of Study Patients
22047,CABG and PCI Outcomes of Patients With Prior CABG
22052,Blood Pressure Differences for the First 4 h of Measurement Between the First and Second Days of a 48 h ABPM in Patients With Mild to Moderate Hypertension
22053,Spectrum of Disease at First Presentation   n   44
22055,Surgical Data   n   30
22056,Variables Predicting Need for Eventual Orthotopic Heart Transplantation in the Surgical Group
22058,Potential Factors in the Incidence of AVF
22059,Potential Determinants of the Incidence of Spontaneous AVF Closures in Patients With Iatrogenic Femoral AVF   n   88
22060,Potential Determinants of the Incidence of Time to Closure of AVF in Patients With Iatrogenic Femoral AVF   n   88
22062,Person years, observed   O   and expected   E   cases, and SIR by cancer and exposure to IVF treatment with ovarian stimulation
22063,Observed   O   and expected   E   cases and SIR by cancer and type of infertility   exposed and unexposed to IVF treatment with ovarian stimulation combined
22064,Observed   O   and expected   E   cases and SIR by cancer and type of ovarian stimulation and response to stimulation
22065,Fertilistion rates and paternal pesticide exposure in a series of 836 couples who underwent IVF treatment
22068,Results of intention to treat analysis
22069,Multivariate Predictors of Atrial Fibrillation
22070,Results of per protocol analysis
22071,Microbiological assessment
22072,Hospital outcomes
22073,Health spending per capita by income group, region, country, and source in 2040
22074,Health spending as a share of gross domestic product, by income group, region, country, and year
22075,Benchmarking country progress by 2040
22077,Summary of significant loci
22078,Summary of risk profile analyses
22079,Age specific and sex specific prevalence of Parkinson s disease
22080,Comparison of Parkinson s disease patients with or without the G2019S mutation
22081,Monthly referral rates and total number of patients admitted to Scottish Liver Transplantation Unit
22082,Risk factors in patients with acute liver failure
22085,Proportion of Differences Between ECG Gated SPECT and Cardiac MRI Measurements
22086,Clinical and Echocardiographic Variables at the Time of Discharge From the Hospital, After Stabilization With Medication   n   115
22088,Hemodynamic Results and Doppler Gradient at the Last Follow Up
22089,Association of US 100 per capita increase in tax revenues and in GDP with health system expenditure in low income and middle income countries, 19952011
22090,Tax regime and government spending on health in low income and middle income countries, 19952011
22091,Official development assistance to maternal, newborn, and child health, 200310
22092,Worldwide official development assistance to maternal, newborn, and child health by donor, 200310
22093,Official development assistance to maternal, newborn, and child health to the 74 Countdown priority countries by type of aid and purpose of projects between 2003 and 2010
22094,Official development assistance to maternal, newborn, and child health to the 74 Countdown priority countries, 200310
22095,Results of ordinary least squares regression models and likelihood ratio tests
22097,Sources of Information Available for the Study
22098,Inter Relations Among Morphologic Variables
22099,Frequency of Occurrence of Associated Malformations
22103,Perioperative and Late Deaths Related to the MTVG Among Patients Who Had AVR Replacement
22106,Success Rates of Collagen Injection
22108,Treatment credibility after the third treatment session and assessment of blinding
22110,Secondary outcomes after 26 weeks and 52 weeks
22113,Individual absolute and relative risks for development of contrast nephropathy
22114,Aminoacid changes caused by variable sequences
22115,Expression of chromosome 1q by comparative expressed sequence hybridisation   CESH   and comparative genomic hybridisation   CGH
22116,Cough duration according to age and sex in total study population
22117,Health care actions taken by men and women with cough for more than 3 weeks
22118,H pylori prevalence by family composition
22119,Effect of birth order on H pylori prevalence
22120,Effect of birth spacing on H pylori prevalence
22121,Effect of H pylori status of siblings on prevalence of Hpylori in 29 year olds
22122,Individual Studies
22124,Individual Study Data
22125,Effect of Rate on the Sensitivity and Specificity of Concealed Entrainment for the Identification of an Isthmus Site
22128,Morgan Russell Hayward subscale and total scores at recruitment, after 6 months, and at outcome
22129,Cohort outcomes
22130,Anorexia nervosa and bulimia nervosapredictors of the Morgan Russell Hayward total mean score 5 years after recruitment, derived by multiple regression
22131,Anorexia nervosafurther predictors of the Morgan Russell Hayward total mean score 5 years after recruitment, derived by multiple regression
22132,Bulimia nervosafurther predictors of the Morgan Russell Hayward total mean score 5 years after recruitment, derived by multiple regression
22134,Univariate Logistic Regression: Unadjusted OR of Each Clinical Variable in Relation to Resolution of LAT
22135,Univariate Logistic Regression: Unadjusted OR of Each Echocardiographic Variable in Relation to Resolution of LAT
22136,The Initial Multivariable Logistic Regression Model: OR of Each Variable, Adjusted for Effects of All Other Varibles in Relation to Resolution of LAT
22137,The Final Model
22139,Mean scores for Griffiths mental development scales at randomisation and 9 month follow up
22140,Audiological tests done at randomisation
22141,Audiological, tympanometric, and otoscopic results at randomisation
22143,1H magnetic resonance spectroscopy metabolite ratios obtained in each brain region
22144,Computed tomographic findings and clinical details
22145,Response amplitudes
22147,Presenting complaints
22148,Primary and secondary outcome measures in drain and non drain groups
22149,Outcome analysis with adjusted logistic regression models, by independent variable
22150,Safety at first follow up visit
22151,Women s attitudes towards project services
22152,Coverage rates
22153,Supervisory visit co assessment
22161,HPV genotype distribution in all HPV positive women and in HPV positive women with cervical neoplasia
22162,p53 genotypes in Italian and Swedish women
22163,Frequencies of conventional and PAPNET results by classification
22164,values   SE   for agreement between PAPNET and conventional results
22165,Agreement between PAPNET and independent review and conventional screening and independent review
22166,values   SE   for agreement between PAPNET and independent review and conventional screening and independent review
22167,Sensitivity and specificity for PAPNET assisted screening and conventional screening
22168,Discrepancies in final classification between laboratory assessments and independent review
22169,Frequencies for conventional final and primary screening
22170,Frequencies for PAPNET final and PAPNET classification results
22173,Additional procedural details of study groups
22175,Primary and secondary endpoints
22176,The AP Parameters in the Hyperthyroid and Control PV Cardiomyocytes or Atrial Myocytes
22179,Associations Between Cardiac Rhythm After the Operation and Clinical Parameters by Multiple Logistic Regression Analyses
22180,Predictive Values Associating the Combination of ANP and Duration of AF and the Duration of AF Alone With the Outcome of the Maze Operation
22182,Prevalence of rectal bleeding in patients with colorectal cancer   n 64   and proportion of colorectal cancer patients with rectal bleeding, out of all new patients with abdominal complaints   n 455
22185,Measures before testing and 1 month after receipt of test results for individuals homozygous for Cys282Tyr and controls
22187,Relationship Between Risk Factors and the Presence of LVSD In Patients With Stroke, TIA or PVD as Compared With Age  and Gender Matched Control Subjects
22188,Uptake of testing in first degree relatives of C282Y homozygotes discovered by genetic testing and after clinical presentation
22189,Epidemiology of LVSD   Ejection Fraction 40
22190,Multiple Logistic Regression Analysis  of Risk Factors for Left Ventricular Systolic Dysfunction   Ejection Fraction 40    in Patients and Control Subjects
22193,Risk Factor Analyses of Mortality of CAVB Diagnosed In Utero, in the Newborn Period or During Childhood
22194,ACC AHA Criteria for Permanent Pacing of 67 of 102 Patients With Diagnosis of CAVB In Utero, as Newborn or During Childhood
22195,Analysis of Heart Rate on 12 Lead ECG, Holter and Exercise Test of Class 1 and Class 2 N and C Patients and Unpaced Cases
22196,Malaria attributed deaths in the present study and estimated national totals, by age
22197,Geographical variation in absolute numbers of malaria deaths in the different populations studied by the MDS and NVBDCP
22198,Countries according to international funding awarded per person at stable malaria risk per year up to end of 2009 and per person gross domestic product
22199,Studies of GPs  ability to diagnose depression
22200,Age Structure of the Henry Ford Health System General Population Taken From a Random Sample   n   3,195   of Enrollees in 1994, the Midpoint of REACH Time Frame legend legend
22202,Age Structure of the REACH CHF Population From 1989 to 1999 legend legend
22203,Deaths, person years of observation, and mortality rates by period of follow up, district, and age
22204,Adjusted mortality rate ratios
22206,Readmission and Death Within One Year of Initial Discharge    legend
22207,Proportional Hazards Model: Intervention Versus Control legend legend
22208,Mean Readmission Costs     Per Patient   legend
22209,Criteria used to calculate months suitable for P falciparum malaria transmission in Africa
22210,Estimated P falciparum malaria exposure and transmission in Africa with the HadCM3 B1, A2a, and A1FI scenarios
22211,Estimated P falciparum malaria population exposure in Africa with the HadCM3 B1, A2a, and A1FI climate scenarios
22213,Outcomes for behavioural and emotional problems reported on the YSR
22214,Outcomes for smoking, excessive drinking, and use of marijuana, MDMA, and hypnotics or sedatives
22215,Differences in outcomes by sex, for adolescents of the affected school compared with those of the control schools
22216,Differences in outcomes for non exposed and exposed adolescents of affected school compared with adolescents of control schools
22217,Nutrition Content of Active and Placebo Bars
22219,Treadmill Data of Subjects Before and After Two Weeks of Therapy legend legend
22220,Rainfall estimates for 2002 expressed as a proportion of monthly average   1995 2001
22221,Correlations with spirituality and depression measures
22223,Regression models by FACIT SWB total score
22224,Regression models with FACIT SWB meaning and faith subscales
22227,Physical and psychological health measures at 4 months
22229,Multi level model of women s views about care showing effect of study group
22230,Number of home visits by midwife and general practioner   GP   from various sources
22231,Incidence of malaria episodes recorded by the refugee village clinics
22232,Parasite prevalence during cross sectional surveys held in October each year.
22233,Density of indoor resting mosquitos during the treatment period of August to November
22234,Parous rates of mosquitoes in treated and untreated groups of villages during the campaign period
22235,Comparison of costs of three rounds of cattle sponging in 1997 with one round of indoor residual spraying in 1992
22236,Association of the Cd36 T188G polymorphism with severe malaria
22238,Multivariate survival analysis of hazard ratios for mortality 2 years after hip fracture in 731 elderly patients
22239,Reasons for failure of tourists to obtain valid results with rapid test for falciparum malaria
22240,Most intense level of suicidal feelings recorded in case notes of elderly persons visiting a doctor during the year preceding suicide
22241,Most intense level of suicidal feelings perceived by close informant during the year preceding suicide
22246,Six Month Clinical Improvement in Surviving Patients
22247,Treatment Strategies for Hypoplastic Left Heart Syndrome Considered at Diagnosis
22248,Probabilities Used in the Decision Tree
22249,Key indicators of health in the countries of the former Soviet Union
22250,Estimated life expectancies at birth in the countries of the former Soviet Union in 1990, 2000, and 2009
22251,Official and WHO estimates of life expectancies in the countries of the former Soviet Union, 2009
22252,Deaths in children with biliary atresia
22254,Results of prion protein immunohistochemistry
22255,Summary of Estimated Annual National Costs  for Persons Age 35 to 84 Years
22257,Cost Effectiveness of Risk Factor Reductions for the Population Age 35 to 84 Years
22260,Selected secondary outcomes by sex and intervention group
22262,Outcome in living donors and recipients
22263,Numbers of acute and chronic rejections
22264,Mean Age, Gender Distribution and Associated Congenital or Acquired Heart Diseases in Patients With Discrete Subaortic Stenosis Who Had an Operation During Adulthood   Group A  , No Operation   Group B   and an Operation During Childhood   Group C   legend
22265,Changes in Left Ventricular Outflow Tract Obstruction and Aortic Regurgitation Degree in 25 Patients Who Had Two Doppler Echocardiographic Assessments Separated by an Interval of 2 Years legend
22267,Rates of Revascularization Procedures by Numbers of Stenosed Vessels and Ethnicity legend legend
22269,Self reported pain in either hip
22270,Previous use of health services for hip disease according to attendance or non attendance at study clinics
22271,Population prevalence and annual incidence of severe hip disease per 1000 people
22272,Estimates of annual incident hip disease requiring primary total hip replacement surgery in the population of England aged 35 to 85
22274,Mortality at 30 days in patients with initial Q waves versus those without, stratified by acute myocardial infarction location and by time to randomisation
22275,Frequency of ST resolution at 60 min in patients with initial Q waves versus those without, stratified by location of acute myocardial infarction and by time to randomisation
22276,Multivariable predictors of 30 day mortality   n 15222
22277,Histology and stage of lung cancers
22278,22 breath VOC picked out by discriminant analysis
22279,Reported measles cases, measles vaccination coverage, estimated measles deaths, and children reached by SIAs by WHO region
22281,Reported conditions in need of surgical care
22282,Anatomical location of conditions needing surgical care
22283,Conditions of deceased household members that might have benefited from surgical care, recalled as occurring in the week before death
22284,Improvement in mortality person years of observation from 195559 to 197882, from 197882 to 200004, and from 195559 to 200004, expressed as percentage of mortality in people aged 134 years in 195559, 197882, and 195559, respectively, by age group and sex
22286,Contributing factors to neurologically favourable 1 month survival after out of hospital cardiac arrests in children
22288,Age stratified outcomes after paediatric out of hospital cardiac arrests of non cardiac and cardiac origins by type of bystander CPR
22292,Description of the types of IMCI trained health workers, by country
22293,Integrated assessment, classification, and management of children by IMCI trained health workers, stratified by length of preservice training
22294,Index of integrated assessment of children by IMCI trained health workers
22295,Odds ratios for correct classification and management by IMCI trained health workers with longer duration of training compared with those with shorter duration of training
22296,Ratio of physicians and nurses, and ranking of child deaths in the four study countries
22297,Effects of Posture on Frequency Domain Measurements of Heart Rate Variability legend legend
22298,Estimated and expected under 5 deaths and under 5 mortality, with uncertainty intervals, by Global Burden of Disease 2005 study subregions and different years   19701990
22299,Estimated and expected under 5 deaths and under 5 mortality, with uncertainty intervals, by Global Burden of Disease 2005 study subregions and different years   19952015
22300,Country specific summary of mean estimated decline in child mortality and 2005 estimates of under5 mortality and number of deaths, with uncertainty intervals
22302,Estimated number   thousands   and percentage distribution of children not reached with first dose of measles vaccine and without second opportunity for measles immunisation in 2005, by WHO region
22303,Estimated cases, deaths, and DALYS   thousands   occurring and averted, 1999 and 2005, by WHO region
22304,Province populations and cluster allocation
22305,Pre invasion and post invasion deaths by age and cause   n 629
22306,Mortality rates by time
22307,Violent deaths by cause and time
22308,Health indicators in Somaliland, Uganda, and the UK
22309,Benefits of KTSP activity, 200205
22310,Under 5 mortality rates in the 60 countries in 1990 and 2004, and progress needed to meet the 2015 target
22311,Median coverage rates for essential interventions in the 60 countries
22312,Correlation between dependent variable   infant mortality rate   and independent variables in various years
22313,Correlation between dependent variable   life expectancy at birth for women and men   and independent variables, in various years
22315,Frequency of end of life decisions
22317,Nature of end of life decision in terms of life shortening intention of physician for the 143 deaths in which an end of life decision was made
22318,Attitudes of physicians towards end of life decisions in neonates and infants   n 121
22320,Maximum accepted blood phenylalanine concentration and frequency of capillary blood sampling as recommended by the National Society for Phenylketonuria   UK   consensus document  4   and by centre
22321,Results expressed as median   IQR   for each centre and each 5 year age group
22324,Rates of serious coronary heart disease by study cohort and NANSAID use
22325,Rates of serious coronary heart disease by specific NANSAID
22326,Rates of serious coronary heart disease by duration of continuous NANSAID use
22328,Cord, milk and serum PCB concentrations at different ages and relative to breastfeeding, and HOME scores
22329,Association of PCR and HOME with mental and motor development
22330,Risk Factors and Outcome Variable legend
22331,Outcomes legend
22332,Operative Mortality for Specific Subgroups by Procedure Type legend
22333,Risk Factors for Isolated Valve Surgery Model    legend
22334,Risk Factors for Coronary Artery Bypass Graft Surgery Valve Surgery Model    legend
22335,Design of randomised trials of unfractionated heparin compared with placebo or untreated control in acute coronary syndrome without ST elevation
22336,Design of randomised trials of LMWH compared with placebo or untreated control in acute coronary syndrome without ST elevation.
22337,Design of randomised trials of LMWH compared with unfractionated heparin in acute coronary syndrome without ST elevation
22339,Number       of persisting and vanishing warts in ALA PDT and placebo PDT groups
22340,Relative change in wart area and area of persisting warts compared with area at entry       at week 7, 14, and 18
22341,Pain assessed by a five point scale of individual warts       immediately and 24 h after each of six interventions
22346,Adjusted difference in linear growth between short duration category and other children according to sanitation conditions
22348,Age at Operation and Previous Palliative Operations
22349,Type of Previous Palliation and Systemic Venous to Pulmonary Connection
22350,Operative and Late Mortality by Era of Operation
22351,Length of Follow up and Present Age of 171 Surviving Patients
22354,Number of events, age standardised 28 day case fatality, and mean   SE   annual event rates per 100000 during registration in men
22355,Numbers of events, age standardised 28 day case fatality, and mean   SE   annual event rates per 100000 during registration in women
22356,Trends in age standardised event rates for men aged 35 64 years expressed as average   SE   annual relative percentage change
22357,Trends in age standardised event rates for women aged 3564 years expressed as average   SE   annual relative percentage change
22358,Populations grouped by trends in MONICA CHD mortality rates to show contribution of change in case fatality and change in coronary event rates
22361,Summary of Procedures legend
22362,In Hospital and Six Month Complications legend
22363,Univariate Analysis of the Predictors of Cardiac Death legend
22364,Odds ratios of mortality associated with related variables
22365,Comparison of Patients With and Without Inducible, Sustained IART legend
22366,Odds Ratios of Independent Variables Associated With Inducible, Sustained Intra atrial Reentrant Tachycardia
22367,Definition of indicators by intervention area used for the coverage gap index
22368,Mean coverage gap index for four intervention areas with indicators within each area by wealth quintile and measures to describe equity, most recent survey data for 54 Countdown countries
22369,Coverage gap       by period and yearly rate of change with summary measures of equity, by country
22370,Coverage trends in three groups of countries by level of coverage gap in the 1990s with absolute and relative declines
22371,Association between type and level of inequity according to the size of coverage gap in 114 national surveys
22374,Measures of pain and happiness by sex and activity
22375,Average proportion of the waking day spent in each activity
22376,Sex specific mean pulse wave velocity measured at groin and foot according to birth size, adjusted for gestation period
22377,Change in pulse wave velocity measured at groin and foot for 1 SD increase in size
22378,Weekly average of daily backpack loads
22379,Tissue and Cellular Responses to Stent Implantation 7, 28, 56 or 180 Days After Stent Implantation legend
22380,Neointimal Extracellular Matrix Composition 28 or 180 days After Stent Implantation legend
22382,Clinical Electrocardiographic and Radionuclide Data Before and After PVR legend
22383,Summary of country case studies
22385,Cognitive measures and depression symptomatology for the 1905 and 1915 cohorts   in person participants only
22386,Activities of daily living and physical performance scores for the 1905 and 1915 cohorts
22388,Probability of an Outcome Event at 15 Years After Valve Replacement legend
22389,Causes of Death     of All Deaths
22391,Genotypic Distributions and Allelic Frequencies of AMPD1 Gene Polymorphism Among Patients by Survival Status legend legend
22392,Cox Multiple Variable Logistic Regression Model  for Cardiovascular Death legend
22395,Incidence of inflammatory bowel disease by country
22396,Description of cohort of index patients with inflammatory bowel disease in Sweden 195595
22397,Description of first degree relatives of patients with inflammatory bowel disease   IBD   in Sweden 195595
22398,Observed   O   and expected   E   numbers of cancers, standardised incidence ratio   SIR   with 95  CI for colorectal cancer in first degree relatives of patients with either ulcerative colitis or Crohn s disease in Sweden 195595
22399,Observed   O   and standardised incidence ratios   SIR   with 95  CI for colorectal cancer according to location in first  degree relatives of patients with ulcerative colitis, Crohn s disease, or both in Sweden 195595
22400,Offspring sex ratio in the study population compared to the exposure status of parents
22401,Father s TCDD serum concentrations in 1976 and sex ratio of offspring
22402,Odds of male births compared to the TCDD serum concentrations of his parents
22404,Sex ratio at birth by quartile of father s TCDD serum concentration at time of conception
22405,Sex ratio of births in residents of A zone from Jan 1, 1966, to Dec 31, 1996
22407,Variables Specific to Transplantation
22408,Families with IBD and FMF
22409,One  and Five Year Survival by Treatment Path: Intention to Treat Versus Treatment Received Analysis
22410,Multivariable Odds Ratios and Prediction Equation Coefficients for One Year Mortality legend
22411,Differences in CBMN assay
22412,Relative risk of micronucleus formation in CBMN assay, adjusted according to radiation exposure, cigarette smoking, sex, and age
22413,Differences in CBMNA assay
22414,Relative risk of micronucleus formation in CBMNA assay, adjusted according to radiation exposure, cigarette smoking, sex, and age of exposure
22415,Comparison of Categorical Variables in Patients With Ligated and Incompletely Ligated Left Atrial Appendages
22416,Left Atrial Size Distribution in Patients With Ligated and Incompletely Ligated LAA legend
22417,Distribution of Mitral Regurgitation in Patients With Ligated and Incompletely Ligated LAA legend
22419,Extracardiac Defects and Syndromes Associated With AVSD legend
22420,Results of Coxs Proportional Hazards Method of Analysis for Independent Variables Affecting Survival legend
22421,Caesarean rates by wealth quintile in 42 developing countries
22422,Caesarean rates by wealth quintile among urban and rural births
22423,Aneurysm related and all cause mortality   intention to treat analysis
22424,Causes of death by group
22425,Postoperative complications      after leaving theatre by operation received   not intention to treat
22427,Resource use during primary hospital admission for patients who had AAA repair
22428,Estimated costs   UK   over 4 years follow up based on intention to treat
22430,Arterial Remodeling Among Groups in the Study legend
22431,Effect of 8 Cl cAMP on Laboratory Studies in Rats After Balloon Angioplasty   Protocol IV   legend
22432,Pearson s r correlations of visual spatial test scores and competency scores in three Z plasty procedures
22433,Details of diagnostic group and previous genital surgery
22434,Results of cosmetic and anatomical genital examination, and recommendations for further treatment
22435,Features of 14 of 34 patients with colorectal cancer who had at least one blood sample positive for circulating colorectal cells
22436,Results of Coronary Artery Segment Classification and Stenosis Assessment by Contrast enhanced Magnetic Resonance Coronary Angiography Compared With Conventional Invasive Angiography   n   350   legend
22437,Relation Between Magnetic Resonance Coronary Angiography and Conventional Invasive Angiography on a Patient Basis   n   50
22438,EMR contributing countries with modelled influenza associated excess respiratory mortality or annual estimates of respiratory mortality by age group for validation
22439,Mean annual influenza associated EMR per 100000 population by age group for EMR contributing countries
22440,WHO Global Health Estimates of respiratory infection mortality rate   per 100000 individuals   by age group and analytic division
22441,Estimated annual influenza associated respiratory deaths and mortality rate per 100000 population by age group, WHO region, and World Bank income classification
22442,Posterior mean estimates from Bayesian analysis of incidence of avian influenza A H7N9 infection before and after LPM closures
22445,Incidence of active tuberculosis in household contacts during 4 year follow up period
22447,Overall Results of Thrombolysis in 12 Patients With Stuck Mitral Valves
22448,Outcome of Treatment According to Thrombolytic Agent   1st Episode   legend
22449,Thrombolysis in Stuck Bileaflet Mitral Valves: Experience in the Main Series   3 Cases   legend
22450,Comparison Between Patients in the Training Population and the Validation Population legend
22451,Univariate Analysis of Clinical, Exercise and Thallium Variables to Identify Predictors of 3VLMD in the Training Population legend
22452,Multivariate Analysis for Independent Predictors of 3VLMD in the Training Population
22453,Angiographic Results by Risk Classification From Model
22454,Risk Stratification of the Validation Population legend
22455,Country pandemic influenza plans
22456,WHO pandemic influenza phases  3
22459,Distribution of 1094 bacteriologically confirmed patients in all 5800 households, 199398, for all patients and for patients with RFLP only
22460,Clustering of patients in Ravensmead and Uitsig for 199398 in community and in households
22461,Carriage of meningococci by serogroup in 1517 year old school students in the UK in 1999 and 2000
22462,Meningococci by serogroup and centre
22463,MUC 1  variable number tandem repeat region   VNTR   sizes in 10 fertile and infertile women
22464,Association Between Explanatory Variables and Age in Patients Who Survived the First Postoperative Month After AVR legend
22465,Results of Univariate and Multivariate Analyses Based on Observed Late   Deaths Within 30 Days of Aortic Valve Replacement Excluded   Survival Using the Cox Regression Model legend
22466,Frequency of the esp gene and purK allele 1 among epidemic isolates, non epidemic isolates, and isolates from healthy individuals
22467,Comparison of Relative Hazards at Different Time Intervals in Survivors After AVR, Based on Analyses of Observed Survival Using a Modified Cox Regression Model
22470,2 analysis of the difference in frequencies of seroconversion according to age group
22471,Age and Mode of Presentation, Duration of Follow up and Associated Features legend
22472,Echocardiographic and Electrocardiographic Features legend
22473,Patients Subjected to Mitral Valve Repair legend
22475,Echocardiographic Results legend
22476,Univariate Analysis of the Prediction of Immediate Results legend
22477,Multivariate Analysis of the Prediction of Immediate Results legend
22478,Predicted Probability of Good Immediate Results       According to the Value of the Three Predictors Identified in the Logistic Multivariate Analysis for a Given Patient
22479,Univariate Analysis of the Prediction of Good Late Functional Results in Patients Who Had Had Good Immediate Results From PMC
22480,Multivariate Analysis of the Prediction of Late Functional Results After Good Immediate Results legend
22481,Predicted Probability       of Good Late Functional Results Five Years After Good Immediate Results, According to the Value of the Three Predictors Identified in Cox Multivariate Analysis, for a Given Patient legend
22482,Status of tuberculosis control in countries reporting to WHO, 1995
22483,Case notifications by World Bank region, 1995
22484,Case detection rates based on World Bank Development Report by World Bank region, 1995
22485,Number of registered cases and treatment results for new smear positive cases by World Bank region and treatment strategy, 1994
22487,Results of the univariate linear regression analysis of serum lipids and dietary factors
22488,Results of multiple linear regression analysis of serum lipids and glycaemic index   full model
22489,Correlation matrix of univariate correlation coefficients for biochemical, anthropometric, and dietary data
22490,Effects of Balloon Coronary Occlusion on Left Ventricular Function and Power Spectral Components Determined With Maximum Entropy Method legend
22491,Mortality data availability by country
22492,Dimensionless values of the traditional and random walk sway parameters for control and noise trials
22494,Multivariate Predictor of Sudden Death    legend
22496,Interventional Procedures
22499,In Hospital Events and Eight Month Follow Up Clinical Outcomes in Studied Patients legend
22500,Thirty Day and Eight Month Follow Up Clinical Outcomes in Studied Patients With Elevated Tn I Levels More Than Three Times Upper Normal
22501,Independent Predictors of Any Cardiac Event   Death, Q wave MI, Coronary Angioplasty or Bypass Surgery   or TLR at Eight Month Follow Up
22502,Standardised mortality ratio by sex and fracture type
22503,Mortality and time to death by sex and fracture type
22504,Life expectancy in years for fracture and general population
22505,Attributable risk of mortality from fractures by age group
22507,Results of Univariate Linear Regression Analysis of Luminal Gain and Loss in the Four Stent Designs Studied
22508,Comparison of Luminal Loss in Each of the Stents Designs Used Within Each Quartile of Luminal Gain legend
22509,Results of Multiple Regression Analysis for Minimal Luminal Diameter, Luminal Loss and Net Luminal Gain at Follow up legend
22512,Quantitative coronary angiography
22513,Major adverse cardiac events to 9 months of follow up
22514,Waiting times and clinical outcomes by urgency category
22515,Distribution of reported incidents by verification status, availability and source of alerts, type of health facility affected, and type of attack
22516,Distribution of reported incidents by category of person involved   several categories possible
22517,Types      of violence to which health workers were subjected   several categories possible
22518,Distribution of victims of reported incidents, by outcome, age, and gender
22519,Number and recurrence of verified reported attacks on hospitals and primary or mobile facilities, by governorate
22520,Distribution of all reported incidents by governorate and by level of service and impact on functionality
22523,Changes in Mitral Regurgitation Overall and by Lesion Type legend
22524,Changes Observed With Regression, Stability or Progression of Mitral Regurgitation Using a Threshold of Change  8 ml legend
22525,Results of Multivariate Analysis legend
22527,Engagement of stakeholders in quality improvement and evidence generation
22528,Quality improvement initiatives and achievements for care of acute myocardial infarction and acute ischaemic stroke care in the USA, the UK, and India
22529,Delivery channels, examples of interventions, and common bottlenecks
22530,Strategies to improve service delivery and reduce bottlenecks
22533,Diagnostic Value of Transesophageal Echocardiography for Specific Mitral Valve Lesions legend
22534,Trends in access to health services in 200311 by region
22535,Incremental Diagnostic Value of Transesophageal Over Transthoracic Echocardiography in Mitral Regurgitant Lesions legend
22536,Trends in health care activities by region: 2003, 2008, and 2011
22537,Outcome of Surgery According to Gross Anatomic Classification by Transesophageal Echocardiography legend
22538,Trends towards financial protection by region: 2003, 2008, and 2011
22539,Trends in equity   ratio between comparison groups   in access and financial protection across regions and income groups: 2003, 2008, and 2011
22540,Outcomes after Biphasic and Monophasic Defibrillation legend
22541,Associated Cardiovascular Anomalies   N   202   legend
22542,Factors Associated with Death Before Hospital Discharge in Patients Undergoing Repair of Persistent Truncus Arteriosus   N   148   legend
22544,Neonatal and predischarge mortality
22545,Cause of death
22546,Frequency of secondary outcomes
22548,Univariate Correlates of Pulmonary Capillary Wedge Pressure in the Training Population   n   20   legend
22549,Diagnostic Accuracy of IVRT, FPV and Related Indexes in the Entire Study Group for Detection of Pw   15 mm Hg legend
22550,Coefficients of the Correlation Between Doppler Parameters and Pulmonary Capillary Wedge Pressure According to Left Ventricular Systolic Function in 54 Patients legend
22551,Reproducibility of IVRT and FPV legend legend
22554,Volumetric ProgressionChanges Over Time legend
22555,Time series analysis of PAD rates   persons affected by disaster per 1000 population   by region in El Nio and post Nio years compared with pre Nio years, and correlation with SST anomalies, 196493
22556,Time series analysis of PAD rates in El Nio and post Nio years compared with pre Nio years and correlation with SST anomalies, by type of disaster, 196493
22557,Quantitative Angiography Acute and Follow up Results   40 Patients   and Planar Intravascular Ultrasound   45 Patients   Procedural Results of Rotational Atherectomy With Adjunct Percutaneous Transluminal Coronary Angioplasty   PTCA   for Diffuse In Stent Restenosis
22558,Outcome by group
22560,Aortic Valve Disease at the Time of Mitral Valve Surgery and at Follow up legend
22561,Cumulative Proportion of Significant Aortic Valve Disease Free Patients
22564,Positions of primers and amplification products in prototypic flavivirus genome
22565,Sequence analysis data for New York isolate genome with Kunjin and West Nile viruses
22566,Results of the Different Time Periods in Accordance With the Cutoff Points of Troponin I Values legend legend
22567,Results in Consideration of Duration of Extracorporeal Circulation and Age in Accordance With Serum Creatinine, Urea, ASAT and ALAT   Indicated as a Quotient of the Upper Limit of Norm  , Duration of Intubation and Troponin I   cTnI   Values legend
22569,Results
22570,Effect of clomipramine on lung and brain uptake of 11C cyanoimipramine
22572,Processes of Care During the Index Hospital Admission for 42,731 Patients Readmitted or Not Readmitted for Congestive Heart Failure
22573,Resource Utilization and Crude Clinical Outcomes During the Index Hospital Admission for 42,731 Patients Readmitted or Not Readmitted for Congestive Heart Failure
22578,Correlation Matrix   R   for Physician Outcomes
22579,Distribution of infectivity and PrPSc of orally infected hamsters
22582,Phantom Exposure Measurements legend
22583,Variation in Exposure Rate With Projection legend legend
22584,PEMNET Exposure ResultsGeneral Grouping legend
22585,PEMNET Exposure ResultsInterventional Subgroups legend
22586,PEMNET Exposure ResultsGrouped by Patient Chest Dimension for Interventional and Diagnostic Procedures legend
22589,Results for the Principal Analyzed Parameters legend
22590,Clinical and Electrophysiology Findings legend
22591,Diagnosis and Preoperative Diagnostic Modality in 503 Patients With Major Congenital Heart Defects
22592,Indications for Cardiac Catheterization in 91 Patients legend
22593,Associated Defects in 76 Patients With a Combination of Defects legend
22594,Major and Minor Diagnostic Errors in 503 Patients
22595,Risk Factors of Patients Undergoing CABG Surgery or Angioplasty for the First Time, in New York: 19931995 legend
22596,Three Year Survival by Treatment in Each Anatomic Subgroup legend
22597,Study 1: Percent Success of Waveforms  legend
22598,Study 2: Percent Success of Waveforms  legend
22600,Operative and Postoperative Data in Patients Undergoing Repair of Outflow Tract Obstruction Due to AV Valvar Anomalies  legend
22602,Heart Rate   beats min   and Systolic Blood Pressure   mm Hg    legend
22603,Forearm Blood Flow   FBF, ml min 100 ml arm   and Platelet cGMP Levels   pmol 109PLT    legend
22604,Predisposing Factors of Preoperative Valve Regurgitation legend legend
22606,Quantitative Angiographic Data legend
22607,Six month Angiographic Restenosis and 1 year Follow up Clinical Events for the Stent and Optimal PTCA Groups legend
22610,Study Population Postoperative Echo Findings
22611,Indications for Dobutamine Echocardiography  legend
22613,Independent Predictors of Mortality  legend
22614,Independent Predictors of Mortality in Revascularized Patients legend
22617,Quantitative Coronary Angiographic Data legend
22618,Clinical Events in the Hospital and During Follow Up and Length of Hospital Stay  legend
22621,Clinical Outcomes of Patients at Time of Last Follow Up   mean 20.9  3.9 months
22623,Resource Utilization After Initial Hospital Stay  a
22624,Independent Pretreatment Correlates of In Hospital LogeCost  a
22625,Overall Independent Correlates of In Hospital LogeCost  a
22630,Independent Risk Factors for Mortality   Cox proportionate hazards modeling    a
22631,Outcomes by Age at First Required Intervention
22632,Most Frequent Specific Cancer Sites in the Study Cohort
22633,Risk Ratio Estimates for Cancer Associated With Calcium Channel Blocking Agent Use
22634,Adjusted Relative Risk Estimates for Total Mortality Associated With Calcium Channel Blocking Agent Use  a
22635,Adjusted Relative Risk Estimates for Cancer Related Mortality Associated With Calcium Channel Blocking Agent Use
22636,Relation Between the Associated Anomalies and Rastelli Classification  a
22637,Geometric Relation Between the Atrioventricular Valve and the Great Arteries
22638,Diametric Ratios of the Great Arteries and the Ventricular Outlets
22639,Degree of Deficiency of the Ventricular Septum
22640,Previous Surgical Procedures in the 75 Study Patients
22641,Early Postoperative Outcome After Initial Resection of Subaortic Stenosis in the 75 Study Patients
22642,Late Surgical Outcome in Patients With a Low   Group I   or a High   Group II   Preoperative Left Ventricular Outflow Tract Gradient
22643,Surgical Procedures Performed at the Second Operation in 13 Patients
22644,Clinical Outcome in Patients With a Low   Group I   or a High   Group II   Preoperative Left Ventricular Outflow Tract Gradient
22645,Invasive Hemodynamic Variables
22646,Agreement Between Invasive and Noninvasive Determinations of Hemodynamic Variables
22647,Associated Cardiac Abnormalities in Propositi and Relatives of Subjects With Familial Versus Nonfamilial Bicuspid Aortic Valve
22649,Results of Questionnaire Used to Assess Patient Discomfort at Highest Tolerable Shock Level   n   19 patients
22650,Requirement for Sedation at Different Shock Levels During Low Energy Transvenous Atrial Defibrillation
22651,Profiles of 15 Patients With Truncus Arteriosus Communis
22652,Logistic Regression Results for Early Discharge Model
22653,Percentage of Patients Discharged Within 5 Days of Coronary Artery Bypass Graft Surgery by State  a
22654,Logistic Regression Results for Death and Cardiovascular Readmission or Death Models
22656,Inclusion Criteria
22657,Patient Profile
22658,Univariate Regression Analysis of Variables That Predict Survival
22659,Frequency of Thrombolysis in Myocardial Infarction Grade 3, 2 and 1 Flow Achieved in Protocols 1 and 2
22662,Success Rate of Ultrasound Guided Compression Repair in Patients With or Without Anticoagulant Therapy, Pretreatment With a Compression Bandage and Length of the Aneurysm Track
22664,Patients Discharged From the Hospital With One or More Coronary Artery Bypass Grafts, All Listed Percutaneous Transluminal Coronary Angioplasty and Cardiac Catheterization Procedures by Race for Those 35 to 84 Years Old in the National Hospital Discharge Survey: United States, 1980 to 1993
22665,Hemodynamic and Echocardiographic Data at Each Pacing Rate and Pacing Site
22669,Reactive Hyperemic Response Before and 6 Months After Heart Transplantation
22670,Serum Phospholipid Fatty Acids and Lipids Before and 6 Months After Heart Transplantation
22671,Cyclosporine Doses Trough Values and Prednisolone Doses
22672,Patient Diagnoses by Primary Bidirectional Cavopulmonary Shunt and Mean Age
22673,Additional Procedures Performed at Bidirectional Cavopulmonary Shunt
22676,Morphometric Variables in Infants With Critical and Severe Pulmonary Valve Stenosis
22677,Catheterization and Balloon Pulmonary Valvuloplasty
22679,Distribution of Perfusion Defects in Patients With Abnormal Findings on Thallium 201 Exercise Myocardial Scintigraphy and Coronary Angiography
22681,Comparison of Follow Up Variables in African Americans and Whites
22684,Stratified Survival Analyses in African Americans and Whites
22686,Angiographic Results of Coronary Angioplasty in Elderly Patients With Unstable Angina
22687,Short Term Clinical Outcomes
22688,Kaplan Meier Survival Estimates for Denver High Risk Patients Treated With Coronary Angioplasty for Unstable Angina
22689,Clinical Failure of Attempted Coronary Angioplasty in 28   21    of 131 Elderly Patients With Unstable Angina
22691,NT proBNP Cutpoints for the Diagnosis or Exclusion of Acute Decompensated HF
22693,Comparisons of Area Under the ROC Curve Along With LR  and LR for BNP or NT proBNP Assays to Diagnose or Exclude Acute HF in Various Large Trials of Acute Dyspnea
22694,Median Values and Mutual Differences, Spearmans Correlation Coefficients, Coefficients of Determination, and AUC Values of Resting Diastolic Indexes With Respectto iFR
22696,Relative Risk   95  CI   of Cardiovascular Events According to Frequency of Nut Consumption
22697,Relative Risk   95  CI   of Cardiovascular Events According to Type of Nuts
22698,Appropriateness of TTEs Ordered by Intervention and Control Group
22699,Proportion of TTEs Ordered by Appropriateness Category and Treatment Group for Physicians With1 TTE Month
22701,Changes in LDL C and Other Lipids and Lipoproteins: Crossover Phase
22704,AE Frequency
22705,Examples of Food Items Constituting the 18 Food Groups   From the 1984 NHS FFQ
22709,Study Endpoints and Outcomes at the Maximum Available Follow Up
22713,Bivariable Proportional Hazards Regression
22714,Trend of Cardiovascular Risk Factors in the Study Cohort Across 2003 to 2011
22715,Multivariable Hierarchical Logistic Regression Model for In Hospital Mortality Among Patients With CLI Admitted to Hospitals During 2003 to 2011
22716,Subgroup Analyses for Death, Major Amputation, Likelihood of Any Revascularization, and Likelihood of Endovascular Revascularization in the Study Cohort on the Basis of A PrioriDefined Subgroups
22720,Clinical Outcomes in Matched Transcatheter Aortic Valve Replacement Plus Left Main Coronary Artery Percutaneous Coronary Intervention and Control Patients
22721,Clinical Outcomes According to Planned and Unplanned Left Main Coronary Artery Percutaneous Coronary Intervention
22722,Univariate Predictors of 30 Day and 1 Year Mortality After Transcatheter Aortic Valve Replacement Plus Left Main Coronary Artery Percutaneous Coronary Intervention
22724,Health Care Use in Later Life by Category of Midlife Fitness   N  19,571
22725,Incremental Decrease in Average Annual Health Care Costs in Later Life per MET Achieved in Midlife   N  19,571
22726,Health Care Use of CCLS Participants Surviving Through Medicare Follow Up Versus CCLS Participants Deceased During Medicare Follow Up by Category of Midlife Fitness   N  19,571
22729,Quality of Care and Clinical Outcomes by EHR Status
22732,Events by Tertiles
22733,Risk of Endpoints
22734,Risk of Endpoints by Tertile
22739,Association Results for Ejection Fraction Response
22741,Survival per Number of Pre Operative Malperfused Organ Systems
22742,Pre Operative Risk Factors for Any Post Operative Malperfusion
22743,Risk Factors for Post Operative Coronary Malperfusion
22744,Risk Factors for Post Operative Cerebral Malperfusion
22745,Risk Factors for Post Operative Visceral Malperfusion
22746,Risk Factors for Post Operative Renal Malperfusion
22747,Risk Factors for Post Operative Spinal Malperfusion
22748,Risk Factors for Post Operative Peripheral Malperfusion
22749,Risk Factors for Death
22751,Percentage of Women Recommended for StatinTherapy and Guideline Performance on the Basis of VaryingRisk Cutoffs
22752,Percentage of Men Recommended for Statin Therapy and Guideline Performance on the Basis of Varying Risk Cutoffs
22756,Reclassification of Study Participants Into Groups With Low, Medium, and High 15 Year Risk of CVD by Addition of Lp  a   toaModel Containing the Reynolds Risk Score Variables
22757,Improvement in 15 Year CVD Risk Prediction by Use of Lp  a   on Top of a Model Containing the Reynolds Risk Score Variables
22760,Comparison of the Clinical Profiles of Patients With or Without Coronary Events
22762,Coronary Events During the Follow Up Period
22763,Univariate Cox Regression Analysis of Risk Factors for All Coronary Events
22764,C Index Analysis Demonstrating Discrimination for Prediction of All Coronary Events
22765,Best Predictive Model Selected by Stepwise Cox Regression Analysis of Risk Factors for All Coronary Events
22767,Effects 7 Days Post Treatment Ordered According to Increasing NEPI Values
22769,FFR Thresholds on The Basis of Outcomes Using Various Models
22770,Summary of Published Data Comparing FFR Guided or FFR Assisted Strategy to an Anatomy Based Strategy
22771,SYNTAX Protocol and ARC ARC Like Definitions of ST and GO
22772,Association of First ARC ST or ARC Like GO Event With 5 Year Cardiac Death
22778,Risk of SBI or log WMHV Q4 Associated With the Presence of PFO or PFO ASA
22779,Risk of Ischemic Stroke and Combined Vascular Events by PFO ASA Status, in the Overall Study Population and in Age, Sex and Race Ethnicity Subgroups
22781,Difference in CT Parameters Between Patients With and Patients Without ACS for Conventional CT Reading and Semiautomated Quantitative Parameters
22790,One Year Mortality HRs Stratified by Age Groups Adjusted for Sex, Age, Comorbidity, and Pharmacotherapy
22791,Long Term Mortality HRs Stratified by Age Groups Adjusted for Sex, Age, Comorbidity, and Pharmacotherapy
22792,Event Rates and HRs of Recurrent Syncope Stratified by Age Groups Adjusted for Sex, Age, Comorbidity, and Pharmacotherapy
22794,Baseline Lesion Characteristics and Procedural Parameters
22795,Angiographic Endpoints at 12 Month Follow Up
22796,Clinical Endpoints at 12 Month Follow Up
22798,Operative Details of Staged Palliative Procedures
22805,Predictors of Incident Heart Failure in Multivariate Analysis   N   5,934
22807,Cost of Health According to Study Assignment    AU
22809,Echocardiographic and Clinical Response to CRT
22817,Factors Predictive of VT Recurrence After Ablation
22819,Differences in OCT Measurements Between Stenoses With FFR  0.80 or 0.80
22820,Differences in IVUS Measurements Between Stenoses With FFR  0.80 or 0.80
22821,Coding Sequence Variants Identified in K  Channel Genes
22822,Distribution of Variants in AF Probands and Control Subjects
22823,Effects of K  Gene Variants on In Vitro Cellular Electrophysiology and Post Translational Modification
22824,Descriptors
22825,Primary Events by Sex
22826,All Cause Mortality by Sex
22834,Predictors for Composites of Death, MI, Repeat PCI, or CABG at 1 Year
22836,Homocysteine and CV Outcomes in the MESA Population
22837,Homocysteine and CV Mortality in the NHANES III Population
22838,Comparison of Risk Prediction Models With FRS With and Without Homocysteine in the MESA and NHANES III Cohorts
22839,6 Year Risk of Hard CHD Event in the MESA Population in Models With and Without Homocysteine
22840,Ten Year Risk of CHD Death in the NHANES III Population in Models With and Without Homocysteine
22845,Electrocardiographic Measurements and Sites of Successful Ablation in the Retrospective Cohort
22848,Value of NGAL Complements Prognosis in Patients Without Diagnostic Creatinine Increase
22849,Outcome According to Urine NGAL Versus Plasma NGAL
22850,Possible Combinations of NGAL and sCREA Status
22853,Incidence of Neoatherosclerosis Stratified by Duration of Implant
22855,Independent Risk Factors for Neoatherosclerosis
22858,Multivariate Analysis   Total Population  : Predictors of First and Recurrent Syncopal Events
22859,Multivariate Analysis   Cox Model  : Recurrent Syncope as a Predictor of ACA SCD
22860,FDA Label: Range of Expected Therapeutic Warfarin Doses   mg day   Based on CYP2C9 and VKORC1 Genotypes
22861,IWPC Cohort: Mean Therapeutic Warfarin Dose   mg day   by CYP2C9 and VKORC1 Genotype in 2,858 Patients
22863,Percentage of Participants Who Reported Use of Pharmacologic Aids for Smoking Cessation During Study Period on 6 Month Survey   n   95
22864,Relationship Between Study Condition and Abstinence at 3  and 6 Month Follow Up
22866,12 Month Results by Randomization in the Non IHD and IHD Groups and Their Interaction by Regression Model
22869,Conventional Risk Factors and Biomarkers for Prediction of Incident HF and AF
22870,Discrimination and Risk Category Reclassification Using Biomarkers
22871,Risk Classification by Models With and Without Biomarkers for HF or AF
22876,Comparison of Risk During Follow Up of Patients in Coenzyme Q10 Tertile 1 Compared to Tertile 3 in the Placebo Group
22879,3 Dimensional Electroanatomic Atrial Mapping Data
22880,Endocardial Conduction During NCAS AT and Pacing Protocol
22882,Readmission Rates According to Group Assignment and Depressive Symptoms
22884,Morphometric Comparison Between Flow Divider Versus Lateral Wall in DES and BMS
22887,Clinical Outcomes After Intervention
22888,Cumulative Incidence of Amputation: Univariate Fine Gray Analysis
22889,Cox Analysis Overall Survival
22890,Comparison of Outcomes in the PaRADISE Study Versus BASIL Study: Amputation Free Survival and Overall Survival
22896,Scan Parameters in Groups 1 and 2
22897,Comparison of Evaluability and Artifacts in Groups 1 and 2
22898,Comparison of Image Quality Score in Groups 1 and 2
22899,Comparison of the Diagnostic Accuracy of MDCT for the Detection of Significant    50    Coronary Stenosis and In Stent Restenosis Between Groups 1 and 2
22900,Comparison of Multidetector Computed Tomography Radiation Dose Parameters in Groups 1 and 2
22902,Coronary Wall MRI Measurements
22905,Multivariable Results for Those With Available Follow Up Medication Information   n   7,719
22911,Distribution of HLHS and Associated CVM in 33 Families   208 Individuals
22912,Distribution of BAV and Associated CVM in 102 Families   805 Individuals
22917,Effects of Shock Strength
22920,Patient Management
22921,Diagnostic Performance of CCA and CTCA to Detect a Functionally Significant Coronary Stenosis   FFR  0.75, FFR  0.80
22924,Independent Predictors of AF According to Stepwise Logistic Regression Analysis
22925,Frequency of Occurrence of Unicuspid and Bicuspid Aortic Valves Morphologies   n   63
22926,Cusp Morphology and Corresponding Repair Maneuvers
22927,Commissure Morphology and Corresponding Repair Maneuvers
22929,Multiple Regression Analyses
22931,Intraobserver and Interobserver Variability for the Different LV Dyssynchrony Parameters
22938,Linkage in Family VAF 1 to Markers at 5p15
22939,Endothelial Cell Specificity of Angiogenesis Assay
22940,Comparison of Early EPCs and OECs
22942,Predictors of High Telomerase Activity in Coronary Plaque Neutrophils in Unstable Angina
22944,Relationships Between Load and E E
22945,Relationships Between Load and S
22946,Relationships Between Load and Late Diastolic   A   Filling
22947,HTN Versus Non HTN Subjects
22949,Below Heart Level Measurements
22950,Heart Level Measurements
22955,Association of the 3 SNPs With CHD in the First Population
22956,Association of the 3 SNPs With CHD in the Second Population
22958,IVUS Measurements
22960,IVUS Measurements Stratified by the Remodeling Index
22961,Temperature Difference Stratified by Remodeling Index and Type of Syndrome
22962,Temperature Difference Stratified by Plaque Rupture and Type of Syndrome
22965,Prevalence of CAC at Year 15 in the CARDIA Study, 2000 to 2001
22972,Pulmonary Function Tests and Selective Blood Tests in 88 Patients With or Without Central Sleep Apnea
22973,Univariate Analysis for Survival Time and 24 Related Variables in 88 Patients With Systolic Heart Failure
22976,Agreement Between Differential Lung Perfusion Estimated by PS Versus Magnetic Resonance Flow Measurements
22978,Effect of Covariate Adjustments on the Association Between Gender and 30 Day Mortality
22982,Survival Benefit of ICD by SBP and DBP Quartiles
22988,Medication Usage of Patients With and Without Stent Thrombosis
22989,Univariate and Multivariate Predictors of Stent Thrombosis
22993,Mortality Risk of Calendar Year 2000 Relative to 1980, Stratified by Age for the Overall Population and Various Subgroups
22994,Multivariable Models for Prediction of Early   Within 4 Months   or Late Death   After 4 Months
22995,Catheterization Data Before and After Initial Stent Placement
22996,Echocardiographic Data Before and After Initial Stent Placement
22998,Variability of Ejection Fraction Determinations   EF Units
23000,Outcomes at 3 Years
23001,Age Adjusted Odds Ratios   With 95  Confidence Intervals   for Elevated EDPR and TR gradients
23002,Multivariate Adjusted    Odds Ratios   With 95  Confidence Intervals   per 5 mm Hg Increase in EDPR or 10 mm Hg Increase in TR
23004,Number of Veins Affected in Each Patient With the Associated Other Veins and the Total Stenosis Index of the Veins Draining Each Lung
23008,Animals and Study Protocol
23011,Quantitative Measurements in Venous Anatomy From MSCT
23014,Effects of Elastic Bandage During Tilt Testing in the 20 Patients With Progressive Orthostatic Hypotension
23017,Multivariate Predictors of Plaque Plus Media Cross Sectional Area Increase
23018,Laboratory Tests and Serial IVUS Data of Patients With and Without Clinical End Points and or Revascularization Procedures During Follow Up
23019,Multivariate Predictors of Adverse Cardiovascular Events   Clinical End Points and or Revascularization Procedures   During Follow Up
23022,Antidepressant Therapy
23024,Metabolic Markers in the Subset of 20 Patients With Available Fasting Plasma
23026,Predictors of Outcome in Univariate and Multivariate Analysis
23031,Major Adverse Cardiac and Cardiovascular Events: In Hospital and During Follow Up
23032,Oral Sirolimus Group at Baseline and at 21 Days: Laboratory Results and Adverse Reactions
23033,Results of Quantitative Coronary Angiography
23036,Indications for Insertion of Covered CP Stents
23037,Results
23040,Current Medication of the Study Population
23041,Multivariate Linear Regression Analysis
23043,Sensitivity, Specificity, and Positive and Negative Predictive Values of SPWMD 130 ms for Reverse Remodeling and Clinical Improvement
23046,Patients With Complications During InSync III Implant Attempts and Follow Up
23047,Percentage Improvement in Stroke Volume
23048,Percent Improvement in Stroke Volume for the Subset of Patients With Maximum Stroke Volume at a V V Delay Other Than Nominal
23053,Expert Panel ECG Diagnoses
23056,P Wave Morphology During Tachycardia
23058,Serial Three Dimensional Intravascular Ultrasound Analysis of Neointima and Plaque Volume
23059,Percent Hypoechogenic Tissue Component in the Plaque and Neointima
23062,Graft Index for All Cause Death Without Left Main or IMA Adjustment
23063,Graft Index With Left Main and Internal Mammary Adjustments Recalculated Using All Patients
23064,Training Set Models for All Cause Death   n   2,729
23065,Validation Set Models for All Cause Death   n   449
23066,Models for All Cause Death With the Graft Index and Clinical Variables
23067,Models for Death or Revascularization With the Graft Index and Clinical Variables
23069,ARI Restitution Slope and Magnitude of Restitution
23070,Clinical and Angiographic Data of the Patients   n   89
23072,Fractional Flow Reserve and Angiographic Percent Stenosis in Jailed SideBranches
23074,Procedural, QCA, and IVUS Data for Non LM Lesions With IVUS of Both Branches   n   20
23075,Comparison Between IC Versus CC in Patients With Non Left Main Lesions and IVUS of Both Branches
23076,Procedural, QCA, and IVUS Data LM Lesions With IVUS of Both Branches   n   5
23078,Angiographic Data
23079,Exercise Hemodynamics
23081,Details of Segmental Coronary Anatomy in the Patient Population as Defined by QCA and Diagnostic Accuracy of Visual Analysis
23082,Reasons for False Positive and Negative Evaluations by MR and MDCT
23083,Sensitivity and Specificity of Wavelet Analysis of Radiofrequency Intravascular Ultrasound Signals for Detecting Lipid Laden Plaque
23084,P Wave Morphology
23086,5 M ADP Induced Aggregation and Clopidogrel Responsiveness
23087,20 M ADP Induced Aggregation and Clopidogrel Responsiveness
23089,24 h Holter Monitoring Analysis in Patients With Successful Procedure
23090,Patients Symptoms and Medications Before Radiofrequency Catheter Ablation
23091,Follow Up Data of Patients With Unsuccessful Procedure
23095,Postoperative Doppler Echocardiographic Data
23096,Independent Determinants of Postoperative Systolic Pulmonary Arterial Pressure
23097,Measurements of LV Chamber and Mitral Apparatus
23107,Plasma Lipids
23110,Clinical and Thyroid Profile in Control Subjects and Patients With Subclinical Hypothyroidism Before Therapy   All Patients Enrolled
23111,Clinical and Thyroid Profile in Subclinical Hypothyroidism Patients Before and After Therapy
23112,Morphologic and Global Functional Parameters of the Left Ventricle in Control Subjects and Subclinical Hypothyroidism Patients Before Therapy   All Patients Enrolled
23113,Morphologic and Global Functional Parameters of the Left Ventricle in the Subclinical Hypothyroidism Patients Before and After Therapy
23114,Anatomic Results of MSCT Versus ICE
23115,Measurements of Ostia Pulmonary Veins: MSCT Versus ICE
23116,Indexes of Diameters Measured in Anterior Posterior and Superior Inferior Direction of Pulmonary Venous Ostia, as Measured With MSCT
23118,Status of Study Patients at Each Angiographic Period
23121,Predictors of Long Term Graft Occlusion Using All Grafts
23122,Predictors of Long Term Graft Occlusion Given Grafts Were Open Early
23124,Acute Hemodynamics Effects of CRT
23125,Mid Term Changes Associated With CRT
23133,Individual Recurrent Events Grouped by Treatment Allocation
23135,Right Heart Catheterization Data of Patients Stratified by Severity of Tricuspid Regurgitation After Pulmonary Thromboendarterectomy
23137,Angiographic and IVUS Measurements at Postprocedure
23138,Diagnostic Values of Optimal Threshold for SES and BMS
23140,Clinical and Angiographic Data
23141,Coronary Flow Velocity Data
23143,Results of Quantitative Coronary Angiography
23144,Two Dimensional Quantitative Intravascular Ultrasound Results
23145,Three Dimensional Quantitative Intravascular Ultrasound Results
23146,Standardized Interpretative Advice Accompanying N BNP Results
23148,Change in Correct Diagnoses of Patients Presenting With Suspected HF in BNP and Control Groups
23155,Adverse Events
23157,In Hospital and One Year Clinical Events
23158,Initial and Follow Up Angiographic Results
23159,Transthoracic Impedance and Current
23160,Shock Induced Toxicity
23161,Comparison of Patients With CTOs With and Without TVF
23167,The P Wave Morphology During Tachycardia
23171,Angiographic and Hemodynamic Data in Seven Dogs
23172,Clinical, Angiographic, and Hemodynamic Data in Angina Patients
23174,Comparison of Electrophysiological Parameters in Ntg and Tg Mice
23175,Echocardiographic and Hemodynamic Parameters Are Summarized for 4 , 8 , and 9  to 12 Month Old Ntg and Tg Mice
23178,Outcomes by Heart Failure Etiology and Treatment Assignment
23179,Discharge Medications by Heart Failure Etiology and Treatment Assignment
23181,In Hospital Outcomes
23182,Multivariate Logistic Regression Model
23184,Unadjusted Outcomes
23190,Final Multiple Variable Cox Regression Model Showing the Independent Protective Effect of Statins
23193,Clinical Outcomes, Electrocardiographic and Hemodynamic Data for the SCD and Control Groups
23195,Regional and Global Left Ventricular Ejection Fraction
23198,Study 2: Effects of Placebo, Sildenafil, and Isosorbide Dinitrate on Exercise Parameters
23199,Stent Engineering Data
23200,Crossing Profile
23201,Stent Consumers Guide
23203,Left Ventricular Volumes and Regional Myocardial Shortening During Long Term Follow Up in Survivors   n   20
23209,Anatomic Combinations of Site of Endocardial Pacing Leads
23210,Single Site Pacing
23211,Biatrial Pacing
23212,Hematologic and Coagulation Values in Each Animal Before and 60 Min After Stent Placement and Histomorphometric Values of Sections of Stented Blood Vessels
23216,Treadmill Exercise Time to Moderate Angina   s
23219,Patients With Aneurysm After Surgical Coarctation Repair
23220,Patients With and Without Aneurysm After Coarctation Repair
23221,Reported Prevalence of Aortic Aneurysm After Coarctation Repair
23222,Multivariate Analysis
23223,Histologic and Morphometric Analysis of the Effects of the Different dODN in the Coronary Angioplasty Model
23224,Estimated Mean Number of Microbubbles After Agitation of 10  Air 90  Saline Mixture, 10  Air 10  Blood 80  Saline Mixture and 10  Air 10  Plasma 80  Saline Mixture legend
23227,Morphologic and Morphometric IVUS parameters
23229,Logistic Regression Model for Predicting Risk of In hospital Death After CABG
23230,Observed In hospital CABG Mortality Rates at Low  and High volume Hospitals Across Risk Groups
23231,Observed Lenth of Stay and Hospital Costs of CABG at Low  and High volume Hospitals Across Risk Groups
23232,Estimated Outcomes of Full and Targeted Regionalization of CABG
23237,Quantitative Coronary Angiography Measurements   means  SE
23238,Intravascular Ultrasound Area Measurements in mm2  means  SE
23239,Relative EEL Areas
23240,Hemodynamic Data Obtained by Electromagnectic Flow Probes and Meters legend
23241,Echocardiographic Assessment of Left Ventricular Volumes: Comparison With EBCT legend legend
23242,Intraobserver and Interobserver Variabilities legend
23243,Components of Global Variability  : Impact of Adding Contrast Injection on the Relative Distribution of Sources of Variability legend
23245,Admission, HF WG, Peak and Subsequent WTs and Corresponding ECG Variables of Patients   n   28   legend legend
23247,Procedural Variables legend legend
23248,In Hospital Results legend legend
23249,Vascular Complications legend
23250,Predictors of Complications legend legend
23253,Fall History and Loss of Balance as Predictors of Falls During One Year Follow up legend
23254,Association between Orthostatic Blood Pressure Decline and Incidence of Falls on Follow up legend legend
23255,Association of Antihypertensive Therapy With Falls on Follow up legend
23256,Multiple Logistic Regression Analysis With Falls on Follow up as Dependent Variable legend
23258,Correlations Between Echocardiographic Variables and Mean Left Atrial Pressure legend
23261,Macrophage Count, Apoptosis Evaluation and Cell Death legend
23263,Qualitative Angiographic and IVUS Data legend
23264,Quantitative IVUS Parameters legend legend
23265,Definitions of Clinical Criteria for the Presence of Atherosclerotic Vascular Disease and Risk Factors
23269,Serial Echocardiogram Readings   n   219   legend
23270,Side By Side Reads   n   219   legend
23271,Reader Agreement: Serial Versus Side by side Reads Percentage Exact Agreement and Kappa Coefficients    legend
23272,Comparison of Anterior and Posterior Right Atrial Electrogram Fractionation legend
23276,Serial Two dimensional Ultrasound Results legend
23277,Serial Volumetric Ultrasound Results in the Peristent Margins
23279,Per Patient Analysis   n   127  : Accuracy for CFVR, rCFVR and FFR Versus the Results of Sestambi Single Photon Emission Computed Tomography, Calculated for Best and Predefined Cut Off Values legend legend
23280,Results of Previous Validation Studies for Intracoronary Derived CFVR, FFR and rCFVR Versus the Results of Noninvasive Stress Testing legend
23281,Effects of Lipid Lowering Treatment on Lipid Moieties legend
23282,Assessment of Coronary Artery Acetylcholine Responses, Pre  and Postlipid Lowering legend
23286,NCP, Adenonucleotides, Glycogen and Lactate in Myocardial Biopsies legend legend
23289,Intraoperative and Postoperative Course for CABG Versus MIDCAB legend
23290,Results of Univariate Logistic Regression for Postoperative AF legend
23291,Results of Multivariate Logistic Regression of Postoperative AF legend
23293,CABG Mortality, Complications, and Length of Stay by Race
23294,Comparison of Operative Mortality for Specific Subpopulations
23295,Multivariate Logistic Regression Model by Race
23297,Preintervention, Post DCA and Stenting and Follow up Quantitative Angiographic Measurements   QCA Analysis   legend
23298,PFO Detection by Three Echocardiographic Methods legend
23299,Prediction of PFO Opening Diameter by TMD Bubble Score legend
23302,Coronary Epicardial and Microvascular Responses According to the AT1 Receptor Gene Polymorphism legend legend
23303,Patient Distribution by Pacing Mode and Therapy Delivery   n   32
23304,Number of Therapy Episodes in the 32 Data Pairs During Each of the 3 Month BV   Biventricular   Pacing and No Pacing Periods
23307,Diagnostic Values of Various Thresholds of VCW to Identify Severe TR legend
23309,Kaplan Meyer Analysis for Major Events legend
23310,Cox Regression Analysis for Major Events legend
23311,Stepwise Multiple Regression Analysis on Pooled Data to Identify Determinants of PV Flow Variables
23316,Multivariate Predictors of SEC in NSR legend
23319,Relationship Between Ultrasound Power and Endothelial Vascular Endothelial Growth Factor Uptake With a Plateau Beyond 0.6 to 0.8 W cm2  legend
23320,Enhanced Endothelial VEGF Uptake With US and Contrast Agent After Intravenous Injection    legend
23322,Determinants of Natriuretic Peptide Levels in Multivariate Analysis legend
23324,Apolipoprotein E Genotype Frequencies in a Sample From the General Population and in Patients With IHD
23325,Fractions of IHD in the General Population Attributed to APOE Genotypes   Relative to the epsilon33 Genotype   and to Conventional Cardiovascular Risk Factors legend
23327,Late Lumen Loss and Relative Late Lumen Loss in Different Segments legend
23328,Distribution of Angiographic and IVUS Dimensions After PTCA Among Different Segments legend
23329,Multivariate Predictors of Late Lumen Loss and Relative Late Lumen Loss legend
23330,Uninterpretable and Sure Confidence Scores legend
23331,Wall Motion: Improved Confidence Scores legend
23332,Evaluating Segmental Wall Motion and Ejection Fragment
23333,Ejection Fraction Confidence Score legend
23337,Relation Between Electrocardiographic Signs of Severe Ischemia During PTCA and Three Variables for Assessing the Recruitable Collateral Extent legend
23339,Study Design: Digital Sequence Subsets
23340,Diagnostic Feature Types Within the 100 Digital Angiograms
23342,Hemodynamic and Angiographic Parameters Before and After BA   No Missing Values
23343,Left Ventricular   LVEF   and Right Ventricular   RVEF   Ejection Fractions, Left Ventricular   LVMP   and Right Ventricular   RVMP   Mean Phases, Left to Right Mean Phase Difference   L RMP   and Phase Standard Deviations   LVPSD and RVPSD   for Both Ventricles in 14 Cases of Right Sided WPW legend
23344,Left Ventricular and Right Ventricular Ejection Fractions, Left Ventricular and Right Ventricular Mean Phases, Left to Right Mean Phase Difference   L RMP   and Phase Standard Deviations for Both Ventricles in 30 Cases of Left Sided WPW legend
23345,Effect of Transthoracic Impedance on Delivered Current   A
23347,First Shock Defibrillation Data for Monophasic and Biphasic Waveform Groups
23348,Patients Stratification legend
23349,Quality of Life Questionnaire
23357,Analysis of Lumen Dynamics legend
23358,Cumulative One Year Clinical Outcome legend legend
23360,Plasma Neurohormone Concentrations for Both Groups at Rest and Peak Treadmill Exercise Both Before and After 16 Weeks of Exercise Training or Control Period legend
23361,Values of Transmitral and Pulmonary Venous Flow Parameters and Their Correlations With LA dP dtmax  legend
23365,Procedural Outcomes and Clinical Events legend legend
23366,Quantitative Angiographic Results legend legend
23367,Final Intracoronary Ultrasound Results legend legend
23371,Associations of Angiographic Findings With Exercise and Recovery Blood Pressure Ratios legend
23372,Logistic Regression Analyses in Which Exercise and Recovery Blood Pressure Ratios Are Adjusted for Potential Confounders legend legend
23373,Logistic Regression Analyses in Which Potential Confounders, Recovery Systolic Blood Pressure Declines and Exercise Systolic Blood Pressure Increases Are Considered Together legend legend
23374,Measured Electrical Parameters at Defibrillation Threshold
23375,Comparison of Clinical Parameters of the High and Low Atrial Defibrillation Threshold Groups
23377,Hemodynamic and Procedural Variables for the Initial and Redo Percutaneous Mitral Balloon Valvuloplasty   PMV
23378,Independent Predictors of Long Term Event Free Survival   Multivariate Cox Regression Analysis   legend
23379,Color and Pulsed Wave Doppler Quality Before and After Contrast Enhancement legend
23380,Blood Flow Velocity and CFR Determined in the Left Anterior Descending Coronary Artery legend
23382,Floating Scheme of Patients Throughout the Study
23388,Restenosis Rate Per Patient and Per Treated Lesion in the Two Treatment Groups legend
23391,Primary Clinical Outcome Events legend
23393,Relationship of Preprocedural Heparin to Antithrombin Activity
23394,Association of Antithrombin Activity With Primary Outcome Events legend
23396,Relationship of Restenosis and Antithrombin Activity
23398,The Nucleotide Sequence of All Primers Used in the Study legend
23399,The Messenger Ribonucleic Acid Levels of Calcium Handling Proteins in Patients With and Without Persistent Atrial Fibrillation for More than 3 Months legend
23400,The p Values of Correlation Between Messenger Ribonucleic Acid Levels of Calcium Handling Genes and Clinical Parameters legend
23401,Effect of Pravastatin on Hospital Admissions by Trial Category legend legend
23402,Difference in Mean Number of Patients Hospitalized, Number of Admissions and Total Bed Days per 1,000 Subject Years legend
23404,Passive Compared With Single Stage Isoproterenol Tilt Table Testing
23408,Angiographic End Point Analysis According to Quintiles
23410,Primary Angiographic and Clinical End Point Analysis After Controlling for the Effect of Concomitant Therapy    legend
23412,Alterations in Skeletal Muscle Biopsies From CHF Patients legend
23414,Implantation Procedures  legend
23415,Defibrillation Threshold Data legend
23418,Simple Linear Regression Correlation Matrix Between Dpl RVol and Echocardiographic Left Atrial and Doppler Variables in the Study Population legend
23419,Multiple Linear Regression Analysis Relating Echocardiographic and Doppler Variables to Dpl RV in the Study Population legend
23420,Serial Volumetric IVUS Results in All 31 Lesions  legend
23423,Final Angiographic Results After PTCA Alone or Debulking Plus Adjunctive PTCA  legend
23424,One Year Event Rates According to Kaplan Meier Analysis  legend
23425,Univariate and Multivariate Predictors of Target Vessel Revascularization legend
23426,Individual and Group Hemodynamics legend
23427,Echocardiographic and Doppler Variables Before and After Therapy
23428,Individual Changes in Mitral Regurgitation Associated with Heart Failure Therapy
23429,Patient Data  legend
23430,Hemodynamic and Electrophysiologic Data With the Three Pacing Modes Tested legend
23431,Individual Hemodynamic Data in the Different Pacing Modes   AAI, DDD RVA, DDD RVOT, DDD Biventricular   legend
23432,Comparison of Responder and Nonresponder Patients legend
23437,Procedural and Short Term Events
23438,Stent Type Distribution in Patients With Follow up Angiography  legend
23440,A Comparison Between Patients With and Without Restenosis in the Total Cohort With IVUS Guided Stenting
23441,Multivariate Predictors of Freedom From Restenosis in Patients With IVUS Guided Stenting in the Total Cohort: Stepwise Multivariate Logistic Regression Analysis
23443,Exclusion of Atrioventricular Reentrant Tachycardia   AVRT   and Atrial Tachycardia  legend
23444,Retrograde AV Nodal Conduction Time During Ventricular Pacing Versus Tachycardia  legend
23445,Demonstration of Atrial Dissociation Between the CS Orifice and the LSRA  legend
23447,Angiographic and Intravascular Ultrasound Measurements in the Restenosis or No Restenosis Groups  legend
23448,Predictors of In stent Restenosis by Logistic Regression Analysis   n   1,501    legend
23449,Predictors of In stent Restenosis in Lesions With Intravascular Ultrasound Guidance by Multivariate Logistic Regression Analsyis   n   1,054   legend
23450,Quantitative Measures of Regurgitant Volume Overload legend
23451,Value of the Aortic Effective Regurgitant Orifice Area Calculated With the Proximal Isovelocity Surface Area Method and Quantitative Doppler and Two Dimensional Echocardiographic Methods in the Overall Study Group and in Subgroups of Patients
23453,Hemodynamic Measures On Individual Patients Before and After NO and Nifedpine  legend legend
23454,Principal Diagnostic Categories   n   103
23455,Risk Factors Assessed for the Development of Systemic Venous Collaterals
23456,Types of Decompressing Venous Channels
23457,Hemodynamic Data Before and After Bidirectional Cavopulmonary Anastomosis  legend
23459,Molecular Markers of Coagulation Activation and Endothelial Cell Damage in the Groups of Hypertensive Subjects With Different ACE Genotypes legend legend
23460,Relationships Between Molecular Markers of Coagulation Activation and Endothelial Cell Damage and Blood Pressure in the Groups of Hypertensive Subjects With Different ACE Genotypes legend
23461,Levels of Markers of Endothelial Cell Damage in the Groups of Normotensive Subjects With Different ACE Genotypes  legend
23464,Time Constant of Force Decay   Tau    legend
23466,Process of Care Measures in Patients With Fee for Service Versus Managed Care Insurance  legend
23467,Hospital Outcomes in Patients With Fee for Service Versus Managed Care Insurance
23468,Defibrillation Thresholds   DFTs   and Ventricular Fibrillation   VF   Duration in Protocol 1
23469,Defibrillation Thresholds   DFTs   and Ventricular Fibrillation   VF   Duration for Right Versus Left Ventricle VF Inductions   Protocol 2
23472,Independent Transesophageal Echocardiographic Correlates of Thromboembolic Risk: Multivariate Analysis
23476,Summary Data of Relative Conduction Times
23477,Comparison Between Intravenous Electron Beam Coronary Angiography and Selective Coronary Angiography in 330 Segments Comprising the Major Coronary Arteries and Side Branches in 28 Patients legend
23478,Comparison Between Intravenous Electron Beam Coronary Angiography and Selective Coronary Angiography in 221 Segments Comprising the Proximal and Mid Major Coronary Arteries   eight segment model   in 28 Patients  legend
23479,Sensitivity and Specificity Data for the Detection of Angiographically Significant Stenoses   50  diameter stenosis   With Electron Beam Computed Tomography legend
23480,Analysis of Coronary Segments   12 per patient   by Intravenous Electron Beam Computed Tomographic Coronary Angiography legend
23484,Major Cardiac Events During 6 Month Follow Up in 463 Patients With Successful Coronary Stenting
23485,Acute Results and 6 Month Follow Up   405 lesions
23486,Univariate Predictors of Restenosis: Clinical Variables
23487,Univariate Predictors of Restenosis: Lesion Related Variables
23488,Univariate Predictors of Restenosis: Procedural Variables
23489,Multiple Linear Regression for the Dependent Variable of Late Loss
23490,Multiple Logistic Regression Analysis for the Dependent Variable of Restenosis  a
23493,Intergroup Differences in Efficacy Criteria During Six Month Trial
23494,Change in Degree of Stenosis During Six Month Trial
23495,Groups 2 to 4: Mean   SD   Neointimal Thickness by Mean Injury Score
23497,Echocardiographic Data
23498,Echocardiographic Doppler Assessment of Mitral Regurgitation
23499,Test Accuracy of Pulmonary Venous Flow Velocity Ratios for Different Degrees of Mitral Regurgitation
23501,Sensitivity and Specificity for the Presence of Four or More Segments With a Biphasic Response on the Preoperative Dobutamine Echocardiogram to Predict 5  Improvement in Left Ventricular Ejection Fraction Late After Revascularization
23502,Localization of Critical Lesions Underestimated or Undetected by Conventional Projections
23505,Comparison of Rest Potential, APD50and APD90in Cells From Either a Paced or Control Dog Studied in the Current Clamp Mode by Perforated Patch   n   5 paced, n   5 control   or in the Whole Cell Mode Before Dialysis   n   10 paced, n   12 control
23506,Comparison of Action Potential Duration Variability Before and After Dialysis in Cells From Paced and Control Animals
23508,Regression Analyses of Association Between Hemodynamic Variables and Plasma or Pericardial Fluid Levels of Atrial and Brain Natriuretic Peptides
23509,Influence of Myocardial Ischemia on Atrial and Brain Natriuretic Peptide Levels in Plasma or Pericardial Fluid  a
23513,Statistical Comparisons of Frequency of Interventions by Study Site Location
23514,Stepwise Logistic Regression Analysis  a
23517,Hemodynamic Measurements During Treadmill Exercise Before and After Administration of N Nitro l Arginine
23518,Myocardial Blood Flow and Subendocardial Subepicardial Blood Flow Ratio in Normal and Collateral Dependent Myocardium During Exercise
23519,Mean Myocardial Blood Flow and Coronary and Collateral Vascular Resistance During Exercise
23520,Hemodynamic Variables and Mean Myocardial Blood Flow During Rest   group 2
23521,Clinical, Doppler and Echocardiographic Variables in Normal Subjects and Those With the Three Grades of Mitral Regurgitation
23522,Sensitivity, Specificity and Positive Predictive Value of Peak E Wave Velocity  1.2 m s for Identifying Severe Mitral Regurgitation in Normal and Low Ejection Fraction Groups
23523,Clinical and Echocardiographic Variables
23524,Patient Data
23525,Hemodynamic Findings Before and After Stent Implantation
23528,Study Group
23529,Patients Without Ischemic Response During First Balloon Inflation
23530,Patients With No or Diminished Angina During Balloon Inflation
23531,Patients With No or Diminished ST Segment Shift During Balloon Inflation
23532,Patients With No or Diminished Angina Plus ST Segment Shift During Balloon Inflation
23533,Surgical Risk Factors in Combined Cardiac Care Network of Ontario Canadian Institute for Health Information Database
23534,Prevalence and In Hospital Mortality Rates for Different Surgical Risk Factors After Coronary Artery Bypass Graft Surgery in Ontario, Canada, 1993   5,517 patients
23535,Odds Ratios and p Values of Variables in Increasingly Comprehensive Risk Adjustment Models
23538,Quantitative Angiographic Analysis of Index Lesion
23539,Univariate Analysis for Prediction of Restenosis
23540,Multivariate Analysis for Prediction of Restenosis
23541,Group 1   anterograde approach  : Clinical and Hemodynamic Data
23542,Group 2   retrograde approach  : Clinical and Hemodynamic Data
23543,Comparison of Anterograde and Retrograde Approaches to Aortic Valve Dilation in Neonates
23544,Comparison of On Line and Off Line Intravascular Ultrasound Analyses
23546,Sensitivity and Specificity of Fluorine 18 Fluorodeoxyglucose Single Photon Emission Computed Tomography for Predicting Functional Recovery After Revascularization in Different Subsets of Segments
23547,Sensitivity and Specificity of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography for Detecting Improvement in Regional Contractile Function After Revascularization  a
23548,Aortic Valve Area Determined by Transthoracic Planimetry, Continuity Equation, Transesophageal Planimetry and Gorlin Formula in 42 Patients
23550,Angiographic and Hemodynamic Data
23551,Correlations
23553,Vascular Study Results for the Chinese and White Subjects
23554,Multivariate Analysis for the Determinants of Endothelium Dependent Dilation in the White and Chinese Subjects
23555,Quantitative Coronary Angiographic Data
23556,Intravascular Ultrasound Dimensions in 17 Patients
23557,Coronary Flow Velocity Data
23558,Correlation Between Anatomic and Physiologic Variables
23559,Clinical and Angiographic Data for 57 Patients Before Coronary Angioplasty
23564,Correlation Between Coronary Vascular Resistance and the Neurotransmitters   neuropeptide Y and norepinephrine   in Protocol 1
23565,Exclusion Criteria
23568,Quantitative and Qualitative Coronary Analysis
23569,Procedural Outcome and Events  a
23570,All Major Adverse Cardiac Events and Their Ranking From PTCA Coronary Angioplasty to 1 Month Follow Up   intention to treat
23571,Relation of Observed Frequency of Syncopal Spells After Tilt Test to Time to First Syncopal Spell After Tilt  a
23572,Relation Between Time to First Recurrence of Syncope and Observed Frequency of Syncopal Spells in Selected Subgroups  a
23573,Examples of Necessary Indications for Bypass Surgery, Coronary Angioplasty and Bypass Surgery or Coronary Angioplasty
23575,Receipt of Bypass Surgery or Coronary Angioplasty by Type of Necessary Procedure
23583,Interim Operative Procedures Performed in 38 Stage I Operative Survivors Before Stage II Operation
23584,Stage II Operations Performed in 72 Patients During Study Period
23585,Concomitant Procedures Performed in 28 Patients at Time of Stage II Operation
23586,Early and Late Mortality After Stage II Operation Classified by Type of Stage II Procedure
23587,Stage II Hospital Mortality Risk Factor Analysis
23589,Univariate and Multivariate Correlates of Pulmonary Capillary Wedge Pressure
23590,Univariate and Multivariate Correlates of Color M Mode Flow Propagation Velocity
23591,Retrospective Analysis of Retrograde P Waves in Atrioventricular Reciprocating Tachycardia
23592,Incorrect Prediction of Tachycardia Mechanism and Accessory Pathway Location in 15 Patients
23593,Patients With Coronary Artery Obstruction
23596,Technical and Procedural Performance
23598,Clinical Outcomes at 12 Months   Frequentist Analysis
23600,Use of Guideline Recommended Acute Medications    and Procedures
23603,Treatment of Patients With LAST
23607,Polymer Based Comparator Drug Eluting and MULTI LINK Vision Bare Metal Stent
23610,Validation of CTCA Compared With ICA for In Stent Restenosis
23611,Comparison of the ISR Classification Between ICA and CTCA
23612,Correlation of Semiquantitative CTCA Grade With  DS on ICA
23613,MGS Values of Injured   Enhanced   Endothelial Segments Versus Non Injured   Non Enhanced   Segments 5 Minutes After 5 mg Anti Fibrinogen ELIP Injection
23614,Intravascular Ultrasound MGS Values for Visually Enhanced Atheroma Segments
23615,Intravascular Ultrasound MGS Values for Visually Non Enhanced Atheroma Segments
23616,Comparison of Echogenic Immunoliposome   ELIP   Enhancement by Intravascular Ultrasound and Immunohistochemical Molecular Expression
23617,Summary Statistics for Long Term Exposure for 3,380 Participants in the HNR Study
23618,Summary Statistics of 3,380 Analyzed Participants of the HNR Study
23619,Estimated Percent Change in Mean CIMT per Change in PM and Distance to High Traffic by IDR
23621,Consistency of Results Between Techniques
23622,Hemodynamic Data
23625,Hazard Ratios for First Cardiac Event Age 18 to 40 Years
23626,Hazard Ratios for First Cardiac Event Age 18 to 40 Years in 570 Patients Without Cardiac Events Before Age 18 Years
23627,Hazard Ratios for Aborted Cardiac Arrest or LQTS Related Death Age 18 to 40 Years
23628,Hazard Ratios for Aborted Cardiac Arrest or LQTS Related Death Age 18 to 40 Years in 570 Patients Without Cardiac Events Before Age 18 Years
23630,Association of Abnormal Scoring With Statin Usage by Psychometric Scales
23631,Association Between Abnormal Scoring With Cholesterol Lowering Treatment by Types of Cholesterol Lowering Drugs
23637,Risk Score to Predict Permanent Pacing After Valve Surgery
23638,Interval Measurements Used to Distinguish Atypical Atrioventricular Node Re Entrant Tachycardia From Orthodromic Re Entrant Tachycardia Using a Septal Accessory Pathway legend legend
23639,Intraobserver Variability    legend
23640,Summary of All Data legend
23641,Is the Hand Carried Device Configured to Evaluate the Clinical Question?   n   99   legend
23642,Did the Hand Carried Device Answer the Clinical Question for Which It Was Configured?   n   84   legend
23643,Patients in Whom Findings Were Missed   n   80   legend
23644,Selected Parameters of Unstable AF Reentrant Circuits legend
23645,Wave Characterization legend
23649,Correlation of Doppler Variables of Pulmonary Venous and Mitral Flow With Mean Pulmonary Wedge Pressure
23650,Multiple Linear Regression Analysis Relating Pulmonary Venous Flow Velocity Variables to Mean Pulmonary Wedge Pressure
23653,In Hospital Mortality and Readmission Rates
23654,In Hospital Outcomes During 30 Day and 6 Month Readmissions Stratified By Unplanned and Planned Readmissions
23655,Multivariable Hierarchical Logistic Regression Model for In Hospital Mortality Among Patients Admitted With Primary CLI
23656,Multivariable Hierarchical Logistic Regression Model for 6 Month Unplanned Readmission Among Patients Admitted With Primary CLI
23659,Decongestion and Renal Endpoints
23660,Clinical Events
23661,Ten Most Common Chronic Comorbid Conditions Among Medicare Beneficiaries With Atrial Fibrillation    36
23662,Writing Group Disclosures
23663,Reviewer Disclosures
23664,Operational Rules for the NCDR Public Reporting Program
23665,Initial CathPCI Public Reporting Metrics
23666,Initial ICD Public Reporting Metrics
23667,NCDR Public Reporting Mission StatementMarch 2014
23671,Mortality at 3 Years After ICD Implantation Among Subgroups Categorized by Acute and Chronic HF Burdens
23674,Multivariate Logistic Regression Analysis of Urinary Biomarkers in the Prediction of the Composite Outcome   In Hospital Dialysis Initiation or Mortality
23677,Echocardiographic Data According to the Three LVEF Cutoffs
23678,Univariate Cox Regression Analyses for Peak Vo 2and Ve Vco 2Slope
23679,Multivariate Cox Regression Analyses for Peak Vo 2and Ve Vco 2Slope
23682,Descriptive Statistics by Patient Race
23683,Patient Level Predictors of Receipt of Coronary Angiography
23684,Physician and Health Care System Level Predictors of Receipt of Coronary Angiography
23687,All cause and Cause Specific Mortality Through 1996 Among Unstable Angina Cohort, Veterans Affairs Puget Sound Health Care System
23689,All Cause Mortality and Coronary Artery Disease Rehospitalizations in Washington State Residents According to First Three Discharge Diagnoses Through 1996 Among Unstable Angina Cohort, Veterans Affairs Puget Sound Health Care System
23694,Cardiac Catheterization Data in Patients With and Without Lateral ST Segment Depression legend legend
23696,Relative Risk of Incident CAC Associated With Increasing Risk Categories According to FRS and RRS Classification
23697,Mean Change in CAC Score   Agatston Units   Associated With Increasing Risk Categories According to FRS and RRS Classification
23698,Relative Risk of Incident CAC and Mean Change in CAC Score With Varying FRS and RRS Groups According to Low  and High Risk Groups Classified by FRS and RRS, Respectively
23699,Relative Risk for Incident and Mean Change in CAC Score Among Participants With Discoordinate Risk Prediction Scores
23700,Hazard Ratio for Incident CHD Among Participants With Discoordinate Risk Prediction Scores
23701,Summary of Long Term Clinical Trials in PAH
23705,Long Term Effects of Currently Approved PAH Therapies on Survival
23706,Scan Parameters of the Different Scanners
23707,Definitions of Descriptive Parameters Used in the Different Diagnostic Analyses
23709,Diagnostic Performance of 64 Slice CTCA for the Detection of 50  Stenosis on QCA in the Per Patient Analysis   95  CI
23710,Diagnostic Performance of 64 Slice CTCA for the Detection of 50  Stenosis on QCA in the Per Vessel Analysis   95  CI
23711,Performance of CTCA to Predict the Extent of CAD as Seen on CCA
23712,Analysis of the Influence of Coronary Diameter, Image Quality, and Coronary Calcium of the Diagnostic Performance of 64 Slice CTCA for the Detection of 50  Stenosis on QCA in the Per Segment Analysis   95  CI
23714,Inotropic and Lusitropic Potencies and Intrinsic Activities of      Norepinephrine at Polymorphic Beta1 Adrenergic Receptors in Right Atrial Trabeculae From Patients Having Long Term Treatment With Beta Blockers
23715,Inotropic Potencies and Intrinsic Activities of      Norepinephrine at Polymorphic Beta1 Adrenergic Receptors in Right Atrial Trabeculae From Patients Not Having Long Term Treatment With Beta Blockers
23718,Correlation Between Exercise Electrocardiographic and Dobutamine Echocardiographic Results and Cardiac Events During Follow Up in the Study Group
23719,Distribution of Cardiac Events in Patients With Either a Positive Dobutamine Echocardiogram or Exercise Electrocardiogram According to the Site of Myocardial Ischemia, Addition of Atropine During Dobutamine Echocardiography and Work Load on Exercise Electrocardiography  a
23720,Summary of the Stepwise Results Considering All Spontaneous Recurring Events and Hard Events Only
23721,Endpoints
23722,Switch to Clopidogrel and Resulting Ischemic and Bleeding Risks
23725,Quantitative Coronary Angiography   N 32
23726,Quantitative Optical Coherence Tomography   N 38
23727,OCT Findings in Regions With Versus Without Thrombus
23728,Efficacy Outcomes
23729,Safety Outcomes
23730,Randomized Trials of Potent P2Y12 Inhibitors Included in the Meta Analysis
23732,Efficacy of the Potent P2Y12 Inhibitors in Men Versus Women
23733,Safety of the Potent P2Y12 Inhibitors in Men Versus Women
23738,Pre Specified Clinical Endpoints in the SAVOR TIMI 53 Trial
23739,Estimates Based on the Comparison of 2 Percentages, Illustrated by the Primary Outcome     of the CHAMPION PHOENIX Trial
23741,A Useful Language for Interpreting p Values
23742,The Simplest Statistical Test
23743,4 Examples Using z
23744,The HORIZONS AMI and EUROMAX Trials
23747,Outcomes in the Pooled Study Population at 30 Days
23749,Procedural Parameters and Discharge Medications, Intention To Treat Population
23750,Angiographic Results   Core Laboratory  , Intention to Treat Population
23751,1 Year In Segment Late Loss in the Per Treatment Evaluable and Intention to Treat Populations
23752,1 Year Clinical Outcomes   Intention to Treat Population
23754,Angiographic Outcomes
23756,Results of the Multivariable Analysis: Independent Predictors of Recurrent Restenosis
23757,Study Outcomes at the 5 Year Follow Up
23758,Platelet Function Testing by Period
23759,Shift Tables for the Individual Responder Status Change Between Periods
23760,Proportion of Individual Subjects With a Change in Platelet Reactivity Between Periods by Clopidogrel Dose and Assay
23761,Treatment Effect by Type of MI as Classified by the CEC or Site Investigator
23762,Comparisons: CEC and Site Investigator
23763,Description of CEC Adjudicated MIs
23769,Efficacy and Safety Secondary Clinical Endpoints
23772,Efficacy and Safety Endpoints
23775,Clinical Outcomes at 12 Months in the Intention to Treat Population
23776,Angiographic Results in Patients Enrolled in the Angiographic Substudy
23778,Covariate Analysis
23780,Data Sources Reviewed
23781,NCRI Data Elements
23782,Newly Defined NCRI Data Elements
23784,In Hospital Outcomes
23787,Features of ATD in 7 Patients With Subsequent Events
23789,Adjusted Risk of Major Cardiac Event Associated With DAT Discontinuation During the First Year After DES Implantation
23791,Summary of Primary and Secondary Adjudicated Efficacy Endpoints
23792,Summary of Safety Endpoints
23794,Event Rates According to On Treatment Platelet Reactivity Status
23795,Selected Subgroup Analysis by On Treatment Platelet Reactivity Status
23797,Phenotypic Patterns of Clopidogrel Hypersensitivity
23799,Results of Skin Testing in Patients With Clopidogrel Hypersensitivity   n   42
23802,Clinical Endpoints
23803,Core Laboratory Angiographic Measurements
23804,Independent Determinants of Presence of Residual Thrombus After PCI
23805,Multivariate Logistic Regression With Death and Clinical Composite Endpoint as a Dependent Variable
23806,Comparison of Cobalt Chromium and Platinum Chromium Everolimus Eluting Stents
23808,Procedural and Angiographic Outcomes of the Randomized Study Groups
23809,1 Year Clinical Outcomes in the ITT Population
23812,Quantitative Angiographic Measurements
23813,Angiographic Patterns of Restenosis
23814,Intravascular Ultrasound Measurements
23815,Clinical Outcomes at 12 Months
23816,Adverse Drug Effects
23817,Rate Dependent Effects of Simvastatin   10 nM   on Electrophysiological Parameters
23819,Deaths From Cardiovascular Disease According to Radiotherapy and the Side of the Breast Cancer
23822,Mean Graft Flow and Pulsation Index by Intraoperative TTFM in A and AC Groups
23823,Prevalence of Graft Occlusion in A and AC Groups
23824,Multivariate Analysis of Relative Risk Factors for Venous Graft Patency at 3 Months After CABG
23825,Main Studies and Published Substudies Included in This Meta Analysis
23829,Proportions of Platelet Function Responses Greater Than Risk Thresholds for Ischemic Events
23830,Platelet Function Responses During Maintenance Therapy According to Treatment With PPIs
23832,Recurrence of Adverse Events in Study Population
23833,Predictors of Primary Composite End Point
23836,In Hospital and Long Term Clinical Events According to Study Group
23837,Hazard Ratios for Primary Safety and Efficacy Clinical Outcomes After Stenting as Compared With After CABG
23839,Univariate and Multivariate Analysis for Predictors of CEC Delta Change
23849,HRs for Clinical Outcomes After Stenting as Compared With After CABG
23850,HRs for Clinical Outcomes After Stenting as Compared With After CABG Among Propensity Matched Patients
23853,Summary of Model Evaluation
23854,Effects of Adding Single Biomarkers to the TRF Model
23857,CTI Delays Collagen Induced But Not Plaque Induced Clotting of PRP and Blood
23858,Clinical Outcome at 4 Years
23860,Design of Trials Included in the Meta Analysis
23862,Random Effects ORs   95  CIs   for Clopidogrel Therapy Versus Placebo in Subgroup Analyses
23863,Estimated Number Needed to Treat or Harm With Clopidogrel Versus Placebo in Sex Stratified Analysis for Each Individual End Point Analyzed
23866,30 Day Clinical Outcomes According to Clopidogrel Loading Dose
23867,Independent Predictors of 30 Day Clinical Events in the Full Cohort
23873,In Hospital and Long Term Follow Up Events
23876,Safety Outcomes Through 30 Days Stratified by the Use of a GP IIb IIIa Inhibitor During Index Hospitalization
23878,Clinical Outcomes at 30 Days and 1 Year in Patients Undergoing CABG According to Clopidogrel Exposure Before Surgery
23880,Clinical Outcomes by Use and Timing of Clopidogrel in Relation to CABG
23883,Clinical Outcome
23891,Clinical Events and Clopidogrel Use During Follow Up
23892,Background of Patients Who Did and Did Not Receive Cilostazol
23893,Details of Lesions in Patients Who Did and Did Not Receive Cilostazol
23894,Major Adverse Cardiovascular Events in Patients Who Did and Did Not Receive Cilostazol
23895,Proportion of PD Poor Responders According to Definitions Associated With Clinical Outcomes
23896,Relative       and Absolute Numbers   n   of Diabetic Patients Among Poor Responders
23898,Procedural Resource Use and Cost
23899,Hospital Outcomes, Resource Use, and Costs
23907,Relationship Between Aortic Plaque Presence Thickness and Coagulation Parameters in Stroke Patients and in Control Subjects
23908,Combined Effect of Plaque Thickness Complexity and Prothrombin Fragment F 1.2 Levels on the Risk of Ischemic Stroke
23909,Incidence of Nonfatal Stroke and Death   Divided by Cause   in Stroke Patients and in Control Subjects
23911,6 Month Clinical Outcome
23912,Predictors of DES Thrombosis and the Composite of Cardiac Death and DES Thrombosis
23914,Platelet Aggregation and Activation in Tertiles of RPs and When Stratified by ASA Dose
23915,Platelet Activation Parameters in ASA LR and ASA NR According to Platelet Size
23916,Platelet Activation Parameters in CLO LR and CLO NR According to Platelet Size
23921,The Additive EuroSCORE System
23924,Incidence of Adverse Events in the Whole Population, in Elective Patients, and in Emergent Patients
23925,ST According to ARC Definitions
23926,Multivariable Predictors of Freedom From Adverse Clinical Events
23928,Clinical and Angiographic End Points
23929,Protocol Defined Stent Thrombosis
23930,Clopidogrel Desensitization Schedule
23931,Days of Clopidogrel Use and Extent of Initial Clopidogrel Reaction
23932,List of Patients by Status, Days From Clopidogrel Exposure PCI to Reaction, Days From Reaction to Desensitization, and Type of Reaction During Desensitization
23933,Reactions During Desensitization
23935,Clinical and Angiographic Details on the SES Patients Who Died
23936,Details on the Specific Time Courses and Reasons of Death in the SES Patients
23937,Clinical Events and Medical Therapy in the 2 Groups at Longest Available Follow Up
23939,Clinical Outcome
23940,Predictors of Stent Thrombosis
23944,Initial Adverse Events
23945,Prognostic Significance of Selected Variables for Ischemic Events According to Multivariate Cox Regression Analysis
23946,Relation Between Platelet Reactivity, GP IIb IIIa Use, and Ischemic Events
23949,Cumulative In Hospital, 6 Month, and 12 Month Adverse Clinical Events Among All Patients and in Each Treatment Group
23952,Intravascular Ultrasound Measurements
23953,Serial Changes for Each Intravascular Ultrasound Measurement
23957,Efficacy End Points
23958,Bleeding Events
23959,Efficacy End Points for Patients Who Received Consistent Therapy Versus Those Who Did Not
23960,Secondary End Points Through 30 Days for Consistent Therapy Subgroup
23963,In Hospital Outcomes by Clopidogrel Use in Patients Undergoing CABG Surgery
23969,Analysis of Infarct Size by Technetium Tc 99m Sestamibi Imaging at 14 to 28 Days
23970,Adverse Events to 30 Days
23973,Procedure Results
23974,Clinical Outcomes
23975,Clinical Outcomes Stratified by Stent Type and Peri Procedure Administration of Platelet Glycoprotein IIb IIIa Inhibitors
23976,Angiographic Follow Up Findings
23978,Quantitative Coronary Angiography Findings
23979,Relationship Between Intimal Coverage and Thrombus
23981,28 Day Bleeding Events
23982,Rates of Clopidogrel Resistance in Aspirin Resistant Versus Aspirin Sensitive Patients
23986,Primary Results of Stroke Prevention Using Oral Thrombin Inhibitor in Atrial Fibrillation   SPORTIF   III and V Studies
23987,Critical Issues in the Design Conduct and Analysis of Non Inferiority Trials
23990,Measurements of Platelet Reactivity
23992,Early   24 h of Admission   Medications and Early Procedural Care   48 h of Admission   by Age Group
23993,Early Clopidogrel and Glycoprotein IIb IIIa Inhibitor Use in Patients Managed With Early Invasive Strategy   Cath 48 h From Admission   Versus Conservative Care   Cath  48 h After Admission or No Cath
23994,In Hospital Outcomes After Acute Coronary Syndrome by Age
23995,Discharge Medications by Age Group
23996,Clinical Results Summary
23997,Life Years Lost Because of Cardiovascular Events
23998,Top 10 Hospitalization Diagnostic Related Groups   DRGs   in CREDO
23999,Cost in U.S. Dollars
24000,Long Term Cost Effectiveness, In Trial Costs Only
24001,Long Term Cost Effectiveness, Including Cost Beyond the Trial Period
24006,Comparisons of Quantitative Intravascular Ultrasound Analysis
24012,Clinical Outcomes
24014,Angiographic and Hemodynamic Data of Treated and Deferred Lesions
24015,Characteristics of Patients in Whom a MACE Was Observed During Follow Up
24018,Correlation Between C Reactive Protein Levels and Continuous Variables
24019,Proportion of Subjects with C Reactive Protein Levels  3 mg l
24024,In hospital Results and Clinical Outcomes at Six Month Follow up
24028,Procedural Data and Follow up
24029,Unit Costs
24031,Event Rates Between One and 12 Months After Percutaneous Coronary Intervention
24032,Modeled Outcomes and Cost Effectiveness: Total Sample
24033,Modeled Outcomes and Cost Effectiveness: High  and Low Risk Subsets
24035,Clinical Outcomes at 30 Days According to Clopidogrel Loading Dose Interval Before Percutaneous Coronary Intervention
24037,Quantitative Coronary Angiographic Results
24039,1 , 6 , and 12 Month Cumulative MACE and Stent Thrombosis
24043,Multivariate Predictors of CIN After Percutaneous Coronary Intervention   Development Dataset
24045,Summary of Western Blot Protein Abundance and Myocyte Morphometry
24046,Twitch Parameters From Isolated Trabeculae
24049,Effect of Pre Treatment on CK MB and Troponin Elevation at 8 and 24 h
24050,Effect of Pre Treatment on Outcome Events at One and Six Months and the Composite End Point After Six Months
24052,Multiple Regression Analysis for Predictors of One Year Mortality
24053,Multivariate Analysis for Predictors of One Year Mortality in High Risk Patients
24058,Recovery of Global and Regional Left Ventricular Function
24059,Multivariate Predictors of Recovery of Global Left Ventricular Function
24060,Multivariate Predictors of Recovery of Regional Left Ventricular Function
24063,End Points
24065,Multivariate Predictors of Mortality Including Treatment Group Assignment
24066,Multivariate Predictors of Mortality Including Measures of Compliance and Health Status
24068,Pretest and Exercise Scores
24069,All Cause Mortality Deaths
24070,All Cause Mortality Using Both Pretest Score and Either the New Exercise Score or the Duke Treadmill Score
24071,Incremental Value of Exercise and Duke Scores Over Pretest Score
24074,Invasive Hemodynamic Measurements Six Weeks Following MI
24077,Temporal Changes in VA of the Proximal Left Anterior Descending Coronary Artery
24080,Size of Occluded Reperfused Vascular Bed   Region at Risk
24083,Medication at Discharge   Other Than Aspirin and Study Drug
24084,Major Adverse Events
24085,Multivariate Association Between Cardiovascular Death and Potential Risk Factors
24089,Independent Correlates of Target Lesion Revascularization
24090,Clinical Restenosis Rates in Patients With Binary Angiographic Restenosis
24093,Adjusted Odds Ratios for Early Stent Thrombosis
24101,Closure Device Outcomes     Incidence
24102,Closure Device Outcomes: Closure Device Versus Manual
24103,Closure Device Outcomes
24104,Multivariate Logistic Regression Analysis
24105,Closure Device Outcomes Excluding Patients With in Laboratory Failed Angioseal and Perclose Devices
24108,Anti Ischemic Medications legend
24109,First 48 H Ambulatory ECG and Symptomatic Ischemia legend legend
24110,Day 21 ECG and Symptomatic Ischemia legend legend
24111,Side Effects to Study Drug legend
24114,Major Adverse Cardiac Events
24117,Effect of Metoprolol CR XL and Placebo Treatment on Cause Specific Mortality and on the Combined End Points in the Subgroups With Severe Heart Failure legend
24118,Cause Specific Data for Number of Patients Hospitalized at Least Once and Total Number of Hospitalizations in the Two Randomization Groups With Severe Heart Failure legend
24121,Glycoprotein Ib Genotype Distribution by 30 Day Composite End Point and Type of Intervention in Patients Who Underwent Coronary Interventions legend
24123,Procedural Data legend legend
24126,Acute Phase Treatment in the Hospital legend legend
24127,Primary End Point
24128,System Organs With Serious Adverse Events legend
24130,Hemodynamic Variables and Arterial Blood pH and Gases legend
24133,Clinical and Angiographic Data: Comparison of Patients With and Without In hospital Angina legend
24134,In hospital   Days 1 and 10   and Follow up Values   Three Months   for Plasma TAT, PAI 1, Fibrinogen and D dimer of Patients With Acute Myocardial Infarction legend
24135,In hospital   Days 1 and 10   and Follow up Values   3 Months   for Plasma TAT, PAI 1, Fibrinogen and D dimer of Patients With Unstable Angina legend
24146,Clinical Outcomes of Treated Patients legend
24147,Platelet GPIIb IIIa Receptor Density per Platelet Prior to and on the Final Day of Treatment legend
24148,Percent Platelets Positive for CD63   SEM   During Treatment With Orbofiban   n   32   or Placebo   n   12   legend
24149,Circumferential Reattachment of Endothelial Cells   Evans Blue Study
24150,Quantitative Angiographic Measures legend
24151,Morphometric Analysis of the Harvested Arteries legend
24153,Classification of All Deaths Occurring During Study Follow up, According to Hormone Use    legend
24156,Thirty Day and Six Month Primary End Point of Death, MI or Urgent Revascularization Hazard Ratios for Each Trial Comparing Abciximab Versus Placebo legend
24157,Bleeding Complications by Gender for Patients Receiving Abciximab legend
24161,Procedural Events legend
24162,In Hospital Clinical Events and Outcomes legend
24163,Angiographic Results legend legend
24165,Clinical Events During First 30 Days After Intervention legend
24166,Quantitative Angiographic Data legend
24167,Comparison of Group I and Group II Patients legend legend
24169,One month Clinical Outcomes   n   140 Patients   legend
24170,Outcome at Six Months   n   115 Patients   legend
24171,Factors Potentially Predictive of TLR Within Six Months legend
24176,Prevalence of FDA Defined Mitral and Aortic Valvular Regurgitation by Treatment Group
24177,Prevalence of Aortic and Mitral Valvular Regurgitation by Severity and by Treatment Group legend
24178,Paired Analysis: Summary of Change From the Initial Echocardiogram to the Follow up Echocardiogram legend
24180,M Mode and Doppler Echocardiographic Data legend
24181,In Vivo Hemodynamics legend
24184,In Hospital Events legend legend
24185,In Hospital Events legend legend
24186,Univariate Correlates of Abciximab Use legend
24187,Multivariate Model for Abciximab Use legend
24188,Multivariate Model for In Hospital Death QWMI Repeat Revascularization legend
24189,Correlates of Death MI Repeat Revascularization From Time of Procedure legend
24190,In Hospital Events for Patients Receiving Abciximab Prior to Initiation of Intervention Versus Those Receiving Abciximab After Initiation of Intervention legend legend
24192,Indications for Registry Enrollment   n   265   legend
24195,Antithrombotic Medications in Registry Patients and Relationship to Primary End Point and Transfusion
24196,Clinical Follow up legend
24199,Parameters of Activation of Coagulation and Platelets in Course After PTCAComparison Between Patients With Effective   n   12   and Ineffective   n   8   Anticoagulation   AC     Median  Range
24200,Parameters of Endogenous Fibrinolysis in Course After PTCAComparison Between Patients With Effective   n   12   and Ineffective   n   8   Anticoagulation   AC     Median  Range
24201,Endothelin 1   ET 1   and Big endothelin 1   BET 1   in Course After PTCAComparison Between Patients With Effective   n   12   and Ineffective   n   8   Anticoagulation   AC     Median  Range
24217,Initial Treatment Received and Complications Observed
24218,Angiographic Findings of 163 Patients who Underwent Angiography on the Index Hospitalization
24219,Results
24221,Correlations Between Hemostasis Markers
24225,Ischemic Complications According to Presence of Thrombus Containing Lesions on Angiography
24226,Ischemic Complications in Patients With Thrombus Containing Lesions on Angiography According to Treatment Group
24229,Hemodynamic Variables
24230,Cessation of Hormonal Therapy
24233,Platelet Counts and Glycoprotein Surface Expression
24235,Arterial Study Results in 30 Genetic Males Investigated   15 male to female transsexuals and 15 male control subjects
24238,Lipid Profiles
24243,In Vivo Hemodynamic and In Vitro Whole Heart Indexes of Cardiac Function
24244,Vasoconstriction in the PTCA and Control Vessels
24246,Cardiovascular End Points in the Two Patient Groups
24247,Causes of Death in the Two Patient Groups
24248,Multivariable Correlates of Cardiovascular Events  a
24256,Procedural Data
24257,Clinical Events During First 30 Days After Intervention
24258,Quantitative Angiographic Data
24260,Fibrinocoagulation Variables During Paroxysmal and Nonparoxysmal Atrial Fibrillation Periods in 21 Patients and 9 Control Subjects
24261,Comparison of Fibrinocoagulation Variables Between PAF I and PAF II Groups and Control Subjects
24265,Quantitative Angiographic Measurements in the Two Study Groups
24266,Correlates of Stent Thrombosis by Logistic Regression Analysis
24271,Variants Associating Genome Wide Significantly With AF   N 13,471
24272,Replication of Loci Previously Reported to Associate With AF   N 13,471
24275,SHFM Adjusted HRs   95  CIs   for the Effect of the ICD on Mortality Versus Controls by Quintile of SHFM and SPRM
24276,HRs for the Effect of the ICD on Mortality by SPRM SHFM Grouping
24278,Comorbidities by Treatment Assignment
24280,Changes in Echocardiographic Measurements After CRT by Comorbidity Groups
24284,Association Between Resting Heart Rate Among AF Patients and Outcomes
24285,Macroscopic and Cellular Parameters
24288,Outcomes Stratified by Age
24289,Adjusted 2 Yr Relative Risks of Outcomes Stratified by Age
24292,Probability of New Events: Univariate Analysis TotalPopulation
24293,Probability of New Events: Multivariate Analysis ofAllData
24294,Comparison of Larger Brugada Syndrome Registries
24296,Univariable and Multivariable Cox Regression Analysis   Continuous Variables
24297,Univariable and Multivariable Cox Regression Analysis   Dichotomized Variables
24298,5 Year Mortality in Subgroups Defined by Expiration Triggered Sinus Arrhythmia and Other Risk Predictors
24300,Single Center Echo Use Rates
24301,HCR Registries Published Since 2008
24302,Cohorts Comparing HCR With Conventional On  or Off Pump CABG Published Since 2008
24303,Angiographic and Clinical Follow up Data in Patients in HCR Registries Published Since 2008
24304,Cohort Studies Comparing Angiographic and Clinical Follow Up in Patients Undergoing HCR Versus CABG
24309,Major Trials for Ablation of AF in Patients With HF
24310,Key Questions Specific to Catheter Ablation of AF in Patients WithHF
24311,Efficiency of the Gene Addition to the AAVS1 Locus
24313,Implanted Valves and Access Site Across Studies
24314,Extracted Predictors Across Studies
24317,Summary of SCN10A Rare Variants Associated With BrS
24318,MRI Data   6 Months After Infarction
24319,Clinical Events
24321,Hazard Ratios for Death of Any Cause With Dronedarone, With No Dronedarone as Reference
24322,Hazard Ratios for Death in Relation to Latest Antiarrhythmic Drug Purchase Up to 30 Days After Index Date
24323,Standardized Mortality Ratios
24326,Optimal Discrimination Values for VC and VD Variants
24328,Genes With Significant Associations Between diLQTS Patients and Drug Exposed Control or ESP Control Subjects According to Aggregated Rare Variant Analysis
24329,Proportion of Subjects Harboring 1 or More Rare Amino Acid Changing Variants   Minor Allele Frequency 1.5  in ESP4300EA  in 20 High Priority Genes
24333,12 Month Efficacy Endpoints
24334,Primary and Secondary Safety Endpoints
24335,RC Subgroup Analysis   ITT Population
24336,Electrophysiological Variables
24338,Ischemic and Bleeding Outcomes at 30 Days and 1 Year in Large TAVI Registries
24339,Relation Between Periprocedural Stroke and Mortality After TAVI
24340,Relation Between Periprocedural Major or Life Threatening Bleeding and Mortality After TAVI
24341,Current Recommendations for Antithrombotic Agents and Strategies for TAVI
24342,Current ACC AHA, ACCP, and ESC Guideline Recommendations for Antithrombotic Therapy Within 3 Months AfterBioprostheticValve Replacement
24343,Possible Future Antithrombotic Strategies for TAVI That Have Not Yet Been Evaluated
24345,Rhythm During Subsequent Shocks Categorized by Rhythm at Time of First Shock
24346,Comparison of Mortality in Patients Who Received Shocks, Categorized by Rhythm at the Time of Shock, Compared With a Matched Group of Patients Who Did Not Receive a Shock
24348,Accuracy of Electrocardiomapping in Defining AblationTargets
24350,Distribution of Events
24351,Univariate Cox Proportional Hazards Analysis
24352,Multivariate Cox Proportional Hazards Analysis
24354,Patient Population   176 Subjects Followed for at Least 90 Days
24355,Summary Statistics and Pearsons Correlation Coefficient of Daily Mean Air Pollutant Concentrations and Meteorological Variables in Boston During the Study Period From September 1, 2006, to June 30, 2010
24356,Percent Change in Risk of ICD Detected Arrhythmias Associated With Each Interquartile Range Increase in Mean Air Pollutioninthe 2 and 24 h Prior to Arrhythmic Event, Adjusted for Temperature and Dew Point
24357,1993 to 2012 LQTS Diagnostic Criteria
24358,Molecular Basis of Cardiac Channelopathies
24364,Mortality at 1 Year Follow Up
24366,Risk for Death From Arrhythmia, Cardiac Causes, and All Causes in Subjects With ERP
24367,Incidence Rates and Risks for Arrhythmia Death, Cardiac Death, and All Cause Death in Subjects With ERP During Follow Up
24372,Univariate and Multivariate Predictors of a Poorer Physical Composite Score of Quality of Life at Follow Up
24373,Covariates Included in the Associative Regression Model
24375,Independent Predictors of POVA From a 24 Variable Associative Logistic Regression Model That Included All Bivariate   Unadjusted   Predictors of POVA
24376,Independent Predictors of Long Term Survival From an Associative Cox Proportional Hazards Model That Contained All 40 Covariates
24377,Electrocardiographic and Echocardiographic Data
24382,Predictors of 1 Year Quality of Life
24383,Animal Numbers
24390,Multivariate Analysis: Effect of the Development of AT and Changes in Cardiac Volume at 1 Year on the Risk for HF or Death and the Separate Occurrence of Death
24391,List of Included Studies
24392,International Participation in NIH Sponsored Cardiovascular Randomized Clinical Trials
24393,International Participation by Disease Category, Disease Acuity, and Invasiveness of Studied Procedure
24396,Multivariate Analysis: Relative Risk of Time Dependent HFEs for the Occurrence of All Cause Mortality in All Patients and When Tracked by Active Device
24398,Electrophysiologic Findings on 22 Patients With Mitral Valve Prostheses and Concomitant AFL
24400,Procedure Related Complications in Patients With and Without Mechanical MVR
24403,Comparison of J PointPositive Individuals From Relatives and Control Groups
24405,Multivariate Analysis: Risk of Ventricular Tachyarrhythmic Events by Echocardiographic Response in CRT Treated Patients and Those Receiving ICD Only
24406,Multivariate Analysis: Risk of Ventricular Arrhythmic Events by Percentage of Reduction in LVESV Among CRT D Patients
24407,Breakdown of SADS Familial Evaluation
24410,Kaplan Meier Survival at 6 and 12 Months for Patients in INTERMACS Profile 1, 2 to 3, and 4 to 7 for Each Group
24411,Adverse Events for the HM II and COMPs Reported to INTERMACS
24412,Temporal Comparison of BTT Outcomes With the HM II LVAD
24413,Comparison of Major Viral Vector Systems
24414,Major Clinical Trials in Gene Therapy for Heart Failure
24417,Major Adverse Cardiac Events at 12 Month Follow Up   in Descending Order of Severity   According to Intention to Treat Analysis
24419,Patients With Clinical End Points as a Function of AT AF Occurrence and Duration
24421,Clinical and Genetic Data for Families 1, 2, and 3
24423,Predictors of Significant Residual Cardiac Lesions in Adulthood After ASO
24424,Reinterventions in Adulthood After ASO
24425,Predictors of Cardiac Intervention in Adulthood After ASO
24427,QTc Duration in the Overall LQTS Patient Cohort Shown by NOS1APSingle SNPs
24430,Unadjusted Analysis of ORs From Variables Measured During STEMI for 6 Month LVEF  50
24431,Multivariable Associations of Variables Measured During Acute STEMI With 6 Month LVEF  50
24433,Univariate Analysis
24434,Multivariate Analysis
24436,Clinical End Points at 5 Years   Hierarchical and Nonhierarchical MACCE Up to 1,800 Days, Per Patient   Counted Since Date of Procedure
24437,ST According to the ARC Definitions
24438,Independent Predictors of MACE and ST in the ARTS II Group
24440,Procedural and 30 Day Outcomes
24445,Cox Regression With Multiple Predictor Variables Including Location of Mutations for First Cardiac Event and Aborted Cardiac Arrest Long QT Syndrome Death
24446,Mutation Group by Location, Type, and Topology
24447,Cox Regression With Multiple Predictor Variables Including Location and Type of Mutations and Their Interaction for First Cardiac Event and for Aborted Cardiac Arrest Long QT Syndrome Death
24448,Principal Discharge Diagnosis Codes Associated With Readmissions After PCI in the Overall Cohort as Well as in Subsets of Patients Without AMI, With AMI, and With Repeat Revascularization
24451,Multivariate Analysis of Predictors of AF Termination
24453,Multivariate Analysis of Predictors of Clinical Outcome
24455,V0.5, Slope Factor k, and  Deactivation at  20 mV
24458,Multivariable Predictors of Ventricular Arrhythmias
24460,Comparison of MDCT and MRI at 8 mm Slice Thickness   n   14
24461,Infarct Parameters at Different Slice Thickness by MDCT   n   12
24463,Clinical and Echocardiographic Parameters   n   75
24464,Biventricular Pacemaker Diagnostics   n   75
24465,Recommendations
24467,Indications for Rest Echocardiograms Who Required Contrast Enhancement
24469,Multivariate Cox Proportional Hazards Survival Model Identifying Predictors of Death or HF Hospitalization
24471,Why Do Some Subjects Pace 92 ?
24473,Clinical End Points at 3 Years in Nondiabetic Patients   Hierarchical and Nonhierarchical MACCE to 1,080 Days, per Patient   Counted Since Date of Procedure
24475,Clinical End Points at 3 Years in Diabetic Patients   Hierarchical and Nonhierarchical MACCE to 1,080 Days, per Patient   Counted Since Date of Procedure
24476,Clinical End Points of Diabetic Patients and Nondiabetic Patients at 3 Years in the ARTS II Trial  Hierarchical and Nonhierarchical MACCE to 1,080 Days, per Patient   Counted Since Date of Procedure
24477,Incidence of J Point Elevation Among 45 Patients With Idiopathic VF and 124 Healthy Control Subjects Matched for Age and Gender
24478,Incidence of QRS Slurring Among 45 Patients With Idiopathic VF and 124 Healthy Control Subjects Matched for Age and Gender
24479,Incidence of ST Segment Elevation Among 45 Patients With Idiopathic VF and 124 Healthy Control Subjects Matched for Age and Gender
24486,Characterization of Myocardial Segments With Earliest VT Activation
24488,Comparison of Magnetic Resonance Imaging of Arrhythmogenic and Nonarrhythmogenic PAPs
24489,Patients Experiencing Inappropriate ICD Shocks
24490,Rhythm Responsible for ICD Shock Episodes
24493,ICD Programming in Patients With and Without Inappropriate ICD Shocks
24496,The ARI of the S1 and S2 at the 2 Right Ventricular Sites
24498,QRS Duration at Premature Beats in the RVA
24501,Clinical and EP Parameters in Patients With and Without SCN5A Mutation
24502,Clinical, Genetic, and EP Parameters in Patients With and Without Spontaneous Type 1 ECG
24503,Clinical, Genetic, and EP Parameters in Patients With and Without Documented VF Episode
24504,Differences in Metabolites Between Hearts in SR and Permanent AF
24505,Differences in Protein Profiles Between Hearts in SR and AF
24506,Metabolite Concentrations in Atria of SR Patients Undergoing CABG or Valve Surgery
24508,Potential Modifiers of the Risk of an ICD Shock for VT VF Associated With an Acute Episode of Driving
24510,Patients With Adenosine Insensitive Focal Atrial Tachycardias
24512,Variables of Patients Who Underwent Randomized Ablation Strategy and Specific Ablation Strategy
24516,Diagnostic Accuracy of 64 Slice CTA in the Detection of Significant Bypass Graft Disease
24517,Hemodynamic Parameters
24518,Summary of Patient Data
24519,Operative Data
24522,Anatomy
24524,Prior Palliative Procedures
24525,Type of Fontan Connection
24526,Variables Associated With Early Mortality
24530,Comparison of the Changes in Clinical and Echocardiographic Parameters After Cardiac Resynchronization Therapy for Heart Failure Patients With Narrow and Wide QRS Complexes
24534,Hemodynamics in Patients With EF 40
24535,Hemodynamics in Patients With EF  40
24536,Patient Inclusion
24538,Diagnostic Performance and Predictive Value of 64 Slice CTCA for the Detection of 50  Stenosis on QCA
24539,Influence of Coronary Calcifications on Diagnostic Accuracy of 64 Slice CTCA on a Segment Based Analysis
24540,Sertindole Induced Changes in Electrophysiological Parameters and Proarrhythmia
24541,Sertindole Induced Changes in Electrophysiological Parameters and Proarrhythmia in the Presence and Absence of Elevated Plasma Potassium Concentrations   n   7
24542,Dose Dependent Changes in Electrophysiological Parameters and Proarrhythmic Frequency Induced by Levcromakalim   n   7
24546,Cardiovascular Events
24549,Relationships Between Intake of Tuna or Other Broiled or Baked Fish and Other Risk Factors Among 5,096 Older Adults
24550,Electrophysiologic Measures According to Intake of Tuna or Other Broiled or Baked Fish
24552,Force Development and EAD Formation With Pacing at 36C
24553,Force Generation and APD90 Norepinephrine Isoproterenol   Acetylcholine
24554,Force Generation and APD90 Hypothermia
24556,Correlates of Left Atrial Dimension and Indexed Left Atrial Volume
24557,Classification of Left Atrial Size Abnormality by the American Society of Echocardiography Guidelines for Both Sinus and AF Subgroups
24560,Effect of Statin Therapy on Cardiac Death and ICD Therapy for Ventricular Tachyarrhythmias
24561,Logistic Regression Equation for Coronary Artery Bypass Grafting In Hospital Deaths in New York State in 2002   N   16,120
24562,Risk Scores for In Hospital Mortality for Coronary Artery Bypass Grafting
24563,Predicted Risk of In Hospital Mortality Associated With Individual Risk Scores and the Distribution of Total Risk Score Among Coronary Artery Bypass Grafting Patients in New York State in 2002   N   16,120
24566,Side Effects
24569,QTc Prolongation and Risk of Sudden Cardiac Death
24571,Hazard Ratio for Outcomes by Definition of Inducibility Using Multivariate Cox Models
24575,Predictive Value of QRS Duration Using 10 ms Cutoffs
24576,Density of Tachycardia Episodes as Related to QRS Duration
24577,Relation of Specific Conduction Abnormalities to Density of VT
24578,Relation of QRS Duration to Mode of Death
24583,Summary of All Cause and Cardiovascular Mortality Reduction by ICDs From Multivariate Regression Analysis
24584,Stratified Analysis of Three Year Mortality for Overall and 1999 Cohorts by Propensity Score Quintile
24585,Summary of Multivariate Regression and Propensity Score Analyses for Three Year All Cause, Cardiovascular, and Noncardiovascular Mortality in Overall Cohort
24587,Adverse Events During the Study
24590,The Electrophysiologic Data of Ventricular Tachycardia or Ventricular Premature Contractions Originating Within the Pulmonary Artery
24592,Prediction of Significant   70    LIMA or Distal LAD Stenosis by LIMA and LAD Flow Derived Indexes Using Transthoracic Doppler Ultrasound
24594,Angiographic Findings at the Site of Stent Fracture
24595,Cryoablation Procedure Details
24596,Cryoablation Details
24600,Programming of Detection Algorithms in the SC Group and DC Group
24601,Inappropriate Classification of Spontaneous Atrial Tachyarrhythmias for Both Groups
24604,Correlations Between the Markers of Ventricular Dyssynchrony and Those of Hemodynamic Status
24608,Comparison of Studied Electrocardiogram Parameters in Subjects With and Without Appropriate ICD Therapy for VT VF
24609,High Risk Quartile of QTVN in the Multivariate Cox Model Predicting Appropriate Therapy for VT VF After Adjustment for Relevant Clinical Covariates
24611,Variables for Which Conditional Logistic Regression Analysis Was Performed, Noted in Mean OR With 95  CI
24612,Basal Heart Rhythm and Mean Variables on ECG and 24 h Holter Recording Before Event
24613,Echocardiography Results
24615,Brachial Blood Pressure Differences in the Population and Clinical Cohorts Showing the Percentile Distributions of Interarm Differences   Right Arm Minus Left Arm
24616,The Prevalence of Subclavian Stenosis in Population Cohorts and Clinical Cohorts
24618,Cardiovascular Diseases Associated With the Presence Versus Absence of Subclavian Stenosis: Results of Multiple Logistic Regression Analysis   n   4,102
24620,Ventricular Arrhythmia Frequency
24621,Univariate Associations With VT VF Events
24622,Study Population
24623,Hydroquinidine in Patients With Brugada Syndrome
24624,Follow Up
24626,Prevalence of Potential Risk Factors Among Cases and Controls
24627,Unadjusted and Adjusted Odds Ratios for Ventricular Tachycardia Fibrillation
24630,SAEs of Interest Occurring in Patients Not in AF and in AF at Baseline
24631,Morphologic and Biologic Parameters
24632,Echocardiographic Parameters
24633,Summary of Included Primary and Secondary Prevention Studies of Defibrillator Versus Medical Therapy
24634,Sensitivity Analysis of Secondary Prevention Trials
24636,Ablation Outcome and Follow Up
24638,Factors Associated with Ventricular Ectopy
24640,Clinical and Angiographic Data
24642,Clinical Events During In Hospital Period
24643,Programming Parameters
24647,Surface P Wave Morphology During Tachycardia
24650,Ventricular Fibrillation Activation Pattern Descriptors in Chronic Amiodarone Group
24654,Predictors for Sudden Death Likely or Possibly Related to AV Node Ablation and Permanent Pacing in Patients With AF
24657,Biventricular Versus Univentricular Stimulation Clinical Effects
24658,Treatment Period Clinical Effects
24661,Causes of Death
24663,Image Depth and Scoring
24664,Defibrillation Thresholds: Protocol 1
24665,Defibrillation Thresholds: Protocol 2
24667,Intraoperative Right Atrial Conduction Velocities
24668,Immunodetectable Connexin Amounts legend
24669,Bayesian Statistics for Five Tests Used to Predict Risk of MAEs After Myocardial Infarction
24670,Comparison of Tests for Predicting MAEs
24671,Staged Application of Tests for Prediction of a MAE
24672,Categories of Ventricular Tachyarrhythmias Compared in This Study
24673,Putative Transient or Correctable Causes of VT VF   n   278
24675,Comparison of Post Event Procedures and Discharge Therapies
24676,The Brugada type ECG and the Typical Brugada Type ECG
24677,Comparison of the Prevalance of the Typical Brugada Type ECG in Healthy Populations legend
24680,Patients With Inducible Ventricular Fibrillation legend
24681,Assignment of Effective Antiarrhythmic Drug Therapy by Programmed Ventricular Stimulation, by Number of Drug Trials legend
24682,Assignment of Effective Antiarrhythmic Drug Therapy by Programmed Ventricular Stimulation, by Drug Class and PVS End Point legend
24684,Cardiac Electrophysiologic Variables of Wild Type and IKACh Deficient Mice Before and After Carbachol Administration legend
24689,Comparison of Chamber Size Dimensions and Volume in Patients Who Have Had the Fontan Operation legend legend
24690,Presence of Clinical Outcomes in Patients Who Have Had the Fontan Operation legend
24692,Coronary Angiography: Qualitative and Quantitative Results legend
24693,Intravascular Ultrasound: Qualitative and Quantitative Results legend
24694,Follow up Data legend
24697,SF 36 Quality of Life Scores Across AF and All Control Groups    legend
24698,Quality of Life Scores Across AF and Study Specific Control Groups legend legend
24699,Relationship Between Objective Indexes of Disease Burden and Subjective Quality of Life Measures    legend
24700,Evolution of Arrhythmias in Affected Dogs During D,l sotalol Protocols   Maximum Number of Arrhythmias min   legend
24702,Time Constants of Adaptation of the APD90 to a Change in Pacing Cycle Length on Endomyocardial Biopsies and Purkinje Fibers in Control Conditions legend legend
24703,Effects of D,l sotalol, E 4031 and Chromanol 293B on Repolarization of Canine Endomyocardial Biopsies and Purkinje Fibers Paced at a Cycle Length of 1,000 ms legend legend
24705,Univariate Predictors of Recurrences of Ventricular Arrhythmias Requiring ICD Intervention During Follow up legend legend
24706,Outcome in Patients With   Group I   and Without   Group II   Lipid Lowering Drugs legend legend
24708,Origin of Human Ventricular Myocytes Used in the Study legend
24709,Criteria for Inclusion in the Study
24710,Collaborating Institutions
24711,Classification of Patient Groups
24713,Odds Ratio   OR   Estimates for Clinical CHF, RV Dysfunction, and LV Dysfunction
24715,Antiarrhythmic Drugs at Implantation and at the End of the Study Period legend
24716,Distribution of Atrial Fibrillation Episodes in the 45 Patients According to the Percentage of Treated Episodes That Occurred During a Valid Monitoring Period legend
24717,Number and Duration of the Treated and Nontreated Atrial Fibrillation Episodes Occurring During Valid Monitoring Periods According to Time Since Implantation legend
24718,Reduction in the Risk of a Treated Atrial Fibrillation Episode Relative to Day 7 After Atrioverter Implantation
24721,Short Term Success Rates of Different Arrhythmia Types for the Total Group and in the Three Age Groups legend
24722,Percent of Patients in the Age Group with Each Arrhythmia Type legend
24723,Complications of Catheter Ablative Therapy and Overall Incidence in Study Population Undergoing 744 Ablation Procedures   N   695 patients   legend
24725,Mitral and Tricuspid Valve Flow Patterns
24726,Effects of Chromanol 293B, d Sotalol and ATX II on the QT Interval, APD90and Transmural Dispersion of Repolarization in Perfused Wedge Preparations legend
24729,Multivariable Model for Ablation of All VTs legend
24730,Procedure related Complications legend
24731,Multivariate Logistic Regression Model: Recurrence and Survival legend
24732,Multivariate Cox Proportional Hazards Models for Prediction of Time to Recurrence legend
24733,Multivariate Cox Proportional Hazards Models for Prediction of Time to Death legend
24737,Delays in Coronary Care Unit Access, Hospital Stays and Use Rates of Procedures by Type of Hospital in Unstable Angina Patients legend
24738,Patients With Standardized Criteria for Urgent and Elective Coronary Angiogram, and Rates of Urgent PTCA and CABG Among These Patients During the 28 Days Following Onset of Unstable Angina, by Type of Hospital
24739,Primary End Points During Follow up Among Myocardial Infarction Patients by Type of Hospital legend
24740,Adjusted RR and 95  CI for Six Month Mortality and Readmission After UA in Patients Admitted to Three Hospitals Without On Site In Hospital Catheterization Laboratory and Coronary Surgery legend
24743,Graft Occlusion Rates at One Year legend legend
24744,Graft Occlusion Rates According to Location of Distal Anastomosis and Coronary Artery Lumen Diameter legend legend
24745,Clinical Outcome at One Year legend legend
24746,Multivariate Logistic Regression Analysis of Myocardial Infarction, Recurrent Angina and Any Primary Clinical End Point legend legend
24748,Previous Studies on Circadian Variation of Ventricular Arrhythmias in Which Information From an Implantable Cardioverter Defibrillator Was Used legend
24750,Therapies at Hospital Discharge from Index Hospital Period legend
24751,Crossover Rates at One and Two Years
24753,Patients With Positive Electrophysiology Study legend
24755,Mortality Data of Patients With Available Follow up
24756,Interval   Mean  SD   Between the Onset of Atrial Activation at Two Subsequent Bipoles of the Crista Terminalis Mapping Catheter   Top   and at Two Opposite Bipoles of the Pacing and the Mapping Catheter   Bottom   legend
24757,Longest Coupling Interval That Resulted in a Functional Conduction Block at the Crista Terminalis During Programmed Atrial Stimulation
24758,Longest Coupling Interval That Resulted in a Conduction Block at the Crista Terminalis in Patients With Atrial Flutter Versus Atrial Fibrillation legend
24759,Longest Coupling Interval That Resulted in a Conduction Block at the Crista Terminalis Before and After Administration of 2 mg kg Disopyramide legend
24764,All cause Mortality for Groups Receiving Different Shock Therapies After Adjustment for Categorical LVEF legend
24765,All Cause Mortality for Groups Receiving Different Shock Therapies With Stratification by Categorical LVEF
24766,Proportional Hazards Regression
24767,Stratification for Ejection Fraction
24769,Hemodynamic and Neurochemical Profile in Patients Matched by Pulmonary Artery Pressure legend
24770,Hemodynamic and Neurochemical Profile in Patients Matched by Cardiac Output legend
24771,Impedance Rises During Ablation legend legend
24772,Lesion Generation With Temperature Control legend
24773,Local Electrical Activity legend legend
24774,Catheter Placement legend legend
24779,Diagnostic Value of the Signal Averaged Electrocardiogram in Post MI Patients legend
24780,Comparisons of Mean Ventricular Rates   VR   Measured over 24 Hours, During Daytime   6 am to 6 pm  , and During Nighttime   6 pm to 6 am
24781,Comparison of Phase Angle of Cosine Fit to 24 Hour Ventricular Rate Data and Calculated Time of Peak Ventricular Rate Among Different Treatment Groups
24782,Mean Exercise Parameters of Subjects Who Exercised for at Least Five Minutes legend
24789,Echocardiography and Doppler in Restrictive and Nonrestrictive Patients legend
24790,Echocardiography and Doppler data after transannular patch repair and disatolic RV physiology legend
24791,Episodes and Duration of Arrhythmia for Three Reperfusion Regimens Versus Permanent Occlusion legend
24792,Mortality After Myocardial Infarction for Permanent Occlusion and Three Reperfusion Regimens  legend
24793,Myocardial Infarct Size for Permanent Occlusion and Three Reperfusion Regimes legend
24797,Significance of Differences in Variables During Follow Up in Measurements Obtained in Patients with Atrial Fibrillation   before and after the event   and in Those Remaining in Sinus Rhythm legend
24798,Probability Estimates and Sources Used in Study Model
24800,Unit of Costs and Charges Used in the Model legend
24801,Base Case Analysis for a 57 Year Old Postinfarction Patient, Showing Incremental Cost Effectiveness Ratios legend
24802,Quantitative Angiographic Analysis
24803,Planimetric Analysis of the Harvested Arteries
24805,P Wave Configuration by Tachycardia Location
24806,Activation Timing by Tachycardia Location
24808,Incidence of Early Afterdepolarizations and Torsade de Pointes Arrhythmias After Administration of d Sotalol and Almokalant
24811,Overall Incidence of Cerebrovascular Events Complicating Acute Myocardial Infarction
24812,Mortality Rates in 1981 to 1983 Versus 1992 to 1994 Cohorts for All Patients With Acute Myocardial Infarction and Patients With Early Cerebrovascular Events
24814,Time to Coronary Care Unit Admission, Length of Hospital Stay and Use of Coronary Angiography and Revascularization Procedures by Hospital Type
24815,Emergency Coronary Angiography and Revascularization Within 28 Days of Onset of Myocardial Infarction in Patients Meeting Standardized Criteria for These Procedures in Tertiary   group A   and Nontertiary Hospitals   group B
24816,Primary End Points During Follow Up in Study Patients Admitted to Tertiary   group A   or Nontertiary Hospitals   group B
24817,Adjusted Relative Risks and 95  Confidence Intervals for 6 Month Mortality After First Myocardial Infarction in Patients Admitted to Three Hospitals Without On Site In Hospital Catheterization Laboratory and Coronary Surgery
24819,Predicted Effective Therapies  a
24820,Alternative Therapies  a
24821,Two  and Five Year Event Probabilities by Outcome
24822,Adverse Outcomes of 1,389 Angioplasty Procedures Performed at Rush Presbyterian St. Lukes Medical Center During 1993 to 1995
24823,Individual Operator Outcomes
24824,Comparison of Overall Outcomes Among Studies
24825,Comparison of Adverse Outcomes
24826,Comparison of Prognostic Variables
24829,Treatments
24830,Clinical Outcomes
24832,Differences Between the First Postpacing Interval and the Flutter Cycle Length   FPPI  FCL   From Sites Close to   C   and Distant From   D   the Tricuspid Annulus
24833,Patient Diagnoses and Frequency of Collateral Channel Development by Diagnosis  a
24834,Results of Statistical Analysis for Factors Associated With Venous Collateral Channels After Bidirectional Cavopulmonary Anastomosis
24836,Definitions of Adverse Effects and Drug Discontinuation
24837,Adverse Effects
24842,Antiarrhythmic Response to 3 Weeks of Oral Placebo and Magnesium Potassium Therapy
24843,Clinical and Angiographic Data for 156 Study Patients
24845,Signs, Symptoms and Events Associated With Incident  a  Syncopal Events: Residents of Rochester, Minnesota Aged 1 to 22 Years, by Time Period
24846,Activities and Locations Associated With Incident  a  Syncopal Events: Residents of Rochester, Minnesota Aged 1 to 22 Years, by Time Period
24847,Attending Physicians Diagnosis After Initial Evaluation of Incident  a  Syncopal Event: Residents of Rochester, Minnesota: Aged 1 to 22 Years, by Time Period
24848,Laboratory and Clinical Tests Performed During Initial Evaluation  a  of Incident  b  Syncopal Event: Residents of Rochester, Minnesota Aged 1 to 22 Years, by Time Period
24849,Medical Conditions Reported During Follow Up: Residents of Rochester, Minnesota Aged 1 to 22 Years With Incident  a  Syncopal Event in 1950 to 1954 and 1987 to 1991
24850,Clinical Features of Patients With and Without Automatic Junctional Tachycardia, 19861994
24851,Efficacy of Therapeutic Stages for Rapid Postoperative Automatic Junctional Tachycardia
24852,Effective Refractory Period at the High Right Atrium During High Right Atrial Pacing and Dual Site Right Atrial Pacing and at the Coronary Sinus Ostium During Single Site Coronary Sinus Ostial Pacing in the Study Patients
24855,Mean Changes in Clinical and Electrocardiographic Variables in Both Study Groups During Percutaneous Transluminal Coronary Angioplasty
24857,Electrophysiologic Study Results
24858,Predictors of Appropriate Implantable Cardioverter Defibrillator Therapy
24859,Patients with Appropriate Therapy According to Initial Electrophysiologic Study Results
24860,Predictors of All Cause Mortality
24863,Mean Plasma Dofetilide Concentrations
24864,Shortest Coupling Intervals
24866,Resting and Peak Exercise Cardiac and Physical Function Variables in HTx, Implanted and Explanted LVAD Patients, and HealthyControls
24867,Individual Patient Data for Peak Exercise Cardiac Power Output and OxygenConsumption
24871,Univariable and Multivariable Predictors of Mortality Rates From the Derivation Cohort
24877,Cardiopulmonary Exercise Test Responses
24878,Association Between Variables Measured During CPX Testing and Mortality   Univariate Analyses
24879,Association Between Variables Measured During CPX Testing and Mortality   Multivariable Analyses
24880,Variables Corresponding to Lower  and Higher Risk Patients at1 YearFollow Up
24881,Mortality Discrimination Based on c Index per RER Categories
24887,ECG Criteria
24890,HR and 95  CI for Incident AF by LVM
24891,HR and 95  CI for Incident AF by ECG LVH Criteria
24893,Predicted Mean Values of RV Parameters by COPD Severity
24894,Predicted Mean Values for and Differences in RV Parameters by Percentage of Emphysema on Computed Tomography
24901,Incidence of Adverse In Hospital Outcomes for Lean, Overweight, Submorbidly Obese, and Morbidly Obese Versus Overweight Patients
24904,Correlations of 6MWD to CPX Indices
24905,Prognostic Utility of 6MWD Versus CPX Indices in Predicting All Cause Hospitalization Mortality
24906,Prognostic Utility of 6MWD Versus CPX Indices in Predicting All Cause Mortality
24907,C Index of 6MWD Versus CPX Indices in Unadjusted and Adjusted Models of All Cause Hospitalization Mortality and All Cause Mortality
24908,6MW Test to Predict HF Outcomes and Studies Comparing 6MW and CPX
24912,Covariate Adjusted     p Values for Exercise Volume   MET h per Week   as a Linear or Logarithmic Transformed   Predictor of Clinical Events in Patients Event Free for at Least 3 Months   n   959
24919,Dietary Intake
24920,Sleep Study Data
24921,Factors Independently Related to the Apnea Hypopnea Index
24922,Factors Independently Related to the Apnea Hypopnea Index in the Obstructive Dominant Group   n   35
24923,Factors Independently Related to the Apnea Hypopnea Index in the Central Dominant Group   n   19
24928,Anatomic Patterns and Final LV Lead Position in Both Groups of Patients
24929,Procedural Data in Groups 1 and 2
24930,NYHA, Echocardiographic, and Functional CPET Changes in Groups 1 and 2
24931,Follow Up Data in Both Groups of Patients
24933,Use of HF Medications Before and After CRT Procedure in Groups 1 and 2
24936,CPX Measurements and Their Comparisons of Between Negative and Positive Mortality, Morbidity, and OB Subgroups in Patients With CHF
24938,Catheterization, CMR, and Exercise Data
24944,Angiographic and Procedural Data
24945,Clinical Data at 30 Days
24946,Change in Regional Wall Motion Score Index of the Infarct Zone at 3 Months
24947,Infarct Size at 14 Days
24949,CPET Data
24951,Univariate Cox Regression Analysis
24952,Multivariate Cox Regression Analysis
24954,Distribution of Parameters of Chronotropic Incompetence, Peak Oxygen Consumption, Presence of Sinus Rhythm, and Use of Antiarrhythmic Medication by Underlying Anatomy
24955,Univariate Predictors of Mortality
24956,Multivariate Predictors of Mortality
24957,Comparisons Between Iron Replete and Iron Deficient Patients
24958,Viscosity Data Compared Between Iron Replete and Iron Deficient Patients
24959,Univariate Correlations for Determinants of Whole Blood Viscosity and Viscosity at Hematocrit of 45    Hct Adjusted Viscosity
24963,Single Values of Intracoronary Bone Marrow Stem Cell Transplantation Group
24964,Cardiac Parameters in the Transplantation Group and in Control Group at the Three Investigation Time Points
24966,Individual Algorithm Component Performance
24968,Predictors of Mortality by Multivariable Analysis: Variables Are Shown in the Order They Entered a Stepwise Cox Regression Model
24969,Association Between Severe Ventricular Ectopy During Recovery and Mortality in Prespecified Subgroups
24971,Effects of Cardiac Resynchronization Therapy on Exercise Capacity and Echocardiographic Parameters
24972,Effects of Cardiac Resynchronization Therapy on Cardiorespiratory Polygraph and Pittsburgh Sleep Quality Index   PSQI
24974,Effects of Cardiac Rehabilitation and Exercise Training   n   235
24976,Changes in Weight, BMI, Body Fat, and HSCRP Following Cardiac Rehabilitation and Exercise Training in Patients Who Achieved Weight Loss   A   Versus Patients Who Gained Weight   B
24978,One Year Event Free Survival in the Current Era Based on Peak Oxygen Consumption and Heart Failure Survival Score
24981,Outcomes Based on Initial Committee Decision
24983,Univariate and Multivariate Cox Proportional Hazards Model for Cardiac Death at Entry to Study
24984,Multivariate Proportional Hazards Model for All Cause Death
24986,Interaction Table for Functional Status by Covariate
24988,Selected Secondary End Point Outcomes
24991,Changes in Antiarrhythmic Drug Use During Follow Up
24992,Mean Comparisons in Quality of Life
24993,Mean Duration of Automatic Mode Switching   h
24999,Electrophysiologic Variables of Patients With and Without ICD Lead Failures
25000,Correlation of Clinical Presentation With Returned Lead Analysis
25001,Anthropometric and Echocardiographic Data on Endurance Athletes and Untrained Control Subjects
25003,Correlation Coefficients Between BNP Levels, Cardiopulmonary Exercise Variables and LVEF
25007,Pulmonary Function and Hemodynamics at Rest legend
25008,Change in Cardiorespiratory Function During Follow Up legend
25009,Cardiorespiratory Variables During Exercise legend
25010,Information of 46 Patients Undergoing Angioplasty for Obstructed Modified Shunt Stenosis legend
25011,Ejection Fraction, Acetate Flow and Metabolic Index, Ammonia Perfusion Index, Fluorine 18flurodeoxyglucose Metabolic Index and Mismatch Index for Each Patient legend
25013,Effect of Surgery on Exercise Parameters in Patients Undergoing Mitral Valve Replacement and Patients Undergoing Mitral Valve Repair legend
25014,Neurohormone Levels Before and After Surgery legend legend
25016,Vasodilator Response to Inhaled NO legend
25022,Concomitant Treatment During Study Period legend
25023,Changes in Secondary End Points During Study legend
25024,Anthropometric Values of Control Group and Patients legend
25025,Spirometric Values of Control Group and Patients legend
25026,Cardiorespiratory Exercise Measurement in Control Group and Patients legend
25028,Laboratory Findings in Strong Heart Study Participants Classified by the Presence and Degree of AR legend
25029,Left Ventricular Geometry in Relation to Presence and Degree of AR    legend
25030,Left Ventricular Function in Strong Heart Study Participants Classified by the Presence and Degree of AR    legend
25032,Hemodynamic Data in Patients at Rest, at Peak Exercise and during Recovery legend
25033,Hemodynamic Data at Rest, at Peak Exercise, and during Recovery in Patients with Overshoot of Cardiac Output at One Minute of Recovery above the Peak Exercise Value and in Patients without Overshoot legend
25035,MBF and Hemodynamics legend legend
25036,Echocardiographic Findings legend
25037,Literature Review of OSAS and Night Ischemia legend
25038,Clinical Data for Patients With and Without IHD legend
25039,The Effects of CPAP on OSAS Severity and Hemodynamic Variables legend
25040,Clinical Parameters of Study Population legend legend
25041,Clinical Parameters in Apoptosis Positive or  Negative Patients legend
25042,Diagnoses of Patients in Group 1   n   46   legend legend
25043,Diagnoses of Patients in Group 2   n   25   legend legend
25044,Hemodynamic Data for Group 1 legend
25045,Hemodynamic Data for Group 2 legend
25047,Coefficients of Correlation and Respective p Values Between RVEF and Other Variables in the Whole Population, in Patients With Ischemic Cardiomyopathy and in Patients With Nonischemic Cardiomyopathy
25048,Differences Between Patients Divided According to the Median Value of the RVEF   Median Value: 39
25049,Results of the Multivariate Stepwise Cox Analysis legend
25051,Cardiac Events and Status at Follow Up   mean 498.8  381 days
25052,Cardiac Event Rates According to Peak Oxygen Uptake, Age and Functional Class in Male Patients
25053,Percent of Event Free Male Patients in Functional Class I or II According to Peak Oxygen Uptake
25055,Multivariate Analysis for End Point of Death or End Point of Death or Listing as Status 1 in 154 Patients With a Peak Oxygen Uptake 14 ml min per kg
25059,Correlates for Peak Oxygen Uptake in Patients With Chronic Heart Failure and in Healthy Control Subjects
25063,Exercise and Gas Exchange Data
25064,Hemodynamic Data
25065,Magnetic Resonance Imaging Measures of Ventricular Volume and Mass Before and After Study Period  a
25066,Exclusion Criteria  a  and Enrollment During the 2 Year Study Period
25069,Changes in Baroreflex Sensitivity and Heart Rate Variability After Rehabilitation
25070,1 Year Clinical Outcomes
25071,Resource Use Over 12 Months After Enrollment
25073,Regression Analyses for Differences in ACh Provoked Spasm Between Patients With and Without Organic Stenosis
25075,Univariate and Multivariate Cox Proportional Hazards Analyses for CorrelatedFactors of MACE During Follow Up
25076,Regression Analyses for ACh Provoked Spasm at Site of Organic Stenosis
25078,Pearsons Correlation Coefficients   r   for Correlations Between on Treatment orPercent Change in Total, NonABCA1 Specific, or ABCA1 Specific Cholesterol Efflux Capacity and on Treatment or Percent Change in Lipid Variables in the Pooled Evacetrapib Monotherapy   n  111   and Pooled Statins Plus Evacetrapib   n  114   Groups
25080,BMI Adapted Tube Current and Voltage
25081,Computed Tomography Acquisition Parameters
25082,Diagnostic Accuracy
25084,Computed Tomography Scan Parameters
25085,Per Vessel Territory Diagnostic Accuracy of Coronary Computed Tomography Angiography, Transluminal Attenuation Gradient, Contrast Opacification Difference   Maximum, Mean, and Minimum  , and Quantitative Coronary Angiography Compared With Fractional Flow Reserve   N   78
25086,Scene, Transport, and Scene to Hospital Times Before and After PH ECG Implementation
25087,Scene, Transport, and Scene to Hospital Times in STEMI Versus No STEMI Diagnosis After PH ECG Implementation
25090,Clinical Results at 5 Years According to Treatment Group
25091,Clinical Results at 5 Years According to DES Type
25095,In Hospital Mortality by Operator Volume
25096,In Hospital Mortality by Operator and Hospital Volume
25098,Procedural Data and Medication at Discharge
25099,Outcome Evaluated by CMR
25101,Effect of  Blockers: Survival Time Inverse Probability Weighting Propensity Score Analysis
25102,Effect of  Blockers: Instrumental Variable Analysis
25105,Association of LOF Mutations in ANGPTL3 With PlasmaLipidConcentrations
25106,Association of ANGPTL3 Concentration With MI Risk in PROMIS
25108,Descriptive Statistics Stratified by Type of Admission
25109,Determinants of CICU LOS and 30 Day Hospital Readmission
25112,Writing Group Disclosures
25114,Incidence Rates and Hazard Ratios for Recurrent MI, CHD Events, and All Cause Mortality Among Medicare Beneficiaries With Statin Intolerance Versus High AdherencetoStatins
25116,Validation Cohort: Model Fitting
25117,Partitioned Risk Score
25119,Risk of AF, MI, and CHF With Alcohol Abuse
25121,Comorbidities
25122,Risk Factors Associated With Adverse Cardiac Events
25123,Risk Associated With Surgery
25126,Outcomes in PCI and CABG Groups Stratified According to SYNTAX Score
25127,Kaplan Meier Estimates of All Cause Mortality Stratified According to SYNTAX Score II Treatment Recommendations in the As Treated Population
25130,Procedure and Procedure Staging
25131,Incidence of MACCE at 30 Days, 12 Months, and Through End of Study
25133,Association of HF   Modeled as a Time Dependent Variable   With Subsequent Cancer Risk
25134,Type of Cancer by HF Status During Follow Up
25137,Statin Use for CAD and All Cause Mortality
25138,Stratified Analyses of Statin Use for CAD and All CauseMortality
25140,Medications at Discharge and Follow Up
25142,Prevalence of Solo and Combination Antiplatelet Prescription in AF Patients at Intermediate to High Risk of Stroke, Stratified by Prescription of Aspirin Versus OAC in the Overall CHADS2 Score2 and CHA2DS2 VASc Score2 Cohorts and Subcohorts of Patients With and Without Any Coronary Heart Disease Risk Equivalent
25145,Standardized Event Rates and Hazard Ratios for Adverse Cardiovascular Events According to Status of BP Control Based on the SPRINT and 2014 Hypertension Recommendations Among Adults With Hypertension in the NHIS Health Examinee Cohort
25148,1 Year Clinical Outcomes in the Intention to Treat Population
25150,Observed Outcomes
25153,Observed Post Discharge Care
25156,Predictors of ScT: Cox Proportional Hazard Analysis
25157,Quantitative Coronary Analysis Predictors of ScT
25158,Implantation Strategy Substudy: Cox Regression Analysis
25160,5 Year Clinical Outcomes
25161,Stent Thrombosis
25162,5 Year MACE, MI, and TLR After Censoring the Patient at the Time of the Stent Thrombosis   Before Target Lesion Revascularization   for Events Not Associated With Definite Stent Thrombosis
25164,Hazard Ratios of Incident Cardiovascular Events and Mortality and the 1 Year Number Needed to Treat to Prevent 1 Event by the Use of Statins: Intention to Treat Analysis
25166,Baseline Characteristics of the Studied Populations
25168,1 Year Clinical Events According to Randomized Allocation
25171,Landmark Analysis at 30 Days
25172,CMR Results
25173,Tissue Changes in the Ischemic Myocardium During Week 1 Post I R
25174,Myocardial Water Content and Hemorrhage Score in Pigs
25176,Mortality rates by age and cause, Katale Camp, Zaire
25177,A40, A42  43  , and total Aaccording to APOE coding and promoter polymorphisms
25178,A40, A42  43  , and total A according to APOE coding and promoter polymorphisms after classification by APOE 4 or age
25179,Results of APOE genotyping
25180,Results of screening for AD with 4 allele and 4 4 genotype as test
25181,Pathological diagnoses of ten non AD patients
25182,Results of 173 patients referred for necropsy
25186,Univariate and Multivariate Analyses of the Predictor of Poorer Outcomes Post TAVR
25189,Return of spontaneous circulation and survival to discharge in all patients, by hospital quartile
25190,Return of spontaneous circulation in patients stratified by presenting rhythm of pulseless electrical activity or asystole versus ventricular tachycardia or fibrillation, by hospital quartile
25191,Survival to discharge in patients stratified by presenting rhythm of pulseless electrical activity or asystole versus ventricular tachycardia or fibrillation, by hospital quartile
25194,Temporal Trends in Proportion of ST Segment Elevation Myocardial Infarction Among Younger Patients With AcuteMyocardialInfarction
25200,Genotype in relation to biochemical phenotype after TMA challenge
25201,Long Term Mortality by Treatment Arm
25202,Multivariate Analysis of 10 Year Mortality
25203,All Cause Mortality by Risk Group
25204,Input data and indicators for regional calculations
25205,Definitions of variables and parameters in the age structured TB model.
25206,Estimates for transition parameters in  Table 1 .
25207,Sensitivity analysis of the tuberculosis model. Partial rank correlation coefficients   PRCC   of key x variables for each of two y  variables   a   the annual rate of fall in incidence   without HIV  , and   b   the fraction of cases prevented under DOTS   with HIV  .
25208,Sense of dignity item scores
25210,Scores on the index of independence in activities of daily living by dignity group
25211,Disease status of preliminary and masked sets
25212,Classification of serum samples from masked validation set by proteomic pattern
25213,Number of patients with available dates 197695
25214,Delays for visits and treatment by different time periods
25216,Delays from family physician visit to treatment by age, extent of disease, and grade
25217,Age  and Sex Adjusted Cox Proportional Hazards Models for Determinants of Incident AF
25218,Hazard ratios for delays for all patients and by age younger or older than 50 years
25219,Incidence Rates of Cardiovascular Events, Heart Failure, and All Cause Mortality per 1,000 Person Years
25220,Association of Incident AF     With Outcomes
25221,Composition of study group
25222,Risk of cancer in carriers of 999del5 BRCA2 mutation
25223,Observed numbers of individuals with onset of regular heroin use in 19922004, by year of first visit to a treatment facility
25224,Effects of Randomized Treatment Allocation on the Risk of Any Coronary Events Adjusted for Parameters of LDL C   as a Continuous Variable
25225,Effects of Randomized Treatment Allocation on the Risk of Any Cardiovascular Events Adjusted for Parameters of LDL C   as a Continuous Variable
25229,Procedural Complications and In Hospital Outcomes in Retrograde Lesions, 2008 to 2012
25230,Univariate and Multivariate Logistic Regression Modeling, Procedural Failure
25233,Clinical Outcomes of Short  Versus Long Term DAPT
25234,Effect Estimates for Cumulative 1 Year Events
25235,Randomized Controlled Trials Included in Network Meta Analysis
25236,Estimates of Risk of ST According to Various Definitions Between Different DES and BMS
25237,Estimates of Risk of Death, Cardiac Death, Myocardial Infarction, and Target Vessel Revascularization With Different Types of Drug Eluting Stents and BMS
25239,Adjusted Cumulative Effect of Smoking Status on MI
25240,Independent Predictors of Outcomes Using Smoking as Time Dependent Covariate
25243,Quantitative Coronary Angiography Measurements
25244,Clinical Outcomes at 9 Months
25245,Type and Dose of Statin Prescriptions Filled
25246,Percentage of Medicare Beneficiaries 75 Years Filling Prescriptions for High Intensity Statins After a CHD Event
25250,LV Systolic and Diastolic Dysfunction at Year 25 Predicted from Cumulative Exposure to SBP and DBP
25251,Relationship of Cumulative Exposure to BP Over 25 Years to Systolic LV Functional Indices
25252,Relationships of Cumulative Exposure to BP Over 25 Years to Diastolic LV Functional Indices
25255,Time Segmented HR Derived by Time Dependent CovariateCox Regression Comparing PCI Modalities   BMSorDES  to SA  and MA CABG Surgery
25267,Efficacy and safety measures at 10, 90, and 180 days.
25268,Functional outcome and symptomatic intracranial haemorrhage by timing of treatment
25269,Reasons for withdrawal from randomised treatment
25270,Adjudicated causes of death up to day 180
25272,Causes of death in patient cohort
25273,Mortality in 3324 first degree relatives of 862 patients with coeliac disease
25274,Annual meningitis incidence, S gou Region, Mali, 198998
25275,Time elapsed between crossing the incidence threshold and reaching the peak for 63 meningitis epidemics in 41 subdistricts, Mali 198998
25276,Performance of weekly meningitis incidence thresholds for detecting and predicting meningitis epidemics, SgouRegion, Mali, 198998
25277,Annual occurrence of epidemic meningitis and crossing of weekly incidence thresholds in 41 subdistricts
25281,Cohorts investigated
25282,Family based linkage and association tests in UK and German families and German trios
25283,Mutation frequency in cases and controls
25285,Concomitant therapy
25286,Clinical outcome
25287,Bleeding and thrombocytopenia
25288,DALE at birth in WHO member states in 1999
25291,6 month mortality models
25293,Invasive colon and rectal cancer incidence rates and standardised incidence ratios for women with incident breast cancer
25298,Blood pressure in relation to early diet
25300,Number of complete pairs and intraclass correlations for monozygotic and dizygotic twin pairs
25301,Estimates and 95  CI of genetic and environmental variance
25302,Age and sex distribution of the controls and patients with Down s syndrome
25303,Median scores for the latencies for pain sensation
25304,Median localisation scores for each site tested on the hand, face, and mouth
25305,Differences in ability of the patients with Down s syndrome and controls to localise stimuli according to age and site
25306,Distribution of clusters according to cluster size, number of mines involved in each cluster, and number of patients linked to other cluster members by current or past employment
25308,Univariate analysis of risk factors for clustering in 371 goldminers
25309,Hospitalization Rates   per 100,000 Persons   for Young Patients With AMIs Stratified by Age andSex,2001 to 2010
25310,Multiple logistic regression of the association of risk factors with clustering
25311,In Hospital Mortality   Percentages   Among Men and Women With AMIs 30 to 54 Years of Age in the UnitedStates, 2001 to 2010
25312,In Hospital Mortality   Percentages   by Race and Sex Among Patients With AMIs 30 to 54 Years of Age in the United States, 2001 to 2010
25313,Length of Stay   Days   Among Men and Women With AMIs 30 to 54 Years of Age in the United States, 2001to 2010
25314,Length of Stay   Days   by Race and Sex Among Patients With AMIs 30to54Years of Age in the United States, 2001 to 2010
25316,Cardiac Events by Use of Beta Blockers
25319,Safety Outcomes in Prohibitive Risk DMR Cohort   N 127
25325,The Impact of NC Prolapse, Medial Tear, and Incomplete Apposition on Early Stent Thrombosis
25326,Univariate and Multivariate Analysis of Histomorphometric Parameters as Determinants of Early Stent Thrombosis
25330,Propensity Matched In hospital Adverse Events in Female and Male PVI Patients
25333,Angiography Results
25334,Major Adverse Clinical Events
25342,Radial Versus Femoral Access by Radial PCI Center Volume
25343,Radial Versus Femoral Access by Radial PCI Operator Volume
25344,Outcome Stratified by STEMI and NSTEACS
25347,1 Year Outcome Rates and Unadjusted and Adjusted Hazard Ratios
25348,Lesion Outcomes Among Patients Undergoing Endovascular Interventions
25351,Cardiac Magnetic Resonance Imaging Results
25352,Angiographic Results
25354,Percentages of Patients Receiving Secondary Prevention Medication, byCountry and Overall, in Phase 1
25355,Multivariable Analysis of Variables That Independently Contribute to Adherence, Phase 1
25356,Differences in Adherence Using MAQ and Pill Count, Primary Endpoint inPhase2
25357,Changes in Mean BP and Mean LDL C Over 9 Months for Polypill Treatment and Control Groups, Phase 2
25358,AEs Reported in Fixed Dose Combination and UsualCare Groups During the Trial, Phase 2
25360,Left Ventricular Size and Shape in Patients With Mild and Moderate Severe MR
25361,Differences in Regurgitant Orifice Area With Different Geometric Perturbations of the Mitral Valve Using the Computational Mitral Valve Model
25364,Adverse Cardiac Events and All Cause Mortality at 30 Days Post Operative TimeInterval: Surgical Versus Nonsurgical Cohort
25365,Adverse Cardiac Events and All Cause Mortality and Risk Differences in the Post Stent Cohort Undergoing Surgery Versus the Matched Nonsurgery Cohort During the Matched 30 Day Interval, Stratified by Time From Coronary Stent Placement
25366,RD for Adverse Cardiac Events in the Stent Surgery Group, by Surgery Characteristic, When Surgery was Performed  6 Weeks After Stent Placement
25367,Temporal Trends in Stent Use During SVG PCI Performed During 20082011 in the VA Health System Nationwide
25370,Procedure Related In Laboratory Complications Seen in the Study Cohort Stratified by Stent Type
25371,Adjusted Mortality and Myocardial Infarction Rates Seen intheStudy Cohort Stratified by Stent Type
25372,Summary of Existing Evidence Comparing DES With BMS in SVG PCI
25375,Baseline Demographics Stratified by MACE at Follow Up
25376,Outcome Events Stratified by IPC Tertile
25380,Clinical Outcomes
25383,Quantitative Coronary Angiographic Analysis
25384,Independent Predictors of SB Occlusion
25385,Clinical Outcomes at 12 Month Follow Up
25387,Segmental Weighting Factors Used in SS
25389,SS Use Among Different Populations
25390,Comparison of SS and Derived SS Systems
25391,Genes Represented by the ARS and Their Correlations With Platelet Function With Aspirin
25392,Aspirin Response Signature Proteins Identified in Platelet Protein and Their Correlations With PFS onAspirin
25396,Echocardiographic Data for 98 Patients With COPD With and Without PH and 34 Healthy Controls
25397,Invasive Hemodynamics and Echocardiographic Functional and Geometry Measurements inThose With No PH Subdivided Into 2 Groups: Mean PAP20 mm Hg   Normal   and MeanPAP 21 to 24 mm Hg   Borderline
25400,Randomized Controlled Trials Included in the Network Meta Analysis
25401,Differences in Clinical Outcomes Among Different Stent Types at 1 Year and Long Term Follow Up
25402,Time Related Differences Among Different Stent Types for the Risk of Definite and Definite Probable Stent Thrombosis
25403,Event Rates per 100 Patient Years and Probability for Each Stent to Be Best at 1 Year and at the Latest Follow Up Available
25406,Outcomes in Randomized Controlled Trials
25407,Outcomes in Observational Studies
25410,Clinical Endpoints at 5 Year Follow Up of the Nordic Bifurcation Study
25415,MACCE in the Hybrid, CABG, and PCI Groups
25416,The Location of the Repeat Revascularization Performed in Hybrid, CABG, and PCI Groups
25417,MACCE in Hybrid, CABG, and PCI Groups From LowtoHigh EuroSCORE Tertile
25418,MACCE in Hybrid, CABG, and PCI Groups From LowtoHigh SYNTAX Score Tertile
25420,Two Year Clinical Outcomes
25421,Outcome Differences Between 1 and 2 Years
25423,Details on Definite or Probable Stent Thrombosis
25430,Clinical Follow Up
25431,Quantitative Coronary Analysis for Main Vessel and Side Branch
25433,Multivariable Adjusted Linear Regressions Between Cardiovascular Risk Factors and Epicardial Fat Volume
25434,Cox Regression for Fatal or Nonfatal Coronary Event per Each Doubling of Epicardial Fat
25435,Current diagnostic and therapeutic applications of Seldinger technique
25437,Health Benefits, Costs, and Incremental Cost Effectiveness Ratio From Statin Therapy for Patients With Different Age, Sex, and Cardiovascular Risk Profiles
25438,Male death rates attributed to smoking   Yes   and not attributed to smoking   No  , by social class, education, or neighbourhood income
25439,Data sources and country codes
25440,Proportion of households with catastrophic health expenditures
25441,Determinants of catastrophic health expenditure
25442,Data for individual patients
25444,Morbidity by level of education for men aged 2569: ordered by odds ratio for perceived general health
25445,Overview for morbidity: ordered by average ranks
25446,Mortality by occupational class in men in manual versus non manual occupations: ordered by risk differences
25447,Overview for mortality: ordered by average ranks
25450,Clinical Outcomes in Crude Population at 1 Year
25451,Stent Thrombosis in Crude Population at 1 Year
25452,Independent Predictors of Target Lesion Failure in Propensity Score Matched Group
25454,Mean annual rates of suicide in different population groups in China, 199599
25455,Leading causes of death in different population groups in China, 199599
25457,Crude and age adjusted   new Segi world population   yearly rates per 100000 for adults in Dar es Salaam, Hai district, Morogoro rural district, and England and Wales
25458,Place of death for people dying from stroke in Dar es Salaam, Hai district, and Morogoro rural district
25459,Analysis of death certificates and occupational records
25460,Breakdown of jobs involving metal exposure listed in lifetime occupational records
25461,Mammography screening trials according to methodological quality
25462,Relative risk of death from breast cancer in screened versus control groups
25463,Number of women and follow up to Dec 31, 1995
25464,Attendance at screening and breast self examination sessions by age at entry
25465,Breast cancer detection rates at screening   all cohorts
25466,Observed and expected deaths from breast cancer   diagnosed in all years   in the initial cohort within 16 years, andrate ratios   intervention centres vs combined comparison centres
25467,Observed and expected deaths from breast cancer in the initial cohort within 16 years and rate ratios   intervention centres vs combined comparison centres   for cases diagnosed within 7 and 10 years of date of entry
25468,Breast cancer deaths in relation to age at entry for all cohorts
25469,Breast cancer mortality rate ratios in relation to age at entry for individual breast self examination centres relative to comparison centres   all cohorts
25471,Overview of protective safeguards for patients who considered euthanasia
25472,Description of Studies Included in Meta Analysis
25473,Fossil fuel energy use   1018 J   under business as usual and climate policy scenarios
25474,Annual avoided mortality with 90  CIs   combined adult and neonatal infants   from climate policy cenarios   15  below 1990 levels by 2010 for A1 countries and 10  below BAU levels by 2010 for NA1 countries
25475,: Sensitivity analysis of avoidable deaths from climate policy: 2000 to 2020
25476,Distribution by Dukes  stage and mortality by time and stage in institution I data set
25477,Distribution by Dukes  stage and mortality in institution II data set
25478,Performance of artificial neural networks trained and validated on data from institution I
25479,Performances of clinicians and previously trained 12 month artificial neural network on data set from institution II
25480,Mortality ratios in 199193
25481,Mortality ratios in 199293
25482,Mortality ratios in the year after the first unemployment experience
25483,Fatal and non fatal railway injury in the Cape Town metropole by injury category from April 1, 1992, to Sept 30, 1994
25484,Temporal distribution of fatal and non fatal railway injury in the Cape Town metropole from April 1, 1992, to Sept 30, 1994
25485,Current and daily prevalence of tobacco use in individuals aged 1564 years in Uruguay and 1864 years in Argentina, 200109
25486,Conversion from ES into NNT
25491,Inhibitory activity of hyperforin in gram positive and gram negative bacteria and in Candida albicans
25492,Suicide data for Scotland 199097  3   and England and Wales 199195  4
25493,Questionnaire results: west African and Afro Caribbean cases compared   both sexes
25494,Relative change in age standardised prevalence of current smoking by WHO region
25495,Probability of achieving the target of a 30  relative reduction in tobacco use by WHO region
25497,Induced and No Induced Clinical VTs During the Ablation Procedure
25498,Recurrent and No Recurrent VTs After the Ablation Procedure
25499,Recurrent VTs After the Ablation Procedure
25500,MRI protocol for patients with suspected acoustic neuroma and noise levels during different scan sequences
25502,Prevalence of overweight and obesity
25505,Efficacy and Safety Outcomes in Patients With STEMI and NSTEACS
25508,Diagnosis of patients following imaging
25512,Angiographic Outcomes at Follow up
25513,Clinical Outcomes
25514,Subgroup Analysis of In Stent   In Balloon   Late Loss
25516,Country level classifications for 0by25 initiative
25518,AKI in earthquakes and regional disasters
25520,Focus areas for the 5 Rs approach to intervention in patients with AKI  1
25521,Strategies to reduce preventable deaths from acute kidney injury   AKI   through the 5 Rs
25522,Potential metrics for an AKI scorecard
25523,Validated health administrative data case definitions used to determine incidence of disease and their validation measures
25524,Lifetime risk of being diagnosed with chronic obstructive pulmonary disease before reaching age 80 years by age
25525,Masking scheme
25526,Modified Medical Research Council dyspnoea score
25528,Composite primary safety endpoint, 6 months post procedure
25529,Respiratory serious adverse events, at 6 months post procedure
25530,COPD exacerbation or infection, up to 12 months post procedure
25536,All serious adverse events, adverse events occurring in 10  or more of patients in any treatment group, and adverse events of special interest
25538,EBF prevalence at ages 12 weeks and 24 weeks based on 24 h recall and 7 day recall
25539,Diarrhoeal morbidity by 2 week recall at ages 12 weeks and 24 weeks
25542,Clinical Outcomes by Treatment and Tertile of Age
25543,First hospital admissions for heart failure per 1000 patient years by category of updated mean HbA 1c
25545,Rates of Death by Treatment Stratified by Tertiles of Age and Diabetes Status
25546,Full Cox regression model for development of heart failure for updated mean HbA1c, risk factors, and comorbidities
25549,Adverse events in the safety population   n 2485
25551,Treatment emergent adverse events leading to discontinuation of study drug in the safety population   n 2485
25553,Current and emerging antiobesity drugs
25554,Subject Incidence of AEs
25556,Established treatments for osteoporosis
25557,Clinical development of novel treatments for osteoporosis
25558,Study programmes of investigational osteoporosis drugs
25561,Assessment of duration of gestation by provider
25562,Outcomes of medical abortion by type of provider
25564,Frequency and type of major adverse cardiac event during initial hospital attendance or 30 day follow up
25565,Occurrence of MACE during initial hospital attendance or 30 day follow up according to results of individual and combinations of the ADP test parameters
25566,Accuracy   95  CI   of POC biomarkers, ECG, and ADP for prediction of MACE
25569,Primary endpoints
25570,Most common adverse events and serious adverse events
25573,Estimated treatment differences in HbA1C, fasting plasma glucose concentration, and bodyweight at trial end
25574,Hypoglycaemic episodes
25575,Estimated rate ratios and odds ratios of confirmed hypoglycaemic episodes
25577,Eradication rates in the PP and ITT populations
25579,TEAEs in the treated population
25581,Progression free survival and best overall tumour response as assessed by independent review and investigator review
25582,Adverse events with an incidence higher than 10  in either treatment group
25583,Review of phase 3 trials in patients with MBC previously treated with an anthracycline and a taxane, including results of the EMBRACE study
25586,Risk Loci for Coronary Artery Disease Myocardial Infarction Discovered by Genome Wide Association Studies
25587,Adverse events in safety population
25590,Treatment emergent adverse events and pregnancy outcomes during 52 weeks of study
25592,Definitive cure at 6 months, by treatment group
25593,Differences in cure rates between treatment groups and the standard group, and between groups
25594,Serious adverse events and most common adverse events related or possibly related to treatment   ITT population
25596,Randomisation scheme for cohorts 14
25597,Dosing table for cohorts 15
25601,Summary of Clostridium difficile infection in countries and hospitals
25606,Description of new drugs for the treatment of gout
25607,Summary of three phase 3 randomised controlled trials of febuxostat
25608,Summary of phase 2 and phase 3 clinical trials of pegloticase
25610,Adverse events during treatment
25611,Events of special interest
25613,Clinical Outcomes Through 1 Year
25621,Causes of death in neonates and at ages 159 months in this study and estimated national totals
25623,Seroconversion 30 and 60 days after vaccination
25624,Titre at birth and 30 and 60 days after vaccination
25625,Adverse events
25628,Treatment emergent adverse events possibly or probably related to treatment in at least 1  of patients   intention to treat population
25629,Treatment emergent adverse events leading to discontinuation of treatment   intention to treat population
25631,Selected pharmacokinetic results
25632,Adverse events during treatment occurring in at least two patients in any treatment group
25635,In Hospital Clinical Outcomes and Mortality at Follow Up
25638,Treatment received and reasons for discontinuation in the intention to treat population
25640,Adverse events reported in patients who received at least one dose of study treatment
25641,Deaths in patients who received at least one dose of study treatment
25649,Adverse events and safety endpoints
25650,Adverse events leading to discontinuation
25652,Univariate and Multivariate Analyses of In Hospital Deaths According to Status of Diabetes and Prior Exposure of Statins
25655,Clinical and Angiographic Outcomes
25657,Clinical and Angiographic Outcomes of the Propensity ScoreMatched Groups
25660,Clinical Outcomes
25661,Definite and Probable Stent Thrombosis in First and Second Years After Index Procedure
25663,Angiographic Findings in the Patients With Significant Coronary Artery Disease
25664,Echocardiographic Findings in Patients With and Without Significant Coronary Artery Disease
25665,Univariate and Multivariate Logistic Regression Analyses of Predictors of Significant Coronary Artery Disease
25666,Echocardiographic Findings in Patients With Significant Coronary Artery Disease Before and After Revascularization
25668,BB on Discharge
25669,Dose Distribution of Metoprolol and Carvedilol on Discharge
25670,Genotype Frequencies and HW p Values
25672,Quality Improvement Resources and Performance Monitoring
25673,Medication Management Practices
25674,Discharge and Follow Up Procedures
25675,Summary Scores of Hospital Practices to Reduce Preventable Readmissions
25677,Procedural Data and Acute Echocardiographic Outcomes
25678,Clinical Outcomes at 30 Days and 12 Months of Follow Up
25680,Multivariable Cox Analyses Estimating HR for High NGAL   Upper Quartile  170.1 g l
25681,Cox Models for Risk of All Cause Mortality in Groups Based on NGAL and CRP
25683,Myocardial Perfusion Abnormalities Among Patients Undertaking Myocardial Perfusion Imaging
25684,Incidences of Adverse Events Over 5 Years
25685,Adjusted HRs of Ischemia Guided Revascularization for Events
25686,Propensity Score Matching Analyses
25688,Pooled 12 Month Event Numbers, RR   95  CI  , and ARR   95  CI   for an Invasive Versus Conservative Treatment Strategy, Stratified by DM Status
25690,Angiographic Endpoints
25691,Major Adverse Cardiac Events   n   529
25692,Late Cardiac Outcomes and Study Graft Failure of Adjudicated Cases
25693,Selected Publications Reporting at Least 1 VARC Criterion in TAVR Population
25694,Proportion of Studies Reporting Outcomes Using Appropriate VARC Definitions
25695,30 Day and 1 Year VARC Outcomes After TAVR
25696,VARC: Prosthesis Related Complications
25699,LV Volumes and Mass According to the Reperfusion Strategy
25701,Multivariate Analysis: Risk of Long Term   8 Year   Mortality in the MADIT II Population by the Type and Number of Risk Factors
25702,Hazard Ratios of ICD Versus Conventional Medical Treatment by Risk Score Subgroups During 8 Year Follow Up
25704,Angiographic and Procedural Variables From the Original Index Procedure of Patients With Subsequent In  and Out of Hospital Definite Probable ST
25706,1 Year Clinical Outcomes in Patients With In Hospital Versus Out of Hospital Definite Probable Stent Thrombosis
25707,Adjusted Hazard Ratios for 1 Year Mortality Following In  Versus Out of Hospital Stent Thrombosis Adjusted for Selected Covariates   Model 1   and Propensity Score   Model 2
25708,Components of Intraprocedural Thrombotic Events   N   121
25711,Clinical Outcome According to Intraprocedural Thrombotic Event Occurrence
25712,Components of IPTE as Predictors of MACE at 1 Month and 1 Year
25713,Independent Predictors of Adverse Events at 30 Days and 1 Year
25716,Quantitative Coronary Angiography and Procedural Results
25717,1 Year Clinical Outcomes in the Intention to Treat Study Population
25720,Quantitative Angiographic Analysis Pre Procedure and Post Procedure
25721,Quantitative Angiographic Analysis at 9 Month Follow Up
25722,Clinical Events at 1 Month and 12 Month Follow Up
25724,Optical Coherence Tomography Findings
25731,Unadjusted 900 Day Event Rates and Adjusted HRs Comparing DES Versus BMS Stratified According to Age Group
25733,Primary respiratory outcomes by intervention group
25734,Primary diarrhoea and impetigo outcomes in children younger than 15 years by intervention group
25735,Mean pneumonia incidence by age and intervention group
25736,Mean pneumonia incidence in children younger than 5 years by nutrition status and intervention group
25740,Bacteriological results
25741,Outcome measures
25744,Clinical Outcomes According to On Treatment Platelet Reactivity
25745,Clinical Outcomes According to CRP Level
25746,C Statistic for Cox Regression Models for Prediction of Primary Endpoint
25748,Logistic regression analysis of clinical and laboratory adverse events attributed to antiretroviral treatment regimens
25749,Logistic regression analysis of adverse events attributed to specific antiretroviral treatment agents
25750,Number of children with rotavirus infection by age and HIV status
25751,Severity of rotavirus disease among inpatients by HIV status
25754,Adverse reactions occurring in more than 5  of patients in any treatment group
25755,Analysis of necropsy tissues from patients with vCJD for PrPSc
25756,Concentrations of PrPC detectable in components from sporadic and variant CJD eye
25760,Plasma Leptin Concentration and Adjusted HR   95  CI   for Incident HF in Men With and Without Pre Existing CHD
25761,Mode of delivery
25762,HR   95  CI   for Incident HF Associated With BMI and WC in Men With and Without Pre Existing CHD
25763,Neonatal outcomes
25764,Retrospective analysis of CD44v6 and galectin 3 expression on resected thyroid lesions
25765,Discrimination between benign and malignant thyroid lesions by immunodetection of CD44v6 and galectin 3 in retrospective study of thyroid histological samples
25766,Retrospective analysis of cell blocks from fine needle aspiration cytology
25767,Discrimination between benign and malignant thyroid lesions by immunodetection of CD44v6 and galectin 3 on cellblocks from fine needle aspiration cytology in retrospective analysis
25768,Prospective study of CD44v6 and galectin 3 expression on fresh cytological specimens
25769,Discrimination between benign and malignant thyroid lesions by CD44v6 and galectin 3 immunodetection on fresh cytological material from preoperative fine needle aspiration
25774,Abstinence rates during treatment and follow up phases
25775,Observed frequencies of abstinence from week 3 to end of week 7
25779,Comparisons of Blood Volume Flow, Blood Velocity, and Pulse Wave Velocity Between Young Smokers and Healthy Controls
25781,Efficacy of group 1 and group 2 regimens: response rates in the evaluable population
25782,Efficacy results of the group 1 and group 2 regimens: response durations and survival
25783,Haematological and non haematological toxicity profile of group 1 and group 2 regimens
25784,Regional Stress Echocardiography Parameters Measured in Patients With Idiopathic Dilated Cardiomyopathy
25785,Number of cases positive for parvovirus B19 by different diagnostic techniques
25786,Clinical and laboratory findings in cases positive for parvovirus B19 DNA
25790,Univariate analyses on risk of severe hypoglycaemia in patients untreated with ACE inhibitors and angiotensin II receptor antagonists
25791,Stepwise regression analysis of risk of severe hypoglycaemia in patients untreated with ACE inhibitors and angiotensin II receptor antagonists
25796,Serious adverse events
25797,Schedule for controlled non heart beating donor lung transplantation
25798,Haemodynamics and lung function ex vivo
25801,Primary and secondary endpoints at study entry and after 6 months
25802,Doses of Pharmacologic Agents Received After 12 Months of Therapy in Patients With Heart Failure in Whom Either Perindopril   ACEI First   or Carvedilol   BB First   Therapy Was Initiated First
25805,Univariate analyses of factors associated with recurrent C difficile diarrhoea
25806,Hospital staffing and case load
25807,Assessment or treatment factors considered likely to increase the risk of poor outcome
25808,Proportion of doctors, nurses, and medical assistants with inadequate knowledge or reported practice for assessing and managing specific conditions
25809,Supplies found in emergency treatment area or entire hospital
25810,Ratings of avoidable morbidity and mortality in study hospitals
25811,Putative HCM Causing Mutations and Nonpathogenic, Nonsynonymous Polymorphisms Identified in MYBPC3
25815,Blood glucose thresholds   mmol L   for symptoms and counterregulatory hormones in type 2 diabetic patients and controls
25817,Subgroup comparisons of calcium antagonists vs other drugs
25818,Subgroup comparisons of calcium antagonists vs ACE inhibitors and diuretics and  blockers
25819,Clinically important genetic polymorphisms of drug metabolism that influence drug response
25820,Distribution of polymorphic genes encoding CYP2C9, CYP2D6, and N acyltransferase 2 in different populations
25821,Clinically important genetic polymorphisms of drug targets and drug transporters
25824,Predictors of 12 month survival   n 123
25825,Health related quality of life in NTDS patients and elderly people in the general population
25826,Dialysis related and inpatient costs      during the 12 month study period   n 171
25828,Mean   SE   outcome measures before and after treatment
25831,SPECT Perfusion Results Per Vascular Territory of the Bypass Graft
25832,Mean   95  CI   change in secondary outcomes after prednisolone treatment compared with placebo
25833,Agreement of SPECT Perfusion and CMR
25834,Agreement Between SPECT and CMR in Four Categories
25835,Known and possible mitochondrial toxicities of nucleoside and nucleotide analogue HIV reverse transcriptase inhibitors
25836,Clinical features of hypersensitivity to antiretroviral drugs
25837,Other antiretroviral drug toxicities
25839,Follow up data and specification of death causes for all participants in 196472, during 30 years of follow up
25840,Relative risks of airway hyper responsiveness and all cause and cause specific mortality after adjustment for major risk factors for mortality during 30 years of follow up
25841,COPD deaths   primary and secondary   according to smoking habits and histamine threshold
25843,Lipids, Lipoproteins, and Apolipoproteins of Carriers and Noncarriers of ApoA I Mutation   L178P
25844,Admission risk markers and associated score component values
25845,Distribution of risk scores for score development and validation groups of patients
25846,Spearman s correlations between scores and length of stay and units of blood transfused   validation group
25847,Fast track screening risk predictions and numbers of patients needing clinical treatment   validation group
25848,Multivariate Analysis of Risk of Coronary Artery Disease Attributable to the L178P Mutation Carrier Status
25850,Effect of vitamin E treatment on cardiovascular outcomes in the SPACE cohort
25851,Causes of death by treatment and disorder in SPACE cohort
25852,LVESVI   ml m2   and Mitral Valve Repair
25853,EF       and Mitral Valve Repair
25854,Preoperative and postoperative symptoms of the five patients with pain and faecal urgency at follow up
25855,Comparison of patients with and without pain and faecal urgency 6 months after stapled haemorrhoidectomy
25856,Details of anorectal physiology tests in affected patients
25858,Serious adverse events
25859,Incidence of significantly elevated prespecified plasma analyses
25860,Most commonly arising treatment emergent adverse events
25861,Death and comorbid events of worsening heart failure
25867,Antihypertensive treatment at final visit
25869,12 most frequent adverse effects
25872,Numbers of patients and events by country
25873,Adverse events reported by investigators
25874,Cox s regression analysis of risk factors
25875,Individual endpoints
25878,Diagnosis in patient population
25879,Sensitivities, specificities, positive and negative predictive values, and probabilities for comparison of differences in sensitivities
25880,Detection of pancreatic carcinoma and chronic pancreatitis by MRCP and ERCP
25882,Changes in anthropometric variables during the intervention
25883,Concentration of zinc in serum and hair at the end of the intervention period
25884,Incidence of anorexia and selected illnesses during the 6 month intervention period
25886,Efficacy variables
25887,Numbers of participants reporting adverse events during the first 28 days after drug intake
25889,Primary outcome and in hospital mortality
25890,Physiological factors
25891,Median nursing workload by group and time period
25894,Numbers of toxic events reported by treatment
25895,Summary of trials in advanced colorectal cancer that compared high dose and low dose folinic acid
25897,Organ volume, haemoglobin, platelet count, and chitotriosidase values before and during OGT 918 treatment
25898,24 H Holter Monitoring Electrocardiographic Recordings in 148 Control Group Athletes
25901,Signs and symptoms recorded during hospital stay
25903,Hemodynamic Parameters at the Time of Study Enrollment
25906,Monthly responders
25907,Summary of all adverse events
25909,Response rates
25910,Logistic regression of predictive factors for response rate
25911,Cox s model for time to progression
25912,Patients with any adverse event and with grade 34 adverse events related to study treatment   weekly regimen
25913,Patients with any adverse event and with grade 34 adverse events related to study treatment   2 weekly regimen
25919,Mean blood pressures in 5489 control patients followed up for 2 years
25921,Tissue measurements
25922,Analysis on a per woman basis
25925,Determinants of Conversion in 104 Patients With AF AFL Treated With Ibutilide and Propafenone
25932,Distribution of deaths by age and cause, and breastfeeding prevalence among controls
25933,Infant mortality associated with not breastfeeding, by country and age group
25934,Infant mortality associated with not breastfeeding, by country, age group, and sex
25935,Mortality at 1223 months of age associated with not breastfeeding, by country and age group
25937,Use of secondary care in participants admitted at least once during study period
25939,Use of primary care facilities during the year from entry to the study
25943,Colitis in patients
25944,Polymerase Chain Reaction Primer Sequences, Cycling Methods, and DHPLC Temperatures
25947,Polymorphisms Identified
25949,Causes of acute pulmonary oedema
25952,Reasons for withdrawal from the trial, categorised by sibutramine dose
25955,Proportion of patients reporting adverse events during the weight loss phase and by at least 5  of patients in either treatment group during the double blind phase
25956,Clinical and Electrophysiological Data on Group I
25957,Positive and Negative Predictive Values of the Induction of Monomorphic Ventricular Tachycardia  270 beats min and Ventricular Fibrillation to Predict All Cardiac Deaths, Sudden Death, and Death Related to Heart Failure in Group I
25958,Clinical and Electrophysiologic Data on Group II
25961,Gastrointestinal ulcer frequency
25962,Most frequently reported adverse events
25963,Positive and Negative Predictive Values of Positive Programmed Ventricular Stimulation   VT and VF   to Predict Total Cardiac Death, Sudden Death, and Death Related to Heart Failure in Group II
25965,Univariate Logistic Regression Results of Hemodynamic Parameters for In Hospital Mortality
25966,Multivariate Logistic Regression Results for In Hospital Mortality   Using Cardiac Power Index     n   178
25967,Multivariate Logistic Regression Results for In Hospital Mortality   Using Cardiac Power Output     n   181
25968,Selected Hemodynamic Parameters of Patients With Shock Due to Predominant Left Ventricular Failure by Culprit Artery
25972,Adverse events
25975,Supine blood pressure   mmHg
25976,Proportions of patients reporting 12 most common adverse events
25977,Frequency of events per 1000 patient years
25979,Neurointerventional and diagnostic procedures
25980,Odds ratios from logistic regression for the training set of 432 cases
25981,Accuracy of gram stain and AOLC test for the diagnosis of catheter related bloodstream infection
25982,Comparative accuracy of gram stain and AOLC test with three other methods for diagnosis
25983,Clinical and Echocardiographic Data Before, During, and After Pregnancy
25984,Comparisons Between Repeat Measurements of Peak Velocities, Pressure Half Time, and Mitral Valve Area With Velocity Encoded Cardiovascular Magnetic Resonance
25985,Congenital dislocation of the hip   CDH   among livebirths
25986,Operative procedures by age at diagnosis of CHD
25989,Comparison of LVIDd in a Subset of Athletes Engaged in High Impact Sports   Cycling, Cross Country Skiing, Canoeing, Rowing, and Soccer      10   and in Professional Cyclists   Current Study   According to BSA
25991,Primary and secondary outcome measures
25992,Reasons for death
25997,Unadjusted Use of Evidence Based Therapies and Outcomes in Ideal Patients With Acute Myocardial Infarction, n
25999,Unadjusted Use of Evidence Based Therapies and Outcomes by Region in Ideal Patients With Acute Myocardial Infarction, n
26002,Serological confirmation of cases of leptospirosis
26003,Bacteriological confirmation of cases of leptospirosis
26009,Histopathology   central review
26010,Results of subgroup analyses
26012,Rate of GFR decline and incidence of ESRF in patients with basal GFR of 45 mL min or less
26013,Events leading to withdrawal of treatment
26014,Diagnosisspecific outcomes
26016,Clinical outcomes
26018,Side effects within 7 days of the first vaccination
26019,Immune responses after two doses of vaccine or placebo
26020,Protective efficacy of 8912 vaccine
26022,Overall risk of cancer in ESRD patients
26023,Site specific cancer risk in ESRD patients
26024,Bladder cancer risk in ESRD patients
26025,Kidney cancer risk in ESRD patients
26027,Compliance
26030,Frequency of malignant disease by size of non calcified nodule among participants with a solitary nodule on low dose CT
26032,Distribution of tumours by size      and stage
26034,Resistance mutations
26036,Treatment regimens in control and genotypic groups
26038,Sleepiness, awake   SaO2, and NCPAP use before and after therapeutic and subtherapeutic NCPAP
26039,SF 36 scores before and after therapeutic and subtherapeutic NCPAP
26041,Laboratory test results by treatment regimen
26042,Course of illness after admission to hospital
26043,Outcome by treatment regimen
26045,Medication at Discharge
26047,Clinical Events
26048,Quantitative Angiographic Data at Angiographic Follow Up
26050,Hazard ratios of mortality in the Leiden area versus the non Leiden area
26052,Severe clinical side effects and laboratory abnormalities
26053,Summary of Studies Evaluating Anemia and Cardiovascular Disease
26057,Risk factors and coexisting disorders
26058,Diagnostic investigations
26059,Adverse events in relation to thrombolytic treatment
26061,Final model   815 patients
26063,Secondary measures of intervention efficacy
26065,Association of Follow Up Variables With Risk of Pacemaker Syndrome
26068,Results of analysis based on Hasemann Elston regression algorithm
26069,Antibiotic resistance patterns by case classification at admission
26070,Course and duration of treatment
26071,Treatment success by patient group and loss to follow up
26072,Variables independently associated with treatment failure by multivariate logistic regression
26074,Adherence to treatment
26075,Biological tolerance to treatment and vital status of women and children post partum
26077,Probability of HIV 1 infection in children during the first 6 months of life
26078,Determinants of overall HIV 1 vertical transmission according to treatment group
26079,Treatment goals for standard and intensively treated groups
26080,Drug treatment in patients at start and end of study
26082,Changes at end of study in clinical, behavioural, and biochemical variables
26083,Mortality and macrovascular events
26085,Treated Vessel and Prevalence of Diabetes Mellitus in Patients Treated With Balloon or Stent
26086,Immediate Angiographic Results
26087,Angiographic Follow Up
26089,Relationship Between the Risk Reduction in Restenosis and Angiographic Variables
26091,Clinical Events
26092,Patients with events during follow up by treatment group
26093,On treatment analysis: relative risk of captopril vs conventional therapy
26094,Sensitivity testing of routine PCRs
26095,Sensitivity testing of antibody negative seroconversion panels before and after spiking PCR negative plasma pools
26096,Comparison of RT 3DE Using the Semi Automatic Algorithm With Manual Tracing and With Results Obtained by CMRI
26097,Observer Variability for the Semi Automatic Algorithm and Manual Tracing
26101,Adverse events
26102,Study design
26103,Incidence of diarrhoea in children under 5 years during fly seasons   MarchJune
26105,Common peroneal nerve electrophysiology
26106,Sural nerve electrophysiology
26108,Median time   days   to alleviation of clinically important symptoms
26109,Sleep disturbance, return to normal activities, and use of relief medications
26110,Mean differences in symptom scores between patients on zanamivir and placebo
26111,Complications and associated antibiotic use in intention to treat and high risk patients
26113,Responses to miltefosine treatment in 30 patients with kala azar
26114,Clinical, Stress, and Echocardiographic Variables in the Dobutamine Echocardiography Groups
26115,Independent Predictors of Events by Dobutamine Echocardiography in the Modeling Group
26116,Relationship of Dobutamine Score With Outcome
26118,Multivariate Cox s analysis
26119,Worst score during study for each EORTC QLQ C30 scale
26120,Patients with National Cancer Institute common toxicity criteria grade 3 or 4
26122,Cox s multivariate analysis of survival
26123,Reasons for treatment discontinuation
26124,Worst scores during study for each EORTC QLQ C30 scale
26129,Events leading to withdrawal during the follow up study among patients with chronic nephropathy and base line urinary protein excretion rate 3 g day who were originally randomised to ramipril or placebo
26130,Clinical details of women participating in study
26131,Incidence of new symptoms occurring after administration of cervical ripening agent
26132,Results of intraoperative recordings for both randomised comparisons and observational study
26135,Comparison of WHO and ADA diagnostic categories in 1989 cohort
26136,Age categories by sex for 1989 cohort
26137,Comparison of WHO and ADA diagnostic categories in African American cohort
26138,Age categories by sex for African American cohort
26139,Prevalence of cardiovascular disease by WHO and ADA diagnostic categories in 1989 cohort
26140,LV Wall Thickness, Cavity Dimensions, and Shortening Fraction Four Weeks After the Designated Treatment
26143,Person years of follow up on assigned and actual therapies for first 15 and all centres
26145,Use of Medications During Follow Up by Patients Assigned to One of Three Groups
26146,Frequency of Major In Hospital Events
26147,One Year Outcomes of the Randomized Groups
26149,Follow up and treatment status by treatment group and year of follow up
26150,Mortality by treatment group
26151,Non fatal endpoints alone and combined with fatal endpoints
26152,Other events
26154,History, findings, and treatment of patients treated with systemic methotrexate who received surgical intervention
26155,Side effects and complications
26156,Outcome measures
26158,Main toxicity related results
26159,Main efficacy related results
26160,Significance of prognostic factors of response, progression free survival, and survival
26161,Distribution of mEPHX genotypes in control and disease groups
26162,Distribution of putative mEPHX phenotypes in control and disease groups
26164,Angiographic Data and Catheterization Laboratory Complications of Study Patients
26165,In Hospital Complications and Long Term Outcomes
26166,Adjusted Odds Ratios of Clinical Variables Associated With the Risk of Ventricular Tachycardia or Fibrillation During Primary Percutaneous Coronary Intervention
26170,Resting haemodynamic data in heart failure patients
26171,Mean   SD   changes during lower body suction
26172,Age Adjusted Descriptive Information for Variables Included in the 10 Year Risk Estimates for Coronary Heart Disease, National Health and Nutrition Examination Survey III, 1988 to 1994
26173,Age Specific and Age Adjusted Distribution Risk for Coronary Heart Disease Among United States Adults Age 20 Years Without Self Reported Coronary Heart Disease or a Coronary Heart Disease Equivalent,   National Health and Nutrition Examination Survey III, 1988 to 1994
26174,Age Specific and Age Adjusted Distribution of Risk for Coronary Heart Disease Among U.S. Adults Age 20 Years After Including People With Self Reported Coronary Heart Disease or Coronary Heart Disease Risk Equivalents   in the Highest Risk Category, National Health and Nutrition Examination Survey III, 1988 to 1994
26175,Distribution of CHD Risk Equivalents Among 3,026   U.S. Adults Age 20 Years With Any Such Risk Equivalent, National Health and Nutrition Examination Survey III, 1988 to 1994
26178,Percentage distribution of projected DALYs for specific two causes
26180,Worldwide deaths attributable to tobacco use in 1990 and 2020
26181,Agreement Between Parameters of Ejection Pressure Difference Curves Obtained by Micromanometers and by Doppler Echocardiography
26184,Factors Related to the Peak Intraventricular Pressure Difference in the Clinical Study
26187,Healthcare resource use for new or recurrent HIV related events
26189,Distribution   of DALYs for specific causes   level 2 categories  , 1990
26190,Thirty leading causes of worldwide DALYs for both sexes in 1990
26191,Estimated total attributable burden for selected conditions as risk factors for death and disability from other diseases and injuries
26192,Percentage worldwide DALYs attributable to each of ten risk factors, by region, 1990
26193,Sources and methods used to estimate mortality by cause for each region in 1990
26194,Distribution of deaths for specific causes   level two categories   in 1990
26195,30 leading causes of death worldwide in 1990
26198,Initial and 2 year serum biochemistry and anthropometric measurements
26200,Univariate Pearson correlations with 2 year decrease in creatinine clearance
26201,Echocardiographic Variables at Rest
26202,Cardiopulmonary Exercise Testing
26203,Predictors of  Predicted Vo 2max in Patients With DCM
26204,Exposure to potential risk factors during the 3 days before onset of illness in case patients and matched controls   univariate analysis
26205,Conditional logistic regression model of selected risk factors for cholera
26206,Timing, findings, and subsequent treatment of aneurysms in patients undergoing total knee replacement surgery for haemophilic arthropathy
26207,Association of duration of injecting drug use, and HGV RNA and anti E2 seroprevalence
26208,Attack rates of culture proven  S sonnei  shigellosis in recipients of  S sonnei  conjugate vaccine and placebo vaccines
26211,Univariate associations between birthweight and maternal 24 h mean ambulatory blood pressure
26212,Birthweight by 24 h mean ambulatory diastolic pressure at mid gestation
26213,Significant predictors of birthweight in multiple regression analysis
26215,Use of interventions and medications by geographical location
26216,Outcome of cardiogenic shock by 30 days and type of revascularisation used
26221,Study End Points
26224,INSS staging of 118 neuroblastoma cases in Quebec for 5 year screened cohort
26225,SIRs for neuroblastoma at 1 year age intervals versus US SEER data
26226,SIRs of early and advanced Evans  stage neuroblastoma versus Greater Delaware Valley data
26228,Exclusion criteria
26229,Non fatal outcome events
26231,Validated events
26232,Intention to treat analysisprimary and secondary outcome clusters
26233,Treatment effect by subgroupischaemic stroke, MI, or vascular death
26234,Treatment effects of patients with a history of MI
26235,Adverse experiences   number and percentage of patients
26239,Primary results of meta analysis
26241,Left ventricular   LV   systolic function and mass
26242,Mean   SD   carotid arterial compliance data
26244,Outcome of patients by serogroup and treatment group
26245,HR, Blood Pressure, and Echocardiographic Parameters in the Carvedilol and Placebo Groups
26246,Median peak serum and stool concentrations ciprofloxacin and doxycycline treatment groups
26247,Assessment of NYHA Class Over the Treatment Period
26248,Secondary End Points and Exploratory Analyses
26249,Exclusion criteria
26251,Reasons for stopping blinded trial treatment
26252,Percentage of time before clinical progression on antiretroviral treatment
26253,Survival and disease progression
26254,Adverse events while on blinded trial treatment
26256,Number of subjects who recognised symptoms during HVPT and placebo test
26258,Description of groups at trial entry
26259,Actual management between trial entry and discharge from hospital   or death before discharge
26260,Principal measures of outcome
26261,Overall status at 1 year follow up of 124 infants enrolled by Dec 1, 1994
26263,Associations Between Pattern of Hyperenhancement and Clinical Phenotype
26264,Pulmonary physiology results
26266,Risk ratio for combined endpoint adjusted for changes in time dependent covariates
26267,Events leading to withdrawal of treatment
26268,Plasma histamine and b endorphin during study periods
26270,Effect of the 9vHPV vaccine on the incidence of persistent infection, cervical, vulvar, and vaginal disease, cervical cytological abnormalities, and medical procedures related to HPV 6, 11, 16, or 18 and HPV 31, 33, 45, 52, or 58 in the per protocol efficacy population
26271,Effect of the 9vHPV vaccine on the incidence of persistent infection, cervical disease, cervical cytological abnormalities, and cervical definitive therapy related to each HPV type in the per protocol efficacy population
26273,HPV 9 cLIA and PBNA geometric mean titres in the per protocol immunogenicity population
26274,Sources of Data for Meta Analysis From Principal Randomized Clinical Trials of ACE Inhibitors and Beta Blockers
26275,Effect of ACE Inhibitors on Mortality From Heart Failure in Male and Female Patients
26276,Effect of ACE Inhibitors on Mortality From Heart Failure in Male and Female Patients Reported Separately for Prevention Studies and Treatment Studies
26277,Effect of ACE Inhibitors on Mortality From Heart Failure in Diabetic and Nondiabetic Patients
26278,Effect of ACE Inhibitors on Mortality From Heart Failure in Black and White Patients
26279,Effect of Beta Blockers on Mortality From Heart Failure in Male and Female Patients
26280,Effect of Beta Blockers on Mortality From Heart Failure in Diabetic and Nondiabetic Patients
26282,Effect of Beta Blockers on Mortality From Heart Failure in Black and White Patients
26284,Summary of facial transplant indications and patient outcomes at long term follow up
26287,Perioperative outcomes, postoperative complications, and pathological characteristics by surgery type
26288,Pain ratings across timepoints and by surgery type
26290,Genes included in the prediction set by array probeID
26292,Primary endpoint
26293,Secondary endpointwin ratio
26294,Safety assessment of ixmyelocel T
26295,Patient Data
26296,Patient Disposition
26299,Procedure related parameters and high risk factors for post ERCP pancreatitis
26301,Outcomes and adverse events
26303,Incidence of Adverse Events
26305,Results of first round of screening
26306,Distribution of clinical stages of breast cancer
26307,Histological findings
26308,Need for biopsy on the basis of first round screening
26310,5 year cumulative incidence of ipsilateral breast tumour recurrence, overall recurrence   local, regional, or distant metastasis  , and overall survival, by age
26311,Clinical Features of the HCM Family
26312,Diabetes remission and relapse and glycaemic control at 5 year follow up
26316,Primary, secondary, and safety endpoints
26318,Clinical Features of Patients With HCM Studied in Referral Centers
26319,Clinical Features of Patients With HCM Studied in Nonreferral Centers
26321,Donor heart management
26323,Causes of transplant failure
26324,All serious infections   opportunistic or requiring admission to hospital   within first 6 months
26325,Frequency and Racial Differences for Cardiovascular Causes of Sudden Death in 286 Young Competitive Athletes
26326,Geographical location of hospital or trust transplant centres, tertiary hepatopancreatobiliary surgical units, and the hepatitis C virus treatment led centres
26327,Routine tests and algorithms compared with transient elastography as surrogate markers of liver fibrosis
26328,Predicted effects of a minimum unit price on different categories of drinkers in the UK  84
26329,Number of people aged 1125 years attending paediatric specialist liver services in England before and after transition
26330,Optimum strategy to reduce the future burden of hepatitis C virus with liver disease
26331,Echocardiographic Findings in the Carriers With Arg820Gln in the MyBP C Gene
26332,Electrocardiographic Findings in the Carriers With Arg820Gln in the MyBP C Gene
26334,Conservation of Arginine 820 in Cardiac MyBP C
26336,Descriptive data at time of discharge and at the 12 month follow up
26337,Phenotypic Characterization    29   and Molecular Epidemiology of the Study Population
26338,Phenotype and Genotype of 12 Patients with DCM Heterozygous for LMNAMutations
26339,Analysis of Clinical Variables as Predictors of LMNAMutations in Patients With DCM
26340,Summary of the Reported LMNAMutations Leading to Cardiac Disease   DCM and or Arrhythmia Conduction Disease
26342,Female Sexual Function Index assessment, by domain
26343,Lung function
26344,Sequence of bronchoscopic treatments with the corresponding placed stent, condition of the transplanted airway, and subglottic stenoses
26348,Adverse events and laboratory abnormalities reported during open label phase
26350,Adverse events
26351,Psychometric assessment scores, by individual patient
26353,Summary of adverse events in patients who reported at least one event
26354,Types and severities of adverse events, by system organ class and preferred term
26359,Rates of prostate cancer progression   pathological and therapeutic
26362,Adverse events
26363,Comparison of Metabolic Profile
26364,Number of patients admitted to hospital with autoimmune disorders in Sweden between 1964 and 2008
26365,Number of patients admitted to hospital for pulmonary embolism in Sweden   19642008   and subsequent pulmonary embolism in patients with autoimmune disease
26366,SIRs for subsequent pulmonary embolism in patients with autoimmune disorders without previous hospital admission for venous thromboembolism or coexisting venous thromboembolism
26368,Relation of Myocardial Perfusion Grade to Mortality
26369,Univariate Cox Model Predictors of Cumulative Mortality
26370,Multivariate Cox Model Predictors of Cumulative Mortality
26371,Clinical summary
26372,Summary of response to AVI 4658
26373,Summary of available drugs that lower blood glucose
26382,Lung function tests
26383,Clinical and pathological findings in CFHR5 nephropathy
26384,Catheter and Doppler Echocardiographic Data Obtained In Vitro, in Animals, and in Patients
26385,Theoretical Values of Doppler Derived Effective Orifice Areas for Given Catheter Derived Effective Orifice Areas and Aortic Diameters
26387,First operation pathology details
26388,Initial and repeat operations
26389,MRI predicted patient management
26392,Risk of stroke associated with risk factors in the overall population   multivariate analyses
26393,Risk of stroke associated with key risk factors by region, sex, age, and stroke severity
26394,Population attributable risk for various risk factor combinations
26395,Risk of ischaemic stroke subtypes      associated with risk factors
26396,Risk of ischaemic stroke associated with risk factors by type of respondent for cases
26397,Risk of ischaemic stroke associated with risk factors by source of controls   community based or hospital based
26398,2,3,7,8 tetrachlorodibenzo p dioxin   TCDD   concentrations   pg g lipid weight  LW  or pg g wet tissue weight  WW    as a function of time   months   after the day of poisoning in samples analysed
26399,Equations for the calculation of concentrations of 2,3,7,8 tetrachlorodibenzo p dioxin   TCDD   eliminated from the body and in tissue samples as a function of time
26400,Concentrations of metabolites of 2,3,7,8 tetrachlorodibenzo p dioxin   TCDD   in samples as a function of time   months   after TCDD poisoning
26404,Vaccine efficacy against cervical intraepithelial neoplasia grade 2 or more   CIN2   , or grade 3 or more   CIN3   , colposcopy referrals, and cervical excision procedures associated with human papillomavirus   HPV   16 18, five non vaccine oncogenic types, and irrespective of HPV DNA in lesion
26405,Safety and pregnancy outcomes in the total vaccine cohort during the entire study
26408,Efficacy of Amiodarone Versus Placebo in Converting AF to Sinus Rhythm at Various Time Points
26409,Efficacy of Amiodarone Versus Class Ic Drugs in Converting AF to Sinus Rhythm at Various Time Points
26410,Differences   placeboavotermin   in VAS scores assigned by the IESAP   lay   and investigators for varying concentrations of avotermin in studies 1002 and 1005   within participant comparisons
26411,Treatment differences   placeboavotermin   in VAS scores assigned to wound sites by the IESAP   lay  , IESAP   clinical  , and investigators at month 7   LOCF   after wounding, with varying concentrations of avotermin, in study 0036   within participant comparisons
26412,Histological analysis of the orientation of collagen fibres in the reticular dermis of scars   study 1005
26413,Clinical Data Grouped by Etiology and Gender
26414,Cardiac and Myocyte Morphology Data Grouped by Etiology and Gender
26416,Reasons for referral to breast MRI
26417,Sensitivity of mammography and MRI for DCIS detection
26419,Biological profiles of DCIS by method of detection
26420,Distribution of Cases and Method of Diagnosis
26424,Screening findings by age in the intervention group
26426,Stage of disease by study group and detection mode
26427,Logistic Regression Model for Variables Associated With Independent Predictors of Idiopathic Giant Cell Myocarditis
26428,Incidence of and mortality from cervical cancer by study group
26429,Overall and age specific hazard ratio for incidence for all cervical cancers, cancers at stage II or worse, and for cervical cancer deaths
26430,Demographic characteristics of the total vaccinated cohort
26432,CIN2  lesions with HPV16 or HPV18 DNA
26433,Efficacy against CIN2  and CIN1  associated with HPV16 or HPV18 in the total vaccinated cohort for efficacy
26434,Vaccine efficacy against persistent infections with oncogenic HPV types in the total vaccinated cohort for efficacy
26435,Safety outcomes
26436,Pregnancy and pregnancy outcomes in the total vaccinated cohort during the entire study
26441,Study design and comparison of protocols 005, 007, 013, and 015
26443,Number of women included in efficacy analyses and reasons for exclusion
26444,Primary analysis of efficacy against HPV16 18 related CIN2 3 and AIS
26445,Vaccine effectiveness against all CIN2 3 and AIS regardless of causal HPV type   ITT population
26446,Analysis of efficacy against HPV16 18 related CIN2, CIN3, and AIS by region
26448,Details of thoracoscopy procedure
26449,Side effects of thoracoscopy
26450,Causes of death within 30 days of thoracoscopy
26453,Multivariable Predictors of the No Reflow Phenomenon
26454,Univariate Association of Clinical, Exercise Stress Test, and Echocardiographic Variables With Risk of Hard Cardiac Events and All Cause Mortality
26455,Independent Predictors of All Cause Mortality Using Four Step Model
26456,Independent Predictors of Hard Cardiac Events Using Four Step Model
26457,Clinical Details
26458,Response to Dobutamine Stress: Intragroup Analysis
26459,Individual Contribution of Coronary Artery Disease and Left Bundle Branch Block by Analysis of Variance
26460,Clinical and Echocardiographic Data of the Study Populations
26461,Unadjusted Best Cut Off Values of AS Indices to Predict Clinical Outcome Efficacy End Points
26462,Multivariate Clinical Efficacy Prediction Models in Group A   n   307
26466,Inter relationship Between Serum Concentrations of Iron Metabolism Parameters, Oxidative Stress, and Endothelial Function in Patients With Hereditary Hematochromatosis
26468,Pacing Threshold at Implantation and After One and Three Months
26472,Left Ventricular mRNA Expression   Per 18S rRNA   and Respiratory Chain Complex Activities
26475,Effect of Vardenafil 10 mg on HR, Blood Pressure, and Rate Pressure Product at Rest and During Peak Exercise   n   41
26476,Adverse Events Reported During Treatment With Vardenafil or Placebo
26478,Response to treatment in prognostic subgroups
26479,Progression free survival at 3 years after randomisation in prognostic subgroups
26480,Overall survival at 3 years after randomisation in prognostic subgroups
26481,CVD Risk Factors by Case Control Status
26482,Multivariate analysis of the effects of various prognostic variables on progression free survival and overall survival in 524 patients
26483,Distribution of Hp Types by Case Control and Diabetes Status
26484,Incidence of grade 3 and 4 adverse events
26486,Countries with and without hospital profiles or pulse oximetry data
26487,Estimated number of operating theatres per 100 hospital beds, by region
26488,Estimated number of operating theatres per head, ranked by estimated number per 100000 population
26489,Estimates of the number of operating theatres from our model compared with direct reports
26490,Estimated number of operating theatres without pulse oximetry, by subregion, ranked by percentage without pulse oximetry
26491,Estimated number of operations without pulse oximetry
26492,Minimum anaesthesia monitoring standards survey, by region
26494,Management of anaesthesia
26495,Incidence of respiratory adverse events
26496,Anaesthetic drugs, airway management, and respiratory complications
26497,Risk factors associated with perioperative bronchospasm
26498,Risk factors associated with perioperative laryngospasm
26499,Risk factors associated with perioperative cough, desaturation, or airway obstruction
26500,Risk of perioperative respiratory adverse events according to timing of upper respiratory tract infection
26501,Risk factors for perioperative bronchospasm, laryngospasm, or all complications according to timing of symptoms and respiratory adverse events
26503,Adequate clinical and parasitological response   ACPR   by timepoint   per protocol population
26504,Adequate clinical and parasitological response   ACPR   by timepoint   intention to treat population
26505,PCR corrected adequate clinical and parasitological response at day 28 in the per protocol population by region and centre
26507,Most frequent adverse events reported in the safety   intention to treat   population
26510,Logistic Regression Analyses for the Presence of Coronary Artery Disease
26512,Virological response
26513,Rates of sustained virological response by time to first undetectable hepatitis C virus RNA
26515,Adverse events during treatment   30  incidence
26516,Haematological parameters
26517,Discontinuations and dose reductions
26520,Adjusted hazard ratios for death in the CD4 and total lymphocyte and haemoglobin prognostic models
26521,Estimates of cumulative mortality at 1 year in highest and lowest risk groups from main analysis and analysis including patients lost to follow up.
26522,Observed and Expected Maternal Mortality in the Study Women With a First Pregnancy After 1954, and Relative Risk According to Age  and Year Specific Maternal Mortality Rates in the General Italian Population Between 1955 and 1984
26523,Clinical Features and Echocardiographic Findings in 40 Women With Hypertrophic Cardiomyopathy and a Pregnancy Within Five Years of Evaluation
26524,Service members who were deployed, medically evacuated, and returned to duty   RTD   by year, military operation, and service branch
26531,Proportion of individuals with psychiatric diagnoses who were medically evacuated and did or did not return to duty   n 2978
26533,Best overall confirmed tumour response status   intention to treat population
26534,Olaparib related adverse events    , according to grade, arising in two or more patients
26535,Dose interruptions and reductions due to adverse events
26537,Best overall confirmed tumour response status   intention to treat population
26538,Best overall confirmed tumour response status   intention to treat population   by BRCA mutation status and hormonal status
26539,Olaparib related adverse events, according to grade, arising in two or more patients
26540,Dose interruptions and reductions due to adverse events
26544,Manual removal of placenta
26545,Secondary outcomes
26548,Enrolment by dose
26551,Grade 34 adverse events and patients who discontinued treatment because of an adverse event, by dose
26554,Differences in Electrocardiographic and Echocardiographic Parameters Before and After One Month of Cardiac Resynchronisation Therapy
26555,Rate of laboratory and clinical dose limiting toxic effects, or grade 3 and 4 toxic effects as defined by the AIDS Clinical Trial Group,  28   by study group
26557,Comparison of One Month Percent Variations Occurring in the Studied Parameters Between Responders and Nonresponders
26559,Subsequent drug exposure groups by first drug exposure group
26560,Comparison of antithrombotic drug exposure groups
26561,Distribution of non fatal and fatal bleeding events
26563,Sensitivity analyses
26565,Outcomes by treatment allocation
26566,Comparison of mosquito densities between intervention and control groups
26567,Comparison of haemoglobin concentrations between intervention and control groups
26568,Anaemia and parasitaemia in intervention and control groups
26571,Short Term CABG and PCI Outcomes of Diabetic Patients
26572,CABG and PCI 36 Month Diabetic Patient Survival, Survival Free of Unstable Angina, and Survival Free of Unstable Angina or Repeat Revascularizations
26574,Hemodynamics of EMCV Infected and Uninfected Mice Based on Pressure Volume Relations on Days 1, 7, and 14
26577,Grade 34 toxic effects per treatment group
26578,Activity of both treatment groups
26579,Management and outcome in published prospective trials of primary CNS lymphomas in immunocompetent patients given chemotherapy alone or combined treatment
26581,Risk periods for each analysis
26582,Protective efficacies of IPTi with sulfadoxine pyrimethamine
26583,Combined estimates and sensitivity analysis
26584,Deaths, non fatal hospital admissions, and serious dermatological adverse events up to 12 months of age, or 3 months after the last dose of study treatment received, whichever is earlier
26585,Bacterial isolates from patients with bacteraemia, stratified by sickle cell anaemia status
26586,Odds ratios for sickle cell anaemia in children with bacteraemia versus controls
26587,Incidence of admission to hospital with bacteraemia per 100 person years of observation, stratified by age group
26588,Serotypes of Streptococcus pneumoniae isolates by status of sickle cell anaemia
26590,Overall worst toxicities
26594,Deaths and hospitalisations from cardiovascular causes
26595,Patients with events   numbers of events   for various cardiovascular hospitalisations or deaths
26596,Patients with serious adverse events
26597,Bone fractures reported as serious and non serious adverse events
26599,Relationship Between Clinical, Morphologic and Functional Features at Initial Evaluation and Occurrence of Stroke or Other Peripheral Vascular Events in 900 Patients With Hypertrophic Cardiomyopathy
26604,Echocardiographic Parameters in SAM Groups
26605,Nonlinear Regression Parameters for y      x
26607,Incidence of antimalarial treatments and illness episodes in children in the community based and clinic based trials
26608,Antimalarial treatment for febrile episodes in the community based trial
26609,Clinical assessments in the community based trial
26612,TWA, LVEF, SAECG, LVDd, NSVT and the Combination of TWA and the OHR or LVEF as Predictor of Event Free Survival
26613,Univariate Predictors of Arrhythmic Events in Dilated Cardiomyopathy Patients With Determinate TWA Results
26614,Multivariate Predictors of Arrhythmic Events in Dilated Cardiomyopathy Patients With Determinate TWA Results
26616,Reasons for non compliance with randomisation to anaesthetic technique
26617,Surgical and anaesthetic procedure
26618,Primary outcomes between randomisation and 30 days after anaesthesia   or after randomisation for patients who were not anaesthetised
26619,Epidemiological summary of malaria in children age less than 14 years, in Kilifi, Kenya, 19902007
26620,Difference in all admissions and slide positive admissions before and after the decline in slide positive admissions
26623,Processes of care and outcomes in the propensity matched pairs
26627,Effect of IPT on health outcomes: anaemia, haemoglobin, and P falciparum parasitaemia
26630,Study Group   n   111
26632,Extent and Severity Scores by Tetrofosmin and BMIPP for Three Groups
26633,Tetrofosmin and BMIPP Findings and Rates of Disease for Three Groups
26634,Comparison of countries with and without available surgical data
26635,Single Photon Emission Computed Tomographic Scores for Coronary Angiographic Findings
26636,Average national rate of surgery for countries in each category of health expenditure, with total volume of surgery contributed by each category
26638,Effect of maternal MMN supplementation on infant deaths
26639,Effect of maternal MMN supplementation on fetal loss and maternal death
26640,Effect of maternal MMN supplementation on early infant mortality in subgroups
26641,Effect of maternal MMN supplementation on low birthweight and mean birthweight
26642,NPC training, entrance requirements, scope of practice, and practice locale in the 25 sub Saharan African countries with NPCs
26643,Reported training cost per year for NPCs in selected sub Saharan African countries
26644,NPCs and physicians per 100000 head of population for sub Saharan countries with NPCs
26646,Non nucleoside reverse transcriptase inhibitor viral drug resistance
26647,Non nucleoside reverse transcriptase inhibitor viral drug resistance at 2 and 6 weeks after delivery, according to HIV 1 viral load at time of delivery
26648,Perinatal HIV transmission at 6 weeks of life
26651,Coronary Artery Disease   or Summed Stress Score 4   According to the Number of Sites With Calcium Deposits   or Sclerosis
26652,Coronary Artery Disease   or Summed Stress Score 4   According to the Multiple Calcium Deposits   or Sclerosis   and DM or Multiple Risk Factors of Coronary Artery Disease
26653,Predictors of Coronary Artery Disease   or Summed Stress Score 4   in Multivariate Analyses
26655,Best response to treatment at 12 months
26656,Second line treatment in patients treated as assigned
26657,Grade 3 or 4 toxic effects
26659,Details of cardiac bypass surgery
26663,Kaplan Meier estimates of the likelihood of recurrent ulcer bleeding at 13 months
26665,Incidence of severe and important adverse events
26667,Complications
26668,Days Length of Hospital Stay
26669,Perception of Perioperative Pain and Activity
26670,Comparison of Variable Costs Patient Charges
26672,Summary of most common micro organisms by site of infection
26674,Safety analyses
26675,Design of included trials
26679,One Year Results in the NSRT and Surgery Groups
26682,Control pattern of targeted motor reinnervation prosthesis in this patient
26683,Functional outcome comparing conventional myoelectric prosthesis with experimental TMR controlled prosthesis
26684,The ten maternal health problems most commonly identified by women attending MaiMwana women s groups in Mchinji District across all periods   n 172
26685,The ten maternal health problems antepartum, intrapartum, and postpartum most commonly identified by women attending MaiMwana women s groups in Mchinji District
26686,Weights and Resting Hemodynamics in Sham and Pacing Induced Rabbits With Heart Failure
26689,Follow up dietary data
26690,6 month infant haematological and iron status by treatment group
26691,Indication for caesarean delivery, according to type of institution
26693,Association between proportion of risk factors, according to institutions, and proportion of caesarean deliveries   multivariable analysis
26694,Association between proportion of all caesarean deliveries and maternal and perinatal outcomes at institutional level
26695,Association between proportion of elective caesarean deliveries and maternal and perinatal outcomes at institutional level
26696,Association between proportion of intrapartum caesarean deliveries and maternal and perinatal outcomes at institutional level
26697,The Effect of CO, CS and Air Inhalation on HR and Blood Pressure
26700,Viral load measures of 397 patients in cross sectional virological survey
26702,Clinical response
26703,Grade 34 adverse events
26705,Results at different times after inclusion
26707,Effect of supplementation with iron and folic acid with or without zinc on serious adverse events, deaths, and admissions to hospital overall, by age group and by duration of supplement compared with placebo.
26708,Effects on overall adverse events, deaths, and admissions to hospital and on cause specific adverse events in the two iron and folic acid groups compared with placebo
26709,Effects of supplementation with iron and folic acid with or without zinc on adverse events overall and by iron status and anaemia   substudy
26711,Mortality, morbidity, and re interventions within 30 days after first intervention
26714,Comparison of use of hospital resources by intention to treat during first 12 months from randomisation
26717,Adverse events during the placebo controlled phase   weeks 024
26720,Numbers of first events contributing to the primary composite and main secondary endpoints
26721,Effect of pioglitazone and placebo on each component of the primary endpoint
26725,Serious adverse event summary
26726,Reports of heart failure
26728,Indications for Use
26729,Summary of Outcomes Complications
26730,Unsuccessful IABP
26731,Risk Factors for Major Complications of IABP
26732,IABP Complications and In Hospital Mortality
26734,Location of colon lesions
26735,Colon imaging test sensitivity
26736,Colon imaging test specificity
26737,Colon imaging test sensitivity by preparation quality
26739,Clinical treatment outcome at day 28   per protocol analysis
26740,Clinical treatment outcome at day 28   intention to treat analysis
26742,Falls and Syncope During 12 Month Follow Up by Treatment Group by History of Falling
26744,Mortality by age and CD4  at randomisation
26745,Hospital admissions and inpatient days
26746,Grade 3 and 4 adverse events possibly or probably related to masked trial drug
26749,Outcome measures and location of recurrences
26750,Etiologies of Cardiogenic Shock by Gender
26753,Hemodynamic Findings in Patients With Predominant LV Failure
26754,Angiographic Findings and Treatment Approaches in Patients With Predominant LV Failure
26756,Summary of confirmed awareness events
26757,Summary of possible awareness events that were not confirmed by the study endpoint committee
26758,Comparison of anaesthetic procedures
26759,Recovery times and postoperative complications
26760,Number of cases of erythropoietin induced pure red cell aplasia in France and Germany, by year of diagnosis
26761,The Predicted Success of a Series of Up to Nine Shocks Including Three at 360 J Was Not Matched in Clinical Practice
26763,Outcome of patients with erythropoietin induced pure red cell aplasia, by immunosuppressive treatment
26765,Maternal haemoglobin concentrations   g L   at time of delivery in women with chronic pregnancy associated P falciparum malariaaccording to their plasma IgG concentration with specificity for type of VSA
26766,Birthweights of children born to mothers with chronic pregnancy associated P falciparum malariaaccording to mothers  plasma IgG concentration with specificity for type of VSA
26767,Multiple linear regression analysis of pregnancy outcome in 89 women with chronic pregnancy associated malaria
26769,Biomarker correlation with oxygen saturation and haematological variables
26772,Effect of epoetin  treatment on study endpoints
26773,Variables of the Three Groups During the Perioperative Period
26774,Analysis of Sjvo 2Values Reported by the Oximetric Catheter
26775,Analysis of Sjvo 2Values Reported by the Oximetric Catheter
26776,Number of Patients With Cognitive Impairment at Seven Days and Six Months After the Operation
26777,Results of a Multivariable Logistic Regression
26779,Intraoperative data
26780,Postoperative follow up data
26781,PASE Activities, Performances and Weight Scores
26784,In Hospital Outcomes of Elderly Patients With and Without Preinfarction Angina
26785,In Hospital Outcomes of Elderly Patients   n   510   According to the Quartiles of Physical Activity
26786,In Hospital Outcomes of Elderly Patients With and Without Preinfarction Angina   n   323   According to the Quartiles of Physical Activity
26787,Effect of Preinfarction Angina in Elderly Patients According to the Quartiles of Physical Activity on In Hospital Death, Cardiogenic Shock and Combined End Points of In Hospital Death and Cardiogenic Shock
26789,Overall morbidity and complication grades
26791,Rate of malarial fever and protective efficacy of amodiaquine during the 6 month intervention phase by treatment group
26792,Rates of anaemia, protective efficacy of amodiaquine, outpatient attendances, and hospital admissions during the 6 month intervention phase by treatment group
26793,Protective effect of amodiaquine on malaria and anaemia episodes during the first and last parts of the intervention
26794,Concentration of antibodies to vaccines
26796,Crude and Adjusted Relative Risks of Cardiovascular Events According to Quartile of Plasma Level of Lp PLA2
26797,Crude and Adjusted Relative Risks of Cardiovascular Events Associated With a One Quartile Increase in the Concentration of Lp PLA2and CRP
26798,Analysis of the components of the IGF I system in ventral horn homogenates
26799,Hemodynamic and Neurohumoral Data
26800,Clinical and laboratory data of patients
26801,Molecular weight determined by MALDI TOFMS compared with molecular weight calculated from aminoacid sequence
26803,Univariate and Multivariate Linear Model of LV Mass Index in 51 DCM Patients With CHF
26804,Effect of  NOS2 1173 CT genotype on malarial outcomes in Tanzanian and Kenyan children
26805,Effect of 1173 C T genotype on development of severe malarial anaemia and parasitaemia in Kenyan children
26806,Effect of CCTTTn long versus short genotype on development of severe malarial anaemia and parasitaemia in Kenyan children
26807,Effect of 1173 CT CCTTT1213 genotype on development of severe malarial anaemia and parasitaemia in Kenyan children
26809,Endpoints
26810,Decreases in haemoglobin concentration or packed cell volume between days 0 and 7
26819,Distribution of preoperative risk factors required for eligibility for randomisation in 915 patients recruited
26820,Visual analogue scale pain scores on the first 3 postoperative days
26821,Endpoints
26822,Summary of deaths within 30 days of surgery
26825,Groin hernia surgery in Denmark, Jan 1, 1998, to June 30, 2000
26826,Rate of reoperation in elective primary or recurrent inguinal hernia operations in 21874 patients   23695 operations
26830,SVR rate by pretreatment variable and treatment group and according to ribavirin dose
26831,Rates of discontinuation of treatment, dose reduction, and adverse events during treatment
26833,Time Schedule of Sampling of Cardiac Lymph, Plasma and Myocardium legend
26834,Course of Plasma and Lymph cTnI Levels During and After CPB in Pigs in Moderate Hypothermia During Surgery or in Normothermia legend legend
26835,Maternal morbidity statistics for normal populations
26837,Pregnancy outcome
26838,Pregnancy complications
26840,Details of pregnancies in female recipients of allogeneic stem cell transplants
26842,Outcome among patients with renal dysfunction at presentation and SAA production within the reference range throughout the study
26843,Outcome among patients with persistently raised SAA production   median SAA  50 mg L between each scan
26845,Differentially Expressed Genes in the Heart in HCM legend
26847,Use of referral facilities and hospital admissions
26849,Secondary outcomes
26851,Costs to providers and women in Cuba and Thailand
26852,Women s and providers  perception and satisfaction
26854,Frequency of main outcomes during first year of life
26855,Serological responses to some EPI vaccines
26856,Categories of reproductive morbidity and their denominators for analyses
26858,Health seeking behaviour in relation to complaint as reported to the fieldworker
26859,Findings on clinical examination
26860,Laboratory findings
26862,Six Month Mortality by Peak CK MB Isoenzyme Ratio legend
26863,Sex and status of patients with homozygous sickle cell disease at end of study   Jan 1, 1997
26864,Six Month Mortality by Peak CK MB Isoenzyme Value legend
26865,Age at entry to study, duration of follow up, and age at death
26866,Six Month Mortality by Postcoronary Artery Bypass Graft Surgery Occurrence of Two Step Minnesota Code Worsening Electrocardiographic Abnormalities legend
26867,Kaplan Meier survival estimates of patients with homozygous sickle cell disease from birth
26869,Final Multiple Logistic Regression Model Predicting Six Month Mortality in Patients Who Survived  10 Days After CABG legend
26871,Toxic effects of treatment in patients who received induction chemotherapy
26872,Response and survival
26873,Summary of functional results at follow up
26878,Outcome summary to day 60
26879,Blood and colloid transfusions to day 7
26881,Relation between parity and placental weight, birthweight, and maternal serum ferritin and haemoglobin
26882,Multiple regression analysis of factors influencing placental weight in 1205 term pregnancies
26883,Morphometric analysis of villous capillarisation in term placentas and relation to serum ferritin and haemoglobin concentrations
26886,Patients  experiences of awareness during surgery
26887,Details of awareness obtained by interview
26889,Reasons for discontinuation of assigned treatment
26890,Occurrence of first outcome events
26891,Types of haemorrhage   number of fatalities
26892,Subgroup analysis of occlusion
26893,Physiologic Variables in Control Mice legend
26895,Echocardiographic Variables in Dbh  Mice Before and After Repletion of Norepinephrine with l Threo 3,4 Dihydroxyphenylserine legend legend
26900,Menstrual status and symptoms at 12 months
26901,Patients  satisfaction and efficacy and acceptability of treatment
26904,Aortic Atherosclerosis in Subjects With Aortic Valve Sclerosis and Upper Quintile Transaortic Velocities legend
26905,Odds Ratios of Aortic Valve Sclerosis and Upper Quintile Transaortic Flow Velocities in Relation to Presence, Location and Severity of Aortic Atherosclerosis legend
26906,Odds Ratios of Aortic Valve Sclerosis and Upper Quintile Transaortic Velocities in Relation to Clinical Coronary Artery and Cerebrovascular Disease legend
26907,Studies of prophylactic bed rest after medical procedures
26908,Randomised controlled trials examining the use of bed rest as a treatment
26910,HIV 1 transmission and HIV 1 free survival at ages 13 days, 68 weeks, and 1416 weeks
26911,Prognostic factors for HIV 1 infection in univariate Cox s regression models
26913,Effect of vitamin A supplementation on malaria and general morbidity
26915,Results of an audit of nurse led sedation from 1995 to 1997
26916,Comparison of factors known to be associated with birth outcome in mebendazole and control groups
26917,Comparison of birth outcomes in mebendazole and control groups
26918,Congenital defects in mebendazole and control groups
26919,Incidence of birth defects according to timing of mebendazole therapy
26920,Frequency of mebendazole use according to birthweight
26922,Cumulative amputations       at 6 month and 2 year follow up
26925,Efficacy and timing of transmission
26928,Defined Ranges of IB Values for the Color Coded Maps in Each Histologic Category legend
26929,Iron content of foods cooked in different types of pot
26935,Effect of intermittent treatment doses of sulphadoxine pyrimethamine compared with placebo on proportion of women with severe anaemia
26936,Effect of intermittent treatment doses of sulphadoxine pyrimethamine compared with placebo on proportion of women with peripheral parasitaemia
26937,Effect of intermittent treatment doses of sulphadoxine pyrimethamine compared with placebo on postnatal outcome
26938,Morphometric analysis of villous capillarisation, macrophage density, and stromal cell proliferation in first and third trimester placentas according to haemoglobin concentrations in maternal blood
26940,Attempted Treatment for MAT legend
26941,Published Reports of MAT in children legend
26944,Postoperative complications in whole group
26945,Proportion of patients with postoperative cognitive dysfunction at 1 week and 3 months by risk factor
26946,Analysis of major risk factors in relation to first postoperative test
26947,Relation of major risk factors to results 3 month test
26950,Treatment responses
26954,Virological responses at end of treatment and follow up by pre treatment HCV RNA concentration and genotype
26958,Incidence of Death and Modes of Death According to Surgical Revascularization Status in Diabetic and Nondiabetic Patients legend
26960,Toxic effects of treatment
26961,Tumour response
26962,Flow of participating infants through trial
26964,Revised infant temperament questionnaire scores
26968,Categories of adverse events
26969,Comparison of patients who had adverse events with all other patients
26970,Comparison of patients who had initial serious adverse events with all other patients
26974,Postoperative morbidity
26975,Unadjusted relation between preoperative haemoglobin mortality and mortality and morbidity
26976,Adjusted odds ratio   95  CI   for mortality and preoperative haemoglobin and decline in haemoglobin stratified by cardiovascular disease
26977,Patients considered for trial entry
26979,Treatment received
26980,Clinical response 6 weeks after initial treatment
26981,Local failure
26982,Causes of death
26983,Morbidity
26985,Haematological measurements at end of treatment
26987,Postintervention questionnaire
26988,Breast duct cannulation and ductoscopy
26989,Lymphocyte phenotype and function in Fas deficient patients
26990,Serum immunoglobulins and autoantibodies in Fasdeficient patients
26991,Serial Observations in Myosin Binding Protein CAffected Adult Relatives Without Phenotypic Evidence of Hypertrophic Cardiomyopathy When Initially Evaluated legend
26992,Presence of infections in AIDS KS biopsy specimens
26994,Clinical course and complications
26995,Causes of death
26996,Univariate analysis of risk factors affecting survival
26997,Multivariate analysis of risk factors affecting survival
27001,Treatment emergent adverse events
27003,Study Logic   Inclusions and Exclusions   legend
27005,Mortality by Risk Groups: Comparison of the Derivation and the Validation Samples legend
27007,Birth outcomes
27008,Induction outcomes
27009,Neonatal outcomes
27011,Correlation Coefficients of Neurohumoral Plasma Levels legend
27012,Effect of Atenolol and Placebo on Neurohumoral Plasma Concentrations legend
27013,Causes of Death
27017,Between group comparison of individual prolapse symptoms at 2 years
27020,Uptake of treatment for prolapse symptoms during year 1 and year 2 of follow up
27022,Falls in the 6 months before and after training
27023,Secondary outcome measures before and after training
27025,Findings in women who received hysteroscopy in the hysteroscopy group
27027,Pregnancy and livebirth outcomes
27029,Seroconversion for poliovirus   types 1, 2, and 3   from week 0 and week 18, and median antibody titres at week 18 by study group   per protocol
27030,Seroconversion for poliovirus   types 1, 2, and 3   from week 0 and week 18, and median antibody titres at week 18 by study group   modified intention to treat
27031,Cumulative seroconversion and median antibody titres by study group
27033,Serious adverse events
27034,Left Ventricular Contractility and Loading Conditions in Response to Intravenous Dobutamine and Intracoronary Enalaprilat and N G Monomethyl L Arginine
27035,Association between edoxaban dose, concentration, anti Factor Xa activity, and outcomes based on treatment regimen
27036,Relative efficacy and safety of edoxaban compared with warfarin stratified by dose reduction status
27037,Outcomes stratified by dose reduction criteria and treatment regimen
27039,Falls outcomes compared between the intervention and the control period
27040,Falls outcomes based on cognition levels
27043,Interventions and costs
27044,Unadjusted outcomes at 36 month follow up
27045,Adjusted outcome estimates, at 36 month follow up
27047,Possible Triggering Conditions at the Onset of Transient Left Ventricular Apical Ballooning legend
27049,Electrocardiographic Findings of Left Ventricular Apical Ballooning
27050,Catheterization Data legend
27052,Absolute and relative health inequalities over three survey cycles of the Health Behaviour in School aged Children study
27053,Absolute health inequalities in 492788 adolescents, 200210
27054,Relative health inequalities in 492788 adolescents, 20022010
27055,Pooled time series analysis of health and health inequality in 102 countries and cycles
27057,Operative and Postoperative Data legend legend
27058,Endotoxin and Interleukin B Ranges at 30 Minutes After Cardiopulmonary Bypass and Associated Ventilation Time legend
27059,Laboratory confirmed cases by age group
27060,Hospital admissions by age group
27061,Description of the 90 confirmed pertussis cases in infants by maternal vaccination status
27062,Effectiveness of maternal pertussis vaccine by infant age at onset and timing of vaccination
27064,Patients  clinical outcomes
27065,Primary and secondary outcomes within 30 days of randomisation
27066,All deaths and venous thromboembolic events   including those in first 30 days   during the 6 month follow up
27070,Clinical and Biochemical Variables of Patients and Controls legend
27072,Individual IGF 1 Levels in Patients With AMI and Controls legend legend
27074,Estimated proportion of participants falling at least once, and average number of falls per participant, attributable to various causes of falling
27075,Differences from pairwise comparison of proportions of participants falling, and average number of falls per participant, attributable to various causes of falling
27076,Estimated proportion of participants falling at least once, and average number of falls per participant, for each activity at time of falling
27077,Differences from pairwise comparison of proportions of participants falling while undertaking various activities
27078,Combinations of cause and activity associated with six or more falls
27079,Annual suicide rates per 10000 patients in contact with National Health Service mental health services implementing up to six recommendations compared with those implementing seven to nine recommendations
27080,Rates of suicide per 10000 per year in target groups before and after implementation of individual recommendations
27082,Treatment outcomes   defined by the TLOVR algorithm   at week 48
27083,Treatment emergent NNRTI and N  t  RTI RAMs   occurring in two or more patients with available resistance data in either treatment group   at 48 weeks
27084,Treatment emergent adverse events and laboratory abnormalities at 48 weeks
27091,Neutrophil recovery, engraftment, and status at last follow up
27092,Frequency of Missed Overall and Major Cardiovascular Findings by PE and POC Echocardiography legend
27093,Frequency of Findings Missed by Exam and Echocardiography
27094,Incidence of Selected Missed Minor Findings   Number of Observations   legend
27095,Incidence of Missed Major Findings   Number of Observations   legend
27097,Adverse events   MedDRA terms
27098,Levels of serum creatinine and creatinine clearance
27101,Rates of hypoglycaemia in participants receiving at least one dose of insulin   safety analysis population
27104,Interventions for maternal health in Matlab between 1976 and 2005
27107,Univariate and Multivariate Linear Model of Transcardiac Gradient of oxLDL in 22 Patients With DCM legend
27112,Unadjusted   crude   rate of CD4 count increases   per year   with viral load of less than 50 copies per mL and relation with current CD4 count   cells per L
27113,Adjusted rate of CD4 count increases   per year   with viral load of less than 50 copies per mL, and relation between CD4 count at starting cART   cells per L   and time since starting cART
27114,Echocardiographic and Other Measurements Before and After Dobutamine Infusion in the Entire Study Group   n   27   legend legend
27115,Echocardiographic Variables Before and After Dobutamine Infusion in the Terminal   Group I, n   9   and Survival   Group II, n   18   Groups legend legend
27116,Changes and Percent Changes in Echocardiographic Variables in the Terminal   Group I, n   9   and Survival   Group II, n   18   Groups legend legend
27117,Change in rates of conceptions among individuals younger than 18 years and proportion of such conceptions leading to abortion, 199498 to 19992003
27119,Summary of trachoma programme personnel, activities, and chronology of interventions
27121,Uptake of SAFE interventions at follow up
27123,Mortality data      and relative risk for Aboriginal and non Aboriginal infants and RR   95  CI   for Aboriginal compared with non Aboriginal infants born in Western Australia between 1980 and 2001 according to population variables
27124,Neonatal and postneonatal mortality rates for Aboriginal and non Aboriginal infants and RR   95  CI   for Aboriginal compared with non Aboriginal infants born in Western Australia in birth year groups, 19802001
27125,Mortality rates for Aboriginal and non Aboriginal infants and RR   95  CI   for Aboriginal compared with non Aboriginal infants born in Western Australia by geographical area and birth year groups, 19802001
27126,Mortality rates for main causes of death in Aboriginal and non Aboriginal infants and RR   95  CI   for Aboriginal compared with non Aboriginal infants born in Western Australia, 19802001
27127,Number      , mortality rate, and RR of out of hospital deaths from infection of Aboriginal compared with non Aboriginal infants born in Western Australia, 19802001
27130,Relationship Between Coronary Artery Disease and Type 2 Diabetes After Adjustment for Other Cardiovascular Risk Factors legend legend
27131,Forward Stepwise Analysis of the Best Predictors of the Various Patterns of Coronary Artery Disease in Patients not Taking Lipid Lowering Agents legend legend
27132,Impact of the New ADA Definition of Impaired Fasting Glucose and Diabetes on Coronary Artery Disease Scores legend legend
27133,HIV 1 prevalence and correlates of infection in women attending antenatal clinics in 200004 in the south and north of India
27136,Individual data of high responders
27137,Proportion of high responders per exposure, for whole group and by number of risk factors   oral contraceptive use, factor V Leiden mutation, or both
27138,Description of haemostatic gene polymorphisms in this review and their associated intermediate phenotypes
27139,Meta analyses of 191 studies of seven haemostatic gene polymorphisms in 66155 cases of coronary disease and 91307 controls, analysed with a co dominant genetic model
27140,Comparison of findings of present meta analyses of 191 studies   including 66155 cases of coronary disease and 91307 controls   with those reported in previous meta analyses of same polymorphisms in seven haemostatic genes, using the same genetic models as in earlier analyses
27141,Socioeconomic markers of SIDS families: trends in Avon over 20 years
27142,Sleeping position before death of SIDS infants: trends in Avon over 20 years
27146,Safety events during 12 week double blind period
27148,Comparison of activities in the maternity wards to promote and support breastfeeding in 1998   before intervention   and 2001   after training  , according to mothers
27149,Comparison of the proportions given water, tea, or other milk and using pacifier or bottle among infants born in hospitals in 2001 after training, with and without home visits
27151,Perioperative data and outcomes
27152,Linear regression analysis between postoperative activated C4 and six dependent variables
27158,Risk of second thyroid cancer by radiotherapy and chemotherapy
27159,Radiation dose and risk of thyroid cancer by: age at diagnosis of first cancer, type of first cancer, sex, latency, and attained age
27160,Size of thyroid cancer and lymph node involvement based on surgical pathology report by type of first cancer diagnosis
27162,Compliance at 24 months
27163,Main outcomes by randomised group and by supplement groups
27164,Quality of life at follow up of 4 months and 2 years
27166,Maternal nutritional biochemistry
27167,Primary, secondary, and stratified outcomes
27168,Mortality outcomes
27170,Pathogens associated with severe disease
27171,Mycobacterial disease course
27172,Left Ventricular Volume and Function legend
27174,Association between PDD and MMR vaccination before index date, before and after third birthday, and before and after age 18 months
27175,Association between diagnosis of autism or other PDD and MMR vaccination
27178,Number of patients responding at 18 month assessment
27179,Change in disease activity, radiographic damage, physical function, and quality of life between 0 and 18 months
27180,Total hospital, community, and patient costs per patient between 0 and 18 months
27182,Risk of subdural haemorrhage related to mode of delivery
27183,Initial Heart Size and Function in Patients With Cardiomyopathy and Control Subjects legend legend
27184,Association of subdural haemorrhage with other variables
27185,Neonates with asymptomatic subdural haemorrhages
27186,Symptomatic neonates
27187,Analyzed Stored ICD Electrograms legend legend
27188,Incidence of Polymorphic Ventricular Tachycardia by Patient legend legend
27190,Fracture rates and relative risks by sex combined percentile category of BUA and VOS in men and women aged 4282 years
27191,Cox multivariate regression of risk factors for fracture according to BUA and VOS in 14799 men and women      aged 4282 years
27192,Relative risks of fracture stratified by risk factors with Cox multivariate regression in men and women aged 4282 years
27193,Estimated population effect on fracture reduction of different prevention strategies in men and women
27198,Recurrent Arrhythmia and Survival Time by Sextile legend
27199,Adverse events
27203,Classification by LVEF Versus Sextile Numbers and Mean    SE   Survival Differences   ICD AAD   legend
27206,Mechanism for sulphonylurea sensitivity
27208,International Classification of Disease   ICD   codes used to define mortality data
27209,Proportion of total strokes classified as cerebral infarct, cerebral haemorrhage, and ill defined cerebrovascular disease from routine mortality data
27210,Ratio of cerebral infarct to cerebral haemorrhage over the twentieth century and details of studies used to estimate ratios
27213,Average annual percentage change in mortality and 95  CI before and after the intervention, with relative change in annual trend from before to after the intervention
27216,Electrocardiographic, Echocardiographic and Scintigraphic Follow Up Data   n   45   legend
27218,Prevalence of first stroke subtype and of second stroke subtype in relation to first stroke subtype   descriptive analysis
27219,Prevalence of prothrombotic defects in paediatric ischaemic stroke in first stroke, and in second stroke in relation to first   descriptive analysis
27220,Independent contributions to the risk of a second ischaemic stroke for prothrombotic risk factors, antithrombotic treatment, and stroke subtypes
27221,Stroke types and restroke rate by antithrombotic treatment   descriptive analysis
27222,Prior probabilities of factors affecting uptake of immunisation, based on qualitative studies and elicited beliefs
27223,Prior and posterior probabilities that factors affect uptake of immunisation   for the four factors with highest prior probabilities
27224,Experimental firing of RCC 95 rubber bullets by the Israeli police force
27225,Injuries to the arms and legs caused by rubber bullets
27226,Specific head and neck and facial injuries caused by rubber bullets
27227,Specific chest, abdominal, and back injuries caused by rubber bullets
27228,Risk factors for venous thromboembolism
27229,Components of the homocysteine remethylation pathway
27230,Components of the homocysteine remethylation pathway divided into quartiles
27231,Multivariate model      predicting venous thromboembolism
27232,Odds ratios of venous thromboembolic disease for quartiles of red blood cell methylfolate, by C677T MTHFR genotype
27236,Predictive Values for Beta Blocker Induced Increase in LVEF legend
27239,Problems and physiotherapy interventions
27240,Patients admitted and discharged from heroin assisted treatment centres in Switzerland, 19942000
27242,Reasons for discharge
27243,Medical data for treatment cohort at time of admission and during follow up   n 237
27244,Socioeconomic status of treatment cohort at time of admission and during follow up   n 237
27245,Nearly daily consumption of psychoactive substances for treatment cohort at time of admission and during follow up   n 237
27246,Data of Patients Submitted to Mitral Balloon Valvuloplasty and Mitral Valve Commissurotomy legend legend
27247,Hemodynamic Data of Patients Before and After Percutaneous Balloon Mitral Valvuloplasty legend legend
27248,Neonatal and Fetal Mortality legend
27251,Survival and adverse outcomes
27252,Neurological outcomes and quality of life of patients who survived to hospital discharge
27253,Survival in clinically important subgroups
27255,Age and haematological data in 200 passengers examined before and after air travel
27256,All drugs taken by volunteers who attended for examination before and after air travel
27258,Maternal Outcome in Patients With Valvular Heart Disease and Their Controls legend
27259,Fetal Outcome in Patients With Valvular Heart Disease Versus Controls legend
27261,Body Weight, Intra arterial Blood Pressure, and Heart Rate   HR   Data in Conscious Animals legend
27262,Measurement of Carotid Hemodynamic Parameters legend
27264,Summary of results of each screening round for the group
27265,Histomorphometric Data of the Thoracic Aorta and of the Carotid Artery legend
27267,Spironolactone: Cardiac Structural Data legend
27271,Results of 1 year follow up
27272,Concentrations of leukotrienes in cerebrospinal fluid, plasma, and urine
27273,Formation of leukotrienes in monocytes and platelets
27274,24 h excretion of hydrogen and methane and maximum rate of gaseous excretion
27275,Faecal weight and composition and whole gut transit time in patients and controls receiving standard and exclusion diets
27276,Findings among patients in group A
27277,Findings among patients in group B
27278,Wexner continence grading scores before and after implantation
27279,Quality of life scores before and after implantation in five patients with intact prosthesis
27280,Resting anal pressure, rectal maximum tolerated volume, and rectal compliance before and after implantation
27282,Frequency of MRI lesions by vegetative state 12 months after injury
27283,Predictors of non recovery
27284,Number of eligible hip fracture cases by age and sex
27285,Cases and controls with previous hospital admission and previous drug exposure
27286,Estimated unadjusted and adjusted odds ratios for hip fracture by timing of exposure
27287,Diagnostic investigations for 22 children presenting with AFP
27288,Clinical features of 20 children presenting with acute flaccid paralysis who had definite JEV status
27290,Blood Pressure and Echocardiographic Parameters in the Carvedilol and Placebo Groups legend
27291,Assessment of NYHA Class Over the Treatment Period legend
27292,Prevalence of respiratory and allergic disorders and bronchial hyper responsiveness to cold air challenge
27293,Changes in prevalence of sensitivity to specific allergens
27294,Results of multivariate logistic regression analysis with hay fever and atopy as outcome variables
27296,Holter Electrocardiographic Findings legend legend
27297,Univariate Predictors of Ventricular Tachycardia legend
27298,Multiple Logistic Regression Analysis legend
27299,Univariate and Multivariate Cox Proportional Hazards Analyses legend
27301,Other bleeding symptoms and symptom scores
27303,PEF values during 72 h before and after vaccine and placebo
27304,Respiratory and systemic symptoms during 72 h before and after vaccine and placebo
27305,Use of medication during 72 h before and after vaccination
27306,Hospital admissions, medical consultations, and use of antibiotics and oral steroids for respiratory complaints during 7 days after vaccine and placebo
27307,Presence of Heart Disease and Cardiac Function legend
27308,Pacemaker Implantation   Age at and Mode of  ; and Average Heart Rate   BPM     Prior to and After   legend
27310,Histologic Findings legend
27311,Abnormal cytogenetic results
27312,Pregnancy complications after sampling
27313,Pregnancy outcome
27314,Birthweight, gestational duration, mode of delivery, and respiratory difficulties among liveborn infants
27315,Congenital defects
27316,Age specific prevalence of active trachoma infection in 1959, 1987, and 1996
27317,Winter climate, populations, and mortality rates in each region
27319,Regression coefficients   R   and their significance   p  , for cause specific indices of cold related mortality on personal cold exposure factors standardised at 7C mean daily temperature
27322,Relation of LVOT Gradient Reduction to Changes in Outflow Geometry and LV Ejection legend
27323,French sibling pair a adducin linkage results
27325,Allelic frequencies of a adducin polymorphisms in control and hypertensive groups
27326,a adducin genotypes in pooled control and hypertensive patients
27329,Median linear analogue pain scores before treatment and at each visit during treatment
27333,Number of pregnancies and fetal loss
27334,Odds ratios of fetal loss in women with thrombophilia
27335,Odds ratios   95  CI   for fetal loss and type of thrombophilia, with control group as reference, adjusted for number of pregnancies and centre
27336,Percentage of women with pregnancies resulting in fetal loss with and without terminations of pregnancy
27338,HHV 8 antibody titres before and after KS diagnosis
27340,Mortality and Other Complications During Hospital Period legend
27341,Independent Predictors of Six Month Mortality in Inferior Myocardial Infarction    legend
27344,Symptoms unrelated to an appetite disorder that distinguished hyperphagic short stature children from others
27348,Effect of aerosolised L NMMA and D NMMA on airway response to bradykinin and methacholine
27349,Cardiovascular effects of aerosolised L NMMA and D NMMA
27352,Spectral Parameters of HRV Measured Before Discharge in the Entire Group, in Patients With Early AF Recurrence and in Patients in Sinus Rhythm 12 to 15 Days After Cardioversion legend
27353,Spectral Parameters of HRV Measured Two Weeks After Cardioversion in Patients Who Were in Sinus Rhythm at Time of First Control Visit and Did or Did Not Develop AF During the Follow up Period legend
27354,Frequency of hip fracture according to fall related variables selected by stepwise Cox regression analysis
27355,Effect of four fall related factors and femoral neck
27356,Fall risk status and femoral neck BMD status
27358,Mean Values for Age and Blood Pressure and Cardiovascular Deaths in Men According to the SBP and DBP Groups legend
27359,Mean Values for Age and Blood Pressure and Cardiovascular Deaths in Women According to the SBP and DBP Groups legend
27360,Total injuries in 1994 related to exposure on different types of surface
27361,Patterns of injuries on different types of surface in 1994
27362,Comparison of fractures and injuries from falls on to bark surfaces according to equipment   199294
27363,Fracture rate and height of climbing frames on bark surfaces   199294
27365,Primary and secondary outcomes
27370,Hemodynamic Parameters in Long Term Survivors at 10 Year Follow Up legend
27371,Multivariate Analysis of Factors Affecting Long Term Survival After Cardiac Transplantation
27373,Primary efficacy results in the intention to treat population for the overall study period
27374,Safety outcomes as adjudicated bleeding events   safety population, on treatment period
27376,Treatment emergent adverse events in the safety population for the overall study period
27379,Adverse events   safety population
27381,Seroconversion and seropositivity rates against serotypes 1, 2, and 3 in the intention to treat population   primary analysis
27382,Median log2 titres of neutralising antibodies against polio serotypes 1, 2, and 3 in the five groups   intention to treat population
27383,Stool poliovirus type 2 shedding for 28 days after mOPV2 challenge in the different study groups   intention to treat population
27384,Humoral   types 1, 2, and 3   and intestinal   type 2   immunogenicity in the different groups   per protocol populations
27386,Results From Cox Multivariate Analysis of Survival legend legend
27391,Adverse events in efficacy population by study group
27394,Systemic and local adverse events with onset within 28 days of a dose   safety population
27395,Infection distribution at study entry and with respect to clinical efficacy by age and disease severity for all recipients receiving at least one dose   modified intention to treat population
27397,Efficacy during the double blind period
27398,Incidence Rates of Recurrent Venous Thromboembolism Among 218 Men According to Presence or Absence of the G20210A Mutation in the Prothrombin Gene legend
27400,Incidence Rates of Recurrent Venous Thromboembolism Among the Subgroup of Men With an Initially Idiopathic Event, According to Presence or Absence of the G20210A Mutation in the Prothrombin Gene legend
27401,Efficacy during the open label period
27402,Dose by cohort
27403,Adverse events in the double blind period
27404,Serious adverse events in the double blind period
27407,Death and dependency at 10 years
27409,Incidence of recurrent subarachnoid haemorrhage from target aneurysm and of resulting death or disability   mRS 35
27410,Causes of death in all UK patients from 2 months after enrolment
27411,Standardised mortality ratios
27412,Number of patients   aged 1599 years   included in analyses in England and Wales diagnosed from 1971 to 2011 and followed up to 2012, by sex and type of malignancy
27413,40 year trends in the index of net survival for all cancers combined at 1, 5, and 10 years after diagnosis in adults   1599 years   in England from 1971 to 2011 and trends in the age adjusted net survival for 21 selected cancers in England from 1971 to 2011 by sex
27414,40 year trends in the index of net survival for all cancers combined at 1, 5, and 10 years after diagnosis in adults   1599 years   in Wales from 1971 to 2011 and trends in the age adjusted net survival for 21 selected cancers in Wales from 1971 to 2011 by sex
27415,Total Study Cohort   n   246   legend
27419,Adherence to treatment in each trial group
27420,Subgroup analyses of treatment effect on days to relapse
27422,Mean cost per participant over the 24 month follow up period
27423,Comparison of trial management according to the eight domains of AHA taxonomy for disease management  11
27425,Pattern of recurrent admission
27428,Incidence of treatment emergent adverse events   safety population
27429,Study population and follow up period for endocrine disorders, by country
27430,Observed and expected numbers of first hospital contacts for endocrine disorder of any type by sex and age in 31723 1 year survivors of childhood cancer in the Nordic countries
27431,Observed and expected numbers of first hospital contacts for endocrine disorders of any type or one or more of 22 subcategories of endocrine disorder in 31723 1 year survivors of childhood cancer in the Nordic countries
27432,Standardised hospitalisation rate ratios for endocrine disorders of any type and for subcategories of endocrine disorders distinguished by a lower 95  confidence limit of 10 by main diagnostic group of childhood cancer   ICCC
27433,Similarity of risk estimates obtained in the ALiCCS study and the CCSS for comparable combinations of childhood cancer and endocrine disorders
27434,Diagnosis of serogroup A meningococcal meningitis in individuals from non vaccinated and vaccinated regions in Chad
27436,Meningococcal carriage in the Mandelia district of Chad before and after vaccination with PsATT
27438,Stroke and mortality by randomisation assignment
27439,Stroke and mortality as treated
27440,Adverse events by randomisation assignment
27443,Univariate Analysis Between Percent Change in Carotid Artery Diameter During CPT, Carotid IMT and Coronary Risk Factors legend
27446,Comparison of costs and QALYs gained from VAT PP versus talc pleurodesis
27447,Deaths and serious adverse events possibly or probably related to treatment
27448,Clinical Data of Study Patients legend legend
27450,Number of Sites Where the Stimulation Protocol Was Performed in Patients in the Washout and Verapamil Groups
27452,Refractory Periods   mean  SD of All Paced Sites   at Each Basic Cycle Length in Washout and Verapamil Groups
27453,Atrial Effective Refractory Periods in Different Right Atrial Sites in Washout and Verapamil Groups
27456,Pertussis antigens 1 month after third vaccination
27457,Participants with any local and systemic reactions within 7 days of any dose of the respective vaccines
27458,Participants with any systemic reactions within 7 days of any dose of the respective vaccines
27459,Refractory Periods at Constant Pacing of 300 and 600 ms Compared With LongShort   600 to 300 ms   and ShortLong   300 to 600 ms   Sequences legend
27462,Age adjusted DALY rates per 100000 population by cancer site and region, 2008
27466,IPTi studies that included assessment of serological responses to EPI vaccines
27467,Proportion of infants in IPTi and placebo groups who did not develop seroprotective antibody concentrations after Expanded Programme on Immunization vaccines; data from Manhica, Kisumu, and Bungoma
27468,Relationship Between the Degree of Mitral Regurgitation and LVOT Peak Gradient legend legend
27471,Clinical Findings in HCM Children With or Without Myocardial Bridging   50  Max. Systolic Compression   legend
27473,Relation of Thallium Perfusion Abnormalities to Clinical Parameters: Logistic Regression Model for Predicting Thallium Perfusion Abnormalities legend
27474,Clinical Findings in HCM Children With or Without Compression of Septal Branches of the LAD Artery
27476,Crude and Multivariable Adjusted Odds of Developing Myocardial Infarction or Death Based on Exercise Duration legend
27477,Medical Management at Last Follow Up legend
27479,Diagnostic Tests Analysis legend
27482,Cox Proportional Hazard Model Comparisons, Including Age and Etiology of Cardiomyopathy legend
27483,Echocardiographic Features of Patients and Carriers    legend
27485,Semiquantitative Perfusion and Wall Motion Scores legend
27488,In Hospital Device related Complications
27489,In Hospital Clinical Outcomes
27490,1 Year Clinical Outcomes
27494,Incidence of Selected Adverse Events According to the Study Period
27495,Risk of Embolism According to the Infecting Microorganism
27496,Echocardiographic Data: Prognostic Factors of Embolism by Univariate Analysis
27497,Effect of Vegetation Size on Embolism Stratified by Type of Microorganism and Valve Infected
27499,Occurrence of Different Pathogens and Relation With Embolic Events legend
27500,Clinical Features of Infective Endocarditis in Patients With and Without Embolism legend
27501,Echocardiographic Localization of Vegetation and Risk of Embolism
27502,Results of Univariate and Multiple Stepwise Logistic Regression Analyses legend
27503,Results of Previous Studies legend
27504,The Association of CAD With Cardiac Risk Factors and Circulating CPn DNA
27505,Hematological Variables in Men With CAD According to the Presence of Circulating CPn DNA legend
27506,Definition of Patient Groups According to von Reyn and Duke Criteria
27507,Comparison Between von Reyn and Duke Criteria
27508,Repartition of Diagnostic Criteria Between Groups
27509,Repartition of Duke Major and Minor Criteria Between the Four Groups
27510,Repartition of Diagnostic Criteria in Group 4 and Causes for Misclassification legend
27511,Criteria for Infective Endocarditis
27513,Systemic Hemodynamic Parameters in Protocols IIII legend
27514,Time Controls: Action Potential Duration and QT Intervals Measured in Arterially Perfused Left Ventricular Wedge Preparations at End of Equilibration Period   1 h   and at End of a 4 h Period of Perfusion
27519,Selected Intravenous Medication and Hemodynamic Parameters During the First 72h After ICU Admission
27520,Distribution of ICHS Components in PESA
27521,Distribution of FBS Components in the PESA Study
27522,Association Between ICHS and FBS and Subclinical Atherosclerosis Measured as Plaque Presence at Any Site and CACS of1
27523,Association Between ICHS and FBS and Multiterritorial Extent of Subclinical Atherosclerosis and CACS Level
27526,Clinical Differences Among the Groups
27527,Incidence of Cardiac Events During Follow Up
27534,Echocardiographic Variables
27538,Prevalence of FH Based on Clinical Scores Versus Genetic Study
27540,Clinical Scores of Patients With or Without FH Mutation
27543,Independent Association of Spontaneous Gasping or Breathing During CPR With 1 Yr Survival With CPC2 for Out of Hospital Cardiac Arrest Patients   n 1,827
27544,Independent Association of Spontaneous Gasping or Breathing During CPR With 1 Yr Survival With CPC2 Stratified by Initial Recorded Cardiac Rhythm
27546,Angiographic Findings and Procedural Outcomes
27549,Procedural Data
27550,Procedural Outcomes
27551,Clinical Outcomes
27554,Primary Clinical Efficacy and Safety Endpoints for the Economic Study Population
27555,Follow Up Hospitalizations and Costs
27557,Lifetime Cost Effectiveness Results for Base Case and Sensitivity Analyses
27558,Lifetime Cost Effectiveness Results for Subgroups
27560,Multivariable Analysis of Mortality Risk in Patients With ATTR
27563,LQTS Treatment Summary by Sex: Pharmacotherapy, LCSD, and ICD
27564,Treatment Outcomes and Comparison by Symptomatic Status
27565,Treatment Outcomes and Comparison by LQTS Genotype
27567,Multivariate Analysis: Independent Predictors of MI During 5 Yr Follow Up
27568,Details of the 27 Cases of Very Late Stent Thrombosis
27572,HCM Patients With LV Apical Aneurysms and HCM Related Death or Life Threatening Events Interventions
27573,Relationship of LV Apical Aneurysm Size to HCM Related Events
27575,Relative Hazards of AF With Per SD HRV Decrease
27579,Effectiveness Outcomes of Radiofrequency HotBalloon PVAblation
27581,Tabulation of Major Complications
27582,List of Serious Adverse Events in HBA Group and Crossover Group
27584,Incidence Rates of Life Threatening Arrhythmias and of Cardiovascular Mortality
27585,Predictors of Arrhythmic Risk at Follow Up
27586,Matched Periods Analysis for the Efficacy of Antiarrhythmic Drugs and Transcatheter Ablation
27590,Locations of Scars
27593,Non PV Trigger Distribution During Isoproterenol Challenge
27595,Ischemic and Bleeding Outcomes in All Randomized Patients According to PCIComplexity
27596,Predictors of MACE and CTEs in All Randomized Patients
27597,Ischemic and Bleeding Outcomes in All Randomized Patients According to PCI Complexity and DAPT Duration
27598,Effect of Long  Versus Short Term DAPT on Risk of MACE Across Clinical Subsets Within the Complex and Noncomplex PCI Groups
27600,PITX2 mRNA Expression in Left Atrial Appendages From AFAblation Patients
27603,Electrophysiological Effects of Reduced Sodium Conductance in a Human Atrial Model
27604,Electrical Activation Time and Conduction Velocity in Isolated Atria in the Presence of Flecainide   1 mol l
27607,Serial Echocardiographic Assessment of the Effects of LVAD Unloading on Structure and Systolic Function in Ischemic and Nonischemic Cardiomyopathy
27608,Serial Echocardiographic Assessment of the Effects of LVAD Unloading on Left Ventricular Diastolic Function in Ischemic and Nonischemic Cardiomyopathy
27610,Adverse Events After Thoracoscopic Ablation for Atrial Fibrillation
27611,Patient Deaths
27613,Echocardiographic Findings   Within 6 Months of Diagnosis
27615,Public OHCAs
27616,Bystander Applied AED Use on Public OHCAs
27617,OHCA Coverage Loss of Registered AEDs
27618,OHCA Coverage Loss of Registered AEDs According to Location Type
27619,Risk Factors in the Analysis, Exposure Metrics, TMRED, and Disease Outcome
27620,Covariate Adjusted Distribution of the Systolic Blood Pressure, Body Mass Index, Smoking, and Physical Activity Over Time
27622,Selected Management: Derivation Cohort
27624,Bivariate Relationship Between Categorical Variables and In Hospital Mortality
27625,Multivariate Model of In Hospital Mortality
27626,Model Performance in Subgroups
27630,Comparison of U.S. wt ATTR and Val122Ile Subjects
27631,ATTR attributable Symptoms and Signs in Symptomatic U.S. Subjects
27632,Electrocardiography, Echocardiography, and Biomarkers: wt ATTR Versus Val122Ile in U.S. Subjects
27633,Univariate and Multivariate Analysis of Predictors of Survival
27635,Events in Patients With or Without Aborted Sudden Cardiac Death
27637,Unadjusted and Multivariable Treatment Models
27640,Clinical and Echocardiographic Data at Follow Up
27642,Discharge Interventions Stratified by Patients With and Without OHCA
27644,Primary and Key Secondary Outcomes at 6 Month Follow Up
27645,6 Month Outcomes: STEMI and NSTEMI Subgroups
27647,30 Day MACE
27648,Algorithmic Diagnostic Accuracy for 30 Day MACE
27649,Algorithmic Diagnostic Accuracy for 30 Day MACE Without UA
27652,Electrocardiographic Parameters
27654,Probability of VF SCD During Follow Up Depending on Clinical and Electrocardiographic Parameters at Presentation: Univariate and Multivariate Analysis
27656,Echocardiographic Parameters
27657,CMR Parameters
27658,Independent Determinant of Presence of Angina
27661,Echocardiographic Data   n  564
27662,Procedural and In Hospital Outcomes
27663,30 Day Outcomes
27664,Procedural Results and Outcomes According to Post Implantation Mitral Regurgitation
27665,Registries of Transcatheter Mitral Valve Repair With the MitraClip
27669,EF Recovery to  35  90 Days After MI
27670,EF Recovery to50  90 Days After MI
27673,Angiographic Findings and Invasive Management ofPatients With Perioperative Myocardial Infarction
27676,Composite Outcomes and Recurrent Ischemic Stroke   Intention to Treat Analyses
27677,Composite Outcomes and Recurrent Stroke   As Treated Analyses
27678,Safety Outcomes   As Treated Analyses
27680,Rates of ED Visits or Hospitalizations for HF Exacerbation
27681,Rate Ratios for ED Visits and Hospitalizations for HF Exacerbation, UsingNegative Binomial Regression Model
27682,Rates of ED Visits or Hospitalizations for COPD, Pneumonia, or Dyspnea
27683,Rates of ED Visits or Hospitalizations for HF Exacerbation: Patients Who Underwent Nonbariatric Surgery
27686,12 Month Rhythm Outcome According to Number of Ablations
27688,Univariable and Multivariate Regression Analysis of Proportional Collagen Content, as Evaluated by Morphometric Analysis of PSR Staining in BrS Cases Versus Control Hearts
27689,Multivariable Regression Analysis of Proportional Connexin43 Content in BrS Post Mortem Cases Versus ControlHearts
27690,Causes of Arrhythmia Induced Cardiomyopathy
27691,An Example of the Clinical Course of AIC When the Culprit Arrhythmia Was Not Eliminated: A 54 Year Old Man With AF and LVEF of 30
27693,Surgical Data
27694,Kaplan Meier Estimates
27695,Pre Operative Clinical Features   N   195
27696,Surgical Features   N   195
27697,Univariate and Multivariate Predictors of Overall Mortality
27698,Most Common TTR Mutations Identified in Patients With Symptomatic Amyloidosis
27699,Selected Trials for TTR Amyloidosis
27700,28 Clinical Reports of Combining TTM and Early Coronary Angiography in Resuscitated, But Comatose Patients With STEMI on the ECG
27701,Angiographic Findings in Patients With Cardiac Arrest and No ST Segment Elevation on ECG
27702,Outcomes of Patients With Cardiac Arrest Referred for Coronary Angiography
27704,Types of Major Infection During Index Hospitalization and Rehospitalization   N  4,320
27705,Mean Extra Costs and Length of Stay During Index Hospitalization
27706,Mean Costs and Length of Stay of Readmission
27709,Univariate Cox Regression Analysis Among Patients Experiencing Appropriate Shocks
27711,Predictors of Mortality During Follow Up in Patients With Acute Heart Failure
27712,Predictors of Short Term Mortality in Patients With Ventricular ArrhythmiaInduced Cardiac Arrest
27714,NSE Cutoff Values
27715,Multivariable Analysis With NSE and Clinical Variables
27717,Post Procedural and In Hospital Outcomes   N  7
27723,Multivariate Predictors of Referral to Cardiac Rehabilitation After PCI in the Overall Population
27729,Absolute MMP and TIMP Concentrations in BAV Aortas
27731,Association Between Randomization, 1 Year, Change from Randomization to 1 Year in OxPL apoB, and Clinical Outcomes
27732,Baseline Characteristics of Patients, Procedures, In Hospital Adverse Events, and Hospitals
27733,Association of LOS on Time to Event Within 30 Days
27734,Association of Selected Covariates on LOS
27735,Association of Each LOS Day on Time to Event Within 30 Days
27736,Description of Included Studies
27738,Event Rates Per 100 PYs at 1 Year and Full Follow Up According to Treatment Strategy Initiated at Day 14 After Discharge With Incident AF
27740,Peri Treatment Variables and Their Association With Overall Survival
27741,Complications Related to Percutaneous Pericardiocentesis
27742,Survey of Screening Guidelines: Results of Survey Assessing Compliance With Pre Participation Screening Guidelines Among Participants in the 2013 Tel Aviv Marathon
27745,Use of Antiplatelet Agents During Follow Up
27746,Cumulative Incidence of Clinical Events Up to 1 Year
27747,Cumulative Incidence of Stent Thrombosis Up to 1 Year
27748,Clinical and Angiographic Details of the 7 Patients Who Had Longitudinal Stent Deformation During the Procedure
27750,Caval Aortic Transcatheter Aortic Valve Replacement Details
27751,In Hospital and 30 Day Outcomes
27754,Some Circulating miRNAs Found Associated With the Enlarged Heart
27755,Effects of the Administration of Some miRNAs and Anti miRNAs on the Cardiovascular System in Animal Models
27759,Meta Analytic Summaries of Test Performance by Predictor Category
27760,Cardiac Structural Athletic Adaptations: 35 Years ofResearch
27761,Reasons CV Specialists See Athletic Patients
27762,Controversies in Sports and Exercise Cardiology
27763,New Paradigm: Cardiovascular Care of Athletes
27766,Predictor of Successful Epi LAVA Elimination From Ablation at Facing Endo Site
27767,Patients With Complete, Partial, and No Elimination of Epi LAVA Endocardially
27772,Major and Minor Adverse Events Observed in Device Compared With Surgical Closure Groups
27774,Peri CABG Antiplatelet Therapies
27779,Prevalence of Complications and Mortality Among Study Sample   N  240,632
27780,Risk Model for Complications After ICD Implantation
27781,Parsimonious Risk Scoring System for Complications After ICD Implantation
27783,Percentage of Patients With Abnormal Strain
27785,Profile of Patients With Cardiac Events
27786,Clinical Outcome of Initial and Follow Up Testing
27787,Univariate Predictors of MACEs
27789,Summary of Variant Filtering
27790,The 9 Variants Shared by Individuals I 2, II 3, II 5, and II 6
27792,Imaging Parameters in Subjects With SCA
27793,Significant Predictors of Time to SCA
27794,Provocation Testing Dosing Protocols
27795,Practice Guidelines for Coronary Spasm Provocation Testing
27798,Procedure Details
27804,Drug Specific Recurrent Cardiac Event Rates     and Covariate Adjusted Hazard Ratios Relative to Propranolol   Among Patients With 1 Prior Cardiac Event on  Blockers
27805,Echocardiographic Morphological Characteristics for DeterminingPatient Eligibility for Percutaneous Valve Repair Therapy
27809,Complications Associated With Percutaneous Valve Implantation
27811,Causes of Death
27812,Univariate Analysis of Death
27813,Multivariate Analysis of Death
27814,Distribution of AAD Values by Quintiles
27816,Relationship of Proximal Aortic Stiffness to Incident Mortality
27817,Relationship of Proximal Aortic Stiffness to Incident Hard CVD
27818,Relationship Between AAD and Incident Hard CVD According to Global Framingham Risk Category
27823,Lifespan Gained and NNT to Gain 1 Life Year Compared With Duration of Follow Up After Device Implantation
27825,Study Endpoints
27828,Univariate Analyses for Associations With Mortality Among All Patients
27829,Univariate Analyses for Associations With Mortality in Patients Without Prior MIs by History or ECG
27830,Univariate Analyses for Associations With Mortality in Patients Without Evidence of MI by Clinical History, ECG, or LGE Imaging
27831,Public Indoor Locations Defined as Typical and Alternative Exercise Facilities
27832,Data Analysis for All Public Indoor Location Cardiac Arrests That Occurred Prior to EMS Arrival
27833,Site Incidence Rates of Cardiac Arrests
27834,Activities at the Time of Cardiac Arrest
27835,Data Analysis for All VF VT Arrests in Public Indoor Locations That Occurred Prior to EMS Arrival
27837,Unmatched Data on In Hospital Outcomes
27838,Propensity Matched Data on In Hospital Outcomes
27839,Recent MI Patients Prescribed a WCD
27841,Summary Data Comparing Asymptomatic Gene Carriers With Healthy Control Patients
27842,Summary Data Comparing Asymptomatic Gene Carriers With Patients With Symptomatic   VT   ARVC
27845,Site of Origin of the 96 PVCs Targeted for Ablation and the Number Involving Patients With SHD  in Brackets
27849,Primary and Secondary Outcomes During the Follow Up Period   N   1,429
27850,Correlated Factors for MACE in VSA Patients and Assigned Score
27852,Echocardiographic Findings
27853,Correlations Between logNT proBNP Levels and Echocardiographic Parameters
27854,Exercise Test   n  198
27858,CMR LGE Scar Size of ICD Cohort
27860,Reclassification Analyses
27864,Predictors of All Cause Mortality
27865,Predictors of Cardiovascular Mortality
27867,Full Model for Predictors of Survival to HospitalDischarge
27868,Final Reduced Model for Predictors of Survival toDischarge
27870,Mean Treatment Differences for DR IPA, C IPA, PRU, and VASP PRI
27871,Prevalence of Patients With High Platelet Reactivity According to Treatment and Smoking Status
27872,Comparison of PK Parameters of the Active Metabolite of Prasugrel and the Active and Inactive Metabolites of Clopidogrel Between Smokers and Nonsmokers
27873,DR IPA by Treatment, Smoking, and CYP2C19 Genetically Determined Metabolizer Status
27874,Definitions of Noncardiac Causes of Death
27876,Rs4245791 Frequency in the ABCG8 Gene and Anthropometric Parameters and Plasma Lipids and Sterol Levels in the LURICandYFS Cohorts
27877,Rs6576629 Frequency in the ABCG8 Gene and Anthropometric Parameters and PlasmaLipids and Sterol Levels in the LURIC and YFS Cohorts
27878,Rs657152 Frequency in the ABO Gene and Anthropometric Parameters and Plasma Lipids and Sterol Levels in the LURICandYFSCohorts
27880,Relationship of Ventricular Ectopic Activity With Bileaflet MVP in OHCA Survivors With Ambulatory Holter Monitoring   n  19
27882,Summary of SCDs Linked to MVP Reported in the English Language
27883,Summary of OHCA and Malignant Ventricular Arrhythmias Linked to MVP Reported in the English Language
27885,Reasons for Anticoagulation Therapy Contraindication   N  52
27886,Procedural and In Hospital Findings
27887,Follow Up Results
27888,Individual Characteristics of Patients With Major Adverse Events at Follow Up
27889,Echocardiographic Findings According to the Presence of New Peridevice Leaks at 6 Month Follow Up
27890,Acute Results and Clinical Events at Latest Follow Up of Patients Undergoing Percutaneous Closure of Left Atrial Appendage in Patients With Contraindication for AnticoagulationTherapy
27891,Effects of Exogenous NO on the Proliferation of Cardiovascular Related Cells
27895,Step by Step Description of the TAO TAVR Procedure
27897,Procedural and Clinical Outcomes by TAVR Approach
27898,Selected Serious Adverse Events Related to Immediate Inaccessibility to Quinidine
27900,Relative Risks and 95  CIs for Peripheral Artery Disease According to Level of OxPL ApoB
27901,Relative Risks and 95  CIs for Peripheral Artery Disease According to Level of Lp  a
27902,Relative Risks and 95  CIs for Peripheral Artery Disease According to Level of AA to MDA LDL
27903,Relative Risks and 95  CIs for Peripheral Artery Disease According to Level of IC
27908,Door to Balloon Times of Patients With and Without Nonsystem Delay
27909,Risk Adjusted In Hospital Mortality
27910,In Hospital Adverse Outcomes of Patients With and Without Nonsystem Delay
27912,Primary Prevention Risk Factors and ICD Interventions in 188 High Risk Children and Adolescents
27914,Event Free Survival: Univariate and Multivariate Analysis of Potential Clinical and Echocardiographic Predictors
27917,Predictors of Infarct Size in Multivariate Regression Analysis
27918,Relationship of CMR Markers and Clinical Outcome at 12 Months
27919,SQTS Diagnostic Criteria: Gollob Score
27920,SQTS Diagnostic Criteria: Modified Gollob Score
27922,Genetic Mutations in the Pediatric Cohort
27923,Comparison of Patients With Versus Without Aborted Sudden Cardiac Death
27926,VARC Outcomes in the Propensity Matched Population
27932,Minimally Adjusted Association Between Indices of LV Function and R R Variation or CAN at EDIC Year 16 17
27933,Association Between Indices of LV function and R R Variation or CAN at EDIC Year 16 to 17 After Adjustment for Traditional Cardiac Risk Factors and Glycemia
27934,Multivariable Analysis of R R Variation and CVD Risk Factors in Relation to LV Function
27935,Study Population
27936,Withdrawals From Therapy
27937,Primary Outcome and Its Components
27938,Primary Outcome and Its Components   On Treatment Analysis
27940,Comparison of Patients With LVAD Implanted as a Bridge to Transplantation or as Destination Therapy
27941,Major Primary Causes of Readmission After LVAD Implantation
27945,Sex Specific Associations of log Zc With Measures of Diastolic Function and Ventricular Arterial Coupling
27946,Associations of Exposure Alleles With CHD Adjusted per Unit of Change in LDL C
27948,Multivariate Analysis: Risk Factors for Cardiac Events   Syncope, Sudden Death, and Aborted Cardiac Arrest   Among Patients With LQT1
27949,Multivariate Analysis: Risk Factors for Cardiac Events   Syncope, Sudden Death and Aborted Cardiac Arrest   Among 369 patients with LQT1 and QTc  500 ms
27950,Multivariate Analysis: Risk Factors for Cardiac Events   Syncope, Sudden Death and Aborted Cardiac Arrest
27951,Multivariate Analysis: Risk Factors for SCD ACA Among All Patients With LQT1
27953,Univariate Predictors of Atrial Fibrillation Recurrence
27956,Site of Origin of PVCs
27957,Change in Various Echo Parameters Before and After PVC Ablation
27958,Change in Echo Parameters After Ablation Stratified by Percentage of PVC Burden
27959,Improvements in Echo Parameters and NYHA Class Post Ablation With Percentage of Pre Ablation PVC Burden Stratified to  22  and  22
27960,Serial Echo Parameters and NYHA Class Before and 6 Months After Successful PVC Ablation, and 6 Months After BiV Pacing Was Turned Off
27963,Summary of Brugada Syndrome Associated Mutations
27964,Summary of Additional Rare Genetic Variants Identified in BrS Probands
27967,Management Strategies Among 64 Patients With Major VC
27968,30 Day and 1 Year Event Rates According to the Occurrence of Major VC Versus No Major VC Up to 30 Days
27969,30 Day and 1 Year Event Rates According to the Occurrence of Minor VC Versus No VC Up to 30 Days
27974,Cause of Death in the 25 Patients Who Reached the Primary Endpoint During Follow Up
27982,Outcome Measurements
27983,Inducibility With EPS and VEPS at Different Gray Zone Threshold Levels
27984,Comparison of Actual and Virtual VT Cycle Lengths
27987,Predictors at Admission of a Poor Outcome   n   158
27988,Example of Cutoff Values for S100B on Arrival   Day 0 Model  , Determined for Specificity of 0.95 and Sensitivity of 0.79
27989,Predictors on Day 3 of a Poor Outcome   n   74
27991,Procedural Parameters and Scar Locations
27993,Monitoring
27994,Supraventricular Tachycardia Recurrence After Hybrid Procedure and Management
27997,Quantitative Coronary Angiography of the Culprit Lesions Treated in the 3 Groups
27998,Clinical Outcomes at 6 Months
28000,Effect of Pre Dilation and Geographical Mismatch on Angiographic Outcomes
28001,Electrocardiographic Patterns in Adolescent African and Caucasian Soccer Players
28002,Cardiac Dimensions in Adolescent African and Caucasian Soccer Players
28006,Post Procedural Complications and Outcomes
28007,Predictors for Midterm Mortality by Cox Regression Analysis
28008,Overview of All In Vivo Studies
28009,Physical Properties, Relaxivities and Half Life of the Various Micelles
28010,Randomized Controlled Trials of Hypothermia Therapy in Cardiac Arrest
28011,Nonrandomized Clinical Studies of Hypothermia Therapy in Cardiac Arrest
28012,Clinical Studies of Hypothermia Therapy in Patients With STEMI
28013,Common Physiological Changes Occurring During Hypothermia
28015,Patients With Events at Follow Up
28016,Prognostic Accuracy of Predictors of Outcome
28017,Cox Multivariate Models
28018,Comparison of Brugada Syndrome Registries
28021,In Hospital Clinical Events Stratified by BMI Category
28024,Comparison of Septal VT Localization
28025,Comparison of Magnetic Resonance Imaging Data
28028,Overall Mortality and Equivalents of Mortality
28029,Clinical and Echocardiographic Predictors of Overall Mortality
28031,Comparison of Functional and Anatomical Parameters Between Patients With Permanent and With Valsalva Induced Shunt
28032,Comparison of Procedural and Follow Up Results Between Patients With Permanent and With Valsalva Induced Shunt
28033,Food Sources of Long Chain n 3 PUFA
28034,RCTs of n 3 PUFA and Clinical Cardiovascular Events
28035,National and International Recommendations for Consumption of n 3 PUFA in the General Population
28037,Multivariate Analysis of the Effects of LAMC and LAVI 33 ml m2 on the Risk for Stroke in the Study Population
28038,Selected Clinical Parameters for Patients Without LAMC by the Occurrence of Stroke
28043,Biodegradable Polymer Versus Permanent Polymer Drug Eluting Stents: Clinical Outcomes Out to 3 Years
28044,EES Versus SES: Clinical Outcomes Out to 3 Years
28046,Biomarker Values Based on 90 Day Outcomes
28047,Multivariate Prediction of All Cause Mortality
28048,Net Reclassification Index for Adding MR proADM to the Best Clinical Model
28049,Risk Factors for SCD in Patients With ESRD    16,18,23,43
28052,Key Questions Specific to ICD and or CRT Placement in Patients With HF and CKD
28057,Comparison of Electrocardiographic Parameters Between Patients With Previous Cardiac Arrest, Patients With Syncope, and Asymptomatic Patients
28058,Comparison of Electrocardiographic Parameters Between Patients With Mutation in HERG and Those Without Mutation in HERG
28059,Comparison of Electrocardiographic Parameters Before and After Initiation of Hydroquinidine in 18 Patients
28060,Patients With Available Data to Compare the Efficacy of Hydroquinidine With Other Antiarrhythmic Treatments
28062,Score Table for Performance Evaluation
28064,Features of Patients Evaluated for Monomorphic VT With Mediastinal Adenopathy Due to Granulomatous Infiltration
28066,EPS RFA Findings of Patients Undergoing RFA, Correlated With DE CMR and 18FDG PET CT Findings
28071,Independent Predictors of ERP in Multivariable Regression Model
28072,Prevalence of ERP by Sex and Age in the Health 2000 Survey
28073,Sibling Recurrence Risks and ORs for ERP in Siblings of ERP  Individuals, Unadjusted and Adjusted for Age and Sex, in the FHS
28077,AEs of Interest During cECG Recording Period by Ventricular Pause Duration
28079,Incidences of Out of Hospital Cardiac Arrest From Cardiac and Noncardiac Causes
28082,Multivariate Adjusted Odds Ratios   Confidence Intervals   of Adiposity Measures and the Presence of AF
28083,Multivariate Adjusted Odds Ratios   Confidence Intervals   of Adiposity Measures and AF Chronicity
28084,Multivariate Adjusted Regressions   Confidence Intervals   Between Adiposity Measures and AF Burden
28085,Multivariate Adjusted Hazard Ratios   Confidence Intervals   of Adiposity Measures and AF Recurrence
28087,Clinical Outcomes at 30 Days and 12 Months for All Patients   2.25  to 4.0 mm Stents
28088,Angiographic and IVUS Measures at 8 Months for Angiographic Cohort
28091,Antithrombotic Regimens Up to 360 Days of Follow Up
28092,Cumulative Rates of Adverse Clinical Events at 30 Day, 6 Month, and 1 Year Follow Up
28094,Relationships Among ARC Definite or Probable ST and Cardiac Death, Myocardial Infarction, TVR, and MB at 1 Year Follow Up
28095,Distribution of Risk Variables in Subjects With Versus Those Without Coronary Events During 5 Years of Follow Up
28096,Crude and Adjusted HR   95  CI   of Coronary Events and All Cause Mortality in the CAC and hsCRP Categories
28097,c Statistics, IDI, and NRI for the Combined Assessment of Traditional Markers of Risk, hsCRP, and log  CAC 1   in Predicting Coronary Events and All Cause Mortality
28099,Relationship of LV Diastolic Function Parameters With BMI, Multivariate Linear Regression
28100,Diastolic Function Parameters by BMI Categories
28101,Risk of Diastolic Dysfunction Associated With Overweight and Obesity
28102,Summary of Sudden Cardiac Death or Cardiac Arrest Events in Israel in the Years 1985 to 2009
28104,Longitudinal Assessment of Treatment Outcome: Post Hoc Comparison of Prevalence at Each Time Point
28105,Clinical and Genetic Features of the Reported Cases of SQTS
28109,The Genetic Subtypes of SQTS and Frequency of Culprit Genetic Mutations
28110,SQTS Diagnostic Criteria
28112,Stratification of Patients by Device Therapy
28113,Model Variables
28114,Event Rates Estimated by the Cost Effectiveness Model Compared With the JUPITER Trial Results
28115,Base Case Results
28118,Factors Independently Associated With LVMI at Visit 2 in Multivariable Analysis
28119,Factors Independently Associated With Left Atrial Volume at Visit 2 in Multivariable Analysis
28120,Factors Independently Associated With LV Midwall FS at Visit 2 in Multivariable Analysis
28121,Factors Independently Associated With RV Fractional Area Change at Visit 2 in Multivariable Analysis
28123,Peak Myocardial Enzyme Rise After Radiofrequency Ablation
28125,Significant Relief of Obstruction   Doppler Echocardiography, p   0.001   and Improvement of Exercise Capacity During 6 Months of Follow Up   p   0.05
28126,Physical and Chemical Properties of LUSPIOs and LSPIOs
28129,Multivariate Analysis: Risk for ACA or SCD Among the 3 Genotype and QTc Categories
28130,Risk Factors for ACA or SCD in Patients With LQTS by QTc Interval Category
28134,Multivariate Model for LVFS z Score
28135,Multivariate Model for Presence Versus Absence of at Least Mild Mitral Regurgitation
28140,Outcomes and Complications Associated With Acute Lead Dislodgements
28141,Adjusted Odds Ratios of the Effect of Acute Lead Dislodgements on the Development of More Serious Adverse Events and In Hospital Death
28142,Anatomic Diagnosis and Surgical Status   n   130
28145,Long Term Outcome After RFCA
28148,Comparison of Voltage Map and Fat Map Patients Without Cardiomyopathy   With Subject as Unit of Analysis
28149,Diagnostic Criteria After CMR Examination in This Population
28150,Functional Parameters of LV and RV
28151,Incidence of VT at 24 h ECG Holter Monitoring
28152,End Points Occurrence in Groups
28153,Hazard Univariate on Prediction of End Points
28156,Hemodynamics at Rest and Peak Exercise in Patients With HFNEF and Controls
28157,Cardiopulmonary Exercise Testing Data in Patients With HFNEF and Controls
28159,Patients Without LGE Compared With Patients With LGE
28161,Univariate Analysis: All Cause Mortality
28162,Univariate Analysis: Cardiac Mortality
28163,Univariate Analysis: SCD
28168,Resting and Exercise Echocardiographic Data
28170,Events by Indication
28171,Estimated 3 Year Mortality Rates in the Composite Traditional ICD Indications Group Compared With Individual Nontraditional ICD Indication Groups
28175,Weight Change Over 60 Months and Risk of Incident AF
28176,Stress Protocols and Radiopharmaceuticals
28178,Concordance of Stress Perfusion Findings
28179,TPD       by High Speed Versus Conventional SPECT
28180,Concordance in Coronary Artery Territories
28181,Concordance in Reversible, Partially Reversible, and Fixed Defects
28184,Multivariate Analysis, Echocardiographic Measures by Treatment Group
28185,Clinical and Laboratory Data
28186,Doppler Echocardiographic Data
28187,Multivariate Predictors of Indexes of LV Geometry
28188,Multivariate Predictors of Indexes of LV Function
28189,Association Between NCEP ATPIII Criteria of Metabolic Syndrome and Indexes of LV Geometry and Function
28190,Characterization of All EMS Treated Victims and Various Subgroups of Interest
28191,Multivariate Analysis of Survival by Site: Cases With Complete Data Only
28192,Survival to Hospital Discharge by Type of Location
28197,Major Versus Minor Complications
28199,Multivariable Predictors of Complications in All ICDs   e.g., Primary and Secondary Prevention
28200,Multivariable Predictors of Complications in Primary Prevention ICDs
28201,Frequent Major and Minor Complications
28202,Adjusted Hazard Ratios for Mortality According to Presence of a Major Nondeath Complication Within 45 Days
28203,Nucleotide Sequences of the Primers, Anchors, and Fluorescence Resonance Energy Transfer Probes for Both Variants
28205,Haplotype Frequencies
28207,Chromosome 4q25 Variants and AF Recurrence in Univariate Analysis
28208,Independent Pre Procedural Predictors of AF Recurrence in Multivariable Analysis
28210,Cox Model for Risk Factors Related to Severe Cardiac Events in Patients Presenting With the First Syncope Event and Repeated Syncope Events On and Off Beta Blocker Therapy
28211,Risk Factors for the First Syncope Event After the Start of Beta Blocker Treatment in Long QT Syndrome Patients With Previous Episodes of Syncope
28219,Thromboembolic Risk Factors According to CHADS2Score in the Off  and On OAT Groups
28220,Incidence of Thromboembolic Events and Major Hemorrhage According to CHADS2Score in Off  and On OAT Groups
28222,Indications for Lead Extraction   n   1,449
28223,Procedural and Clinical Success
28224,Adverse Events
28225,Demographic Characteristics: Procedural MAE
28226,Device Related Endocarditis and Pocket Infection
28227,Hemodynamic Parameters of Vehicle and RAD Treated Animals 28 Days After Myocardial Infarction
28228,Effect of Apnea on Blood Pressure
28229,Comparison of AF Inducibility and Atrial Refractoriness   Atrial Capture   Before and After Ganglionated Plexi Ablation
28230,Blood Gas Analysis Before and After Induced Apnea
28232,Transesophageal Echocardiographic Correlates of Thromboembolic Risk   CHADS2Score
28236,Clinically Actionable Events
28238,CAE Summary
28241,Clinical Worsening: Cumulative Incidence of Events Through 1 and 2 Years of Treatment
28242,Most Common Adverse Events Leading to Discontinuation of Study, Study Drug, or Death Through 2 Years
28243,Description of the Study Groups
28244,Definitions
28246,30 Day Outcome
28247,Coronary Angiography Results and Revascularization Procedures
28250,Distribution of Abnormal Epicardial Electrograms in Epicardial Low Voltage Areas
28251,Mapping Findings in Patients With Nonischemic Cardiomyopathy and Ventricular Tachycardia
28252,Endocardial and Epicardial Electroanatomical Mapping Features
28257,Multivariate Analysis: Predictors of ACA or LQTS Related Sudden Death During Ages 1 to 10 Years
28258,Multivariate Analysis: Predictors for Second ACA or LQTS Related Death During Ages 1 to 10 Years by First ACA in the First Year of Life Versus First ACA Ages 1 to 10 Years
28261,Univariate and Multivariate HRs of Tested Predictors
28267,In Hospital Outcomes in the Study Population
28268,Causes of Death in 75 Patients Treated With TAVI
28269,Comparison of Risk Profiles and Hospital Outcomes in First 25 and Last 50 Patients Treated With Transcatheter Aortic Valve Implantation
28270,Multivariate Analysis of the Predictors of Late Mortality in Patients Treated With TAVI
28274,MACE and Adverse Events
28276,Electroanatomic Mapping Data
28279,Inducibility With Programmed Stimulation
28282,MACE at 12 Month Follow Up   in Descending Order of Severity
28287,Correlations Among OxLDL Biomarkers at Randomization
28288,Correlation Between OxLDL Biomarkers With Lipid Parameters and Inflammatory Markers at Randomization
28290,Immunohistochemical Methods
28291,Frequencies of Concentric Vessel Morphology in Different Plaque Types
28292,Spearman  Correlation Coefficients of Microvessel Density and Plaque Morphology
28293,Electron Microscopy Analysis of Endothelial Cell Morphology, Junctions, and Leukocyte Infiltration in Intraplaque Microvessels
28296,Targeted Arrhythmias With Mapping and Ablation Sites
28297,Scar Involvement Relative to Mapped Chamber and Identification of Target Sites
28298,CHD Risk Factors     Among 63,469 Women Without Prior CHD, Stroke, or Cancer According to Depression Symptom Category in 1992
28301,HRs   95  CI   for Mortality MI Among 75,718 Women Without Prior CHD, Stroke, or Cancer Followed From 1996 to 2004
28303,Predictors of Death for the Entire Group   C Index   0.92; n   98
28304,Predictors of Neurologic Deficit for the Entire Group   C Index   0.89; n   98
28305,Predictors of Death for the Unresponsive Group   C Index   0.90; n   59
28306,Angiographic Findings and Intervention in the Entire Group   n   98
28307,Angiographic Findings in Unresponsive Patients   n   59
28309,Prediction of Incident CHD as a Function of CAC Percentiles and CAC Absolute Scores in Women
28310,Prediction of Incident CHD as a Function of CAC Percentiles and CAC Absolute Scores in Men
28311,Risk of CHD Events Associated With Increasing Absolute CACS Across Age Sex Race Ethnicity CAC Percentiles
28312,Risk of CHD Events Associated With Age Sex Race Ethnicity CAC Percentiles Across Increasing Absolute CACS
28315,Univariate Analysis of Cox Regression Performed in 184 Children With Ventricular Pre Excitation
28316,Covariate Adjusted Cox Proportional Analysis Showing Factors Associated With Potentially Life Threatening Arrhythmias
28317,Study Protocol
28319,Summary of Desmosomal Gene Changes Isolated in LDAC Cohort
28320,Events Recorded in LDAC Cohort
28322,Clinical Diagnostic Features of LDAC
28324,Repolarization and Conduction Dynamics: Clinical Data
28325,Repolarization Dynamics: Simulation Data
28328,Risk Factors for Sudden Cardiac Death
28333,Patients at 3 Month Follow Up
28335,Multivariate HRs and 95  CIs of Mortality From Ischemic Heart Disease, Cardiac Arrest, Heart Failure, Stroke, Total Cardiovascular Disease, and Total Death According to Quintiles of Fish Intake, 22,881 Men and 35,091 Women
28336,Multivariate HRs and 95  CIs of Mortality From Ischemic Heart Disease, Cardiac Arrest, Heart Failure, Stroke, Total Cardiovascular Disease, and Total Death According to Quintiles of  3 PUFA Intake, 22,881 Men and 35,091 Women
28341,Association of Lipoprotein  a   With Incident Cardiovascular Disease in Women Not Taking Hormone Replacement Therapy
28342,Lipoprotein  a  , LDL C, and Hazard Ratios of Future Cardiovascular Events Among Women Not Taking Hormone Replacement Therapy
28343,Lipoprotein  a   and Incident Cardiovascular Disease in Women Taking Hormone Replacement Therapy
28344,Lipoprotein  a  , LDL C, and Hazard Ratios of Future Cardiovascular Events Among Women Taking Hormone Replacement Therapy
28345,Heart Rate Variability Parameters
28348,Electrophysiological Parameters
28351,Events During Follow Up in Patients With and Without Prior CABG
28352,Events During Follow Up in CABG Patients in the 10  and 80 mg Group
28353,Examination Protocol, Label, Definition, and Meaning of CAF Tests
28354,Comparison of Clinical Variables Among Subjects With Different Blood Pressure, Including Normotension With and Without a Family History of Hypertension, Pre Hypertension, and Hypertension
28355,Univariate Analysis for the Comparison of Cardiac Autonomic Function Among Subjects With Different Blood Pressure, Including Normotension With and Without a Family History of Hypertension, Pre Hypertension, and Hypertension
28361,Summary of Clinical Adverse Experiences
28362,Pre Specified Laboratory and Clinical Adverse Events
28365,Combined Echocardiographic Measurements Made at 6 and 9 Months After 3 Months of 2 V Versus 3 Months of 3 V Biventricular Stimulation
28366,Adverse Clinical Events in 40 Patients Who Underwent Implantation of CRT Systems
28367,EuroSCORE Logistic Regression Model
28368,Distribution of Patients by Different Chronic Health Conditions and In Hospital Risk Assessment Stratified to Their Individual Post Operative Course
28370,Comparison of Patients With Cardiac Amyloidosis Versus Other Patients
28371,Late Gadolinium Enhancement Versus Endomyocardial Biopsy
28374,Impact of Ablation of Targeted Regions
28377,Instrumental Findings of the Overall Sample and According to Results of Voltage Mapping
28378,Electrophysiological Findings of the Overall Sample and According to Results of Voltage Mapping
28380,Patient Reported Medication Use at Time of Enrollment and During Follow Up
28381,Adjusted Hazard Ratios for the Capacity of the Individual Parameters to Predict Development of the Primary Outcome   Cardiac Death or Resuscitated Cardiac Arrest   in the Acute and Nonacute Early Post MI Periods
28383,Adjusted Hazard Ratios for the Capacity of the Noninvasive Parameters Alone and Combined With Ejection Fraction to Predict the Development of the Primary Outcome   Cardiac Death or Resuscitated Cardiac Arrest
28389,Angiographic Outcomes at Follow Up Stratified by Gender and Stent Type
28390,Clinical Outcomes Stratified by Gender and Stent Type
28400,Multivariable Regression Analysis for Prediction of LV Dyssynchrony
28403,Multivariable Relationships With Total Mortality
28404,Multivariable Relationships With Arrhythmic Death or Cardiac Arrest
28405,Calculation of Total Mortality Score
28406,Calculation of Arrhythmic Death Cardiac Arrest Score
28407,Prevalence of Additional Risk Factors in Relation to Ejection Fraction
28408,The Electrophysiological Findings in Patients With and Without Conduction Block Line During Sinus Rhythm
28413,Comparison Between the Different Ablation Strategies Used
28414,Accuracy to Reach the Design Line
28416,Electrical and Ultrasound Pacing Parameters of All Cardiac Chambers Evaluated
28418,Serum Cholesterol, Body Weight, and Atherosclerotic Morphologic Analysis
28427,Univariate and Multivariable Predictors of Death in ICD Recipients
28431,Odds Ratios and 95  Confidence Intervals for the Presence of Clinical Conditions Across Increasing Myeloperoxidase Tertiles
28432,Univariate and Multivariate Cox Proportional Hazard Analyses of Death, Cardiac Transplantation, or HF Hospitalization Across MPO Tertiles
28433,Hemodynamic and Angiographic Findings in Sham Operated and CCM Treated Dogs With Heart Failure Before and 3 Months After Initiating Treatment or Follow Up
28434,Treatment Effect
28435,Chronic Histomorphometric Findings in Left Ventricular Myocardium of Normal Dogs, Sham Operated Untreated HF Dogs, and CCM Treated HF Dogs
28436,mRNA and Protein Expression of Fetal Program and Sarcoplasmic Reticulum Genes Proteins in Left Ventricular Free Wall
28437,Protein Expression of Total PLB and P PLB at Ser 16 and Thr 17 in the Interventricular Septum and LV Free Wall
28438,Angiographic Findings
28439,Histomorphometric Findings and Expression of Sarcoplasmic Reticulum Calcium Cycling Proteins in Left Ventricular Myocardium
28441,Indications for ICA in Patients of Group 2   n   139
28442,Type and Dosage of Beta Blocker Therapy
28443,Causes of Nondiagnostic MDCT Imaging in the 15 Coronary Artery Segments of the 2 Study Groups
28444,Diagnostic Accuracy of MDCT Imaging in the 15 Coronary Artery Segments of the 2 Study Groups
28447,Validation Study: Diagnostic Accuracy of P  or F Wave Indexes for Focal AT
28448,Polymorphisms Evaluated for Their Relationship to Cognitive Decline After CABG Surgery
28450,Genotype Frequencies in European Americans   n   443   for 5 SNPs Selected for Pair Wise Modeling
28453,Patient Outcome
28454,Hemodynamic Data
28457,Correlation Coefficients of LV Dyssynchrony, Assessed With TDI, Versus the Different LV Dyssynchrony Parameters, Derived From Phase Analysis of GMPS   Idiopathic Dilated Cardiomyopathy vs. Ischemic Cardiomyopathy
28458,Regression Model With TDI as Dependent Variable
28460,Electron Beam Tomography, Ablation, and Outcome Data
28463,The Hazard Ratios for Any Cardiac Event and Life Threatening Events   Aborted Cardiac Arrest or LQTS Related Death   in the Pregnancy, Postpartum, and Post Postpartum Time Periods for 391 Women With Live Births Between 1980 and 2003
28464,The Hazard Ratios for Any Cardiac Event for Time Dependent Beta Blocker Use During the Pregnancy, Postpartum, and Post Postpartum Time Periods for 391 Women With Live Births Between 1980 and 2003
28466,Alteration of Laboratory and Lipid Parameters by the Study Medication
28467,Platelet Surface CD 63 Expression After Stimulation with ADP and TRAP
28468,Maximum Platelet Aggregation   MA   After ADP and TRAP Stimulation
28469,Maximal Slope of Aggregation After ADP and TRAP Stimulation
28471,Echocardiographic and Doppler Features of Sickle Cell Patients Versus Normal Controls
28472,Associations With TR Velocity, Spearman Rank Correlation Coefficient
28473,Proportional Hazards   Cox   Regression Analysis of Mortality
28474,Clinical Features of Hypertrophic Cardiomyopathy Patients With Surgical Myectomy or Alcohol Septal Ablation
28475,Comparison of Anatomical Differences Between Surgical Myectomy and Alcohol Septal Ablation
28476,Distribution of the ApoE Polymorphism in Acute Coronary Syndrome Patients   n   166   and Chronic Stable Angina Patients   n   70
28479,Estimated Adjusted Means of Interleukin 10   IL 10   and C Reactive Protein   CRP   in Different ApoE Genotypes in the Acute Coronary Syndrome Patient Group
28481,Estimated Adjusted Means of Interleukin 10   IL 10   and C Reactive Protein   CRP   in Different ApoE Genotypes in Chronic Stable Angina Patient Group
28484,Agents Used for Pulmonary Vasoreactivity Testing
28485,Venous Access Sites
28486,Serious Adverse Events Related to Right Heart Catheter Procedures in Patients With Pulmonary Hypertension
28487,Description of Nonfatal Serious Adverse Events Related to Right Heart Catheter Procedures in Patients With Pulmonary Hypertension Performed in the Years 2000 to 2005
28490,Clinical, Electrocardiographic, and Electrophysiological Details of the Study Group
28491,Effect of Naloxone Pretreatment on Inhibition of TNF  Production From the THP 1 Cell Culture After LPS Stimulation
28492,Regression Model of Carotid Ligation Response in Mice Receiving Naloxone or Saline Treatment
28494,Agreement Between SPWMD and Septal to Lateral Delay
28499,Hemodynamic and Brachial Artery Vasoactivity Values Before and Four Hours After Fatty Meals
28500,Values of LDL Oxidation Analytes Before and Four Hours After Fatty Meals
28506,P Wave Morphology for Right Atrial Focal Atrial Tachycardia
28507,P Wave Morphology for Left Atrial Focal Atrial Tachycardia
28508,P Wave Morphology
28512,Adjusted HR for Cardiac Events of the Maximum QTc Summary Measure, Dichotomized at Different QTc Intervals
28517,Mean PNV at the Protected Isthmus and RA Maximal PNV
28518,Summary of Cross Correlation and Absolute Timings Between Virtual and Contact Unipolar Electrograms During Sinus Rhythm
28520,Echocardiography   n   54   and Blood Chemistry   n   55   Analysis Before and After the Race
28521,Impedance Cardiography   n   27
28522,Changes in Frequency Components of HR and BP Variability
28525,Hemodynamic Values, Right and Left Ventricular Parameters Assessed by Cardiac Magnetic Resonance Imaging
28526,Clinical Parameters Determined in Hypertensive Patients With Chronic Heart Failure
28527,Collagen Volume Fraction in Normotensive Subjects and Hypertensive Patients With Chronic Heart Failure
28528,Grade of MMP 1 and TIMP 1 Deposits in Normotensive Subjects and Hypertensive Patients With Chronic Heart Failure
28533,Correlation Between Levels of Anti OxLDL Autoantibodies and Antipathogen Antibodies in 1995 and 2000
28534,Association Between Serum and Inflammatory Parameters, Vascular Risk Factors, and Cu OxLDL IgG and IgM Autoantibodies
28535,Association Between Levels of Anti OxLDL Autoantibodies and Pathogen Burden and Chronic Infection
28539,Criteria Used to Identify 41 Critical Isthmus Sites
28543,Mapping and Ablation Results
28544,Clinical Features of the Study Population
28545,QRS Duration   ms   During Junctional Escape Rhythm With Nodal AV Block Post RF Ablation   Basal  , During Hisian and Para Hisian Stimulation   Pacing His  , and During Right Apical Conventional Stimulation   Pacing Apex
28549,Diagnosis of Myocardial Infarction or Ischemic Symptoms Among SCD Cases That Underwent Attempted Resuscitation
28553,Comparison of Different Cooling Techniques in Humans and Animals
28555,Atherosclerotic Events in VALIANT
28556,Composite Cardiovascular Mortality and Morbidity Outcomes
28558,Hospital Volume for Cardiovascular Procedures by Race and Ethnicity
28559,Adjusted Predictors of Low Volume Hospital Use by Procedure
28560,Unadjusted In Hospital Mortality for Cardiovascular Procedures by Race and Ethnicity
28561,Impact of Hospital Volume on Risk Adjusted Odds Ratios for Mortality by Race and Ethnicity
28564,Systolic and Diastolic Function Indexes of the Study Groups
28565,Age, LVEF, Renal Function, and B Type Natriuretic Peptides in 1,049 Patients With Stable Ischemic Heart Disease
28566,Multiple Linear Regression Assessing Age, Renal Function, Gender, BMI, and LVEF as Independent Predictors of Plasma BNP and NTproBNP
28567,Peptide Test Performance in Detection of Selected LVEF Thresholds in Patients With Stable Ischemic Heart Disease
28568,Clinical and Hemodynamic Variables After CRT
28569,Echocardiographic and Doppler Variables After CRT
28570,Tissue Doppler and Color M Mode Variables by LVEF Response After CRT
28572,Focal AT Versus Localized Re Entry
28574,Hazard Ratios   95  CI   of Mortality from Cardiovascular Disease According to Walking Time
28575,Hazard Ratios   95  CI   of Mortality from Cardiovascular Disease According to Sports Time
28579,Comparison of the Clinical Parameters Between the VF PVT Group and the RVOT VT Group
28583,Causes of Death   n   9   and Reintervention   n   7
28584,Univariate Predictors of Overall and Coronary Related Operative Death, and Multivariate Predictors of Operative Death and Duration of Stay in the ICU
28585,Clinical, Morphologic and Functional Parameters in the Overall Patient Population
28586,Scintigraphic Findings in the Patient Population and Control Group
28589,Univariate Analysis of LPL Polymorphisms in Association With TVR and the Distributions of Polymorphisms
28590,Multivariable Cox Regression of Clinical Variables and LPL Ser447Ter Polymorphism Associated With TVR
28591,Flutter Wave Polarity in the 12 Lead ECG
28592,Flutter Wave Amplitude in the 12 Lead ECG
28594,Biochemical Data
28596,RH and 95  CIs With a BP Increase of 10 mm Hg for CVD Mortality, Stroke Morbidity, and the Composite of CVD Mortality Stroke Morbidity
28599,Coagulation Parameters in Healthy Volunteers   Negative Control Group  , Patients With Septic Shock   Positive Control Group  , and Patients Admitted After Successfully Resuscitated Out Of Hospital Cardiac Arrest
28601,Effect of Treatment on Clinical Events
28604,Medians, Interquartile Range, and Cardiovascular Event Rates for Women Below and Above the Median for Each Variable
28605,Univariate Predictors of Outcomes
28606,Cross Correlations of ECG Variables With Each Other
28607,Hazard Ratios and 95  Confidence Intervals for Significant Univariate and Multivariate Predictors of Cardiovascular Events
28608,Serum and Lipoprotein Lipids   mmol l   Off and On Statin Treatment
28609,Cholesterol and Squalene in Arterial Tissue   T   and Serum   S
28610,Ratios to Cholesterol   102 g mg of Cholesterol   of Non Cholesterol Sterols in Arterial Tissue   T   and Serum   S
28611,Cholesterol   Tissue mg 100 g, Serum mg dl   and Ratios to Cholesterol   102 g mg of Cholesterol   of Squalene and Noncholesterol Sterols in Arterial Tissue   T   and Serum   S   Off and On Statin Treatment
28613,Annualized Death Rates in Disopyramide  and Non Disopyramide Treated Patients
28615,Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value of Various Cut Off Values for the Indicated Parameters
28617,PVAI Results and Follow Up
28625,Quantitative Coronary Angiography
28626,Major Adverse Events
28632,Clinical Details
28633,Autonomic Neuropathy Details
28635,LV MBF Reserve on CPT
28636,LV Diastolic Function
28637,Definitions
28638,Registration Accuracy Based Upon FeO Injection Targets
28639,Blood Pressures   mm Hg   Pre Arrest and Without Epinephrine
28640,Blood Pressures   mm Hg   Achieved Pre Arrest and With Epinephrine
28643,Number of Patients       with Detectable MES During the Different Phases of CAS
28644,MES Counts During the Different Phases of CAS
28646,Angiographic Data
28647,In Hospital Complications and Outcomes
28648,Multivariate Predictors of In Hospital Outcome
28649,One Month Outcomes
28650,Multivariate Predictors of One Month Outcomes
28651,Different Gradations of Clinical Risk and 30 Day Outcomes
28652,Clinical Data and Previous CPVA Design
28655,Binary Logistic Regression Analysis Showing the Independent Predictors ofReceiving a Defibrillator Among Survivors of Sudden Cardiac Death in the UnitedStates for the Years 2000 and 2001
28657,Biomarkers in the Different Patient Groups
28658,Laboratory Findings in Acute AD Patients With Versus Without Complications
28659,Laboratory Findings in Acute AD Patients With Fatal In Hospital Course Versus Survivors
28662,Platelet Parameters According to the Presence or Absence of Target Organ Damage
28663,Analysis of Data Based on Utilization of Aspirin
28664,Principal Correlations
28666,Changes in Echocardiographic Measurements During Follow Up
28668,KCNQ1Mutations by Location, Amino Acid Coding, Type of Mutation, and Reported Functional Effects
28672,Conduction
28674,Coronary Sinus Concentrations of Antioxidants and Lipid Peroxidation Products
28675,Electrophysiological Parameters
28676,Classification and Regional Differences of CFAE Distributions
28678,Mapping and Follow Up Data of Patients Undergoing VF Storm Ablation
28680,Drugs and Electrocardiographic Modifications
28682,Left Ventricular Structure and Systolic and Diastolic Function
28683,Echocardiographically Calculated Individual Left Ventricular Dimensions, Ejection Fraction, QRS Duration, and Mitral Valve Regurgitation Before AVJ Ablation
28684,Comparison of Parameters During Different Types of Pacing
28685,Echocardiographic Evaluation of Mitral Valve Regurgitation, Using the 1   Mild   to 4   Severe   Scale, at Various Pacing Modes and Consequent QRS Durations
28686,Immediate and Intermediate Follow Up Results
28687,Echocardiographic and MRI Intermediate and Long Term Results
28688,Alphabetical List of Randomized Trials of Atherectomy, Atherotomy, or Laser Angioplasty Versus Percutaneous Transluminal Coronary Angioplasty
28690,Follow Up Results
28691,Pulmonary Vein Ostia Size
28692,Changes in Quality of Life Before Versus After Pulmonary Vein Isolation
28693,Complications
28697,In and Out of Hospital to Seven Month Follow Up Major Adverse Cardiac Events   per Patient
28698,Results of Quantitative Coronary Angiography
28700,Clinical Features of the Patients
28701,Ejection Fraction and Natriuretic Peptides in Survivors and Patient Groups According to Type of Mortality
28702,Predictors of Sudden Cardiac Deaths and Non Sudden Cardiac Deaths in Univariate and Multivariate Analyses   Adjusted for Age, Diabetes, and New York Heart Association Class
28703,Sensitivity, Specificity, and Positive, Negative, and Overall Predictive Accuracies of Brain Natriuretic Peptide and Left Ventricular Systolic Function for Prediction of Sudden Cardiac Death at Different Cut Points
28704,Summary of Biopsy and Survival Results
28707,Electrocardiographic Findings
28708,Echocardiographic Findings
28709,Immunohistochemical Staining Results
28711,Predictive Ability of Model 2
28714,Comparison Between Group A and Group B Patients
28715,Comparison Between Patients With LBBB and Those Without
28721,Magnetic Guidance System Navigation Success
28723,Two Year Outcome in Relation to cTnT and IL 6
28724,Predictors of Death
28728,Gene Polymorphisms Examined for Association With Coronary Artery Disease
28729,Primers, Probes, and Other Conditions for Genotyping
28731,Multivariate Logistic Regression Analysis of Polymorphisms Associated With Coronary Artery Disease in the Total Study Population
28734,Multivariate Logistic Regression Analysis of Polymorphisms Associated With Coronary Artery Disease in Low  or High Risk Men
28735,Multivariate Logistic Regression Analysis of Polymorphisms Associated With Coronary Artery Disease in Low  or High Risk Women
28738,Genomic Frequencies of the PlA1 A2, C807T, and C 5T Kozak Polymorphisms in Controls, Patients, and Aspirin Sensitive and Aspirin Resistant Patients
28741,Predictors of PPM Placement After NSRT by Univariable Analysis
28742,Multivariate Analysis for Prediction of PPM Placement After NSRT
28743,Comparison of Clinical and Echocardiographic Outcome of Patients Who Required PPM and Those Who Did Not Require PPM
28745,Clinical and Echocardiographic Implication of PPM Requirement: Age and LVOT Gradient Matched
28747,Left Ventricular Dimensions and Systolic Function
28748,Left Ventricular Diastolic Function
28749,Univariate Coefficients for Correlation Between Diastolic Function, Myocardial Metabolism, and Metabolic and Cardiovascular Risk Factors in Patients With Type 2 Diabetes and Controls
28750,Number and Follow Up of LQTS Gene Carriers by Gender and Age
28752,Relative Hazards of First Cardiac Event by LQTS Genotype and Age
28753,Cardiac Events and Sudden Death in LQTS Family Members by Family Genotype and Gender
28755,LV Systolic Function
28756,Left Ventricular Diastolic Filling
28757,Systemic Hemodynamics
28758,Sensitivity, Specificity, and Predictive Values
28760,Screening of Troponin Positive Patients for Coronary Artery Disease
28761,Cytokine and C Reactive Protein Levels of Troponin Positive Versus Troponin Negative Patients
28763,Clinical, Doppler Echocardiographic and Hemodynamic Parameters, and CA125 Serum Levels in CHF Patients Classified According to NYHA Functional Class
28764,Multiple Regression Analysis and Simple Correlation Between CA125 and Serum Sodium and Doppler Echocardiographic and Hemodynamic Parameters
28768,Adverse Events
28769,Included Trials
28770,Sensitivity Analyses Based on Quality of Randomized, Controlled Trial
28772,Resting Lung Function in PPH Patients and Control Subjects
28773,Pearson Correlation Coefficients Relating Resting Lung Function Parameters to CPET and NYHA Class in PPH Patients
28774,Resting Lung Function in PPH Patients Grouped by Severity of Reduction in Peak o 2
28776,Univariate Predictors of Cardiac Deaths
28777,Doppler Echocardiographic parameters  Mean   95  CI    and Survival
28778,Multivariate Analysis   Backward Stepwise   Predictors of Cardiac Mortality
28780,TUNEL Staining in Isolated Cardiac Myocytes
28788,Ablation Guidance and Recurrences During Follow Up
28794,Cardiac Diagnoses of Patients Catheterized on ECMO
28795,Indications for Cardiac Catheterization on ECMO
28796,Subsequent Interventions Based on Catheterization Findings
28799,Clinical and Electrophysiologic Data
28801,Group 2 Patients Separated According to Ablation Catheter Used
28802,Number of Sectors Isolated in Relation to Distal or Ostial Pulmonary Vein Isolation
28803,Group 2 Patients Separated According to Type of Atrial Fibrillation
28804,Plasma Lipid Profiles in the Three Experimental Groups at 12 Weeks
28807,Electroanatomic Maps of Atrial Tachycardia
28808,Underlying Lesions and Procedures in the Maze Group
28812,Early   30 Day   Crude Counts and Event Rates
28813,Late   31 Day to 5 Year   Kaplan Meier Event Rates
28815,LV Echocardiographic Profile of 1,953 Children With DCM at Diagnosis, by Era of Diagnosis
28816,Unadjusted Cox Proportional Hazards Regression Analysis of Predictors of Death Among 1,953 Children With DCM Not Undergoing Heart Transplantation
28817,Final Multivariable Cox Regression Model of Predictors of Death Among 1,953 Children With DCM Not Undergoing Heart Transplantation
28820,Predictors of Epicardial Vasospasm and Coronary Microvascular Dysfunction in 1,379 Consecutive Patients With Angina With Nonobstructive CAD
28822,Cardiac Parameters Among 214 HIV Infected Children Born to HIV Infected Mothers, by HAART Exposure Status
28825,Medication at Admission and at Discharge
28826,Number of Deaths and Mortality Within 60, 90, and 120 Days of Follow Up
28828,Reciprocal Bone Marrow Transplantation
28829,AT II Effect on Echocardiographic Assessments and HeartMassRatios
28831,Incidence Rates and HRs for the Main Outcomes Associated With Utah Stage of LA LGE
28833,Utilization of Care
28837,Ivabradine Dosing: Per Protocol Population     of Children Who Reached the Primary Endpoint
28838,Adverse Events
28840,Prevalence of Atherosclerosis and Plaque Burden Distribution by 3DVUS
28842,Univariate and Multivariate Predictors of Plaque Burden
28843,Relationship With ASCVD Risk of the Number of Affected Territories, the Total Number of Plaques, and Plaque Burden
28845,PAL HF Patient Provider Encounters
28855,Incidence of Mortality and Adverse Events in Newly Diagnosed AF According to Treating Specialty
28856,Association of Cardiology Care to Mortality and Adverse Events in Newly Diagnosed AF
28861,Comparing the Model With Conventional Parameters
28862,Design Features, Enrollment, and IS Assessment of the Included Trials
28864,C Statistics for the Relationships Between Infarct Size and Adverse Events During Follow Up
28865,Significant Multivariable Predictors of Adverse Events From Time of StudyEntry
28867,Comparison of Outcomes at 1 Year Among the RSS and SRI Subgroups
28873,Nonobstructive Patients With HCM Related Death or Aborted Life Threatening Events
28876,In Hospital Outcomes of Nonagenarians and Patients Age 90 Years
28877,Post Discharge Outcomes in Nonagenarians and Patients Age 90 Years and Unadjusted Hazard Ratios
28878,30 Day and 1 Year KCCQ 12 Overall Summary Scores in Nonagenarians and Others Age 90 Years
28880,Echocardiographic Measurements at Rest in Hypertrophic Cardiomyopathy Patients Without Obstruction Versus Patients With Obstruction
28881,Paradoxical Response to Exercise Patients Versus Obstructive Hypertrophic Cardiomyopathy at Rest With Increased Gradient or No Change During Exercise Patientsat Rest and During Exercise
28893,Results of Diagnostic Polysomnography in the StudyPopulation
28894,Univariate Predictors of SCD
28895,Independent Predictors of SCD in the Total Study Population   Results of Multivariate Regression
28897,Independent Predictors of SCD in Subjects With OSA   Results of Multivariate Regression
28899,Study Endpoints in Matched Patients: Admission Rate, Length of Stay, MACE, Additional Patient Follow Up, and Downstream Resource Utilization With CCTA Versus Standard Evaluation   Both, n  894
28900,ORs of Study Endpoints: Standard Evaluation Versus CCTA   Both, n  894
28901,Description of Neuropsychological Tests
28904,Impaired Performance at 90 Days on Neuropsychological Tests
28905,Clinical and Echocardiographic Features of the 275 HCM Patients in Relation to BMI
28906,Cardiovascular Magnetic Imaging Findings in 275 HCM Patients With RespecttoBMI
28908,Predictive Value of Clinical Risk Scores in the Test Group
28909,Predictive Value of Degree of Stenosis and Plaque Composition
28910,Incremental Predictive Value of Proximal Plaque in CCTA
28913,Medication     Treatment Rates, Stratified by Socioeconomic Status
28920,Electrophysiologic History of Patients
28921,Univariate Analysis of Risk Factors for Post Operative VA
28922,Multivariate Cox Regression Model of RiskFactorsforPost Operative VA
28923,Risk of Post Operative VA With Respect to Pre Operative VA
28924,Prolonged Ventricular Arrhythmias
28925,Causes of Death
28927,Echocardiography Data
28928,Relationship of B Type Natriuretic Peptide to Clinicaland Echocardiographic Variables
28929,Cardiopulmonary Exercise Data
28931,Anticancer Treatment Received by Patients Prior to and During the Study Period
28933,Clinical Endpoints
28936,Examples of Recent Discoveries of Genetic Etiology of Monogenic Cardiovascular Diseases Using Next Generation Sequencing
28937,Current References on Genome Wide Sequencing
28939,Unadjusted Odds Ratio of Age and Sex for PAD, CAS, and AAA
28940,Adjusted Odds Ratio of Age and Sex for PAD, CAS, and AAA
28944,Quantitative Angiographic Analysis
28945,In Hospital and 30 Day Follow Up Outcomes   n   164
28948,BSA Indexed LV Parameters per Age Group Compared With Reference Values by 1 Sample t Test
28949,BSA Indexed RV Parameters per Sex and Age Group Compared With Reference Values by 1 Sample t Test
28950,Comparison of Ventricular Volumes and Mass Between Survivors Exposed or Unexposed to Cardiac Irradiation
28951,Intraobserver and Interobserver Variability   Bland Altman
28953,Time Dependent Multivariate Cox Regression Analysis on Endpoints Comparing Carvedilol With Metoprolol
28955,Main Outcome Measures According to Clopidogrel Dose Comparison
28956,Main Outcome Measures According to Statin Comparison
28957,Odds Ratios for the Primary Endpoint in the Clopidogrel Dose and Statin Groups According to the Factorial Design
28958,Recommendations for Competitive Sports Participation Among Athletes With Potential Causes of SCD    4,29
28959,European Society of Cardiology Classification of Abnormalities on the Athlete s 12 Lead Electrocardiogram    37
28964,Clinical Risk Stratification and Medications in HCM Cohort
28968,Correlation Between HR, SBP, and DBP Changes and Other Measured Clinical Outcomes
28969,Differences in Clinical Outcomes at Various Compliance Levels Pre  and Post Yoga
28971,Pre Operative Echocardiographic Measurements
28972,Patient Variables Associated With Severe AS Alone   Isolated AS   Versus AS CAD
28973,Overall Model for Incremental Risk Factors for Death After Procedure
28975,Revised Cardiac Risk Index
28981,One Year Mortality in Patients Undergoing Cardiac Surgery Stratified According to Pre Operative Plasma Levels of GDF 15 and Other Risk Stratification Methods
28982,Logistic Regression for 30 Day and 1 Year Mortality
28983,Net Reclassification Improvement of Additive EuroSCORE With GDF 15 for 30 Day Mortality
28985,Hospital Admission and Mortality Rates   95  CI   After Heart Failure Diagnosis per 10 Person Years
28990,Individual Electrocardiographic and Echocardiographic Measurements Before and After 12 Months of Cardiac Resynchronization
28992,Prediction of Outcome Using QRS Duration
28993,Observed Annualized Event Rate According to QRS Duration
28997,Surrogate End Points
28998,Clinical End Points
28999,ST Segment Resolution and 6 Month Clinical Outcome
29000,Predictors of Early ST Segment Resolution and MACCE
29002,Rate of Adverse Events, Stratified by Quartiles of Hospital Annual ICD Volume
29004,Fully Adjusted ORs of Any Complication Comparing the Lowest 3 Quartiles of Hospital Annual ICD Volume With the Highest Volume Quartile as the Reference Group
29005,Definition of Lipid Parameter Combinations in MESA 2000 to 2002
29006,Mean, Minimum, and Maximum Values for HDL C, LDL C, and Triglycerides for Each Lipid Parameter Combination in MESA 2000 to 2002
29009,Age Adjusted Annual Rate of CV Events   MI, CHF, Stroke, TIA, or Death   Among Participants With and Without Specific Depressive Symptoms
29010,Bivariate and Multivariate Associations of Specific Depressive Symptoms   Entered as Continuous Variables   With CV Events
29012,Exercise Performance
29013,Cardiovascular Reserve Responses at Peak Exercise
29014,Relationships Between Reserve and Peak Exercise Capacity or Symptoms at Matched Low Level Workload   20 W
29017,Breakdown of Events Contributing to Overall MACE Rate in 217 HCM Patients With and Without Fibrosis
29019,Various Approaches Incisions of Minimally Invasive Valve Surgery
29022,STICH SVR Hypothesis Assessment of CABG Plus SVR Versus CABG in Subgroups Defined by RAR
29023,Significant Covariates in the RAR Multivariate Model
29026,Hemodynamic Parameters Before and After LVAD Unloading
29027,Correlation Matrix Showing Inter Relationships Between Measures of Reflection and Their Timings
29030,Multivariate Linear Regression Analysis of the Relationship Between Measures of Wave Reflection and Measures of Left Ventricular Structure and Function
29032,Index   First   and Total Adverse Events During Follow Up
29033,Decreasing LogCFR and Risk for Adverse Outcomes
29034,Multivariate Modeling of Major Events
29036,Association With and Without Cardiovascular Events
29039,Clinical Laboratory Data for Those Patients Who Completed All Clinic Visits
29040,Lipid Profile Data for All Patients Who Completed All Clinic Visits
29041,Major Adverse Cardiac Events
29042,Adverse Events
29044,Intravascular Ultrasound Parameters
29045,Comparison of the Changes in IVUS Parameters in Lipid Sciences Selective Delipidation Trial, ApoA I Milano Trial, and REVERSAL Trial
29047,Multiple Regression Predicting FMD Within Caregivers
29048,Cardiovascular Magnetic Resonance Results
29050,Univariable and Multivariable Linear Regression Analysis for the Prediction of MSI
29051,Predictors of Major Adverse Cardiac Events in Univariable and Stepwise Multivariable Cox Regression Analysis
29053,Acute and Delayed Major and Minor Complications Related to Epicardial and Endocardial VT Ablation
29055,Electrogram and Electroanatomical Mapping Data
29056,Distribution of LP in Low Voltage Area
29057,Results of Mapping and Ablation
29059,Predictors of Complicated 30 Day Outcome
29065,Results of Multivariate Regression Model Incorporating Rhythm Control Strategy
29066,Results of Multivariate Regression Analysis Incorporating Cardiac Rhythm Status
29072,Neurological Complications and Deaths Within 30 Days After Carotid Stenting
29074,Logistic Regression Analysis for the Presence of Ischemic Heart Disease in Female Patients Complaining of Chest Pain
29076,Adjusted AUC for Different Models, With 95  Confidence Interval for Difference in Adjusted AUC Comparing Various Models With TRF Only Model
29077,Number and Percent Reclassified in CHD Risk Categories and Observed CHD Risk    When CIMT and Plaque Information Are Added to Traditional Risk Prediction Models   Overall Sample
29078,Number and Percent Reclassified in CHD Risk Categories and Observed CHD Risk    When CIMT and Plaque Information Are Added to Traditional Risk Prediction Models   Men
29079,Number and Percent Reclassified in CHD Risk Categories and Observed CHD Risk    When CIMT and Plaque Information Are Added to Traditional Risk Prediction Models   Women
29080,NRI Using Various Comparison Models in Overall Sample, Men, and Women
29081,Indexes of LV Function at Initial and Most Recent Evaluation in the 114 Olympic Athletes
29082,Cardiac Dimensions at Initial and Most Recent Evaluation in the 114 Olympic Athletes
29084,Echocardiography Measurements
29085,Left Ventricular Physiology 3 Weeks After Transaortic Constriction
29086,AC6 Knockdown, Phenylephrine, and Cardiac Myocyte Size
29087,Diagnosis and Outcomes in 189 Patients
29088,Multivariable Probability Hazard Analysis for Death or Transplantation
29091,Post Operative Risk Factors by Presence of Atrial Fibrillation
29092,Discharge Medications by Presence of Atrial Fibrillation
29094,Atrial Fibrillation as a Predictor of Mortality Among Different Subgroups
29095,Clinical Features in Family EI
29096,Genes Residing in 5.7 Mb Region of Linkage
29097,ACTN2Variants Identified in Australian HCM Population Studied
29098,Summary of the Clinical Features in Australian HCM Families With ACTN2Mutations
29100,Carotid PP: Multiple Regression Analysis in Step 1
29102,Adjusted Risk of All Cause Mortality and CV Mortality Associated With the Increase of 1 SD of Brachial PP, Carotid PP, and C B Ratio
29103,Study Population and Comparisons According to the Presence of PAD at Each Anatomic Level
29104,Association Between Proximal Peripheral Arterial Disease and Prognosis
29105,Association of Peripheral Arterial Disease Localization and Fatal and Nonfatal Cardiovascular Events in Patients With a Single Level Disease   n   130
29108,Characteristics at 1 Year Follow up
29109,Independent Predictors of AF Progression Resulting From Multivariate Logistic Regression Analysis
29111,Echocardiographic Parameters
29112,Aortic Dimensions of the Bicuspid Aortic Valve Population Assessed by Cardiac Magnetic Resonance Imaging
29113,Vascular and Humoral Parameters
29115,Unadjusted Odds Ratios for Peripartum Cardiomyopathy
29116,Final Statistics of the Forward Selection Logistic Regression Analysis
29117,Stratified Odds Ratio of Peripartum Cardiomyopathy for African Americans
29118,Relative Risk of African American Descent for Peripartum Cardiomyopathy in This and Other Studies
29120,Correlation Between ET 1 and Inflammatory Mediators
29122,Task Force Diagnostic Criteria for ARVC
29123,PKP2Gene Variants Identified in Patients With ARVC
29125,Heterozygous Mutations Identified in Desmosomal Genes Other Than PKP2
29128,Comparison of Lead Placement Strategies
29129,Basic Patient Data and Chronotropic Autoantibody Positivity in Chronic Chagas  Disease
29131,Associations of Ankle Brachial Index Categories With Left Ventricular Mass
29132,Relative Strength of Association of Risk Factors for Left Ventricular Mass
29133,Associations of High ABI With LV Morphology and Function
29134,Examples of Emotional and Physical Stressors Triggering Heart Failure in SC Patients
29135,Patients With Recurrence of SC
29143,Maternal Adverse Cardiovascular Outcomes During Pregnancy
29144,Predictors of Adverse Cardiac Events in Pregnant Women With Dilated Cardiomyopathy
29145,Obstetric and Fetal Outcomes
29148,Primary End Point Events by Randomized Therapy
29149,Cholesterol and CRP Among Patients With No Events, a Single Event, or Multiple Events
29150,Diagnostic Test Characteristics and CAD Health Risks
29152,Health State Utilities and Costs
29153,Clinical Outcomes in 55 Year Old Men and Women With Chest Pain
29154,Health Care Costs in 55 Year Old Men and Women With Chest Pain
29161,Outcomes by Statin Therapy Among Patients With PCI for Index Event
29162,General Features of FVB and ALDH2 Mice With or Without Acute Ethanol Challenge
29164,Relationship Among Infarct Location   LAD vs. Non LAD   and Time to Treatment, Infarct Size, and LVEF
29165,Influence of Time to Reperfusion on Left Ventricular Function Assessed by CMR
29166,Left Ventricular Function After Primary Angioplasty and at Follow Up
29169,Partition Values for Different Indexing of Left Atrial Volume
29170,Crude Prevalence of LAE
29171,Relation of Volume and Pressure Load to Indexed Left Atrial Volume
29174,Relationship of Stent Gap by CTA to ISR by CCA
29179,HCM and Control Patients
29182,Multivariate Analysis of In Hospital Mortality in the Propensity Matched Cohort
29183,Multivariate Analysis of Post Operative Inotropic Support in the Propensity Matched Cohort
29184,Multivariate Analysis of Post Operative Renal Dysfunction in the Propensity Matched Cohort
29185,Multivariate Analysis of Post Operative Atrial Fibrillation in the Propensity Matched Cohort
29186,Multivariable Cox Regression Models of Relation of Traditional Risk Factors and Central and Brachial PP Quartiles to Cardiovascular Outcome
29188,Performance of Central PP 50 mm Hg for Prediction of Cardiovascular Outcome in Population Subsets
29190,Complications Related to No Stress Versus Stress Cardiovascular Magnetic Resonance
29191,Indications, Image Quality, and Complications Related to Patient Age
29192,Impact of CMR on Patient Management
29193,Impact of CMR on Patient Management by Indication
29194,Additional Diagnostic Procedures Avoided Due to Results of CMR
29195,Clinical Status of Patients With HCM
29196,LV Structure in the Control Group and in Patients With HCM
29197,LV Function in the Control Group and in Patients With HCM
29198,LV Function Before and After Septal Ablation
29200,Effect of PON 1 Genotypes on Clinical Outcome
29203,Angiographic PCI Findings for Patients Randomized to PCI   OMT
29204,Primary and Secondary Outcomes by Treatment Arm and Age Group
29207,Electrophysiologic Effects of IgG   n   14
29208,Univariate and Multivariate Logistic Regression Analyses for 14 Variables
29210,Doppler Echocardiographic and Systemic Arterial Indexes of Valvular Load, Arterial Load, and Global LV Hemodynamic Load According to the Level of Zva
29211,Doppler Echocardiographic Data of LV Geometry and Function According to the Level of Zva
29212,Univariate and Multivariate Analysis of Predictors of Overall Death in the Total Cohort   544 Patients
29213,Phenotypic and Genetic Data for Families With DCM
29216,Multiple Regression Analysis Between Direct Sympathetic Nerve Activity and QT Data After Pacing Induced CHF
29219,Outcome Data of Survivors Rescued With ECMO Support for Post Operative Graft Failure Compared With the Overall Transplant Population
29221,Stepwise Multiple Regression Analysis of Central Pressures and Hemodynamic Variables
29222,Comparison of Central Pressures and Hemodynamic Variables Between BP Lowering Treatment Arms Before and After Adjustment for Heart Rate
29228,Associations Between Sotalol and Ventricular Arrhythmias in ARVC
29230,Echocardiographic Data
29231,Echocardiographic Data in ARVD C Patients With and Without RV Dyssynchrony
29235,Clinical Events During Follow Up
29236,Univariate and Multivariate Predictors of All Cause Mortality
29237,Univariate and Multivariate Predictors of All Cause Mortality or Severe Symptoms
29241,MRI Parameters in HCM Patients and Control Subjects
29243,Prevalence of Adult Risk Factors of Sudden Death
29246,Univariate and Multivariate Logistic Regression Analysis Testing the Association Between Myocardial Scarring and Various Parameters
29248,Cumulative Incidence of Definite Stent Thrombosis
29249,Adjusted Hazard Ratios for Pair Wise Comparisons Between Stents
29251,Angiographic and Procedural Data
29252,Intravascular Ultrasound Data
29253,Major Diagnostic Categories for Congenital Heart Disease Patients Undergoing Heart Transplantation
29254,Multivariable Analysis for Risk Factors Associated With Both Early Phase and Constant Phase Mortality in Patients With Congenital Heart Disease
29260,Rates of Reported Serious Adverse Events   in Percentages   in Nonresponders and Responders   Entire Study Period
29261,Laboratory Values, Anticoagulation, Bleeding, and Thrombotic Neurological History in HMII Treated Patients Before and After HTx
29262,Basic Laboratory Values of HMII Treated Patients Before and After HTx and Patients With CHF
29265,Change in Magnetic Resonance Imaging Signal Intensity, Microemboli Count, and Lipid Profiles
29266,Primer Sequences for the Renin Angiotensin Aldosterone System Genotype Assays
29268,Echocardiographic and Hemodynamic Data
29269,Frequency of High Risk Alleles   n   103
29273,Anatomic Sites of Origin of Focal Atrial Tachycardia for Entire Study Population
29275,Unadjusted and Adjusted Results From Time to Event Analyses for Pre Specified End Points
29277,Selected Pre  and Post PCI Indicators and Peak Biomarkers According to Q Wave and Time From Symptom Onset to PCI
29279,Univariate and Multivariate Predictors of Death Cardiac Related Emergency Hospital Admission
29281,Insulin Therapy, Nutrition, and Early AMI Complications
29282,Glucose Lowering Treatment and Metabolic and Echocardiographic Parameters
29283,Clinical Features on Admission of Patients With Stress Cardiomyopathy
29290,Ability of the Task Force Criteria to Discriminate Between Family Members With and Without a Desmosomal Mutation Before and After Inclusion of the Accordion Sign as a Minor Criterion Under Structural Abnormalities
29293,Volumetric Assessment of Vascular Geometry and Progression of Allograft Vasculopathy During 12 Month Follow Up   n   38
29294,Comparison of MRI Findings Between Control and DMD Groups
29300,Left Atrial Sites Where CFAEs Were Ablated in All Patients
29303,Predictive Value of Anger Induced TWA and Clinical Variables for Occurrence of VT VF
29305,Results for Measures of Cardiac Magnetic Resonance Imaging After 5 Days
29306,Safety Data and Clinical Outcomes
29307,Cardiovascular Related Serious Adverse Events
29308,Clinical Features of Overall Sample and According to Endomyocardial Biopsy Findings
29309,Noninvasive and Invasive Instrumental Findings of Overall Sample and According to Endomyocardial Biopsy Findings
29311,Actuarial Event Rates by Group Assignment
29312,Comparison of the Performance of Various Potential Risk Stratification Strategies Derived From the Pre Specified 1 Year Primary End Point Event Rate   n   39   of the ABCD Population   n   566
29313,Comparison of Patient Groups
29314,LGE Relationship to Left Ventricular Parameters
29316,Depression Related Differences in Age and Coronary Artery Disease Severity Score Adjusted Health Care Costs by Cost Category
29317,5 Year Cardiovascular Costs by Depression Status and Presence Absence of Significant CAD
29327,Clinical and Hemodynamic Parameters of Patients With Serological Analyses
29328,Clinical and Hemodynamic Parameters of Patients With Gene Expression Analysis
29330,The Relationship of LV End Diastolic Volume and Mass to CHD Events
29331,The Relationship of LV End Diastolic Volume and Mass to Stroke Events
29332,The Relationship of LV End Diastolic Volume and Mass to HF Events
29334,Magnetic Resonance Study Parameters
29335,Univariate Correlations Between Diastolic Function and Anthropometric and Biochemical Markers and Fat Compartments
29336,Multivariable Associations Between E A and Myocardial Triglyceride Content
29338,Clinical Presentation and Hospital Course
29339,Primary and Secondary Outcomes, Unadjusted
29340,Logistic Regression Model of Predicting Reoperation
29341,Relationship Between Clopidogrel and Transfusion and Chest Tube Output, Unadjusted
29344,Improvement in Functional Parameters by 3 Months in Relation to Changing Preferences
29346,Trial Outcome Events
29347,MTWA Prediction for VTE Within Subgroups
29348,Comparison of VTE Between MTWA Positive, Negative, and Indeterminate Groups
29349,Blood Velocity and Vessel Diameter Values for the Native and PEM Treated UnA After 2, 4, 7, and 10 Weeks of Implantation
29352,Linear Regression Analysis Model of Factors Affecting the IMTmean of BIFmean of the Study Population   N   1,011
29355,Predictors of Triggers
29357,Cellular Origins of MPs Isolated From Human Atherosclerotic Plaque Between Asymptomatic and Symptomatic Patients
29358,Mutation Type, Position   Exons and Class With Respect to the NLS Region  , Clinical Phenotypes, and Rate of Events per Family
29362,Data at Time of First Diagnosis: Prognostic Factors of SCD in 94 Mutated Patients at Univariable Analysis
29363,Main Clinical and Procedural Features
29370,Hierarchical Multivariate Regression for LA Dilation
29371,Hierarchical Multivariate Regression for LV Hypertrophy
29373,In Vivo T of Aortic Valves in Patients With AVS and AVI
29374,Immunohistological Analysis of Aortic Valve Leaflets Between the 2 Groups of Patients
29375,Semiquantitative VEGF Immunoreactivity Between Leaflets of Patients With AVS and Patients With AVI
29377,PREPARE VT VF Programming Parameters
29381,Primary and Secondary End Point Analyses by Propensity Score Quintile
29382,Syncopal Adverse Events in the PREPARE Study Patients
29383,Clinical Features in 264 Patients With HCM and CMR
29384,CMR Findings According to Gender in 264 HCM Patients
29386,Extent of Atherosclerosis in Japanese, White, and Japanese American Men in 2002 to 2006
29387,Serum Levels of Fatty Acids in Japanese Men, White Men, and Japanese American Men in 2002 to 2006
29388,Multivariable Adjusted Associations of Marine n 3 Fatty Acids With Intima Media Thickness and Prevalence of Coronary Artery Calcification in Japanese Men, White Men, and Japanese American Men
29389,Multivariable Adjusted Mean Differences in Intima Media Thickness and Prevalence of Coronary Artery Calcification Between Japanese Men and White Men
29394,Predictors of Subclinical Coronary Atherosclerosis on CTA
29396,Bivariate Relations Between Childhood Adolescence Apolipoproteins and Lipids on Adulthood Carotid IMT Measured 21 Years Later
29398,Bivariate Relations Between Childhood Adolescent Apolipoproteins and Lipids on Adulthood Brachial FMD Measured 21 Years Later
29403,Detection of Thrombus by CMR
29404,Thrombus Morphology
29406,Risk Adjusted Hazard Ratios   95  Confidence Intervals   for Death According to CAC Scores Within Separate Models by Age Decile
29407,Risk Adjusted Hazard Ratios   95  Confidence Intervals   From an Interaction of Gender by CAC Score in Age Decile Subsets
29408,Cost Analysis to Identify 1 New High Risk Case and 1 Death Among Low Intermediate Risk Patients
29412,Relations of Brachial and Carotid Pressures to LV and Carotid Remodeling
29413,Predictors of Cardiovascular Events
29414,Independent Predictors of Cardiovascular Events
29416,Number of Index and Cumulative Events Grouped by Presence or Absence of CMR LGE
29417,Cox Proportional Hazards Analysis for the Time to Occurrence of an Index Composite Cardiac Event
29419,Univariate and Multivariate Cox Analyses of the Incidence of Death or Readmission for HF
29420,Comparison Between Black Athletes, White Athletes, and Black Control Subjects
29422,Clinical, Angiographic, and CMR Data of Patients With or Without Early Systolic Retrograde Flow on Coronary Flow Velocity Pattern
29423,Clinical, Angiographic, and CMR Data According to the Presence and Extent of MO Measured by CMR
29425,Uni  and Multivariate Logistic Regression Analysis for the Relation Between CMR Parameters and the Presence of Early Systolic Retrograde Flow
29426,Uni  and Multivariate Linear Regression Analysis for the Relation Between CMR Parameters and the Diastolic Deceleration Rate
29428,Sensitivity and Specificity of the Binary Endocardial Appearance
29429,Previous Pediatric ICD Retrospective Series
29430,Age at First ICD Implantation
29431,ICD Related Complications
29437,Relevant Data About Animals 1 to 6
29440,Incidence and HRs of Heart Failure by Presence of Diabetic Retinopathy, the Atherosclerosis Risk in Communities Study
29441,Echocardiography: Effects of Increased ACVI Expression
29442,Basal Left Ventricular Function: Effects of Increased ACVI Expression
29443,Echocardiography: Nontransgenic C57BL 6 Mice  Doxycycline
29445,Comparison of Patients Operated in the 1990 to 1999 Era and the 2000 to 2005 Era
29446,Predictors of Overall Mortality on Univariate Analysis in the 217 Patients in the Study
29450,Percentage of Segments Showing Hypoxia or CD68 Immunoreactivity
29451,Presumptive Causes for All Post Randomization Syncopal Episodes   458 Episodes Among 356 Patients
29453,Syncope After Randomization Predicts Death
29456,Prevalence of Plaque Components Based on 260 Arteries Grouped by Duplex Categories
29457,Correlation of Quantitative Plaque Area Measurements With the Occurrence of Complicated Plaque Features Based on 260 Arteries
29458,Distribution of Athletes in Relation to Sporting Discipline
29459,Echocardiographic Features in Athletes With Left Ventricular Wall Thickness  12 mm
29460,Echocardiographic and Cardiopulmonary Exercise Parameters in Athletes With Left Ventricular Hypertrophy and a Nondilated Left Ventricular Cavity Size
29462,Univariate and Multivariate Association Between Risk Factors, FMD, and Cardiovascular Events in Our Population of 2,264 Women
29463,Cardiovascular Event Rates and Association Between FMD Tertiles and Cardiovascular Events in Our Population
29467,Major Eligibility Criteria
29468,Pivotal Group Patient Qualification by High Risk Criteria
29470,Primary End PointPivotal Group
29471,Adverse Event Rates in the BEACH Pivotal Group Symptomatic and Asymptomatic Patients
29472,Late Neurologic Events
29473,Internal Carotid Artery Maximum Peak Systolic Velocity
29474,Hemodynamic Measurements at Cardiac Catheterization
29475,Catheterization Criterion
29477,Adverse Short Term Events in Admitted and Discharged Patients
29478,Reasons and Time of Death, Age, and Gender of Each Patient Who Died Within 10 Days From the Emergency Department   ED   Visit
29479,Major Therapeutic Procedures and Early Readmission Within 10 Days From Syncope
29480,Risk Factors for Severe Short Term Outcomes Within 10 Days   Univariate and Multivariate Analysis
29481,Risk Factors for Severe Outcomes From the 11th Day Up to 1 Year After the ED Visit   Univariate and Multivariate Analysis
29482,Causes of Death From 11th Day Up to 1 Year After the Emergency Department Visit
29483,Hospital Admission Adjusted With Long Term Risk Factors   Logistic Regression
29485,LL, Follow Up  DS, and 1 Year TLR Rates
29486,Z Scores     for Treatment Difference in LL and Follow Up  DS  , Each for In Stent and In Segment, and TLR for 11 Randomized Trials of Drug Eluting Stents
29487,c Statistics Summarizing the Strength of Association of TLR With Each of the 4 Potential Surrogate End Points With Data for All Patients   Both Groups Combined   in Each Trial
29488,Comparison of Actual and LL Predicted Numbers of Patients With TLR in 22 Treatment Groups in 9 Trials, Based on Logistic Model Corrected for Vessel Size
29489,The Percentage of Treatment Effect on TLR Explained by Each of 4 Potential Surrogate Outcomes     in the 5 Largest Trials Comparing Drug Eluting and Bare Metal Stents: Percent Treatment Effect Explained
29491,Multivariate Analysis
29492,Occurrence of Post Operative AF According to Quartiles of Atrial NADPH Oxidase Activity
29494,Summary of the Enzymatic and Genetic Screening of the Index Patients
29495,Genotype and Phenotype in the Index Patients With Low Enzymatic Activity
29503,Association Between MCP 1 Levels at 4 Months and Events From 4 Months Through End of Study
29505,Hazard Ratios Comparing 80 mg Versus 20 mg Simvastatin Stratified by 4 Month MCP 1 Levels
29514,Events During Follow Up
29515,Role of TWA Tests   Abnormal vs. Normal   on the End Points
29517,Surgical Procedures
29518,Hemodynamic Variables at Cardiac Catheterization
29519,Factors Associated With Lower Weight for Age Z Scores
29521,Kaplan Meier Mortality Estimates for All GUSTO I Trial 30 Day Survivors in the U.S. Based on Events During Index Hospitalization
29523,30 Day and Long Term Mortality for All GUSTO I Trial Patients in the U.S. Stratified by Shock Status and Age
29525,Comparison of Long QT Syndrome Patients With and Without a Device
29527,Primer Sequences
29530,HR by Cox Regression Analysis for a Composite of Death From Any Cause or Hospitalizations for Worsening Heart Failure From Day 31 After CABG to the End of Follow Up Period
29531,Clinical Outcome From Day 31 After CABG to End of Follow Up Period in 4 Groups of Patients According to Degree of Post CABG Dyssynchrony and Myocardial Viability
29534,Severity of Heart Failure in UNOS Status 1 and 2 Candidates for Heart Transplantation Across Eras: I   1990 to 1994, II   1995 to 1999, and III   2000 to 2005: U.S. Scientific Registry for Transplant Recipients   n   48,982
29535,One Year Outcomes of the Waiting List in UNOS Status 1 and Status 2 Candidates for Heart Transplantation Across Eras: I   1990 to 1994, II   1995 to 1999, and III   2000 to 2005: U.S. Scientific Registry for Transplant Recipients   n   48,982
29536,Multivariable Analysis of Risk Factors for Death Within 2 Months After Listing of UNOS Status 1 Candidates for Heart Transplantation: U.S. Scientific Registry for Transplant Recipients: Years 2000 to 2005   n   5,451
29537,Multivariable Analysis of Risk Factors for Death Within 2 Months After Listing of UNOS Status 2 Candidates for Heart Transplantation: U.S. Scientific Registry for Transplant Recipients: Years 2000 to 2005   n   6,937
29542,Multivariate Predictors of Total Mortality
29544,OCT, CAS, and IVUS Findings for Corresponding Images
29545,OCT Findings of the Culprit Lesion in 30 Patients With AMI
29546,Range of Values of Markers for RDS
29549,TBR Variability Over 2 Weeks
29550,Intraclass Correlation Coefficient Values   95  Confidence Intervals in Parentheses
29552,Task Force Criteria in the Study Population
29553,Details of Electrophysiology Catheter Ablation Procedure and VT Recurrence
29554,Clinical and Hemodynamic Data of Patients With DCM and ICM
29557,Baseline Clinical and Cardiovascular Magnetic Resonance Imaging Characteristics and Clinical End Points for Patients Undergoing Cardiac Resynchronization Therapy, Grouped According to Degree of Dyssynchrony
29559,Univariate and Multivariate Cox Proportional Hazards Analyses of Clinical End Points in Relation to Cardiac Magnetic Resonance Variables
29561,Agreement Between TWA and EPS Results
29562,2 Year Event Rates and Univariate Hazard Ratios
29563,Hemodynamic Function During the Procedures
29565,Procedural Data
29566,Procedural MACCE      Nonhierarchical
29567,30 Day Clinical Outcome
29570,Final Multivariable Model for Cardiovascular Death or Heart Failure Hospitalization in the CHARM Cohort   Including Laboratory and Clinical Variables
29571,Final Multivariable Model for All Cause Mortality in CHARM Cohort   Including Laboratory and Clinical Variables
29572,Final Multivariable Analysis for All Cause Mortality From Duke Databank Cohort
29575,Results of Genotyping in Probands With Restrictive Phenotype
29576,Echocardiographic Doppler Findings in 31 Family Members Who Carried a Mutation
29578,Haplotypes Around the LMNA Gene
29579,Multiplex Ligation Dependent Probe Amplification Normalized Peak Area Ratios of the LMNA Gene
29581,Linear Regression Analysis: Depending Variable EPC Number
29582,Linear Regression Analysis: Depending Variable EPC Function   Migratory Capacity
29584,Linear Regression Analysis: Depending Variable CFU GM
29587,Incremental Risk Factors for Death
29591,Resource Consumption and Cost Calculations for Testing
29593,Diagnostic Outcome
29594,Cost of Testing and Sensitivity Analysis
29595,Muscular Dystrophy Diagnosis and Treatment
29597,Cardiovascular Magnetic Resonance Ventricular Function and Creatine Kinase Levels in Muscular Dystrophy With and Without Myocardial Fibrosis
29598,Segmental LV MF Distribution
29601,Mortality Rate and Hazard Ratio in WBC Count Groups
29602,Mortality Hazard Ratio Comparing WBC Count Groups From the Longitudinal Time Dependent Model
29605,Prevalence of CAC Scores by Vascular Territory
29606,Univariable Predictors of Death From All Causesin Reverse Order by Chi Square Value
29607,Prevalence of CAC by Dataset
29608,Risk Adjusted Models for All Cause Death
29610,Assessment of the Quality of the 7 Included Studies
29612,Clinical Variables Stratified by Quartiles of SUV
29613,Multiple Stepwise Regression Analysis for Factors Associated With SUV of FDG Levels in Carotid Artery
29616,Risk Factors for Mortality in the Entire Group
29618,Correlation of PW Doppler and CW Doppler Velocities and Time Intervals
29619,CW Doppler Flow and TDI Parameters in Patients With OHCM, Patients With NOHCM, and Control Subjects
29620,Doppler Parameters Before and After Gradient Abolition With Disopyramide
29621,Dyssynchrony: Lateral Septal Delay in Onset of Contraction, Peak of Contraction Velocity, and End of Contraction   in ms   in Patients With OHCM, Patients With NOHCM, and Control Subjects
29622,Lateral Septal Delay in Onset of Contraction, Peak of Contraction Velocity, and End of Contraction in OHCM Patients Before and After Successful Gradient Abolition
29623,Underlying Cause Type of SVC Obstruction
29624,Symptoms and Indications for SVC Intervention
29625,Hemodynamic Data at Initial and Follow Up SVC Interventions
29627,Events in IHD and Non IHD Subgroups and Interaction Between Study Medication and Subgroups
29628,Arterial Measurements in CoA Subjects and in Control Subjects
29629,Arterial Measurements in Subtypes of Aortic Arch Geometry and in Control Subjects
29631,Electrocardiographic Features of the Study Population
29632,Unadjusted Analysis of Hazard Ratio for All Cause Mortality
29633,Cardiovascular Magnetic Resonance Imaging Measurements of the Study Population
29634,Multivariable Associations With All Cause Mortality
29637,In Hospital and Follow Up Results
29639,Comparison in MP Cellular Origins Between Asymptomatic and Symptomatic Plaques
29645,Echocardiographic Data
29650,Adverse Events
29652,Correlations Between ROCK Activity Before and After L NMMA and Variables
29653,Correlations Between the Ratio of SNP Stimulated Maximal FBF to Basal FBF and Variables
29654,Correlations Between Endothelial Function and Variables
29655,Correlations Between Pulse Wave Velocity and Variables
29657,Diagnostic Procedures
29658,Interventions Performed Planned at Enrollment
29659,Treatment in Relation to Symptoms
29660,Drug Therapy at Discharge in Patients Discharged Alive
29661,Intracardiac Repolarization Alternans Prevalence and Magnitude During Atrial Pacing
29662,Episodes of Discordant Intracardiac Alternans
29664,Study End Points
29665,Stepwise Logistic Regression Analysis for Predictors of Post CABG AF
29668,Summary of Study End Points for ICD and Non ICD Patients Stratified by MTWA Test Status
29670,Logistic Regression Model for Propensity Score Based on Likely Variables Predicting ICD Placement
29672,Comparison of Cardiovascular Symptoms Between Hyperthyroid and Control Cohorts
29673,Comparison of Hemodynamic Parameters Between Hyperthyroid and Control Cohorts
29674,Comparison of Electrocardiogram and Holter Data of Hyperthyroid Patients With Matched Controls
29675,Comparison of Electrocardiogram and Holter Data Between Patients With Biochemical Subclinical Hyperthyroidism During Follow Up With Matched Controls
29676,Comparison of Electrocardiogram and Holter Data Between Patients Rendered Euthyroid at Follow Up With Matched Controls
29678,Detailed Description of HCM Mutation Carriers
29679,Inclusion and Exclusion Criteria    6
29680,Therapeutic Considerations    6
29682,Coronary Angiography, Revascularization, and Events
29683,Relative Risks for Cardiac Events Based on Gated ADSPECT Variables
29684,Multivariate Predictors of Risk
29685,Cost Analysis and Length of Hospital Stay in the INSPIRE Risk Groups
29687,Unadjusted and Adjusted Cox Regression Models for Predicting New Cardiovascular Events
29695,Clinical Data for the 13 Patients
29696,Equations Using Oxygen Consumption   Vo 2   to Calculate Hemodynamics and Oxygen Transport Parameters
29697,Systemic Hemodynamic Condition and Oxygen Transport Before and After Termination of Dopamine in 13Neonates During the Early Period After the Norwood Procedure
29699,Procedural Data and Angiographic Results
29700,Electrocardiographic Analysis
29701,Classifier Gene Set in DCM
29704,rhNRG 1 Inhibits Renin Angiotensin System Activation Due to LAD Ligation
29705,rhNRG 1 Given 2 Months After LAD Ligation Improves Hemodynamics
29706,rhNRG 1 Does Not Alter Echocardiographically Determined Cardiac Dimensions or Function in Normal Rats
29707,rhNRG 1 Protects Against Doxorubicin and Coxsackie B3 Induced Cardiac Dysfunction and Myocardial Cell Damage
29708,rhNRG 1 Does Not Alter Hemodynamics or Cardiac Contractility in Normal Dogs
29709,Task Force Criteria for the Diagnosis of ARVD C
29713,Medication During the Study of Patients Randomized to the Acute Versus Routine Serial Cardioversion Group
29714,Medication During the Study of Patients Randomized to the Digoxin Versus Verapamil
29715,Predictors of Occurrence of Permanent AF
29718,Mean Myocardial Perfusion Measures Across Levels of Coronary Artery Calcification in Subjects With No Clinical Coronary Heart Disease, Stratified By Age and Gender From the Multi Ethnic Study of Atherosclerosis
29720,Mean Myocardial Perfusion Measures Across Number of Coronary Arteries Containing Calcium   Coronary Artery Calcium Score  0 in the Respective Artery   in Subjects With No Clinical Coronary Heart Disease From The Multi Ethnic Study of Atherosclerosis
29722,Subgroup Analysis of Differences in the Incidence of Contrast Induced Nephropathy Between Iodixanol and Ioxaglate
29724,Blood Flow, Blood Velocity, and Pulse Wave Velocity of Elite Rowers and Sedentary Control Subjects
29725,Univariate Analysis of Cardiovascular Risk Factors in MI
29726,Univariate Analysis of Cardiovascular Risk Factors in IS Cases and Control Subjects
29727,Univariate and Multivariate Analysis of v aCS in MI Cases and Control Subjects
29728,Univariate Analysis of Thrombophilia Results in MI Cases and Control Subjects
29729,Univariate and Multivariate Analysis of v aCS in IS Cases and Control Subjects
29730,Univariate Analysis of Thrombophilia Results in IS Cases and Control Subjects
29734,Correlations   r   Between Maximal Exercise Performance and Quality of Life   QOL   Measures
29736,Cardiac Morbidity and Major Cardiovascular Risk Factors in Relation to Presence of MI Scars and Clinical MI
29738,Severe Adverse Event Rates for Each Trial
29741,Clinical Outcome at Follow Up
29742,Initial Hospital, Follow Up, and Total Costs   in Euros
29744,Procedural Resource Use and Cost
29745,Initial Hospital Events, Resource Use, and Costs
29746,Follow Up Events, Resource Use, and Costs
29747,Cost Effectiveness of Paclitaxel Eluting Stents Under Alternative Assumptions About Adjunctive Medications
29750,Cumulative In Hospital and 9 Month Clinical Outcomes
29751,Clinical Data of Patients With CAD and CVD
29753,Serious Adverse Events
29755,Results of Multivariable Logistic Regression for 2 Year Mortality Among the Placebo Treated Patients
29756,Results of Multivariable Logistic Regression for 2 Year Mortality Among the Acadesine Treated Patients
29757,Results of Multivariable Logistic Regression for 2 Year Mortality Among All Patients
29758,Major Eligibility Criteria
29759,High Risk Inclusion Criteria
29760,Exclusion Criteria
29763,Incidence of Adverse Events at 30 Days
29764,Summary of Major Adverse Events at 30 Days After CAS
29766,Quantitative IVUS Data
29767,Correlation Between IVUS Variables and Percentage Restenotic Area at Follow Up
29769,Association of Carotid IMT With Myocardial Systolic Strain   Regression Coefficients for IMT
29770,Association of Carotid IMT With Myocardial Diastolic Strain Rate   Regression Coefficients for IMT
29771,Association of Age With Global and Regional Left Ventricular Function   Regression Coefficients for Age
29773,All Cause Mortality of Patients With Recently and Remotely Diagnosed Cardiomyopathy: 3  and 9 Month Cut Points
29774,Clinical Presentation and Plaque Histologic Types Observed in the 65 Carotid Plaques Submitted to Histologic Examination
29776,Outcome Data
29780,Clinical and ICG Variables Measured at Visits Immediately Preceding and Not Immediately Preceding a Heart Failure Event
29781,Multivariate Analysis of Association of Clinical and ICG Variables With Occurrence of a Heart Failure Event Within 14 Days
29782,Frequency of Occurrence and Value of ICG Scores in Predicting Occurrence of a Heart Failure Event Within 14 Days
29783,Rest and Exercise Interobserver and Intraobserver Variabilities
29784,Hemodynamic Parameters
29786,Agreement Between LV Dyssynchrony Measurements With TDI and MRI
29787,Standard Noninvasive Evaluation in 165 Survivors
29788,Preoperative Diagnosis in 165 Survivors on Follow Up and in 28 Patients Lost to Follow Up
29789,Previous Surgical Procedures in 193 Survivors
29790,Exercise Data During Follow Up in 127 of 165 Patients Without Major Late Complications
29791,Patients With Conduit Obstruction
29792,Reinterventions
29793,10 Year Survival After Fontan Type Operation
29795,Heart Failure Medication During the Course of the Study
29796,Comparison of Functional Class According to the NYHA Classification, Echocardiographic, and Electrocardiographic Parameters Before Device Implantation, After Three Months of RVP, and After Three Months of BVP
29797,Effect of RVP Versus BVP on NT proBNP Release, Quality of Life, and Exercise Capacity
29799,Summary Table of End Points Stratified by Defibrillator Status
29800,Summary Table of Unadjusted and Adjusted Stratified Cox Models for MTWA in Predicting Mortality
29801,Mortality Comparisons Between MTWA Positive, Negative, and Indeterminate Groups
29805,Causal Mutations in the Alpha Gal Gene Identified in the 12 Fabry Families Studied
29806,Genetic, Clinical and Echocardiographic Features of Patients With Fabry Disease and MWT 15 mm
29808,Echocardiographic Data of Study Population
29809,Tissue Doppler Data of Study Population
29811,Diagnostic Performance of the Interpretation Algorithm According to the Severity of Coronary Stenosis
29812,Diagnostic Performance of the Interpretation Algorithm According to the Extent and Location of Coronary Disease   Stenosis 70  or Left Main 50
29815,Distribution of Atrial Fibrillation Prevalence According to Height Quartiles
29816,Multivariate Regression Analysis of Factors Associated With AF Prevalence With Height Representing Stature
29817,Multivariate Regression Analysis of Factors Associated With AF Prevalence With BSA Representing Stature
29818,Transcriptional Profiling of MMP and TIMP Genes in CRP Stimulated HUVEC
29820,Correlation Coefficients Between MMP 1, MMP 10, and Cardiovascular Risk Factors
29821,Correlation of CRP With MMP 1 and  10 in Multiple Linear Regression Analysis With MMP 1 and  10 as Dependent Variables
29827,Hemodynamic, Inflammatory, and Vascular Parameters of HIV Infected Patients With   MS  Group   and Without   MS Group   the Metabolic Syndrome, Type 2 Diabetic Patients, and Healthy Control Patients
29828,Spearman Correlation Coefficients   r   Between Vascular Measurements and Other Parameters for the Total Group of HIV Infected Patients   n   37
29831,Incidence of Primary and Secondary Outcomes
29833,Average Longitudinal, Transverse, Circumferential, and Radial Strain Values
29834,Longitudinal and Transverse Segmental Strain Values
29835,Comparison Between Longitudinal TDI Strain and 2D Strain: Mean Values and Standard Deviations Measured on Three Consecutive Cycles by Each Method
29836,Interobserver and Intraobserver Variabilities for the Different Components of Strain Assessed by 2D Strain
29837,Interobserver and Intraobserver Variabilities for Longitudinal Strain Assessed by 2D Strain and TDI Strain
29840,Age Standardized Prevalence Ratios for LVSD in RD Stratified by Gender
29842,Features Associated With LVSD in RD Patients on Univariate Analysis
29843,Clinical and Echocardiographic Features of the 51 Study Patients Based on Dip MBF Values
29844,Individual Features of 11 Patients With Systolic Dysfunction at Final Evaluation
29847,Unadjusted and Adjusted Cox Proportional Hazards Model for Admission for HF According to Quartiles of CRP
29850,Early and Late Clinical Events
29851,Quantitative Coronary Angiography Results
29852,Distribution of Angiographic In Stent Restenosis
29853,Multivariate Analysis of Candidate Predictors for Adverse Outcomes
29855,KCCQ Score and Event Free Survival: Multivariable Adjustment
29857,SPECT Data
29858,Cox Proportional Hazards Regression Model   Multivariate Analysis
29860,Coronary Risk Factor Profile for WISE Women by Menopausal Status
29861,Prevalence of Angiographic CAD for WISE Women by Menopausal Status
29862,All WISE Women: Variation of the Effect of Menopausal Status, Systolic Blood Pressure, and Pulse Pressure on the Presence of CAD, Adjusted and Unadjusted for Age
29866,Rates of Ischemia and Indeterminate Test Results   i.e.,  85  Predicted Maximum Heart Rate   by DASI Measurements of METs
29868,Functional and Tagged Magnetic Resonance Imaging Results
29874,Magnetic Resonance Parameters of the Acquisitions
29875,Global Function Parameters of the Subjects
29876,Results From the Multilevel Regression Analysis of the Relation Between Onset Time   Outcome Variable   and Peak Time of Shortening   Independent Variable
29877,Orthogonal Components of the Onset of Shortening Delay Vectors and Peak Shortening Delay Vectors for Both Patients and Normal Control Subjects
29878,Patient Therapies Before and After CRT Pacemaker Placement
29879,Type of CRT System and Adverse Events by Type of Heart Disease
29880,Effect of CRT Pacing by Type of Heart Disease
29882,Acute and Late Adverse Events
29893,Heart Failure Morbidity in Relation to Established and Novel Risk Factors in the Total Sample   n   2,321
29894,Multivariable Cox Proportional Hazards Backward Stepwise Model, Examining the Independency of Novel and Established Risk Factors to HF Incidence in the Total Sample   n   2,321
29897,Adverse Clinical Events: In Hospital and at 30 Days
29898,Adverse Clinical Events at 6 and 12 Months
29904,Percentage of Patients With AF Episodes of Given Duration for the Group of Patients With and Without Arterial Embolic Events
29905,Distribution of Patients, Antiplatelet Therapy, Anticoagulation Therapy, Arterial Embolic Events, and Annual Rate as a Function of Embolism Risk Factors
29907,Procedural Variables
29909,Multivariate Predictors of Slow Flow
29912,Clinical Events Observed in Patients Who Underwent Dilated Hypokinetic Evolution During Follow Up and in Patients Who Maintained Classic HCM
29914,The Relationship Between CRP at 4 Months and Individual Risk Factors   Both Arms Combined  , and a Comparison of CRP By Statin Therapy in Subjects With Individual Risk Factors
29916,Relationship Between Statin Regimen and CRP Levels in Patients With and Without the Metabolic Syndrome
29918,Myocardial Fibrosis by MRI
29920,Major Safety and Efficacy Outcomes   Percent of Subjects
29924,Incidence of the Primary End Point and Its Components According to Gender
29925,Incidence of the Primary End Point and Its Components According to Treatment Strategy and Gender
29928,Univariate Associations for Recurrence at One Month
29929,Multivariate Logistic Model for Recurrence at One Month
29932,Univariable and Multivariable Analysis
29938,Cox Regression Analyses for Cardiovascular Events Including FMD or NMD
29939,Cox Regression Analysis for Cardiovascular Events Including FMD and IMT
29940,Blood Pressure Measurements and Correlations With Echocardiographic Parameters
29941,Coarctation Index and Echocardiographic Measurements of Group 1 and Group 2 Patients
29943,Percentage of Y Chromosome Containing Nuclei
29944,Study Protocol
29952,Events Occurring During Follow Up
29953,Univariate and Multivariate Predictors of Primary Composite End Point by Cox Regression
29954,Univariate and Multivariate Predictors of Total and Cardiovascular Mortality by Cox Regression
29955,Univariate and Multivariate Predictors of Non Fatal Cardiovascular Events: Acute Coronary Events, Stroke or TIA
29957,The Distribution of CHD Events by Coronary Calcium, Framingham Risk Score Categories, and Family History of CHD
29958,Cox Models Evaluating the Incremental Predictive Value of Coronary Calcium Presence on the Risk of CHD Events in Men
29959,Cox Models Evaluating the Incremental Value of Coronary Calcium Severity on the Risk of CHD Events in Men With Coronary Calcium Present
29960,Early Events in Different mTIMI and TIMI Groups
29961,Early Events in Different CE Groups
29962,Intermediate Events in Different mTIMI and TIMI Groups
29963,Intermediate Events in Different CE Groups
29964,Late Events in Different mTIMI and TIMI Groups
29965,Late Events in Different CE Groups
29967,Comparisons of Frequency in Use of Medications Before PCI, Newly Added orIncreased Immediately After PCI, and Medications During the Follow Up Period
29969,Brachial Artery Diameter and Blood Flow
29970,Multivariate Logistic Regression Analysis; Association of ISR With FMD, Clinical, Lesion, and Procedural Variables
29971,Sensitivity and Specificity for Identification of ISR
29974,Carotid Intima Media Thickness Values Among Subjects With and Without Metabolic Syndrome
29975,Prevalence of Metabolic Syndrome    and Carotid Intima Media Thickness
29976,Components of Metabolic Syndrome    as Predictors of Carotid Intima Media Thickness
29979,Circumstances Leading to Initial HCM Diagnosis According to Gender
29980,Features at Final Evaluation and Clinical Outcome
29981,Relation Between Clinical Variables at Initial Evaluation and Outcome   Age Adjusted Multivariate Cox Proportional Hazards Analysis
29983,Resting Physiology
29984,Effect of Dobutamine Stress on Cardiac Physiology
29985,Predictors of Mortality
29987,NYHA Congestive Heart Failure Functional Class by SHOCK Trial Treatment Assignment, All Available Data
29988,NYHA Congestive Heart Failure Functional Class at Two Weeks After Discharge Versus Outcome at One Year After MI
29989,MILQ Physical Function Domain Scores of One Year Survivors by Treatment Modality and Time
29995,Left Atrial Appendage Occlusion Verified by Transesophageal Doppler Color Flow and Angiography
29996,Occurrence of MAEs During 90.7 Documented Implant Years
30001,Spearman Analysis of the Relations Between Metabolic and Macrovascular Risk Markers
30003,Bivariate Correlations   Pearsons Correlation Coefficients   Between Cardiovascular Risk Factors and Ultrasound Measures of Subclinical Atherosclerosis and Endothelial Dysfunction
30004,Relationship Between Carotid IMT and Brachial Artery FMD Across Quintiles of Carotid IMT and Brachial FMD
30006,Risk of Incident Congestive Heart Failure According to Fish Consumption
30008,Heart Rate and Blood Pressure Responses to Carotid Sinus Massage
30009,Cognitive Function in Fallers and Syncopal Patients With Carotid Sinus Syndrome
30012,Multivariate Model of Predictors of the Use of Filter Instead of Distal Occlusive Embolic Protection Devices   c  0.746
30013,Hospital Medication and Hospital Events
30015,In Hospital Outcomes
30016,Unadjusted and Adjusted Odds Ratios for Death in New York Versus Michigan
30017,Multivariate Model for In Hospital Death
30019,Hemodynamic Measurements Between CP and RCMP
30020,Modified Guidelines for the Diagnosis of Cardiac Sarcoidosis Based on the Study Report on Diffuse Pulmonary Diseases From the Japanese Ministry of Health and Welfare, 1993    9
30022,Twelve Patients With Cardiac Sarcoidosis   Modified Japanese Guideline
30023,Abnormal Findings With CMR
30025,Univariate Logistic Regression Analysis of Risk Factors for CAD in Patients With DM
30026,Multivariate Logistic Regression Analysis of Risk Factors for CAD in Patients With DM
30030,Rate of Cardiovascular Events and Cardiac Structure in Primary Aldosteronism Patients and Controls
30032,Incidence of Cardiac Death, Development of Severe Heart Failure, or Atrial Fibrillation During Follow Up in HCM Patients With or Without LV Outflow Obstruction
30034,Modifying Effect   Interaction   of NYHA Functional Class, Atrial Fibrillation, LV Wall Thickness, and Age on the Prognostic Power of LV Outflow Obstruction
30036,Clinical and Family Studies to Assess Frequency of Familial Dilated Cardiomyopathy
30038,Possible Outcomes of Clinical Screening for Familial Dilated Cardiomyopathy
30040,Fasting Plasma Glucose, Insulin, Cholesterol, and Triglyceride Concentrations in Plasma and Major Lipoprotein Fractions and Relationships to the Common Carotid Artery IMT
30041,Fasting and Postprandial ApoB100 and ApoB48 Concentrations in Lipoprotein Subfractions
30042,Fasting and Postprandial ApoCI Concentrations in Plasma, TRL Subfractions, and TRL Particles
30043,Primer and Probe Sequences
30047,Proportional Hazards Models of Time to First Appropriate ICD Discharge   Cox Model   and Time to Any Appropriate ICD Discharge   Anderson Gill Model  , All Patients
30048,Proportional Hazards Models of Time to First Appropriate ICD Discharge   Cox Model   and Time to Any Appropriate ICD Discharge   Anderson Gill Model   Among Patients With CAD
30049,Multivariable Proportional Hazards Model of Time to First Episode of 2 or More Appropriate ICD Discharges Within 24 Hours   Cox Model  , All Patients
30052,Multivariate Cox Proportional Hazard Analysis: Predictors of Cardiac Events
30053,Clinical Features of Individual Families With PRKAG2 Mutations
30056,Sensitivity, Specificity, and Predictive Value of Ventricular Arrhythmias on 24 h Ambulatory ECG as Predictors of Sudden Death in HCM
30058,Univariable Cox Proportional Hazards Analysis of Electrocardiogram Variables
30059,Regression Coefficients and Weightings for Covariates From Multivariable Modeling
30060,Subgroup Analysis Within Prognostic Score Categories
30061,Beta Coefficients From the Training and Validation Sets for the Simplified Model
30065,Complication Outcomes
30066,Associations of Various Parameters With the Risk of Complications
30069,Clinical Manifestations of ARVC in 48 Subjects at High Risk Who Received an ICD and 58 Matched Control Subjects From 11 Families With ARVC Linked to 3p25
30072,Multivariate Predictors of the Combined End Point of Congestive Heart Failure or Cardiac Death in Asymptomatic Post MI Patients
30075,Net Change in Serum Lipids Concentration in Subjects Treated With Fibric Acid Derivatives as Compared With the Control Group
30076,Risk Reduction for Major Coronary Events and Deaths From Coronary Disease, Cardiovascular Disease
30077,Net Change in Serum Lipids Concentration in Subjects Treated With Nicotinic Acid Derivatives as Compared With the Control Group
30078,Subgroup Analysis With Net Change in mg dl of Fibric Acid Derivatives and Nicotinic Acid Derivatives in Different Study Populations
30080,Correlation of MR Myocardial Delayed Enhancement With EP and Histologic Findings in ARVD Patients
30082,Univariate Cox Regression Analysis
30086,BNP and Hemodynamic Parameters in AS Patients With and Without Impaired Preload Reserve
30087,Preoperative BNP and Hemodynamic Parameters in AS Patients With and Without Clinical Deterioration After Aortic Valve Replacement
30088,Post infarction Body Weights, Organ Weights, and Infarct Sizes
30089,Body and Organ Weights After Chronic Isoproterenol Challenge
30091,Summary Statistics for Multivariable Logistic Regression Model of Predictors of Depressive Symptoms at One Year
30093,Strand specific Detection of Enteroviral Genome and Clinical Outcomes
30094,Clinical Variables Between Patients With and Without Enterovirus RNA legend
30095,Clinical and Angiographic Findings of the 29 Patients legend legend
30096,Percentage of NN and MM Segments According to the Echocardiographic Wall Motion Score    3   at Different Time Points legend
30097,Clinical Background of Study Subjects legend
30098,Scintigraphic and Right Ventriculographic Data of Study Subjects legend
30099,Agency for Health Care Policy and Research Risk Prediction Model of Death or Nonfatal Myocardial Infarction in Patients With Symptoms Suggesting Unstable Angina
30101,Results: Comparison of Therapy by Groups legend
30102,Length of Stay
30103,Complications by Agency for Health Care Policy and Research and Rush Groups
30105,Coronary Risk Factors by Reported Weight Cycling legend
30106,Significant Independent Predictors of HDL C   mg dl     Linear Regression Model   legend
30107,HDL C Levels   mg dl   by Presence or Absence of Obesity Weight Cycling    legend
30108,Follow Up Data of the Patients With VF Recurrence After ICD Implantation legend
30110,Progression to Hypertension Over Six Years of Follow up and Relative Risks as a Function of Three Categories of BP Response to Exercise legend legend
30113,Optimal Treatments for CHF in 102 Patients With CHF During Three Months
30114,Univariate and Multivariate Predictors of Mortality of 102 Patients With CHF According to Survival legend
30115,Univariate and Multivariate Predictors of Morbidity and Mortality of 102 Patients With CHF According to Cardiac Event Free legend
30119,Comparison of Hemodynamic Variables and Wall Motion Analysis in 35 Patients Undergoing TAPSE and DSE legend
30120,Changes in Hemodynamic Variables From Rest to Peak Stress in 35 Patients Undergoing Two Stage TAPSE and DSE legend
30121,Comparison of Procedure Duration   Mean  SD   in 35 Patients Undergoing Two Stage TAPSE and DSE
30122,Doppler and M Mode Measurements in 25 Patients With Systolic Anterior Motion   SAM   legend
30123,Clinical and Hemodynamic Data of Patients and Healthy Subjects    legend
30124,Titers of Human, Rabbit, and Monoclonal Mouse Anti beta1 AR Obtained for ELISA, Western Blotting, and Immunoprecipitation legend
30125,Basal and     Isoprenaline Stimulated cAMP levels of CHW beta1 Cells in the Presence of Rabbit   70 nmol liter  , Mouse   7 nmol liter  , or Human Anti beta1 ECII   2 mol liter
30126,Mechanical Function of Spontaneously Beating Control and Hypertrophied Working Rat Heart Reperfused After Ischemia legend legend
30127,Mechanical Function and Glucose Metabolism in Spontaneously Beating Nonischemic Control and Hypertrophied Working Rat Hearts legend legend
30128,Mechanical Function of Control and Hypertrophied Working Rat Hearts Paced During Reperfusion After Ischemia legend legend
30129,Descriptors of Test Performance for Electron Beam Computed Tomography for All Coronary Events at Various Calcium Score Thresholds legend
30130,Descriptors of Test Performance for Electron Beam Computed Tomography for the Combined End Point of Myocardial Infarction and Death at Various Coronary Calcium Score Thresholds legend
30131,Multivariate Analyses of the Association of Coronary Artery Calcium Scores and Self Reported Traditional Coronary Disease Risk Factors With All Events legend legend
30133,Results of Echocardiographic and Antimyosin Studies and ECG Pattern   Between Parenthesis ECG Leads   in Athletes With MRA legend
30135,Arterial Endothelial Dysfunction in Heavy Passive Smoking legend
30137,Hemodynamic Profile of Registry Patients    legend
30138,Effect of Revascularization on Mortality Odds Ratio for Death Revascularization vs. No Revascularization legend
30139,Effect of Early Revascularization on Mortality Odds Ratio for Death Revascularization Within 18 h of Shock vs. No Late Revascularization legend
30140,Profile of Patients With Predominant LV Failure in the SHOCK Trial Registry legend
30141,Hemodynamics for Patients With Predominant LV Failure in the SHOCK Trial Registry legend legend legend legend
30142,Treatment of Patients With Predominant LV Failure in the SHOCK Trial Registry legend
30145,Etiology, Complications and Hemodynamic Measures of CS in AMI legend
30146,In hospital Treatment of AMI Patients With CS legend
30147,SHOCK Trial Mortality of AMI Patients With CS
30150,Predictors of Shock Developing Among Patients Who Have Acute Coronary Syndromes but Do Not Have Persistent ST Segment Elevation legend legend
30152,Use of Coronary Angiography, Revascularization Procedures, and Assist Devices Based on Shock Status legend
30153,Predictors of Mortality Within 30 Days After Enrollment Among Shock Patients Who Have Acute Coronary Syndromes but Do Not Have Persistent ST Segment Elevation legend
30154,Comparison of Clinical Features of Cardiac Rupture Tamponade Patients and Other Suspected Shock Patients Excluding Those With Mechanical Causes
30158,Hemodynamic Data for Patients With CS and VSR or Predominant LV Failure legend legend
30159,Angiographic Findings in Patients With CS and VSR or Predominant LV Failure legend
30160,Management of Patients With CS and VSR or Predominant LV Failure legend
30161,Profile of Surgically Managed Patients With CS and VSR legend legend
30162,Profile of Surgical Survivors With CS and VSR legend
30166,Treatment and Outcomes of Patients With CS Due to Severe MR Versus LV Failure legend
30167,Timing of Events in Patients With Severe MR Versus LV Failure. All Times Are in Hours Unless Otherwise Noted legend
30168,Infarct Size, Hemodynamics, Treatment and In hospital Mortality by Valve surgery Status of Patients With Severe Complicating Acute MI. Hemodynamics Reported Are Those Closest to Shock, Which Were Often Recorded While the Patient Was on Support legend
30173,In hospital Mortality and Intervention Rates by Angiographic Disease Severity in Patients with LV or RV Failure
30175,Etiology of CS and In hospital Mortality
30176,Hemodynamic Findings Measured Close to Shock Onset While Patients Often on Mechanical or Pharmacological Support
30177,Registry Angiographic Findings, Overall and by Shock Etiology legend
30178,In hospital Event Rates by Angiographic Findings in Patients with LV or RV Failure
30179,Studies Reporting Angioplasty Outcomes in Octogenarians legend
30182,Clinical Outcomes legend
30183,Multivariable Predictors of Octogenarian Mortality legend legend
30184,Age Specific Outcome Trends 19941997 legend legend
30188,Resting Diastolic Indexes in Individuals with HCM, Elite Athletes With and Without LVH and Recreational Athletes legend
30189,Control Hemodynamic Values for Study Groups legend legend
30190,Countershock Success After Five Minutes of Ventricular Fibrillation legend legend
30194,Fatal and Nonfatal Cardiovascular Events During Follow up
30196,Echocardiographic Data at Initial Presentation    legend
30197,Long Term Follow up Data legend
30201,High Dose Chemotherapeutic Schedules Utilized
30202,Clinical Charateristics in Troponin Positive   cTnI    and Troponin Negative   cTnI   Groups legend legend
30203,Somatic and Cardiac Growth at 15 Weeks legend
30204,mRNA Levels and Collagen Content at 15 Weeks legend
30211,Operation and Early Postoperative Data legend legend
30212,Follow Up in Patients With Atrial Fibrillation Requiring Cryoablation and in the Control Group legend legend
30214,Reason for North American Symptomatic Carotid Endarterectomy Trial   NASCET   Exclusion in 79 Patients legend
30215,Procedural Details legend legend
30216,Adverse Events by Age Group legend
30217,Histomorphometry: Results of the Different Study Groups legend
30218,Kinetic Parameters for 6  18F  FluorodopamineDerived Radioactivity in Normal Volunteers and in Patients With Hypertrophic Cardiomyopathy legend
30219,Details of the Study Patients legend
30220,Quantitation of the Bcl 2 Family of Proteins After Western Immunoprobing legend
30221,Grading of the Bcl 2 Family of Proteins After Immunocytochemistry legend legend
30222,Quantitation of TUNEL legend
30224,Amount of T lymphocyte Subtypes Infiltrating the Biopsies of Patients With a Normal or an Altered ANT Isoform Transcription Pattern legend
30226,Two dimensional and M mode Echocardiographic Measurements legend legend
30227,Doppler Left Ventricular Diastolic Filling Variables legend legend
30232,Regional Left Ventricular Morphology legend
30233,Normal and Shear Strains legend
30236,Comparison of Biomedical Variables and Incident Congestive Heart Failure legend legend
30238,Percentage of Incident Congestive Heart Failure in the Population Attributable to Selected Risk Factors legend
30244,Previously Published Reports of Wrong Sinus Coronary Artery Anomalies in Persons Aged 35 Years in Whom ECG Data Were Available legend
30246,Etiology of CHF
30247,Comparison of the Presence of Signs of Pleural Effusion Between Plain Chest X ray and Thoracic Ultrasonogram in Normal Controls and Patients With Decompensated CHF legend legend
30248,The Frequency of the Detection of Body Fluid Accumulation in 60 Patients With Decompensated CHF by Two Clinicians
30249,Observer Disagreement on Clinical Tests for Identifying Body Fluid Accumulation in 60 Patients With Decompensated CHF
30250,Comparative Diagnostic Value of Traditional Clinical Signs and Ultrasonographic Test for Identifying Body Fluid Accumulation in Decompensated CHF
30252,Univariate Clinical and Rest Echocardiographic Predictors of Postoperative Events in 530 Patients Undergoing Nonvascular Operation legend
30253,Univariate Stress Echocardiographic Predictors of Postoperative Events in 530 Patients Undergoing Nonvascular Operation legend
30254,Multivariate Predictors of Postoperative Hard Cardiac Events in Patients With Inducible Ischemia legend
30255,Incremental Value of Dobutamine Stress Echocardiography Versus Clinical Variable for Preoperative Cardiac Risk Stratification for Nonvascular Operation legend
30259,Final Angiographic Results legend
30260,Procedural and In hospital Outcome legend
30261,Follow up QCA Results legend
30262,Follow up Results legend legend
30263,Study Designs legend
30264,Internal Consistency of the KCCQ
30267,Correlation of KCCQ Physical Limitation Scale legend
30270,Formulas for Calculation of Stretch, Recoil and Gain
30271,Associated Cardiac Lesions
30272,Hemodynamic and Angiographic Results Immediately Before and After Angioplasty legend
30273,Comparison of Patients With Early Failure Versus Success legend
30274,Factors Associated With Decreased Time to Reintervention    legend
30275,Distribution of Diagnoses for Which Emergent Repair of the Aorta was Undertaken
30278,Subgroup Analysis of In Hospital Mortality Based on Coronary Angiography Status legend
30279,Indications for CABG in Patients With or Without a History of MI
30280,Patient Data and Preinterventional Echocardiographic Findings
30281,Morbidity and Mortality
30282,Mean   SD   Values for Left Ventricular End Diastolic Volume, End Systolic Volume and Ejection Fraction for the Four Imaging Strategies legend
30283,Patient Classification by Systolic Function as Normal   A, LVEF 55   , Depressed   B, LVEF  35  to  55    or Severely Depressed   C, LVEF 35       legend
30284,Interobserver and Intraobserver Reproducibilities for Left Ventricular Ejection Fraction    legend
30285,Summary of Clinical Data legend
30286,Drugs Used for Control of Fetal AF legend
30287,Prior Series Reporting Postoperative Mortality and Complications in Octogenarians After CABG
30290,Outcomes of Cardiac Surgery by Age Category legend
30291,Multivariate Logistic Regression Model for the Prediction of In Hospital Mortality After CABG in Order of Descending Chi Square legend legend
30294,Effect of Simvastatin on Hematologic Variables in Rats After Balloon Angioplasty legend legend
30299,Revascularization and In hospital Mortality in Relation to Timing of Shock Onset legend
30304,Changes With Biventricular Pacing legend
30309,Genotype and Allele Frequencies of Candidate Gene Polymorphisms in Cases and Controls legend
30310,Patient Data legend
30311,Relations Between Hemodynamic Data and PET Data legend
30312,Positron Emission Tomographic Measurements in the Three Different Regions legend
30313,Doppler Echocardiographic Right Ventricular Filling Variables in Control Subjects and Patients With Hypertrophic Cardiomyopathy in the Supine Position and at 10 min of Different Degrees of Head Up Tilting legend legend
30314,Doppler Echocardiographic Left Ventricular Filling Variables in Control Subjects and Patients With Hypertrophic Cardiomyopathy in the Supine Position and at 10 min of Different Degrees of Head Up Tilting legend legend
30315,Doppler Echocardiographic Pulmonary Venous Flow Variables in Control Subjects and Patients With Hypertrophic Cardiomyopathy in the Supine Position and at 10 min of Different Degrees of Head Up Tilting legend legend
30316,Hemodynamic Data in Control Subjects and Patients With Hypertrophic Cardiomyopathy in the Supine Position and at 10 min of Different Degrees of Head Up Tilting legend legend
30319,Patient Profile legend
30320,Dimensions of the Myocardial Tracts and TH Staining legend
30324,Patients and Procedures
30325,Complications of Endomyocardial Biopsy legend
30326,Body Weight, Blood Glucose and Serum Fructosamine legend
30327,M Mode Measurements legend
30328,Systolic Doppler Measurements legend
30329,Diastolic Doppler Measurements legend
30330,Mechanical Variables In Vivo and in the Isolated Whole Heart legend
30332,Pre  and Immediately Post Cardiopulmonary Bypass Echocardiographic Measurements legend legend
30333,Pre MVRep, Immediately Post MVRep and Final Echocardiographic Measurements of Four Group 1 Patients in Which the Final TEE Exam Showed Resolution of Both SAM and LVOTO legend legend
30334,Precardiopulmonary Measurements of Patients in Group 1 legend legend
30335,Interobserver Variability for PreCardiopulmonary Bypass Measurements legend
30336,Some Familial Ventricular Tachyarrhythmias in the Absence of Structural Heart Disease or Associated Known Syndromes legend
30338,Distribution of Important Risk Factors Within Various Treatment Groups legend legend
30339,Hazard Ratios for Death as Compared With the NST Group legend
30343,Subjective Assessment of Exercise Difficulty
30346,Acute and Long Term Outcome of First and Second Internal Cardioversion   n   18   legend legend
30348,Clinical and Hemodynamic Parameters of Patient Subgroups With Valvular or Hypertensive Heart Disease legend legend
30350,Load Sensitivity of Various Time Constants of Relaxation legend legend
30353,Number of Patients With ST Episodes in Relation to ECG on Admission legend
30354,Number of Patients With ST Episodes in Relation to Diagnosis Within 24 H of Admission legend
30355,Univariate Analysis of Clinical, Biochemical and Electrocardiographic Predictors of Cardiac Death or MI legend
30357,Left Ventricular Minor Axis Function and Doppler Velocities legend
30358,Left Ventricular Long Axis Function legend
30359,Electrocardiogram Values legend
30362,Independent Predictors of Hospital Death, Odds Ratios and Coefficients for the Cleveland Clinic Model and the Northern New England Model legend
30364,Observed and Predicted Mortality Rates in Patient Subgroups legend
30366,Complications legend
30368,Associations Between Angiographic, Hemodynamic and Treatment Data and In Hospital Mortality legend
30369,Prediction of the Risk of In Hospital Mortality After PCI legend legend
30373,Contractile Responses to Potassium   K 125 mmol liter   Phenylephrine   PE, 1 mol liter   and Angiotensin II   1 and 100 nmol liter  , and Dilator Responses to Acetylcholine   10 mol liter   in Human Internal Mammary Artery Segments From Patients With the DD or the II ID Genotype legend
30374,PCR Primers Used to Detect Viral Sequences in Cardiac Samples
30375,Clinical, Pathologic and Virologic Findings in HIV Infected Patients at Autopsy legend legend
30376,Primary Anatomic Diagnoses in Patients Who Did and Did Not Undergo Fenestration
30380,Univariate and Multivariate Analysis: Determinant of TWA
30382,Reasons for Beta blocker Prescription, Randomized Patients After Their Index Arrhythmia   n   220
30385,Modes of Death, Randomized Patients legend
30389,Comparison of Group Values for IMT and SAC legend
30390,Study Population
30391,Analysis of the Difference Between Sporadic and Familial Dilated Cardiomyopathy at Uni  and Multivariate Analysis legend
30392,Summary of Clinical, Immunologic, Morphometric and Molecular Genetic Findings in Familial Dilated Cardiomyopathy   FDC   legend
30393,Uni  and Multivariate Analysis of the Difference Between Familial Dilated Cardiomyopathy   FDC   With and Without Skeletal Muscle Involvement legend
30394,Pre  and Post treatment Data for Patients with Drug Refractory HOCM legend
30395,Differences Between Patients With 4 Viable Segments   Group A   and  4 Viable Segments   Group B   on Dobutamine Stress Echocardiography legend
30396,Events in Patients With 4 Viable Segments   Group A, n   23   and  4 Viable Segments   Group B, n   45   on Dobutamine Stress Echocardiography
30398,Breakdown of Vessel Type Supplying Protected Regions
30399,Cause of Perioperative and Long Term Deaths
30400,Results of Univariate Analysis of Factors Correlating With Risk of Perioperative Mortality
30403,Electrocardiographic and Echocardiographic Data legend
30404,Cardiac Catheterization Data legend
30405,Cardiac Anomalies Identified by Telemedical Echocardiography
30406,Neonates With Congenital Heart Disease in Whom Transfer Was Immediately Recommended or Avoided legend
30409,Influence of Treatment With Trandolapril on the Occurrence of Secondary End Points in Patients With and Without Diabetes legend
30411,Comparison Between the Two Electrode Locations legend
30413,Adverse Clinical Outcome at 30 Days legend
30416,Effect of Carvedilol Versus Metoprolol at 12 Months on Categorical Measures of Clinical Status, LV Function and Ventricular Arrhythmias in 30 Dilated Cardiomyopathy Patients
30420,Womens Ischemia Syndrome Evaluation Site Specific Methodologies legend
30423,Echocardiographic Features of Affected Family Members legend
30424,Data on 13 Patients With Idiopathic Dilated Cardiomyopathy legend
30425,Mean Myocardial Trace Elements Concentration   ng g   in Patients With Idiopathic Dilated Cardiomyopathy   Group A  , Secondary Forms of Cardiac Dysfunction   Group B  , Control Subjects   Group C   and Normal Subjects   Group D   as Determined by Neutron Activation Analysis legend
30429,Univariate Predictors of Long Term Neurologic Events, All cause Mortality, and All Events legend
30430,Event Rates in the Study Patients According to Severity of Ascending Aorta Atherosclerosis legend
30431,Independent Predictors of Long Term Neurologic Events, All cause Mortality, and All Events legend
30432,Incidence of Long Term Events According to Severity of Ascending Aorta Atherosclerosis legend
30434,Outcomes of 335 Primary Angioplasty Procedures legend
30435,In Hospital Outcomes in Patients Undergoing Immediate Coronary Angiography legend
30436,Cardiac Catheterization Laboratory Complications in 506 Immediate Coronary Angiograms legend legend
30438,Preoperative Cardiac Medications legend
30439,Perioperative Cardiac Morbidity legend
30440,Perioperative Noncardiac Morbidity legend
30441,One Way Analysis of Variance of Potential Risk Factors for Perioperative Death After Transmyocardial Laser Revascularization legend
30442,One Way Analysis of Variance of Potential Risk Factors for Perioperative Cardiac and Noncardiac Morbidity After Transmyocardial Laser Revascularization legend
30444,Predictors of Conversion by Drug Treatment   Univariate Assessment   legend
30445,Conversion Rate       of Significant Predictors Dichotomized at the Statistical Median legend
30446,Studies of Carvedilol in Heart Failure legend
30448,Nonfatal Adverse Events legend
30449,Adverse Events on Carvedilol   NYHA Class IV Patients   legend
30451,Genotypic Distributions and Allelic Frequencies of HindIII and PvuII Polymorphisms Among CAD Patients and Control Subjects legend legend
30452,Odds Ratios for CAD Associated With Carriage of HindIII  and PvuII Carrying Genotypes legend
30453,Associations Between HindIII and PvuII Polymorphisms: Observed   Expected   Genotypic Frequencies legend
30454,Estimated Haplotypic Frequencies With Association legend legend
30455,Multivariate Conditional Logistic Regression Model for CAD legend
30456,Mean Gray Scale Values  legend
30457,Statistical Analysis for Intravascular Ultrasound   IVUS   Images  legend legend
30458,Statistical Analysis for Transvascular Ultrasound   TVUS   Images legend legend
30459,Patients Population legend
30460,Reoperations legend
30463,Summary of Cardiac Events Within First Year of Follow Up legend
30464,Rest Wall Motion and Incidence of Positive Stress Echocardiograms, Myocardial Infarctions, and Cardiac Events legend
30466,Measurement Precision legend legend
30467,Measurement Accuracy legend legend
30468,Patient Population legend
30472,Left Atrial Appendage Velocity and Mitral A Wave Velocities Before, During and After Brief Duration Atrial Fibrillation in Patients Reverting With an Endocardial Shock   n   14   or Spontaneously   n   10   legend
30473,Left Atrial Appendage Velocity and Mitral A Wave Velocities Before, During and After Brief Duration Atrial Fibrillation in Patients Taking Chronic Amiodarone Therapy   n   14   or Chronic Sotalol Therapy   n   10   legend
30474,Left Atrial Appendage Velocity and Mitral A Wave Velocities Before, During and After Brief Duration Atrial Fibrillation in Patients With   n   14   and Without   n   10   Spontaneous Echocardiographic Contrast During AF legend
30478,Study Population legend
30479,Pattern of Distribution of Hypertrophy at Apical Level legend
30480,Wall Thickness   mm   on First MR Images legend
30481,Wall Thickness   mm   on Second MR Images legend
30482,Comparison of Clinical Feature legend
30485,Hemodynamic Responses to Clonidine
30486,Neurochemical and Flow Responses to Clonidine
30487,Risk of Events by Definitions
30488,Distribution of Risk Factors in Cases and Control Subjects and Associations of Risk Factors With Events Using Primary Case Definition  legend
30489,Clinical, Hemodynamic and Ventriculographic Data  legend
30490,LV Systolic and Diastolic Function Data  legend
30491,Summary of Patients Dying   n   12    legend
30492,Postulated Risk Factors for Reduced Time to Death or Resuscitated Sudden Death  legend
30494,Prevalence and Type of Perfusion Abnormalities in Patients With Normal and Abnormal BPR  legend
30496,Echocardiographic Findings in the Probands With HCM legend
30497,Mutations in the Cardiac Beta Myosin Heavy Chain    MHC   and Alpha Tropomyosin    TM   Genes Causing Hypertrophic Cardiomyopathy
30498,LOD Scores of the Two Point Linkage Analysis Between Familial HCM Locus   Dominant Inheritance Mode With a Penetrance of 95    and Two Polymorphic Markers MYO I and MYO II of the Cardiac  Myosin Heavy Chain Gene With Recombination Fractions      0 and 0.01 in 16 Families With Confirmed or Suspected Familial HCM legend
30499,Clinical Features of 3 Different Subsets of Affected Family Members  legend
30501,Procedural Variables  legend
30502,Long Term Outcome of Patients With Stable and Unstable Angina legend
30504,Cut Points for Electron Beam Computed Tomographic Coronary Calcium Scores for Differentiating Ischemic and Nonischemic Cardiomyopathy  legend
30505,Mortality During Follow Up in 392 Discharged Patients
30506,Total Mortality in the First Year After Discharge for the Index MI   tTest, Chi Square Test    legend
30507,Total Mortality After Discharge in 392 Patients   KaplanMeier Method, Proportional Hazards Model    legend
30508,Clinical and Echocardiographic Data for Subjects Enrolled in the Comparative Study  legend
30509,Clinical and Echocardiographic Data for Patients Enrolled in the Follow up Study Protocol Before and After the Therapy legend
30510,Transmitral Flow Velocity and Tissue Doppler Indices in the Comparative Study  legend
30513,Age Adjusted Cox Proportional Hazards Analyses Relating Risk of Major Events to Failure to Reach 85  of the Age Predicted Maximum Heart Rate and Echocardiographic Myocardial Ischemia
30514,Age Adjusted Cox Proportional Hazards Analyses Relating Risk of Major Events to Chronotropic Index and Echocardiographic Myocardial Ischemia
30517,Frequency of Aortic Root and Valve Abnormalities on Transesophageal Echocardiography legend
30520,Noncardiac Mortality
30522,Clinical and Hemodynamic Variables
30523,Ultrastructural Morphometric Analysis of Gap Junctions
30525,Side Effects Considered to Be Agent Related legend
30530,Multiple Linear Regression Analysis of Clinical and Hemodynamic Variables and Follow Up Left Ventricular Ejection Fraction  legend
30537,Incidence of Failed Thrombolysis and Rescue Angioplasty
30540,Technical Results of Attempted Rescue Angioplasty legend
30542,Procedure Related Complications
30543,Left Ventricular Function at 5 to 7 Days  legend
30545,Interaction of Rescue Angioplasty Attempt and Cardiogenic Shock on 30 Day Mortality in Patients With All Closed Infarct Related Arteries  legend
30546,Echocardiographic Data
30547,Asynchrony Index Obtained From Color Kinesis Images at Different Percentages of Left Ventricular Filling Time in Normal Subjects and in Different Subgroups of Patients With Dilated Cardiomyopathy
30551,Comparison of Preoperative and Postoperative Echocardiographic Findings in all Patients legend
30552,Comparison of Postoperative Echocardiographic Findings Between Patients With Hypertrophic Obstructive Cardiomyopathy and Control Subjects  legend
30558,Plasma Concentration of Amiodarone or Desethylamiodarone in Each Treatment Group   mean  SD
30560,Doppler Blood Flow Velocity Measurements and Sinus Rate Before and After Endocardial Direct Current Shocks in Sinus Rhythm and Ventricular Fibrillation and Transthoracic 360 J Shocks in Sinus Rhythm in 13 Patients
30562,Time to Treatment Intervals for Lytic Eligible Patients
30565,Baroreflex Sensitivities in Patients With Hypertrophic Cardiomyopathy Versus Control Subjects
30568,Risk Factor Associations With Angiographic Disease Severity by Multiple Linear Regression Analysis  a
30569,Risk Factor Associations With Electron Beam Computed Tomographic Total Calcium Score Quintiles by Multiple Linear Regression Analysis  a
30571,Linear Correlations With Body Height as Dependent Variable
30572,Stepwise Multiple Regression
30573,Clinical Manifestations and Diagnostic Study Results in 13 Patients With Hypertrophic Cardiomyopathy
30574,Events During Follow Up in Patients With an Implantable Cardioverter Defibrillator and Hypertrophic Cardiomyopathy
30575,Clinical, Hemodynamic and Echocardiographic Data of Patients With Hypertrophic Cardiomyopathy and Control Subjects
30576,Coronary Hemodynamic Variables at Basal Conditions and After Vasodilation in Patients With Hypertrophic Cardiomyopathy and Control Subjects  a
30577,Morphometric Findings in the Right Septal Subendocardium
30578,Intraobserver and Interobserver Variabilities of Morphometric Investigations
30580,Metabolic and Hemodynamic Variables on Study Entry and at 10 Weeks
30585,Comparison of Echocardiographic Variables Between Giant Left Atrium and Control Group Before and After Maze Procedure
30588,Follow Up and Clinical Events in 10 Study Patients
30589,Coronary Events in Eight Study Patients
30590,Annualized Rates of Procedures by Tercile
30593,Unadjusted Rates for In Hospital Outcomes
30597,In Hospital Course
30598,Factors Associated With In Hospital Death   univariate analysis
30599,Multivariate Analysis for In Hospital Death  a
30601,Vessel Size and Time Averaged Velocity at Reactive Hyperemia in Study Participants
30602,Comparison of Clinical and Echocardiographic Indexes Among Patients Who Did and Did Not Have Spontaneous Conversion to Sinus Rhythm
30604,Comparability of Previous Medical History of Patients Receiving Saruplase or Streptokinase at Randomization
30605,Causes of Death in Patients Receiving Saruplase or Streptokinase
30606,Cardiac Events up to 30 Days in Patients Receiving Saruplase or Streptokinase
30607,In Hospital Bleeding Events   excluding stroke   in Patients Receiving Saruplase or Streptokinase
30608,Strokes and Transient Ischemic Attacks at 30 Days in Patients Receiving Saruplase or Streptokinase
30609,Implantable Cardioverter Defibrillator Variables Temporarily Reprogrammed During Clinical Testing
30610,Antenna Generated Fields Used to Simulate Digital Cellular Telephone Technology Modulation During In Vitro Testing of Implantable Cardioverter Defibrillators  a
30611,In Vitro Test Results of Implantable Cardioverter Defibrillators Subjected to Near Field Effects of Analog and Digital Telephone Technologies
30612,Analog and Digital Cellular Telephone Models Used During In Vitro Testing for Near Field Effects on Implantable Cardioverter Defibrillators  a
30614,Tachyarrhythmias and Syncope During Follow Up
30618,Mode of Clinical Presentation
30622,Hemodynamic Changes With Adenosine
30623,Myocardial Blood Flow and Flow Reserve
30624,Comparison of Exercise Performance Between Survivors of Anomalous Left Coronary Artery From Pulmonary Artery Surgical Repair and Control Subjects
30627,In Hospital Outcome of 66 Patients With Cardiogenic Shock
30629,Six Month Clinical and Angiographic Follow Up of 49 In Hospital Survivors
30632,Univariate Comparison of Indexes of Left Ventricular Function in Patients With and Without Calcium Lowering Medications During Atrial Fibrillation
30634,Thirty Day Mortality by Type of Bundle Branch Block
30635,Independent Predictors of 30 Day Mortality
30636,Reversion Rates by Initial Bundle Branch Block Type
30637,Infarct Related Artery by Type of Bundle Branch Block
30641,Electrocardiographic and Echocardiographic Findings in 28 of 48 Families With Confirmed Familial Dilated Cardiomyopathy
30642,Prevalence of Paroxysmal Supraventricular Tachycardia per 1,000 Persons by Age and Gender
30643,Incidence Rates of Paroxysmal Supraventricular Tachycardia per 100,000 Person Years by Age and Gender
30645,Comparison of Incident Patients With Lone Paroxysmal Supraventricular Tachycardia and With Paroxysmal Supraventricular Tachycardia and Cardiovascular Disease
30650,Progression of Disease During Follow Up Period of 39  14 Months
30651,Logistic Regression: Relation Between Progression of Left Ventricular Enlargement to Dilated Cardiomyopathy and Main Noninvasive Variables
30653,Thrombolytic Therapy Assignment and In Hospital Management by Recurrent Angina Category
30655,Outcomes and Clinical Events  a  by Recurrent Angina Category
30658,Hemodynamic Changes During Exercise
30659,Effects of Right Atrial Pacing and Exercise on Tau
30661,Selected Clinical and Electrophysiologic Features of Study Patients  a
30663,Multiple Linear Regression Analysis Results With Augmentation Index as the Dependent Variable  a
30664,Multiple Linear Regression Analysis Results With Subendocardial Viability Index as the Dependent Variable
30666,Relation of Thromboemboli to Anticoagulation
30667,Thromboembolic Events Probably Not Related to Atrial Flutter
30670,Hemodynamic Variables
30672,Comparison of Regional Myocardial Flow Reserve
30673,Lesions and Degree of Left Ventricular Hypoplasia
30674,Preoperative and Postoperative Volume Variables
30675,Relations Between Preoperative and Postoperative Left Ventricular Volumes
30676,Clinical Findings at Diagnosis in 1,001 Study Patients
30677,Diagnostic Workup
30679,Treatment of Acute Major Pulmonary Embolism
30680,Contraindications to Thrombolytic Treatment in 1,001 Registry Patients
30681,In Hospital Clinical Course
30682,Age and Gender Data of People Who Died of Atherosclerotic Cardiovascular Disease and Ischemic Heart Disease
30683,Changes in Doppler Indexes Before and After Left Ventricular Assist Device Insertion
30686,Number of Shocks, Peak Delivered Energy, Peak Current and Transthoracic Impedence in 10 Patients  a
30687,Results of Head Up Tilt Testing
30689,Comparison of Minimal and Maximal RR Intervals During Autonomic Testing in Subjects With and Without Positive Head Up Tilt Test Responses
30690,Coronary Artery Disease Prognostic Index  a
30693,Independent Clinical Predictors of 5 Year Mortality in Patients With Cardiomyopathy
30696,In Hospital Outcomes of Adult Patients    65 years old   With or Without Previous Angina 48 Hours Before Acute Myocardial Infarction
30697,In Hospital Outcomes of Elderly Patients   65 years old   With or Without Previous Angina 48 Hours Before Acute Myocardial Infarction
30698,Protective Role of Angina 48 Hours Before Acute Myocardial Infarction in Adult and Elderly Patients: Unadjusted Regression Model for In Hospital Death and Congestive Heart Failure or Shock and Combined End Points   in hospital death, congestive heart failure or shock
30699,Protective Role of Angina 48 Hours Before Acute Myocardial Infarction in Adult and Elderly Patients: Adjusted Regression Model for In Hospital Death and Congestive Heart Failure or Shock and Combined End Points   in hospital death, congestive heart failure or shock    a
30700,Multivariate Analysis Including All Variables for In Hospital Mortality in Adult    65 years old   and Elderly Patients   65 years old
30701,Anatomic Diagnoses and Surgical Procedures
30702,Early Success of Radiofrequency Ablation for Intraatrial Reentrant Tachycardia in Study Group
30704,HRV Variables in Control Group and Patients With IDC
30705,HRV Variables in Control Group and Patients With IDC Without and With CHF
30706,Correlation Between Mean RR and HRV Variables in Control Group and Patients With IDC Without and With CHF
30707,Correlation Between HRV Variables and Hemodynamic Indexes in Patients With IDC
30708,HRV Variables According to Presence or Absence of Severe Ventricular Arrhythmia   Lown grade 4b   or Late Ventricular Potentials in Patients With IDC
30709,Holter Monitor Analysis
30710,Underlying Rhythm With Initiation of Spontaneous Atrial Flutter  a
30711,Atrial Flutter After Modified Fontan Operation
30712,Effects of Six Months of Metoprolol Treatment
30714,Effect of Clinical Variables on Recovery of Effective Mechanical Atrial Function: Odds Ratios and 95  Confidence Intervals
30715,Mitral Inflow Variables After Cardioversion: A Comparison of Electrically Cardioverted   Group I   With Pharmacologically or Spontaneously Cardioverted   Group II   Patients
30719,Patient Variables for Successful Versus Unsuccessful Results
30720,Patient Variables in Hospital Survivors Versus Hospital Deaths
30721,Patient Variables: No Emergency Versus Emergency Coronary Artery Bypass Graft Surgery
30722,Clinical and Echocardiographic Data for Patients With Hypertrophic Cardiomyopathy, Athletes, Patients With Hypertension and Aged Matched Normal Subjects
30723,Accuracy of Diagnosis of Patients With Hypertrophic Cardiomyopathy Based on Measurement of Myocardial Velocity Gradient
30725,Contraindications for Thrombolytic Therapy
30726,Reperfusion
30727,Results of Best Subsets Method and Logistic Regression
30734,Angiographic Analysis
30735,Follow Up Results
30736,Analysis of Predictors of Clinical Events After Repeat Intervention
30737,Classification of Estimated Functional Capacity According to Age and Gender
30740,Results of Proportional Hazards Analyses for Prediction of All Cause Mortality: Final Models
30742,Randomized Trials of Beta Blockade in Patients With Congestive Heart Failure: Effect of Beta Blockade on Mortality
30743,Randomized Trials of Beta Blockade in Patients With Ischemic Cardiomyopathy: Effect of Beta Blockade on Mortality
30744,Randomized Trials of Beta Blockade in Patients With Nonischemic Cardiomyopathy: Effect of Beta Blockade on Mortality
30745,Subgroup Differences of the Effect of Beta Blockade on Total Mortality
30747,In Hospital Course of Patients With Acute Myocardial Infarction and Cardiogenic Shock Treated With or Without Intraaortic Balloon Counterpulsation
30748,Community Hospital Complications of Patients With Acute Myocardial Infarction and Cardiogenic Shock Treated With or Without Intraaortic Balloon Counterpulsation
30749,Survival of Patients With Acute Myocardial Infarction and Cardiogenic Shock Treated With and Without Intraaortic Balloon Counterpulsation
30750,Patient Groups and Exercise Testing
30751,Comparison of Cardiorespiratory Variables in Patients With Ebsteins Anomaly Before and After Surgical Repair
30752,Variables Predicting Maximal Oxygen Uptake Preoperatively and Postoperatively
30753,Variables Predicting Blood Oxygen Saturation at Peak Exercise Preoperatively and Postoperatively
30754,Exercise Performance Preoperatively in Patients With and Without an Atrial Septal Defect
30755,Variables Predicting Heart Rate at Peak Exercise Preoperatively and Postoperatively
30760,Histomorphometric Endomyocardial Biopsy Results
30763,Mortality and In Hospital Outcome
30764,In Hospital Management
30765,Clinical Outcome by Use of Angioplasty
30766,30 Day Mortality Modeling
30769,Procedural Data for 86 Study Patients
30770,Procedural Success in the 92 Stented Lesions in Relation to Implantation Strategy
30773,First Cardiac Catheterization Hemodynamic Variables in Seven Patients
30775,Exercise Treadmill Time Before and After Permanent Dual Chamber Pacing
30776,Second Cardiac Catheterization Hemodynamic Variables in Six Patients
30778,Results of Transvenous Low Energy Cardioversion in 141 Patients Included in Multicenter Trial
30780,Clinical Data of the Patients
30781,Intracardiac Cardioversion Data
30782,Clinical, Electrocardiographic and Echocardiographic Data in Members of Pedigrees 0 and 9 Carrying the Arginine 92 Tryptophan Mutation
30783,Clinical Features Associated With Hypertrophic Cardiomyopathy in Pedigrees 0 and 9
30784,Clinical Features of Familial Hypertrophic Cardiomyopathy in 21 Individuals With the Alpha Tropomyosin Gene Mutation Asp175Asn
30785,Disease Gene Haplotypes in Three Families With Familial Hypertrophic Cardiomyopathy Caused by the Alpha Tropomyosin Gene Mutation Asp175Asn
30791,Survival Data
30792,Device Utilization
30793,Multivariate Predictors of Mortality During Follow Up
30795,Heart Rate Variability in the Study Patients
30796,Prevalence of Atherosclerotic Changes in the Brachial Artery, Common Carotid Artery and Left Anterior Descending Coronary Artery in 52 Subjects According to Age and Severity
30797,Clinical and Angiographic Data for Six Sites of Stent Compression in Dialysis Conduits
30798,Intravascular Ultrasound Data for Six Sites of Stent Compression in Dialysis Conduits
30799,Clinical and Angiographic Data for Six Patients With Superficial Femoral Artery Stent Compression
30800,Intravascular Ultrasound Data for Six Patients With Superficial Femoral Artery Stent Compression
30801,Correlations of the Expression of Perforin and T Cell Intracellular Antigen With Other Endomyocardial Biopsy Markers From Patients With Idiopathic Dilated Cardiomyopathy
30803,Failure of Pharmacologic and External Cardioversion Attempts and Success of Internal Cardioversion
30804,CHGB Promoter Variants A 296C and A 261T: Context Dependent Allelic Effects on Luciferase Reporter Activity
30805,CHGB Common Promoter Variant Effects on Blood Pressure in a European Ancestry Population Sample With Extreme BP Values
30807,Mortality Outcome in Elderly Post MI Patients Discharged With or Without Statins
30808,Relative Risk of All Cause Mortality for Different Subgroups in Population C
30810,Genes With Abbreviations, Main Functions, and p Values
30818,Summary of Outcome Measures
30825,Segment Specific Slopes for Years Before After the FMP for Cardiovascular Risk Factors Where Piecewise Linear Trajectory Fits Better Than Linear Trajectory   Relative Fit  1
30827,Multiple Regression Analysis: Adjusted Models for Prediction of SCD
30829,Multivariable Analyses Performed With and Without NT proBNP and hsCRP Included in the CORONA Multivariable Model    17    for a Range of Pre Specified End Points and for 2 Post Hoc End Points
30830,Total Number   Episodes   of Hospitalizations According to Tertile of NT proBNP
30833,Effect of Apneas on BNP
30835,Physical Examination Findings by the Cardiology Consultant
30836,Clinical Diagnoses in Each of the Disease Categories in the Older Age Group
30837,Clinical Diagnoses in Each of the Disease Categories in the Neonatal Group
30839,Accuracy of Diagnosing Cardiovascular Disease by the BNP Assay on the Basis of the Maximal NPV
30841,Univariate Predictors of LVDSD
30842,Multivariate Analysis to Predict the Combined End Point   Derivation Set
30843,Randomized Trials of Dronedarone or Amiodarone Versus Placebo
30845,Organ Specific Adverse Reactions Requiring Study Drug Termination
30847,Cardiovascular Events in Patients With High or Low EMP Levels
30848,Univariate and Multivariate Cox Proportional Hazards Analysis for Cardiovascular Events in Follow Up Patients
30849,C Statistics for Cox Proportional Hazards Model to Predict Cardiovascular Events in Follow Up Patients
30853,Cumulative Study Results
30854,Heart Rate Variability Variables During Dipyridamole Echocardiographic Tests With Negative Results: Comparison of Basal Value and Peak Effect
30855,Analysis of Variance for Repeated Measurements on Normal and Ischemic Group Data   Fisher F values
30857,Serum Cholesterol, LDL, Glucose, and Insulin Levels After Four Months
30858,Echocardiographic Evaluation of Aortic Valve in Vivo After Four Months of Normal or HF HC Diet
30862,Univariate and Multivariate Predictors of Mortality in Diabetic and Nondiabetic Patients
30863,Univariate and Multivariate Predictors of Hard Events in Diabetic and Nondiabetic Patients
30865,Hemodynamics, MBF, and MVo 2
30868,Independent Predictors of RV smand RV emin Overweight and Obese Patients
30870,Hazard Ratio by Cox Regression Analysis for Clinical Events and All Causes of Mortality
30873,Effects on dP dtmaxas Estimated by Mixed Model
30875,Angiographic Results at Follow Up
30876,Clinical Outcome at One Year
30882,Evaluation of Platelet Function Tests by Light Transmittance Aggregometry and TEG
30883,Observed Frequency       of Patients Without Ischemic Events and With Ischemic Events in Risk Factor Groups, Estimates of the Parameters of the Logistic Regression Model, Odds Ratio, and 95  Confidence Intervals for the Odds Ratio
30886,Primary End Points During Follow Up
30887,Secondary End Points During Follow Up
30889,Individual Value of Cardiovascular Magnetic Resonance Imaging Derived Viability Indexes Analyzed at the First Week for Predicting Normal Segmental Wall Motion at the Sixth Month   Wall Thickening  2 mm
30890,Value of Response to Dobutamine at the First Week   Wall Thickening With Dobutamine  2 mm   for Predicting Normal Segmental Wall Motion at the Sixth Month   Wall Thickening  2 mm   Depending on the Transmural Extent of Necrosis
30893,Outcomes Before and After Program Initiation
30894,Multiple Logistic Model for Variables Associated With Failure to Survive to Discharge
30897,In Hospital Outcome
30898,12 Month Outcome
30899,Patient Details
30900,Characteristics of Randomized Trials on ARBs in HF That Were Included in the Meta analysis
30903,Variables in Rats With Chronic Heart Failure at 12 Weeks After Myocardial Infarction, as Compared With Sham Operated Animals legend
30904,Acetylcholine  and Sodium Nitroprusside Induced Relaxations in the Aortic Rings of Rats With Chronic Heart Failure at 12 Weeks After Myocardial Infarction, as Compared With Sham Operated Animals legend
30910,Clinical Outcomes After High Dose Versus Low Dose Enalapril Therapy
30911,Echocardiographic Responses After High Dose Versus Low Dose Enalapril Therapy
30926,Systolic Function Response During Exercise in Placebo and Verapamil Treated Patients
30927,Morphometric and Echocardiographic Measures of Control and Volume Overload Hypertrophy Animals at Three Weeks of Age legend legend
30928,Acetyl Coenzyme Carboxylase   ACC   and 5 Adenosine MonophosphateActivated Protein Kinase   AMPK   Activity in Fetal, Newborn and Three Week Old Pig Hearts legend
30929,Malonyl Coenzyme A levels   nmol g dry weight   in Fetal, Newborn and Three Week Old Control and Hypertrophied Pig Hearts legend
30932,Frequency of Structural Valve Abnormalities in Patients With Normal and Elevated Levels of APA legend
30933,Patient Data, Stress Heart Rate, Scintigraphic Findings and Coronary Flow Reserve in Patients With Left Bundle Branch Block legend
30937,Family History of Diabetes Between Patients With and Those Without LVH Criterion legend
30939,Electrocardiographic Findings of Patients Having Diabetic Mothers   M    and Those Having Nondiabetic Mothers   M   legend
30940,Multiple Logistic Regression Analysis in 834 Diabetic Patients legend
30941,Multiple Logistic Regression Analysis in 834 Diabetic Patients legend
30942,Echocardiographic Findings of Patients With Diabetic Mothers   M    and Those With Nondiabetic Mothers   M   legend
30943,Angiotensin Converting Enzyme Inhibitor Therapy of Study Subjects Prior to Study Entry
30946,Drug Discontinuation or Hospitalization for Worsening Heart Failure
30955,Mortality Rates and Modes of Death
30956,Mortality Reduction Associated With the Use of Beta Blockers in Patients Randomized to Enalapril and Placebo legend
30959,Hemodynamic Variables of Survivors and Nonsurvivors
30960,Cox Univariate and Multivariate Analyses of Variables Predictive of One Year and Two Year Mortality or Urgent Transplantation   p   0.01 Level of Significance at Univariate Analysis   legend
30965,Angiographic and Coronary Collateral Data legend
30966,Data on Myocardial Ischemic Adaptation legend
30967,Age, Body Mass Index and Systolic and Diastolic Blood Pressure in Control   n   10   Compared With Hypertriglyceridemic   HTg; n   11   and Hypercholesterolemic   HCh; n   10   Subjects legend
30968,Total Plasma Lipoprotein Compositions in Control   n   10   Compared With Hypertriglyceridemic   HTg; n   11   and Hypercholesterolemic   HCh; n   10   Subjects
30969,Lipoprotein Compositions in Control   n   10   Compared With Hypertriglyceridemic   HTg; n   11   and Hypercholesterolemic   HCh; n   10   Subjects
30971,Late Mortality in Relation to Peak Periprocedural CK Ratio legend
30975,Univariate Survival Analysis: Cox Model  legend
30976,Multivariate Survival Analysis: Cox Model With a Backward Selection legend
30980,Genotypic Distributions and Allelic Frequencies of PIA1 A2Polymorphism Among Patients and Control Subjects legend
30981,Multivariate Logistic Regression Models for CAD and MI legend legend
30983,Stress Myocardial Perfusion Tomography Results
30984,Angiographic Covariates Associated with the Outcome of Stress Echocardiography Tests by Univariate Logistic Regression Analysis legend
30985,Multivariate Predictors of the Outcome of Stress Echocardiography Tests by Logistic Regression Analysis
30986,Biochemical and Physiologic Parameters legend
30987,Angiographic Results Before and After Angioplasty legend
30988,Morphometric Analysis legend
30990,Comparison of Symptoms and Dysrhythmias Between Dobutamine Stress Echocardiography and Transesophageal Atrial Pacing Stress Echocardiography legend
30991,Comparison of Stress Echocardiography Interpretations Between Dobutamine Stress Echocardiography and Transesophageal Atrial Pacing Stress Echocardiography
30993,Hemodynamic Data legend
30994,Neurohumoral Data legend
30995,Univariate and Multivariate Linear Model of Plasma Endothelin 1 Extraction in the Lower Limb in Patients With CHF legend
30997,Clinical Outcomes
30998,Postprocedure Peak CK and CK MB by Diagnostic Category legend
30999,Procedural Success and Abrupt Closure and Clinical Outcome
31000,Clinical Outcomes in Patients With Successful Procedures Without Abrupt Closure legend
31001,Postprocedure CK MB by Device Type
31002,Clinical Outcomes by CK MB Level and Device Type legend
31003,PCR Primers and Reaction Conditions
31005,The Number of Vessels   Percentage   Positive for C. pneumoniaeDNA by PCR
31008,Peak Values Collected in Sedentary Heart Transplant Recipients   S HTRs   and in Trained Heart Transplant Recipients   T HTRs   During Bicycle Tests legend
31009,Plasma Lactate, Epinephrine and Norepinephrine Peak Values During Bicycle and Treadmill Testing legend
31010,Peak Values collected in Trained Heart Transplant Recipients   T HTRs   legend
31011,Inclusion and Exclusion Criteria
31015,P Wave Duration on Standard Electrocardiogram legend
31016,Sensitivity, Specificity and Predictive Accuracy of P SAECG for AVRT legend
31017,Results of Quantitative Computerized Digital Analysis of Micro CT Images by Normal and the Balloon injured Coronary Arteries
31019,Comparison of U.S. Hospitals Participating in GUSTO IIb and Other U.S. Hospitals  legend
31020,Discharge Medication Use in the Overall Population and Selected Subgroups legend
31021,Discharge Medication Use in Ideal Patients by Enrollment Location legend
31022,Odds Ratios with 95  Confidence Intervals for the Likelihood of Ideal Patients Receiving Discharge Medication  legend
31023,Estimated Lives Saved by Guideline Recommended Use of Medications
31028,Plasma Glucose and Insulin After Oral Glucose Ingestion  legend
31029,Comparison of Autopsy Specimens to Echocardiographic Measurements of Aortic Circumference legend
31030,Number, Gender and Mean Age of the Four Groups  legend
31031,Persistent Fetal Dispersion of the AV Node  legend
31032,His Bundle Fragmentation  legend
31033,Statistical Analysis  legend
31035,Correlations Between Quantitative and Visual Assessments in Total Patients   n   1043  , Men   n   678   and Women   n   365   legend
31036,Nuclear Variables of Patients With and Without Hard Events legend
31037,Multivariable Cox Proportional Hazards Models legend
31038,Prevalence of Congenital Cardiovascular Malformations   CCM   in Infants   Neonatal Cohort   of HIV Infected Mothers  legend
31039,Summary of All Congenital Cardiovascular Malformations   CCM   Among 558 Infants From the Neonatal Cohort
31040,Prevalence of Congenital Cardiovascular Malformations   CCM   and Lesion Status at One Year of Age Among the Neonatal Cohort
31041,Summary of All Congenital Cardiovascular Malformations   CCM   Among 201 Infants From the Older HIV Infected Cohort
31042,Prevalence of Congenital Cardiovascular Malformations   CCM   Among the Neonatal Cohort Including Patent Foramen Ovale in Children Over One Year of Age legend
31046,Exercise Test Results of the Three Patient Groups legend
31049,Forearm Blood Flow Responses to Intraarterial Infusion of Increasing Doses of Acetylcholine and Sodium Nitroprusside  legend legend
31051,Changes in Average Peak Velocity, Endothelium  Dependent and Flow Dependent Coronary Flow Reserve of the Left Anterior Descending Artery at Each State legend
31053,Absolute Difference Between Echocardiographic and Magnetic Resonance Imaging Measurements  legend
31057,Quantitative Coronary Analysis   n   100   legend
31058,Univariate Predictors of Recurrent In stent Restenosis after Rotational Atherectomy legend
31060,Frequency of Small and Large NonQ Wave MIs in Each Patient Group  legend
31061,Frequency of Procedure Related NonQ Wave MI According to Duration of Pretreatment With Ticlopidine: Results of Stratified Analyses  legend
31062,Visual Uptake of Antimyosin Antibodies in the Ventricular Wall legend
31065,Echocardiographic Variables in Patients With Mitral Regurgitation  legend
31066,Correlation Coefficient Between Mitral Regurgitant Volume   by ACM   and Related Factors legend
31067,Correlation Coefficient Between Qualitative Grading of Mitral Regurgitant Severity and Related Factors legend
31068,Interobserver and Intraobserver Variability legend
31069,Activities of NOS II, NOS III and Total NOS legend
31071,Effect of Sodium Nitroprusside on Myocardial Contraction and Relaxation  legend
31074,Results for Variables of Myocardial Damage
31075,Changes in Tl 201 DSI and r EF
31077,Coronary Diameters and Hemodynamic Variables Before and After Coronary Stenting in Pigs legend
31078,Age at Operation   Months
31079,Causes of Death  legend
31080,Patients with Echocardiographic Right Ventricular Dysfunction But Without Right Ventricular Failure: Echocardiographic, Radiographic, Radionuclide, and New York Heart Association Classification  legend
31081,Patients With Raised Pulmonary Vascular Resistance 4 U.m2  legend
31082,Patients With Decreased Ability Index
31085,Quantitative Angiographic Results
31086,IVUS Findings Preintervention
31087,IVUS Results Postintervention
31088,In Hospital Complications
31089,Late Clinical Follow Up
31090,Ninety Minute TIMI Flow Grade According to Infarct Related Artery  legend
31092,Multivariable Analysis: Predictors of 90 Minute Infarct Related Artery   IRA   TIMI 3 Flow legend
31094,Results of Muscle Testing  legend
31095,Results of Neuroendocrine Assays  legend
31096,Echocardiographic Measurements and Calculations  legend
31097,Means and SDs of Anthropometric Measurements and Blood Pressure   BP  , by Gender
31098,Mean Values and SDs of Unindexed and Indexed Left Ventricular Mass   LVM   by Gender, and Absolute and Relative Gender Differences
31099,Partial Correlation Coefficients   r  , Controlled for Age, of Body Size, Body Composition and Blood Pressure With Unindexed and Indexed Left Ventricular Mass   LVM
31100,Changes in Left Ventricular Mass   LVM   Associated With an Increase of 1 SD in Body Fat   adiposity   or Systolic Blood Pressure   BP   Results Are Expressed as Absolute Changes With 95  Confidence Intervals and as Relative Changes
31102,Total and Early Duration of Repolarization and Heart Rate Corrected QT Intervals in Symptomatic and Asymptomatic LQT1 Patients and Controls  legend
31103,Application of Various Diagnostic Alternatives in LQTS in Regard to Molecular Classification of Patients and Their Relatives
31104,Frequency of the 22q11 Deletion in Patients With a Conotruncal Heart Defect
31105,Association Between Secondary Cardiac Diagnoses and Deletions of Chromosome 22q11 in Patients With TOF, TA, IAA or PMVSD   n   185  , and in Patients With TOF Only   n   126    legend
31106,Predicted Probability of Having a Deletion of Chromosome 22q11 Based on the Full Logistic Regression Model
31107,Summary of Model Fitting Using Logistic Regression Analysis
31108,Odds Ratios and 95  Confidence Intervals Estimated From the Full Logistic Regression Model
31109,Distribution of Clinical Variables  legend
31110,Changes in Hemodynamics and Plasma Norepinephrine Concentration  legend
31112,Benefits of Training on the Incremental Maximal Exercise Test and on the 45 Min Endurance Test  legend
31113,Results of CT of the Thigh before and after 6 Weeks of Training in C and HTRs  legend
31114,Morphometry of Muscle Ultrastructure legend
31116,Coronary Angiographic and Dobutamine Stress Echocardiographic Results for Patients With Both Positive DSE and Coronary Angiography  legend
31118,Electrocardiographic and Radionuclide Data  legend
31120,QRS Duration and Mean EF for the Subgroup of Patients with EF   45    n   80    legend
31121,Quantitative Coronary Angiography and Intravascular Ultrasound Results in 104 Patients With Complete Studies legend
31122,Results in 28 Lesions That Were Restenotic at Follow Up  legend
31123,Subset Intravascular Ultrasound Analyses of Changes in the Cross sectional Area of Lumen External Elastic Membrane and Plaque Media  legend
31127,Summary of Studies on Risk Assessment Using Stress Single Photon Emission Computed Tomographic Technetium 99m Sestamibi  legend
31128,Summary of Studies on Risk Assessment Using Technetium 99m Sestamibi in Coronary Artery Disease legend
31129,Results of Rest Sestamibi Single Photon Emission Computed Tomography in Patients With Chest Pain in Emergency Department legend
31131,Results of Repeated Measures Analysis of Variance  legend
31132,In Vitro Results  legend
31133,In Vivo Results  mean   range
31134,In Vivo Statistics  legend
31135,Inclusion and Exclusion Criteria for Study
31139,Preischemic and Postischemic Functional and Hemodynamic Variables of Different Groups of Hearts
31140,Coronary Vascular Resistance Determined at End of Early and Late Phase of Reperfusion and at End of Postischemic Work Phase
31142,Dobutamine Stress Echocardiographic Results, Cardiac Events, Number of Rejection Episodes and Follow Up Time in 22 Male Study Patients  legend
31144,Number of Rejection Episodes and Angiograms and Date of Event in Three Subgroups of Patients  legend
31146,Selected Variables by Left Ventricular Geometry in Patients With or Without Coronary Artery Disease legend
31148,Adjusted Relative Risk and 95  Confidence Interval of Death Associated With Left Ventricular Geometry in Patients With or Without Coronary Artery Disease
31149,Adjusted Relative Risk   95  confidence interval   of Death Associated With Each 40 g m2Increment in Left Ventricular Mass Index and Each 13  Increment in Relative Wall Thickness
31150,Types of Stenosis
31154,Cardiovascular Events in the Baltimore Coronary Observational Long Term Study
31159,Summary of Results
31162,Clinical Features of Study Groups
31163,Distribution of Coronary Scores
31164,Serum Lipid and Lipoprotein Levels in Study Groups
31165,Adjusted Odds Ratio for Risk of Patients Having Angiographic Coronary Artery Disease   extent score 1    a
31167,Comparison of Changes in Various Hemodynamic Variables With Mental Stress and Exercise in Patients With Coronary Artery Disease and Normal Subjects and Between Mental Stress and Exercise in Each Group
31168,Comparison of Changes in Various Hemodynamic Variables With Mental Stress and Exercise in Patients With a Mental StressInduced Fall in Left Ventricular Ejection Fraction   Group I   and Patients With No Fall in Left Ventricular Ejection Fraction   Group II
31169,Comparison of Changes in Various Hemodynamic Variables Between Two Different Mental Stressors in Patients and in Normal Subjects
31170,Comparison of Changes in Various Hemodynamic Variables With Mental Stress and Exercise in Patients With an Exercise Induced Fall in Left Ventricular Ejection Fraction   Group A   and Patients With No Fall in Left Ventricular Ejection Fraction   Group B
31172,Primary and Secondary Cardiac Events in 357 Patients With Acute Chest Pain and Technetium 99m Tetrofosmin Single Photon Emission Computed Tomographic Imaging
31173,Multiple Logistic Regression Analysis of Univariate Predictors of Acute Myocardial Infarction
31174,Net Cost and Cost Effective Analysis of Early Rest Technetium 99m Tetrofosmin Single Photon Emission Computed Tomographic Imaging in Relation to Varying Intepretation Criteria
31175,Abnormal Rest Myocardial Perfusion Imaging in the Emergency Department for Prediction of Cardiac Death or Acute Myocardial Infarction
31176,Percent Changes in Coronary Artery Lumen Diameter in Response to Acetylcholine
31177,Ventricular Fibrillation, Mortality and Exclusion  a
31178,Myocardial Protection  a
31180,Area at Risk  a
31182,Age Related Coronary Flow Reserve in 47 Patients With Kawasaki Disease and Normal Coronary Arteries   group 1
31183,Coronary Flow Velocity Change in Coronary Aneurysms at Rest and Coronary Flow Reserve in 25 Patients With Kawasaki Disease and Aneurysmal Lesions in 29 Coronary Vessels   group 2
31184,Coronary Flow Velocity Dynamics in 15 Patients With Kawasaki Disease and Stenotic Lesions in 18 Vessels   group 3
31185,Coronary Flow Velocity Dynamics in Eight Patients With Kawasaki Disease and Ischemic Findings on Exercise Stress Testing and Normal Coronary Arteries on Angiography   group 4
31187,Variables Analyzed  a
31188,Exercise Thallium 201 Results in 411 Study Patients
31189,Events During Follow Up
31190,Associations Between Clinical, Exercise and Thallium 201 Imaging Variables With Total Mortality
31191,Associations Between Clinical, Exercise and Thallium 201 Imaging Variables With Initial Cardiac Death or Nonfatal Myocardial Infarction
31192,Associations Between Clinical, Exercise and Thallium 201 Imaging Variables With Initial Cardiac Death, Nonfatal Myocardial Infarction or Late Coronary Angioplasty Bypass Surgery
31193,Associations Between Global Stress and Reversibility Scores and Outcome
31194,Angiographic Results
31195,Diagnostic Performance of Quantitative and Semiquantitative Positron Emission Tomographic Measurements for Detection of Coronary Artery Disease   sensitivity specificity for all regions using a criteria of 2 SD
31197,Age and Gender Distribution of Subjects
31198,Aging Effects on 24 h Heart Rate Variability and Heart Rate by Decade
31199,Effects of Aging on Lower and Upper 95  Confidence Limits of 24 h Heart Rate Variability and Heart Rate  a
31201,Low Heart Rate Variability With Age: Relation to Cutpoints for Risk of Mortality
31206,Hemodynamic and Electrocardiographic Changes  a
31207,Comparison of Thallium 201 and Technetium 99m Tetrofosmin Single Photon Emission Computed Tomographic Dipyridamole Imaging Data in 364 Scan Segments
31208,Inclusion and Exclusion Criteria
31209,Distribution by Randomization Variables  a
31222,Outcome of All Diabetic Patients
31224,Outcome of Insulin Requiring Patients
31227,Effects of 48 Hours of Treatment With NTG or Placebo on Systemic and Forearm Hemodynamic Variables in Patients With or Without Captopril Treatment  a
31228,Pertinent Data in Patients With and Without Coronary Artery Disease
31231,Frequency of Side Effects During Dipyridamole Infusion in Patients With and Without Coronary Artery Disease
31234,Summary of Cardiopulmonary Exercise Responses in the Three Study Groups
31235,Catecholamines and Fibrinolytic and Procoagulant Factors
31236,Whole Blood Flow Cytometry
31237,Categories of Perfusion and Uptake Patterns
31239,Comparative Sensitivity, Specificity, Predictive Values and Accuracy of Perfusion by Myocardial Contrast Echocardiography and Contractile Reserve by Dobutamine Echocardiography in Predicting Late Functional Recovery
31240,Coronary Blood Flow Response to Acetylcholine, Papaverine and Glyceryl Trinitrate
31242,Clinical Outcome of Patients Receiving Vented Electric Outpatient Device Versus In Hospital Pneumatic Device  a
31243,Complications Among Patients Receiving Outpatient Vented Electric Devices and Inpatient Pneumatic Devices
31244,Sample numbers, lithologies and localities within the Newer Volcanic Province of southeastern Australia, of the xenoliths comprising this study
31251,Predicted Volume and 95  Confidence Interval for Discrete Values of Left Ventricular Diameter
31253,Prevalence and Distribution of Valve Excrescences Within Groups
31254,Length and Width of Valve Excrescences
31255,Embolic Substrate in Patients With Suspected Cardioembolism
31256,Prevalence of Valve Excrescences by Etiology of Stroke or Embolism
31259,Histologic and Immunohistologic Findings in 80 Patients With Clinically Suspected Myocarditis With and Without Elevated Levels of Cardiac Troponin T
31260,Clinical Data of 49 Patients With Myocarditis With and Without Elevated Levels of Cardiac Troponin T
31262,Values of Tissue Type Plasminogen Activator, von Willebrand Factor and Plasminogen Activator Inhibitor 1 in Patients With Stable Versus Unstable Angina
31263,Values of Tissue Type Plasminogen Activator, von Willebrand Factor and Plasminogen Activator Inhibitor 1 in Patients Receiving Stents Versus Percutaneous Transluminal Coronary Angioplasty  a
31265,Heart Rate Variability
31266,Heart Rate Variability and QTc Dispersion for the Original Study Cohort According to Presenting Clinical Arrhythmia  a
31267,RR Interval, QT Intervals and QT Dispersion
31268,Sensitivity, Specificity and Positive and Negative Predictive Accuracy of QTc Dispersion and Heart Rate Variability in Predicting Vulnerability to Ventricular Tachyarrhythmias
31269,Preoperative Data
31270,Causes of Death During Long Term Survival
31271,Risk Factors for Short Term Survival
31272,Risk Factors for Long Term Survival
31274,Hemodynamic and Electrocardiographic Variables
31276,Left Ventricular Functional Outcome
31277,Exercise Stress Test Results in Patients and Control Subjects
31278,Doppler Echocardiographic Data at Rest
31279,Dobutamine Stress Hemodynamic Data at Each Stage
31280,Two Way Analysis of Varian Patients Versus Control Subjects and Stage
31281,Peak Stress Data in Patients and Control Subjects
31285,Echocardiographic and Cardiac Catheterization Data
31290,Multivariate Analysis Including Lipid Variables
31291,Percent Intramyocardial Circumferential Shortening, Iodine 123 Metaiodobenzylguanidine Uptake, Myocardial Blood Flow and Blood Flow Reserve by Level in Control Animals  a
31292,Percent Intramyocardial Circumferential Shortening, Iodine 123 Metaiodobenzylguanidine Uptake, Myocardial Blood Flow and Blood Flow Reserve by Level in Animals After Infarction
31293,Regional Myocardial Blood Flow, Blood Flow Reserve and Iodine 123 Metaiodobenzylguanidine Uptake in Control and Animals After Infarction
31294,Results of Visual, Quantitative and Regional Washout Rate
31295,Two Dimensional Echocardiographic Results in All 14 Runners
31296,Hemodynamic Measurements for All 14 Runners
31297,Right Ventricular Echocardiographic Measurements
31298,Comparison of Age, Weight and Oxygen Saturation Levels in Runners Who Developed Right Ventricular Dilation and Those Who Did Not
31302,Mitral Inflow, Pulmonary Venous Flow and Mitral Annulus Velocity in 59 Normal Volunteers
31303,Patient Population
31307,Frequency of Coronary Angioplasty or Bypass Surgery at 42 Days After Thallium 201 Imaging
31309,Ischemia Related Events
31310,Patients With Antianginal Medication
31311,Ischemia Related Events During Withdrawal Period
31312,Comparison of Transesophageal Echocardiographic and Pathologic Grading of Aortic Atheroma  a
31314,Univariate Correlates of Cardiac Outcome With Clinical, Exercise and Echocardiographic Findings
31315,Clinical and Tomographic Data of Heart Transplant Recipients and Normal Volunteers
31316,Effect of Inhaled Nitric Oxide on Steady State Hemodynamic Variables
31317,Effect of Inhaled Nitric Oxide on Load Independent Indexes of Contraction and Diastolic Compliance
31320,Comparison of Lipid and Lipoprotein Values   by p value   in Subjects With Low or High Coronary Flow Reserve
31321,Dobutamine Stress Tele Echocardiography in Emergency Department
31322,Agreement Between Dobutamine Stress Tele Echocardiography and Conventional Interpretation and Predictive Measures of Tele Echocardiography With Clinical Outcome
31323,Dobutamine Stress Tele Echocardiography Versus Other Tests for Clinical Heart Disease
31327,Relative Coronary Flow Reserves for Adenosine and Papaverine and Volumetric Coronary Flow Reserve for Acetylcholine in Five Patients with the Adenosine Defect and Twenty Four Control Subjects
31328,Heart Rate and T Wave During Arousal  a
31329,T Wave Configuration Before and During Arousal
31330,Measured and Interpolated QT Intervals During Arousal
31331,Relation of QT Interval and QT Apex Interval to Cardiac Cycle Length
31332,Measured and Corrected QT Intervals During Arousal
31333,Clinical, Echocardiographic and Angiographic Features of the Study Patients
31338,Effect of Pravastatin on Platelet Aggregability, Prostaglandin Production and Platelet Activity in Hypercholesterolemic Patients
31340,Heart Failure Score Computation
31342,Components of Heart Failure Score in the Patient Groups
31343,Adjusted Risk of Treatment Failure: Mild and Moderate Patient Groups Versus Digoxin Continued Patient Group
31346,Univariate Cox Regression Analysis of Association Between Variables Studied and Survival Time
31347,Multivariate Cox Regression Analysis of Study Variables  a
31351,Mutivariate Analysis of Clinical Variables and QT Dispersion as Predictors of Death in Patients Awaiting Heart Transplantation
31352,Overall and Cause Specific Mortality as a Function of Interlead Variability of the QT Interval
31354,Correlations of Exercise Electrocardiographic Positivity Onset, Recovery Time and Metabolic Equivalents With Angiographic and Scintigraphic Variables
31355,Exercise Electrocardiographic, Angiographic and Scintigraphic Correlations of Slope of Maximal Exercise Induced ST Segment Depression
31356,Correlations of Angiographic and Scintigraphic Variables
31358,Distribution of Confirmed Diagnoses for 10,783 Women and Men
31359,Killip Class Distribution in 894 Patients With Acute Myocardial Infarction  a
31360,Distribution of Hospital Procedures by Gender Among 2,541 Patients With Acute Cardiac Ischemia
31361,Hospital Mortality Rates for Women and Men by Final Diagnosis
31362,Unadjusted Odds Ratios for Hospital Mortality From Acute Cardiac Ischemia
31367,Preoperative Data of 31 Study Patients and Results of Heart Catheterization
31369,Exercise Treadmill Variables in the Four Patient Groups
31370,Exercise Thallium Single Photon Emission Computed Tomography in Patients With a Ventricular Pacemaker
31374,Site of Anomalous Pulmonary Vein Connection
31376,Forearm Blood Flow During Brachial Artery Infusion of Saline, l Arginine Alone, Nitroprusside, Acetylcholine and Acetylcholine Plus l Arginine in Control Subjects and Hypertriglyceridemic Patients
31377,Fast and Slow Pathway Conduction Time
31379,Classification of Embolic Events by Gender
31380,Incidence and Crude Relative Risk of Thromboembolic Events According to Gender and Ejection Fraction Quartile
31381,Univariate Analysis: Relative Risk of a Thromboembolic Event According to Gender
31382,Multivariate Analysis: Relative Risk of Thromboembolic Event According to Gender
31383,Multivariate Analysis: Relative Risk of Thromboembolic Events by Gender After Exclusion of Pulmonary Emboli
31385,Accuracy of Various Modalities in Prediction of Recovery of Function After Revascularization in Severely Dysfunctional Segments
31386,Sensitivity and Specificity of Different Techniques in Hypokinetic and Akinetic Segments
31387,Sensitivity, Specificity and Accuracy for Predicting Recovery of Contractile Function: Analysis by Vascular Territory and by Patients
31388,Independent Predictive Variables Used for Univariate and Multivariate Analysis
31389,Exercise Data During Rest and at Peak Exercise
31390,Univariate and Multivariate Analysis of Predictive Variables for log Vo 2max kg2 3
31391,Univariate and Multivariate Analysis of Predictive Variables for Peak Exercise Oxygen Saturation
31392,Univariate and Multivariate Analysis of Predictive Variables for Maximal Heart Rate
31393,Comparison of Nuclear Imaging and Transient Response Imaging in Detecting Perfusion Abnormalities  a
31395,QT RR Index in the Two Study Groups
31396,Body Weight, Food Ingestion, Serum Lipoprotein Levels and Extent of Intimal Lesions in the Three Study Groups
31397,Maximal Relaxation Responses to Acetylcholine in the Presence of Various Sex Hormones
31399,Multivariate Analysis of Maximal Vasoconstriction on AT1Receptor Genotypes and Covariables
31401,Stepwise Multiple Regression of Predictors of Left Atrial Size
31402,Pulmonary Function Tests in Normal Subjects and Patients With Heart Failure
31403,Hemodynamic, Metabolic and Ventilatory Response to Exercise in Normal Subjects and Patients With Heart Failure Breathing Room Air and Helium During Rest and Exercise
31404,Regional Fluorine 18 Fluorodeoxyglucose Uptake and Nitrogen 13 AmmoniaDetermined Flow, Washout and Volume of Distribution
31405,Accuracy of Nitrogen 13 Ammonia Kinetic Methods for Predicting Viability Defined by Fluorine 18 Fluorodeoxyglucose in Abnormal Regions of 16 Patients
31408,Neurohumoral Variables  a
31411,Effects of Beta Blockers According to Absence or Presence of Neurohumoral Activation in the Neurohumoral Subgroup  a
31412,Cox Proportional Hazards Analysis of Interaction Between Beta Blocker Use and Neurohumoral Activation
31413,Electrophysiologic Anterograde and Retrograde Properties of Atrioventricular Node in Children and Adolescents
31414,Clinical, Angiographic and Hemodynamic Correlates of Collateral Vessels During Coronary Occlusion
31416,Predicted Probability of Recruitable and Spontaneously Visible Collateral Vessels and 95  Confidence Intervals
31418,Cardiac Hemodynamic Variables and Central Venous Pressure Determined in Anesthetized Rats After 9 Month Survival Study
31419,Plasma Renin Activity, Plasma Catecholamine Levels and Cardiac Morphology in Animals Killed After 9 Months
31422,Perfusion and Metabolism Patterns in Myocardial Segments Improving With Dobutamine
31423,Positron Emission Tomographic and Echocardiographic Detection of Myocardial Segment Viability
31424,Treadmill Stress Test Data for 48 Study Patients
31425,Dipyridamole Test Data for 37 Study Patients
31426,Thallium 201 and Technetium 99m Sestamibi Image Quality in 85 Patients and 30 Volunteers
31427,Patient Diagnosis: Thallium 201 Versus Technetium 99m Sestamibi
31429,Mean Rate Corrected QT Values in Blood Relatives From Pooled Genotypically Characterized Long QT Syndrome Families Linked to Chromosome 7q   HERG   or 11p   KVLQT1
31430,Mean Heart Rates in Blood Relatives From Pooled Genotypically Characterized Long QT Syndrome Families Linked to Chromosome 7q   HERG   or 11p   KVLQT1
31431,Mean Absolute QT Values in Blood Relatives From Pooled Genotypically Characterized Long QT Syndrome Families Linked to Chromosome 7q   HERG   or 11p   KVLQT1
31432,Multiple Regression Analysis of Variables Predictive of Rate Corrected QT Interval in Pooled Genotypically Characterized Long QT Syndrome Families Linked to Chromosome 7q   HERG   or 11p   KVLQT1
31433,Multiple Regression Analysis of Variables Predictive of Absolute QT Interval in Pooled Genotypically Characterized Long QT Syndrome Families Linked to Chromosome 7q   HERG   or 11p   KVLQT1
31436,Left Ventricular Angiographic Data in Normotensive and Hypertensive Subjects With and Without Coronary Artery Disease  a
31437,Severity of Atherosclerosis, All Segments  a
31438,Transesophageal Echocardiography Versus Epiaortic Ultrasound, by Segment
31439,Epiaortic Ultrasound and Transesophageal Echocardiography Versus Palpation for Detection of Ascending Aortic Atherosclerosis
31440,Atherosclerosis of Ascending Aorta Versus Aortic Arch and Descending Aorta  a
31442,Results of Morphometric Analysis of Biopsy Samples of Vastus Lateralis Muscle
31443,Sequential Intravascular Ultrasound Analysis   according to individual lesions
31444,Axial Distribution of the Changes in Lumen, External Elastic Membrane and Plaque Plus Media Cross Sectional Areas   according to individual slices
31448,Comparison of Patients With Balanced Versus Unbalanced Common Atrioventricular Canal According to Presence of Down Syndrome, Unrestrictive Ventricular Septal Defect and Hemodynamically Significant Preoperative Atrioventricular Valve Insufficiency
31449,Atrioventricular Valve Index and Ventricular Cavity Ratio  mean   SD    for the Various Study Groups
31452,RR Interval Measurements
31453,Correlations Between Approximate Entropy and Linear Measures of Heart Rate Variability
31457,Functional Outcome in Regions With Mild   sestamibi uptake 51  to 70 , n   27  , Moderate   31  to 50 , n   15   or Severe   30 , n   12   Perfusion Defects by Presence or Absence of Mismatch Pattern  a
31460,GRS of All Lipid Fractions and MAC Association
31461,Triglyceride GRS Associations With Triglycerides and MAC in MESA HispanicAmericans
31463,Forward Stepwise Selection Model for Incident ASCVD
31464,Change in Discrimination With Adding Cholesterol Efflux Capacity to Risk Factors for Incident ASCVD
31465,Net Reclassification of Events and Nonevents With Adding Cholesterol Efflux Capacity to Risk Factors for IncidentASCVD
31466,Distribution of CYP2C19 Genotype and Functional Phenotypes
31468,Association of CYP2C19 Functional Variants   EM vs. RM   With Ischemic Outcomes in Genetics Cohort
31469,Association of CYP2C19 Functional Variants With Longitudinal and 30 Day PRU Values
31472,Evaluation of Model Performance
31475,Clinical Events
31477,Work Related Musculoskeletal Pain and Involvement inProcedures With Radiation Exposure
31478,Medical Conditions Potentially Associated With Radiation Exposure
31482,1 Year Rates of Major Events Stratified by the Severity of Target Lesion Calcification
31484,Risk Factors for Coronary Calcification
31485,Studies of Medical Therapies for Targeting CAC Progression
31486,Outcomes of Studies Comparing DES and BMS in Calcified Lesions
31487,Studies of Cutting and Scoring Balloons in Calcified Coronary Lesions
31488,Studies of High Speed RA in Calcified Coronary Lesions
31489,Studies of Laser Coronary Angioplasty in Calcified Coronary Lesions
31492,Correlation Matrix Between the Number of Lp PLA2 Transcripts and Clinical Data
31494,CHD and CVD Event Rates per 1,000 Person Years and 5 Year NNT for Each of the Polypill Studies
31495,HRs   95  CIs   for CHD and CVD Events With Increasing Burden of CAC for the Polypill Studies
31497,Systolic and Diastolic BF in the 3 Main Intestinal Arteries
31498,Bowel Wall Thickness of Terminal Ileum, Ascending Colon, Transverse Colon, Descending Colon, and Sigmoid in Noncachectic and Cachectic Patients With Chronic HF and Control Subjects
31499,Concentration of Bacteria in Patients With Chronic HF and Control Subjects
31500,Logistic Regression Model With Presence of Cachexia Serving as the DependentVariable
31503,Procedural Outcomes
31505,Clinical Outcomes at 30 Days
31508,Effects of Severe Absolute AVC and Severe AVCdensity on Survival: Univariateand Multivariate Analyses
31511,Angiographic Findings
31513,OCT Measurements of Lipid Plaque
31514,Criteria for Inclusion Into Destination Therapy Clinical Trials
31515,INTERMACS Patient Profiles    20
31516,Risk Factors for RV Failure After LVAD Implantation
31527,Association of LDL C or LDL C Genetic Risk Score With CAC 75th Percentile in the FHS
31528,Association of Lipid Measures or Genetic Risk Scores With CAC 75th Percentile in the Pooled FHS Offspring and Third Generation Cohorts   n   3,110
31529,Association Between Untreated LDL C Level and CAC 75th Percentile at Each Exam Cycle in the FHS Offspring Cohort
31530,Association of HDL C or HDL C Genetic Risk Score With CAC 75th Percentile in the FHS
31531,Association of TG or TG Genetic Risk Score With CAC 75th Percentile in the FHS
31533,ORs and 95  CIs for CAC in Adulthood in a Multivariable Logistic Regression Model   N   563   Adjusted for All of the Listed Variables
31534,Age  and Sex Adjusted Spearman s Correlations Coefficients Between Risk Variables   LDL C and Systolic Blood Pressure   and Regional Calcium Scores
31535,Candidate SNPs, Their Frequencies, and Their Associations With On Treatment Reactivity at 12 to 24 h, 30 Days, and 6 Months After PCI
31539,Descriptive Statistics for the Total Study Cohort and According to Annular or Valvular Calcification Status
31540,Risk Ratios   95  Confidence Intervals   Describing the Associations Among MAC, AAC, and AVSc and Covert Brain Infarcts
31541,Risk Ratios   95  Confidence Intervals   Describing the Associations Among AVSc, MAC, and AAC and High WM Grade    4
31542,Risk Ratios   95  Confidence Intervals   Describing the Associations Among AVSc, MAC, and AAC and Either Covert Brain Infarcts or High WM Grade    4
31543,Covert Brain Infarct Location According to Calcific Annular or Valve Disease Status
31545,CAC Prevalence, Amount, and Number Needed to Screen Compared With Framingham Risk Score Categories
31546,CAC Prevalence and Amount Compared With Framingham Risk Score Categories, Stratified by Sex
31547,Univariate and Multivariable Odds Ratios and 95  CIs for CAC Score 300 by Framingham Risk Score Strata
31548,Morphometric Parameters of Rats at Sacrifice
31550,Cardiac MRI Parameters of Chronic Thromboembolic Pulmonary Hypertension Patients and Healthy Volunteers
31552,Echocardiographic Parameters of Rats at Sacrifice
31553,Agreement Between VECAC and AS in 492 Patients With 2 Readers per Patient
31554,Individual Reader Agreement Between VECAC and AS
31555,Individual Reader Agreement Between VECAC and AS for 99 Cases From Columbia University Medical Center
31556,Agreement Between Readers in 492 Patients
31558,Prevalence of Valvular or Vascular Calcification Stratified by Bisphosphonate Use
31559,Prevalence Ratio for Vascular and Valvular Calcification With Bisphosphonate Use Stratified by Age
31561,Repartition of Genetic Polymorphisms of Cytochrome 2C19 2According to Their Response to the First Loading Dose of Clopidogrel
31562,In Hospital Outcomes
31564,Parameter Estimates and Performance Measures of the Framingham Refitted and the Framingham Plus CAC Models
31565,Cardiovascular Risk Reclassification Comparing the Framingham Refitted Model With the Model Additionally Including CAC
31566,Cardiovascular Risk Reclassification Comparing the Framingham Refitted Model With the Model Additionally Including CAC, by Gender
31568,Number of Coronary Hard Events in the 3 FRS and ATP III Risk Categories and Relative Risks in the HNR Study During 5 Years of Follow Up: Intermediate Risk Thresholds 10  to 20  and 6  to 20
31569,Reclassification of Intermediate   Defined as 10  to 20  and 6  to 20    Risk Participants With or Without Hard Coronary Events During 5 Year Follow Up Based on CAC Results
31570,Reclassification for the Total Cohort Based on Models Using FRS Variables With or Without Hard Coronary Events During 5 Year Follow Up Based on CAC With Definition of Intermediate Risk as 10  to 20  and 6  to 20
31571,Cumulative and Relative Risks of Hard Events Associated With Increasing CAC Scores in the HNR Study
31572,NRI Using Other Variables of Extended Risk Stratification
31573,Multivariate Binary Logistic Regression Analysis for Low Response to Clopidogrel
31574,Multivariable Linear Regression Model for RPA After Stimulation With 5 mol l ADP
31576,Association of Long Term Average of Individual Atherosclerosis Risk Factors   Examinations 1 Through 7   With the Presence of Aortic and Mitral Valve Calcium
31577,Association of Early Atherosclerosis Risk Factors   Examinations 1 Through 3   With the Presence of Aortic and Mitral Valve Calcium
31579,Univariable   Crude   and Multivariable   Adjusted   Logistic Regression Analysis of Factors That May Be Associated With Presence of 50  Coronary Lesions in Patients With 0 Coronary Calcium Score   n   72
31581,Frequency   Percentage   of Noninvasive Test Layering at 6 Months and Downstream Follow Up Testing at 6 Months, 1 Year, and 4 Years of Follow Up in CAC Subsets
31582,Frequency   Percentage   of Noninvasive Test Layering in CAC Subsets
31583,Early and Late Revascularization Rates   Percentage   by CAC Subsets
31584,Estimated Annual Cardiovascular Procedural and Overall   Costs in CAC Subsets
31588,Patient Based Analysis
31589,Vessel Based Analysis
31592,Adjusted HR for Increasing Severity of Limb Ischemia at Presentation
31593,HRs for Major Amputation in Patients Presenting With PAD
31595,G CSF Therapy
31603,Pre Operative Echocardiographic Data of the Study Population
31604,Stent Shape After Deployment According to Aortic Valve Pathology
31612,IVUS and VH Data
31613,Independent Predictors of the Highest HITS Count Tertile by Multivariate Analysis
31614,CFVR Before and After PCI
31616,Comparison Between STR Group and Non STR Group
31617,Prevalence of Cardiac Risk Factors in 14,812 Asymptomatic Individuals Undergoing CAC Screening
31618,Multivariable Model on the Impact of Ethnicity in Clinically Risk Adjusted and Calcium Adjusted Cox Proportional Hazards Models
31619,Multivariable Model RRR for All Cause Mortality by CAC Scores According to Ethnicity
31621,Quintile Ranges for Obesity Measures
31622,C statistic Values for Univariable and Adjusted Models of Prevalent Atherosclerosis
31627,Use of Therapies and Risk Factor Control of Subjects With a Calcium Index   or  Median
31628,Serial Change in Atheroma Burden and Remodeling of Subjects With a Calcium Index   or  Median
31629,Definitions of Tissue Types of Each ROI
31630,Interobserver Variability of Each Imaging Diagnosis
31631,Assessment of IB IVUS and Conventional IVUS for Plaque Characterization
31632,Comparison Between Imaging Diagnosis and Histological Diagnosis
31633,Comparison Between IVUS Diagnosis and OCT Diagnosis
31635,Angiographic Analysis
31636,Qualitative Intravascular Ultrasound Findings
31637,Quantitative Intravascular Ultrasound Findings
31638,Quantitative Analysis of Western Blot and RT PCR
31639,Heart Weight and Histological Data 14 Days After MI
31640,Summary of Results From Ventricular Function Study   45 Min Occlusion Protocol
31641,Summary of Results From Ventricular Function Study   90 Min Occlusion Protocol
31642,Patient Data and Operating Parameters During Patient Exposures
31644,Organ and Effective Dose Values Normalized Over Total Dose Area Product
31645,Patient Peak Skin Dose, Effective Dose, and Gonadal Dose Following Typical Cardiac Rhythm Device Implantation Procedures
31646,Risks for Fatal Carcinogenesis and Severe Hereditary Disorders Following Resynchronization Device Implantation Procedures
31649,Prevalence of Coronary Artery Calcification and Calcium Score in Cases and Controls
31651,Coronary Calcium Score and All CoronaryDisease Events
31652,Univariate Correlations: Standard Risk Factors, C Reactive Protein, and Coronary Calcium Score   n   1,293
31658,Lesion Detection Stenosis 50
31661,Results: Detection of Significant   50    Stenoses With 16 Row Multislice Spiral Computed Tomography Coronary Angiography
31662,Diagnostic Performance of Multislice Spiral Computed Tomography Coronary Angiography for the Detection of Significant Obstructive Lesions
31665,Association Between VE VCO2Slope and Independent Variables in Univariate and Multivariate Analysis
31666,Association Between Lean Peak VO2and Independent Variables in Univariate and Multivariate Analysis.
31668,Blood Hormone and Cytokine Analyses
31669,Biochemical Parameters and Vitamin D Receptor Genotype of Patients With Congestive Heart Failure and of Elderly Controls
31670,Cardiovascular Risk Variables Among White and Black Patients Studied With Coronary CT
31671,Coronary Calcium Scores and Prevalence in Black and White Subjects
31672,Logistic Regression Coefficients and Confidence Intervals for a Multivariate Model Evaluating Associations With Coronary Artery Calcium
31673,Data Abstracted From Questionnaire, Telephone Interview and Medical Record Review
31674,Spectrum of Disease in Pregnant Women With History of Aortic Coarctation
31675,Obstetrical and Neonatal Data for 118 Pregnancies
31676,Contingency Table of Relation Between Hypertension During Pregnancy and Presence of Coarctation
31678,Calcium Scores in Symptomatic Men and Women legend
31679,Calcium Score Nomogram for 1,764 Symptomatic Subjects
31680,Exclusion of Coronary Calcium   Score   0   legend legend
31681,Sensitivity and Specificity of Coronary Calcifications at Different Score Levels legend
31683,Cardiac Risk Factors legend
31685,Prevalence of Detectable Calcium   score   0   and Mean Calcium Score
31686,Relation of Lipoprotein  a   and the Other Variables to Calcium Score legend
31689,Total Calcium Score Quartiles, NCEP Risk Groups and Radionuclide Imaging Score Quartiles as a Function of CAGE 20 or CAGE 50 Scores
31690,Multiple Linear Regression Analysis to Determine Independent Predictors of the Number of Angiographic Segments with 20  or Greater Maximum Stenosis   CAGE 20 score   or 50  or Greater Maximum Stenosis   CAGE 50 score   legend legend
31691,Coronary Heart Disease Risk Factors and Ethnicity legend
31692,Medication Use by Race
31693,Comparison of the Topological Distributions of Coronary Calcium by Race legend
31694,Independent Predictors of the Presence of Any Coronary Calcium legend
31695,Coronary Events and Ethnic Origin at 70 Months of Follow up legend legend
31696,Race, Calcification and Coronary End Points legend
31697,Independent Predictors of Any Coronary Event by Multivariate Logistic Regression, Along With Odds Ratios and 95  Confidence Intervals legend
31698,Distribution of the Study Population According to the Type of Prosthesis Implanted and the Valve Involved
31699,Outcome of Pregnancies legend
31700,Survey of Three Previously Published Studies Using EBCT and Any Coronary Calcium   i.e., a Score  0   for the Diagnosis of Obstructive Coronary Disease   50  Stenosis at Angiography   legend
31701,Input to the Model   Noninvasive Testing and Angiography   legend
31702,Number of Patients out of 100 in Each Prevalence Group and for Each Testing Pathway Undergoing Angiography Directly or for a Positive or Nondiagnostic Noninvasive Test legend
31703,Total Combined Costs per Patient for Each of the Eight Diagnostic Testing Pathways as a Function of Prevalence of Coronary Artery Disease in the Population Tested legend
31704,Percentage of Patients Correctly Diagnosed   True Positive Rate   and Absolute Number   in Parentheses   With Obstructive Coronary Disease out of 100 Tested in Each Prevalence Group at Completion of Any Testing Pathway legend
31705,Cost Effectiveness   Total Direct Costs in Dollars per Patient Correctly Diagnosed With Obstructive Coronary Artery Disease   for the Individual Diagnostic Testing Pathways legend
31706,Negative Predictive Value of Testing Pathway as a Function of Prevalence of Disease in the Population Tested legend
31707,Positive Predictive Value of Testing Pathways as a Function of Prevalence of Disease in the Population Tested legend
31710,Independent Predictors of Angiographic Three Vessel and or Left Main Disease legend legend
31711,Predictive Power of the Noninvasive Index legend
31712,Distribution of Continuous Variable Risk Factors legend
31713,Distribution of Coronary Calcium Scores for Each Category of Disease
31714,Association of Risk Factors for Coronary Disease and the Coronary Calcium Score With the Presence of Any Angiographic Coronary Artery Disease by Multiple Logistic Regression  legend
31715,Association of Risk Factors for Coronary Disease and the Coronary Calcium Score With the Presence of Angiographic Obstructive Coronary Artery Disease by Multiple Logistic Regression  legend
31716,Odds Ratio for Any Coronary Disease and Obstructive Coronary Disease, Highest Quartile Vs. Lowest Quartile, by Multiple Logistic Regression  legend
31719,Operator Reasons for Not Stenting 72 Lesions  a
31720,Site and Core Laboratory Angiographic Measures
31721,Major In Hospital Adverse Effects in 312 Patients
31722,Predischarge Cardiac Catheterization: Indications and Findings
31723,Adverse Events Occurring Within 30 Days After Hospital Discharge
31724,Left Ventricular Hypertrophy and Blood Pressure legend
31726,Tissue Cyclic GMP Levels legend legend
31727,Classification of Coronary Calcifications Observed on Electron Beam Computed Tomographic Images
31728,Morphologic Classification of Segments With Calcification
31729,Prediction of All Coronary Atherosclerotic Lesions by Calcification According to Segment  a
31730,Prediction of Significant Coronary Stenosis by Calcification According to Segment  a
31731,Positive Predictive Value of Calcification Morphology for All Coronary Atherosclerotic Lesions According to Patient Age
31732,Positive Predictive Value of Calcification Morphology for Significant Coronary Stenosis According to Patient Age
31733,Prevalence of Aortic Valve Abnormalities by Echocardiography
31734,Bivariate Relations of Clinical Variables to Aortic Valve Abnormalities
31735,Clinical Factors Associated With Aortic Stenosis or Sclerosis by Stepwise Multiple Logistic Regression
31736,Interlesion Comparison in Intravascular Ultrasound Calcification   in 521 patients with two lesions imaged
31737,Correlates of Intravascular Ultrasound Target Lesion Calcium
31744,Multivariable Logistic Regression Model for Prediction of AoD
31746,Annual Hospitalizations   2011
31747,Cost     and Cost Differences   Between Smokers and Nonsmokers   2011
31751,Average BW, HW, Ratio of BW to HW, and BloodGlucoseLevels of T2DM and Control Animals
31754,Comparison of Compliance With Coronary Artery Disease Measures Among Patients Receiving Care From Advanced Practice Providers and Physicians
31755,Comparison of Compliance With Heart Failure and Atrial Fibrillation Measures Among Patients Receiving Care From Advanced Practice Providers and Physician Providers
31756,Comparison of Compliance With Coronary Artery Disease Performance Measures Between Practices With Both Physician and Advanced Practice Providers and Physician Only Practices
31757,Comparison of Compliance With Heart Failure and Atrial Fibrillation Performance Measures Between Practices With Both Physician and Advanced Practice Providers and Physician Only Practices
31759,Major Bleeding Events During Hospitalization in theStudy Population   n  154
31760,Reasons for Procedural Failure of Left AtrialAppendage Ligation With the Lariat Device   N  22
31761,Medical Therapy at Discharge After TranscatheterLeftAtrial Appendage Ligation   n  154
31762,Description of the Prospective Randomized Pooled Trials
31765,Clinical Outcomes at 30 Days and 1 Year According to Diabetic Status
31769,Angiogenesis Inhibitors and Stimulators
31770,Examples of Animal and Human Studies Implicating Monocytes in Angiogenesis
31771,Family of VEGF and Their Functions
31772,Monocytes Subsets and Their Functions
31773,Left Ventricle Remodeling and Dysfunction by Echocardiography at 1 and 30 Days After Myocardial Infarction
31774,Effect of MSC Therapy on Global LV Remodeling and Function With and Without Macrophage Depletion by Conventional Echocardiography at 1 and 7 Days After Myocardial Infarction
31775,Effect of MSC Therapy With and Without Macrophage Depletion on Regional and Global LV Function by Speckle Tracking Based Strain Imaging in Parasternal Long Axis View
31776,Components of the Metabolic Syndrome
31777,Age Standardized Prevalence of the Metabolic Syndrome in the United States, 1999 to 2010
31779,Grades of Stenosis Severity and In Stent Minimum Lumen Diameter on Follow Up Coronary Angiography in Patients With Restenosis   N   48
31782,Incidence of Death or MI and Death After Clopidogrel Cessation
31783,Multivariate Analyses for Selected Subgroups for Risk of Death or MI in 0  to 90 Day Interval After Clopidogrel Cessation Compared With Subsequent 91 to 365 Days
31784,Reclassification of Study Participants Into MI Risk Groups by Addition of miR 126, miR 197, and miR 223 to a Model With the FRS for Hard Coronary Heart Disease
31785,Summary Statistics of MI Risk Reclassification by Addition of miR 126, miR 197, and miR 223 to a Model With the FRS for Hard Coronary Heart Disease
31786,Lack of Association Between SNPs in PLA2G7 and Circulating Lp PLA2 Protein Mass or Activity But Significant Relation of Multiple SNPs in CRP With Circulating CRP Levels
31787,Association of SNPs in PLA2G7 But Not in CRP With CAC
31789,Laboratory Measurements
31791,Angiographic Results, Revascularization Procedure, and Biological Data   n   45
31794,2 Way Contingency Tables for Biomarker Detection of CMR LGE
31796,Hazard Ratios of Heart Failure According to Different Levels of Occupational Physical Activity
31797,Hazard Ratios of Heart Failure According to Different Levels of Commuting Physical Activity
31798,Hazard Ratios of Heart Failure According to Different Levels of Leisure Time Physical Activity
31800,Kaplan Meier Cumulative Incidence of Adverse Outcomes at 4 Years
31802,Inflammatory Markers According to Incident HF Development
31806,Per Cell Fluorescence 24 h After IV Injection
31807,Heart and Body Weights
31809,Outcomes
31811,Novel Cardiovascular Risk Factor Concentrations by Race
31813,Odds Ratio of Peripheral Arterial Disease Among African Americans Compared With Caucasians Across Studies
31815,Composition of Cocoa Drinks
31820,Prediction of MI Risk by Overall Anxiety in Multivariate Cox Regression Models Controlling for Age, Education, Marital Status, Fasting Glucose, BMI, HDL C, SBP, and Additional Psychologic Variables   n   735
31824,Incidence of Stroke or Non CNS Systemic Embolism in Patients With Paroxysmal Versus Persistent Permanent AF Treated With Aspirin Plus Clopidogrel or OAC
31825,Effect of Allocated Treatment on the Incidence of Total and Major Bleedings in Patients With Paroxysmal Versus Persistent Permanent AF
31830,Guideline Based Medication and Invasive Procedure Use
31831,Guideline Based Discharge Therapies
31834,Hemodynamic and Angiographic Measures at Pre  and Post Treatment
31835,Histomorphometric Measures
31838,In Hospital, 30 Day, and Follow Up Clinical Events in the 2 Groups
31839,Quantitative Coronary Angiographic Data
31841,Prevalence of Metabolic Syndrome Components by Case Control Status
31842,Adjusted    Association Between Joint Categories of Metabolic Syndrome   MetS   and Diabetes and Early Onset Coronary Artery Disease
31843,Adjusted    Odds Ratios   95  Confidence Intervals   of Early Onset Coronary Artery Disease Associated With Categorically Defined Components of the Metabolic Syndrome   MetS   and With the Syndrome Above and Beyond Its Components
31844,Adjusted    Odds Ratios   95  Confidence Intervals   of Early Onset Coronary Artery Disease Associated With Continuously Defined Components of the Metabolic Syndrome   MetS   and With the Syndrome Above and Beyond Its Components
31849,Quantitative Coronary Angiographic Data
31850,In Hospital and Follow Up Clinical Events in the Total Cohort, According to the Pattern of Restenosis
31852,Outcomes of Non Diabetic Patients Compared With Diabetic Patients
31856,Weekly Frequency Consumption   in Servings   of Several Food Groups, According to the Mediterranean Diet Score
31857,Inflammation and Coagulation Markers by Tertile of the Mediterranean Diet Score
31858,Results From Multivariate Regression Analysis   Beta Coefficient  SE   Regarding the Association Between the Mediterranean Diet Score   per 10 U Increase   and Inflammatory and Coagulation Markers in Subgroups of Participants
31860,Antioxidant Consumption in Patients With Acute Myocardial Infarction   Group 2, n   74
31861,Cytokines in the Study Population
31862,Contrast Perfusion and Pathologic Diagnosis of Cardiac Masses
31863,Subset of Masses With Quantitative Echocardiographic Perfusion
31864,Specification of the Primer Sets Used to Analyze Messenger Ribonucleic Acid Expression
31866,Effects of Placebo or Oral Candesartan on Lipids and Endothelial Function in Hypertensive Patients
31868,Local Skeletal Muscle Cytokine and iNOS Expression
31869,Assessment of the Systemic Parameters of the Recipient After Surgery
31870,Morphometric, Echocardiographic, and Hemodynamic Assessment of the Donor Heart
31871,Morphometric, Echocardiographic, and Hemodynamic Assessment of the Recipient Heart
31872,Fundus Findings of Type 2 Diabetic Patients Who Underwent CABG
31874,Causes of Death According to the Presence or Absence of Diabetic Retinopathy During the Entire Follow Up
31875,Multivariate Analysis Among Diabetics With Retinopathy and Diabetics Without Retinopathy Who Underwent Coronary Artery Bypass Graft Surgery
31876,Association Between Severity of Diabetic Retinopathy and Overall Mortality After CABG Among Type 2 Diabetic Patients
31877,The Demographics of the Unstable Patients Divided According to the Subsequent Occurrence of MACE
31883,Correlations of Leukocyte Mitochondrial Transmembrane Potential With Clinical Markers of Congestive Heart Failure
31884,Outcomes of Recipient Twin Fetuses With RVOTO
31885,Morphometric Results legend
31890,Side Branch Occlusion: Initial Stenting versus Treatment of In Stent Restenosis. SB Occlusion   TIMI flow grade 0   During Intervention for In ST Restenosis   n   24      legend
31894,Changes in Heart Rate and Blood Pressure After Albuterol and Glyceryl Trinitrate in Patients With Type II Diabetes Mellitus and Control Subjects legend
31896,Comparison of Solubilized Adhesion Molecules and Cytokine Receptors Between Patients With Coronary Heart Disease and Control Subjects legend legend
31897,Comparison of Age and Serum Levels of Solubilized Adhesion Molecules and Cytokine Receptors by Receiver Operating Curve Analysis With Respect to the Presence of Coronary Heart Disease legend
31898,Multiple Logistic Regression Analysis of the Association Between Age, Serum Levels of Solubilized Adhesion Molecules and Cytokine Receptors and the Presence of Coronary Heart Disease as an Independent Variable legend
31899,eNOS and MCP 1 Specific Primers
31903,Logistic Regression Analysis of Combined Major Events legend
31904,Major Recent Trends legend
31906,Natural Variability in Cytokine Receptors legend legend
31907,Determination of Sample Size to Show Statistically Significant Changes in Cytokines and Cytokine Receptors legend
31909,Procedural Success and Complications of Angioplasty
31910,Logistic Model for In Hospital Death legend
31911,Effects of Denopamine on HW BW and Myocardial Histology on Day 7  legend
31912,Effects of Denopamine on HW BW and Myocardial Histology on Day 14  legend
31913,Effects of Denopamine and Metoprolol on HW BW and Myocardial Histology on Day 6  legend
31914,Mortality from Day 7 to Day 14  legend
31915,Frequency of Genotypes of Endothelial Nitric Oxide Synthase Gene in Control Subjects and Patients With Myocardial Infarction legend
31917,Results of Multiple Logistic Regression Analysis: Final Significant Variables in Equation Using Forward Stepwise Selection   Wald
31919,Results of Cytokine Assays With Log Transformed Data
31920,Results of Serum Urea, Creatinine Albumin and Protein Estimations
31922,Coronary SinusAortic Differences in Leukocyte mRNA Expression After Incubation With Plasma From Patients With an Acute Myocardial Infarction   percent of glyceraldehyde 3 phosphate dehydrogenase
31923,Location of Papillary Fibroelastomas in Groups 1 and 2
31924,Presenting Symptoms of Patients With Papillary Fibroelastoma
31925,Indications for Echocardiography
31926,Interstitial Heart Disease Can Occur as a FinalCommon Pathway From a Variety of MyocardialInsults
31927,Treatments Targeting Myocardial Fibrosis in Development
31929,High On Treatment Platelet Reactivityin Very Elderly and Nonelderly Patients Treated With Prasugrel   5 mg or 10 mg   or Clopidogrel   75 mg
31930,Bleeding Events Related to Study Drug in Very Elderly and Nonelderly Patients With Stable Coronary Artery Disease Treated With 5 mg Prasugrel, 10 mg Prasugrel, and 75 mg Clopidogrel
31933,Primary and Secondary Endpoints
31935,Subjects With Drug Related Treatment Emergent Adverse Events in the Safety Population
31938,Age Adjusted CVD Incidence Rates According to Framingham Risk Score and ED Status
31939,The Relationship Between ED and CVD in Various Multivariate Models
31940,Discrimination of CVD in Various Multivariate Models
31943,Overall Incidence of AEs, Discontinuations Due to AEs, and AEs Occurring in 2  of Patients During the Double Blind Treatment Period   Safety Population, n   672
31946,Descriptive Anthropometric and Cardiac Variables of the Whole Sample
31947,Clinical Variables According to the C664G ANP Polymorphism Genotypes
31948,Echocardiographic Variables According to the C664G ANP Polymorphism Genotypes
31949,One Way ANOVA Adjusted for the Following Covariates: Age, Gender, Body Mass Index, BP, Duration of Hypertension, 24 h Urinary Na Output, ALDO PRA Ratio, With the ANP C664G Polymorphism as Independent Variable
31950,Clinical Variables According to the NPRA Genotypes
31951,Echocardiographic Variables According to the NPRA Genotypes
31954,Correlational Analysis Between Forearm Blood Flow as Dependent Variable, ADMA, L Arginine, and L Arginine ADMA
31955,5 Item International Index of Erectile Function   IIEF 5
31957,Age Adjusted Mean Heart Disease Risk Factors by Erectile Dysfunction Category for Men in the Rancho Bernardo Study, 1972 to 1974
31958,Primer Pairs and Probes for T786C and Glu298Asp Polymorphisms
31966,ACE and AGT Genotype Distribution in Cases and Controls legend
31967,AGT   M235T   Genotype Distribution in Hypertensives and Normotensives
31968,Estimates of Risk of CHD Associated With Clinical, Biochemical and Angiotensinogen Genotypes   Adjusted for Multiple Risk Factors   legend
31971,Correlation Coefficients Between Indexes of Cardiac and Vascular Structure in the Different Groups
31972,Incidence and Total Number of Atherosclerotic Plaques in the Carotid Arteries  legend
31974,Cardiac Magnetic Resonance Data in Patients and Control Subjects
31975,Myocardial T1 Values in Healthy Control Subjects and Patients With CAD at 1.5 T
31976,Myocardial T1 Values in Healthy Control Subjects and Patients With CAD at 3 T
31978,Coronary Physiology and CMR Parameters
31980,Changes After Aortic Valve Replacement   N 116
31983,The Relationship of LV T1 Indices With Plasma Log NT proBNP
31984,Cross Sectional Association Between CMR Markers of Fibrosis and Log NT proBNP in the Fully Adjusted Model
31988,Clinical Outcomes at 30 Days and 1 Year
31991,HRs With 95  CIs for All Cause Mortality, MI, and Heart Failure in Relation to hs cTnT Levels in 19,460 Patients With No MI
31993,Comparison of Marfan Patients in GenTAC Who Completed the SF 36 Versus Those Who Did Not
31994,Bivariate Analysis of PCS Subscale Scores and Composite Scores With GenTAC Variables
31995,Association of Unable to Work Due to Disability and Other Variables
31996,Adjusted Model of PCS Composite and Subscale Scores
31997,Comparison of SF 36 PCS Scores in MFS Patients Across Different Studies
31998,Performance in the PAL Test, Estimated Difference in Cognitive Age, and Mean Values of Risk Factor Variables Across the Early Life Cumulative Cardiovascular Risk Factor Burden
31999,Associations Between Cumulative Burden of Early Life Vascular Risk Factors   Age 6 to 24 Years   and Midlife Visual and Episodic Memory and Visuospatial Associative Learning   PAL Test   in 1,733 YFS Participants
32001,Cumulative Event Rate by Treatment Strategy
32002,Multivariate Predictors of Death or Spontaneous MI at 10 Year Follow Up
32003,Hemodynamic Classification of Pulmonary Hypertension
32007,Univariate and Multivariate Associations of Cpc PH in PH LHD
32008,Unadjusted and Adjusted Hazard Ratio for Mortality in Cpc PH Compared With Ipc PH
32009,Significant Gene Ontology Groups Identified for the 141 Genes Associated With Cpc PH and PAH Compared With Ipc PH Control Subjects
32016,Association Between TMAO and SYNTAX Scores and hs cTnT
32020,Measurements of Myocardial Water Content in the Ischemic and Remote Myocardium at Different Time Points During the First Week After I R
32022,Ischemic and Bleeding Outcomes in all Randomized Patients, According to Acute Myocardial Infarction Status, From12 to 30 Months After Coronary Stent Treatment
32023,Ischemic and Bleeding Outcomes 12 to 30 Months After Coronary Stent Treatment in all Randomized Patients, Stratified by Presentation With Versus Without Acute Myocardial Infarction
32025,Comparison Between Models With and Without ECG Changes and Resting Heart Rate
32026,Model Validation
32027,Calculating 10 Year Risk of Fatal CVD and of Fatal or Nonfatal CVD
32033,The 99th Percentile Values and Corresponding 95  CIs for hs cTnT and Percentiles Corresponding to cTnT  14 ng l in Subcohorts 1     of the DHS, ARIC, and CHS Studies, With Further Stratification by Sex, Age, and Race
32034,The 99th Percentile Value for the hs cTnT Assay, With 95  CIs, and Percentiles Corresponding to cTnT  14 ng l in Subcohorts 2     of the DHS, ARIC, and CHS Studies, With Further Stratification by Sex, Age, and Race
32035,The 99th Percentile Values for the hs cTnT Assay   ng l   Stratified by Sex, Age, and Race in DHS Study Subcohort 2: Sensitivity Analyses
32037,Cardiac Catheterization Data
32038,Cardiac Magnetic Resonance Imaging and Echocardiography Data
32048,TAVR Implants in Each Nation
32049,Implant Centers
32050,TAVR Penetration, 2011
32051,Economic Indexes and Reimbursement Schemes
32057,Values of NRI and IDI for Myocardial Infarction and Coronary Heart Disease for Extreme Lipoprotein  a   Levels, for Risk LPA Genotypes, and for Combinations of Extreme Levels and Risk Genotypes
32059,Follow Up Events and Combined Endpoints
32060,Univariate Analysis of Factors Associated With All Cardiac Events
32063,Adverse Events
32065,X ray Angiography Data
32066,CMR Data
32067,Sensitivity and Specificity of 3D Whole Heart Myocardial Perfusion CMR Versus Coronary Angiography and FFR on Patient Basis
32068,Sensitivity and Specificity of 3D Whole Heart Myocardial Perfusion CMR Versus Coronary Angiography and FFR on Coronary Territory Basis
32069,Sensitivity and Specificity of 3D Whole Heart Myocardial Perfusion CMR Versus Coronary Angiography and QCA on a Patient Basis
32070,Ischemia Volumes According to 3D Whole Heart Myocardial Perfusion CMR and Duke Jeopardy Scores   n   53
32072,Genotype Frequencies in the Study Population
32073,Logistic Regression Analysis of Genetic Predictors of Response to AADs
32074,Response       Distribution of AAD by Class Among Responders for SNP rs10033464
32075,Distribution of AF Recurrence by Genotype
32076,Multivariable Logistic Regression Analysis for Genetic Predictors of AF Recurrence
32077,Global RV Volumes and Hemodynamics
32078,Preload Independent Indices of Systolic and Diastolic RV Function
32080,Odds Ratios   95  CI   for Elevated hs TnT by Clinical Categories of HbA1c
32081,Odds Ratios   95  CI   for Elevated hs TnT by Clinical Categories of Glucose
32082,Hemodynamic Status Measurements of Myocardial I R Mice
32083,Hemodynamic Status Measurements of Il17a  Mice After I R
32086,Univariate and Multivariate Predictors of Recurrent ISR
32087,Univariate and Multivariate Predictors of Recurrent Occlusion
32089,Fibrosis and Fatty Tissues in Relation to Age and AF History
32090,Inflammatory Cell Count in Major Atrial Pathways and Posterior Left Atrial Wall in Patients With and Without AF History
32098,Invasive Techniques for Imaging the Vulnerable Plaque
32100,Noninvasive Technique for Imaging the Vulnerable Plaque
32104,Image Quality Scoring of Dynamic 3D CMR Perfusion
32107,Timing of  Blocker Initiation Before Surgery and Post Operative Outcome
32108,Association of Time, Between Timing of  Blocker Initiation and Presence of 30 Day Cardiovascular Events in Vascular Surgery Patients
32109,Association of Time, Between Timing of  Blocker Initiation and Long Term Mortality of Vascular Surgery Patients
32115,Univariable and Multivariable Determinants of Favorable Response to CRT
32117,Impact of High Heart Rate on Image Quality Score of Whole Heart Coronary MRA
32118,Diagnostic Accuracy of Whole Heart Coronary MRA Compared With Radiographic Angiography
32120,Impact of BMI on Diagnostic Performance of Whole Heart Coronary MRA
32122,Imaging Findings
32124,Cumulative Event Rate and Hazard Ratios of the Composite Outcome and the Individual Outcomes at 5 Years
32130,Summary of Study Results
32131,Inclusion and Exclusion Criteria for Patients With ICDs
32132,Study Design for ICDs in the MRI Environment
32134,ICD Data Before and After MRI and at Follow Up in 18 ICD Patients
32138,Image Quality of 62 Patients With Successful CMRA
32139,Diagnostic Performance of 3.0 T Contrast Enhanced Whole Heart CMRA
32142,Copeptin Value Used With Troponin T 0.01 g l at Presentation to Rule Out Acute Myocardial Infarction
32145,Exercise and Hemodynamic Results After Randomization
32148,Predictive Value for the 20 V Cutpoint
32149,Predictive Value for the 60 V Cutpoint
32150,Unadjusted and Adjusted Hazard Ratio Values for the Sensitive   20 V   and Specific   60 V   Cutpoints
32152,Myocardial Function and Mass in Infarct Typical, Infarct Atypical, and Combined CE MRI
32153,Independent Variables Examined in the Multiple Regression Models
32156,Coefficients of Determination for PHN Fontan Patients Without Pacemakers That Achieved a Maximal Aerobic Capacity   n   140
32157,Regression Results for PHN Fontan Patients Without Pacemakers That Achieved a Maximal Aerobic Capacity
32164,Procedural Results
32165,ST Segment Monitoring Data
32167,Culprit Drugs
32170,Multivariate Logistic Regression Analysis
32172,Results of Timing Parameters in 21 Patients and 11 Healthy Control Subjects
32173,Paired Samples t Tests   2 tailed   Between Timing Parameters of the Patients
32174,Results of Linear Regression Analysis
32176,Performance of Biomarker Estimates of Infarct Size in Various Categories
32177,Independent Predictors of Infarct Size
32184,Predictors of Long Term Outcome in Unstable Angina
32188,Clinical Outcome in Patients Stratified According to Responsiveness to Clopidogrel and Ticlopidine
32193,Data for Quantitative Coronary Angiography and Intravascular Ultrasound
32194,Simple Regression Analysis With Percentage Lipid Volume or Percentage Fibrous Volume As the Dependent Variable
32195,Multiple Regression Analysis With Percentage Lipid Volume   r   0.40, p   0.01   or Percentage Fibrous Volume   r   0.37, p   0.03   as the Dependent Variable
32196,Logistic Regression Model for Prediction of Lipid Rich Plaque
32198,Percentage WT of Intra Acinar Pulmonary Arteries With ED From 50 to 200 m
32200,Regional Detection of Q Wave and NonQ Wave Infarction by CMR and SPECT
32202,Statistical Association of 11 Risk Variables With Serious Arrhythmic Events in Univariate and Multivariate Analyses
32203,Predictive Values of Positive Microvolt T Wave Alternans, Nonsustained Ventricular Tachycardia, and Ventricular Late Potentials Risk Variables With Serious Arrhythmic Events
32205,Distribution of the Patients in the Categories of CAD Atherosclerotic Burden Estimated With a Modified Duke Index Prognostic Score
32207,History and Medical Treatment in the Patients Stratified by T786C eNOS Genotype
32208,Allele Frequencies and Pairwise Linkage Disequilibrium D Between C894T and T786C Polymorphisms
32209,Estimated Haplotype Frequencies Under Linkage Disequilibrium in Non CAD and CAD Patients
32210,Cardiovascular Death Free Survival at Cox Regression Analysis
32212,Effects of Beta Blockers on 24 h ECG Parameters in 24 LQT1 Patients
32214,Incremental Cost Effectiveness Ratios in Base Case Estimates
32218,30 Day Outcomes
32219,Quantitative Coronary Angiography in the Main Stented Branch
32221,Comparison of Target Ablation Time in Remote and Standard CPVA
32223,Pulmonary Function and Inspiratory Muscle Function Tests Before and After Intervention for Patients Randomized to P IMT or IMT
32224,Results Obtained in the Maximal Cardiopulmonary Exercise Test for the P IMT and the IMT Group
32226,Procedural Variables
32229,30 Day and Long Term Outcomes
32230,Quantitative Coronary Angiography Analysis of the Main Branch
32231,Quantitative Coronary Angiography Analysis in the Side Branches
32232,Quantitative Intravascular Ultrasound   IVUS   Results
32233,Multivariable Adjusted Hazard Ratios for the Incidence of Death or Myocardial Infarction During Long Term Follow Up
32235,Individual Event Rates   Event Month   and Therapy Episodes   Episode Month   of Patients Pre  and Post CRT Implantation
32236,AUC of the Different Parameters After the Ingestion of a Phenol Rich Olive Oil Meal   400 ppm   as Compared to a Low Phenol Olive Oil Meal   80 ppm
32237,Postprandial Changes of Nitrates Nitrites, Lipoperoxides, and 8 epi Prostaglandin Plasma Levels After the Ingestion of a Phenol Rich Olive Oil Meal   400 ppm   as Compared to a Low Phenol Olive Oil Meal   80 ppm
32238,Multiple Regression Analysis for Variations in Ischemic Reactive Hyperemia, Oxidative Stress Markers, and NO  x  Plasma Concentrations
32240,Results of 19 Prospective Studies of Microvolt T Wave Alternans
32241,Summary Estimates of PPV, NPV, and Univariate RR in 19 Prospective Studies of Microvolt T Wave Alternans for the Prediction of Cardiac Arrhythmic Events
32242,Summary Estimates of PPV, NPV, and Univariate RR in Prospective Studies of Microvolt T Wave Alternans for the Prediction of Primary versus Secondary Arrhythmic Events
32243,Multivariate Predictive Value in Three Prospective Studies of Microvolt T Wave Alternans
32246,Clinical, Morphologic, and Morphometric Data
32247,Distribution of the Various Plaque Types in the Three Groups of Patients
32248,Distribution of the Various Plaque Types and Quantitative Evaluation of Inflammatory Infiltrate Present in the Plaques of Patients Dying of AMI
32250,ECG and intracardiac temporal and spatial regularity
32253,Comparison of Parameters of Systolic Asynchrony Derived by TSI Between Responders and Nonresponders of Left Ventricular Reverse Remodeling
32254,Correlation Analysis Between Parameters of Systolic Asynchrony Measured by TSI and LVESV or Absolute Gain in Ejection Fraction after CRT
32256,The Cutoff Values of Each Parameter of Systolic Asynchrony Measured by Tissue Synchronization Imaging for the Prediction of Reverse Remodeling With Corresponding Sensitivity and Specificity
32257,MCE versus PET: Summary of Hemodynamic and Perfusion Data at Rest   20 Volunteers   and During Hyperemia   5 Volunteers
32262,Multivariable Logistic Regression Model for Death and Nonfatal Myocardial Infarction During Six Months of Follow Up
32263,Multimarker Assessment: Stepwise Multivariable Logistic Regression Model for Death and Nonfatal Myocardial Infarction During Six Months of Follow Up
32267,Short Form 36 Component Scores at Four Month and One Year Follow Up
32268,Seattle Angina Questionnaire Components at Four Month and One Year Follow Up
32278,Association of Preoperative Thalium and Coronary Revascularization With Postoperative Ischemia and Infarction
32279,Peoperative Predictors of Postoperative Troponin   Logistic Regression Analysis
32280,Peoperative Predictors of Postoperative Troponin as Selected by the Multivariate Logistic Regression Analysis
32282,Serious Complications Classified According to the Mode of Detection
32283,Alert Events Caused by Serious Complications   n   14     True Positives
32284,Alert Events Caused by Non Serious Complications   n   10     False Positives
32285,Hemodynamic Parameters and Coronary Diameters Pre  and Post Mibefradil in 10 Patients With the CSFP
32286,Changes in Hemodynamic Parameters During Four Weeks of Placebo and Mibefradil 100 mg Therapy in 20 Patients With the CSFP
32287,Median Values   25 , 75  Interquartile Ranges   of Total Anginal Episodes, Prolonged Anginal Episodes   i.e.,  20 Min   and Sublingual Nitrate Consumption During Four Weeks of Placebo and Mibefradil 100 mg Therapy in 20 Patients With the CSFP
32288,The SF 36 Scores in 20 Patients With the Coronary Slow Flow Phenomenon, After Four Weeks of Placebo or Mibefradil Therapy
32290,Cardiac Outcomes and Test Results Based on Peak Cardiac Troponin I Value
32292,Presenting Symptoms Signs of Patients With Dissection of the Aorta, Based on Age Category
32294,Aortic Dimensions Among Patients  40, With or Without Marfan Syndrome in the International Registry of Aortic Dissection
32295,Complications of Aortic Dissections, Based on Age
32296,Patients With Kawasaki Disease: MRA and XCA Measurements
32298,Reflow and Patency Status
32299,Platelet Aggregation and Bleeding Time
32300,Platelet Aggregation and Eptifibatide Levels After Cessation of Eptifibatide Infusion
32301,Body Weight, LV Weight, Hemodynamics, LV Size, and LV Function
32302,Percentage of Subjects Experiencing Clinically Important Blood Pressure Findings   Tadalafil Placebo
32303,Number of Clinically Important Blood Pressure Findings   Tadalafil Placebo
32304,Adverse Events
32305,Location and Functional Effects of HERGMutations in Eight Study Patients
32307,Corrected QT Interval Variability   Lead V2   on Pre Treatment Electrocardiograms
32309,Association of Longest Ischemia Duration With Biochemical Markers of MI
32310,Univariate and Multivariate Cox Regression Survival Analyses
32315,Clinical and Hemodynamic Findings in the Initial Population
32316,Doppler Findings in the Initial Population
32317,Clinical, Hemodynamic, and Doppler Findings in the Prospective Population
32318,Correlation Between Doppler Variables and Catheter PCWP in the Prospective Population
32319,Basic Data on the 15 Patients With Recurrent Pericarditis
32320,Clinical Findings During Initial Attack of Pericarditis and Recurrences
32322,Haplotype Frequencies in Subjects Without Significant Coronary Stenosis
32323,Relationship Between Matrix Metalloproteinase 3 Gene Polymorphisms and Number of Coronary Arteries With  50  Stenosis
32324,Analyses of Individual Polymorphisms in Relation to MI
32325,Stepwise Logistic Regression Analyses of Matrix Metalloproteinase 3 Haplotypes in Relation to Previous Myocardial Infarction
32326,Reporter Assays
32327,Total Number       of Coronary Segments Seen by SH RT
32328,Mean Image Quality   1 to 4   of Each Coronary Segment
32329,Sensitivity and Specificity   Total Number   of SH RT Images in the Detection of Lesions in Individual Coronary Artery and of Patients With Coronary Artery Disease
32330,Validation of Microarray Method
32331,Patient Data Before Left Ventricular Assist Device Support
32332,Genes Common to Ischemic and Nonischemic Patients Before and After Left Ventricular Assist Device Support
32334,Results of Logistic Multivariate Analysis for T 786C
32335,Presence of ECG Confounders at Presentation
32336,Differences in Treatment Outcome at One Year: Patients Classified According to Summed ST Segment Deviation
32337,Differences in Treatment Outcome at One Year: Patients Classified According to the Total Number of Leads With ST Segment Deviation
32339,Troponin T Values at Presentation
32340,Coronary Angiographic Findings   Invasive Group Only
32341,Invasive Treatment Procedures   Invasive Group Only
32344,Multiple Logistic Regression Analyses on Troponin T and C Reactive Protein as Predictors of Death, MI, and Death or MI at 30 Days
32345,Mortality at 30 Days in Relation to Quartiles of Troponin T and C Reactive Protein
32346,Rates of Death Myocardial Infarction at 30 Days in Relation to Quartiles of Troponin T and C Reactive Protein
32352,Study population
32354,Biventricular CMR Indices   Tetralogy Patients, n   85, vs. Healthy Controls, n   26   and Effects of RVOT Aneurysm Akinesia on Biventricular Function
32355,Independent Predictors for CMR Derived Ventricular Volume, Mass, and Function in Adults With Repaired Tetralogy of Fallot   n   85
32358,Incidence of Deaths From Any Cause   A   and Cardiovascular Causes   B
32359,Hazard Ratios   95  Confidence Intervals   for All Cause and Cardiovascular Mortality Stratified by ST T Segment Changes and Microalbuminuria
32362,Prevalence of Echocardiographic Left Ventricular Hypertrophy and Abnormal Left Ventricular Geometry in Relation to Increasing Magnitude of ST Segment Depression in Leads V5 or V6
32364,Logistic Regression Analyses to Assess the Predictive Value of Increasing Magnitude of ST Segment Depression in Leads V5 or V6 for the Presence of Left Ventricular Hypertrophy
32367,Hemodynamic and Electrocardiographic Data in Patients With and Patients Without New or Further ST Elevation at Peak Stress Testing
32369,Accuracy       of ST Elevation and T Wave Normalization During Ergometric Exercise in Detecting Patients With Viability, Scar Tissue, and Biphasic Response
32370,Results From the Multivariate Statistical Analysis for the Evaluation of ST Segment Elevation onPeak Exercise Electrocardiogram
32371,Transcatheter Non Intervention Patient Group
32372,Current Data and Literature Review
32374,Events Within Six Months of Study Entry
32376,Resource Use Per Patient by Treatment Assignment in Constant 1998 U.S. Dollars
32380,Quantitative Angiographic Measurements
32381,Early and Late Outcomes
32383,Findings at Echocardiography   n   1,867   in Relation to Troponin T Levels legend
32384,Findings at Coronary Angiography in the Invasive Cohort   n   1,142   in Relation to Troponin T Levels legend
32385,Clinical End Points at 12 Months in the Noninvasive Cohort in Relation to Troponin T Levels   n   1,168   legend
32386,Multivariate Logistic Regression Analyses Regarding Death and MI at 12 Months, Respectively, in the Noninvasive Group   n   1,148   legend
32387,Effect of Cell and IgG Transfer on Atherogenesis in LDL RD Mice legend
32389,Contributing Factors for Coronary Artery Disease   Multiple Logistic Regression Analysis in 292 Patients   legend legend
32390,Contributing Factors for Coronary Artery Disease   Multiple Logistic Regression Analysis in 168 Patients With CP Seropositivity and 124 Without CP Seropositivity   legend legend
32391,Contributing Factors for Myocardial Infaction   Multiple Logistic Regression Analysis in 168 Patients With CP Seropositivity and 124 Without CP Seropositivity   legend legend
32393,Outcomes for Studies of Troponin T legend
32394,Outcomes for Studies of Troponin I legend
32395,Summary Results for Troponin and Mortality legend
32397,Echocardiographic Findings in Relation to Electrocardiographic Strain in Hypertensive Patients With and Without Evident CHD legend
32398,Prevalence of Echocardiographic LVH, Abnormal LV Geometry and Abnormal LV Midwall Function in Relation to Electrocardiographic Strain in Hypertensive Patients With and Without Evident CHD legend
32400,Multivariate Logistic Regression Analyses to Assess the Predictive Value of Electrocardiographic Strain for the Presence of LVH, Abnormal LV Geometry and Abnormal LV Midwall Function in Patients With and Without Evident CHD    legend
32402,Gender Distribution in Severity of Coronary Artery Disease in Patients Randomized to the Invasive Strategy legend
32403,Some Background and Clinical Variables of the Different Strategy Groups legend
32404,First Revascularization Procedure and Outcome at 12 Months of Follow Up in the Group Randomized to the Noninvasive Strategy According to Gender legend
32405,Effect of Female Gender on Death or Myocardial Infarction at 12 Months legend
32406,Outcomes at 12 Months in the Group Randomized to the Early Invasive Strategy With Respect to Gender legend
32407,Outcomes at 12 Months of Follow Up in Women and Men Randomized to the Early Invasive Strategy in Relation to the Type of First Coronary Intervention legend
32408,Outcome of Periprosthetic Regurgitation legend
32412,Metabolic and Clinical Variables on Study Entry and After Six Months in Training and Control Groups legend
32414,Results of Follow up Angiography legend legend
32415,Quality of Life as Assessed by the Duke Activity Status Index   DASI   and Medical Outcomes Study   MOS   Questionnaires in Training and Control Groups legend
32416,Cardiac Events According to Study Group and Cause legend
32418,Perioperative Myocardial Ischemia and Infarction Details of Patients With Ischemia legend
32422,Quantitative Immunohistochemical Data of Initial Coronary Atherectomy Specimens of All Patients Without or With   Stable or Unstable Angina Pectoris   Recurrent Angina During One Year Follow Up legend
32424,Epinephrine Induced Changes in the Mean QTc e, the Mean QTc p, the Mean Tcp e, and the Mean Tcp e QTc e Ratio, Which Are Averaged Among All 87 Leads, in LQT1, LQT2, and Control Patients legend
32425,Epinephrine Induced Changes in the max QTc e, the min QTc e, the QTc eD, the max QTc p, the min QTc p, and the QTc pD, Which Are Obtained From all 87 Leads, in the LQT1, LQT2, and Control Patients legend
32431,Statistical Association Between Peak Troponin T Levels and Legend Variables Listed in ACS Patients
32432,Multivariate Logistic Regression Model of Positive Peak cTnT Status    0.1 g liter   With the Legend Variables Listed in UAP Patients
32435,End Points After Six Month Follow Up legend
32436,Findings at the Predischarge Symptom Limited Exercise Test   n   1,173   legend
32437,Comparison of Troponin T and the Predischarge Exercise Test Regarding Different Endpoints After Six Month Follow up
32438,Univariate and Multivariate Logistic Regression Analysis of Clinical, ECG, and Laboratory Parameters in Relation to Myocardial Infarction and Cardiac Death During a Six Month Follow up Period legend
32440,Time Intervals, Reperfusion Therapy and Concomitant Medications Within the First 48 Hours legend legend
32441,Clinical Events During the Hospital Period legend legend
32442,In Hospital Death and Combined End Point in Patients With In Hospital Myocardial Infarction   n   403  : Relation to Reperfusion Therapy legend
32445,Results of Multivariate Analysis legend
32447,Acceleration  and Deceleration Dependent Sensitivity and Specificity of V alt  1.9 V in Late Versus Throughout Repolarization for VT legend
32451,Angiographic Characteristics, Outcome and Adverse Procedural Outcomes of the Study Population legend
32452,Adverse Cardiac Events at One Year legend
32456,Predictive Values and Univariate Cox Regression Analyses Associating Three Indices Used Alone and in Combination With Arrhythmic Events legend
32457,Result of a Multivariate Cox Regression Analysis
32458,Electrocardiographic and Left Ventricular Echocardiographic Changes After AMI During Six Month Study Period legend legend
32459,Echocardiographic Changes After AMI in Patients With  WMA 31.25   Large AMI   and in Patients With  WMA  31.25   Small AMI   legend
32460,ECG Changes After AMI in Patients With  WMA 31.25   Large AMI   and in Patients With  WMA  31.25   Small AMI   legend
32461,Clinical Features of the Patient Population and the Ventricular Arrhythmia Subgroup
32462,Statistical Performance of the Noninvasive Tests to Predict the Results of EPS legend
32463,Event free Survival at 400 Days for Different Combinations of TWA and SAECG Outcomes legend
32466,Phases I and II of Neointimal Generation legend
32467,Phases IIII of Endothelial Regeneration legend
32468,Diagnostic Feature Type Within the 91 Cine Runs
32469,Assignments Between Rater Groups legend
32471,Rater Compliance With the Quality Scale legend
32472,Summary of Results for the Six DC  Raters legend
32473,Summary of Results for the 13 DC Raters   compare  Table 5
32479,Cardiac Markers in Patients Suffering Cardiac Events Within a Three Month Period legend
32480,Comparison of Sensitivity, Specificity and Predictive Values of the Troponins for Cardiac Events Within a Three Month Period legend
32481,A Comparison of Patient Variables as They Relate to Levels of Cardiac Troponin T legend
32482,A Comparison of Patient Cardiac Risk Factors as They Relate to Levels of Cardiac Troponin T legend
32483,Variables in Patients With Chronic Renal Failure Not Undergoing Dialysis legend
32487,Analysis of Risk Factors for cTNI Rise Above Cutoff Level   Multivariate Analysis   legend
32490,Extraction Outcomes and Reasons for Failure
32491,Total Extraction Time: Intention to Treat Analysis
32492,Complications legend
32494,Clinical Events at 2 Years legend
32495,Predictors of Death, Reinfarction or Target Vessel Revascularization
32496,Predictors of Death or Reinfarction at 2 Years in Patients Randomized to Angioplasty legend
32498,In Hospital Clinical Events legend
32499,Pre Discharge Cardiac Catheterization legend
32500,Cumulative Sixth Month Adverse Clinical Events    legend
32502,Clinical Outcomes
32503,Sensitivity and Specificity of Biochemical Markers legend
32504,Sensitivity and Specificity of Biochemical Markers for Predicting Ischemic Outcomes by 6 months legend
32508,Physiologic Parameters in Normal Subjects From the Age of 2 Months Up to 19 Years: Comparison of Median   Range   or Mean  SD Values Between Age Groups  legend
32509,Multivariate Analysis of Diastolic Flow Parameters and Time Intervals in Normal Subjects from the Age of 2 Months up to 19 Years   n   281    legend
32510,Multiple Linear Regression Analysis in Left Ventricular Diastolic Flow Parameters in Normal Subjects from the Age of 2 Months Up to 19 Years   n   281   legend
32511,Inflammatory and Immune Markers in UA vs. CSA  legend
32512,Specific IgG titre for Cp legend
32513,Inflammatory and Immune Markers in the 4 Programs Subgroups  legend
32514,Lumen Area, Vessel Area and Plaque Area of Cross Sections Arranged in the Six Sections  legend
32515,Composition of Ischemic ECG Findings in Men and Women  legend
32516,Age Specific Number of CVD Deaths and Age Standardized CVD Mortality Rates in Subgroups According to Ischemic ECG Findings in Men and Women  legend
32517,Adjusted Risk Ratios    95  CI   for CVD Mortality According to Ischemic ECG Findings in Both Men and Women legend
32519,Square Table Analysis of Retrospective Intraindividual Longitudinal Comparison of Troponin T Serum Concentrations Measured by ELISA and Histological Rejection Grades in Concomitant Myocardial Biopsies in 15 Heart Transplant Recipients During Long Term Follow up  legend
32520,Occurrence of Spontaneous Tachyarrhythmias and Ventricular Fibrillation Threshold During Ischemia and Reperfusion legend
32521,Left Ventricular Pressures, Mean Arterial Pressure and Heart Rate legend
32522,Clinical, Electrocardiographic and Coronary Angiographic Data for Study Patients  legend
32523,Left Ventriculographic, Stress Testing and Positron Emission Tomographic Data for Study Patients legend
32526,Serial Electrocardiographic Changes Between Prehospital and Initial Hospital Electrocardiogram in Patients With Prehospital Versus In Hospital Thrombolysis   randomized patients
32528,Serial Electrocardiographic Changes in Patients With Suspected Acute Myocardial Infarction Who Were Not Receive Randomized to Prehospital Versus In Hospital Thrombolysis
32529,Leisure Time Physical Activity Score
32531,Coronary Artery Disease History and Coronary Angiographic Data  legend
32532,Characterization of Coronary Collateral Circulation and Physical Activity Score legend
32534,In Hospital Bleeding Complications of Patients With ST Segment Elevation Myocardial Infarction According to Thrombolytic and Antithrombin Therapy
32535,Clinical Outcomes at 30 Days in Patients With ST Segment Elevation Myocardial Infarction According to Thrombolytic and Antithrombin Therapy
32536,Clinical Data  legend
32537,Values of Biochemical Markers at Start of and 30, 60, 90 and 120 Minutes After Streptokinase Infusion legend
32538,Utility of 60  and 90 Minute Marker Ratios for Predicting Failed Thrombolysis  legend
32546,Effect of Time to Treatment on Patency Rate: Logistic Regression Analysis
32547,Data on the Fibrinolytic System and Hemostasis in Three Patient Groups
32550,Neg   negative rapid assay; Pos   positive rapid assay; Rec isch   recurrent ischemia.
32551,Health Outcomes After Interventions for Acute Myocardial Infarction
32552,Costs Used in Analysis of Interventions for Acute Myocardial Infarction
32553,Projected Outcomes of Primary Angioplasty and Thrombolysis Policies for a Hypothetical Cohort of 10,000 Patients With Acute Myocardial Infarction
32555,Sensitivity and Specificity of Different Tests for Predicting Sustained Ventricular Tachycardia Fibrillation in Study Patients
32556,Measures of Efficiency of Thrombolysis With Study Agents
32560,In Hospital Treatment and Outcome
32561,Adjusted 42 Day and 1 Year Kaplan Meier Event Rates
32562,Relation of Degree of ST Segment Deviation and Outcome  a
32565,Adjunctive Therapy
32566,Changes in Fibrinolytic Variables
32567,Effects of Saline and Each Sodium Channel Blocker on Left Ventricular Pressure and Aortic Pressure
32569,Correlates for Cardiac Complications Within 6 Months After Discharge
32570,Subgroup Analyses: Correlation of Postoperative TnT and CK MB Levels With Postdischarge Cardiac Complications
32572,In Hospital Outcomes Stratified by Reperfusion Modality
32573,In Hospital Charges Stratified by Reperfusion Modality
32574,In Hospital Outcomes and Charges Stratified by Reperfusion Modality in Patients Defined as High Risk and Not High Risk
32575,Univariate and Multivariate Correlates of In Hospital Charges  a
32576,Late Events After Hospital Discharge in 340 Surviving Patients at a Mean Follow Up Time of 2.1  0.7 Years
32578,Changes of Cardiovascular Risk Factors in Well Controlled Hypertensive Elderly Patients After the Hanshin Awaji Earthquake
32579,Earthquake Induced Stress and Changes in Cardiovascular Risk Factors in Well Controlled Hypertensive Elderly Patients
32580,Relations Between d Dimer and Other Cardiovascular Risk Factors in Elderly Patients With Well Controlled Hypertension After the Hanshin Awaji Earthquake
32581,Changes in Cardiovascular Risk Factors in Hypertensive and Normotensive Elderly Groups After the Hanshin Awaji Earthquake
32582,Hemodynamic Variables at Peak Dobutamine Stages
32583,End Point Responsible for Test Termination at Peak Dobutamine Stages
32586,Timing of Coronary Artery Bypass Graft Procedures Relative to Onset of Symptoms
32587,Clinical Outcomes in Surgically and Nonsurgically Treated Patients After Acute Myocardial Infarction
32588,Clinical Outcome Events in Patients Undergoing Coronary Artery Bypass Graft Surgery: Timing Relative to Operation
32589,Clinical Outcomes in Surgically and Nonsurgically Treated Patients After Acute MI Patients, Adjusted to Eliminate Early Deaths
32592,Reasons for Nonuse of Radial Artery
32593,Radial Artery Graft Anastomosis
32599,Diagnostic Performance of QFR0.8 and QCA Diameter Stenosis50  Versus FFR0.8
32606,Risk Stratification According to the Corelab SYNTAX Score Defined Tertiles
32607,Change in Treatment Recommendations     According to the cSS and the sSS Models
32608,Recommendations According to the cSS  and the sSS Based SS II Models
32609,Reclassification TableComparing 4 Year Mortality Risk Strata for OriginalcSS and the sSS Based SS II
32614,Per Patient and Per Vessel Diagnostic Performance of FFRCT, Coronary CTA, and ICA
32615,Per Patient Diagnostic Performance of FFRCT in Patients With Intermediate Stenosis Severity   30  to 70    According to Coronary CTA
32617,Hemodynamic Variables With Stress
32618,Univariate and Multivariate Models of EFS   Death MI
32619,Univariate and Multivariate Models of EFS   Death MI
32620,Oversight Committee and Panel Membership Criteria
32621,Appropriateness Categories and Scores
32624,Long Term Cardiovascular Outcomes
32625,Factors Associated With Long Term Adverse Cardiovascular Outcome in Women With a Prior Pregnancy
32626,Independent Correlates of Long Term Adverse Cardiovascular Outcome in Women With a Prior Pregnancy
32627,Syncope Frequency Depends on the Setting in Which the Measurement Is Made
32628,Established Diagnosis at Initial Evaluation: Commonly Accepted Diagnostic Criteria
32629,Short Term High Risk Criteria That Require Prompt Hospitalization or Early Intensive Evaluation
32630,Diagnostic Yield of the Most Used Tests for Diagnosis of Uncertain Syncope After Initial Evaluation in 2 Different Clinical Settings
32632,Diagnostic Performance of FFRCT and CCTA on a Per Vessel and  Patient Basis
32634,Prevalence of Cerebral Ischemic Lesions in Women and Men With or Without Myocardial Infarction Scars on Cardiac Magnetic Resonance Imaging
32637,Predictive Capabilities of Cardiac Events
32638,Incidence of Cardiac Events According to Symptoms Before Exercise Testing
32641,Association of 9p21 Gene Dosage With Modified Duke and Gensini Scores
32642,Combined Analysis of Early and Late Onset Coronary Artery Disease Patients Diagnosed by Angiogram
32643,Distribution of Disease Severity Among Patients With MI Versus Non MI
32644,Association of 9p21 With MI Once Stratified for Number of Diseased Vessels
32647,Sensitivity, Specificity, Likelihood Ratio, PPV, and NPV
32649,AEs and Rehospitalization Summary
32652,Inclusion Exclusion Criteria for Study Entry
32653,Schedule of Follow Up Testing
32654,Primary Outcome Measures
32656,Acute Hemodynamic Catheterization Data   n   29
32657,Cardiac Magnetic Resonance Imaging Results Before and 6 Months After Melody Valve   Medtronic, Inc.   Implantation   n   25
32659,Exercise Test Variables in Patients Achieving 85  of Their MAPHR Relative to Workload Attained
32661,Multivariable Logistic Regression Analysis Predicting 10  Ischemia of the Left Ventricle
32667,CVD Risk Factors by 3 Year Morbidity Mortality Status, 508 Vascular Laboratory Patients, San Diego, California, Recruited 1990 to 1994
32668,Association of 3  and 6 Year CVD Outcomes With Visit 2 ABI and Change From Visit 1 in ABI, Vascular Laboratory Patients, San Diego, California, Recruited 1990 to 1994
32670,Medications at Randomization and at Discharge
32671,Unadjusted Kaplan Meier Estimates of Outcomes
32672,Outcomes by Continent, Relative to North America
32673,Overall Event Rates
32674,Hemodynamic Result of Acute Fontan Fenestration Occlusion   n   16
32675,Exercise Performance Before and After Fontan Fenestration Closure   n   20
32677,Occurrence of RV Failure Based on Pre Operative Clinical Events and Medical Interventions
32678,Pre Operative Intravenous Medication Requirements and Incidence of RV Failure After LVAD Implantation
32679,Echocardiographic and Cardiopulmonary Hemodynamic Measurements Before LVAD Implantation With Associated RV Failure
32680,Pre Operative Laboratory Values and Associated Post Operative RV Failure
32681,Right Ventricular Failure Risk Score and Likelihood of RV Failure by Score Strata
32684,Adjusted Hazard Ratios   and 95  Confidence Intervals   of SS   BSPD 15   for Total and CVD Mortality   Mean Follow Up 9.4 yrs
32685,Reasons for Not Accomplishing Trans Septal Catheterization
32686,Complications Related to Trans Septal Catheterization
32691,In Hospital and Long Term Major Adverse Events Among 208 Patients
32693,ECG and Laboratory Variables
32694,Univariate Analysis of the Associations Between 25 Clinical Variables and a High Risk Scan
32695,Variables Independently Associated With High Risk Scan by Multivariate Analysis
32697,Yield of High Risk Scans in Selected Patient Subgroups
32698,Results of Coronary Angiography
32700,Frequency of Procedure Type by Cohort
32701,Outcomes by Procedure Type
32702,Odds Ratio for 30 Day Mortality
32703,Outcomes
32704,Observed 30 Day Mortality by Cohort, Procedure Type, and Heart Failure Stratified by Presence of CAD
32705,Semi Quantitative Scores
32707,SPECT Results of Those Undergoing Early Revascularization    60 Days   Versus Non Early Revascularization Patients
32708,Unadjusted, Univariable Two Year Cox Cardiac Death or Myocardial Infarction Free Survival by Clinical History and SPECT
32709,Risk Adjusted   Multivariable Cox Model Estimating Cardiac Death or Myocardial Infarction
32710,Annualized Cardiac Death or Nonfatal Myocardial Infarction Rates for SPECT Results in Key Patient Subsets
32711,Post Test Use of Coronary Angiography, PCI, and CABG by SPECT Results
32713,Final Clinical Diagnosis in 135 Patients Without Heart Failure
32717,Heart Rate Variability Measures of Survivors, of Subjects Who Died During the Follow up and of Subjects in Various Mortality Subgroups legend
32718,Unadjusted and Adjusted Association of Heart Rate Variability Variables With All Cause Mortality, Cardiac Mortality, Sudden Cardiac Mortality, Sudden Cardiac Autopsy Verified Mortality, Sudden Cardiac Mortality for Both Genders, Nonsudden Cardiac Mortality and Nonsudden Cardiac Mortality With Cerebrovascular Mortality legend legend
32719,The Number of Subjects With Short Term Fractal Cut Off Point Value  1 and 1 in Different Mortality and Clinical Variable Categories legend
32721,Medical Treatment legend legend
32724,Serious Adverse Events at Different Dose Levels
32726,Comparison of OUES at 100 , 90  and 75  of Exercise Duration legend
32728,Regression Equations to Predict OUES legend
32729,Comparison of Treadmill Exercise Tests Two Years Apart   Round 1 vs. Round 2   legend legend
32730,Final Results of Ergonovine Echocardiography and Invasive Coronary Angiography With Spasm Provocation Test legend
32731,Prevalence of Positive Test According to theClinical Diagnosis
32732,Comparison of Potential Advantages and Disadvantages of Ergonovine Echocardiography Versus Invasive Spasm Provocation Test During Angiography
32733,Annual and Four Month Operator Volume
32735,In Hospital and One Month MACE legend
32736,Major Cardiac Events at One Month legend
32737,Independent Predictors at One Month legend
32738,Observed and Expected Event Rates legend
32739,Procedural Differences Between Volume Groups
32740,Hemodynamic Changes During Laparoscopy   Study 1   legend
32741,Metabolic Changes During Laparoscopy   Study 1   legend
32742,Endocrine Changes During Laparoscopy   Study 1   legend
32743,Patient Data   Study 2    legend
32744,Estimated Incidence of Cardiac Perforation From Catheter based Procedures Requiring Echo guided Pericardiocentesis at the Mayo Clinic, January 1979 through November 1997
32745,Patients Who Underwent Surgery after Rescue Pericardiocentesis for Perforation Secondary to a Catheter based Procedure  legend
32746,Comparison of Diabetic and Normal Rats
32751,Reason for Ineligibility in ACIP Trial
32752,Associated Cardiac Abnormalities at Hospital Admission in 33 Neonates
32753,Immediate Results in 33 Neonates
32754,Procedure Complications in 33 Neonates
32755,Follow Up Data
32756,Surgical and Transvascular   percutaneous, umbilical   Balloon Dilation Management of Neonatal Critical Aortic Stenosis
32760,Echocardiographic Variables
32766,Correlation Between Clinical Variables and Reverse Remodeling
32767,Clinical Predictors of Mortality
32769,Linear Regression of the Association Between Psychological Distress Profiles and Adult CMR   n  6,714
32770,Linear Regression of the Association Between Psychological Distress Summary Scores and CMR   n  6,714
32771,Association Between Psychological Distress Profile and Individual Biomarkers, Adjusting for Sex and Child Covariates   n  6,714
32774,Association Between Pre Frailty Status     and CVD Risk
32777,Univariable and Multivariable Cox Proportional Hazards Models for Mortality
32779,Five Pre Specified Risk Factors and Survival by Each Risk Factor and by Cumulative Number of Risk Factors, Patients Age80 Years, NYHA Functional Class III to IV, and NYHA Functional Class II
32782,Heart Weights, HW BW Ratios, and Histological Morphometry of the Heart
32784,Repartition of Low and Slow Response According BMI Group
32785,VASP Index According to the Initial Response   Slow vs. Fast
32787,Hemodynamics, Vascular Function, and Blood Parameters Before and After HD
32788,Univariate Analysis for Predictors of the Change in FMD During a Single HD Session
32789,Morphometric Analysis of the Carotid Arteries 14 Days After Balloon Injury
32790,Physiological Parameters and Echocardiographic Analysis of In Vivo Cardiac Size and Function by Echocardiography 4 and 8 Weeks After Left Coronary Artery Ligation
32794,Adverse Events Profile
32796,Relationship of Retinal Vascular Calibers and Retinopathy With LV Mass, Volume, and Remodeling
32797,Logistic Regression of LV Mass, Volume, and Remodeling by Retinal Vascular Caliber and Retinopathy
32798,Relationship of Retinal Vascular Caliber, Retinopathy, and LV Concentric Remodeling   Highest Quintile of M V Ratio      , Stratified by Race, Diabetes, Hypertension, Coronary Calcification, and Retinopathy Status
32800,Blood Pressure and Hematologic Values During the Two Observation Periods
32802,Procedural Outcome and Follow Up
32803,Adjusted 30 Day MACE Odds Ratio and 1 Year Mortality Hazard Ratio for Anemia
32804,Blood Chemistry and Hemodynamic Data on Lean Control Subjects and Obese Subjects in the Untrained or Trained State
32808,Plasma Concentrations of Hemoglobin A1cand Glucose, Serum Lipid Concentrations, and Change in Body Mass Index Stratified by Grade of Transplant Coronary Artery Disease as Determined by Angiography
32809,Plasma Concentrations of Hemoglobin A1cand Glucose, Serum Lipid Concentrations, and Change in Body Mass Index Stratified by Mean Intimal Thickness, as Determined by Intracoronary Utrasound
32813,Fasting Serum Squalene and Noncholesterol Sterols legend
32814,Correlations Between Factors Related to CAD legend legend legend
32815,Associations Between Risk Factors and Coronary Artery Disease legend legend
32820,Procedure and In Hospital Outcome legend
32821,Cause of Death legend
32822,Univariate Cox Analysis of Pharmacologic Treatment for Two Year Death Rates among Diabetics
32823,Univariate and Multivariate Cox Analysis for Death legend
32825,Surgical Procedures in Hemolysis Patients   Group 1    legend
32828,Correlation Coefficients of Monocyte   Subset   Counts With Traditional and Nontraditional Cardiovascular Risk Factors
32829,Adjusted Cox Regression Analysis   Different Models   for Cardiovascular Events
32830,C Statistics Corresponding to the Cox Regression Analyses Reported in  Table 3
32834,Clinical and Laboratory Parameters of 49 Obese Individuals and 49 Lean Controls
32840,Clinical Events During 12 Months Follow Up
32846,Plasma PlGF Levels on Third Day After AMI and the Coronary Risk Factors
32847,Multiple Regression Analysis for Chronic Phase Left Ventricular Function
32850,Multivariable Model for Death Myocardial Infarction
32851,Univariable Results for Neutrophil Lymphocyte Ratio   Q4 vs. Q1   in Primary and Three Secondary Interest Populations
32853,Physiologic, Hemodynamic, and Echocardiographic Parameters on Day 14
32856,Multiple Regression Analysis for Predicting In Stent Neointimal Volume
32859,Histopathologic Quantification of Vascularity legend
32860,Plasma Lipid Profiles in Human Subjects
32863,Fibrinogen Binding on Single Myeloid Leukocytes   GP Ib    and on Platelet Leukocyte Aggregates   GP Ib     legend legend
32864,Immunostaining of Myeloid Leukocytes at 24 h After Revascularization in AMI legend legend
32868,Ex vivo Platelet Stimulation Studies legend legend
32869,Time Course of Chimeric 7E3 Fab Effect on Detectable Platelet and Leukocyte Receptors
32873,Preprocedural Heparin Administration
32874,Angiographic Outcomes
32875,Frequency of Composite End Point
32876,Elements of Composite End Points at 30 Days and 6 Months  a
32879,Clinical Outcomes at 30 Days in the As Treated Population   CEC Adjudicated
32881,In Hospital Evolution and Outcome of 16,867 Episodes of IE in Spain   2003 to 2014
32882,Variables Independently Associated With In Hospital Mortality Adjusted by Risk in a Multivariable Logistic Regression Model and a Multilevel Model, With Odds Ratio and 95  Confidence Intervals for Each Variable
32883,Center Volume, Length of Hospital Stay, Readmissions, and Risk Adjusted In Hospital Mortality: Episodes From 2014
32885,Factors Associated With Atrial Fibrillation as the Presenting Arrhythmia in Univariable and Multivariable Analyses
32886,Porcine Atrial Ablation Parameters   N   64
32888,Procedural Details
32889,Study Population
32890,LV Unloading and Remodeling
32892,Kaplan Meier Estimates for Cumulative Number   Rate   of MACE
32893,Conditional Logistic Regression Analyses of All MACE and NC MACE
32895,Quantitative and Qualitative OCT Findings   Lesion Level Analysis
32897,Procedural Data
32898,Termination Rates, Focal Impulse and Rotor ModulationGuided Ablation
32900,Surface Area
32901,Distribution of Dispersion Areas
32902,Per Procedural Outcome   Index and Redo Procedures
32905,Predictors of Poorer Clinical Outcomes Post TAVR
32907,Mortality   Including Emigrated Patients
32908,Incidence of CHD Related Deaths by Time Period of Operation
32909,Causes of CHD Related Deaths by Defect Severity and Decade of Operation
32910,Summary of Recommendations for AS: Choice of Surgical or Transcatheter Intervention
32912,ASCVD Event Hazard Associated With Additional Risk Markers
32913,NRI: Risk Markers Added to cPCE
32914,NRI: Risk Markers Added to cFRS
32915,Polymorphisms Associated With Smoking Behavior in Genome WideAssociationStudies
32916,CHADS2 and Associated Stroke Risk in the NRAF and ASSERT Trials
32919,Prevalence and Estimated Incidence of BPVT
32921,Predictors of BPVT
32926,Interobserver Variability for MRI and Echo
32927,Comparison of MR Severity: MRI Versus Echo
32928,ACC AHA Class Indications, MRI Regurgitant Severity, the Presence of Symptoms, and Echocardiographic LV Dimensions in 38 Patients Referred for Isolated Mitral Valve Surgery
32929,Comparison of Pre Surgical and Post Surgical Left andRight Ventricular Indexes, as Quantified by Magnetic Resonance Imaging
32933,Clinical Outcomes at 30 Days in the AT Population
32934,Sizing Guidance for the SAPIEN 3 THV on the Basis of 3 Dimensional CT Dimensions
32936,Success Rate After Single Ablation Procedure and OffDrugs   Effectiveness Cohort
32937,Multivariate Logistic Regression Analyses of Risk Factors for Primary Effectiveness Endpoint   Effectiveness Cohort, n 122
32944,Procedural Variables
32945,Clinical In Hospital Outcomes
32946,Ratio of Actual THV Stent Area Measured With CT to Nominal THV Area According to THV Size and Degree of Underfilling
32947,ASD Procedures
32948,PDA Procedures
32949,Pulmonary Valvuloplasty Procedures
32950,Aortic Valvuloplasty Procedures   Single Balloon Technique
32951,Coarctation Angioplasty and Stenting Procedures
32952,Pulmonary Artery Stenting Procedures
32955,Objective Predictors of Heart Failure Prognosis According to Patient Clusters
32956,Multidetector Computed Tomography Annular Area Sizing Algorithm
32959,Procedural Outcomes
32961,Multivariate Predictors of AF Recurrence in PVI       Patients   Comparison to PVI       OSA       Group
32962,Multivariate Predictors of AF Recurrence   Comparisonto PVI       Group
32964,Summary of Adverse Events On Treatment Analysis
32966,Procedure and Fluoroscopy Times With Different Balloons and 2 Balloons, Respectively, for Patients With Follow Up Data After 3 Month Blanking Period   n   553
32967,Acute Adverse Events
32968,Correlations and Differences Between Similar Measurements Made by Cross Sectional CT      and 3D TEE   n   104
32970,Evidence Based Device Sizing Derived From ROC Curve Prediction of PVAR
32973,30 Day Outcome for the 23 mm Portico Valve
32974,Hemodynamic Function After Implantation and at 30 Day Follow Up
32975,CT Determined Cross Sectional Aortic Annular Dimensions Compared in Systole and Diastole in 20 Randomly Selected Cases From the Original 2D TEE Guided Cohort
32979,Comparison of Outcomes Related to Prosthesis Sizing With TEE  and CT Guided Approaches
32983,Area Under the Receiver Operator Curve for the Prediction of Moderate or Severe PAR After TAVR
32984,The Relationship Between Undersizing a THV Relative to the MDCT Annular Size and Increasing Grade of PAR
32989,Parameter Estimates and HRs From Multivariate Cox Regression Models
32991,Hemodynamic Variables, AR Index, and Laboratory Parameters at 48 h After TAVI According to the Degree of PeriAR
32992,Clinical Outcomes According to the Occurrence of Moderate Severe PeriAR After TAVI
32994,Pre Procedural Parameters of Patient Group as a Whole and Divided Into Subgroups Taking Into Account Post Procedural Regurgitation
32995,Intraprocedural Parameters of Patient Group as a Whole and Divided Into Subgroups Taking Into Account Post Procedural Regurgitation
32996,Predictive Factors of Post Procedural Regurgitation   Results of Univariate Logistic Regression
32997,Predictive Factors of Post Procedural Regurgitation   Results of Multivariate Logistic Regression
32998,Predictive Morphological Factors   Parameters From Multislice Computed Tomography   of Significant Intraprocedural and or Post Procedural Regurgitation   Results of Multivariate Logistic Regression
33000,Outcomes During and After Hospitalization for AF Ablation
33001,Multivariable Analysis for Predictors of Inpatient Complications Plus All Cause 30 Day Rehospitalizations
33003,Procedural Considerations and Outcome
33007,Univariate and Multivariate Analyses of Immediate AF Recurrences After Catheter Ablation
33008,Univariate and Multivariate Analyses of Early AF Recurrences After Catheter Ablation
33009,Cox Regression Analysis of AF Recurrences After Catheter Ablation
33012,Cox Proportional Hazards Models of SHS Exposure, Smoking, and CVD Mortality
33013,Cox Proportional Hazards Models of SHS Exposure, Smoking, and All Cause Mortality
33015,Cardiovascular Responses to Maximal Normoxic Cycle and KE Exercise in Control Subjects and CHF Patients
33016,Arterial and Venous Epinephrine, NE, and Calculated NE Spillover From the Muscle During Maximal Cycle and KE Exercise in Control Subjects and CHF Patients
33019,Type of Fracture and Clinical Outcomes
33020,Eight Patients   9 Lesions   With Grade V Fracture and Clinical Outcomes
33022,Primary Efficacy End Point on 7 Day Continuous Holter ECG
33023,Annual Number of Admissions for Adults With Simple Congenital Heart Disease Diagnoses in the U.S, 1998 to 2005
33024,Annual Number of Admissions for Adults With Complex CHD Diagnoses in the U.S., 1998 to 2005
33025,Frequency of Specific Diagnoses and Procedures Associated With Hospitalizations for ACHD
33028,Procedural Parameters Results for the Robotic System
33031,Exclusion and Inclusion Criteria
33035,Success Rates With and Without Antiarrhythmic Drugs in Patients With Persistent and Permanent Atrial Fibrillation Who Underwent Biatrial and Left Atrial Ablation
33038,ECG, Repolarization, and Depolarization Parameters in Control and in the Brugada ECG Condition With or Without Phase 2 Re Entrant Extrasystoles
33039,ECG, Optical Repolarization, and Depolarization Parameters Just Before Polymorphic VT or VF in the Brugada ECG Condition
33041,Infarction Changes in LV After MI in HIF 1      and Control Mice
33042,ECHO Parameters of LV Function
33044,Univariate and Multivariate Analysis for the Presence of Non Pulmonary Vein, Superior Vena Cava, and Left Atrial Posterior Free Wall Ectopic Beats
33047,Univariate Predictors of Late Atrial Fibrillation Recurrence
33048,Clinical Data
33049,Electrocardiographic Data of Mahaim Fibers
33052,Echocardiographic Parameters of AVERT Patients, by Type of Valve
33053,Echocardiographic Parameters of AVERT Patients, by Type of Valve
33055,Procedure Data   n   123 in 100 patients
33056,Types of Stents Used
33058,Comparison of Patients With and Without AFL During Catheter Ablation to Isolate the Pulmonary Veins
33063,Tachyarrhythmias During Sinus Node Artery Perfusion With Catecholamines Before and After Atropine
33064,Effects of Isoproterenol and Propranolol on Acetylcholine Mediated Atrial Fibrillation
33065,Previously Reported NKX2.5Mutations
33066,Frequency of NKX2.5Mutations Among 608 Patients With Congenital Heart Disease
33067,NKX2.5Mutations Identified Among 608 Patients With Congenital Heart Disease
33070,Waiting Times of Patients Revascularized Within One Year After AMI for Patients Hospitalized at Invasive Versus Non Invasive Institutions Between 1994 and 1998
33071,Outcomes of Patients Revascularized Within One Year After AMI at Invasive Versus Non Invasive Institutions Between 1994 and 1998
33074,Comparison of the Most Significant Historic Features in Patients With Seizures and Established Diagnoses of Syncope
33075,Point Scores for the Diagnosis of Seizures, in the Absence of Knowledge of the Numbers and Historic Duration of Losses of Consciousness and Lightheaded Spells
33076,Point Scores for the Diagnosis of Seizures With Knowledge of the Numbers of Spells and the Length of the History of Losses of Consciousness and Lightheaded Spells
33077,Diagnostic Questions to Determine Whether Loss of Consciousness Is Due to Seizures or Syncope
33079,Micro CT Parameter
33081,Study Patient Profiles
33082,Response to Combined Therapy
33084,Genotypic Distributions and Allelic Frequencies of P1A1 A2Polymorphism Among Smokers and Nonsmokers
33085,Multivariate Predictors of Carriage of the P1A2Polymorphism
33087,Distribution of the AF Cycle Lengths in Different Regions of the RA in Patients With PAF and CAF legend
33088,Percentage of Time During Which Different Types of AF Are Encountered During 10 s of the Processed Data legend
33089,Right Atrial Activation Patterns legend
33090,ATP Test: Definitions
33091,Anomalies of Aortic Arch Laterality or Branching and Frequencies of Chromosome 22q11 Deletion in Our Study Cohort legend legend
33092,Correlation Between Anatomic Clinical Variables and Chromosome 22q11 Deletion legend
33094,Five Prospectively Identified Diagnostic Pacing Maneuvers and Questions Asked legend
33097,Diagnostic Value of Pacing Maneuvers during Supraventricular Tachycardia legend
33099,Pacing Protocol
33102,Postoperative Beta Blocker Therapy legend
33104,Results of Cardiac Catheterization legend
33105,Prevalence of Coronary Artery Disease in the GUSTO Angiographic Substudy
33106,Cardiac Catheterization Rates in Various Subgroups legend
33107,Estimation of Marginal Five year Survival Benefit with U.S. Pattern of Cardiac Catheterization    legend
33108,Quantitation of Residual Ductal Shunt
33109,Clinically Used Devices for Transcatheter Occlusion of Patent Ductus Arteriosus
33111,Clinical and Electrocardiographic Data legend
33112,Summary of Medications Tried for Control of PJRT legend
33113,Electrophysiologic DataAnterograde legend
33114,Electrophysiologic DataRetrograde legend
33115,Histopathology Versus Dobutamine Echocardiography, PET Imaging and Tl SPECT
33116,Sensitivity and Specificity of Dobutamine Echocardiography, PET and Tl SPECT for the Detection of Segments With  50  and  25  Viable Myocytes
33117,Clinical and Closure Data for All Patients
33118,Distribution of Selected Variables in 336 Case Patients With Acute Myocardial Infarction Who Never Smoked and 446 Control Patients Who Never Smoked
33119,Prevalence of 336 Case Patients With Acute Myocardial Infarction Who Never Smoked and 446 Control Patients Who Never Smoked According to the Smoking Status of Their Relatives
33120,Odds Ratios   95  confidence intervals   for Acute Myocardial Infarction in 336 Case Patients Who Never Smoked and 446 Control Patients Who Never Smoked According to the Smoking Status of Their Close Relatives
33121,Odds Ratios  a    and 95  confidence intervals   for Acute Myocardial Infarction in Relation to Smoking Status of Close Relatives by Strata of Selected Covariates
33122,Odds Ratios  a    and 95  confidence intervals   for Interaction Between Passive Smoking and Other Selected Risk Factors for Acute Myocardial Infarction
33124,Summary of Coil Implantation in Lambs
33126,Comparison of Heart Rate Variability Between 24 and 1 h Before Onset of Atrial Flutter in 12 Patients
33127,Atrial Extrasystoles and Onset of Paroxysmal Atrial Flutter in 12 Study Patients
33130,Prejunctional Vagal Modulation of Sympathetic Effect
33131,Protocol 1: Drug Induced Protocol for Coronary Vasospasm  a
33132,Protocol 2: Mechanical Injury Protocol for Coronary Vasospasm  a
33133,Sensitivity to Vasospasm Stimuli
33134,Hemodynamic Variable Changes at Control, Serotonin and U46619 Combination and Recovery Steps in Drug Induced Vasospasm Protocol in Seven Ovariectomized Rhesus Monkeys  a
33135,Summary of Coil Occlusion in Piglets
33136,Clinical Features of Seven Patients With Spontaneous but Noninducible Paroxysmal Supraventricular Tachycardia
33140,Procedures per Patient
33141,Surgical Procedures
33142,Catheter Based Interventions
33143,Short  and Long Term Survival
33145,Predictors of Morbidity and Costs in UnivariableAnalyses
33146,Adjusted Costs, Costs per Day, Length of Stay, and Post Operative Length of Stay
33147,Effects of Age at Operation on Major Morbidity
33148,Effects of Age at Operation on the Log of Adjusted Costs
33149,Additional Benefits of TEE Over TTE
33151,Clinical Presentations, Signs, and Diagnostic Imaging Results of All Patients With Type A Aortic Dissection
33152,In Hospital Treatments and Surgical Data of All Patients With Type A Dissection
33153,In Hospital Complications   Including Postoperative   and Mortality of All Patients With Type A Dissection
33154,Clinical Data on Patients With   Group I   and Without   Group II   Periannular Complications
33155,Predictive Factors of Periannular Complications in 211 Patients With Left Sided Endocarditis: Univariate Analysis
33158,Seroprevalence of Chlamydia pneumoniaeand Helicobacter pyloriInfection in Patients and Controls
33159,Odds Ratios for Chlamydia pneumoniaein Aortic Valvular Stenosis After Adjustment for Possible Confounding Factors legend
33160,Odds Ratios for CRP in Aortic Valvular Stenosis After Adjustment for Possible Confounding Factors legend
33161,CRP in Patients and Controls According to Chlamydia pneumoniaeInfection legend
33166,Serial Changes in Echocardiographic Parameters in Control and Hypertensive Rats legend legend
33167,Hemodynamic and Pathological Parameters at the Ages of 7, 13 and 19 Weeks in Control and Hypertensive Rats legend legend
33169,Prevalence of Antibodies Against Chlamydial LPS and Chlamydia pneumoniaein Cases and Controls
33170,Prevalence of IgG Antibodies Against Chlamydial LPS in Relation to Classical Risk Factors and Socioeconomic Variables in the Study Population   n   791
33171,Association of Chlamydial LPS and Chlamydia pneumoniaewith CAD
33172,Markers of Systemic Inflammation in Relation to Serostatus Against Chlamydial LPS in Cases and Controls
33174,Hemodynamic Variables Before and Immediately After Balloon Dilation Atrial Septostomy legend
33176,Hemodynamic Variables Before and Immediately After Repeated Balloon Dilation Atrial Septostomy legend
33178,Seropositivity to Three Candidate Infectious Agents in Patient and Control Groups  legend
33179,C Reactive Protein Concentrations in Serologic Positive and Negative Groups  legend
33182,Summary of Duke Criteria for Infective Endocarditis
33183,Predisposing Factors and Clinical Features in Patients With and Without Infective Endocarditis
33184,Comparison of Findings Detected by Transthoracic and Transesophageal Echocardiography
33185,Comparison of Clinical Outcome Among Patients With and Without Infective Endocarditis
33187,Comparison of Protocols Between Patients With and Without MACE
33188,Predictive Accuracy for MACE
33192,Clinical Presentation and Management
33196,Target Organ Damage and Cardiovascular Event Rates
33204,Ultrasound Treatment Regimens
33206,Angiographic Variables and Troponin Levels in STEMI Patients
33207,Changes in LV Function and Myocardial Perfusion
33210,Hemolysis Parameters at the Time of Clinical Presentation Before Treatment and 48 H After Treatment Presented According to the Type of Flow Obstruction
33211,Treatment of Blood Flow Abnormalities and Success Rate According to the Obstruction Type
33216,Studies on Mechanisms of Atrial Fibrosis in AF in Humans
33217,Studies on Mechanisms of Atrial Fibrosis in AF in Animal Experiments
33218,Suggested Mechanisms of Predisposition of AtrialVersus Ventricular Myocardium to Fibrosis
33219,Studies on the Prognostic Significance of Atrial Fibrosis in AF Patients
33221,TTE Data: 8 Month Cohort
33224,Periprocedural Clinical Outcomes of the Propensity Score Matched Population
33225,Clinical Outcomes of the Propensity Score Matched Population at 1 Year
33227,Treatments for Comorbidities in Patients With HFpEF and Those With HFrEF
33228,Antiplatelet Agents and Dyspnea
33230,Primary and Secondary Angiographic and Electrocardiographic Outcomes
33232,Previous Publications of Patients Having an Anomalous Cord Extending From the Raphe of a Congenitally BAV to the Wall of the Aorta Causing Either Acute or Chronic Pure Aortic Regurgitation
33233,Clinical Data for 6 Men Having AVR for a Purely Regurgitant   4  4    Congenitally Bicuspid Aortic Valve With an Anomalous Cord Extending From the Raphe of One Cusp to the Wall of the Aorta
33237,Short Term Pregnancy Outcomes
33245,Incident Rates of AF in Comparison to 5 Previous Large, Population Based Studies
33247,Diagnostic Performance and Accuracy of iFR 0.80
33248,Diagnostic Performance and Accuracy of iFR 0.83
33254,Outcomes of Heart Failure Hospitalization, by Primary Versus Secondary Diagnosis of Heart Failure
33258,Most Frequent TEAEs Occurring in  10  of Patients Who Entered PHIRST 2
33260,Clinical Outcomes
33261,Quantitative Coronary Angiography Outcomes
33265,IVUS Parameters Measured at Each Segment
33268,Hemodynamic Changes With Nitroprusside
33270,Relation of HPV to Various Metabolic Risks
33271,Association Between Cardiovascular Disease and HPV
33272,Pathophysiological Mechanisms of Exercise Intolerance in Heart Failure
33273,Exercise Responses in Patients With Dyspnea Due to Heart Failure Compared With Pulmonary Disease
33274,Summary of Selected Adverse Events in the HF ACTION Study
33275,Summary of Resistance Training Studies in HF
33276,Beneficial Effects of Exercise in Heart Failure
33279,Cox Regression Survival Analysis
33282,Summary of DES Deployed for On  and Off Label Indications for Survivors  30  and 30 Day Duration
33285,Morphometric Analysis of DES   30 Days
33286,Underlying Causes of Thrombosis in First Generation DES
33287,First Generation DES With Localized Hypersensitivity and Malapposition Secondary to Excessive Fibrin
33290,Breakdown of Major Adverse Cardiac Events at Week 16 and at End of Study
33291,MedDRA Summary of Treatment Emergent Adverse Events Occurring in  3  in Either Treatment Group by Primary System Organ Class and Preferred Term: All Subjects Population
33294,Indications for Extraction
33295,Odds Ratio Estimates of Predictors of the Need for CTS Assistance
33296,Procedural Complications
33298,Angiographic and Procedural Findings
33299,Concomitant Medication
33301,Cumulative Clinical Outcomes at Different Time Points
33302,Safety Events Until Day 30
33306,Electrocardiographic and Clinical Outcome in the 2 Study Phases
33307,Clinical Outcome and Safety Related Parameters
33308,Transcriptional Analysis of EPC and MSC
33309,Secretome of EPC and MSC
33310,MRI Data at 1 Week and 7 Weeks After AMI
33318,Overlapping Stents: Reason for Overlapping Stent Implantation per Lesion
33319,Clinical Events at 3 Years
33320,Clinical Events at 30 Days
33322,CT Perfusion Scan Parameters
33324,Per Vessel and Per Patient Diagnostic Accuracy of CT Perfusion and SPECT MPI
33325,Diagnostic Accuracy of CTP With SPECT as Reference Standard for All Subjects   n   34
33327,Comparison of Vasoreactivity in Proximal and Distal Segments Among SES, ZES, and BMS
33329,Multivariate Logistic Regression to Examine the Association of Psychological Distress With Behavioral and Pathophysiological Risk Factors
33330,The Extent to Which Behavioral and Pathophysiological Risk Factors Explain the Association Between Psychological Distress and CVD Events
33332,Association Between SNPs in the FGA and FGB Genes and Plasma Fibrinogen Levels
33333,Association Between FGA, FGB, and FGG Haplotypes and Plasma Fibrinogen Levels
33334,Association Between Mean Plasma Fibrinogen Levels and SNPs rs2070011 in FGA and rs1800790 in FGB, Stratified by Quartiles of Plasma IL 6 and CRP Levels
33335,Association Between Mean Plasma Fibrinogen Levels and FGA, FGB, and FGG Haplotypes, Stratified by Quartiles of Plasma IL 6 Levels
33339,Incidence of CIN Among Patients at High Risk for Development of CIN
33341,Dobutamine Stress Data
33342,Standard Medication Protocols for the Cleveland Clinic Heart Failure Intensive Care Unit
33345,Hemodynamics at Admission and Time of Pulmonary Artery Catheter Removal   CI and PAP   and Discharge From Hospital   MAP   Between Patients Who Did and Did Not Receive SNP During Hospitalization
33346,Use of Medication on Admission, During Admission, and on Discharge
33347,Primary Outcomes
33348,Predictors of All Cause Mortality on Multivariate Analysis
33350,Clinical Events on Follow Up
33352,CRP Values   mg l; Mean  SD   in Relation to Primary End Point and Unadjusted Odds Ratios
33353,Independent Predictors and Adjusted Odds Ratios of CRP for the Occurrence of the Primary Outcome at 1 Year
33354,Independent Predictors and Adjusted Odds Ratios of CRP for the Occurrence of Death at 1 Year
33357,Doppler and Tissue Doppler Echocardiography After Infusion
33358,Neurohormones, Renal Function, Cardiac Troponin, and Electrophysiology With Istaroxime at 6 h
33359,Adverse Events
33360,Effects of Sirolimus on Vascular Reactivity
33361,Effects of Sirolimus on the Expression of NADPH Oxidase Subunits
33362,Effects of Sirolimus on the Expression of NOX1, NOX2, and eNOS
33363,Assessment of Remodeling Associated Parameters
33368,MRI Measurements
33370,Risk Estimates     for Death, MI, and Recurrent ACS 30 Days After ACS Using Selected Continuous Variables
33371,Risk of Death, MI, or Recurrent ACS With LDL C  70 mg dl and Selected On Treatment TG or NonHDL C Cut Points 30 Days After ACS
33372,Percentage of TG Reduction and Proportion of Atorvastatin  and Pravastatin Treated Patients Attaining Designated Cut Points for LDL C, TG, and or CRP 30 Days After ACS
33373,Risk of Death, Myocardial Infarction, or Recurrent ACS by Number of Parameters Achieved     30 Days After ACS
33377,Univariate and Multivariate Analysis of the Day 1 Predictors of Left Ventricular Remodeling at Follow Up
33378,Univariate and Multivariate Analysis of the Day 1 Predictors of Left Ventricular Remodeling at Follow Up in Patients With Grade 3 TIMI Flow
33379,Multiple Linear Regression
33381,Effect of 80 mg Atorvastatin Versus 40 mg Pravastatin on Death or Major Cardiovascular Events According to KIF6 Trp719Arg Genotype
33382,Hemodynamic Parameters
33383,Variabilities of Myocardial Strain Measurement by 2 Dimensional Strain
33384,Hemodynamic Data of the 5 Dogs at the Different Series of Measurements
33393,Release Profile of the TGF 1Eluting Stents Used for the Animal Experiments
33394,30 Day, 12  and 24 Month Outcome
33396,Comparison of Morphometric Measurements Among Treatment Groups 42 Days After Stent Implantation
33397,Comparison of Morphometric Measurements of the Neointima Among Treatment Groups 42 Days After Stent Implantation
33398,Comparison of Histologic Findings Among Treatment Groups 42 Days After Stent Implantation
33399,Comparison of Proliferation Index and Luminal Eosinophils Heterophils Among Treatment Groups
33401,In Hospital Therapies and Procedures
33402,Continuous 3 Lead Electrocardiographic Results
33403,Clinical Events Through 42 Days
33405,Patients Achieving Suboptimal Platelet Inhibition With Single Bolus Eptifibatide
33407,Patients Achieving Suboptimal Platelet Inhibition With Double Bolus Eptifibatide
33413,Non Inferiority Testing of Primary and Pre Specified Secondary End Points
33414,Clinical Outcomes at 9 and 12 Months in the Intention to Treat Population
33415,9 Month Angiographic Outcomes
33417,Frequency of Adverse Effects During the Trial Period
33420,Relationship Between Regional Ecc and Log CRP in Men and Women
33424,Safety Characteristics of the Study Population
33427,Thresholds for Ventricular Fibrillation Induction at Different Positions Before and After Cocaine Infusion
33428,Histopathological Findings in the Pig Hearts
33429,EMPIRIC Arm Programming of VT VF Settings
33432,Additional Shock and ATP End Points
33433,Histomorphometric Data
33434,Clinical, Histological, and CMR Features of Patient Population
33436,Hazard Ratios for Myocardial Infarction According to Tyr402His Genotype
33442,Echocardiographic analyses after repeated I R
33446,Angiographic Findings Stratified by the Clinical Syndrome
33447,Individual Data of the Study Population
33450,Clinical Outcomes
33451,Restenosis Outcomes From Quantitative Coronary Analysis at Nine Month Follow Up
33452,TVR Rates by Country
33454,Perioperative Complications From CRT Device Implantation
33455,Postoperative Complications From Discharge Through Six Month Follow Up
33457,Unadjusted and Adjusted Mean C Reactive Protein Levels by Ethnic Group in Participants With and Without Hypertension
33458,Relative Odds of Hypertension by Category of C Reactive Protein
33460,Coronary Angiography: Quantitative Analysis of Vessel Diameter
33461,Coronary Angiography: Quantitative Analysis of Vessel Diameter for Each Segment in the ASO Group
33462,Intracoronary Doppler: Coronary Flow Velocity in ASO and in Control Groups
33463,Extrapolated Data for CFR Calculated With Administration of Acetylcholine
33464,Extrapolated Data for CFR Calculated With Administration of Adenosine
33465,Risk of Death, Myocardial Infarction, or Rehospitalization With Acute Coronary Syndrome in Different Subgroups by Statin Regimen for the Entire Study, at 30 Days, and Between 6 Months and End of Study
33468,Odds Ratios as Estimates of Relative Risk for Premature Myocardial Infarction in Carriers of the 894T Allele
33470,Effects of G894T Polymorphism on eNOS Gene on the Inflammatory Process, Endothelial Cell Injury, and Oxidative Stress in the Acute Phase of Premature Myocardial Infarction, One Year After the Event and in Matched Control Patients in the Follow Up Study
33472,Initial Versus Repeat PCI: Technical Factors
33476,Multiple Regression Analysis for Predicting Angiographic Late Lumen Loss
33477,Cardiac Catheterization and Postmortem Examination 12 Weeks After Coronary Stenosis or Myocardial Infarction
33480,Exclusion Criteria
33482,Primary Clinical End Points
33483,Adverse Events by Treatment Groups
33485,Cox Proportional Hazards Models of High Sensitivity C Reactive Protein and ST Segment Depression Criteria for Prediction of All Cause and Cardiovascular Mortality
33486,Cox Proportional Hazards Models of Combined High Sensitivity C Reactive Protein and ST Segment Depression Criteria for Prediction of All Cause and Cardiovascular Mortality
33487,Pre Intervention Intravascular Ultrasound Findings of Culprit Lesions
33489,Angiographic Findings
33490,Distribution of Variables According to Seropositivity to Helicobacter pylori
33491,Vascular Function by Infectious Agent
33494,Adverse Effects Observed in RTCE and in Conventional DSE
33495,Diagnostic Parameters of MPI and WMA by RTCE for Detecting Angiographically Significant Coronary Artery Disease
33496,Heart Rate, Hemodynamic, and Blood Flow Data at Rest
33497,Mean Pressure Gradients   mm Hg   at Rest and Stress
33498,Echocardiographic Parameters
33499,Hemodynamic Parameters
33500,Hematologic Parameters and Results of Coagulation Assays
33501,Hemodynamic Data
33502,Myeloperoxidase Activity   IU g   in Myocardial Samples After Coronary Injury Followed by 48 min of Occlusion and 1, 2, or 4 h of Reperfusion in Swine
33503,Clinical and Angiographic Findings
33507,Correlation Coefficients   r   Between Each Variable and LAP, dP dtmin, or Tau
33511,Angiographic Parameters and Relationship With IPA
33512,Bleeding Complications and Thrombocytopenia During Admission
33519,Age  and Gender Adjusted Regression Models for Serum sICAM 1 Levels
33520,Multivariable Correlates of sICAM 1 Levels
33523,Clinical Outcome at Six Months
33524,Causes and Frequencies of Coronary Venous Lead Implantation Failure
33526,Causes and Frequencies of Temporary and Permanent Loss of CRT During Follow Up in 443 Patients Who Underwent Successful Implantation of a Defibrillator With CRT
33528,Accuracy of Myocardial Contrast Echocardiography to Detect Residual Infarct Related Artery Stenosis    50
33529,Accuracy of Myocardial Contrast Echocardiography to Detect Multivessel Disease
33531,Effect of Atrial Fibrillation on Levels of Plasma CRP, IL 6, TF and Plasma Viscosity: Linear Regression Analyses
33534,Cardiac Nerve Density With 20 Hz Versus 5 Hz Stimulation to the Left Stellate Ganglion
33535,Summary of Protocol 2
33537,Continuous ST Segment Recovery Parameters
33538,Static ST Segment Recovery Parameters
33539,Sixty Minute Angiographic Results for Patients Enrolled in the Continuous ST Segment Monitoring Substudy
33540,Thirty Day Clinical Outcomes
33541,Correlations Between ST Segment Recovery Parameters and Clinical Outcomes
33542,Relative Change in Systolic and Diastolic Indices of Cardiac Function in Neonatal Pigs
33544,Results of Determination of Various Laboratory Indexes Upon Emergency Department Admission  McNemar Test
33545,Clinical, Electrocardiographic, and Echocardiographic Findings in Patients With Viral or Idiopathic Acute Pericarditis With and Without Detectable cTnI
33546,Complications and Clinical Events During a Mean Follow Up of 24 Months   Range 8 to 30 Months
33547,cTnI Elevation in Viral or Idiopathic Acute Pericarditis: Comparison Between This Report and Previous Studies
33549,Bivariate and Multiple Analyses of Preoperative Levels and Risk Factors
33555,Correlation Between Strain Rate and Tissue Velocity During Isovolumic Contraction   Peak  dP dt   or Isovolumic Relaxation   Peak dP dt   With Invasive Measurements
33556,Hemodynamics
33557,Regional Myocardial Blood Flow
33559,Procedure and Device Data
33565,Results of Univariate Linear Regression Analysis Between Different Covariates and Peak in ACh  and SNP Stimulated Forearm Blood Flow
33566,Independent Predictors of Peak Increase in ACh Stimulated Forearm Blood Flow After Multivariate Analysis
33567,Distribution of Chlamydia pneumoniaeImmunoglobin Antibody Titers in Relation to the Presence and Severity of Aortic Atherosclerotic Plaques
33568,Association of Chlamydia pneumoniaeIgG Antibody Titers With the Presence and Severity of Aortic Atherosclerotic Plaques
33569,Distribution of Chlamydia pneumoniaeIgG Antibody Titers in Relation to Frequency of Clinical Coronary Artery Disease and Cerebrovascular Disease
33570,Blood Cell Counts, Fibrinogen, and hs CRP in Relation to Chlamydia pneumoniaeAntibody Titer
33575,Comparison of Different Heparin Doses in Clinical Trials in the 1990s
33576,Comparison of Bleeding Risk in ESPRIT and IMPACT II Patients Using TIMI Major Minor Bleeding Criteria
33582,Safety
33585,Clinical Outcome in the Hospital and During Follow Up
33586,Levels of CK, CK MB, and Troponin I Before and 6, 24, 48 h After the Procedure; Levels of CRP Before and 72 h After the Procedure
33587,Angiographic Outcome at 6 Months
33590,Clinical Outcomes and WBC Count
33591,WBC Count, CRP, and 6 Month Mortality
33593,Frequency of Induction of Coronary Spasm, Augmentation of ST Segment Elevation, and Induction of Ventricular Fibrillation
33594,Frequency of Induction of Coronary Spasm, Augmentation of ST Segment Elevation, and Induction of Ventricular Fibrillation in Six Patients With Brugada Syndrome in Whom Both Acetylcholine and Ergonovine Maleate Were Injected
33597,Prevalence of Seropositivity by Gender
33598,Prevalence of Cytomegalovirus Seropositivity by Age    and Gender   Group
33599,Seropositivity and Risk of Cardiovascular Disease
33600,Co Infection and Risk of Cardiovascular Disease
33601,Prevalence of Seropositivity and Risk of Cardiovascular Disease With Variable Threshold Values
33605,HALT MI: Angiographic and Angioplasty Results
33606,HALT MI: Clinical and Adverse Events at 30 Days
33613,Cost Effectiveness Among CABG Only Patients Assuming 26  Effectiveness and  973 Cost of Intravenous Amiodarone Therapy   1 g per day 2 days
33614,Cost Effectiveness Among Valve Replacement Only Patients Assuming 26  Effectiveness and  973 Cost of Intravenous Amiodarone Therapy   1 g per day 2 days
33615,Cost Effectiveness Among Combined CABG and Valve Replacement Patients Assuming 26  Effectiveness and  973 Cost of Intravenous Amiodarone Therapy   1 g per day 2 days
33616,Marginal Cost Utility Analysis for CABG Patients Assuming 26  Effectiveness of Therapy, 3  Discount Rate and  973 Cost of Therapy
33620,Plasma Levels of sCD14   g ml  , Genotype and Allele Distribution for CD14 Polymorphism in Patients and Controls
33621,Soluble CD14 Plasma Levels   g ml   and CD14 C   260  T Polymorphism
33622,Age  and Gender Adjusted Plasma Levels of sCD14   g ml   According to Serostatus of C. pneumoniaeand Serostatus of H. pylori
33623,Crude and Adjusted OR for Coronary Artery Disease Associated With sCD14 Plasma Levels and CD14C   260  T Polymorphism
33624,Mean Concentrations      of Various Markers of Inflammation and Hemostasis in Patients and Controls in the Top Quintile of sCD14 Receptor Distribution Compared With the Combined Lower Four Quintiles
33625,Mean Concentrations      of Various Markers of Inflammation and Hemostasis in Patients and Controls According to CD14 Genotypes
33626,Hemodynamic Changes Induced by Dipyridamole and Dobutamine
33633,Clinical Course of the Two Patient Groups
33636,Comparison of Outcomes Between Device and Surgical Closure Groups
33637,Comparison of Complications Between Device and Surgical Closure Groups
33638,Antisense Histopathologic Findings
33639,Histomorphometric Results in Porcine Coronary Arteries 28 Days After Local Delivery of Antisense and Stent Implantation
33643,Correlation Coefficients for CRP and Angiographic Measures of CAD
33644,Hazard Ratio of Elevated CRP for Death or Nonfatal Myocardial Infarction Among Subjects With Angiographic Adjusted for Various Angiographic Markers   on Disease Severity
33647,Ergometric Parameters
33649,Clinical Events at Six Month Clinical Follow Up
33650,Quantitative Coronary Angiographic Analysis
33654,Hemodynamics
33660,Results of Survival Analysis   Cox Proportional Hazards Model   for the Combined End Point: Cardiac Mortality   Urgent Heart Transplantation   Readmission for Congestive Heart Failure
33661,Comparison of Surgical Outcomes and Survival Between Mice With MI and Sham Operated Mice
33662,Study Schedule, Mortality Distribution and Three Day Blood Pressure Measurements of the Various Treatment Groups
33664,Changes in Clinical Parameters After Two Weeks of Sauna Treatment legend legend
33665,Presence or Absence of Correlation Between Plaque Area and IEL Area in Right and Left Femoral Arteries legend legend
33666,Number of Plaques in Which Lipid Rich Core Occupies 40  of Total Plaque Area in Right and Left Femoral Arteries legend
33667,Number of Plaques With Superficial Inflammation in Right and Left Femoral Arteries legend
33668,Histomorphometric Measurements of the Four Studied Groups One Month After Implantation in Porcine Coronary Arteries legend
33669,Two Way ANOVA and Interaction Term of the Histomorphometric Variables Studied legend
33671,Plasma Concentrations of Arginine, Methylarginines, 8 epi PGF2, Lipid Profiles and Blood Pressure Before   Visit 1   and at the End   Visit 2   of Treatment With Oral Arginine Placebo legend
33672,Exercise Tolerance and Ischemia Before   Visit 1   and at the End   Visit 2   of Treatment With Oral Arginine Placebo
33673,CFV Ratio in the LAD During Dobutamine Infusion legend
33675,Intention to Treat Analysis of Mortality Reduction With Abciximab in Studies Randomizing Patients to Standard Therapy or Standard Therapy Plus Abciximab With a 12 h Infusion After PCI legend legend
33676,Mortality Over Time Among All Patients in PCI Studies Randomizing Patients to Standard Therapy or Standard Therapy Plus Abciximab With a 12 h Infusion After PCI   Excludes Patients Not Randomized to a Common Intervention  EPISTENT PTCA Abciximab Group    legend
33678,Relative Changes in Platelet Monocyte Interaction, Mac 1 Expression on Monocytes With Adherent Platelets and P Selectin Surface Expression on Platelets legend legend
33680,Intravascular Nitroprusside Administration legend legend
33681,Change in Cineangiographic Flow with Intravascular Nitroprusside Administration legend legend legend
33682,Hemodynamic Effects of Intravascular Nitroprusside Administration
33684,Comparison of Changes in Lipid Profiles After the Two Week Treatment Period       SEM, n   35   With Cerivastatin or Placebo legend
33690,Plasma Hormone Concentrations   mean  SEM   legend
33692, re  Infarction by Antithrombotic Treatment
33693,Mortality
33697,Follow up Quantitative Angiographic Analysis legend
33698,Major Adverse Clinical Events at One Month and Six Month Clinical Follow up legend
33699,Logistic Regression Analysis for Stent Restenosis legend
33700,Logistic Regression Analysis for Clinical Outcome   MI, Death, TVR   legend
33702,Regional Coronary Blood Flow   ml g min   in LAD and LCX Territory legend
33704,Comparison of BITA versus SITA for Hospital Mortality and Morbidity legend
33705,Multivariate Analysis for Determination of Propensity Score for the Performance of BITA versus SITA Revascularization legend legend
33706,Odds Ratio for Hospital Mortality and Deep Sternal Wound Infections in Bilateral versus Single Internal Thoracic Artery With Various Adjustments legend
33707,Hospital Mortality in BITA versus SITA Revascularization According to Mortality Risk Quartile legend
33710,Unadjusted 30 Day Death or Myocardial Infarction by Transfer Status and Randomized Treatment legend
33711,Incidence and Timing of 30 Day Death or Myocardial Infarction in Transfer Patients legend
33712,Safety by Transfer Status legend
33715,Angiographic Findings in Patients With and Without Coronary Steal legend
33717,Clinical and Electrocardiographic Findings During Coronary Vasodilation in Patients With and Without Coronary Steal legend
33723,Troponin I   g l   and C reactive protein   CRP     mg l   Concentrations According to Prior Aspirin Use: Data for Troponin I Are Number       of Patients With Serum Concentration  0.1 g l, and for CRP Are Medians   Interquartile Range
33724,C Reactive Protein Concentrations   mg l   as a Univariate Predictor of Death or Nonfatal Myocardial Infarction at 30 Days and 12 Months According to Prior Aspirin Treatment: Data Are Median Values   Interquartile Range
33725,Odds Ratios for Association of Maximum C Reactive Protein   CRP   Concentrations With 30 Day and 12 Month Event Free Survival According to Prior Aspirin Treatment legend
33728,Incidence of Adverse Events Recorded During the Early 30 Days
33729,Results at Follow up Angiography legend
33730,Results at Follow up Angiography in Patients  60 Years legend
33735,Patient Population legend legend
33738,Major Adverse Cardiovascular Events and Revascularization legend
33741,Degree of Postthrombotic Syndrome as Defined by Venographic Criteria  After 12 Months legend
33742,Follow up Results After 12 Months Comparing Patients With and Without Postthrombotic Syndrome legend
33743,Efficacy and Safety Results After 7 Days According to Venographic Findings legend
33748,Coronary Diameter and Blood Flow legend
33749,The Effect of Tranilast on the Vessel Response to Balloon Injury legend
33750,The Effect of Tranilast on the Vessel Response to Stent Injury legend
33751,Effects of L Arginine on Brachial Artery Endothelial Function legend
33752,Effects of L Arginine on Cell Adhesion Molecule Expression on Leukocytes legend
33753,Results of RFA of Inappropriate Sinus Tachycardia legend
33755,Clinical Features of Patients With Coronary Artery Disease legend legend
33756,Atherosclerotic Events and Macrophage ColonyStimulating Factor Concentrations in Study Patients legend
33757,Coronary Angiographic Findings and Macrophage ColonyStimulating Factor Concentrations in Patients With Acute Coronary Events legend
33758,Cox Proportional Hazards Regression Analysis for the Predictors of Acute Coronary Events legend
33759,Clinical Features of Patients With a Macrophage ColonyStimulating Factor   MCSF   Concentration 950 pg ml or  950 pg ml legend legend
33760,Study Population legend
33761,Effects of Placebo and Dipyridamole   15 mg in 30 min   on Hemodynamic, Echocardiographic and Electrocardiographic Parameters legend
33762,Results of Exercise Stress Echocardiography After Placebo and Dipyridamole in the Total Population
33764,Technical Results of Angioplasty legend
33766,Initial and Convalescent LV Function by Treatment Group and by Patency Grade
33767,Adverse Outcomes
33768,Association of Traditional Risk Factors With Presence of CAD
33769,Association of CAD Risk Factors With CRP
33771,Quantitative Angiographic Data of the Proximal LAD, Pre  and Postintervention, and at the Time of Study legend
33772,Multivariable Analysis of Change in Luminal Diameter in Response to Maximal Acetylcholine Infusion
33781,Clinical, Angiographic Findings and CFR Values by Both IDFW and Enhanced TTE legend
33786,Incomplete Drug Infusion
33787,Incidence of Major Morbidity and Mortality
33789,Conduits Used for Coronary Revascularization legend
33790,Causes of Operative Death
33791,Operative Morbidity legend
33792,Conduits Used for Coronary Revascularization and Occurrence of Chest Wound Infections legend
33795,Number of HLA Mismatches in A, B and DR Loci legend
33796,Comparison Between Taiwan and Western Series    legend
33798,Ischemic Events and Angiographic Parameters legend legend
33799,In Hospital Complications legend legend
33801,Functional Outcomes   Cases of OnsetReperfusion Time 6 h   legend
33802,Clinical and Echocardiographic Data in DSE Subsets legend
33804,Data in Medically Treated Patients With Hard, Soft and No Events legend
33805,Computer Directed and Clinically Directed Stepwise Multiple Logistic Regression and Cox Proportion Hazard Analysis of Determinants of Hard Events in Medically Treated Patients legend
33807,Summary of Infarct Size Data
33813,Events at 30 Days  legend
33814,Composite Event Rates at 30 Days and During the Total Follow up Period After Exclusion of Diabetic Subjects
33815,Events During the Total Follow up Period
33816,Predictors of Medium Term Outcome in Uni  and Multivariate Analysis
33818,Combined Trial Results for the 30 Day Death Myocardial Infarction Urgent Intervention Outcome by Case Report Form   CRF   Defined Lesion Morphology legend
33824,Intensity of Single Photon Emission Computed Tomographic Perfusion Defects, Wall Motion Abnormalities and Contrast Effects on Patients in Each Randomized Dosage Group legend
33825,Comparison of Sensitivity and Specificity of Myocardial Contrast Effect for Prediction of Moderate and Severe Single Photon Emission Computed Tomographic Perfusion Defects at Each Dose and With Each Imaging Technique  legend
33826,Patient Weighted Data Comparing the Sensitivity and Specificity of Myocardial Contrast Effect for Prediction of Moderate and Severe Single Photon Emission Computed Tomography Perfusion Defects at Each Dose and With Each Imaging Technique  legend
33827,Correlation of Single Photon Emission Computed Tomography   SPECT   With Harmonic Myocardial Contrast Echocardiography in the Triggered Mode, According to the Correlation of SPECT with Wall Motion Analysis   After Exclusion of Nondiagnostic Studies   legend
33828,Subanalysis of Sensitivity, Specificity and Feasibility of Harmonic Myocardial Contrast Echocardiography for Detection of Patients With Moderate and Severe Single Photon Emission Computed Tomographic Defects  legend
33830,Definitions of Events and Derived Time Indexes
33833,Perinatal and Postnatal Data  legend
33835,Arterial Pressure Response to Magnesium or Saline   control group   Infusion legend
33842,Six Month End Points: RESTORE Angiographic Substudy  legend
33844,Flow Data: RESTORE Angiographic Substudy  legend
33845,Six Month Follow Up: RESTORE Angiographic Substudy
33850,Vascular Access Site Complications by Treatment Received in 3,871 Study Patients
33860,In Hospital Clinical Course and Adverse Events  a
33862,One Year Follow Up Data
33863,Study Sample
33867,Effects of Procedure and Drugs on Coronary Diameters
33868,Wall Thickness and Systolic Thickening
33871,Left Ventricular Functional Response to Inotropic Modulation
33875,Clinical Data of the 30 Patients With Isolated Left Anterior Descending Coronary Artery Lesions
33876,Angiographic, Intracoronary Doppler Flow Velocity and Dipyridamole Stress Echocardiographic Data for 30 Study Patients
33877,Results of Discriminant Analysis
33878,Coronary Artery Morphometric Measurements in 21 Stented Vessels
33880,Hemodynamic Responses Before and After Addition of Atropine During Dobutamine Stress in 73 Patients
33886,Effect of Abciximab Administration on Target Vessel Stenosis, Thrombus Grade and TIMI Flow Grade
33889,Results of Discriminant Analysis for RestRedistribution Thallium 201 Single Photon Emission Computed Tomography
33892,Thirty Day Outcome Among Patients With Unstable Angina in the EPIC Trial
33893,Bleeding Complications and Hematologic Values for Patients With and Without Unstable Angina in the EPIC Trial
33894,Outcome Among Patients With Unstable Angina From Study Entry Through 6 Months
33895,Outcome Among Patients With Unstable Angina From 30 Days Through 6 Months
33901,Prevalence of Morphologic Features of Plaque in the Different Groups
33903,Clinical Profile of Patients Undergoing Coronary Angioplasty   PTCA group
33904,Clinical Profile of Patients Undergoing Coronary Arteriography   control group
33905,Summary of Heart Rate and Systolic Blood Pressure Response in 14 Patients With Paradoxical Sinus Deceleration
33906,Summary of Symptoms, Wall Motion Abnormalities and Electrocardiographic and Angiographic Findings in 14 Patients With Paradoxical Sinus Deceleration
33907,Clinical Variables and Medication in Patients Undergoing Dobutamine Stress Echocardiography, According to Heart Rate Response
33908,Symptoms and Heart Rate, Electrocardiographic and Echocardiographic Variables During Dobutamine Stress Echocardiography in Patients With and Without a Decrease in Heart Rate
33909,Hemodynamic Data   mean  SEM
33910,Regional Function in Left Anterior Descending Coronary Artery Territory   mean  SEM
33911,Regional Function in Left Circumflex Coronary Artery Territory   mean  SEM
33912,Hemodynamic Variables and Regional Function Before Each Intervention
33913,Hemodynamic Data and Regional Function at an Ischemic Segment End Diastolic Length of 10 Millimeters   Mean  SEM
33914,Results of Multivariate Regression Analysis of Hemodynamic Determinants of Systolic Bulging
33916,Effects of Dobutamine and MCI 154 on Hemodynamic Variables
33917,Effects of Dobutamine and MCI 154 on Mechanoenergetic Variables
33918,Variables of Vo 2Relation During Control Conditions
33919,Effects of MCI 154 on Vo 2PVA Relations
33920,Effects of Dobutamine and MCI 154 on Emax and PVA Independent Vo 2
33923,Multivariate Stepwise Regression Analysis of Time to Detection of Angiographic Allograft Coronary Artery Disease in a Consecutive Series of 233 Heart Transplant Recipients
33924,Comparison of Risk Factors in Older and Younger Donor Groups
33926,Procedural Details of Patients Undergoing Percutaneous Transluminal Coronary Angioplasty or Directional Coronary Atherectomy
33927,Multivariable Logistic Regression Modeling for Predictors of Non Q Wave Myocardial Infarction
33928,Thirty Day Outcomes by Treatment Group and Interventional Device Used
33929,Bleeding Complications by Treatment Group and Interventional Device Used
33930,Six Month Outcomes by Treatment Group and Interventional Device
33931,C Type Natriuretic Peptide Mediated Coronary Relaxation
33937,Reasons for Discontinuation of DE Treatment at 2 Years
33938,Main Predictors of DE Nonpersistence
33940,Hospital Presentation
33942,Potential Predisposing Factors
33943,Involvement With Noncoronary FMD
33944,In Hospital and Follow Up MACE
33945,Medications at Discharge and Last Follow Up
33946,Univariate and Multivariate Predictors of Recurrent SCAD
33948,Serious Adverse Events and Most Common Side Effects According to Treatment Group
33950,Comparison of EPC Number, EPC Function, and HPC Number Between CAV Negative and CAV Positive Patients
33951,Comparison of CEC and Circulating Endothelial Microparticles Between CAV Negative and CAV Positive Patients
33953,Logistic Regression Model for Prediction of CAV
33956,Summary of AEs
33957,Relatives of 38 HLHS Probands Affected With CVM
33958,Valve Phenotype in 38 HLHS Probands
33959,Hypoplastic Left Heart Syndrome and CVM R
33960,Morphometric Data and Quantification of the Inflammatory Infiltrates of Patients With ARVD and Myocarditis in Normokinetic and Ipo Dyskinetic Right Ventricular Biopsy Sites
33961,Electrocardiographic Arrhythmic and Morphofunctional Parameters of Patients With ARVD Compared With Patients With Myocarditis
33962,Arrhythmic Profile, Histology, Treatment, and Follow Up of 30 Patients With Clinical Profile of ARVD
33963,Clinical Features of Patients With Akinesia at Rest Who Did   Group A   and Did Not   Group B   Develop Dyskinesia With Exercise Echocardiography
33964,Exercise Echocardiographic Features of Patients With Akinesia at Rest Who Did   Group A   and Did Not   Group B   Develop Dyskinesia With Exercise Echocardiography
33965,Predictors of Cardiac Death and Non Fatal Acute Myocardial Infarction.
33966,Predictors of All Cause Mortality
33967,Clinical and Echocardiographic Features of Patients With Akinesia at Rest Who Developed Dyskinesia Following Exercise   Group A   and Patients Who Developed Dyskinesia in Normal or Hypokinetic Myocardium and Did Not Have Akinesia at Rest   Group C
33968,Quantification and Location of Apoptotic Smooth Muscle Cells and Macrophages
33970,Quantitative Coronary Angiographic Results
33971,Quantitative Intravascular Ultrasound Results legend
33973,Global Assessment Data
33974,Change in NYHA Data legend
33976,Adverse Events by Treatment Group legend
33981,Angiographic and Procedural Data of Patients With Diabetes Mellitus Versus Patients Without Diabetes Mellitus With Restenosis After Successful Coronary Atherectomy legend
33982,Total and Segmental Areas of Coronary Restenotic Tissue From Patients With Diabetes Mellitus Versus Patients Without Diabetes Mellitus legend
33983,Total and Segmental Areas of Coronary Restenotic Tissue From Patients With Diabetes Mellitus Treated With Insulin or Hypoglycemic Medication Versus Patients With Diabetes Mellitus Treated With Diet legend legend
33984,Parental History of Premature CHD Death by Study, Age and Gender legend
33985,Symptomatic CHD by Study, Age and Gender in the Offspring legend
33986,Association Between Parental History of Premature CHD Death and CHD in the Offspring in the Three Studies legend
33988,Prevalences of CHD Risk Factors by Study in Men aged 45 to 64 Years legend
33989,Association Between Parental History of Premature CHD Death and CHD Risk Factors in the Offspring in the Three Studies legend
33991,Noninvasive Signs of Reperfusion
33992,TIMI Grade 3 Flow in Infarct Related Arteries in All Patients and in Subgroups With Noninvasive Signs of Reperfusion Treated with Placebo versus Dalteparin
33993,Postthrombolytic Ischemic STVM Episodes 024 Hours and 624 Hours in All Patients and in Subgroups with Noninvasive Signs of Reperfusion legend
33994,Clinical Events Until Follow Up Day 21
33995,Mean and Maximum Lumen and Stent Measurements by QCA, IVUS and Histology
33996,Previously Reported In Vitro IVUS Validation Studies
33998,Left Ventricular Resting Echocardiography
33999,Left Ventricular Exercise Echocardiography
34000,Predictors of Ejection Fraction Increase at 60  Exercise Load
34002,Clinical Outcomes of BrS Patients According to ICD Indication
34004,Parameters Associated With ICD Therapy
34006,Resting Arterial Properties and Central Hemodynamics
34007,Submaximal   20 W   Exercise Arterial and Ventricular Function
34008,Peak Exercise Arterial and Ventricular Function
34009,Effect of Nitrite on Arterial Properties at Rest and Exercise
34011,Clinical Events During 10 Years
34013,Resting and Post Exercise Echocardiographic Data in the StudyPopulation
34015,Reclassification of Patients Who Survived and Who Died During Follow Up
34024,Test Results and Event Rates
34025,Association Between NIT Type and Positive Test Results
34026,Association Between NIT Result and the Primary Composite Outcome
34028,Association of Pulse Pressure With Adverse Cardiovascular Events on Unadjusted and Multivariate Adjusted Analyses
34030,Multivariable Cox Proportional Hazards Regressions: Association Between the Gender Related Score and RecurrentACS
34031,Stepwise Proportional Hazard Regressions: Potential Pathways of the Association Between the Gender Related Score and Recurrent ACS
34033,Resource Use Over 90 Days, by Cohort and Evaluation Strategy: Number of Times Used   Number of Patients With Any Use
34034,Mean Medical Costs Over 90 Days, by Cohort and Evaluation Strategy   U.S. Dollars
34036,Unadjusted and Adjusted Regression Coefficients for Female Sex Predicting thePercentage of YPLL
34037,Unadjusted and Adjusted Regression Coefficients for Black Race Predicting thePercentage of YPLL
34038,Overview of Reports Included in the TTE and TEE Analyses
34039,Overview of Reports Included in the SE, SPECT, and CTA Analyses
34040,Proportion of Appropriate Tests and Their Association With Publication Year in the Total Sample and Among Classifiable Imaging Studies and Examination of the Association Between the Proportion of Classifiable Tests and Publication Years
34041,Meta Regression of the Associations of the Proportion of Appropriate Tests
34042,Meta Regression of Proportion of Rarely Appropriate Tests of Total Sample and Classified Studies as Dependent Variables
34043,Meta Regression of Proportion of May Be Appropriate Tests of Total Sample and Classified Studies as Dependent Variables
34045,Proteomic Profiling in Swine With Hibernating Myocardium With and WithoutRevascularization
34046,Maximum LRC and Mean LRC Changed With the Time of HFC Diet Feeding
34049,Adjusted Risks of Definite Stent Thrombosis
34050,Diagnostic Modalities for Myocardial Bridging
34051,Schwarz Classification for Myocardial Bridges and Treatment
34052,Studies of Percutaneous Coronary Intervention for Myocardial Bridging
34053,Studies of Surgical Interventions for Myocardial Bridging
34055,CT Scan Parameters   n  75
34056,Per Vessel Territory Diagnostic Accuracy of QCA, Coronary CTA, Combined CTA  CTP, Combined CTA  TAG320, and MDCT IP Assessments, Compared With FFR
34057,Per Vessel Diagnostic Accuracy of CTA  TAG320, CTA  CTP, and MDCT IP Methods in 97 Vessels
34060,3 Year Outcomes for Propensity Matched Patients With Single Vessel Proximal Left Anterior Descending Disease Receiving CABG Surgery and Stenting With DES in NewYork State: January 1, 2008 to December 31, 2010 and Followed Through to December31, 2011
34067,Procedural and In Hospital Outcomes of Patients Receiving 6Months and 12 Months of DAPT
34068,Medication Use During Trial in Patients Receiving 6Months and 12 Months of DAPT
34069,Clinical Outcomes in Patients Receiving 6 Months and 12 Months of DAPT
34070,Predictors of the Primary Endpoint at Multivariable Analysis
34072,GRADE Method Evidence Summarizing the Outcomes Measured
34073,Sex Differences in Clinical Presentation for Patients Clinically Referred to Rb 82 Myocardial Perfusion PET
34074,Unadjusted and Adjusted Hazard for CAD Death in Women and Men Undergoing Stress Myocardial Perfusion Rb 82 PET Imaging
34075,Model Subset Including Rest LVEF Measurement and Stress Myocardial Perfusion Rb 82 PET in 2,101 Women and Men
34076,Net Re Classification Improvement for Estimation of CAD Death Using Clinical Risk Variables Combined With Stress Myocardial Perfusion Rb 82 PET Imaging in Women and Men
34078,Performance of CTA, CTP, and Combined CTA CTP for the Detection of Coronary ISR
34079,Performance of CTA and Combined CTA CTP for the Detection of Any Coronary Artery Stenosis
34084,Relationship Between PTSD and CHD Outcome Measures in PTSD Discordant Twin Pairs
34087,Differences in Indications and Appropriateness Among Modalities
34088,Most Common Indications by Modality and Appropriateness Rating
34089,Likelihood of an Abnormal Result by Appropriateness Among the Most Common Indication Groups for Testing
34092,p Values for the Statistical Assessment of Interaction Between Treatment and Presence or Absence of Ischemia for Each Pre Determined Clinical Endpoint
34094,Features Associated With Revascularization
34096,Cox Proportional Hazards Model for Aggregate Clinical Risk Score
34097,Cox Proportional Hazards Model: Aggregate Clinical Risk Score With Imaging Data
34098,Studies Regarding Coronary Intervention Associated Oxidative Stress
34100,Temporal Prevalence of Abnormal SPECT According to Clinical Parameters
34101,Temporal Prevalence of Abnormal SPECT According to Clinical Parameters in Propensity Matched Patients
34102,Temporal Risk Adjusted OR for Having an Abnormal SPECT Study
34104,Multivariable Adjusted Regression Analysis for Cross Sectional Associations of Cardiovascular Risk Factors With Presence of Definite ER at Each Examination
34107,Exercise Capacity Among Patients With Without MSIMI or ESIMI       n   290
34109,Reactivity of Blood Pressure, HR, RPP, and Physical Symptoms During Stress Testing   n   290
34111,Comparison of Diagnostic Protocols in Predicting Functionally Significant CAD   FFR 0.80
34112,Analysis of CTP in Predicting Reversible Perfusion Defects as Assessed by CMR Perf
34113,NPY Promoter Variant 880 rs3037354: Effects on Heritable Autonomic Traits in Twins and Sibs
34114,Meta Analysis of a Human NPY Promoter Variant on NPY Secretion
34116,AgeAdjusted Mean SBP and DBP Among U.S. Adults   20 Years  : NHANES 1999 to 2010
34117,AgeAdjusted Prevalence of Hypertension and Pre Hypertension among U.S. Adults   20 Years  : NHANES 1999 to 2010
34118,Age Adjusted Awareness, Management, and Control of Hypertension Among U.S. Adult Hypertensive Participants: NHANES 1999 to 2010
34121,Medication at Discharge
34122,Clinical Results at 30 Days and 1 Year of Follow Up
34124,TV Versus Remote Clinical Events During Months 7 to 60
34129,Differences Between Different Classes of Medical Therapies   n   76
34130,Univariate Survival Analyses of Changes in Follow Up Variables
34131,Dependence of Myocardial Stiffness on Pressure   n   6
34132,Linear Regression Between Systolic Stiffness and Systolic Pressure
34134,DCMR Findings in Participants With and Without Pulmonary Edema
34135,DCMR Findings in Participants With and Without Isolated Pulmonary Edema and No Inducible Ischemia
34136,NF Donor and Severe Chronic HF Patient Group Details
34139,Univariate and Multivariate Logistic Regression Analysis for Prediction of Reverse Remodeling After Catheter Ablation
34142,International Classification of Diseases 9th Revision Clinical Modification Indications for Initial Stress Testing After Revascularization
34143,Stress Testing Incidence at 24 Months After Index Coronary Revascularization
34147,Unadjusted Factors Associated With SCD
34148,Significant Multivariable Predictors of SCD in Patients With CAD and LVEF  35
34149,Unadjusted HRs 3 U Change in the Summed Stress Score for Different Outcomes
34150,SPECT SCD Nomogram
34151,SCD Rates Across SPECT Nomogram Scores
34152,3 Year Risks for SCD as Predicted by Models That Do and Do Not Include Resting Myocardial Perfusion Data
34154,Magnetic Resonance Results
34157,Clinical Outcomes in Patients Receiving SES Compared With PES
34159,Study Inclusion and Exclusion Criteria
34161,Invasive Procedures in the 2 Randomization Groups
34163,Clinical Outcomes at 30 Days and 12 Months
34164,30 Day Bleeding Events   GUSTO Classification
34167,Predictors of Overall Mortality on Univariate Analysis in the 81 Patients With Low Flow Low Gradient Aortic Stenosis Without Contractile Reserve
34174,CHGA 3 UTR Common Variant C 87T: Effect of the T Allele on BP Status and BP Values
34175,Heritability of Intermediate Traits in Twin Pairs
34178,Adjusted Cox Proportional HR for Nonpropensity  and Propensity Matched Patients
34179,Adjusted Cox Proportional HR for Nonpropensity  and Propensity Matched Patients According to Pre Selected Subgroups
34181,MACE in Different Types of Lesions
34182,Stent Thrombosis
34183,Pre  and Post Operative Data of NYHA Functional Class and of Doppler Echocardiographic Variables in the 24 Patients Included in the MVA Group
34184,Comparison of Resting and DSE Among the Control Group   n   20   and the MVA Group   n   24
34185,Doppler Echocardiographic Data at Rest and During ESE in a Subset of 9 Patients With MVA
34187,Comparisons With the Results of Previous Studies in Patients With Stenosis of Their Native Mitral Valve or With Mitral Prosthetic Valve
34188,Prioritization of Tables from ACCF ASNC Appropriateness Criteria for SPECT MPI
34190,Agreement Between 2 Cardiovascular Nurse Abstractors on Overall Patient Classification   n   582
34191,Classification of Stress SPECT and Stress Echo Patients, According to Table of Indications in Appropriateness Criteria
34192,Inappropriate Studies for Stress SPECT and Stress Echo by Appropriateness Table and Specific Indication
34194,Detailed List of MAE in CABG and PCI Group During the First Year After the Procedure
34196,Hemodynamic Findings During BEE in 104 Individuals
34197,Interpretation by Experienced Observers With or Without Intermediate Stages in Detection of CAD
34198,Interpretation by Less Experienced Observer With or Without Intermediate Stages in Detection of CAD
34199,Comparison of Selected Echocardiographic Variables Between Patients With and Without Ischemia
34200,Comparison of Changes in LVESV From Rest and Smallest LVESV During Exercise to Maximal Exercise Between Patients With and Without Ischemia
34202,Comparison of Different Measures of Functional Capacity in Men
34205,Per Patient, Per Coronary Territory Analysis
34206,Quality Assessment
34207,Baseline Characteristics of the Whole Study Group and of Patients With and Without MACE
34208,Cardiovascular Magnetic Resonance Imaging Data of the Whole Study Group and of Patients With and Without MACE
34210,Cardiovascular Magnetic Resonance Imaging Data of Patients With and Without Major Events in the Whole Study Group
34211,Independent Predictors of MACE and Major Events in the Whole Study Group and in Nonrevascularized Patients
34213,Summary of Blinded and Stenosis Specific MPR Data
34215,Multiple Regression Analysis of Variables Associated With CD40L Levels; Entire Model   Regression Summary for Dependent Variable: R2  0.60, F   5.58; p   0.00005   and Final Model With Stepwise Method
34217,Correlations Between Global Strain Doppler and Cardiac Markers
34218,Multivariate Regression Analysis of All Parameters Versus Magnetic Resonance Imaging
34220,Unadjusted and Multivariable Adjusted Hazard Ratios for the Primary and Secondary End Points
34225,Patient Outcome at 30 Days After Surgery
34231,Stress and Echocardiographic Data in the Invasive Hemodynamic Study
34232,Correlation Between Exercise Capacity and Echocardiographic Variables in the Noninvasive Study
34233,Exercise Capacity According to Resting E E and Subsequent Change in E E With Exercise
34234,Regression Analysis of Clinical and Echocardiographic Variables to Predict Reduced Exercise Capacity    8 METs   in Patients Without Evidence of Ischemia
34236,Hemodynamic Changes and Perfusion Results During Rest and Peak Mental Stress in Individual Subjects
34238,Echocardiographic Data
34239,Hemodynamic Parameters by Cardiac Catheterization
34246,Independent Predictors of Normal Versus Reduced Functional Capacity   DASI 20 vs.  20
34248,Response to Treadmill Exercise and Dipyridamole Stress   n   26
34249,Semi Quantitative and Quantitative Analysis of N 13 PET Myocardial Perfusion Images
34250,Image Quality of N 13 Ammonia PET Myocardial Perfusion Images   Exercise vs. Dipyridamole
34252,Quantitative Coronary Angiography
34253,Major Adverse Cardiac Events During Seven Months of Follow Up
34255,Detection of Coronary Artery Disease in Patients Without Resting Perfusion Defects
34257,Intracellular Recordings
34258,Clinical Features of the Study Patients
34259,Clinical and Stress Test Data of Patients With and Without Events
34260,Material Parameters for Arteries, Plaques, Calcifications, and Lipids Used in Finite Element Models
34264,Unadjusted Outcomes by Operator Volume According to the 75 Procedures Year Definition
34265,Unadjusted Outcomes by Quintile of Operator Volume
34266,Relationship Between Lung Uptake and Summed Stress Score    Category
34268,Stepwise Regression Analysis for the Occurrence of a Primary Event for All Patients
34270,Stepwise Regression Analysis for the Occurrence of a Primary Event for Patients Who Performed Treadmill Exercise Stress Only
34271,Past Medical History by Ethnic Subsets of the Stress Testing Registry
34272,Stress Test Results by Ethnic Subsets of the Stress Testing Registry
34273,Overall Rates of Major Adverse Cardiovascular Events
34274,Comparative Analysis of Ethnicity by SPECT Imaging Results for 90 Day and 2 Year Hospitalization Rates for Nonfatal Cardiovascular Events and Revascularization Procedures
34275,Dipyridamole and Exercise Treadmill Stress Clinical and ECG Data
34276,Dipyridamole and Exercise Treadmill Stress Image Data
34277,Bland Altman and Repeatability Analysis of Summed Scores and Quantitative Defect Size
34278,Concordance of Normal and Abnormal Studies for Exercise Versus Dipyridamole Stress Studies
34279,Body and Heart Weight
34280,Histological Measurements
34281,Differentially Expressed Genes
34286,Predictors for the Healing of Nonculprit Ruptured Plaques
34288,Angiographic Data
34289,In Hospital Complications
34290,MACE at Six Months   In Hospital Complications Included
34291,Clinical Data of the Study Patients
34292,Hemodynamic Data at Different Stages of the Dobutamine Stress Test
34293,Overall Accuracy of Myocardial Contrast Echocardiography and Wall Motion Analysis for the Diagnosis of Coronary Artery Disease   50  Stenosis
34294,Regional Accuracy of Myocardial Contrast Echocardiography and Wall Motion Analysis for the Diagnosis of Coronary Artery Disease in the Three Major Arterial Regions
34296,Comprehensive CMR Analysis and Analysis of Individual CMR Components for the Detection of the Presence of Significant CAD
34297,Combinations of Separate Analyses of CMR Components in the Detection of the Presence of CAD Requiring Revascularization   as Confirmed by X Ray Angiography
34304,Relationship Between Percent Heart Rate Reserve Achieved and Ability to Reach 85  Maximal Age Predicted Heart Rate
34306,Predictors of Postoperative Cardiac Events   MI, Death   in 397 Patients Without Inducible Ischemia During DSE Testing
34307,List of Patients and Specific Assays for Each Group of Samples
34308,Comparison Between Myocardial Contrast Echocardiography and Single Photon Emission Computed Tomography Perfusion Scores
34309,Agreement With Single Photon Emission Computed Tomography for a Moderate to Severe Perfusion Defect
34310,Concordance Between Myocardial Contrast Echocardiography and Single Photon Emission Computed Tomography   SPECT   According to SPECT Results
34312,Independent Predictors of Subsequent Myocardial Infarction Using a Four Step Model
34313,Comparison of Carriers Versus Non Carriers of the Class S Allele in the Heme Oxygenase 1 Gene Promoter in 210 Patients After Femoropopliteal Balloon Angioplasty
34315,Offline Quantitative Coronary Analysis by Core Laboratory
34317,Sensitivity and Specificity of Q Wave of ECG for Diagnosis of Myocardial Scars Identified by a Positron Emission Tomography in Different Infarct Location in the QMI Group   n   43
34318,Comparison of a Signal Region With and Multiple Regional Infarctions   Scar   Identified by a Positron Emission Tomography
34319,Prediction of Ischemic Viable Myocardium by Echocardiography and Electrocardiography
34322,Multivariate Analysis of Clinical and Doppler Echocardiographic Variables   Obtained at Rest and During Maximal Dobutamine Infusion
34323,Multivariate Analysis of Clinical and Doppler Echocardiographic Variables   Obtained at Rest and During Maximal Dobutamine Infusion in Patients With a Mitral Valve Area  1.0 cm2
34324,Hemodynamic and Tissue Doppler Data at Rest and During Dobutamine Stress in the Subgroup of 12 Patients Who Underwent Cardiac Catheterization
34325,Comparison of Ventricular Function Data of Systemic RV in TGA Patients   n   80   With Systemic LV and Subpulmonary RV in Controls   n   55
34326,Comparison of RV Function in TGA Patients With Normal and Abnormal RV Wall Motion
34332,Poor Outcome as a Function of One Negative Emotion at a Time, Adjusting for Age, Left Ventricular Ejection Fraction, and Use of Antidepressants
34333,Independent Predictors of Major Cardiac Events and Health Care Consumption
34336,Periprocedural Events
34338,Variables Associated With Late Occlusion at Follow Up Angiography
34341,Logistic Regression Model Predicting Early Catheterization
34342,Observed Referral Rates to Catheterization as a Function of EF and  Myocardium Ischemic
34343,Logistic Regression Model Predicting Early Revascularization
34347,Risk of Death in Prespecified Subgroups on Univariate Analysis
34348,Results of Cox Multivariate Proportional Model
34353,Longitudinal Systolic Left Ventricular Function Estimated by Regional Velocities and Deformation Parameters in the Apical Four Chamber View
34354,Longitudinal Systolic Left Ventricular Function During Isovolumic Contraction and Ejection in Mid Wall Segments
34355,Septal and Lateral Timing of Left Ventricular Motion and Deformation During Left Bundle Branch Block and Cardiac Resynchronization Therapy in Mid Wall Segments
34356,Effects of CRT on Echocardiographic Parameters
34358,Multivariate Analysis of Clinical, Stress, Perfusion, and Perfusion Function Variables for Predicting Severe 3VD CAD
34359,Odds of Abnormal Scintigraphic Vascular Territories by Perfusion Function Versus Perfusion Alone Matching Angiographic Disease
34361,Outcome Events   n   307
34362,Independent Predictors of Composite End Point
34363,Information Regarding Oligonucleotide Primers Used in Study
34364,Accuracy of Clinical, Electrocardiographic, and Exercise Echocardiographic Findings for the Detection of Significant Infarct Related Artery Stenosis
34366,Effects of Heart Rate and Ischemia in the Infarct Zone on the Accuracy of Exercise Parameters for Detecting Multivessel Disease
34368,Rest and Stress Findings in the Study Population
34369,Univariate Predictors of Total and Cardiac Mortality
34371,Doppler and Other Parameters Recorded at Maximum Hyperemia From the LACB and LCx
34376,Premenopausal WISE Women Historical Reproductive Variables
34377,Significant Predictors of Coronary Artery Disease
34378,Significant Predictors of Hypoestrogenemia of Hypothalamic Origin
34379,ECG, PAT Alone, and PAT Enhanced Sensitivities and Specificities
34384,Mitral Valve Area Before and During Dobutamine Infusion in Group II Patients
34386,Clinical Features of Patients With and Without Hard Cardiac Events
34387,Exercise Test and Echocardiographic Data for Patients With and Without Hard Cardiac Events
34389,Cumulative Event Rate During Five Year Follow Up According to the Presence and Extent of Exercise Echocardiographic Abnormalities
34390,Independent Predictors of Cardiac Events Using Five Step Model
34392,Maximal and Submaximal Exercise Performance in Control and Training Groups
34393,Leg and Respiratory Muscle Strength, Endurance, and Anthropomorphic Measurements of Control and Training Groups
34394,Quality of Life Scales in the Control and Training Groups
34397,Patients With Redistribution Compared With Those With Reverse Redistribution
34402,Echocardiographic Results
34403,Preoperative Data: Patients With or Without Evidence of Mismatch
34404,Predictors of PPM at Univariate Analysis
34405,Changes in LVMI   g m2
34408,Clinical Outcomes of the Comparison Groups at 12 Months After Randomization
34413,Events by Risk Group in the Study Population During Follow Up
34414,Events by Risk Group in the Control Population During Follow Up
34415,Survival Rates by Risk Group in Study and Control Populations
34418,Univariate and Multivariate Predictors   of Outcome
34422,Laboratory Data in Patients With Cyanotic and Acyanotic Congenital Heart Disease
34423,MRI Flow Reserve Indices and Coronary Flow Reserve by PET in Normals and Patients
34424,Forms of Induced AVNRT
34427,Univariable Predictors of Cardiac Events
34428,Multivariable Predictors of Cardiac Events   Cox Regression Analysis   in Patients Undergoing Exercise Stress Echocardiography
34429,Peak Tissue Doppler Velocity at Rest and During Dobutamine Stimulation Related to Results of 18F Fluorodeoxyglucose Positron Emission Tomography for 192 Dyssynergic Segments at Rest
34430,Peak Systolic SR Data at Rest and During Dobutamine Stimulation Related to Results of 18F Fluorodeoxyglucose Positron Emission Tomography for 192 Dyssynergic Segments at Rest
34431,Diagnostic Accuracy of Two Dimensional Dobutamine Stress Echocardiography, TDI and SRI for Detection of Viability Determined by 18F Flurodeoxyglucose Positron Emission Tomography
34432,Acoustic Intensity Ratios in the Hypoperfused Zone Compared to the Normal Bed
34433,Arteriolar Dimension and Hemodynamic Data From Intravital Microscopy Experiments
34434,Clinical Variables of Patients According to Blood Pressure Response to Exercise legend
34436,Hemodynamic Monitoring Four Weeks After MI
34437,Heart and Lung Weight Four Weeks After MI
34442,One Year Event Rate legend
34443,Angina Pectoris Between Six Months and One Year
34445,Temporal Changes in the DFT legend
34447,Pre Procedural, Post Procedural and Six Month Follow Up Quantitative Coronary Angiographic Analysis of Treated Lesions legend legend
34448,Multivariate Analysis: Clinical and Quantitative Coronary Angiographic Predictors of Coronary Restenosis legend
34449,Angiographic Results legend legend
34450,Intravascular Ultrasound Data legend legend
34451,Time Trajectory of High and Low Frequency HRV Components Before Ischemia and Heart Rate matched Nonischemic Control Periods   Mean  SD   legend
34452,HRT Use Patterns by Onset of HRT legend
34454,Index Myocardial Infarction legend
34455,Unadjusted Cardiac Event Rates During Follow Up by HRT Use legend
34456,Adjusted Risk of Cardiac Events Among Prior Current and New Users of HRT Compared With Never Users   Hazard Ratio and 95  CI   legend
34458,Comparison of IVUS Findings Between the Yellow and the White Plaques legend legend
34461,Cox Proportional Hazard Analysis of the Effect of Surgical Treatment on Survival Duration in the Two Groups
34464,Coronary Risk Factor Variables legend
34465,Multiple Regression Analysis to Predict the Progression Regression Score legend
34468,Incidence of Clinical End Points in Different Treatment Groups legend
34469,Two Year Event Free Survival Rate in Different Treatment Groups legend
34470,Incidence of TVR and MACE in Different Treatment Groups According to Diabetes Status legend
34471,Freedom From Repeat Revascularization at Six Months
34472,Six Month Clinical Outcomes With and Without Stent Like Results legend
34473,Predictors of Repeat Revascularization at Six Months
34474,Six Month Clinical Outcomes and Costs for Stenting Strategies
34476,Two Dimensional and Doppler Echocardiographic Parameters legend legend
34477,Correlations Between Pulmonary Doppler Variables and Pulmonary Vascular Resistance legend
34478,Results of Stepwise Regression Analysis of Doppler Indexes on Pulmonary Flow Versus Pulmonary Vascular Resistance legend legend
34483,Multivariate Analyses Predicting Mental Stress Induced Coronary Diameter Response From Diastolic Blood Pressure Increases and Control Variables
34484,Lung and Liver Wet Dry Weight Ratios and Hemodynamic Parameters at 16 Weeks Post MI With and Without Losartan Treatment legend legend
34485,Myocardial Reduced   GSH   and Oxidized   GSSG   Glutathione Levels in Sham Control and Post MI Rats at 16 Weeks With and Without Losartan Treatment legend legend
34487,Univariable Predictors of Cardiac Events   Cox Regression Analysis   in Patients Undergoing Exercise Stress Echocardiography legend
34489,Multivariable Predictors of Cardiac Events in Patients Undergoing Exercise Echocardiography legend
34490,Multivariable Predictors of Cardiac Death in Patients Undergoing Exercise Echocardiography legend
34491,Agreement Between MCE, SPECT and Wall Motion Abnormalities: Analysis by Patients legend
34492,Agreement between MCE, SPECT and Wall Motion Abnormalities: Analysis by Coronary Territory legend
34493,Comparison of MCE, SPECT, Wall Motion and the Combination of MCE and Wall Motion With Results of Coronary Angiography: Analysis by Patients   n   44   legend
34497,Mean 24 h Values   SD   for QT Interval, QT Interval Variability and RR Interval in Patients With and Without MAE legend
34499,Levels of TxB2, iPF2 III and iPF2 VI in the Coronary Sinus and in the Left Main Coronary Artery Before PTCA legend
34500,Levels of iPF2 III and iPF2 VI in Patients Undergoing Diagnostic Coronary Angiography   n   4   legend
34503,Independent Predictors of Cardiac Death legend
34504,Changes in Echocardiographic Parameters in the Control Rats and Rats of Group CAND     and CAND      legend legend
34505,Results of Hemodynamics and Pathology at 19 Weeks legend legend
34506,Effects of Candesartan and Enalapril on Geometry, Hemodynamics and Pathology at 19 Weeks legend legend
34508,Metabolic and Neuroendocrine Measurements legend
34509,Cardiac and Renal Measurements legend
34510,Clinical Data on 10 Patients With Transplant Coronary Artery Disease Who Died Suddenly With No Prior Diagnosis legend
34511,Clinical Data on 14 Patients With Angiographic Diagnosis of Transplant Coronary Artery Disease legend
34513,Rejection Frequency Following Transplantation in Patients With and Without Transplant Coronary Artery Disease legend
34515,First Cardiac Event per Patient After Randomization legend legend
34518,Coronary Angiography legend legend
34519,Pacing Stress Echocardiographic Results According to Lesion Severity
34525,Myocardial Perfusion at Rest legend
34526,Myocardial Perfusion at Peak Exercise legend
34529,Predictors of Future Cardiac Events According to Univariate Cox Analysis
34531,Number of Events       legend
34532,Univariable and Adjusted Relative Risks of Total Mortality, Cardiac Death, Repeat Coronary Bypass Surgery or Coronary Angioplasty legend
34533,Effects of Three Day Nitroglycerin Treatment of Rabbits   Continuous or 12 h Patch On Patch Off   on the Potency and Efficacy of Nitroglycerin or Acetylcholine to Produce Relaxations in Aortic Rings legend
34534,Effects of Continuous or Intermittent Nitrate Therapy on 50  Effective Concentration and Maximal Constrictions to Phenylephrine, Serotonin, Angiotensin II and Potassium Chloride legend legend
34536,Medications Administered in the Drug Therapy Group After Enrollment legend
34537,Quality of Life and Symptoms Scores in the Drug Therapy Group legend
34538,Quality of Life and Symptoms Scores in the Catheter Ablation Group legend
34541,Coronary Anatomy legend
34543,Mean Workload, Cardiac Output, Maximal Rate Pressure Product, Mean Heart Rate and Percent of Age predicted Heart Rate
34547,Univariate and Multivariate Cox Proportional Hazard Analysis for the Identification of Patients at Risk for PAF legend
34548,Prediction of the Development of Paroxysmal Atrial Fibrillation by an Abnormal P SAECG Elevated ANP Level and a Combination of the Two legend
34552,Lipid Levels During Placebo and Pravastatin Treatment legend
34553,Scintigraphic Values During Dipyridamole Stress and at Rest During the Placebo and Pravastatin Phases legend
34555,Accuracy of Different Modalities in Prediction of Recovery of Function in Severely Dysfunctional Segments legend legend
34556,Prediction of Recovery of Function in Akinetic Dyskinetic Segments and in Severely Hypokinetic Segments legend legend
34557,Sensitivity and Specificity for Improvement in Left Ventricular Ejection Fraction of 5  Using Increasing Cutoffs of Number of Viable, Dysfunctional Segments by EDWT, Tl 201 Scintigraphy and DSE legend
34558,Distribution of Cardiac Events in Relation to Stress Results legend
34559,Univariate Predictors of Cardiac Events legend
34560,Stepwise Predictor of Cardiac Events legend
34563,Cause of Death legend legend
34564,Cause of Death
34565,Cause of Noncardiac Deaths legend
34567,Final Classification: Events Committee Versus Principal Investigator
34568,Variables Evaluated for Association With Exercise Performance legend
34569,Ventricular Morphology in Study Patients legend
34570,Exercise Performance in the Study Population legend
34571,Association Between Candidate Predictors and VO2max   Percentage Predicted
34572,Comparison of Exercise Performance Between Early and Late Volume Unloading Groups legend
34575,Summary of Coronary Angiography, Cardiac Catheterization and Revascularization in 12 Patients With Transient Atrioventricular Block legend
34576,Clinical and Dobutamine Stress Echocardiographic Parameters in Patients With and Without AVB legend
34578,Sensitivity, Specificity, Positive and Negative Predictive Values and Accuracy With 95  Confidence Intervals of Low Level Exercise and Low Dose Dobutamine Echocardiography to Predict Reversible Dysfunction legend
34579,Clinical and Coronary Angiographic Data in 14 Patients legend
34580,Myocardial Blood Flow   ml min 100 g   and Coronary Flow Reserve by Positron Emission Tomography legend
34581,Clinical and Angiographic Base line Data
34582,Quantitative Coronary Angiography Results Analyzed by Intention to Treat and by Treatment legend
34583,Events and Clinical data legend
34584,Pooled End Points of the Four Stenting for Chronic Occlusion Trials SPACTO, SICCO    9   , Mori et al.    10   and GISSOC    11   , analysis by intention to treat legend legend
34585,Corresponding Quantitative Angiographic Data of SPACTO, SICCO    9   , Mori et al.    10   and GISSOC    11   , analysis by intention to treat legend
34586,Event Rate Occurrence in Relation to Dobutamine Echocardiographic Results legend
34587,Comparison of Patients With and Without Cardiac Events   Univariate Analysis   legend
34588,Characterization of Hypertrophy and In Vivo Left Ventricular Function legend legend
34589,Left Ventricular Gene Expression in Male and Female Normal Rats legend
34593,Comparison of Intravascular Ultrasound Measurements and Indexes Between the Two Groups With Positive and Negative Myocardial Perfusion SPECT Results legend
34594,Functionally Significant Coronary Artery Stenosis Determined by Intravascular Ultrasound Imaging legend legend
34597,Concordance Between Results of Supine Bicycle and PostTreadmill Exercise Echocardiography legend
34598,Aortic Atheroma Classification and Location of Aortic Plaques on Thoracic Aorta legend
34599,Treatment According to the Aortic Atheroma
34600,Follow up According to the Aortic Atheroma legend
34601,Comparison of Events According to Aortic Atheroma and Antithrombotic Treatment
34603,Clinical Correlates legend legend
34604,Echocardiographic Correlates legend
34607,Changes in Quality of Life Responses After Revascularization
34608,Correlation Between Change in Constituent QOL Indices and Extent of Viable Myocardium by PET and DbE
34610,Hemodynamic Findings legend
34612,Results of Mental Stress Testing: Radionuclide Ventriculography legend
34613,Results of Mental Stress Testing: Radionuclide Ventriculography Diastolic Variables  legend
34614,Percentage of Viable Myocardium in Relation to 99mTc Tetrofosmin Activity   Number of Segments   legend
34617,Angiographic Analysis
34618,LV Remodeling: 6 Weeks After Aortic Banding legend
34619,LV Remodeling: 20 Weeks After Aortic Banding legend
34620,Morphometric Data at 20 Weeks
34621,Utilization  of Stress Tests in Olmsted County, Minnesota, 1987 to 1988 legend
34622,Incidence of Stress Tests in Olmsted County, Minnesota, 1987 to 1988 legend
34624,Indications and Stress Test Results in Persons With an Incident Stress Test, Olmsted County, Minnesota, 1987 to 1988, by Gender legend
34625,Coronary Disease   International Classification of Diseases, 9th revision codes 410 to 414   Mortality Rates for Olmsted County Residents for Years 1987 to 1993 legend
34627,Cardiac Events During Follow up in the Three Groups of Patients legend
34634,Clinical Data of Patients With a First Transmural Acute Myocardial Infarction With or Without Rupture  legend
34635,Frequency of Admission Delay   24 h  , In Hospital Unusual Physical Effort and Angina in Patients With Rupture   years 1978 to 1989 and 1990 to 1995   and Control Patients  legend
34636,Segment Distribution According to Visual Score of Stress Images During Single Photon Emission Computed Tomography With and Without Antianginal Therapy  legend
34637,Results of Visual Analysis Indexes legend
34638,Quantitative Analysis: Mean Defect Size   percent coronary artery territory at stress and rest imaging   legend
34640,Hemodynamic Responses to Dipyridamole and Exercise Stress Testing  legend
34641,Comparison of Regional MDR in Each Region of Interest
34642,Comparison of Clinical Variables in Patients With Versus Those Without a Cardiac Event
34643,Comparison of Stress Testing Variables in Patients With Versus Those Without a Cardiac Event
34644,Comparison of Thallium Variables in Patients With Versus Those Without a Cardiac Event
34645,Data at First Operation
34646,Follow Up Results Between Operations
34647,Follow Up Data
34648,Relation Between the Slopes of the End Systolic Tactile StiffnessVolume Relation and the End Systolic PressureVolume Relation
34649,Comparison Between Stiffness of Infarcted and Intact Myocardium
34650,Clinical, Left Ventriculographic, Coronary Angiographic and Prerevascularization and Postrevascularization Magnetic Resonance Imaging Findings
34651,Comparison of Magnetic Resonance Imaging Findings Based on Dobutamine Induced Systolic Wall Thickening and End Diastolic Wall Thickness With Postrevascularization Recovery of Systolic Wall Thickening
34652,Infarct RegionBased Predictive Accuracy of Magnetic Resonance ImagingAssessed Dobutamine Induced Systolic Wall Thickening and Preserved End Diastolic Wall Thickness for Recovery of Regional Left Ventricular Function After Successful Revascularization
34653,Myocardial Infarct Size in Untreated and Treated Rats
34654,Body and Heart Weights
34655,Hemodynamic Variables Before Thoracotomy
34657,Peak Cardiac Performance
34658,Stiffness Values
34659,Operating Volume and Volume Left Ventricular Weight Ratio
34662,Clinical Events at 1 Year
34663,Preoperative Clinical Data
34664,Left Ventricular Size and Function Before and After Mitral Valve Replacement
34665,Univariate Analysis of Stress Variables
34671,Angiographic and Hemodynamic Data for Target Lesions
34672,Intracoronary Flow Velocity Measurements in Target Lesions
34673,Determinants of Coronary Flow Velocity Reserve: Stepwise Regression Analysis
34675,Subgroup Analysis of Accuracy for Reversible Segmental Dysfunction
34677,Sensitivity and Specificity of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography for Detection of Improved Regional Contractile Function After Revascularization
34678,Sensitivity and Specificity of Thallium 201 Reinjection Imaging for Detection of Improved Regional Contractile Function After Revascularization
34679,Sensitivity and Specificity of Thallium 201 RestRedistribution Imaging for Detection of Improved Regional Contractile Function After Revascularization
34680,Sensitivity and Specificity for Technetium 99m Sestamibi Scintigraphy With and Without Addition of Nitrates for Detection of Functional Recovery After Revascularization
34681,Sensitivity and Specificity for Low Dose Dobutamine Echocardiography for Detection of Improved Regional Contractile Function After Revascularization
34682,Sensitivity and Specificity for the Different Imaging Techniques   based on weighted mean values from available studies
34684,Individual Peak Myocardial Videointensity Data   in gray scale units   in Middle and Lateral Segments of Original Stenosis Zone and Adjacent Perfusion Bed in the Presence of One  and Two Vessel Stenosis During Both Rest and Dobutamine Stress Echocardiography
34686,Transluminal Extraction Catheter Atherectomy Stent Equipment
34687,Procedural Outcomes
34688,In Hospital Outcomes in 49 Study Patients
34689,Late Outcome in 46 Study Patients
34691,Clinical Features of Patients Undergoing Follow Up Examination or Primary Revascularization Versus Patients Lost to Follow Up
34692,Association of Clinical, Stress Testing and Echocardiographic Features With Total Cardiac Events by Multivariate Proportional Hazards Survival Analysis
34693,Association of Clinical, Stress Testing and Echocardiographic Features With Spontaneous Cardiac Events by Multivariate Proportional Hazards Survival Analysis
34694,Frequency of Ischemia Related Adverse Clinical Events
34696,Factors Associated With Ischemia Related Adverse Outcomes: Multivariate Analysis  a
34700,Dobutamine Stress Protocol and Hemodynamic Responses in 3,011 Patients Studied Between 1991 and 1995
34701,Major Arrhythmias in 3,011 Dobutamine Echocardiograms Between 1991 and 1995
34703,Myocardial Perfusion Patterns by Vascular Territories
34704,Multivariate Prediction of Cardiac Geometry
34705,Multivariate Prediction of Carotid Geometry
34706,Relations Between Cardiac and Carotid Geometry Independent of Stroke Volume
34708,Events After Dobutamine Stress Echocardiography
34709,Long Term Follow Up Results in Patients With Normal Exercise Thallium Test Results or Angiographically Normal or Minimally Diseased Coronary Arteries
34710,Clinical Findings in Patients With Painful or Silent Reversible Sestamibi Perfusion Defects During Exercise
34711,Comparison of Exercise and Scintigraphic Data in Patients With Painful or Silent Reversible Sestamibi Perfusion Defects
34712,Multivariate Predictors of Painful Reversible Perfusion Defect
34713,Thallium 201 Myocardial Perfusion Scintigraphic Studies Comparing the Amount of Ischemic Myocardium in Patients With or Without Chest Pain During Exercise Testing
34716,Diagnostic Test Results
34717,Clinical Variables Associated With Cardiac End Points  a
34719,Results of the Exercise Test and Extent of Ischemia   polar map   in the 20 Patients With and Without Simultaneous Dipyridamole Administration
34720,Results of 99mTc MIBI SPECT
34721,Rest and Dobutamine Stress Findings in 778 Study Patients
34722,Event Rate Occurrence in Relation to DobutamineAtropine Stress Echocardiographic Results
34723,Stepwise Predictors of Cardiac Death
34724,Effect of Exercise Induced Ischemia on Postexercise Diastolic Filling, Blood Pressure and Heart Rate in the Three Study Groups
34725,Effect of Exercise on Postexercise Diastolic Filling, Blood Pressure and Heart Rate in the Three Control Groups
34726,Effect of Exercise Induced Ischemia on Postexercise Systolic Function in Study Groups
34727,Effect of Exercise on Postexercise Systolic Function in Control Groups  a
34728,Postexercise Ischemia Induced Regional Wall Motion Abnormalities
34730,Clinical Events
34733,Results of Logistic Regression Analysis: Independent Predictors of Sustained Monomorphic Ventricular Tachycardia Occurrence
34734,Univariate Analysis of In Hospital Death
34735,Results of Logistic Regression Analysis: Independent Predictors of In Hospital Death
34736,Comparison of Patients with Sustained Monomorphic Ventricular Tachycardia and Those with Ventricular Fibrillation
34738,His Ventricle Interval and His Potential Amplitude in Patients with 2:1 Atrioventricular Block During Atrioventricular Node Reentrant Tachycardia
34740,Arterial Pressures and Muscle Sympathetic Nerve Activity During Intrinsic Rhythm and During Single  and Dual Chamber Pacing
34742,Incidence of Balloon Deflation
34743,Number of Patients in Total Study Group and Subgroups
34744,Electrocardiographer and Artificial Neural Network Classifications of 1,664 Electrocardiograms
34747,Quantitative Coronary Angiography Analysis   Per Patient Analysis, Index Lesion
34748,Cumulative Incidence of Clinical Events Up to 1 Year   Intention to Treat Per Patient
34751,Clinical Outcomes at 6 and 12 Months According to Statin Medication
34752,Cumulative Secondary Endpoints at 12 Months According to Statin Medication
34754,Paired QCA Analysis
34755,IVUS Results
34758,Associations of Serum 25 OHD Concentration With Study Outcomes
34759,Associations of Serum PTH Concentration With Study Outcomes
34760,Combined Associations of 25 OHD and PTH Concentrations With Study Outcomes
34761,Studies Included in the Meta Analysis
34763,1 Year Outcomes in Left Main Patients Revascularized by PCI or CABG
34765,Outcome Data: Subsequent Aortic Valve Replacement, All Cause Mortality, Cardiac Mortality, and Sudden Cardiac Deaths According to the Pattern of LGE
34766,Cox Proportional Hazards Model: Univariate Analysis for All Cause Mortality
34767,Cox Regression Multivariate Analysis for All Cause Mortality
34769,Correlations Among Psychosocial Measures in the Nova Scotia Health Survey 1995
34771,Cook Medley Subscales and Incident IHD
34775,Adverse Events at 1 Year
34778,1 Month Outcomes in GR   VASP Index  50    and in Patients With HTPR   VASP Index 50
34779,Univariate Analysis Comparing Patients With and Without Events
34782,Influence of rs1333040 Genotype on the Primary Endpoint and on the Individual Components of Primary Endpoint
34783,Independent Predictors of the Primary Endpoint: Estimated Hazard Ratios, 95  Confidence Intervals, and p Values
34784,Administration of Intravenous tPA to Acute Ischemic Stroke Patients
34785,Administration of Intra Arterial Thrombolysis to Acute Ischemic Stroke Patients
34786,Outcomes of Recent CBT Trials for Acute Stroke
34789,Clinical Outcome
34791,Clinical Events During Follow Up
34792,Outcome Differences Between 1 Year and 2 Years
34794,Aspirin and Thienopyridine Usage
34795,Adverse Events at 1  and 2 Year Follow up According to Stent Randomization
34796,Adverse Events Between 1 Year and 2 Years   Landmark Analysis
34798,1 Year Clinical Outcomes According to SYNTAX Score Tertiles
34800,Receiver Operator Characteristic Curve Analysis Demonstrating the Association Between SYNTAX Score and Individual Adverse Ischemic Outcomes
34803,Bleeding Complications in the 2 Groups
34804,Ischemic Complications in the 2 Groups
34805,Outcomes in the Switch Group According to the ACT at the Beginning of Cardiac Catheterization Before Bivalirudin Administration
34808,Procedural Results Stratified by Complexity
34809,Clinical Events at 30 and 360 Days Stratified by Complexity
34810,ARC Defined ST Stratified by Complexity
34811,Angiographic Results at 13 Months Stratified by Complexity
34813,HRs for Clinical Outcomes After DES Implantation Compared With CABG, According to SYNTAX Score Category
34814,Cox Proportional Hazards Analyses of Time to Clinical Events Among Overall Patient Group
34816,Pre Randomization LDL C and LDL C Response to Simvastatin in the Heart Protection Study by KIF6 Trp719Arg   rs20455   Genotype
34818,Distribution   Prevalence,     of Ideal Cardiovascular Health Metrics in Various Subgroups of the ARIC Study Participants Free of Cardiovascular Disease, 1987 to 1989
34820,Incidence Rate and Hazard Ratios of Cardiovascular Disease According to the Number of Ideal Cardiovascular Health Metrics, ARIC Study, 1987 to 2007
34823,Univariate and Multivariate Predictors of ISR
34826,Incidence Rates of CV Events in Fabry Registry Patients
34827,Univariate and Multivariate Analyses of Parameters Related to the Occurrence of CV Events
34831,QCA in Entire Cohort of Patients
34832,Quantitative Coronary Analysis for POC Area
34833,Clinical Outcome
34834,Patients With ST
34835,Wild Type Mi Echocardiographic, Hemodynamic, and Morphometric Analyses
34836,eNOS Deficient Mi Echocardiographic, Hemodynamic, and Morphometric Analyses
34837,Subsequent Modifications to Initial STEMI Protocol
34838,Definitions of Times and Intervals
34840,Treatment Times
34841,Median Treatment Times by Individual Community Hospital
34842,Treatment Times by Workday Hours Versus Off Hours
34843,In Vivo Cardiac Functional Parameters After Adrenal Gene Delivery
34846,Univariate and Multivariate Cox Regression Analysis for All Cause Death and Coronary Events
34848,Hazard Ratios for Clinical Outcomes After DES as Compared With After CABG in the Overall Population and in Selected Major Clinical Subgroups of Patients
34849,Hazard Ratios for Clinical Outcomes After DES as Compared With After CABG According to Extent of Diseased Vessels
34850,Hazard Ratios for Clinical Outcomes After DES as Compared With After CABG, According to Clinical Scoring   EuroSCORE   and Anatomic Scoring   SYNTAX Score   Systems
34855,HRs   95  CI   for Adverse Clinical Outcomes by Different S and SRs With and Without Adjustment for LVEF and Clinical Variables
34856,HRs   95  CI   for All Cause Mortality With and Without Adjustment Stratified by Longitudinal S and SRs Group
34857,HRs   95  CI   for All Cause Mortality With and Without Adjustment Stratified by Circumferential S and SRs Group
34859,Kinesin Like Protein 6 Trp719Arg Polymorphism   rs20455   Allele Frequencies, Genotype Counts, and Odds Ratios Adjusted for Age and Sex in 19 Case Control Studies of CAD, Stratified by Race Ethnic Group
34860,Kinesin Like Protein 6 Trp719Arg Polymorphism   rs20455   Allele Frequencies, Genotype Counts, and Odds Ratios Adjusted for Age and Sex in 19 Case Control Studies of CAD, Stratified by Race Ethnic Group and Restricted to Early Onset Disease   Age at Onset of CAD Younger Than 50 Years of Age for Men and Younger Than 60 Years of Age for Women   and Similarly Aged Controls
34862,Angiographic Findings of Patients Previously Using and Not Using Aspirin
34863,Management of the ACS According to Prior Aspirin Use
34864,Clinical Outcomes at Day 30 According to Prior Aspirin Use
34865,Clinical Outcomes at Last Follow Up Visit   Mean 328 Days   According to Prior Aspirin Use
34868,Clinical Events at Follow Up
34869,Quantitative Angiographic Analysis
34871,Treatment Strategy of Statin Therapy
34872,Assessment of Study Quality Components
34874,Univariable Meta Regression Evaluating for Effect Modification of Statin Therapy on Post Procedure Myocardial Infarction
34877,Spatial Resolution of Pace Mapping for 12 Lead ECG and Far Field ICD Signals
34879,Comparison of ICD EGMs by Manufacturer
34880,Discriminatory Value of ICD Signals
34882,Clinical Outcomes
34883,Stent Thromboses
34887,Univariable and Multivariable Associations With All Cause Mortality
34890,Clinical Outcomes at 360 Days After Index PCI Based on Tertiles of SXscore
34892,Procedural Results
34893,End Points at 2 Years
34895,Overview of Bivariate and Multivariable Associations of Anxiety With Incident CHD
34897,LDL C as a Function of PCSK9R46L Genotype
34898,Risk of IHD, MI, and Mortality in PCSK946L Allele Carriers Versus Noncarriers in the CCHS, CGPS, and CIHDS
34901,Angiographic Outcomes at 6 to 8 Months
34902,Clinical Results at 1 Year
34904,Management and Long Term Outcomes on the Basis of Troponin Results
34905,Number of Major Adverse Events Across the 4 Subgroups on the Basis of H FABP Concentrations and Stratified by Troponin Results
34906,HRs for Death or MI After Median Follow Up Period of 18 Months
34907,HRs for Death or MI Stratified by H FABP Results Among Troponin Negative Patients
34909,Clinical Events at 1 and 2 Years
34910,Angiographic Data at 6 to 8 Months and Composite Angiographic Data at 2 Years
34912,Outcomes by Study and Treatment
34913,Univariable Associations With CV Death or MI
34914,Multivariable Predictors of CV Death or MI   Cox Regression
34915,Treatment Effect by Integer Risk Category of CV Death or MI
34918,Frequency of No Reflow and 5 Year Mortality in Patients With No Reflow and Reflow in Each Infarct Size Tertile
34922,Univariate and Multivariate Cox Proportional Hazards Analysis
34923,Definition of MI
34928,All Cause 5 Year Cumulative Mortality Rates for Matched Pairs of CR Users and Nonusers by Clinical Groups
34929,One  and 5 Year Benefit of CR Use by Analytic Technique
34931,Unadjusted and Adjusted Risk for Significantly Obstructive CAD Prevalence and MACE at 3 Years With Decreasing Quartiles of GABR and Arginine Levels
34932,Unadjusted and Adjusted Risk for Significantly Obstructive CAD Prevalence and MACE at 3 Years With Increasing Quartiles of Citrulline and Ornithine Levels
34934,Inclusion Criteria, Exclusion Criteria, and End Point Definitions of the Trials
34936,Adverse Events at 10 Years
34939,Quantitative Angiographic Measurements
34940,Angiographic Patterns of Restenosis
34941,Clinical Outcomes at 9 Months
34944,RR   95  CI   for Cardiovascular Disease According to Categories of Anthropometric Indexes Among 16,332 Men
34945,Multivariable Model Adjusting for the Variables in Model 1     Plus History of Diabetes, Hypertension, or Elevated Cholesterol
34946,RR   95  CI   for Cardiovascular Disease According to Categories of Anthropometric Indexes Among 32,700 Women
34947,Multivariable Model Adjusting for the Variables in Model 1     Plus History of Diabetes, Hypertension, or Elevated Cholesterol
34948,RR   95  CI   for Cardiovascular Disease According to WHtR and Age Among Men
34949,RR   95  CI   for Cardiovascular Disease According to WHtR and Age Among Women
34952,HR for Cardiovascular Events and OR for Angiographic Progression   and 95  CI   Among Post CABG Participants According to BMI and Statin Treatment
34954,Comparison of Cardiovascular Events Between the Positive Group and the Negative Group
34956,Multivariate Cox Regression Analyses
34958,Relationship Between Angiographic Electrocardiographic Parameters, and First Pass Perfusion and Late Gadolinium Enhanced Imaging
34961,Cases of Acute Myocardial Infarction   Ami   Reported Each Season to the National Registry of Myocardial Infarction BY all Core Hospitals During the Study
34963,Adjunctive Medical Therapy
34964,Diabetes and 90 Minute Angiographic Patency
34965,Quantitative Coronary Angiography 90 Minutes after Thrombolytic Therapy
34966,Global and Regional Left Ventricular Function in Diabetic and Nondiabetic Patients with a Patent   Timi Flow Grade 2 or 3   Infarct Related Artery
34967,Multivariable Analysis: Clinical and Angiographic Independent Determinants of Left Ventricular Global and Regional Function in Acute Myocardial Infarction
34969,Angiographic Outcome and Frequency of Adverse Events During 30 Days After Attempted Angioplasty of an Occluded Vein Graft
34970,Clinical Features
34971,Pathologic Features
34973,Median Lipoprotein  a   Concentrations for Different Subgroups   univariate analysis
34974,Risk for Acute Myocardial Infarction by Quintiles of Lipoprotein  a   Concentrations
34975,Costs of Primary Angioplasty Under Varying Assumptions About Resources  a
34979,Global Left Ventricular Function and Regional Wall Motion 3 Weeks After Myocardial Infarction in Patients Treated With Intraaortic Counterpulsation and in Control Subjects
34980,Clinical Outcomes in Patients Treated With Intraaortic Balloon Counterpulsation and in Control Subjects
34981,Hemorrhagic and Vascular Complications in Patients Treated With Intraaortic Balloon Counterpulsation and in Control Subjects
34983,Procedural Results of Patients Undergoing Rotational Atherectomy Compared With Patients Undergoing Coronary Angioplasty
34984,Echocardiographic Data
34985,Percent Responses of All Respondents to Selected Likert Attitude Scales   1995
34989,Comparison of Doppler Echocardiography and Corresponding Magnetic Resonance Velocity Mapping Results in 12 Healthy Children and 19 Patients With Repair of Tetralogy of Fallot
34990,Results of Pulmonary Artery and Transtricuspid
34991,Results of Multisection Gradient Echo Magnetic Resonance Imaging Calculations of Ventricular Volumes and Mass
34992,Indexes of Right Ventricular Diastolic Function As Assessed From Time Filling Velocity and Time Volume Curves
34993,Exercise Function in Patients With Repair of Tetralogy
34995,Subjects With Specific Types of Congenital Cardiac Malformations Who Were Diagnosed Prenatally, Atlanta, Georgia1990 1994
34996,Subjects With Congenital Cardiac Malformations Who Were Diagnosed Prenatally and Classified by the Presence of Associated Anomalies and Syndromes, Atlanta, Georgia, 19901994
34997,Pregnancy Outcomes of Subjects With Congenital Cardiac Malformation Prenatally Diagnosed With Fetal Echocardiography, Atlanta, Georgia, 19901994
35003,Relative Risk of Men Versus Women in Subsets Defined by Interaction of Gender and Ischemic Nonischemic Etiology
35009,Angiographic and Electrocardiographic Findings in 18 Men
35017,Outcomes of Initial, Second, and Third Steps legend
35018,Detection of Coronary Stenoses With Hard and Soft Plaques According to Positive Electron Beam Computed Tomography Score
35019,Detection of Significant Coronary Stenoses by Electron Beam Computed Tomography Versus Coronary Angiography for 267 Analyzed Segments
35020,Results of Electron Beam Computed Tomography Versus Coronary Angiography and Intracoronary Ultrasound for 267 Analyzed Segments
35021,Statistical Values for Comparison of Electron Beam Computed Tomography, Coronary Angiography and Intracoronary Ultrasound
35022,Coronary Angiography Versus Intracoronary Ultrasound for Detection of Atherosclerotic Plaques in 267 Analyzed Segments
35023,Distribution of Angiographic Disease Severity in 213 Consecutive Patients
35025,Optimal Electron Beam Computed Tomographic Coronary Calcium Score Maximizing Sensitivity and Specificity for Associated Range of Severity for Maximal Angiographic Lumen Stenosis
35026,Cutpoints for Electron Beam Computed Tomographic Coronary Calcium Scores for Sensitivity of 90  and Associated Specificity and for Electron Beam Computed Tomographic Quantified Coronary Calcium Scores for Specificity of 90  and Associated Sensitivity as a Function of Decade of Associated Maximal Angiographic Lumen Stenoses
35030,Sensitivity Analyses of the Association Between Morbidity and Mortality in SERAPHIN and GRIPHON
35032,Overall Dietary Profile of PESA Study Participants According to Breakfast Pattern
35033,Distribution of CVD Risk Factors of PESA Study Participants According to Breakfast Pattern
35034,Association Between Breakfast Pattern and Coronary Artery Calcification
35035,Association Between Breakfast Patterns and Presence of Atherosclerotic Plaques in Several Territories According to Breakfast Habits Categories Among PESA Study Participants
35037,All Cause and Cause Specific Mortality According to Alcohol Consumption Status
35038,All Cause and Cause Specific Mortality According to Binge Drinking Status
35040,Rates of Incident HF in Patients With New Onset RA
35041,Events and Relative Risks From Start of Follow Up
35042,Incident HF Among Patients With RA of Any Duration
35043,Univariable Predictors of MACE
35044,Rates of MACE, Death or MI, and Urgent and Nonurgent Revascularization at 2 Years for Each FFR Quartile
35045,Multivariable Predictors of MACE
35046,Energy Adjusted     Daily Intake of Selected Foods
35048,Determinants of Dietary Patterns
35050,Cardiovascular Imaging
35051,Prevalent Subclinical Atherosclerosis
35053,Improvement in Goodness of Fit to Model for Stroke or CAD by Addition of CSBP and or MHSBP
35055,Echocardiographic Measurements Performed With the Various Methods in the Local and the Reference Centers
35056,Agreement and Bland Altman Bias Matrix Between EFs Assessed Using Various Methods
35057,Interrater and Intrarater Reliability of EF and LS Measurements in MAA and PAD
35058,Time Needed for and Variability in Automated EF Measurements in Different Studies
35059,Inclusion and Exclusion Criteria
35063,Comparison of Various Variables Among Patients Having Isolated MV Repair or Replacement for Mitral Valve Prolapse
35064,Comparison of Various Variables Among 8 Patients Having Isolated MV Repair for MV Prolapse Whose Valves Are IllustratedBothGrossly and Histologically
35066,CBP Levels and Cardiovascular Mortalities With Different Cuff SBP and DBP Cutoffs Based on Conventional Criteria intheDerivation Cohort
35067,Determining Central SBP Cutoff Values Based on the Sensitivity and Specificity Associated With Cuff SBP Cutoff Values for Predicting Cardiovascular Mortality
35068,Proposal for Outcome Driven Diagnostic Thresholds forCBP Measurement
35069,Hazard Ratios for Total, Cardiovascular, and StrokeMortality in Relation to CBP at Entry in the Validation Cohort   n  2,501
35071,Intraoperative Measurements and Stent Graft Choice
35072,Outcomes of Open Surgery and Medically Treated Patients
35073,Quantification of 14 Day Endothelial Cell Proliferation
35074,Quantification of 14 Day Endothelial Coverage by Scanning Electron Microscopy
35076,Comparison of Lifetime Risks     for Cardiovascular Disease Death by Traditional Risk Factor Burden Measured at Ages 45, 55, and 65 Years   Men   in the CCLS and the Cardiovascular LRPP
35077,Lifetime Risk for Cardiovascular Disease Death Stratified by Fitness Level Measured at Ages 45, 55, and 65 Years in the Cooper Center Longitudinal Study
35079,Pre BAVP and Acute Post BAVP Aortic Valve Function   n   528
35080,Most Recent Follow Up After Post BAVP for Congenital AS   n   528
35081,Comparison of Exercise Restricted Versus Unrestricted Patients After BAVP for Congenital AS   n   403
35082,Deaths After BAVP for Congenital AS   n   528
35083,SUD After BAVP for Congenital AS
35085,Multivariate   Adjusted   Analysis of Factors Related to Inappropriate Use of SPECT
35086,Most Frequent Inappropriate Indications
35087,Vessels and Lesions Characterized by FFR and IVUS
35088,Analysis of Lesion Dimensions With CTCA and IVUS
35089,Genotype and Minor Allele Frequencies of ZNF202 SNPs in the General Population
35090,Risk of Severe Atherosclerosis   ABI  0.7 vs. 0.7   in the General Population   Cross Sectional Study  , Risk of IHD in the General Population   Prospective Study  , and Risk of IHD in Case Control Studies 1 and 2 as a Function of ZNF202 g.660A G Genotypes, Using an Assumption Free Model of Inheritance
35091,ZNF202 g.660A G and Risk Factors for Ischemic Heart Disease Among Individuals From the General Population
35094,Mean Group Data for the Forearm Exercise Experiment During Respiratory Exercise at 2  of PImax and 60  of PImax in CHF Patients Before and After IMT and Normal Control Subjects
35095,Quantitative Data of the In Vitro Effect of Everolimus on the mTOR Pathway and Protein Synthesis in Cultured Mouse Macrophages and SMC
35097,Detection of Pathology With the Four Echocardiographic Techniques
35099,Image Quality, Sensitivity, and Specificity of the Whole Heart Coronary Magnetic Resonance Angiography in the Individual Segments
35100,Diagnostic Accuracy of Whole Heart Coronary Magnetic Resonance Angiography to Detect Stenoses of 50  in 113 Patients Who Completed Acquisition of Coronary Magnetic Resonance Data
35102,Organs and Structures With Noncardiac Findings
35103,Diagnostic and Therapeutic Consequences in the Patients With Significant Noncardiac Findings During the 6 Months After the MDCT Scan
35104,Multislice Computed Tomography Scan Parameters
35106,Effective Dose from Multislice Computed Tomography Coronary Angiography
35107,Effective Dose from Conventional Coronary Angiography
35109,Age  and Gender Specific Prevalence of Individual Components and the Number of Components of MetS Based on the Criteria of NCEP and IDF in Chinese Elderly People
35110,Odds Ratios and 95  Confidence Interval   CI   of Cardiovascular Diseases for MetS by the NCEP and IDF Criteria and Their Individual Components
35113,Comparison of the Serial IVUS Data According to Follow Up Remodeling Index
35116,Regional Wall Motion Abnormalities   RWMA   Detected by Each of the Four Imaging Modalities
35117,Interobserver Agreement   Kappa Value   on Detection of Regional Wall Motion Abnormalities for Each Imaging Technique
35118,Intermethod Agreement   Kappa Value   for Off Site Reader 1 on Detection of Regional Wall Motion Abnormalities
35119,Agreement   Kappa Value   Between Each Imaging Method on Detection of Regional Wall Motion Abnormalities and Presence of Regional Wall Motion Abnormality Defined by a Panel Decision
35120,Diagnostic Accuracy of Each Imaging Method   Mean From All Three Readers   to Detect the Presence of Regional Wall Motion Abnormalities Defined by a Panel Decision
35122,Quantitative IVUS Measurements at Ruptured Plaque Segments Between Culprit Target Lesions and Non Culprit Non Target Lesions
35123,Quantitative IVUS Measurements at Ruptured Plaque Segments Between ACS and SAP
35125,Feasibility of Intracardiac Echocardiographic Guided Device Closure of Atrial Septal Defects
35130,Acquisition Parameters of Gadolinium Enhanced Three Dimensional MRA in 67 MRAs legend
35131,Summary of Pulmonary and Systemic Venous Anomalies in 61 Patients legend
35133,Results of Univariate and Multivariate Analyses for Distinguishing Between the LMCA and LAD Groups
35134,Results of Univariate and Multivariate Analyses for Prediction of Clinical Outcome
35136,Respiratory Change in Patients With CP and Normal Sinus Rhythm legend legend
35137,Respiratory Change in Patients With CP and AF legend legend
35138,Respiratory Change in Patients With AF Without CP legend legend
35139,Comparison of the Respiratory Variation in Patients With CP and SR and With AF legend legend
35141,Plasma Triglycerides and Remnant Lipids After High Fat Meals
35142,Systemic Arterial Compliance   SAC   After Low Fat Meal   Control   and High Fat Meal   Test   legend
35144,Duration of the Procurement Process by Donor Group, in Minutes legend
35146,Correlation  Between Hospitals Unadjusted and Risk Adjusted Bypass Mortality Rates
35147,Comparison of Outlier Hospitals by Observed to Expected Ratios legend
35148,Comparison of Outlier Hospitals by Observed to Expected Ratios After Recalibration legend
35149,High and Low Performers Using Random Effects Model legend
35151,Interreader Comparison of Diagnosis Prevalence
35152,Multivariate Analyses for Echocardiographic Processes
35153,Echocardiographic Measurements, Stratified by Interpreting Physician
35156,Quantitative Coronary Angiographic Results by Edge Detection Method legend legend
35157,Quantitative Coronary Angiographic Results by Videodensitometry legend legend
35158,Quantitative Coronary Angiographic Variables Univariate Analysis of Predictors for Long Term Outcome legend
35159,Multivariate Models Using Quantitative Coronary Angiographic Variables legend
35160,Reference Chart Generated Using Model II legend
35161,Velocity of Labeled Erythrocytes and Vessel Diameter in Arterioles and Venules Before and After Administration of QW7437   0.05 ml kg   legend legend
35162,Velocity and Transient Stoppage Frequency of Labeled Microbubbles in Venules legend
35163,Regurgitation Indexes in Three Groups of Patients legend
35165,Hemodynamic Values Measured in the Patient Group Without Collateral Vessels   Group 1  , Recruitable Collateral Vessels   Group 2   and Spontaneously Visible Collateral Vessels   Group 3   in Patients With and Without Ischemia During Balloon Angioplasty legend
35168,Logistic Regression Model
35173,Hemodynamic and Oxygenation Variables
35176,Slopes of Regression Lines Comparing Mean and Peak Frequency Shifts Recorded by Clinical Doppler Catheter at Different Rotational Positions With Reynolds Number for Scaled In Vitro Model
35178,Biophysical Variables of First Ineffective and Effective Ablation Sites in Patients Who Required Two or More Radiofrequency Pulses
35181,Risk of Ischemic Stroke by PFO ASA Status
35182,Association Between PFO and Ischemic Stroke by Gender, Age, and Race Ethnicity
35183,Trade Off Between Diagnostic Accuracy and Need for Adenosine
35184,Combined Pressure Flow Data in All Patients With Relative iFR Error by Tertile
35185,Comparison Between Best Fit Parameters and Clinical Observations in Patients
35186,Systolic Blood Pressure and LVW BW Ratio
35187,Hemodynamics at the Age of 17 Weeks
35189,Summary of Infarct Size Data in Protocol 1
35191,Summary of Infarct Size Data in Protocol 2
35193,Associations Between Gestational Age at Birth and Incident HF: Unadjusted and Adjusted IRRs   95  CIs   for Incident HF in Relation to Gestational Age at Birth
35194,Associations Between Birth Weight for Gestational and Incident HF: Crude and Adjusted IRRs   95  CIs   for Incident HF in Relation to Birth Weight for Gestational Age
35197,Clinical and Procedural Outcomes
35198,Multivariate Analysis of Clinical and Procedural Predictors of Adverse Events for CFA Interventions
35199,Multivariate Analysis of Outcomes for 4 Different Patient Subgroups
35201,Per Segment, Per Vessel, and Per Patient Analysis
35202,Pooled Summary Results
35203,Quality Assessment   QUADAS
35206,Incremental Risk Factors for Time Related Transition to End States After Initial Operation
35207,Reoperations After Complete Intracardiac Repair
35208,Hemodynamics of the Studied Subjects
35209,Quantitative Intracoronary Ultrasound Analysis of the 37 Studied Coronary Arteries
35212,Summary of Diagnostic Accuracy of CMRA Against Conventional X Ray Angiography in Evaluable Segments, Vessels, and Patients
35213,Subgroup Analyses of Evaluable Segment Level Data: Random Effects Estimates and 95  CI
35214,Percentage of Total Cross Section Represented by Plaque Area   Difference Between Lumen Area and Area Delimited by Internal Elastic Lamina   at Either 7 or 21 Days After Treatment with rhVEGF   2 g kg by a Single Intramuscular Injection   or Albumin legend
35215,Percentage of Total Lumen Circumference Represented by Plaque at Either 7 or 21 Days After Treatment With rhVEGF   2 g kg by a Single Intramuscular Injection   or Albumin legend
35216,Maximal Plaque Thickness   mm   Was Determined for Cross Sections Obtained at Either 7 or 21 Days After Treatment With rhVEGF   2 g kg by a Single Intramuscular Injection   or Albumin legend
35217,Endothelial Positive Area: Number of CD31 Positive Cells Normalized to Total Plaque Area   cells mm2   at Either 7 or 21 Days After Treatment With rhVEGF   2 g kg by a Single Intramuscular Injection   or Albumin legend
35218,Macrophage Infiltration: Number of RAM 11Positive Cells Per Cross Section Obtained at Either 7 or 21 Days After Treatment With rhVEGF   2 g kg by a Single Intramuscular Injection   or Albumin legend
35219,Patient Details: Previous Surgical Palliation, Presence of a Residual Ventricular Septal Defect, Use of a Transannular Patch, Presence or Absence of Restrictive Physiology, Inotropic Support and Details of Extended Studies legend
35220,Ventilatory Parameters During Intermittent Positive Pressure Ventilation and Negative Pressure Ventilation legend
35221,Standard Studies in All Patients. Hemodynamic Data During Intermittent Positive Pressure Ventilation and After a 15 min Period of Negative Pressure Ventilation legend
35222,Comparison of Metabolic Acid Base Status, and of Changes in Pulmonary Blood Flow During Standard Studies in Nonrestrictive   n   15   and Restrictive   n   8   Patients
35223,Pulmonary Blood Flow, Oxygen Consumption and Mixed Venous Saturation in Sub group 1   Nine Patients   in Whom the Study Period Was Extended to Include Measurements Made After Re instituting Intermittent Positive Pressure Ventilation legend
35224,Hemodynamic Data for Sub group 2: Eight Patients Who Received an Extended Period of Negative Pressure Ventilation legend
35225,Subgroup 2: Restrictive   n   4   vs Nonrestrictive   n   4   Patients Who Received an Extended Period of Negative Pressure Ventilation legend
35226,Summary of Published Adverse Cardiovascular Events in People Using Nicotine Replacement Therapy
35227,Pharmacokinetic and Pharmacodynamic Considerations Concerning Cardiovascular Safety of Nicotine
35228,Risk Factors Associated With Atrial Fibrillation    7
35236,Predictors of Death in 46 Patients With SMV legend
35237,Stenosis Severity Based Coefficients Versus Loss Coefficients Determined From Laboratory Model Studies
35238,Patient Data and Pressure Gradients
35239,AR Signaling in WT, CSQ, and CSQ PI3KinactMice
35240,Echocardiographic Measurements in WT, CSQ, and CSQ PI3KinactMice
35242,Risk Ratios for Taking Nonstatin Lipid Lowering Medications Among MedicareBeneficiaries With CHD
35243,Risk Ratios for Taking Nonstatin Lipid Lowering Medications Among Medicare Beneficiaries With CHD
35244,Lack of Association Between SNPs in PLA2G7 and Circulating Lp PLA2 Protein Mass or Activity But Significant Relation of Multiple SNPs in CRP With Circulating CRP Levels
35245,Association of SNPs in PLA2G7 But Not in CRP With CAC
35247,Location of Angioplasty of Patients Who Underwent 3 Month Angiography and Restenosis Rate in Relation to the Treated Artery and Site of the Treated Segment
35248,Criteria for Evaluation of Clinical Care
35249,Basic Research Measures
35250,Criteria for Evaluation of Clinical Research Quality
35253,Aortic Pressure, Blood pH and Blood Gas Data of Dogs in Protocols 1 and 2
35255,Clinical Composite Score
35257,Hemodynamic Effects of Pacing at Various Sites in Hearts With Normal Impulse Conduction
35258,Hemodynamic Effects of Pacing at the RV and LV Septum and at the LV Apex in Hearts With Normal Impulse Conduction
35259,Acute Canine Model: Hemodynamic Indices legend
35260,Acute Canine Model: Mitral Valve and Geometric Indices legend
35261,Chronic Sheep Model: Hemodynamic, Left Ventricular and Mitral Valve Indices legend
35262,Age at Operation in 40 Patients Who Had a Fontan Operation for Pulmonary Atresia With Intact Ventricular Septum, 1979 to October 1, 1995
35263,Previous Procedures in 40 Patients Who Had a Fontan Operation for Pulmonary Atresia With Intact Ventricular Septum
35264,Management of Tricuspid Valve in 40 Patients Who Had a Fontan Operation for Pulmonary Atresia With Intact Ventricular Septum
35265,Connections Used to Direct Systemic Venous Blood in 40 Patients Who Had a Fontan Operation for Pulmonary Atresia With Intact Ventricular Septum
35266,Surgical Results in 40 Patients Who Had a Fontan Operation for Pulmonary Atresia With Intact Ventricular Septum
35269,Stent Type and Number
35271,Quantitative Angiographic Measurements, Procedural and Follow Up Data in the 121 Patients With Successful Stenting
35273,Side Branch Analysis
35274,Individual Defibrillation Thresholds
35277,Quality of Life Adjustments
35278,Model Predicted Number of Events 10,000 Patients
35279,General Principles to Consider in the Design of Clinical Trials    16
35280,Judging the Evidence for Clinical Practice Recommendations    24
35281,Class I, Level of Evidence A, Recommendations from Selected ACC AHA Guidelines
35282,Class III, Level of Evidence A, Recommendations from Selected ACC AHA Guidelines
35283,Clinical and Echocardiographic Features of Patients With Tricuspid Regurgitation
35284,Mortality Versus Echocardiographic Findings by Univariable Proportional Hazards Analysis
35285,Clinical and Echocardiographic Parameters Associated With Long Term Survival
35286,Description of Included Studies
35288,Final Population Pharmacokinetic Model
35289,Age Specific Dose Regime for Sotalol in Children With Supraventricular Tachycardia
35290,Electrophysiologic Parameters in Relation to the Site  s   of Pacing   A   All Dogs; B   Septal Subgroup   legend
35291,Functional Conduction Blocks in Relation to the Site  s   of Pacing   n   13   legend
35292,Intra Observer Analysis Between the Repeated   t1   and First   t0   Calibrations of 48 Catheters in the Original and the Compressed Decompressed   CR 6, 10 and 16   Image Series legend
35293,Intra Observer Analysis Between the Repeated   t1   and First   t0   Measurements of 48 Coronary Obstructions in the Original and the Compressed Decompressed   CR 6, 10 and 16   Image Series legend
35294,Fixed Inter Compression Analysis Between the First Calibrations   t0   of 48 Catheters in the Compressed Decompressed   CR 6, 10 and 16   and Original Image Series legend
35295,Fixed Inter Compression Analysis Between the First Measurements   t0   of 48 Coronary Lesions in the Compressed Decompressed   CR 6, 10 and 16   and Original Image Series legend
35296,Variable Inter Compression Analysis Between the Repeated Calibrations   t1   of 48 Catheters in the Original and the Compressed Decompressed   CR 6, 10 and 16   Image Series and the First Calibrations   t0   in the Original Image Series legend
35297,Variable Inter Compression Analysis Between the Repeated Measurements   t1   of 48 Coronary Obstructions in the Original and the Compressed Decompressed   CR 6, 10 and 16   Image Series and the First Measurements   t0   in the Original Image Series legend
35298,Variable Inter Compression Analysis Between the Repeated Measurements   t1   of 48 Coronary Obstructions in the Original and the Compressed Decompressed   CR 6, 10 and 16   Image Series and the First Measurements   t0   in the Original Image Series legend
35299,Minimal Radiofrequency Power Required to Induce Transient Right Bundle Branch Block per Ablation ElectrodeTarget Distance, With and Without Intracavitary Flow
35302,Clinical and Hemodynamic Data of Patients and Healthy Subjects    legend
35303,Titers of Human, Rabbit, and Monoclonal Mouse Anti beta1 AR Obtained for ELISA, Western Blotting, and Immunoprecipitation legend
35304,Basal and     Isoprenaline Stimulated cAMP levels of CHW beta1 Cells in the Presence of Rabbit   70 nmol liter  , Mouse   7 nmol liter  , or Human Anti beta1 ECII   2 mol liter
35305,Reasons for Medication Nonadherence
35306,Fixed Dose Combinations in CV Prevention Studies
35307,Time Course of Residual Atrial Shunt Disappearance After Amplatzer Septal Occluder Implantation in All 151 Patients in the Study
35308,Clinical Data
35309,Morphologic Data for AF and No AF Groups
35310,Morphologic Data for Men and Women
35311,Morphologic Data for Patients with Paroxysmal and Persistent AF
35312,Interobserver Agreement on Plaque Characterization and Quantitative OCT Measurements Before Development of Image Interpretation Criteria: Analysis I
35313,Interobserver Variability of Plaque Characterization and Quantitative OCT Measurements After Development of ImageInterpretation Criteria: Analysis II
35314,Provision of Cardiovascular Disease Prevention Counseling Services to US Adults, 1995; National Ambulatory Medical Care Survey legend
35315,Provision of Cardiovascular Disease Prevention Screening and Medication Services to US Adults, 1995; National Ambulatory Medical Care Survey  legend
35316,Provision of Cardiovascular Disease Prevention Services to US Adults With Specific Risk Factors, 1995; National Ambulatory Medical Care Survey
35317,Rating Cases as Appropriate for Revascularization According to ACC AHA Appropriate Use Criteria Patients
35318,Most Common Clinical Scenarios for CABG Surgery Patients With No ACS No Prior CABG Surgery Classified as Inappropriate, Uncertain, and Appropriate
35319,Most Common Clinical Scenarios for PCI Patients With No ACS No Prior CABG Surgery Classified as Inappropriate, Uncertain, and Appropriate
35320,Exploration of No ACS No Prior CABG Surgery Eligible Cases With No Rating
35323,Simulated Impact of Different In Stent Late Loss Variances on TLR in the TAXUS Stent Population
35324,Simulated Impact of Different In Stent Late Loss Skewedness on TLR in the TAXUS Stent Population
35332,Results on a Per Patient and Per Vessel Level Using Hyperemic MBF as a Perfusion Parameter to Assess Diagnostic Accuracy of  15O H2O PET
35333,Diagnostic Accuracy of Quantitative  15O H2O PET MPI Using Hyperemic MBF as a Perfusion Parameter
35334,Diagnostic Accuracy of Quantitative  15O H2O PET MPI for Detecting Angiographic Obstructive CAD
35335,Univariate and Multivariable Regression Analysis Describing the Relationship Between Hyperemic MBF, CAD Risk Factors, and Functional CAD Severity
35336,The Influence of Sex and Age on the Diagnostic Performance of  15O H2O Hyperemic MBF Imaging
35340,Alcohol Related Variables Assessed in 9 Administrations of the NHIS
35344,Correlation Between FVII Genotypes, FVIIc and FVIIa legend
35345,30 Day Composite End Point and FVII Genotypes legend
35346,Relative Risk for the Composite End Point in Logistic Regression Analysis legend
35347,Key Issues Regarding Composite Endpoints
35348,Key Issues Regarding Randomization Methods
35349,New Methods for Quantitative Assessment of MR: Clinical Use, Advantages, and Disadvantages
35350,Real Time 3DE Studies of the Accuracy and Reproducibility of the VCA Technique for MR Quantification and the Relevant 2D Methods Compared
35351,Real Time 3DE Studies of the Accuracy and Reproducibility of the Mitral and LVOT SV Quantification and the Relevant 2D Methods Compared
35352,CMR Studies Using Direct and Indirect Methods of Quantifying MR
35353,Cardiac CT Study for MR Quantification by LV and RV Planimetry
35354,3DE Studies for 3D PISA and Anatomic Regurgitant Orifice Area   Last Row Only   Techniques
35355,CMR and CCT Studies Using Direct Planimetry To Measure Anatomic Regurgitant Orifice Area
35356,Stakeholders and Their Interest in Public Reporting
35357,Advantages of Clinical   Registry   Data Over Claims Data in Public Reporting
35358,American College of Cardiology Foundations Principlesof Public Reporting
35359,American College of Cardiology Measures to Be Publicly Reported
35360,LV EDV, ESV, SV, CO, EF, Mass and Heart Rate in Volunteers, Patients with HHD, AVD, and DCM
35363,Crude and Adjusted Relative Risks of Cardiovascular Events According to Quartile of Plasma Level of Lp PLA2
35364,Crude and Adjusted Relative Risks of Cardiovascular Events Associated With a One Quartile Increase in the Concentration of Lp PLA2and CRP
35367,Number of Initial Strokes and Initial Strokes per 1,000 Person Years of Follow Up After Initial AF Diagnosis
35368,Hazard of Stroke by Race Ethnicity, Relative to White Patients, After Controlling for CHA2DS2 VASc Score   Model 1   and CHA2DS2 VASc Score Plus Anticoagulant Use   Model 2
35369,Comparison of CHA2DS2 VASc and CHA2DS2 VASc R Scores in Predicting Stroke: Relative Hazard Associated With 1 Point Increase in Stroke Risk Score, and C Statistic
35370,Relative Contribution of Each Risk Factor of CHA2DS2 VASc R Score in Stroke Prediction
35372,Univariate and Multivariate Associations Between Total Plasma Lp PLA2 Mass and Activity, HDL Lp PLA2 Mass and Activity, Ratios of Lp PLA2 to HDL Lp PLA2 Mass and Activity, Natural Log of hsCRP, and Cardiac Death at Follow Up
35374,Electrocardiographic Measurements and Sites of Successful Ablation in the Retrospective Cohort
35375,Clinical Variables Stratified by Quartiles of SUV
35376,Multiple Stepwise Regression Analysis for Factors Associated With SUV of FDG Levels in Carotid Artery
35377,Proportion of Patients in the PROVE IT TIMI 22 Trial Reaching Dual Goals of Low Density Lipoprotein Cholesterol  70 mg dl and C Reactive Protein  2 mg l in the Total Cohort and According to Statin Allocation
35378,Relative Efficacy of Pravastatin 40 mg and Atorvastatin 80 mg in Achieving LDL C Levels  70 mg l and CRP Levels  2 mg l in the PROVE IT TIMI 22 Trial
35379,Change in Heart Body Weight Ratio   mg g   in Wistar Rats Treated With AB or ADR After 2, 8 and 14 Weeks   n   8
35380,Left Ventricular Function, Expressed as dP dtmax  kPa s  , in Each Group at Different Times   n   6
35381,Anatomic Measurements of Hearts   mm2   From Each Group at the End of the Experiment
35382,Collagen Volume Fraction       of the Left Ventricle in Both the Aortic Banding and Adriamycin Groups   n   8
35383,Changes in the Ratio of CD4  CD8 Before and After Treatment in Both the AB and ADR Groups   n   8
35385,Effects of Tolvaptan on Hemodynamic Parameters
35387,Pathology details
35388,Surgery details
35389,Adjuvant radiotherapy received   within 3 months after surgery
35390,Adjuvant radiotherapy received   within 3 months after surgery  , nodes removed, nodal status, and external beam radiotherapy   EBRT   received in node positive patients by risk group defined according to ASTEC radiotherapy eligibility
35391,Cause of death
35392,Site of recurrence
35396,Events after allocated treatment
35397,Overview of stage I seminoma treated with adjuvant carboplatin
35399,Deaths, myocardial infarctions, and new interventions during median 27 years  follow up
35400,Secondary events during follow up
35401,Antianginal medication
35405,Frequency of increases in serum creatinine
35406,Deaths   and causes of death   and admissions for heart failure or for any reason
35407,Primary reason for discontinuation of study medication before completion of study
35408,Characterlstlcs of cases and controls
35409,Adjusted relative risk estimates for all cancer associated with use of calcium channel blockers and ACE Inhibitors
35410,Adjusted relative risk estimates for all cancers associated with use of calcium channel blockers by age, dose, and duration of use
35411,Adjusted relative risk estimates for specific calcium channel blockers
35412,Adjusted relative risk estimates for calcium channel blockers for specific cancer sites
35414,Geometric mean CRP and SAA concentrations by risk factor status
35415,Relative risk of coronary events for each 1 SD increase in CRP or SAA concentration, and for CRP concentration by angina type
35416,Relative risk of coronary events by CRP concentration
35417,Responses to questions on assisted suicide in 322 psychiatrists in UK and Ireland
35418,Translocations and physical estimates of dose in controls and residents of contaminated homes
35419,Linear fit to the data in  table 1
35420,Median life expectancy by radiation dose or distance from hypocentre of bomb
35421,Mutations within the TULP1 gene in 171 patients with autosomal recessive retinitis pigmentosa
35423,Packed cell volume in elite athletes and in controls
35424,Alcohol consumption and health status at age 33 years
35425,Frequencies of MBL genotypes in patients and controls
35426,Hair mercury concentrations and dental fillings for different occupations within the crematoria
35428,Confirmed culture positive melioidosis in England and Wales, 1988September 1998
35431,Prefrontal regions showing hypofunction during left hand movement in two patients with hysteria and two feigners
35432,Summary data of AECP patients with cancer
35433,Rate of detection of colorectal cancer according to age and sex
35434,Presenting symptoms of patients from the patient consultation questionnaire and diagnostic value for colorectal cancer
35435,Malignancy score distribution       from general practitioner s letter and from patient consultation questionnaire   PCQ
35436,Referral patterns of the weighted numerical score, malignancy risk score, and NHS guidelines
35437,Cancer risk and the weighted numerical score
35438,Cancer cases seen at Tenwek Hospital between 1989 and 1998 by sex
35439,Prevalence of valvular heart diseases in population based studies
35440,Valvular heart diseases diagnosed in Olmsted County
35441,Cardiac chamber remodelling associated with valvular heart diseases in the population
35443,Quit attempts among smokers before, during, and after the Tips campaign
35444,Communication about the dangers of smoking and recommendation of cessation services by non smokers before, during, and after the Tips campaign
35445,Effects of herb extracts and alpha tocopherol respectively, on formation of lipid peroxidation products   LPP   in cultured lung cells exposed to iron or ozone
35447,Adverse drug reactions reported by nurses
35448,Accounts that included a dispute with doctors
35449,Accounts without a dispute with doctors
35450,Population based family designs
35452,Data included in the maternal mortality model
35453,Categorisation of countries based on evidence for progress in reducing the maternal mortality ratio between 1990 and 2015
35454,Projections of MMR and maternal deaths for 2030
35455,Expected health spending in 2030 and 2040
35456,Expected health spending by source in 2040
35457,Potential total and government health spending for low income and middle income countries in 2040
35458,Health spending by source, 2014
35459,Health spending relative to expected health spending, 2014
35465,Habitual activity scores   MET times per week   by overall activity status and by study year
35467,Details of patients
35468,Effects of sildenafil on retinal function
35469,Performance of filariasis antigen card test
35470,Cases of childhood empyeme at Birmingham Children s Hospital, 199296
35475,Mean   SD   MMSE and age according to APOE genotype
35476,Genotype frequencies of the DLST gene in AD patients and age matched controls
35477,Plasma concentrations of homocysteine and vitamins mean   SD   and presence of vascular risk factors       in the study populations
35478,Patients enrolled and proportions with complete data
35480,Biochemical findings
35481,Risk of ovarian cancer mortality according to reported use of paracetamol. Cancer Prevention Study II, 19821994
35482,Pathogens isolated from writing tools
35483,Cases in community outbreak November, 1995January, 1996
35484,Number of individuals recommended per 2000 of population
35485,Attitudes to xenotransplantation
35486,Results in wound protector and control groups
35487,Effects of treatments
35489,Surgical procedures by the pelvic floor service
35490,Diagnostic sensitivities   SE  , specificities   SP  , false negative   FN   and false positive   FP   cases in each conventional BIT subtest and in combinations of two and three subtests   n 52
35491,Coronary events by tertile of calcium score
35493,Genotype and allele frequencies of 1438G A 5 HT2A promoter polymorphism in OCD and two populations of eating disorder patients
35494,Distribution of 21438G A genotypes and allele frequencies
35495,Scores of language function   SLTA   and in cerebrospinal fluid   CSF   in four patients with fluent aphasia and anomia
35497,Percentage of codon 129 PRP genotypes in sporadic CJD by 10 year age groups in the European study 19931998   numbers of cases in parentheses  , and codon 129 distribution in the normal population and in previous studies of sporadic CJD
35498,Clinical, parasitological, and laboratory findings of patients
35499,Rate of P vivax and P falciparum infection by age and sex in Boktar district
35500,Susceptibility to HSV 1 infection in patients with and without AD
35501,Features of autosomal dominant episodic ataxias
35502,Patient details
35504,Details of patients with neuroleptic sensitivity
35505,Relative odds for appendicectomy associated with mothers  and cohort members  smoking
35506,Mean number   SE   of nuclei of non melanised neurons, melanised neurons, and blood vessel endothelial cells
35507,Incidence of first non melanoma skin cancer by immunosuppressive regimen
35509,Mean   SD   plasma lipids, apolipoproteins, and glucocerebrosidase enzymatic activities in each group
35510,Decile values for statistic blood pressure by age group and sex
35511,Risk classification by systolic blood pressure
35512,Hazard ratios for mortality in men per 10 mm Hg increase in systolic and diastolic blood pressure
35513,Autosomal dominant acute porphyrias
35514,Symptoms and signs of acute porphyria
35515,In vitro mefloquine susceptibility of P falciparum isolates
35516,Distribution by age and sex, of malaria cases in Maela
35519,Clinical and parasitological outcomes
35520,Pairwise comparison of treatment efficacy
35521,Parasitological results
35523,Yearly population and mortality data for children enrolled in the sponsorship programme
35526,Results by treatment group
35527,Results of prespecified subgroup analyses
35529,Prevalence of subtle chromosomal abnormalities in children with mental retardation and in normal controls
35530,Extent and origin of chromosomal rearrangements
35531,Percentage frequency of cytogenetic abnormalities and fragile X syndrome in individuals with unexplained moderate to severe mental retardation  6,2836
35532,Patients  age and circumstances of injury
35533,Injuries sustained and outcome of surgery
35534,The discrimination by auxotype serovar classes compared with  opa  type for classes with five or more cases
35535,The link between epidemiological and microbiological cluster size for the 120 Sheffield cases
35537,Values used in calculations of PIDrisk
35538,Results of analysis of faecal DNA for BAT26 alterations
35540,Results of genital examinations
35541,Sexual function of 28 participants, according to GRISS
35543,Protective measures reported by infected and non infected staff
35544,Effect of Interferons on virus induced cytopathogenic effects of SARS CoV and vesicular stomatitis virus
35545,Origins and epidemiological data of the key virus isolates used in the study
35546,Primer sequences used for nested PCR and sequencing
35548,Household and individual sample obtained and response rates, by site
35550,Lifetime and current prevalence of physical and sexual violence against women by an intimate partner among ever partnered women, by site
35551,Controlling behaviours by an intimate partner, by site
35553,Sexual partners, practices, behaviours, and attitudes reported by men in Natsal 3, by age group
35554,Sexual partners, practices, behaviours, and attitudes reported by women in Natsal 3, by age group
35555,Change in numbers of sexual partners and prevalence of sexual practices, behaviours, and attitudes in Natsal 3 and Natsal 1 relative to Natsal 2, by sex
35558,Univariate relative risk of cardiac mortality
35559,Multivariate Cox proportional regression models
35560,First six clinical cases of computer assisted cardiac surgery
35563,Adverse events during the 24 h treatment period
35564,Changes in haemological and biochemical variables
35567,Seroconversion to HIV 2 infection according to age and sex, 198792
35568,Mortality according to HIV 2 infection and age, 198795
35569,Reported causes of death
35571,Effect of NEPs on HIV seroprevalence
35572,Complications after caesarean section in HIV 1 positive mothers and in HIV 1 negative mothers
35573,Molecular analysis of glioblastoma multiforme, its recurrent and metastatic lesions, and normal tissues of donor and recipient
35574,Plasma glucose and insulin, and fasting plasma free fatty acid concentrations before and after glucose challenge
35575,P carinii ITS sequence types and clinical variables in first episode PCP
35576,Statistical associations   p 10107   between Affymetrix SNPs and circulating concentrations of LDL cholesterol in a genome wide meta analysis of five study populations consisting of up to 11685 participants
35577,Statistical associations   p 10107   between Illumina SNPs and circulating concentrations of LDL cholesterol in a genome wide meta analysis of three UK study populations consisting of up to 4337 participants
35578,Imputed SNPs showing genome wide statistical association   p 10107   with circulating concentrations of LDL cholesterol; meta analysis of four study populations consisting of up to 9988 participants
35579,Revised injury severity classification   RISC   score
35581,Logistic regression models 1   TRISS whole body CT   and 2   RISC score whole body CT
35582,Logistic regression model 3   TRISS whole body CT level of hospital year   based on data from 2259 patients
35583,Logistic regression model 4   RISC whole body CT level of hospital year   based on data from 4113 patients
35585,Care quality across the 42 time categories in the week
35586,Adjusted odds ratios of receiving each care quality indicator
35587,Reading habits and attendance at cultural events
35588,Type of literature read by doctors who reported reading books during the previous 24 h
35589,Proportions of participants who wanted change in how they spent their time
35590,Effects of oestrogen replacement therapy and smoking history among female patients and controls
35591,Distribution of cases and controls according to menopause category
35592,Relative risk   RR   of breast cancer by time since last use, duration of use, and type and dose of preparation mainly used
35593,Estimated cumulative incidence of breast cancer in 1000 women in North America or Europe associated with postmenopausal use of HRT for various durations, beginning at various ages
35594,Some examples of biological, virulence, and vaccine potential of pathogenic bacteria
35596,Acceptable pelvic measurements for vaginal delivery
35597,Statistical analysis of differences between study group and control group
35599,Mean   SD   birthweight and 1 min and 3 min Apgar scores of infants
35601,Univariate predictors of death
35602,Univariate predictors of death or non fatal myocardial infarction
35603,Thallium perfusion defects and risk of death: results of multivariate Cox proportional hazards regression analyses
35604,Thallium perfusion defects and risk of death or non fatal MI: results of multivariate Cox proportional hazards regression analyses
35605,Associations of thallium ischaemia with death and major events in stratified Cox proportional hazards analyses: impact of time elapsed since bypass surgery
35606,Hepatic antimony concentrations in infants
35607,Frequency of mtDNA haplogroup U among patients who had had occipital stroke, patients with migraine, and population controls
35608,Water hardness and prevalence of eczema among primary school children
35609,Chlorine content of water supply and prevalence of eczema among primary school children
35610,Water hardness and prevalence of eczema among secondary school children
35612,Factors significantly associated with increased or reduced risk of unsafe sex in men
35613,Factors significantly associated with increased or reduced risk of unsafe sex in women
35615,Concentrations of organochlorine compounds in blood samples
35616,Risk of breast cancer in relation to lipid adjusted serum concentrations of organochlorines in quartiles
35617,Results of exploratory factor analysis   factor loadings100   of symptoms reported in past month in Gulf War cohort   n 3214
35618,Confirmatory factor analysis of factor structure of Gulf War   n 3225  , Bosnia   n 1770  , and Era   n 2384   cohorts
35619,Factor structure of Gulf War cohort to be tested in confirmatory factor analysis
35620,Structure of Haley model based on our symptoms
35621,SSLRs for GHQ 12
35622,Hazard ratios, risk points, and predictive score for independent predictors of outcome in medical and surgical models
35623,5 year actuarial risk of ipsilateral carotid territory major ischaemic stroke in 394 patients with 7099  stenosis in medical treatment group
35624,30 day risk of any major stroke or death after carotid endarterectomy in 596 patients with 7099  stenosis in surgery group
35625,Effect of endarterectomy on 5 year risk of ipsilateral carotid territory major ischaemic stroke and operative major stroke or operative death in patients with 7099  stenosis
35626,Non validated Cox s proportional hazards model for ipsilateral carotid territory major ischaemic stroke on treatment derived from 1208 patients with 099  stenosis in medical treatment group
35627,Non validated logistic regression model for any major stroke or death from other causes within 30 days of carotid endarterectomy derived from 1799 patients with 099  stenosis in surgery group
35628,Accuracy of three risk factors   age  60 years,  TBSA  40 , inhalation   for predicting mortality in adults with severe burns
35629,Responses of elderly people   n 443   versus younger people   n 189   to standing aside in the queue for cardiac services for a younger or self employed person
35630,Independent predictors of elderly people s beliefs that they should stand aside for younger or self employed persons in the queue for cardiac services
35632,Early results of primary surgical treatment for biliary atresia in individual centres over a 2 year period   March1993February 1995
35633,Early results of primary surgical treatment for biliary atresia grouped by centre caseload
35634,Mammographic outcomes for women attending first round screening in 1994   n 103 770
35635,Age specific sensitivity   2 year interval   and specificity by HRT use
35636,Multiple logistic regression analysessensitivity, specificity, positive predictive value, and small cancer detection rate
35637,Summary of studies on HRT use and sensitivity of screening mammography
35642,Mean results for dark adaptation and ERGs
35643,Significance of variables analysed for risk effects on socket survival
35644,Significance of variables assessed for risk effects on femoral prosthesis survival
35645,CDT results at each test interval after cochlear implantation
35646,Correlation analysis of CDT with variables at the 5 year interval
35647,Nipple fluid bFGF   ng L
35648,Number of patients and procedures by country
35649,Survival after liver transplantation in Europe according to different risk factors in univariate analysis
35650,Risk factors for death after liver transplantation in multivariate analysis
35651,Interactive factors in multivariate analysis for adults and children
35652,Estimated mortality after correction for risk factors   normalised intrinsic mortality risk
35653,Comparison of causes of death between total population and optimum group
35654,Estimated mortality rate in relation to each single factor, in adults
35657,Relative risks
35662,Use of treated and untreated nets in cases and controls
35663,Correlation weighted by population size between income inequality   gini coefficient   with mortality and life expectancy OECD among 16 countries   198992  , adjusted for gross domestic product per capita
35664,Correlations between mortality, life expectancy, low birthweight, self rated health, and distrust, organisation membership, volunteering, control, trade union membership, and the   of women elected to national government among OECD countries   198992  , adjusted for gross domestic product per capita and weighted by population size
35668,Association between type of abuse and major depression
35669,Association between stage of abuse and major depression
35670,Association between severity of abuse and major depression
35672,Distribution of numbers of heterosexual partners over lifetime and in the past 5 years by gender and age group: Natsal 2000
35673,Distribution of behaviours with regard to new partners and concurrency in past year, partners from outside the UK in past 5 years, and frequency of heterosexual sex in past 4 weeks, by gender and age group: Natsal 2000
35674,Prevalence of sexual behaviours and injecting drug use: Natsal 2000 and Natsal 1990 by gender and by residence in Greater London and rest of Britain for selected variables
35675,Change in prevalence of behaviours in Natsal 2000 compared with Natsal 1990 by gender   all variables   and for London and the rest of Britain   for sexual partners and drug use
35676,Distribution of the 344 patients in five WCEI classes
35677,Frequency of ten elements of NDE
35679,Significant differences in life change inventory scores  16   of patients with and without NDE at 2 year follow up
35680,Total sum of individual life change inventory scores  16   of patients at 2 year and 8 year follow up
35681,PCR primers used for amplification of EGF promoter
35682,EGF genotype and allele frequencies in patients with malignant melanoma and in healthy controls
35683,Association between EGF genotype and allele frequencies with Breslow thickness in malignant melanoma patients
35685,Contribution of combined or individual loci of 571 ancestral haplotype to susceptibility to abacavir hypersensitivity
35686,Distribution of combined and individual alleles of 571 ancestral haplotype
35687,Parental periconceptional smoking and the offspring sex ratio   male:female
35690,Univariate analysis of predictive factors
35692,Direction of association between birthweight and subsequent systolic blood pressure   SBP   in the 55 studies that contributed to previous quantitative estimates   web references 137   and in the 48 studies that did not   web references 3875
35693,Adjustment for potential confounding factors in the 55 studies that reported regression coefficients for the association between birthweight and subsequent blood pressure
35694,Prohibitin 3 untranslated region C T polymorphism: genotype distribution in patients with breast cancer and in controls
35695,Risk of breast cancer associated with Prohibitin 3 untranslated region C T polymorphism
35696,Description of journals reviewed in 1997
35697,Examples of non supporting claims
35700,Numbers of participants in each group in every centre
35701,Discriminatory ability   areas under ROC curves, with 95  Cls   of individual tests by region
35702,Discriminatory ability of individual tests and combined algorithm
35703,Number       within each group accorded GMS AGECAT   stage 2   diagnoses by region
35704,Calibration model   logistic regression   derived from the development dataset including the four assessments independently predictive of dementia status   n 1413
35705,Independent predictor variables in GMS AGECAT dementia diagnosis and CSI D probable dementia screening
35706,Breast cancer cases and deaths from breast cancer by period and age at diagnosis in two Swedish counties
35707,Unadjusted breast cancer incidence and mortality from incident tumours, with unadjusted and adjusted relative risks of breast cancer death
35708,Adjusted relative risks of all cause and all cancer mortality in 197897 compared with 195877, for women diagnosed with breast cancer at 4069 years
35709,Adjusted relative risks of breast cancer, all cause and all cancer mortality in 197897 compared with 195877, in women diagnosed with breast cancer at 4049 years
35711,Adjusted and unadjusted Cox regression results for all cause mortality by depression status
35713,Adjusted and unadjusted Cox regression results for all cause mortality by course of depression
35714,Mean   SD   left ventricular dimensions and mass 8 weeks after myocardial infarction and 12 weeks after myocardial infarction   4 weeks after cell transplantation
35715,Estimated organ specific radiation doses   mGy    1113   by type of diagnostic X ray
35716,Estimated cumulative risk of cancer to age 75 years and number of cancer cases per year from diagnostic X rays in the UK
35717,Estimated number of radiation induced cases of cancer per year in the UK by type of X ray
35718,Estimated number of radiation induced cases of cancer per year  in the UK by age at exposure
35719,Effect of varying assumptions on UK radiation induced cumulative risk estimates
35720,Frequency of diagnostic X rays per 1000 population, percentage of cumulative cancer risk to age 75 years attributable to diagnostic X rays, and number of radiation induced cases of cancer per year for 15 countries
35721,Estimated population, total deaths, deaths due to injuries and suicides, and percentage of deaths due to suicides, 19922001
35722,Numbers and rates of suicides by age and sex
35723,Descriptive statistics for the analysed population
35724,The 15 most common exposure combinations   of 149
35725,Final estimated overall logistic regression model predicting long term sickness absence and hospital admission in 199799 by exposure to workforce changes 199196   n 24036
35726,Logistic regression model predicting long term sickness absence for men and women working during 199799 by exposure to workforce changes 199196
35727,Mean viewing hours and correlation between ages
35728,Regression of health outcomes at age 26 years on television viewing during childhood, adolescence, and early adulthood
35729,MCC vaccine effectiveness in immunised cohorts to end of March, 2004
35731,Prevalence of schizophrenia in people aged 15 years or older in mainland China:1995 99
35732,Estimated rates, relative risk, and attributable risk proportion of suicide in people with schizophrenia aged15 years in mainland China:1995 99
35734,Proportion of children with positive ELISPOT and TST results by diagnostic category
35735,Concordance of TST and ELISPOT results for all categories of children with both test results available
35736,Effect of age, HIV infection, and malnutrition on test sensitivity in children with confirmed or highly probable tuberculosis   n 133
35737,Summary information on selected papers
35738,Cox model for 5 year risk of ipsilateral ischaemic stroke on medical treatment in patients with recently symptomatic carotid stenosis derived from ECST
35739,Variation in health system coverage and capacity and functioning across settings with different NMRs   based on 192 countries
35741,Obstacles to and strategies for scaling up of neonatal care for family community, outreach, and clinical services
35742,Predicted effect and incremental cost per year of various scenarios for increasing coverage of neonatal health care in Ethiopia, Madagascar, and Gujarat State, India
35744,Aneurysm related and all cause mortality   intention to treat analysis
35745,Causes of death by group
35746,Postoperative complications      for all patients receiving EVAR   not intention to treat
35748,Estimated costs   UK   over 4 years of follow up based on intention to treat
35749,Human resources for health by destination country
35750,Schematic illustration of some factors involved in producing migration outcomes in health labour market
35751,Person years available for analyses and proportions with complete smoking data and complete smoking and socioeconomic data
35752,Person time and deaths among 4574 year old individuals, by strata of census cohort, sex, ethnicity, and smoking
35753,Standardised rates   SR   of all cause mortality per 100000 and SRR and SRD age standardised and age smoking standardised
35756,Serum CRP and SAA in FMF patients, carriers, and controls
35757,Preoperative   KPS 0  , discharge   KPS 1  , and at 6 months follow up   KPS 2   scores
35758,Patients  views of the advantages and disadvantages of a patient held record   PHR
35759,Financial burden of AIDS response in low income and middle income countries, grouped by epidemic category
35760,Resource needs of low income and middle income countries in four scenarios, grouped by epidemic category, 201430
35761,Performance of national treatment programmes of selected countries, 2013  116
35762,Domestic spending by top ten countries with highest numbers of people living with HIV
35763,Welfare gains and benefitcost ratios from modelled scenarios relative to Current Effort scenario, by epidemic category
35764,HIV spending in selected sub Saharan African countries  200
35765,Prevention interventions for high risk populations in high incidence areas of Kenya
35766,Clinical features and gastric emptying results
35767,Oral surveys of institutionalised elderly
35768,MRI findings in all relatives
35769,Sleep variables in DQB1   0602 positive and negative volunteers
35770,Patients  recall of the risk of stroke without the operation and as a result of CEA
35771,Studies examining the relation between H pylori infection and NSAID use in patients with uncomplicated peptic ulcer disease   listed in order of year of publication
35772,Contribution of each study to the Cochrane Q, the statistical test of heterogeneity in a fixed effects model
35773,Analysis of studies with controls matched for age and sex by H pylori status
35774,Sensitivity analysis of controlled studies with matching for age, sex, or both, by H pylori status
35775,Analysis of effects of H pylori infection and NSAID use on the site of peptic ulcer
35776,Studies examining the relation between H pylori infection and NSAID use in patients with peptic ulcer bleeding
35778,Predictors for carotid plaque and carotid intima media thickening
35779,SNPs, primers, and molecular beacons
35781,Effect of predictors on recurrence   Cox s proportional hazard model
35784,Twin pair correlation coefficients   r   of the activation markers
35785,Estimates of heritability   h2   and unique environment   e2   from best fitting models
35787,Characterisation of patients according to detection of a RET germline mutation and disease phenotype
35788,RET c135G A genotypes and association with phenotype of Hirschsprung s disease and with RET germline mutations
35789,Primers and probes for allele specific oligonucleotide hybridisation and ligation detection reaction
35790,MBL genotype in patients with invasive pneumococcal disease and in controls
35791,Comparison of clinical data in patients with invasive pneumococcal disease with and without homozygous MBL variant genotypes
35793,Single nucleotide polymorphism   SNP   haplotype frequency estimates in German and Norwegian patients with Crohn s disease and controls
35794,Analysis of the genotype phenotype relation of three NOD2 polymorphisms
35795,Single nucleotide polymorphism   SNP   haplotype frequency estimates in patients with Crohn s disease with and without ileal disease
35796,Single nucleotide polymorphism   SNP   haplotype frequency estimates in patients with Crohn s disease with and without right colonic disease
35797,Prevalence of obesity and severe obesity at 3942 months by risk factor
35802,Numbers of study participants and odds ratios for developing future cardiovascular events, according to quartiles of MIC 1
35805,Gene frequencies for MIC 1 polymorphism, overall and according to case or control status
35806,Bivariate and multivariate analysis of time to reinfection as a function of reinfection event and total number of reinfections
35807,Effect of age and work experience on susceptibility to reinfection with schistosomiasis in univariate and multivariate analyses
35808,Egg counts at time of enrolment for individuals in the groups with different total number of reinfections
35809,Household income and per capita health expenditure    US   in south Asian countries
35810,Prevalence of cardiovascular disease risk states in south Asian countries
35811,Relatives identified for cases and controls, and rates of suicide and psychiatric admission
35812,Family history distribution and risk of suicide
35813,Familial information in people with and without history of admission to hospital for psychiatric disorder and risk of suicide
35815,Number of individuals recruited, by area
35816,Median scores   IQR   on all measures for YAT and ad hoc areas
35817,Odds ratios   95  CI   of participation in society based on all variables from conceptual model
35818,Odds ratios   95  CI   of participation in society based on significant variable from conceptual model
35819,Estimated costs for YAT and ad hoc services
35820,Comparison of MRI and EUA findings
35821,Significant factors associated with recurrent primary sclerosing cholangitis according to univariate analysis
35826,Differences in incremental cost, effect, and cost effectiveness
35827,MHC typing in patients with variant Creutzfeldt Jakob disease and controls
35828,MHC typing in relation to age of onset and duration of disease in variant Creutzfeldt Jakob disease
35829,Meta analyses included in our study
35830,Type of immunodeficiency, according to donor origin and HLA matching
35832,Factors affecting outcome in SCID patients after HLA identical or after related HLA mismatched stem cell transplantation
35833,Immunological reconstitution, according to SCID phenotype
35834,3 year survival in non SCID patients, according to primary disease and donorrecipient compatibility
35836,Protective effectiveness of meningococcal C conjugate vaccine   MCCV  , dependent on presence of risk factors
35838,Presence of HLA B27 in controls and haemophilia patients with and without chronic synovitis
35841,Hazard ratio of atorvastatin treatment on primary, secondary, and tertiary endpoints
35842,Hazard ratio of atorvastatin treatment on primary endpoint by subgroup
35844,Clinical information for discordant cases
35845,Case control study: association of   874A T with tuberculosis
35846,TDT: association of   874AT with tuberculosis
35847,Distribution of codon 129 genotype
35849,Cumulative and excess incidence of invasive breast cancer in 1000 women who had never used and ever used HRT, based on incidence rates typical of developed countries
35851,Variation in the hazard ratio of progression to AIDS over calendar time
35852,Variation in the hazard ratio of death over calendar time
35853,Incidence of invasive group B streptococcal disease in infants in the UK and Republic of Ireland
35854,Incidence of invasive group B streptococcal disease in infants in England by birthweight
35855,Determinants of carotid intima media thickness of children with familial hypercholesterolaemia and unaffected siblings   n 281
35857,Crude odds ratios for HIV seropositive status by experience of intimate partner violence
35859,Crude odds ratios for HIV seropositive status by self  reported participation in HIV risk behaviours
35860,Odds ratios and 95  CI for self reported participation in risk behaviours by reported experience of gender based violence
35861,Association between risk behaviour, intimate partner violence, SRPS score, and HIV serostatus
35862,Cross tabulation for colonisation with S pneumoniae and S aureus
35863,Odds ratios of colonisation with S aureus for co colonisation with S pneumoniae and other independent risk factors   n 3085
35864,Relative risk of nosocomial S aureus bacteraemia by nasal carrier status
35865,Comparison of patients with nosocomial S aureus bacteraemia by nasal carrier status
35866,Cardiovascular risk factors, income, education, and other psychosocial variables in controls   both working and non working   by general stress score
35867,Psychosocial risk factors in cases and controls
35868,Psychosocial risk factors in cases and controls by sex
35869,General stress by age, smoking, income, and education in cases and controls
35870,Odds ratios for combined effect of general stress and depression or locus of control on risk of acute myocardial infarction
35873,Prevalence of incapacity
35874,Individual capacity ratings   interviewed sample
35875,Associations of incapacity
35876,Outcomes 6 months after injury by treatment allocation
35879,Surgery details
35880,Outcomes at 6 months
35882,Summary of all outcomes for ESD services versus conventional care
35884,Crude and age standardised prevalence of the individual components of the metabolic syndrome      and overweight
35885,Crude and age standardised prevalence of one or more components of the metabolic syndrome
35886,Rate of clinical malaria from 1 month after dose three until end of follow up
35887,Interview measures
35889,Number       of incidents of physical abuse, neglect, and total incidents   physical abuse or neglect   per family by group, over the 3 year follow up, based on CPA records
35890,Number of incidents of physical abuse, neglect, and total incidents   physical abuse or neglect   per family by group, over the 3 year follow up period, based on hospital records
35894,Association of prognostic factors with starting HAART
35896,Numbers of cases of bilateral PCHI 40 dB hearing level at age 79 years in children born during periods with and without universal newborn screening, by risk status, source of referral, and age at referral
35897,Numbers of true and false positive newborn screening tests for PCHI 40 dB hearing level
35898,Descriptive statistics of study subjects and correlations with telomere terminal restriction fragment   TRF   length before and after adjusting for chronological age
35899,Standardised incidence ratios for cancers of the breast, prostate, and all other sites in the first degree relatives of bilateral breast cancer cases
35900,Comparative effect of 1 standard deviation increase in a specific measure of obesity in the overall population and separately in men and women
35901,Increases in odds ratio for myocardial infarction for 1 SD increase in body mass index, waist circumference, or waist to hip ratio in different ethnic groups adjusted for age and sex
35902,Odds ratios and population attributable risk of myocardial infarction for raised waist to hip ratio or body mass index
35904,Randomised trials of breast screening in women younger than 50 years
35905,Mortality from all causes and from breast cancer in the intervention and control groups
35906,Mortality in attenders and non attenders at first screen in intervention group
35907,Breast cancer mortality in intervention and control groups by time period
35908,Total number of school children enrolled, illnesses, and DALYs lost to illness, by year
35909,DALYs lost to dengue illness
35910,The burden of dengue in Thailand compared with other infectious diseases in the region in 2002
35911,Cost and duration of dengue and non dengue illnesses
35912,Analyses of the cost of dengue illness
35916,Age at onset, course, and treatment for lifetime major depressive disorder
35917,Quality of life      of people with and without 12 month major depressive disorder   MDD     n   134
35918,Severity of role impairment associated with 12 month major depressive disorder   n 134   assessed by the Sheehan disability scale
35919,Pattern and correlates of symptom severity of 12 month major depressive disorder
35921,Numbers of women with ER poor disease, by age, in trials of polychemotherapy, tamoxifen, or both, that began before 2000
35923,Summary of the sites and samples
35925,Prevalence   95  CI   of 10 66 dementia by age group, sex, and country
35926,Prevalence   95  CI   of DSM IV dementia by age group, sex, and country
35927,Prevalence   95  CI   of 10 66 dementia and DSM IV dementia, by region and clinical severity, to compare prevalence from 10 66 studies with EURODEM DSM IV prevalence and prevalence estimates from the ADI and  Lancet  consensus study
35928,Prevalence ratios   95  CI   from a Poisson regression for the independent effects of age, sex, education, and assets on dementia prevalence
35929,Distribution of WHODAS disability scores by dementia status and site, and the effects of dementia   main effect of 10 66 dementia, modified by DSM IV dementia   on WHODAS score
35931,Preinfluenza periods and influenza seasons
35933,Classification of WHO budget lines according to disease classification, 200607
35935,Sensitivity analyses
35936,Sensitivity analyses
35938,Responses for positive and negative experienced discrimination
35939,Responses for anticipated discrimination by category
35940,Regression models for total experienced discrimination
35943,Kaplan Meier event rates for efficacy and safety endpoints in the TRITON TIMI 38 trial
35944,Adjusted hazard ratios   95  CI   for the association between different types of proton pump inhibitors and the risk of MI or the composite of CV death, MI, or stroke through long term follow up
35945,Effects of influenza A H1N1 by age group and region, AprilJuly 2009
35955,Follow up in ablation and control groups
35956,Endpoints in ablation and control groups
35957,Summary of previous prospective studies on catheter ablation of ventricular tachycardia in patients with structural heart disease
35958,Abnormalities in free light chain ratios by presence of intact heavy chain immunoglobulin
35959,Age specific and sex specific prevalence of light chain MGUS and any MGUS
35960,Risk of progression to multiple myeloma and related disorders
35962,Association between light chain MGUS and renal disease
35967,Primary and major secondary endpoints in the ivabradine group, according to groups defined by heart rate achieved at 28 days   bpm
35968,Estimated total number of DALYs per 1000 population for those aged between 10 and 24 years, and 25 years and older
35969,Main causes of DALYs for 1024 year olds and for 5 year age groups  14
35970,Association of published GWAS loci for myocardial infarction with angiographic CAD   study A: angiographic CAD versus control   and myocardial infarction in patients with angiographic CAD   study B: myocardial infarction versus no myocardial infarction
35971,Study A: Association of ADAMTS7 rs1994016 with angiographic CAD   angiographic CAD versus control
35972,Study B. Association of ABO SNPs with myocardial infarction in patients with angiographic CAD   myocardial infarction versus no myocardial infarction
35973,Association of   A   the ABO rs514659C allele and   B   ABO blood groups with CAD phenotypes in PennCath
35974,Estimates of dementia prevalence worldwide according to the Delphi consensus study in 2005
35975,Alzheimer s disease risk genes
35976,Treatments for Alzheimer s disease
35977,Meta analyses or systematic reviews of risk factors for dementia and Alzheimer s disease
35978,Mean number of disability adjusted life years lost per million population with and without vector control
35981,Sensitivity, specificity, and positive and negative predictive values for identification of individuals with impaired fasting glucose at different HbA1c thresholds
35985,Full output from interval censored parametric survival analysis showing the effect of community level mean lifetime partners and prevalence of partnership concurrency in men on a woman s hazard of acquiring HIV infection   N 7284
35986,Sensitivity analysis of the effect of size and shape of the kernel   used to derive the male community level sexual behaviour variables   and an alternative community level concurrency measure on a woman s hazard of HIV acquisition   N 7284
35988,HIV sentinel surveillance of women in antenatal clinic sites in the six Avahan states
35989,Mean, median, and highest HIV prevalences per 1000 in sentinel surveillance antenatal clinic sites in 2003
35990,Estimated fixed effect coefficients from the mixed effects logistic model   sample size, n 626232
35992,Common operations or tasks that involve exposure to free crystalline silica
35993,Radiographical classification of silicosis
35994,Recommended measures for detection and treatment of LTBI and tuberculosis in patients with silicosis
35995,Suggested preventive measures
35996,Proportion of adults reporting walking to work, cycling to work, or using any type of active transportation   walking or cycling   by country
35997,Relevant risks and developmental period for illustrative preventive interventions by age group
35999,Costbenefit of selected programmes
36000,Pathologies noted in eyes with pathological myopia
36002,Association summary statistics for the eight replicating signals
36003,Age standardised prevalence of diabetes and hypertension in Iran
36004,Diabetes and hypertension diagnosis and treatment coverage in Iran
36005,Coefficients of regression to estimate the effect of diabetes and hypertension treatment on fasting plasma glucose and systolic blood pressure of treated individuals
36006,Coefficients of regression to estimate the effect of Behvarz worker density   per 1000 population aged 25 years or older   on fasting plasma glucose and systolic blood pressure in Iran
36007,Prevalence of self harm by wave and category and summarised over adolescence and young adult phases, by sex
36008,Longitudinal association between background factors and time varying exposures measured in the previous wave with incident adolescent self harm in 1672 cohort participants who responded to the self harm component in at least two consecutive waves in the adolescent phase   wave two in addition to waves three to six
36009,Adolescent measures associated with incident young adult self harm in cohort participants with no reports of self harm in adolescence and at least one observation in both adolescent and young adult phases   N 1507   and restricted to participants with complete data for all seven waves of data   N 880
36014,Relationship between platelet reactivity and subsequent definite or probable stent thrombosis through 1 year follow up
36016,Propensity adjusted multivariable risk of high platelet reactivity for subsequent 1 year adverse events
36018,Relationship between adverse events and death though 1 year follow up
36019,Independent predictors of all cause mortality, including adverse events occurring during follow up as time adjusted covariates
36022,Surgery details
36023,Prespecified outcomes at 6 months
36024,Key enabling advances, 19932013
36025,Examples of interventions delivered across key delivery platforms
36026,Policy instruments to reduce risk of disease and injury, by risk factor cluster
36027,Health indicators in 4C countries and in other selected regions and countries, 2011
36028,Years of life expectancy lost relative to the 4C countries in 2008, by region
36030,Incremental costs of enhanced investment scenario across low income countries as a group
36032,Incremental costs of enhanced investment scenario across lower middle income countries as a group
36033,Key population based interventions for non communicable disease risk factors
36034,Tobacco and alcohol taxes as percentage of GDP in selected countries
36035,Five potential pathways to universal health coverage
36036,Four essential functions of international collective action
36037,Priorities for research and product development identified by World Development Report 1993
36038,Examples of products that could help achievement of convergence
36039,Years of life lost per person in major mortality shocks of the 20th century
36042,Age standardised regional and national estimates of the prevalence of overweight and obesity combined and obesity alone for girls, boys, men, and women for 2013, for 188 countries and 21 GBD regions
36043,Casemix and treatment for patients with AMI in Sweden and the UK
36046,Nurse staffing and education in nine European countries
36049,Global mortality rate   deaths per 1000 livebirths   for early neonatal, late neonatal, postneonatal, child, and under 5 age groups for 1970, 1980, 1990, 2000, and 2013
36050,Global number of deaths   thousands   for early neonatal, late neonatal, postneonatal, child, and under 5 age groups for 1970, 1980, 1990, 2000, and 2013
36051,Early neonatal, late neonatal, postneonatal, childhood, and under5 mortality rate and under5 deaths in 2013, and annualised rates of change in mortality rates for 19902000, 20002013, and 19902013 for 188 countries and 21 Global Burden of Disease regions
36052,Regression models for the log of the under5 mortality rate for different model specifications for 188 countries 19702013
36053,Shapley decomposition analysis of the change in the number of under 5 deaths   thousands   related to changes in income per person, maternal education, HIV child death rate, births, secular trends, and unexplained factors, 2013 versus 1990, worldwide and in the 21 GBD regions
36054,Population at risk   millions   by malaria endemicity class in 2000 and 2010 in malaria endemic countries in Africa
36058,Procedural and discharge data
36059,Clinical outcomes
36060,Procedure related complications
36063,Detection of AKI in adult patients admitted to hospital in China by region
36065,Recognition of AKI by physicians in charge during hospital stay
36066,Multivariate logistic regression analysis for factors associated with all cause in hospital mortality in AKI
36067,The Edmonton obesity staging system and stratified management scheme  34,47
36068,Pooled average weight loss recorded from interventional trials of dietary programmes lasting 12 months or longer  3851
36069,Comparison of the energy deficit required for weight loss with the energy deficit to maintain weight after weight loss, by initial body mass index
36070,Efficiency of airport based interventions to screen international travellers departing Guinea, Liberia, and Sierra Leone by frontier
36071,Modelled estimates of Ebola virus exportation from Guinea, Liberia, and Sierra Leone via commercial air travel
36072,Top 20 final destination countries of individuals initiating air travel from within Guinea, Liberia, and Sierra Leone and corresponding indicators of health system capacity
36075,Clinical outcomes
36077,Subsequent myocardial infarction or cardiac death in patients with troponin concentrations below the 99th centile in the derivation cohort
36079,Associations between genotype and age at diagnosis achieving genome wide significance
36080,Associations between genotype and disease location, behaviour, extent, surgery, and colectomy achieving genome wide significance
36084,Predictions of public health impact and cost effectiveness of RTS,S for the 69 month three dose and four dose immunisation schedules at 15 years of follow up in regions with a parasite prevalence in 210 year olds of 1065
36089,Procedural and angiographic results   core laboratory assessments  , pooled across the four trials
36090,Meta analysis summary for all ischaemic endpoints
36092,Deaths, YLLs, YLDs, and DALYs attributable to viral hepatitis, by year
36093,Deaths, YLLs, YLDs, and DALYs attributable to viral hepatitis in 2013, by region
36095,Meta analyses of the associations between sitting time and all cause mortality   N 1005791; 84609 deaths   stratified by quartiles of physical activity
36096,Meta analyses of the associations between TV viewing time, and all cause mortality   N 465450; 43740 deaths   stratified by quartiles of physical activity
36098,Death and recurrent myocardial infarction   including repeated events
36099,Total death and cardiac death
36100,Death and readmission to hospital for ischaemic heart disease   including repeated events
36103,Mortality, disability in ADL, and cognitive and physical function for cohorts born in 190918   aged 8089 years in 1998   and born in 191928   aged 8089 years in 2008
36104,Mortality, disability in ADL, and cognitive and physical functions for cohorts born in 18991908   aged 9099 years in 1998   and born in 190918   aged 9099 years in 2008
36105,Mortality, disability in ADL, and cognitive and physical function between cohorts born in 189398   aged 100105 years in 1998   and born in 190308   aged 100105 years in 2008
36106,Annual rates of changes in mortality, ADL disability, and physical and cognitive function between same age cohorts across the two survey timepoints
36108,Size of the smoking population, prevalence, and 19902015 percent change in prevalence, by sex, for the ten countries with the largest smoking populations and worldwide
36109,Total health spending and spending by source, 2015
36110,Health spending on HIV AIDS, 2015
36113,Effect of mecamylamine   MEC   in Tourette s syndrome in seven patients with follow up information
36115,Observed number of deaths and standardised mortality ratios   SMR
36116,Risk of death for individuals with a serum thyrotropin concentration  05mU L compared with those with a concentration of  0 5mU L
36118,Laboratory measurements before, 48 h after, and 6 weeks after treatment
36120,Relative risks of oral, lung, and pancreatic cancer in relation to tobacco smoking status at entry
36121,Relative risks of oral, lung, and pancreatic cancer in relation to snus use in 125576 never smokers
36125,Concordance and discordance between self reported smoking behaviour and salivary cotinine findings at 1 year and 2 year follow up
36126,Patterns of tobacco use, by sex, in the UK, USA, and 14 GATS countries
36127,Current smoking prevalence      , by sex and age, in the UK, USA, and 14 GATS countries
36128,Prevalence of ever smoking and mean age of initiation of daily smoking among ever daily smokers, by sex and age in the UK, USA, and 14 GATS countries, and similar estimates for ever regular smokers in the UK and USA
36129,Percentage of ever daily smokers   and ever regular smokers        who are former smokers, by sex and age, in the UK, USA, and 14 GATS countries
36131,Indication for oral anticoagulation
36132,Bleeding events
36133,Bleeding events stratified by risk factors
36134,Multivariate risk ratios
36135,Other diseases and risk factors at start of oral anticoagulation in 78 of 141 patients with bleeding complications
36136,Disability classes based on person trade off method
36137,Prevalence per 1000 for seven classes of disability for age, sex, and region
36138,DFLE at birth by sex and region in seven classes of disability
36139,Life expectancy at birth with and without disability and proportion of life affected by disability
36140,Life expectancy at age 60 years with and without disability and proportion of life affected by disability
36141,Results of first 3 weeks  treatment for stabilization patients in computer dose and traditional dose group
36142,Results from study centres for computer dose and traditional dose groups
36143,Results from all ranges, all sites
36144,Proportion of INRs lower and higher than target ranges
36145,Mean proportion of time in target range
36147,Cycling test
36148,Peak systolic velocity measurements with Doppler examination
36149,Results of preoperative imaging
36150,Exposures to occupational driving and possible confounding
36151,Differences in lumbar degenerative findings in upper and lower lumbar regions between drivers and their co twins
36152,Recent history of back problems in drivers and their twin siblings
36154,Reasons for diagnostic angiography
36155,Medical and behavioural risk factors and associated disorders that might predict rupture of an unruptured intracranial aneurysm
36156,5 year cumulative rupture rates according to size and location of unruptured aneurysm
36157,Outcome 30 days and 1 year after surgery
36158,Sequences of synthetic peptides derived from HR1 and HR2 regions of SARS CoV spike protein
36159,Comparison of pairwise aminoacid identity and similarity of spike glycoproteins of SARS CoV and other coronaviruses
36160,Molecular masses of the isolated peptides NP 1 and CP 1 and the NP 1 CP 1 complex measured by sedimentation equilibrium
36162,Genotype and predicted phenotypes, by treatment
36163,Outcomes in relation to the CYP2C19 genotype
36164,Outcomes in relation to the ABCB1 genotype
36166,Angiographic and intravascular ultrasound analyses before and after the procedure, and at 3 year follow up
36167,Exercise test   intention to treat population, excluding tests subsequent to any revascularisation
36168,Secondary clinical outcomes at 3 year follow up
36170,Unadjusted odds ratios between cases and controls by drug regimen at index date
36171,Use of calcium antagonists and history of cardiovascular disease
36172,Adjusted odds ratios by logistic regression
36175,Relative risks of first myocardial infarction associated with sICAM 1 concentrations of more than 260 ng mL after control for other lipid and non lipid risk factors
36176,Availability of data from randomised trials that began before 1990 of adjuvant tamoxifen versus no adjuvant tamoxifen
36177,Effects of treatment allocation on selected outcomes
36178,Analysis of selected Polish cigarette brands, 1994
36179,Glycoprotein IIb IIIa blockers
36183,15 most frequent self reported symptoms by deployment
36187,15 most frequently self reported exposures      by deployment
36188,Association of 15 most frequent exposures and exposures of interest with principal health outcomes
36189,Frequency of reported vaccines by theatre of war and vaccine records
36190,Associations between reported vaccinations and CDC syndrome, stratified by theatre of war and whether respondent had vaccination record
36191,Associations between multiple vaccination and CDC syndrome
36192,Associations between multiple vaccination and CDC syndrome, controlled for experience of side effects and biological warfare vaccine, Gulf only
36194,Self reported symptoms, association by deployment
36196,Self reported exposures, by deployment
36197,Association   OR,   95  CI     between exposures and and principal health outcomes.
36200,Event rates for three periods of time by troponin I status
36201,Distribution of cases and controls according to predictors included in the study
36202,Predictors for suicide in the general population adjusted for age and sex
36203,Attributable risk
36204,Summary of recurrence
36205,Recurrences and deaths in patients by DPI status and Dukes  stage
36207,Age specific and sex specific mortality rates
36208,Classification of low, standard, and high doses of  blocker therapy
36210,Admission for heart failure in relation to  blocker dose in 8232 patients with no history of heart failure
36211,Mortality in relation to  blocker dose in 13623 survivors of myocardial infarction
36212,Sensitivity analyses of survival in relation to dispensing of  blocker therapy
36213,Number of adenocarcinomas adenosquamous carcinomas in the analysis, by year of diagnosis
36214,Estimated trends in adenocarcinoma of the cervix in five cancer registries in four age at diagnosis groups
36215,Number of months gained with chemotherapy   chemotherapy minus control   within first 10 years  follow up for each Q TWiST clinical health state subdivided by age, nodal status, and ER status   patients  age  50 years
36216,Number of months gained with chemotherapy   chemotherapy minus control   within first 10 years  follow up for each
36217,Number of months gained with chemotherapy   chemotherapy minus control   within median follow up of each trial for each Q TWiST clinical health state
36219,Any indication of a mental health problem or social maladjustment by year of birth
36220,Logistic regression models for mental health disorders and social maladjustment
36221,Crude rates of specific indicators of mental health disorders and social maladjustment
36222,Logistic regression of risk factors in the adoptee study group
36224,Detection of Y chromosome positive cells in cheek scrapings from female transplant recipients
36228,Univariate and multivariate analyses for distant metastasis free survival in the testing set of 171 patients
36229,76 genes from the prognostic signature
36230,Pathway analysis of the 76 genes from the prognostic signature
36231,Comparison of the 76 gene signature and the current conventional consensus on treatment of breast cancer
36232,Parental postnatal depressive symptoms and emotional and behavioural problems in children aged 42 months
36233,Paternal depression and subsequent emotional and behavioural problems in children   controlling for later paternal depression at 21 months
36234,Differential effects of parental depression on boys and girls
36236,Actual management after randomisation
36237,Death and severe disability
36238,Length of stay
36239,Follow up assessment at 6 months
36240,Cost effectiveness of allocation to extracorporeal membrane oxygenation versus conventional management
36241,Cost utility analysis results for CESAR trial   bootstrap estimates
36242,Mortality by cause and incidence of second cancers, for ER positive disease only
36244,Patient populations in randomised trials of MRI for selection of local therapy
36245,Outcomes of randomised trials of MRI for selection of local therapy
36246,MRI for contralateral cancer detection
36247,Proportion of the male sample   n 12359   with a lifetime record of any offence and a lifetime record of a violent offence by age group at the time of data linkage
36249,Effect of combat role and traumatic experiences during deployment on risk of violent offending in 8280 male military personnel on return from deployment
36250,Post deployment mental health and behaviour problems and violent offending
36251,Examples of inadequate reporting in studies other than randomised controlled trials and systematic reviews
36252,Main features of the four randomised controlled trials
36253,Cases of invasive cervical carcinoma, number of person years, and median duration of follow up
36255,Study adjusted pooled relative detection rate of invasive cervical carcinoma, by morphology, stage, and age at enrolment
36256,Biopsy procedures undertaken in the four randomised trials, individual and pooled effects
36257,The global tobacco industry   2013 data
36258,Studies included in analysis
36259,Age distribution of women in each study group
36260,Distribution of grade of cervical intraepithelial neoplasia at initial diagnosis in each study group
36261,Number of woman years of follow up and invasive cancers, cumulative rate of invasive cervical cancer at end of follow up, and rate of invasive cancer during follow up by treatment method and centre
36262,Pretreatment data of the three patients treated with LDDM
36263,Urodynamic results
36264,Correlations and partial correlations between birthweight and leg length, trunk length   or sitting height  , and overall height in four longitudinal studies
36265,Observed and expected numbers of invasive breast cancer and corresponding standardised primary incidence rates, after a primary diagnosis of carcinoma in situ
36266,Distributions of genotypes and alleles at VNTR polymorphism in serotonin transporter gene in puerperal psychosis probands and comparison controls
36268,Mean   SD   total problem score and scores on internalising and externalising broad band categories in extremely low birthweight   ELBW   group and reference group   norm or control   in four cohorts by sex
36269,Frequency of selected cancers in longshoremen by exposure level and year of hire
36270,Mean breastfeeding associated differences between first and second babies
36271,Mean milk output at 1 week by quartiles for first and second babies
36273,Entry criteria and distribution by treatment group
36276,Thromboembolic, cerebrovascular, and cardiac events according to treatment
36277,Side effects reported at any time and of any severity, according to allocated treatment
36278,Gynaecological procedures and gynaecological and vasomotor symptoms in premenopausal and postmenopausal women   defined at randomisation   according to allocated treatment
36279,Detailed breakdown of deaths
36280,Relative risk of acquiring a cytological abnormality after exposure to HPV 18 and HPV 16, after controlling for exposure to other HPV types, according to severity of cytological abnormality
36283,Odds ratios for the associations of polymorphisms in NAT and GST genes and bladder cancer risk
36285,Examples of some polymorphisms or haplotypes that have shown consistent association with complex disease
36286,Criteria for selection of candidate genes
36287,Approximate sample sizes necessary to detect significant association   power 90 , two sided  0001   by effect size and allele frequency for predisposing allele
36288,Effect of differing statistical significance levels on sample size
36289,Number of women who completed visits in extended follow up phase, according to timing of visit relative to their enrolment in initial efficacy study
36290,Numbers of women, according to type of analysis
36292,Vaccine efficacy for incident HPV 16 18 infections, in cervical samples
36293,Vaccine efficacy for persistent HPV 16 18 infections, in cervical samples
36294,Overview of combined initial and extended follow up vaccine efficacy against cytological and histological endpoints
36295,Vaccine efficacy against incident infection with HPV 45, HPV 31, HPV 52, HPV 33, and HPV 58 in cervical samples from intention to treat analyses
36296,Reported adverse events
36298,Associations with use of combined oral contraceptives in control women by subgroup
36299,Effect of stratification by potential confounding factors on the relative risk of invasive cervical cancer per year of use of combined oral contraceptives in current users   restricted to 4716 cases and 9157 controls with data for all variables
36300,Expected genetic and environmental correlations in disease liability
36301,Recurrence risks for schizophrenia and bipolar disorders
36302,Estimates of genetic and environmental effects for liability to schizophrenia, bipolar disorder, and their comorbidity
36303,Genome wide association studies of bipolar disorder in European origin samples
36304,Genome wide significant association in European origin samples for bipolar disorder
36306,Significance of variables for prediction of hepatocellular carcinoma from Cox regression analysis
36307,Relative risks of progression to hepatocellular carcinoma
36308,Relative risks of progression to hepatocellular carcinoma among patients for HCV
36311,Efficacy of tamoxifen within subgroups defined by covariates in multivariate analysis
36312,Meta analysis of trials comparing tamoxifen alone versus no active treatment in HCC
36313,CSF hypocretin 1 levels and clinical features of narcoleptic and control subjects
36315,AIDS defining opportunistic illnesses and causes of death according to HCV serostatus
36318,Age distribution of cytotoxic activity by follow up status
36319,Relative risk of cancer incidence for cytotoxic activity levels
36320,Summary of skin tests, serological assays, and HPV DNA analysis in three groups of women with CIN
36321,Data from ten patients with positive recall reactions to HPV 16 E7   cytology histology in regressors before regression occurred   and from seven cancer patients with negative skin test
36324,Major adverse cardiac events, acute and late
36326,Causes of death
36327,Reasons for treatment discontinuation among patients who received embolisation
36329,Cox s proportional hazards analyses for probability of death
36330,Primers used in TP53 sequence analysis
36331,IP53 mutations in disseminated cancer cells
36333,Incidence per 100 PYFU of AIDS, all deaths, and HIV 1 related deaths according to treatment era and latest CD4 count
36334,Relative hazard   RH   of AIDS or death according to treatment era
36338,Percentage of patients positive for binding to peptides by ELISA
36339,Intrafamilial correlation coefficients for TRF length
36340,Expression of cell surface markers on undifferentiated hES cells and their haemopoietic progeny
36343,Primary outcomes
36344,Secondary outcomes
36345,Serological response and survival after lethal H5N1 virus challenge in mice immunised with HAd H5HA vaccine
36347,Treatment response at 6 months after initiating therapy by calendar year of starting HAART, ART CC, 2004
36349,Crude and adjusted hazard ratios for AIDS and death by year of starting HAART, ART CC, 2004
36350,Crude and adjusted hazard ratios for tuberculosis and AIDS defining conditions other than tuberculosis, ART CC, 2004
36351,Formulae for calculation of the rate of AIDS, AIDS death, and death for any CD4cell count according to WHO clinical stage
36353,Rate and 6 month risk of death according to CD4 cell count and WHO clinical stage
36354,Rate and 6 month risk of AIDS and AIDS or death according to current CD4 cell count and WHO stage
36356,Health indicators for overall   20 years or older   population by period of follow up
36357,Crude and standardised rates of mortality by period of initiation and period of follow up
36358,Health indicators stratified by sex and injecting drug use
36362,Lung cancer mortality by study group
36364,Observed death rates and standardised mortality ratios based on 77936 person years of follow up from 38997 patients
36369,Regions of the genome showing the strongest association signals with the continuous trait
36371,Relative risk of hip fracture for one SD reduction in ultrasonographic and densitometric values
36372,Multivariate models of association between ultrasonographic and densitometric values and risk of hip fracture
36373,Number and incidence of hip fracture according to calcaneal broadband ultrasound attenuation   BUA   and femoral neck BMD
36374,History and allergy tests in five children with atopic dermatitis due to cow dander
36375,Single, low dose PS after scrapie infection
36377,Complications and persistent or recurrent dysphagia, after brachytherapy and stent placement
36378,Medical costs of brachytherapy and stent placement
36379,Time of onset of clinical features of meningococcal disease before hospital admission
36380,Age specific frequency of clinical features of meningococcal disease before hospital admission
36381,Overall frequency and time of onset of clinical features of meningococcal disease in children before hospital admission
36382,Cumulative proportion of children developing clinical features during the course of meningococcal disease
36383,Frequency of type of cancer by Indigenous status, and distribution of cancers treated in public hospitals in Queensland
36384,Frequency of use of cancer treatments in Indigenous and non Indigenous patients
36385,Hazard ratios of selected variables for overall survival
36386,Problems and referrals
36387,Timely completion of referrals according to outreach availability
36388,Adjusted main effects, other than outreach, in the final survival analysis and logistic regression models
36389,Hazard ratio   95  CI   of altered fractionated radiotherapy versus conventional radiotherapy on overall population and by type of radiotherapy for locoregional, local, regional, and metastatic control   n 7073
36391,Events at long term follow up
36392,Type and timing of first active treatment for the patients who relapsed in the wait and see group
36393,Comparison between the SWOG S8794 and EORTC 22911 trials
36394,Withdrawal from the ORBIT study after randomisation
36396,Change in IBDQ B score
36397,Change in score of the gastrointestinal secondary endpoints
36398,Changes in quality of life secondary endpoints
36399,Frequently used chemotherapeutic regimens in non small cell lung cancer
36400,Approved targeted drugs for non small cell lung cancer
36401,New diagnoses and deaths from cancer in 2008: number and proportion by sex of patients and economic development  2,82
36403,Grade 3 and higher toxic effects
36404,Recurrences
36408,Response to treatment
36409,Cause of death and number of deaths by prognostic category, tumour type, and response to treatment
36410,Chemotherapy delivery
36411,Worst toxicity experienced
36412,Child contact, nappy changing, and risk of giardiasis
36413,Frequency of intercourse and relative risk of HIV transmission
36414,Probabilities of HIV 1 transmission per coital act
36415,Rate of absence or presence of nasal bone in trisomy 21 and chromosomally normal fetuses at 1114 weeks
36416,Estimated sensitivity and false positive rate for risk cutoffs in screening for trisomy 21 by maternal age, nuchal translucency thickness, and presence or absence of the nasal bone by comparison with the results obtained in a multicentre study of screening by maternal age and fetal nuchal translucency thickness
36417,Cumulative incidence of reported STIs
36421,Coverage and follow up
36426,Coverage by country of contributing registries and constitution of datasets for various analyses
36427,Neoadjuvant pharmacotherapy to reduce the effects of chemotherapy on the ovaries
36428,Summary of the deployment by main administrative divisions   townships   from May, 2014, to April, 2017
36429,Changes in malaria yearly cumulative incidence by main administrative divisions   townships   from May, 2014, to April, 2017
36430,Effect of the interventions on incidence of clinical episodes of falciparum and vivax malaria
36431,Detection of molecular markers of antimalarial resistance in rapid diagnostic tests or dried blood spots
36433,Degree of desensitisation for maximum   max   and 6 h bronchodilator responses after treatment with formoterol for 2 adrenoceptor homozygous polymorphisms at codon 16 and codon 27
36434,Geometric mean   GM   sensitivity with 95  CI to inhaled spasmogens before   day 0  , and after   day 7  , regular inhalation of salbutamol
36435,Epidemiology of death
36436,Use of medical interventions
36438,Proportions of cases   asthma deaths   and controls prescribed fenoterol in studies in New Zealand, Saskatchewan, and Japan
36439,Haplotype distribution
36440,Difference in FEV1 by maternal cigarette smoking compared with FEV1 of offspring whose mothers never smoked
36442,Reported adverse events   in order of frequency
36448,Odds ratios for asthma in occupations with excess asthma risk  30
36449,Asthma risk in cleaners
36450,Risk of asthma and occupational exposure to specific agents assessed by job exposure matrix or self reported by questionnaire
36451,Attributable risk of asthma and occupational exposures
36452,Patient details with mean   95  CI   change in measures after treatment with budesonide in those stratified according to sputum eosinophil   eos   count
36453,Prevalence of CCR532 and asthma in Scottish children   n
36454,Responses of hospital physicians and GPs to the euthanasia attitude questionnaire
36456,Stepwise introduction of interventions and coverage
36457,Home based case management of suspected neonatal sepsis and outcome   199598
36459,Change in case fatality by birthweight and maturity
36462,Exacerbations in the two randomised groups
36465,Estimated adjusted odds ratios for new asthma attacks obtained from dynamic logistic regression modelrisk changes after severe life events with and without chronic stress
36471,Estimated rate of ELDs in medical practice in Netherlands, Australia, and Flanders
36472,Relationship of sensitisation specific IgG antibody, and exposure
36473,Univariate logistic regression analysis of risk factors for asthma
36474,Multivariate logistic regression analysis of risk factors for asthma
36477,Frequency and risk   adjusted      odds ratio, 95  CI   of asthma, hay fever, and atopic sensitisation in relation to exposure to stables and farm milk in the 1st year of life
36478,Frequency and risk   adjusted      odds ratio, 95  CI   of asthma, hay fever, and atopic sensitisation in relation to farming activity of pregnant mothers in farmers  children exposed to stables and farm milk in the 1st year of life
36479,Frequency and risk   adjusted      odds ratio 95  CI   of asthma, hay fever and atopic sensitisation in relation to amount and duration of exposure to stables
36481,Evaluable patients reporting efficacy by treatment group
36482,Effect of treatment   adjusted means of severity scores   on migraine associated symptoms at 2 h after dosing and patient overall impression
36483,Patients reporting common adverse events   frequency  10  over all treatment groups or significant   by treatment
36484,Plasma concentration and resulting pain intensity at 2h
36485,Definitions of index complications associated with stroke during the first 3 months
36486,A comparison of the processes of acute assessment and investigation between patients randomised to the stroke unit and general medical wards with specialist support
36487,Types of treatment received in the first 7 days by patients randomised to the stroke unit or general wards with specialist support
36488,Processes of multidisciplinary coordination and communication in the first 4 weeks between the stroke unit or general wards with specialist support
36489,Proportion of patients suffering stroke related complications in the first 3 months after stroke between the stroke unit or general wards with specialist support
36490,Multivariate analysis of preventive measures, and their effect on Rankin score 46   poor outcome
36491,IL12B promoter genotype and asthma severity
36492,Effect of IL12B promoter heterozygosity on asthma severity
36493,IL12B genotype and asthma severity by atopic status
36494,Patients and findings
36497,Median NO2 exposures before and after infection by exposure tertile
36501,End of life practices in the Netherlands in 1990, 1995, and 2001
36502,Interview study findings on euthanasia, physician assisted suicide, and ending of life without a patient s explicit request in 1990, 1995, and 2001
36504,Interview study findings on physicians  attitudes towards end of life decision making in 1990, 1995, and 2001
36506,Causes of death
36507,Multivariate and univariate analyses of overall   A   and cause specific survival   B
36509,Interleukin 9 mRNA and protein production on day 1 and day X
36512,Change in outcome variables at 16 weeks within each genotype and between genotypes
36514,Genotype frequencies and prevalence of minor alleles for ADRB2 single nucleotide polymorphisms in relation to incidence of asthma, wheeze, or both
36515,Genotype frequencies and prevalence of minor alleles for ADRB2 single nucleotide polymorphisms in relation to prognosis of childhood asthma, wheeze, or both
36516,Combined Arg16Gly and Gln27Glu genotypes in relation to prognosis of childhood asthma, wheeze, or both
36517,Genotype frequencies and prevalence of minor alleles for ADRB2 single nucleotide polymorphisms in relation to frequency of asthma, wheeze, or both in childhood and adulthood
36518,Regression analyses      for age adjusted mortality rates     of asbestos related diseases versus historical asbestos consumption     weighted by the size of sex specific national populations
36520,Cytological and HPV DNA test results at subsequent round
36525,Association between paracetamol use for fever in the first year of life and symptoms of asthma, rhinoconjunctivitis, and eczema at 67 years of age
36526,Association between paracetamol use for fever in the first year of life and symptoms of asthma, rhinoconjunctivitis, and eczema at 67 years of age worldwide
36527,Association between paracetamol use and severe asthma symptoms in children aged 67 years
36528,Association between paracetamol use in the past 12 months and symptoms of asthma, rhinoconjunctivitis, and eczema in children aged 67 years
36529,Association between paracetamol use in the past 12 months and symptoms of asthma, rhinoconjunctivitis, and eczema in children aged 67 years worldwide
36534,Adverse events reported by 2  or more of participants in any study group
36535,Alcohol, illicit drug use and measures of anxiety and stress in house officers
36536,Jhum jhum symptom profile
36537,Clinical and laboratory features of patients with sexual dysfunction
36538,ELISA analysis of mean   ng mL; SE   TGF1 and TGF2 concentrations in IVIG preparations
36540,Frequency of axillary lymph node metastasis according to tumour size in BRCA1 associated breast cancer cases and controls
36541,Chills, bacteraemia, endotoxaemia, and cytokines in febrile patients
36543,Mitochondrial DNA genotype, ponderal index at birth in ALSPAC children, and IGT type 2 diabetes in Hertfordshire men, in changers and non changers
36545,Site, cumulative incidence, rate, and rate ratios of first events
36547,Adverse events by treatment group
36548,Relation of micrometastases to prognostic factors
36549,Estimates of relapse free and overall survival
36550,Relapse free survival   distant relapse or breast cancer death   and overall survival   all cause mortality
36551,Relapse free survival   distant relapse or breast cancer death
36552,Age specific incidence of culture confirmed typhoid detected by active surveillance over a 1 year period in urban Dehli
36553,Severity of culture confirmed typhoid cases detected in active surveillance during a 1 year period in urban Delhi
36555,Correlations between absolute errors of NPH insulin suspension, blood glucose tests, and HbA1c
36556,Primary treatment methods by tumour size
36557,Deaths from 19 mm and 1014 mm tumours by mammographic findings, lymph node status, and histological grade
36558,Relative hazards of death from breast cancer by mammographic findings and tumour size
36559,Summary registration information for 44 EURODIAB centres
36560,Summary of Poisson regression analyses showing the incidence trend in each country during 198994
36561,Summary of Poisson regression analyses of incidence trends for data from 40 centres grouped into 29 countries
36566,TNF  genotype and allele distribution between groups
36567,Interaction between TNF  and apolipoprotein E  4 in Alzheimer s disease
36568,Interaction between TNF  and apolipoprotein E 4 in vascular dementia
36569,Frequency of T16189C variant in patients and controls
36573,Response to chemotherapy and TP53 status
36576,Relative risk of type 2 diabetes by volume of coffee consumption
36577,Viruses, source, passage history, and genetic homology with H5N1 97 viruses
36578,cDNA array profile of cytokine gene expression of primary human macrophages 3 h after infection with H5N1 97 or other human and avian influenza viruses
36579,Transmission of ICAM 1 R241 in 3695 families affected by type 1 diabetes
36581,Relative hazards   RH   for risk of new breast cancer event in HRT group versus non HRT group
36582,Clinicopathological features of patients
36583,HLA class II genotypes in Golden Years and BOX cohorts, subdivided according to age at onset
36586,Relation between completeness of excision for primary basal cell carcinomas and clinical variables
36587,Comparison of defect after multiple MMS stages or incomplete SE
36588,Mean TNF and interleukin 1 response   ng L   with five TLR ligands in wild type cells
36589,Data on microsatellite and single nucleotide polymorphism markers
36591,Allele frequencies of 11 consecutive markers in EBV positive and EBV negative subgroups
36592,Sex adjusted odds ratios for risk locus in EBV positive patients
36593,Frequencies of TNF and TNF single nucleotide polymorphisms
36595,Adverse effects from acute radiation
36596,Events in long term outcome
36597,Treatment effects by postoperative prognostic factors
36598,First active salvage treatment for patients who relapsed in wait and see group   n 207
36599,Global Fund programme evaluation scores
36604,Intervention costs and incremental cost effectiveness over 2 years
36605,Summary information for 20 EURODIAB centres with registration data
36606,Summary of Poisson regression analyses of incidence trends
36607,20 non governmental organisations registered in the USA with highest cumulative overseas health expenditure from 2002 to 2006
36609,Independent risk factors for lymphoproliferative disorder
36610,Standardised incidence ratios of lymphoproliferative disorder according to thiopurine therapy and anti TNF therapy at clinical onset
36613,Summary of events
36614,Hazard ratios for overall survival
36615,Time to first deterioration in quality of life score or death for subscales of EORTC QLQ C30 questionnaire
36617,Effect of low dose   75300 mg   aspirin versus control on subsequent long term incidence and mortality due to colorectal cancer
36618,Effect of aspirin   751200 mg   versus control on long term risk of colorectal cancer
36620,Causes of protocol deviation
36621,First events and deaths
36622,Multivariate analysis of overall survival and recurrence free survival
36625,Summary of estimates of the prevalence of physical inactivity, RRs, and PAFs for coronary heart disease, type 2 diabetes, breast cancer, colon cancer, and all cause mortality associated with physical inactivity
36626,Estimated PAFs, calculated with adjusted relative risks,      for coronary heart disease, type 2 diabetes, breast cancer, colon cancer, and all cause mortality associated with physical inactivity, by WHO region and country
36627,Estimated gains in life expectancy if physical inactivity were eliminated, by WHO region and country
36629,Adverse events of any cause in more than 10  of patients in the everolimus group
36633,Safety endpoints and treatment emergent adverse events of special interest, by treatment assignment over weeks 010   study part 1   and weeks 1020   study part 2
36634,Prevention of myocardial infarction and other events by aspirin and anticoagulants in coronary artery disease patients
36635,Clinical profile
36636,Cumulative CHD events during 5 years of follow up
36637,Mean   SD   PDS hostility and submissiveness scores by age in 774 men and 740 women
36640,Cytomegalovirus and Chlamydia pneumoniae seropositivity in patients with and without restenosis after PTCA
36642,Interpretation of and response to case history by sex and ethnic subgroup
36643,Predictors of immediate care seeking action by univariate and multivariate associations
36645,Main effects, warfarin: numbers of events   rates 1000 person years  , proportional and absolute reductions
36646,Main effects, aspirin: numbers of events   rates 1000 person years  , proportional and absolute reductions
36647,Separate group effects: numbers of events   rates 1000 person years
36648,Numbers of men having major, intermediate, or minor bleeding episodes   fatal events in parentheses
36649,Comparison of equipment use and procedural costs
36652,Outcome of procedures
36653,Rates of clinical and haemodynamic success
36655,Results of acetylcholine challenge and diameter stenosis after isosorbide dinitrate in patients who underwent coronary sinus catheterisation
36656,Effects of 17 oestradiol at rest and during exercise
36657,Cross reactivity of bradykinin precursors and metabolites with antiserum
36659,Accuracy of captopril renography in prediction of presence of significant renovascular disease
36661,Stent and technical data
36662,Stroke and bleeding complications
36663,Heparin and anticoagulation
36666,Frequency of primary clinical endpoints during follow up
36667,Functional class at 6 months  follow up or at time of repeat intervention for 823 patients in intention to treat analysis
36668,Immediate and long term angiographic results among patients assigned angiographic follow up
36669,Costs and efficiency after 12 months
36670,Deaths, myocardial infarctions, and reinterventions by treatment group and extent of disease
36672,Changes in angina grade between 1 year and 5 year follow up visits
36673,Mean health service costs per patient after 5 years  follow up
36674,Main clinical features and follow up data of patients
36676,First manifestations of coronary heart disease for cases, and causes of death for people who died free of coronary heart disease
36677,Lifetime risk of first coronary heart disease event at different ages reached free of coronary heart disease
36678,Lifetime risk of a first coronary heart disease event, excluding angina pectoris
36680,Success and complications of the primary procedure
36682,Clinical results at 6 months   intention to treat
36684,Limiting factors in exercise testing
36685,Number of myocardial sites with reversible or irreversible ischaemia
36686,Changes in median lifetime in subgroups
36688,Results of coronary angiography in invasive and non invasive groups
36689,Coronary procedures in invasive and non invasive groups
36690,Death, myocardial infarction, or both after 6 months
36691,Effect of invasive and non invasive treatment strategies on death, myocardial infarction, or both at 6 months in predefined strata and subgroups
36692,Symptoms, re admission, and medication during 6 months  follow up in invasive versus non invasive groups
36693,Medication in invasive and non invasive groups after 3 months  follow up
36694,Effect of invasive and non invasive treatment strategies on symptoms of angina pectoris in different predefined strata and subgroups at 6 months
36695,Adverse events in invasive and non invasive treatment strategies for open label treatment with dalteparin
36696,Adverse events in invasive and non invasive treatment strategies for double blind treatment with dalteparin
36697,Major events at 1 year follow up
36698,Events according to presence or absence of diabetes
36701,Distribution of ACE I D genotypes among confirmed myocardial infarction cases and controls
36702,Risk ratios confirmed for myocardial infarction with ACE I D genotypes
36703,Distribution of ACE I D genotypes among confirmed myocardial infarction cases and controls, classified by prespecified risk criteria
36704,Risk ratios confirmed for myocardial infarction with ACE I D genotypes, according to prespecified risk criteria
36705,Chronology of evidence based coronary care
36706,Populations, time periods, numbers of events studied, and data quality scores
36707,Acute coronary care and coronary event data for two time periods in men
36708,Acute coronary care and coronary event data for two time periods in women
36709,Correlation of changes in treatments with treatment scores, coronary endpoints, and quality control items for men   top triangle   and women   bottom triangle
36710,Regression of percentage change in coronary endpoints against change in treatments and treatment scores   univariate analysis
36712,Endpoint results
36714,Angiographic and procedural findings
36715,Event rates at 6 months in the routine stent and optimum PTCA with provisional stent groups
36718,Differences in blood lipid concentrations between pravastatin and placebo treatment groups at the end of the LIPID trial
36724,Quantitative coronary angiography   per protocol population
36727,Outcome events within 30 days after first treatment
36728,Technical outcome of first attempt at endovascular treatment
36729,Comparison of vascular risk factors and perioperative complication rates in surgical patients in CAVATAS, ECST, and NASCET
36731,Major outcome events
36732,Primary outcome   cardiovascular death, myocardial infarction, urgent revascularisation   events prevented at various times within 30 days of PCI   intention to treat analysis
36733,Main outcomes adjusted for covariates that influence likelihood of undergoing PCI   propensity score
36734,Bleeding after PCI
36737,Cardiac events during 12 months of follow up
36738,Prediction of cardiac events in Cox proportional hazard model
36739,Percentage of depressed or not depressed patients with cardiac events
36741,Cardiac procedures since randomisation
36742,Deaths, myocardial infarctions, and refractory angina by treatment strategy
36743,RITA 3 data analysed according to ESC ACC definition of myocardial infarction
36745,Cardiovascular events during main LIPID study, during extended follow up, and over total period by original treatment group
36748,Comparison of treatment effects in selected subgroups in main LIPID study and in total study period
36749,Absolute benefits of pravastatin during main LIPID study and total study period
36750,Serious adverse events, including cancer, during total follow up period and relative risk of adverse events with long term pravastatin treatment   number of patients having at least one adverse event
36754,Concomitant medications and hospital procedures
36755,Occurrence of primary endpoint at 30 days
36756,Occurrence of selected secondary endpoints and events at 30 days
36758,Death by cause during a median 20 years follow up
36759,Anginal symptoms and number of antianginal drugs taken at 1 year
36760,Number of patients with events by 1 year
36761,Randomised clinical trials investigating DES
36763,Clinical events and restenosis rates in randomised clinical trials investigating DES
36764,Edge restenosis and potential complications of DES
36766,Outcome by intention to treat and per protocol analysis
36767,Detection of apoptosis induced on an immortalised macroglial cell line by urine samples from MS patients, non MS patients, and healthy controls
36768,Histories and results for patients
36769,Borna disease virus   BDV   in cerebrospinal fluid
36770,Prevalence of type 1 diabetes in individuals with multiple sclerosis   MS   and in their parents and siblings
36771,Odds ratio for risk of type 1 diabetes in patients with multiple sclerosis   MS   and their healthy siblings, calculated according to individual and familial MS status in first degree and second degree relatives with logistic regression
36772,Prevalence of type 1 diabetes according to personal and family multiple sclerosis   MS   status
36773,Prevalence of type 1 diabetes mellitus according to personal and family multiple sclerosis   MS   status in families with only one diabetic offspring
36776,Multivariate model of risk factors for suicide comparing suicides and deaths due to other types of injury in China
36777,Patients  serum antibody titres to  L iduronidase
36778,Immunohistochemistry primary antibodies
36779,Summary of immunohistochemical and organ bath results, for both circular and longitudinal muscle, in controls and diverticular disease
36780,Age adjusted risks for full siblings and half siblings of 1567 index cases
36781,Age adjusted risks for maternal and paternal half siblings
36782,Global healthy life expectancy by age, in 1990, and 2010
36783,Life expectancy and healthy life expectancy at birth in 1990, and 2010, by country   95  uncertainty intervals
36784,Country rankings for healthy life expectancy at birth in 1990
36785,Country rankings for healthy life expectancy at birth in 2010
36787,Odds ratios   OR   for any mental health disorder by age, sex, socioeconomic status, and number of physical disorders
36788,Clinical outcomes at 12 months
36790,Incidence of fractures and other disorders associated with acute extremity compartment syndrome
36793,Effect of vaccine on cases of Ebola virus disease in different study populations
36794,Distribution of confirmed cases of Ebola virus disease among enumerated contacts and contacts of contacts in all clusters
36795,Frequency of solicited adverse events by time since vaccination in children and adults.
36797,Hazard ratios and 95  CIs for the associations between residential proximity to major roadways in 1996 and the risks of incident dementia, Parkinson s disease, and multiple sclerosis in Ontario, during the follow up period 200112
36798,Hazard ratios and 95  CI for associations between residential proximity to major roadways in 1996 and the risk of incident dementia in Ontario during the follow up period 200112
36799,Hazard ratios and 95  CI for associations between residential proximity to major roadways in 1996 and risk of incident Parkinson s disease and multiple sclerosis in Ontario, during the follow up period 200112
36801,Site of first disease free survival event
36802,Donor recipient mismatched combinations with significant influence   adverse or beneficial   on graft survival
36803,Magnitude of effect of taboo combinations
36807,Outcome measures
36808,Distribution of aneurysms detected by MRA and DSA according to vascular location
36809,Size of incidental IAs measured from DSA in the FIA and PCKD groups
36810,Number of affected members per family in FIA and PCKD families
36811,Relationships between affected family members after screening
36813,Distribution of cancers
36815,Prevalence of complications in PKD1 and PKD2
36816,Mixed model regression analysis for creatinine clearance rate
36817,Comparison of lipid profiles of individuals from Algeria, France, and Ireland
36819,Age adjusted risk ratios   one SD change   in different model specifications
36820,Age adjusted risk ratios   one SD change   in models with LDL cholesterol   LDL C   with and without apolipoprotein B   ApoB
36821,Composition per 100 g of RUTF
36823,Outcome data
36824,Sphere key indicators  14   for therapeutic feeding programmes and study results
36825,Immunohistochemical analysis of renal angiomyolipoma
36826,Clinical and mutation details of patients with vascular phenotype
36827,Comparison of PKD1 pedigrees with and without vascular disease
36829,HLA types of HLA homozygous donors selected from a series of 10000 consecutive cadaveric organ donors
36830,Blood samples available from study participants with myocardial infarction and controls by ethnic origin
36831,Concentrations of lipids and their ratios in cases and controls
36832,Mean concentrations of lipids, lipoproteins, apolipoproteins and their ratios in the control population of men and women by ethnic origin
36833,Change in risk for myocardial infarction with a 1 SD change in each of the lipid measures in each ethnic group
36834,Prediction of risk by age with a 1 SD change in each lipid measure
36835,Population attributable risks for ratios of total cholesterol to HDL cholesterol and apolipoprotein B100 apolipoprotein A1
36836,APOA5 1131T C genotypes and lipoprotein particle size and concentration in controls in the EPIC Norfolk Study  10
36840,Unadjusted transplant outcomes
36841,Cox proportional hazards regression model for graft failure in first time recipients of kidneys from cardiac death donors, adjusted for age of donors and recipients, and cold ischaemic time
36842,Cox proportional hazards regression model for individual factors affecting graft failure in first time recipients of kidneys from cardiac death donors, adjusted for age of donors and recipients, and cold ischaemic time
36843,Multiple linear regression model of graft function in first time recipients of kidneys, adjusted for age of donors and recipients, cold ischaemic time, and cause of death in donors
36844,Association of myocardial infarction   MI   with single nucleotide polymorphisms   SNPs   previously found to relate to plasma LDL cholesterol
36845,Association of myocardial infarction   MI   with single nucleotide polymorphisms   SNPs   previously found to relate to plasma HDL cholesterol
36846,Instrumental variable analysis estimate of the association of genetically raised HDL cholesterol and risk of myocardial infarction using LIPG Asn396Ser as an instrument
36847,Estimate of the association of genetically raised LDL cholesterol or HDL cholesterol and risk of myocardial infarction using multiple genetic variants as instruments
36848,Patients readmitted after 12 major operations in five surgical specialties
36853,Sensitivity analysis
36855,Cause specific mortality
36856,Non fatal cardiac events
36857,Adverse events requiring discontinuation of study medication
36860,Causes of death and hospital admission during an average of 19 months of follow up
36862,Causes of death
36865,Frequency of GSTM1 and GSTT1 genotypes in MDS patients and controls
36867,Extent of myocardial infarction measured by enzymatic infarct size and left ventricular ejection fraction
36869,Frequencies of GvHD and other procedure related complications
36870,Causes of death
36872,Prevalence of definite left ventricular dysfunction   left ventricular ejection fraction 30
36873,Risk factors for left ventricular dysfunction in symptomatic and asymptomatic participants
36875,Blood pressure and urinary sodium excretion rates during low sodium and high sodium diets by sodium sensitivity status
36876,Total cardiovascular events
36877,Relative risks of total cardiovascular events by Cox s proportional hazards regression
36878,Distribution of genotypes for mutation 35delG in GJB2 gene in autosomal recessive and sporadic deafness
36879,Distribution of mutations in GJB2 gene in unrelated patients with congenital deafness
36880,Composition of treatment regimens
36882,Deaths in complete remission by risk group
36883,Outcome after relapse
36886,Number of children with cancer in developed and less developed countries
36887,Distribution of new children with neoplastic diseases diagnosed and treated at La Mascota hospital in 199097
36888,Distribution and sources of funding by institutions and solidarity groups from Italy and Switzerland for La Mascota programme
36889,Clinical symptoms of congenital syphilis
36892,Odds ratios for selected treatments by age
36893,Independent predictors of death during the first year after acute myocardial infarction
36894,Risk of death within first year of acute myocardial infarction
36898,CX26 mutations in 43 deaf families
36899,Variations in the severity of hearing loss between both ears in prelingually deaf children
36900,Distribution of audiogram shapes in children with prelingual deafness with biallelic CX26 mutations or no mutation
36901,rCBF analyses for control group
36902,Comparison of statistical parametric maps of control groups and dyslexic groups
36904,Cancer diagnoses and deaths
36905,Details of radioiodine treatment and cancer diagnoses and deaths in patients with thyroid and small bowel cancers
36906,Clinical features of eight infants of diabetic mothers with left isomerism sequence
36908,Volumetric brain analyses in patients and controls
36909,Proportion of raw brain volume to whole brain volume in patients and controls
36910,Childhood leukaemias and the time weighted average of residential 24 h electric and magnetic field measurements in the bedroom and living room   overall measurement values combining both rooms  . Restricted to case control pairs where each child lived in the same house as that monitored 2 years before the reference date
36911,Flight activity of 3790 male pilots and cockpit crew members
36912,Observed and expected cancers and standardised incidence ratios in Danish pilots and cockpit crew for all cancers and selected sites
36913,Observed and expected cases of leukaemia, melanoma, and skin cancer and standardised incidence ratio by aircraft type and accumulated flying hours
36915,Abnormalities of chromosomes 5 and 7 in cases of myelodysplasia and acute myeloid leukaemia
36916,Paired urine and semen samples from 44 men in Androvakely
36917,Observed and expected site specific number of cancer cases among 2814 individuals with Down s syndrome
36918,Person years at risk and observed and expected numbers of solid tumours in 5 year age groups
36919,Observed and expected number of all malignant diseases combined and analysed separately for solid tumours and leukaemias
36920,Observed and expected number of leukaemia cases according to age
36922,Recurrence free intervals and hazard ratios according to treatment
36923,Daytime and night time blood pressure and left ventricular mass index in patients and controls
36924,Multivariate analysis with all reported variables including centres   n 427
36925,Multivariate analysis after stepwise selection of variables   n 456
36926,Relative risk for each centre in relation to the average centre and adjusted for other prognostic factors
36927,LFS estimated by the product limit method8 at 3 years
36928,TRM estimated by the product limit method8 at 3 years
36929,Detection of BCR ABL fusion gene in haemopoietic cells and cultured endothelial cells
36930,Matched case control analysis of household radon levels at diagnosis
36932,Phenotype of admission HIV 1 viral isolates   labelled 117  , classified as either syncytia inducing   SI   or non syncytia inducing   NSI  , and admission CD4 cell count
36933,HIV inhibitory effects in vitro of sera from typhusinfected patients and mice
36934,Case numbers   incidence rate per 1000000 child years   by period and diagnostic grouping
36935,Clinical indices of heart failure and device function
36936,Serial echocardiographic measurements
36937,Relation between pump speed and pulse pressure in systemic circulation
36941,5 year survival estimates in relation to wall thickness and number of risk factors
36942,Clinical features in velopharyngeal incompetence patients with and without 22q11 deletion
36943,Leukaemia deaths in wartime and postwar cohorts of Orkney and Shetland children
36945,Primary, secondary, and other endpoints
36946,T cell repertoire and proliferative responses to candidin after transplantation
36947,Details of PPRA and GPRA patients
36948,QTc time as determined by the longest QT time divided by the square root of the RR interval
36949,Susceptibility of Salmonella typhi strains to antimicrobial agents
36950,Median   range   urinary 3 methylglutaconate and 3 methylglutarate concentrations
36951,Estimates of incidence of cholera among travellers and expatriates in three studies
36952,Guidelines for clinical evaluation of dehydration and recommendations for rehydration and maintenance fluid therapy
36954,Pregnancy prevalence rates associated with HIV 1 infection and other sexually transmitted diseases   STDs
36956,Clinical and echocardiographic data
36957,Growth data at birth
36958,Frequency of chronic illness at 18 months of age
36959,Frequency of common disorders
36960,Major malformations identified by 18 months of age
36961,Physiological responses to a laboratory based submaximal treadmill test
36963,Crude risk ratios and adjusted odds ratios for study outcomes in HIV 1 infected and non infected women
36965,Risk of death in relation to physical activity at Q92 among men without cardiovascular diseases or self reported poor health at Q92
36966,Type of physical activity and adjusted relative risk for all cause mortality among men without cardiovascular disease or self reported poor health at Q92
36967,Physical activity changes between Q1 and Q92
36968,Risk of mortality in relation to changes in physical activity between Q1 and Q92
36970,Changes in physical activity, mortality rates, and risk of mortality for men with coronary heart disease, stroke, or heart trouble, excluding men with poor health
36971,Indicators of deficiency and WHO severity grades1 in different groups
36972,Number of pregnancies with nuchal translucency thickness above 95th centile and an estimated risk for trisomy 21 of 1 in 300 or greater
36973,Accuracy of estimated risk of trisomy 21 by a combination of maternal age and fetal nuchal translucency thickness
36974,Quality of reporting of 127 RCTs assessed by a scale  16,17   and individual quality components under masked and unmasked conditions  3
36975,Influence of different method of quality assessment on treatment effect estimates
36976,Relation between different methods of incorporating quality scale into meta analyses and resulting estimates of intervention effects
36977,Comparison of measured volumes with 3D volume estimates of test objects
36978,Estimates   SE   of regression coefficients by linear regression analysis
36979,Distribution of embryos and fetuses according to Carnegie staging system
36983,Pregnancies during entire follow up period of six menstrual cycles
36985,Mantel Haenszel estimates for comparison of pregnancyassociated breast cancer in rererence groups BRCA1 and BRCA2
36986,Proportion of 356 patients with CHD risk  2  per year   20  over 10 years   or  3  per year    15  over 5 years   by Framingham equation and proportions recommended statin treatment by NCEP guidelines and Sheffield table
36987,Numbers of women enrolled and pregnancies by centre and treatment group
36989,Details of pregnancies
36990,Pregnancy rates and prevented fractions by treatment group
36991,Prematurity and maternal breast cancer risk among uniparous Swedish women
36992,Principal diagnoses in 28 pregnancies with umbilical  artery AEDF
36993,Outcome data for 19 pregnancies showing a return of end diastolic flow and nine pregnancies with persistent AEDF
36997,Epithelial ovarian cancer risk in mothers with twin births among parous women in Sweden, 19611995
36999,Selected model variables for prevention in pregnancy
37000,Selected model variables for improvement in case management
37001,Mid trimester maternal serum immunoglobulin concentrations among women delivering prematurely
37002,Method of antenatal screening for Down s syndrome offered by Health Authorities and Boards in the UK in 1991, 1994, and 1998
37003,Fetal diagnosis of common lesions   199395
37004,Population, livebirths, serious congenital heart disease, and terminations of pregnancy for England and Wales, Scotland, and Northern Ireland   1994
37005,Effect of prenatal diagnosis   199395
37008,Significance of continuous variables in estimating cumulative measure of atherosclerosis in univariate analysis
37009,Significance of dichotomous variables in estimating cumulative measure of atherosclerosis in univariate analysis
37010,Models of multiple linear regression analysis assessing role of group, age of child, birthweight, maternal age, and coronary heart disease history on atherosclerosis of child
37011,Deaths from intentional and unintentional injuries in women
37012,Male to female ratio in offspring of Swedish women with hyperemesis gravidarum during pregnancy, 19871995
37014,Distribution of patients, numbers of cycles, and outcome of the three treatment programmes
37015,Calculated costs per pregnancy resulting in at least one livebirth after a maximum of six treatment cycles for groups of 100 fictional couples in each age and treatment category
37016,Summary of comparative studies on congenital malformations associated with the treatment of asthma during the first trimester of pregnancy
37017,Birthweight placental weight ratios of pregnancies delivering at or beyond 25 weeks gestation at Monash Medical Centre
37018,Summary of case histories
37019,Serum and urine hCG assay results
37021,Distribution of respondents by starting time of exposure to unprotected intercourse
37022,Time to pregnancy in Great Britain, 196193
37023,Trends in fertility in Great Britain, 196163
37025,Associated chromosomal anomalies with HLHS and outcome
37026,Extracardiac structural anomalies associated with HLHS   including hydrops fetalis
37027,Study participants and pregnancies
37029,Fetal death among singleton pregnancies reported by women according to employment and monitoring around the time of conception
37030,Reported congenital malformations among pregnancies which were conceived after first employment in the nuclear industry
37034,Details of stillbirths and neonatal deaths   excluding lethal anomalies
37035,Perinatal or neonatal mortality at  28 days of age and serious neonatal morbidity
37036,Details of neonatal morbidity
37037,Maternal mortality and morbidity
37038,Hazard ratio        95  CI   for mortality according to a 1 SD     increase in birth outcome measure or for premature delivery
37039,Comparison of cases and controls
37040,Effect of tubal ligation on ovarian cancer risk in BRCA1 carriers.
37042,Maternal serum DDE concentration in relation to odds of preterm or small for gestational age birth
37044,Differences between non responders and responders among Aboriginal people and European people
37046,Frequency of single or combined cardiovascular events
37047,Determinants of atherosclerosis
37048,Determinants of low income
37049,Determinants of CVD
37050,Details of studies included in these analyses
37051,Risk ratios for breast cancer, by number of first degree relatives with a history of breast cancer
37052,Age specific risk ratios for breast cancer in women with one first degree relative with a history of the disease, according to the relative s age at diagnosis of breast cancer
37053,Age specific risk ratios for breast cancer in women with two first degree relatives with a history of the disease, according to the relatives  ages at diagnosis of breast cancer
37054,Probability       that women in more developed countries who are free from breast cancer at certain ages would develop breast cancer over the next 10 years, according to the number of affected relatives
37055,Probability       that women in more developed countries who are free from breast cancer at certain ages would develop breast cancer by age 50 and by age 80, according to the number of affected relatives
37056,Distribution of women with and without breast cancer in studies from more developed countries, according to their age and family history of breast cancer
37057,Example of how to compare the respective variances of the unstratified and fully stratified data   from table 2
37058,Clinical details and FISH results
37059,Correlation of FISH results with pathological diagnoses
37060,Children who required treatment at a childhood disability centre
37061,Distribution of diagnoses among children born after in vitro fertilisation   IVF   and controls
37062,Logistic regression analysis showing independent effects of in vitro fertilisation   IVF  , maternal age, male sex, and low birthweight   upper panel   or low gestational age   lower panel   on the risk of needing contact with a childhood disability centre, risk of cerebral palsy, and risk of suspected developmental delay
37064,Percent distribution for all causes of death
37066,Number of reported barriers to health care and number of women reporting 1 barrier by level among Afghan refugee women who died of maternal and non maternal causes
37070,Compliance with allocated treatment
37071,Side effects and problems at injection site, for women who received trial treatment
37072,Eclampsia and maternal death
37073,Secondary outcome for all women
37074,Hospital stay and use of intensive care facilities, for all women
37075,Baby deaths before discharge from hospital for those randomised before delivery
37076,Gestation at birth and age at death for liveborn babies, without lethal congenital malformation
37077,Outcomes relevant only to women randomised before delivery
37078,Neonatal morbidity for liveborn babies of women randomised before delivery
37079,Relation between lifetime duration of breastfeeding and various other aspects of childbearing in parous cases and controls
37080,Relative risk of breast cancer in parous women, in relation to lifetime duration of breastfeeding
37081,HB EGF expression in placental tissues
37086,Cardiac complications and non cardiac morbidity and mortality
37087,Pregnancies by centre and treatment group
37089,Pregnancy rates and prevented fractions
37090,Efficacy analysis stratified by intercourse treatment interval, intercourse after treatment, and ethnic group
37091,Side effects within 7 days and delay of menses
37092,Mortality rate ratios associated with short versus long telomeres in whole blood DNA
37093,Results of antenatal screening for Down s syndrome with quadruple test   including maternal age   and with maternal age alone
37094,Detection rates   DR   and odds of being affected given a positive result   OAPR   for a fixed 5  false positive rate by method of screening
37096,Mean width of the intervillous space and of fetoplacental villous arteries in subchorionic and basal half of human placenta
37099,Risk of antepartum stillbirth after 24 weeks gestation in relation to previous caesarean section in 120633 second births
37100,Number of events and life table analysis of unexplained stillbirths at or after 34 weeks gestation in second pregnancies in relation to previous caesarean delivery   n 119350
37101,Risk of adverse pregnancy outcome in second pregnancies in relation to previous caesarean delivery adjusted for outcome of first pregnancy   n 103790
37102,Country, study region, and number of cases and controls
37103,Prevalence of multivariately significant potential risk factors for SIDS in cases and controls
37104,Multivariately significant potential risk factors for SIDS not recorded by all centres
37105,Change in sleeping position on last occasion of cases and controls with ORs
37106,PAFs for avoidable risk factors for SIDS derived from adjusted ORs, in order of magnitude, with intercentre IQRs
37108,Effect of HIV on amount of antibody according to gravidity and malaria status
37109,Univariate and multivariate analysis of factors influencing concentrations of antibody to CS2 VSA, AMA 1, and MSP
37111,Primary analyses of outcome measures
37116,Second opinion process
37117,Effect of the second opinion policy on women s preferences and satisfaction with care process
37118,Completion rates for different types of referral in children
37119,Caretakers  reasons for not completing referral
37120,HIV prevalence in women attending antenatal clinics in the WHO Africa region
37121,HIV prevalence trends in pregnant women attending antenatal clinics by country and subregion in the same clinics
37123,Unprotected first heterosexual intercourse      by sex and school
37125,First ten women s group meetings
37127,Mortality rate comparisons between intervention and control clusters
37128,Process indicator outcomes
37133,Cumulative prevalence rates and 95  CIs of detrimental actions undertaken by parents to stop the crying of their child
37135,Means   SDs   of variables
37136,Multiple regression equations with human resources for health as an independent variable
37137,Multiple regression equations with doctors and nurses as separate independent variables
37138,Maternal gestational histories
37139,Findings and treatments of neonates born after gestational IVIG therapy
37140,Outcomes of previous affected pregnancies selected randomly versus index pregnancies during which mothers received IVIG therapy   all participants
37142,Evidence of efficacy for interventions at different time periods
37143,Evidence based packages of interventions at different periods
37144,Cause specific effect of intervention packages delivered at different periods
37145,Estimated number of neonatal deaths in 75 countries by region that could be averted by universal   99  coverage   delivery of all      evidence based interventions
37146,Estimated number of neonatal deaths that could be averted by delivering packages of interventions      during the indicated periods at 90  coverage in 75 countries
37147,Effect of interventions packaged by service delivery mode      and delivered in programmatically relevant models of implementation in 75 countries
37148,MDGs for maternal and child health
37150,HIV incidence among pregnant or lactating women and women who were neither pregnant nor lactating
37151,Male reported sexual behaviours and HIV acquisition in married women linked to their male partners
37152,HIV acquisition among women in discordant relationships with an HIV infected male partner
37154,Risk of maternal premature cardiovascular disease after maternal placental syndrome in index pregnancy
37155,Risk of maternal premature cardiovascular disease, according to type of maternal placental syndrome and concomitant presence of poor fetal growth or intrauterine fetal death
37157,Description of project activities
37158,Key results on the cost and cost effectiveness of the intervention
37159,Socioeconomic determinants of use of basic professional obstetric care with a midwife at home or in a health facility   19872001
37160,Trends in use of basic obstetric care with a midwife by wealth quintile   19872001
37162,Perinatal outcomes
37163,Adverse events in women
37165,Pregnancy data per woman
37166,Pregnancy data per embryo transfer
37168,Summary of data sources for measures
37169,Population information by country
37170,Indicator measures by country
37173,Clinical events during 1 year follow up
37175,Primary and secondary outcomes
37176,Process outcomes after trial entry
37177,Health and development outcomes at 2 years in a sample of surviving infants without the primary outcome selected for follow up
37178,Study indicators and source
37180,Hierarchical mixed modelling results
37181,PASI scores
37182,TDT for S gene polymorphisms in psoriasis family trios
37190,Adverse events reported by two or more patients
37192,Reasons for patients  withdrawal from treatment
37195,Functioning, disability and use of health services by psychiatric status
37196,Categories of trauma
37197,Associations between indices of psychiatric status and trauma exposure
37199,DSM IV disorders in people with and without exposure to armed conflict associated violence   ACAV
37200,1 year comorbid categories of DSM IV disorder in people with and without experience of armed conflict associated violence   ACAV
37201,12 month prevalence and severity of DSM IV disorders
37203,Associations of exposure to war related traumatic events with 12 month DSM IV disorders
37204,Distribution of 12 month DSM IV disorder severity as a function of exposure to war related traumatic events
37205,12 month treatment by severity of DSM IV disorders
37207,Estimated crude rate and number of victims by type of violation for greater Port au Prince area
37208,Perpetrators of human rights violations
37209,Post stratification analysis
37210,Forms of partner violence during pregnancy
37213,Association of postnatal depression with level of exposure to partner violence during pregnancy
37214,Association of postnatal depression with psychological partner violence or physical or sexual partner violence during pregnancy
37216,Hazard ratios for the association between psychotropic medication and violent crime in a Swedish population cohort of 82647 patients with prescriptions
37217,Hazard ratios for different crime outcomes in 82647 patients prescribed mood stabilisers, antipsychotics, and clozapine, compared with periods when these same patients are not on medication   within individual analyses
37218,Hazard ratios for violent crime in patients with different psychiatric disorders who have been prescribed antipsychotics and mood stabilisers   within individual analyses
37219,Hazard ratios for the association between violent crime and different exposures to psychotropic medications
37222,Maternal outcomes
37223,Major maternal complications   as diagnosed by clinician at the time
37224,Fetal and neonatal interventions and outcomes
37225,Neonatal complications and fetal and neonatal loss
37226,Overall satisfaction with maternity care
37227,Satisfaction with choice, information, decision making, and individualised care
37230,Estimated risk of late postnatal transmission from eight included studies by breastfeeding practice
37231,Induction of labour and mode of delivery in lawyers, doctors, and controls
37232,Mutual information scores for use of you just and look by doctor
37233,Comments on diagnosis and prognosis: doctors  and patients  use of worr , concern , anxi
37234,Prevalence of reproductive tract infections in women with symptoms
37236,Accuracy of algorithms compared with microbiological findings
37237,Costs of drugs and diagnostic aids for treating women with vaginal discharge   n 320
37238,Patient characteristics at baseline
37239,Results of preoperative evaluation
37240,Complications during and soon after fundoplication as seen in 57 laparoscopic and 46 open Nissen fundoplications
37241,Number of patients with primary endpoints requiring medical treatment or intervention   oesophageal dilatation, reoperation   after laparoscopic and open Nissen fundoplication
37242,Endocrinological test results
37243,Headache as a symptom of myocardial ischaemia cases reported in English publications
37244,Frequency of clinical features in 48 patients with A3243G
37245,Mitochondrial transfer DNA sequence haplogroups in patients with A3243G and A12308G
37248,CSF laboratory findings in 905 children undergoing lumbar puncture and the proportions with proven acute bacterial meningitis
37250,Case mix and crude outcome of study cohort related to birthweight quintile
37251,Crude and adjusted hazard ratios   95  CI   for death from any cause, death due to IHD, and admission for or death from IHD in relation to birthweight quintile, preterm delivery, and pre eclampsia
37252,Crude and adjusted hazard ratios   95  CI   for death from any cause, death due to IHD, and admission for or death from IHD in relation to combinations of adverse obstetric outcomes
37253,Crude and adjusted hazard ratios   95  CI   for death from any cause, death due to IHD, and admission for or death from IHD related to absolute values of birthweight
37254,Multivariate analysis of risk factors for overall survival after histocompatible bone marrow transplantation
37256,Results of porphyria screen
37257,Comparison of titres of IgM and IgG antibodies against staphylococcal slime polysaccharide antigens   SSPA     ELISA units  EU    in sera from patients with an ongoing staphylococcal late onset infection of synthetic vascular graft   LO SVGI   and in controls
37259,Data related to surgical intervention and morbidity
37260,Tumour recurrence and mortality in patients with non metastatic colon cancer
37261,Results of Cox s regression analysis in patients with non metastatic colon cancer
37262,Presenting features and final diagnostic categories
37263,Frequency of haemoglobin S in diagnostic groups
37264,Laboratory results for each diagnostic group
37265,Number of patients in each diagnostic group with specific discriminators
37267,Univariate analysis comparing admission variables between patients with tuberculous and bacterial meningitis
37268,Second cerebrospinal fluid analysis taken after 4872 h of parenteral ceftriaxone
37269,Change in cerebrospinal fluid variables after 4872 h of parenteral ceftriaxone
37270,Multivariate logistic regression analysis of admission data
37271,Weighted diagnostic index scores for dichotomized clinical variables used for admission diagnostic rule
37272,Sensitivity and specificity of diagnostic aids
37273,Results of household investigations
37274,Biochemical measures of galactosaemia
37275,Thrombophilic defects identified by laboratory testing
37280,Main outcomes for women with minimal screening abnormalities
37281,Persistence of HPV in women in surveillance group   n 411
37282,Initial and follow up cytology and HPV results in women in surveillance group who attended follow up and had adequate cytology and HPV tests   n 296
37284,Perioperative outcomes
37285,Complications of surgery
37286,Survival and recurrence   stage IIII diseases
37287,Maternal health indices in Adjumani district
37288,Population and sample size in the four study sites
37289,Frequency distribution of maternal causes of death among women in the four study sites
37292,Likelihood ratios for white blood cell count in diagnosing appendicitis
37293,Likelihood ratios for prostate specific antigen in diagnosing prostate cancer
37294,Likelihood ratios and bedside estimates
37295,Examples of likelihood ratio applications
37297,Operative details and postoperative recovery
37298,Operative procedure undertaken
37299,Intraoperative complications
37300,30 day postoperative complications
37301,Diagnostic criteria for Marfan s syndrome  2,3
37303,Outcome data in relation to death of either infant from SIDS
37304,Risk of adverse outcome in the second recorded pregnancy in relation to infant outcome of preceding birth
37306,Targeted laboratory tests, brief educational messages, and cues for activating addition of messages as reminders to results report
37308,Requests for total and individual targeted tests before and during the intervention period
37309,Effect of interventions on requests for total and individual targeted tests
37312,Risk factor profile in the NHEFS population
37313,Laboratory based and non laboratory based models for predicting cardiovascular disease outcomes
37314,Predictive discrimination of models at different 5 year cardiovascular risk thresholds
37320,Interventions meeting selection criteria for analysis of prevention of preterm birth
37323,Treatment emergent AEs in the safety analysis population
37325,Comparison of symptoms at illness onset of laboratory confirmed cases of human infection with avian influenza A H7N9 and H5N1 viruses in mainland China, based on available data
37326,Average numbers of close contacts traced for laboratory confirmed cases of human infection with avian influenza A H7N9 and H5N1 in mainland China, based on available data
37329,Outcomes
37330,CACE analyses
37331,Subgroup analyses for primary outcome   30 day survival
37333,Crude and adjusted ORs for gonorrhoea diagnosis
37334,Crude and adjusted ORs for gonorrhoea diagnosis excluding partly vaccinated participants
37336,Comparison of assessment of Canadian Cardiovascular Society angina class with   masked   and without   investigators    concealment of treatment allocation
37337,Changes in Seattle angina questionnaire   SAQ   scores
37338,Adverse events during follow up   including periprocedural events
37340,Odds ratios   95  CI   of the relations of ELISPOT and TST with intensity of M tuberculosis exposure in school and with risk factors for exposure outside school
37341,Effect of previous BCG vaccination on ELISPOT and TST results
37344,Patterns of failure
37346,Results of the three tests in patients with a diagnosis of active tuberculosis
37347,Positive results obtained with tuberculin skin test, QuantiFERON TB Gold, and T SPOT.TB in participants recently in close contact with a patient with active tuberculosis
37350,Screening activity, identification of active and latent tuberculosis, and BCG coverage
37353,Primer sequences
37354,Purity of cell fractions by FACS analysis
37355,Risk group, CD4 and other cell counts, and blood virus load
37356,Absolute cell counts and frequency of infection of 106 cells from different subsets of peripheral blood mononuclear cells   PBMCs   with HIV
37357,Detection of HIV proviral sequences in cells separated by CD8 MACS beads
37358,Risk of HIV 1 infection according to duration of prostitution by calendar year
37359,Univariate Cox proportional hazards modelling of risk factors for HIV 1 seroconversion
37360,Multivariate Cox proportional hazards modelling of risk factors for HIV 1 seroconversion
37361,Observed MBP genotypes and allele frequencies in patients with acute or chronic hepatitis and HBsAg negative controls
37362,Serum MBP concentrations in Caucasian patients with chronic HBV infection
37363,MBL genotypes in HIV infected men, healthy controls, and HIV negative, high risk controls
37364,Distribution of  MBL  genotypes in HIV infected men
37365,Multivariate analysis of serum MBL concentration and CD4 T cell count as predictors of death in patients with AIDS
37366,Median survival   Kaplan Meier   from first presentation of various infections in men who developed AIDS by  MBL  genotypes
37367,Regions of brain examined for HSV1 DNA
37368,APOE genotypes of AD patients and aged non AD patients positive or negative for HSV1 in brain   frontal lobe and temporal lobe
37369,APOE genotypes of AD patients and aged non AD patients positive or negative for HSV1 in all brain regions
37370,Odds ratios for presence of  APOE  e4 allele
37371,APOE genotypes of cold sore sufferers and non  sufferers
37372,Mutation frequencies in patients with sporadic porphyria cutanea tarda and in controls
37373,Genotypes of patients with sporadic porphyria cutanea tarda and of controls
37374,Distribution and allele frequency of Pt u  polymorphism among cases and controls
37375,Relative risks of thrombosis associated with carriage of P  allele
37376,Relative risks of myocardial Infarction   MI  , stroke, or venous thromboembolism   VTE   associated with carriage of P2 allele for all study participants and in prespeclfled subgroup analyses
37377,Distribution and allele frequency of p1 A2 polymorphlsm among study participants, stratified by randomised aspirin assignment
37378,Clinical features and FGFR3 mutation status of patients in cohort
37379,Definition of children s HIV status
37380,Enrolment, follow up, and infection status of children by mother s HIV serologic status
37381,Occurrence of late postnatal transmission by maternal and child factors
37382,Details of michrochimerism and rejection
37383,Air pollution   24 h averages  , meteorology   24 h averages  , and plasma viscosity on days of MONICA survey   October, 1984, to June, 1985
37384,Associations between raised plasma viscosity and 1985 air pollution episode
37385,Multivariate logistic regression analyses for plasma viscosity above 95th percentile
37386,Associations between plasma viscosity above 95th percentile and measures of air pollution treated as continuous variables
37387,Borna disease virus in human brains
37388,5 HT2A receptor densities and T102C polymorphism
37389,Amplification of fetal Y chromosomal sequences from maternal plasma, serum, and blood
37391,Proportion of women with polycystic ovaries by birthweight and completed weeks of gestation
37392,Proportion of women with polycystic ovaries and plasma LH concentrations   IU L   by length of gestation and adult body mass index   BMI
37393,Proportion of women with polycystic ovaries by birthweight and mother s weight in early pregnancy
37394,Proportion of women with polycystic ovaries, mother s weight, body mass index, and mean concentrations of plasma LH and testosterone according to birthweight among women whose mothers  weight in pregnancy was above 58 kg   median
37396,Frequency of events at 1 month by PlA  genotype
37397,Univariate and multivariate analysis of stent thrombosis
37398,Classic risk factor scores for stent thrombosis by PlA  genotype
37400,Relative risk for recurrence of pneumonia by age, estimated by Cox proportional hazard regression
37401,Results of quantitative tests for male DNA
37402,Women with at least one HLA compatible child for class II Loci DRB1, DQA1, and DQB1
37403,Standardised incidence ratios   SIRs   for all cancers
37404,Standardised cancer incidence ratios   SIRs   for patients admitted to hospital for VTE
37405,PCR positive C pneumoniae in heart transplant donors
37408,Results of assays and predictive accuracy for aspartate aminotransferase and alanine aminotransferase concentrations
37409,Multiple regression models for prediction hepatitis activity index
37411,Rates       of interventions and major clinical events, by country
37412,Rates       of intervention or outcome
37414,Adjusted rates of major outcomes among patients initially admitted to hospitals with or without cardiac catheterisation facilities
37415,Adjusted rates of procedures and outcomes up to 6 months
37417,PCR analysis of PERV proviral sequences in lymphocytes from 10 diabetic patients given pig islet cell xenografts between June, 1990 and April, 1993
37418,RGH sequences in plasma from patients and controls
37419,Background of women and results of plasma PCR
37420,Distribution of HCMV gB genotypes in different organs from immunocompetent people
37421,Distribution of alleles and genotypes of GST polymorphisms
37422,Distribution of GSTP1 1 polymorphisms in participants exposed to pesticides
37423,Results of bronchoalveolar lavage and clinical outcomes
37424,Diagnosis of parvovirus B19 infection in four children with FH
37427,Results of PCR in microdissected epidermis and dermis of pregnant women with or without PEP
37428,Frequency of  CYP2D6  PM genotype and exposure to solvents among cases and controls
37430,WWW services linked to RIDOM in a context sensitive manner
37431,Prevalence of major risk factors for coronary artery disease among patients and controls
37432,Genotype distribution of the C807T G873A polymorphisms among patients and controls according to age
37433,Relative risk of myocardial infarction associated with carriage of 807T 873A
37434,Relative risk of myocardial infarction for homozygous 807T 873A collagen receptor polymorphism and or smoking status
37435,HIV 1 viral load by CD4 strata
37436,Geographical distribution of 29 cases of EFE
37437,Signs and symptoms detected in 29 cases of EFE
37438,Distribution of potential risk factors for EFE in 27 case households and 112 control households
37439,Dicarboxylic acid concentrations in urine samples from two cases of EFE and three controls
37441,Adverse events in mothers and babies
37442,HIV 1 transmission and treatment efficacy at birth and ages 4weeks and 3 months
37444,24 h mean and median winter air pollution   g m3
37445,Estimated odds ratios   95  CI   for prevalence of respiratory symptoms and decrease in peak expiratory flow   PEF   with increase in air pollutants in children with BHR and relatively high serum total IgE   n 121
37446,Estimated odds ratios   95  CI   for prevalence of respiratory symptoms and decrease in peak expiratory flow   PEF   with increase in air pollutants in children without BHR and with relatively low serum total IgE   n 167
37447,Estimated odds ratios   95  CI   for prevalence of respiratory symptoms and decrease in peak expiratory flow   PEF   with increase in air pollutants in children with BHR and relatively low serum total IgE   n 67
37448,Estimated odds ratios for prevalence of respiratory symptoms and decrease in peak expiratory flow   PEF   with increase in air pollutants in children without BHR but with relatively high serum total IgE   n 104
37450,HIV 1 infection status of children according to allocated and actual mode of delivery
37451,HIV 1 infection status of children by allocated and actual mode of delivery: analysis in strata of prophylactic zidovudine therapy and maternal CD4 cell count
37452,Comparison of  MBL  variant gene frequencies
37453,OPV3 coverage by routine immunisation
37454,Number of patients in each of the groups based on the family history, the number referred as idiopathic pancreatitis, and the number with a mutation in the cationic trypsinogen gene
37455,Reported dengue cases in Guayana and bordering countries 1990 98
37456,Combined results of culture and PCR investigations of 12 middle ear fluid samples
37457,Relation between PAI 1 concentrations, clinical presentation, and disease outcome
37458,Relation between PAI 1 concentrations,  PAI 1  genotype, and clinical presentation
37459,PAI 1  promoter region genotype frequencies
37460,Outcome of meningococcal sepsis in children classified by PAI 1 genotype
37461,Fatal cases
37462,Non fatal AFP cases
37463,Sites of isolation of enteroviruses and adenoviruses from fatal cases
37464,DHPS genotypes according to previous or current exposure to sulpha drugs in 152 episodes of PCP
37466,Cox regression analysis of predictors for 3 month survival after diagnosis of PCP
37467,Patient specific TEL and AML1 sequences and PCR conditions for Guthrie studies
37468,Summary of TEL AML1 Guthrie card blood spot screening for clonotypic TEL AML sequences
37470,Alignment of 39 UTR sequences
37474,Odds ratios for the impact of health care worker vaccination on mortality in patients
37475,Results of tissue culture and PCR for influenza infection on nose and throat swabs
37476,Detection of paternal mtDNA after in vitro fertilisation   IVF   and intracytoplasmic sperm injection   ICSI   treatments
37477,Dominant wind direction, rates of dust deposition,  PM10 and phosalone concentrations for sampling sites in eastern Turkmenistan
37480,Indications for colonoscopy
37481,Correlation of appearance with histology
37482,Correlation of size with appearance and histology
37483,Logistic regression analysis to define the risk of CMV disease associated with a 025 log10 initial CMV load
37484,Univariate and multivariate logistic regression analyses relating factors of initial CMVload, peak CMV load   both per 025log10 genomes  mL increase   and rate of change in CMVload   per 025log10 genomes mL per day increase   to the development of CMV disease
37486,Capsular serogroups implicated in the 34 invasive pneumococcal episodes by vaccine and placebo in 25 individuals
37487,Effects of vaccination on pneumococcal events and death: numbers of events observed together wih estimated hazard ratios   HR   and incidence rate ratios   IRR   for vaccine versus placebo
37488,Effect of vaccination on first events within 6 months of vaccination and after 6 months
37489,Interaction between effect of vaccination on first events and CD4 cell count at enrolment
37491,HPV 16 status in relation to cytological diagnosis
37492,HPV 16 status in first and last smear among cases and controls with two or more smears
37493,Odds ratios   95  CI   for cervical carcinoma in situ in relation to HPV 16 Ct values at different years before diagnosis
37495,Odds ratios   95  CI   of developing cervical carcinoma in situ in relation to mean estimates of HPV 16 viral load per actin positive woman
37496,Odds ratios of developing cervical carcinoma in situ in relation to HPV 16 viral load in first smear among  actin positive women
37497,Frequency of serological markers of hepatitis B virus infection in patients with a known number of autohaemotherapy treatments
37498,Health outcome definition and sources of data
37499,Health outcomes with relative risks, outcome frequency, and attributable cases   per 10 g m3 and 1 million population
37500,Population exposure distribution of PM10
37501,Number of attributable cases to air pollution, and cases attributed to traffic pollution
37502,Sensitivity of the estimation of air pollution attributable number of cases of death   mortality  30 years of age   compared with the quantified uncertainty   95  CI of epidemiological risk estimates  , based on Swiss data only
37503,Maternal risk factors for vertical HCV transmission
37504,Results of various approaches for assessing HBsAg and HBV DNA in 17 liver samples from patients with HBV infection and two donors
37505,Age, physical examination, and history relevant to reproductive system in young men prenatally exposed to PCBs PCDFs and unexposed controls
37506,Semen indices in PCB PCDF exposed young men and unexposed controls
37507,Patient details: colonoscopy examination results
37508,Sedation dose and quality of bowel preparation
37509,Frequency and type of loop seen during colonoscopy
37510,Number and duration of loops and number of straightening attempts per procedure
37511,Frequency and efficacy of abdominal hand pressure   HP   during colonoscopy
37512,Primer and probe sequences for RT PCR amplification of cytokeratin 19 and glyceraldehyde 3 phosphate dehydrogenase   GAPDH   mRNA
37513,Standardised incidence ratios   SIR   and 95  CIs for cancer after diagnosis of dermatomyositis or polymyositis
37514,Standardised incidence ratios   SIR   and 95  CIs for cancers of different histological type in dermatomyositis and polymyositis
37515,Standardised incidence ratios   SIR   and 95  CIs of cancer by year after diagnosis of myositis
37516,Sequence of PCR primers and sequence specific probes for different targets
37517,Proportion of vaccinated and unvaccinated individuals in Stockholm County by age and sex
37518,Hospital admissions between Dec 1, 1998, and May 31, 1999
37519,Incidence of admission for endpoint diagnoses
37520,Deaths from all causes according to age group in mean years per 1000, and vaccination status between Dec 1, 1998, and May 31, 1999
37521,Assessing the use of methylation markers for early detection of breast cancer
37523,Clinical details of 21 patients homozygous for CCR532
37524,Results of adenovirus cultures and detection of viral DNA in serum by PCR in four categories of recipients of stem cell grafts
37525,Age distribution of samples and positives during three successive winters
37527,Matched unadjusted and adjusted odds ratios for venous thromboembolism
37528,Percentage changes of mRNA levels for Down s syndrome and control samples
37531,4 year pollution concentrations in high and low pollution communities
37535,Odds ratios for case status for polymorphisms at positions 192 and 55 of PON1
37536,Presence of SV40 T antigen sequences in lymphomas, other human tumours, and control tissues
37537,Increase in emergency department visits associated with an increase in allergen concentrations equal to their mean
37538,Distribution of thymidylate synthase genotypes in patients with acute lymphoblastic leukaemia with and without an event
37539,Distribution of cases of squamous cell carcinoma and adenocarcinoma or adenosquamous carcinoma of cervix, and controls
37540,Risk of squamous cell carcinoma of the cervix among HPV positive women according to reproductive factors
37541,Risk of HPV positivity according to reproductive factors among control women
37542,Classification of erythrocytoses
37544,Results of simple two step swallowing test in elderly patients with or without aspiration pneumonia
37547,Grading of dural ectasia and aortic dilatation in patients and controls
37548,Analysis of patients with suspected pneumonic plague
37549,IgG anti F1 ELISA test for plague contact population
37550,Simian foamy virus zoonosis among zoo workers
37552,Rates of new actinic keratoses and basal cell carcinomas by Poisson modelling
37554,Numbers of new basal cell carcinomas
37555,Numbers of new squamous cell carcinomas
37556,Numbers of new melanomas
37557,Regression model summary for the period 196098
37558,Incidence of IE, Microbiology, and Valve Replacement From 2000 to 2011
37559,Summary of the virological investigations and sequence data
37560,Observed and expected number of deaths and excess mortality in Bristol relative to other 11 centres in England
37561,Observed and expected mortality relative to other 11 centres in England: 11 open and two closed procedure groups on children younger than 1 year during epoch 3   April, 1991, to March, 1995
37563,Status at admission and comorbidity for open class of procedures, Hospital Episode StatisticsApril, 1991, to March, 1995
37564,Parameter estimates from the conditional logistic regression with two continuous variables and the interaction term
37566,Observed   obs   and expected   exp   numbers and standardised incidence ratios   SIRs   for all cancers in 42277 siblings of children with cancer, stratified by age at diagnosis
37567,Observed   obs   number of sibling pairs with cancer and standardised incidence ratios   SIR   in siblings of children with cancer, followed up in childhood and adolescence, stratified by type of cancer of index patient
37568,Clinical details of sibling pairs with tumour combinations   other than retinoblastomas   that suggest hereditary or familial cancer syndromes   see  table 3    and of twins who both had cancer
37569,Observed   obs   number of sibling pairs with cancer and standardised incidence ratios   SIR   in siblings of children with cancer, followed up in adulthood, stratified by type of cancer of index patient
37570,Results of laboratory testing
37571,Prevalence of seronegativity to rubella virus by ethnic group, as measured at antenatal screening at the Royal London Hospital   Jan 1, 2000Dec 31, 2000
37575,Proportion of treatments, procedures, and complications associated with mortality in hospital and at discharge in patients younger than age 80 years   n 21912  , and their dispersion between different hospitals
37576,Propensity scores for revascularisation within 14 days of acute myocardial infarction   AMI
37577,1 year mortality by propensity score divided into quartiles
37578,Sensitivity analysis and 1 year mortality in all patients and in patients who survived until day 14, day 30, day 60, and day 90 after acute myocardial infarction   AMI
37579,Effect of revascularisation within 14 days compared with early revascularisation in patients with acute myocardial infarction   AMI
37580,Age adjusted relative increase in risk of fracture   with 95  CI   in women for every 1 SD decrease in bone mineral density   absorptiometry   below the mean value for age  20
37581,10 year probability of fracture       in men and women from Sweden, according to age and risk relative to the average population  33
37582,Estimated low and high cumulative mortality rates among infants or children with HIV infection, by mother to child transmission cohort and time since birth
37583,Estimated under 5 mortality, HIV mortality, and all cause mortality, 1999
37584,Preintervention frequency of leishmania infection in children and dogs
37585,Post intervention incidence of leishmania infection in children
37586,Post intervention incidence of leishmania infection in domestic dogs
37587,Comparison between plague RDT, bacteriology, and F1 ELISA for specimens tested at Central Laboratory
37588,Comparison between plague RDTs done at remote sites and at Central Laboratory on the same specimens
37589,Comparison between plague RDT done at remote sites and at Central Laboratory and combination of bacteriology and F1 ELISA
37590,Diagnosis of pneumonic plague in sputum with plague RDT, F1 ELISA, and bacteriology
37591,Prevalence of self reported clinical symptoms in cases confirmed by Department of Health
37592,Summary of included studies
37593,Number of children, events, and years of follow up by endpoint and laboratory marker
37594,Estimated risk       of AIDS and death within 12 months at selected values of age and CD4  or viral load
37595,Results of Cox proportional hazards models
37596,Occurrence of breast cancer in women grouped by result of CE MRI and mammography   XRM   examinations
37597,Details of the 35 breast cancers that arose during the study
37598,CE MRI screening for breast cancer in women at raised genetic risksummary of results from our study and two other prospective studies  4,5
37599,Prevalence of T brucei sensu lato and T b rhodesiense in livestock in Soroti district in 2004, diagnosed by PCR
37600,Projected global deaths and burden of disease   DALYs   due to chronic diseases by age, 2005 and 2015
37601,Estimated risk of AIDS and death within 12 months at selected values of age and total lymphocyte count
37602,Modifiable factors underlying the deaths of mothers, babies, and children in South Africa, according to the three national mortality audits  24
37604,Risk factors, key investigations, diagnosis, and treatments by socioeconomic strata
37605,Origin of patients, mode of transport to hospital, and method of payment by diagnosis
37606,Origin of patients, mode of transport to hospital, and method of payment by socioeconomic status
37607,Mortality rates by socioeconomic strata
37608,Comparison of acute coronary syndromes in developed and developing countries
37609,Age specific incidence rates of type 1 diabetes in Finland per 100000 per year during 19802005
37610,Generalised additive models fitted to the data for type 1 diabetes incidence rates for ages 014 years in Finland
37615,Number of studies with Haemophilus influenzae type b disease burden data that populated the meningitis and non pneumonia, non meningitis models     , by WHO region
37616,Haemophilus influenzae type b cases and deaths, with uncertainty estimates, by syndrome and WHO region
37617,Age related bone loss in the intracortical and trabecular compartments
37619,Concomitant Drug Therapy at Last Follow Up
37620,Deaths and Transplants
37623,Primary and secondary endpoints, by patient
37624,Clinical events according to enrolment criteria and Villefranche diagnostic criteria
37627,Summary of interventions and effect sizes for 15 studies of parenting education programmes, support programmes, or both, comparing interventions with standard of care
37628,Summary of interventions and effect sizes for 15 studies with preschool programmes, preschool improvement programmes, or both
37629,Analysis of benefits and costs of increasing preschool enrolments
37630,Global life expectancy in years   95  uncertainty interval   by sex, year, and age, 19702010
37631,Life expectancy in years   95  uncertainty intervals   at birth, by sex and decade for 187 countries and 21 Global Burden of Disease regions
37632,Global deaths   95  uncertainty intervals   by sex and age group in 1970, 1990, and 2010
37634,Important pathogen threats for introduction into new regions and range extensions within endemic regions, and probable sources and pathways for introduction
37636,Patient outcomes, by hypertrophic cardiomyopathy phenotype category
37638,Multivariable regression models for time to death or heart transplantation by age at diagnosis of hypertrophic cardiomyopathy and causal or phenotypic subgroup
37639,Transmission tree sizes resulting from our interpretation of Middle East respiratory syndrome coronavirus data
37641,Crude and cause specific infant mortality rate for preterm and term infants
37642,Summary of adolescent prognostic factors, by sex
37643,Prevalence and continuity of common mental disorders at 1529 years of age
37644,Adolescent predictors of persistence into young adulthood   waves 79   for 733 adolescents with at least one adolescent occurrence of common mental disorder   CIS R 12  ,      by adolescent risk factor
37650,Distribution of suspected cases by category, according to sex, gestational age, and residence, and concordance with original classification
37651,Head circumference and birthweight according to sex and diagnostic categories
37652,Input datasets used in the pandemic potential framework
37654,Proportion of non travelling versus travelling participants with yaws in the post MDA period according to genotypes
37656,Antibodies to KSHV orf 65 protein and latent immunofluorescence antigen in different HIV risk groups and controls
37657,Comparison of antibody reactivity to orf 65 protein and to latent antigen  s
37658,Comparison of PCRdetection of KSHV and antibody reactivity to orf 65 and latent antigen  s
37659,Prevalence rates in US born and Haitian born pregnant women and their offspring
37660,Observed cases, expected cases, and relative risks of malignant diseases among people with AIDS
37662,Estimated annualised incidence of microbial keratitis and estimated relative risk of microbial keratitis
37663,Microbial isolates of ulcerative keratitis in cosmetic contact lens wearers   n 30
37664,Morbidity and ultimate visual outcome in 92 cases of contact lens associated microbial keratitis
37665,Serum concentrations of p,p  DDT, p,p  DDE, and predominant PCBs in cases of exocrine pancreatic cancer with and without a mutation in the K ras gene
37666,Results of multivariate conditional logistic regression analysis
37667,Serum concentrations of compounds among the 26 hospital controls, and significance of differences between them and all 51 cases of pancreatic cancer, 34 cases with a K ras mutation, and 17 cases without a K ras mutation
37669,Median survival and time to AIDS
37670,Exposure category and age at seroconversion for individuals included in analyses of mortality
37671,Effect of age at seroconversion by exposure category and time since seroconversion
37672,Mortality and development of non Kaposi s sarcoma AIDS by time since seroconversion
37673,Summary of results from review of studies on osteoarthritis of the knee
37674,Summary of patients  responses to the question: how helpful do you find these treatments for reducing pain and disability?
37675,Summary of patients  responses to the question: which treatments should be made a priority for researchers?
37676,HHV 8 prevalence among males and females by age
37677,Distribution of pairs according to the familial relationship and the HHV 8 serological status
37678,Distribution of sib sib pairs according to the HHV 8 status of the mother and age difference between siblings
37679,Prognostic value of variables at the time of diagnosis, tested by the Kaplan Meier method
37680,Details of primers used in the QF PCR multiplex
37681,Comparison of quantitative PCR results with the gold standard of karyotype analysis for chromosomes 13, 18, and 21
37683,Number of patients offered follow up appointments   intention to treat analysis
37684,Tests, investigations, and contacts with health care services over 6 months
37685,Patients  outcomes
37687,Annual incidence, per 100000 children younger than age 5 years, of Kawasaki disease in children younger than age 5 years by ethnic origin
37689,Patients with venous thromboembolism
37690,Total volume of blood loss   intraoperative and postoperative   and total volume of blood transfused   intention to treat population
37691,Patients with severe bleeding per treatment group and type of surgery   intention to treat population
37692,Mean   SD   concentrations of MMP 1 and MMP 13 produced by dissociated rheumatoid synovial cells from wrist joint, encapsulating, and invasive tenosynovial samples
37693,Multivariate logistic regression analysis of sex, early onset of treatment, and presence of MBL mutations for development of coronary artery lesions in children with Kawasaki disease
37694,Analysis of mesenchymal stem cells in bone marrow and bone
37695,Main reasons for referral for karyotyping and detection rates of abnormal results
37696,Types of abnormal karyotypes detected in samples referred after screening programmes for Down s syndrome
37697,Risk categories of undetected chromosome abnormalities after screening for Down s syndrome
37698,Proportion of abnormal karyotypes in referrals after screening for Down s syndrome detected by rapid aneuploidy diagnosis   RAD
37699,Comparison of rapid aneuploidy testing and karyotyping combinations for trisomies 13, 18, and 21
37700,Changes over time in mental health, job stress, and job satisfaction
37702,Scenarios and key assumptions
37705,Unadjusted Outcomes at Six Month Follow Up
37707,Subsidary Multivariate Analyses
37708,Description of comparison groups, by bearing surface
37709,Predicted revision rates for 55 year old men by prosthesis and head size   95  CIs
37710,Predicted revision rates for 55 year old women by prosthesis and head size   95  CIs
37711,Comparison of most commonly used brands
37712,Reasons for revision   incidence per 1000 patient years, 95  CIs   by articulation and fixation
37713,Interventions directed at clinical decision making
37714,Interventions directed at health systems
37715,45 day mortality by age and sex
37716,Changes in mortality by year of primary operation
37717,Cox proportional hazards models of 45 day mortality by variables
37719,Patient survival at 5, 10, 15, and 20 years after total hip replacement
37720,Patient survival at 5, 10, 15, and 20 years after total knee replacement
37721,Details of patients by intention to treat analysis at screening
37722,Details of patients after transplantation
37723,Current TCDD concentrations   ppt   by zone and gender
37724,Pregnancy terminations in women who were users of other or third generation oral contraceptives
37725,Size of final infarcts and of sub compartments defined by initial level of residual perfusion   in mL
37726,Mean stroke scale scores and lesion volumes   on day one, five, 30 or 90   for the recanalisation and non recanalisation group
37731,Electroradiological features of the patients
37733,Data for censored patients
37734,Odds ratio for terminal remission
37735,Results of OLIG2 in situ hybridisation in brain tumours
37737,Additional treatments during follow up   652 weeks
37738,Improvement in primary and secondary outcome measures
37739,Adverse reactions during 6 week intervention period
37740,Relative risk   95  CI   of sex, age, epilepsy type, and neurological disorder      for death
37742,Activity of glutamine synthetase
37747,Long Term Treatment in the Four Patient Groups
37749,Actuarial cumulative percentages achieving each outcome at selected intervals from randomisation with differences   95  CI
37750,Patients reporting adverse events at any follow up
37751,Echocardiographic Measurements in Groups IA and IB
37752,Echocardiographic Measurements in Groups IIA and IIB
37753,Results of Stress Test at 3 Months After Discharge
37755,Predictors of survival
37756,Medications given during cardiac arrest resuscitation
37757,Duration of critical steps in resuscitation sequence
37758,Outcomes
37759,Effect estimates for prespecified covariates in logistic regression model
37761,Dose taken by adults at withdrawal or last follow up
37762,Treatment failure   all events
37763,Seizure outcomes by drug
37764,Frequency of clinically important adverse events
37765,Incremental cost effectiveness ratioscost per QALY
37766,Incremental cost effectiveness ratioscost per seizure avoided
37767,Probabilities that the new antiepileptic drugs are cost effective relative to carbamazepine across a range of ceiling ratios
37769,Dose taken by adults at withdrawal or last follow up
37770,Treatment failure
37771,Seizure outcomes by drug
37772,Frequency of clinically important adverse events
37773,Incremental cost effectiveness ratioscost per QALY
37774,Incremental cost effectiveness ratioscost per seizure avoided
37775,Probabilities that the new antiepileptic drugs are cost effective relative to valproate across a range of ceiling ratios
37776,Distribution of 8172 deaths and 23 million person years at risk
37777,Adjusted mortality rate ratios   MRR   according to number of years since discharge with first febrile seizure
37778,Cause specific mortality rate ratios   MRR   within 2 years of a first febrile seizure
37781,PCR corrected day 28 cure rate by analysis population
37782,PCR corrected day 28 cure rate by bodyweight group in the modified ITT population
37783,PCR corrected day 14 and day 42 cure rates by analysis population
37784,Time since first admission with brain injury and relative risk   RR   of epilepsy
37785,Age at first admission with brain injury and relative risk of epilepsy
37786,Duration of first hospital stay with brain injury and relative risk of epilepsy
37787,Family history and relative risk of epilepsy after traumatic brain injury
37788,Data sources for cause of death estimation for 2004 Global Burden of Disease study  17
37789,Estimated total number of deaths and all cause mortality rates   per 100000   in people aged 1024 years in 2004, classified by economic and geographic groupings
37790,2004 all cause mortality rates   per 100000   stratified by country classification, age group, and sex
37791,Ten most common causes of death by sex and age group
37792,Surgical procedures and pathological findings in study population
37793,Univariable and multivariable survival analysis of time to first seizure   OC3
37794,Effect of pathological findings on time to first seizure after temporal lobe resections, allowing for age at surgery
37795,Estimated percentage of patients remaining free of seizures with loss of awareness   with 95  CIs   at intervals after temporal surgery in patients who did, and did not have, SPS in first 2 years after surgery
37796,People remaining seizure free after continuous periods of postsurgical seizure freedom, estimated by survival analysis, at each subsequent follow up
37797,People gaining 1 year of seizure freedom after continuous periods of ongoing seizures, estimated by survival analysis, at each subsequent follow up
37798,Patterns of seizure remission and relapse after surgery
37800,Hemodynamic Changes During PASE   n   46
37801,Risk factors for SUDEP from the ILAE Task Force on Epidemiology pooled analysis from four major case control studies
37802,SUDEP incidence rates after epilepsy surgery
37804,Prevalence of pre existing, new, and lifetime psychiatric morbidity in individuals with epilepsy
37805,Prevalence and odds of premature mortality in epilepsy, by International Classification of Diseases chapter
37806,Risks of premature death in individuals with epilepsy compared to population controls and unaffected siblings
37807,Mortality risks after diagnosis with epilepsy, stratified by diagnostic threshold, sex, severity, patient type, epilepsy subtype, age group, birth order, and time after first diagnosis
37808,Associations of external causes of death in epilepsy with psychiatric comorbidity
37809,Potential biomarkers   grouped by pathway   and targeted combination therapies to overcome resistance to targeted monotherapy
37810,Novel and rare SCN4A variants in SIDS cases of European ancestry and ethnically matched controls
37811,Biophysical parameters of NaV1.4 variants
37812,Clinical data
37813,Operations
37815,Postoperative infections and complications
37816,Distribution of blood transfusions
37817,Association between GBV C RNA and aetiologies of fulminant hepatic failure
37819,Clinical and biochemical data
37820,Prevalence of metabolic disorders
37822,Detection of HHV 8 KS330233 DNA and RNA sequence from peripheral blood mononuclear cells   PBMC   of blood donor
37824,Primary composite efficacy outcomes and components   intention to treat analysis
37825,Secondary efficacy endpoints   analysis of patients who received any amount of study drug
37826,Adverse events   intention to treat analysis
37827,Ages of children younger than 5 testing positive for HIV 1
37828,Means of ascertainment, sex, and age of acutely infected outbreak related cases
37829,Geographical distribution of women screened during pregnancy according to residence and serologic status
37830,Number of individuals in National Haemophilia Register exposed to blood products carrying high risk of HCV infection during 196985, by severity of haemophilia, HIV 1 status, and vital status
37831,Mortality from primary liver cancer and liver disease in UK haemophilia population exposed to high HCV risk blood products, by calendar year, based on death certificate information
37832,Mortality during 198592 from primary liver cancer and liver disease in UK male haemophilia population exposed to high HCV risk blood products, by HIV 1 status and severity of haemophilia, based on death certificate information
37834,25 year cumulative risk of death from chronic or unspecified liver disease or liver cancer
37835,Annual death rates per 1000 in UK haemophilic men and boys exposed to high HCV risk blood products
37837,Respiratory chain enzyme activities in mitochondria from surgical biopsy samples from the quadriceps muscle
37838,Haemosiderosis of liver and spleen specimens, liver iron content, and serum iron metabolism
37839,Comparison of neonatal and full term cord blood
37841,Third stage management
37842,Primary and secondary maternal outcomes
37843,Neonatal outcomes
37844,PPH by randomly allocated active or expectant management: stratified analysis
37845,Prevalence of TTV infection in patients with chronic liver diseases and healthy controls
37846,Liver histology in 14 patients with TTV infection
37847,Detection of TTV in plasma derived blood products
37848,TTV infection in haemophilic patients
37849,Detection of TTV in patients with idiopathic fulminant hepatic failure
37851,Effects of risk factors on leukaemia free survival, overall survival, transplant related mortality, and relapse incidence
37852,5 year probability of leukaemia free survival   LFS  , survival, transplant related mortality   TRM  , and relapse incidence   RI
37853,Haemochromatosis allele frequencies by TFR genotype in myeloma patients and controls
37855,Composite and individual efficacy outcomes at 7 days   primary outcomes   and 72 h   end of masked treatment
37856,Details of patients with refractory angina up to day 7
37857,Cardiac interventions by day 7
37858,Safety outcomes within 7 days
37859,Combined results of OASIS 1 and OASIS 2 studies at 7 days and 35 days
37861,Risk of CJD by surgical procedures
37862,Risk of CJD by residence and occupation
37863,Risk of CJD by blood transfusion
37865,Distribution of morbidity causes leading to at least one severe event
37867,Seroconversion and transmission rates in pregnant women and birth prevalence of toxoplasma infection in infants
37868,Serological findings in eluate from PKU cards from children born to 30 women who seroconverted during pregnancy   199596
37869,Effects of aspirin on non fatal vascular events and deaths in hip fracture patients up to day 35
37870,Effects of aspirin on bleeding episodes and related complications in hip fracture patients up to day 35
37871,Effects of aspirin on measures of blood loss in hip fracture patients up to day 35
37873,Effects of aspirin on non fatal vascular events and deaths in elective arthroplasty patients up to day 35
37874,Effects of aspirin on bleeding episodes and related complications in elective arthroplasty patients up to day 35
37875,Results of testing for HCV infection
37876,Comparison of TGA patients and controls
37878,Adjusted excess risk of various factors for ARI and ALRI estimated with a linear model
37879,Adjusted odds ratios of various factors for ARI and ALRI estimated with a logistic model
37880,Frequency of haemochromatosis genotypes
37881,Transferrin saturation in patients with late onset type 1 diabetes mellitus
37884,Stroke and intracerebral bleeding
37885,Non cerebral bleeding
37886,Comparison of incidence of febrile seizure by age in the French cohort and a reference study of a general population
37887,Independent predictors of operative mortality
37888,Trends in volunteer whole blood donation from Shenzhen City
37889,HIV test reults from whole blood donors in Xinjiang in 2000
37890,Risk factors associated with HIV infection in whole blood donors in Xinjiang
37892,Transfusion requirements, duration of operation, and hospital admission in the three study groups
37893,Number of recipients transfused, by year and blood component given
37894,Dead recipients   n 31   of labile components from vCJD donors
37895,Living recipients   n 17   of labile blood components donated by vCJD cases
37898,Species and geometric mean number of flies caught from the eyes of volunteer children by treatment group and triplet
37902,Infectivity of wires exposed to ten fold serial dilutions of 263K strain hamster scrapie brain homogenates
37903,Effect of various treatments on contaminated wires
37905,Distribution of infectivity in whole blood, challenge, and resin flow through
37907,Adjusted rate ratios of cancer among recipients of precancerous blood, relative to recipients of non cancerous blood
37908,Adjusted rate ratios of cancer among recipients of precancerous blood from donors with cancers at different anatomical sites, relative to recipients of non cancerous blood
37909,Adjusted rate ratios of site specific cancers among recipients of precancerous blood, relative to recipients of non cancerous blood
37910,Lung function test results
37912,Death by cause
37913,Vascular occlusive events, need for transfusion and surgery, and level of dependency
37916,Adverse events reported in at least 10  of patients given mipomersen, and significant laboratory abnormalities
37917,Analysis of trends from 19992002 and 200306 for government health expenditure as source   GHE S  ; share of general government expenditure spent on health   GHE S GGE  ; share of gross domestic product   GDP   spent by government   GGE GDP  ; and GDP
37918,Time series cross sectional regression results for government health expenditure as source   GHE S   as a share of gross domestic product   GDP   for countries in Global Burden of Disease developing regions based on the Arellano Bover Blundell Bond model
37919,Time series cross sectional regression results for government health expenditure as source   GHE S   as a share of gross domestic product   GDP   for subgroups of countries based on the Arellano Bover Blundell Bond model
37923,Treatment emergent adverse events in every treatment group during the 12 week treatment period   safety population
37930,Clinical efficacy outcomes at 48 h and at 30 days
37931,Site reported angiographic complications
37932,Non CABG related bleeding events at 48 h
37933,Numbers and rates of treatment emergent and serious adverse events in CHAMPION pooled safety population
37936,Results for the primary endpoint at 1 year
37937,Location of worst bleeding per patient
37938,Secondary and safety endpoints at 1 year
37940,Weight increase in the first 2 min after birth and mother s position during delivery
37941,Weight increase, by centre
37946,Distribution of parasitaemic samples in exposed and non exposed patients receiving treated or untreated whole blood
37947,Pre transfusion and post transfusion haematology and serum chemistry parameters   per protocol population
37948,Treatment related adverse events
37950,Secondary outcomes in the intention to treat population
37951,Safety outcomes occurring during hospital admission in the intention to treat and as treated populations
37953,Kaplan Meier 5 year estimates by intention to treat
37954,Outcomes between index procedure and 30 days of follow up by treatment group
37955,1 year clinical outcome by treatment group
37957,Clinical bleeding by day 7 or hospital discharge and by day 21
37958,Adverse events
37960,Frequency of reduced leaflet motion in different transcatheter and surgical valve types
37961,Antiplatelet and anticoagulation therapy at the time of the CT scan
37963,Clinical outcomes
37964,1950 confirmed cases of infection related microcephaly by diagnostic method and occurrence after the first epidemic wave of Zika virus infection in regions of Brazil; January, 2015November, 2016
37965,Individuals recruited into Karonga Prevention Trial by previous BCG scar status and trial vaccine
37966,Comparison of vaccine groups by age, sex, initial household contact with leprosy, and by proportions later examined at least once
37967,Incidence rate ratios of leprosy among recipients of trial vaccines, by different case definitions and criteria
37968,Incidence rate ratios of tuberculosis among recipients of trial vaccines, by different case definitions and criteria
37969,Detection of HGV and HCV RNA in factor VIII and factor IX concentrates
37970,Detection of HGV in immunoglobulin and in immunoglobulin recipients
37971,Frequency of HGV and HCV infection in haemophiliacs
37973,Treatment outcomes for AFB positive patients treated with 12 month regimen   phase two
37974,Treatment outcomes for AFB positive patients treated with 8 month regimen   phase three
37976,Deaths associated with MgSO4 exposure
37977,Comparison of tuberculosis control measures before and after implementation of infection control policies, June, 1994, to August, 1995
37978,Main clinical and microbiological features
37980,Individual first outcome events at end of period 2
37982,Treatment related adverse events   in  15  of participants   and rates of withdrawal from study medication
37984,Treatment outcome
37985,Treatment outcome by supervision method
37988,Univariate analysis of rifampin monoresistant relapse among HIV seropositive participants assessed for relapse
37989,Univariate analysis of risk factors for relapse among HIV seropositive participants assessed for relapse, by treatment group
37991,Multivariate Cox s proportional hazards regression analysis of variables evaluated as factors in sputum conversion
37992,Culture status at month 6 by treatment group and HIV status
37993,Serious adverse events and causes of death
37995,Concentrations and limits of detection   LOD   of therapeutic drugs in drinking water, river water, and sediments
37996,Randomised trials comparing efficacy and safety of bolus compared with infusion thrombolytic treatment in acute myocardial infarction
37997,Incidence of intracranial haemorrhage and non haemorrhagic stroke in randomised trials of bolus compared with infusion thrombolytic treatment
37998,Incidence of death and reinfarction in randomised trials of bolus compared with infusion thrombolytic treatment
38000,Treatment outcomes among enrolled patients
38001,Treatment outcomes among patients who received health worker DOTS strategy
38002,Treatment outcomes among enrolled patients by sex
38003,Adjusted odds ratios for factors that might affect treatment outcome
38004,Number and type of drugs tested with number of samples failing to comply with British Pharmacopoeia limits
38005,Descriptive statistics of individual drug preparations tested
38007,Stroke and intracranial haemorrhage
38009,Summary of treatments used
38011,Antimicrobial resistance among isolates from 463 patients with culture positive Mycobacterium tuberculosis
38012,WHO treatment outcomes
38013,Smear, culture, and cavity conversion rates
38014,Choice of screening and prevention in 4475 women at risk of breast cancer
38015,Results of nucleic acid sequence based amplification of RNA detected by electrochemiluminescence
38016,Comparison of RT PCR,   data from ref 2  , and NASBA results for samples of saliva and CSF from patients with rabies
38017,Plasma concentrations of aminopeptidase P and carboxypeptidase N
38019,Factors contributing to anti HBs   log   immune response
38020,Factors contributing to anti HAV   log   immune response
38021,Number of people carrying at least one HLA DRB1  allele
38022,Intraclass correlations   r   of anti HBs and anti HAVs after third vaccination for monozygotic and dizygotic twins
38023,Effect of shared HLA DRB1  alleles
38025,Study events by NSAID
38026,Blood cell counts, coagulation, and complement variables before and after human islet perfusion with fresh ABO compatible blood
38027,Breast cancer prevention trials
38028,Major events in the tamoxifen prevention trials and other related studies   tamoxifen vs control
38029,Major events by age at randomisation   tamoxifen vs placebo
38030,Deaths from major causes in chemoprevention trials   tamoxifen vs control
38031,Clinical features and treatment outcomes among SARS children
38034,Primary analysis: CHF outcomes
38035,Subgroup analyses of congestive heart failure outcomes
38039,Robust linear regression analyses of CD4 cell count slopes based on 9173 observations from 1848 patients on treatment with stable viral load
38040,Blood component cell numbers and volumes before and after leucoreduction
38041,Concentration of TSE infectivity in whole and leucoreduced blood
38042,Information on H3N2 in fluenza A virus infected patients from whom samples were taken
38043,Aminoacid mutations in viruses isolated from patients treated with oseltamivir
38044,Effect of aminoacid mutations on neuraminidase sensitivity to GS4071
38045,Changes in viral titre before and after treatment with oseltamivir
38046,Dates, target population, and measles vaccination coverage of SIA, 2000 to June, 2003
38047,Estimated annual measles deaths averted by SIA completed between 2000 and June, 2003
38048,Results of case based measles surveillance with laboratory confirmation in areas after SIA, 200203
38049,Measles outbreaks detected at least 60 days after SIA in children aged 9 months to 14 years, 2001 to June, 2003
38052,Risk of acute myocardial infarction with use of selected NSAIDs compared with remote use of a NSAID or with current use of celecoxib
38053,Aspirin use, over the counter NSAID use, smoking history, and family history of acute myocardial infarction in 817 randomly selected controls with remote NSAID exposure or current exposure to celecoxib, ibuprofen, naproxen, or rofecoxib
38054,Risk of cholera and protective efficacy of killed oral cholera vaccines, by level of cholera vaccine coverage of the bari during the first year of follow up
38055,Risk of dysentery in recipients of cholera vaccine or placebo, by level of cholera vaccine coverage of the bari during the first year of follow up
38056,Predictors of cholera risk in recipients of vaccine or placebo, in three multivariable models
38059,Univariate odds ratios of relations between risk factors and M tuberculosis infection as determined by ELISpot and TST
38060,Multivariate adjusted odds ratios of relations between risk factors and M tuberculosis infection, as determined by ELISpot and TST
38066,Outcomes for all new smear positive patients registered in every district
38067,Comparison of success rates between community DOTS and family member DOTS strategies
38070,Diagnostic performance of classifiers
38073,Seroconversion   by PRNT50 antibody assay   and geometric mean titre on day 56 in per protocol population   n 735
38075,Antiplatelet Trialists  Collaboration   APTC   endpoints and overall mortality
38076,Surveys included in the secondary analysis
38077,Basket of 15 medicines found in at least 80  of surveys
38078,Average of country level mean percentage availability of any generic product, by WHO Region
38079,Median price ratios      of public sector procurement prices for lowest priced generics, overall and by WHO Region
38080,Median price ratios      of originator brands and lowest priced generics in the private sector, and of lowest priced generics in the public sector, by WHO Region
38081,Mean number of day s wages of the lowest paid unskilled government worker needed to purchase a course of treatment, by WHO Region
38082,Cumulative percentage mark ups between manufacturer s selling price or Cost, Insurance, and Freight price, and final patient price in the public and private sectors
38084,Event rates for cardiovascular outcomes of intensive glucose lowering versus standard treatment
38086,Clinically significant bleeding   TIMI major, TIMI minor, or requiring medical attention  , categorised by total daily dose for the entire population, stratum 1, and stratum 2
38087,Adverse events in at least 3  of patients in either treatment group by system organ class and preferred term, excluding bleeding events
38088,Death, myocardial infarction, stroke, or severe recurrent ischaemia requiring revascularisation, categorised by total daily dose for the entire population, stratum 1, and stratum 2
38089,Death, myocardial infarction, or stroke, categorised by total daily dose for the entire population, stratum 1, and stratum 2
38092,Adverse events      in group 1   pandemic vaccine only   and group 2   pandemic and seasonal vaccine
38093,Geometric mean of haemagglutinin inhibition titres before and after immunisation in group 1   pandemic vaccine only   and group 2   pandemic and seasonal vaccine
38095,Predictors of triple class virological failure
38097,Treatment outcome at week 48
38098,Most prevalent treatment emergent NNRTI and N  t  RTI RAMs   in two or more patients with available resistance data   at the time of week 48 analysis
38099,Overview of treatment emergent adverse events and laboratory abnormalities at the time of week 48 analysis
38101,Summary estimates for efficacy   standardised mean difference and response rate   and dropout rates in meta analyses of direct comparisons between pairs of antimanic drugs or placebo
38102,Prescribed Medications in the Patients With Coronary Artery Disease
38105,Population and process data by study group
38108,Prevalence of culture positive Mycobacterium tuberculosis in adults   per 100000 adult population  , by trial group, household intervention, and ECF intervention
38109,Incidence of TST conversion in schoolchildren   per 100 person years  , by trial group, household intervention, and ECF intervention
38110,Details of breast cancer prevention trials
38111,Breast cancer incidence in the chemoprevention trials
38112,Major non breast cancer events in the prevention trials
38113,Outcomes at 2 years
38114,Serious adverse events within 2 years of recruitment
38115,End of season surveillance of Guillain Barr syndrome after use of influenza A   H1N1   2009 monovalent vaccine, according to surveillance system
38116,Analyses of the association between influenza A   H1N1   2009 monovalent inactivated vaccines and Guillain Barr syndrome
38117,Attributable risk for Guillain Barr syndrome associated with influenza A   H1N1   2009 monovalent inactivated vaccines, by age group
38118,Association between influenza A   H1N1   2009 monovalent inactivated vaccines and Guillain Barr syndrome, by period
38119,Validation evidence of putative treatment development targets in bipolar disorder
38120,Randomised trials of adjunctive psychosocial intervention in bipolar disorder
38121,Top ten causes of disability adjusted life years in the Arab world by sex and overall in 1990, 2005, and 2010
38122,Decomposition analysis of the change of DALY numbers   thousands   by level 1 causes from 1990 to 2010 into total population growth, population ageing, and changes in age specific, sex specific, and cause specific DALY rates for the Arab world
38123,Top ten causes of disability adjusted life years in low income Arab countries by sex and overall in 1990, 2005, and 2010
38124,Top ten causes of disability adjusted life years in middle income Arab countries by sex and overall in 1990, 2005, and 2010
38125,Top ten causes of disability adjusted life years in high income Arab countries by sex and overall in 1990, 2005 and 2010
38128,Treatment emergent adverse events group in all participants who received 1 dose of study drug   occurring in 5  in either treatment
38129,Blood components associated with viraemic donations
38130,Association between transfused blood components and transmission of hepatitis E virus in 43 of 60 exposed patients in whom follow up was possible
38131,Outcome in 18 recipients infected by transfusion of a blood component from a viraemic donor, ranked by immunosuppression
38133,Shedding of poliovirus in stool samples detected by PCR
38134,Serum neutralising antibody titres before and after vaccination with inactivated poliovirus vaccine   IPV   or bivalent oral poliovirus vaccine   bOPV
38136,Patients who met the primary endpoint
38138,Virological failure and emerging resistance mutations per trial arm
38140,Occurrence of cholera with severe dehydration and cumulative overall protection by the killed oral cholera vaccine during 2 years of follow up
38141,Occurrence of cholera with severe dehydration and cumulative total protection by the killed oral cholera vaccine during 2 years of follow up
38142,Properties of P2Y12 inhibitors
38143,Properties of non vitamin K dependent oral anticoagulants
38144,Onset and duration of action for short acting and long acting nitrates in patients with coronary artery disease
38146,Important side effects and contraindications with use of  blockers and calcium channel blockers
38148,Considerations for prescription of emerging anti angina drugs to patients
38149,Anti ischaemic effect of physiological anti angina therapies
38150,Anti ischaemic effect of emerging metabolic anti angina therapies
38151,Treatments investigated to reduce angina or ischaemia, but not recommended for use in patients
38154,Efficacy and safety endpoints
38158,Incidence and adjusted relative risk of coronary events by supplementation with either a tocopherol or b carotene
38162,Results of logistic regression
38164,Measles antibodies in group 1
38165,Measles antibodies in groups 2 and 3
38166,Geometric mean titres   95  CI   in mIU according to breastfeeding at 18 months for seroconverted infants
38167,Univariate correlates of HIV 1 infected cells in cervical and vaginal secretions
38168,Fetal deaths among women who received multivitamins or vitamin A compared with those who did not receive the respective regimen
38169,Birth outcomes in women who received multivitamins or vitamin A compared with those who did not receive the respective regimen
38172,LSM   SE   of cardiovascular risk factors in intention to treat population from start of the lead in period to week 104
38173,Adverse events remotely, possibly, or probably related to treatment
38174,Reasons for premature withdrawals
38175,Pain perception in acupuncture and placebo: VAS scores
38178,Relation between doctor patient communication and patients  opinions, feelings, and choices of treatment
38181,Estimated proportions of children who were HIV 1 infected by 3 months of age
38184,Antioxidant status in healthy controls and mild asthmatic patients
38187,Occurrence of pre eclampsia in intention to treat and completed study cohorts
38188,Perinatal outcomes and characteristics in intention to treat and completed study cohorts
38192,Logistic regression analysis
38194,Differences in proportions of incontinent patients between the treatment and the control group
38195,Average loss of urine per 24 h
38196,Scores on the visual analogue scale preoperatively, and at 1, 6, and 12 months
38198,Reasons for stopping treatment
38199,Clinical outcomes for ramipril and placebo groups
38201,Numbers and types of clinical trials attached to drug licensing applications for postmenopausal hormone therapies
38202,Description of trials reporting cardiovascular events
38203,Number of women with cardiovascular adverse effects, odds ratios, and probability of finding observed odds ratios
38205,Hysteroscopical and histological findings at entry for women who completed the trial and those who withdrew
38206,Hysteroscopical and histological findings at the end of the trial
38209,Vaginal bleeding patterns at different intervals over the trial period
38210,Laboratory blood test results on admission
38211,MTHFR mating types of 167 couples ascertained for a child with NTD, genotypes of 3 of their surviving affected offspring, and 181 unaffected offspring
38215,Treatment outcomes
38216,Comparison of IL10.R alleles in RA patients from different locations
38217,Effects of lipid lowering drugs on plasma aminoacids concentrations
38220,Clinical strategies to manage breastfeeding while on codeine
38221,Patient responses
38222,RF titres in different cohort subsets
38223,Current B CLL stage   Binet  , year of diagnosis, and treatment history
38224,ATM expression and ATM mutations in B CLL
38225,Analysis of loss of heterozygosity   LOH   at 11q22 23
38226,Haematological and immune reconstruction after AHSCT
38227,Clinical rheumatological tests before and after AHSCT
38230,30 day endpoints by intervention and genotype
38231,Odds ratio for risk of coronary artery disease among heterozygous and homozygous   A2 A2   carriers
38232,Relative risks for coronary artery disease and complications among heterozygous and homozygous carriers
38233,Clinical features of patients with probable or possible MSA and PSP and atypical parkinsonism
38239,Outcome and HIV infection
38241,Comparison of treatment response
38242,Effect of HIV infection on oxygen requirements and outcome
38243,Mortality rates and associated statistics for operations by procedure type and age group
38244,Mortality rates and associated statistics for marker operations
38245,Mortality rates and associated statistics for operations by procedure type and operating centre
38246,Mortality rates for marker lesions by department
38247,Mortality rates and associated statistics for marker operations by surgeon
38249,Events after 14 days
38250,Frequency of symptomatic and asymptomatic cerebral haemorrhage after 14 days
38251,Causes of death   14 days
38252,Outcome at 14 days
38253,Outcome at 3 months
38255,Number of isolates of each pathogen identified by each diagnostic technique
38256,Distribution of pathogens observed in HIV 1 positive and HIV 1 negative patients, and in patients with different radiological categories of pneumonia
38257,Number of pneumonia patients who died or survived after 3 weeks of follow up
38258,Adjusted odds ratios for death within 3 weeks of admission with acute pneumonia
38259,Number of pneumonia patients who died or survived after 3 weeks of follow up
38260,Descriptive statistics of BMD measurements relative to cosmonauts who completed 1 month or 2 month missions in the Russian MIR station
38261,Friedman and Wilcoxon tests for the 6 month flight and recovery cohort
38262,Distribution of genotypes of unrelated individuals   parents   in the two panels
38263,Migraine symptoms in everyday life before closure of cardiac right to left shunts
38264,Fortification spectra after closure procedure
38265,Effect of closure of cardiac right to left shunts on migraine in everyday life
38269,Causes of death   numbers of patients
38270,All cause mortality by subgroup of patients
38271,Adverse events occurring in 10  or more of the study population
38275,Stepwise logistic regression model for prediction of postoperaive atrial fibrillation
38278,Non atrial fibrillation clinical outcomes
38279,Regional activation during migraine headache and rest
38280,Population prevalence and odds ratios   1998 1990   of respiratory symptoms, diagnoses, and health care use
38281,Population prevalence and odds ratios of different patterns of wheeze in 1990 and 1998
38282,Population prevalence estimates and odds ratios   1990 1998   of environmental and social risk factors for wheeze
38283,Ethnic group distribution
38285,Prevalence of ejection fraction  40  and 4050  by age and sex
38286,New York Heart Association functional class   and definition   of subjects with ejection fraction  40
38287,Rates of definite, probable, and total heart failure on defined criteria
38288,Definite heart failure by age and sex
38289,Oligonucleotide primers used for detection of B19 NS1 and VP1 genes
38290,Clinical information and B19 markers in 12 patients with B19 meningoencephalitis
38291,Frequency of autism spectrum disorders   ASD   in boys
38293,Prevalence of parasite eggs in stool samples in case control groups, and odds ratios for wheeze
38294,Distribution of dust allergens and odds ratios for wheeze
38295,Relation between IgE concentrations and allergen skin sensitisation to D pteronyssinus in the random subsample
38296,Relation between parasite eggs per gram and allergen skin sensitisation to D pteronyssinus in the random subsample
38297,Odds ratios for wheeze in relation to D Pteronyssinus allergen skin sensitisation, stratified by quartiles of total parasite infection intensity
38300,Early clinical outcomes within 30 days of surgery
38301,Midterm clinical outcome
38303,Primary outcome measures at 1 year
38304,Secondary outcomes measures at 1 year
38305,Prevalence of atopy in 1987 and 1998
38306,Relation between exposure to a cat and cat allergen at age 23 months and total serum IgE concentration at 2 years, stratified by maternal history of asthma
38308,Type and number of antiarrhythmic drugs being taken at cardioversion
38310,Primary outcomemoderate to severe neonatal morbidity and mortality
38311,Neonatal secondary outcome measures
38312,Maternal secondary outcome measures
38313,Antenatal risk factors in infants with evidence of acute brain injury only, or non acute antenatal injury, or other diagnoses
38314,Detection of SMN1 mutation in fetal cells isolated from maternal blood
38315,Symptoms of 50 patients with SARS at presentation
38316,Initial laboratory findings of 50 patients with SARS
38317,Risk factors associated with severe disease requiring intensive care and ventilatory support
38318,Skin prick test reactivity
38319,Immunoreactivity to recombinant human ECM1 protein in patients with lichen sclerosus and comparison groups
38320,Coronary deaths of patients with diabetes treated with losartan or atenolol
38321,Neurological manifestations of HIV
38323,Antibodies against coronavirus in patients and controls
38324,Nucleotide sequence variation of the S gene of SARS CoV viruses
38326,Maternal serology
38327,Histological descriptions of tissues examined for maternal microchimerism
38328,Permutation analysis results for decline in distance from centre and increase in grey matter density
38330,Environmental conditions: thermal and chemical
38331,Environmental conditions: organisms
38332,Organisms detected on surface samples   coupons   before and after UVGI exposure
38333,Participants assessment of environmental conditions
38334,Matched unadjusted analysis of reported symptoms
38335,Within person subject estimates of effect of UVGI on symptoms, adjusted for environmental covariates measured at work sites
38338,Effects of antibodies to interleukin 10, interleukin 12, and interferon  on cytokine mRNA expression and immunoreactivity in atopic mucosa from children stimulated with allergen and lipopolysaccharide
38340,Concomitant DMARD therapy and corticosteroid administration according to study drug assignment
38341,Differences after 6 months of treatment
38344,Activation and inactivation parameters from wild type and mutant SCN5A cDNA in transiently tranfected tsA201 cells
38346,Compliance by allocated treatment in hospital
38347,Effects of metoprolol on main clinical events during scheduled treatment period in hospital
38348,Effects of metoprolol on other clinical events during scheduled treatment period in hospital
38349,Effects of metoprolol on main clinical events, by day of first such event
38351,Effects of metoprolol on combined efficacy   death, reinfarction, ventricular fibrillation, or other arrest   and safety   cardiogenic shock   endpoint by shock index and day of event
38353,Primary and secondary outcomes
38354,Stroke severity
38356,Clinical outcomes and use of oral anticoagulation therapy at study entry
38357,Reasons why patients identified with atrial fibrillation did not take part in the study
38359,Nature of primary events
38360,Risk of primary event and major haemorrhage by treatment allocation for different patient subgroups
38361,Risk of secondary and composite outcomes by treatment allocation for different patient subgroups
38363,Subgroup analysis for fracture
38365,Sensitivity analysis by methodological criteria
38366,Distribution of patients between participating hospitals
38368,Treatments and prescribed drugs
38369,Primary endpoints and other outcomes obtained by angiography of left ventricles
38371,Study treatment exposure and discontinuation
38372,Outcome events
38373,Risk   CHADS2 score   and efficacy and safety outcome events
38375,Rate of potential confounding variables
38378,Development of diabetes in children who completed the study
38379,Number and duration of adverse events in the treatment groups
38382,Risk scores for factors associated with 10 year risk of atrial fibrillation
38383,Predicted 10 year risk of atrial fibrillation assigned to the risk score
38385,Clinical outcomes
38386,Adverse events
38388,Association results for two variants in IL6R and chromosome 11q13.5 in the discovery, follow up, and overall analyses
38389,CHADS2, CHA2DS2VASc, and HAS BLED score calculators
38391,Endpoints by CHADS2 score
38392,Endpoints by CHA2DS2VASc score
38393,Endpoints by HAS BLED score
38395,Results for composite clinical score
38396,Results of telemonitoring and clinical reactions
38398,Causes of deaths      in patients with heart failure and sinus rhythm or atrial fibrillation
38401,Examples of devices for transcatheter closure of atrial septal defect
38402,Randomised controlled trials included in the network meta analysis
38403,Estimated differences of the effect of interventions on percent diameter stenosis
38404,Odds ratios of the effect of interventions for binary restenosis
38405,Odds ratios of the effect of interventions for targetlesion revascularisation
38409,Time dependent HFdigoxin interactions
38410,Time dependent sexdigoxin interactions
38411,Atrial fibrillation incidence rates and age adjusted period prevalence, by sex and decade
38414,Population attributable risks of incident atrial fibrillation risk factors, by decade of onset of atrial fibrillation
38415,Epidemiology of frontotemporal dementia  810
38417,Genetic and pathological correlation in FTLD
38418,Subtypes of vascular dementia
38419,Significant benefits of drugs reported from randomised controlled trials of cholinesterase inhibitors in vascular dementia
38421,Primary and secondary outcomes
38422,Adverse events
38423,Presenting rhythm, as assessed retrospectively by electrocardiograph review
38424,Some of the more common side effects associated with pharmacological treatment
38426,C indices for the ABC bleeding score   including alternative biomarkers   compared with the HAS BLED and ORBIT scores in the full cohorts and in subgroups
38427,Pooled analysis of the early risk of recurrent vascular events, given per time period after randomisation, in trials of aspirin versus control in secondary prevention after transient ischaemic attack and ischaemic stroke
38428,Pooled analysis of the effect of any aspirin versus control in secondary prevention after TIA and ischaemic stroke on the early risk of any recurrent ischaemic stroke and on disabling or fatal ischaemic stroke stratified by the nature of the presenting event   TIA and minor stroke vs major stroke   and by time from presenting event to randomisation   14 days vs  14 days
38430,Crude data for patient outcomes
38431,Crude mortality data based on the reason for initial emergency department visit
38436,Summary of key efficacy results
38437,Summary of adverse events in the safety population
38439,Joints injected
38441,Differences between deprivation groups at each assessment wave
38442,Adjacent contrasts testing differences between assessment waves within deprivation groups
38444,Main results
38445,Sensitivity analyses
38448,Secondary clinical outcomes in the intervention and control groups
38451,Adverse events
38453,Participants with new vertebral fractures
38454,Participants with clinical fractures
38455,Participants with upper gastrointestinal adverse experiences
38456,Description of cases with acquired drug resistance
38460,Participants in the analyses
38461,Relative risk of UGIB with regular and occasional use of aspirin products in week before index day
38462,Regular use of aspirin products in week before index day according to bleeding site
38464,Endpoints by groups
38465,Non arrhythmic cardiac deaths and non cardiac deaths
38466,Severe adverse effects
38467,Causes of early discontinuation of study medication
38469,Concomitant medication at time of enrolment
38470,Early permanent discontinuation of study medication
38471,Primary and secondary outcome events
38474,Rates of initial haemostasis and recurrent bleeding
38475,Admission rates in the West Midlands Region for infectious intestinal disease 199095   per 10000 population
38478,Risk of breast cancer in premenopausal women who had ever or never smoked
38479,Risk of breast cancer in postmenopausal women who had ever or never smoked
38480,Relation between body mass index   BMI   and risk of breast cancer in postmenopausal women who ever or never smoked
38481,Numbers of Borrelia sp and malaria infections
38484,Primary and secondary endpoints for groups assigned MIT therapy versus no MIT therapy and prayer versus no prayer
38485,Primary and secondary endpoints for: no prayer versus two tiered prayer   subset of patients randomised after two tier prayer was introduced
38486,Unadjusted Kaplan Meier rates for primary and secondary endpoints in factorial treatment groups
38487,Days of monitoring, incidence, and clinical presentation of TBRF, according to age and sex
38488,Prevalence of Borrelia infections in small mammals, by year
38495,Chemotherapy regimens
38497,Univariate and multivariate analyses of prognostic factors associated with 10 year overall and recurrence free survival
38498,Reasons for early termination of treatment
38501,Frequency of common adverse events
38505,Safety outcomes
38510,Adverse events
38513,Safety outcomes at weeks 24 and 48
38514,Effect of covariates on parasite clearance half life of Plasmodium falciparum examined by univariate analysis
38515,Admission variables associated with parasite clearance half life of Plasmodium falciparum in multivariate regression analysis
38518,Adverse events
38521,Treatment efficacy at week 36 for the modified intention to treat population in the open label period and at week 88 for the modified intention to treat subpopulations in the double blind period
38522,Safety summary
38525,Adverse events
38530,Comparison of early palliative care intervention and standard care
38532,Palliative care intensity for intervention and control groups
38536,Primary and secondary outcome variables at months 3, 6, 9, 12, 15, and 18
38537,Estimates of treatment effect   common to all follow up times
38538,Number of participants achieving improvement deterioration on adjusted PANSS total scores at 9 and 18 months
38539,Hospital admissions during the treatment phase
38540,Description of the studies   N 22   included in the systematic review of community empowerment approaches to address HIV among sex workers
38541,Clinical outcomes at 1 year and 5 years for the intention to treat population
38543,Localisation of the peak voxels of the connectivity assessment
38550,Secondary outcome measures at 56 days, by allocation
38551,Adverse events
38555,Treatment emergent adverse events and serious adverse events
38556,Melatonin in feverfew and other medicinal plants
38558,Patient s mutations and family history
38559,Estimated cumulative risk of cancers in BRCA1 and BRCA2 mutation carriers
38560,All deaths and cardiac transplantation during the double blind eriod of MDC study, and at 18 and 36 months after randomisation during open follow up
38561,Blood test results, 199294
38562,Frequency and grade of acute rejection   AR   after liver transplant   clinically significant episodes requiring treatment and untreated AR reported on protocol biopsy   in patients receiving Neoral   n 94 99   and Sandimmun   n 64 67   based triple therapy during first 2 postoperative weeks; and 1 month and 1 yr graft and patient survival         Kaplan Meier
38563,Serum and urine electrolytes during terlipressin treatment
38564,Results of postal survey
38565,Liver function tests before hospital admission
38566,Der p 1 allergen on human skin
38567,Studies of oral ACE inhibitors in aortic stenosis
38568,BP measurements in diagnosis of orthostatic hypotension
38569,Distribution of the intron 8 polythymidine polymorphism of CFTR in the neonates
38570,Mean   SD   bone density and biochemical data of cystic fibrosis adults receiving intravenous pamidronate
38571,Blood glucose   mmol L   after oral glucose tolerance tests
38572,Death rates   per 1000 person years  , number of deaths, and mortality ratios for various causes of death among men aged 4455 years, according to diabetic   NIDDM   and non diabetic   non DM   status in the Whitehall, Paris Prospective, and Helsinki Policemen studies
38573,Thrombotest and trail lengths
38575,Lymphocyte subsets and proliferative responses to T cell mitogens of a DGA patient treated by transplantation of blood mononuclear cells
38576,Endocrine evaluation at presentation and during follow up period
38577,Biochemical, histological, and virological features of the four couples
38578,Associations of blood donors with GBV C exposure
38580,SimpliRED D dimer results overall and in each probability category
38581,Mortality rate by cause of death and treatment after acute ischaemic stroke
38583,Changes in lipid concentrations and event rates after substitution of fluvastatin for simvastatin
38584,Laboratory and clinical results of erythropoietin supplementation given enterally to premature infants
38586,Percentage incidence of oestrogen and progesterone receptors in breast tumours
38587,Standardised mortality ratios   SMR   of suicides in male prisoners by age band   in years  , 19782003
38588,Neuroimaging in Lewy body dementias
38589,Evidence for treatment of dementia with Lewy bodies and Parkinson s disease dementia  129,130
38591,Comparison of nursing contacts for women and men in intervention group
38592,Causes of death, non fatal MI, and readmissions for revascularisation
38594,Clinical trials of homoeopathy
38595,Trials in meta analysis
38596,Pooled odds ratios and 95  CI   random effects model
38597,Results of four placebo controlled randomised multicentre trials of Galphimia glauca for pollinosis
38598,Results of randomised trials of various homoeopathic remedies for postoperative ileus after abdominal surgery
38599,Screening process and rate of pulmonary tuberculosis in Zomba Central Prison
38600,Sputum smear results for prisoners with cough of longer than 1 week s duration
38601,Number of HIV seropositive prisoners with cough of 1 or more weeks  duration
38602,Total sales of HRT preparations in Denmark, 199093
38603,Risk of subarachnold haemorrhage according to use of HRT and identified risk factors in women aged 4564 years
38604,Risk of intracerebral haemorrhage according to use of HRT and identified risk factors in women aged 4564 years
38605,Risk of thromboembolic infarction according to use of HRT and identified risk factors in women aged 4564 years
38606,Risk of transient ischaemic attack according to use of HRT and identified risk factors in women aged 4564 years
38608,Standardised mortality ratio
38609,Comparison of acid fast bacilli smear positive, smear negative, and smear indeterminate patients
38610,Psychiatric admission rates through the criminal justice system of housed and homeless people in central London
38611,Heart rate, time domain and frequency domain factors of heart rate variability and mean blood pressure   BP   in postmenopausal women without or with HRT
38612,Arrival times and times to each stage in the assessment of stroke patients in a large UK teaching hospital
38614,Height velocity percentiles and height percentiles in children with third degree burns
38615,Ordered logistic regressions for predicting outcome group 213 years after first hospitalization
38616,Pairing of the tabias by their under 5 mortality rates
38617,Under 5 mortality rate per 1000 child years according to intervention and control tabias from Jan 1, to Dec 31, 1997
38618,Under 5 mortality per 1000 child years in intervention and control tabias by age and sex
38619,Cause of death according to verbal autopsy in under 5s
38622,Regression models for death at home
38623,Use of nursing home beds
38624,Use of hospitals
38625,Cholecystecomy rate   per 100000 population   by age and sex category in prelaparoscopic   198490   and laparoscopic period   199399
38626,Trend in postoperative mortality after cholecystecomy in prelaparoscopic   198190   and laparoscopic   199198   periods
38627,Comparison of laparoscopic and open cholecystectomies   199698
38628,Effect of surgeon s cumulative laparoscopic experience and cholecystectomy caseload on the proportion of operations done laparoscopically, postoperative stay, and 90 day postoperative mortality   January, 1990, to March, 1999
38629,Potential sources of misestimation of HIV AIDS data in CRS
38630,Overseas development budgets for sexually  transmitted disease control, including HIV AIDS, in least developed and other low income countries   199098
38631,Overseas development budgets for sexually transmitted disease control, including HIV AIDS, in sub Saharan Africa   199098
38632,All donors and lenders   199098   and all allocations to recipient countries
38633,Nutritional regimens
38636,Number of patients with postoperative complications
38637,Complications in detail
38638,Adverse effects of artificial nutrition
38639,Cases of HIV 1 infection, Orel oblast, Russia, 19962000
38640,Effect of potential confounders on risk of venous leg ulcers or pressure ulcers associated with HRT use
38641,Type of accommodation at prevalence screen by sex
38642,Prevalence of dementia in respondents from institutions by age and sex
38645,HIV 1 incidence per treatment group per centre, and overall
38646,Incidence of sexually transmitted infections   time to first event
38647,HIV 1 incidence per treatment group and frequency of gel use
38648,Incidence of lesions with an epithelial breach per treatment group and frequency of gel use
38649,Comparison of results on questionnaire between group of participants who received a single consent meeting and group Who received three information sessions and a consent meeting
38651,A general grouping of the deaths
38652,Classification of deaths in 27 families with completed enquiries ccording to explained or SIDS
38653,Probability that index death and first CONI death were both udden unexpected deaths in infancy versus one or both were unnatural
38654,Probability that index death and first CONI death were both IDS versus one or both were probably covert homicide
38655,Prevalence of self reported experience of racial discrimination   ever   by ethnic group
38656,Mori and European health inequalities, adjusted for various factors
38659,Analysis of the odds of having a unique strain
38660,Consensus disposition classification and tolerance for rate of consequential medical events
38661,Critical interventions and expert panel consensus of likelihood consequential medical event if procedure or treatment modality withdrawn
38662,Difference in difference estimates with nationally representative data   CSPLC   from 1998 and 2004
38663,All cause, infectious, and non infectious disease hospital admissions by 5 year periods in New Zealand   19892008
38664,Health expenditure in six countries of the Organisation for Economic Co operation and Development
38667,Cluster adjusted toolkit mean scores and differences in the postintervention assessment
38668,Cluster adjusted view of informal carers evaluation of services symptom scales in the postintervention assessment
38669,Cluster adjusted estimates of medications administered in the last 2 days of life of the patient in the postintervention assessment
38670,Estimated differences in toolkit scales between hospital and hospice bridged by the LCP I implementation in hospital wards
38671,Management in the comprehensive geriatric assessment and care and the orthopaedic care groups
38673,Clinical assessments
38674,Health care use
38675,Cost per patient
38676,Firearm legislation during 2009
38677,Risk of firearm death associated with protective firearm laws in four US states in 2010
38678,Change in national firearm mortality per 100000 people with federal implementation of the three most effective firearm laws
38679,Firearm legislation in 2009 and the risk of fatal firearm homicides and suicides
38681,Procedural results and 30 day clinical events
38682,Clinical events during 12 month follow up
38683,Description of the PREDICT 1 cohort in women and men
38684,Adjusted hazard ratios for total CVD in the PREDICT 1 equations
38686,Standard performance metrics for PREDICT 1 equations   estimating 5 year risk of total cardiovascular disease   and the 2013 American College of Cardiology American Heart Association Pooled Cohort Equations   estimating 5 year risk of hard atherosclerotic cardiovascular disease   applied to the whole PREDICT 1 cohort
38687,Adjusted hazard ratios for hard atherosclerotic cardiovascular disease of new PREDICT 1 equation variables added to the Pooled Cohorts Equations
38688,Relation of ultrasound classification of risk of neurological deficits to quality of movements and outcome at 2 years
38689,Correlation of rCBF in different brain regions   normalised to cerebellum   to single positive and negative symptoms in neuroleptic nave patients before and after neuroleptic treatment
38690,Principal component factor analysis of five symptoms and three regions of interest   n 8
38691,Principal component factor analysis of six symptoms and four regions of interest   n 10
38692,Comparison of regional blood flow in drug nave schizophrenic patients and matched healthy volunteers
38693,Cosmetic results of abdominal scars
38694,Mamillary body values for all groups
38696,Mean   SD   regional brain volumes in cm3
38697,Volumes of structures of interest in high risk group according to presence or absence of affected first degree relatives
38698,Mean   SD   number of fingers per hand that showed Raynaud s phenomenon during laboratory cooling
38699,Relative risks of having received at least one conviction for those men with schizophrenia in the 1975 and 1985 groups, compared with controls matched for age, sex, and residence
38701,Frequency of diagnosess of mental disorder and learning disability, and comorbidity of substance abuse disorders
38702,Number of criteria for Diogenes syndrome met, and variation by presence of active mental disorder and contributory physical disorder
38703,Multivariate associations with LCRS interior scale scores and with having mental disorder
38705,Previous Cardiovascular Therapies by Drug Class  a
38707,Clinical Status Assessment at End of Study
38709,Activity at Onset of Symptoms by Age Group
38710,Comparison of Patients by Activity at Onset of Symptoms of Myocardial Infarction
38711,Association Between Activity at Onset of Symptoms and Outcome
38714,Intravascular Ultrasound Findings of Coronary Aneurysms
38718,Survival Benefit Associated With Beta Blocker Use After PCI
38721,Association Between Metabolic Syndrome and Systolic and Diastolic Echocardiographic Abnormalities in Adult Survivors of Childhood Cancer
38724,Population With Central Measurements   n   181  : Main Cardiovascular Parameters: Adjusted   Means  Standard Error of Means Are Presented at M0, M6, M12
38733,Adverse events reported at least once by patients on self questionnaires completed each day after 1000 mg of methylprednisolone and until day 28
38736,Adverse events and tolerability measures during the augmentation phase
38738,Adverse events
38740,Common treatment emergent adverse events   20  or more of patients   in the safety population
38742,Breast cancer first events
38743,Breast cancer free interval and disease free survival events by age group
38744,Non breast cancer events
38745,Adverse events by treatment group
38746,Studies of TAVR
38750,Patient treatment stratified by line of therapy and the results of routine molecular analyses
38751,Outcomes stratified by line of therapy and molecular alteration
38753,Unadjusted clinical outcomes in the as treated populations
38754,Primary endpoint composite by propensity score quintile
38756,Grade 34 severe treatment adverse events according to assigned treatment group
38759,Clinical outcomes of patients 30 days after device implantation
38761,Type of intervention in isolated mitral regurgitation
38763,Antibiotic susceptibility testing in mice   15 per group  . The number   percentage   of mice surviving at day 24 is given for each treatment
38764,Doxycycline susceptibility testing in mouse fibroblast cell culture: mean percentage of L929 cells which contain rickettsia after 30 h   95  CI
38765,Input variables and sources
38766,Cost effectiveness       of screening and treatment at age 50 years
38767,Patients infected with ceftazidime resistant and blactam resistant Pseudomonas aeruginosa,198795
38768,Distribution of variables
38769,Distribution of confirmed sites of relapse       within randomised groups
38770,Control of loco regional   L R   relapse within randomised groups and according to whether or not breast remains conserved
38771,Percentage with loco regional   L R   relapse according to variables and total follow up for randomised groups
38772,Sites of recurrence of breast cancer in patients who received systemic therapy according to ER status of primarytumour
38773,5 year relapse rates in treated breast in trials of local excision with or without radiotherapy
38774,Modified Jerger s classification
38776,Reported side effects
38777,Outcome at follow up visit at 2 weeks
38780,Univariate analysis of risk factors for thrombosis events
38781,Multivariate analysis of risk factors for stroke and arterial thrombosis
38782,Age and sex distribution of children by treatment group
38783,Mean proportions of children with resolution and healing       at 8, 12, and 16 weeks by treatment group
38784,Effects on average hearing threshold at different time periods due to improvements in CSOM
38785,US licence applications for sale of medical products to Cuba
38787,Findings of repeat scintigraphy
38788,Patients with abnormal findings of the urinary tract
38789,Resistance to clprofloxacln in 40 clinical Isolates of Escherlchla call
38790,1 month evaluation study of patients put forward for study by 40 general practitioners
38793,Geometric mean red cell and plasma folate concentrations in pregnant and non pregnant women, according to genotype
38794,Reports of S aureus from blood or cerebrospinal fluid in UK, 198995
38795,Resistance rates for S aureus from blood or cerebrospinal fluid, England and Wales, 198995
38796,Resistance rates to methicillin by former English National Health Service region, 199395
38797,Resistance rates to other antibiotics in MSSA and MRSA isolates, UK, 198995
38798,MICs of subclones of Mu3 obtained by selection with various concentrations of vancomycin
38799,Pretreatment and post treatment red cell folate   RCF   and estimated NTD risk per 1000 births
38800,Incremental changes in red cell folate   RCF
38802,Average consumption of selected foods   g per person per day   in Albania and selected countries
38803,Epidemic  Salmonella typhi  from Tajikistan isolated in 1997
38804,Mean daily intakes of trans fatty acids in men and women in 14 European countries
38805,Salmonella bacteraemia in England and Wales, 199496
38806,PCR amplification of wild housefly abdominal extracts
38807,ELISA results
38808,Sex of 137 live births in Taiwan 19781985, by date of birth
38809,Rates of twinning by use of folic acid before conception
38811,Resistance to ciprofloxacin in S typhi in the UK, 199199
38812,Absorption of iron from a 3 mg reference dose of iron as iron   II   sulphate with 30 mg ascorbic acid and a 1 mg dose of reduced iron in bread
38813,Geometric means   within treatment 95  CI   for placebo inhaler, 2 mg nominal dose of fluticasone propionate delivered via a pressurised metered dose inhaler and spacer   pMDI spacer  , and via a dry powder Accuhaler   Diskus   device
38814,Sensitivity of bacterial isolates and place of acquisition
38815,Laboratory tests on second admission
38817,Virulence factor   VF   and antibiotic resistance profiles
38819,Quantification of exosomes
38820,Functional activity of bulk lymphocytes stimulated with DC     exosomes or tumour cells
38822,Primary outcome
38824,Rate of treatment failure or relapse by presence of specified risk factor
38825,Number of adverse events by treatment group
38826,Treatment outcomes
38830,Comparison of treatment success with failure by site
38833,Ploidy status of patients, by molecular marker
38834,Prognostic and predictive value of molecular markers
38835,Observed and predicted concentrations of arsenic in cooked rice
38838,Number of cycles of allocated treatment received
38839,Side effects in first 3 months of randomisation
38840,Tumour response rates at 12 weeks
38842,Rates of multiple birth and crude and adjusted rate ratios for multiple birth, according to folic acid pill taking status
38843,Distribution of children by age, sex, and socioeconomic status
38844,Care seeking behaviour by number and duration of symptoms
38845,Differences by sex in morbidity and care seeking behaviour
38846,Socioeconomic differences in morbidity and care seeking behaviour
38849,Primary and secondary events after randomisation
38851,Pregnancy outcomes
38852,Clinical details and indications for delivery of 11 women with elective preterm delivery
38853,Difference in percentage of spontaneous preterm deliveries and miscarriages between treatment groups by factors that might affect outcome
38855,Association between total dietary fibre and distal colorectal adenoma
38856,Association between fibre food groups and distal colorectal adenomas
38857,Description of the EPIC cohort
38859,Numbers of cancers and hazard ratios by quintile of sex specific total fibre intake
38860,Intakes of fibre and colorectal cancer by quintile of sex specific source of fibre intake
38861,Covariate definitions
38862,Results of neuro development tests for cognition and achievement by prenatal exposure
38863,Neurodevelopmental tests for motor, perceptual motor and memory by prenatal exposure
38864,Neurodevelopmental tests for attention and behaviour by prenatal exposure
38865,Social and environmental covariate effects
38866,Sample description of gonococcal isolates seen in participating GRASP clinics,     200002
38867,Trends in ciprofloxacin resistance in N gonorrhoeae in participating GRASP clinics,      200002
38868,Quintiles of fat and hazard ratios by quintile
38869,Proportion of resident population tested for Chlamydia trachomatis by Amplicor
38870,Relation between culture positivity, LightCycler   LC   positivity, and estimated number of copies of omp1 per swab in individuals from Rombo with signs of active trachoma and an Amplicor positive swab
38871,Amplicor positivity by clinical sign of trachoma in the swabbed eye
38872,Estimated copies of omp1 per swab by clinical sign of trachoma in the swabbed eye
38873,Chronological description of cases
38874,Risk factors for abandonment of treatment
38875,Environmental samples of various origins tested for the presence of E sakazakii
38876,Antimicrobial susceptibility, plasmid profile, and antimicrobial resistance phenotype of the clinical isolates of S choleraesuis   SCB43 and SCB67   and the control strain   NCTC8393
38877,Prognostic value of the variables included in univariate analysis for first episode of severe bacterial infection
38879,Chest radiograph findings on admission
38880,Age adjusted hazard ratios by group and outcome
38881,Age adjusted hazard ratios by group and outcome when wheezing children omitted
38883,Haematological reconstitution and transplant outcomes
38884,Primer sequences
38885,Taqman validation with laboratory isolates
38886,IC50 values for antimalarials in relation to pfmdr1 copy number
38888,Temporal trends of the efficacy of mefloquine monotherapy and parasite genotype in primary infections
38889,NSABP B 14: outcome according to treatment group, age, menopausal status, and tumour oestrogen receptor concentration
38890,NSABP B 20: outcome according to treatment group, age, menopausal status, and tumour oestrogen receptor concentration
38891,NSABP B 14 and B 20: quantitative concentrations of tumour oestrogen receptors by age or menopausal status and treatment group
38892,Doses of drugs
38894,Culture results at 2 months
38895,Status at the end of treatment
38896,Status 12 months after the scheduled end of treatment
38897,Difference between regimens in proportions with an unfavourable status 12 months after the end of treatment
38898,Adverse events resulting in a change of treatment or interruption of 7 days or more
38900,Relative risk of myocardial infarction comparing rofecoxib with control, from stratified meta analyses
38904,Treatment differences and odds ratios for specified comparisons for overall improvement according to the patient at week 18
38905,Effect of skin colonisation with tetracycline resistant propionibacteria on treatment outcome
38907,Relative cost effectiveness of treatment regimens based on patients  self assessment of improvement
38908,Correlation between antibiotic use and resistance, by organism and year of isolation
38909,Comparison of transmission rates in primates and cattle infected orally with similar BSE brain inocula
38911,MRS score, primary outcome, and death
38912,Accommodation and feeding at 6 months  follow up
38914,Number and proportion of patients with each Modified Rankin scale   MRS   score and with our primary outcomes by treatment allocation
38915,Incidence of invasive pneumococcal disease in metropolitan Atlanta by year, age group, macrolide resistance, and mechanism of resistance
38916,MIC to erythromycin of mefE containing S pneumoniae, metropolitan Atlanta, 19952002
38917,Incidence of invasive pneumococcal disease in metropolitan Atlanta by year, serotype, macrolide resistance, and mechanism of resistance
38918,Incidence of macrolide resistance in pneumococcal serotype 14 isolates by year and age group
38919,Indicators of tuberculosis transmission between March, 1995, and February, 2000
38920,Treatment outcome of new and retreatment tuberculosis cases according to M tuberculosis drug susceptibility pattern, March, 1995, to February, 2000
38922,Number of carers who correctly answered questions on age specific feeding practices
38923,Feeding practices   24 h recall
38924,Child growth at 18 months by intervention group
38925,Microfilaraemia and antigenaemia values of W bancrofti from start of treatment
38926,Ultrasound detection of filarial dance signs of adult worms at 14 month follow up
38929,Main outcomes in children treated with chloramphenicol and placebo eye drops
38931,Disease status at two step approach and response during the study
38932,The first 40 days of life in Sylhet district, Bangladesh
38933,Room where newborn stays during first month of life
38934,Sleeping surface of neonate during first week of life
38935,Checkup by a trained or untrained health care provider for sick neonate during first 30 days of life
38937,Antibiotic combinations most commonly received
38938,Changes in lung function, dyspnoea, hospital length of stay, treatment failure rates, and sputum bacterial density according to treatment assignment
38940,Perioperative management
38941,Principal results
38942,Multiple logistic regression results for surgical wound infection
38943,IBCSG trials and treatment groups
38944,Disease free survival and overall survival comparing 85  dose level versus  85  dose level according to oestrogen receptor   ER   cohort and body mass index   BMI   group
38949,Results of genetic testing in a hypothetical patient in 2010   from Collins,  18    , and updated estimates of relative risks
38950,Potential confounders by quartiles of C reactive protein  112
38951,C reactive protein, and potential confounders by 1059G C genotype of the CRP gene  112
38952,Large population based research biobanks   planned and current
38953,The expected rate of accrual of incident cases of selected complex diseases in UK Biobank  141
38955,Favourable responses to treatment and all cause mortality
38956,All cause adverse events and reasons for discontinuation from study drug in patients who received at least one dose of study drug
38957,Randomised trials for primary treatment of candidaemia in non neutropenic patients and effect of efficacy endpoint definitions, by antifungal agents studied
38958,Odds ratios for lung cancer by cruciferous vegetable consumption      and GST status
38959,Odds ratios for lung cancer by cruciferous vegetable consumption and GSTM1 and GSTT1 status for ever and never smokers
38961,Pooled risks of stroke   95  CI   in meta analysis according to study variables
38962,Age specific incidence estimates of presentation to hospital with bacteraemia
38963,Sensitivity and specificity of clinical signs, malaria parasitaemia, and white blood cell count for diagnosis of bacteraemia
38964,IMCI clinical syndromes      of children with and without bacteraemia
38965,Pregnancy after IVF
38966,B vitamin intake and nutrient status, and outcome of fertility treatment
38967,Genotype distribution, according to fertility status
38968,B vitamin related genotype, history of infertility, and outcome of fertility treatment
38973,Wheeze, asthma, and medication use at age 5 years in the treatment group compared with the placebo group
38975,Results from diary cards in the first 3 months of the study
38976,Change in height Z score after randomisation
38978,Distribution of culture results and drug resistance categories by group for all patients   n 1539   for whom sputum culture was done
38980,Countries or geographical settings studied in the third round of the Global Project
38981,Prevalence of drug resistance in new cases in 76 countries or settings, 19992002
38982,Trends in resistance in new cases in 26 countries or settings
38983,Prevalence of drug resistance in previously treated cases in 66 countries or settings, 19992002
38984,Trends in resistance in previously treated cases in 24 countries or settings
38987,Difference in mean proportion of macrolide resistant streptococci between groups
38988,Carriage of the macrolide resistance genes, mef and erm  B  , in streptococci isolated from volunteers treated with clarithromycin or azithromycin
38990,Maternal antenatal CD4 cell counts and HIV point prevalence rates at 26 weeks by method of feeding at 26 weeks
38991,Mother to child transmission risk during exclusive breastfeeding   n 1034
38992,Factors associated with HIV free survival in exclusively breastfed infants in the first 6 months of life   n 1034
38993,Long term therapies   given for 3 months or more
38994,Cost of adding screening for cystic fibrosis to an established newborn screening service in Scotland
38995,Mean and median estimated yearly treatment costs per patient   US    in 2002, by genotype and age group
38996,Linear regression analysis results for mixed genotype and homozygous F508 patients
38997,Effects of screening using a 31 CFTR mutation assay and age at diagnosis on estimated cost savings to the estimated cost of a newborn screening programme for cystic fibrosis
38998,Details of trials included in overview
39000,Hazard ratios   95  CI   for outcomes by age, nodal status, tumour size, and BMI in univariate and multivariate Cox models for women with hormone receptor positive cancer
39001,Percentage change in hazard ratios   95  CI   for outcomes in women with hormone receptor positive cancer
39002,Percentage change in hazard ratios   95  CI   for outcomes in women with hormone receptor positive cancer by age
39003,Percentage change in hazard ratios   95  CI   for outcomes in women with hormone receptor negative cancer
39006,Pooled relative risk for stroke, stratified by intervention duration, percentage change in homocysteine concentration, grain fortification, and history of stroke
39007,Relative risk of stroke and change in homocysteine concentration
39010,Participants with solicited local   injection site   and general symptoms within 7 days after one or both vaccinations by vaccine group
39011,Haemagglutination inhibition antibody response to the homologous recombinant A Vietnam 1194 2004 NIBRG 14 vaccine strain after the first and second vaccine dose
39012,Neutralising antibody response to the homologous recombinant A Vietnam 1194 2004 NIBRG 14 vaccine strain after the first and second vaccine dose by vaccine group
39014,Stent thromboses according to ARC criteria for definite stent thrombosis and according to per protocol definitions used in individual trials
39015,Estimated numbers needed to treat and numbers needed to harm for different outcomes
39016,Sensitivity analyses
39017,Results of in situ hybridisation and immunohistochemistry in selected organs and cell types
39018,Results of in situ hybridisation, RT PCR, and NASBA for H5 detection assay in selected brain regions of patient 2
39019,Results of RT PCR, strand specific RT PCR, real time RT PCR, and NASBA for H5 detection in specific tissue samples
39021,Mean GHA scores for 3 year old and 8 9 year old children by challenge type
39025,Hospital anxiety and depression   HAD   scale subscores for all eligible studies
39026,Case reports of fibrinogen transmitted hepatitis
39029,Postoperative complications, surgery data, and hospital stay for the 1354 patients who had bowel resections
39030,Anastomotic leakage rates, according to various factors and results of multivariate analysis for the 1354 patients who had bowel resection
39032,Cumulative treatment failure and specific causes by day 3 and 6, and relapse by day 14
39035,Risk factors for venous thromboembolism
39036,Contraindications to anticoagulation
39037,Type of prophylaxis used in at risk patients
39038,Patients at risk for VTE and prophylaxis use by country
39041,Child anthropometry by allocation group, with four analytic models for differences between group means
39042,Mean measurements at birth and at follow up, with mean and proportional increments
39043,Underweight, stunting, and wasting according to WHO standards, and estimates of mean upper arm total and fat areas
39045,Mean child anthropometric outcomes at final survey
39046,Programme participation and use of services
39047,Trials included
39053,Survival analyses of relapse and mortality according to fractionation schedule
39054,Incidence of ischaemic heart disease, symptomatic rib fracture, and symptomatic lung fibrosis according to fractionation schedule
39057,GVHD grade and organ involvement
39059,GVHD response and outcome
39062,Coronary heart disease and high risk patients and their partners achieving the primary endpoints at the initial assessment
39063,Coronary heart disease and high risk patients and their partners achieving the primary endpoints at 1 year
39064,Risk factor distributions in coronary heart disease and high risk patients
39067,Mortality rates for children aged 259 months in the IMCI intervention area before and after the modification of guidelines
39071,Overall incidence of treatment emergent adverse events occurring in 10  or more of patients who received one or more doses of study drug
39072,Percentage of patients with at least one episode of hypoglycaemia, by treatment and concomitant sulphonylurea use
39074,Overall level of functional impairment at age 7 years from the mark III Multi Attribute Health Scale in children whose mothers had SPL
39075,Deaths in ORACLE II and during OCS II in children whose mothers had SPL
39076,Inside the table analysis of overall level of functional impairment at age 7 years from the mark III Multi Attribute Health Scale in children whose mothers had SPL
39077,Behaviour at age 7 years from the Strengths and Difficulties Questionnaire in children whose mothers had SPL
39078,Educational attainment in reading, writing and mathematics, for England only, for children whose mothers had SPL
39079,Medical conditions reported by parents of children at age 7 years in those whose mothers had SPL
39080,Functional impairment outcomes of the children with cerebral palsy whose mothers had SPL
39082,Overall level of functional impairment at age 7 years from the mark III Multi Attribute Health Scale in children whose mothers had PROM
39083,Inside the table analysis of overall level of functional impairment at age 7 years from the mark III Multi Attribute Health Scale in children whose mothers had PROM
39084,Deaths in ORACLE I and during OCS I in children whose mothers had PROM
39085,Behaviour at age 7 years from the Strengths and Difficulties Questionnaire in children whose mothers had PROM
39086,Educational attainment in reading, writing, and mathematics at key stage one, for England only, for children whose mothers had PROM
39087,Medical conditions reported by parents of children at age 7 years whose mothers had PROM
39090,Cumulative incidence of main endpoints and corresponding relative risks
39092,Non double blind studies favour second generation antipsychotic drugs
39093,Second generation versus first generation antipsychotic drugsefficacy in various domains
39094,Quality of life
39095,Extrapyramidal side effects
39096,Weight gain
39097,Sedation
39098,Effects of haloperidol dose on the effect sizes of overall symptoms and extrapyramidal side effects
39099,Dosing classification based on lower and upper dosing range quartiles
39100,Studies included in the multiple treatments meta analysis
39101,Response and dropout rates for efficacy and acceptability in meta analyses of direct comparisons between each pair of antidepressants
39102,Efficacy and acceptability using fluoxetine as reference compound
39103,Clinical, surgical, and histopathological details
39104,Disease related events and data for time to event
39109,Univariate and multivariate logistic regression analysis for culture conversion at week 8 in the modified intention to treat population
39110,Serious adverse events
39112,Summary of primary and secondary outcomes
39113,Adverse events reported from randomisation to 12 months
39115,Parameter estimates related to puerperal sepsis and other post partum maternal deaths in Malawi
39119,Survival outcomes by treatment adjusted for significant factors in the Cox multivariate model
39120,Mortality and morbidity during the first and subsequent years of treatment
39121,Summary of biochemical and radiological findings during treatment
39122,Stratification of patients by aldosterone renin ratio
39126,Mortality   thousands of deaths   by sex due to risk factors in 14 GBD subregions
39127,Burden of disease   thousands of DALYs   by sex due to risk factors in 14 GBD subregions
39128,Health outcomes at age 26 years according to childhood socioeconomic position and adult socioeconomic position
39130,Quantification of clonotypic T cells in peripheral blood
39132,Causes of acute lower gastrointestinal haemorrhage and degree of diagnostic certainty
39133,Predictive performance of the three different models in the internal and external validation groups
39134,Numbers of children in each age group, by diagnosis
39135,Yearly age group specific incidence and cumulative incidence of SVI BL
39136,Incidence by sex, ethnic group, country of residence, and birthweight
39137,Disorders causing SVI BL grouped by anatomical site or sites affected
39138,Prenatal causal factors causing SVI BL
39139,Perinatal and neonatal causal factors causing SVI BL
39140,Childhood and unknown causal factors causing SVI BL
39141,Potentially preventable or treatable   avoidable   SVI BL
39143,Dose and time dependence of HIV inhibition by GBV C
39144,Distribution of study population
39145,Median age   years   of presentation of cases
39146,Risk of acute myocardial infarction associated with risk factors in the overall population
39147,PARs associated with nine risk factors in men and women by geographic region
39148,Importance of risk factors in young and old individuals
39150,Myocardial infarction and medication at discharge and at 1 year
39152,Frequency of death and cardiac events
39154,Primary outcome variables   intention to treat, all visits
39156,Prespecified adverse events on treatment or within 14 days of discontinuation
39160,Aflatoxin B1 in groundnuts at main survey points
39163,Compliance and reasons for discontinuation of trial treatment
39164,Effects of clopidogrel on primary and other clinical outcomes during scheduled treatment period in hospital
39165,Effects of clopidogrel on cerebral and major non cerebral bleeding during scheduled treatment period in hospital
39167,Time intervals between onset of symptoms, randomisation, and the catheterisation procedure
39168,Medications given before, during, and after catheterisation
39169,TIMI flow grades of participants
39170,Single clinical endpoints within 90 days of randomisation
39171,Strokes and non cerebral bleeding complications within 90 days
39172,Causes of death
39173,Presence of C trachomatis DNA assessed by PCR compared with detection by the clinical sign TF and POC assay positivity
39174,Performance of the clinical sign TF and the POC assay compared with PCR
39175,Age and sex distribution across groups
39176,Proportion of participants with solicited injection site and systemic reactions within 7 days after one or both vaccinations
39177,Haemagglutinin inhibition antibody response on horse erythrocytes after one and two vaccinations
39178,Neutralising antibody response after one and two vaccinations
39180,Incidence rate by group and incidence rate ratio of death and of severe morbidity
39183,Number   rate per 100 patient exposure years   of patients who had adverse events in combined analysis at 48 weeks
39184,Number   rate per 100 patient exposure years   of grade 34 laboratory abnormalities
39185,Prehospital response, triage categories, and mortality
39186,Injuries sustained by seriously injured trauma patients admitted to the Royal London Hospital
39187,Radiological investigations during first 24 h at the Royal London Hospital
39188,Operations on day of major incident at the Royal London Hospital
39190,Adjusted standardised hazard ratios for mortality
39191,Adjusted standardised hazard ratios for combined, fatal, and non fatal cardiovascular endpoints
39192,Adjusted hazard ratios   95  CI   associated with extreme, decreased, and reverse dipping versus normal dipping
39194,Adjusted standardised hazard ratios   95  CI   for systolic blood pressure excluding one cohort at a time
39195,Number of patients seeking medical attention after a first event, stratified by place of initial referral, or by type of presenting event
39197,Risk of stroke during the 90 days after first seeking medical attention, stratified according to the place of initial referral, or by type of presenting event
39198,Delay to seeking medical attention and subsequent delay in being seen in the clinic for all patients who were referred to the study clinic
39199,Measures of process of care, assessed at 1 month follow up, in all patients with TIA or stroke who were referred to the study clinic
39202,Times, drugs at discharge, and 30 day events
39204,ECG parameters on arrival at PCI centre, and after angiography or PCI
39205,Angiographic outcomes
39206,Clinical outcome and safety parameters
39207,Grade of age related macular degeneration according to the Age Related Eye Disease Study   AREDS   for both UK and US cohorts
39208,Genes tested in primary screen
39209,Allelic and genotypic tests of rs2511989 from primary screen of UK sample   n 953  , US sample   n 500  , and the two cohorts combined
39213,Adverse events at 1 year
39214,Occurrence of the primary and major secondary endpoint events at 1 year by assigned pharmacological and stent groups
39215,Adverse events between 30 days and 1 year
39216,Major adverse cardiovascular events within 1 year according to the occurrence of major bleeding not related to coronary artery bypass graft surgery
39217,Baseline characteristics of participants
39218,Efficacy of recombinant hepatitis E vaccine
39219,Safety outcomes
39221,Primary endpoint and its components according to centre s mean time in therapeutic range
39222,Bleeding events according to centre s mean time in therapeutic range
39223,Composite cardiovascular events and total mortality according to centres  mean time in therapeutic range
39224,Relative risk   95  CI   of death with tranexamic acid, overall and by time to treatment
39227,Clinical outcomes at 3 years
39229,Absolute number of events, incidence rates, and hazard ratios   HRs   for cardiovascular endpoints, death, and diabetes in the JUPITER trial in participants with or without major diabetes risk factors, according to random allocation to rosuvastatin or placebo
39230,Adverse events and measured laboratory values for fasting glucose and HbA1c during follow up in participants with and without major diabetes risk factors
39232,Serious adverse events
39233,Causes of poor outcome in patients with modified Rankin scale score of 36 at 3 months
39234,Summary results of meta analyses of the effect of aspirin on risk of non vascular death during 51 trials of aspirin versus control in prevention of vascular events stratified by dose of aspirin    300 mg vs 300 mg   and the indication   primary vs secondary prevention
39235,Pooled analysis of the effect of aspirin on cancer deaths in 51 trials   77549 participants   of aspirin versus control in prevention of vascular events, stratified by years to death
39236,Pooled analysis of the effect of allocation to aspirin versus control on the risk of all incident cancer during trial follow up in the six trials of low dose aspirin in primary prevention of vascular disease,  1621   by years to notification
39237,Visual outcomes in major treatment trials of age related macular degeneration
39238,Keratoplasty techniques, indications, and technique selection
39239,Comparison of the advantages and disadvantages of the different keratoplasty techniques
39240,Complications of keratoplasty techniques
39242,Short term and long term outcomes
39243,Annual growth rate       of volume consumption per person in low income and middle income countries, and high income countries between 1997 and 2009
39244,Top five companies responsible for sales of packaged foods in different countries
39245,Effects of vitamin A allocation on plasma retinol, haemoglobin, weight, height, Bitot s spots, and recent ill health   generally as reported by the child s guardian   in a subsample from each of the 72 blocks during the second half of the study, by age
39246,Effects of albendazole allocation on pre school child mortality: absolute numbers of deaths per anganwadi child care centre   AWC   by allocated treatment, albendazole versus control   A vs C  , and, from these, mortality rate ratio   A C   and approximate absolute risk of death from age 10 to 60 years
39247,Developmental factors associated with nephron number, kidney size, and function
39248,Clinical surrogates for nephron number
39250,Procedural details by DAPT status
39251,Cumulative incidence of adverse events
39252,Number of events for each clinical outcome by worst DAPT cessation status achieved before the MACE event
39255,Adverse events
39256,Secondary outcomes
39257,Ongoing pregnancy by natural conception in prespecified subgroups
39258,Age adjusted percentage of adult population with selected chronic disease risk factors and conditions in the USA, 19992012  30
39259,Four domains of chronic disease prevention activities for preventing heart attacks and strokes from the Million Hearts Initiative
39261,Primary outcome
39262,Secondary outcomes
39263,Self reported symptoms
39264,Risk factor scenarios used in the analysis
39265,Data sources for risk factor exposures and their associations with non communicable diseases
39266,The impact of achieving risk factor targets on premature mortality from non communicable diseases
39268,Hierarchical outcomes
39269,Clinical outcomes at 28 days
39270,Summary of observational and intervention studies on dietary patterns for diabetes prevention and management
39271,A comparison of nutrition therapy main recommendations for patients with type 2 diabetes from various organisations
39273,Adverse events regarded as related to treatment   occurring in 2 patients
39274,Maternal mortality ratio, numbers of maternal deaths, and annualised rates of change for 21 Global Burden of Disease regions and 188 countries
39275,Global and regional maternal deaths in 2013, by cause and timing
39276,The Chronic Liver Failure Consortium organ failure score
39278,Sensitivity analysis showing the effect size for mortality after removing individual trials included in the meta analysis
39279,Clinical outcomes stratified by different durations of dual antiplatelet therapy established by network meta analysis
39280,INR and dosing data among patients taking warfarin, across genotype bins
39281,Bleeding outcomes among patients taking warfarin in the first 90 days of treatment, across genotype bins
39282,Bleeding outcomes among patients taking warfarin beyond 90 days of treatment, across genotype bins
39283,The four large trials comparing non vitamin K antagonist oral anticoagulants with warfarin for stroke prevention in atrial fibrillation
39284,Appropriate indications for use of non vitamin K antagonist oral anticoagulants   NOACs   in different clinical scenarios of atrial fibrillation  20,21
39285,Laboratory test for monitoring of non vitamin K antagonist oral anticoagulants in laboratory and emergency settings  29
39286,Antidotes to non vitamin K antagonist   VKA   oral anticoagulants
39287,Current trials with non vitamin K antagonist oral anticoagulants after percutaneous coronary intervention in patients with atrial fibrillation
39291,Details regarding medical treatment at inclusion, discharge, and coronary angiography
39292,Clinical outcomes and complications
39294,Procedural and discharge data
39295,Clinical outcomes
39296,Left ventricular ejection fraction at 18 months
39297,Procedure related complications
39299,PAR for all risk factors by region   all stroke, ischaemic stroke, and intracerebral haemorrhage
39300,Risk factors for all stroke   ischaemic and intracerebral haemorrhage   in men and women
39301,Risk factors for all stroke   ischaemic and intracerebral haemorrhage   by age group
39302,Global Burden of Disease 2015 risk factor hierarchy, exposure definitions, theoretical minimum risk exposure level, and data representativeness index for 19852015, pre 2005, and 200515
39303,Epidemiological evidence supporting causality for risk outcome pairs included in the Global Burden of Disease study 2015
39304,Global age standardised summary exposure values for all risk factors for 1990, 2005, and 2015
39305,Global all age deaths and DALYs attributable to each risk factor at each level of the risk factor hierarchy and outcome for both sexes combined in 2005 and 2015
39308,Proportion of participants experiencing at least one grade 35 adverse event by 52 weeks that was possibly, probably, or definitely related to study treatment using a modified intention to treat analysis for a model based on the raw dataset and imputed dataset
39310,Bleeding endpoints
39311,Exploratory ischaemic endpoints
39313,Effect of tranexamic acid on maternal death
39314,Effect of tranexamic acid on composite primary endpoint   death or hysterectomy   by subgroup
39315,Effect of tranexamic acid on need for surgical intervention
39316,Effect of tranexamic acid on thromboembolic events, complications, use of uterotonics, and quality of life
39318,Age specific reasons for major bleeds not identified by administrative coding alone
39323,Treatment emergent ocular adverse events in the intervention group in 1 year   mITT
39326,Safety outcomes by treatment group
39328,All cause adverse events across all uncomplicated malaria episodes treated with study drugs   safety population
39329,Standardised mortality ratios   SMRs   for homicide, suicide, and accident, by diagnostic category
39330,Prevalence of passive smoking by centre
39331,Odds ratios for respiratory symptoms, current asthma, and allergic rhinitis in passive smokers compared with participants without regular involuntary exposure to tobacco smoke
39332,Odds ratios   95  CI   for respiratory symptoms, current asthma, and allergic rhinitis in passive smokers categorised by daily exposure duration compared with participants without regular involuntary exposure to tobacco smoke    1 h daily
39334,Estimated effect   95  CI   on total serum IgE, bronchial responsiveness   ECRHS slope   and lung function in passive smokers categorised by daily exposure duration compared with participants without regular involuntary exposure to tobacco smoke    1 h daily
39335,Severity and duration of upper respiratory tract   URT   and lower respiratory tract   LRT   symptoms associated with rhinovirus infection
39336,Results of patch testing
39337,Weight, height, lung function results, skin test results, and maternal smoking in children who had wheezed, and those who had never wheezed during the first 3 years of life
39338,Pulmonary function in children who had never wheezed in relation to risk group, as defined by parental atopic status
39339,Pulmonary function in children who had never wheezed: adjusted sRaw   geometric means and 95  CI   for fixed factors in the model of covariance
39340,Pulmonary function in children who had never wheezed. Specific airway resistance, geometric means, and 95  CI
39342,Effects of transfusions of cryopreserved autologous platelets and fresh allogeneic platelets
39343,Platelet aggregation response
39344,Alloimmunisation and platelet refractoriness
39346,Number of patients who received more than 90  of planned total dose or dose intensity   based on MRC data only
39347,Non protocol treatments, including more than six cycles of study treatment, given before progression
39348,Moderate or severe toxic effects seen during treatment   grade 3 4 except where stated
39349,Treatments given on first progression
39350,Frequency of atopy   skin test weal 2 mm   at ages 13 and 21 years, and asthma at ages 926, by breastfeeding history
39352,Effect of duration of breastfeeding on development of atopy and asthma
39353,Effect of family history of allergy   either parent reporting asthma or hayfever   on effect of breastfeeding on development of atopy and asthma in the New Zealand birth cohort
39354,Univariate and multivariate analyses of risk factors for current asthma at age 9 years, positive skin test responses to mite or to any allergen at age 13 years, and for current asthma age 926 years by repeated measures analysis
39355,Classification of outcomes
39357,Relative risks for various mortality outcomes 199198 for children living with single parents compared with children with two parents
39358,Multivariate models for severe psychiatric diseases and injuries 199199 for children in single parent families compared with those in two parent families
39359,Topiramate dose escalation schedule
39361,Mean difference between topiramate and placebo averaged over trial period
39364,Protocol treatments received during trial
39365,Moderate or severe toxic effects experienced during treatment
39366,Death from all medical causes, by smoking and age, among men in urban and in rural India
39367,Death from specific medical causes, by smoking, among men aged 2569 years in urban India   Chennai
39368,Death from selected medical causes, by smoking, among men aged 2569 years in rural India   South Arcot district
39369,Death from pulmonary tuberculosis, by smoking and age, among men in urban and in rural India
39370,Prevalence of smoking, by age, and prevalences among smokers and non smokers of self reported pulmonary tuberculosis   past or current   in population survey of urban and rural men aged  35 years
39371,Prevalence of self reported pulmonary tuberculosis at ages 3569 years, by amount of cigarettes or bidis smoked, in a population survey of men in urban India   Chennai
39372,National numbers   year 2000   of male deaths attributed to smoking in all India, urban and rural
39373,Stimulation index for participants practising unprotected sex
39374,Comparison of stimulation index scores between women and men practising protected and unprotected sex
39375,Comparison of geometric means of infection with CCR5 and CXCR4 strains of HIV 1 between women or men practising protected sex longer than 12 months compared with those practising protected sex for 612 months
39377,Phenotype of CD4 CD25  and CD4 CD25 T cells from non atopic and atopic donors
39379,Relative risk for incident gout according to daily alcohol intake
39380,Relative risk for incident gout according to individual alcoholic beverage intake
39382,Renal variables at birth and at most recent follow up in patients with neonatal membranous glomerulonephritis
39385,Alcohol consumption at follow up
39386,Determinants of SPT wheal size in HDM SPT positive individuals: Spearman correlation
39387,Determinants of SPT wheal size in HDM SPT positive individuals: multiple stepwise linear regression
39388,Asthma associated outcomes: univariate analysis
39389,Determinants of symptomatology in HDM sensitive atopics: univariate analyses
39390,BHR in non atopics: univariate analyses
39391,Logistic regression modelling of relation between asthma associated outcomes and immune response variables in children
39392,Predictors of airway hyper responsiveness at age 7 years, stratified for wheezing at school age   57 years
39393,Predictors of lung function at ages 7, 10, and 13 years from repeated measure analysis with mixed linear models
39398,Change in cognitive performance within groups during 3 years and difference in cognitive change attributed to folic acid supplementation
39399,Outcome of questionnaire survey in cases and controls
39400,Distribution of cases and controls by outcome of proxy questionnaire interview
39402,Association of mortality from all causes with frequency of non beverage alcohol drinking and mean volume ethanol consumed from beverages
39403,Association of beverage ethanol volume drunk per week stratified by non beverage alcohol drinking status
39404,Association of mortality from all causes with alcohol drinking pattern and problem drinking adjusted for smoking and education
39408,Total alcohol abstinence by Child Pugh classification
39409,Effects of drug, time, and interaction on addiction and laboratory variables, estimated by ANCOVA mixed models
39410,Clinical features of the two cases
39411,Detailed exposure of case two to the index case before the onset of illness
39412,Type of exposure and sera collection of 91 close contacts
39414,Prevalence of serodiscordance among cohabiting and non cohabiting couples in Lusaka and Kigali by sex of at risk partner and age
39417,Sensitivity analysis of the mean probability of incident HIV infection within marriage or cohabitation in urban Zambia and Rwanda, with changing assumptions about transmission of HIV per unit time and protection from condom use
39418,Sensitivity analysis of mean probability of incident HIV infection within marriage or cohabitation in urban Zambia and Rwanda, with varying estimates of potential error in the data sources used to estimate serodiscordance and numbers of sexual partners
39424,1 month prevalence of mental disorders in a sample of 63004 individuals aged 18 years or older from Shandong, Zhejiang, Qinghai, and Gansu provinces in China
39425,Comparison of the prevalence of main groups of mental disorders and the most common specific disorders in a sample of 63004 men and women aged 18 years or older from Shandong, Zhejiang, Qinghai, and Gansu provinces in China
39426,Comparison of the prevalence of main groups of mental disorders and the most common specific disorders in a sample of 63004 individuals aged 18 years or older in rural versus urban areas in Shandong, Zhejiang, Qinghai, and Gansu provinces in China
39427,Comparison of the prevalence of main groups of mental disorders and the most common specific disorders by age group in a sample of 63004 individuals from Shandong, Zhejiang, Qinghai, and Gansu provinces in China
39430,Male relative risk of death at ages 1574 years, by proxy reported alcohol intake   other drinkers vs reference drinkers, excluding never drinkers   and certified cause   other causes vs control diseases
39431,Female relative risk of death at ages 1574 years, by proxy reported alcohol intake   other drinkers vs reference drinkers, excluding never drinkers   and certified cause   other causes vs control diseases
39432,Male dose related excess mortality in ever drinkers as a proportion of all mortality in male ever drinkers and never drinkers, by age and underlying cause of death
39433,Female dose related excess mortality in ever drinkers as a proportion of all mortality in female ever drinkers and never drinkers, by age and underlying cause of death
39436,Deployment experiences of study participants, by deployment location
39441,Association between time since return from deployment and probable mental disorders for regulars
39443,Cytomegalovirus viraemia and treatment in subgroups of transplant patients with defined donor and recipient serostatus
39444,Homicide mortality per 100000 inhabitants by macro regions of Brazil, 19912007
39445,Period prevalence   12 months   of psychological and physical abuse against women by region
39446,Traffic related mortality per 100000 inhabitants by type of victim and by age group, 2007
39447,Important benchmarks in tackling domestic violence in Brazil, by year
39448,Measures related to traffic related injuries and deaths in Brazil, by year
39450,Grade 3 or higher toxic effects in all patients randomly assigned to treatment groups, by chemotherapy regimen over entire treatment period
39451,Second line therapy received by KRAS wild type patients, by chemotherapy received
39452,Proportion of YLDs, YLLs, and DALYs explained by the ten leading causes of total burden in 2010
39457,Maximum local and systemic reactogenicity
39458,Antibody titres
39460,Primary and secondary outcomes
39461,Costs per person and cost effectiveness analyses   2015 international dollars
39462,Cost effectiveness analyses from health system and societal perspectives   2015 international dollars
39463,Cause specific deaths within 10 years after index injury admission, by sex and type of index injury
39464,Relative risk of cause specific death within 10 years after adversity related index injury vs accident related index injury
39465,Relative risk of cause specific death within 10 years after each type of adversity related index injury vs accident related index injury
39467,Plasma concentrations of functional C1 INH   intention to treat population
39468,Adverse events   safety population
39469,Laboratory data of patients 13
39470,CLCN5 mutations in cases of hypercalciuric nephrolithiasis with tubular proteinuria
39472,Use of calcium channel blockers and their relation to cancer
39473,Relation of use of calcium channel blockers with specific types of cancer
39474,Woman years of exposure to steroid contraceptives and mean ages of women between 1991 and 1995
39475,Woman years of exposure to OCs, numbers of cases, and rate of VTE in each age group
39476,Cases of VTE by exposure, crude incidence rates, and rate ratios from cohort study
39477,Rate ratios for VTE by type of OC use adjusted for 5 year age bands
39478,Odds ratios of VTE by use of different types of OC
39479,Clinical findings in five cases of non fatal citalopram overdose
39482,Laboratory indices before, during, and after treatment with moxonidine
39483,  Rate and intensity of microfilaraemia before   1994   and after   1995   one single dose mass treatment
39485,Results for primary outcome measures in group A   predominant isosorbide dinitrate   and group B   predominant furosemide
39486,Results for secondary outcome measures in group A   predominant isosorbide dinitrate   and group B   predominant furosemide
39488,Laboratory data
39489,Body composition data
39490,Western Aphasia Battery   WAB   summary scores before and after resection for patients whose language was classified as normal   aphasia quotient 938   before resection
39491,Western Aphasia Battery   WAB   summary scores before and after resection for patients with dominant hemispheric tumour who were dysphasic   aphasia quotient  937   before resection
39492,Western Aphasia Battery   WAB   subtest scores before and after resection for patients with dominant hemispheric tumour who were dysphasic   aphasia quotient  937   before resection
39493,Mean scores before and after surgery for asphasia quotient, language quotient, and Boston Naming Test   BNT   for patients with left sided intracranial tumours grouped according to neuropathology
39494,Boston Naming Test   BNT   scores before and after resection for patients with dominant hemispheric tumour who were anomic   score 48   or not   score 49   before resection
39496,Incident and fatal cancer by treatment group
39497,Risks of different types of incident cancer
39498,Primary HIV 1 infection treated with hydroxyurea, didanosine, and indinavir
39499,Prevalence of continuing use of antihypertensive drugs among 450000 elderly people in British Columbia
39500,Annual incidence of new use of antihypertensive drugs among elderly people in British Columbia
39501,Proportion of elderly people in British Columbia in 1996 who were newly treated with an antihypertensive drug, grouped by drug class and relative contraindication for thiazide and b blocker
39502,Comparison of brain dead donors
39503,Comparison of the kidney recipients
39504,Long term follow up in recipients
39505,Prescribing data
39508,Odds ratio for road traffic accident in current users of anxiolytic and hypnotic benzodiazepines
39509,Odds ratio for road traffic accident by dose of antidepressant drug or benzodiazepine
39512,Primary and secondary endpoints and exploratory analyses
39514,Phase 3 efficacy trials with meloxicam
39515,Phase 3 efficacy trials with celecoxib
39516,Phase 3 endoscopic safety studies with celecoxib
39517,Phase 3 efficacy studies with rofecoxib
39518,Incidence rate of new AIDS events and death in people treated with triple therapy when CD4 count was less than 20 L, according to latest CD4 count after starting treatment
39519,Clinical information
39520,Number of episodes treated by seizure type
39522,Odds ratios of hip fracture associated with use of oral contraceptives
39523,Odds ratios of hip fracture associated with age at oral
39525,Mean   SD   plasma concentrations of endotoxin and inflammatory markers in healthy volunteers and patients with chronic heart failure
39527,The drugs used for the rotation
39528,Mean supine blood pressure at study entry and at the end of the three wash out periods
39529,Comparison of response rates to each patient s first and best drug
39530,Trials of immediate versus deferred zidovudine
39531,Trials of zidovudine plus didanosine or zalcitabine versus zidovudine alone
39532,Risk of venous thromboembolism among new users of second and third generation oral contraceptives
39533,Ecstasy related deaths among individuals aged 1524 years in England and Scotland
39534,Heroin related deaths among individuals aged 1524 years in Scotland
39535,Effect of pharmacological interventions on blood loss and number of transfused units
39537,Performance of measures of arrhythmic risk at 18 months of follow up
39538,Allergy histories
39539,HIV kinetics during sequential structured treatment interruptions
39542,Clinical outcome
39543,Mortality in phenobarbital and placebo groups, according to number of doses of diazepam
39544,Side effects during prophylactic treatment
39545,Standardised heart failure scoring system
39547,Total cardiovascular events for patients in the BNP and clinical groups during median 95 months follow up
39548,Key design features of trials
39550,Summary of major clinical events
39551,Outcomes according to ejection fraction stratum
39553,Observed opportunities for hand hygiene in consecutive observational studies, University of Geneva Hospitals, Switzerland, 199497
39554,Compliance with hand hygiene in successive observational surveys, and odds ratios for compliance, unadjusted and adjusted for known risk factors, University of Geneva Hospitals, Switzerland, 199497
39555,Details of hospital cleaning chemicals used in the study
39556,Trials included in the first round of analyses
39557,Blood pressure differences, proportion remaining on randomised treatments, and proportion achieving blood pressure goals
39558,Underlying diagnosis in 1014 patients with hypopituitarism
39559,Regional and national observed and expected cause mortality rates in 1014 patients with hypopituitarism
39560,Univariate analysis of regional and national standardised mortality ratio   SMR   versus sex, year of diagnosis, age of diagnosis, tumour type, treatment with surgery and radiotherapy, and sex steroid replacement therapy
39561,Effect of hormonal axis deficiency on mortality in patients with hypopituitarism
39562,Association between degree of hormone deficiency and mortality in patients with hypopituitarism
39563,Univariate analysis of regional and national standardised mortality ratios in 573 patients with non  functioning pituitary tumours
39564,Multiple regression analysis using Cox s proportional hazards model to determine the influence of individual variables on survival in hypopituitarism
39565,Total percentage change in laboratory markers
39566,Factors associated with progression to any lipodystrophy
39567,Factors associated with progression to specific types of lipodystrophy   multivariate models
39569,Observed and expected number of deaths during follow up
39570,Frequency of cancer
39571,Frequency of cancers in the STOP Hypertension 2 cohort
39572,Frequency of cancers for every treatment group
39573,Frequency of cancers for all treatment groups in the STOP Hypertension 2 cohort
39574,Patients who received randomly assigned drug class with or without additional antihypertensive drugs among those who attended annual visit
39577,Major adverse cardiac events
39579,Description of 10 popular magazines studied24
39580,Headlines of 15 selected advertisements
39582,Pooled estimates of advantage of new versus old antihypertensive drugs with respect to cause specific mortality
39583,Variance explained by initial blood pressure and blood pressure difference
39584,Observed odds ratios and odds ratios predicted by differences in systolic blood pressure in metaregression
39585,PCR detection of Wolbachia in plasma after diethylcarbamazine chemotherapy
39588,Number of participants on study drug at endpoint or end of follow up
39589,Endpoints
39590,Adverse events
39592,Prevalence ratio   PR   of hypospadias
39597,Distribution of major clinical outcomes
39602,Severe adverse effects in chemosensitive patients
39603,Causes of death in chemosensitive patients at last follow up
39604,Overall survival and freedom from treatment failure   FFTF   at 3 years
39605,Bacterial susceptibility during the study period
39608,Neurological sequelae, overall and by causative agents
39609,Outcome of survivors from hospital, overall and by causative agents
39610,Hearing outcomes, overall and by causative agents
39612,Time course of 24 h urinary protein excretion rate   g 24h   in individual patients from 24 weeks before study entry   week 0   up to study end   week 20
39615,Age, ethnic groups, and parity in the HIV 1 positive cohorts
39617,Reperfusion therapy for index myocardial infarction
39618,Medications given concurrently with study drug
39619,Subgroup analyses
39620,Multivariable logistic regression model
39623,Causes of heart disease
39624,Diagnostic investigations
39625,Treatment
39627,Outcomes
39628,Organisms isolated from blood cultures
39629,Median lactulose mannitol ratios on the day before start of treatment   L M start   and at maximum neutropenia   L M max  , according to treatment group
39630,Adjusted survival curves showing time to death from all causes in patients with cardiovascular disease
39631,Interventions evaluated
39632,Annual costs, effects, and cost effectiveness of interventions
39633,Annual incremental costs, effects, and cost effectiveness of interventions
39635,Body composition abnormalities in cases and non assigned patients
39638,Antiretroviral and metabolic drug use in training dataset
39640,Model sensitivity and specificity according to lipodystrophy score
39643,Cox proportional hazard analysis for the effect of covariates on survival in patients with chronic heart failure   SOLVD
39644,Effect of weight loss on survival in patients with chronic heart failure   SOLVD
39645,Cumulative frequency of weight loss of 6  or more in the SOLVD treatment study and in V HeFT II
39647,Peak nausea and antiemetic use
39648,Cumulative all cause and cause specific mortality for the enalapril and placebo groups in the prevention trial
39649,Cumulative all cause and cause specific mortality for the enalapril and placebo groups in the treatment trial
39651,Causes of death among fluvastatin treated and placebo treated patients
39653,Frequency of most relevant adverse events and abnormal laboratory values
39655,Primary endpoints and components of the composite endpoint
39656,Safety variables
39658,Secondary outcomes hierarchically ordered
39659,Permanent study drug discontinuations for adverse events
39661,Primary and secondary outcomes
39662,Numbers of hospital admissions for worsening heart failure
39663,Permanent study drug discontinuation for adverse events
39666,Immunological category, progression to a new opportunistic infection or cancer, and mortality by calendar year
39669,Details of patients with confirmed diagnosis of recent Chandipura virus infection
39670,Antibody status and relation to time of sample collection
39674,Cumulative risk of extensive virological failure of for individual drug classes according to years from start of that class
39677,Adherence to study medication
39678,Effects of study treatment on primary and secondary outcomes at 30 days
39679,Outcomes for patients with a non fatal myocardial infarction and non fatal stroke
39680,Independent predictors of death and stroke and their associated population attributable risks
39682,Rates of myocardial infarction by exposure to various NRTIs
39684,Exposure to NRTIs and risk of first myocardial infarction, cardiovascular death, or invasive cardiovascular procedure, and of risk of possible or definite stroke
39686,Summary of study events
39687,Most frequently occurring adverse events
39689,Medication at a median of 438   402486   days follow up
39690,Adverse clinical events at 1 year follow up
39691,TIMI risk score variables of the combined endpoint of cardiac death or non fatal reinfarction
39695,Effects of treatment group assignment on outcomes of retention and heroin use
39698,Secondary outcomes
39699,Causes of death
39700,Predefined subgroup analysiscomposite endpoint of all cause death or admission to hospital for cardiovascular reasons
39701,Permanent treatment discontinuations and adverse drug reactions
39704,Incidence of serious adverse events during the study by system organ class
39705,Primary and secondary endpoints
39707,Secondary outcomes
39708,Causes of death
39709,Predefined subgroup analysiscomposite endpoint of all cause death or admission to hospital for cardiovascular reasons
39710,Permanent discontinuations and adverse drug reactions
39712,Maternal treatments and outcomes
39713,Primary and other neonatal outcomes
39714,Primary neonatal outcome in infants born before 32 weeks  gestation and within 7 days of repeated study drug administration
39718,Adverse events
39725,Change in use of heroin and crack cocaine by treatment type and drug use group
39726,Parameters from the mixed linear model analysis
39727,Change categories     at review by treatment type and drug use group
39728,Changes in use of drugs other than heroin and crack cocaine from admission to review
39732,Selected adverse events and adverse events with discontinuation
39736,Most frequent symptoms or side effects at 12 months
39739,Primary endpoint and components
39740,Summary of adverse events
39744,Therapeutic protocol
39746,Trial outcome as at June, 2009
39747,Endpoint of progression free survival grouped by competing risks
39748,Reported outcomes of trials in relapsed childhood acute lymphoblastic leukaemia
39750,Response to different treatment phases and best response, according to central assessment
39751,Cox regression analysis of progression free survival in subgroups of patients with poor prognosis
39752,Multivariate analysis of variables favourably affecting progression free survival
39753,Serious adverse events and grade 3 or 4 adverse events reported in at least 2  of patients during induction therapy
39754,Non haematological adverse events of any grade reported in at least 10  of patients during induction therapy
39755,Number of communities and participants by country income
39757,Drug use in participants with coronary heart disease or stroke, by country economic status and overall
39758,Participants with coronary heart disease or stroke, by urban or rural locations stratified by country economic status
39759,Drug use in participants with coronary heart disease or stroke, by region
39760,Country   between country   and individual   within country   variances and their contributions as a percentage to the total variance based on multilevel modelling
39761,Triggering factors in occupational rhinitis
39762,Benefits and harms of treatments for allergic rhinitis
39767,Costs, outcomes, and incremental economic analyses associated with PINCER intervention and simple feedback
39768,Transplacental transfer of chemotherapeutic agents in pregnant baboons, from simultaneously collected maternal and fetal plasma samples  70,71
39772,Lipid and lipoprotein concentrations
39773,Mortality risk by fitness
39774,Mortality risk for the combined fitness and statin categories
39775,Distinguishing hypertrophic cardiomyopathy from athlete s heart when left ventricular hypertrophy is within the grey zone of overlap   thickness, 1315 mm in males and 1112 mm in females
39776,Availability of data for analyses
39778,Key genetic alterations in B lymphoblastic leukaemia, by gene
39780,Classification of causes of chronic kidney disease based on presence or absence of systemic disease and location within the kidney of pathological anatomical findings
39781,Monogenic and complex kidney diseases
39782,Most important causes of 166 cases of paediatric acute kidney injury in South India
39786,Home systolic blood pressure dose response   higher vs lower dose
39787,Adverse events and withdrawals
39789,Clinical outcomes
39790,Safety outcomes
39793,Patient incidence of adverse events and serious adverse events in all patients who received at least one dose of study drug
39794,Summary of primary and secondary mitral regurgitation
39796,Primary and secondary outcomes in the intention to treat population
39797,Primary and secondary outcomes in the per protocol population
39800,Primary and secondary cocaine use related outcomes
39802,Adverse events reported by at least two patients
39804,Randomised controlled trials included in the systematic review and network meta analysis
39805,Number of patients with suicidal behaviour or ideation according to study treatment
39808,Serious adverse events
39813,Participants who reported a hypertension medication specific symptom or adverse effect at 12 month follow up visit   ten most reported symptoms plus hypertension specific symptoms not reported in the top ten
39815,Effects of clinical variables on time to resolution and duration of oxygen therapy
39816,Effects of dexamethasone in selected patient subgroups for time to resolution and duration of oxygen therapy
39818,Smoking and risk of AMI
39819,Fasting blood glucose   FBG   and serum insulin
39820,Relative risk in groups by tertile of fasting blood glucose   FBG   and insulin
39821,Effect of multiple risk factors, modelled with logistic regression: prediction of cases versus controls
39822,Different types of VRE recovered from patients or environment
39823,Colonisation with VRE in mechanically ventilated patients and in MICU environment
39824,Proportion of severe visual impairment and blindness due to ROP in children aged 015 years in schools for the blind
39826,Outcome variables
39828,Linkage of insulin gene region of chromosome 11p15.5 to PCOS
39829,Association of insulin VNTR class  III  allele with PCOS
39830,Intrafamilial association analysis of  INS  VNTR allele with PCOS
39832,Logistic regression models
39833,Deaths in Trent and Victoria by diagnostic category and by expected mortality
39835,Clinical histories of patients with MDR TB treated with interferon
39837,Age specific rate of diabetes by infant feeding group
39838,Odds ratios for diabetes from logistic regression model
39839,Paediatricians  statements about their practices for end of life decisions   interview study
39840,Diagnosis in neonates and infants in whom death was preceded by a medical end of life decision   interview study
39841,Paediatricians  statements about decision making   interview study
39845,Reasons for withdrawal of patients from study
39848,Total number of chemotherapy cycles received
39849,Reasons for termination of protocol chemotherapy schedule
39850,Total doses of drugs received and protocol intended doses
39851,Grade 3 and 4 toxic effects during chemotherapy
39852,Planned and actual surgery received
39854,Outcomes for patients assigned magnesium or placebo
39855,Functional outcome for resuscitated patients
39856,Proportion of patients successfully resuscitated in predefined subgroups
39857,Inclusion and exclusion criteria
39859,Clinical outcome   n 26
39860,Glycaemic control, insulin secretion, insulin sensitivity, lipids, and lipoprotein   a   values before and after treatment
39862,Geometric means of plasma glucose and insulin concentrations
39863,Geometric mean 120 min plasma glucose concentrations by exposure, birthweight, and body mass index
39868,Plasma IGF I concentrations by case or control status
39869,Relative risk of breast cancer by plasma IGF I quintiles or tertiles
39870,Results of Bayley test on 201 ICSI and 131 IVF children between the ages of 22 and 26 months
39872,Site of first disease recurrence
39873,Most frequently occurring adverse events in 248 patients treated with interferon  2a
39874,Infections or immunisations preceding GBS that have been confirmed by case control studies or demonstrated in large numbers or series
39875,Fatty acid composition   g 100 g fat   of LCPUFA and no LCPUFA formulae
39876,Median   quartiles   problem solving scores on entire problem and each individual step
39877,Criteria for scoring intention on steps of three step problem
39880,Sensitivity and specificity of IL 1ra, IL 6, cICAM 1, and CRP
39884,Treatment response by the end of treatment and end of follow up   sustained response   according to treatment received
39886,Sustained virological response to different regimens according to the number of response factors
39888,Responses according to skin detachment, SAPS, and mortality
39889,Plasma and blister fluid TNF a and interleukin 6 concentrations
39891,Clinical response data
39892,Proportions of patients reporting moderate or severe symptoms
39893,APACHE II scores for patients
39894,Staff disciplines and seniority by case management group
39896,Days in hospital over 2 years
39897,Secondary and tertiary outcomes at 2 years
39898,Premorbid estimated IQs of elderly individuals competent to complete advance directives compared with those who are incompetent
39900,Haematological data before, during, and after surgery
39901,Mean   SD   blood loss, blood component transfusion, and re exploration rates
39902,Mean   SD   haemodynamic data 5 min before and after study drug administration
39906,Days in hospital and number of admission over 2 years by intelligence status
39907,Handwashing compliance by health care workers
39908,Frequency and duration of contact between health care workers and patients
39909,Biochemical features of autoimmune thyroid disease after Campath 1H treatment
39910,General data of patients in supine and semirecumbent position
39911,Microorganisms recovered on the day of clinical suspicion of pneumonia
39913,Univariate variable statistics for extrinsic risk factors of nosocomial pneumonia
39914,Univariate variable statistics for extrinsic risk factors of nosocomial pneumonia
39916,Association of MHC class II allele frequencies and self limiting and persistent HCV infection   European cohort
39917,Association of MHC class II allele frequencies and self limiting and persistent HCV infection   Lookback cohort
39918,Association of MHC class II allele frequencies and histological injury due to HCV infection
39919,Association of MHC class II allele frequencies and response to interferon in patients with persistent HCV infection
39920,Features of children in the KIGS database
39922,Incidence of diabetes or IGT for all patients and for selected disorders
39923,Incidence of type 1 diabetes by age group
39924,Consensus decisions of intensivists
39925,Relation of place enrolled, consensuses decision, and mean APACHE score
39926,Rate of patients per 1000 adult population of IMH area by quartile of deprivation and appropriate place of care
39927,Average number of critical care beds needed by hospital   number required to meet need 95  of times
39929,Decreased concentrations of serum IGF 1 and serum IGFBP 3 and the risk of osteoporotic fracture in postmenopausal women
39931,Risk of colonisation with resistant gram negative bacilli and antibiotic regimen
39932,Episodes of bacteraemia by causative organism
39933,Antibiotic use
39934,Causes of death
39935,Proportion of discharges at night from ICUs participating in UK APACHE II study compared with CMPD
39936,Case mix for night   22000659   versus day discharges
39937,Outcome for night versus day discharges
39938,Reason for discharge for night   22000659 h   versus day discharges
39939,Outcome for night versus day dischargesimpact of premature discharge
39940,Discharge destination and length of stay for night   22000659 h   versus day discharges
39941,Outcome for night discharges direct to the ward versus day discharges
39942,Outcome for night discharges direct to the ward versus day dischargesimpact of premature discharge
39944,Mean   SD   adolescent to adult personality functioning assessment scores
39945,Associations between poor functioning in love sex relationships and friendships
39946,Comparison of guidelines used during control and intervention periods
39948,Incidence of nosocomial infections, before and after intervention
39949,Sample size and response rates
39951,Proportions of physicians who had ever decided   alone or with others   to set limits to intensive interventions
39952,Proportions of physicians who had made specific decisions
39953,Results of multivariate logistic regression for selected reported practices
39954,Adjusted proportions of physicians who had made specific decisions
39956,Association between individual measures of ICU workload and mortality
39957,Multivariate analysis of ICU workload in relation to adjusted mortality
39959,Mean   SD   test scores for the 68 individuals who completed all WAIS subtests at ages 50 years and 80 years and underwent MRI
39960,Correlations between MRI hyperintensity scores and 80 year WAIS results
39961,Product moment correlations between MRI hyperintensity scores and decline in WAIS scores between age 50 and age 80
39962,Product moment correlations between two WAIS subtests and decline in cognitive performance during each of the decades from age 50 to age 80
39963,Admission details, length of stay, and standardised mortality ratios for each study group
39965,Proportion of individuals expressing individual alleles in the first intron of the interferon gamma gene
39966,Proportion of individuals who expressed the 126 bp allele, 122 bp allele, both, or neither in the first intron of the interferongamma gene
39967,Estimates of effects from fitted logistic regression model of clinical variables, HLA DRB1, and interferon gamma on odds of severe disease
39968,Mean   SD   anthropometric variables of individual bone marrow transplantation   BMT   patients and groups of former leukaemia patients and healthy controls
39969,Biochemical variables of individual bone marrow transplantation   BMT   patients and groups of former leukaemia patients and healthy controls
39973,Protocol for management of patients at risk of or with pulmonary hypertension
39975,Risk of prostate cancer for all patients and stratified according to PSA concentrations for specified increments of IGF 1 and IGFBP 3
39977,Chronic illnesses in ICU patients with and without
39978,Acute organ system failures in 807 ICU patients at time of decisions to withhold or withdraw life support treatments
39979,Reasons given for withholding or withdrawal of life support treatments
39980,Involvement and information of patients and families in the decision making process
39981,Life support therapies withheld or withdrawn in 807 ICU patients
39982,Clinical features of seven identified cases
39986,Occurrence and severity of hypoglycaemic episodes
39989,Clinical profiles, plasma lipids, and parameters of glucose metabolism in five patients with CD36 deficiency
39991,Maternal outcomes of women with pPROM randomly assigned erythromycin
39992,Neonatal outcomes of babies born to women with pPROM randomly assigned erythromycin
39993,Maternal outcomes of women with pPROM randomly assigned co amoxiclav
39994,Neonatal outcomes of babies born to women with pPROM randomly assigned co amoxiclav
39995,Maternal outcomes of women with pPROM randomly assigned co amoxiclav and erythromycin, or any antibiotic
39996,Neonatal outcomes of women with pPROM randomly assigned co amoxiclav and erythromycin, or any antibiotic
39998,Maternal outcomes of women with preterm labour randomly assigned erythromycin
39999,Maternal outcomes of women with preterm labour randomly assigned co amoxiclav
40000,Maternal outcomes of women with preterm labour randomly assigned both co amoxiclav and erythromycin or any antibiotic
40001,Neonatal outcomes of babies born to women with preterm labour randomly assigned erythromycin
40002,Neonatal outcomes of babies born to women with preterm labour randomly assigned co amoxiclav
40003,Neonatal outcomes of women with preterm labour randomly assigned both co amoxiclav and erythromycin or any antibiotic
40004,Overall status by age 4 years
40005,Outcome at age 4 year by prestratified analysis
40006,Factors affecting relative risk of death, local recurrence, and metastasis by the Cox proportional hazards model
40008,Site of involvement in central nervous system during first attack
40011,Tuberculosis exposure category, BCGvaccination status, ESAT 6 ELISPOT, tuberculin skin test   TST   and PPD ELISPOT results for all contacts
40012,Odds ratios of the relations between intensity of exposure to M tuberculosis and BCG vaccination status with each of the tests
40013,Visual acuity and ocular score of inflammation at panuveitis relapse   day 0  , and 1, 4, and 14 days after infliximab administration
40015,Composition of preoperative oral supplement per 100 mL
40018,Infectious morbidity
40021,Multivariate analysis on survival   Cox s regression model
40023,Comparison of labour and delivery factors in relation to vaginal instrumental delivery and caesarean section
40024,Comparison of maternal outcome in relation to vaginal instrumental delivery and caesarean section
40025,Comparison of neonatal outcome in relation to vaginal instrumental delivery and caesarean section
40026,Comparison of maternal and neonatal factors
40029,Univariate coefficients for correlation between body fat distribution and metabolic cardiovascular risk factors in 39 obese children
40032,Adverse effects occurring in at least 10  of patients treated with pegvisomant   n 160
40034,Clinicians establishing an explicit cardiopulmonary resuscitation directive
40038,Average workload by unit type
40039,Relation between within unit measures of workload and primary outcomes
40041,Multiple regression analysis of clinical variables independently associated with early lactate concentration in 103 patients of initial sample
40042,Univariate logistic analysis of admission clinical predictors of a fatal outcome in 93 patients from initial sample
40043,Multivariate logistic analysis of independent clinical predictors of a fatal outcome in 93 patients from initial sample
40044,Assessment of arterial blood lactate measurement and King s College Hospital   KCH   criteria as prognostic indicators in 99 patients from validation sample
40047,Mean   SE   fasting and 8 h mean concentrations of insulin, C peptide, glucagon, and free fatty acids during 8 h profiles
40048,Insulin, C peptide, and glucose concentrations during hyperinsulinaemic euglycaemic clamps
40049,Mean   95  CI   incremental C peptide concentrations during hyperglycaemic clamp expressed as first phase and second phase responses and peak values after arginine stimulation in GLP 1 group only
40050,Mean   SE   bodyweight, fat mass, lean body mass, and fat distribution
40051,Appetite in GLP 1 group only
40052,Association between a polymorphism in IGF I and birthweight
40053,Number of participants who showed a postnatal gain in weight during life, stratified by genotype
40054,Details of patients and response to terlipressin
40056,Treatment and leucocyte and eosinophil counts in patients 14
40064,Percentage change in frequency of problems between the first and second interview
40065,Interventions recommended by clinicians
40069,Summary of antibiotic usage and pulmonary exacerbation rates
40070,Values of first available laboratory markers after seroconversion
40072,Univariate and multivariable analyses of all laboratory markers as time updated covariates
40073,Neurophysiological examination before and after haemodialysis
40074,Factors associated with incidence of myocardial infarction in HOPS patients infected with HIV 1
40075,Supply of transferrin bound iron to S epidermidis mediated by catecholamine inotropes
40077,Maximum glucose stimulated plasma insulin and C peptide responses during hyperglycaemic clamp and insulin sensitivity index   M I   during euglycaemic clamp
40078,Composition of diets   g per 100 mL
40081,Early diet and fasting proinsulin, insulin, and glucose concentrations in adolescents born preterm
40082,Regression analyses of proinsulin concentrations on early growth in adolescents born preterm
40083,Comparison of adolescents born preterm and at term
40085,Primary and secondary endpoints
40086,Patients hormone concentrations before and during treatment with imatinib
40089,PELOD scoring system  12
40091,Relation between the number of organ dysfunctions, PELOD score, and mortality
40092,Goodness of fit test for the PELOD score
40093,Relative contributions of each organ dysfunction to the PELOD score
40094,Calibration and discrimination of the dPELOD score
40096,Mean   SE   biochemical variables of participants
40098,Insulin concentrations, glucose infusion rates, and insulin sensitivity during the hyperglycaemic clamp
40100,Mortality
40101,Patients with resistant bacteria at inclusion
40102,Acquisition of resistant bacteria
40103,Resistant bacteria in the ICU environment
40104,Prescribed antibiotics per 1000 patients
40106,Comparability of patients who were censored at follow up, changed preparation, or dropped out of treatment
40107,Reasons for changing preparation or dropping out of treatment
40108,Development in numbers of antibody positive patients   neutralisation capacity 20  in medium sensitivity assay   during treatment
40109,Pretreatment clinical features and development of neutralising antibodies
40110,Frequency of relapses in neutralising antibody positive and negative periods by assay sensitivity and cutoff point for positivity
40111,Development of mean EDSS in neutralising antibody positive and negative patients
40112,Associations between detection of interleukins 6 and 10 in cord blood and indications of acute perinatal fetal distress
40113,Associations between cytokine detection and asthma and atopy responses
40114,Associations between detection of interleukin 4, interferon, and TNF in cord blood and asthma and atopy outcomes at age 6 years adjusted for respective cytokine propensity score
40115,Dose of study medication
40117,Responses to category rating scales
40118,Assessment of treatment benefit at visit 8
40119,Frequency of serious adverse events
40120,Frequency of minor adverse events
40123,HSV in the throat and lower respiratory tract   LRT   in relation to SOFA and SOFA max scores
40124,Outcome in patients with HSV in the respiratory tract
40126,Comparison of splice variant expression in normal islets and insulinomas
40127,IGF2 LOI, 11p15 LOH, and IGF2 ROI in tumours from Japanese and white children
40128,Frequency of PLNR and ILNR lesions associated with Wilms  tumours from Asian and white children
40130,Haernatological and immunological data
40132,Observed primary outcomes for all randomised neonates
40133,Factors associated with primary outcomes
40134,Primary outcomes among neonates not receiving additional analgesia
40135,Factors associated with primary outcomes among neonates who did not receive additional analgesia
40137,Effects of open label morphine analgesia   within each randomised group
40140,Summary of available information from questionnaires completed by parents, and from attendance for physical examination at scheduled visits
40141,Measurements of physical size at every age assessed, by time
40142,Developmental measures administered up to 8 years of age
40143,Crude, adjusted, and multivariate odds ratios for abnormal outcomes for the intensive ultrasound group relative to those in the regular ultrasound group, by developmental measure
40145,Lymphocyte proliferation responses
40147,Activities of mitochondrial enzymes and GAPDH in skeletal muscle of critically ill patients
40148,Reported frequency of fast food restaurant visits   times per week   by race, sex, and time in the CARDIA study
40153,Hazard ratios for MRSA acquisition estimated from the Cox proportional hazards model
40154,Colonisation with or acquisition of MRSA in every study phase
40155,PFGE typing of MRSA during every study phase   excluding repeat isolates on same patient
40157,Take rates, local signs and symptoms related to vaccination   cohorts one to four
40158,Local and systemic reactions within 60 days of vaccination
40159,Cell mediated immune responses after undiluted vaccine
40160,Concordance between three results of cell mediated immune response test in recipients of undiluted vaccination
40166,Primary cause of death in betamethasone exposed and placebo exposed groups who died between age 28 days and the 30 year follow up
40169,Outcome at 30 years in betamethasone exposed and placebo exposed groups
40171,Calling incidence and rate of documentation of MET criteria in control and MET hospitals during study period
40172,Primary and secondary outcomes during study period
40175,Outcomes
40177,Treatment comparison by endpoint
40178,Effect of treatment on DMFI, DMFS, and survival by group after adjustment for stage of melanoma or for stage and number of lymph nodes
40179,Reported side effects
40180,Cognitive and educational test scores at age 1718 years
40181,Results of two regression analyses, showing effects on cognitive and educational test performance at age 1718 years of psychosocial stimulation in early childhood and stunting in early childhood
40182,Associations between plasma CRP concentrations and components of the metabolic syndrome
40183,Allelic frequencies for CRP SNPs
40184,Common haplotypes for the CRP region
40185,Comparison of associations between CRP and other variables estimated by linear regression and with instrumental variables   with CRP haplotypes as instruments
40187,6 month survival of patients with severe sepsis subdivided into the major European mtDNA haplogroups
40188,Pathological findings
40189,Overall response rates and final outcomes
40190,The distribution or frequency of neonatal variables in children assessed compared with survivors not assessed
40191,Comparison of the distribution or frequency of neonatal factors among 185 infants included in unpaired analyses
40193,Frequency of death and disability in the study population
40194,Details of the functional outcome grades for children allocated CNEP   n 69   or standard treatment   n 64
40195,Comparison of the measures used to assess behavioural, cognitive and neuropsychological function, and health related quality of life in the two assigned study groups
40196,Number, age specific and age adjusted incidence per 100000 children per year according to features of first ever episodes of convulsive status epilepticus in north London
40197,Numbers of children with first ever episodes of convulsive status epilepticus, according to cause
40198,Components of the metabolic syndrome and anthropometric measures by country and sex in 9 year old and 15 year old children
40199,Correlation between physical activity   mean cpm   and cardiovascular disease risk factors after adjustment for age and sex
40200,Time per day spent at physical activity intensities above 2000 cpm in the five quintiles of physical activity, and the mean intensity
40204,Children with suboptimal outcomes and their corresponding maternal seafood consumption   unadjusted
40205,Maternal seafood consumption and suboptimum childhood outcomes:logistic regression models adjusted for 28 factors
40207,Main and secondary endpoints
40208,Univariate analysis of risk factors for postextubation laryngeal oedema
40209,Multivariate analysis of risk factors for postextubation laryngeal oedema   Cox regression
40210,Adverse events
40215,Percentage of variation explained by univariable and multivariable linear regression models relating KIDSCREEN domains to impairment and pain in children with cerebral palsy
40218,All cause mortality rates
40219,Adjusted treatment effects on mortality rates at day 28
40220,Length of stay in intensive care, days not in intensive care, and pressor free days until day 28 and day 90
40221,Serious adverse events
40226,Distribution of severe and preventable iatrogenic events by category
40231,Recurrence free survival, distant metastasis free survival, and overall survival in the intention to treat population
40232,Recurrence free survival, distant metastasis free survival, and overall survival in patient subgroups
40233,Subgroup analysis in patients with stage III N1   microscopic   disease with only one positive lymph node or with an ulcerated primary melanoma, as indicated on case report forms
40234,Adverse events occurring in 4  or more of patients   grade 3 and 4
40236,HIV specific CD4  and CD8  T cell response frequencies in male vaccine recipients
40238,Interferon  ELISPOT summaries at week 8 for the vaccine group
40239,Results of prespecified interim analysis for the subgroup with Ad5 antibody titre 200 or less   infection and viral load endpoints
40245,Comparison between Apgar score and resuscitation status
40246,Mean verbal, performance, and full scale IQ scores for resuscitated infants, with or without symptoms of encephalopathy
40247,Proportion of low verbal, performance, and full scale IQ scores for resuscitated infants, with or without symptoms of encephalopathy
40248,Probability of low IQ score for resuscitated infants, with or without symptoms of encephalopathy
40249,Difference in mean Weschler intelligence scale for children   WISC III   scores for resuscitated infants, with or without symptoms of encephalopathy, compared with the reference group
40251,Fixed effects for multilevel models of change for fasting glucose, 2 h postload glucose, HOMA insulin sensitivity, and HOMA  cell function before diagnosis of diabetes or the end of follow up
40253,Primary and secondary endpoints and intubation condition for study patients
40256,Physiological variables of patients at entry into the study
40257,Outcome variables, length of stay, and causes of death
40258,Univariate and multivariate analysis of predictors of respiratory failure after extubation
40261,Number of chest radiographs, length of stay, duration of mechanical ventilation, and mortality in intensive care units
40262,Numbers of women by country and method of delivery
40264,Risk of maternal mortality and morbidity by method of delivery
40265,Perinatal outcomes for singleton and first child of multiple births by method of delivery
40266,Perinatal outcomes for singleton and first child of multiple births by fetal presentation at delivery and method of delivery
40270,Main outcome variables
40271,Studies that have used procalcitonin to reduce patient exposure to antibiotics
40273,Selected rare non synonymous variants in genes associated with inherited disease
40274,Pharmacogenomic variants with summary of effects and level of evidence
40275,Pharmacogenomic rare and novel non synonymous damaging variants
40276,Breakdown of admissions to 29 paediatric intensive care units by admission source and type of retrieval team
40277,Casemix for admissions from within the same hospital and from other hospitals to paediatric intensive care
40278,Resource use and outcomes for admissions from within the same hospital and from other hospitals to paediatric intensive care
40279,Casemix for children transported for admission to paediatric intensive care unit   PICU   by specialist and non specialist retrieval teams
40280,Resource use and outcomes for children transported for admission to paediatric intensive care unit   PICU   by specialist and non specialist retrieval teams
40281,Multivariable analysis of the effect on risk of mortality in paediatric intensive care unit   PICU   of additional distance travelled by patients not admitted to the nearest PICU
40282,Global burden of large, rare CNVs
40283,Overlap between CNVs identified in ADHD   IQ 70   and loci implicated in autism and schizophrenia
40285,Primary and secondary outcomes
40286,Case series of patients who died during treatment
40288,Treatment status
40289,Overall and progression free survival   intention to treat population
40290,Primary causes of deaths within the first 120 days after randomisation
40291,Response rates after induction therapy   intention to treat population
40292,Adverse events   safety population
40294,Distribution of patients with low risk and high risk within the quarters according to prediction of complete remission   CR
40296,Clinical outcomes at 30 days
40298,Outcomes for all enrolled patients
40300,Number of patients by worst grade of adverse effects
40301,Number of events and patients by type of adverse event
40302,Differences between the society managed health insurance plans
40303,Age, gender, race, income, and comorbidity distributions for 2008 Medicare decedents
40304,Comparison of patient level mean number of hospital admissions, days in hospital, and days in intensive care for 2008 Medicare decedents, adjusted for age sex, race, income, and comorbidity, who have been admitted to hospital and did or did not undergo a surgical procedure during their last year of life
40305,Comparison of mean adjusted death rate, mean number of acute care hospital beds, mean number of surgeons, and mean total Medicare enrollee reimbursements by regions of high, middle, and low adjusted surgical intensity at the end of life
40308,Adverse events
40310,Primary outcome
40311,Secondary outcomespulmonary outcomes
40312,Secondary outcomesdrug treatments and serious adverse events
40313,CPAP, surfactant treatment, and outcome data from published trials
40316,Adverse events
40317,Modified WHO bleeding scale
40319,Primary and secondary endpoints by treatment and transfusion group
40320,Subtypes of Hodgkin s lymphoma, association with Epstein Barr virus, epidemiology, and clinical features  8
40321,Risk stratification of early stage Hodgkin s lymphoma, by research group
40322,Reductions in 5 year freedom from progression and overall survival relative to score on international prognostic index
40323,Evolution of management of haemorrhagic shock
40324,Topical haemostatic agents
40325,Distribution of maternal BMI category by country and region
40327,Association of maternal BMI category with neonatal mortality at the most recent birth, stratified by timing of neonatal death   n 81120
40328,Summary of conventional bariatric procedures
40329,Guidelines and position statements for eligibility for bariatric surgery in adults with type 2 diabetes
40330,Studies comparing bariatric surgery with conventional medical treatment for type 2 diabetes
40331,Studies that have directly compared two bariatric surgical procedures for remission of type 2 diabetes
40332,Vascular actions of insulin
40333,Randomised controlled trials testing blood pressure goals in patients with diabetes and hypertension
40335,Incidence of death by study group and hazard ratios for mortality in the ADDITION Cambridge trial
40336,De novo variants
40337,Mutations
40338,Missense, nonsense, frameshift, and splice site de novo variants in genes associated with intellectual disability in each patientparent trio
40339,Probable disease causing de novo variants in each patientparent trio
40343,Primary and secondary outcomes
40344,Recommendations for diagnostic procedures
40345,Treatment and prognosis of haematological cancers
40346,Association of IL6R genotypes with levels of inflammation markers and conventional vascular risk factors
40347,Summary effects of tocilizumab   8 mg kg   and the IL6R rs7529229 variant on inflammatory, lipid, hepatic, and haematological biomarkers
40348,Description of cohort
40349,Relation between country and in hospital mortality
40352,Intraoperative data
40353,Postoperative data
40354,Mid term follow up
40357,Adverse event summary   safety population
40359,Univariable and multivariable Cox regression model for first noscomial infection during follow up   primary endpoint
40360,Distribution of nosocomial infections during intervention and follow up
40361,Secondary outcomes during follow up and throughout duration of study
40363,Primary endpoint Bayesian analysis of ASAS20 responders at week 6
40364,Most frequent adverse events seen in more than 5  of patients on secukinumab
40365,Proposed actions to achieve universal health coverage in Bangladesh
40367,Primary and secondary efficacy endpoints
40368,Key clinical trials of red blood cell transfusions
40369,Key clinical trials of platelet transfusions
40370,Medical society clinical practice guidelines for red blood cell transfusion
40371,Medical society clinical practice guidelines for trigger for prophylactic platelet transfusions
40372,Medical society clinical practice guidelines for plasma transfusion
40374,Difference in endpoints between treatment and control units
40375,Microorganisms isolated from bacteraemia and CLABSI episodes, per protocol population
40376,Association between confounders and maternal iodine status
40377,Proportion of children classified as having suboptimum outcomes by maternal iodine status   unadjusted
40378,Risk of suboptimum outcomes in children according to urinary iodine to creatinine ratio    150 g g vs 150 g g  , unadjusted and adjusted for potential confounders
40379,Risk of suboptimum outcomes in children according to urinary iodine to creatinine ratio when the less than 150 g g group was divided into less than 50 g g and 50150 g g
40381,Adverse events by worst grade experienced in the canakinumab trial
40382,The number of events and participants by adverse event type in the canakinumab trial
40384,Adverse events by worst adverse effect grade experienced in the anakinra trial
40385,The number of events and participants by adverse events type in the anakinra trial
40387,Risks of adverse outcomes for patients with laboratory confirmed infection with avian influenza A H7N9 virus who were admitted to hospital
40388,Systemic dysfunctions that impede global governance for health
40389,Clinical interpretation of serological markers of hepatitis B virus infection
40392,Most frequent ICD 10 categories of underlying cause of death for the study cohort of people with intellectual disabilities and for all deaths in England and Wales in 2011
40393,Factors identified as having contributed to the deaths that were significantly different for the intellectual disabilities subset and comparator cases
40394,Composition of study fluids
40398,Adverse events
40402,Adverse events for UNCOVER 2 and UNCOVER 3 pooled
40403,Baseline data for participants without diabetes in 20 large statin trials
40406,Treatment emergent adverse events
40407,Overview of peptic ulcer disease management
40408,Novel techniques or translational innovations for the treatment of perforated peptic ulcer
40410,Outcomes of primary and secondary endpoints
40411,List of cardiac related serious adverse events   as treated population
40412,Basic information about the three health insurance schemes in China
40413,Summary of consolidating health insurance schemes in South Korea, Japan, Taiwan, and Thailand
40420,Infant and maternal outcomes
40421,Prespecified subgroup analyses for neonatal sepsis
40423,Detection of Zika RNA   by RT PCR  , Zika and dengue IgM   by IFA  , Zika IgG   MIA  , and neutralising antibodies
40424,Dengue IgG   by microsphere based immunoassay   and neutralising responses   neut
40425,Zika virus and dengue virus serological patterns associated with Guillain Barr syndrome
40426,Evolution of motor nerve conduction parameters   mean values   after onset of Guillain Barr syndrome
40427,Positive    50    reactivity to glycolipids in sera of patients with Guillain Barr syndrome   n 42   and controls   n 20   in French Polynesia 201314
40429,Endpoint frequency according to central venous catheter allocation   intention to treat analyses   and central venous catheter received   safety analyses
40430,Risk differences and relative effect measures by central venous catheter allocated   intention to treat analyses
40432,Effect of treatment on primary outcome
40433,Effect of treatment on the occurrence of secondary outcomes and severe adverse events
40436,Mixed model analysis with bacterial content as outcome, from all infants whose stools were sequenced in the St Louis cohort and in all cohorts combined
40438,Treatment effect on primary and secondary endpoints
40439,Adverse events
40441,Adverse events
40442,Univariate analyses of EFS and OS
40443,Multivariate analyses of EFS and OS stratified by treatment group
40444,Change in absolute DALY numbers and age standardised rates   per 100000   for mental, neurological, and substance use disorders in China and India between 1990 and 2013, showing disaggregated change in DALY numbers due to population growth, age structure, and change in rates due to other factors
40445,Projected DALYs with uncertainty intervals, China and India, 2013 and 2025
40448,Safety and laboratory data
40452,Overview of treatment emergent adverse events   MedDRA preferred terms   and injection site reactions   MeDRA high level terms   in the safety population
40453,Specialist intensity and weekend mortality, by trust size quintile
40454,Relative odds of in hospital death by day of admission, adjusted for casemix
40457,Main   primary and key secondary  , secondary, and tertiary outcomes in the intention to treat analyses
40458,Grade 1 and 2 reported adverse events
40462,Adverse events, injection site reactions, and hypersensitivity during the on treatment period in the safety population
40467,Adverse events, injection site reactions, and hypersensitivity during the on treatment period   all patients  n 1306
40470,Primary and secondary outcomes
40474,Outcomes of antenatal expressing
40475,Infant and maternal outcomes
40476,Serious adverse events
40479,Adverse events reported in patients in any treatment group during the 52 week treatment period   safety analysis set
40481,Primary and secondary efficacy endpoints at 12 weeks in reSURFACE1 part 1   full analysis set
40482,Primary and secondary efficacy endpoints at 12 weeks in reSURFACE2 part 1   full analysis set
40483,Secondary efficacy endpoints at 28 weeks in reSURFACE1 part 2   full analysis set
40484,Secondary efficacy endpoints at 28 weeks in reSURFACE2 part 2   full analysis set
40485,Summary of adverse events in reSURFACE 1
40486,Summary of adverse events in reSURFACE 2
40488,Mode and attendance of, and satisfaction with, GES
40491,Safety outcomes
40495,Incidence rates   per 100 person years   and HRs for all incident cancers, lung cancers, and non lung cancers
40496,Changes to platelet, leucocyte, neutrophil, and erythrocyte counts after 12 months of treatment
40497,Incidence rates   per 100 person years   of serious adverse events and selected on treatment safety laboratory data
40500,Glycaemic and adverse outcomes of pregnancy trial participants
40501,Obstetric and neonatal health outcomes of pregnancy trial participants
40502,Adverse events in pregnancy trial participants
40503,Linkage disequilibrium between CASR A986S polymorphism and adjacent loci
40504,Biochemical analytes by A986S genotype
40505,A986S genotype and total or ionised calcium concentrations
40506,Regression model for total serum concentrations of calcium
40507,Scintigraphic findings and surgical results
40508,Distribution of skin test reactivity to mite with odds ratios and 95  CIs according to age, sex, tissue helminth infections, total IgE antibodies, and skin test histamine wheal size in 520 schoolchildren surveyed in the Lambarn area
40510,Odds ratios and 95  CIs for skin test reactivity against mite for log transformed concentrations of four immunological factors in a multivariate model
40512,Frequency of solicited symptoms during 4 days after each dose of vaccine   not including dose 4
40513,Lymphocyte proliferative responses 2 weeks after third vaccination
40514,Results of Cox s proportional hazards regression analysis for risk of developing parasitaemia after three doses of vaccine
40515,Comparison of screening for the SRA gene by PCR analysis with characterisation by isolation from a human being, the HSR in vitro test, and RFLP analysis of 70 T brucei sl isolates from Tororo District, Uganda
40518,Biochemical features of the two patients
40519,Adjusted odds ratio for type of grass pea foods consumed during neurolathyrism epidemic in Delanta Dawint district
40521,Experimental design and results
40523,Parasitological and clinical outcomes in children younger than 5 years at days 14 and 28 after treatment
40524,Difference in clinical and parasitological outcomes between each group and the next best group
40525,Parasitological failure rates in year 1, corrected for reinfection assessed by msp2 PCR genotyping
40526,Development of fluorescence in the extracellular presence of 10 mol L DB99 in various cell lines
40527,Drug sensitivity of P falciparum isolates in Cambodia, French Guiana, and Senegal
40528,Effect of MDA on filariasis infection variables
40529,Effect of MDA on antifilarial antibody prevalence rates in primary schoolchildren
40530,Effect of MDA on mosquito infection rates
40532,Cumulative and additive effects of co trimoxazole prophylaxis, antiretroviral therapy, and bednets on the incidence of malaria in HIV infected adults, Uganda, 20012005
40536,Parasitological response to treatment by day 28
40538,Haematological and biochemical values in parasitaemic study women at enrolment and at days 14 and 28 after treatment
40539,Reporting of adverse effects
40540,Perinatal and postpartum outcomes
40541,Number of individuals reporting possibly or probably related solicited adverse events
40542,Clinical applications of factors affecting bone repair
40544,HR for development of adverse effects for subgroups of patients with at least two measurements of lithium concentration, by main effects, two factor interactions, and risks
40545,HR for renal failure, hypothyroidism, hyperthyroidism, and high serum calcium   total or adjusted   concentrations in patients taking lithium, by age, male sex, serum median lithium concentration, length of time between first and last lithium measurements, and diabetes
40546,Association of lymphatic filariasis status and other covariates with HIV incidence
40547,Influence of different factors on HIV incidence stratified by age
40548,Effect of HIV risk factors on the association between lymphatic filariasis and HIV incidence
40551,Adverse events in the safety set
40552,Comparison of livebirth rates by age of woman?
40553,Livebirth rates per embryo transfer in women who used their own eggs and women who received donated eggs
40554,Livebirth rates by duration of infertility
40555,Livebirth rates by cause of infertility
40556,Effect of previous pregnancies   including livebirths   on livebirth rates
40557,Livebirth rates by number of previous unsuccessful IVF attempts
40558,Multiple logistic regression for predicting probability of a livebirth
40560,Logistic regression of factors associated with serious reactions to ivermectin
40561,Transmission of forest strain and savanna strain O volvulus by sibling species of S damnosum s l
40564,Maximum and average pain relief and number of responders by diagnostic group
40566,Crude and adjusted odds ratio of ocular hypertension or open angle glaucoma by past exposure to oral glucocorticoids
40567,Outcome in women receiving ACE inhibitors in early pregnancy
40569,Incidence of cytomegalovirus disease
40570,Cytomegalovirus disease in risk groups
40571,Adverse events
40572,Adjusted distribution of causes of blindness by definition
40573,Apparent adjusted distribution of causes of blindness without visual field and detailed dilated fundus assessments
40574,Effect of age, socioeconomic status, sex, and religion on rate of blindness in univariate analysis
40575,Effect of age, socioeconomic status, sex, and religion on risk of blindness in multivariate analysis
40576,Percentage of total blindness by age group
40580,Clinical and laboratory severe adverse events
40581,Mortality rates by treatment group and CD4 cell count at enrolment
40582,Hospital admission rates by treatment group and CD4 cell count at enrolment
40583,Frequency of hospital admission for specific diagnoses, by treatment group
40584,Clinical and hormonal features of patients with idiopathic spermatogenic disorders
40586,Adult death rates adjusted for exponential population growth in Mumbai, India
40588,Univariate comparisons of reproductive histories of cases and controls
40589,Number of full term pregnancies versus nulliparity
40590,Timing of pregnancies in relation to breast cancer diagnosis
40593,Immunohistological and PCR based comparison of onchocercomata
40595,Outcome
40596,Cox regression analysis
40597,IBCSG trials I, II, V, and VI: study designs and drug reatments
40599,Disease free survival and overall survival comparisons according to age at randomisation in IBCSG trials I, II, V and VI
40600,Cox s proportional hazards regression models stratified by trial for patients with known oestrogen receptor status   n 3098
40601,9 month landmark analysis of disease free survival and overall survival according to age at randomisation for subpopulations defined by amenorrhoea status and oestrogen receptor status
40603,BRCA1 and BRCA2 test use in relation to sex, age, parenthood, and genetic risk
40604,Choices of unaffected carriers
40606,Tuberculosis recurrence rates
40608,Factors associated with treatment of first breast cancer
40609,Association between tamoxifen, oophorectomy, chemotherapy, and radiotherapy and risk of contralateral breast cancer
40610,Odds ratio   95  CI   for contralateral breast cancer, associated with treatment, by time since primary breast cancer
40612,Multivariate analysis of risk factors for ARF
40614,Patient management and outcomes
40615,Univariate correlation and values of variables from history for clinically important brain injury
40616,Univariate correlation values of variables from mechanism of injury for clinically important brain injury
40617,Univariate correlation and values of variables from examination for clinically important brain injury
40618,Model developed by stepwise logistic regression analysis to predict clinically important brain injury
40619,Summary of 58 potential cases of congestive heart failure
40622,Congenital anomalies in study and control groups
40623,Mean   SD   scores on the Griffiths scales
40624,Neurodevelopmental outcomes of case children according to paternal sperm analysis
40625,Congenital anomalies in study group according to whether the father had oligozoospermia
40628,Outcome data
40630,Variation in chimerism of CD3  T cell and peripheral mononuclear neutrophils   PMN   in two patients after infusion of allodepleted cells
40632,Residual proliferation of allodepletion tested against recipient peripheral blood mononuclear cells   PBMCs  , third party PBMCs, and bacterial and viral antigens for the same patients as  figure 2
40634,Immune reconstitution after haemopoietic stem cell transplantation   HSCT
40636,Results of round 2 nodulectomies in August to September, 1997
40637,Results of round 3 modulectomies in May to June, 1998
40638,Results from round 4 nodulectomies in November, 1998
40640,Standardised incidence ratios   SIRs   of ovarian cancer in 30552 women diagnosed with breast cancer
40641,Estimates of absolute risk of developing ovarian cancer within 30 years of breast cancer diagnosis
40642,Clincal features of 45X 46XY patients with deletion of AZFc
40643,Buprenorphine dose regimens for control and treatment groups
40646,Frequency of chlamydia by age
40647,Hormone concentrations of patients with chronic pain
40648,Pituitary gonadal axis hormones in patients with chronic pain
40649,Summary of data on mortality and blindness obtained by the OCP from 1971 through 2001
40650,Analysis of deviance for Poisson regression between the expected number of deaths in the complete OCP dataset   19712001   and covariates
40651,Relative risks from fit of log linear Poisson model to host mortality data   with allowance for overdispersion   overall, in pre ivermectin data, and restricted to those with non zero microfilarial load
40655,Clinical details of patients with mtDNA deletion disorders
40656,Clinical symptoms and signs of patients
40657, 18F CFT uptake values
40658,Oxygen consumption and biochemical activities of respiratory chain enzymes in isolated muscle mitochondria
40659,Cumulative yield of M tuberculosis from repeated induced sputum or gastric lavage specimens
40663,Risk factors associated with disease free survival, survival, treatment related mortality, relapse, acute GVHD, chronic GVHD, and neutrophil engraftment after unrelated donor bone marrow transplantation, by Cox proportional hazards regression
40665,Intervention coverage by treatment group
40666,Umbilical cord infection by treatment group
40667,Umbilical cord infection by treatment group stratified by timing of intervention and skin cleansing trial intervention
40668,Neonatal mortality by treatment group
40669,Neonatal mortality by treatment group stratified by timing of intervention and skin cleansing trial intervention
40671,Days of exposure to individual antiretroviral agents    90 days of treatment   in individuals on HAART at diagnosis of Kaposi s sarcoma
40672,Univariate Cox regression analysis and log rank tests
40673,Validation of coefficients in Cox analysis of KS data   HAART era
40674,Probability of survival   95  CI   by prognostic score and from diagnosis of Kaposi s sarcoma
40679,Adverse events occurring in more than one case
40681,Summary of studies showing distribution of smear negative pulmonary and extrapulmonary tuberculosis in HIV positive patients
40682,National tuberculosis control programme recommendations of selected countries for diagnosis of smear negative pulmonary tuberculosis
40683,CMFL and nodule and microfilaria prevalence rates for O volvulus, before treatment and 1 month after ivermectin treatment, in 20 onchocerciasis endemic communities in Ghana
40684,Geometric mean densities   microfilaria per skin snip   of O volvulus before treatment and at different times after treatment in ten onchocerciasis endemic communities in Ghana
40685,Distribution of microfilaria counts at day 7, day 90, and day 180 in the study communities
40687,Protocol adherence and sedative use
40688,Main outcomes
40689,Results of the spontaneous awakening trials and spontaneous breathing trials
40691,Safety summary by treatment group
40693,Notified proportion of drug resistance in new tuberculosis cases tested for resistance to at least isoniazid and rifampicin in 83 countries or territories, by WHO region
40694,Notified proportion of drug resistance in previously treated tuberculosis cases tested for resistance to at least isoniazid and rifampicin in 83 countries or territories, by WHO region
40695,Estimates of multidrug resistant   MDR   tuberculosis in 2006 by epidemiological region
40698,Follow up successful outcomes in surgical and non surgical groups
40702,ICD 9 and ICD 10 codes used to identify disease outcomes
40703,Incidence of disease events that might be temporally associated with vaccine, by country and age group
40704,Mortality by country, age, and sex   2006    30
40705,Rates of spontaneous abortion by country, surveillance year, and age group
40706,Selected rates of preterm labour or delivery    37 weeks gestation  , by country and year
40713,Drugs used in treatment regimens for patients   n 174   with extensively drug resistant tuberculosis
40714,Cox proportional hazards regression model of factors associated with risk of death in all patients given treatment for extensively drug resistant tuberculosis, and in HIV infected patients only
40715,Adverse drug reactions   n 161   in 67 of 115 patients from the Western Cape, Northern Cape, and Gauteng provinces started on treatment for extensively drug resistant tuberculosis
40719,Serious adverse events
40720,Randomised controlled trials of substitution treatment with a supervised injectable opioid versus an oral opioid for treatment of opioid dependence
40722,Direct medical costs
40724,Descriptives of disease free survival events and causes of death in the intention to treat population
40725,Adverse events
40728,Clinical adverse events
40730,Cox regression analyses of mortality among men
40731,Cox regression analyses of mortality among women
40732,Cox regression analyses of mortality among participants with some form of substance abuse
40734,Incidence of omphalitis
40735,All cause neonatal mortality
40739,Adverse events
40741,Conventional drugs used in the treatment of systemic lupus erythematosus
40744,Treatment effects at 14 weeks, 6 months, and 12 months
40745,Treatment effect modification on primary outcome at 14 weeks
40747,Trial process measures
40748,Secondary outcomes during study follow up
40749,Concomitant drugs used in weeks 14 and weeks 512
40750,Concomitant health services used in weeks 14 and weeks 512
40752,Participant flow through the vaccination schedule
40753,Completers of hepatitis B vaccination schedule and outcome analysis
40754,Own and cross price elasticities of demand for ten beverage categories
40759,Number and percentage of patients with adverse events of interest during period 2 by treatment group
40762,AEs during the overall study period      in the safety population
40765,Rate of new and enlarging T2 lesions between over 0 to 25 months and relapse rate over 0 to 24 months
40766,Adverse events
40769,Clinical outcomes measured at 1 month after release from incarceration.
40770,Cost associated outcomes measured at 1 month after release from incarceration
40771,Distribution of 5580 deaths and 249 million person years at risk in the overall cohort
40772,MRR according to age at first diagnosis of ADHD, compared with those without ADHD at same age
40773,Mortality rate ratios in individuals with ADHD in combination with oppositional defiant disorder, conduct disorder, or substance use disorder compared with individuals with none of the four disorders, in the overall cohort
40774,Sensitivity analysis showing MRR according to age at first diagnosis of ADHD, compared with people without ADHD
40776,Outcomes
40777,Adverse events
40779,All breast cancer, invasive, and DCIS recurrences according to treatment allocation
40780,Frequency of cancers other than breast according to treatment allocation
40781,Adverse events reported at any time according to treatment allocation
40783,Ovarian and primary peritoneal cancers grouped by primary site and screening status
40784,Summary of analyses of relative reduction of ovarian and primary peritoneal cancer deaths
40786,Diagnostic accuracy of urine LAM test
40787,Effects of urine LAM guided initiation of tuberculosis treatment on 8 week all cause mortality
40788,Anti tuberculosis treatment
40792,Grade 3 or higher laboratory events by week 24
40793,Mean per annum S DDD and DDD use worldwide, regionally, and at the country level in the years 200103 and 201113, ordered by 201113 S DDD use, and absolute changes in use
40794,Impediments in relation to availability of opioid analgesics
40798,Primary and secondary outcomes
40802,Adverse events
40804,Overview of incidence of treatment emergent adverse events by treatment at adverse event onset by system organ class
40805,Numbers of laboratory confirmed MenB cases for five comparable annual time periods in England in cohorts eligible and non eligible for 4CMenB vaccination and estimates of vaccine impact from different comparison models
40807,Previous biological treatments
40809,Adverse events through week 24 and week 52
40811,Analysis of mRS
40812,Analysis of secondary outcomes at months 3 and 6
40814,Relapse and mortality by treatment group
40815,Local relapse, second cancers, and deaths by treatment group
40816,Patient assessments of moderate or marked late adverse events
40817,Clinician assessment of moderate or marked late adverse events
40819,Adverse events
40821,On treatment serious adverse events of special interest
40823,Parents  report of vaccine associated reactions during first 48 h after vaccination
40824,Hib polysaccharide antibody concentrations
40825,Geometric mean antibody concentrations   with 95  CI   at age 7 months
40827,Number of cramps and cramp days during qualification, treatment, and washout periods
40828,Side effect
40829,The Expanded Programme of Immunisation schedule recommended by the Gambian government
40831,PRP antibody concentrations in infants before and 1 month after receiving their third dose of PRP T vaccine or placebo
40832,Cases of confirmed invasive Hib disease by vaccination status and diagnosis
40833,Episodes of pneumonia in all children enrolled and in fully vaccinated children by pneumonia definition and vaccine group
40834,Hib disease in infants after receipt of one dose of PRP T: comparison of convalescent PRP antibody concentrations in matched pairs discordant for tetanus toxoid priming
40835,Efficacy of vaccination with Hib conjugate vaccine in the UK
40836,Seroconversion rates 1 month after last injection
40839,Events that occurred from 72 h to day 31
40840,Events occurring in patients who completed the minimum 72 h active treatment
40841,Outcome of patients given tetanus toxin contaminated pertussis immune serum
40843,Relative risk of pertussis at randomisation and the third dose, in the 3 months, 5 months, 12 months schedule for the three component and five component vaccines compared with whole cell vaccine
40844,Relative risk of pertussis from randomisation at the first dose, and between the second and third dose in the 3 months, 5 months, 12 months schedule for the three component and five component acellular vaccines, and for the whole cell vaccine compared to the two component vaccine
40845,Relative risk of parentally reported whooping cough from first trial dose   RR   to October, 1996
40846,Breast and testicular cancer cases by zygosity, sex of co twin, and age
40847,Odds ratios for breast and testicular cancers in relation to zygosity, by age, based on zygosity identified from questionnaire, and estimated zygosity for all twins
40848,Relative risks of breast and testicular cancers in same sex twins of probands with these cancers, by zygosity, 197192
40849,Relative risks of breast cancer in female twins of probands with this cancer by age of twin, and risk in non twin sisters of women with breast cancer at young ages
40850,Relative risks of breast cancer in female twins of probands with this cancer by time since diagnosis in proband
40851,Maternal mortality ratios   MMR   in MCH FP and comparison area
40852,Maternal mortality due to direct obstetric causes by area and period
40854,Serum antibody concentrations against capsular polysaccharide of Haemophilus influenzae type b   PRP   in Chilean infants given different primary immunisation regimens of PRP T and PRP CRM197 conjugate vaccines
40855,Persistence of serum PRP antibody at 12 months of age and evidence of immunological memory assessed by inoculation with purified PRP polysacharide as an antigenic challenge that simulates natural infection with virulent Haemophilus influenzae type b
40857,Frequency of responders and non responders poor responders to PPS antigen and conjugated tetanus haemophilus type b antigen
40858,Serum IgA, IgG1, and IgG2 concentrations in PPS antigen responders and non responders   all ages
40859,Additional table: PPS and Hib antibody concentrations prevaccination and post vaccination and total serum IgG, IgG1, IgG2, and IgA in paediatric cardiac transplant recipients
40860,Vitamin A status of infants by visit in Ghana, India, and Peru
40861,Point prevalence of acute lower respiratory infections and diarrhoea during previous 24 h up to age 9 months
40862,Rates per child year of clinic visits and hospital admissions in infants aged up to 9 months
40863,Percentage of infants with bulging fontanelle within 48 h of administration of study dose
40866,Reasons for dropping out of study and stopping treatment
40870,Adverse events significantly associated with interferon  1b treatment
40872,Signs in children with atopy
40873,Patient s plasma biochemistry on admission to hospital
40875,Primary clinical endpoints by diagnosis
40877,Severity of coronary disease by number of protected regions
40878,Serious adverse events
40879,Comparison of proportion       of investigator and independent scores in each CCSA class at 12 months
40880,Incidence of Hib meningitis in Gambian children less than 1 year of age
40881,Adult HUS TTP cases
40882,Reasons for patients not receiving TPE
40886,Distribution of  thalassaemia in nine hospitals in Sri Lanka
40887, globin genotype and  thalassaemia frequencies in  thalassaemia major and  thalassaemia carriers attending thalassaemia clinics in Sri Lanka
40888,Preliminary population screen
40889,Consequences of the common thalassaemia mutations in Sri Lanka
40891,Spearman s rank correlation coefficients between nave T cells and numbers of TREC
40898,Number of adverse events of all intensities
40899,Cardiac diagnoses and surgical procedures
40901,Mean postoperative changes in echocardiographic variables
40903,Electrocardiographic, radiographic, and Holter data
40904,Reinterventions in 198595
40905,Multivariate analysis of predictors of ventricular tachycardia, sudden death, and atrial flutter fibrillation after repair of tetralogy of Fallot
40906,Advantage of butyrate over placebo in the treatment of ARP
40907,Sonographic findings in mountain bikers and healthy controls
40911,Trends in age adjusted death certification rates per 100000 men from testicular cancers
40912,UGT1       1 promoter genotype, bilirubin, and gallstones in patients with HbE thalassaemia
40913,Cancer familial index by site
40914,Immunisation status in adopted and Dutch children
40915,Poliomyelitis antibodies in adopted and UK children
40916,Standardised mortality odds ratios   SMORs   of selected medical disorders in people with Down s syndrome
40917,Standardised mortality odds ratios   SMORs   and observed number of deaths from selected medical disorders among people with Down s syndrome
40918,Standardised mortality odds ratios   SMORs   and observed number of deaths for selected cancer types
40922,Adverse events
40927,Paired comparisons of heart and liver iron content and indices of left ventricular function
40928,Comparison of the desferrioxamine control group with a larger population of patients with thalassaemia major treated with subcutaneous desferrioxamine
40929,Periods of diagnosis and follow up included in most recent estimates of survival obtained by cohort and period analysis
40930,Most recent cohort and period estimates of relative survival rates, by sex
40931,Most recent cohort estimates of relative survival rates, by cancer site
40932,Most recent period estimates of relative survival rates, by cancer site
40933,Concentrations of mercury in blood, urine, and stool of infants who received vaccines containing thiomersal and those who did not
40935,DTaP Hib doses received by children with Hib and controls matched for date of birth
40937,Oral glucose tolerance test
40938,Study design, age of administration of vaccines, and mortality in trials of HTMV
40939,Mortality rates and female male mortality ratios between 4 and 10 months of age in the HTMV trial
40940,Mortality rates in HTMV recipients and controls according to whether they received additional DTP IPV or IPV vaccinations at age 910 months
40941,Female male mortality ratios in recipients of EZ HT measles vaccine used in routine immunisation according to number of additional DTP IPV vaccinations received after measles vaccine, Senegal, 198994
40942,DTP3 verification factors for seven countries from DQA s
40943,Primer and probe sequences for real time PCR
40944,Genes differentially regulated after preconditioning
40945,Genes differentially regulated after injurious ischaemia
40946,Genes differentially regulated after preconditioning followed by injurious ischaemia
40947,Validation of gene regulation by real time PCR
40948,Genes regulated suggestive of neuroprotective aspects of hibernation and hypoxia tolerant states
40949,Detection of unmethylated XIST DNA fragments in plasma and tumour tissue
40951,Prevalence of congenital cryptorchidism according to clinical subtypes
40952,Prevalence of cryptorchidism at expected date of delivery stratified by birthweight
40953,Prevalence and risk of cryptorchidism at expected date of delivery in Finnish and Danish boys, with respect to birthweight, gestational age, and weight for gestational age
40954,Prevalence of congenital cryptorchidism in total Finnish hospital cohort at expected date of delivery and at 3 months of age stratified according to birthweight, gestational age, and weight for gestational age
40957,Incidence of clinical events
40958,Incidence of combined endpoints
40961,Association between vaccination and death from infectious or respiratory disease   Cox model with time dependent covariates
40963,Cox time dependent survival model for infants aged 960 months
40964,Association between mortality and age at BCG vaccination
40965,Technical outcome of first procedure
40966,Clinical outcome at 2 months and 1 year
40967,Causes of death
40968,Angiographic occlusion of target aneurysm on first follow up angiography done after treatment
40969,Confirmed rebleeding from target aneurysm
40970,Seizure occurrence by treatment allocation
40972,Incidences of vaccine preventable Hib pneumonia
40973,Incidences of vaccine preventable Hib meningitis
40974,Vaccine preventable Hib mortality
40975,Comparison of four studies that investigated the effect of Hib conjugate vaccine on pneumonia outcomes
40978,Proportion of preterm births and babies of low birthweight by type of delivery and year
40979,Neonatal mortality rates by birthweight and gestational age
40980,Classification of patients
40981,Frequencies of V 24 invariant NKT cells according to disease activity, category, and corticosteroid use
40985,Donor lymphocyte infusions in individual patients: dose and response
40988,Interleukin 10 to interferon ratio deduced from epitope specific cytokine production of PBMC of patients with oligoarticular and polyarticular juvenile idiopathic arthritis, respectively, in active disease and disease remission
40989,MHC binding assays
40990,Vaccine efficacy against Hib disease after one, two, and three doses of vaccine
40992,Coverage of each child survival intervention, by country
40993,Number and distribution of interventions received by children, by country
40994,Summary of equity results, by country
40996,Protective efficacy of pneumococcal protein D conjugate vaccine for time to first occurrence of acute otitis media during per protocol and intention to treat follow up
40997,Protective efficacy of pneumococcal protein D conjugate vaccine for any episode of acute otitis media during per protocol follow up
40998,Carriage of S pneumoniae and H influenzae in nasopharyngeal swabs taken at 1518 months of age
40999,Serum concentrations of antibodies against individual pneumococcal vaccine serotypes and protein D one month after the third protein D conjugate vaccine dose and before and 1 month after booster vaccination
41002,Global response
41003,Adverse events and laboratory abnormalities
41008,Most frequently reported adverse events
41012,Primary and secondary outcomes
41013,Adverse events reported throughout hospital admission
41015,Effectiveness of one or more doses of pneumococcal conjugate vaccine against invasive disease in children 359 months of age by pneumococcal serotype and the presence of chronic illnesses or immunocompromising disorders
41016,Effectiveness of one or more doses of pneumococcal conjugate vaccine against invasive disease in children aged 359 months by pneumococcal serotype
41017,Effectiveness of pneumococcal conjugate vaccine against invasive pneumococcal disease caused by vaccine serotypes in children aged 359 months by number and timing of doses, compared with no vaccine
41018,Direct comparison of different vaccine schedules for risk of invasive disease caused by serotypes included in the seven valent pneumococcal conjugate vaccine
41019,Model assumptions for countries eligible for support from the Global Alliance for Vaccines and Immunization, by under 5 mortality rate per 1000 births
41020,Projected outcomes of pneumococcal conjugate vaccination in 72 low income countries, by under 5 mortality rate per 1000 births
41021,DHS country years and vaccination coverage
41022,Means of variables
41023,Multiple regression equations
41026,Adverse effects
41029,Vaccine efficacy from 14 days after third dose   month 3   of Engerix B or RTS,S AS02D until visit at month 6
41032,Asthma exacerbations by Gly16Arg genotype for each study
41038,Overview of adverse events
41039,Most common adverse events   occurring in four or more patients
41041,Clinical responses at week 12 and week 28 as reported by physicians and patients
41043,Adverse events during the three phases of the trial
41045,Discontinuation of study medications and selected reasons for permanent discontinuations
41046,Components of the primary outcome
41047,Other secondary events and hospitalisations
41048,Combined analyses of the results of TRANSCEND and PRoFESS trials comparing telmisartan with placebo
41049,Regression results with the dependent variable as officially reported coverage minus survey based coverage
41053,Adverse events
41055,Quality of data for DTP1, by child s age at interview, for surveys with data for children aged up to 5 years
41056,Target ages and median   IQR   for estimated coverage at different ages across 45 countries
41057,Variation between countries in estimated coverage for BCG, DTP1, DTP3 and MCV1, and in opportunities taken
41058,Delay in vaccination   weeks  , showing variation between and within countries, across children in a country sample
41060,Patients with endoscopic lesions at 12 weeks
41061,Adverse events
41063,Cross tabulation of radiation doses to uterus and ovaries for survivors of childhood cancer
41064,Association between organ specific radiotherapy doses and risk of stillbirth or neonatal death in offspring of survivors of childhood cancer
41065,Association between radiotherapy doses to uterus and ovaries and risk of stillbirth or neonatal death in offspring of survivors of childhood cancer
41066,Association between chemotherapy with alkylating drugs and risk of stillbirth or neonatal death in offspring of female and male survivors of childhood cancer
41068,Treatments given
41069,Burden of infectious diseases for India in 2004 according to estimates from the Global Burden of Disease Study  16
41070,Effect estimates for interventions before pregnancy, during pregnancy, and at birth to reduce maternal and neonatal deaths and stillbirths
41072,Cost per death averted in 2015 with implementation of intervention packages at 99  coverage
41073,Priorities for reduction of stillbirths and maternal and neonatal deaths according to stillbirth rates in 2015
41074,Rankings of research priorities for implementation of interventions to reduce stillbirths in low income and middle income countries by 2015
41076,Enrolment by study site for random assignment on day 5
41078,Outcomes by study group
41079,Organisms identified at the time of enrolment by treatment
41080,New drugs for hypertension
41082,Estimates of CSF penetration of antibiotics used for the treatment of bacterial meningitis  8,9
41083,Recommended antibiotics in patients with community acquired meningitis by result of cerebrospinal fluid Gram stain
41084,Antibiotics for bacterial meningitis after microorganism identification and in vitro susceptibility testing
41086,Cardiovascular events   fatal and non fatal   and causes of death
41087,Hazard ratios by plasma ADMA concentration
41088,Cox s proportional hazard models for all cause mortality and fatal and non fatal cardiovascular events
41089,Estimates of risk reduction for stroke and myocardial infarction for a given difference in systolic blood pressure
41092,Previous Cardiovascular Therapies by Drug Class  a
41100,Clinical, Angiographic, and Intravascular Ultrasound Findings in Patients With CANs
41102,IVUS Data of Coronary Aneurysm According to Clinical Outcome
41108,Association Between Metabolic Syndrome and Systolic and Diastolic Echocardiographic Abnormalities in Adult Survivors of Childhood Cancer
41110,Population With Central Measurements   n   181  : Main Cardiovascular Parameters: Adjusted Absolute Means  Standard Error of Means Are Presented at M0, M6, M12
41112,Factors Modulating Brachial and Carotid Adjusted SBP Changes       Under Drug Treatment: Stepwise Linear Regressions for Brachial   Upper Panel   and Central   Lower Panel   Measurements
41113,Major Limitations to Angiotensin Converting Enzyme Inhibitor Use
41114,Baseline Characteristics of Patients With Heart Failure Treated With and Without ACEIs
41115,Discharge Medications in Relation to ACEI Use or CRLimit
41117,Medication Use in Heart Failure Cohort Based on Provider Type
41118,Medication Use   Based on Underlying Comorbidity
41119,Unadjusted Deaths and CV Hospitalizations
41120,Cox Proportional Hazards Analyses for Predicting Death or Cardiovascular Hospitalization
41128,Mortality Before Surgery
41134,Adverse Events for All Randomized Patients
41135,ICD Therapy Analysis
41142,Procedural Technique and Angiographic Outcomes of the Study Population
41143,3 Year Target Lesion Failure and Scaffold Thrombosis Rates According to Technique
41144,1 Year Target Lesion Failure and Scaffold Thrombosis Rates According to Technique
41145,1  to 3 Year Target Lesion Failure and Scaffold Thrombosis Rates According to Technique
41154,Outcomes Through 30 Days   N  100
41155,Key Complications
41156,Computed Tomographic Findings
41162,Univariate Correlation of Augmentation Index   Correlation Coefficient, p Value    legend
41163,Partial Regression Coefficients   All Subjects, n   262   for Forward Stepwise Linear Regression for Dependent Variables Augmentation Pressure and Augmentation Index    legend
41165,Echocardiographic and CMRI Measurements of Athletes and Nonathletes With and Without ATWI
41167,Procedural Characteristics in Patients Undergoing CTO PCI
41168,Imaging Outcomes
41169,Adjudicated Clinical Outcomes From Randomization to 4 Month Follow Up
41171,Indications for Concomitant Mitral Valve Surgery   N 174
41173,Comparison of Patients Who Underwent Surgery With Single CPB Versus 2Periodsof CPB
41175,Imaging Modality Used for Initial Diagnosis
41176,Predictors of TEC
41177,Definition of ECG Abnormalities in Athletes According to the 2010 ESC Recommendations    3   , Seattle Criteria    2   , and Refined Criteria    7
41178,Cost and Frequency of Additional Investigations Following Abnormality in History and Physical Examination, or ECG
41180,Location of Aneurysm and Dissection
41181,History and Clinical Presentation of Patients with FMD
41182,Therapeutic Procedures and Complications
41184,CMR and Cardiac MRS Findings
41185,Liver Assessments
41186,Recommendations for the Diagnostic Evaluation, Follow Up, and Timing of Surgical AVR in Patients With Asymptomatic, Severe, High Flow, High Gradient AS
41187,Observational Studies of Patients With Asymptomatic Severe AS
41188,Predictors of Adverse Events at Follow Up in Patients With Asymptomatic Severe AS
41189,Abnormal Stress Test Among Large Observational Series of Asymptomatic AS
41192,Studies Evaluating BNP in AS
41193,Theoretical Pros and Cons of Early AVR in Patients With Asymptomatic Severe AS
41195,INTERMACS Profiles and Interventions
41196,Laboratory and Hemodynamic Data
41197,Adverse Events
41202,Gastrointestinal and Cardiovascular Clinical Endpoints
41203,Kaplan Meier Estimates of Event Rates at 180 Days Post Randomization
41207,Determinants of Long Term Mortality
41208,Determinants of MR Recurrence for the Entire Cohort
41209,Transition Specific Determinants of MR Recurrence
41213,Clinical Outcomes at 1 and 2 Years After Self Expanding TAVR
41214,All Cause Mortality or Major Stroke for Select Subgroups
41216,Distribution of Number of Visits and Follow Up Time by Age Group
41228,Summary of Initial Programming
41229,All Type I to III Complications
41230,Animal Study Design
41232,Pre Operative Risk Factors
41234,Adverse Events Through 6 Months
41238,Biomarker Profile of HFpEF Patients With and Without Diabetes
41239,Ventricular and Vascular Remodeling and Function in HFpEF Patients With and Without Diabetes
41240,Indications and Highest Level of Evidence for ECMO in Cardiopulmonary Disease
41243,Hypothyroid Myopathy and Response to Hormone Replacement Therapy
41244,Development of Statin Induced Myopathy and Response to Treatment
41245,Results of Investigations in Ambulatory Patients
41247,Comorbidities and Frailty   N   489
41248,Disability Assessments   N  489
41249,Clinical Outcomes at 30 Days and 12 Months
41252,International Registry of Acute Aortic Dissection Pre operative Prediction Model Variables
41253,Operative Parameters
41254,30 Day In Hospital Adverse Events
41255,Biomarker Correlation
41256,Cardiovascular Outcomes and HRs
41257,Prognostic Discrimination
41258,Reclassification for CV Death or HF at 1 Year
41259,Biomarkers and Adjusted Risk of Cardiovascular Outcomes
41261,Left Ventricular Echocardiographic Profile at Diagnosis in Children With Idiopathic DCM and Abnormal Left Ventricular Function and Dilation at Diagnosis   N  741  , by Echocardiographic Status or Clinical Outcome Within 2 Years After Diagnosis
41262,Left Ventricular Echocardiographic Profile From Time of Cardiomyopathy Diagnosis to 2 Years in Children With Idiopathic Dilated Cardiomyopathy and Abnormal Left Ventricular Function and Dilation at Diagnosis   N  741  , by Echocardiographic Status or Clinical Outcome Within 2 Years After Diagnosis
41264,Study Endpoints for Safety and Performance of the NeoChord DS1000 Device   for Treatment of Mitral Regurgitation Due to Isolated Posterior Leaflet Prolapse
41266,MAEs in the Entire Patient Cohort as Well as in the Latter 15 Patients Who Underwent Implantation Through a Posterolateral Approach
41267,Post Procedure MR2  and 30 Day MR2  Results for the Entire Cohort of Patients, Patients Who Underwent Implantation of Multiple Neo Chordae, and Patients Who Underwent the Procedure Using a Posterolateral Approach on the Cardiac Apex
41271,Relationship Between IPST and Subsequent 48 Hour and 30 Day Adverse Ischemic Events
41272,Relationship Between IPST and Subsequent 48 H and 30 Day Adverse Ischemic Events in Patients With PostPCI TIMI Flow Grade 3
41273,Association Between IPST and Subsequent 48 Hour Bleeding Events
41274,Adverse Events in CDC Treated and Control Patients
41276,Efficacy Endpoints Through 7 Days and 30 Days
41277,Bleeding Endpoints Through 7 Days and 30 Days
41278,Patient Characteristics
41279,Predictors of MACE in Univariate and Multivariate Cox RegressionAnalysis
41280,C Statistics: Additive Prognostic Value of CMRMarkersofMyocardial Damage
41282,Univariate Predictors of Resuscitation Outcome
41284,PK Profile of Clopidogrel Active Metabolite in Diabetic and Nondiabetic Patients
41286,Serial Echocardiographic Assessment of the Effects of LVAD Unloading on Myocardial Structure and Systolic Function
41288,Imaging Follow Up
41289,PmMR Findings Compared to Autopsy Findings in 76 Forensic Cardiac Cases
41290,Review of the Literature on Abdominal Alterations Underlying Cardiorenal Dysfunction in Congestive Heart Failure
41292,Electrocardiographic Findings
41293,Cardiac Hemodynamic Parameters
41296,Summary of the Primary Hypothesis: the Diagnostic Performance of the Current Guideline   no rule out at 0 h   Versus a Negative Troponin in Conjunction With a Negative Copeptin for Early Rule Out
41301,Cox Proportional Hazards Regression Analysis Evaluating the Risk of All Cause Mortality Associated With the Change in cTnI Levels in a Model Adjusted for Established CV Risk Indicators   n   806
41308,Mechanism of Aortic Regurgitation
41309,Aortic Valve Calcification
41310,Procedural Results
41311,Clinical and Safety Outcomes According to VARC
41312,Comparison of Secondary Prevention Risk Factor Targets by Trial
41318,Microbiological Data of the 152 Patients With Infection
41319,Echocardiographic Data Related to the Duke and Sohail Criteria
41320,Localization and Dimension of Intracardiac Masses in Patients With Positive ICE and Negative TEE
41323,Guideline Recommendations for Surgery for Degenerative Mitral Regurgitation
41324,Mortality of Asymptomatic Patients With Degenerative MR Without Surgery
41325,Guideline Recommendations for Surgery for Functional MR
41326,Guideline Recommendations for Surgery in Patients With Aortic Regurgitation
41330,Clinical and Electrocardiographic Data of Affected   ER    and Unaffected   ER   Patients in 4 Families
41331,VM in Affected and Unaffected Patients at Rest
41332,Bleeding Definition
41335,In Hospital and Follow Up Clinical Outcomes
41339,Cause of Death: Number of Patients     of Total Mortality
41341,Logistic Regression Model for Determination of Propensity Score: Adjusted OR for Risk Factors Predicting Uninterrupted Statin Use During Anthracycline Chemotherapy in Patients With Breast Cancer   n   628, C Statistic   0.87
41344,Multivariate HRs for Incident HF by Uninterrupted Statin Treatment, Adjusting for Potential Covariates
41346,Adverse Events
41347,Clinical and Doppler Echocardiographic Data
41348,Univariable and Multivariable Analyses of Combined   AVR or Death   Event Free Survival
41349,Univariable and Multivariable Analyses of Overall Mortality
41350,Univariable and Multivariable Analyses of Cardiovascular Mortality
41353,Univariate Analysis for Overall Survival
41354,Multivariable Proportional Hazard Models
41355,Comprehensive Clinical Models
41356,Comparison of Multivariate Cox Regression Models
41358,Outcome Comparison by Era
41359,Risk Factors for Death or Fontan Takedown Within 30 Days of Fontan
41360,Risk Factors for Prolonged Hospital Stay    14 Days
41361,Risk Factors for Prolonged Pleural Effusion    14 Days
41362,Multivariate Analysis of Cardiac Catheterization Subgroup   N   668
41363,Sensitivity and Specificity of PAP as a Predictor of Unfavorable Outcome
41364,Variables Associated With Total Support Time
41365,Summary of Contemporary Reports of Early Postoperative Outcomes
41366,Association of LPA Score With Carotid IMT
41367,Association of LPA Score With Angiographic CAD Severity
41368,Association Between LPA Score and the Age at Diagnosis of CAD
41371,Univariate OR for Stroke TIA
41374,Clinical Outcomes per Study Group
41376,PAPP A Concentration and Cardiovascular Outcomes
41377,The ADAPT ADP
41379,Frequency and Type of Major Adverse Cardiac Event During Initial Hospital Attendance or 30 Day Follow Up
41380,Test Parameter Performan Occurrence of Major Adverse Cardiac Events During Initial Hospital Attendance or 30 Day Follow Up According to the Results of Individual and Combination of the Accelerated Diagnostic Protocol Test Parameters
41381,Diagnostic Accuracy: Accuracy of cTnI, ECG, TIMI, and ADP for Prediction of MACE
41383,Prevalent Comorbidities in SCDs and in AIDS and Other Natural Deaths
41384,Inclusion and Exclusion Criteria
41386,High Priority Knowledge Gaps in Heart Transplantation and Potential Research Approaches
41387,Selected Grant Mechanisms
41389,Clinical and Hemodynamic Indices Stratified by Median ADMA   1.29 mol l   and Median GABR   0.9   in Patients With ADHF
41390,Etiology of Myocarditis
41394,Multivariate Regression Analysis of Influence of Ees, Eaand Age on the Cardiac Volume Sensitivity of Systolic Blood Pressure and Cardiac Stroke Work legend
41396,Potential Measurements for HF Monitoring
41397,Future Challenges and Opportunities in Home Hemodynamic Monitoring
41402,Univariate Linear Regression Model Predicting Increase in GFR 1 Month After LVAD Implantation for Patients With Admission GFRs  60 ml min 1.73 m2
41406,Logistic Regression of 2 Common 1 AR Polymorphisms, Arg389Gly and Ser49Gly, and Response to Rate Control Therapy
41407,Drug Prescription Distribution Among Responders by Haplotype Arg389Arg Ser49Ser   n   85   and Arg389Gly Ser49Ser   n   97
41409,Randomized Trials Evaluating Calcium Antagonists for Hypertension and or Coronary Artery Disease
41410,Functional Parameters of Wild Type and Cxcr4    Hearts
41411,Covariates Used in Propensity Score Model
41413,Cardiovascular Hospital Stay Profiles in the Propensity Score Matched Patient Cohorts for Individual Antiarrhythmic Drugs in the AFFIRM Trial
41415,Relationship Between Time Dependent Changes in Clinical Status and Risk of CVH
41417,Medication Use in Patients With and Without In Hospital Major Bleeding
41418,Cumulative Rates of Major Adverse Clinical Events in Patients With Versus Without In Hospital Major Bleeding
41419,Independent Predictors of 3 Year Mortality After Primary PCI in All Patients and In Hospital Survivors
41420,Characteristics of Randomized Trials
41423,Regression Analysis of First Time Heart Failure Hospitalization Risk on Education and Income, Stratified by Race Ethnicity
41428,Revascularization Procedural Complications in Patients Randomized to Prompt Revascularization
41433,Subject Profiles by Current Fenestration Status
41434,Principles of Effective Leadership
41435,Principles for Effective Teamwork to Avoid Medical Errors
41436,Properties of Beta Blockers Approved for the Treatment of HF
41437,Randomized Controlled Trials of Cardioselective Beta Blockers in Patients With COPD
41438,Exclusion Criteria, Prevalence of COPD, and Respiratory Symptoms in Major Beta Blocker Trials
41439,Association Between Beta Agonists and HF
41440,Clinical Data for 5 Pedigrees Carrying SCN5A Mutations
41441,Novel SCN5A Single Nucleotide Polymorphisms Identified in Familial Cardiomyopathy Registry Screening
41443,Incidence and Unadjusted HRs of Adverse Clinical Outcome by the Presence Absence of RMD
41444,Cox Proportional Hazards Models for Incident Cardiovascular Events as a Function of RMD
41446,Parameters That Significantly Contribute to ProBNP1108      in Multivariable Analysis
41447,Age  and Sex Specific Median Values and Ranges for Plasma ProBNP1108 in Normal Subjects
41448,ProBNP1108 to NT proBNP176 Ratio by Stage of Heart Failure
41449,Detection of Moderate or Severe Diastolic Dysfunction by ProBNP1108, NT proBNP176, and BNP132
41451,Clinical and Echocardiographic Data for Children With Prior Anthracycline Exposure
41453,Echocardiography Assessments After 4 Weeks of Doxy Treatment
41455,Bleeding Events Requiring Transfusion
41457,Transfusion Requirements During Heart Transplantation
41458,von Willebrand Factor Levels   n   31
41460,Odds Ratio   95  CI   of CAD by Tertiles of OxPL apoB and Lp  a
41461,Odds Ratio   95  CI   for CAD Events According to Tertiles of Selected Biomarkers
41463,Relationship of OxPL apoB and Lp  a   Levels to the Metabolic Syndrome and Framingham Risk Score Estimates
41465,Elective Procedures Combined With Transapical Implantation
41466,Predictive Factors of 30 Day Mortality
41467,Predictive Factors of Cumulative Late Mortality
41471,Multiple Logistic Regression Comparing Atrial Fibrillation to Sinus Rhythm
41472,Multivariate Multinomial Logistic Regression Comparing Paroxysmal and Persistent AF to Sinus Rhythm
41474,Correlation Coefficients   Rho   Between Percent Change in FMD and Changes in Cardiometabolic Biomarkers
41479,Cut Point Analyses for DBT, Time to Presentation, and TIMI Risk Score
41480,1 Year Mortality Rate by DBT, Time to Presentation, and TIMI Risk Score
41484,MAE to 360 Days by Physician Training Level
41485,MAE to 360 Days by Operator Volume
41486,MAE to 360 Days by Academic Versus NonAcademic Centers
41487,MAE to 360 Days by Geographic Location
41488,Hemodynamic Data Obtained From Either Sham or PCO Groups 48 h After PCO
41489,Hemodynamic and Morphometric Data Obtained From Either Sham or 3 Week PCO Groups
41495,Duration of Follow Up
41496,Initiation of Therapy in Subtypes of LQTS
41497,Number of Subjects With Follow Up
41498,Deceased LQTS Patients During Follow Up
41499,2 Definitions of Metabolic Syndrome Used in This Study
41500,Prevalence of Metabolic Syndrome Components in Controls and Cases, Overall and by Sex
41502,Levels of Copeptin, TnT, Myoglobin, CK MB, and NT proBNP According to Time of Chest Pain Onset and Final Diagnosis
41503,Median Concentration of Copeptin According to Categorical Risk Factors and Correlation With Continuous Variables According to Diagnosis
41504,AUC, Sensitivity, Specificity, PPVs, and NPVs for NCCP Versus AMI for TnT, Copeptin, Myoglobin, CK MB, and Combination According to Time of Chest Pain Onset
41505,Sensitivity, Specificity, PPVs, and NPVs for NCCP Versus AMI and ACS for a More Sensitive TnI and Copeptin in Patients Presenting Within 3 h After Chest Pain Onset
41507,Clinical Worsening Events
41508,Adverse Events Occurring in 10  of Patients Receiving Inhaled TRE
41510,DW MRI Lesion Localization and Size After TAVI
41511,Individual Neurological Risk and Outcome in Consecutive TAVI Patients
41515,Hazard Ratios for Cardiovascular Mortality by Tertiles of Nitrotyrosine
41517,Risk Reclassification Table for Myeloperoxidase
41519,Procedural Data
41520,Clinical End Points and Long Term Follow Up
41521,Procedural Complications   n   105
41523,Association of NT proBNP and Incident Heart Failure and Cardiovascular Mortality
41528,HRs for Future Coronary Heart Disease According to LDL C, NonHDL C, and Triglyceride Levels and the TC to HDL C Ratio
41529,Hazard Ratios for Future CHD According to 1 SD Increase in LDL C, NonHDL C, and TG Levels and the TC to HDL C Ratio
41530,Hazard Ratios for Future CHD According to NonHDL C and TG Levels and the TC to HDL C Ratio in Participants Classified on the Basis of LDL C Levels
41535,Operative and Post Operative Data
41536,Renal Function After Operation
41537,Characterization of Liposomes by Dynamic Light Scatter Analysis
41541,Markers of Apoptosis and Oxidative Stress
41543,Summary of Grafts
41545,Location of Angiographic Graft Finding Versus Type of Graft Intervention
41547,Planned Versus Unplanned Hybrid Groups
41550,Biophysical Properties of WT and M1875T Channels
41552,Risk Estimates for a Major Coronary Event Per 1 SD Increase of HDL C, HDL Particle Size, and ApoA I in the IDEAL and EPIC Norfolk Studies
41553,Risk Estimates for a Major Coronary Event by Categories of HDL C   IDEAL and EPIC Norfolk   or HDL Particle Size   EPIC Norfolk  , Unadjusted or Adjusted for ApoA I and B
41554,Risk Estimates for a Major Coronary Event by Categories of ApoA I in IDEAL and EPIC Norfolk, Unadjusted or Adjusted for HDL Cholesterol Content and Apolipoprotein B
41556,Patient Disposition
41560,Cumulative MACE
41561,Stent Thrombosis According to ARC Criteria
41566,Cause of Death
41568,Identification of Independent Predictors of Death at 1 Year in Dyspneic Patients
41571,Odds Ratios for Future CAD Events by MPO Quartile and for MPO as Continuous Variable
41572,Odds Ratios for Fatal and Nonfatal Future CAD Events and Gender Specific Odds Ratios by MPO Quartile   Unadjusted
41573,Odds Ratio and 95  Confidence Intervals for MPO in Subgroups Otherwise Associated With Low Risk
41575,Hemodynamic Data at Peak Stress for Perfusion Imaging at 1.5  and 3 T
41576,Diagnostic Performance of 1.5  and 3 T Perfusion Imaging for the Detection of Significant Coronary Artery Stenosis
41579,Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value of the Parameters That Were Significantly Associated With the Occurrence of Complete Heart Block After TASH
41581,Diagnostic Accuracy of 64 Slice MSCT to Detect Significant In Stent Restenosis
41582,Relationship Between Stent Size and Accuracy
41583,Results From the 2 Scanners From the 2 Centers Separately
41585,Estimated 5  and 10 Year Survival for BARI Randomized Patients by Assigned Treatment and by Treated Diabetes Status
41586,Estimated Cumulative Rates of Subsequent Revascularization Procedures    at 10 Years by Assigned Treatment and by Treated Diabetes Status
41588,ACE I Medication in LVAD Patients
41589,General Medication in Both LVAD Groups
41590,Angiotensin I and II Measurements and Collagen Characterization
41591,Stiffness Measurements
41593,Comparisons of Selected Independent Variables by Year
41594,Comparison of Hospitalizations by Age: 12 to 20 Years and 21 to 44 Years   Aggregate 2000 to 2003
41595,Multivariate Logistic Regression Analysis for Predictors of Admission Via the ED
41597,Spearman Correlation Coefficients Between Measured Variables
41598,Odds Ratios for Future Coronary Artery Disease by Quartile of Lipid Lipoprotein Variable in Univariable and Multivariable Models
41599,Odds Ratios for Future Coronary Artery Disease by Quartile of LDL C and LDL P, Both Entered Into One Model
41600,Odds Ratios for Future Coronary Artery Disease by Quartile of LDL Size, With and Without Adjustment for LDL Particle Number
41601,Odds Ratios for Future Coronary Artery Disease After Taking Into Account the Framingham Risk Score
41603,Summary of LQTS Associated Mutation PolymorphismPositive Cases
41604,Study Population
41605,Quantitative Vessel Analysis at IVUS Stratified Into Coronary Segments
41606,Plaque Composition Along the Left Coronary Artery Stratified Into Coronary Segments
41608,Coronary Angiographic Data
41609,Hemodynamic and Collateral Circulation Data
41613,Myocardial Necrosis Markers
41614,Electrogram Results in Porcine Coronary Occlusion Model
41615,Correlation of Electrogram Data With Necropsy Findings
41616,Summary of Neuromuscular Incapacitating Device Discharges
41618,Dimensional Data
41619,Functional Data and Contractility Index
41621,Association of OxPL apoB and Lp  a   Level with Presence, Severity, and Progression of Carotid and Femoral Artery Atherosclerosis, and with Cardiovascular Disease
41622,Grading of Carotid Artery Stenosis by Duplex Ultrasound in Correlation With the Angiographic Degree of Stenosis
41627,Clinical Outcomes
41628,Cumulative Survival Free of MACE at Nine Months
41629,Patients With a Definite or Probable Post Procedural Stent Thrombosis
41630,Quantitative Coronary Angiography
41631,Quantitative Coronary Angiography With Respect to the Use of Kissing Balloon Post Dilation
41633,Univariate Predictors of Increased Coronary Calcification: Ordered Logistic Regression Analysis
41634,Bivariate Correlation Between Plasma Osteoprotegerin Levels and Cardiovascular Risk Factors
41635,Univariate Predictors of Cardiovascular Event Free Survival, Cox Proportional Hazards Model
41637,Binary Logistic Regression Model to Predict Hemodynamic Depression
41640,Clinical and Angiographic Outcomes of Patients Stratified by CKpeak
41641,Baseline Features and Outcomes of Patients Stratified by Timing of CKpeak
41644,Consensus Table of 64 Slice CT and IVUS to Detect and Classify Coronary Plaques
41646,Results of Two Dimensional Echocardiography, Categorized With Respect to Renal Function, GFR   Dichotomized With GFR Cut Point of 60 ml min 1.73 m2  , and the Presence or Absence of CHF
41647,Ablative Approach and Results of Cryothermal Balloon Ablation of Pulmonary Veins
41650,Concomitant Medication Used During Double Blind Treatment Phase
41651,Body Systems With Treatment Emergent Adverse Events Affecting Two or More Patients   5
41652,Changes in Vital Signs at Peak at the End of Treadmill Exercise   Week 8, 80 mg Three Times Daily
41654,Mini Mental State Examination   MMSE   Scores
41655,Heart Rates for Six Minute Walk Test at Initial and Follow Up Visits
41657,Associations Between Age and Arterial Parameters for Males and Females
41658,Comparison of the Effect of Aging by 10 Years on Arterial Parameters in Younger   20 to 30 Years   and Older   70 to 80 Years   Subjects
41659,Stepwise Regression Analyses
41660,ACC AHA Recommendation for Anticoagulation During Pregnancy in Patients With Mechanical Prosthetic Valves
41661,Recommendations of the Seventh ACCP Consensus Conference on Antithrombotic Therapy for Prophylaxis in Patients With Mechanical Heart Valves
41662,Recommended Approach for Anticoagulation Prophylaxis in Women With PHV During Pregnancy
41664,Respective Diagnostic Values for TTE and TEE Compared With Surgical Findings   n   Specified in Echocardiographic Report
41665,Perioperative Mortality, Frequency of Valve Repair, and Long Term Survival in the Group as a Whole and According to Etiology of MR
41666,Multivariate Predictors of Perioperative Mortality
41667,Multivariate Predictors of Long Term Mortality
41668,Salient Patient Details
41670,Oligonucleotides Used as Primers for PCR Reaction
41677,Analysis by Coronary Segments
41678,Analysis by Patients
41680,Incidence and Type of Early   30 Days   Morbidity in Patients With Pulmonary Hypertension   n   145   After Noncardiac Surgery
41687,Clinical Outcomes at 1 Month and 9 Months
41688,Serial Quantitative Analysis of the Stented Segment by QCA and IVUS   n   15
41689,Evolution of Endothelial Progenitor Cell Capture Stent: Improvement From HEALING FIM   H1   to HEALING II   H2
41691,NYHA Functional Class Before and After Randomization
41693,Primary Outcome Measure and its Components at 240 Day Follow Up
41694,Primary Outcome Measure and its Components at 450 Day Follow Up
41695,Results of Multivariate Cox Regression Analysis
41696,Summary of Forward Selection
41697,Patient Contacts Not Resulting in Hospitalization
41699,Adverse Event Rates in the Derivation and Validation Sets
41703,Initial TIMI Flow Grade According to Admission Glucose
41704,Multivariate Analysis of Initial TIMI Flow Grade 0 to 2
41707,Tachycardia Origin and Results of Radiofrequency Catheter Ablation for Idiopathic Ventricular Arrhythmias
41712,Relations of QRS Duration and Echocardiographic Variables
41713,Echocardiographic Measurements According to Type of Bundle Branch Block
41716,Conservation of Cardiac Troponin I Amino Acid Residues Affected by Missense Mutations
41717,Phenotypic Features at First Clinical Evaluation of HCM Families With TNNI3Mutations
41719,Type and Distribution of Stents
41721,Nucleotide Sequence of Primers Used in This Study
41723,Relative Binding of Wild Type and Mutant Tcap to MLP, Titin, and CS 1, as Assessed by the Y2H Assays
41724,Relative Binding of Wild Type and Mutant Tcap to MLP, Titin, and CS 1, as Measured by the GST Pull Down Competition Assays
41726,Conservation of Cardiac Troponin T   cTnT   Amino Acid Residues Affected by Mutations
41727,Conservation of Cardiac Troponin C   cTnC   Amino Acids Affected by Mutation
41728,Clinical Features of Patients With Chronic Orthostatic Intolerance   Frequency of Findings
41729,Systemic and Hemodynamic Values During the Phases of the Tilt Test Entered in the Stepwise Discriminant Analysis
41730,Clinical and Operative Details
41731,Hemodynamic, Blood Gas Parameters, Oxygen Consumption, and Co oximetry
41732,Calculated Flows, Flow Ratios, and Resistances
41733,Cerebral Blood Flow Markers
41734,Patient Description
41738,Impact of ST Segment Parameters on Death and Reinfarction: All Patients
41739,Impact of ST Segment Parameters on Death and Reinfarction: Patients With TIMI Flow Grade 3 After Procedure
41740,Model Fit Statistics for the Multivariate Analyses of Outcomes, Examining the Relative Prognostic Value of Different ST Segment Parameters
41741,Antiarrhythmic Drug Use    79
41743,Drug Therapy
41744,Arrhythmic Events
41745,Torsade de Pointes Ventricular Tachycardia
41746,Torsade de Pointes VT
41751,Potential Variables Associated With Mortality in Bootstrap Models, Presented in Descending Order of Strength; 1,000 Bootstrap Models Performed in Each Iteration
41753,Macrophage Density in Lipid Rich Plaques
41755,Initial and Intercurrent Revascularization by Randomization Assignment
41756,Angiographic Evaluation at 5 Years by Randomization Assignment
41760,In Hospital, 30 Day, and 1 Year Outcomes Stratified by Baseline Anemia
41764,Serial QCA Analyses   Intention to Treat
41765,IVUS Analyses   Intention to Treat
41766,Most Severe   Hierarchical   MACE, Revascularization Procedures   Event Per Patient  , and Total Count of Cardiac Events Up to 12 Months
41767,Baseline Features, Randomization, and Outcomes of Patients With and Without Film Reanalysis
41769,Procedural and Angiographic Outcomes Stratified by Postprocedure Myocardial Blush Grade
41770,Clinical and Angiographic Outcomes Stratified by Myocardial Perfusion Status Postintervention
41773,Outcome for Patients With Dyspnea Compared With Those Having Chest Pain
41774,Predictors of Cardiac Death or MI for Patients With Dyspnea
41775,Patient Data
41777,Catheterization Laboratory and In Hospital Outcomes
41778,Multivariate Predictors of 30 Day Mortality Stratified by Pre Admission Beta Blocker Use
41780,Cytokine Substudy
41783,Clinical Outcomes Stratified by the Severity of Mitral Regurgitation
41786,Quantitative Angiographic Results
41787,In Hospital Outcomes of Patients Lesions
41791,Presenting Neurologic Deficits of Patients With a Cerebrovascular Accident After Percutaneous Coronary Intervention
41792,AFFIRM Definition of Adequate Ventricular Rate Control
41795,Cumulative Achievement of Adequate Ventricular Rate Control
41796,Reasons for Discontinuation of Rate Controlling Drugs
41799,Long Term Mortality Risk in Diabetic Patients Compared With Non Diabetic Patients: Results of Univariate and Multivariate Models
41802,Imaging Investigation Results
41803,Univariate and Multivariate Predictors of Any Event by Cox Regression
41804,Univariate Predictors of an Event Based on the Presence of Coronary Disease and Two Year Risk of a Cardiac Event
41805,Univariate Predictors of an Event Based on the Presence of Coronary Artery Disease, Dialysis, or Multiple Risk Factors
41806,Representative Genes Differentially Regulated Between Mice With Femoral Artery Ligation and Sham Control Operation
41807,Changes of Three Selected Genes Validated by Real Time RT PCR   MCP1, MT1 at Day 1, and MMP12 at Day 7
41808,Anthropometric and Biochemical Variables According to the Three Genotypes
41809,Echocardiographic Variables According to the Three Genotypes
41810,Simple Regressions Between Cardiac Variables Versus CYP11B2
41811,Multiple Regression Analysis
41816,Clinical Events at 14 Day Follow Up
41820,Factors Independently Associated With Embolic Events
41821,Factors Independently Associated With Embolic Events Evaluated Only in Patients Without LAA Ligation Performed at Surgery   n   147
41823,Multivariate Model for Prediction of First Age Related Events
41824,Risk Scoring Algorithm for the Prediction of First Age Related Cardiovascular Events
41825,Kaplan Meier Event Rates for the Study Population and Prospective Validation Cohort
41827,Findings in Patients With Hyperintense Areas on MRI
41829,Core Laboratory Angiographic Analysis
41830,Early and Late Clinical Outcomes
41831,Economic Analysis
41835,Electrocardiographic Data Summary
41836,Electrophysiologic Data Summary
41838,Crude Mortality and Cause of Death
41840,Cost Calculations for Testing
41842,Cost of Testing Before and During the Study
41844,Adjusted Relative Risks and 95  Confidence Intervals for Coronary Heart Disease   Nonfatal MI and Fatal CHD   According to Quintile of Vitamin C Intake
41846,Adjusted Relative Risks and 95  Confidence Intervals for Coronary Heart Disease   Nonfatal MI and Fatal CHD     According to Use of Vitamin C Supplements
41848,Antiarrhythmic Drug Use
41849,Randomization Scheme: Numbers Eligible for Treatment Arms
41850,Randomization Scheme: Totals Used for Comparison
41852,First Antiarrhythmic Drug Substudy End Points: Amiodarone Versus Class I Drugs
41853,First Antiarrhythmic Drug Substudy End Points: Amiodarone Versus Sotalol
41854,First Antiarrhythmic Drug Substudy End Points: Sotalol Versus Class I Drugs
41855,Adverse Effects Causing Discontinuation of First Antiarrhythmic Drug Within the First Year
41856,Principal Indications for Intra Aortic Balloon Pump Use in 5,495 Patients With AMI
41857,Effect of IABP Placement on Hemodynamic Measures
41858,Failure and Complications of the IABP   n   5,495
41859,Percutaneous and Surgical Procedures in Patients With Acute Myocardial Infarction Receiving an Intra Aortic Balloon Pump
41860,Independent Correlates of In Hospital Mortality by Logistic Regression Analysis
41862,Total Mortality According to Quintiles of Hematocrit
41863,Total Mortality According to Quintiles of Hematocrit Among Men and Women
41864,Mortality by Different Causes According to Quintiles of Hematocrit
41866,Reasons for Discontinuation of Study Medication
41867,Critical Cardiovascular Events in Intention to Treat Population
41870,Univariate Predictors of One Year Mortality Plus Urgent Transplantation
41871,Multivariate Analysis of the Variables Associated With One Year Mortality Plus Urgent Transplantation
41872,Comparison of Mortality for Clinical Profiles to Mortality in Trials of Hospitalized Patients With Advanced Heart Failure
41875,Relationship Between Exercise Stress Testing Responses, Holter Monitoring Results, and Severity of Anginal Symptoms
41878,Triggering Factors
41879,Angiographic Results
41880,Indices of Doppler Guidewire
41881,Pathologic Findings
41882,Ratios   95  CIs   of Shed Blood F1 2, TAT and  TG Levels Between Comparator   r hirudin and Enoxaparin   Treatment Groups and 60 mg Ximelagatran Group
41884,Ratios   95  CIs   of Venous F1 2, TAT and  TG Plasma Levels Between Treatment Groups and the Control Group   Treatment Control
41886,Clinical Features, Risk Profile, and Mortality Rates Among the Five LV Thickness Classes
41887,Comparison of Outcomes Among HCM Patients With Extreme Hypertrophy   Maximum LV Thickness  30 mm   in Three Different Patient Populations
41889,Relationship Between Weaning or Survival and CPR Duration
41890,Analysis of the Factors in Weaning and Survival by the Spearman Method
41891,Predictive Levels for Different Probabilities of Weaning and Survival
41893,Adjusted Risk of Bradyarrhythmia Requiring a Permanent Pacemaker
41895,Measurements of Anticoagulation Before, During, and After PCI
41896,Levels of Anti Xa Activity in Patients Undergoing PCI, According to Age, Renal Failure, and Weight
41897,Clinical Events and Bleeding Complications at 30 Days Follow Up
41900,Survival According to Creatinine Clearance   High   Ranks 3 and 4; Low   Ranks 1 and 2   in Selected Subgroups
41901,Variables Associated With Mortality in Multivariable Models
41903,Periprocedural Neurologic Complications According to Procedural Outcome
41905,Left Ventricular Function and Hemodynamics in MR: Effect of AT1RB
41911,Comparison Between All Patients and Patients With Myocardial Energetics Measurements
41918,Incidence and Odds Ratios of In Hospital Events According to BMI: Percutaneous Transluminal Coronary Angioplasty Group
41919,Incidence and Odds Ratios of In Hospital Events According to BMI: Coronary Artery Bypass Graft Surgery Group
41920,Incidence and Relative Risks of Long Term Mortality According to BMI: Percutaneous Transluminal Coronary Angioplasty Group   n   2,090
41921,Incidence and Relative Risks of Long Term Mortality According to BMI: Coronary Artery Bypass Graft Surgery Group  n   1,503
41922,Definitions of Extent of Revascularization
41923,Algorithm for Functional Revascularization   Strategy 2     Refer to  Fig. 1
41924,Evaluation of Definition 1: Traditional Complete Revascularization
41925,Evaluation of Definition 2: Functional Complete Revascularization
41926,Evaluation of Definition 4: Number of Distal Sites to Different Vessels
41929,Follow Up Intravascular Ultrasound Results According to Treatment Groups
41930,Major Adverse Cardiac Events to 210 Days: Hierarchical Ranking of Worst Event per Patient   Intention to Treat   According to Treatment Group
41933,Observed Survival With 95  Confidence Intervals for Patients Undergoing PTCA vs. Observed Survival for CABG Patients in the Different Anatomic Subsets
41937,Clinical Details of 28 Homozygotes With Naxos Disease
41940,Blood Gas Analysis and Hemodynamic Data at Each of Examined Treatment Steps legend legend
41942,Underlying Disease in Nonprimary Pulmonary Hypertension legend
41944,Effect of Iloprost Inhalation on Hemodynamics and ANP and cGMP Levels in PPH and NPPH
41946,Procedures Performed on 1,142 Saphenous Vein Grafts legend
41947,In hospital Complications in 1,062 Patients legend
41948,Incidence of MACE in 1,056 Patients legend
41949,Multivariate Predictors for Late MACE legend
41950,Blood Pressure and Heart Rate Responses to Study Drug in the Three Groups legend
41952,Aldehydes and Isoprostanes: Individual Levels and Totals of the Compounds Measured legend
41954,Effect of Digoxin and Age Group on Clinical Outcomes legend
41955,Mean Digoxin Dose Prescribed and Mean Serum Digoxin Levels by Age Group at One Month After Randomization
41956,Suspected Symptoms and Signs of Digoxin Toxicity by Age Group
41957,Clinical Outcomes by Age Group and Ejection Fraction legend
41958,Cox Proportional Hazard Model Analysis to Determine the Effect of Age and Treatment on All Cause Mortality   n   7,746      legend
41959,Survey on the Diagnosis of Heart Disease in Groups of Patients With SR and AF legend
41960,Ischemic and Remote Region Circumferential Segment Shortening    S   legend
41962,Pulmonary Hemodynamic Variables legend
41964,Mortality Rate in Patients for the Two Years After the One , Three , and Five Year Tests Based on Whether the Test Was Taken legend
41965,Combined Mortality or Myocardial Infarction Rates for the Two Years After the Scheduled EXTs for the Test Takers and Non Test Takers legend
41966,Relationship Between Parameters Measured on Each EXT and the Univariate and Multivariate Risk Ratios for Survival for the Two Years After the Test legend legend
41967,Relationship Between Parameters Measured on Each EXT and the Univariate and Multivariate Risk Ratios for Survival Free of Myocardial Infarction for the Two Years After the Test legend legend
41968,The Number of Patients Revascularized Within 90 Days of the One Year EXT Segregated by Angina Reported Before the Test, Angina on the Test and ST Depression legend
41969,Sensitivity, Specificity, Positive Prognostic Value and Negative Prognostic Value of the Ability to Exercise to Bruce Stage 3 and a Duke Score 6
41970,Acute and Six Month Rhythm Outcome After Linear Lesions legend
41971,Biographical and Hemodynamic Data of Cardiac Patients legend legend
41975,Crude Five year Mortality legend
41976,Selected Clinical and Electrophysiologic Features of Study Patients    legend
41977,Right Atrial Repolarization and Refractoriness at Identical BCL in Control Patients, Patients With Aflut and Afib legend legend
41981,Influence of Atenolol on Cell Shape Alterations Caused by Norepinephrine legend
41985,Univariate Comparisons of Specialist and Generalist Patient Cohorts legend legend
41987,Incidence of Atrial Flutter in the General Population
41988,Odds Ratio, Association Between Atrial Flutter and Clinical Variables
41989,Echocardiographic Findings in 132 Affected Family Members legend
41990,Correlation Between Arrhythmias and Extent of the Disease legend
41991,Late Potentials Values Correlated With the Extent of the Disease and the Presence of Arrhythmias legend
41993,Hemodynamic Variables at all Stages of the PLV Procedure legend
41995,Predictive Accuracy of Troponin I Value  1.0 ng ml for Predicting Outcomes in All Patients and After Excluding Patients With Ischemic Electrocardiograms legend legend
41996,Predictive Accuracy of an Ischemic Electrocardiogram for Predicting Outcomes legend legend
41997,Multivariate Predictors of Myocardial Infarction, Death or Significant Disease legend
41998,Multivariate Predictors of Significant Complications legend
41999,Multivariate Predictors of Significant Disease Alone legend
42002,Anatomic Variants of Coronary Artery Branching in TOF legend legend
42003,Diagnostic Accuracy of Coronary Echocardiography in Detecting a Major Coronary Artery Crossing the RVOT legend
42004,Surgical Approach in Patients With Tetralogy of Fallot and Coronary Anomalies From 1990 through 1995 legend
42008,Hemodynamics and Coronary Anatomy of Patients With CS Caused by Predominant LV Failure legend
42009,In hospital Treatment of Patients With CS Due to Predominant LV Failure
42010,Summary of 36 Patients With Prosthetic Valve Thrombosis legend
42012,Comparison of Thrombolytic Success for the Initial and Subsequent Doses of Thrombolytics According to Valve Type and Location
42015,Risk of Embolization After Thrombolytic Treatment of Left Sided Prosthetic Heart Valves   Single Center Series With 8 Patients   legend
42016,Literature Review of Dystrophin Defect Associated DCMs
42017,Diagnostic Criteria for X linked DCM Derived From Reports
42018,Clinical Data and Genetic Defects of Dystrophin Related CMD Patients legend
42022,Cut off Points, Predictive Accuracy, Sensitivity and Specificity Values for All Continuous Parameters legend
42023,Results of Uni  and Multivariate Analysis for Predicting MACE legend
42024,Results of Uni  and Multivariate Analysis for Predicting MACE legend
42025,Odds Ratio and 95  Confidence Intervals of Parameters Included Multivariate Nominal Regression Analysis for Predicting MACE legend
42026,Coronary Collateral Conductance and the IZ NZ Perfusion Ratio   Central Venous Study
42027,Coronary Collateral Conductance and the IZ NZ Perfusion Ratio   Peripheral IV Study
42028,Final Coronary Collateral Conductance and the IZ NZ Perfusion Ratio   Pericardial Study
42029,Coronary Collateral Conductance and the IZ NZ Perfusion Ratio   IC Study
42032,Mean Change Values   mg dl, SD   for All Subjects Randomized to the Placebo or Garlic Group legend legend
42033,Mean Change   mg dl   by LDL Pattern After Placebo or Garlic Treatment legend legend
42036,Results of Multivariate Analyses in the SOLVD Prevention Trial legend
42037,Results of Multivariate Analyses in the SOLVD Treatment Trial legend
42041,Relative Risk and 95  CI for Cardiovascular Mortality in the Nine Groups legend
42043,Estimated Subsequent Revascularization Procedures Rates at 7 Years legend
42045,Coronary Structural and Functional Variables and Collateral Data at Rest
42047,Coronary Collateral Hemodynamics Relative to the Collateral Receiving and Supplying Vascular Bed legend
42049,Echocardiographic Findings by TEE and Presence of Atrial Fibrillation for Each Age Group legend
42050,Consecutive Patients Randomized in BARI at Four Investigative Centers legend
42053,Long Term   Four Year   Clinical Events After One Year Angiography legend
42055,Treatment Details legend
42056,Number and Percent of Patients With Assessment of Myocardium at Risk and Final Infarct Size legend
42057,Multivariable Regression Modeling
42058,Final Infarct Size, Myocardium at Risk and Myocardial Salvage Index
42059,Secondary End Point Clinical Outcome Events
42060,In hospital Cardiovascular Events legend
42062,Valvular Regurgitation    n   226
42063,Valvular Regurgitation by Dose and Duration of Medication legend
42064,Comparison of Groups With and Without Valvular Heart Disease
42065,Prevalence of Valvular Heart Disease in the Framingham Heart Study Compared With Our Phen fen Subjects
42069,Biochemistry   Mean  SD
42070,Histomorphometric Analysis of the Abdominal Aorta and of the Left Interventricular Coronary Artery in the Three Groups
42071,Hemodynamics and Wall Mechanics in the Iliac and Renal Arteries of Pigs legend
42072,Biochemical Analyses and Collection Sample Collection Schedule
42075,Biochemical Measures During Exercise and Mental Stress Testing by Hot Pain Threshold    41C vs. 41C
42076,Cardiovascular Responses to Mental Stress Testing by Hot Pain Threshold    41C vs. 41C   legend
42077,Cardiovascular Responses to Bicycle Exercise by Hot Pain Threshold    41C, 41C   legend
42079,Impact of Congestive Heart Failure on Mortality: Results of Multivariable Cox Proportional Hazards Regression Models legend
42080,Impact of Normal Versus Reduced Left Ventricular Ejection Fraction on the Mortality of Congestive Heart Failure Cases: Results of Cox Proportional Hazards Regression Models
42084,Findings in Women With Significant Angiographic Coronary Disease and Normal or Indeterminate Dobutamine Stress Echocardiography legend
42087,Initial Procedural Outcome   Among 608 CABG and PTCA Patients With IR Intended and 579 PTCA Patients With CR Intended if Randomized to PTCA Who Received Their Assigned Treatment   legend
42088,Freedom From Untoward Events at Five Years   CABG vs. PTCA Patients With IR Intended if Assigned to PTCA
42089,Power Calculations   All CABG vs. PTCA Patients With IR Intended if Assigned to PTCA   legend
42090,Freedom From Untoward Events at Five Years   PTCA Patients With CR vs. IR Intended
42091,Power Calculations   All PTCA Patients With CR vs. IR Intended   legend
42093,Ambulatory Electrocardiogram   AECG   and Exercise Treadmill Test   ETT   Findings by Presence of Mental Stress Ischemia legend
42095,Patient Outcomes for the Initial 6 Months After Placement on the UNOS Status 2 Waiting List
42096,Patient Outcomes for the 6 Month Survivors Over the Entire Follow up Period
42098,Hemodynamic Findings legend
42099,Unidirectional Transfer Constant Values   ml g1 min1   and Myocardial Perfusion Reserve Index Grouped According to Percent Diameter Stenosis legend
42100,Causes of Death of the 29 Patients Who Died Within the Hospital Stay Associated With the Current Acute Myocardial Infarction
42102,Clinical and Investigational Data of the Patient Population   n   497   legend legend
42103,Clinical Information on the 11 Deaths of Patients Discharged Home Directly From the Coronary Intermediate Care Unit legend
42105,Procedural Variables and Angiographic Outcomes
42106,Clinical Endpoints
42107,Randomized Trials Comparing the Effects of Ionic Versus Nonionic Contrast Media in Patients Undergoing Coronary Angioplasty
42108,Comparison of Clinical Features at Presentation Between Patients in Group 1 and in Group 2
42109,Comparison of ECG, Hemodynamic, Echocardiographic and 24 h Holter ECG Data at Presentation Between Patients in Group 1 and in Group 2
42110,Primary Defects in Eisenmenger Patients Having Noncardiac Surgery
42111,Noncardiac Surgeries Performed in 24 Eisenmenger Patients
42113,Operative Records of Noncardiac Surgeries Done at Mayo Clinic
42114,Summary of Clinical, Implantation, Follow Up and Postmortem Device Data on the 25 Study Patients legend
42115,Evidence of Terminal Tachyarrhythmic Events in the 25 Patients Who Had Out of Hospital Sudden Death legend
42116,Summary of Device Responses and Outcome for Stored Tachyarrhythmic Events Obtained From Postmortem Device Analysis    legend
42117,Comparison of Mitral Doppler Measurements in Chronic Obstructive Pulmonary Disease and Constrictive Pericarditis legend
42118,Comparison of Superior Vena Cava Peak Forward and Reverse Flow Velocity in Chronic Obstructive Pulmonary Disease and Constrictive Pericarditis  legend
42119,Comparison of Superior Vena Cava Forward and Reverse Flow Velocity Integrals in Chronic Obstructive Pulmonary Disease and Constrictive Pericarditis  legend
42121,Cardiac Events According to the Result of Stress Echocardiography  legend
42122,Univariate Predictors of Hard Cardiac Events   Death, Myocardial Infarction    legend
42123,Univariate Predictors of Spontaneous Cardiac Events   Death, Myocardial Infarction    legend
42125,Inhibition of Platelet Aggregation, Part A legend
42126,Inhibition of Platelet Aggregation, Part B legend
42127,Inhibition of Platelet Aggregation, Part C legend
42128,Safety End Points legend
42129,Efficacy Outcomes  legend
42130,Safety and Efficacy End Points: All Lamifiban Versus All Placebo  legend
42131,Continuous Electrocardiographic Monitoring End Points
42132,Continuous Electrocardiographic Monitoring, All Lamifiban Versus Placebo
42133,Histopathologic Data  legend
42134,Clinical, Hemodynamic, Angiographic and Conventional Coronary Collateral Data legend
42135,Intracoronary Distal Flow Velocity and Pressure Data During PTCA and the Respective Collateral Flow Indices  legend
42136,Diagnostic Accuracy of Different Tests to Assess the Human Coronary Collateral Circulation  legend
42138,Major Clinical Outcomes  legend
42139,30 day Mortality
42141,Occurrence of Systemic Hypertension   Systolic Pressure  140 or Diastolic  90 mm Hg  , Coronary Vasculopathy, and a Rejection Grade of II, III or IV in the 50 Transplanted Patients Over Their 5 to 6 Year Posttransplant Course  legend
42143,Clinical and Electrocardiographic Findings legend
42144,Radionuclide Studies legend
42145,Clinical Outcome Events legend
42149,Predictors of Discharge Angiotensin Converting Enzyme Inhibitor Use in Group 1: Treatment Definitely Indicated legend
42150,Predictors of Discharge Angiotensin Converting Enzyme Inhibitor Use in Group 2: Treatment Probably Indicated legend
42151,Predictors of Discharge Angiotensin Converting Enzyme Inhibitor Use in Group 3: Treatment Possibly Indicated legend
42154,Two Dimensional Echocardiographic Findings
42155,Correlations among Three Dimensional Area of Prolapse, 3D Volume of Prolapse Compared to ROA by Convergence Method, and 3D Echo Planimetry  legend
42156,Heart Rate and Pulmonary Artery Hemodynamic Variables in Patients With Chronic Pulmonary Thromboembolism and Primary Pulmonary Hypertension
42157,Cases of Acute Myocardial Infarction Reported to the Second National Registry of Myocardial Infarction by Region
42158,Cases of Acute Myocardial Infarction Reported to the Second National Registry of Myocardial Infarction by Gender and Age Group
42159,Origin of Primer Pairs Used for PCR Analysis of Viable Cardiovascular C. pneumoniaeIsolates
42162,Hemodynamic Variables After Dobutamine Administration
42163,Prebypass and Postbypass Hemodynamic Measurements Before and After Epinephrine Infusion and Administration of Bicarbonate and Calcium
42164,Total Serum Cholesterol Levels   mg dl
42165,Semiquantitative Analysis of Immunohistochemical Staining
42167,Doppler Tissue Imaging Annular Velocities in the Three Study Groups
42168,Reproducibility of Doppler Tissue Imaging Measurements
42172,Respiratory Changes in Hemodynamic and Pulmonary Venous Flow Velocity Variables in the 10 Study Dogs
42173,Changes in Doppler Pulmonary Venous Flow Velocity Variables With Changes in Heart Rate in the 10 Study Dogs
42174,Doppler Pulmonary Venous Flow Velocity Variables and Intervals in the 10 Study Dogs at Different Left Atrial Pressures
42176,Echocardiographic and Electrocardiographic Results During Dobutamine Administration in 25 Patients With Right Coronary Artery Stenosis
42179,Use of Medications and Procedures
42180,Bleeding Outcomes
42181,Clinical Outcomes
42182,Thirty Day Mortality After Revascularization
42183,Procedures Performed With Intraaortic Balloon Counterpulsation
42188,Treatments Received During First 6 Months in 328 Randomized Patients
42189,Adverse Events   first event patient
42193,Clinical Profile, Diagnostic Investigations and Sites of Measurement of Pericardial Thickness in 11 Patients With Constrictive Pericarditis
42194,Sensitivity, Specificity and Predictive Accuracy of Using Pericardial Thickness 3 mm Measured With Transesophageal Echocardiography in Predicting Pericardial Thickening Found Intraoperatively
42196,Predictors of Surface Morphology and Intimal Hyperplasia
42197,Surface Morphology and Risk Factors
42198,Pigmented Hyperplasia: Surface Contour and Risk Factors
42199,Results of Exercise Treadmill Testing
42200,Results of Transesophageal Dobutamine Stress Echocardiography
42204,Chemosensitivity and Cardiopulmonary Exercise Test Results of Patients After Placebo and Dihydrocodeine Administration
42205,Pulse, Systolic Blood Pressure, End Tidal Carbon Dioxide Concentration and Arterial Oxygen Saturation at Rest, at 3 Minutes of Exercise, at 6 Minutes of Exercise and at Peak Exercise With Placebo and Dihydrocodeine
42206,Modified Borg Scores for Dyspnea and for Fatigue During Exercise Testing With Placebo and Dihydrocodeine
42207,Angiographic Data
42208,Morphometric Results in Animals During Phase II
42211,Medications at the Time of Hospital Discharge Based on the Clinical Setting of Index NSVT Among All Untreated Patients
42216,Clinical Details and Absolute Ratio of IGF I to GH of Control Subjects   Study 1   and Patients With CHF in Studies 1 to 3 legend
42217,Variables of the GH IGF I Axis in Healthy Control Subjects and Patients With CHF legend legend
42219,The Relationship of the Biochemical Marker of GH Resistance   IGF I GH log ratio   to Clinical and Biochemical Variables in Healthy Control Subjects and Patients With CHF    legend legend
42225,Concomitant Medication Usage by the 33 Postmenopausal Women With Coronary Artery Disease
42227,Implantation Data
42228,The Effect of Septal Pacing on P Wave Duration
42229,Univariate and Multivariate Linear Model of Left Ventricular End Diastolic Volume Index in 113 Patients With CHF legend
42230,Univariate and Multivariate Linear Model of Transcardiac Gradient of Plasma Aldosterone in 113 Patients With CHF legend
42231,Hemodynamic and Neurohumoral Data legend
42236,Inclusion and Exclusion Criteria of the Study
42239,Angiographic Data: Comparison of Randomization Groups
42240,End Points: Comparison of Randomization Groups
42241,End Points: Comparison of TIMI Flow Rates After Thrombolysis in the Two Groups
42242,End Points: Six Months Follow Up Intention to Treat Analysis   Including Secondary Excluded Patients  : Comparison of Randomization Groups
42245,Multivariable Analysis for the Presence and Multiterritorial Extent of Atherosclerosis in the CVRF Free PESA Study Population and in the CVRF Optimal Subgroup
42246,Multivariable Analysis for the Presence and Multiterritorial Extent of Atherosclerosis in the CVRF Free PESA Population and in the CVRF Optimal Subgroup With LDL C Levels 130mg dl
42249,Number of Events, Event Rates per 100 Person Years, and Hazard Ratios With 95  CIs
42250,Sensitivity Analysis by Mean INR of Warfarin Treated Patients, Hazard Ratio, and 95  CI Comparing a NOAC With Warfarin
42252,Two Dimensional, Doppler, and Speckle Tracking Echocardiographic Parameters of the 2,996 HyperGEN Participants by ESI
42253,Association of Urinary Sodium With Systolic Strain, Early Diastolic Tissue Velocity, and Estimated LV Filling Pressure on Crude and Multivariable Adjusted Analyses
42254,Association of Urinary Sodium With Systolic Strain and Early Diastolic Tissue Velocity in Participants With ESI  3.7 g day on Mediation Analysis
42256,Events and Event Rates in Patients With Renal Indication for Dose Reduction
42257,Events and Event Rates in Patients Without Renal Indication for Dose Reduction
42259,Renal Function
42260,Acute Kidney Injury
42261,Associations of AKI During Index Hospitalization
42263,Association of APOL1 Risk Alleles With SBP
42264,Association of APOL1 Risk Alleles With DBP
42265,Association of APOL1 Risk Alleles with eGFR
42267,Overall Treatment Emergent Adverse Event Incidence and Selected Adverse Events of Interest in Patients With at Least 2 Consecutive Low Density Lipoprotein Cholesterol Values 25 or 15 mg dl   Pooled Safety Population
42268,Propensity Analysis of the Risk of Certain Adverse Events of Interest in Alirocumab Treated Patients With 2 or More Consecutive Low Density Lipoprotein Cholesterol Values 25 mg dl   Safety Population; Pool of Phase 3 Studies
42270,Correlation Between Low Density Lipoprotein Cholesterol Determined by BetaQuantification and Calculated by Friedewald Equation
42273,Independent Predictors of PENK Levels
42274,Significant Predictors
42276,In Hospitality: NRI
42277,Newborn Screening for Fabry Disease
42285,Subject Disposition
42288,MACE
42291,Clinical Criteria for Enrollment
42292,Overall Organ and Tissue Involvement in Mutated Family Members
42295,Multivariable Predictors of Death or Delisting Due to Worsening in ACHD
42297,Prognostic Factors for Cardiac Amyloidosis
42300,Correlations Between CI and Selected Renal Metrics
42303,Percentage of U.S. Adults Meeting Each Sequential SPRINT Eligibility Criterion, Overall and in Subgroups
42304,Percentage of U.S. Adults, Overall and With Treated Hypertension, Meeting the SPRINT Eligibility Criteria in Select Populations
42306,Antihypertensive Medication Use Among U.S. Adults50 Years of Age and With Treated Hypertension, Overall and Among Those Eligible for SPRINT
42307,Percentage and Number of U.S. Adults With Systolic Blood Pressure120 mmHg Without SPRINT Exclusion Criteria
42308,Comparison of Thromboelastography   ROTEM   and the GTT, With Respect to Assessment of Thrombosis
42309,Studies From 1999 to 2015 That Utilized Multivariate Analysis in Patient Cohorts  1,000 to Assess the Predictive Value of Plasma Fibrinolysis Markers for Adverse CV Events
42310,Clinical Studies Evaluating the GTT in the Prediction of Cardiovascular Risk
42311,Studies Utilizing TEG in the Evaluation of Platelet Reactivity and its Correlation to the Risk of Ischemic Events in Nonsurgical Cardiovascular Patients
42312,Equations for Estimating GFR and CrCl
42317,Improvement in Model Calibration and Reclassification of Abeta40 Over Best Predictive Model for Endpoints
42319,Complications Associated With CRT D and ICD Implantation Across CKD Stages
42320,Unadjusted 3 Year Event Rates and Unadjusted and Adjusted Analyses Comparing Outcomes Among CRT D and ICD Recipients
42322,Within Day and Between Week Variation in Cardiac Troponin T Levels
42323,The Individual Diurnal Variation of Cardiac Troponin T Is Significant, as Described by Using a Cosine Curve
42325,Associations of Arterial Stiffness Indices of the Carotid, Femoral, and Brachial Arteries With Incident CV Events and All Cause Mortality
42326,Associations of the cfPWV, Aix, and SAC With Incident Cardiovascular Events and All Cause Mortality
42329,Association Between Cardiac Troponin T and Primary Outcomes Using Cox Proportional Hazards Regression Analysis
42330,Prevalence of ECG Criteria Indicative of Acute Myocardial Ischemia in Patients With and Without Elevated cTnT
42331,New York Heart Association Function Classification
42332,Echocardiography Criteria
42334,Factors Identified as Precipitating Hospital Admissionin the OPTIMIZE HF Registry
42336,Echocardiographic Findings at the Time of Presentation in the RO AHFS Registry
42339,Multivariate Analysis of Risk Factors Associated With the Presence of Atherosclerotic Renal Artery Stenosis
42340,Multivariate Analysis Showing Patient and Procedural Factors Associated With Lower Pre Discharge GFR, Renal Replacement Therapy, and Longer Operative Length of Stay
42341,Patient and Procedural Factors Associated With Incremental Risk for Death After Open Heart Surgery
42342,Characteristics of the 1,141 AMI Patients According to PENK Quartiles on Admission
42343,Univariate General Linear Model Showing Independent Predictors of PENK Levels
42344,Cox Regression Analysis for MACE at 2 Years Post AMI
42345,Cox Regression Analysis for Death and or MI at 2 Years Post AMI
42346,Cox Regression Analysis for Death and or Heart Failure at 2 Years Post AMI
42347,Cox Regression Analysis for Re MI at 2 Years Post AMI
42348,Cox Regression Analysis for Endpoints at 6 Months   MACE, Death and or MI, Death and or HF
42350,Quality and Process Care Measures for Hospitalized Heart Failure Patients, by Principal Diagnosis
42351,Relationship of Quality and Process Care Measures With 1 Year Mortality Following HF Hospitalization, by Principal Diagnosis
42352,Quality and Process Care Measures for Hospitalized HF Patients for 2 Alternative Definitions of Acute HF, Physician Documentation of HF as Reason for Hospitalization, andARICAdjudicated Acute HF
42354,Univariate Analysis: WRF and Cardiovascular Death and HF Hospitalizations
42355,Multivariable Analysis: WRF and Cardiovascular Death and HF Hospitalizations
42356,WRF and Primary and Secondary Outcomes
42357,Summary of Studies With Data on Prognostic Value of Significant TR After Left Sided Procedure
42358,Echocardiographic Parameters Used for Grading TR Severity
42360,Echocardiographic Data
42361,Causes of Death
42362,Univariable and Multivariable Cox Regression Analysis for All Cause Mortality
42365,Clinical 30 Day Follow Up After Contrast Medium Administration
42366,Multivariable Analysis for CI AKI Predictors of CI AKI
42367,Occurrence of CI AKI in Statin Naive and Non Naive Patients
42372,Adverse Clinical Events at 30 Days by TreatmentGroup
42373,Characteristics of Acute Myocardial Infarction Patients According to ProSP Quartiles on Admission
42374,General Linear Model Showing Independent Predictors of ProSP Levels
42375,Cox Regression Analysis for MACE at 2 Years Post AMI
42376,Cox Regression Analysis for Death and or Reinfarction at 2 Years Post AMI
42377,Cox Regression Analysis for Death and or HF at 2 Years Post AMI
42378,Cox Regression Analysis for Endpoints at 6 Months   MACE, Death and or Reinfarction, Death and or HF
42379,Reclassification Analysis Using Continuous Reclassification
42383,LDL Independent Effects of PCSK9
42384,Therapeutic Approaches Targeting PCSK9
42387,Reasons for Hospitalizations
42388,Cox Regression Models   Unadjusted
42390,Independent Correlates of CI AKI After PCI
42391,In Hospital Complications
42392,In Hospital Complications and Degree of Hemoglobin Decrease
42394,T1 Indices in Each Age Category
42395,Regression Models for Association of T1 Indices With Age Across Sex   Regression Coefficients B p Value
42396,Candidate Predictor Variables Considered in the Models
42406,Coronary Artery Calcification   CAC   Scores   in the CRIC Genetic Subsample
42407,Top Associations With CAC Traits in CRIC, With Directionally Consistent Associations in PennCAC or AFCS
42408,Association of Top CAC SNPs   With MI in PROMIS
42409,American Diabetic Association 2003 to 2004 Guidelines to Assess Pregnancy at Risk for Gestational Diabetes    16,72
42410,Approaches to the Diagnosis of GDM: 1 Step    12    and 2 Step Algorithms    14
42411,Canadian Diabetes Association Recommended Criteria for Diagnosis of Type 2 Diabetes and Pre Diabetes    23
42412,Studies Examining Vascular Responsiveness in Gestational Dysglycemia
42414,Multivariable Adjusted Linear Regression Models of Relation of Natriuretic Peptides to Adiposity Phenotypes
42416,In Hospital Treatment Related Parameters
42418,Hazard Ratios for All Cause Death, Combined Endpoints of Death and MI, and Combined Endpoints of Death, MI, and Revascularization According to Biomarker Levels
42419,C Statistic for Cox Regression Models Predicting Major Adverse Cardiovascular Events
42420,NRI and IDI for Death and MI Using Biomarker Score
42423,Multivariable Cox Models for CV and Renal Outcomes
42427,Model Comparison by Risk Category
42429,Rate of Stroke TE per 100 Person Years in All Patients and in Patients With CHADS2 Score   0 With and Without Renal Impairment
42433,Procedural Data
42435,Ventricular Remodeling and Regional Function by Cardiac MRI, Stratified by BMI and NFG or IFG
42436,Table of Regression Coefficients From a Multivariate Linear Regression Model for LV Mass to Volume Ratio
42440,Final Multivariate Cox Regression Models for Cardiovascular Death or Congestive Heart Failure
42441,Final Multivariate Cox Regression Models for Myocardial Infarction
42442,Final Multivariable Cox Regressions Models for Cardiovascular Death or Congestive Heart Failure Dichotomized at Sex Specific 99th Percentile of Healthy Subjects
42443,Risk Associated With Concordant or Discordant Levels of hs TnI and hs TnT
42444,C Index and IDI: Effect of Adding hs TnI and hs TnT to Multivariate Models for Cardiovascular Death or Heart Failure
42451,Adverse Events and Drug Discontinuation During Titration
42454,Summary of Adverse Events During Randomized Treatment
42455,Summary of Safety Data
42457,Causes of Death During Follow Up Period
42458,Univariate and Multivariate Predictors of Cumulative Late Mortality
42459,Univariate and Multivariate Predictors of Cumulative Cardiac Mortality
42460,Univariate and Multivariate Predictors of Late    30 Days   Mortality
42466,Cox Regression Model for Mortality Using BF and LMI as Categoric and Continuous Variables
42467,Impact of COPD on Mortality in the Coronary Cohort
42468,Echocardiography Data
42469,Hemodynamics and Aortic Mechanical Properties
42474,Distribution of Patients by Renal Function According to the 3 Formulas
42475,Qualitative and Quantitative Correlations Between Methods
42481,HR of Sustained Anemia in 1,743 Outpatients With Heart Failure
42482,HRs for Death, MI, Revascularization, and Bleeding According to CKD Subgroup at 30 Months
42484,Death, MI, Revascularization, and Bleeding Rates at 30 Months
42486,HRs for Major CV Events Across Quartiles of Serum Testosterone, SHBG, Free Testosterone, and Estradiol
42487,HRs of Testosterone   Q4 vs. Pooled Q1 to Q3   for Major CV Events, First Years of Follow Up Excluded and Adjustment for Covariates
42489,Multivariate Association Between Level of Renal Function and the Risk for Presentation of CHD as Acute Myocardial Infarction Versus Stable Exertional Angina
42491,Operative and Post Operative Data
42492,Early and Late Results
42493,Post Operative Serum Creatinine
42495,Association Among Circulating NT proBNP, Testosterone, and SHBG
42496,Multivariable Models Assessing the Association Among Sex Hormone Status, Androgens, and NT proBNP Concentrations
42497,Subgroup Analysis by Menstrual Phase
42499,Hazard Ratio of Impaired Fasting Glucose Compared With Normoglycemia for the Primary Outcome of Cardiovascular Disease Events and Individual Cardiovascular Disease Outcomes in the MESA Study
42503,Uni  and Multivariable Cox Proportional Hazards Models for Time to All Cause Mortality
42505,Laboratory Parameters According to Renal Function and Platelet Responsiveness to Clopidogrel
42508,Outcomes According to Platelet Responsiveness to Clopidogrel
42509,Outcomes According to Renal Function and Platelet Responsiveness to Clopidogrel
42510,Outcomes at Follow Up According to PRI Quartiles in CKD Patients
42511,Univariate Analysis for Prediction of Cardiac Death and MACE in the Whole Population
42512,Multivariate Analysis for the Prediction of Cardiac Death and MACE Following PCI
42514,Hazard Ratios for Mortality for the Individual Biomarkers in Univariate Cox Regression
42516,Multimarker Risk Score for Mortality
42517,Discrimination of Cox Regression Models in Predicting Mortality in STEMI Patients
42519,RR of All Cause and Cause Specific Mortality by 10th to 90th Percentiles of Cys C Levels and Other Confounding Risk Factors
42521,Cardiorespiratory, Echocardiography, and Muscular Results Before and After 6 Months of Testosterone Supplementation Therapy
42522,Metabolic and Hormonal Results Before and After 6 Months of Testosterone Supplementation Therapy
42524,Events Prevented and Caused by Aspirin Therapy for Every 1,000 Patients Treated According to eGFR Category
42526,Clinical Profile of the 2 Groups
42527,Operative and Post Operative Data
42528,Post Operative Data
42529,BNP, EF, ANP, and the RAAS After Operation
42531,Unadjusted Rates of CI AKI According to Pre Procedural Glucose Level
42535,Occurrence of Monitored Adverse Events, Measured Laboratory Values, and Other Reported Events of Interest During Follow Up
42538,Associations of CKD    With High and Low ABI
42539,Association of CKD With High and Low ABI, Stratified by Diabetes Status
42543,Cardiorespiratory and Muscular Results Before and After 3 Months of Testosterone Supplementation Therapy
42544,Metabolic and Hormonal Results Before and After 3 Months of Testosterone Supplementation Therapy
42548,Prognostic Value of Biochemical Markers Measured at Different Time Points
42549,C Statistics: Incremental Prognostic Value of Biochemical Markers Regarding the Composite of Death or Myocardial Infarction During 5 Year Follow Up
42552,Main Efficacy Analysis: Primary, Secondary, and Additional CIMT Outcomes
42554,Major Cardiovascular Events
42556,Multiple Linear Regression Analysis Assessing the Independent Influence of Different Variables on Natriuretic Peptides
42558,Cox Regression Models for the Prediction of Death
42562,Correlations Between GFR and FEs
42565,Relation of Age  and Sex Adjusted Levels of Resistin and Adiponectin to Each Other and to HOMA IR, CRP, and BNP
42567,Primary Indication for Heart Catheterization
42569,Multivariate Stepwise Cox Regression Model
42574,Cox Proportional Hazards Model Analysis of Factors Predictive of Mortality for the Cohort
42576,Single Predictor and Multivariable Stepwise Cox Regression Analysis for 24 Month Mortality for Various Clinical Variables
42577,Stepwise Cox Regression Analysis for Predicting Survival Depending on NYHA Functional Class
42584,Selected Safety Outcomes in Patients With CKD and Patients With Normal eGFR by Treatment
42590,In Hospital Clinical Outcomes by CKD Agreement Groups
42597,Odds Ratios and 95  Confidence Intervals by Glucose Subgroup for 4 Year Incidence of CHD According to 1997 and 2003 IFG Definitions
42598,Odds Ratios and 95  Confidence Intervals by Glucose Subgroup for 4 Year Incidence of Cardiovascular Disease According to 1997 and 2003 IFG Definitions
42599,Odds Ratios and 95  Confidence Intervals for 4 Year Incidence of Diabetes Examining the 1997 and 2003 IFG Definitions in Age  and Multivariable Adjusted Models
42602,Treatment Benefit of Perindopril at Different Levels of Renal Function   n   12,056
42603,Absolute Risk Reduction by Perindopril for the Primary End Point   n   12,056
42604,Data From the EUROPA and PEACE Trials
42608,Hazard Ratios   95  CI   for All Cause Mortality and or Hospital Stay for HF Stratified by eGFR Group
42610,Univariate Associations Between Serum Sex Hormone Levels and ABI
42611,Serum Free Testosterone Positively and Independently Associates With ABI, and Estradiol Negatively and Independently Associates With ABI
42612,Low Serum Free Testosterone as Well as High Free Estradiol Independently Associate With Lower Extremity PAD
42614,Univariate Predictors of Primary End Point of Cardiac Mortality and Need for Urgent Heart Transplantation
42615,Predictors of Primary End Point and Cardiac Mortality in Multivariate Cox Regression Analysis
42616,Antibody Response to Treatment and Rate of Plaque Inflammatory Cells
42619,Cox Regression Coefficients for the Cohort of Individuals With CKD and for the Original Framingham Cohorts for 10 Year Cardiac Outcomes
42621,Differential Diagnosis of AIT
42623,Therapy Received for Hyperthyroidism   n   84
42624,Time to Normalization of Thyroid Hormone Values
42625,Duration of Follow Up and Incidence of the Primary Composite End Point in All Patients and in Patients Stratified According to Left Ventricular Function at the Time of AIT Diagnosis
42629,Surgical Procedures
42630,Number of Patients Receiving Selected Concomitant Postoperative Cardiovascular Medications
42631,Degree of Postoperative Inotropic and Vasoactive Pharmacotherapy
42632,Adverse Events
42634,Quantitation of Infarct Size in Hp 1 and Hp 2 Mice
42635,Myocardial Lipid Peroxidation Products of Arachidonic Acid in Hp 1 and Hp 2 Mice With and Without IR
42637,Spearman Correlation Coefficients Between Hormones and Natriuretic Peptides
42638,Multivariable Associations Between Menopausal Variables, Hormones, and Natriuretic Peptides
42642,Multivariate Analysis Using Individual and Combined Measures of Cardiac and Renal Insufficiency for the Prediction of Death by 60 Days Following Presentation With Acute Heart Failure   HF
42643,Clinical Laboratory Data of Patients With Acute KD, Comparing IVIG Treatment Responders and Nonresponders
42644,Serum Concentrations of MRP 8 MRP 14 and C Reactive Protein in Patients With Acute KD, Comparing IVIG Treatment Responders and Nonresponders
42646,Relative Risks of Coronary Heart Disease and Mortality From Cardiovascular Disease in Persons With Chronic Kidney Disease   CKD   and Without CKD, With or Without History of Myocardial Infarction   MI  : the ARIC Study, 19872001
42648,Prevalence of Coronary Heart Disease Risk Factors According to Glucose Category
42649,Prevalence of Coronary Heart Disease According to Glucose Category
42651,Relationship Between HOMA IR and Cardiac Risk Factors
42653,Relationship Between Markers of Oxidative Stress and Inflammation Groups and Carotid IMT
42655,Univariate and Multivariate Linear Model of Transcardiac Increase in Log BNP
42656,Univariate and Multivariate Linear Model of Plasma Log BNP
42658,Group Comparison Between Patients With Chronic Heart Failure Above and Below the Median Insulin Sensitivity Value   1.82 min1   U  ml1   104
42659,Univariate Cox Proportional Hazards Analyses in Patients With Chronic Heart Failure
42660,Stepwise Cox Proportional Hazard Analysis in Patients With Chronic Heart Failure
42664,Univariate Correlations   r   of Log BNP and Log NT proBNP With Hemodynamic and Other Parameters in the Overall Cohort   n   40
42665,Univariate Correlations   r   for Log BNP and Log NT proBNP in Patients With eGFR  60 ml min   n   15   and  60 ml min   n   25
42667,Hazards Ratio of Future Cardiovascular Events   n   112   According to Prognostic Variables in 639 Patients
42669,Univariate and Age Adjusted Correlates of Carotid Artery Intima Media Thickness in 236 Men
42671,Quartiles of Renal Function and Mortality Risk in Elderly Patients With Heart Failure
42674,Multivariate Analysis of Predictors for Developing Cardiac Events
42675,Comparison of Body Weight and Food Intake
42676,Comparison of Blood Chemistry
42678,Comparison of Hemodynamic and Echocardiographic Parameters
42682,Glucose Tolerance Status of the Two Experimental Groups   p   0.05
42684,Univariate and Multivariate Predictors of All Cause Mortality
42685,Selection Criteria for Renal Artery Angiography
42686,Results of Renal Angiography Categorized by Severity of Renal Artery Stenosis
42687,Prevalence and Severity of Renal Artery Stenosis According to Individual Selection Criteria
42689,Prevalence and Severity of Renal Artery Stenosis According to Cardiac Catheterization Findings
42690,Multivariate Associations With Severe Renal Artery Stenosis
42692,Two Dimensional and Doppler Echocardiographic Parameters
42697,Univariate and Bivariate   Adjusting for CRP or CAD Score   Hazard Ratios for Death and or MI for RI or RF, and Univariate Risk Among Patients With and Without ACE inhibitors at Discharge
42698,Hazard Ratio of Death or Myocardial Infarction in Multivariate Analysis
42700,Multivariable Analysis of CAC and Disease Status
42702,Genotype Frequencies of GCLC129C T Polymorphism in Control Subjects and Patients With MI
42707,General Echocardiographic Measurements in 55 Female Patients With AndersonFabry Disease
42709,Systolic Function in Patients With Increased LVM   n   35   Versus Normal LVM   n   20
42710,Diastolic Function in Patients With Increased LVM   n   35   Versus Normal LVM   n   20
42712,Low  and High Dose NEP Inhibition on DNP
42714,Simple and Partial Correlation Coefficients   r   Between Coronary Heart Disease Risk Factors, BMI, and SSPG
42715,Multiple Regression Analysis of the Relationship Between the CHD Risk Factors With BMI and SSPG Jointly, Without an Interaction Term   Model A   and With the Interaction Term   Model B
42718,Concentrations of Plasma Pteridine Derivatives and Erythrocyte Dihydropteridine Reductase Activity in the Coronary Sinus
42719,Multiple Stepwise Regression Analysis of Variables Significantly Associated With Percent Changes of Acetylcholine Induced Left Anterior Descending Artery Diameters
42721,Comparison of the Lipid and Lipoprotein Concentrations in the Three Study Groups     Mean  SEM
42722,Comparison of the Plasma Triglyceride and Remnant Lipoprotein Responses in the Three Study Groups   Mean  SEM   to the Oral Fat Load
42726,Standardized  RR for All Cause Mortality Predicted by Level of GFR and Hematocrit   Including the Interaction Term   legend
42727,Prevalence of CAD in the Study Population legend
42729,Multiple Logistic Regression of Determinants of CAD legend legend
42731,Insulin Profiles and Hemostatic Factors in Hypertensive Subjects legend
42732,Multiple Logistic Regression Analysis With All Silent Cerebral Infarcts or Silent Multiple Cerebral Infarcts as the Dependent Variable in Hypertensive Subjects legend
42733,Multiple Logistic Regression Analysis of Silent Subcortical Cerebral Infarcts or Silent Basal Ganglia Infarcts as the Dependent Variable in Hypertensive Subjects legend
42738,Cardiovascular Results in AAS Users and Bodybuilding Controls legend
42740,Glucose, Insulin and Lipid Values Before and After Oral Glucose Loading, Alone or With Vitamins legend
42741,Hemodynamics, Basal Brachial Artery Diameters, Brachial Artery Flow and Reactive Hyperemia Before and After Oral Glucose Loading, Alone or With Vitamins
42742,Systemic Markers of Oxidative Stress Before and After Oral Glucose Loading, Alone or With Vitamins legend
42745,Results of IVUS Measurements
42748,Results of Serial Intravascular Ultrasound Analysis legend
42750,Multiple Regression Analysis of Predictors of the Neointimal Index at Follow up legend
42752,Oral Glucose Tolerance Test legend legend
42753,Plasma Vitamin C Concentration legend legend
42755,LVEF and Biochemical and Hematological Parameters by NYHA Class in 142 Patients With CHF
42756,Number       of the 26 Patients Taking Each Type of Medication Before and During the Intervention Period and the Reason Why the Medication Was Not Used legend
42757,Mean Dose of Each Medication Initially and at the End of the Intervention Period in the 26 Patients
42758,The Hematological and Clinical Data of the 26 CHF Patients at Onset and at the End of the Intervention Period legend
42760,Hemodynamic Data and Blood Sampling Data During Oral Glucose Tolerance Test legend
42764,Glucose Tolerance Status of Cases and Controls
42765,Values That Best Discriminated Myocardial Infarction Cases from Controls
42766,Multivariate Odds Ratios for the Independent Determinants of Myocardial Infarction
42768,Atherosclerotic Indexes in Patients With and Without Restenosis After Percutaneous Transluminal Coronary Angioplasty legend
42769,Oral Glucose Tolerance Test Results in Patients With and Without Restenosis After Percutaneous Transluminal Coronary Angioplasty  legend
42770,Diagnosis of Early Allograft Vasculopathy
42771,Clinical, Angiographic and Scintigraphic Features of 22 Episodes of Vascular Occlusions Detected in 18 Patients and the Response to Augmentation of Immunosuppressive Treatment legend
42772,Clinical Response According to Diagnostic Criteria and the Time of Treatment After Transplantation
42774,Cardiac Medications in Patients in Each Functional Class
42775,Antioxidant Levels and New York Heart Association Functional Class
42778,Clinical Details and Humoral Determinations in 38 Patients With Chronic Heart Failure and 20 Healthy Control Subjects
42779,Insulin and Glucose Metabolism Data Assessed in 38 Patients With Chronic Heart Failure and 20 Healthy Control Subjects
42780,Clinical Details and Measures of Carbohydrate Metabolism in Men With Chronic Heart Failure Due to Coronary Artery Disease or Dilated Cardiomyopathy and in Men With Coronary Artery Disease Without Chronic Heart Failure
42781,Lung and Liver Wet Dry Weight Ratios in Sham and Infarcted Rats at 1, 4 and 16 Weeks After Operation and Effect of Afterload Reduction Therapy at 16 Weeks
42782,Left Ventricular Pressure in Sham and Infarcted Rats at 1, 4 and 16 Weeks After Operation and Effect of Afterload Reduction Therapy at 16 Weeks
42783,Antioxidant Enzyme Activity and Lipid Peroxidation in Sham and Infarcted Rats at 1, 4 and 16 Weeks After Operation and Effect of Afterload Reduction Therapy at 16 Weeks
42784,Linear Regression Analysis of Morphometric Results for Phase 2 High Molecular Weight Poly l Lactic Acid Stents  a
42786,All Cause, Cardiovascular, and Noncardiovascular Mortality in HFpEF Patients With and Without Abdominal Obesity
42788,Admission and Discharge Medications in HF Patients by EF Groups
42789,Mortality, Readmission, and Composite Outcomes at 5 Years Post Admission in HF Patients by EF Groups
42792,Hazard Ratios for Different Endpoints per 1 SD Increase of ST2 Level or NT proBNP Level   on the Log2 Scale   at Any Point in Time Using Repeated ST2 and Repeated NT proBNP Measurements in a Joint Model
42795,Regression Modeling for All Cause Mortality andtheComposite Endpoint of Mortality and or HF Related Hospitalization
42798,Univariable Association for MACE and Death: Clinical Variables
42799,Univariable Association for MACE and Death: CMR Variables
42800,Univariable Association of LGE Parameters for MACE Based on Acuteness of Presentation
42804,Unadjusted Mortality and Mortality Adjusted for Absolute Changes in HF Medication Dose Over 6 Months
42805,Major Lipid Classes
42807,Log Transformed Door to Furosemide Time
42808,Logistic Regression Analysis
42811,Event Rates According to Duration of Heart Failure
42818,Drug Use Within 120 Days
42819,Downstream Testing, Revascularization, and Costs Within 120 Days
42820,No Enrichment of Variations in TLR3  or IFN   Related Genes in Patients With AM
42821,Enrichment of Homozygous Rare Variations in Cardiomyopathy Associated Genes in Patients With AM
42824,Incidence of Aortic Stenosis Accounting for Competing Risks, Stratified by Age, Sex, and Risk Factors   per 100,000 Person Years
42825,Estimates of the Adjusted Hazard Ratios for Severe Aortic Stenosis in Prediction Models for All Individuals, Men, and Women
42826,Population Attributable Risk of Aortic Stenosis by Cardiovascular Risk Factors
42830,Secondary Endpoints at 6 Months
42832,Changes in Likert Numerical Dyspnea Score
42835,Patients With Adverse Events
42837,Frequency of Valvular Heart Disease Subtypes in Patients Randomized in RE LY, ROCKET AF, ARISTOTLE, and ENGAGE AF TIMI 48 Trials
42838,Entry Criteria as Met by Trials Comparing Calcium Channel Blockers With Conventional Therapy
42839,Stroke: Calcium Channel Blocker Based Therapy Versus Conventional Therapy of Hypertension
42840,Myocardial Infarction, Heart Failure and Major Cardiovascular Events: Calcium Channel Blocker Based Therapy Versus Conventional Therapy of Hypertension
42841,Diabetic Hypertensive Therapy Based on Calcium Channel Blockers and Angiotensin Converting Enzyme Inhibitors
42846,Characteristics of Trials
42848,Pooled Relative Risk of Efficacy and Safety Outcomes With Intensive Versus Standard BP Lowering in Elderly Patients
42850,Unadjusted and Adjusted Association Between Appropriateness of NOAC Dosing and Clinical Outcomes
42852,Descriptive Analysis of Causes of Death as Total Numbers and as Percentage of Total Deaths
42853,Descriptive Analysis of Causes of Death and Adjusted Event Rates per 100 Patients per Year   All Study Patients, Regardless of TreatmentGroup
42854,Absolute Difference in Events per 10,000 Patients Treated per Year for the Different Cause Specific Deaths
42855,Clinical Characteristics of the Study Population and Patient Clinical Outcome
42856,Echocardiographic Analysis
42857,CMR Results and Patient Clinical Outcomes
42858,Clinical Characteristics and Univariate Predictors of Events
42859,CMR Results and Univariate Predictors of Events
42861,Net Reclassification Analysis
42862,Clinical Characteristics and Univariate Predictors of Events in High Risk Patients
42863,CMR Results and Univariate Predictors of Events in High Risk Patients
42868,Outcomes: Incidence Rates and Hazard Ratios
42871,Patient Selection Criteria
42873,Safety Data 30 Days and 6 Months After the Procedure
42877,Change in Primary and Secondary Outcome Variables in VINDICATE at 12Months Post Randomization: Intention to Treat Population
42879,Clinical Endpoints, Serious Adverse Events, and Hospitalizations
42880,Mitral Valve Configuration and Echocardiographic Parameters
42884,Previous Diagnoses and Treatments
42889,Adverse Events
42895,Adverse Events Reported During Treatment
42897,Metabolite Levels and Hemodynamic Indexes of RV PV Function
42898,IDO TM and Hemodynamic Measurements in Adjusted Models
42899,Validation Cohort: Metabolite Levels and RV PV Function
42900,Variables Predicting the Presence of RV PV Dysfunction
42902,Clinical Inputs Derived From Meta Analyses and Pivotal Trials
42903,Stroke Outcomes and Health State Utilities
42904,Cost Inputs
42905,QALY and Cost Results at 5, 10, 15, and 20 Years
42907,Overall Survival Estimate PostFontan Operation
42908,Overall Survival PostFontan Operation
42909,Late Survival     PostFontan Operation
42910,Late Survival PostFontan Operation
42911,Risk of Death or Cardiac Transplant
42912,Risk of Death or Reoperation
42913,Risk of Developing PLE PostFontan Operation
42915,Procedural Data
42916,Primary Adverse Events
42918,MOGE  S   Classification
42919,Examples of MOGE  S   Annotations in Patients With DCM
42922,Multivariate Logistic Regression Models
42923,HIPARCO Score to Estimate Favorable BP Response
42924,Efficacy Endpoints for the PEGASUS TIMI 54 Trial
42925,A Summary of Key 1  and 5 Year Findings From the SYNTAX Trial
42927,Primary Endpoint Event Rates by Risk Group and Treatment in the EMPHASIS HF Trial
42930,Anatomical Locations of GI Bleeding Events
42931,Overall Rates of GI Bleeding by Treatment Arm
42932,Study Drug, Antiplatelet Therapy Use Relative to GI Bleed Events
42934,Geographic Variation in GI Bleeding Rates and Treatment Effect
42935,Updated Classification of PH
42936,Checklist for the Echocardiographic Evaluation of PH
42937,High Risk Factors
42939,Summary of Pharmacological Treatment of Hypertension in the Management of Ischemic Heart Disease
42940,Summary of BP Goals
42941,Writing Group Disclosures
42942,Reviewer Disclosures
42944,Safety at 6  and 12 Month Follow Up
42945,CHA2DS2 VASc Risk Factor Components of AF Patients
42946,Risk of Ischemic Stroke in AF Male Patients   CHA2DS2 VASc Score of 1
42947,Risk of Ischemic Stroke in AF Female Patients   CHA2DS2 VASc Score of 2: Female Plus 1 Additional Stroke Risk Factor
42951,Incidence Rate of Appropriate Shock by Last LVEF Measurement Before Appropriate Shock
42953,Aortic Dilation Rate During Follow Up and Association With Type B Aortic Dissection
42956,Multivariable Cox Regression Analysis for Risk of Composite Primary Endpoint and Cardiovascular Death
42957,Measurements of Performance of the Models for the Composite Endpoint of Cardiovascular Death and HF Hospitalization and for Cardiovascular Mortality at 4 Years
42962,Multivariable Predictors of Exercise Capacity
42963,Reproducibility of Myocardial Deformation Parameters
42965,Periprocedural Details, Discharge Medication, and Ischemia Testing
42966,Clinical Outcomes at 12 Months
42968,Cox Regression Models Showing the Hazard Ratio of ESVEA in Relation to Stroke and Death or Stroke, Where Subjects are Censored at the Time of Atrial Fibrillation
42969,Cox Regression Models Showing the Hazard Ratio of ESVEA in Relation to Stroke and Death or Stroke, Where Atrial Fibrillation is Modeled as a Time Varying Exposure
42970,Number of Strokes per 1,000 Person Years in Relation to ESVEA and AgeGroups
42975,Structure, Function, and Ischemia Evaluation
42977,Multivariable Analysis for Independent Predictors of Survival in HFpEF Patients   Cox Proportional Hazard Model
42978,Multivariable Analysis for Independent Predictors of Survival in HFpEF Patients With CAD   Cox Proportional Hazard Model
42980,Comparison of Procedural Variables Between Patients on Rivaroxaban and Warfarin
42981,Comparison of Complications between Rivaroxaban and Warfarin
42982,Event Rates and HRs and 95  CIs for Bleeding Events
42983,Major Bleeding or Nonmajor Clinically Relevant Bleeding by Site
42985,HAS BLED Score in ROCKET AF Trial and Original HAS BLED Cohort
42986,ATRIA Score in ROCKET AF Trial and Original ATRIA Cohort
42989,Univariable and Multivariable Cox Regression Models for 30 Day and 1 Year Post Discharge Mortality Among Patients With Acute HF
42990,Prevalence of PDD
42991,Natural History of PDD and Subsequent Progression to Symptomatic HF
42992,CHADS2 Scores
42993,Results of Large RCTs of New Anticoagulants Versus Warfarin
42994,Efficacy and Safety Results at 2.3 Year Follow Up of the PROTECT AF Trial
42996,5  and 10 Year Unadjusted Event Rates for Those With and Without AP
42997,AP as a Predictor of Outcome on Adjusted Analysis
42999,Observed Rates and Number of Events for Efficacy and Safety Endpoints in Patients With Amiodarone and No Amiodarone at Randomization andbyStudyDrug Assignment
43000,Observed Rates and Number of Events in Patients Included in the Propensity Matched Analysis
43004,Univariate Analysis: Variables Related to Collateral Flow
43005,Univariate Analysis: Coronary Angiographic Data and Collateral Channel Assessment
43007,Management and Clinical Outcomes
43009,Change in MRI Parameters Over the 9 Month Study Period
43010,Changes in Measured Parameters Analyzed as Subgroups Above and Below Median LVM
43011,Changes in Measured Parameters Analyzed as Subgroups Above and Below Median LVMI
43012,Change in Blood Parameters Over the 9 Month Study Period
43013,Changes in Parameters of Endothelial Function, Blood Pressure, and Body Mass Index
43014,Summary of Applications and Limitations of Doppler Parameters in Patients With ValvularHeart Disease
43016,Symptoms and Signs Stratified by Age
43017,Investigative Findings Stratified by Age
43018,Clinical Presentation, Precipitating Factors, and Treatment Related to Unplanned Hospitalization for Heart Failure Occurring After Randomization
43019,Kaplan Meier Mortality Rates for Each Age Category
43022,Summary Statistics for Echocardiographic Measurements by NYHA Functional Class
43023,Associations Between Echocardiographic Parameters and Risk of All Cause Mortality, Cardiac Transplantation, or VentricularAssist Device Implantation
43024,Associations Between Echocardiographic Parameters and Risk of Cardiac Hospitalization
43025,Mechanisms and Markers of DM Related Endothelial Dysfunction
43026,Agents Interfering With Endothelial Dysfunction in Diabetes Mellitus
43029,AR and Excess Risk of Cardiac Mortality in HodgkinsDisease Survivors
43030,Effects of Radiation Therapy on the Heart
43031,Risk Factors for Radiation Induced Cardiotoxicity
43033,Safety Evaluation
43035,Clinical Outcomes
43037,Quantitative Myocardial Perfusion and CAC
43038,Cause of Death and Cardiac Events by Groups of CAC and CFR
43039,Multivariable Survival Analysis
43041,Incidence of ECV, PCV, and AF Ablation
43042,Multivariable Model of Factors Associated With the Utilization of ECV, PCV, or AF Ablation
43043,Multivariable Model of Factors Associated With ECV or PCV
43044,Association Between ECV PCV AF Ablation and Outcomes
43045,Outcomes After ECV, PCV, or Catheter Ablation According to Randomized Treatment
43046,Outcomes after ECV, PCV, or Catheter Ablation Among Those Taking Study Drug on the Day of Procedure
43051,Efficacy Endpoints
43052,Safety Endpoints
43054,Diagnostic Performance of Key Indexes of Steady and Pulsatile Arterial Function and of Echocardiographic Measurements
43055,Univariable Logistic Regression Models Differentiating Between HFPEF and No HFPEF Patients
43056,Multivariable Logistic Regression Model Differentiating Between HFPEF and No HFPEF Patients
43057,Combined Approach to Diagnose or Exclude HFPEF
43060,Comparisons of Responses to LBPP Between Obstructive Dominant and Central Dominant Groups
43064,Multivariate Analysis of the Factors Associated With 30 Day Mortality in a Fully Adjusted Model
43065,30 Day Mortality Hazard Ratio in Various Clinically Relevant Subgroups
43066,Sensitivity Analyses
43067,Rate Control Targets and Drug Therapy at End of Dose Adjustment Phase
43069,Cumulative Incidence of Composite Primary Outcome and Its Components
43070,Heart Rate During Follow Up and Left Ventricular Ejection Fraction at End of Study
43071,Symptoms of AF at End of Study
43072,Trial Characteristics
43074,Trial Specific Factors Stratified by Participation
43076,Transitions to Open Label Vitamin K Antagonist or Aspirin Within 30 Days After Study Drug Early Study Drug Discontinuation and Study Completion
43077,Stroke or NonCentral Nervous System Embolism Rates and Stroke, NonCentral Nervous System Embolism, Myocardial Infarction, or Vascular Death During PostStudy Drug Discontinuation Risk Period
43078,Discontinuation Events: Major Bleeding Occurring During PostStudy Drug Discontinuation Risk Period
43079,Risk for CHD Among ART Treated HIV Infected Patients
43080,Main Classes of Antiretrovirals and Their Impact on Lipid and Glucose Metabolism and CHD
43081,Spectrum of Cardiovascular Risk Factors in Several Studies Including HIV Infected Patients With ACS
43082,Angiographic and Revascularization Features of CHD in HIV Infected Patients
43083,Clinical Studies Published on CABG Surgery in HIV Infected Patients
43084,Interactions Between Lipid Lowering Drugs and ART
43086,Medication Profile at Randomization and at Discharge
43087,Reasons for Early Discontinuation of Study Treatment
43088,Clinical Outcome Rates Among Participants Groups Based on Site Enrollment Status
43090,Summary of Median SSS and SRS Among Readers by Number of Vessels With Coronary Stenosis
43091,Summary of SDS in Patients With Angiography Positive Results
43092,Summary of SDS in Patients With Angiography Negative Results
43095,Prognostic Value of Individual Elements of the 1 Week Follow Up Examination
43096,Precipitating Factors and Multivariate Risk Adjusted In Hospital Clinical Outcomes
43097,General Considerations Regarding Gaps in Transitions of Care in Heart Failure
43098,Components of Early Post Discharge Follow Up
43100,Factors Associated With All Cause Mortality
43101,Causes of Death
43103,Factors Associated With New Onset Cardiomyopathy
43107,Comparison of Individuals With and Without LVRR at 3 and 6 Months of FU
43111,Clinical Presentation
43112,Use of Stress Testing and Calcium Scores and Coronary CT Angiography
43114,Diagnostic Procedure Findings and Recommendations
43116,Procedure Related Complications in Patients Without STEMI
43117,STEMI Quality Metrics and PCI Complications
43119,Univariate Correlations Between Left Ventricular Global Longitudinal Strain and Clinical and Echocardiographic Indices
43120,Univariate and Multivariate Cox Proportional Hazards Analysis
43122,Rates of HPR in LBW and HBW Patients Treated With Prasugrel 5 or 10 mg or Clopidogrel 75 mg
43123,Bleeding Events Related to Study Drug in LBW and HBW Patients Treated With Prasugrel 5 or 10 mg or Clopidogrel 75 mg
43128,Cardiovascular Events in Patients With HFNEF With Low or High RHI
43129,Cox Proportional Hazards Analysis for Future Cardiovascular Events in Patients With HFNEF
43130,C Statistics for Cox Proportional Hazards Analysis to Predict Future Cardiovascular Events in Patients With HFNEF
43131,Reclassification of Risk of PF5 for Cardiovascular Events After Addition of RHI
43132,Pathobiological Classification of Types of Potential Mechanisms Causing Elevations of Cardiac Troponin
43133,Acronyms
43134,Bleeding Academic Research Consortium Definition for Bleeding
43135,Net Changes in Spending During Follow up After Elimination of Copayments for Drugs Post MI    98
43136,Composition of Derivation and Validation Cohorts
43138,HRs and CIs for Complete Model Covariates
43139,HRs and CIs for Abbreviated Model Covariates
43141,Univariate and Multivariate Analysis in Normotensive and Pre Hypertensive Subjects Not on Antihypertension Medications
43142,Univariate Analysis of Biomarkers and Stage of Hypertension
43143,Univariate and Multivariate Analysis in Normotensive and Pre Hypertensive Subjects
43145,Cardiac Events in the 2 Groups
43149,Top Drug Induced Arrhythmia Associated SNPs   p   0.01   in the Group of 27 Amiodarone Users, the Group of 15 Sotalol Users, and the Whole Group of 58 Case Subjects Compared With 87 Control Subjects
43150,Top Drug Induced Arrhythmia Associated SNPs   p   0.01   Corrected for QTc Interval in the Group of 19 Amiodarone Users, the Group of 13 Sotalol Users, and the Whole Group of 44 Case Subjects Compared With 74 Control Subjects
43151,Top SNPs From the DARE Cohort   p   0.05   Associated With the Continuous QTc Interval in 74 Control Subjects Ordered According to Their Significance Together With the Results of the BRIGHT Cohort   n   1,480   and of the Meta Analysis of the 2 Cohorts
43154,Weighted Average Effects of New OAC Versus Warfarin
43155,Indirect Comparison Using Warfarin as Single Common Comparator, on the Basis of the RE LY, ROCKET AF, and ARISTOTLE Trials
43156,Guidelines and Scientific Statements
43157,State of the Art Reviews
43158,Key Clinical Trials in Heart Failure From Academic Year 20102011
43159,Evidence Grading
43160,Published Recommendations for Testing for CAD in Asymptomatic Kidney Transplantation Candidates
43161,Summary of Survey and Registry Data Demonstrating Variation in Cardiac Evaluation Practices Across U.S. Transplantation Centers
43162,Recent Descriptions of the Outcome Implications of Angiographic CAD in Patients With ESRD, Including Transplantation Candidates
43163,Accuracy of Noninvasive Testing for Detection of Coronary Artery Stenosis in End Stage Renal Disease Patients
43164,Summary of Recent Studies of Associations of Cardiac Biomarkers With Clinical Outcomes in Kidney Transplantation Candidates and Recipients
43165,Revascularization to Improve Survival Compared With Medical Therapy
43166,Recommendations from the 2007 AHA ACC SCAI ACS ADA Science Advisory on the Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents    159
43167,Summary of Published Randomized Clinical Trials of Statin Therapy in Dialysis Patients
43168,Summary of Published Randomized Clinical Trials of Statin Therapy in Kidney Transplantation Recipients
43169,Proposed Randomized Controlled Trials in Kidney and Liver Transplantation Candidates
43170,Writing Group Disclosures
43171,Reviewer Disclosures
43172,Abbreviations
43173,Sources of Pharmacogenetic Variation
43174,Main Genetic Associations With the Response to Statins
43175,Main Genetic Associations With the Response to Clopidogrel
43176,CYP2C19 Diplotype Classification
43177,Main Genetic Associations With the Response to Warfarin
43178,Main Genetic Associations With the Response to Beta Adrenergic Receptor Antagonists
43186,Effects of the Clinical Algorithm Compared With Control on Primary and Secondary Outcomes Among High Risk Individuals
43187,Agreement Between Nonphysician and Physician Healthcare Workers Using the Algorithm
43188,Effects of Health Promotion Compared With Control on Primary and Secondary Outcomes in Adults Age 30 Years or Older
43200,Sex Adjusted Blood Pressure, Vascular, and Cardiac Geometry Parameters
43201,Sex Adjusted Doppler Echocardiography Parameters
43202,Sex Adjusted Hemodynamic, Cardiac, and Vascular Function Parameters
43209,Cox Proportional Hazard Ratio Model to Predict Appropriate ICD Therapies
43210,Cox Proportional Hazard Ratio Model to Predict Appropriate ICD Shocks
43212,Procedure Related Complications
43213,Survival Rate After Alcohol Septal Ablation
43218,Clinical Events
43220,Continuous and Prevalence of Categorical Patient Variables Significantly Different From the EVEREST II Study
43225,Procedural Data
43226,Short Term Clinical Outcomes
43228,Predictors of All Cause Mortality at 30 Months
43231,Echocardiographic and Humoral Assessment After Volume Expansion and Placebo or BNP Treatment
43233,Relationship Between the K Sparing Effect and the Crude Event Rates
43235,Cardiorespiratory and Metabolic Responses to Maximal Normoxic Cycle and KE in Patients With CHF and in Controls
43236,Arterial and Venous Epinephrine, Ne, and Calculated Ne Spillover From the Muscle During Maximal Cycle and KE in Controls and Patients With CHF
43239,Relative Change in Measures of Aortic Geometry With Age: Comparison of Young   Age  30 yrs   and Older Subjects   Age  70 yrs
43240,Relationships Between Measures of Aortic Geometry and LV Mass and Geometry Adjusted for Age, Sex, Height, Weight, and Central SBP
43242,Iron Status
43244,Implant Details
43245,Responders and Hemodynamic Response Depending on LV Lead Position
43246,Sensitivity and Specificity for 10  Rise in LV dP dtmax for LV Pacing and Standard Echocardiographic Measures of Dyssynchrony Predicting 15  Reduction in ESV
43248,Differences in Hemodynamic and Chronic Response Between DCM and ICM
43249,Detection of Coronary Artery Disease by Cine, Visual, and Quantitative SENC
43255,Clinical Factors Associated With Changes in Echocardiographic Parameters
43257,Effect of Allopurinol and Placebo on Endothelial Function, Serum Urate, and Serum Biomarkers
43258,Incidence of PPCM in the United States
43259,Outcomes of Patients With PPCM in the United States
43262,Cardiopulmonary Exercise Performance
43263,Predictors of Peak Oxygen Consumption
43264,Studies of Determinants of Exercise Intolerance in HFPEF
43266,Cox Analysis for the Composite of Cardiovascular Events   Stroke, Acute Coronary Syndrome, Acute Heart Failure
43267,Cox Regression Analysis for All Cause Mortality
43268,Multivariate Cox Analysis for Cardiovascular Death
43269,Cox Analysis for the Composite of Major Hemorrhagic Events
43270,Additive Value of vWF Levels to CHADS2 and CHA2DS2 VASc Scores for the Composite of Thrombosis and Mortality
43271,Additive Role of vWF Levels to HAS BLED Score for Hemorrhagic Events
43280,Clinical Outcomes
43282,Stent Thrombosis
43285,Post Operative Outcomes
43286,Univariate and Multivariate Analysis for Predictors of the Late Post Operative SVEF
43287,Univariate Cox Regression Model to Predict Post Operative Mortality or Need for Cardiac Transplantation   n   58
43289,Individual Components of Secondary Efficacy Endpoint of Persistent WRF
43302,Events in the Patients With LVRR at Mid Term Follow Up Compared With the Other Patients on Long Term Follow Up
43305,Pharmacodynamic Studies That Evaluated the Administration of Clopidogrel to Subjects Receiving Atorvastatin
43306,Pharmacodynamic Studies That Evaluated the Administration of Clopidogrel to Subjects Receiving Proton Pump Inhibitors
43307,Clinical Studies That Reported the Coadministration of Clopidogrel and Atorvastatin
43308,Clinical Studies That Evaluated the Coadministration of Clopidogrel and Omeprazole
43311,Measures of Atheroma Burden and Vessel Wall Dimensions in Patients With and Without PAD
43314,Peripheral and Central Hemodynamic Parameters
43315,Simple Correlations Between Arterial Stiffness and Diastolic Function in Both Sexes
43316,Independent Correlation Between Arterial Stiffness and Diastolic Function in Men and Women
43318,Causes of Death
43319,Relationship of Adiponectin to CAD and ACS
43320,Effect of Adiponectin on Atherosclerosis and the Vulnerable Plaque
43321,Interventions That Increase Adiponectin Levels
43323,Risk of Death or Heart Failure by Sex
43326,Logistic Regression Analysis of Clinical Factors for the Presence of HFNEF Among Patients With Normal LVEF
43328,Logistic Regression Analysis of the Factors for the Presence of HFNEF Among Patients With LVDD and Normal LVEF
43329,Echocardiographic Parameters in Heterozygous Plako   and WT Mice Before and After Training Without and With Pre LoadReducing Therapy
43330,Electrophysiological Parameters of WT, Trained Treated, and Trained Untreated Heterozygous Plako   Mice
43333,Risk Associated With CCB Treatment
43335,Risk Associated With CCB Treatment
43340,In Hospital Medications, Medications at Discharge, and In Hospital Procedures by Years of Education
43342,Relationship Between Years of Education and 1 Year Mortality Rates by Enrolling Country
43343,Independent Correlates of 0  to 7 Day and 8  to 365 Day Mortality Derived Using Cox Proportional Hazard Model
43345,Secondary Outcome Measures
43346,Response to Elevated NT proBNP Levels During Follow Up
43347,Use of Evidence Based HF Medication at the Index Admission, Discharge, and During Follow Up
43348,Number of Increases of HF Medication During Follow Up
43349,Changes in NT proBNP, Urea, and Creatinine Levels During Follow Up
43350,Time Dependent HR if the Outpatient NT proBNP Level Is Above the Individually Set Target Value
43352,Regression Outcomes Predicting Changes in CTX I to 10 nmol l Response to Exercise With BDI and NE as Potential Moderators
43354,Mechanism of Action of Diuretic Classes
43355,Summary of Reviewed Studies in Heart Failure Patients
43356,Potential Benefits and Adverse Effects of CDT
43357,Important Considerations Regarding CDT
43358,Dosing and Duration of Action of TD
43359,Effects of Ranolazine   5 mol l  , Dronedarone   10 M  , and Their Combination on Atrial Excitability and Induction of ACh Mediated Persistent AF in the Isolated Canine Coronary Perfused Right Atria
43360,Effects of Ranolazine   5 mol l  , Dronedarone   10 mol l  , and Their Combination to Terminate Persistent ACh Mediated AF and Prevent Its Reinduction in the Isolated Canine Coronary Perfused Right Atria
43362,Blood Pressure Results, Mean Change      Presented for Office and Ambulatory Readings
43364,Effects of Ranolazine on Heart Rate and Systolic Blood Pressure at Each Stage of Exercise
43365,Effects of Ranolazine on Rate Pressure Product and Change From Pre Exercise in ST Segment Depression at Each Stage of Exercise
43366,Effects of Ranolazine on Change From Pre Exercise in ST Segment Depression at Each Stage of Exercise Controlled for Rate Pressure Product
43367,Composite Cardiovascular Score
43369,Fatal and Nonfatal Events Through 12 Weeks
43370,Serious Adverse Events by Treatment Group at 12 Weeks
43371,Nonfatal Cardiovascular Events During Long Term Follow up
43373,Risk of Death and Cardiac Events Among Patients With Chronic Organic MR in Sinus Rhythm Under Medical Management
43374,Drug Device Effects of Mortality Compared With Placebo in Patients With Heart Failure and LVD
43380,Trends in Medication Use Before and After a First Hospitalization for Heart Failure in the VA Health Care System
43381,Trends in Procedure Use and Outcome for Patients With a First Hospitalization for Heart Failure in the VA Health Care System
43383,sAM Levels Taken on Admission and Discharge and NT ProBNP Levels Across Different Patient Groups
43384,Cox Regression Analysis and Receiver Operator Characteristic Curve c Statistic for Admission and Discharge sAM Levels Across Primary and Secondary End Points
43385,Multivariate Cox Regression Analyses Comparing Admission sAM, GRACE Score, and NT proBNP for Prediction of Death at 1 Month, 6 Months, and Extended Follow Up
43386,Improvement in Identification of Event Free Patients and Those Who Died by Day 30 Using Admission sAM Levels in Addition to GRACE Score Tertiles Using Reclassification Analysis
43390,Univariate and Multivariate Predictors for Severe CVI in Fontan Patients
43397,Adverse Events During Treatment in Patients With or Without Diabetes
43404,Membrane Capacitances
43405,Twitch Parameters of Trabeculae From Patients in Sinus Rhythm
43413,Multivariate Model With Risk Factors Associated With Major Adverse Cardiovascular Events, Controlling for Study
43414,Characteristics of Included Studies
43419,ARR Deciles and Mean Peripheral and Central   Aortic   BP Measurements After Adjustment for Important Confounders
43420,Multivariate Stepwise Regression Analysis to Identify Predictors of BP
43422,Acute Heart Failure Diagnostic Performance of MR proANP Cut at 120 pmol l and BNP Cut at 100 pg ml
43423,Additive Value of MR proANP in Gray Zone Areas for Logistic Regression Models to Predict Acute Heart Failure
43424,Multivariable Diagnosis Models With BNP and MR proANP
43425,Summary of Predictive Performance for BNP, NT proBNP, and MR proADM for Predicting All Cause or Cardiovascular Death, Rehospitalization, Revisit, or Any of the Previous Events at 90, 30, and 7 Days After Initial Presentation to ED
43426,Single Predictor and Multivariable Cox Proportional Hazard Models for Survival Among Patients With Acute Heart Failure   n   568
43428,Clinical Features of the Study Patients and Genotype Positive Family Members
43431,Risk Factor Goals in the COURAGE Trial
43432,Pharmacologic Therapy in the COURAGE Trial
43437,Outcome for Adjudicated Major Cardiovascular Events
43442,Multivariate Discharge Predictors of Death in the ESCAPE Trial
43443,Simplified Discharge Score Model of Mortality From the ESCAPE Study
43444,Estimated Probability of Dying in 6 Months on Basis of Discharge Score Model
43447,Event Rates, HRs, and p Values for End Points
43450,Interventions and Days in Hospital Due to HF
43451,Medical Therapy: Discharge and Follow Up
43453,Cardiac Events in the 3 Study Groups
43454,Heart Failure Score
43456,Medications and Serial Measures
43457,Clinical Outcomes
43459,Medication at Admission and During Follow Up
43461,Laboratory Values According to Specific ACHD Diagnosis
43462,Comparison Between Anemic and Nonanemic Patients
43470,Clinical Data
43471,Magnetic Resonance Imaging Data
43472,Univariate Analysis for Prediction of Events
43473,Relation Between Diuretic Usage, Statin Usage, and Infarct Size   Spatial Extent of Scar Tissue   on LGE MRI
43474,Multivariable Cox Proportional Hazard Model for Prediction of Events
43482,Heritability   h2   and Effects of NPY1R3 UTR Variant A 1050G on Physiological Traits in Twin Siblings Pairs
43484,Changes in Blood Pressure, Laboratory, and CMR Variables
43486,Multivariate Regression Models for the Prediction of Change in Left Ventricular Mass
43489,Adverse Events   n   281
43494,Hemodynamic Status and Doppler Echocardiography
43495,2 Dimensional Strain and Rotation
43496,Vp
43497,Derived Measurements
43503,Mean Values of IVUS, Angiographic, and Hemodynamic Parameters in Patients With an HSG 21 mm Hg Versus  21 mm Hg
43506,Primary and Main Secondary Outcomes   Time to First Event   for High and Low EF
43507,Primary and Main Secondary Outcomes   Time to First Event   for LVEF 40
43512,Management of AF Patients With Versus Without HF and LSVD HF Versus PSF HF
43513,Univariable and Multivariable Effect of HF on Mortality and Adverse Events in AF Patients
43514,Multivariable Determinants of All Cause Mortality in Patients With AF and HF
43516,Efficacy Outcomes
43517,Performance on ETT at 8 Months   s, mean  SEM
43518,Safety and Tolerability Outcomes
43521,Incidence of Ischemia on cECG and Association With Clinical End Points
43524,Inclusion and Exclusion Criteria for Study Randomization
43527,Biventricular Pacemaker Diagnostics   n   40
43528,Hemodynamic and Echocardiographic Changes in Patients With CRT ON and CRT OFF   n   40
43529,Selected Hemodynamic Changes in Patients Who Improved With CRT OFF
43531,The SHFM Performance for Combined End Point and Mortality Predictions
43532,Observed Versus SHFM Expected Mean Survival
43533,Recalibrated 1 Year Risk Predictions for the Combined End Point
43535,Discharge Therapy and Procedures for Eligible Patients With Heart Failure and Left Ventricular Systolic Dysfunction
43536,Hazard Ratios for Initiation of Beta Blocker Therapy Versus No Beta Blocker Therapy
43537,Sensitivity Analyses of Subgroups in Patients With Heart Failure and Left Ventricular Systolic Dysfunction
43539,Clinical Correlates of BRS Measurements in Treated and Untreated Patients
43543,Results of Cox Proportional Hazards Multivariate Regression Analysis   n   247
43544,Relative Risk of MI According to Use, Treatment Duration, and Daily Dose of NSAIDs
43545,Relative Risk of MI According to Plasma Half Life and Release Formulation of NSAIDs and Stratified by Daily Dose
43546,Relative Risk of MI According to Daily Dose of Individual NSAIDs
43547,Relative Risk of Myocardial Infarction According to Concomitant Use of Aspirin and NSAIDs
43554,Univariate Correlations Between ST2, NT proBNP, BNP, and Selected Covariates
43555,Selected Univariable and Multivariable Predictors of 1 Year Mortality in Acute Heart Failure
43561,Cumulative Incidence of Cardiac and Arrhythmic Related ED Visits or Hospitalizations
43562,Relationship Between Defibrillator Therapy and Cardiac Related ED Visits or Hospitalizations
43563,Cardiac Related ED Visits or Hospitalizations and ICU Stays
43564,Frequency of In Hospital Procedures by Treatment
43571,Univariate and Multivariate HF Prediction Model Based on Plasma sACE2 Activity
43574,Clinical Genetic Analysis
43575,Haplotype Frequencies and Copy Numbers for ADRB1 and ADRB2
43576,Clinical Factors in Heart Failure Survival Studies Studying Adrenergic Receptor Genetics
43577,Results of Genetic Studies in  blockerTreated Heart Failure Patients With Survival End Points
43580,Variables Predictive of In Hospital Mortality
43585,Questionnaires
43586,Univariate and Multivariate Predictors of Any Reoperation
43587,Self Reported Exercise Tolerance
43588,Univariate and Multivariate Predictors or Excellent Indeterminate or Poor Outcomes
43589,Symptoms Reported by 285 Survey Responders
43590,Medications Indicated by Survey Responders
43591,Reasons for Subsequent Hospitalization After First Operation at Mayo Clinic as Reported by Survey Responders
43592,Pregnancies Reported by 82 of 285 Respondents
43595,Univariable Predictors
43596,In Hospital Mortality Model
43597,Risk Prediction Nomogram
43598,Comparison With Other Prediction Models
43600,Concomitant Medications Before Randomization and at 1 Year
43601,Reasons Leading to Discontinuation by Treatment and Race
43610,Cause of Death During the Perioperative and Long Term Period
43616,Hemodynamic Parameters of Subjects During Coronary Dobutamine Stress Test
43617,Hemodynamic Parameters of Subjects During Coronary Flow Reserve Study
43619,Multivariate Analysis of Variables Associated With Mortality in Primary Pulmonary Hypertension legend
43622,Relation of Changes in IAP or Serum Creatinine With Hemodynamic Variables Stratified According to All Patients and in Patients With IAP 8 mm Hg
43626,Multivariate Proportional Hazards Regression Model: Risk of All Cause Mortality in the Conventional Therapy Group for Selected Risk Factors
43627,Risk Score and Outcome in the Main Study Population: All Cause Mortality by Treatment Group
43628,Risk Score and Outcome in the Main Study Population: Multivariate Analysis for the End Point of All Cause Mortality
43632,Hematologic and Biochemical Parameters
43633,Single Predictor and Multivariable Cox Proportional Hazard Models for Various Clinical Variables   Derivation Study, n   525
43635,Cox Proportional Hazard Models for MR proANP and NT proBNP to Predict Survival in Different Subgroups of Patients With Chronic Heart Failure   Derivation and Validation Samples Combined
43637,Causes of Death Among T. gondiiSeronegative and Seropositive Recipients   n   288
43638,Multivariate Predictors of All Cause Mortality Beyond 1 Year After Heart Transplantation   n   255
43639,Multivariate Predictors of CAV Mortality Beyond 1 Year After Heart Transplantation   n   255
43640,Etiology of Congestive Heart Failure in the 2 Groups
43644,ADHF Protocol Patient Disposition
43647,ADHF Protocol Serious Adverse Events
43650,Comparisons of AMI Related Variables and Lesion and Procedural Variables During PCI
43652,Medications Before and After CRT
43657,Pharmacokinetic Parameters on Days 1, 6, and 10
43658,Adverse Events Reported by at Least 2 Patients   20    in Any BG9928 Group
43666,Association Between BNPs as Continuous Variables and Cardiovascular Outcomes Adjusted for Randomization Status
43667,Multivariable    Analysis of the Association Between BNPs as Continuous Variables and Cardiovascular Outcomes
43668,Multivariable    Analysis of the Association Between Quartiles of BNPs and Cardiovascular Outcomes
43669,Overall Prognostic Merit of BNP and NT ProBNP
43670,Incremental Prognostic Value of BNP and NT ProBNP to the Best Available Multivariable    Model for Cardiovascular End Points
43672,Patient Disposition
43678,Most Frequent Side Effects and Safety Assessments
43680,Concomitant Medications
43681,Primary and Secondary Efficacy and Bleeding End Points
43682,Rates of Cardiovascular Death, Myocardial Infarction, or Stroke at Different Time Intervals From the Ischemic Event to Randomization
43684,Indexes of Platelet Activation in Patients With AF Compared With Healthy and Disease Control Subjects
43686,Effect of Aspirin or Warfarin Therapy on Platelet Activation in Atrial Fibrillation
43691,Effects of Add On Pioglitazone Therapy Versus Placebo on Cardiac Related Events in Patients With Type 2 Diabetes and Previous MI
43693,Heart Failure in Patients With Type 2 Diabetes With and Without Previous MI
43695,Time to Event Analysis of Major Adjudicated Clinical End Points
43696,Proportion of Patients With Other Adjudicated Clinical End Points
43699,Summary of Previous Antidiabetes and CV Medications   All Randomized Patients
43703,Multivariate Hazards Ratios for Mortality Rate
43704,Description of Pooled Trials
43706,Multivariable Predictors of Death: Hazard Ratios With 95  Confidence Intervals
43707,Multivariable Predictors of Death or Hospitalization: Hazard Ratios With 95  Confidence Intervals
43712,Patient Disposition by Time on Open Label Treatment
43713,Summary of All Adverse Events 4  Incidence Reported During the ROLE Program
43714,Influence of Demographic and Clinical Categorical Variables on Risk of Discontinuations Due to AEs
43716,Cumulative Mortality to Date
43717,Patient Survival in ROLE and Other Published Patient Cohorts
43720,Adverse Events
43727,Spearman Correlations of Sol CXCL16 Levels With Cardiovascular Risk Factors
43728,Multivariable Association of Plasma Sol CXCL16 and CRP Quartiles  With CAD
43731,Clinical and Echocardiographic Summary of the 3 Groups: Control, SHF, and DHF
43732,Hemodynamic and Echocardiographic Measurements in DHF Patients Stratified According to Presence or Absence of Systolic and Diastolic Dyssynchrony
43733,Hemodynamic and Echocardiographic Measurements in SHF Patients Stratified According to Presence or Absence of Systolic and Diastolic Dyssynchrony
43739,Cause Specific Mortality by Gender and Treatment Groups
43741,Event Rates and Hazard Ratios for Study End Points
43742,Types of Stroke in Treatment Groups
43743,Factors Predictive of Cerebrovascular Events
43744,Cerebrovascular Events According to On Treatment Low Density Lipoprotein Cholesterol   LDL C
43746,Mean Initial and Final Values of Ejection Fraction, Body Weight, Blood Pressure, R R Interval, and R R Interval Variability Parameters
43747,Clinical Parameters of CHF With or Without Famotidine
43753,Adjusted Multivariate Analysis for Death Within 60 Days and for the Composite of Death Recurrent Heart Failure Within 60 Days
43757,SAEs
43759,Patient Variables   Mean  SD   Before   Pre   and After   Post   Enhanced External Counterpulsation   EECP
43764,Incidence of Adverse Cardiovascular Events and Hospitalization During Follow Up of Study Patients
43767,Univariable Surgical Predictors of POAF
43768,Postoperative Complications
43769,Univariable Echocardiographic Predictors of POAF
43770,Multivariable Cox Model Predicting POAF
43776,Concomitant Medications
43777,Weekly Angina Frequency and Nitroglycerin Consumption
43778,Primary Efficacy End Point Stratified by Subgroup   LAN Use, Gender, and Age
43780,Summary of Randomized Clinical Trials With Ranolazine
43782,Systemic Hemodynamics in the Supine and Upright Position and Mean Tilt Duration
43783,Supine and Upright Catecholamines With Placebo and With NET Inhibition
43785,Summary of All Double Blind Studies   75 to 125 mg
43786,Distribution of TdP Cases by Treatment Indication and Dose
43788,Multivariate TdP Risk Factor Analysis: Logistic Regression Model
43790,Medication Use
43795,Clinical Outcomes, 90 Days
43796,Mortality and Adverse Events, 180 Days
43799,Metabolic Parameters of Symptomatic Patients After Rosiglitazone and Placebo Treatments
43801,Changes in Clinical Variables During the Follow Up Period
43805,Unadjusted and Adjusted Outcomes Based on Beta Blocker Use During Hospitalization
43806,Outcomes of Patients With Respect to Beta Blocker Therapy
43808,Summary of Number of Cases and Controls for Each End Point Examined in the High  and Low Risk Cohorts
43811,Unadjusted Risk Ratios and 95  Confidence Intervals in the High  and Low Risk COPD Cohorts
43814,Patient Population Outcomes
43815,One Year Transplant Free Survival by Weber Class
43817,Treatment Effects in Patients With Low EF Depending on Heart Rhythm
43819,Cumulative Distribution and Reason for Days of Life Lost Over 4 Years
43821,Echocardiographic Features of Cushing Patients and Controls
43822,Systolic Performance and Diastolic Filling Parameters
43826,RT PCR Analysis of the Abundance of Ca2  Handling Protein mRNAs   Normalized by the Amount of GAPDH mRNA   in Endomyocardial Biopsy Specimens
43827,Univariate and Multivariate Predictors of Cardiac Events in IDCM Patients
43829,Number of Patients       Receiving Cardiac Medication
43832,Patient Population
43838,Correlations Between AS Plasma Induced Maximum in Vasoconstriction     KClEmax   and CCS Functional Class, Angiographic Diameter Stenosis, and IVUS Plaque Volume and Plaque Burden of the 19 Patients
43840,Exercise Parameters of Patients on Combination Therapy
43841,Exercise Parameters of Patients on Monotherapy
43844,Medication Use of CHF Patients
43845,Prevalence of TD in CHF Patients and Control Subjects
43846,Univariate Analysis of the Relationship Between Study Variables and TD as the Dependent Variable
43847,Multiple Logistic Regression Analysis
43851,Kaplan Meier Event Rates and Hazard Ratios for Risk Predictors
43852,Interactions between Microvolt T Wave Alternans and Other Risk Predictors
43855,Use of Non Intravenous Medications Before Hospitalization
43856,Use of Non Intravenous and Intravenous Medications During Hospitalization
43857,Use of Non Intravenous Medications at Discharge
43858,Clinical Outcomes During Hospitalization
43859,Multivariate    Odds Ratios and 95  Confidence Intervals for Identified Mortality Risk Factors
43860,Mortality According to Renal Function
43862,Mean Maximum Hemodynamic Changes With Regadenoson
43863,Imaging Visual and Quantitative Summed Scores by Pharmacologic Stress Agent
43864,Adverse Events Associated With Regadenoson Administration
43865,Clinical Signs and Symptoms of Volume Overload
43866,Early Ultrafiltration Therapy: Clinical and Laboratory Outcomes
43867,Number and Percentage of Patients Receiving Drug
43869,Medical Management During First 24 h After Enrollment
43871,Changes in Global Heart Failure Symptoms
43872,Changes in Global Dyspnea Symptoms
43882,Comparison of Selected Preoperative and Operative Data in Unmatched   All Patients   and Matched African American   AA   and Caucasian CABG Patients
43883,Comparison of Operative Outcome Data in Unmatched   All Patients   and Matched African American   AA   and Caucasian CABG Patients
43884,Multivariate Predictors of 0  to 12 Year Mortality Derived by Cox Regression Analysis Applied in All Patients
43885,Medicaid Status as a Predictor of 0  to 12 Year Survival After Isolated CABG in 6,377 at Saint Vincent Mercy Medical Center   Toledo, Ohio, 1991 to 2003
43888,Risk Ratios for One Year Mortality Associated With Aspirin Treatment in Subgroups
43890,Outcomes and Use of ASA Before Admission
43891,Independent Effect of Aspirin Use Before Admission on Mortality
43892,Effect of ASA Use Before Admission on Readmission
43893,Prevention of Type 2 Diabetes by ACE Inhibitors or ARBs
43896,Concomitant Medications at Bosentan Initiation
43898,Patient Survival and Treatment Status at Data Cutoff Date
43899,Multivariate Analysis Relating Time to PAH Worsening to Risk Factors
43900,Cox Modeling Based on Risk Factors Selected in the Univariate Selection Process on Time to PAH Worsening
43902,Summary of End Points at 30 Days After Randomization
43903,Urinary Ca2 and Mg2 Excretion at Week 4 Treatment
43905,Clinical and Laboratory Parameters Before   at Entry   and After Six Days of Treatment
43906,Laboratory Parameters of Renal Function at Discharge
43907,Results of the Study   30 Days  : Side Effects, Readmissions, and Mortality
43908,Changes in BNP Levels During the Study Period   30 Days
43909,Bioimpedance Analysis Parameters in Decompensated Heart Failure Patients Before and After Intravenous Treatment With HSS Plus Furosemide
43910,Bioimpedance Analysis Parameters in Decompensated Heart Failure Patients Before and After Intravenous Treatment With Furosemide Without HSS
43912,Design of Included Studies
43914,Description of the Left Ventricular Ejection Fraction   LVEF    at Different Time Periods: At the Time of Transplant Evaluation, While on the Waiting List to be Transplanted, and During the Follow Up After Kidney Transplantation
43918,Logistic Regression Models for Pre  and Post Transplant Predictors for Normalization of Left Ventricular Ejection Fraction   LVEF 50    in the Post Transplant Period   Reference Group: Group With LVEF 50  in the Post Transplant Period
43921,Echocardiographic Predictors of Outcomes on Univariate Analysis
43924,DRGs, Associated Costs, and Distribution of DRGs for Initial and Subsequent Hospitalizations
43925,Life Years Lost Attributable to Cardiovascular Events
43926,Costs
43927,Cost Effectiveness
43931,Comparison of Asymptomatic and Symptomatic Patients With MR
43932,Correlation Among Natriuretic Peptide Levels, Age, Body Surface Area, and Echocardiographic Measures of the Severity of MR and LV Function
43940,PREVENT: Comparative Mean Absolute TBARS Serum Levels With Specific Vascular Events and Procedures
43943,Multivariate Models for All Cause Mortality, Cardiac Death, and Composite End Point   All Cause Mortality, Stroke, or Nonfatal MI   During Follow Up   Average 27 Months
43944,Unadjusted Risk Ratios for All Cause Mortality and Cardiovascular Events After Various Time Points in Relation to High    4.1 ng ml  4th Quartile    and Low   4.1 ng ml  Quartiles 1 to 3    Osteoprotegerin Levels During Follow Up
43946,Group Hemodynamic Profile According to Adrenoceptor Genotype in Patients With Congestive Heart Failure
43947,Norepinephrine Spillover According to Adrenoceptor Genotype in Patients With Congestive Heart Failure
43950,Clinical Outcomes in Patients with ISH
43951,Electrolyte and Renal Data
43952,Study Flow Chart
43955,Frequency of AEs
43957,Heart Period Sequences and Heart Rate Variability During the Three Recording Periods
43958,Contributions of Each of the Specific Activities During the Scripted Activity Day Depicted in Figure 3 to the Total SDANN
43959,Contributions of Mean Heart Period and Coefficient of Variation to the Reduced SDANN in Patients With Heart Disease
43962,Predictors of Cardiovascular Morbidity in a Multivariate Cox Model in 1,742 Hypertensive Patients
43963,Prevalence and Prognostic Significance of the Single Components of the Metabolic Syndrome in 1,742 Hypertensive Patients
43964,Independent Predictors of Cardiovascular Morbidity and All Cause Mortality in 1,637 Nondiabetic Hypertensive Patients in a Multivariate Cox Model
43966,Heart Failure Signs and Symptoms
43967,Beta Blocker Use at 60 Days Postdischarge
43968,Percent of Target Dose Achieved for Carvedilol, Bisoprolol, Metoprolol Tartrate IR or Metoprolol Succinate XL at Day 60
43969,Withdrawal Due to Serious Adverse Events
43970,Clinical Events at 60 Days
43973,Most Frequently Occurring Adverse Events, Incidence 3  for Any Treatment     n   191
43974,Prospective Studies Showing Superior Stroke Protection by Diuretics Compared With Placebo or Other Antihypertensive Treatment
43975,Prospective Studies Comparing Calcium Antagonists and Diuretics
43977,Frequency of Adverse Events Commonly Attributed to Adrenergic Blockade
43979,Frequency of Adverse Effects Noted With Sildenafil and Placebo During the Trial Period
43980,Comparison of Efficacy of Sildenafil With Placebo   n   22
43982,Change in RR Interval, Mean Arterial Pressure   MAP  , RR Interval Variability, and Baroreflex Sensitivity   Alpha Index   Following Control Infusion of Saline or Active Treatment With Potassium Canrenoate   K Can     n   13
43984,Univariate Analysis of Factors Associated With Poor Clinical Status   NYHA Class III
43985,Multivariate Analysis of Variables Associated With a NYHA Class 3
43987,Hemodynamic Data During PET Studies   Mean  SD
43988,Echocardiographic Parameters   Mean  SD
43990,Outcome of Patients Enrolled in GUSTO V Based on Diabetic Status
43992,Complications of MI and its Treatment in Diabetics Randomized to Standard Versus Combination Therapy
43993,Predictors of 30 Day Mortality in Diabetics in a Multivariable Model
43994,Outcome and Medication Use in Diabetics in GUSTO I, GUSTO III, and GUSTO V
44001,Prevalence of Lipid Lowering Medication in the Study Cohort
44003,HR of Death or Urgent Transplant for Statin Treatment Versus No Statin Treatment: Univariate and Multivariate Analyses
44005,Treatment at Hospital Discharge in Patients With and Without Diabetes Mellitus
44008,Mitral Inflow Pattern at Doppler Echocardiography in the Three Groups of Patients
44009,Proteinemia, Albuminemia, COP, and PAWP in the Three Groups of Patients and in the Normal Control Group
44012,Number and Distribution of Coronary Plaques
44014,Arrhythmia Risk Variables
44015,Arrhythmia Risk Variables as Predictors of SCD and Arrhythmia Events
44016,The Number of Patients With True Positive, False Negative, True Negative, and False Positive Test Results
44017,Measures of Peak Exercise During Active and Inactive Pacing in Each Individual Patient
44018,Measures of Submaximal Exercise During Inactive and Active Pacing in Each Patient
44019,Hemodynamics and Left Ventricular Function at Supine Rest in HTRs   n   8
44026,Phase Analysis in Patients With IDC With QRS Duration  120 ms or  120 ms
44027,Correlations Between QRS Duration and Ventricular Dyssynchrony   Intraventricular in LV and RV and Interventricular   Expressed in Degrees      and Milliseconds   ms
44028,Correlations Between Hemodynamic Status and Ventricular Dyssynchrony   Left and Right Intraventricular and Interventricular   Expressed in Milliseconds
44029,Hazard Ratio   and 95  Confidence Intervals   in Univariate and Multivariate Analysis of Predictors of Major Cardiac Events   Cardiac Death or Worsening of Heart Failure Leading to Heart Transplantation
44033,Absolute Changes in Serum Creatinine Concentrations After Coronary Procedures and the Incidence of Acute Reductions in Renal Function in the Acetylcysteine and Control Groups
44035,Goals and Tools of Care Process of Patients Exposed to Heart Failure Management Program
44037,Economic Profile of Patients Grouped According to Management Strategies
44040,Nonfatal Cardiovascular Events Required Hospitalization Recorded During Follow Up   Mean 67 Months  Range 57 to 78 Months
44041,Incidence Rates of Cardiovascular Events Among 400 Postmenopausal Women
44043,Number of Patients With Events in Both Dose Groups Combined and in the Low  and High Dose Groups, Respectively
44044,Relative Risk Reduction and 95  CI for the Comparison of the Two Dose Groups Combined   Cox Adjusted Estimates, see Statistical Methods   and for the Comparison of the Low Dose Metoprolol CR XL Group With All Placebo and High Dose Metoprolol CR XL Group Versus All Placebo, Respectively
44045,Reason for Lower Than Expected Dose of Study Medicine at the Three Month Visit in the Two Randomization Groups
44050,Reasons for Not Administering Second Bolus of Reteplase
44051,In Hospital Events
44053,Cumulative Shock Success
44054,Progressive Tendency for Skin Tenderness Within Each Protocol, for Patients Having No Cross Over or Nonprotocol Shocks
44055,Dependence of Success on Duration of Current AF Episode
44059,Reason for Discontinuation of Patients Randomized
44061,Hemodynamics and Medical Regimens Before and After Therapy
44063,Analysis of the Combined Study End Point of Cardiac Death or Hospital Admission Due to Worsening Heart Failure Within 12 Months
44064,Cox Regression Analysis
44068,Dietary and Supplement Intake and Plasma Levels of Antioxidant Vitamins
44069,Adjusted   Mean IMT According to Gender Specific Quartiles of Dietary Antioxidant Vitamin Intake
44070,Adjusted   Mean IMT According to Gender Specific Quartiles of Plasma Antioxidant Levels
44072,Changes in Left Ventricular Ejection Fraction by Etiology, Carvedilol Use and ASA Use
44074,Pearson Correlations of Cardiovascular Disease Risk Factors and Other Markers With Serum Uric Acid Level
44075,Pearson Correlations of Cardiovascular Disease Risk Factors and Other Markers With Flow Mediated Vasodilation
44080,Results of the Multivariate Analysis
44082,Angiographic Results of Primary Stenting   n   50
44083,Primary and Secondary End Points legend
44084,Indications for Unscheduled Angiograms During Index Hospitalization legend
44085,Medications at Discharge and at Six Months in Surviving Patients legend
44087,EC50 and Maximum Responses to Bradykinin in Arteries from CHF and CHD legend legend
44090,Univariate Predictors of End Points legend
44092,Exercise Variables by Study Group  legend
44095,Types of Surgery
44102,Standard Pulmonary Function Tests in Controls   n   18   and in Chronic Congestive Heart Failure Patients Undergoing Ultrafiltration   n   28   legend
44103,Lung Diffusing Capacity for Carbon Monoxide   DLco  , Alveolar Capillary Membrane Diffusing Capacity for Carbon Monoxide   Dm  , Capillary Volume   Vc  , Alveolar Volume   Va   and Lung Tissue   Lt   in Controls   n   18   and in Chronic Congestive Heart Failure Patients Undergoing Ultrafiltration   n   28   legend
44104,Pulmonary Hemodynamics in 28 Chronic Congestive Heart Failure Patients Before Ultrafiltration and Four Days Thereafter legend
44108,Selected Concomitant Medications
44112,Association Between Dobutamine Response for Regional Wall Motion and Wall Hypertrophy
44114,Flow Mediated Vasodilation   Percent Change in Brachial Artery Diameter   After Release of 1, 3 and 5 Min of Transient Arterial Occlusion Before and After Study Drug Administration in Patients With Heart Failure According to Treatment Assignment
44115,Mean Brachial Artery Blood Flow Velocity   cm s   After Release of 1, 3 and 5 Min of Transient Arterial Occlusion Before and After Study Drug Administration in Patients With Heart Failure According to Treatment Assignment
44116,Heart Rate and MAP Before and After Study Drug Administration in Patients With Heart Failure According to Treatment Assignment legend
44117,Hemodynamic Data and Left Ventricular Function During Supine Rest in Heart Transplant Recipients   n   8   legend
44118,Fluid Volume, Plasma Electrolytes and Fluid Regulatory Hormone Values in Heart Transplant Recipients   n   8   Before and After High Dose Captopril
44120,Kaplan Meier Analysis for Major Events legend
44121,Cox Regression Analysis for Major Events legend
44123,Delays in Minutes Between Pain and Intervention legend legend
44124,Angiographic Results   Qualitative Assessment   legend legend
44125,Clinical Outcome During the Hospital Period legend legend
44126,Causes of Death During the Hospital Period legend legend
44127,Predictive Factors of One Year Mortality in 759 Patients Who Underwent Early Percutaneous Transluminal Coronary Angioplasty: Univariate Analysis legend legend
44128,Clinical Outcome From Discharge to One Year legend legend
44129,One Year Clinical Outcome: Comparison Between Patients With Failed and Successful Angioplasty legend legend
44130,Estimated Interventional Costs in U.S. Dollars During the First Year After Acute Myocardial Infarction Treated With Rescue or Primary Percutaneous Transluminal Coronary Angioplasty legend
44137,Reasons for Premature Discontinuation of Blind Study Medication
44139,Number       of Patients by the Most Common Adverse Events   Occurring for  2 Patients   legend
44141,Concomitant Cardiovascular Drugs of the Study Patients
44144,Adverse Events
44146,Causes of Death According to the Level of Alcohol Consumption
44147,Ischemic Left Ventricular Dysfunction   n   5,331  : Relationship Between Light to Moderate Alcohol Consumption and Outcome legend
44148,Nonischemic Left Ventricular Dysfunction   n   1,278  : Relationship Between Light to Moderate Alcohol Consumption and Outcome    legend
44149,Relationship Between Light to Moderate Alcohol Consumption and Cause Specific Mortality
44151,Results of the Two Way Repeated Measures ANOVA legend
44155,Sensitivity and Specificity of Various Tests and Their Cutoff Values to Differentiate Full Adherence From Full Nonadherence With ACEI Therapy
44161,Change in Hemodynamic and Echocardiographic Variables in Response to Dobutamine legend
44165,Variables Associated With the Use of Acute Reperfusion, Coronary Angiography, Angioplasty and CABG legend
44166,In Hospital Invasive Coronary Procedures, Medications, Complications and Mortality of Patients Treated or Not Treated by Acute Reperfusion legend
44167,Multivariate Stepwise Logistic Regression Analyses to Predict 30 Day, 30 Day to Three Year and Three Year Cumulative Mortality
44168,Crude and Adjusted Mortality Rates of Patients Treated or Not Treated by Acute Reperfusion by Reason for Exclusion
44171,Cerebral Proton Magnetic Resonance Spectroscopic Data legend
44172,Factors Associated With a Decreased Level of Creatine in 50 Patients With CHF   Univariate Analysis   legend
44173,Changes of Cerebral Metabolites Levels in 10 Patients With Cardiac Transplantation
44175,Time Domain and Frequency Domain Measurements of HRV on 24 h Ambulatory ECG in Patients With IDC legend
44179,Cox Proportional Hazards Analysis for All Cause Mortality legend
44180,Cox Proportional Hazards Analysis for Cardiovascular Mortality legend
44181,Resting Hemodynamics and Patient Weights Before and After Therapy
44183,Drug Therapy at Discharge From Hospital Following Enrollment   n   417   legend
44185,Procedural Factors
44187,Specific Renal Outcomes by Intent to Treat, Experimental Arm Versus IV Hydration Alone   Control   Arm legend
44190,Prevalence of Variables in 1 , 2  and 3 System Disease   CASS Surgical Registry
44191,Mean Values of Variables in 1, 2 and 3 System Disease
44193,Objective Clinical Findings of No Echocardiography and Echocardiography Groups
44194,Medical and Surgical Therapy of No Echocardiography and Echocardiography Groups
44195,Multivariate Analysis of Factors Predictive of Not Receiving a Doppler Echocardiographycardiographic Examination
44197,Causes of 30 Day Mortality
44198,Medication at Follow up legend
44199,Effect of Captopril on Left Ventricular Function According to TIMI Flow Grades legend
44200,Effect of Captopril on Regional Wall Motion According to TIMI Flow Grade
44201,Effect of Captopril on Regional Wall Motion According to Corrected TIMI Frame Count
44202,Types and Doses of Beta Receptor Antagonists  legend
44204,Univariate Regression Analysis legend
44205,Multivariate Regression Analysis legend
44207,Reasons for Premature Discontinuation During the Study   n   25 of 244 patients
44209,Risk of Treatment Failure Relative to Triple Therapy legend
44213,Programmed Stimulation in Patients with Dilated Cardiomyopathy without a History of Sustained Ventricular Arrhythmias  legend
44215,Events for Participants in Atrial Fibrillation Compared to Sinus Rhythm  legend
44216,Multivariate Analysis: Variables Significantly Associated With All Cause Mortality
44217,Multivariate Analysis: Variables Significantly Associated With Pump Failure Death
44224,Multivariate Cox Proportional Hazards Models legend
44228,Medical Regimen
44230,Functional Status Response to Therapy in 179 Patients
44233,Failure of Therapy Profile at 6 Weeks for Men and Women by Strategy and NonQ Wave Myocardial Infarction Status: TIMI IIIB
44234,TIMI IIIB Patients Who Had Invasive Strategy: Comparison of Angiographic Findings by Gender
44236,Adverse Events and Laboratory Abnormalities
44239,Infection Details
44240,Procedure Details by Presence or Absence of Hospitalization for Device Infection
44241,Sensitivity and Heterogeneity Analysis of Pooled RRs of Mortality or VTA
44245,Periprocedural Adverse Events
44247,Predictive Variables for Embolic Events Determined Using the Fine and Gray Model   Development Sample
44249,Echocardiographic Measurements in 2 Groups
44250,Hemodynamic Measurements by Right Heart Catheterization
44251,Assessment of Functional Capacity
44254,The ECG Parameters of the Patients With and Without VF Storms Among the Patients With J Waves
44255,Definition of Prosthetic Valve Endocarditis Accordingto the Proposed Modified PET CT DukeCriteria
44257,Results of PET CT According to the Final Diagnosis
44258,Results of PET CT According to the Results of the Initial Echocardiography Study   TTE and TEE
44259,Diagnostic Value of the Modified Duke Criteria at Admission With   Duke PET CT   and Without the Implementation of the PET CT Results
44261,S ICD Related Adverse Events
44266,Hemodynamic Values
44270,Major Adverse Events and Limb Salvage at Follow Up in Patients With Critical Limb Ischemia and Intermittent Claudication
44271,Patient Population
44272,Post Operative 30 Day Mortality
44273,Literature Review of Surgical and Percutaneous Lead Extraction Mortality
44275,Pre Operative Diagnoses
44276,Arrhythmia Incidence and Timing
44277,Perioperative Clinical Variables
44278,Immunosuppressive Regimens, Typical Doses
44279,Echocardiographic Indexes   AF AFL Patients
44280,Biopsy Results   ISHLT Grades Heart Lung
44281,ARVD Diagnosis Criteria
44282,Predictors of Proper ICD Therapy
44283,Main Indications for ICD Implantation in the Study Patients
44284,Medications of the Study Population
44285,In Hospital, 1 Year, and Very Late Clinical Events
44286,Episodes of Stent Thrombosis: First Year and Very Late
44287,Predictors of Very Long Term Clinical Outcome
44290,Hazard Ratio and 95  CI for Risk Factors Associated With Definite ST During the Entire Follow Up Period From Multivariable Cox Regression
44291,Using RT PCR Primer Design for Mice
44293,Major Cardiac Events According to Diabetic Status and Extent of Coronary Artery Disease   1 Year Follow Up
44294,Risk Factors for Stent Thrombosis
44296,Clinical Presentation of Patients With CDI   n   189
44298,Mayo Clinic Guidelines for the Diagnosis and Management of Cardiac Device Infections
44302,Body and LV Weight
44303,Indexes of Cell Shortening
44304,Indexes of  Ca2  iTransient
44307,Definition of Hematoma in Studies Included in the Meta Analysis
44308,Clinical Features of Randomized Patients With Left Sided Infective Endocarditis
44309,Results of Investigations of Randomized Patients With Left Sided Endocarditis
44310,Outcome of Patients With Left Sided Infective Endocarditis
44311,Abnormal Endocarditis Findings on Cerebral Computed Tomography
44314,Cumulative Incidence of Disease Progression
44318,Most Frequent Adverse Events in the BPS and Placebo Groups
44320,Peri Interventional Complications
44322,Patients With Recurrent TIA Related to Postinterventional Residual Shunt
44323,Number of Dogs Assigned to and Excluded From Each Group for Measurement of Infarct Size
44324,Coronary Hemodynamics, Collateral Blood Flow and Area at Risk Among Experimental Groups
44325,Percentage of Survival and Incidence of Ventricular Fibrillation in Each Group
44326,Myeloperoxidase Activity of the Reperfused Myocardium
44327,Clinical, Laboratory and Therapeutic Variables in 80 Patients With Congestive Heart Failure
44328,Linear Range of the Assays and 95th Percentile Levels for Each Cytokine, Soluble Receptor or Receptor Antagonist for Control Subjects
44330,Frequency, Type, and Timing of Infection
44331,Organisms
44333,Management Practices and Unadjusted Risk Ratios   Major Infection
44336,18F FDG PET CT Results
44338,Patient Comorbidities
44339,Presenting Symptoms
44343,Reasons for Discontinuation of Study Drug in the HOPE Study Women
44347,Angiographic and Interventional Data of the TOPSTAR Trial
44348,Production of Anandamide and 2 Arachidonyl Glycerol in Platelets and Monocytes of Control, Sham or Coronary Ligated   Mycardial Infarction
44350,Medical Conditions and Contributing Factors to Congestive Heart Failure in the 16 Patients Treated for the Anemia and in the 16 Controls legend
44351,Number and Percentage of Cases Taking Each Medication and the Doses used in mg day in the Treatment and Control Groups During the Study legend legend
44354,Event Rates According to Median Levels of Prognostic Markers legend legend
44357,Myocardial Inotropic Reserve in Patients With and Without Pre Infarction Angina legend
44364,Predictors of Survival: Multivariate Analysis legend
44366,Frequency of Death and Heart Transplantation in Relation to Mitral Inflow Patterns and Maximal Oxygen Uptake legend legend
44369,Selection of Patients legend
44371,Percent of Patients with Positive Tests for Ischemia before Randomization legend
44375,Incidence and Risk Reduction in Cardiac Events According to Treatment Group legend
44376,Causes of Death in Study Patients According to Treatment Group
44379,Antihypertensive Drugs Used in Patients With Essential Hypertension legend
44383,Patient Flow From Time of Randomization to Follow Up in the Amlodipine and Placebo Groups legend
44384,Angiographic Variables of the Per Protocol Analysis Group legend
44385,Coronary Quantitative Angiographic Analysis in the Per Protocol Analysis Group legend legend
44386,Clinical End Points in All Randomized Patients   Intention to Treat   and All Patients Who Underwent the Scheduled Percutaneous Transluminal Coronary Angioplasty legend
44387,Body and Left Ventricle Weight in Adult and Sedentary or Trained Senescent Rats
44388,Hemodynamic Parameters of Ischemia   20 min   and Reperfusion   40 min   in Hearts from Adult and Sedentary or Trained Senescent Rats   Control Group   legend
44389,Hemodynamic Parameters of Transient Ischemia Preconditioning Stimulus   2 min   on Ischemia   20 min   and Reperfusion   40 min   in Hearts from Adult and Sedentary or Trained Senescent Rats   Preconditioning Group   legend
44390,Hemodynamic Parameters of Transient Ischemia Preconditioning Stimulus   2 min   on Ischemia   20 min   and Reperfusion   40 min   After Pretreatment With Reserpine in Adult and Sedentary or Trained Senescent Hearts   Reserpinized Preconditioning Group   legend
44399,Comparisons of Changes During Lower Body Negative Pressure in Patients With Restrictive and Nonrestrictive Left Ventricular Filling Patterns
44401,Adjusted Hazard Ratios of Mortality, Morbidity and Cause of Death in Antiplatelet Agent Users Versus Nonusers in the Studies of Left Ventricular Dysfunction Combined Trial
44402,Adjusted Hazard Ratios of Mortality and Morbidity in Antiplatelet Agent Users Versus Nonusers in the Studies of Left Ventricular Dysfunction Prevention and Treatment Trials
44403,Interaction Between Antiplatelet Agent Use and Selected Patient Variables in Relation to End Points   reported as p values   in the Studies of Left Ventricular Dysfunction Combined Trial
44404,Adjusted Hazard Ratios of Mortality and Morbidity in Antiplatelet Agent Users Versus Nonusers in the Studies of Left Ventricular Dysfunction Combined Trial Patients Grouped by Drug Randomization
44405,Adjusted Hazard Ratios of Mortality and Morbidity in Patients Randomized to Enalapril Versus Placebo Therapy Grouped by Antiplatelet Agent Use
44406,Hemodynamic Data
44407,Neurohumoral and Cytokine Data
44408,Univariate and Multivariate Linear Model of Plasma Interleukin 6 in Femoral Vein of Patients With Congestive Heart Failure
44409,Univariate and Multivariate Linear Model of Interleukin 6 Spillover in Peripheral Circulation of Patients With Congestive Heart Failure
44410,Univariate and Multivariate Predictors of Mortality in 100 Patients With Chronic Heart Failure
44412,Relation of Circadian Rhythm Variables Between Average Ventricular Response Interval and Lorenz Plot Measures
44413,Regression Analysis of Circadian Rhythm Variables of Average Ventricular Response Interval With Those for Lorenz Plot Measures
44414,Relations Between Clinical Features of Atrial Fibrillation and Circadian Rhythm Variables of Average Ventricular Response Interval and Lorenz Plot Measures
44415,Intraindividual Reproducibility of Circadian Rhythm Variables of Average Ventricular Response Interval and Lorenz Plot Measures
44416,Prevalence of Left Ventricular Hypertrophy at Electrocardiography
44419,Independent Predictors of Total Cardiovascular Morbid Events   Cox model    a
44421,Independent Predictors of Fatal Cardiovascular Events   Cox model    a
44423,Relative Risks and 95  Confidence Intervals for Each Drug Comparison  a
44424,Relative Risks and 95  Confidence Intervals for Calcium Antagonist Use Versus Use of Neither Calcium Antagonists nor Beta Adrenergic Blocking Agents  a
44430,Relation Between Age Category and Use of Reperfusion Oriented Strategy   intravenous thrombolysis or primary percutaneous transluminal coronary angioplasty
44431,Relation Between Usage of Beta Adrenergic Blocking Agents or Angiotensin Converting Enzyme Inhibitors and Killip Class or Left Ventricular Ejection Fraction
44432,Univariate Analysis of Factors Related to Five Day Mortality
44433,Multivariate Logistic Regression Analyses of Factors Related to Five Day Mortality
44434,Acute Hemodynamic Data at Variable Atrioventricular Delays
44435,Doppler Assessment of Cardiac and Valvular Function
44437,Incidence and Relative Risk of Ischemic Cardiovascular Disease and Myocardial Infarction in PlA1 PlA2Heterozygotes or PlA2 PlA2Homozygotes Versus PlA1 PlA1Noncarriers by Cox Regression Analysis
44438,Incidence and Relative Risk of Ischemic Cardiovascular Disease and Myocardial Infarction in PlA1 PlA2Heterozygotes or PlA2 PlA2Homozygotes Versus PlA1 PlA1Noncarriers by Cox Regression, Stratified by Age
44439,Age at First Event in PlA1 PlA2Heterozygotes, PlA2 PlA2Homozygotes, and PlA1 PlA1Noncarriers
44440,Correlations Between  Trace Protein, Cystatin C, and Clinical Variables
44443,Performance of Measures of Renal Function and NT proBNP for Prediction of 1 Year Mortality and or HF Hospitalization in Patients With ADHF
44444,Cox Regression Risk Analysis for Prediction of Mortality and or HF Hospitalization
44445,Pre Natal Clinical Features of Patients Diagnosed With Maternal Autoantibody Induced Cardiomyopathy
44446,Pre  and Post Natal Medical Treatment of Fetuses and Infants With Maternal AutoantibodyInduced Cardiomyopathy
44450,Number of patients with congenital adrenal hyperplasia, by sex and year of birth
44451,Frequency of underlying mutations in the congenital adrenal hyperplasia population in Sweden
44452,Management recommendations for hyperthyroidism in patients with Graves  disease or a history of Graves  disease who become pregnant
44453,Nucleobase and nucleoside analogues used in cancer chemotherapy
44455,Differentially expressed genes between each endotype
44457,Operative details
44458,First recurrence sites
44460,Interactions of fluid management with risk factors for in hospital early deaths
44461,Adjusted rates of occlusive vascular death among people with and without diabetes at recruitment, by age and sex
44468,Prevalence of RLS in patients with cryptogenic events compared with patients with events of known cause
44469,Studies included in the meta analysis
44475,Univariate Cox regression models for the association of neuropsychiatric and developmental disorders among individuals with a 22q11.2 deletion or duplication
44477,Investigational product exposure in the safety analysis population
44478,Adverse events during neoadjuvant treatment in the safety analysis population
44479,Adverse events during adjuvant treatment in the safety analysis population
44480,Adverse events of interest during neoadjuvant treatment in the safety analysis population
44481,Adverse events of interest during adjuvant treatment in the safety analysis population
44483,2 year depression course indicators across six age categories and linear associations with continuous age
44486,Clinical PROMISE score and biological PROMISE score   clinical plus TIMP1
44488,Treatment responses in the intention to treat population as assessed by computational algorithm based on IMWG URC
44489,Adverse events in the safety population
44490,Adverse events of interest in the safety population
44493,Adverse events from any cause
44495,Incidence of treatment emergent adverse events judged to be related to tucatinib
44496,Steady state pharmacokinetic parameters of tucatinib
44497,Best response in patients with measurable disease treated with tucatinib plus capecitabine or trastuzumab at the maximum tolerated dose
44499,Adverse events
44501,Adverse events
44502,Potential immune mediated diseases, as defined by MedDRA
44504,Patient disposition
44505,Cumulative response assessment
44506,Relation between best response to quizartinib and overall survival in all FLT3 ITD positive patients in cohort 1 and between response to quizartinib, HSCT, and overall survival in all FLT3 ITD positive patients in cohort 2
44507,Treatment emergent adverse events in all patients      that occurred in 10  or more of patients   grade 12   or 2  or more of patients   grade 3
44511,Overall summary of adverse events during CT P13 treatment   safety population
44513,Summary of best response by modified RECIST criteria in the randomised population
44514,Treatment emergent adverse events of all grades occurring in more than 15  of patients in the safety population
44519,Pathogen isolates from the paired cough swab, sputum induction, and bronchoalveolar samples
44521,Excess cause specific mortality at ages 3574 years associated with previously diagnosed or undiagnosed diabetes at recruitment
44529,Associations between circadian relative amplitude quintile and mental health and wellbeing outcomes
44531,Loci identified in the age at onset analyses and followed up in the replication stage
44532,Loci identified in the case control analysis and followed up in the replication stage
44534,Prevalence of major congenital malformations in offspring exposed prenatally to one of eight different antiepileptic monotherapies
44535,Association between prevalence of major congenital malformations and exposure to one of the four monotherapies in which a dose response was detectable
44536,Results of multivariable analysis of major congenital malformations in the study cohort
44537,Major congenital malformations associated with eight different antiepileptic monotherapies and their time of detection
44539,Proposed screening strategy for site specific gastrointestinal cancer in patients with cystic fibrosis
44541,Adverse events in the safety population
44543,Associations between job strain variables at age 45 years and new onset CMD caseness at age 50 years by use of logistic regression
44545,Progression events and survival status
44546,Grade 3 and 4 adverse events deemed treatment related
44548,Variables affecting the probability of maintaining MMR 6 months after TKI discontinuation in the learning sample   n 448
44549,Probability of maintaining MMR 6 months after TKI discontinuation, by duration of deep molecular response   years   before imatinib discontinuation
44550,Adverse events
44557,Treatment complications in both study groups
44560,Main and secondary study outcome measures
44563,Prevalence of hypertension and dyslipidaemia in US adults aged 20 years and older, by glycaemic status, 19882014
44564,Mean blood pressure and lipid concentrations by glycaemic group, hypertension, and dyslipidaemia status, in US adults aged 20 years and older, 19882014
44565,Estimates of 10 year risk of cardiovascular events, prevalence of myocardial infarction, and prevalence of strokes in US adults aged 20 years and older, by glycaemic status, 19882014
44566,Diabetic renal disease markers in US adults aged 20 years and older, by glycaemic status, 19882014
44568,Adverse events
44570,Total chemotherapy dose received by patients and dose intensity achieved
44571,End of treatment response by CT
44572,Adverse events by treatment
44574,Relative effects of transformed predictors
44576,Treatment emergent adverse events occurring in the safety population of part 1 and part 2
44577,Treatment emergent serious adverse events in the safety population in part 1 and part 2
44579,Patient outcomes at data cutoff
44580,Treatment related adverse events in at least 10  of patients and all grade 3 or 4 events
44582,Best overall confirmed response by treatment group
44583,Adverse events irrespective of causality by treatment group
44585,Hazard ratios for risk of developing dementia, stratified by time since TBI and number of TBIs
44588,All adverse events   safety population
44589,Serious adverse events
44592,Most frequently reported treatment emergent adverse events in the safety population
44594,Primary composite, secondary, and other long term outcome measures
44595,Serious adverse events, movement disorders, metabolic measures, and general side effects
44597,Administered doses of chemotherapeutic drugs
44598,Surgical and pathological outcomes in patients who had potentially curative surgery
44599,Adverse events associated with preoperative and postoperative treatment
44600,Surgical complications in patients who had potentially curative surgery
44602,5 year overall survival in the validation cohort by prognostic single patient classifier groups
44603,5 year overall survival in the validation cohort by predictive single patient classifier groups
44604,Availability of data for measuring the effects of gastroprotectants
44606,Recovery of bowel function and anastomotic leakage and treatment
44607,Morbidity and mortality
44608,Clavien Dindo complications of grade IIIa or higher
44610,Adverse events deemed at least possibly related to napabucasin or placebo by investigator
44612,Estimated age of attainment for each of the motor milestones among children in the study sample compared with the WHO reference population
44613,Relative rate of motor milestone attainment in each of the intervention groups
44614,Standardised differences in scores on the communication, gross motor, personal social, and combined scales of the Extended Ages and Stages Questionnaire
44616,Estimated age of attainment for each of the motor milestones among children in the study population compared with the WHO reference population
44617,Relative rate of motor milestone attainment after 1 year of intervention
44618,Standardised differences in scores on the communication, gross motor, personal social, and combined scales of the Extended Ages and Stages Questionnaire after 2 years of intervention
44619,Effect of the interventions on communication and executive functions after 2 years
44621,Study drug related side effects
44625,Proportion of patients achieving glycaemic targets and weight loss responses at week 40
44626,Adverse events overview
44634,Causes and grade of adverse events by treatment periods
44641,Progression free survival   PFS   according to the predictor score in each validation cohort and in FLIPI risk categories
44642,Studies of conversion   functional neurological   disorder included in meta analysis
44643,Summary meta analysis data for studies of maltreatment in conversion   functional neurological   disorder and associated PAFs
44644,Proportion of cases with no exposure to specific stressors when compared with controls
44646,Primary causes of death in SMaRT Oncology 2 and SMaRT Oncology 3 trial participants
44648,Distribution of events
44649,Summary of adverse events by schedule
44650,Summary of adverse events by aromatase inhibitor
44652,Maximum grade of adverse event during treatment
44654,Electroconvulsive therapy   ECT   and all cause dementia in relation to age at study entry
44655,Electroconvulsive therapy   ECT   use and incident dementia during follow up in patients aged 70 years and older
44656,Risk of association between electroconvulsive therapy   ECT   and all cause dementia in relation to age at study entry
44658,Summary of common   any grade in 10  and grade 34 in 2    adverse events reported, regardless of causality
44660,Adverse events
44661,Malignant lesions detected with use of fluorescence imaging
44664,Adverse events of grade 3 or worse
44668,Number of adverse events
44675,Unadjusted prevalence of overweight and obesity, hypertension, diabetes, and lifestyle risk factor categories among study participants
44676,Associations of risk factors with overweight and obesity: age adjusted and distal factor adjusted risk ratios
44677,Associations of risk factors with hypertension: age adjusted and distal factor adjusted risk ratios
44678,Associations of risk factors with diabetes: sex specific crude and adjusted risk ratios
44681,Interventions during the 20 week treatment period
44682,Primary and secondary outcome, safety, sensitivity, and post hoc analyses
44684,Association between BMI and progression free survival
44685,Association between BMI and overall survival
44687,Multivariable Firth s logistic regression prediction model for lobar intracerebral haemorrhage associated with moderate or severe cerebral amyloid angiopathy
44689,Prevalence of childhood   age 011 years   socioeconomic background factors by birth year and sex at the start of follow up   age 12 years
44690,Cumulative incidence of specialised service use among girls from their 12th to their 18th birthday, stratified by birth cohort
44691,Cumulative incidence of specialised service use among boys from their 12th to their 18th birthday, stratified by birth cohort
44693,Summary of key safety results
44694,Most frequent treatment emergent adverse events
44696,Survival and recurrence outcomes
44697,Multivariable analysis of prognostic factors for overall survival
44698,Multivariable analysis of prognostic factors for failure free survival
44699,Adverse events reported during treatment
44700,Adverse events reported at 6 months after randomisation
44702,Chromatin heterogeneity in analysis of cancer specific survival
44705,Results of primary and secondary outcomes for the risk of repeat self harm in the treatment groups and covariates
44706,Adverse events
44710,All grade 4 and 5 adverse events, and all adverse events of any grade in 20  or more patients, occurring during protocol treatment
44711,Patient characteristics
44712,Overview of different treatment modalities by cancer type
44713,Obstetric outcomes, stratified by cancer type
44714,Multivariable analysis of the most common obstetric and neonatal complications
44716,Effect of independent variables on cost and inpatient bed days in the last year of life
44717,Effect of independent variables on early unplanned readmission in the last year of life and unplanned hospital death
44719,Efficacy outcomes for primary endpoint and major secondary endpoints
44720,Safety summary
44722,Definitions for clinical outcomes at follow up
44723,Cumulative incidence and incidence of epilepsy, motor, and intellectual disability after childhood CSE
44724,Prevalence of epilepsy, motor, and intellectual functioning after CSE in childhood
44727,Regression results of the Cox s proportional hazard model to examine the effect of specialised physiotherapy on mortality
44728,Regression results of the random effects model to examine the effect of specialised physiotherapy on Parkinson s disease related complications
44731,Deaths by suicide   201113  , hospital presenting non fatal self harm   201113  , and community occurring non fatal self harm   2015  , by sex and age group
44733,Logistic regression analysis of out of home placement and Cox proportional hazards model of time to first offence
44740,Differences in costs    at 201213 prices   and outcomes per participant over the 18 months  follow up
44742,Adverse events that occurred in at least 20  of patients in either group
44744,Treatment exposure in the safety population
44745,Adverse events
44752,Adjusted mean difference in 12 month primary and secondary outcome measures in the DVDB, face to face, and usual care treatment groups in the intention to treat and per protocol populations
44753,Number of patients having asthma attacks over 12 months in the DVDB, face to face, and usual care treatment groups in the intention to treat and per protocol populations, by number of corticosteroid courses used
44755,Incidence of cardiometabolic outcomes and mortality
44756,Standardised cumulative incidence of cardiovascular events
44760,Adverse events
44766,Top gene burden results
44768,Primary outcome
44769,Probability of primary outcome or relapse at 24 weeks
44771,All adverse events reported in at least 5  of patients in a treatment group   in an overall category
44773,Details of focused ultrasound subthalamotomy procedures
44774,Adverse events
44776,Trials of neoadjuvant versus adjuvant chemotherapy that began by 2005
44777,Local therapy, planned versus done, in women allocated to neoadjuvant chemotherapy, by clinical response
44780,Adverse events   safety population
44782,Maximum grade of targeted adverse events reported during the 5 year treatment period
44783,Study characteristics
44784,Univariate associations between childhood maltreatment and non suicidal self injury
44785,Univariate and multivariate moderator analyses
44788,Treatment related adverse events by grade
44790,Best overall response to treatment according to local investigator assessment
44791,PIK3CA status assessed in plasma ctDNA at study entry by BEAMing assay and in archival tumour tissue by PCR
44792,Concordance in PIK3CA status between archival tumour tissue   by PCR   and plasma ctDNA assessed by BEAMing assay
44793,Most frequent   10    adverse events regardless of study treatment
44795,Clinical outcomes at weeks 4 and 12 by initial therapy
44799,Pooled relative risks of type 2 diabetes according to levels of linoleic acid and arachidonic acid biomarkers
44802,Adverse events
44804,Definitions of suicide in custody
44805,Number and rates of suicide in prisoners compared with the general population
44806,Results of meta regression analyses comparing prison suicide rate with general population suicide rate, incarceration rate, and other prison level variables
44807,Cause specific mortality for people with and without mental disorders
44808,Life years lost and excess life years lost by cause of death in people with and without mental disorders
44810,Efficacy endpoint analyses at 5 years post randomisation in the intention to treat population
44811,Site of first invasive disease free survival event in the intention to treat population
44812,Treatment emergent adverse events
44814,Grade 2 adverse events occurring in at least 10  of patients in either group
44815,Grade 35 adverse events occurring in at least 1  patients in either group   all attributions
44818,Comparison of treatment responses   RECIST 1.1   among evaluable patients in the intention to treat population
44819,Treatment related adverse events of interest, according to the MedDRA coding version 19.0 in the safety population
44820,Estimated new cancer cases and ASR per 100000 people per year and by sex, for all cancers combined and 27 cancer types, among 2039 year olds worldwide in 2012
44821,Estimated cancer related deaths and ASR per 100000 people per year and by sex, for all cancers combined and 27 cancer types, among 2039 year olds worldwide in 2012
44824,Association of disease progression with score for GHS QOL
44825,Frequency and prevalence of background and adolescent covariates in 1671 participants by adolescent self harm, and their association with adolescent self harm, adjusted for gender and age
44826,Prevalence of outcomes at 35 years in 1671 participants by self harm during adolescence, and unadjusted associations between adolescent self harm and outcomes at 35 years
44827,A series of predictive models examining the associations between self harm during adolescence and outcomes at 35 years with progressive adjustment for adolescent confounders or mediators in 1671 participants
44829,Clinical outcomes by AKI status
44830,Prediction models for clinical outcomes
44832,Country level economic development, health, and gender equality indices
44834,Unadjusted mediating variables by country and gender
44835,Direct and indirect effects of gender on the EAP ECDS composite score
44837,Retention in care at 18 months
44840,Primary and secondary cardiovascular outcomes
44841,Selected adverse events
44842,Hypoglycaemic events
44844,Primary and secondary outcomes
44845,Adverse events
44847,Gene variants with genome wide significance for idiopathic pulmonary fibrosis
44850,Safety summary
44851,Summary of recurrent hypoglycaemic events
44853,Association results for lead single nucleotide polymorphisms reaching genome wide significance in the discovery meta analysis
44854,Candidate genes linked to functions in neurodevelopment
44855,Incidence ratios of ADHD per 1000 births by month of birth, in boys and girls
44856,Incidence ratios of ADHD per 1000 births by month of birth, in boys and girls
44857,Incidence ratios of ADHD by year of diagnosis, age at first diagnosis, and month of birth
44863,Efficacy endpoint events in patients who were disease free at 3 years after randomisation
44864,Adverse events by treatment group
44866,Best overall response by masked independent review   intention to treat population
44867,Adverse events   safety population
44869,Adverse events   safety analysis set
44872,Summary of treatment emergent adverse events occurring in 10  or more patients in the safety analysis set
44874,Site of infection and pathogens identified in neonates and children with blood culture proven bacterial sepsis
44875,Severity of sepsis episodes in neonates and children with blood culture proven bacterial sepsis
44876,Risk factors for death in neonates and children with blood culture proven bacterial sepsis
44877,Summary of evidence of lung function measures used in the diagnosis of asthma
44882,Peanut ingestion and skin prick test
44883,Reported reactions from completion of study treatment to time of long term follow up study
44884,Peanut sIgE and sIgG4 concentrations, and sIgG4:sIgE ratio 4 years after completion of study treatment
44885,Long term peanut challenge outcomes in participants who underwent sustained unresponsiveness food challenge after 8 weeks  peanut elimination
44890,Serious adverse events
44891,Studies included in analysis of prognostic effect of nodal status
44892,Effect of misclassified true LNP on observed prognostic discrimination
44893,Patients  characteristics
44896,Association of disease progression with HRQOL and utility
44898,Treatment exposure   safety population
44899,Summary of secondary efficacy endpoints
44900,Summary of adverse events in the safety population
44902,Subsequent antimyeloma therapies
44903,Adverse events
44905,Objective responses
44906,Adverse events
44909,Pathogen yields in relation to specimen type
44910,Overall yields in relation to specimen type, for any pathogen, for the entire cohort   n 1519
44911,Post transplantation sensory, motor, and functional milestones
44920,Weighted means of hazard ratios for cardiovascular, mortality, and other outcomes in Denmark, Norway, and Sweden for new users of SGLT2 inhibitors versus new users of other glucose lowering drugs
44922,Features associated with acute complications of asparaginase associated pancreatitis
44923,Factors associated with the risk of a second asparaginase associated pancreatitis in patients re exposed to asparaginase
44925,Associations between aspects of cannabis use and suicidal thoughts and behaviours in male and female twins from the Australian Twin Registry
44926,Unadjusted within pair associations between aspects of cannabis use and suicidal thoughts and behaviours, in discordant monozygotic and dizygotic same sex twin pairs, by dependent variable
44927,Within pair associations between cannabis use and suicidal thoughts and behaviours in discordant monozygotic twin pairs
44928,Prevalence of major depressive disorder and suicidal ideation in monozygotic twins from pairs concordant for frequent cannabis use, pairs concordant for less frequent or never use, and discordant pairs where one twin reported frequent cannabis use and the other less frequent or never use
44931,Adverse events
44932,Dose modifications and discontinuations owing to adverse events
44934,Disease free survival events
44935,Causes of death
44936,Non breast cancers
44938,Adverse events reported in each treatment group
44940,Chemotherapy details
44941,Surgery details
44942,Chemotherapy toxicity
44943,Pathology details
44945,Antitumour responses assessed with RECIST in the intention to treat population
44946,Treatment emergent adverse events
44947,Treatment emergent adverse events of special interest
44949,Prevalence of single, dual, and triple infections with blood borne viruses
44950,Odds of infection with blood borne viruses in people with severe mental illness compared with the general population
44955,Description of the 19 new trials
44956,Summary of main results for trials comparing altered fractionation and conventional fractionation radiotherapy
44957,Acute and late severe toxicities between conventional and altered fractionation radiotherapy
44959,Derivation of HALT HCC model with preoperative factors in the CCF dataset
44960,Distribution of HALT HCC scores, and 5 year overall survival estimates, by Milan criteria status
44962,Study drug and DEB TACE administration and efficacy outcomes
44963,Disease response assessed locally using RECIST v1.1 and modified RECIST criteria
44964,CTC adverse event categories   occurring in 10  or more of patients
44966,SVR12 in the immediate treatment and deferred treatment groups
44967,Adverse events and laboratory safety
44970,Overview of study cohorts
44971,Global cognitive impairment with cognitive risk scores by quartile
44972,Risk of dementia with cognitive risk scores by quartile in the replication population
44974,Treatment emergent adverse events in the safety analysis set
44975,Primary causes of death   safety analysis set
44976,Responses to gilteritinib, overall and by FLT3 mutation status   full analysis set
44978,Changes in tic severity, global health functioning, depression, anxiety, and quality of life during the double blind period
44979,Adverse events
44981,Haematological and non haematological adverse events
44983,Multivariable analysis on grade IIIV acute graft versus host disease, event free survival, non relapse mortality, and relapse risk
44985,Multivariable analysis for freedom from local recurrence
44988,Adverse events
44989,Spatial or service setting identifiers present in the Mental Health Minimum Data Set 201011
44991,Results of four level cross classified null models
44992,Results of three level   patient LSOA provider trust   cross classified models
44994,Subsequent therapies
44995,Adverse events
44996,Baseline characteristics
44997,Treatment delivered
44998,Radiotherapy treatment delivered in patients receiving concurrent chemoradiotherapy   as per protocol
44999,Acute adverse events   3 months after completion of study treatment
45000,Late adverse events    3 months after study treatment
45002,Outcomes of comparative studies
45005,Gastrointestinal adverse events of at least moderate severity, or vomiting, in participants in the three dose study
45006,Gastrointestinal adverse events of at least moderate severity, or vomiting, in participants in the 16 dose study, by participant
45007,Whole blood interferon  release assay with Nexvax2 peptides after gluten challenge after treatment   post hoc analysis
45010,Incident rate ratios estimated by generalised additive mixed model and variables included in the model
45011,Parsimonious models assuming patients with missing smoking data are either smokers   worst case scenario   or non smokers   best case scenario   and variables included in the model
45013,Efficacy outcomes
45014,Maximum grade adverse events, regardless of study drug relationship
45016,Events contributing to analyses of time to tumour recurrence and numbers of distant relapses, second cancers, and deaths
45017,Adverse events during cycles one to four of chemotherapy among patients in the quality of life and toxicity substudy
45018,Adverse events during cycles five to eight of chemotherapy among patients in the quality of life and toxicity substudy
45019,Late adverse events by epirubicin regimen
45020,Late adverse events by CMF or capecitabine group
45021,Risk of disease recurrence by nodal status in trials of dose dense chemotherapy
45023,Adverse events
45025,Predictors of progression free survival
45026,Predictors of overall survival
45027,Effect of previous thoracic radiotherapy on frequncy of all recorded pulmonary toxicities and treatment related pulmonary toxicities
45030,Adverse events in all patients and by Child Pugh score
45033,Serious adverse events
45034,Baseline patient and tumour characteristics
45035,Best tumour response
45036,Safety summary of events occurring in 10  or more of patients by grade
45040,Mean differences in cardiovascular risk factors between more intensive glucose control and less intensive glucose control to the end of followup
45042,Age at which the percentage of each ATN prevalence curve reaches its peak for women and men
45049,Re presentation for self harm in the 6 months following the index presentation
45050,Logistical regression analyses investigating association between group assignment   intervention vs control  , past admission to hospital for self harm, and re presentation with self harm
45051,Negative binomial models to predict repeat self harm as function of group and past admission to hospital for self harm
45053,Associations between risk factors and violent crime in the derivation sample from the multiple regression model   after multiple imputation
45055,Haematological toxicity
45056,Non haematological toxicity
45057,Dose intensity
45060,Treatment related adverse events
45062,Adverse events by maximum grade and CTCAE   version 3   category
45063,Selected adverse events related to bevacizumab treatment
45065,Treatment emergent adverse events
45067,Adverse events
45069,Summary of overall survival analyses in the EMILIA study
45070,All adverse events
45071,Mean number of standard drinks per day across countries, by sex and WHO drinking risk level
45072,Wave 1 drinkers, by WHO drinking risk levels
45073,Changes in WHO drinking risk level at Wave 2, by Wave 1 WHO drinking risk level for all drinkers and alcohol dependent drinkers
45074,Alcohol dependence at Wave 2, by WHO drinking risk level at Wave 1 and change in WHO risk level between Waves 1 and 2
45079,Adverse events overview in the safety analysis set
45081,HbA1c concentrations       by treatment groups, over the course of four visits
45082,Cumulative incidence of new initiation of insulin therapy in patients with diabetes not on insulin at screening during the course of follow up in PARADIGM HF, by treatment assignment
45083,Changes in triglycerides and HDL cholesterol concentrations, and body mass index by treatment groups, over the course of four visits
45087,Adverse events overview
45089,Secondary outcomes for groups 2 and 3 combined
45090,Treatment emergent adverse events for groups 2 and 3 combined
45091,Post hoc outcomes for early treatment    36 h   for groups 2 and 3 combined
45093,Secondary clinical outcomes and other follow up assessments up to 12 months post randomisation
45094,Accumulated causes of mortality at 90 days and 12 months post randomisation
45096,Group comparisons of 18F FDOPA uptake and 11C MP binding in the first study, by age
45097,11C DTBZ and 11C DASB binding in the second study, by group
45099,SMRs for selected causes in people with severe mental illness
45100,Adjusted HRs for all cause mortality, by ethnic group and time since diagnosis
45101,Adjusted HRs for all cause mortality, by covariates
45102,Sub HRs for natural cause and unnatural cause mortality
45104,Primary outcomeClincal Global Improvement raw score
45105,Adverse events
45107,Response to treatment
45108,Treatment related adverse events   safety population, initial treatment phase
45110,Variables determining starting doses and stratification factors for random assignment
45111,Best tumour response
45112,Haematological and non haematological adverse events
45114,Adverse events at 3 months after randomisation
45115,Post study treatment
45118,Overview of adverse events in the safety population
45119,Grade 3 or more adverse events with an incidence of 2  or more in either group in the safety population
45121,Tumour responses according to Response Evaluation Criteria in Solid Tumors version 1.1
45122,Adverse drug reactions occurring in at least 10  of patients in any group according to preferred term   as treated population set
45124,Operative and pathological results
45125,Late grade 24 adverse events
45130,Safety and tolerability of evolocumab
45132,Main underlying diseases with the ASCOD phenotyping system
45134,Outcomes
45136,Association of variables with DNA TGN concentration
45137,Adjusted HR for relapse free survival in non high risk patients in clinical remission at start of maintenance therapy
45140,Logistic regression analyses of pathological complete response
45141,Pathological complete response at the time of surgery, by intrinsic molecular subtype assessed at day 14
45142,Adverse events
45143,Estimates of the generalised estimating equation analysis of frequent substance use and predictor variables
45146,Adverse events irrespective of causality in at least 10    grade 1 or 2   or at least 2    grade 3 or 4   of patients in either treatment group
45148,Association results for the three markers that reached genome wide significance
45150,Univariable analysis of prognostic variables
45151,Multivariable analysis by overall survival
45152,Adverse events by CTCAE category
45154,Frequency of carcinoid syndrome in patients with well differentiated   grade III   neuroendocrine tumours
45155,Cox regression model of overall survival
45156,Multivariable logistic regression analysis of treatment use in the 3 months after neuroendocrine tumour diagnosis
45158,Subsequent treatments   intention to treat population
45159,Selected adverse events   safety analysis set
45162,Results of the mega analysis of subcortical brain volumes in the total sample
45163,Results of the mega analysis of subcortical brain volumes in the stratified age groups
45164,Results of the exploration of the effect of medication on case control differences
45166,Anti HBs seroconversion
45167,Adverse events and laboratory abnormalities from week 0 to week 48
45169,Incidence rates of HCV reinfection in participants who cleared primary infections in British Columbia, Canada
45170,Hazard ratios from Cox proportional hazards models for time to HCV reinfection in British Columbia, Canada
45171,Adjusted hazard ratios from Cox proportional hazards models for time to HCV reinfection, stratified by clearance type, in British Columbia, Canada
45172,Hazard ratios from Cox proportional hazards model for time to HCV reinfection among current injection drug users in British Columbia, Canada
45175,Adverse events
45176,Discontinuation clinical trials for patients with major depressive disorder
45177,Model selection
45181,Clinical outcomes   MITT population
45182,Incidence of adverse events occurring in 10  or more of patients in either treatment group
45184,Surgical and pathological findings
45185,Adverse events reported during pre operative chemotherapy
45186,Adverse events reported during post operative chemotherapy
45188,Confirmed objective responses
45189,Treatment emergent adverse events leading to discontinuation of study drugs
45190,Treatment emergent adverse events by predefined categories in the safety population
45191,Treatment emergent serious adverse events      by preferred term in the safety population
45193,Oncological outcomes and postoperative complications by allocated treatment in the three arm randomisation at the end of follow up
45194,Oncological outcomes and postoperative complications by allocated treatment in the pooled short course radiotherapy comparison at the end of follow up
45199,Adverse events, irrespective of relation to study treatment
45201,Pre migration potentially traumatic events and post migration stressors of 2399 humanitarian migrants in the Building a New Life in Australia project, 201314
45203,Baseline characteristics
45205,Responses in patients with or without del  17p
45206,Responses in patients with unmutated or mutated IGHV
45207,Treatment emergent adverse events and laboratory abnormalities   occurring 10  of patients in both groups
45208,Serious adverse events   any grade; 2  of patients
45209,Treatment related adverse events leading to death   per investigator assessment
45210,Major gastrointestinal bleeding with different anticoagulant medications and prespecified sensitivity tests
45212,GRADE summary of findings reporting the comparative efficacy of drugs strategies
45214,Primary treatment of African patients with hepatocellular carcinoma
45215,Predictors of survival in African patients with hepatocellular carcinoma
45217,Adverse events   in at least 10  of patients
45218,Summary of the qualifying variant criteria in the four models, by cohort
45219,Genes that confer a risk of epilepsy
45220,Multivariable analysis of the Erasmus Breast Cancer Cohort for distant metastasis free survival
45221,Clinical cohort description and multivariate analysis for the effect of GARD on selected endpoints
45225,Adverse events per breast
45226,Reoperations per breast
45227,Risk of medical complications, reoperation for medical reasons, and removal of implants
45230,Treatment emergent adverse effects
45231,Sociodemographic, socioeconomic, and medical characteristics of study participants by demographic surveillance area
45232,Behavioural and emotional scores and problems for the CBCL seven syndrome scales and the DSM IV oriented scales
45233,Factors associated with total behavioural and emotional problems in 2903 children who received the risk factor questionnaire
45234,Medical and neurocognitive comorbidities of behavioural and emotional problems by age group in children randomly selected for clinical assessment
45236,Stratified sensitivity analysis for patients who achieved the primary endpoint
45237,Post hoc analysis of patients who achieved the primary endpoint, by individual endpoint components
45240,Treatment emergent adverse events occurring in at least 10  of patients during the 8 week treatment period
45242,Sensitivity and specificity estimates for the individual biomarkers comparing non dysplastic Barrett s oesophagus and Barrett s oesophagus with high grade dysplasia
45243,Risk classification results for the discovery and validation cohorts
45247,Major adverse cardiovascular events according to insulin dosage using conventional analyses
45249,Rates of all cause mortality and death with functioning graft up to 10 years after kidney transplantation stratified by diabetes status and age
45251,Infection in infancy and the risk of childhood obesity
45252,Exposure to antibiotics in infancy and the risk of childhood obesity
45255,Prevalence of prediabetes by definition
45259,Primary clinical outcome
45260,Lead time to treatment and response rate
45261,Electro clinical secondary outcome
45262,Adverse reactions
45266,Model for prediction of cognitive impairment in patients with newly diagnosed Parkinson s disease
45270,Comparison of Kaplan Meier estimates of proportions of patients remaining free from seizures after 6 months of treatment at the last assessed dose
45271,Numbers of patients with treatment emergent adverse events
45273,Objective response rates by homologous recombination deficiency subgroup
45274,Treatment emergent adverse events
45276,Variant allele frequency changes of driver mutations by patient and gene from the time of primary cancer diagnosis to therapy related myeloid neoplasm diagnosis
45277,Fine Gray proportional hazard regression model for therapy related myeloid neoplasm development in the external cohort
45280,Components of reported haematological toxicity
45281,Components of reported nephrotoxicity
45283,Outcome variables at 3 months
45284,Adverse events
45286,Differences between patients who were and were not admitted to acute mental health services within 12 months of index episode with crisis resolution and home treatment teams
45287,Risk factors for admission to acute mental health services within 12 months of index episodes with CRTs
45288,Risk factors for admission to inpatient wards within 12 months of index episodes with CRTs
45292,Univariate and multivariate analyses of progression free survival and overall survival
45294,Adverse events occurring up to week 28, regardless of causality
45296,Prevalence of neuronal cell surface antibodies in patients and controls
45300,Adverse events   safety analysis set
45302,Symptom prevalence between cohorts
45303,Key inclusion and exclusion criteria for the TwiLyte, MoonLyte, and NightLyte studies
45305,Overall adverse event profile up to week 12 in the TwiLyte, MoonLyte, and NightLyte studies   safety population
45307,Efficacy endpoints
45308,Adverse events of interest
45317,Biochemical measures of prediabetes
45319,c statistics   with 95  CI   for early stroke discrimination with ABCD2, ABCD2 I, and ABCD3 I scores at each timepoint after transient ischaemic attack
45321,Median survival and median time to initiation of non invasive ventilation
45322,Non fatal serious adverse events and causes of death
45324,Safety outcomes
45325,Functional outcomes
45327,Overall survival using a Cox proportional hazards analysis, a restricted means analysis, and a log rank test
45328,Patients receiving long term olaparib maintenance monotherapy, by number of years of treatment received
45331,Adverse events, in the safety population
45334,Suicide counts, rates, and regression adjusted hazard ratios among military personnel
45335,Association of past deployments with death by suicide
45336,Hazard ratios of suicide, categorised by deployment history
45337,Hazard ratios of death by suicide among individuals who had left military service anytime between 2001 and 2011
45339,Number of psychoeducation and peer support sessions attended
45341,Antitumour activity
45342,Objective response by Bellmunt prognostic risk factor
45343,Treatment related adverse events of any grade reported in at least 10  of patients and all grade 34 events in 78 patients who received nivolumab
45345,Adverse events related to treatment in cycles one to eight
45346,Serious adverse events related to treatment in cycles one to eight
45347,Adverse events
45348,Response to treatment
45349,Treatment related adverse events
45351,Survival outcomes and response to treatment
45352,Summary of multivariable analyses of prognostic factors
45353,Cumulative adverse events during treatment by maximum grade per patient during treatment
45355,Treatment emergent adverse events, by maximum severity
45356,Improvement in risk classification for first onset composite cardiovascular disease outcomes by addition of information about NT proBNP concentration compared with that about HDL C
45360,Difference in weight loss   kg   for POWeR  versus control, with imputed data
45362,Incremental overall National Health Service cost per kg of weight lost in the POWeR  groups versus the control group
45365,Treatment effects
45366,Safety outcomes and adverse events
45368,Summary of patients who received postoperative MAP and MAPIE
45369,Postoperative treatment related adverse events
45370,Summary of worst grade toxicity during postoperative chemotherapy
45373,Safety events
45376,Treatment emergent adverse events
45378,Comparison of cancer risk in the polycystic kidney disease cohort and the control cohort
45379,Comparison of individual cancer risk in the polycystic kidney disease cohort and the control cohort
45381,Cannabis use pattern and relapse outcome
45382,Multiple regression analyses of cannabis use pattern and relapse outcome
45383,Training   n 2790   and validation   n 7691   sample distributions by tumour type
45385,EPICUP prediction accuracy compared with other clinical diagnostic tests
45386,Cases of cancer of unknown primary classified by tumour types predicted by EPICUP that received specific therapy   n 31
45387,Treatment efficacy in the final RAS wild type population
45388,Comparison of the tumour dynamics in the RAS wild type CT assessable centrally reviewed population
45389,Overall survival and progression free survival in patients with and without early tumour shrinkage in the RAS wild type CT assessable population
45393,Biochemical outcomes after adrenalectomy
45395,Association of neonate TSH concentrations for children with scores lower than the national minimum standard for numeracy and reading, developmentally high risk, or having special needs
45397,Results from regression models of thrombin generation parameters, in vivo coagulation activation markers, and quality of life, adherence, and clinical and safety measures in all patients assigned treatment
45399,Primary, secondary, and safety outcomes
45402,Kaplan Meier estimates of 3 year case fatality
45403,Clinical and pedigree details of individuals participating in this study
45406,Safety outcomes
45408,Discomfort with body aspects and behavioural changes performed during interview index period to be more like the desired gender, by assigned sex at birth
45409,Differences between study participants by reporting and not reporting distress during interview index period
45410,Multivariate logistic regression models for dysfunction and distress among study participants   n 250
45414,Patterns of missing values in the SACT dataset for PS, stage, and BMI for all patients with breast or NSCLC
45415,Summary of 30 day mortality rates in patients with breast or lung cancer by treatment intent
45416,30 day mortality rates in patients with lung cancer by morphology and treatment intent
45417,Regression analysis results showing 30 day mortality for breast cancer patients treated with curative intent by age, PS, ID, previous SACT   previously treated or treatment naive  , and BMI
45418,Regression analysis results showing 30 day mortality for breast cancer patients treated with palliative intent by age, PS, ID, previous SACT   previously treated or treatment naive  , and BMI
45419,Regression analysis results showing 30 day mortality for patients with NSCLC treated with curative intent by age, PS, ID, previous SACT   previously treated or treatment naive  , BMI, sex, and cancer stage
45420,Regression analysis results showing 30 day mortality for patients with NSCLC treated with palliative intent by age, PS, ID, previous SACT   previously treated or treatment naive  , BMI, sex, and cancer stage
45421,Reasons for treatment discontinuation   safety population, n 561
45422,Summary of treatment exposure   safety population, n 561
45424,Treatment after discontinuing study therapy   intent to treat population
45425,Association results between HLA DPB1 rs9277378   A G   and NKTCL, by study cohort
45426,Associations between haplotypes at aminoacid positions 8487 of HLA DPB1 and NKTCL
45427,Number of times people were admitted for hypoglycaemia during the study period
45430,Results of post hoc univariate and multivariate Cox proportional hazards analysis for disease relapse
45432,DALYs due to stroke for selected risk factors and risk factor clusters by country income level for both sexes combined in 2013
45435,Relation of cerebral vessel disease with Alzheimer s disease dementia
45436,Relation of cerebral vessel disease with cognitive domains
45437,Summary of cohorts, miRNA platforms, and chip arrays used for model development
45439,miRNAs entered into the prognostic model
45440,Univariate and multivariable analysis of progression free survival
45441,Univariate and multivariable analysis of progression free survival in patients in OC263 with type II ovarian cancer
45443,10 year overall survival
45444,10 year distant metastasis free and relative survival in the 2003 cohort
45447,Adverse events in the safety population
45449,PTM development
45450,Subgroup analyses for the primary outcome
45451,Visual analogue scale scores, quality of life variables, and morphine equivalent doses
45452,Adverse events related to radiotherapy, according to the trial protocol
45454,Distribution of toxicity grades for each type of adverse event according to treatment group   per protocol dataset
45457,All cause adverse events by treatment phase   safety population
45458,All cause adverse events occurring in 10  or more patients in either treatment group   safety population
45460,Haematological and non haematological adverse events
45461,Multivariable analysis for overall survival
45463,Treatments categorised by sex
45464,Summary statistics for deaths categorised by sex
45465,Standardised mortality ratios   SMRs   with date of entry as date of cure plus 10 years
45468,Adjusted hazard ratios of clinical outcomes by burden of microvascular disease
45470,Cumulative incidence rates of new onset dementia according to subgroups of interest
45472,Independent risk factors of new onset dementia as determined by backward stepwise multivariable analysis in the overall population
45473,Age adjusted association of new onset dementia with MRI lesions after the 6 month landmark point   in the overall population with MRI data available
45474,Independent prognostic factors of new onset dementia with MRI lesions after the 6 month landmark as determined by backward stepwise multivariable analysis   in the overall population with MRI data available
45475,Multivariable Cox regression model analyses by cohort
45476,Multivariable logistic regression model analysis for treatment outcome after neoadjuvant chemotherapy
45477,Level of evidence   Oxford criteria   of suicide prevention by means restriction
45478,Level of evidence   Oxford criteria   of suicide prevention strategies by treatment interventions
45479,Level of evidence   Oxford criteria   of suicide prevention using population level prevention strategies
45480,Personality disorder and background factors at age 24 years and outcomes at age 35 years in the observed      and multiple imputed datasets
45481,Estimated associations between severity of personality disorder at age 24 years and social difficulties and mental health at age 24 years
45482,Estimated associations between severity of personality disorder at age 24 years and social difficulties at age 35 years
45483,Estimated associations between severity of personality disorder at age 24 years and mental health and illicit substance use at age 35 years
45484,Estimated associations between severity of personality disorder at age 24 years and licit substance use and dependency at age 35 years
45491,Adverse events
45493,Multivariable analysis of the effects of various prognostic variables on progression free survival
45494,Response to treatment overall and in post hoc analysis of subgroups
45495,Incidence of adverse events during the whole study period
45497,Adverse events by patient
45500,Top genome wide associations and HLA associations with agranulocytosis induced by all drugs and by antithyroid drugs
45501,Data sources
45503,Effect of neighbourhood deprivation on type 2 diabetes risk
45505,Crude event rates, stratified by treatment group
45506,Results of survival model assessing the effect of testosterone replacement therapy on the primary and secondary outcomes
45508,Intra arterial treatment effect by ASPECTS subgroup
45509,Safety outcomes and serious adverse events by ASPECTS subgroups
45511,Single nucleotide polymorphism associated with risk of stroke at p 5106
45512,Validation of top loci in independent cross sectional case control studies associated with risk of stroke
45514,Summary of adverse events within 31 days of administration, by maximum Common Terminology Criteria for Adverse Events grade   total treated cohort
45515,Summary of serious adverse events with fatal outcome   total treated population, as treated
45516,Potential immune mediated diseases determined from a predefined list of preferred terms or by the investigator
45520,Complier average causal effect analysis at 12 months
45521,Most common adverse events, grade 3 or worse adverse events, and serious adverse events during the overall treatment period   neoadjuvant and adjuvant
45522,Cardiac events for neoadjuvant, adjuvant, and post treatment follow up periods and for all periods combined
45524,Grade 3 or worse adverse events in three or more patients
45525,Summary of adverse events
45526,Reasons for discontinuation
45527,Suicide rates   per 10000 contacts with mental health services   before and after implementation of service changes or recommendations between 1997 and 2012
45528,Correlations between service features and suicide rate   per 10000 contacts with mental health services
45529,IRR for suicide rates before and after service implementation stratified by high and low staff turnover and patient safety incidents
45532,Acute adverse events previously associated with hormone therapy
45533,Quality of life scores
45535,Final multivariable model   training, internal validation, and external validation datasets
45536,Survival data of CLL IPI risk groups in the training, internal validation, and external validation datasets
45539,Safety outcomes
45544,Goodness of fit statistics for one to five class solutions
45547,Current and target levels of scaled up treatment coverage for depression and anxiety disorders   all interventions combined  , by country income level
45548,Costs and benefits of scaled up treatment of depression and anxiety disorders, 201630
45550,Likelihood of reporting first pregnancy and livebirth in survivors of childhood cancer compared with siblings
45551,Likelihood of reporting first pregnancy and livebirth, by individual chemotherapy exposures and cyclophosphamide equivalent dose
45555,Drug related adverse events   10  of patients in either treatment group with grade 12 and all grade 3 adverse events; NCI CTCAE 3.0
45557,Pazopanib related adverse events   n 76
45558,Pazopanib related serious adverse events   n 76
45559,Patients with evaluable mutations
45562,Observational associations of plasma urate concentration with cardiovascular risk factors
45563,Causal analysis of urate on risk of coronary heart disease derived from Mendelian randomisation analyses
45565,Effect of aliskiren on progression and regression of albuminuria
45567,Clinical outcomes
45568,Adverse events
45569,Secondary outcomes
45571,Specific symptoms according to treatment group
45573,Symptoms for late gastrointestinal and genitourinary toxicity that are significantly associated with the significant prognostic factors identified in the multivariate analysis
45576,Treatment emergent adverse events   safety population
45577,Demographics and baseline clinical characteristics
45578,Pharmacokinetic secondary outcome parameters
45579,Baseline demographics and clinical characteristics of patients in the placebo and AMG 334 groups
45580,Primary and secondary endpoints
45581,Summary of adverse events in the placebo and AMG 334 groups
45582,Meta analysis of clinical outcomes in patients with bipolar disorder who did or did not have a history of childhood maltreatment
45583,Meta regression of clinical outcomes in patients with bipolar disorder who did and did not have a history of childhood maltreatment
45585,Reasons for treatment discontinuation
45586,Secondary efficacy endpoints
45587,Adverse events
45589,Multivariable Cox regression analysis of candidate predictors of treatment resistant schizophrenia, according to the main proxy definition and two alternative definitions   N 8044
45591,Multivariable analysis of risk of death
45592,Hazard ratios for risk of death by TN combination
45593,Hazard ratios for risk of death for the three stage classifications
45594,Re termed ICON S T and N categories and corresponding hazard ratios for risk of death within each T category
45596,Multivariate Cox regression of overall survival
45597,Secondary endpoints
45598,Treatment emergent adverse events of interest
45599,Most common serious adverse events, and causes of death, in the safety population
45601,Progression free survival by multivariable Cox model for all patients   n 738
45602,Overall survival by multivariable Cox model for all patients   n 778
45605,Adverse events
45607,Investigator assessed best overall tumour response by treatment and according to PIK3CA mutation status
45608,Grade 12 adverse events occurring in 10  or more of patients and all grade 35 adverse events in the fulvestrant plus palbociclib safety population   all causalities and all cycles
45610,Primary and secondary outcomes.
45611,Meal test results
45612,Patient reported outcome measures
45613,Adverse events
45616,Patient or physician decision for drug discontinuation in standard care and intervention groups
45619,Comparison between different definitions of pathological complete responses and selected secondary endpoints including clinical response assessment after neoadjuvant therapy and the proportion of patients requiring breast conserving surgery and axilla surgery
45620,Adverse events
45621,Adverse events of special interest, assessed without grade
45623,Invasive disease free survival events in the intention to treat population
45624,Treatment emergent adverse events occurring in at least 10  of patients in the safety population
45626,Overall response
45627,Summary of adverse events by NCI Common Toxicity Criteria version 4.0 and treatment
45629,Treatment, service contact, and risk assessment
45630,Suicide methods
45633,Tumour responses
45634,Most common treatment related adverse events
45636,Number of chemotherapy cycles delivered by tumour location
45637,Haematological and non haematological adverse events associated with chemotherapy
45639,Efficacy outcomes with lenalidomide compared with investigator s choice   central review
45640,Treatment emergent haematological and non haematological adverse events   10  grade 12, 5  grade 34
45643,Proportion of excess risk mediated by haemodynamic variables at diagnosis
45647,Adverse events and withdrawals in the modified intention to treat population
45649,Age standardised prevalence of non fatal cardiovascular diseases among patients with early onset versus late onset type 2 diabetes
45650,Odds ratio of early onset versus late onset type 2 diabetes for non fatal cardiovascular disease by level of hospital
45651,Validation of odds ratios of early onset versus late onset type 2 diabetes for non fatal cardiovascular disease in the 3B study
45652,Sugar sweetened beverage consumption and its contribution to sugar and energy intake in the UK population
45653,Predicted reduction in energy intake from a 40  reduction in sugar contents of soft drinks over 5 years   including fruit juices
45654,Predicted reduction in energy intake   kcal per day, 95  CI   from a 40  reduction in sugar added to soft drinks over 5 years   excluding fruit juices
45656,Hazard ratios and estimated 5 year risks of outcome events for core predictors in prognostic models
45658,Analysis of primary outcomes
45659,Analysis of secondary outcomes
45660,Visual analysis of MRI by score   secondary outcome
45661,Case and control cohorts in NINDS SiGN
45662,Novel and previously identified loci implicated in ischaemic stroke and its subtypes through genome wide testing
45664,Bayesian analyses
45665,Efficacy results
45666,Adverse events
45670,Ongoing adversities, protective factors, and mental health indices stratified by severity of conflict across affected zones
45671,Population attributable fraction estimates for predictor variables associated with depression and anxiety symptoms
45673,Subsequent first disease event and treatment in the 129 patients with a clinical complete response managed by watch and wait
45674,Key patient and tumour prognosticators by treatment group after propensity score matching
45676,Compliance with allocated screening strategy
45677,Occult malignancy diagnosed initially and during follow up
45679,Cost utility analysis from a National Health Service and personal social services perspective
45681,Quality of life scores at 12 months after transplantation
45682,Organisms that caused serious infections during the study
45684,Multivariable analysis of prognostic factors in overall survival and melanoma specific survival
45685,Deaths from melanoma and other causes in different age groups
45687,Treatment emergent adverse events    10  patients
45688,Bleeding related events
45690,Characteristics of studies included in the systematic review that could not be included in the meta analyses
45691,Assessment of risk of bias
45693,Safety overview
45694,Summary of common adverse events
45697,Adverse events
45700,Clinical predictors included in admission predictive model in the derivation dataset   n 350
45703,Prevalence of the studied functional gastrointestinal disorders by group
45704,Multivariable analysis of functional gastrointestinal disorders and associated factors by primary headache types
45705,Multivariable analysis of the association between migraine and functional gastrointestinal disorders by migraine subtype
45706,Multivariable analysis of the association between migraine and functional gastrointestinal disorders by age subgroups
45709,Initial symptoms
45710,Subsequent symptoms
45711,Total diagnostic interval, patient interval, and health system interval for any symptoms
45712,Predictors of total diagnostic interval, patient interval, and health service interval
45714,Remaining lifetime and 10 year risks of prediabetes, diabetes, and insulin use, by age
45715,Lifetime risk at age 45 years for prediabetes, diabetes, and insulin use, by BMI and waist circumference strata
45716,Lifetime risk for the development of diabetes in individuals with prediabetes at age 45 years and lifetime risk for use of insulin in individuals aged 45 years with diabetes but not using insulin, stratified by BMI and waist circumference
45722,Adverse events in at least three people, with the exception of falls
45727,Primary, secondary, and exploratory outcomes related to relapses
45728,Adverse events and serious adverse events
45734,Adverse events and serious adverse events
45738,Univariate associations of family, social and adolescent cognitive health behaviour factors with sustained good adolescent mental health
45739,Univariate associations of family, social and adolescent cognitive or health behaviour factors with mood and behaviour resilience at final follow up
45741,Adverse events of grade 12 that occurred   regardless of grade   in at least 10  of patients or that occurred as grade 3 or worse in at least 1  of patients
45742,Pattern and severity of diarrhoea
45743,Haematological adverse events by planned AUC
45744,Adverse events leading to permanent drug discontinuation in at least 05  of patients in either treatment group
45746,Patient responses
45747,Grade 14 adverse events in both treatment groups
45748,Haematological toxic events of all grades per number of cycles in patients receiving at least one dose of study treatment
45750,Treatment responses in the intention to treat population
45751,Adverse events in the safety population
45752,Adverse events of interest in the safety population
45754,Incident HPV infection and HPV infection status
45756,Adverse events in the safety population
45764,Adverse events and serious adverse events during double blind phase
45774,Adverse events
45776,Primary and birth outcomes
45777,Secondary outcomes
45778,Adverse outcomes
45780,Incidence of events and hazard ratios of drug groups for all events during 6 month follow up
45781,Hazard ratios of events during 6 months follow up in the propensity score matched samples
45782,Hazard ratio for self harm during 6 months  follow up in varenicline versus NRT users, adjusted for an unmeasured binary confounder with a hazard ratio of 3  43
45783,Cases of type 2 diabetes and current census counts by year and season of birth   193038  , and sex, by severity of Ukraine famine   193233   in the region of birth
45784,Odds of type 2 diabetes by regional severity of Ukraine famine 193233, comparing men and women still alive in 2000 who were born in 1934, with all other births in 193038, by region of birth and sex
45785,Different criteria used for diagnosis of gestational diabetes
45786,Confounder adjusted association of gestational fasting and 2 h post load glucose with primary outcomes
45787,Thresholds of fasting and post load glucose concentrations that would identify an odds ratio of roughly 175 for birthweight  90th percentile and sum of skinfolds  90th percentile
45788,Prevalence of gestational diabetes in south Asian and white British women using different criteria
45791,Adverse events
45794,Summary of treatment emergent adverse events
45796,Relative risks   99  CI   for the prevalence of ASD phenomenology in each included syndrome compared with other syndromes
45798,Community care over 36 months and legal status by randomised groups
45799,Outcomes at 36 months  follow up of randomised groups
45800,Associations between readmission outcomes and CTO experience at 36 months
45801,Levels of discontinuity and disengagement from service and associations with duration of compulsion
45809,Adverse events in the safety population
45810,Included studies
45812,Major cardiovascular outcomes with albiglutide versus all comparators, placebo, and active comparators
45813,Major adverse cardiovascular events or hospital admission for unstable angina by study
45814,Other adjudicated events
45815,On treatment and post treatment atrial fibrillation and atrial flutter adverse events   post hoc analysis
45816,Summary of registers used in the study
45818,Substance use disorders as predictors of all cause mortality, suicide, and deaths from accidents in people with schizophrenia, bipolar disorder, or depression
45819,Substance use disorders as predictors of natural causes of death in people with schizophrenia or depression
45820,Numbers of relapses in the eligible population
45821,Late surgical adverse effects in the eligible patient population by lymph node field
45822,Late radiotherapy adverse effects in the eligible population
45823,Quality of Life outcomes
45825,Relative risks of psychiatric disorders and attempted suicide in adults during the 5 years after the tsunami
45826,Relative risks of psychiatric disorders and attempted suicide in children and adolescents
45827,Relative risks of stress related disorders and other psychiatric disorders at different times after the disaster
45829,Odds ratio for depression and self harm at 18 years for each category of goth identification
45835,Patients with locoregional or distant progression in the two treatment groups
45838,Mortality from breast cancers diagnosed during the intervention phase by time since randomisation
45839,Mortality from all causes and from breast cancer in the intervention and control groups for a 17 year follow up
45840,Breast cancer mortality by period in trial
45841,All cause and breast cancer mortality in attenders and non attenders at first screen in the intervention group
45842,Breast cancer incidence for all follow up and to date of first NHSBSP screen
45844,Response in all patients and predefined subgroups
45845,Treatment emergent adverse events
45847,Overall and selected toxicities between groups without bevacizumab and those with bevacizumab
45848,Disease free survival events for groups with bevacizumab and those without bevacizumab
45849,Results from Cox proportional hazards models with multiple covariates
45851,Between group comparisons of other efficacy endpoints, by period after chemotherapy   modified intention to treat population
45852,Treatment emergent adverse events in cycle 1   safety population
45853,Treatment emergent adverse events of grades 3, 4, and 5   safety population
45855,Complete responses, by phase and type of chemotherapy
45856,Between group comparisons of other efficacy endpoints   modified intention to treat population
45857,Treatment emergent adverse events in cycle 1   safety population
45858,Treatment emergent adverse events of grades 3 and 4   safety population
45859,Details of studies and women included
45860,Relative risk of endometrial cancer in ever versus never users of oral contraceptives by histological subtype
45862,Risk of death and metabolic acidosis in patients with type 2 diabetes and advanced   approximately stage 5   chronic kidney disease after propensity score matching   n 3252
45863,Risk of chronic dialysis, death before ESRD, and death after ESRD
45865,Comparisons of dual hormone artificial pancreas, single hormone artificial pancreas, and conventional pump therapy
45866,Hypoglycaemia and hyperglycaemia events
45867,Predicted loss of function mutations identified in patients with Alzheimer s disease
45868,Description of the Alzheimer s disease probands carrying ABCA7 Glu709fs
45870,Lifetime prevalence of anxiety disorder in individuals with bipolar disorder
45871,Comparison of lifetime prevalence of anxiety disorders between people with bipolar I and bipolar II disorder
45872,Comparison of lifetime prevalence of anxiety disorders between people with and without bipolar disorder
45879,Cardiovascular outcomes of included cohorts
45882,Univariate Cox regression analysis for time to death
45884,Comparison of the US and European prospective studies
45885,Adolescent use of marijuana in the 48 US contiguous states between 1991 and 2014
45886,Adolescent use of marijuana before and after passage of medical marijuana in the 21 US contiguous states that passed medical marijuana laws up to 2014
45888,Efficacy endpoints
45889,Adverse events of interest
45891,Similarities and differences between the ALSPAC and GSMS longitudinal studies
45892,Mental health outcomes of maltreatment and being bullied by peers
45893,Mental health outcomes of maltreatment and being bullied by peersadjusted analysis   all results are adjusted
45895,Mortality and causes of death of study participants
45896,Risk factors for suicide and recurrent self poisoning after a first self poisoning episode in adolescence
45897,Incidence rate ratios of single and recurrent depressive episodes associated with anxiety diagnoses   19942012
45898,Incidence rate ratio of single depressive episodes and recurrent depressive disorder in offspring of parents with various psychiatric diagnoses   19942012
45900,Summary of fracture annual incidence rates in HypoCCS patients who received growth hormone and who did not
45901,Adjusted HR   95  CI   summary of significant fracture predictors in a reduced proportional hazard model in HypoCCS patients with and without pre existing osteoporosis
45907,Overview of adverse events   safety analysis population
45908,Total intracellular cytokine response, presented as frequency of CD4 T cells and CD8 T cells producing specific cytokines
45909,Primary and secondary efficacy results   per protocol population
45911,Assessment across the 44 associations of environmental risk factors with multiple sclerosis
45913,Adjusted odds ratios   aORs   and ratio of odds ratios   RORs   of violent crime in patients with depression, and in unaffected half siblings and full siblings
45914,Prevalence of risk factors and rates of violent crime in individuals with depression with different background risk factors
45916,Cannabis use
45917,Risk for first episode psychosis for each measure of cannabis exposure
45918,Population attributable fraction for daily use of cannabis, skunk use, and skunk use every day
45920,Treatment beyond first line therapy in patients with common EGFR mutations
45924,Association of cholesterol efflux capacity with incident coronary heart disease events
45926,Definitions and sources of contributing data for main study outcomes
45928,Number of cis acting and trans acting eSNPs and their relation to genes
45929,Results of integrating lung eQTLs with FEV1 and FEV1 FVC GWAS reported associations in the SpiroMeta and CHARGE consortia reports  46
45930,Results of lung function eSNP regulated genes  mRNA regression on FEV1 and FEV1 FVC in 727 participants from the lung eQTL study
45931,Mendelian randomisation estimates of the association between 1 SD lower 25  OH  D concentrations and glycaemic traits
45934,Final diagnoses and stages of non small cell lung cancer
45935,Secondary outcomes
45939,Adverse events in the safety population   PLANET I
45942,Number of events, crude estimates of event proportions, and Cox proportional hazards regression for mortality, cardiovascular death, and myocardial infarction
45944,Efficacy outcomes
45945,Clinically important adverse events associated with the interventions
45948,Maternal outcomes
45949,Maternal nutritional and physical activity outcomes, by period of gestation
45950,Neonatal outcomes
45951,Adverse events not prespecified as secondary outcomes
45953,Effects of renin angiotensin system inhibitors on diabetic retinopathy in the meta analysis
45955,Comparisons of dual hormone artificial pancreas, single hormone artificial pancreas, and conventional insulin pump therapy for the overall study period   0800 h to 0800 h
45956,Comparisons of dual hormone artificial pancreas, single hormone artificial pancreas, and conventional insulin pump therapy for the overnight study period   2300 h to 0800 h
45957,Hypoglycaemia rates and nocturnal hypoglycaemia
45960,Risk of severe malaria and inpatient death in the case control study
45961,Incidence of malaria and other common childhood diseases in the mild disease cohort study
45962,Plasmodium falciparum densities in the case control and mild disease cohort studies
45966,Adverse events in the 3 months after randomisation
45967,Adverse events in the 12 month follow up period
45969,Logistic linear regression analysis of associations between imaging signs and age, NIHSS score, and time to randomisation
45970,Logistic linear regression analysis of associations between individual imaging signs and primary and secondary outcomes, adjusted for age, NIHSS score, and time to randomisation
45971,Full multivariate logistic regression models for symptomatic intracranial haemorrhage and functional outcome at 6 months
45972,Multivariate logistic regression models selected by stepwise logistic regression for symptomatic intracranial haemorrhage and functional outcome at 6 months
45974,Planned or enrolling phase 2 and phase 3 trials in progressive multiple sclerosis
45975,Phase 2 trials in progressive multiple sclerosis
45977,Most common adverse events reported in more than 10  of patients and all grade 3, 4, or 5 adverse events
45980,Adverse events in the all patients treated population
45983,Adverse reactions and events
45985,Prevalence of different risk factors in cryptogenic versus other transient ischaemic attack and ischaemic stroke subtypes
45986,Outcome and prognosis of cryptogenic stroke and ischaemic stroke of known cause
45987,Subtypes of first recurrent ischaemic stroke or presumed embolic peripheral vascular events by index event subtype
45989,Accumulation of disability from the primary analysis
45992,Cumulative incidences of acute genitourinary and gastrointestinal toxicity by grade
45993,Specific symptoms according to treatment group
45996,Outcomes within 3 months
45997,Adverse events
45999,Outcomes during follow up   intention to treat analyses
46000,Serious adverse events during complete follow up
46001,Follow up imaging of symptomatic vertebral artery stenosis   per protocol analysis
46002,Comparison of VAST and other completed and ongoing trials of vertebral artery stenting
46004,Variant filtering
46005,Alternative minor allele frequencies of identified CHCHD2 variants
46008,Number of patients with symptoms before diagnosis or index date
46009,Incidence risk ratios of symptom presentations recorded in over 1  of patients at 2, 5, and 10 years before diagnosis
46011,Time to NHP and deaths
46012,Summary of time to nursing home placement by donepezil group and separately by memantine group
46014,Survival and quality of life outcomes
46015,Average daily use of non invasive ventilation and diaphragm pacing after initiation
46016,Adverse events
46017,Difference in location between atypical teratoid rhabdoid tumour subgroups
46018,Summary of clinical features and treatment outcomes in atypical teratoid rhabdoid tumour molecular subgroups
46019,Cox proportional hazard analyses of molecular and clinical prognostic factors in atypical teratoid rhabdoid tumour molecular subgroups
46020,Clinicopathological and survival features of atypical teratoid rhabdoid tumour risk categories
46024,Adverse events in all 15 patients during the whole study period
46025,Symptom frequency in progressive multiple sclerosis
46026,Studies of symptomatic management in chronic progressive multiple sclerosis
46028,Univariate and multivariate analysis of biochemical progression free survival
46029,Chronic late radiation toxicity
46030,Studies addressing the duration of androgen deprivation combined with conventional dose and high dose radiotherapy in high risk prostate cancer
46031,Prevalence of PALB2 mutations in 12529 patients with breast cancer, by age groups and family history
46033,Factors predicting mortality for patients with breast cancer with a PALB2 mutation   n 116
46035,Incidences of other types of cancers according to follow up period and treatment allocation
46036,Specific causes of death according to treatment group and follow up period
46038,Number of outcomes, exposure, and rates per 100000 length of by follow up
46039,Odds ratios and absolute risk measures by length of follow up
46040,Odds ratios for subgroup analysis with respect to deliberate self harm and death by suicide
46043,Clinical characteristics and illness severity of trafficked adults in contact with secondary mental health services in South London, 200612
46044,Clinical characteristics and illness severity of trafficked children in contact with secondary mental health services in South London, 200612
46045,Logistic regression analyses comparing the clinical outcomes of trafficked and matched non trafficked adults in contact with secondary mental health services in South London, 200612
46047,Surgical results
46048,Pathological tumour response
46049,Summary of surgical complications by Clavien Dindo grading
46050,Univariable and multivariable regression for pathological complete response
46052,Recurrence free survival per independent review committee, overall and by type of lymph node involvement
46053,Post hoc subgroup analyses of the effect of ipilimumab on recurrence free survival by type of lymph node involvement and ulceration status of the primary tumour
46054,Adverse events in the safety population
46057,Treatment exposure
46058,Treatment emergent adverse events
46059,Study deaths in the safety population
46062,Risk for diabetes associated with age 3564 years and the joint effect of antipsychotic drug treatment and family history of diabetes in people with psychosis
46064,Treatment emergent adverse events in the induction and consolidation treatment phases
46065,Treatment emergent adverse events in the maintenance treatment phase
46066,Lenalidomide and prednisone dose reduction and duration of maintenance
46069,Efficacy results in RAS and BRAF subgroups
46071,Treatment exposure   safety population
46073,Treatment emergent adverse events occurring in 10  or more of patients
46074,Interventions assessed in included studies
46075,Pre intervention and post intervention suicide rates for individual studies
46076,Primary analysis of overall survival and updated analysis of progression free survival
46077,Overall survival in predefined subgroups
46080,Cytokine analysis   n 27
46081,Pittsburgh sleep quality index score by treatment group and study week
46083,Efficacy outcomes
46084,Treatment emergent adverse events
46086,Locally assessed best overall response   full analysis set and HR negative subpopulation
46087,Median relative dose intensities   full analysis set and HR negative subpopulation
46088,Adverse events of 10  incidence in either treatment group or grade 3, 4 adverse events of 05  incidence in either treatment group   safety set
46089,On treatment deaths at data cutoff date   May 30, 2014; safety set
46091,Drug related adverse events   10  of patients in either treatment group with grade 12 and all grade 3 adverse events  .
46093,Univariate and multivariate analyses of the relationship between variables and recurrence free interval in the validation study
46094,Estimated PAFs and numbers of cancer cases associated with high BMI in men in 2012
46095,Estimated PAFs and numbers of cancer cases associated with high BMI in women in 2012
46097,Effects of pharmacological prevention for PTSD or ASD compared with control: incidence risk ratio
46098,Effects of pharmacological prevention for PTSD or ASD compared with control: Hedges  g
46100,Summary of efficacy in the intention to treat population
46101,Treatment related adverse events
46103,Smoking cessation at 12 months
46105,Relation of adverse events to study
46109,Response to treatment in maintenance phase overall and according to tumour KRAS status
46110,Adverse events during the maintenance phase
46112,Drug related adverse events reported in three or more patients in either treatment group
46113,Pharmacokinetic parameters of linsitinib after one dose   cycle 1   and several   cycle 2   doses
46115,Efficacy endpoints
46116,Adverse events of interest
46118,Long term toxic effects in patients treated locally with radiotherapy
46124,All cause deaths and unintentional drug related overdose deaths by treatment and treatment period
46125,Mortality risk after an in treatment medication switch compared with methadone only or buprenorphine only treatment induction
46127,Mortality rates
46130,Intention to treat analysis of first events for primary endpoint disease free survival
46131,Intention to treat analysis of all cause deaths
46132,Chemotherapy and radiotherapy in female patients with Hodgkin s lymphoma treated in the DAL HD studies HD 78 to HD 90
46134,Effects of seven variables on parenthood in female adult survivors treated for Hodgkin s lymphoma during childhood and adolescence
46136,Treatment related adverse events occurring in at least 2  of patients   any grade   by preferred term
46138,Best abscopal responses based on patient diagnoses and completion of scheduled therapy
46139,Treatment related adverse events
46143,Pathological data
46144,Reduced multivariable Cox regression model analysis of disease free survival in all patients
46145,Reduced multivariable Cox regression model analyses of disease free survival in UICC stage II and III patients
46147,Comparison of effectiveness   incidence rate ratios   between high intensity, low intensity, and practice as usual   PAU   general practices
46148,2 year costs and cases identified per general practice, by intervention group
46150,Clinical adverse events by system organ class in at least a 10  of patients in at least one treatment group
46151,Grade 35 clinical adverse events by system organ class in greater than 0  of patients in at least one treatment group
46153,Summary of genotyping analyses done in the CORRECT trial
46154,Frequency of individual hot spot mutations detected by BEAMing of plasma DNA in the CORRECT trial
46157,Treatment related adverse events according to treatment group
46159,Studies included in the primary analysis
46161,Adverse events
46163,Primary and secondary outcomes
46164,Most frequently reported adverse events by term, definitely, probably, or possibly related to protocol treatment
46165,Most frequently reported adverse events by category, definitely, probably, or possibly related to protocol treatment
46168,Progression by tumour site
46169,Treatment related adverse events
46171,Patients with evaluable mutation data in the intention to treat population
46172,Progression free survival overall and in KIT exon 11positive patients according to data source   adjudicated, local, or central review
46173,Common adverse events   10  in either treatment group   reported up to 28 days after study drug discontinuation   safety population
46175,Summary of antitumour activity of trabectedin after randomisation
46176,Adverse events
46177,Treatment related and non treatment related grade 3 and grade 4 adverse events
46178,Randomised phase 2 trials assessing the activity of trabectedin in doxorubicin refractory soft tissue sarcoma
46181,Comparison pharmacokinetic parameters between Japanese and western patients
46182,Adverse events
46184,Reasons for not proceeding to re induction
46185,RAS and BRAF mutation status
46186,Adverse events relevant to treatment during maintenance
46187,Antineoplastic drugs administered   at least once   at second line or further
46189,Dose reductions and interruptions
46190,Toxic effects
46192,Participants, deaths, and crude mortality rates by cause of death and parental exposure status
46193,Non cancer mortality after parental radiation exposure to the gonads by age at death
46194,Cancer mortality after parental radiation exposure to the gonads by age at death
46196,Drug related adverse events occurring at any grade in at least 10  of patients, or at grade 3 or higher in any patients in either group, from the start of treatment to 30 days after the end of treatment   safety population
46198,Treatment exposure
46199,Post study chemotherapy before and after disease progression
46200,Efficacy of study treatment
46201,Drug related adverse events
46202,Serious adverse events
46207,Summary of on study adverse events
46209,Best overall response and progression free survival probability
46210,Common adverse events by grade
46211,Main differences between trials investigating concomitant chemotherapy and those investigating concomitant plus adjuvant chemotherapy
46212,Summary of the results overall, and by chemotherapy timing, for all endpoints
46213,Toxicity data
46215,Treatment after discontinuation
46216,Adverse events
46218,Laboratory and non laboratory adverse events occurring in at least 10  of patients in either group during chemotherapy and study drug period
46219,Subsequent therapy for prostate cancer
46220,Overall survival at interim analysis 1, interim analysis 2, interim analysis 3, and final analysis
46221,Adverse events
46222,Adverse events of special interest
46225,Most common treatment related adverse events
46227,Study drug exposure
46228,Reasons for discontinuation
46229,Adverse events and drug related adverse events occurring in 5  of patients
46231,Local recurrences, analysed by subgroup
46232,Treatment received after local recurrence
46233,Other recurrences   as first event   or new cancers after 5 years
46235,Type specific incidence of childhood leukaemia in study cohorts and competing risk regression analysis
46236,Incidence density rate and SHR of leukaemia in patients by type of enterovirus infection estimated with competing risk regression analysis
46239,Activity of sonidegib by treatment group in the primary efficacy analysis population
46240,Activity of sonidegib by treatment group in the intention to treat population
46242,Most common adverse events reported by investigators in  10  of patients and all grade 3 or 4 adverse events
46246,Health related quality of life improvement at any time during the trial   intention to treat analysis
46249,Treatment emergent adverse events occurring in 10  patients, or of special interest, irrespective of cause
46251,Treatment exposure in the modified intention to treat population
46252,Common adverse events
46253,Number of overall cancers cases for indigenous and non indigenous people, 200206
46254,Ranking of most frequent cancers in indigenous men and women in each jurisdiction as a proportion of all cancers in indigenous people, 200206
46256,Response to salvage therapy
46257,Factors associated with post transplantation event free survival
46259,Adverse events related to brentuximab vedotin
46261,Bowel, urinary, and sexual domain scores at 24 months for UCLA PCI and EPIC QoL instruments
46263,Treatment exposure   safety population
46264,Patterns of recurrence
46265,Adverse events   safety population
46267,Best RECIST response, as determined by independent review committee
46268,Adverse events reported by 10  or more patients for grades 1 and 2 and all adverse events for grades 35   safety population
46270,Summary of coefficients for instrumental variable ratio analyses, with the synthesis score as an instrumental variable
46272,Patient disposition and discontinuations during the double blind period
46274,Overall incidence of TEAEs   safety population  , most common TEAEs   reported by 5  of patients of the safety population  , and frequency of opportunistic infections
46278,Adverse events in the safety population
46281,Progression free survival and overall survival estimates for 12 included randomised trials
46282,Sensitivity analyses
46285,Adverse events in patients with one or more event
46286,Most common AEs   in  10  of patients overall   and most common grade 3 AEs   in  2  of patients
46287,Tumour response at end of induction
46288,Exploratory analysis of investigator assessed tumour responses at end of induction
46291,Cumulative incidence of second primary malignancies, and death at 3 years and 5 years
46292,Univariate and multivariate analyses of factors potentially affecting solid and haematological second primary malignancy development
46293,Assessment of risk of bias
46296,Mortality expressed as hazard ratios on multivariate analysis for HRCT patterns and pulmonary function tests including the CPI in sarcoidosis group A   n 251
46297,Mortality expressed as hazard ratios on univariate analysis for the entire cohort   n 503  , in relation to the sarcoidosis staging model, categorised by radiologists   n 2   and physicians   n 2
46298,Mortality expressed as hazard ratios on univariate analysis for the sarcoidosis staging model in various patient subgroups within the entire cohort   group A and group B, n 503
46300,Matched odds ratio of acute pancreatitis associated with exposure to incretins in the 6 months before index date
46303,Summary of treatment emergent adverse events
46304,Quality assessment of all included studies
46305,Absolute sensitivity and specificity of human papillomavirus testing on self samples, and human papillomavirus testing and cytology on clinician taken samples, by clinical setting and grade of cervical intraepithelial neoplasia
46306,Pooled relative sensitivity and specificity of human papillomavirus testing on self samples versus cytology or human papillomavirus testing on clinician taken samples, by grade of cervical intraepithelial neoplasia
46307,Subgroup meta analysis of the relative sensitivity and specificity of human papillomavirus   self sampled vs clinician sampled   testing for cervical intraepithelial neoplasia of grade 2 or worse, by covariate
46308,Subgroup meta analyses of the relative sensitivity and specificity of human papillomavirus   self sampled vs clinician sampled   testing      for cervical intraepithelial neoplasia of grade 2 or worse, by self collection device
46311,Patients with Cretzfeldt Jakob disease who had neuropathological assessment and analysis of brain levels of doxycycline
46313,Multivariate analysis with Cox proportional hazard modelling of factors that predict the development of complications
46314,Specific breakdown of procedures and diagnoses used to define complication categories
46316,Best overall tumour response
46317,Most common treatment related adverse events
46318,Symptoms described in the vignettes, by risk level
46320,Number of participants who would choose to be investigated, by cancer and risk level
46321,Multivariable analysis for each cancer
46322,Number of participants who would choose to be investigated, by cancer and variables identified in the multivariable analysis
46323,Main reasons for choices
46325,Response to treatment according to Brief Pain Inventory score and daily oral morphine equivalent at 2 months in the intention to treat and per protocol populations
46328,Response evaluation by stratification factor variable
46331,Overview of adverse events, classified by Common Terminology Criteria for Adverse Events   version 3.0   in all patients who received at least one dose of study drug
46333,Multivariable proportional hazards regression model of disease free survival
46335,Response to treatment
46336,Toxic effects in all patients   n 49
46337,Autoimmune syndromes in patients diagnosed with thymoma
46338,Systemic treatment in patients with relapsed thymic epithelial tumours
46340,Glycaemic parameters at weeks 52 and 104 in the full analysis set
46342,Patients with adverse events occurring up to week 104 in the treated set
46347,Adverse events up to week 52 in the treated set
46350,Childhood and adulthood overweight or obesity and carotid intima media thickness at age 6064 years
46352,Doses of angiotensin receptor blocker and angiotensin converting enzyme inhibitor in patients included in the efficacy analyses
46355,Adverse events
46357,Missed opportunities to diagnose COPD in the years preceding diagnosis
46358,Prevalence of comorbidities at time of COPD diagnosis
46359,General linear model derived rate ratios for missed opportunities
46360,Mean differences in age at diagnosis from general linear model
46362,Most common adverse events    5  in any treatment group   in safety analysis set
46363,Hyperglycaemia related adverse events according to baseline diabetic status in the safety analysis set
46370,Most common   10    treatment emergent adverse events by study group and preferred term   safety population
46374,Prediction statistics and differences between models
46381,Antibiotic prescription and the risk of wheezing and severe asthma exacerbations
46382,Antibiotic prescription and risk of severe asthma exacerbations and hospital admissions for asthma or wheeze among children with a history of wheezing
46383,Effect of antibiotic prescription on the development of atopic sensitisation during the first 11 years of life
46384,Association between variants in 17q21 and antibiotic prescription in the first year of life by SNP
46386,Proportions of patients reaching HbA1c targets
46387,Treatment emergent adverse events that occurred in at least 5  of patients in any treatment group
46390,Predictors of early and late remission after Roux en Y gastric bypass surgery in patients who were not using insulin before surgery
46391,Predictors of early and late remission after Roux en Y gastric bypass surgery in patients who were using insulin before surgery
46392,Variables contributing to the DiaRem score
46393,Calculation of DiaRem score for prediction of the probability of diabetes remission after Roux en Y gastric bypass surgery
46394,Number of patients in each DiaRem score subgroup
46397,Adverse events and hypoglycaemic events in each treatment group, by system organ class
46399,Treatment response in the primary analysis, and by 5 5 and 5 x x x strata
46400,Secondary outcomes
46401,Non serious adverse events
46403,Mortality causes of deaths in each group
46404,The distribution of plasma phospholipid saturated fatty acids by categories of age, sex, and BMI in the subcohort of the EPIC InterAct study, and by type 2 diabetes status
46407,Summary of all treatment emergent adverse events
46409,Comparison of patient mastery   primary outcome   and secondary outcomes measured at week 6 of study, by trial group
46410,Survival: number of patients alive by study group and diagnosis during the first 6 months of the study
46411,Models of incident diabetes risk prediction included
46413,Discrimination and calibration of models for the prediction of incident type 2 diabetes at 10 years of follow up overall and by subgroup
46416,Comparison between secondary outcomes relating to diabetes and weight change
46418,Cost analysis
46423,Effect of lifestyle intervention on all cause mortality, cardiovascular disease mortality, and diabetes   19862009
46424,Effect of lifestyle intervention on all cause mortality, cardiovascular disease mortality, and diabetes in women and men   19862009
46427,Adverse events that occurred in 5  or more of patients in the treatment groups combined.
46429,New diabetes diagnoses during up to 7 years of follow up
46434,Infant development and respiratory outcomes at 2 years compared between treatment groups
46438,Overview of treatment related adverse events
46440,Mean difference in change in outcome measures in the intention to treat analysis
46442,Adverse events in more than 5  of study participants
46444,Primary MRI endpoint and clinical outcomes during the double blind period of ATAMS
46446,Treatment emergent adverse events during ATAMS   including 60 week safety follow up
46449,Risk factors for aneurysms
46450,Management of the 114 aneurysms identified with screening by size
46451,Summary of resource use and cost estimates
46452,Estimates of the direct treatment cost of preventing venous thromboembolism events or death during treatment with IPC in immobile patients with stroke
46453,Overall survival and 6 month QALDs
46454,Trials included in the meta analysis
46455,Previously published randomised, double blind, placebo controlled insomnia treatment trials of longer than 3 months  duration
46457,Summary of adverse events over the 1 year treatment phase   primary endpoint
46462,Inpatient investigational variables and treatment profile
46464,Secondary outcome measures
46467,Primary endpoint, secondary endpoints, and safety endpoints in the target population
46468,Prespecified adverse events in the target population
46469,Summary of reported adverse events in the target population
46472,Adverse events, serious adverse events, discontinuations, and deaths
46473,History of depression, suicidal ideation, and suicide plans or attempts in individuals diagnosed with Asperger s syndrome, stratified by age group and sex
46474,Suicidal ideation and suicide plans or attempts in people diagnosed with Asperger s syndrome who reported a history of depression, stratified by age and sex
46475,Number of patients with comorbid diagnoses, stratified by sex
46476,Mean age, Autism Spectrum Quotient score, and Empathy Quotient score, by outcome measure
46477,Comparison of prevalence of suicidal ideation
46481,Summary of association of top hits with cis methylation levels at 6p21.3
46482,Bidirectional analysis of single nucleotide polymorphisms and loci associated with other neurodegenerative disorders and our study population
46486,Adverse events in the safety population
46489,Adverse events in the safety population and first dose monitoring events
46491,Adverse events
46494,Incidence rates of arterial ischaemic stroke according to racial group
46495,Results of three source capturerecapture analyses
46496,Presenting features of arterial ischaemic stroke
46497,Presenting features of arterial ischaemic stroke by age group
46498,Summary of randomised controlled trials of treatments for bipolar disorder with at least 12 weeks  follow up
46502,Grade 3 or higher adverse events occurring in more than one patient in the safety population
46508,Sensitivity analyses of survival outcomes for XELOX versus FOLFOX in all treated patients
46509,3 year, 4 year, and 5 year disease free, relapse free, and overall survival rates, by treatment group
46510,Grade 3 or 4 adverse events of interest for oxaliplatin therapy
46511,Multiple Cox regressions for post relapse survival
46512,Use of post relapse therapies in patients who relapsed   excluding patients in NSABP C 08
46513,Cumulative doses of chemotherapy and radiation in present protocols for treatment of standard risk ALL and definition of dose ranges for inclusion for CCSS subcohort of ALL survivors
46515,Late mortality in survivors
46516,Chronic health disorders in survivors and siblings
46517,Comparison of survivors with and without grade 35 chronic health disorders
46520,Justice outcomes in ADHD cohort and controls, 19952010
46521,Age of first justice encounter
46522,Type of first offence for community correction and mean age at first offence
46523,Numbers of children diagnosed with cancer by country and region
46524,Country weighted 5 year survival by ICCC diagnostic category, sex, and age
46525,5 year age standardised survival and average annual reduction in mortality from childhood cancers diagnosed in Europe from 1999 to 2007
46527,Linear regression analysis of the association between maternal postnatal depression at 6 months and child psychological functioning at 10 years
46528,Logistic regression analysis of the association between maternal postnatal depression at 6 months and clinically significant psychological difficulties at age 10 years
46532,Most common adverse events
46535,Risk of postoperative delirium as a function of brain and cognitive reserve markers: bivariable association   n 566
46536,Multivariable adjusted risk of postoperative delirium as a function of brain and cognitive reserve markers   n 566
46539,Summary of on study adverse events
46541,Comparison of treatment efficacy by various endpoint
46542,Haematological and non haematological toxic effects
46544,Summary of efficacy endpoints
46545,Sensitivity analyses of event free and overall survival
46546,Multivariate and subgroup analyses of pCR and event free survival
46548,Cox proportional hazards model for progression free survival
46549,Worst grade of toxic effect, according to treatment assignment
46551,Best overall response to treatment in the intention to treat and RAS populations
46552,Adverse events
46553,Service use in the 18 months before randomisation
46554,Voice commands, compliance, and appeasement behaviour
46556,Primary and secondary outcomes at 9 months and 18 months
46557,Biomarker summary for each prognostic clinical variable and for PGA in each cohort
46558,Most recurrently aberrant regions
46560,Performance of the 100 loci DNA signature
46563,Types of health needs detected and treated during 9 months after randomisation
46564,Most often reported health needs detected and treated during 9 months after randomisation
46565,Long term disorders during 9 months after randomisation and relevant QOF items for each disorder
46566,Health promotion needs during the 9 months after post randomisation
46569,Response by subgroup
46570,Grade 3 and 4 toxic effects
46572,Results of multivariate analysis for progression free survival
46573,Severe adverse events and adverse events grade 3 or higher reported by more than 10  of patients according to common toxicity criteria
46574,Groups of interest for survival analysis
46576,Treatment according to period of diagnosis of trilateral retinoblastoma
46578,Cox regression analysis
46582,Adverse events according to Common Toxicity Criteria for Adverse Events, stratified by time of occurrence   preoperative vs postoperative chemotherapy period   and by worst grade experienced
46584,Outcome measures
46585,Data from randomised controlled trials of dose escalated external beam radiotherapy for prostate cancer
46587,Treatments received for depression
46590,Best overall response
46591,Efficacy by geographic region
46593,Treatment emergent adverse events occurring in at least 10  of patients on ramucirumab plus paclitaxel, irrespective of causality
46594,Adverse events of special interest
46595,Treatments given after a recurrence or new occurrence of gastric cancer
46596,Stratified Cox regression analysis of disease free survival and overall survival
46597,Disease free survival and overall survival by disease stage in the intention to treat population
46599,Type of treatment in patients who received treatment of physician s choice
46600,Summary of adverse events during the planned treatment period in the safety population
46601,Adverse events of grade 3 or worse with an incidence of 2  or higher in either treatment group
46603,Locally assessed best overall response in full analysis set
46604,Exposure to study treatments in the safety population
46605,Adverse events in the safety population
46607,Best response per RECIST
46608,Adverse events in 10  of patients in either treatment group
46613,Input parameters
46614,Base case scenario results
46616,Cumulative probability of survival time
46617,Estimates of survival in various subgroups of patients
46618,Complications and side effects after stent placement
46620,Type of invasive disease free survival
46622,Anticancer therapies received after initial treatment   randomised population
46624,Summary of selected adverse events in treated patients   safety population
46625,Selected adverse events in patients treated with vemurafenib, by mutational status
46626,Quality assessment criteria
46627,Description of studies reporting the proportion of pregnancy related maternal deaths attributable to suicide and injuries
46629,Dose delivery summary
46630,Treatment related adverse events that occurred in more than 10  of patients
46631,Best overall response by independent review
46633,Second line chemotherapy delivered   safety population, n 483
46635,Adverse events occurring at any grade in more than 5  of patients or grade 3 or greater in more than 2  of patients in the second line therapy safety population
46636,Adverse events of special interest for bevacizumab   second line safety population
46637,Demographic and baseline characteristics of registered patients and randomly assigned patients, per treatment group
46638,Best response in all registered patients after PAD induction, and in all randomly assigned patients after randomised treatment
46639,Adverse events occurring during protocol treatment in the safety population
46643,Overall survival
46644,Survival factors by univariate analysis
46645,Details of toxic effects affecting at least 10  of patients or causing death, by CTCAE category
46648,Events in MRD high risk patients who were randomly allocated to the two treatment groups
46649,Toxicity by treatment group
46651,Association between cumulative deployment length and number of deployments in the last three years, and mental illnesses in the total sample   Royal Navy, Royal Marines, Army and RAF; N 3982
46652,Association between cumulative deployment length and number of deployments in the past 3 years, and problems at home during deployment and post deployment in the total sample   Royal Navy, Royal Marines, Army, and Royal Air Force; N 3982
46653,Adjusted analyses with months on deployment as a continuous variable
46654,Adjusted analyses of problems at home and relationship or family problems, with months on deployment as a continuous variable
46656,Treatment exposure in the KRAS safety populations
46657,Adverse events in the KRAS exon 2 wild type safety population
46658,Grade 3 and 4 special adverse events in the KRAS exon 2 wild type and KRAS exon 2 mutated safety populations
46660,Association between health assessments and information and practices opting into the incentivised health check scheme
46661,Common comorbidities newly diagnosed after Jan 1, 2009
46663,Adult populations included 200007 survival analysis of the EUROCARE 5 study
46664,5 year age standardised relative survival for adult patients with cancer, diagnosed 200007
46666,Results from the multivariate analyses for overall survival and disease free interval
46667,Patterns of disease recurrence
46668,Overview of adverse events
46669,Quality of life standardised area under curve analyse
46671,Treatment related adverse events
46673,First recurrent suicidal behaviour   attempted suicide or completed suicide  , by timepoint   ad hoc analysis
46674,First recurrent suicidal behaviour   attempted suicide or completed suicide  , by subgroup   ad hoc analysis by timepoint
46675,Outcomes according to maximum frequency of cannabis use before age 17 years in each study and when data were combined
46676,Maximum frequency of cannabis use before age 17 years, and each young adult outcome in combined data, before and after adjustment with the null covariate approach
46679,Adjusted interaction analysis of overall survival
46680,Best RECIST response by treatment and proteomic test classification
46681,Third line therapy by treatment group and proteomic test classification
46682,Drug related adverse events
46684,Best response and secondary efficacy endpoints
46685,Adverse events and haematological laboratory abnormalities
46686,On treatment deaths
46689,Treatment emergent adverse events   5    and selected laboratory abnormalities
46693,Multivariate analyses
46695,Toxic effects in randomised patients
46696,SREs over 96 weeks in the intention to treat population
46699,Incidence of adverse events
46700,Developmental steps in the formation of the uterine cervix and ontogenetic staging of cervical carcinoma
46701,Tumour and treatment specification of the study cohort
46702,Local spread pattern of cervical carcinoma related to ontogenetic tumour stage by tissues infiltrated
46703,Oncological features related to ontogenetic tumour stage
46704,Cox regression analysis   overall survival
46705,Treatment related morbidity according to the Franco Italian glossary
46706,Comparison between pathological and ontogenetic staging by pathological tumour stage
46708,Radiologically assessed spontaneous remissions and responses
46709,List of second malignancies
46712,Adverse events
46714,Adverse events
46717,Haematological malignancies diagnosed in 19962007, by European region and country
46718,Lymphoid malignancies diagnosed 19962007, by European region
46719,Myeloid malignancies diagnosed 19962007, by European region
46720,Time trends in age standardised 5 year relative survival
46721,Relative excess risks of death in the 5 years after diagnosis
46724,Rilotumumab pharmacokinetic parameter estimates
46725,Phase 2 treatment emergent adverse events
46727,Causes of death
46728,Responses to treatment
46729,Reasons for discontinuation of treatment
46730,Grade 34 adverse events
46731,Post protocol treatment
46733,Causes of death
46734,Univariate endpoint data, 65 years after randomisation
46735,Test for interaction in prostate specific antigen progression
46736,Test for interaction between zoledronic acid use and Gleason score in bone progression
46738,Subgroup analysis of overall survival and progression free survival for dacomitinib vs placebo   logrank comparison
46739,Treatment responses
46740,Treatment related adverse events
46742,Grade 3 and 4 toxic effects
46745,Adverse events, by docetaxel subgroup   safety population
46746,Incidence of blood transfusions, by docetaxel subgroup   intention to treat population
46750,Skeletal events occurring in trials with patients with metastatic CRPC
46753,Descriptive data for risk factors in patients with diagnoses of schizophrenia and related disorders
46754,Rates and adjusted odds ratios of adverse outcomes in patients with schizophrenia and related disorders, in unaffected siblings, and in general population controls
46755,Multivariate risk factor models for conviction of a violent offence, suicide, and premature mortality in patients with schizophrenia and related disorders   n 24297
46756,Multivariate risk factor models for conviction of a violent offence, suicide, and premature mortality in unaffected siblings   n 26357
46757,Effects of year of diagnosis and inpatient nights per year on adjusted odds ratios of adverse outcomes
46759,Adverse events
46761,Clinical factors affecting survival after stereotactic radiosurgery
46762,Median overall survival for five primary cancer sites
46763,Treatment outcomes after stereotactic radiosurgery
46764,Secondary endpoint analyses
46765,Adverse events and maintenance of neurocognitive function
46767,Baseline demographics of the intention to treat population
46768,Distribution of first skeletal related events in the intention to treat population
46773,Adverse events in 15  or more of participants
46774,Serious adverse events
46776,Quality assessment of included randomised controlled trials
46780,Adverse events in the safety population
46781,Clinical studies of opioid monotherapy for patients with restless legs syndrome
46785,Events identified during follow up according to allocated group   intention to treat population
46787,Skin side effects   per protocol analysis
46790,Adverse events and laboratory abnormalities
46795,Patients with adverse events in the treated set and open label set
46798,Secondary outcomes and adherence to dietary intake and physical activity recommendations at the end of follow up
46803,Prespecified safety events in the safety sample
46804,Stopping boundaries and observed statistics for overwhelming efficacy and futility
46806,Safety profile
46808,Proportions of endometrial thickness scans with known contraceptive pill use during decade of ultrasound scan
46809,Endometrial thickness as a function of menstrual cycle in women by BRCA1 and BRCA2 mutation status
46811,Secondary efficacy endpoints
46812,Adverse events occurring in 10  of patients
46814,Discontinuation of neoadjuvant protocol therapies
46815,Comparisons of pathological complete response   pCR   in the different groups of the trial
46816,Selected toxic effects in the three treatment groups
46819,Time to deterioration of functional status, as measured by the Functional Assessment of Cancer TherapyProstate questionnaire
46820,Mean excess bodyweight and calculated excess energy intake in children, by age
46823,Summary of hypoglycaemic episodes
46828,Relapse and mortality according to fractionation schedule in START A
46829,Physician assessed normal tissue effects by fractionation schedule in START A
46830,Incidence of other late adverse effects according to fractionation schedule
46831,Relapse and mortality according to fractionation schedule in START B
46832,Physician assessed normal tissue effects by fractionation schedule in START B
46833,Summary of randomised controlled trials of adjuvant treatments for pancreatic adenocarcinoma by trial and region
46835,Best response to treatment, according to RECIST
46836,Summary of adverse events
46837,Selected adverse events of special interest for bevacizumab and chemotherapy
46839,Best response based on investigator s assessment      as of data cutoff   March 1, 2013
46840,Patients with an overall response based on investigator s assessment by subgroup analyses, as of data cutoff   March 1, 2013
46841,Summary of the most commonly reported adverse events occurring in more than 10  of the safety population
46845,Multivariable regression results for relative telomere length
46846,Multivariable regression for telomerase activity
46848,Progression free survival
46849,Overall survival in all randomly allocated patients who received at least one dose of study treatment in the intention to treat population
46850,Time to progression, based on independent adjudication review in the intention to treat population
46851,Objective responses based on independent adjudication review of the intention to treat population
46852,Adverse events
46853,Patients with grade 3 or worse specific adverse events   incidence 10  in at least one treatment group
46855,Reasons for study drug termination
46856,Outcomes
46857,Use of other antipsychotics
46858,Use of sedatives and analgesics
46859,Adverse events
46861,Progressive white and grey matter atrophy in patients with spinal cord injury
46862,Group analyses showing cortical changes both of atrophy and microstructure in patients compared with controls at 12 months
46863,Structural correlates of clinical outcome at 12 months
46866,Summary of main results
46868,Serious adverse events and most common adverse events
46869,Prospective cohort studies combined in the collaborative reanalysis
46870,Geometric mean hormone concentrations   with 95  CIs
46871,Odds ratios for breast cancer associated with a doubling in concentrations of hormones and SHBG, subdivided by oestrogen receptor status
46872,Results of multivariate analysis for progression free survival and overall survival
46874,Adverse events
46876,Post progression treatment
46877,Best response to treatment
46878,Safety analysis
46879,Drug related adverse events
46881,Univariate and multivariate hazard ratio for hospital contact for any mental disorder and for main diagnostic groups and subgroups
46884,Secondary efficacy outcome measures
46885,Summary of adverse events occurring in more than 10  of patients   any grade   or 2  or more of patients   for grade 3 of higher
46886,Grade 3 or higher adverse events reported in previous clinical trials of bevacizumab
46887,Summary of selected adverse event categories leading to bevacizumab treatment discontinuation by treatment phase
46889,Best response by RECIST
46890,Adverse events and drug related adverse events
46892,Summary of protocol required targeted toxic effects, and non hematological toxic effects that occurred in 5  of patients or more
46902,Adverse events
46904,Meta analyses of associations between air pollutants and traffic indicators and the risk for lung cancer
46905,Associations between PM10 and PM25 and risk for lung cancer for all participants and those who did not change residence during follow up, according to histological cancer subtype
46908,Multivariable analysis of stratification and other risk factors and atrasentan with overall survival and progression free survival
46909,Adverse events   at least one grade 4   in patients who received any protocol treatment
46911,Time to re intervention or death   time dependent analysis, intention to treat population
46912,Re interventions or deaths by actual temozolomide use   intention to treat population
46914,Adverse events   safety population
46915,CNS related adverse events
46917,Participating studies
46918,Patients with different subtypes of invasive epithelial ovarian cancer by study
46920,Hormone receptor expression and disease specific survival by subtype
46921,Joint effects of PR and ER expression on disease specific survival in endometrioid carcinoma
46923,Best response to treatment
46924,Summary of adverse events in greater than 15  of patients in either treatment group   safety population
46925,Summary of grouped adverse events of interest        safety population
46926,Summary of adverse events in either treatment group   safety population
46928,Best overall response according to RECIST
46929,Post study treatment in the second line and third line settings
46930,Summary of the most commonly reported adverse events in the safety population
46931,Efficacy outcomes from clinical trials evaluating EGFR tyrosine kinase inhibitors in the first line treatment of non small cell lung cancer
46933,Treatment received   safety population
46934,Time to event efficacy outcomes, by treatment group
46935,Other secondary outcomes
46936,Treatment emergent adverse events
46937,Trials comparing docetaxel plus prednisone alone or with a targeted agent in men with metastatic castrate resistant prostate cancer
46939,Disease free survival events
46940,Effects of trastuzumab duration according to stratification variables
46944,Best overall response
46945,Overall survival in the two treatment groups by region
46946,Treatment emergent adverse events in the safety analyses
46947,Primary tumour site by p16 status
46948,Overall and progression free survival in the two treatment groups by p16 status
46950,Results of moderator analysis
46951,Studies of depression and anxiety in long term cancer survivors versus spouses
46953,Admission to hospital
46956,Length of stay, intensive care unit and high dependency unit admission, and use of ventilation
46957,Adverse events and side effects
46958,Drugs provided at discharge at 4 h
46961,Adverse events
46964,Adverse events
46966,Outcomes of screening
46967,Breast cancer detection rates, and incremental detection from integrated 2D and 3D screening mammography
46968,Outcomes of screening, stratified by age
46969,Outcomes of screening, stratified by breast density
46970,False positive recalls for mammography screening
46971,Number of interventions delivered to improve palliative care
46972,Summary of endpoints before and after programme of interventions
46974,Complete remissions with each induction treatment
46975,Survival results
46976,Toxic effects during induction treatment
46978,Breast cancer treatments received by patients who discontinued study treatment
46979,Exposure to study treatment in safety population
46980,Adverse events   safety population
46981,Adverse events after discontinuation of docetaxel
46983,Incidence of breast cancer related lymphoedema
46987,Responses by treatment group in 492 patients
46988,Reported toxicities according to treatment group in 542 assessable patients
46989,Relative dose intensity in 542 patients who started chemotherapy
46990,Biomarker frequencies
46992,Final relative dose intensity of cyclophosphamide and doxorubicin, by treatment arm
46993,Use of granulocyte colony stimulating factor during every cycle
46994,Analysis of events for event free survival
46995,Causes of death
46996,Prevalence of toxic effects
46998,Grade 3 and 4 adverse events judged likely to be related to the study drug
47000,Model outcomes for univariable Cox proportional hazards models of overall survival
47001,Treatment related adverse events
47004,Overall survival by time to progression on previous sunitinib treatment
47005,Landmark analyses of overall and progression free survival in patients by diastolic and systolic blood pressures subgroups
47006,Systemic treatment after discontinuation of study drug
47008,Primary tumour response at 26 weeks
47009,Causes of death
47010,Grade 34 adverse events during chemoradiation
47011,Reported grade 34 adverse events during maintenance treatment
47013,Treatment exposure
47015,Adverse events in the safety population
47017,Summary of adjusted effects of deprivation on clinical outcomes and use of treatments in patients with cystic fibrosis in the UK
47020,Rates of amyloid  deposition, grey matter and hippocampal atrophy, and cognitive decline in participants who had amyloid  accumulation during the study
47022,Long term surgical events
47023,Disease free survival events and deaths at 50 years median follow up of intention to treat population
47024,Multivariable proportional hazards regression analysis of disease free survival
47025,Insulin like growth factor 1 receptor status according to histological subtype in at least five patients for all screened patients
47028,Adverse events of grade 1 or higher experienced by at least 5  of patients
47035,Summary of adverse events   safety population
47037,Treatment compliance during chemoradiotherapy
47038,Grade 34 toxic effects
47039,Objective disease response at 26 weeks from registration
47040,Patterns of disease progression at 12 months from registration
47043,Cardiovascular events
47045,Toxic effects reported up to 6 months in men who remained on assigned treatment without additional therapy
47046,Prevalence of active convulsive epilepsy in five centres in sub Saharan Africa
47047,Age specific and sex specific prevalence of active convulsive epilepsy by centre
47048,Risk factors for active convulsive epilepsy in children   aged  18 years
47049,Risk factors for active convulsive epilepsy in adults   aged 18 years
47050,Risk factors for adult onset active convulsive epilepsy
47051,Population attributable fractions associated with each risk factor in children   aged  18 years
47052,Population attributable fractions associated with each risk factor in adults   aged 18 years
47058,Change in area under the curve for amyloid  plasma concentration in the intention to treat population
47061,Adverse events
47063,Kaplan Meier estimates for specific events at 5 years
47064,Prognostic factors for relapse free survival in the trial overall
47065,Treatment related deaths
47066,Number of specific toxic effects by clinical risk groups
47067,Events in MRD low risk patients who underwent randomisation
47068,Toxic effects in MRD low risk patients who underwent randomisation
47070,Operative findings
47071,Postoperative recovery, morbidity, and mortality within 28 days
47072,Pathology
47075,Adverse events
47077,Pattern of disease failure   36 cancer failures
47078,Summary of outcomes
47079,Toxic effects   frequencies shown
47080,Number and severity of symptoms during the first month of the disease
47081,Overview of treatments   n 501
47082,Factors associated with good outcome   mRS 02
47084,Treatments at progression
47085,Toxic effects reported in the first 6 months of treatment
47087,Treatment administered after discontinuation of study therapy   intention to treat population
47088,Adverse events of any grade in 10  of patients, or grade 3 in 2  in either group, irrespective of relation to study treatment   safety population
47090,Summary of primary and secondary outcomes
47091,Adverse events
47093,Quality of life results at the end of docetaxel treatment
47094,Prognostic models and distributions of risk groups
47096,Associations of overall survival with six prognostic risk factors from the Database Consortium model
47097,Measures of model fit from Cox regression in the validation group
47098,Predicted 2 year death rate for each model
47100,Summary of non serious adverse events   intention to treat population
47105,Comparative prognostic ability for overall, early, and late distant recurrence of BCI, 21 gene recurrence score, and IHC4 in all patients and in the HER2 negative subset
47106,Prognostic ability of HOXB13 IL17BR and MGI for early and late distant recurrence in oestrogen receptor positive, node negative patients
47109,KRAS mutation type
47110,Dose reductions and interruptions for selumetinib or placebo in the safety population
47111,Best response by RECIST version 1.0
47113,Summary of adverse events
47114,Most frequent adverse events   incidence of more than 15  in either study group
47117,Single nucleotide polymorphisms associated with recurrence free survival
47118,Association between outcomes and variants of the MET polymorphism rs11762213
47120,Traumatic brain injury incidence by age, sex, and severity of injury
47121,Traumatic brain injury incidence by ethnic origin and injury severity
47122,Traumatic brain injury incidence by residency and injury severity
47123,Incidence of traumatic brain injury by cause, age, sex, and residency
47125,Events by intention to treat at 10 year follow up
47126,Haematological malignancies   safety population
47127,Cardiac adverse events   safety population
47128,Changes in left ventricular ejection fraction   evaluable population
47130,Chemotherapy received during the study
47132,Incidence of grade 35 adverse events occurring in 2  or more of patients given chemotherapy with or without bevacizumab after disease progression following first line bevacizumab based treatment   safety population
47134,Margin status
47135,Postoperative surgical measurements
47136,Operative time and complications
47138,Primary and secondary outcomes for the intention to treat population and for patients who had HER2 positive disease confirmed centrally by fluorescence in situ hybridisation
47139,Self reported acute toxic effects   grade 14
47142,Best overall responses
47143,Drug related adverse events occurring in 5  of patients in any treatment group during double blind treatment
47146,Treatment emergent, all causality adverse events
47148,Estimated ages at fibrillar amyloid  onset and plateau in PSEN1 E280A mutation carriers
47150,Location and magnitude of the most significant functional and structural brain measures in young adult PSEN1 E280A mutation carriers, when compared with non carriers
47152,Dose and dose intensities
47153,Response to treatment by treatment group
47154,Grade 34 non haematological adverse events by treatment arm
47155,Cause of death
47157,Site of tumour recurrence in patients with stage III disease   intention to treat population
47158,Most common grade 35 adverse events   5    and grade 35 adverse events of special interest to bevacizumab   safety population, including patients with stage III and high risk stage II disease
47160,Duration of study and cancer burden according to intervention group
47161,Cox proportional hazards analysis and Poisson regression for colorectal cancer   adjusted for sex and duration of aspirin taken   based only on participants randomly assigned to resistant starch or resistant starch placebo
47162,Cox proportional hazards analysis and Poisson regression for non colorectal Lynch syndrome cancers   adjusted for sex and duration of aspirin taken   based only on participants randomly assigned to resistant starch or resistant starch placebo
47163,Cox proportional hazards analysis and Poisson regression for all Lynch syndrome cancers   adjusted for sex and duration of aspirin taken   based only on those randomly assigned to resistant starch or resistant starch placebo
47170,Most common adverse events
47171,MRI outcomes at 24 days
47172,Pre specified neurological outcomes at 30 days
47174,Adverse events among all patients who started study treatment
47175,Summary of multivariate analysis for overall survival and progression free survival
47177,Top eight two gene models
47178,Training set and validation set mean and median survival   months   from blood draw   six gene Cox model based on gene expression measurement
47179,Cox model for survival measured from CRPC diagnosis or from time of blood draw
47180,Effect of combining the six gene signature and clinicopathological variables
47182,Treatment exposure   per protocol population
47183,Efficacy outcomes
47184,Adverse events   safety population
47185,Clinical response and outcome after treatment with RG7112
47186,All adverse events and serious adverse events that occurred in at least one patient
47187,Pathological classification algorithm
47190,Incidence of probable Alzheimer s disease, by year of study
47192,Adverse events
47194,Clinical and radiological outcomes
47196,Overall survival by stratification factorsmultivariate analysis   intention to treat population
47198,Other efficacy endpoints
47199,Adverse events reported during treatment
47202,Definitive surgical treatment of patients in the trial
47203,Chemotherapy toxic effects, worst grade per patient
47204,Causes of death in the 141 patients   40    who had died at the date of analysis
47206,Adverse events with a frequency of at least 3  in the safety population
47207,Cancer treatment after discontinuation of study treatment
47214,Frequency of restenosis after carotid artery stenting or carotid endarterectomy in trials from Europe, Canada, and the USA
47215,Independent predictors of timing of withdrawal
47216,Adjusted and unadjusted relation between timing of antiepileptic drug withdrawal and seizure outcome measures
47217,Relation between timing of AED withdrawal and seizure outcome in subgroups of patients at high risk of recurrence
47220,Hearing loss and disability outcomes
47221,Neurocognitive outcomes
47222,Psychological outcomes
47223,Major and minor deficits
47225,Progression free survival in patients randomly allocated to treatment groups
47226,Common adverse events of any grade   20  incidence   and adverse events of grade 3 or more during randomised treatment
47228,Relapses and deaths
47229,Serious adverse events
47230,Comparison of outcome from EsPhALL with historical data
47232,Trastuzumab pharmacokinetic parameters before surgery in the per protocol pharmacokinetic population
47234,Safety overview   safety population
47235,Adverse events and serious adverse events by severity
47236,Summary of severe   grade 3   adverse events with an incidence of 1
47237,Overview of serious adverse events
47239,Total corticosteroid therapy   mg m2
47240,Joints affected by osteonecrosis in 143 patients
47242,Survival data
47243,Adverse events for patients in the three group randomisation who started assigned treatment
47245,Chemotherapy regimens
47246,Obstetrical outcome
47247,Obstetrical complications in women with early breast cancer with and without chemotherapy during pregnancy   n 343
47248,Multivariate analysis for disease free and overall survival
47249,Univariate analysis of factors associated with failure to seek biomedical treatment
47250,Multivariable analysis of factors associated with failure to seek biomedical treatment
47251,Adherence as assessed with the self reported Morisky scale compared with that as assessed by detection of AEDs in blood samples
47252,Univariate analysis of factors associated with non adherence to AEDs
47253,Multivariable analysis of factors associated with non adherence to AEDs
47257,Dosing scheme and early adverse events and DLTs
47258,Treatment related adverse events
47259,Pharmacokinetic parameters after repeat once daily dose administration of trametinib   day 15
47261,Treatment emergent adverse events
47263,Serious adverse events and adverse events
47265,Side effects and toxic effects
47266,Prespecified study endpoints
47267,Sites of first treatment failure
47269,Acute adverse effects and treatment compliance in patients who received preoperative chemoradiotherapy
47270,Surgical procedures, related toxicities, and grading of TME in patients who underwent surgery
47272,Acute adverse effects and treatment compliance in patients who began protocol specified adjuvant treatment
47273,Phase 3 trials adding oxaliplatin to preoperative fluorouracil based chemoradiotherapy in stage 23 rectal cancer
47276,Kaplan Meier estimates of progression free survival in bevacizumab and placebo treated groups in AVOREN, according to rs7993418, rs9513070, and rs9554316 genotypes
47278,Numbers of grade 24 adverse events
47279,Prognostic and predictive factors for overall and event free survival with temozolomide on multivariate Cox s regression analysis
47281,First site of disease progression
47282,Adverse events in each group, by grade
47284,Progression free and overall survival in patients with circulating tumour cells
47285,Cox regression analyses of survival associated with presence of circulating tumour cells
47287,Multivariable Cox regression analysis of microRNA   miRNA   signature expression and survival in the combined training and validation set
47289,Cancer risk in patients with Huntington s disease, spinobulbar muscular atrophy, and hereditary ataxia in Sweden
47290,Cancer risk in patients with Friedreich s ataxia
47291,Cancer risk in patients with Huntington s disease and spinobulbar muscular atrophy by age at diagnosis
47292,Cancer risk in unaffected parents of patients with Huntington s disease, spinobulbar muscular atrophy, and hereditary ataxia in Sweden
47295,Cumulative treatment failures
47296,Changes in secondary outcomes   intention to treat analysis
47297,Nerve conduction parameters in the two most relevant motor nerves for the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy in each patient   intention to treat analysis
47298,Patients with adverse events
47305,Major eligibility infringements
47307,Sites of first relapse
47308,Early adverse events   grade 3 and 4
47310,Disease related events
47311,Kaplan Meier survival estimates
47312,Patients receiving scheduled treatment, per cycle
47313,Toxic effects per treatment group, according to National Cancer Institute Common Toxicity Criteria   CTC   version 2.0
47315,Distribution of variables of interest according to time to death after withdrawal of life sustaining measures
47316,Frequency of death after withdrawal of life sustaining measures according to donation after cardiac death in patients in a neurocritical state   DCD N   score
47317,Probabilities of death within 60 min according to the combinations of predictive variables
47318,Frequency of death after withdrawal of life sustaining measures according to donation after cardiac death in patients in a neurocritical state   DCD N   score in the retrospective cohort of 149 patients  6
47322,Analysis of key subgroups for EGFR mutation positivity by tissue testing
47323,Objective response rate and disease control
47324,Analysis of key subgroups for EGFR mutation positivity
47325,Subsequent cancer treatment after discontinuation of study drug
47326,Adverse events with at least 5  incidence in one group
47328,Treatment after discontinuation      of trial in the intention to treat group
47329,Compliance rate with Functional Assessment of Cancer Therapy Lung questionnaire
47330,Adverse events      of more than 2  difference between treatment groups   for all grade adverse events   and adverse events of CTC grade 3   EFS population
47331,Statistical design parameters according to study stage
47333,Incidence of adverse effects any time after randomisation, by category
47335,Multivariable model hazard ratios for time to overall treatment failure, treatment failure because of inadequate seizure control, and treatment failure because of unacceptable adverse events, by prognostic factor
47336,Multivariable model hazard ratios for prognostic factors for time to 12 months of remission
47339,Multivariable regression models assessing the effect of HLA DPB1 T cell epitope match status on clinical outcome
47340,Multivariable regression models assessing the effect of HLA DPB1 T cell epitope match status on clinical outcome
47342,Incidence of distant recurrence and death in the two treatment groups
47343,Cox proportional hazards model for distant metastases and death
47344,Hazard ratios for time to distant metastases and overall survival after breast conserving therapy compared with mastectomy in two subgroups, by patient age
47345,Cases of carpal tunnel syndrome and musculoskeletal symptoms in the tamoxifen and exemestane treatment groups
47349,Diagnosis, treatment, and outcome of carpal tunnel syndrome in postmenopausal patients with breast cancer
47350,Multiple regression analysis of potential risk factors for disease free and overall survival from 9 months after randomisation
47351,Description of studies included in the analysis
47352,Cases and controls with endometriosis according to study site and histological subtype of ovarian cancer
47353,Association between history of endometriosis and the histological subtypes of ovarian cancer
47354,Sensitivity analysis for the association between endometriosis and risk of invasive ovarian cancer based on timing of diagnosis between the two diseases
47355,International Classification of Diseases   ICD   10 codes used to define different cancers
47357,ORs and 95  CIs for visiting a general practitioner three or more times before hospital referral obtained from multivariate logistic regression adjusted for age, sex, deprivation, ethnicity, cancer type, and interactions between cancer type and sex, cancer type and age, and ethnicity and age
47359,Rates of efficacy and safety outcomes in patients with and without history of stroke or TIA
47360,Effect of apixaban on efficacy and safety outcomes in patients with and without history of stroke or TIA
47362,Proportional hazards regression analyses of risk factors for ARIA E associated with bapineuzumab treatment
47364,Drug related adverse events   maximum CTCAE grade reported
47366,Correlation of time to worsening of symptoms with efficacy endpoints
47368,Treatment related adverse events reported in at least 2  of patients in either group
47369,Safety analyses
47370,Summary of further treatment received by patients
47372,Common adverse events in the safety population
47373,Safety data
47376,Adverse events possibly related to study drug occurring in 3  or more of patients in either group during maintenance treatment
47377,Summary of post discontinuation anticancer systemic therapy for all eligible patients
47381,Most frequently reported emergent adverse events   5  incidence in any treatment group   during the treatment phase
47383,Efficacy outcomes
47386,Description of the post remission treatment scores and four prognostic factors in the final model for 452 patients with complete data
47389,Summary of serious adverse events
47390,Summary of all non serious adverse events
47392,Efficacy of treatment, according to histological, surgical, and clinical outcome
47394,Clinically relevant adverse events by maximum grade
47395,Comparison of trials of trastuzumab alone, lapatinib alone, and two anti HER2 directed agents given simultaneously with short or long duration chemotherapy, with or without anthracyclines
47397,Adverse events
47398,Best tumour response by RECIST 1.0
47401,Response to treatment in prognostic subgroups
47402,Prospective therapy trials in PTLD
47404,Treatment efficacy
47405,Radiotherapy compliance and quality assurance
47406,Chemotherapy compliance
47407,Acute toxic effects
47408,Comparison by treatment group of distribution at randomisation of prognostic factors for the USA and Australasia randomised trials
47409,Odds ratios from logistic regression analyses for observation of the candidate surrogate in men randomised to radiotherapy and 6 months of androgen suppression compared with radiotherapy alone
47410,Unadjusted and adjusted HRs from the competing risks regression analysis  15   showing risk of prostate cancer specific mortality for treatment and the candidate surrogates
47411,Proportion of treatment effect   PTE    16   explained by the surrogate and the partial proportion of the variation explained   pPVE    17   by treatment when the surrogate was included in the competing risks multivariable regression model  14
47413,Survival and response to treatment
47414,Summary of prognostic factors multivariable analyses
47415,Adverse events
47417,Frequency of C9orf72 repeat expansion carriers in the Flanders Belgian cohort
47422,Total number of events, hazard ratios, and cumulative proportion with events by 2 years for bowel, bladder, and sexual dysfunction endpoints by allocated treatment group
47423,Effect sizes, quantified as the OR between carriers and non carriers that can be resolved with 99  power and a nominal  of 27105
47424,98 SNPs selected from the literature review
47425,Results from testing of previously proposed SNP profiles
47427,Effect of treatment on conversion to McDonald multiple sclerosis
47428,Effect of treatment on conversion to clinically definite multiple sclerosis
47429,2 year cumulative probability of a diagnosis of McDonald multiple sclerosis by selected randomisation stratification factors and subgroups
47430,Incidence of prespecified treatment emergent adverse events   preferred terms   during the double blind period   safety population, n 515
47431,Comparison of the REFLEX study and other large trials of disease modifying drugs in patients with a first clinical demyelinating event
47434,Cervical cancers and high grade intraepithelial neoplasia by test results in the first and second screen rounds
47437,Efficacy in the ITT population and EGFR expression groups
47438,Grade 3 and 4 adverse events in the safety population and EGFR expression groups
47442,Comparison of published MRI criteria with proposed predictive parameters for diagnosis of multiple sclerosis
47443,Distribution of eGOS at 6 months by depolarisation category
47444,Covariates for outcome prediction
47445,Outcome prediction   multivariate ordinal regression analysis
47447,Response rate, progression free survival, and overall survival
47448,Overview of adverse events and serious adverse events
47449,Non haematological adverse events   5  of patients
47450,Grade 3 and 4 haematological adverse events, irrespective of causality
47452,Presenting signs and symptoms of child and adolescent meningioma from study level data
47453,Location of child and adolescent meningioma from study level data
47454,Histological classification of child and adolescent meningioma from study level data
47455,Multivariable Cox regression results for individual patient data; relapse free and overall survival according to prognostic factor
47461,Risk of death according to the allocated treatment groups
47462,Incidence of death according to the allocated treatment groups
47464,HER2 and TOP2A gene status by trial and rate of concordance with the external laboratory
47466,Polymorphisms genotyped and allele frequency
47467,Multivariable analysis of polymorphisms associated with response, progression free survival, and overall survival in patients with renal cell carcinoma treated with sunitinib
47468,Genetic factors associated with sunitinib dose reductions and toxic effects
47470,Secondary and tertiary endpoints
47471,LRRK2 exonic variants investigated in the study
47473,Common single LRRK2 variant associations with Parkinson s disease
47474,LRRK2 rare variants
47476,Summary of results for predefined primary and secondary endpoints
47477,Post hoc analysis of the proportion of patients who remained seizure free for 6 or more continuous months during the efficacy assessment phase, by pretreatment seizure classification   intention to treat population
47478,Summary of adverse events
47479,Treatment emergent adverse events occurring in 2  or more of patients in either treatment group in MedDRA preferred terms
47483,Relative dose intensity and total dose
47484,Efficacy results
47485,Adverse events associated with sequential versus combination treatment during first line treatment
47486,Adverse events associated with sequential versus combination treatment during all lines of treatment
47487,Results of the main strategic randomised trials in advanced colorectal cancer
47489,Treatment histories of ALK positive patients
47493,Details of patients with complications
47498,Clinical symptoms and signs, morphological and biochemical findings, and serum FGF 21 concentrations in adults with mitochondrial disorders and adult disease controls, listed by participants  numbers
47499,Clinical symptoms and signs, morphological and biochemical findings, and serum FGF 21 concentrations in children with mitochondrial disorders, child disease controls, and children with LCHADs, listed by participants  numbers
47500,Results from repeat measurement of FGF 21 in serum, listed by patients  numbers
47501,Distribution of abnormal values in different patient groups, by biomarker
47502,Sensitivity, specificity, and positive and negative predictive values for FGF21 and conventional serum biomarkers for mitochondrial diseases
47504,Incidence and crude and adjusted risks of ovarian cancer
47505,Bootstrap sensitivity analysis of Cox s regression model for risk of ovarian cancer in patients with PID
47506,Risk of ovarian cancer in patients with PID, according to use of oral contraceptives
47507,Risk of ovarian cancer, according to age
47509,Occurrence of documented relapses
47511,Adverse events occurring with greater than 5  frequency in either treatment group
47514,Univariate and multivariate analyses of intracerebral haemorrhage volume in the discovery phase
47515,APOE 2 and 4 and intracerebral haemorrhage volumes
47516,Predictors of outcome in patients with lobar intracerebral haemorrhage in the discovery phase
47517,APOE 2 and 4 and 90 day mortality and poor functional outcome after intracerebral haemorrhage
47519,Predictors of outcome in patients with deep intracerebral haemorrhage in the discovery phase
47521,Cumulative annual incidence of first and subsequent skeletal related events for the intention to treat population after randomisation
47525,Reports of EPP within trimodal therapy
47529,Results of survey done after study completion
47531,Most common adverse events of all grades reported in 3  of patients or more in either treatment group
47532,Summary of safety data
47534,Patient subgroups in the biomarker population according to biomarker status
47535,Efficacy data according to tumour biomarker status
47536,Efficacy data according to treatment
47538,Multivariate analysis   Cox regression model   of prognostic factors for progression free survival
47540,Safety profile of rituximab and bortezomib rituximab treatment groups   safety population
47541,Most common adverse events by treatment group, reported by 15  of patients at any grade or by 3  of patients at grade 3 severity   safety population
47543,Response at 12 weeks and best response in arms A and C and response after rechallenge   arm C only
47545,Overview of the 83 included study populations from 68 studies
47546,Prevalence ratios per reason for investigation, adjusted for sex and age
47547,Prevalence ratios per country adjusted for sex and age
47548,Proportions of aneurysms by size and site
47550,Distribution of worst histological diagnosis since the second HPV test and Pap smear in women negative for both HPV and cytology at enrolment
47552,Number of offspring with malformations for the four monotherapies at different doses at conception   mg per day
47553,Types of malformations for the four different monotherapies at different doses
47554,Results of multivariable logistic analysis
47556,Univariate Cox s regression analysis
47557,Multivariate Cox s regression analysis
47558,Parameters included in the Monte Carlo simulation
47560,Events by treatment group   intention to treat population
47561,The most frequent adverse events and serious adverse events on treatment
47562,Chemoradiotherapy and chemotherapy regimens in randomised trials included in the meta analysis
47563,Perioperative mortality   absolute 30 day or in hospital mortality   after chemotherapy or chemoradiotherapy
47565,Primary endpoint and components of the primary endpoint
47566,Primary endpoint and components of the primary endpoint by symptomatic groups
47568,First events contributing to progression free survival
47569,Clinical and pathological complete responses
47570,Univariate and multivariate analyses   first model
47571,Multivariate analysis of overall survival   second model with addition of subgroups defined by hormone receptor and HER2 status
47572,Worst grade 3 or 4 adverse events during chemotherapy in 1846 patients who started treatment according to randomisation
47575,Summary of adverse events and serious adverse events in the modified full analysis data set   at the time of database lock
47577,Incidence   cases per 1000 person years   of adenoma and colorectal cancer by age, sex, and faecal Hb concentration
47578,Crude and adjusted HRs for risk of colorectal neoplasia
47580,Causes of death in patients who were operated with a negative circumferential margin
47581,Local recurrence and survival in patients specified per TNM stage and treatment group
47583,Individual results of the three independent masked readers
47584,Majority read results of the masked read for all three PET imaging periods
47585,Quantitative PET data analysis by brain region
47588,Models for prediction of multiple sclerosis in children with acute demyelinating syndrome
47590,Effects of treatment on UPDRS subscores at week 36 and week 72
47592,Summary of 10 year endpoint data
47593,Cause of death by treatment group
47594,Anatomic sites of relapse at time of prostate cancer death   N 159  , by treatment group
47595,Local and distant progressions at time of prostate cancer death, by treatment group
47597,Univariate analyses of prognostic factors for overall survival
47598,Multivariate analyses of prognostic factors for overall survival
47599,Association of deaths with treatment during the treatment phase
47600,Response at end of treatment
47601,Incidence of non haematological toxicity by grade
47602,Serious adverse events
47603,Proportions of patients free from disease activity over 96 weeks
47604,Proportions of patients free from disease activity using 6 month sustained EDSS progression
47607,Overall treatment effect for clinical disease activity   CDA
47608,Overall treatment effect for sustained reduction in disability
47610,Post study cytotoxic or cytostatic compounds, apart from methotrexate
47611,Adverse events reported with more than 5  difference in incidence in either treatment group
47614,Secondary outcomes   intention to treat population
47615,Patients with complications
47617,Association of the KRAS variant with ER PR positive versus ER PR negative breast cancer in women in study group 1
47618,Association of the KRAS variant in 230 patients with triple negative breast cancer compared with 930 controls from pooled analysis of study groups 13
47619,Association of the KRAS variant with pathway signatures in tumours of patients with triple negative breast cancer and positive KRAS variant status
47621,Objective response rate   all patients assigned to treatment
47622,Selected toxicities   all patients who received treatment
47623,Summary of treatment emergent adverse events   all patients who received treatment
47627,Adverse events   all causes   reported in 15  or more of patients, and haematological laboratory abnormalities
47628,Non haematological grade 3 or 4 adverse events   all causes   attributable to VEGF inhibition or of clinical interest
47630,Summary of statistical analysis of transurethral resection of the prostate cohort
47632,Adverse events and cardiac endpoints by safety analysis population and observation arm cohorts after May 16, 2005
47633,Reported prospective randomised placebo controlled clinical trials of selective serotonin reuptake inhibitors in motor recovery after ischaemic stroke
47635,Fugl Meyer motor scale   FMMS   scores
47636,Secondary endpoints
47637,Adverse events
47639,Maximum acute and late side effect grades by treatment group
47640,Concordance between unstimulated contralateral saliva flow and LENT SOMA subjective xerostomia at 12 months
47642,Multivariate logistic regression of clinicopathological parameters of GEM in the test cohort
47644,Toxic effects reported in the three study groups, by grade
47645,HRs for death and for relapse in the two treatment groups combined, and in each treatment group, compared with observation   group A
47646,HRs for death and for relapse in the two treatment groups combined, and in each treatment group, compared with observation   group A  , in patients with ulcerated, non ulcerated, and primary melanomas with unknown ulceration status
47647,Summary of pivotal trials and meta analyses comparing interferon with observation only
47649,Summary of overall and progression free survival
47650,Tracheostomy and dependence on gastric feeding tube
47651,Overview of interview based prevalence studies of mood in patients with cancer
47652,Summary of depression prevalence and heterogeneity findings
47653,Overview of clinical features of dopamine transporter deficiency syndrome
47654,SLC6A3 mutations identified in patients with dopamine transporter deficiency syndrome
47655,Comparison of dopamine transporter deficiency syndrome with infantile neurotransmitter disorders of dopamine biosynthesis
47657,Risk of cancer and cancer related death with the antihypertensive agents
47658,Proportion with cancer and the probability that each treatment is the best   lowest event proportion   from multiple treatment comparison analysis
47659,Sensitivity and subgroup analyses   multiple comparison analysis   for risk of cancer
47660,Sensitivity and subgroup analyses   multiple comparison analysis   for risk of cancer related deaths
47661,Risk of cancer and cancer related death for telmisartan when compared with other drug classes from multiple treatment comparison analysis
47662,Summary of antihypertensive agents and risk of cancer and cancer related death
47666,Analysis of variables associated with cognitive impairment, defined by a score of 23 or less on the MMSE, in the pooled data from the ONTARGET and TRANSCEND studies
47667,New breast events
47668,New breast events and 10 year estimates of percentages with an event in patients randomised to tamoxifen or not
47669,New breast events and 10 year estimates of percentages with an event in patients according to radiotherapy randomisation
47670,All new breast events and 10 year estimates of percentages with an event in patients according to grade and age
47671,Causes of death
47672,Trials of the treatment of ductal carcinoma in situ
47674,Time from start of treatment to the first occurrence of acne like rash in patients alive on day 21
47675,Incidence and severity of acne like rash for patients alive on day 21
47676,First cycle rash analysis: efficacy in evaluable patients alive on day 21
47677,Landmark analysis of overall and progression free survival and odds for response in all evaluable patients and histology subgroups
47679,Efficacy outcomes according to treatment group
47680,Safety outcomes
47682,Outcomes in cerebral malaria survivors and controls
47684,Risk factors for adverse neurological outcomes
47686,Differentially expressed genes in early onset and late onset bortezomib induced and vincristine induced peripheral neuropathy
47687,Single nucleotide polymorphisms associated with bortezomib induced and vincristine induced peripheral neuropathy
47689,Response to first line chemotherapy and associated grade 34 toxic effects, by age group
47690,Progression free and overall survival   per protocol population
47691,Univariate and multivariate analyses for progression free survival and overall survival   per protocol population
47693,Sites of disease progression
47694,Phase 3 studies addressing use and duration of androgen suppression and irradiation dose as combined modality adjuvant treatments for prostate cancer
47696,Single nucleotide polymorphisms that achieved genome wide significance
47697,Population attributable risk percent associated with the chromosome 9p21 risk haplotype carrier status and with homozygous D90A SOD1 allele status
47698,Clinical features of patients with amyotrophic lateral sclerosis in the independent analysis
47700,Associations for genes reported to be associated with amyotrophic lateral sclerosis in previous genome wide association studies
47702,Concomitant drug treatments during the study
47703,Adverse events other than haemorrhage
47705,Mean echocardiographic left ventricular Z score measurements after treatment, by year since treatment completion
47706,Cardiac troponin T concentration as a predictor of left ventricular abnormalities on echocardiography at 5 years after treatment completion
47708,First reported site of treatment failure for sentinel node   SLN   negative patients
47710,Reported findings from radiographs at 9 months and 24 months
47712,Rates of intracerebral haemorrhages detected by use of imaging scans
47713,Main outcomes for patients treated within 3 h compared with those treated within 345 h
47717,Adjusted hazard ratios   95  CI   from multivariate Cox proportional hazards model
47719,Safety analysis
47725,Site specific number of cancer deaths and percent distribution, by sex and within region   n 424519
47726,Age  and smoking adjusted HRs for cancer mortality according to BMI after left censoring at 3 years   n   401215
47727,Region specific age  and smoking adjusted HRs for cancer mortality according to BMI after left censoring at 3 years   n 401215
47728,Number and outcome of participants in relation to screening visit
47729,Prostate cancers diagnosed in the study groups
47730,Treatments for prostate cancer, by study group
47731,Outcome of men in relation to birth cohort at entry to the study
47734,Multivariate logistic regression analysis of objective response in unselected and KRAS wild type population
47735,Multivariate Cox regression analysis of overall survival in unselected and KRAS wild type population
47736,Multivariate Cox regression analysis of progression free survival in unselected and KRAS wild type population
47737,Discontinuation and loss to follow up
47740,Safety assessments
47742,Primary and secondary endpoints
47743,Primary analysis
47745,Secondary analysis
47746,Embolic signals at the start of each 6 month period and risk over the subsequent 6 months
47748,Adverse events reported in at least 10  of patients in either group   safety population
47750,Adherence and dropout or loss to follow up in trials included in meta analysis
47751,Solid organ cancers reported in randomised controlled trials of angiotensin receptor blockers
47752,Description of studies
47753,Assay methods
47755,Relationships of IGF1 with breast cancer risk among postmenopausal women, according to plasma concentrations of oestradiol and testosterone
47758,Adverse events
47760,Acute and late radiation related morbidity by fractionation schedule
47762,Overall results and causes of failure among randomised AML patients
47763,Analysis of prognostic factors among patients with AML
47764,Multivariable analysis of prognostic factors
47765,Frequency of the major European mitochondrial DNA haplogroups in the OXVASC study population and in controls
47766,European mitochondrial DNA haplogroups in the total OXVASC study population with acute transient ischaemic attack or stroke versus controls
47768,Adverse events
47769,Variability of clinic blood pressure by randomised treatment allocation in ASCOT BPLA
47770,Effects of randomised treatment allocation in ASCOT BPLA on risk of stroke and coronary events adjusted for parameters of blood pressure during follow up
47771,Blood pressure parameters on ambulatory blood pressure monitoring by randomised treatment allocation in ASCOT BPLA
47772,Visit to visit systolic blood pressure variability by randomised treatment group in the MRC trial
47774,Standard incidence ratios   SIR   with 95  CI for different groups of patients with prostate cancer patients in PCBaSe Sweden
47775,Standard incidence ratios   SIR   for different groups of thromboembolic diseases in patients with prostate cancer according to their treatment and stratified by age and tumour stage
47776,Standard incidence ratios   SIR   for different groups of thromboembolic disease by type of endocrine treatment
47777,Standard incidence ratios   SIR   for different groups of patients with prostate cancer in PCBaSe Sweden stratified by time since prostate cancer diagnosis
47778,Absolute risk and absolute risk difference for deep venous thromboembolism and pulmonary embolism disease by prostate cancer treatment in PCBaSe Sweden
47779,Absolute risk and absolute risk difference of deep venous thrombosis by prostate cancer treatment and age group in PCBaSe Sweden
47783,DWI parameters used at participating centres
47785,Clinical outcome within 30 days of treatment
47786,New DWI lesions on post treatment scans
47787,MRI findings at 1 month follow up
47791,Adverse events with at least 15  incidence for one of the treatment groups
47792,Treatment schedule
47794,Primary outcome measure
47796,Adverse events
47797,Number of participants and periods of randomisation and follow up at each centre
47798,Total number of cases of invasive cervical cancer by screening group, age, and screening round
47799,Detection of histologically confirmed and reviewed CIN2 and CIN3 by study group, recruitment phase, and screening round in women aged 3560 years at recruitment
47800,Detection of histologically confirmed and reviewed CIN2 and CIN3 by study group, recruitment phase, and screening round in women aged 2534 years at recruitment
47801,Relative detection   95  CIs   of CIN2 and CIN3 with HPV testing versus cytology by age at recruitment for women 2534 years
47804,Primary endpoints for each study and for all patients assigned to steroid therapy
47805,Exploratory analyses of the influence of age and HIV infection on the treatment effect of dexamethasone
47806,Biomarker analysis and relation with overall and relapse free survival
47809,Incidence of intracerebral haemorrhage according to age
47810,Case fatality and functional outcome of intracerebral haemorrhage
47811,Intracerebral haemorrhage case fatality at 1 month according to sex and age
47813,Frequent differentially expressed microRNAs   gastric cancer signature
47814,Univariate and multivariable Cox regression analysis of overall survival
47815,Univariate and multivariable Cox regression analysis of disease free survival
47816,Multivariable Cox regression analysis of disease free survival and overall survival of patients with intestinal type and diffuse type gastric cancer
47819,Composite endpoint data
47820,Adverse events reported in more than 1  of patients
47821,Discontinuations owing to adverse events
47823,Grades of cerebral lesions seen on MRI in cooled and non cooled infants
47824,Postnatal age at scan, MRI abnormalities, and outcome up to 18 months of age in cooled and non cooled infants
47825,Predictive ability of major MRI abnormalities during first 4 weeks after birth for death or severe disability at 18 months
47827,Efficacy outcomes
47828,Efficacy endpoints for all patients and hormone receptor positive patients in different follow up periods
47829,Non breast cancers in the safety population
47830,Deaths in the full study population
47831,Trials of third generation aromatase inhibitors as adjuvant treatment for early breast cancer
47833,Preoperative toxicity
47834,Response to treatment
47835,Tumour resection
47836,Perioperative morbidity
47837,Response rates in current randomised trials comparing three drug regimens with two drug regimens
47838,Outcome of children with B cell precursor acute lymphoblastic leukaemia by chromosomal abnormality
47839,Final multivariate Cox models of relapse free survival for individual chromosomal abnormalities
47840,Outcome of children with B cell precursor acute lymphoblastic leukaemia by cytogenetic risk group
47841,Final multivariate Cox models of relapse free survival for cytogenetic risk groups
47842,Association between cytogenetic risk group and time of relapse, site of relapse, and relapse risk group
47844,Reasons for not complying with the scheduled radiotherapy and chemotherapy regimen specified in the trial protocol   did not receive the full dose, or did not receive the therapy at all
47845,The number and causes of death, and the number of first events in patients who were disease free at 6 months after randomisation   used to examine event free survival  , according to trial group
47846,Estimated absolute risk differences   99  CI   5 and 10 years after randomisation, among patients without previous surgery
47847,Toxicities reported during treatment and at least 6 months after randomisation according to trial group
47849,Disease free survival hazard ratios adjusted for number of positive nodes for chemotherapy benefit by recurrence score over time
47851,Most common adverse events
47853,Multivariate analysis of overall survival
47854,Best overall response to therapy
47855,Major grade 3 or higher toxicity
47856,Reason for discontinuation
47858,Factors associated with acute anticoagulant use in childhood arterial ischaemic stroke
47859,Factors associated with any acute antiplatelet use in childhood arterial ischaemic stroke
47860,Predictors of early adverse outcome   death or neurological disability   in childhood arterial ischaemic stroke
47867,Main treatment emergent adverse events
47869,Summary statistics of HRQoL functional and symptom scales by time periods
47870,Mixed model results for HRQoL functional and symptom scales   F tests of fixed effects
47871,Summary statistics assessed by the MFI 20 questionnaire by age group: fatigue at end of treatment as dependent variable
47872,Summary statistics assessed by the MFI 20 questionnaire at the end of treatment: persistent fatigue as dependent variable
47875,SNPs that compose the weighted genetic risk score and weights assigned to each marker
47876,wGRS scores and odd ratios of multiple sclerosis in derivation, TT, and NHS NHS II sample sets, by wGRS groups
47880,Multivariable analysis of factors associated with AIDS defining cancers based on Poisson regression models
47881,Multivariable analysis of factors associated with three non AIDS defining cancers based on Poisson regression models
47882,Multivariable analysis of factors associated with HPV related cancers based on Poisson regression models
47884,Breast cancer recurrence and survival in the modified intention to treat population
47885,Adverse events in safety population
47888,Treatment effect of early versus delayed interferon beta 1b on confirmed EDSS progression in subgroups at time of first event
47890,Other efficacy measures over 5 years
47894,Distribution of antiphospholipid antibodies and odds ratios for myocardial infarction and ischaemic stroke
47895,Risk of myocardial infarction or ischaemic stroke in relation to lupus anticoagulant and cardiovascular risk factors
47896,Hospital based studies of pre stroke and post stroke dementia
47897,Population based studies of pre stroke and post stroke dementia
47898,Studies of post stroke MMSE
47902,Results of meta analysis comparing extended lymphadenectomy   EL   versus non extended lymphadenectomy   non EL
47903,Sensitivity analysis comparing extended lymphadenectomy   EL   versus non extended lymphadenectomy   non EL
47905,Adverse events   grade 3 or higher   recorded within 6 months
47906,Duplex ultrasound velocity criteria equivalent to NASCET angiography measures used for grading the degree of carotid stenosis
47908,Carotid restenosis after endovascular treatment compared with endarterectomy
47909,Carotid restenosis after endovascular treatment with stenting compared with balloon angioplasty alone
47910,Ipsilateral non perioperative cerebrovascular events during follow up in patients with 70  or more restenosis compared with patients with less than 70  restenosis diagnosed in the first year after treatment
47912,Outcome events within 30 days after first treatment
47913,Major long term outcome events
47914,Hazard ratios for all outcome measures
47916,Cancer site and chemotherapy by treatment group
47917,Thromboembolic events by treatment group and cancer site
47918,Serious adverse events by treatment group
47919,Detection of paratarg 7 specific paraproteins in 252 consecutive patients with MGUS and multiple myeloma
47921,Principal cause of death
47922,Adverse events other than infections for which a relationship to ATG F cannot be ruled out, by system organ class
47923,Comparison of prospective randomised trials using anti T cell globulins for GvHD prophylaxis in haematopoietic cell transplantation from unrelated donors
47928,Adjusted risk ratios for poor outcome according to treatment comparisons by severity of initial disease
47929,Risk ratios for poor outcome according to severity initial disease and time to treatment
47931,Combination of the different migraine subtypes recorded in the patients  diaries, including tension type headache, during both treatment periods   excluding washout period
47932,Primary efficacy variables in different treatment groups
47933,Adverse events reported during the study   n 38
47934,Overview of the 49 studies included in the pooled reanalysis with individual data
47937,Pooled estimates of associations of TP53 codon 72 genotype and cervical histology of 33 studies; and invasive cervical cancer cases of 25 studies in subgroups of HPV status, ethnic group, and different quality criteria
47938,Pooled estimates of associations of TP53 codon 72 genotype and cervical disease of six studies; and invasive cervical cancer cases of five studies, only studies with controls in HardyWeinberg equilibrium, epidemiological study, and genotyping with white blood cells
47939,Pooled estimates of associations of TP53 codon 72 genotype and cervical disease of the seven studies that used white blood cells to determine TP53 genotype
47944,Crude and adjusted percentage decrease in weighted case fatality rate per year
47945,Functional outcome after subarachnoid haemorrhage
47947,Vascular risk factors and retinal vascular signs in patients with lacunar and other ischaemic stroke
47948,Retinal vascular signs and lacunar stroke
47949,Retinal vascular signs and lacunar stroke in patients without diabetes
47950,Number and percentage of women screened in round 1 who attended for round 2 of screening, by age, cytology, and HPV status at entry to round 1
47951,Cytology and histology results in rounds 1 and 2   highest grade histology within 30 months of either round
47952,Positive predictive values   PPVs   and 95  CIs for CIN2  and CIN3  in screening rounds 1 and 2 by randomisation group, HPV status, and cytology
47953,High grade disease in screening rounds 1, 2, and overall, by randomisation group
47954,Relative sensitivity and specificity for CIN2  and sensitivity for CIN3  under different screening policies based on 220 CIN2 and 233 CIN3  histologies detected in 18386 women in the revealed group in round 1
47955,Proportion of women with CIN3  detected over two rounds of screening in randomised screening trials of cytology with and without HPV testing
47956,Multivariate logistic regression analysis in the SIOPEN GPOH cohort
47957,Multivariate logistic regression analysis in the COG cohort
47958,A summary of human hereditary ciliopathies
47960,Distribution of documented relapses between 0 and 96 weeks
47963,Yearly relapse rate and number of new or enlarging T2 lesions on MRI in patients grouped according to neutralising antibody status
47964,Adverse events according to treatment group
47971,Serious adverse events
47974,Standardised mortality ratios calculated for UK cohort, conditional on survival at 1 year
47975,Clinical outcomes at 5 years
47976,Standardised incidence ratios   SIRs   for early onset and late onset nervous system tumours in 709 offspring whose parents and or siblings were probands
47977,Standardised incidence ratios   SIRs   for histological types of early onset and late onset nervous system tumour in offspring whose parents and or siblings were probands diagnosed with any nervous system tumour
47978,Standardised incidence ratios   SIRs   for nervous system tumour types subdivided by age at diagnosis in offspring with a sibling diagnosed with any nervous system tumour
47979,Standardised incidence ratios   SIRs   for histological types of early onset and late onset nervous system tumours in offspring whose parents, siblings, or parents and siblings were probands   tumours with concordant histology
47982,Adverse events and toxicity
47984,Kaplan Meier overall survival including subgroup analyses
47985,Salvage treatment by treatment group after progression
47987,Patients with graft versus host disease and response to ganciclovir treatment
47989,Outcome of prevalence screen in UKCTOCS
47990,Histology in women who underwent surgery as a result of screening   screen positives
47992,Details of follow up of women who underwent screening
47994,Comparison of outcomes of different ovarian cancer screening strategies in recent general population trials
47996,Genes overexpressed   more than two times   in breast cancer compared with benign lesions
47997,Pathways with more genes differentially expressed among the phenotype classes than expected by chance
47998,Exons located in unchanged genes that are overexpressed in malignant tumours with high splice indices in cancer
48000,Proportions of patients without disease activity over 2 years
48001,Sensitivity analyses of the proportion of patients who were free of disease activity over 2 years
48003,Overall survival and time to progression to acute myeloid leukaemia comparison for groups according to investigator preselection
48004,Haematological response and improvement by treatment group and investigator preselection
48005,Deaths, discontinuations, and grade 3 or 4 haematological toxicity by treatment group and investigator preselection
48014,Number of worst grade drug related toxic effects in 48 assessable patients
48015,Univariate Cox regression analyses for overall and progression free survival   n 48
48016,Multivariate Cox regression analyses for overall and progression free survival   n 46
48017,Multivariate Cox regression analyses for overall and progression free survival, including rash and diarrhoea as predictor variables   n 46
48018,Mean fluorescent intensity   SD   of biomarker expression in tumour and endothelial cells
48021,Abnormal laboratory results at the final visit
48022,Adverse events
48024,Incidence of breast cancer recurrence in the ITT population
48025,Main safety outcomes during the trial in the all patients treated population
48026,Adverse events during treatment with an incidence of 2  in the all patients treated population
48028,Vascular causes of death by treatment in the mITT population
48029,Vascular causes of death by treatment in the ITT population
48031,CHHIPS primary outcomes
48032,Outcome in patients with intracerebral haemorrhage at randomisation
48035,Response rates by Response Evaluation Criteria in Solid Tumors
48036,Drug related adverse events, dose reductions, and discontinuations
48038,Operative data
48040,Survival at 3 and 5 years according to procedure
48041,Multivariable analysis   Cox regression   of disease free survival   DFS   and overall survival   OS   according to various factors
48043,Risk of death related to size of the largest tumour and number of tumours
48044,Outcome of liver transplantation for hepatocellular carcinoma according to Milan criteria and up to seven criteria, in relation to microvascular invasion
48047,Adverse events reported by 3  of patients in either treatment group
48049,Women with hormone receptor positive tumours and who did not report either symptom at trial entry with vasomotor symptoms or joint symptoms at the 3 month follow up visit according to treatment group
48050,Breast cancer recurrence rate and adjusted hazard ratios for endocrine symptoms reported at the 3 month follow up visit according to treatment group in women with hormone receptor positive tumours and not reporting either symptom at entry
48053,Incremental cost effectiveness ratio for primary and recurrent BCC
48056,Patients in the modified intention to treat analysis with complete recovery per follow up visit
48057,Rates of complete recovery
48058,Adverse events
48059,Breakdown by trial arm of prognostic variables at randomisation   n 802
48060,Breakdown by trial arm of time to biochemical   Phoenix   failure and PSA doubling time at Phoenix failure   n 436
48061,Application of the Prentice criteria to the surrogate candidates   TTBF and PSADT   at various cutpoints with time taken from randomisation
48062,Application of the Prentice criteria to the surrogate candidates   TTBF and PSADT   at various cutpoints with time taken from end of radiotherapy
48069,Rates of periprocedural events for the primary outcome event and secondary endpoints on the basis of the intention to treat and per protocol analyses
48070,Patients given antithrombotic treatment during follow up
48071,2 year endpoints for intention to treat and per protocol populations
48072,Rate of ipsilateral ischaemic stroke within 2 years plus periprocedural   30 day   stroke and death for predefined clinical variables in the intention to treat group
48073,Rate of ipsilateral ischaemic stroke within 2 years plus periprocedural   30 day   stroke and death for predefined clinical variables in the per protocol group
48075,Major outcome events up to 4 years
48079,Most common treatment emergent adverse events
48083,Findings for all 441 women who were negative on initial colposcopy and were called back for a second colposcopy, including four quadrant cervical biopsies and endocervical curettage, because of unsatisfactory or ASC H  cytology, positive careHPV   RLU cut off ratio cut point of 05  , or positive HC2 findings
48084,Distribution of findings in all 2388 women for whom complete data were available
48087,Comparisons of all studies  2339   and subgroups for non small cell lung cancer
48088,Comparisons of all studies  5663   and subgroups for metastatic colorectal cancer
48091,Evaluation times
48092,Overall primary and secondary analyses
48094,Adjudication disagreements
48096,Univariable and multivariable logistic regression of seizure termination after treatment with first line AED at accident and emergency department   n 203
48097,Logistic regression analyses of the factors that are associated with respiratory depression
48098,Logistic regression analyses of factors associated with CSE that lasted for longer than 60 min compared with CSE that lasted for 3060 min   n 240
48099,Logistic regression analyses of the factors that are associated with respiratory depression
48102,Effects of antihypertensive treatment on incident cognitive decline or dementia
48103,Population coverage and number of adults   aged 1599 years   diagnosed with cancer of the breast, colon, rectum, or prostate during 199094      and included in the analyses: continent, country, and region
48104,5 year relative survival      , age standardised to ICSS weights      with 95  CIs for adults   aged 1599 years   diagnosed with cancer of the breast   women  , colon, rectum, or prostate during 199094 and followed up to Dec 31, 1999: continent, country, and region
48105,5 year relative survival       by use of state specific and race specific life tables and age standardised to ICSS weights      with 95  CIs     for adults   aged 1599 years   diagnosed with cancer of the breast   women  , colon, rectum, or prostate during 199094 and followed up to Dec 31, 1999, by ra US populations
48107,Univariate and multivariate Cox regression models for metastasis free survival
48108,Best multivariate Cox regression model for metastasis free and local recurrence free survivalcomparison of the learning sample and the validation sample
48109,Univariate and multivariate Cox regression models for local recurrence free survival
48112,Hazard ratios and 95  CIs for proportional hazards model assessing the effect of variables associated with survival
48114,Surgical procedures and resectability of patients undergoing surgery, pathological response, and mediastinal downstaging of patients with complete resection
48115,Treatment related mortality
48116,Progression free survival   PFS   in patients undergoing tumour resection
48117,Overall survival   OS   in patients undergoing tumour resection
48118,Progression free survival   PFS   and overall survival   OS   in patients with incomplete versus complete resection
48119,Resectability, surgical mortality, and numbers of patients with stage III non small cell lung cancer undergoing surgery in randomised trials that used surgery after induction treatment
48121,Adjusted incidence rates, hazard ratios, and 95  CIs for cigarette smoking and lung cancer by sex
48122,Adjusted incidence rates, hazard ratios, and 95  CIs for cigarette use and lung cancer by sex and histology
48124,Primary and combined endpoints
48125,Incidence and frequency of mild adverse events
48126,Bleeding events
48128,Number of teeth, periodontal disease, and risk of cancer incidence in the Health Professionals Follow up Study cohort   19862004   with hazard ratios provided before and after adjusting for smoking variables   714294 person years
48129,Number of teeth, periodontal disease, and risk of cancer in never cigarette, pipe, or cigar smokers in the Health Professionals Follow up Study cohort   19862004, 308928 person years
48130,Number of teeth, periodontal disease, and risk of leukaemia, non Hodgkin lymphoma, and multiple myeloma in the Health Professionals Follow up Study cohort   19862004, 714294 person years
48131,Grouping of patients according to maximum tumour diameter and tumour location   n 802
48132,Patients classified as having bulky disease according to the cut off points defined by their respective   national   cooperative study group
48133,Predicted 3 year event free survival and overall survival according to maximum tumour diameter
48134,USA and UK prostate cancer mortality trends   joinpoint analysis  , by age group   19752004
48135,USA and UK age specific and age adjusted prostate cancer peak mortality and percentage decline since peak, by age group
48137,Survival analyses of relapse and mortality according to fractionation schedule in START Trial A
48138,Incidence of ischaemic heart disease, symptomatic rib fracture, and symptomatic lung fibrosis according to fractionation schedule
48142,Effect of reperfusion on radiological, neurological, and functional outcomes for mismatch patients
48143,Comparison of imaging and clinical outcomes between patients with and without mismatch
48145,Comparison of cases and controls with methylation data
48146,Association of global DNA hypomethylation status and risk of bladder cancer in cases and controls
48147,Joint effect of hypomethylation and smoking status on risk of bladder cancer
48149,Distribution of molecular marker expression
48150,Univariate analysis of freedom from biochemical failure
48152,Multivariate analysis of freedom from biochemical failure with expression of molecular markers included
48154,Intervention used and extent of angiographic obliteration after treatment
48155,Univariate and multivariable analyses of first progression to OHS 26 during the first 3 years of follow up
48157,Cancer incidence by site
48158,Cancer incidence at selected sites by karyotype group
48159,Response assessment according to conventional International Neuroblastoma Response Criteria   INRC    11
48160,Protocol dose received and relative dose intensity by induction treatment for all drugs combined
48162,Toxic effects during preoperative chemotherapy
48163,Response to induction treatment according to INRC
48167,Haematological and nonhaematologic adverse events
48168,Regional standardised uptake value ratios   SUVR90120   in healthy controls and patients with Alzheimer s disease
48172,Patient survival in validation cohort
48173,Cox regression analysis of validation cohort with inclusion of gHDAC expression   n 123
48174,Unadjusted prevalence of active convulsive epilepsy by age and sex
48175,Age adjusted odds ratios for sociodemographic and medical history associated factors
48176,Possible risk factors for active convulsive epilepsy from final multivariate models
48177,Deaths in the anastrozole and tamoxifen treatment groups according to randomised treatment   intention to treat population
48178,Serious adverse events on and off treatment before recurrence for the safety population: number   and annual rate
48179,New primary cancers at non breast cancer sites before recurrence   safety population
48180,Patients with joint symptoms by severity and treatment first received for all women   safety population   and for those without joint symptoms at entry   study population
48183,Number       of women reporting joint symptoms at any time during treatment according to treatment first received and selected risk factors in women without joint symptoms at entry   study population
48186,Response to treatment
48187,Summary of National Cancer Insitute Common Toxicity Criteria grade 3 to 4 toxic effects
48188,Number of deaths and death rates in 1990 and 2016 in the WHO European region, ages 59 years, both sexes
48189,Number of deaths and death rates in 1990 and 2016 in the WHO European Region, ages 1014 years, both sexes
48190,Mortality rates for the top ten leading causes of death in 2016 globally and in the WHO European Region   51 countries and four subregions  , ages 514 years, both sexes
48192,Discontinuations, adverse events, and haematological abnormalities
48194,Most common treatment related adverse events in all patients   n 54
48195,Mental health documents
48196,High resolution manometry metrics to define abnormal oesophageal motility
48197,Analysis of the solid test meal in healthy volunteers and patients
48198,Comparison of CC S diagnoses based on STM in patients with major motility disorders diagnosed by CCv3
48200,Summary of pharmacokinetic parameters in children and adults
48201,Adverse events
48204,Primary and secondary outcome variables
48205,Estimated coefficients for treatment by time interactions from fitting of random intercept and slope models to each outcome variable
48206,Neuropsychological outcome variables
48207, to  power ratios   logarithmically transformed   in the eyes open and eyes closed conditions
48209,Prespecified subgroup analyses for primary and secondary outcomes
48210,Coverage of the world population aged 019 years, person years, numbers of cancer cases, and quality indicators of data included in the analyses, overall and by region, 200110
48211,Numbers of cancer cases, person years, and overall cancer incidence, by sex, age group, and malignant status
48212,Numbers of cases and age standardised incidence of tumours in children aged 014 years, 200110, by main diagnostic group
48213,Numbers of cases and age specific incidence of tumours in young people aged 1519 years, 200110, by main diagnostic group
48215,Efficacy
48216,Adverse events
48217,Viraemic hepatitis C virus epidemiology for EU countries in 2015
48218,Requirements to meet WHO targets in the European Union
48220,Stomatitis with first onset after week 8   day 56   by patient number
48221,Adverse events with a total incidence of 5  regardless of causality   n 92
48222,Most common adverse events leading to everolimus and exemestane discontinuation, dose adjustment, or dose interruption, with suspected relation to everolimus   safety population, n 92
48223,Prognostic factors and their classification
48224,Prognostic effect of PRETEXT annotation factors
48226,Proportion of replicates that had a significant association with event free survival in bootstrapping, by backbone group
48227,Kaplan Meier estimates of event free survival in risk categories defined by statistical analysis, by backbone group
48229,Brigatinib dose regimens
48230,Treatment emergent adverse events occurring in at least 10  of all patients by grade
48231,Safety summary for all patients and by phase 2 expansion doses
48238,Investigator assessed best whole body responses for all patients with ALK rearranged NSCLC receiving at least one dose of ceritinib   n 246
48240,Adverse events occurring at grades 12 in 10  or at grade 3 or grade 4      in 2  of patients with ALK rearranged NSCLC   n 246
48242,Adverse events
48244,Virological response of individuals who achieved an ultrarapid virological response at day 2 and received 3 weeks of treatment
48245,Adverse events and laboratory abnormalities during the treatment period
48249,Included studies of HIV in people with serious mental illness
48250,Pooled prevalence in people with serious mental illness
48251,Included studies of hepatitis B
48252,Included studies of hepatitis C virus in people with serious mental illness
48253,Sensitivity analysis
48255,Primary and secondary outcomes during evening and night, morning, and 24 h   modified intention to treat analysis
48257,Rates of psychiatric disorders by domain
48258,Symptom counts by psychopathology domain
48260,Haemoglobin concentration in children receiving umbilical cord red blood cell transfusions, stratified by age
48261,Serious adverse events and adverse events in children receiving umbilical cord red blood cell transfusions
48262,Serious adverse events within 1 month of umbilical cord red blood cell transfusion
48265,Adverse events
48267,Adverse events at baseline
48268,Treatment adherence and reasons for stopping treatment
48269,Adverse events during the 24 week treatment stage and at the PTAV
48271,Subgroup analyses of complete responders versus non responders   per protocol population
48273,Adverse events
48278,Adverse events
48280,Dose escalation and dose limiting toxicities in phase 1   n 24
48281,Pharmacokinetic parameters of CH5424802 at steady state in the patients under fasting and non fasting conditions   n 24
48282,Treatment related adverse events reported in 10  or more of patients enrolled in phase 2   n 46
48284,Response rates 4 weeks after the end of treatment
48285,Cumulative recurrence rates
48286,Response to treatment   per protocol   for peri anal and intra anal lesions separately
48287,Univariable and multivariable log binomial regression
48288,Side effects
48290,EEG, CSF, and MRI findings in 12 children with nodding syndrome examined serially, by patient number
48291,Cognitive tasks in 65 case control pairs of children with and without nodding syndrome
48293,Dose level, drug administration details, and response in each individual patient
48294,Adverse and serious adverse events
48295,Results for measurement of serum DKK1, AFP, or both,      in the diagnosis of HCC
48296,Results for measurement of DKK1 in serum      in the diagnosis of AFP negative or AFP positive patients with HCC
48297,Summary of identified studies
48299,Pathological complete responses in the ITT population, by hormone receptor status, and by axillary lymph node status at surgery
48300,Clinical responses by clinical breast examination during neoadjuvant treatment
48301,Summary of the ten most common adverse events   any grade
48302,Most common adverse events of grade 3 or higher and serious adverse events
48303,Vaccine efficacy against CIN1 , CIN2 , CIN3 , and AIS associated with HPV 16 18 stratified by age   TVC naive and TVC
48304,Vaccine efficacy and number of cases prevented for CIN1 , CIN2 , CIN3 , and AIS, irrespective of HPV DNA in the lesion, stratified by age   TVC naive and TVC
48305,Safety and pregnancy outcomes throughout the study   TVC
48309,Summary of cross protective efficacy across endpoints and cohorts
48311,Estimated vaccine efficacy against anal and cervical HPV 16 18 infections
48312,Estimated vaccine efficacy against anal and cervical infection with HPV 31, 33, or 45
48313,Estimated vaccine efficacy against anal and cervical infections with HPV 16 18 by self reported anal sex status in the full and restricted cohorts
48315,Risk of developing CIN grade 2 or higher according to different confounding risk factors
48316,Prediction of recurrent high grade disease according to different follow up algorithms
48321,Quantification of JC virus in patients treated with natalizumab
48322,Data summaries of the trials included in the different meta analyses
48323,Correlation coefficients for the candidate surrogate endpoints and overall survival in the different meta analyses
48326,CNV loci with nominal p values
48327,Genes located in CNVs
48330,Adverse events reported in 5  of patients in a treatment group, irrespective of causality
48332,Adverse events by Common Terminology Criteria for Adverse Events grade        safety population
48333,Antitumour activity   efficacy population
48335,Adverse events
48336,Post hoc objective responses and disease control
48339,Treatment related adverse events   safety analysis set
48340,Immune mediated adverse events      by grouped preferred term   safety analysis set
48342,Summary of adverse events
48349,Primary outcomes at child age 2 years
48351,Secondary outcomes at child age 2 years
48352,Secondary outcome of emotion discrimination task at 2 years of age
48356,Treatment related adverse events
48357,Venetoclax pharmacokinetic parameters for groups A and B in cycle 2, day 5
48358,Responses to treatment
48361,Prespecified outcome analysis and joint models for primary and secondary outcomes
48364,Comparison of adults born small for gestational age who received growth hormone treatment versus untreated controls
48365,Components of metabolic syndrome at mean age 21 years
48367,Primary outcomes in children at mean age 54 years
48368,Secondary outcomes in children at mean age 54 years
48370,Adverse events during pregnancy and delivery
48372,Cumulative risk estimates of PML according to number of natalizumab infusions and anti JCV antibody index scores in patients with and without previous immunosuppressant use
48374,Overall response as assessed by investigator and independent review committee
48375,Grade 12 adverse events occuring in 10  or more of patients and all grade 3, 4, and 5 events, regardless of association with study drug   n 36
48377,Proportion of patients who achieved a response
48379,Adverse events
48380,All cause mortality
48382,HBsAg response rates
48384,Overview of adverse events in the modified intention to treat population
48386,Primary and secondary endpoints
48387,Adverse events
48389,Edinburgh postnatal depression scale   EPDS   factor structure
48390,Comparison of factor scores among the subtypes of perinatal depression
48391,Edinburgh postnatal depression scale   EPDS   categories, self harm, and anxiety subscale in the subtypes of perinatal depression
48392,Data quality indicators for children aged 014 years diagnosed with leukaemia between 19952009: by continent and country
48393,5 year age standardised net survival in children aged 014 years diagnosed with leukaemia
48395,Treatment related adverse events   worst grade per patient
48397,Confirmed responses, progression free survival, and overall survival associated with PD L1 expression   n 142
48399,Adverse events
48403,Summary of adverse events
48404,Complete clinical response at all three assessments in patients with primary tumour response data at all three assessments
48405,Distribution of patients and tumour response for patients who attended all three assessments   n 691
48406,Distribution of patients and tumour response for all patients in the trial   n 940
48409,Repeated measurements analysis of outcome measures during 5 years after cessation of treatment
48410,Comparison of outcome measures between groups at age 21 years
48411,Attributable burden of disease in the USA for 15 exposureresponse relations
48412,Annual costs for disorders associated with exposure to endocrine disrupting chemicals in the USA
48413,Comparison of attributable disease burden and costs in the USA and European Union
48414,Modelled exposures to an organophosphate pesticide and a PBDE in the USA and European Union
48416,Treatment related toxicities of cabozantinib
48418,Adverse events
48419,Ricolinostat pharmacokinetics
48420,Best responses to ricolinostat plus lenalidomide and dexamethasone
48423,Adverse events
48426,Clinical details and survival of carriers of germline TP53 pathogenic variants with cancer from families with Li Fraumeni syndrome, by surveillance group
48428,Safety outcome measures in randomised patients during the 24 weeks of treatment
48431,Antitumour activity in patients receiving dabrafenib plus trametinib as second line or later treatment
48432,Adverse events
48434,Responses to treatment
48435,Adverse events
48437,External validation performance of a risk score predicting 1 and 2 year violent reoffending and any reoffending of released prisoners in Sweden
48439,Follow up time, recurrences, and cause of death in the intention to treat population
48440,Multivariate proportional hazards regression analysis of survival outcomes in the intention to treat population
48442,Clinical activity endpoints in patients with measurable disease at baseline receiving dabrafenib as second line or later treatment
48443,Adverse events in all treated patients
48445,Adverse events in the safety population
48446,Best response in evaluable dose escalation patients   n 37
48448,Complete response rates during all phases of the first on study chemotherapy cycle   full analysis set
48449,Proportions of patients with no vomiting or emetic episodes, and who avoided antiemetic rescue medication, during all phases of the first on study chemotherapy cycle   full analysis set
48450,Treatment emergent adverse events recorded in the first on study chemotherapy cycle   safety population
48451,Drug related treatment emergent adverse events by MedDRA system organ class and preferred term in the first on study chemotherapy cycle   safety population
48453,Top 25 predictive items in elastic net model
48457,Adverse events
48467,Areas with significantly different BOLD responses for the contrast punished reversal error trials versus rewarded correct response trials
48469,Diagnostic performance of threshold tracking transcranial magnetic stimulation in amyotrophic lateral sclerosis, by clinical group
48472,Periprocedural complications
48473,Postprocedural complications
48474,Baseline demographic and transplant characteristics
48475,Causes of death
48476,Prognostic factors for outcomes at 1 year after transplantation
48477,Adverse events
48478,Regimen related toxic effects by organ system within 28 days after transplantation in the per protocol population
48480,Drug related adverse events in more than three patients given emactuzumab and serious adverse events independent of incidence   safety population, n 25
48482,Key performance indicators between intensive case management and Early Psychosis Prevention and Intervention Centre treatment as usual
48484,Clinical features of individuals in the studied pedigree with familial ALL
48486,Class membership and EPDS symptom Endorsement Probabilities across latent classes, including cases and controls
48489,Frequency of phenotypes across latent classes
48491,Numbers of participants in each biomarker group by 5 year age stratum
48495,Adverse events by system, grade, and attribution
48499,Treatment emergent side effects that led to drug interruption or drug withdrawal
48503,Developmental substudy
48507,Estimates of slope from each amyotrophic lateral sclerosis register   all age groups  2574 years
48510,HPV DNA prevalence in head and neck squamous cell carcinoma by anatomical site
48511,HPV attributable fractions of HPV infection in head and neck squamous cell carcinoma according to different biomarkers
48512,Effect of selected study covariates on the HPV DNA prevalence in head and neck squamous cell carcinoma
48514,PTSD checklist   PCL   administration order effects   identical symptoms on both PCL versions
48515,Direct comparison of DSM 5 and DSM IV TR symptoms, clusters, and full criteria based on PCL 5 and PCL S
48516,Associations between clinical measures and screening positive for post traumatic stress disorder   PTSD   by the PCL 5 or PCL S
48517,Clinical features, treatment, and outcome
48518,Types of sleep recording and main findings
48521,Clusters showing significant connectivity with the amygdala in the diagnosis by valence interaction     , by Montreal Neurological Institute coordinates   x,y,z
48523,Adverse events reported by at least 5  of 3222 patients irrespective of association with vemurafenib
48526,Association of repeat length with age at onset, age at sample collection, and length of wild type allele
48527,Association of repeat length with survival after disease onset
48529,Device related adverse events and serious adverse events
48530,Algorithm performance, by patient
48531,Seizure rates before and during the study, by patient
48533,Adverse events attributed   possibly, probably, or definitely   to crizotinib therapy across all strata and all dose levels
48534,Dose limiting toxic effects observed at each dose level   mg m2 per dose twice daily   by cohort
48535,Best response in patients with anaplastic large cell lymphoma, inflammatory myofibroblastic tumour, or non small cell lung cancer, by accession number
48536,Best response in patients with neuroblastoma, by accession number
48539,Adverse events by group and cohort
48540,Adverse events by enrolment
48541,Predicted and measured human plasma concentration of ISIS 333611 by cohort
48542,The proportion of villages and women screened in Keremet and Abugota
48543,The number of women screened and the number of those referred or diagnosed with cancer in each village in Keremet
48544,Diagnosis of patients in experimental and control villages
48545,Patients diagnosed with cancer during the study period in Keremet and Abugota
48546,Duration of exposure
48550,Summary of adverse events
48551,Adverse events occurring in 20  or more of patients
48552,Serious adverse events occurring in more than 3  of patients
48554,Differences from valproate in mean IQ scores in all children in the study   n 311   and in children at 6 years of age   n 224
48555,Adjusted mean verbal and non verbal index scores at age 6 years
48556,Adjusted means for the general memory index, the executive index from neuropsychological assessment, and the parent index from the BRIEF at 6 years of age
48557,IQ outcomes at age 6 years by median group dose for the age 6 completer sample   n 224
48559,Secondary outcome measures, by time since randomisation
48560,Serious adverse events
48561,Previous studies of lithium treatment in patients with amyotrophic lateral sclerosis
48563,Survival and response outcomes
48564,Safety of sapacitabine schedules and treatment delivery
48565,Adverse events occurring in more than 15  of patients
48566,Adverse events occurring in more than 15  of patients   previously untreated vs first relapsed
48567,Prognostic factors associated with 30 day mortality, 60 day mortality, and 1 year survival   n 105
48570,Patients who received crizotinib for more than 2 weeks after progression
48571,Treatment related adverse events reported in at least 10  of patients in the safety population   N 149  , by descending frequency   all grades
48573,Non relapse mortality, relapse incidence, and disease free survival 12 months after randomisation in the per protocol population
48574,Non haematological toxic effects, engraftment, graft versus host disease, and early deaths in the per protocol population
48577,Diagnostic agreement between visual binary florbetapir PET measurement by five readers and neuropathologist s rating of neuritic amyloid plaques
48578,Frequency of the pathogenic GGGGCC hexanucleotide repeat expansion of C9orf72 in patients diagnosed with sporadic ALS or sporadic FTD classified by region
48579,Frequency of the pathogenic GGGGCC hexanucleotide repeat expansion of C9orf72 in patients diagnosed with familial ALS and familial FTD classified by region
48582,Cognitive categories according to neuropsychological test results
48583,Executive function test results
48587,Participation rate by age, sex, and socioeconomic status
48588,Most advanced lesion per participant and per invitee for colonoscopy and CT colonography
48589,Histology and dysplasia of detected adenomas
48590,Morphology of detected adenomas and location of colorectal cancers and advanced adenomas
48591,Complications within 30 days after the examination among colonoscopy and CT colonography participants
48593,Outcome measures and relevant findings from articles included in the meta analysis
48595,Occurrence and intensity of symptoms and distress associated with sexual and urinary function, by category of function
48596,Occurrence and intensity of psychological symptoms
48597,High penetrance and moderate penetrance breast cancer susceptibility genes
48598,Low penetrance loci associated with breast cancer risk, identified by genome wide association studies
48599,Genetic variants with a significant association with breast cancer risk in meta analysis
48600,Additional genetic variants with a significant association with breast cancer risk, in meta analyses using dominant or recessive models
48601,Genetic variants with no association with breast cancer risk, in meta analyses with at least 10000 cases and 10000 controls
48602,Mean age at diagnosis and cumulative risk by age 70 years of colorectal and endometrial cancers in carriers of a mutation associated with Lynch syndrome
48603,Extracolonic and extraendometrial cancers in carriers of an EPCAM deletion
48605,C statistics for early stroke discrimination
48606,Multivariate logistic regression model for stroke recurrence in the derivation group
48607,ABCD3 and ABCD3 I scores
48608,Risk reclassification from ABCD2
48609,Multivariate logistic regression model for stroke recurrence in the derivation group
48610,Molecular subtype classifications of breast cancers
48611,Agreement between single sample predictors for molecular subtype assignments
48612,Agreement between single sample predictors for classification of each molecular subtype individually
48613,Univariate and multivariate Cox s regression analysis of overall and metastasis free survival for the NKI 295, Wang, and TransBig datasets combined
48615,Imaging classification relative to final clinical diagnosis: discriminative measures
48617,Dutch Childhood Oncology Group   DCOG   ALL 9: overview of treatment results
48618,Dutch Childhood Oncology Group   DCOG   ALL 9: overview of treatment results
48619,Univariate analysis of prognostic factors in ALL 9 for event free survival   n 859
48620,Multivariate analysis of prognostic factors in ALL 9 for event free survival   n 859
48621,Treatment results for ALL 9 according to National Cancer Institute criteria
48622,B lineage ALL   National Cancer Institute criteria  ; treatment results for protocols ALL 6, ALL 7, ALL 8, and ALL 9
48623,T lineage ALL   National Cancer Institute criteria  ; treatment results for protocols ALL 6, ALL 7, ALL 8, and ALL 9
48625,Adjusted between group and within group differences for measurements
48626,Clinical data and SDHB immunohistochemistry related to various syndromes
48627,SDHB immunohistochemistry test results according to subgroups within SDH related and non SDH related tumours
48629,TNM stage distribution   all patients
48630,Clinically relevant toxicity during induction chemotherapy and radiotherapy
48631,Surgery and postoperative complications
48632,Selected studies of induction chemotherapy for locally advanced NSCLC
48634,Complete responses   defined as no emetic episodes and no use of rescue medication   in the modified intention to treat cohort   N 1114
48635,Subgroup analysis by stratification criteria of the proportion of complete responses   defined as no emesis and no rescue medication   in the acute and delayed phases in the modified intention to treat cohort   N 1114
48636,Complete control   defined as no emetic episodes, no use of rescue medication, and no more than mild nausea   in the modified intention to treat cohort   N 1114
48637,Proportion pf patients with no nausea or episodes of emesis in the modified intention to treat cohort   N 1114
48638,Treatment related adverse events occurring in at least 2  of patients in each treatment group in the safety cohort   N 1119
48639,Frequency of LRRK2 Gly2019Ser in patients with PD and controls across 24 world populations
48640,Rate of disease progression in patients with all LRRK2 mutations and LRRK2 Gly2019Ser
48644,Treatment response to sofosbuvirvelpatasvirvoxilaprevir
48647,Adverse events and laboratory abnormalities
48649,Clinical outcomes
48650,Incidence of all non haematological and haematological toxic effects during induction treatment
48652,Baseline demographics and clinical characteristics
48653,All treatment related adverse events
48659,Inter rater reliability and comparison of clinical and non clinical groups for AANEX CAR appraisals
48660,Comparisons of threatening versus non threatening appraisal scores, global ratings, personal relevance, and incorporation
48662,Associations between paternal and adolescent depressive symptoms in multiply imputed samples
48663,Associations between paternal and adolescent depressive symptoms in complete case samples
48667,Type, method, and number of self harm episodes per patient
48668,Hospital costs by general self harm method and service use
48669,Adjusted association of self harm with total hospital costs
48671,Primary outcome results
48672,Mediation analysis      results
48673,Secondary outcome results
48674,Secondary dichotomous outcome results
48676,Identification of prognostic survival markers in MBSHH Child cohort
48678,Select model parameters
48679,Calibration targets and model fit
48684,Adverse events
48685,Mutations carried by the patients in the cohort
48686,Prevalence of phenotypes and neurological features in individuals with APP or PSEN1 mutations
48688,Treatment efficacy compared with drug placebo
48689,Efficacy of psychological and pharmacological interventions compared with SSRIs
48691,Treatment emergent arterial occlusive events
48692,Treatment emergent adverse events
48699,Neuroendocrine outcomes
48700,Cumulative incidence of any neuroendocrine outcomes by subgroup
48701,Survival outcomes
48702,Acute and late toxic effects
48707,Dutch military personnel deployed to Afghanistan reporting post traumatic stress symptoms at each timepoint
48708,Variable estimates for change in post traumatic stress symptoms over time relative to pre deployment status of Dutch military personnel deployed to Afghanistan
48710,Treatment response at 12 months   primary outcomes
48711,Treatment response over 3 months   secondary outcomes
48718,Primary and secondary outcome measures
48719,Standard care provided in the CBT intervention group and the control group
48721,Response outcomes and transplant realisation
48722,Adverse events and neurologic events   irrespective of causality
48723,Treatment regimens
48725,Proportion of patients achieving efficacy endpoints   intention to treat population
48726,Overall adverse event profile
48727,Adverse events reported in 10  or more of patients
48729,Previous treatments in patients with breast cancer and small cell lung cancer   response assessable population
48730,Summary of efficacy for response assessable patients
48731,Most frequently reported all cause and drug related adverse events
48733,Adverse events that occurred in at least three participants in any treatment group
48739,Reported grade 3 severe toxic effects
48740,Reported grade 4 severe toxic effects
48742,Most frequent adverse events, regardless of posited relation to drug
48743,Serum concentration of MABp1 by dose level
48744,Patient responses according to tumour type and dose
48746,Pharmacokinetic studies of vorinostat 100 mg twice daily
48747,Serious adverse events and adverse events among 58 participants who received at least one dose of vorinostat
48748,Cumulative incidence of graft versus host disease
48749,Causes of non relapse mortality, 2 years after transplantation
48751,Adverse events
48753,Distribution of preoperative pain scores
48754,Adjusted associations between preoperative pain levels and risk of delirium
48755,Adjusted associations between preoperative pain and delirium stratified by presence of depressive symptoms
48757,Relative reductions versus placebo in monthly number of combined unique active lesions at month 3   full analysis set
48758,Adverse events during 6 months of treatment in cohort 1   siponimod 10 mg, 2 mg, and 05 mg and placebo   and 3 months of treatment in cohort 2   siponimod 125 mg and 025 mg and placebo
48761,Secondary outcomes at 3 months after injury
48762,Adverse events
48764,TNA or TIA in the 90 days preceding stroke by territory
48765,Vascular risk factors and duration of isolated vertigo versus other vertebrobasilar TNAs preceding vertebrobasilar stroke
48766,Events in the 90 days preceding ischaemic stroke or TIA with 50  symptomatic stenosis
48768,Responses to treatment
48770,Non myelosuppressive adverse events during course one of inotuzumab ozogamicin
48772,Treatment related grade 3 or 4 adverse events that occurred in 5  of patients or more
48773,Best treatment responses
48776,Patients with adverse events within 1 month
48777,Patients with serious adverse events over 1 month after study entry
48779,Adverse events during induction treatment   n 57
48780,Adverse events during maintenance treatment   n 37
48781,Treatment activity
48783,Early secondary clinical outcomes
48784,Mortality and functional outcomes at 6 months
48790,Adverse events
48792,Incidence and causes of late deaths   3 years or later
48793,Incidence of chronic GvHD and organ involvement
48794,Haematopoietic function   at 5 years after allogeneic stem cell transplantation   of long term survivors and performance status
48795,Multivariable analysis with Cox proportional hazard ratio for overall survival
48797,Breast, arm, or shoulder symptoms and body image scale scores, according to radiotherapy regimen, over time from randomisation
48800,Breast, arm, or shoulder symptoms and body image scale scores at 5 years      according to radiotherapy regimen, type of primary surgery, and boost
48802,Details of surgery and pathology
48805,Mean scores from two quality of life questionnaires at month 24
48807,Treatment related adverse events of interest and those that occurred in at least 10  of all 4371 patients   modified intention to treat population
48808,Tumour response according to RECIST criteria and clinical benefit   only evaluable patients included
48809,Summary of median progression free survival and overall survival
48814,Areas stimulated on the basis of volume of brain tissue activated around the therapeutic contacts and postsurgical complications
48815,Study medication dosing schedule
48817,Efficacy endpoints in the modified intention to treat population
48818,Adverse events
48819,Grade 4 neutropenia by chemotherapy type
48820,Complete response in phase III studies of NK1 receptor antagonists in combination with 5 HT3 receptor antagonists in patients receiving cisplatin based chemotherapy
48822,Ancillary tests and treatment
48824,Treatment outcomes
48825,Grade 3 and 4 toxic effects occurring in 3  of patients in at least one group
48830,Serious adverse events in the psychiatric domain reported after DBS or best medical treatment
48832,Treatment findings
48833,Multivariate analysis of outcome adjusted for strata
48834,Grade 3 and 4 Common Toxicity Criteria toxicities and therapeutic interventions
48836,Primary and secondary outcomes for cilostazol versus aspirin
48837,Primary and secondary outcomes for probucol versus non probucol
48838,Adverse events   safety population
48840,Participants  randomly assigned treatment vs treatment received
48841,Outcomes on the Positive and Negative Syndrome Scale
48842,Secondary outcomes
48843,Participants with improvements or deteriorations in total scores on the Positive and Negative Syndrome Scale at 24 and 52 weeks
48844,Secondary outcomes   adverse effects
48848,A score to predict the safe discharge of patients presenting with acute lower gastrointestinal bleeding
48849,Probability of safe discharge by total score
48850,C statistics for our score   the Oakland model   compared with existing models for safe discharge and adverse clinical outcomes
48857,ANOVA results for cognitive, clinical, and functioning variables
48859,Adverse events
48861,Glycaemic control, insulin therapy, hospital complications and hypoglycaemia outcomes
48863,Final multivariable      predictors of hospitalisation   all p 001
48864,Risk of hospital admission: simple scoring system
48865,Proportion of placebo responders by half decades
48869,Frequency of cognitive, behaviour, and academic problems in adolescent survivors and siblings
48870,Multivariable models of risk of cognitive and behaviour problems CRT dose, age at diagnosis, sex, and neurological events
48872,Validated predictive performance of classifiers trained on the 4 week and 52 week outcome endpoints
48873,Analysis of trajectory differences between predicted poor   GAF score  65   versus good   GAF score 65   52 week outcome groups, covering five treatment domains
48881,Annual incidence of disability and mortality, by diabetes status
48885,Self reported quality of life score from the EQ5D questionnaire by timepoint
48887,Percentage change in lipid parameters at week 12 in evolocumab treated versus placebo treated or ezetimibe treated patients with and without type 2 diabetes
48888,Safety of evolocumab in patients with and without type 2 diabetes
48895,Cumulative incidence of local relapse and distant metastases
48898,Summary of treatment emergent adverse events   safety population
48899,Summary of treatment effects compared with waitlist
48900,Data acquisition and imaging protocols
48902,Mean circumferences and percent change during spontaneous unilateral migraine attacks and on attack free day
48903,Mean circumference and percent change during spontaneous unilateral migraine attacks and 30 min after treatment with subcutaneous 6 mg sumatriptan
48905,Adverse events
48907,Morphine use
48908,Survival over time
48909,Secondary outcomes
48913,Adverse events
48916,Primary and secondary outcomes after 1 year
48917,Subgroup analyses of primary and secondary outcomes at 1 year
48919,Selected clinical and biological presenting features of patients with ETP ALL in the St Jude cohort
48920,Univariate and multivariate analysis of event free survival according to the diagnosis of ETP ALL and selected variables in patients in the St Jude cohort
48922,Univariable analysis of predictors associated with time to first late seizure in the derivation cohort
48923,Final multivariable Cox proportional hazards model of time to first late seizure in the derivation cohort
48924,Calculation of the SeLECT score
48926,Sensitivity and specificity of the Xpert HCV Viral Load assay for HCV RNA detection compared with the Abbott RealTime assay
48927,Sensitivity and specificity of the Xpert HCV Viral Load assay for HCV RNA quantification compared with the Abbott RealTime assay
48928,Modelled 2015 hepatitis C viraemic prevalence and chronically infected population   all ages   and genotype distribution
48929,Regional prevalence and number of infected individuals   all ages
48932,Summary of adverse events and clinical system affected in serious adverse reactions
48934,Changes in stroke incidence and performance measures of adequate stroke care in patients during 2010 and 2013
48942,Prespecified safety endpoints and other serious adverse events
48945,Predictors of the primary outcome
48947,Comparison by study group
48948,Predictors of visibility of acute ischaemic lesions on FLAIR imaging
48949,Predictive values of DWI FLAIR mismatch for the identification of patients within either 45 h or 6 h of symptom onset
48951,Serious adverse events thought to be related to bevacizumab that were reported in more than 1  of patients in the ITT population   N 2212
48952,Adverse events of special interest in the ITT population   N 2212  , by Common Terminology Criteria grade
48953,Safety and efficacy of bevacizumab based therapy, by chemotherapy regimen
48954,Adverse events of special interest, by outcome and action taken
48956,Multivariable analysis of leukaemia free survival, transplant related mortality, relapse, and acute and chronic graft versus host disease
48957,Early causes of death   within 100 days after transplantation
48958,Late causes of death   more than 100 days after transplantation
48960,Management of patients
48962,Clinical outcomes and serious adverse events at day 90
48965,Details of neoadjuvant and adjuvant therapy in liver transplant recipients with intrahepatic cholangiocarcinoma
48966,Genetic mutation analysis of liver transplant recipients with intrahepatic cholangiocarcinoma
48967,Cancer cases in adolescents   aged 1519 years   and young adults   2039 years   diagnosed in 200007, in 27 European countries, with data quality indicators
48968,5 year relative survival estimates for major cancers affecting European adolescents      and young adults     diagnosed in 200007
48969,5 year relative survival in European children in comparison to survival in adolescents, young adults, and AYAs for major cancers affecting children and AYAs diagnosed in 200007
48970,5 year relative survival in European AYAs in comparison with survival in adults for major carcinomas affecting AYAs and adults for cases diagnosed in 200007
48971,Clinical and laboratory findings of the 20 patients with positive MRD on week 7 of continuation treatment
48973,ERR per Gy of cumulative red bone marrow dose for causes of death
48975,Associations between decreasing fractional anisotropy and increasing systolic blood pressure and age by fibre label
48976,Associations between increasing mean diffusivity and increasing systolic blood pressure and age by fibre label
48977,Medical assessments by age group
48978,Echocardiographic data of children exposed to anthracyclines in utero and their matched controls
48979,Neuropsychological tests and corresponding cognitive domains
48981,Tumour localisation
48982,Significant correlations between radiological abnormalities and cognitive performance
48983,Diagnostic test values for the classification of acute lymphoblastic leukaemia by three fold cross validation approach
48984,Diagnostic test values for independent validation group
48986,Summary of recurrent genetic abnormalities found in BCRABL1 like, BCRABL1 positive, and other precursor B ALL cases
48988,Number of centres visited and individuals interviewed by Sanisphere in the ten surveyed countries
48989,Field survey of paediatric oncology status in the ten surveyed countries
48990,Estimated current and future paediatric cancer burden in the ten surveyed countries
48992,Correlation of health and economic indicators with postulated 5 year survival of paediatric cancer in the ten surveyed countries
48993,Correlation between paediatric oncology care infrastructure and postulated survival
48994,Estimated annual number of new cases and number of deaths for the main types of cancer diagnosed before age 15 years in a European country with total population about 60 million
48995,Number of participants needed in superiority trials and non inferiority trials with two parallel groups of equal allocation and comparison of event free survival
48997,Primary and secondary endpoints
48998,Most commonly reported treatment emergent and severe adverse events
48999,Patients who sought medical attention after first event
49001,Predictors of new disability or death and of overall disability or death by multivariate analysis
49002,All cause hospital admission and bed days during the 90 day follow up
49003,Total days in hospital and total costs per patient for admissions for TIA, stroke, or other vascular disease
49004,Multivariate analyses of predictors of admission to hospital, subsequent length of stay, and total hospital costs
49009,Self endangering behaviour and absconding during treatment
49010,Effect of hospital type on self endangering behaviour and absconding during treatment
49011,Effect of ward type on self endangering behaviour and absconding during treatment
49014,Comparison of primary outcomes for charged particle therapy cohorts and photon therapy cohorts
49015,Comparison of primary outcomes for proton beam therapy cohorts and intensity modulated radiation therapy cohorts
49016,Comparison of toxic effect event rates for charged particle therapy and photon therapy
49017,Characteristics of patients dying by suicide while under the care of crisis resolution home treatment teams or as an inpatient, compared with other deaths by suicide in the community
49019,Outcome and mortality rates
49020,Factors associated with medical treatment after hospitalisation
49021,Laboratory findings
49022,Complications, critical complications, and episodes of complications
49024,Candidate variants in six families with hereditary diffuse gastric cancer without CDH1 pathogenic variants
49025,PALB2 variants identified in hereditary diffuse gastric cancer sequencing studies
49027,Clinical response evaluation outcomes per diagnostic modalities and tumour regression grade in patients who underwent oesophagectomy after neoadjuvant chemoradiotherapy
49028,Sensitivity analysis for accuracy of residual tumour detection in clinical response evaluations and predictive value of the tumour regression grades
49030,Treatment details, types of surgery, and outcomes
49032,Treatment related adverse events
49034,Imaging response at 3 months after last cycle of LuPSMA received
49035,Treatment emergent adverse events
49038,Best response to treatment
49039,Treatment related adverse events during study treatment period
49041,ESMO MCBS and ASCO VF scores among US Food and Drug Administration registration trials within a cohort of randomised controlled trials in non small cell lung cancer, breast cancer, colorectal cancer, and pancreatic cancer, published 201115
49043,Primary and secondary efficacy endpoints in the per protocol population
49044,pCR analyses in the PP and ITT populations
49045,Summary of adverse events   safety population
49048,Treatment emergent adverse events observed in more than 20  of patients   safety population
49049,Veliparib pharmacokinetic parameters after oral capecitabine coadministration by dose escalation cohort
49050,Tumour response measures   efficacy population
49052,Histopathological subtypes of prostate cancer detected on repeat biopsy or transurethral resection of the prostate after benign initial biopsy
49053,Observed and projected cases and incidence of cervical cancer under different scenarios for women aged 3074 years in the six countries
49055,Toxicity reported by physicians using Common Terminology Criteria for Adverse Events version 30 during treatment and at 6 month and 12 month follow up
49059,Volume at first detection and lung cancer probability of new solid nodules   N 1131; 1083 benign nodules and 48 lung cancer nodules
49062,Tumour response
49063,Treatment related adverse events
49065,Treatment related adverse events
49067,Responses by PD L1 expression
49069,Treatment related adverse events
49071,Best overall response assessed by independent review committee for the full analysis set
49072,Adverse events occurring in at least 10  of patients
49074,Tumour response to treatment
49075,Patterns of treatment failure
49076,Grade 12 adverse events occurring in more than 10  of patients in either group, and all grade 34 adverse events
49078,Predictive factors for the success of genomic testing with comparative genomic hybridisation array
49079,Genomic targets and matched drugs
49082,Usage of StopAdvisor versus the control website
49084,Procedures for staging lymph node involvement and radiation dose delivered in the modified intention to treat population
49085,Summary of treatment emergent adverse events occurring in more than 10  of the safety population
49086,Overview of all adverse events in the safety analysis population
49090,Treatment emergent adverse events by CTCAE grade by week 25
49092,Primary reasons for patients  preferences   evaluable intention to treat population
49093,Adverse event profile during the cross over period   four cycles of subcutaneous trastuzumab and four cycles of intravenous trastuzumab, safety population
49094,Description of trials by setting
49095,Individual and trial level correlation coefficients and sensitivity data for DFS and PFS
49097,Perioperative complications in the preoperative plus postoperative chemotherapy group compared with the postoperative chemotherapy group
49099,Methods for calculation of the population attributable fraction   PAF  , by infectious agent and cancer site or subsite
49100,Number of new cancer cases      in 2008 attributable to infection, by infectious agent and development status
49101,Number of new cancer cases      in 2008 attributable to infectious agents, by geographical region
49102,Number of new cancer cases      in 2008 attributable to infectious agents, by anatomic site
49106,SLN detection rate by subgroup
49107,Contribution of SLN procedure to detect metastases in patients with low risk and intermediate risk endometrial cancer
49109,Adverse events
49110,Response to treatment
49111,Human papillomavirus   HPV   types in cases of invasive cervical cancer by geographical region and histological categories
49112,Human papillomavirus   HPV   genotypes in cases of invasive cervical cancer that were positive for HPV DNA, by region
49113,Human papillomavirus   HPV   genotypes in cases of invasive cervical cancer that were positive for HPV DNA, by histological diagnosis
49114,Numbers of patients in the Dutch Gastric Cancer Trial
49115,Reasons for R1 rather than R0 resections
49116,Univariate analysis of overall survival at 15 years   median   follow up
49117,Causes of death
49118,Recurrence sites and patterns at time of death
49119,Effect of age, sex, splenectomy, and pancreatectomy on mean overall survival
49120,Randomised trials of surgery only versus surgery combined with chemotherapy or chemoradiotherapy
49121,Randomised trials comparing the extent of lymphadenectomy
49122,Commonly used staging systems for assessing risk of GIST
49124,Concordance probabilities of the nomogram compared with other commonly used staging systems
49125,Calibration of the nomogram on the validation cohorts
49126,Calibration of the AFIP Miettinen staging system compared with that of the nomogram
49128,Grade 5 bleeding events   deaths
49134,Procedure related complications
49135,Univariate analysis of variables potentially affecting median survival
49136,Cox proportional hazard analysis for all clinical and endoscopic factors with p 01 in univariate analysis
49137,Trials of preoperative chemotherapy in gastric cancer
49139,Cases of CCP CUP management
49140,Relative risk of dying after curative rectal cancer surgery compared with the general population
49141,Relation between morbidity and 6 month mortality in the Dutch TME trial
49142,Studies reporting post CT colonography and post imaging colorectal cancer rates meeting inclusion criteria
49147,Number of endoscopists and patients completing analysis at each study site
49149,Adenomas detected and missed with standard forward viewing and full spectrum colonoscopy
49150,Adenomas detected and missed per patient
49151,Polyps detected and missed
49152,Time to the caecum, withdrawal time, and total procedure time
49154,Diagnostic performance of optical diagnosis, by technique
49156,Dose escalation schema, DLTs, adverse events, and dose reductions
49157,Treatment related adverse events occurring in at least 10  of participants in all cycles
49158,Pharmacokinetic variables by dose
49159,Antitumour responses in patients with ovarian and primary peritoneal cancer by BRCA1 and BRCA2 mutation status and platinum free interval
49160,Distribution of MMR deficient crypt foci in intestinal mucosa for patients with Lynch syndrome   LS110   and control patients   C19; set 1   and by resected segment
49161,MMR deficient crypt foci
49162,Allele patterns of microsatellite markers in MMR deficient crypt foci
49163,Clinical details and survival in germline TP53 mutation carriers with cancer in Li Fraumeni syndrome families
49164,Tumour development and survival in families with germline TP53 mutations
49166,Per polyp analysis for optical diagnosis using histopathological results as a reference
49167,Difference in diagnosis according to polyp size   only polyps with optical and histological diagnosis included
49168,Surveillance intervals found after optical diagnosis and formal histopathology
49169,Distribution and histological typing   post operatively   of follicular thyroid nodules with indeterminate FNA cytology
49170,Comparison of galectin 3 negative findings on preoperative FNA derived cell blocks with final histological assessment
49171,Comparison of galectin 3 positive findings on preoperative FNA derived cell blocks with final histological assessment
49172,Summary of major discrepancies noted at central blind review of a representative group of unselected histological diagnoses   n 294   and potential diagnostic accuracy of galectin 3 test, by histological findings   n 21
49173,Intercentre variability based on galectin 3 test in patients with cancer
49174,Intercentre variability based on galectin 3 test in patients with benign lesions
49180,Adverse events related to intervention
49182,Associations of maternal 25  OH  D concentrations during mid pregnancy with bone outcomes in children aged 6 years
49183,Associations of maternal 25  OH  D concentrations during mid pregnancy with bone outcomes at 6 year visit in children with available information on 25  OH  D concentrations at age 6 years
49184,Associations of fetal 25  OH  D concentrations at birth with bone outcomes in children aged 6 years
49185,Associations of fetal 25  OH  D concentrations at birth with bone health at 6 year visit in children with available information on 25  OH  D concentrations at 6 years of age
49186,Associations between schizophrenia polygenic risk scores and phenotypic variables at age 79 years
49187,Associations between schizophrenia polygenic risk scores and Strengths and Difficulties Questionnaire subscales at age 4 years
49189,Adverse events related to photochemical internalisation, by TPCS2a dose cohort
49190,Investigator assessed target lesion response
49193,Summary of adverse events for the 12 week treatment period
49196,Distribution of BMI measurements by age and sex
49197,Rates of dementia per 1000 person years and rate ratios compared with healthy weight by category of BMI, adjusted in various ways
49199,Additional treatment received after final 12 month   52 week   trial outcome assessment
49202,Systemic treatment before progression
49203,Systemic therapy in patients with progression of disease
49204,Details of locoregional treatment
49206,Prevalence and associations of major depression in cancer outpatients
49210,Adverse events
49212,Best tumour response and disease control
49213,Adverse events in 29 patients in the study population
49217,Summary of adverse events
49219,Primary outcomes
49221,Adverse events
49222,Correlation of continuous tumour shrinkage and progression free survival   PFS   with cytokine and angiogenic factors   CAFs   in the phase 2 study
49223,Cytokine and angiogenic factors and progression free survival   PFS   in the biomarker population of the phase 3 trial
49224,Cytokine and angiogenic factors and overall survival   OS   in the phase 3 trial
49225,Cytokine and angiogenic factors   CAFs   and clinical classifications as prognostic markers for progression free survival   PFS   in the placebo group
49228,Adjusted annualised change in quantitative motor and oculomotor, UHDRS, and neuropsychiatric measures
49230,Surgical procedures done
49231,Local tumour spread and ontogenetic staging
49232,Early postoperative complications
49233,3 year and 5 year survival
49235,Multivariable analyses of prognostic factors by outcome
49236,Adverse events during treatment
49238,Summary of molecular alterations detected by next generation sequencing
49240,Adverse events
49243,Primary global health related quality of life results
49245,Summary of change from baseline in HRQoL score at week 10 by treatment and adverse event status at week 10 visit
49247,5 year prevalence of late side effects
49249,Included trials and chemotherapy
49251,Unadjusted and adjusted prognostic overall survival differences in patients with metastasis in one organ
49252,Unadjusted and adjusted prognostic overall survival differences among subgroups defined by peritoneal metastasis status
49253,Unadjusted and adjusted prognostic overall survival differences among subgroups defined by peritoneal metastasis status among those with known wild type BRAF tumours
49260,Treatments for peripheral neuropathic pain and quality of the evidence
49264,Summary of drug related treatment emergent adverse events
49266,Adverse events
49268,Haematological, renal, and hepatic adverse events
49269,Clinical outcomes during follow up
49271,Adverse reactions to chemotherapy in part 1 for the intention to treat population
49273,Adverse reactions to radiotherapy in part 2 of the study
49275,Most common treatment emergent adverse events in 10  patients by severity   n 499
49276,Incidence of treatment emergent adverse events according to duration of vismodegib exposure   12 months vs  12 months; n 499
49277,Best response to treatment
49278,Study drug administration and reasons for discontinuation
49279,Events in the intention to treat population
49280,Patients included in 30 week landmark analyses
49281,Frequency of adverse events per patient by treatment group   N 448
49282,Global distribution of patients
49284,Grade 3 and 4 adverse events in the easy access protocol population
49287,Selected prespecified secondary   timed function tests, NSAA, and muscle function   and exploratory   percent predicted 6MWD   efficacy endpoints   intention to treat population
49288,Dystrophin expression at week 25 compared with pre treatment per patient, by testing method
49289,Adverse events   safety population
49295,PSA distribution, biopsy, and prostate cancer diagnosis by age and PSA concentration in the main ProtecT trial
49300,Non neurological adverse events   worst grade in each patient   occurring in more than 5  of patients in all treatment cycles combined
49301,Secondary outcomes
49302,Number of patients in each group that had progressed or died at the time of analysis, and numbers of patients receiving the various salvage therapies after progression in the BELOB trial
49303,MGMT promoter methylation status in relation to PFS at 6 months and overall survival at 9 months
49305,Best tumour response by RECIST 1.0 in the intention to treat population
49306,4 month progression free survival according to KRAS, BRAF, and EGFR tumour status and treatment group
49307,Adverse events
49308,Selected randomised trials of treatment for advanced biliary tract cancer
49310,Adverse events   all grades   occurring in more than 10  of 110 patients
49312,Relative dose intensity in patients included in safety analyses
49313,Safety analysis
49315,Survival status and main causes of death
49316,Overall survival
49317,Progression free survival   long term update
49319,Summary of 2 year and 3 year DFS and overall survival by pathological feature or gene copy number
49320,Treatment related adverse events in the safety population        n 486   by grade
49323,Toxic effects associated with induction chemotherapy and radiotherapy
49324,Toxic effects associated with consolidation chemotherapy and radiotherapy
49325,Toxic effects associated with adjuvant chemotherapy
49326,Late toxic effects not related to radiotherapy
49327,Late toxic effects related to radiotherapy
49329,Technical aspects of sentinel lymph node biopsy procedures in the trial
49330,Detection of sentinel lymph nodes, according to selected factors
49331,False negative rate of sentinel lymph node resection in patients with positive nodes, according to selected factors
49333,CNS relapse by group
49334,Type of CNS relapse by group in patients for whom forms were returned and who had died with CNS relapse
49337,Tumour response rates by visit   CR PR; intention to treat population
49338,Treatment related adverse events occurring in at least 5  of patients   safety analysis set population
49345,Protocol treatment received
49346,Number of patients with treatment related adverse events, by category and grade
49347,Haemorrhages
49348,Monotherapy analysis: estimates of relative treatment benefit of letrozole versus tamoxifen monotherapy according to follow up time
49350,Second malignancies
49353,Tumour recurrence by treatment group
49354,Median disease free interval by treatment group
49356,Treatment emergent adverse events occurring in at least 5  of patients   safety population
49359,Adverse events and serious adverse events reported for patients switched from interferon beta 1a to fingolimod   extension safety population
49361,Univariate and multivariate analysis of tumour tissue collection A
49362,RT PCR expression analysis of selected miRNA from the initial survival signature
49363,RT PCR expression analysis of the S2 signature in the validation set
49364,Cox proportional hazards regression analysis of the relation between the S2 miRNAs and overall and progression free survival for the 89 patients with stage I EOC from tumour tissue collection A
49365,RT PCR expression analysis of the S3 signature
49366,Univariate and multivariate analysis of tumour tissue collection B
49367,Univariate and multivariate analysis of association between VEGFA and TUBB3 expression and survival in the two tissue collections
49369,Distribution of endometrial thickness measurements in women with or without endometrial cancer or atypical endometrial hyperplasia
49373,Number of further interventions predicted if endometrial thickness measurements were used to screen for EC AEH
49375,Individual tumour data in the interruption group by age at inclusion
49377,Tumour response rates   Intention to treat population
49378,Adverse events   all causality   occurring in  10  of the safety population
49380,Association between gene sets and treatment response for all patients and for triple negative patients for each cohort
49381,Univariate and multivariate analysis for response to treatment   combined analysis
49382,Performance of the paclitaxel response metagene compared with published gene expression signatures in univariate and multivariate logistic regression   combined analysis
49384,Discriminatory accuracy of Adjuvant! and a multivariate Cox model fitted to the outcome
49387,Bayesian posterior mean probability of significant neurocognitive decline at 4 months by treatment group, by HopkinsVerbal Learning TestRevised
49388,Percentage of patients with intracranial progression who were symptomatic by treatment assignment and type of salvage therapy
49389,Comparison of randomised trial outcomes
49391,Safety studies and adverse reactions documented during the trial
49392,Dystrophin expression in muscle myofibres in patients 37, who were treated with high dose AVI 4658
49393,Estimation of oestrogen receptor   ER   binding by tamoxifen and some of its metabolites in postmenopausal and premenopausal women at steady state concentrations with treatment of 20 mg day tamoxifen, stratified by CYP2D6       4 genotype
49396,Univariate analysis of event free survival and overall survival according to different variables
49397,Event free survival and overall survival estimates from selected radiotherapy series reporting 5 year and 10 year outcomes
49405,Selected adverse events and serious adverse events on treatment
49408,Summary of drug related adverse events with  5  frequency   safety population
49412,Management of all patients, and final histopathological findings from 71 patients
49413,Histology and International Federation of Gynaecology and Obstetrics stage of malignant adnexal tumours
49414,Outcome of patients managed expectantly
49417,Univariate analyses of potential survival prognostic factors
49418,Cox proportional hazards analyses of survival prognostic factors
49419,Prognostic scores of each factor in the three nomograms
49422,Treatment emergent adverse events reported in at least 5  of patients in any group in the safety set
49425,Treatment emergent adverse events
49427,Best overall response
49428,Most common all cause adverse events that occurred in at least 10  of patients   safety population
49430,Treatment emergent adverse events occurring in at least 10  of patients treated with polatuzumab vedotin by pooled dose cohorts and histology
49431,Selected pharmacokinetic parameters for conjugate MMAE, total antibody, and unconjugated MMAE after cycle 1 of polatuzumab vedotin in patients with NHL
49432,Best response by dose cohort for single agent polatuzumab vedotin
49439,Best overall response by PD L1 expression status
49440,Treatment related adverse events that occurred in at least 5  of all treated patients
49445,Adverse events that occurred in 5  of patients in any treatment group during months 012
49446,Most common types of adverse event that led to discontinuation during months 012
49449,Treatment related adverse events
49450,Immune mediated adverse events of any attribution
49451,Association of biomarkers with clinical outcomes
49453,Treatment related adverse events
49454,Immune related adverse events
49455,Confirmed best overall responses and objective responses
49456,Objective response by PD L1 expression on immune cells
49458,Adverse events by treatment group   safety population
49460,Treatment related adverse events
49461,Immune mediated adverse events
49462,Anti tumour activity
49467,Cohort description
49468,Adjusted hazard ratios   HRs   for mortality in relation to childhood BMI and BMI change during puberty for 37672 Swedish men followed for a mean of 378 years after age 20 years
49469,Cardiovascular disease mortality according to overweight at age 8 years   childhood   or at age 20 years   young adult age  , or both
49473,Summary of base case results and and sensitivity analysis scenarios
49474,Distribution of story types published after index cluster and non cluster suicides
49475,Types of stories about suicide published after index cluster and non cluster suicides
49478,Adverse events related to either study drug
49479,Immune related adverse events to either study drug
49480,Recruitment of patients by cohort
49482,Immune related adverse events by dose and grade
49483,T cell specific responses in patients positive for the HLA A2 serotype by dose
49484,Diagnosis and previous genetic screening of patient cohorts
49485,Clinical summary of patient cohorts
49486,Summary of identified mutations and polymorphisms
49488,Summary of adverse events of grade 1 or 2 occurring in at least 10  of patients   n 30
49490,Change in T cell activation signatures in tumours after pidilizumab treatment that correlated with PFS
49492,Number of adverse events of grade 2 or higher attributed to figitumumab   N 29
49493,Plasma exposure for figitumumab   mean  SD    given at 20 mg kg, according to dosing regimen
49494,Duration and type of response according to histology subtype
49497,Risk of hypertension with angiogenesis inhibitors
49499,Primary and secondary outcomes
49500,Late complications leading to unplanned endoscopy or admission
49503,Disease presence and activity based on the consensus reference standard
49504,Per patient sensitivity and specificity for disease presence and extent against the consensus reference standard for patient groups combined
49505,Sensitivity and specificity for disease presence and extent against the consensus reference standard according to patient cohort
49506,Per patient sensitivity and specificity for the presence of active disease versus the consensus reference standard for patient groups combined
49508,Reasons for stopping treatment
49509,Serious adverse events
49511,Summary of clinically relevant adverse events and osteoporosis related fractures
49513,Adverse events   all causality   in the safety population   n 90
49515,Number of deaths reported at 12, 18, and 24 weeks by cancer type
49518,Mood assessment and standard tests of intelligence and memory results
49519,Long term forgetting assessment results
49520,Proposed stages of progressive memory impairment in Alzheimer s disease, relative to healthy ageing
49526,Treatment emergent adverse events
49531,Outcomes of health economics analyses   adjusted multiple imputation
49533,SVR12 of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin by duration of treatment, presence or absence of cirrhosis, and previous treatment history   full analysis set
49534,Safety and tolerability   full analysis set
49537,Adverse events
49540,Adverse events and laboratory abnormalities
49542,Best overall response by treatment regimen
49544,Treatment related adverse events
49548,Secondary analysis of responders according to motor function scores
49549,Adverse events
49552,Primary analysis results
49558,Adverse events observed in all patients during therapy   n 21
49561,All treatment related adverse events observed in patients
49562,Confirmed pembrolizumab activity in the full analysis population per RECIST
49566,Adverse events in all participants who received at least one dose of polyunsaturated fatty acids or placebo, or who attended at least one multidomain intervention session
49569,Participants achieving study endpoints by treatment group
49570,Adverse events
49572,Overall day and night glucose control during closed loop and control periods based on sensor glucose measurements
49573,Insulin delivery over 24 h period
49574,Night time and daytime glucose control during closed loop and control periods based on sensor glucose measurements
49576,All adverse events
49578,Efficacy outcomes of all patients and in subgroups by treatment group
49579,Toxicities by treatment group assessed by NCI CTCAE
49583,Overall glucose control based on sensor glucose measurements
49584,Pre meal and pre bed capillary glucose concentrations
49585,Overnight   00000800 h   and daytime   08000000 h   outcomes
49587,Summary of treatment emergent adverse events listed by system and class
49588,Response by dose level
49589,Descriptive information about control groups from eight randomised clinical trials in metastatic castration resistant prostate cancer available in Project Data Sphere
49590,Summary of the data analysis for each trial
49591,Summary of the median values of g, d, and  for all studies
49595,Adverse events, irrespective of cause, in the randomised study
49600,Summary of treatment emergent adverse events
49606,Prostate cancer complications
49607,Reported serious adverse events, including whether they were related to treatment and their current status
49608,Completion parameters  18   for quality of life questionnaires during the first 2 years, by visit
49610,Best response
49611,Summary of treatment emergent adverse events
49616,Selected treatment related adverse events of special interest
49620,Treatment emergent adverse events and laboratory abnormalities
49622,Efficacy of ombitasvir, paritaprevir, and ritonavir plus ribavirin in patients with hepatitis C virus genotype 4 infection and compensated cirrhosis
49623,Adverse events and post baseline laboratory abnormalities   safety population
49625,Epilepsy syndromes and underlying causes
49626,Adverse events and treatment emergent serious adverse events
49628,Primary, secondary, and post hoc outcomes
49629,Safety outcomes
49630,Adverse events
49631,Regression coefficients for the relation between probit transformed prevalence of diabetes based on FPG or 2hOGTT versus diabetes based on FPG only
49632,Regression coefficients for the association between probit transformed prevalence of diabetes based on HbA1c and probit transformed prevalence based on FPG
49633,Pooled sensitivity and specificity of diabetes diagnosis using different definitions among participants without diagnosed diabetes
49634,Univariate metaregression coefficients for sensitivity of HbA1c versus FPG in participants without diagnosed diabetes
49638,Frequently occurring adverse events
49643,Incidence and rate of hypoglycaemia in patients in the premix group versus the basal bolus group   safety analysis set
49645,Treatment delivery
49646,Proportions of patients achieving responses in the efficacy population
49647,Safety outcomes
49649,Response      to treatment in the per protocol objective response population
49650,Treatment related adverse events within 30 days of last dose of study treatment for the per protocol population
49652,Incidence of pain flare   intention to treat
49653,Change in pain score and duration of pain flare for early and late onset
49654,Adverse events
49659,Distribution of patients treated with carbon ion radiotherapy at the National Institute of Radiological Sciences by tumour type
49663,Adverse events recorded in more than 5  of patients in either group
49665,Univariable and multivariable analyses of the IMDC prognostic factors for overall survival at second line targeted therapy
49666,IMDC prognostic risk groups for overall survival at second line therapy
49668,Response to treatment
49669,Treatment related adverse events in all 51 patients
49672,Summary of adverse events
49674,Most common treatment emergent adverse events by preferred term   safety population
49679,Important adverse and serious adverse events
49684,Screening test performance
49685,Retrospective radiological assessment of participants with interval lung cancers
49690,Adverse events occurring in 5  or more patients: expanded dose levels, safety population   n 124
49692,Imaging results at week 12
49696,Treatment related adverse events reported in at least 5  of patients   N 111
49701,Success at years 1, 2, and 3 in the modified intention to treat analysis and at year 3 in the per protocol analysis
49702,Patients who failed treatement as stratified by timepoints, by type of basal cell carcinoma and treatment group   modified intention to treat analysis
49703,Cosmetic appearance of lesion   excellent or good   at 6 months and 3 years as rated by two independent dermatologists
49704,Pain during, and 16 weeks after, treatment
49705,Number of participants who had adverse events and number of adverse events   safety dataset
49706,Number of participants who had higher frequency mild or moderate or severe, life threatening, or disabling adverse events of all types   safety dataset
49709,Haematological and non haematological adverse events
49712,Incidence of cardiorespiratory arrest, SUDEP or near SUDEP, death, and SUDEP in epilepsy monitoring units
49714,Adverse events
49715,Surgery in cohort 2
49716,Investigator determined disease status and clinical benefit in cohorts 1 and 2
49718,Best response to second line nab paclitaxel
49719,Results of multivariable Cox analyses of progression free survival and overall survival
49720,Most common toxic effects of grade 3 or higher
49722,Estimated initial and sustained clearance rate and overall treatment success   modified intention to treat population
49723,Differences in proportions of tumour free survival at 1 year follow up between therapies with 95  CI   modified intention to treat population
49724,Patient reported pain
49725,Patient reported adverse events
49728,Frequency of RB1     unilateral retinoblastoma at five diagnostic laboratories
49730,Attrition in returns of health related quality of life data
49736,Best response to treatment
49737,Patient disposition at database lock
49738,Number of treatment cycles by database lock
49739,Acute and chronic adverse events in 52 patients
49740,Acute toxicities in cycle 1 in 52 patients
49741,Tumour response   complete or partial   by BRAF and KRAS mutations
49743,Characterisation of BAP1 mutant tumours and tumours exclusively mutated for PBRM1 in the UTSW and TCGA cohorts
49744,Multivariate analysis of time to death for patients with mutated tumours in the TCGA cohort
49745,Gene expression signatures in BAP1 mutant and PBRM1 mutant tumours
49747,Adverse events by grade and type
49749,24 h urinary albumin excretion
49750,Blood pressure before and after treatment with daglutril and placebo and differences between treatments
49751,Renal function and explicative variables
49753,Neurological symptoms at inclusion
49754,Objective CNS response in assessable patients
49755,Treatment related adverse events   N 45
49757,2 year conditional survival   conditioned on time survived regardless of whether still on the first line targeted therapy   for all patients and stratified by Heng risk group
49758,2 year conditional survival   conditioned on time on first line targeted therapy   for all patients and stratified by Heng risk group defined at therapy initiation
49760,Primary and secondary endpoints
49761,Efficacy of ipilimumab and fotemustine treatment in patients with brain metastases
49762,Summary of adverse events occurring in the study population
49764,Disease response by mWHO and irRC criteria after 12 weeks
49765,Disease control and objective response after 12 weeks
49766,Median progression free survival
49767,Adverse events
49769,Features of trials screening for ovarian cancer in the general population compared with those of the DOvE study
49771,Summary of abnormal test results and need for retesting among 1455 study patients
49776,Adverse events
49778,Reasons for not proceeding to second transplantation or maintenance therapy in patients with standard risk disease
49779,Disease responses in patients with standard risk disease, by treatment group
49780,Grade 35 toxic effects in patients with standard risk disease, by treatment group after second transplantation
49782,Adverse events in the phase 1 and phase 2 cohorts
49787,Previous therapy   enrolled population, n 128
49788,Progression free survival at 12 weeks   activity population, n 115
49789,Response and status at 12 weeks after start of therapy, and best overall tumour response   activity population, n 115
49790,Incidence of adverse events occurring in 10  of patients or more by subtype   safety population n 127
49792,Treatment exposure
49793,Rates of response to treatment by group in the response evaluable population
49794,Summary of safety profile by treatment group, including rates of adverse events according to system organ class
49795,Rates of adverse events of any grade in 15  or more of patients and of grade 3 or higher in 5  or more of patients in either treatment group, and haematology parameters
49796,Rates of peripheral neuropathy events and risk factors by treatment group
49797,Pharmacokinetic and pharmacodynamic parameters by route of administration
49801,Adverse events that occurred in at least two patients from either treatment group
49803,Response rates
49804,Treatment related adverse events reported in more than 10  of patients with rituximab sensitive mantle cell lymphoma   group 1, n 48
49805,Treatment related adverse events in more than 10  of patients with rituximab refractory mantle cell lymphoma   group 2, n 21
49808,General adverse event classifications and treatment emergent adverse events reported in at least 5  of patients
49810,Participants with IRBD with reduced 123I FP CIT uptake
49811,Mean striatal 123I FP CIT uptake ratios in participants and controls
49812,Midbrain transcranial sonography in participants and controls
49815,Best response at any point during induction treatment
49816,Toxicity profile   grade 3 or worse   during induction therapy
49817,Toxicity profile during maintenance therapy
49818,Response in hyperdiploid and non hyperdiploid groups
49820,Treatment related adverse events   any grade and grade 3   by body system reported in more than 5  of patients
49821,Documented post study treatments received
49826,Serious adverse events in the first year
49828,Grade 3, 4, and 5 adverse events reported during the study   N 37
49830,Summary of efficacy results
49831,Safety results
49834,Outcome variables
49835,Adverse events in at least 10  of patients in one treatment arm
49836,Treatment given to each study group
49840,Adverse events
49842,Treatment emergent adverse events in more than 5  of patients in either treatment group
49843,Changes in cardiovascular parameters and bodyweight during the study
49844,Incidence of treatment emergent ECG abnormalities during the study
49845,Evidence suggesting that early cancers detected by screening are not precursors of advanced cancer   data from  reference 13
49846,Findings of three studies of CT screening   data from  reference 20
49847,Relation between sex, smoking exposure, and lung cancers in a study by Henschke and colleagues  21
49848,Radiofrequency ablation protocol according to tumour size
49851,Outcome of radiofrequency ablation in 85 patients with malignant lung tumours who were assessed for the primary efficacy endpoint of target tumour response
49854,Treatment emergent adverse events
49857,Means and SDs for RAND 36 subscales, in survivors and in Dutch controls   aged 2544 years   at visit 1
49858,Patient satisfaction with shared care follow up according to Likert scale
49860,Path estimates for cannabis use and medication adherence as predictors for relapse outcome
49861,Mediation of the effect of cannabis use on relapse outcome
49865,Mean difference in standard scores of the Movement Assessment Battery for ChildrenSecond Edition
49866,Standard scores in the Movement Assessment Battery for ChildrenSecond Edition for each familial risk group
49867,Final model estimates on suicide rate in four world regions and overall   non linear, by 6 month time lagged unemployment rate
49868,Final model relative risks   RR   of suicides in four world regions and overall   non linear, by 6 month time lagged unemployment rate
49869,Estimated suicide numbers and ratestotal and those associated with unemployment   final model, overall
49876,Clinical, EEG, and MRI data for pharmacoresistant and seizure free patients with temporal lobe epilepsy
49884,Clinical, neuroimaging, and olfactory test data of the patients that remained disease free in the 2012 assessment, and of those who were diagnosed with mild cognitive impairment in the 2005 and 2012 assessments
49886,Semiquantitative assessment of Alzheimer s disease neuropathology in the three patients who underwent post mortem brain examination, by brain region
49887,Staging of Alzheimer s disease neuropathology in the three patients who underwent post mortem brain examination
49888,Frequency of GBA mutations in patients with Parkinson s disease
49889,Practical cut off titres for neutralising antibodies   tenfold reduction units   used in routine clinical practice
49890,Effect of NAbs on relapse rate and MRI outcomes in trials of interferon beta for relapsing remitting MS
49891,MxA mRNA bioactivity studies in patients with multiple sclerosis treated with interferon beta
49892,Practical consequences of NAbs measured after 12 years of treatment with interferon beta therapy in patients with multiple sclerosis
49894,CD3 immunoreactive area     of microscopic field   at the invasive margin of 286 pT3 or pT4 colorectal cancers, by tumour microsatellite status and other clinico pathological features
49895,Predictive factors for metachronous distant organ metastasis in 286 patients who underwent radical resection for deeply invading   pT3 or pT4   colorectal cancer
49896,Prediction of risk for metachronous distant organ metastasis by CD3 immunoreactive percentage area in 286 deeply invading pT3 or pT4 colorectal cancers, subgrouped by nodal status
49900,Summary of samples
49904,Costs of person centred care and dementia care mapping interventions
49906,Change in COPD Assessment Test score with pulmonary rehabilitation compared with external anchors   Study 1; n 565
49915,Weighted prevalence of diabetes and prediabetes in phase II and the northeastern phase of the study, by state and urban versus rural
49916,Multiple logistic regression with diabetes as the dependent variable, in urban and rural populations
49921,Distribution of outcome variables, commuting exposure variable, and hypothesised confounding covariates in the BMI analytical sample
49927,Attitude trends among the English population before and after the Time to Change anti stigma campaign 200413
49930,Relative risks   RRs   and 95  floated CIs   FCIs   for total cancer incidence, by category of height reported at recruitment   mean measured height
49931,Relative risks   RRs   and 95  CIs per 10 cm increase in height, for total incident cancer: effect of adjustment by various factors
49934,Association between log  VEGF D   and clinical measurements at enrolment
49936,Haplotypes and abbreviated genotypes according to serum MBL expression
49938,Genotype frequencies and serum concentrations in patients with non cystic fibrosis bronchiectasis and controls
49940,Markers of severity in patients with MBL deficiency, according to serum concentration
49942,Comparison of patients with seizure relapse with matched asymptomatic controls
49943,Association studies of deletions at chromosome 22q11.2
49944,Patients with Parkinson s disease entered into the age at onset analysis
49945,Comparison of deletions at 22q11.2 according to Parkinson s disease age at onset
49946,Clinical features of the patients with Parkinson s disease carrying 22q11.2 deletions
49948,Potential factors for prediction of molecular relapse by univariate analysis
49949,Potential factors for prediction of molecular relapse by multivariate Cox regression model analysis
49951,Performance of Cmi and AFP for detection of hepatocellular carcinoma
49952,The performance of Cmi and  fetoprotein in detection of preclinical hepatocellular carcinoma by month before clinical diagnosis
49954,Assessment of studies for risk of bias
49957,Summary of imaging data
49960,Comparisons between patients with HCHWA D and age matched healthy controls
49961,Comparisons between patients with sporadic CAA and controls   healthy individuals or those with Alzheimer s disease
49963,Enrichment of genes targeted by antipsychotics
49964,Sensitivity and specificity of NMDAR antibodies tests in serum and CSF
49965,Multivariate analysis of the change in titres in CSF and serum samples
49966,Reactivity of patients  serum and CSF with GluN1 mutants
49970,Sensitivity, specificity, positive predictive values, and negative predictive values, by CSF  synuclein cutoff value
49971,Clinical presentation of groups positive and negative for the THAP1 mutation
49976,Criteria for classification of PSEN1 E280A carriers
49978,Classification of PSEN1 E280A carriers according to failure type and censoring for each stage
49979,Cognitive impairment subtypes in participants for whom an exact age at onset was available
49981,Cerebral blood flow measurements
49983,Neuropathological data in patients with synucleinopathies, stratified by burden of Alzheimer s disease pathology
49984,Genetic data in patients with synucleinopathies, stratified by burden of Alzheimer s disease pathology
49987,Quantification of neuropathological features by AD subtype
49988,MAPT and APOE 4 genotyping
49990,Patients who had serious adverse events
49991,Mutations identified in TBC1D24
49992,Clinical features of patients with DOORS with the TBC1D24 mutations
49993,Clinical features of patients with DOORS without the TBC1D24 mutations
49996,Skeletal related events in the intention to treat population
49997,Skeletal related events free survival in the intention to treat population
49999,Clinical outcome of patients with stage II III colorectal cancers according to tumour POLE proofreading domain mutation and mismatch repair status
50001,Clarithromycin, metronidazole, levofloxacin, amoxicillin, and tetracycline resistance in the Asia Pacific region
50002,Meta regression univariable analysis of the prevalence of antibiotic resistance in Asia Pacific region
50003,Meta regression multivariable analysis of the prevalence of antibiotic resistance in Asia Pacific region
50004,Coefficients from the Cox proportional hazard models for laboratory based and office based risk scores
50005,Laboratory based and office based mean 10 year risk of fatal and non fatal cardiovascular disease and of fatal cardiovascular disease in ten countries with a recent national health survey in people aged 4064 years
50014,Relative risks for Alzheimer s disease and shared variance between risk factors
50015,Estimates for population attributable risk and the number of attributable cases in 2010
50016,Estimated reduction in future numbers of cases of Alzheimer s disease with 10  or 20  reduction per decade in the relative prevalence of the seven risk factors
50022,Univariable and multivariable Cox regression analysis of predictors of aneurysm rupture risk in patients with unruptured intracranial aneurysms from the pooled data from six cohorts
50023,Predictors composing the PHASES aneurysm rupture risk score
50028,Secondary outcomes
50033,Insulin doses and severe hypoglycaemic events in the per protocol population, overall and according to number of daily doses of long acting insulin
50034,Causality and severity of severe hypoglycaemic events in the intention to treat population
50036,CASI Z scores by time of assessment
50037,Statistical significance for models used to assess change in CASI Z score over time by assigned treatments, for various subgroups
50039,Dose stratified vaccine efficacy against incident HPV 16 18 infection for women in the modified total vaccinated cohort   Costa Rica Vaccine Trial and PATRICIA combined
50040,Dose stratified vaccine efficacy against incident HPV 16 18 infection for women in the total vaccinated cohort naive
50041,Dose stratified vaccine efficacy against incident HPV 31 33 45 infection for women in the modified total vaccinated cohort in Costa Rica Vaccine Trial and PATRICIA combined
50042,Two dose vaccine efficacy stratified by timing of the second dose for the modified total vaccinated cohort in the Costa Rica Vaccine Trial only
50046,Diagnostic performance of Xpert MTB RIF assay compared with the combined reference standard   smear microscopy, Lwenstein Jensen medium, and Bactec MGIT960 system
50047,Diagnostic performance of Xpert MTB RIF assay compared with smear microscopy, Lwenstein Jensen medium, and Bactec MGIT960 system
50049,Concordance between single WGS and routine laboratory methods for mycobacterial speciation
50050,Whole genome sequencing resistance predictions for Mycobacterium tuberculosis complex specimens compared with phenotypic DST
50051,Total cost per sample by process, accounting for error rates
50054,Changes in pretransplantation and post transplantation MRI and EDSS in patients without clinical relapse
50055,Changes between pretransplantation and post transplantation MRI and EDSS in patients with clinical relapse
50057,Brain regions in which grey matter volumes of patients with classic or variant Lesch Nyhan disease were significantly smaller than those of healthy controls, and regions in which neither patient group differed from healthy controls
50062,Behavioural and neuropsychological estimates in mutation carriers and non carriers, by estimated time from expected symptoms onset
50063,Imaging estimates in mutation carriers and non carriers, by estimated time from expected symptoms onset
50065,Model performance
50069,Accuracy of HPV DNA testing for detection of CIN grade 2 or worse and grade 3 or worse
50070,Risk ratios for developing CIN grade 3 or worse at various relative light unit cutoff values
50071,Uncorrected and corrected accuracy of HPV DNA testing by age groups
50074,Linear regression analysis for the prediction of clinical, functional, cognitive, and quality of life measures based on the first 25 years of disease duration
50075,Estimates of incidence and survival for rare and common cancers
50076,Age standardised incidence in 19992002 and 200307
50077,Age standardised 5 year relative survival in 19992001 and 200507
50078,Annual number of cases of rare tumours by country
50079,Personhood and deep and continuous palliative sedation, by philosopher
50083,Glucose concentrations measured by CGM and fingerstick testing during 24 h day and night only
50085,Screening events attended in the FH01 study
50086,Outcomes of prevalence and incidence screening events in the FH01 study
50088,Mean glandular dose by screening event in one centre in the FH01 study
50089,Distribution of lifetime number of laparoscopic and open radical prostatectomies done by surgeons
50092,Number of children in each epilepsy syndrome category
50094,Number of children in each group who achieved 50  and 90  seizure reduction at 3 months
50095,Side effects reported after 3 months on the ketogenic diet.
50099,Clinical outcome measures in non carriers and carriers of SCA mutations
50100,Relations between clinical outcome measures and time from onset in SCA mutation carriers
50102,Results of functional neuroimaging
50104,Endpoint diagnosis and transcranial sonography
50105,Overall adequacy of treatment in the first 6 months after CIN3 diagnosis, by period of CIN3 diagnosis, age, ethnicity, parity, and maximum procedure within 6 months of diagnosis
50106,Incidence of cancer of the cervix or vaginal vault by adequacy of initial treatment and extent of initial procedure
50107,Risk of invasive cancer of the cervix or vaginal vault in women with persistent CIN3 after initial treatment, by age, ethnicity, parity, period of CIN3 diagnosis, and maximum initial procedure
50108,Proportions of women developing cancer of the cervix or vaginal vault in those with minimum disturbance of the CIN3 lesion   group B   and in those with adequate or probably adequate initial treatment   group C
50112,Changing trends in cancer specific age adjusted incidence
50113,Scenarios of prostate cancer screening trials
50116,Initial method of detection and actual size of sentinel node metastasis
50117,Risk of non sentinel node metastases by largest tumour burden in the sentinel node
50124,Multiple Cox proportional hazards model for female cancer incidence from start of year 4
50130,Estimated differences in cognitive function, as a function of diabetes status   cross sectional analysis at 199799 assessment
50131,Estimated differences in cognitive decline over 10 years, as a function of diabetes status in 199799
50132,Association of glycaemic control   one percentage point increment in HbA1c   with estimated differences in cognitive decline, by diabetes status in 199799
50134,Prediction of risk of a motor diagnosis of Huntington s disease: joint modelling results
50135,Similarities and differences in health care between the intervention and control regions
50137,Consultations by medical specialists and allied health professionals during the 8 month study period
50139,Previous studies of multidisciplinary interventions for Parkinson s disease
50141,Coupled phase 2 and phase 3 trials assessing the same drug at the same dose
50142,Sample sizes for trials of a biosimilar or generic versions of interferon beta or glatiramer acetate
50144,Perinatal events for women enrolled in the FGLS and the FGLS like subpopulation from the NCSS
50145,Variance component analysis for crown rump length, fetal head circumference, and newborn length
50146,Number of patients eligible and included for analysis, and percentage exclusions, for adults diagnosed with one of 21 common cancers in England and Wales between 19962006 and followed up to 2007
50147,1 year relative survival       for patients diagnosed in selected years, and year on year trends       within calendar period of diagnosis and overall   19962006   for 21 common cancers in England and Wales
50148,National trends in relative survival       at 3, 5, and 10 years after diagnosis, and 5 year conditional survival, by sex and calendar period of diagnosis, and predicted survival for 2007
50149,Regional trends in relative survival       at 1 year after diagnosis, and year on year change      , by sex and calendar period of diagnosis for selected cancers
50150,Probability of lung cancer diagnosis within 2 years after a screening test, by nodule volume, diameter, and volume doubling time
50154,Serious adverse events
50156,Comparison of overnight glucose control from 0000 to 0700 h during closed loop and control period with unadjusted   raw   sensor glucose over 28 days in the home setting
50157,Insulin delivery overnight   00000700 h   and over 24 h
50158,Utility and failure analysis of closed loop operation
50159,24 h glucose control during closed loop versus control with unadjusted   raw   sensor glucose over 28 days in the home setting
50161,Prevalence of behavioural risk factors in the migrant worker population
50162,Mean estimates of metabolic risk factors in the migrant worker population
50163,Prevalence of metabolic risk factors in the migrant worker population
50164,Risk factors associated with the presence of metabolic syndrome, by sex
50166,Multiple regression analysis of daughters  MRI breast measurements against daughters  and mothers  risk factors, and mothers  mammography breast measurements
50167,Simple and multiple regression analysis of MRI breast measurements against growth factors and hormones of daughters who did not use oral contraceptives at the time of the study
50172,Results of the multivariable Cox models, including the nomogram variables for overall survival and distant metastases
50173,Descriptive statistics of the 5 year cancer survivors by site of first cancer
50174,Relative risk of second solid cancer at high dose sites for radiotherapy versus no radiotherapy by age at diagnosis of the first cancer and first cancer site
50175,Relative risk of second solid cancer at high dose sites for radiotherapy versus no radiotherapy by time since first cancer diagnosis   latency   and first cancer site
50176,Estimated number of excess second solid cancers related to radiotherapy treatment and attributable risk in those treated with radiotherapy by first cancer site
50178,Participation at second invitation for all women in the trial
50179,Participation at second invitation for prevalent screen women, by age group
50180,Participation at second invitation for incident screen women, overall and by time since last attendance
50181,Participation at second invitation for all national IMD quintiles   from most to least deprived
50182,Costs of cancer in the European Union in 2009, by country
50183,Health care costs of all cancers and of colorectal, lung, breast, and prostate cancers in the European Union in 2009, by country
50185,Performance of the different combined MRI criteria for DIS, DIT, and DIS plus DIT for development of clinically definite multiple sclerosis in the final cohort at 36 and 60 months  follow up
50186,Adjusted hazard ratios and bootstrap based comparisons of different combined MRI criteria with the 2010 McDonald criteria
50188,Breast cancer detection rates and incremental cancer detection from integrating 3D mammography in screen reading versus 2D mammography alone
50189,False positive recall proportion shown according to double reading protocols, and comparison of false positive recall for screening integrating 3D mammography vs standard 2D mammography alone
50190,DCIS and invasive cancer detection frequency, and subsequent invasive interval cancer frequency by year of screening
50191,Results of secondary analyses of association of DCIS detection frequencies with subsequent invasive interval cancer incidence
50192,Association of categorised DCIS detection frequencies at screening with subsequent invasive interval cancer incidence
50194,Mean number of years of life lost due to diabetes and years spent with diabetes according to age at diagnosis, by time period in US adults, 19852011
50195,Cumulative years lost due to diabetes and years spent with diabetes, by race or ethnic origin, and time period, in the overall population of US adults, 19852011
50196,Counterfactual analysis of the magnitude of lifetime risk of diabetes on the basis of counterfactual scenarios retaining mortality or incidence levels
50197,Effect of age   years   on the 6 year incidence of invasive breast cancer detection   cases per 100000
50198,Sensitivity analyses, by age   years
50201,Sensitivity and positive predictive value of cytology triage and methylation triage
50207,Incidence and mortality of lung cancer in participants who had a T0 screen, by screen results
50209,Cox regression comparing results from two models on the risk of lung cancer diagnosis
50210,Background information about drugs included in the analysis and their selected presentations, and unit prices
50211,Ex factory prices    per unit   of selected cancer originator drugs in the 18 surveyed countries, as of June, 2013
50212,Crude incidence rate of cancer in India per 100000 in 1996
50213,Clinical features of 174 index patients with neonatal diabetes mellitus
50214,Results of neuropsychomotor testing in index patients with neither DEND nor intermediate DEND
50215,Genetic subtype distribution according to age at diagnosis of neonatal diabetes mellitus
50216,Results of multivariate analysis of factors independently associated with 6q24 abnormalities
50218,Absolute and relative costs for diabetes by World Bank income group
50220,Clinical summary of patients with Parkinson s disease
50222,Association of neonate TSH concentrations for children with scores lower than the national minimum standard for numeracy and reading, developmentally high risk, or having special needs
50224,Summary of imaging data
50226,Adverse events reported by at least 5  of 3222 patients irrespective of association with vemurafenib
50229,
50230,Cardiovascular and diabetes risk factors in non Hispanic white adults aged 2079 years in NHANES 200310
50231,Validation of the cardiometabolic model by age groupUS life tables  19
50232,Validation of the cardiometabolic model by BMI statusPeeters and colleagues  24
50234,Clinical outcomes
50235,Incidence of non haematological toxic effects following the first course of treatment
50236,Incidence of non haematological toxic effects following two courses of treatment
50237,Supportive care for patients with acute promyelocytic leukaemia in the two groups during treatment courses 1 and 2
50240,Scores for the primary and secondary outcome measures
50242,Adverse events during chemoradiotherapy
50243,Details of early and salvage surgery
50245,Cardiovascular parameters and fasting serum levels in thermoneutral and cold induced conditions
50246,Indirect calorimetry in thermoneutral and cold induced conditions
50247,Thermoregulation in thermoneutral and cold induced conditions
50250,Effect of environmental risk factors   direct brain injury and cannabis   on measures of disease severity and socioeconomic functioning in male patients with schizophrenia
50251,Effect of environmental risk factors   psychological damage   on measures of disease severity and socioeconomic functioning in male patients with schizophrenia
50254,Subgroup specific median time to recurrence and survival post recurrence across all three cohorts
50255,Anatomical patterns of recurrence across medulloblastoma subgroups
50256,Anatomical pattern of recurrence combining all three cohorts, stratified by treatment with CSI, across medulloblastoma subgroups
50257,ATP1A3 mutations and paroxysmal clinical features of 24 patients with alternating hemiplegia of childhood
50258,Non paroxysmal clinical features of 24 patients with alternating hemiplegia of childhood
50259,Clinical features of alternating hemiplegia of childhood versus rapid onset dystonia parkinsonism
50261,Disease recurrence after stereotactic ablative radiotherapy
50266,Diagnosis of biopsy by central pathology review panel, stratified by liquid based cytology and HPV test results
50267,Clinical performance of Pap and HPV testing for identifying women with a biopsy diagnosis of CIN3 or CIN2, or worse
50268,Strategies for triage to colposcopy for women who test HPV positive for the immediate identification of women with CIN3 or CIN2, or worse
50271,Adverse events reported in at least 5  of patients in either group, irrespective of cause
50273,Summary of relevant clinical trials on spinal and bulbar muscular atrophy, by method
50276,Pathological tumour response to chemotherapy by treatment group and tumour subtype
50277,Number of grade 34 serious adverse events
50278,Registration period, population covered, follow up period and method, number of cancer sites, and data quality indices for registries in each country
50279,Number of cases included for survival analysis, median age, and number included for extent of disease analysis by cancer site and country
50280,5year age standardised   074 years   relative survival for cancers by country
50281,5 year survival and frequency distribution for cancers by clinical extent of disease, based on data from countries with more developed   group A   vs less developed   group B   health services
50284,Health outcomes
50285,Cost components and total costs
50287,Adverse events
50289,Adverse events
50291,Clinical outcomes
50292,Adverse events
50294,Unscheduled and scheduled admissions
50295,Primary treatment related serious adverse events in the per protocol population
50297,Adolescents, young adults, and adults receiving the first antenatal visit during the first trimester of pregnancy and at least four antenatal visits during pregnancy for their first birth
50298,Global absolute numbers and age standardised rates per 100000 people for neurological disorders and percentage changes between 1990 and 2015
50299,Global absolute number of DALYs and age standardised rates per 100000 people for all neurological disorders combined and percentage changes between 1990 and 2015 by country
50301,Observed and estimated values of the primary outcome   PANSS positive score   and the four key adverse outcomes during 12 weeks of intervention
50303,Comparisons between quetiapine ER and aripiprazole of the distributions of adverse events or reactions graded according to seriousness and UKU clinical category
50305,Primary and secondary endpoints
50306,Summary of adverse events in the placebo and erenumab groups
50308,Adverse events   preferred terms   with at least 3  incidence during the study
50310,Quality of life during 6 months  follow up
50311,Perioperative data of patients who required resection during follow up
50312,Top SNPs from loci meeting the threshold for genome wide significance in the combined Barrett s oesophagus and oesophageal adenocarcinoma meta analysis
50313,Estimated coverage for mental, neurological and substance use disorder prevalence data from China and India, in GBD 2013
50314,Age standardised prevalences in 1990 and 2013, with percentage change, for mental, neurological, and substance use disorders
50316,Adverse events by treatment group occurring in more than two participants
50317,Classification of patient case report forms according to time of return after start of treatment
50318,Subjective parameter score of the 4 point rectal and intestinal LENT SOMA scoring scales  5
50320,Overall returns of IBDQ and LENT SOMA assessment forms and those returned within prespecified timeframes
50321,Median changes in the IBDQ bowel function component and IBDQ rectal bleeding scores from baseline to 12 months in patients assessed within 1014 months
50324,Operative data of all 75 randomised patients with full thickness rectal prolapse
50326,Postoperative data of all 75 randomised patients with full thickness rectal prolapse
50328,Estimates of effect in primary and secondary outcome measures at 6 weeks
50330,Treatment emergent adverse events   n 50
50331,Best clinical response and survival outcomes overall and by Ki 67 status
50333,Co occurrence of cardiovascular disease risk factors in adolescents aged 1215 years by WHO region by number of risk factors
50336,Serious adverse events
50338,Summary of overall treatment effect for dual energy x ray absorptiometry body composition variables   intention to treat population
50339,Adverse events grades 12 with an incidence of more than 10  in either group plus any grades 35   safety population
50340,Comparison of scans for the detection of malignant lesions in children
50343,Echocardiographic parameters after 12 weeks by treatment group
50344,Secondary outcomes before and after 12 weeks of treatment by group
50347,Adverse events experienced by over 4  of patients   safety population
50350,Adverse events   any grade
50352,PET results
50353,Treatment compliance
50354,Efficacy of treatment according to histological, surgical, and clinical outcomes
50355,Grade 12 adverse events occurring in more than 10  of patients in any group and all grade 34 adverse events that occurred after randomisation
50357,Treatment exposure
50358,Safety profile of ixazomib plus lenalidomide and dexamethasone
50359,Drug related adverse events
50361,Stem cell mobilisation approaches and results
50363,Overall best response to treatment
50364,Adverse events that occurred in 10  or more of patients
50367,Comparison of GLP 1R imaging and conventional imaging in patients with suspected insulinoma
50368,Comparison of imaging, surgical, and histological results in 30 patients with suspected insulinoma
50370,Best RECIST response within 12 months of randomisation in the intention to treat population
50371,Adverse events
50372,Prognostic analysis
50374,Other outcome measures
50375,Description of cohorts used in analysis by study population
50376,METASTROKE association signals for SNPs identified in previous genome wide association studies by gene and disease subtype
50377,Association signals for SNPs selecting for testing in the independent replication cohort by subtype
50379,Pathological clinical response rate according to Sataloff classification   assessed by central review or investigators   and Chevalier classification   assessed by central review   in 52 enrolled participants
50380,Adverse events occurring in more than 10  of patients by grade
50383,Predictors of mortality
50384,Overall response based on neurological rating scales
50385,Details of responders
50386,Grade 3 or 4 and serious adverse events and reactions, and adverse events leading to quinacrine discontinuation or dose reduction
50388,Responsiveness to indometacin
50389,Previous drug or surgical treatment for headache by drug class
50390,Responses to injections in the greater occipital nerve with corticosteroid and lignocaine
50391,Patients  estimate of outcome and recommendations
50392,Migraine Disability Assessment Scores   MIDAS
50393,Adverse events
50394,Pulse sequences used to obtain MR images
50395,Results of MDCT and MRL in all centres
50396,Results of MRL in experienced and less experienced participating hospitals
50398,Adverse events possibly associated with JX 594 treatment
50400,Responses of non injected tumours in patients with PR or SD according to RECIST for target tumours
50403,Adverse drug reactions possibly related to study drug in both trials
50406,Adverse events
50407,Genetic associations with specific ANDIS clusters reaching at least nominal significance for difference among clusters 25
50409,Dose cohorts
50410,Treatment emergent adverse events
50411,Baseline characteristics
50413,Adverse events reported in at least 10  of patients overall, regardless of study drug relationship
50418,Progression free survival per investigator radiological review   full analysis set
50419,Treatment emergent adverse events, irrespective of association with study drug, by preferred term      and treatment   safety set
50422,Adverse events
50423,Serious adverse events reported in more than 1  of patients overall, arranged by MedDRA preferred term
50425,Summary of treatment emergent adverse events by group
50426,Pharmacokinetic properties of trastuzumab deruxtecan
50431,Likelihood of symptoms occurring during STM in the development set
50432,Microbiological analysis of cases
50433,Ultrasound findings at different gestational ages
50435,Objective response, best overall response, and disease control per investigator and masked independent central review assessments
50436,Investigator assessed objective response and disease control in patients locally assessed as having dMMR MSI H   n 74
50437,Treatment related adverse events in patients locally assessed as having dMMR MSI H   n 74
50439,Summary of overall TEAEs, and TEAEs of opioid withdrawal or possible opioid withdrawal   safety population
50442,Any cause adverse events
50444,Adverse events in patients who received the maximum tolerated dose
50446,Treatment related adverse events occurring at any grade in 10  of patients in any cohort or at grade 3 in any patient
50447,Overview of safety
50448,Summary of pharmacokinetic parameters for avelumab dose groups
50450,Effect of psychological therapy on disease activity, psychological wellbeing, and quality of life in patients with quiescent inflammatory bowel disease
50454,Adverse outcomes in adolescents after Roux en Y gastric bypass during the 5 year study period
50455,Clinical pathological features
50456,Surgical results in patients who had pelvic lymphadenectomy
50457,Sensitivity and specificity data
50458,Risk factors for lymphatic metastasis
50460,Objective response, time to response, and duration of response in all treated patients
50461,Treatment related adverse events of any grade reported in 5  of patients, and select adverse events   all treated patients
50462,Number of cases of severe necrotising enterocolitis and associated deaths, by gestational age at birth
50463,Unadjusted and adjusted odds ratios for severe necrotising enterocolitis in babies born before a gestational age of 32 weeks
50465,Secondary endpoints
50466,Adverse events per treatment group from before crossover
50469,Treatment related adverse events in the modified intention to treat population
50472,Hazard ratios for predictors of overall survival   unmatched complete datasets
50474,Treatment related adverse events during the first induction period
50475,Treatment related adverse events during the second induction period
50476,Treatment related adverse events during the continuation period
50477,Response to treatment
50478,Prevalence of overweight among Chinese adults aged 2059 years in 200014
50479,Prevalence of obesity among Chinese adults aged 2059 years in 200014
50480,Prevalence of underweight among Chinese adults aged 2059 years in 200014
50481,Prevalence of central obesity among Chinese adults aged 2059 years in 200014
50482,Percentage of participants meeting the minimum recommendations for leisure time physical activity among Chinese adults aged 2059 years in 200014
50484,Median overall and progression free survival
50485,Grade 3 or 4 adverse events
50486,Proportion of patients who underwent radiotherapy or chemoradiotherapy, resection, and R0 resection
50488,Incidence and mortality of pancreatic diseases stratified by the WHO regions
50489,Meta regression analysis
50491,Primary endpoint
50492,Secondary endpoints
50494,Treatment emergent adverse events grade 3 or higher in more than one patient, by schedule
50495,Pharmacokinetic parameters for guadecitabine subcutaneous injection, by dose
50496,Pharmacokinetic parameters for decitabine formed after guadecitabine subcutaneous injection, by dose
50500,Summary of treatment emergent adverse events   all randomly assigned patients
50502,Grade 1 and 2 adverse events occurring in at least 10  of patients in one or both treatment groups
50503,All grade 3 and 4 adverse events
50505,Adverse events that arose in at least one patient
50506,Dose reductions
50508,Adverse events during neoadjuvant chemoradiotherapy
50509,Patients with adverse events during neoadjuvant chemoradiotherapy
50510,Surgery related adverse events for all eligible patients who underwent surgery
50514,Best overall response
50515,Treatment related toxic effects encountered during induction and consolidation chemotherapy cycles regardless of causality
50517,Clinical activity of sunitinib in thymic malignant diseases
50518,Treatment related adverse events
50521,Adverse events
50523,Treatment emergent adverse events arising in 10  patients, or of special interest, irrespective of cause
50527,Adverse events   any grade   experienced by 15  or more of patients in either treatment group, and CTCAE grade 3 or higher events occurring in 3  or more of patients in either group
50530,Adverse events and device complications
50533,Adverse events
50534,Proportion of deaths attributable to the individual and combined effects of high BMI, blood pressure, blood glucose, and serum total cholesterol in 2010
50537,Adverse events
50538,Best response to treatment
50539,Germline BRCA mutation status according to tumour BRCA mutation status
50541,Adverse events   any grade   in 10  of patients overall and grade 3 events in 3  of patients in either treatment group
50544,Adverse events
50546,Summary of drug exposure
50547,Summary of adverse events occurring in more than 10  of patients in either group   any grade   or 2  or more of patients in either group   for grade 3 or higher
50548,Selected all grades and grade 35 composite term adverse events
50551,Adverse events
50553,Objective response in the intention to treat population
50554,Subgroup analysis of efficacy variables
50555,Adverse events
50558,Axitinib pharmacokinetic parameters prior to decision for dose titration   day 15 of lead in period   and after dose titration   cycle 2 day 15
50559,Treatment emergent, all causality adverse events reported in 10  of patients in the total treated population
50562,Toxicity of thermochemotherapy in 44 children
50564,Short term toxicity in the SIOPEL 4 trial
50565,Response and outcome results of SIOPEL 4 compared with previous studies
50567,Comparison of infertility and use of medical services for infertility between survivors and their siblings
50570,Reasons for exclusion from analysis of evaluable patients
50571,Plexiform neurofibroma response by age, location, and plexiform size
50572,Adverse events, by grade
50574,Diabetes incidence, according to time since first cancer treatment and to attained age in a cohort of 2520 patients treated for a cancer during childhood
50576,Diabetes according to the radiation dose to the tail of the pancreas in a cohort of 2520 patients treated for a first cancer during childhood
50577,Diabetes according to the radiation dose to the tail of the pancreas in a cohort of 1849 patients treated in France for a first cancer during childhood
50579,Grade 25 adverse events stratified by dose cohort for each patient
50580,Tumour response at 6 and 12 weeks after radioembolisation
50582,Response according to RECIST   version 1.1   in 41 patients with urothelial cancer given at least one dose of pazopanib
50583,Treatment related adverse events in 41 patients given at least one dose of pazopanib according to NCI CTCAE   version 4.03
50584,Results of the multivariable Cox proportional hazard model for overall survival in 41 patients given at least one dose of pazopanib
50585,Treatment regimens for study and comparator drugs
50587,Summary of efficacy in the intention to treat population
50588,Summary of efficacy in the histologically confirmed intention to treat population and in patients with aggressive B cell lymphoma
50589,Effect of previous rituximab therapy and number of previous chemotherapy regimens on efficacy of pixantrone and comparator agents
50590,Summary of adverse events
50592,Common adverse events in patients in phase 1   n 14   after 107 cycles of lenalidomide plus rituximab
50593,Common adverse events in phase 2   n 44   after 379 cycles of lenalidomide plus rituximab
50594,Response rates at the maximum tolerated dose in phase 2
50596,Summary of efficacy endpoints in the ITT population during the double blind period
50597,Summary of TEAEs in the safety population
50598,TEAEs occurring in 20  or more of patients in either group and other TEAEs consistent with possible effects of VEGF blockade in the safety population during the double blind period
50600,Summary of efficacy results   intention to treat analyses
50602,Adverse events reported in the two treatment groups, for patients who received at least one round of treatment
50605,Adverse events
50607,Distribution of dose levels between patients in the phase 1 study
50608,Treatment related adverse events
50609,Best response to combination treatment
50610,Time to event analysis
50612,coefficient and hazard ratio estimation from development cohort with multivariate Cox proportional hazards model and corresponding risk score
50613,Cumulative risk score and associated 3 year, 5 year, and 10 year risk of developing hepatocellular carcinoma in patients with chronic hepatitis B
50614,Demographic and clinical characteristics of patients at baseline and navitoclax doses
50615,Clinical and laboratory toxic effects of navitoclax
50616,Pharmacokinetic profile of navitoclax in cycle one of the intermittent 14 21 dosing schedule
50620,Intraoperative and postoperative adverse events
50622,Numbers and types of complications per treatment group
50623,Secondary outcomes
50625,Response to treatment and survival in all patients assigned to treatment
50626,Anti tumour efficacy in the extremity subgroup   N 149; all patients randomly allocated treatment
50627,Anti tumour efficacy in the non extremity subgroup   N 192; all patients randomly allocated treatment
50628,Adverse events according to treatment   safety population
50630,Adverse events deemed to be possibly, probably, or definitely related to treatment
50631,Sites of disease progression triggering discontinuation of pazopanib
50632,Summary of results of published clinical trials in differentiated thyroid cancers
50634,Treatment related adverse events with GEMOX B in patients with biliary tract cancer   n 35
50637,Treatment related adverse events   n 37
50640,Complications and sequelae of 212 patients treated with total mesometrial resection graded according to the Franco Italian glossary  12
50641,Histopathological investigation of intracompartmental tumour propagation and resection margins of 212 total mesometrial resection specimens
50642,Comparison of total mesometrial resection and classical radical hysterectomy
50645,Treatment emergent adverse events during segment 1 treatment
50647,Adverse events related to axitinib or pembrolizumab treatment in all patients   n 52
50648,Potentially immune related adverse events related to pembrolizumab in all patients   n 52
50651,Primary outcome according to treatment
50652,Antenatal course and management
50653,Neonatal outcome according to treatment
50655,Adverse events for BAT
50658,Treatment emergent adverse events
50659,Patient incidence of pulmonary toxic effects
50661,Association of TSPO VT in grey matter regions with duration of untreated major depressive disorder
50664,Adverse events and serious adverse events during treatment
50666,Pooled proportions of incomplete excisions by treatment procedure and location of the margin involvement
50667,Observed prevalence of different forms of traditional bullying and cyberbullying for female and male adolescents
50668,Linear regression model examining the effects of bullying on mental well being
50669,Multinomial logistic regression model examining effects of bullying on mental well being
50670,Linear regression model examining the effects of bullying on life satisfaction
50674,Adverse event scores
50676,Treatment related adverse events in 74 patients with small cell lung cancer
50677,Activity outcomes in response assessable patients treated at active doses, assessed by the investigator and by central review
50679,Inter rater agreement     95  CI
50680,Diagnostic accuracy for the various subgroups and disorders in the validation cohort
50681,EEG features in patients fulfilling the Salzburg criteria in the validation group
50682,Sample statistics   Jan, 2000, to June, 2011
50686,Child developmental outcomes of mothers in the prenatally depressed intervention and control groups
50687,Child developmental outcomes by prenatal depression status of the mother
50689,Operative and pathological data
50690,3 year survival
50691,Univariate and multivariable Cox regression analyses for disease free survival
50696,Clinical findings
50697,CLCN2 and GJB1 mutations
50698,Histology results for all ages
50699,Final automated read versus final manual read of borderline or mild abnormalities
50700,Relative sensitivity for final automated and final manual readings in the paired arm
50701,Relative specificity for final automated and final manual readings in the paired arm
50702,Relative sensitivity for final automated readings and final manual readings for the BD FocalPoint GS Imaging System and the ThinPrep Imaging System
50703,Analysis of BD FocalPoint GS Imaging System for samples allocated to quintiles and for samples designated as needing no further review, by suggested management outcomes
50704,Reasons for discordance between automated and manual results
50706,Surgery data
50708,Postoperative recovery and complications
50709,Antibody prevalence in patients with gluten ataxia defined as idiopathic sporadic ataxia with positive antigliadin antibodies and in patients with idiopathic sporadic ataxia negative for antigliadin antibodies
50710,Neurological presentations of 424 patients with gluten sensitivity, who presented with neurological dysfunction and were seen in the gluten sensitivity neurology clinic, in Sheffield, UK, from 1994 to 2009
50711,Summary of studies on the prevalence of antigliadin antibodies in patients with idiopathic sporadic ataxia and in controls
50712,Proportion of women with positive p16 INK4A   p16   immunostaining at different cut offs, by histology
50713,Sensitivity and specificity of p16 INK4A   p16   immunostaining in HPV DNA positive women by age and cut off
50714,Relative sensitivity and relative referral for different HPV based screening strategies versus conventional cytology
50716,Univariate analyses for all potential prognostic variables for all patients
50717,Univariate analyses for all potential prognostic variables for patients with stage III disease
50718,Multivariate analyses for all independent prognostic variables for all patients
50719,Multivariate analyses for all independent prognostic variables for patients with stage III disease
50721,All adverse events associated with pembrolizumab treatment, by worst grade in each patient
50723,Patient reported outcomes   modified intention to treat population
50724,Adverse events   safety population
50726,Activity of nivolumab
50727,Adverse events and treatment related adverse events
50728,Serious adverse events and serious treatment related adverse events
50733,Serious and non serious adverse events
50735,Perioperative outcomes in men undergoing focal high intensity focused ultrasound for unifocal and multifocal localised prostate cancer
50736,Histological outcomes at 6 months in men undergoing focal high intensity focused ultrasound for unifocal and multifocal localised prostate cancer
50740,Adverse events
50742,Frequency of the most commonly reported serious adverse events
50743,Modified Rankin scale   mRS   scores at 3 months after recurrent stroke
50744,Barthel index scores 3 months after the first recurrent stroke
50745,Distribution of patients with MMSE score 24 points over time
50746,Number of patients with a decrease of 3 points or more in MMSE score from 1 month to penultimate visit
50748,Cumulative incidence of Alzheimer s disease, dementia, and death by other causes by age
50750,Linear regression between rate of acetylcholinesterase hydrolysis and age, by network or region of interest
50751,Rates of acetylcholinesterase hydrolysis, adjusted for age
50753,Treatment related adverse events
50754,Exploratory, post hoc analyses of the relationship between PD L1 expression and clinical response per RECIST   version 1.1   by masked, independent central review of the full analysis set
50757,Effect of service type on quality of life, autonomy, and satisfaction with care
50758,Frequency of contacts with specific professionals and methods of contact within accommodation types in previous 3 months
50759,Costs of contact with professionals and access to care per service user in the 12 months before enrolment
50762,Treatment emergent adverse events for the duration of the study through the extended analysis by preferred term
50767,Genotype. age, and time to onset in ATXN2 mutation carriers during the follow up assessments
50768,Progression of early clinical manifestations in ATXN2 mutation carriers during follow up assessments
50769,Mean comparisons of electrophysiological parameters between carriers of the ATXN2 mutation and controls for two distinct periods before ataxia onset
50770,Clinical features of 174 index patients with neonatal diabetes mellitus
50771,Results of neuropsychomotor testing in index patients with neither DEND nor intermediate DEND
50772,Genetic subtype distribution according to age at diagnosis of neonatal diabetes mellitus
50773,Results of multivariate analysis of factors independently associated with 6q24 abnormalities
50779,Patient characteristics
50781,Response rates by 24 months by Sokal risk
50782,Long term endpoints on treatment
50783,Safety findings
50786,Adverse events
50788,Sustained virological response at 12 weeks for the four treatment groups according to genotype
50789,Safety and tolerability for the four treatment groups and the overall population
50791,Comparison of total length of hospital stay in 1 year from enrolment and cost between treatment groups   intention to treat analysis
50792,Results of multiple linear regression analysis exploring relationship between treatment group and outcomes adjusting for minimisation factors   intention to treat analysis
50796,Summary of treatment emergent adverse events
50797,Serious treatment emergent adverse events
50799,Proportion of patients with best response, as defined by IWWM criteria progression free survival, overall survival and by mutation status
50800,Overview of treatment emergent adverse events grade 12   occurring in 10  of patients  , all grade 3 and worse adverse events, and all serious adverse events
50802,Treatment related adverse events
50805,Grade 1 and 2 adverse events occurring in at least 10  of patients in one or both treatment groups
50806,All grade 3 and 4 adverse events
50810,Adverse events in the intention to treat population during the entire study period
50812,Adverse events that occurred in more than 2  of patients in either group
50814,Responder rates
50817,Adverse event summary by system organ class and preferred term
50819,Operative details
50820,Grade 34 postoperative morbidity
50822,Second line treatments after study treatment failure
50823,Reasons for treatment interruption, except progression, and main types of adverse events   all grades
50824,Responses to treatment
50825,Data sources used to answer NOMAD study research questions
50826,Summary of documented effects of the introduction of a tamper resistant formulation of controlled release oxycodone in Australia
50829,Treatment emergent safety outcomes in all treated patients
50830,Serious treatment emergent adverse events in all treated patients
50831,Univariable predictors of seizure recurrence and the presence of seizures in the last year of follow up
50834,Prevalence of marijuana use; marijuana use disorders; and perceptions of risk, availability, and state legalisation for medical use in the USA, 200214
50838,Other correlates of marijuana use in adults   n 596500   and other correlates of marijuana use disorders and of the number of days of marijuana use in adult users   n 114700   in the USA, 200214
50843,Factors independently prognostic of overall and progression free survival in the training cohort
50846,Secondary endpoints
50847,Criteria included in classification systems and number of participants in the POINT cohort that meet criteria
50848,Estimated lifetime prevalence of opioid use disorder in POINT cohort according to different diagnostic classifications, by sex
50849,Prevalence of specific criteria according to diagnostic definitions in participants meeting criteria for each diagnostic system
50851,Prevalence of potentially traumatic events, continuing adversity, and intimate partner violence
50852,Sequential models examining pathways to perinatal depression
50853,Standardised direct and indirect effects of variables in final model
50854,Analysis of susceptibility to bias in published and unpublished trials
50855,Drugs or drug classes with strong or weak recommendations for use based on the GRADE classification
50856,Summary of GRADE recommendations
50858,Fidelity assessment of the GetREAL staff training intervention
50862,Secondary outcome analyses
50863,Prospective randomised treatment trials in patients with type 2 diabetes reporting heart failure as a cardiovascular outcome
50864,Cardiovascular events in diabetic subgroups of patients in clinical trials of patients with chronic arterial disease, hypertension, or acute MI
50865,Occurrence of cardiovascular events in two large trials of thiazolidinediones
50866,Cases and controls, by index GWAS
50867,Genome wide associated loci at p 50  107
50868,Sleep outcomes
50869,Nightly sleep before, during, and after space missions
50870,Sleep outcomes on nights aboard space shuttle and ISS missions with and without sleep promoting drugs
50877,Median interferon score in patients, and score by genotype
50878,Results for individual patients with an interferon score sampled at more than one timepoint, by patient number
50879,Mutation positive patients assayed for CSF or serum interferon activity, or both
50880,Comparison of interferon score and type I interferon activity measured in serum of mutation positive patients, by patient number
50882,Treatment compliance in randomly assigned patients
50883,CTCAE grade 3 or 4 toxicity in patients during treatment   weeks 1 to 12
50884,Failure free rate at 24 weeks, and subsequent pattern of treatment failure and treatments given
50888,Secondary outcomes
50889,Adverse events   safety analysis set
50890,Top 20 and bottom 20 countries ranked by age adjusted stroke mortality rates among 192 WHO member countries in 2002
50891,Top 20 and bottom 20 countries ranked by age adjusted DALY loss rates among 192 WHO member countries in 2002
50892,Distribution of stroke risk factors by national income classification
50893,Univariate and multivariable predictors of age adjusted stroke mortality in 192 countries
50894,Univariate and multivariable predictors of age adjusted DALY loss rates in 192 countries
50899,Adverse events in the neoadjuvant and adjuvant phases
50902,Reasons for 53 patients not having bevacizumab administered for four cycles
50903,Chemotherapy modifications in the 4418 cycles
50904,Bevacizumab modifications in the 1426 cycles in the Bev D FEC group
50905,Adverse events
50907,Reason for discontinuing neoadjuvant treatment
50908,Types of surgery and pathology findings
50910,Cardiac and most common adverse events reported as possibly, probably, or definitely related to treatment
50912,Parameter estimates from the ordered probit model for discharge destination of 123 patients
50916,Distribution of prognostic variables after cardiac arrest in the derivation cohort
50920,Summary of adverse events in all participants who were randomly assigned and on double blind treatment
50927,Internal and external validation statistics for microvascular and macrovascular RECODe
50929,Effectiveness and cost effectiveness of TTT and BTT strategies for reducing complications of type 2 diabetes
50931,Comparison of patients treated more intensively   ie, with more medications   by TTT or BTT strategies for reducing complications of type 2 diabetes
50933,Activity of vemurafenib
50934,Adverse events
50936,Number and size of total and target brain metastases in patients with melanoma or NSCLC
50937,Neurological adverse events and treatment related non neurological adverse events in all treated patients with melanoma or NSCLC
50938,Coefficients and HR from the Cox proportional hazard model used to parameterise the risk scores for fatal cardiovascular disease and fatal plus non fatal cardiovascular disease
50940,Meta analysis of inflammatory markers in PTSD
50941,Multiple meta regression model of inflammatory markers in PTSD
50942,Multiple meta regression model of inflammatory markers in PTSD
50946,Exposure to study drug
50947,Treatment emergent adverse events
50949,Primary and secondary outcomes
50950,Study characteristics
50953,Systolic blood pressure, measured before and immediately after event, by stroke subtypes
50954,Relation between time to assessment and mean systolic blood pressure before and after event
50955,Increase in systolic blood pressure after stroke in comparison with three measures of premorbid blood pressure control in intracerebral haemorrhage versus ischaemic stroke
50958,Thrombotic and haemorrhagic events within 14 days and death or dependence at final follow up
50959,Prediction models for thrombotic and haemorrhagic events developed in the IST dataset
50960,Number of thrombotic and haemorrhagic events by quintiles of predicted risk of event in evaluation datasets   TAIST, TOAST, FISS tris, HAEST
50961,Absolute risk difference of death or disability at final follow up between patients treated with heparins and those treated with aspirin or placebo across all five trials, presented by quartiles of risk of haemorrhagic events and quartiles of risk of thrombotic events   absolute risk difference for whole population 000  001 to 001
50965,Treatment emergent adverse events reported by 2  of 450 patients during the open label dose conversion
50966,Treatment emergent adverse events reported by 2  of patients in either treatment group during the double blind maintenance period
50967,Barrier assessmentinteractive educational intervention components
50969,Change in use of alteplase
50974,Adverse events reported by more than 10  of patients in either group
50978,Adverse events
50983,Radiological responses
50984,Pathological responses
50986,Survival outcomes
50987,Treatment related grade 35 toxic effects
50988,Cardiac and thromboembolic adverse events during neoadjuvant chemotherapy
50993,Comparison of efficacy outcomes according to grade of recanalisation in the IVendovascular group
50999,Primary efficacy endpoint   composite responder rate at day 90   in the intention to treat population
51000,Mortality within 90 days
51006,Treatment emergent adverse events
51008,Relative risk of new onset type 2 diabetes in Indian Asians versus Europeans after various adjustments
51009,Association of methylation markers with future type 2 diabetes incidence
51010,IARC classification of some organophosphate pesticides
51013,Treatment emergent adverse events occurring in 3  or more of patients in either treatment group   all patients treated set
51014,Studies and women included
51016,Relative risk of all and subtypes of ovarian cancer in current versus never smokers in various subgroups of women
51018,Treatment emergent adverse events
51019,Changes in ADAS cog and MMSE from screening to week 12
51021,Number of patients with normalisation of alkaline phosphatase according to week  s   of treatment
51022,Common Terminology Criteria adverse event categories occurring in two or more individuals per group
51024,Genome wide association results of antipsychotic treatment responses for the discovery, validation, and combined samples, by chromosome
51025,Pathways most associated with individual difference in therapeutic effects of 6 weeks  antipsychotics treatment, by Kyoto Encyclopedia of Genes and Genomes database pathway
51028,Adverse events, sport participation, and concomitant therapy
51030,Yearly exposure adjusted participant incidence of adverse events per 100 participant years of follow up for placebo and for the combined FREEDOM, long term, and crossover denosumab participants, up to 10 years
51032,Efficacy measures in the modified intention to treat   ITT   analysis
51033,Second line and third line treatments in the modified intention to treat population
51034,Grade 14 adverse events
51037,Surgical and pathology results
51038,Histopathological tumour regression in the modified ITT population according to Becker
51039,Serious adverse events with perioperative morbidity
51040,Adverse events
51042,Treatment emergent adverse events of specific interest by category   safety set
51043,Treatment emergent adverse events reported by 5  of clazosentan treated patients   safety set
51044,Primary cause of death by preferred term   all randomised
51046,Objective response rates
51047,Kaplan Meier estimates of median overall survival by response to lapatinib and previous trastuzumab use in the HER2  population
51048,Summary of events for responders to lapatinib
51049,Adverse events reported by more than 10  of patients in cohort A during treatment
51050,National Cancer Institute Common Terminology Criteria for Adverse Events versions 2 and 3 for gastrointestinal perforation
51052,Incidence and relative risk of gastrointestinal perforation with bevacizumab among patients with various tumour types
51054,Adverse events
51055,Number of surgeries before and after vismodegib treatment
51056,Reasons for temporary or permanent discontinuation of vismodegib in 19 of 25 patients at the California sites
51057,Diagnostic information by gender
51059,Nature and location of voices
51061,Causes and effects of voices
51067,Summary of efficacy with dacomitinib in all patients and by EGFR mutation status
51068,Adverse events
51070,Treatment related adverse events occurring in 10  of patients
51071,Serious adverse effects suspected to be related to treatment
51072,Clinical activity
51074,Treatment related adverse events
51075,Tumour response and progression free survival
51077,Best confirmed treatment response according to RECIST 1.0
51078,Summary of progression free survival and overall survival by mutation type and line of treatment
51079,Treatment related adverse events recorded in at least 10  of patients by starting dose
51081,Adverse events of any grade reported during study treatment and follow up, according to vorinostat dose received
51082,Grade 3 adverse events according to vorinostat dose received
51085,Viral shedding after intracranial injection
51086,Adverse events
51088,Setscreen enrichment p values for the 14 pathways highlighted in the GeM HD study
51090,Treatment related adverse events
51094,Response to treatment by blinded independent central review in the evaluable for response set
51095,Safety overview of adverse events
51096,Possibly treatment related      adverse events
51098,Best response
51099,Follow up anticancer treatments     in the intention to treat population   data cutoff Sept 30, 2015
51101,Summary of adverse events in the safety population       data cutoff Sept 30, 2015
51103,Response to treatment with afatinib in patients with uncommon mutations
51104,Activity of afatinib in specific compound uncommon mutations
51105,Patients and their PPT1 mutations
51106,Natural history of infantile neuronal ceroid lipofuscinosis
51107,Summary of neurodevelopmental findings
51110,Genetics of participants
51111,Toxic effects
51112,Discovery tests of rs1799990 and four novel candidate SNPs in patients with vCJD and UK controls
51113,rs1799990 and three novel candidate SNPs in samples from Papua New Guinea
51114,Replication tests of rs1799990 and four novel candidate SNPs in patients with iCJD, patients with sCJD, and UK controls
51116,Primary and secondary efficacy endpoints
51117,Adverse events
51119,Clinical outcome according to intervention
51121,Best response in 80 evaluable patients by sarcoma histological subtype
51122,Serious adverse events related to treatment
51123,Proportion of variance accounted for by model in internal cross validation   PPMI   and external validation   LABS PD   datasets
51126,Adverse events
51129,Duration of response
51130,Treatment related adverse events of grade 2 or worse experienced by at least 5  of patients
51131,2016 estimates of HBsAg prevalence, treatment, and prophylaxis, by country
51132,2016 estimates of HBsAg infection prevalence, treatment, and prophylaxis, by region
51133,2016 estimates of HBsAg infection prevalence, treatment, and prophylaxis, by WHO or World Bank region
51137,Treatment emergent adverse events and expected reactions during two MDMA sessions and 7 days following these sessions
51139,Larotrectinib related adverse events
51142,Psychiatric serious adverse events reported during the 2 year follow up   safety population
51145,Circulating leucocyte and haematopoietic stem cell numbers before and after G CSF
51147,Adverse events
51149,Response with venetoclax monotherapy as assessed by the investigator
51150,Summary of treatment emergent adverse events
51154,Serious and non serious adverse events by group
51156,11C PK11195 BPND and 18 F DOPA Ki values for patients with IRBD and controls
51157,Number of patients with IRBD with abnormal 11C PK11195 BPND and 18F DOPA Ki values
51158,Neoantigens per variant class
51161,Between group and within group meta analyses
51162,Between group meta regressions, by moderator
51165,CGM derived outcomes
51168,Clinical and neuroimaging features of all patients included in this study
51169,Clinical and neuroimaging features of patients harbouring PI3KR2 mutations
51170,Mutations, levels of mosaicisim, and methods of detection of PIK3R2 mutation positive patients
51172,Treatment emergent adverse events attributed to RRx 001 in decreasing order of frequency for 5  of patients or more
51173,Pharmacokinetic properties for RRx 001 GSH, by dose
51174,Changes in density versus changes in lesion diameter in 22 individual non pulmonary lesions at week 8
51175,Scenarios of diabetes used in the analysis
51176,Avoidable cases of tuberculosis and deaths from tuberculosis by reducing diabetes prevalence in 13 high burden countries, 201535
51178,Absolute and percent predicted forced expiratory volume in 1 s in each subgroup in heavy and never smokers
51179,Novel genome wide significant signals of association with extremes of forced expiratory volume in 1 s or smoking behaviour
51181,Adverse events in randomly assigned patients during post induction treatment phases
51182,Grade 4 adverse events post induction therapy
51184,Induction serum asparaginase activity after one dose of intravenous PEG asparaginase, by day post administration
51185,Post induction nadir serum asparaginase activity in randomly assigned patients, by week post administration
51189,6 month to 12 month changes in imaging and blood biomarkers by treatment group
51190,Known and unknown aspects of the disease mechanism in progressive multiple sclerosis
51193,Adverse events
51197,Serious adverse events and adverse events up to day 100 after transplant
51199,Surgery details for patients with phaeochromocytoma
51200,Adrenal sparing surgery
51202,Adverse events that occurred in 10  or more of patients and all grade 35 events
51203,Best response to treatment, assessed by Revised Response Criteria for Malignant Lymphoma  21
51204,Ibrutinib pharmacokinetic parameters by dose
51205,Whole genome sequencing results and patient information, by patient ID
51206,Designation of recurrence strains by MIRU VNTR, by whole genome sequencing designation
51208,Final multivariable model of the diabetes specific dementia risk score in 27512 patients
51209,Dementia risk by each level of the risk score
51210,Dementia risk associated with sum score stratified by age groups
51216,Adverse events and serious adverse events during the initial 6 month study and the 5 year study extension period
51219,Overall best tumour response in 48 treated patients
51220,Incidence of drug related, treatment emergent adverse events
51221,Pharmacokinetic parameters of regorafenib and its metabolites
51223,Functional MRI blood oxygen level dependent signals in patients with Parkinson s disease compared with controls
51224,Blood oxygen level dependent signal differences in patients with Parkinson s disease with mild cognitive impairment versus those without
51225,Region of interest analyses in patients with Parkinson s disease without mild cognitive impairment versus those with mild cognitive impairment
51226,Donorrecipient HLA match categories
51228,Results of multivariate analysis for transplant related mortality
51229,Results of multivariate analysis for overall mortality
51230,Results of multivariate analysis for neutrophil recovery
51233,Adverse events
51234,Clinical features, outcome measures, and type of SCN1A mutation
51235,Relation of pertussis vaccination after seizure onset to intellectual disability
51237,Univariate and multivariate analysis of progression free survival
51238,Adverse events occurring in more than 10  of either of the treatment groups listed according to incidence in the gefitinib group
51239,Recent clinical trials assessing EGFR mutations as predictors of efficacy of gefitinib compared with chemotherapy
51241,Relative median daily hot flush score changes according to the hot flush diary
51242,Daily mean hot flush score relative changes according to the hot flush diary
51243,Improvement in daily hot flush score after 4 weeks
51244,Adverse events in the 3 months after randomisation by treatment group
51246,Diagnostic tests, treatment, and outcome
51247,Clinical, electrophysiological, and structural imaging data of patients in MCS
51248,Peak voxels for significant changes in regional cerebral blood flow in response to noxious stimulation
51249,Peak areas that show greater activation in response to noxious stimulation in patients in MCS compared with patients in PVS
51250,Areas that show preserved functional connectivity in patients in MCS and controls and in patients in MCS compared with patients in PVS
51252,Individual patient LTA T doses and toxicity descriptions
51253,Changes in pleural fluid cytokine concentrations before and after LTA T administration in patients in whom pleural fluid was available
51256,Summary of adverse events by actual treatment received from baseline to week 37
51258,Neutrophil and platelet recovery after intrabone cord blood cell transplant   200608   according to total nucleated cells transplanted and HLA matching
51259,Summary of patient profiles
51262,Admission to Kilifi District Hospital because of CSE
51263,Significant risk factors for mortality and neurological sequelae following confirmed CSE
51270,Multivariate analysis evaluating the associations of participants with Rome IV functional dyspepsia and subtypes in comparison with individuals with no dyspepsia
51272,Treatment outcomes
51273,Worst grades of acute toxic effects within 90 days of commencing treatment
51274,Baseline characteristics
51276,Treatment related adverse events and immune related adverse events
51278,Response to chemotherapy
51279,Acute toxic effects of chemotherapy
51282,Tumour response to pembrolizumab in patients enrolled at least 4 months before data cutoff, by subgroup
51283,Treatment related adverse events   n 370
51286,All related TEAEs occurring in the base and extension studies   n 58
51289,Summary of treatment related adverse events in first 8 weeks of treatment
51290,Treatment related inflammatory symptoms and pain in full dose and adapted regimen groups
51294,ECT treatment variables and re orientation in the two treatment groups
51297,Details of adverse events or reactions with a frequency of greater than 5
51299,Grade 3 and 4 adverse events in the safety population according to the National Cancer Institute Common Toxicity Criteria
51300,Bearman grades 13 adverse events
51301,Event free survival in all randomised patients according to different prognostic subgroups
51302,Multivariable analyses
51304,Treatment related adverse events
51305,Treatment related select adverse events and treatment related adverse events leading to discontinuation of both study drugs
51306,Clinical activity
51308,Responses assessed per RECIST version 1.1 by masked, independent central review in the intention to treat population
51309,Adverse events in the as treated population
51311,Treatment related adverse events
51315,All treatment related adverse events observed in patients
51316,Confirmed pembrolizumab activity in the full analysis population per RECIST
